<SEC-DOCUMENT>0001193125-12-137599.txt : 20120328
<SEC-HEADER>0001193125-12-137599.hdr.sgml : 20120328
<ACCEPTANCE-DATETIME>20120328171156
ACCESSION NUMBER:		0001193125-12-137599
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		26
CONFORMED PERIOD OF REPORT:	20111231
FILED AS OF DATE:		20120328
DATE AS OF CHANGE:		20120328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		12721330

	BUSINESS ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d275067d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>UNITED STATES SECURITIES AND
EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 10-K </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Mark One) </FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:10%"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>
 <P STYLE="margin-top:4px;margin-bottom:0px; margin-left:10%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the fiscal year ended December&nbsp;31, 2011 </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>or </B></FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:10%"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px; margin-left:10%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the transition period from
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission file number: 001-33958 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(Exact name of registrant as specified in its charter) </I></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20-8099512</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(State or other jurisdiction of</I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>incorporation or organization)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(I.R.S. Employer</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><I>Identification Number)</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, OR</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>97034</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><I>(Zip code)</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(Address of principal executive offices)</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(855)&nbsp;855-4253 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section&nbsp;12(b) of the Exchange Act: </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Each Class</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:137pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Exchange on Which Registered</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock, $0.0001 Par Value Per Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The NASDAQ Capital Market</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section&nbsp;12(g) of the Exchange Act: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>None </B></FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;No </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Exchange
Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;No </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;No </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will
not be contained, to the best of the registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;No </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant has submitted electronically and posted on it corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405
of Regulation&nbsp;S-T (&#167;&nbsp;232.405 of this chapter) during the preceding 12 months (or for any such shorter time that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;No </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act (Check one): </FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated&nbsp;filer&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Do not check if a smaller reporting company)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act):&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;No </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate market value of the voting common stock held by non-affiliates of the registrant, based on the closing sale price of the
registrant&#146;s common stock as reported on The NASDAQ Capital Market on June&nbsp;30, 2011, was approximately $41,000,064. </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;26, 2012, the registrant had 50,493,396 shares of common stock outstanding. </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Documents incorporated by reference: </B></FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Portions of the registrant&#146;s definitive proxy statement for its 2012 annual meeting of stockholders, to be filed pursuant to Regulation&nbsp;14A with the Securities and Exchange Commission not later
than 120 days after the registrant&#146;s fiscal year end of December&nbsp;31, 2011, are incorporated by reference in this Form&nbsp;10-K. </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:4px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC.</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM 10-K &#151; FISCAL YEAR ENDED DECEMBER 31, 2011</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART I.</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_1">BUSINESS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 1A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_2">RISK FACTORS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 1B.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_3">UNRESOLVED STAFF COMMENTS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_4">PROPERTIES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_5">LEGAL PROCEEDINGS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_6">MINE SAFETY DISCLOSURES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II.</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_7">MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 6.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_8">SELECTED FINANCIAL DATA</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 7.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item&nbsp;7A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_10">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 8.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_11">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 9.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_12">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 9A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_13">CONTROLS AND PROCEDURES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 9B.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_14">OTHER INFORMATION</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART III.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 10.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_15">DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 11.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_16">EXECUTIVE COMPENSATION</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 12.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_17">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 13.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_18">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 14.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_19">PRINCIPAL ACCOUNTANT FEES AND SERVICES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART IV.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 15.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_20">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc275067_21">Signatures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INTRODUCTORY NOTE </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;26, 2011, we changed the name of our company from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. In this
annual report, we sometimes refer to Galena Biopharma, Inc. as &#147;Galena&#148; or the &#147;Company&#148; and to our wholly-owned subsidiary, Apthera, Inc., as &#147;Apthera.&#148; On September&nbsp;26, 2011, we also announced the contribution of
our historical RNAi assets to a new subsidiary formed by us for this purpose and the proposed partial spin-off of the subsidiary referred to under &#147;Item&nbsp;1. Business &#151; Recent Developments&#148; in this annual report. Our new
subsidiary, which assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in our name, is referred to in this annual report as &#147;RXi.&#148; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We recently announced that our board of directors had declared a conditional dividend on Galena common stock of one share of common stock of RXi for each outstanding share of Galena common stock to be
made pursuant to the registration statement filed by RXi with the Securities and Exchange Commission and declared effective on February&nbsp;14, 2012. For the reasons described under &#147;Item 1. Business&nbsp;&#151; Recent Business
Developments&#148; in this annual report, there is no assurance that the payment and distribution of the RXi&nbsp;shares will be completed as planned. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless the context otherwise indicates, references in this annual report to the &#147;company,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148; refer (i)&nbsp;to Galena, Apthera and RXi,
collectively, prior to the proposed partial spin-off of RXi; and (ii)&nbsp;to only Galena and Apthera, together, after the partial spin-off of RXi, assuming it is completed. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>&#147;SAFE HARBOR&#148; STATEMENT </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some of the information contained in
this annual report may include forward-looking statements that reflect our current views with respect to our research and development activities, business strategy, business plan, financial performance and other future events. These statements
include forward-looking statements both with respect to us, specifically, and our industry, in general. We make these statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include
the words &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;project,&#148; &#147;estimate,&#148; &#147;may,&#148; &#147;should,&#148; &#147;anticipate,&#148; &#147;will&#148; and similar statements of a future or
forward-looking nature identify forward-looking statements for purposes of the federal securities laws or otherwise. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These factors include, but are not limited
to, those factors set forth in the sections entitled &#147;Business,&#148; &#147;Risk Factors,&#148; &#147;Legal Proceedings,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148;
&#147;Quantitative and Qualitative Disclosures About Market Risk&#148; and &#147;Controls and Procedures&#148; in this annual report, all of which you should review carefully. Please consider our forward-looking statements in light of those risks as
you read this annual report. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If one or more of these or other risks or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual
results may vary materially from what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by this &#147;Safe Harbor&#148;
Statement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_1"></A>Item&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>BUSINESS</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Galena is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. We are pursuing the
development of novel cancer therapeutics using peptide-based immunotherapy products, including our main product candidate, NeuVax</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (E75), for the treatment of breast cancer and other tumors. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate
HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>; Genentech/Roche). On
January&nbsp;19, 2012, we initiated enrollment in our Phase&nbsp;3 PRESENT clinical trial for NeuVax&#153; (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence
(Clinicaltrials.gov identifier NCT01479244). The PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study is a randomized, multicenter, multinational clinical
trial that will enroll approximately 700 breast cancer patients. The trial design has been updated to include current National Comprehensive Cancer Network (&#147;NCCN&#148;) guidelines and has received Special Protocol Assessment, or
&#147;SPA,&#148; concurrence from the U.S. Food and Drug Administration, or &#147;FDA.&#148; The Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival, or &#147;DFS.&#148; The FDA has agreed in the SPA that the design and
planned analysis of the Phase 3 PRESENT study is adequately designed to provide the necessary data that, depending upon the outcome, could support a regulatory submission for marketing approval. We previously reported the Phase 2 trial data in which
none of the Phase 3 targeted low-to-intermediate, node-positive patients treated with the optimal regimen had experienced a relapse after 36 months of treatment. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also plan to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. We previously
reported a Phase 2 trial of sequential therapy with trastuzumab followed by HER2 vaccination in the adjuvant setting. Of 62 patients who received standard-of-care trastuzumab, the 32 who received no NeuVax vaccine experienced a 12.5% breast cancer
recurrence rate (4/32), which is comparable to reported rates of similarly staged and treated patients. In contrast, none (0%) of the 30 patients who received the NeuVax vaccine following trastuzumab therapy experience a recurrence. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our second product candidate, Folate Binding Protein-E39 (FBP), is a targeted vaccine, consisting of the peptides E39 and J65, aimed at
preventing the recurrence of ovarian, endometrial, and breast cancers. On February&nbsp;14, 2012, we announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein
has very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We acquired Apthera and our NeuVax product candidate in April 2011. Prior to that time, we were engaged primarily in conducting discovery
research and preclinical development activities based on RNA interference, or &#147;RNAi,&#148; a naturally occurring cellular mechanism that has the potential to effectively and selectively interfere with, or &#147;silence,&#148; expression of
targeted disease-associated genes. Our acquisition of Apthera followed from the determination by our board of directors to broaden our strategic direction by giving us access to a late-stage product candidate, NeuVax. In connection with our
acquisition of Apthera, we reduced the scope of our RNAi activities to focus primarily on RXI-109, our lead RNAi-product, while maintaining our key development alliances and core RNAi discovery and development capability. Following the Apthera
acquisition, our board of directors undertook to explore strategic alternatives for our RNAi platform that would enable us to commit more resources to our later-stage oncology drug programs. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;24, 2011, we contributed to a new wholly-owned subsidiary formed by us for this purpose substantially all of our
RNAi-related technologies and assets and entered into a number of agreements relating to RXi&#146;s ongoing business and operations. Our new subsidiary, which assumed the RXi name, will focus solely on developing and commercializing therapeutic
products based on RNAi technologies for the treatment of human diseases, including fibrotic disease, with financing provided by institutional investors in RXi. In the agreements, we have agreed, among other things, to undertake to distribute to our
stockholders a portion of our shares of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
common stock of RXi, which we sometimes refer to as the &#147;partial spin-off&#148; of RXi. See &#147;Recent Developments,&#148; below, for information on the status of the partial spin-off of
RXi, and &#147;RXi&#146;s RNAi Program,&#148; below, for a summary of RXi&#146;s current research and development activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Oncology
Therapeutic Programs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The chart below summarizes the current status of our oncology drug development programs, with the
dark shading indicating completed stages of development and the light shading indicating development activities we intend to prioritize in the near-term: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g275067g35o58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing a pipeline of immunotherapy product candidates for the treatment of various cancers
based on the E75 peptide, the most advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who
have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). We recently initiated our Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer
recurrence in early-stage low-to-intermediate HER2 breast cancer patients. For the results of a single trial to support registration for an indication, the results of the trial must be internally consistent, clinically meaningful, and statistically
very persuasive. Specifically, FDA has indicated that, in general, the results from two Phase 3 studies would be required to support approval, and it would accept a single pivotal study in support of approval if the results of the trial was
internally consistent, clinically meaningful and statistically very persuasive. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax is an immunotherapy that stimulates the
immune system to actively seek out and selectively kill cancer cells. NeuVax directs &#147;killer&#148; T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic,
colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to
stimulate and activate components of the immune system such as macrophages and dendritic cells. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax has been shown to be
most effective in patients with low-to-intermediate HER2/neu expressing patients with HLA type A2+ or A3+. We believe that approximately 25,000-40,000 of the approximately 200,000 women diagnosed with breast cancer in the United States each year
meet these criteria. We believe that NeuVax&#146;s specificity provides for a highly targeted therapy to prevent breast cancer recurrence for a selected subset of breast cancer patients and we believe it will increase the chance of the patient
remaining disease free following a successful treatment for these patients. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also developing novel
applications for NeuVax based on preclinical studies and Phase 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein.
Based on these results, in 2012 we will commence a randomized, multicenter Phase 2 trial in 300 patients that will compare NeuVax with trastuzumab versus trastuzumab alone. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also are pursuing additional therapeutic indications for NeuVax that
are currently in Phase 1/2 clinical trials. Under our investigational new drug application, or &#147;IND,&#148; open protocols for the treatment of prostate cancer, ovarian cancer and bladder cancer exist for patient populations with the same
general criteria for eligibility as in breast cancer (<I>i.e.</I>, early-stage disease and adjuvant treatment setting after surgery with immunologic competence). An early stage clinical study in high-risk prostate cancer confirmed the ability of the
patients to mount an E75 specific immune response. We may explore whether NeuVax provides clinical benefits in other areas, such as a prophylactic vaccine against breast cancer occurrence in healthy women with a high likelihood for developing breast
cancer based on genetic assays or biomarkers and a strong positive familial history of breast cancer, and in HER2 overexpressing gastric cancer. Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is approved for this indication, and there is a significant clinical rationale for NeuVax&#146;s potential efficacy in this indication. We also may investigate the
use of NeuVax in combination with other therapies with a view to leveraging NeuVax&#146;s attractive safety profile and targeted mechanism of action. Clinical trials conducted on NeuVax have provided proof-of-principle data in early-stage
node-negative breast cancer, although such data is preliminary and not statistically significant, since the trials were not designed to provide statistically significant efficacy data. Both the early-stage node-negative breast cancer indication and
the high-risk patient indication are longer-term areas of interest that we currently expect to explore only with support from corporate partners. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Developments </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September 24, 2011, we contributed to RXi
substantially all of our RNAi-related technologies and assets and entered into a securities purchase agreement with Tang Capital Partners, LP and RTW Investors, LLC, which we sometimes refer to as the &#147;RXi investors,&#148; and other agreements
relating to the financing and other aspects of the subsidiary&#146;s ongoing business and operations. RXi will focus on developing and commercializing therapeutic products based on RNAi technologies for the treatment of human diseases, including its
lead anti-scarring and anti-fibrosis product candidate, RXI-109. In these agreements, we committed, among other things, to undertake to distribute to our stockholders a portion of the RXi common stock held by Galena, which we sometimes refer to in
this annual report the &#147;partial spin-off of RXi.&#148; To date, RXi&#146;s activities have consisted of completing its organizational activities, acquiring our RNAi-related assets and entering into the agreements described in detail in our
Current Reports on Form 8-K filed with the SEC on September 26, 2011 and September 27, 2011, respectively, and furthering the development of RXI-109 in preparation for RXi&#146;s recent submission to the FDA of an IND for RXI-109. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;27, 2012 we announced, as required by NASDAQ Listing Rule 5250(e)(6), that our board of directors had declared a
conditional dividend on Galena common stock of one share of common stock of RXi for each outstanding share of Galena common stock. The spin-off shares will be payable, subject to certain conditions described below, to our stockholders as of close of
business (Eastern time) on March 8, 2012, the record date for the distribution, in the ratio of one RXi share for each share of Galena common stock held as of the record date. In light of the conditional nature of the partial spin-off of RXi, our
board of directors has not set a payment date for the distribution, and under NASDAQ rules our common stock is not yet trading &#147;ex-dividend.&#148; The distribution of the spin-off shares will be taxable to Galena stockholders who receive RXi
shares in the distribution. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution to Galena stockholders of the shares of common stock of RXi, which we sometimes
refer to as the &#147;spin-off shares<B>,</B>&#148; is to be made pursuant to the registration statement filed by RXi with the Securities and Exchange Commission and declared effective on February 14, 2012. Because the RXi registration statement
will go &#147;stale&#148; on April 30, 2012, we must complete the distribution of the spin-off shares by that date, unless we were to cause RXi to amend the registration statement. It is likely that we would abandon the partial spin-off of RXi if
the distribution of the spin-off shares has not been made by April&nbsp;30, 2012, although our board of directors has not made any decision in this regard. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The establishment of a payment date for the distribution and the payment of the distribution is dependent upon the timing of effectiveness of an application filed with the Financial Industry Regulatory
Authority, or &#147;FINRA,&#148; to permit RXi common stock to be traded in the OTC Markets Group under the symbol &#147;RXII.&#148; The payment of the distribution also is conditioned upon the closing of the RXi financing, which is subject to
certain closing conditions that may or may not be satisfied. In addition, the securities purchase agreement among Galena, RXi and the RXi investors provides that the agreement may be unilaterally terminated by us or by the RXi investors if the
closing of the transactions has not occurred by March&nbsp;31, 2012, and it is not possible for the clos-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ing to occur by this date. Accordingly, unless this date is extended by mutual agreement of the RXi investors and us, either we or the RXi investors generally may terminate the securities
purchase agreement at any time after March 31, 2012, unless the failure of the closing to occur was due to the fault of the party seeking to terminate the securities purchase agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we have no present intention to terminate the securities purchase agreement or to abandon the partial spin-off of RXi, the RXi
investors may choose to do so. We also may decide to do so at any time if our board of directors determines that it is in the best interests of our company. For all of the foregoing reasons, there is no assurance that the payment and distribution of
the spin-off shares will be completed. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For a discussion of the risks and uncertainties relating to the partial spin-off of
RXi, see the &#147;Risk Factors - Risks Relating to the Spin-Off&#146; section of this annual report. We have been sued in connection with the contribution and spin-off transactions by some of the holders of our outstanding warrants. See &#147;Risk
Factors - Risks Relating to Our Financial Position and Capital Requirements - <I>We have been sued by some of our warrant holders, and we could be found liable to repurchase their warrants</I>.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RXi&#146;s RNAi Program </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXI-109, RXi&#146;s first RNAi product candidate, is a dermal anti-scarring therapy that targets connective tissue growth factor, or
&#147;CTGF,&#148; and that may inhibit connective tissue formation in human fibrotic disease. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Data
obtained from preclinical studies of RXi&#146;s sd-rxRNA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> compounds in preliminary preclinical models using
local administration to the skin have shown robust delivery and effective target gene silencing. RXi has targeted filing an IND application and commencing clinical trials of RXI-109 in 2012. If clinical studies of RXI-109 produce successful results
in anti-scarring, we understand that RXi may explore opportunities in other dermatology applications and other anti-fibrotic indications, possibly including pulmonary fibrosis, liver fibrosis, acute spinal cord injury, ocular scarring and
restenosis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Condition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We had cash and cash equivalents of approximately $11.4 million as of December&nbsp;31, 2011. We had cash and cash equivalents of approximately $8.2 million as of March&nbsp;26, 2012. On February&nbsp;17,
2012, we entered into a Controlled Equity Offering</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> sales
agreement with Cantor Fitzgerald&nbsp;&amp; Co. (&#147;Cantor&#148;), pursuant to which we may offer and sell from time to time through Cantor, acting as agent, shares of our common stock, $0.0001 par value per share, having an aggregate offering
price of up to $10 million. The offer and sale of our shares through Cantor will be registered pursuant to our Registration Statement on Form S-3 (File No.&nbsp;333-167025) declared effective by the Securities and Exchange Commission (the
&#147;SEC&#148;) on May&nbsp;21, 2010 and is described in detail in the related prospectus supplement dated February&nbsp;17, 2012 filed with the SEC and the prospectus dated May&nbsp;21, 2010 included as part of our Registration Statement.<B>
</B>The offering pursuant to the sales agreement will terminate upon the sale of all shares subject to the sales agreement or the earlier termination of the sales agreement as permitted therein. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the sales agreement, Cantor may sell shares of our common stock by any method permitted by law deemed to be an
&#147;at-the-market&#148; offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, but not limited to, sales made directly on The NASDAQ Capital Market, on any other existing trading market for our common stock or to or
through a market maker. Cantor may also sell our shares under the sales agreement by any other method permitted by law, including in privately negotiated transactions. Cantor has agreed in the sales agreement to use its commercially reasonable
efforts to sell shares in accordance with our instructions (including any price, time or size limit or other customary parameters or conditions we may impose). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe that our existing cash and cash equivalents and the proceeds from the sales agreement should be sufficient to fund our operations through at least the first quarter of 2013. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not generated revenue to date and may not generate product revenue in the foreseeable future, if ever. We expect to incur
significant operating losses as we advance our product candidates through the drug development and regulatory process. We expect to continue to devote a substantial portion of our resources to research and development programs. As a result of the
costs expected to be incurred in connection with our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
recently commenced clinical trials of NeuVax and FBP, we expect that our research and development expense will increase significantly from historic levels for the foreseeable future. We will need
to generate significant revenue to achieve profitability and might never do so. In the absence of product revenue, our potential sources of operational funding are expected to be the proceeds from equity financings, funded research and development
payments and payments received under partnership and collaborative agreements. There is no guarantee that additional funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be
forced to scale back or terminate our operations, or to seek to merge with or to be acquired by another company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Information
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing
major unmet medical needs using targeted biotherapeutics. We are pursuing the development of novel cancer therapeutics using peptide-based immunotherapy products, including our main product candidate, NeuVax<B>&#153;</B> (E75), for the treatment of
various cancers. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our principal executive offices are located at 310 N. State Street, Suite 208, Lake Oswego, Oregon 97034, and
our phone number is (855)&nbsp;855-4253. Our website address is www.galenabiopharma.com. We do not incorporate the information on our website into this annual report, and you should not consider such information part of this annual report.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated as Argonaut Pharmaceuticals, Inc. in Delaware on April&nbsp;3, 2006 and changed our name to RXi
Pharmaceuticals Corporation on November&nbsp;28, 2006. On September&nbsp;26, 2011, we changed the name of our company from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc., as described under &#147;Recent Developments&#148; above.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Competitive Strengths </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe we are well positioned to compete successfully in the cancer immunotherapy markets due to the following competitive strengths: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, we began our Phase&nbsp;3 PRESENT clinical trial of our lead product candidate, NeuVax, for low-to-intermediate HER2-expressing breast
cancer patients not eligible for Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2012, we initiated Phase 1/2 clinical trials of our second product candidate, Folate Binding Protein-E39 (FBP) in two gynecological
cancers: ovarian and endometrial adenocarcinomas; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2012, we will commence our Phase 2 trial comparing NeuVax in combination with Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (trastuzumab) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our accomplished scientific and business team has significant experience in building and managing emerging life sciences companies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our scientific advisors are recognized leaders in research, including Dr.&nbsp;George Peoples, Chief of Surgical Oncology at San Antonio Military
Medical Center in Houston, Texas and the Director and Principal Investigator of the Cancer Vaccine Development Program at Uniformed Services University of the Health Sciences in Bethesda, Maryland; and David&nbsp;A. Scheinberg, M.D., Ph.D., to
Memorial Sloan-Kettering Cancer Center&#146;s Vincent Astor&#146;s chair and chair of the Molecular Pharmacology and Chemistry Program in the Sloan-Kettering Institute, founder and Chair of the Experimental Therapeutics and Nanotechnology Centers at
Memorial Sloan-Kettering and a member of the Leukemia Service; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are focused on unmet medical needs representing significant market opportunities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of NeuVax </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NeuVax is a cytotoxic T-cell activating, epitope-specific immunotherapy comprised of a peptide called E75 and an immune adjuvant called GM-CSF (sargramostim). E75 is derived from HER2, a 185-Kd
transmembrane glycoprotein that is part of the epidermal growth factor (&#147;EGF&#148;) family of tyrosine kinases. GM-CSF is recombinant human granulocyte-macrophage colony stimulating factor, a stimulator and activator of
macro-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">
phages and dendritic cells. HER2 is expressed at very low levels in a number of normal epithelial tissues but is amplified and overexpressed in many epithelial tumors. HER2/neu is key to growth
of cancer and has proven to be a profitable target for such drugs as Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Tykerb. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials have shown that NeuVax boosts a pre-existing immune response found in most cancer patients. Its active component, the
9-amino acid peptide, E75 (derived from amino acids 369-377 in the extracellular domain of the HER2 protein), is the synthetic version of an epitope recognized by cytotoxic T-lymphocytes (&#147;CTLs&#148;) and was originally found in
tumor-infiltrating lymphocytes of breast and ovarian cancer patients. In contrast to previous clinical studies with peptides, E75 induces a 1,000-fold increased T-cell response; typically 1-2% of circulating T-cells become reactive to the E75
peptide. Such E75-reactive T-cells are therapeutically active as measured by a reduction in disease recurrence in early-stage breast cancer patients. Figure 1 below shows the 24-month follow-up data for all patients treated during the Phase 2
clinical trial, including both node positive and node negative patients, HER2 1+, 2+, and 3+ patients, as well as optimally dosed and sub-optimally dosed. The Kaplan-Meier Disease Free Survival rate improved for the patients receiving NeuVax (N=106)
compared to the control group (N=76). An even greater improvement can be seen when we focus on Phase 2 patients who meet the proposed Phase 3 clinical protocols (<I>i.e.</I>, node-positive, low and intermediate HER2+ expressor, optimally-dosed
patients) (N=18) compared to the control (N=27). Figure 2, below, shows the 24-month follow-up data for such patients, and the results are statistically significant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Figure 1 &#151; Kaplan-Meier Disease-Free Survival for All Patients </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px">


<IMG SRC="g275067g72o39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Figure 2 &#151; Kaplan-Meier Disease-Free Survival for Node-Positive Low-Expressor Optimally-Dosed Patients
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px">


<IMG SRC="g275067g33o37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Another potential significant advantage of NeuVax is that the process to manufacture it is relatively
simple and can be accomplished using standard peptide synthesis techniques and automated methods. This results in cost of goods that are potentially significantly lower than both antigen-specific and polyvalent/whole-cell vaccines, which have
increasingly complex manufacturing schemes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Along with our research collaborators, we have developed this therapy using a treatment
approach that focuses on treating early-stage cancer patients with no/low tumor burden and relatively healthy immune systems compared to patients with advanced/metastatic disease. Also, we intend to use a clinical trial endpoint focused on disease
recurrence and disease-free survival in its Phase 3 trial for breast cancer as the basis for conditional approval of NeuVax rather than an overall survival endpoint. In contrast, cancer vaccines to date have been evaluated in patients with
advanced/metastatic disease, resulting in equivocal survival data in clinical trials and several clinical development failures. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax has been evaluated in Phase 1/2 clinical trials in early-stage breast cancer patients and a Phase 1/2 trial in prostate cancer
patients at high risk for disease recurrence. On January&nbsp;19, 2012, we initiated our PRESENT trial for NeuVax&#153; (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2expressing breast cancer patients (often referred to as HER2
negative) in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment)
study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The trial design has been updated to include current National Comprehensive Cancer Network (&#147;NCCN&#148;) guidelines and
has received Special Protocol Assessment, or &#147;SPA,&#148; concurrence from the U.S. Food and Drug Administration, or &#147;FDA.&#148; Based on a previous Phase 2 trial of NeuVax that achieved its primary endpoint of disease-free survival, or
&#147;DFS,&#148; the FDA has agreed in the SPA that the design and planned analysis of the Phase 3 PRESENT study is adequately designed to provide the necessary data that, depending upon the outcome, could support a regulatory submission for
marketing approval. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to breast cancer, we intend to further develop NeuVax for the treatment of prostate cancer
patients at high risk for disease recurrence, as well as for other solid tumor types that express HER2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Market
Opportunity for NeuVax </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax targets a significant unmet medical need and blockbuster market
opportunity. There are approximately 230,000 cases of invasive breast cancer diagnosed in the United States every year, by far, the most commonly diagnosed malignancy in women. Of these women, about 70-80% test positive for HER2 (IHC 1+, 2+ or 3+),
but only 20-30% of all breast cancer patients, those with HER2 3+ disease, are eligible for Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
(trastuzumab; Roche-Genentech). Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> revenues totaled more than $5.5 billion in 2011, with approximately
$4.5 billion from U.S. sales due to its use in the adjuvant setting. NeuVax targets the remaining 50% of HER2 positive patients (HER2 1+ and 2+) who achieve remission with current standard of care, but have no available HER2 targeted adjuvant
treatment options to maintain their disease-free status. Based on the Phase 3 target patient population, the target market for NeuVax is approximately 35,000-40,000 patients annually. <I></I><B><I></I></B><I></I> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NeuVax Target Market </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g275067g17q90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Introduction to the Field of RNAi Therapeutics </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following the planned partial spin-off of RXi, RXi will continue to develop novel RNAi-based therapies. RNAi is a naturally occurring
phenomenon where short double-stranded RNA molecules interfere with the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
expression of targeted genes. RNAi technology takes advantage of this phenomenon and potentially allows us to effectively interfere with particular genes within living cells by designing
RNA-derived molecules targeting those genes. RNAi is regarded as a significant advancement in the scientific community, as evidenced by the journal Science&#146;s selection of RNAi as the &#147;Breakthrough of the Year&#148; in 2002 and by the
awarding of the 2006 Nobel Prize in Medicine to the co-discoverers of RNAi, including Dr.&nbsp;Craig Mello, a founder of the Company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">RNAi offers a novel approach to the drug development process because, as described below under &#147;The RNAi Mechanism,&#148; RNAi compounds can potentially be designed to target any one of the thousands
of human genes, many of which are undruggable by other modalities. In contrast, an article published in the December 2005 edition of Drug Discovery Today, by Andreas P. Russ and Stefan Lampel, reported that only a subset of the proteins encoded in
the human genetic code (human genome) are able to be targeted efficiently by traditional medicinal chemistry or antibody-based approaches. The specificity of RNAi is achieved by an intrinsic well-understood biological mechanism and potential
therapeutic RNAi compounds can be designed to target the sequence of a disease-causing gene and take advantage of this mechanism. According to studies cited in Nature Review of Drug Discovery, the specificity of RNAi may be sufficient to permit
therapeutic targeting of only a single gene, and may even selectively reduce or eliminate expression from a single abnormal copy of a gene while preserving expression from a normal copy (&#147;allele-specific&#148; targeting). This is critical in
diseases such as cancer and neurodegenerative disorders that are often caused by abnormal copies of genes. In one study cited, for example, an siRNA was introduced into the cell and the specificity of silencing was evaluated using microarray
analysis. According to the article, each siRNA silenced the intended target to the highest extent guided by sequence homology and other, non-targeted genes were not significantly altered. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>The RNAi Mechanism </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The genome is made of a double-strand of DNA (the
double helix) that acts as an instruction manual for the production of the roughly 30,000 to 50,000 human proteins. Proteins are important molecules that allow cells and organisms to live and function. With rare exceptions, each cell in the human
body has the entire complement of genes. However, only a subset of these genes directs the production of proteins in any particular cell type. For example, a muscle cell produces muscle-specific protein, whereas a skin cell does not. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order for a gene to guide the production of a protein, it must first be copied into a single-stranded chemical messenger (messenger RNA
or mRNA), which is then translated into protein. RNAi is a naturally occurring process by which a particular messenger RNA can be destroyed before it is translated into protein. The process of RNAi can be artificially induced by introducing a small
double-stranded fragment of RNA corresponding to a particular messenger RNA into a cell. A protein complex within the cell called RISC (RNA-Induced Silencing Complex) recognizes this double-stranded RNA fragment and splits the double-strands apart,
retaining one strand in the RISC complex. The RISC then helps this guide strand of RNA bind to and destroy its corresponding cellular messenger RNA target. Thus, RNAi provides a method to potentially block the creation of the proteins that cause
disease. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since gene expression controls most cellular processes, the ability to inhibit gene expression provides a potentially
powerful tool to treat human diseases. Furthermore, since the human genome has already been decoded, and based on numerous gene-silencing reports, we believe that RNAi compounds can readily be designed to interfere with the expression of any
specific gene. Based on our internal research and our review of certain scientific literature, we also believe that our RNAi platform may allow us to develop therapeutics with significant potential advantages over traditional drug development
methods, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">high specificity for targeted genes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">high potency (low doses); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ability to interfere with the expression of potentially any gene; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">accelerated generation of lead compounds; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">low toxicity, natural mechanism of action. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RXi&#146;s RNAi Therapeutic Platform </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RNAi Compound Design </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">RNAi compounds are made from a strand or strands of RNA or modified RNA that are manufactured by a nucleic acid synthesizer. The synthesizer is programmed to assemble a strand of RNA of a particular
sequence using the four kinds of nucleotide units (Adenine (&#147;A&#148;), Uracil (&#147;U&#148;), Cytidine (&#147;C&#148;) and Guanosine (&#147;G&#148;)) that match a small segment of the targeted gene. The hallmark of an RNAi compound is that it
has a double stranded region. The compounds can be of various lengths of nucleotide units (nt). The two strands can have overhangs, or they can have blunt ends. A single strand can form an RNAi compound by forming a structure referred to as a
hairpin. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The length and shape of the compound can affect the activity and hence the potency of the RNAi in cells. The first
design of RNAi compounds to be pursued for development as a human therapeutic was a short double-stranded RNA that included at least one overhanging single-stranded region, known as small interfering RNA, or siRNA, which we also refer to as classic
siRNA. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the case of classic siRNA, double-stranded RNA with single-stranded overhangs is used. We believe that classic
siRNAs have drawbacks that may limit the usefulness of those agents as human therapeutics, and that we may be able to utilize the technologies we have licensed and developed internally to optimize RNAi compounds for use as human therapeutic agents.
It is the combination of the length, the nucleotide sequence and the configuration of chemical modifications that are important for effective RNAi therapeutics. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our internal research leads us to believe that next generation rxRNA compounds offer significant advantages over classic siRNA used by other companies developing RNAi therapeutics, highlighted by the
following characteristics: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potent RNAi activity; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">more resistant to nuclease degradation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">readily manufactured; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially more specific for the target gene; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">more reliable at blocking immune side effects than classic siRNA; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of sd-rxRNA, the unique ability to be &#147;self-delivering,&#148; without the need for any additional delivery vehicle.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on our own research, we have developed a variety of novel siRNA configurations with potential
advantages for therapeutic use. The first of these has been termed rxRNA ori. This configuration has some similarities to classic siRNA in that it is composed of two, short RNA strands. We have found that by using a somewhat longer length (25-29
bp), removing the overhangs and using proprietary chemical modification patterns we achieve a higher hit rate of very potent (picomolar potency) compounds in a given target sequence. These rxRNA ori compounds are modified to increase resistance to
nucleases and to prevent off-target effects including induction of an immune response. These novel RNAi compounds are distinct from the siRNA compounds used by many other companies developing RNAi therapeutics in that they are designed specifically
for therapeutic use and offer many of the properties that we believe are important to the clinical development of RNAi-based drugs. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The second novel configuration has been called &#147;sd-rxRNA&#148; to indicate its novel &#147;self-delivering&#148; properties which do not require additional delivery vehicles for efficient cellular
uptake and RISC-mediated silencing. A combination of at least three characteristics is required for activity: (1)&nbsp;specific, proprietary chemical modifications; (2)&nbsp;a precise number of chemical modifications; and (3)&nbsp;reduction in
oligonucleotide content. Kinetic analyses of fluorescently-labeled compounds demonstrate that efficient cellular internalization is observed within minutes of exposure. These molecules are taken up efficiently and cause target gene silencing in
diverse cell types (cell lines and primary cells). This novel class of RNAi compounds may afford a broad opportunity for therapeutic development. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that both chemical modification and formulation of RNAi compounds may be utilized
to develop RNA drugs suitable for therapeutic use. The route by which an RNAi therapeutic is brought into contact with the body depends on the intended organ or tissue to be treated. Delivery routes can be simplified into two major categories:
(1)&nbsp;local (when a drug is delivered directly to the tissue of interest); and (2)&nbsp;systemic (when a drug accesses the tissue of interest through the circulatory system). Local delivery may avoid some hurdles associated with systemic
approaches such as circulation clearance and tissue extravasation (crossing the endothelial barrier from the blood stream). However, the local delivery approach can only be applied to a limited number of organs or tissues (<I>e.g.</I>, skin, eye,
lung and potentially the central nervous system). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key to therapeutic success with RNAi lies in delivering intact RNAi
compounds to the target tissue and the interior of the target cells. To accomplish this, we have developed a comprehensive platform that includes local, systemic and oral delivery approaches. We work with chemically synthesized RNAi compounds that
are optimized for stability and efficacy and combine delivery at the site of action and formulation with delivery agents to achieve optimal delivery to specific target tissues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Local Delivery </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">sd-rxRNA molecules have unique properties which improve
tissue and cell uptake. Delivery of sd-rxRNA by a local route of administration may avoid hurdles associated with systemic approaches such as rapid clearance from the bloodstream and inefficient extravasation (<I>e.g.</I>, crossing the endothelial
barrier from the blood stream). We have studied sd-rxRNA molecules in a rat model of dermal delivery. Administration of sd-rxRNA by intradermal injection with no additional delivery vehicle demonstrates that target gene silencing can be measured
after direct delivery to the skin. The dose levels required for these direct injection methods are small and suitable for clinical development suggesting that local delivery indications will be very accessible with the sd-rxRNA technology platform.
Additional target tissues that are potentially accessible by local delivery using sd-rxRNA compounds include lung, eye, CNS, mucosal tissues and tumors (direct administration). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Systemic Delivery </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Systemic delivery occurs when a drug accesses the tissue
of interest through the circulatory system. In some cases, such as in targeting a treatment to the liver, the optimal route of delivery may be by a systemic route. We have developed a portfolio of systemic delivery solutions utilizing our RNAi
therapeutic platforms. One novel approach involves the use of sd-rxRNA compounds. The self-delivering technology introduces properties required for in vivo efficacy such as cell penetration and improved blood clearance and distribution properties.
Systemic delivery of these compounds to mice has resulted in gene specific inhibition with no additional delivery vehicle required. In addition, we have developed novel nanotransporter formulations to aid in transport of RNAi compounds to both liver
and various other target tissues in the body. These nanotransporters are chemically-synthesized compounds that form nanometer-sized particles when mixed with RNAi compounds and alter the clearance, distribution and tissue penetration properties of
the RNAi compounds. Delivery of RNAi compounds to the liver might be critical for the treatment of many diseases and using rxRNA or sd-rxRNA in conjunction with such delivery vehicles has enabled us to demonstrate gene specific inhibition in a mouse
model after intravenous, systemic delivery. Target tissues that are potentially accessible using rxRNA compounds by systemic delivery include liver, lung, adipocytes, cardiomyocytes, bone marrow, sites of inflammation, tumors, vascular endothelium
and kidney. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Alliance Partners in Therapeutic Areas </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are actively seeking to leverage our technology platforms by seeking to work with pharmaceutical and biotechnology partners in the partners&#146; fields of interest. Our team has experience targeting
genes in virtually every major therapeutic area, and based on this experience, we believe we can discover many more drug candidates by working with partners than we can develop with our own resources. We are seeking to work with partners in the
discovery and development of drugs in a number of therapeutic areas. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patents and Patent Applications </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Galena-related Patents and Patent Applications </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Galena exclusively licenses from the University of Texas an issued US patent covering the E75 peptide contained in NeuVax as a composition of matter. The patent expires in 2015 and was not filed outside
the US. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena also is actively prosecuting two patent families, including 13 pending applications,
exclusively licensed from Henry Jackson Foundation covering particular uses of E75. The first family claims methods of using E75 to induce immunity against breast cancer recurrence, and was filed the United States, Australia, Canada, China, Europe,
Japan, Korea and Mexico. The applications in the United States and Mexico were recently allowed and are expected to issue in 2012. Once issued, these patents are expected to expire in 2028, not including any patent term extensions. The second family
claims methods of using E75 in combination with trastuzumab (Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) as a vaccine, and was filed in the
United States, Australia, Canada, Europe and Japan. The Australian application was recently allowed and is expected to issue in 2012. Once issued, this patent is expected to expire in 2026, not including any patent term extensions. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena also exclusively licenses from the Henry Jackson Foundation a patent family covering folate binding peptide variants, including the
lead product candidate, and their use alone or combination as a vaccine. Patents have issued in issued in the United States, Canada and Japan, and there are pending applications in the United States, Europe and Japan. Patents in this family are
expected to expire in 2022, not including patent term extensions. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RNAi-related Patents and Patent Applications
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi is actively prosecuting 13 patent families, including four pending PCT patent applications and nine patent
families that have entered national stage. The nine patent families that have entered national stage include ten (including one continuation-in-part application) United States, four Canadian, two Chinese, four European, and five Japanese pending
patent applications. Our portfolio does not include any issued patents. The patent applications encompass what we believe to be important new compounds and their use as therapeutics in RNAi, chemical modifications of RNAi compounds that improve the
compounds&#146; suitability for therapeutic uses (including delivery) and compounds directed to specific targets (i.e., that address specific disease states). Any patents that may issue from these pending patent applications will be set to expire
between 2028 and 2031, not including any patent term extensions that may be afforded under the Federal Food, Drug and Cosmetic Act (and the equivalent provisions in foreign jurisdictions) for any delays incurred during the regulatory approval
process relating to human drug products (or processes for making or using human drug products). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>License Agreements
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Immunotherapy-related Licenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We acquired exclusive and non-exclusive rights to develop NeuVax for the treatment of cancer by licensing key patent rights from third parties. These rights include composition of matter on E75, the
active peptide component of NeuVax, and methods of use thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Board of Regents, University of Texas and Henry
Jackson Foundation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We obtained an exclusive license from the University of Texas through our Patent and Technology License
Agreement with The Board of Regents of the University of Texas System (the &#147;Texas License&#148;). The Texas License provides an exclusive right to use the E75 peptide in humans for therapeutic purposes, under Issued U.S. Patent
No.&nbsp;6,514,942, titled &#147;Methods and Compositions for Stimulating T-lymphocytes.&#148; This patent expires in 2015, without taking into account any patent extensions that may be available, and we do not expect to commence commercialization
of NeuVax prior to 2017, if at all. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have also secured an exclusive license to practice the inventions described in PCT
Published Patent Application WO/2008/15057, titled &#147;Vaccine for the Prevention of Breast Cancer Relapse&#148; from the Henry Jackson Foundation. National applications have been filed in the United States, Australia, Canada, China, Europe,
Japan, Korea and Mexico. The applications in the United States and Mexico were recently allowed and are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
expected to issue in 2012. These applications provide protection on improved methods for inducing immunity against breast cancer recurrence using the E75 peptide as identified in clinical trials.
Patents in these countries, if issued, would be expected to expire in 2028, not including any patent term extensions. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also have an exclusive license from the Henry Jackson Foundation to practice the inventions described in PCT Published Patent Application WO/2007/030771, titled &#147;Targeted Identification of
Immunogenic Peptides&#148;, insofar as they cover the use of E75 in combination with trastuzumab (Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) as
a vaccine. National applications have been filed in the United States, Australia, Canada, Europe and Japan. The Patents in these countries, if issued, would be expected to expire in 2026, not including any patent term extensions. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The issued United States patent and any patents that may issue from the licensed or pending patent applications will be set to expire
between 2015 for our composition of matter patent and we have no equivalent protection outside of the United States and 2026 and 2028 for other patent applications covering methods of treating cancer patients, not including any patent term
extensions. In connection with the Texas License, we are obligated to pay specified milestones and royalties on sales of products covered by the licensed patents, including royalties possibly extending beyond the expiration date of a patent.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are preparing to apply for Orphan Drug status for NeuVax, which, if granted, could provide seven years of market
exclusivity in the United States and ten years of market exclusivity in Europe. We also anticipate that NeuVax will qualify for 12 years of data exclusivity under the Patient Protection and Affordable Care Act. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we have an exclusive license from the Henry Jackson Foundation to practice the inventions described in PCT Published Patent
Application WO/2002/072766, titled &#147;Induction of Tumor Immunity by Variants of Folate Binding Proteins&#148;, covering folate binding peptide variants and their use alone or in combination as a vaccine. The patent, if issued, would be expected
to expire in 2022, not including any patent term extensions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RNAi-related Licenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi has secured exclusive and non-exclusive rights to develop RNAi therapeutics by licensing key RNAi technologies and patent rights from
third parties. These rights relate to chemistry and configuration of RNAi compounds, delivery technologies of RNAi compounds to cells and therapeutic targets. As RXi continues to develop its own proprietary compounds, it continues to evaluate both
its in-licensed portfolio as well as the field for new technologies that could be in-licensed to further enhance RXi&#146;s intellectual property portfolio and unique position in the RNAi space. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>University of Massachusetts Medical School</I>.&nbsp;&nbsp;&nbsp;&nbsp;RXi holds a non-exclusive license from the University of
Massachusetts Medical School (&#147;UMMS&#148;). This license grants to RXi rights under certain UMMS patent applications to make, use and sell products related to applications of RNAi technologies in particular fields, including HCMV and retinitis,
amyotrophic lateral sclerosis, known as &#147;ALS&#148; or &#147;Lou Gehrig&#146;s Disease,&#148; diabetes and obesity. Throughout the term of the license, RXi must pay UMMS an annual maintenance fee of $15,000. RXi also will be required to pay to
UMMS customary royalties of up to 10% of (i)&nbsp;any future net sales of licensed products, (ii)&nbsp;income received from any sublicensees under this license, and (iii)&nbsp;net sales of commercial clinical laboratory services, subject to a
minimum royalty of $50,000 beginning in 2016. RXi also agreed to pay expenses incurred by UMMS in prosecuting and maintaining the licensed patents. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Dharmacon</I>.&nbsp;&nbsp;&nbsp;&nbsp;RXi holds a license agreement with Dharmacon, Inc. (now part of Thermo Fisher Scientific Inc.), pursuant to which RXi has an exclusive license to certain RNAi
sequences to a number of target genes for the development of its rxRNA compounds. Furthermore, RXi holds the right to license additional RNAi sequences, under the same terms, disclosed by Thermo Fisher Scientific Inc. in its pending patent
applications against target genes and has received an option for exclusivity for other siRNA configurations. As partial consideration for this license, RXi has agreed to pay future clinical milestone payments in an aggregate amount of up to
$2,000,000 and royalty payments of either 0.25% or 0.5% based on the level of any future sales of siRNA compositions developed in connection with the licensed technology. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Advirna</I>.&nbsp;&nbsp;&nbsp;&nbsp;RXi has entered into agreements with Advirna pursuant to which Advirna assigned to RXi its existing patent and technology rights related to sd-rxRNA technology in
exchange for RXi&#146;s agreement to pay Advirna an annual $100,000 maintenance fee and a one-time milestone payment of $350,000 upon the issuance </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the first patent with valid claims covering the assigned technology. Additionally, RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi with respect to
future licensing of the assigned Advirna patent and technology rights. RXi also agreed to grant back to Advirna a license under the assigned patent and technology rights for fields of use outside human therapeutics and diagnostics and to issue to
Advirna, upon the completion of the partial spin-off of RXi, shares of common stock equal to approximately 5% of RXi&#146;s outstanding common stock on a fully diluted basis assuming the conversion of all outstanding Series A Preferred Stock.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Immunotherapy-related Competition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have a number of competitors in the oncology immunotherapy field. These competitors include large and small pharmaceutical, chemical and biotechnology companies, as well as universities, government
agencies, and other private and public research organizations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A number of multinational pharmaceutical companies, as well as
large biotechnology companies, including Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc are pursuing the development or are currently marketing pharmaceuticals that target
oncology pathways on which we are focusing. It is probable that the number of companies seeking to develop products and therapies for the treatment of unmet needs in oncology will increase. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Anti-scarring and RNAi-related Competition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe numerous companies are investigating or plan to investigate a variety of proposed anti-scarring therapies in clinical trials. The companies include large and small pharmaceutical, chemical and
biotechnology companies, as well as universities, government agencies and other private and public research organizations. Such companies include Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz
Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics and Pharmaxon. In particular,
Excaliard Pharmaceuticals, Inc., which has been acquired by Pfizer, Inc., has successfully advanced an anti-CTGF antisense oligonucleotide through several Phase 1 and Phase 2 trials, demonstrating improved scar outcome over placebo. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe other companies working in the RNAi area, generally, include Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere
Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics
Inc. and Santaris, as well as a number of large pharmaceutical companies. Many other companies are pursuing non-RNAi-based therapies for one or more fibrotic disease indications, including ocular scarring or other indications that we may seek to
pursue. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most of these competitors have substantially greater research and development capabilities and financial, scientific,
technical, manufacturing, marketing, distribution and other resources than RXi, and RXi may not be able to successfully compete with them. In addition, even if RXi is successful in developing its product candidates, in order to compete successfully
RXi may need to be first to market or to demonstrate that its RNAi based products are superior to therapies based on different technologies. A number of RXi&#146;s competitors have already commenced clinical testing of RNAi product candidates and
may be more advanced than RXi is in the process of developing products. If RXi is not first to market or are unable to demonstrate superiority, any products for which RXi is able to obtain approval may not be successful. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The United States and other developed countries extensively regulate the preclinical and clinical testing, manufacturing, labeling,
storage, record-keeping, advertising, promotion, export, marketing and distribution of drugs and biologic products. The FDA regulates pharmaceutical and biologic products under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act
and other federal statutes and regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To obtain approval of our future product candidates from the FDA, we must, among other
requirements, submit data supporting safety and efficacy for the intended indication as well as detailed information on the manufacture and composition of the product candidate. In most cases, this will require extensive laboratory tests and
preclinical and clinical trials. The collection of these data, as well as the preparation of applications for review by the FDA involve significant time and expense. The FDA also may require post-marketing testing to monitor the safety and efficacy
of approved products or place conditions on any approvals that could restrict the therapeutic claims and commercial applications of these products. Regulatory authorities may withdraw product approvals if we fail to comply with regulatory standards
or if we encounter problems at any time following initial marketing of our products. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The first stage of the FDA approval
process for a new biologic or drug involves completion of preclinical studies and the submission of the results of these studies to the FDA. These data, together with proposed clinical protocols, manufacturing information, analytical data and other
information submitted to the FDA, in an IND, must become effective before human clinical trials may commence. Preclinical studies generally involve FDA regulated laboratory evaluation of product characteristics and animal studies to assess the
efficacy and safety of the product candidate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the IND becomes effective, a company may commence human clinical trials.
These are typically conducted in three sequential phases, but the phases may overlap. Phase 1 trials consist of testing the product candidate in a small number of patients or healthy volunteers, primarily for safety at one or more doses. Phase 2
trials, in addition to safety, evaluate the efficacy of the product candidate in a patient population somewhat larger than Phase 1 trials. Phase 3 trials typically involve additional testing for safety and clinical efficacy in an expanded population
at multiple test sites. A company must submit to the FDA a clinical protocol, accompanied by the approval of the Institutional Review Boards at the institutions participating in the trials, prior to commencement of each clinical trial. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To obtain FDA marketing authorization, a company must submit to the FDA the results of the preclinical and clinical testing, together
with, among other things, detailed information on the manufacture and composition of the product candidate, in the form of a new drug application, or NDA, or, in the case of a biologic, a biologics license application, or BLA. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount of time taken by the FDA for approval of an NDA or BLA will depend upon a number of factors, including whether the product
candidate has received priority review, the quality of the submission and studies presented, the potential contribution that the compound will make in improving the treatment of the disease in question, and the workload at the FDA. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may, in some cases, confer upon an investigational product the status of a fast track product. A fast track product is defined as
a new drug or biologic intended for the treatment of a serious or life threatening condition that demonstrates the potential to address unmet medical needs for this condition. The FDA can base approval of an NDA or BLA for a fast track product on an
effect on a surrogate endpoint, or on another endpoint that is reasonably likely to predict clinical benefit. If a preliminary review of clinical data suggests that a fast track product may be effective, the FDA may initiate review of entire
sections of a marketing application for a fast track product before the sponsor completes the application. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that
our products will be manufactured by our strategic partners, licensees or other third parties. Before approving an NDA or BLA, the FDA will inspect the facilities at which the product is manufactured and will not approve the product unless the
manufacturing facilities are in compliance with the FDA&#146;s current good manufacturing practice (&#147;cGMP&#148;), which are regulations that govern the manufacture, holding and distribution of a product. Manufacturers of biologics also must
comply with the FDA&#146;s general biological product standards. Our manufacturers also will be subject to regulation under the Occupational Safety and Health Act, the Nuclear Energy and Radiation Control Act, the Toxic Substance Control Act and the
Resource Conservation and Recovery Act and other applicable environmental statutes. Following approval, the FDA periodically inspects drug and biologic manufacturing facilities to ensure continued compliance with the good manufacturing practices
regulations. Our manufacturers will have to continue to comply with those requirements. Failure to comply with these requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing or recall or
seizure of product. Adverse patient experiences with the product must be reported to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
FDA and could result in the imposition of marketing restrictions through labeling changes or market removal. Product approvals may be withdrawn if compliance with regulatory requirements is not
maintained or if problems concerning safety or efficacy of the product occur following approval. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The labeling, advertising,
promotion, marketing and distribution of a drug or biologic product also must be in compliance with FDA and Federal Trade Commission requirements which include, among others, standards and regulations for off-label promotion, industry sponsored
scientific and educational activities, promotional activities involving the internet, and direct-to-consumer advertising. We also will be subject to a variety of federal, state and local regulations relating to the use, handling, storage and
disposal of hazardous materials, including chemicals and radioactive and biological materials. In addition, we will be subject to various laws and regulations governing laboratory practices and the experimental use of animals. In each of these
areas, as above, the FDA has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of product approvals, seize or recall products, and deny or withdraw approvals. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will also be subject to a variety of regulations governing clinical trials and sales of our products outside the United States. Whether
or not FDA approval has been obtained, approval of a product candidate by the comparable regulatory authorities of foreign countries and regions must be obtained prior to the commencement of marketing the product in those countries. The approval
process varies from one regulatory authority to another and the time may be longer or shorter than that required for FDA approval. In the European Union, Canada and Australia, regulatory requirements and approval processes are similar, in principle,
to those in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Environmental Compliance </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals and various radioactive compounds. We are subject
to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. We are also subject to numerous environmental, health and workplace safety laws and regulations,
including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials. The cost of compliance with these laws and regulations could be significant and may adversely affect capital expenditures
to the extent we are required to procure expensive capital equipment to meet regulatory requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Human Resources </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;1, 2012, the Company had 19 full-time employees, of whom 13 were engaged in research and development and six were engaged
in management, administration and finance. None of our employees are represented by a labor union or covered by a collective bargaining agreement, nor have we experienced any work stoppages. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;1, 2012, RXi had ten full-time employees, eight of whom were engaged in research and development and two of whom were
engaged in management, administration and finance. None of RXi&#146;s employees are represented by a labor union or covered by a collective bargaining agreement, nor have we experienced any work stoppages. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Insurance </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently
purchase insurance policies for property and liability risks arising out of current operations. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_2"></A>Item&nbsp;1A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>RISK FACTORS</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Our business is subject to numerous risks. We caution you that the following important factors, among others, could cause our actual results to differ materially from those expressed statements made by
us or on our behalf in filings with the SEC, press releases, communications with investors and oral statements. Any or all of our statements in this annual report and in any other public statements we make may turn out to be wrong. They can be
affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in the discussion below will be important in determining future results. Consequently, actual future results may vary materially from those
anticipated in this annual report. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Galena&#146;s Business and Industry </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We recently changed our strategic focus, and the anticipated benefits of our new strategic focus may not be realized.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may have difficulty evaluating our business, because we acquired Apthera only in the past year and are undertaking
to partially spin off RXi. Following the partial spin-off, our financial statements will no longer reflect the consolidated financial condition and results of operations of RXi, and we will account for our partial ownership of RXi based on the cost
method of accounting. For these reasons, the historical consolidated financial information included in this annual report do not necessarily reflect the financial condition, results of operations or cash flows that we will achieve in the future.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;24, 2011, we contributed to RXi substantially all of our RNAi-related technologies and assets and entered
into a number of agreements in contemplation of the partial spin-off of RXi. RXi will focus solely on developing and commercializing therapeutic products based on our RNAi technologies for the treatment of human diseases, including fibrotic disease.
There is no assurance that the partial spin-off of RXi will be completed or that RXi will be able to succeed as a stand-alone company. There also is no assurance that we will be successful in implementing our new focus as an oncology product
development pipeline company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For a discussion of the risks and uncertainties regarding the proposed partial spin-off of RXi,
see &#147;Risks Relating to the Partial Spin-Off of RXi,&#148; below in this section. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are largely dependent on the
success of our two leading drug candidates neither of which may receive regulatory approval or be successfully commercialized. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our business prospects depend heavily on successfully developing and commercializing our lead product candidate, NeuVax. On May&nbsp;8, 2009, we submitted an SPA for a Phase 3 clinical trial for NeuVax,
but did not include required chemistry, manufacturing, and controls (&#147;CMC&#148;) information. In July 2009, FDA placed our IND application for a Phase 3 trial for NeuVax on partial clinical hold pending submission of the missing CMC
information. We submitted the CMC information August&nbsp;8, 2011, and the FDA removed the partial clinical hold on September&nbsp;7, 2011, allowing us to proceed with the Phase 3 clinical trial. The FDA has agreed in the SPA for our Phase 3 PRESENT
clinical trial of NeuVax that the design, resulting data, and planned analyses of the Phase 3 study support an acceptable regulatory submission for marketing approval. There is no assurance, however, that the Phase 3 study will be successful, that a
single Phase 3 trial will support marketing approval, or that we will be able to obtain marketing approval for NeuVax or any other product candidate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently generate no revenue from sales, and we may never be able to develop marketable products. Before they can be marketed, our products in development must be approved by the FDA or similar
foreign governmental agencies. The process for obtaining FDA approval is both time-consuming and costly, with no certainty of a successful outcome. Before obtaining regulatory approval for the sale of any drug candidate, we must conduct extensive
preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. Although NeuVax has demonstrated safety during Phase 1 and Phase 2 clinical trials, further testing in our Phase 3 trial may undermine
those determinations or unexpected side effects may arise. A failure of any preclinical study or clinical trial can occur at any stage of testing. The results of preclinical and initial clinical testing of these products may not necessarily indicate
the results that will be obtained from later or more extensive testing. It also is possible to suffer significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A number of different factors could prevent us from obtaining regulatory approval or commercializing our product candidates on a
timely basis, or at all. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We, the FDA or other applicable regulatory authorities or an institutional review board, or
&#147;IRB,&#148; which is an independent committee under the oversight of the United States Department of Health and Human Services, or &#147;HHS,&#148; that has been formally registered with HHS and functions to approve, monitor and review
biomedical and behavioral research involving humans, may suspend clinical trials of a drug candidate at any time for various reasons, including if we or they believe the subjects or patients participating in such trials are being exposed to
unacceptable health risks. Among other reasons, adverse side effects of a drug candidate on subjects or patients </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
in a clinical trial could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing to approve a particular drug candidate for any or all indications of
use. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials of a new drug candidate require the enrollment of a sufficient number of patients, including patients who
are suffering from the disease the drug candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, and delays in patient enrollment can result in increased costs and longer
development times. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials also require the review and oversight of IRBs, which approve and continually review
clinical investigations and protect the rights and welfare of human subjects. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or
information derived from a clinical investigation not subject to initial and continuing IRB review and approval. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition,
cancer vaccines are a relatively new form of therapeutic and a very limited number of such products have received regulatory approval. Therefore, the FDA or other regulatory authority may apply standards for approval of a new cancer vaccine that is
different from past experience. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Numerous factors could affect the timing, cost or outcome of our drug development efforts,
including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties or delays in enrolling patients in our Phase 3 PRESENT study of NeuVax or our Phase&nbsp;1/2 clinical trials of FBP in conformity with
required protocols or projected timelines or in our other NeuVax clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">conditions imposed on us by the FDA, including the possibility that that the FDA would require an additional Phase 3 trial of NeuVax, or comparable
foreign authorities regarding the scope or design of our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties or delays in arranging for third parties to conduct clinical trials of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">problems in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our drug candidates having very different chemical and pharmacological properties in humans than in laboratory testing and interacting with human
biological systems in unforeseen, ineffective or harmful ways, and the possibility that our previous Phase 2 trials were not indicative of our drug candidates&#146; performance in larger patient populations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insufficient or inadequate supply or quality of our drug candidates or other necessary materials necessary to conduct our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effects of our drug candidates not being the desired effects or including undesirable side effects or the drug candidates having other unexpected
characteristics; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of our clinical trials may be greater than we anticipate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to our own or inability to
generate statistically significant data confirming the efficacy of the product being tested; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse results obtained by other companies developing similar drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">modification of the drug during testing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the FDA&#146;s requirements for our testing during the course of that testing; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reallocation of our limited financial and other resources to other clinical programs. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that none of the product candidates that we develop will obtain the
appropriate regulatory approvals necessary for us to begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. The time required to obtain FDA and
other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the complexity of the drug candidate. Any analysis we perform of data from clinical activities is subject to confirmation and
interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenue from the particular drug
candidate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also subject to numerous foreign regulatory requirements governing the conduct of clinical trials,
manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval described above as well as risks attributable to the satisfaction of
local regulations in foreign jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will rely upon third parties for the manufacture of our clinical product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We do not have the facilities or expertise to manufacture supplies of any of our potential product candidates for clinical trials. Accordingly, we will be dependent upon contract manufacturers for these
supplies. There can be no assurance that we will be able to secure needed supply arrangements on attractive terms, or at all. Our failure to secure these arrangements as needed could have a materially adverse effect on our ability to complete the
development of our product candidates or, if we obtain regulatory approval for our product candidates, to commercialize them. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current plans call for the manufacture of our compounds by contract manufacturers offering research grade, Good Laboratory grade and
Good Manufacturing Practices grade materials for preclinical studies (<I>e.g.</I>, toxicology studies) and for clinical use. Certain of our product candidates are complex molecules requiring many synthesis steps, which may lead to challenges with
purification and scale-up. These challenges could result in increased costs and delays in manufacturing. NeuVax is administered in combination with GM-CSF, a compound produced by Genzyme. If Genzyme were to discontinue supplying GM-CSF, we may
experience delays in securing a replacement supplier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to establish or maintain the third-party
relationships that are necessary to develop or potentially commercialize some or all of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
expect to depend on collaborators, partners, licensees, clinical research organizations and other third parties to support our discovery efforts, to formulate product candidates, to manufacture our product candidates, and to conduct clinical trials
for some or all of our product candidates. We cannot guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties
on favorable terms, if at all. Our ability to successfully negotiate such agreements will depend on, among other things, potential partners&#146; evaluation of the superiority of our technology over competing technologies and the quality of the
preclinical and clinical data that we have generated, and the perceived risks specific to developing our product candidates. In addition, we reduced the scale of our RNAi operations in connection with the partial spin-off of RXi, which could affect
our ability to maintain or enter into new alliances. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates.
Under certain license agreements that we have already entered into, we have minimum dollar amounts per year that we are obligated to spend on the development of the technology we have licensed from our contract partners and other obligations to
maintain certain licenses. If we fail to meet this requirement under any of our licenses that contain such requirements or any other obligations under these licenses, we may be in breach of our obligations under such agreement, which may result in
the loss of the technology licensed. We cannot necessarily control the amount or timing of resources that our contract partners will devote to our research and development programs, product candidates or potential product candidates, and we cannot
guarantee that these parties will fulfill their obligations to us under these arrangements in a timely fashion. We may not be able to readily terminate any such agreements with contract partners even if such contract partners do not fulfill their
obligations to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we may receive notices from third parties from time to time alleging that our
technology or product candidates infringe upon the intellectual property rights of those third parties. Any assertion by third parties that our activities or product candidates infringe upon their intellectual property rights may adversely affect
our ability to secure strategic partners or licensees for our technology or product candidates or our ability to secure or maintain manufacturers for our compounds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory review. If we fail to comply with ongoing regulatory requirements, we could lose our approvals to
market drugs and our business would be materially adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following regulatory approval of any drugs we
may develop, we will remain subject to continuing regulatory review, including the review of adverse drug experiences and clinical results that are reported after our drug products are made available to patients. This would include results from any
post marketing tests or vigilance required as a condition of approval. The manufacturer and manufacturing facilities we use to make any of our drug products will also be subject to periodic review and inspection by the FDA. The discovery of any new
or previously unknown problems with the product, manufacturer or facility may result in restrictions on the drug or manufacturer or facility, including withdrawal of the drug from the market. We would continue to be subject to the FDA requirements
governing the labeling, packaging, storage, advertising, promotion, recordkeeping, and submission of safety and other post-market information for all of our product candidates, even those that the FDA had approved. If we fail to comply with
applicable continuing regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approval, product recalls and seizures, operating restrictions and other adverse consequences. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we receive regulatory approval to market our product candidates, our product candidates may not be accepted commercially,
which may prevent us from becoming profitable. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeuVax and our other cancer-targeted product candidates may not achieve
market acceptance. Factors that we believe will materially affect market acceptance of our product candidates include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safety, efficacy and ease of administration of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advantages of our product candidates over those of our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">willingness of patients to accept relatively new therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">success of our physician education programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of government and third-party payor reimbursement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pricing of our products, particularly as compared to alternative treatments; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of effective alternative treatments and the relative risks and/or benefits of the treatments. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will be subject to competition and may not be able to compete successfully. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The biotechnology industry, including the cancer therapy vaccines market, is intensely competitive and involves a high degree of risk. We
compete with other companies that have far greater experience and financial, research and technical resources than us. Potential competitors in the United States and worldwide are numerous and include pharmaceutical and biotechnology companies,
educational institutions and research foundations, many of which have substantially greater capital resources, marketing experience, research and development staffs and facilities than us. Some of our competitors may develop and commercialize
products that compete directly with those incorporating our technology, introduce products to market earlier than our products or on a more cost effective basis. We may be unable to effectively develop our technology or any other applications on a
cost effective basis or otherwise. In addition, our technology may be subject to competition from other technology or methods developed using techniques other than those developed by traditional biotechnology methods. Our competitors compete with us
in recruiting and retaining qualified scientific and management personnel as </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
well as in acquiring technologies complementary to our technology. Our collaborators or we will face competition with respect to product efficacy and safety, ease of use and adaptability to
various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent position, including potentially dominant patent positions of others. An
inability to successfully complete our product development could lead to us having limited prospects for establishing market share or generating revenues from our technology. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">For patients with early stage breast cancer, adjuvant therapy is often given to prevent recurrence and increase the
chance of long-term disease free survival. Adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, radiation therapy, or combinations thereof. In addition, the HER2 targeted drug trastuzumab (Herceptin<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) may be given to patients with tumors with high expression of HER2 (IHC 3+). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a number of cancer vaccines in development for breast cancer, including but not limited to Lapuleucel-T (Dendreon), AE-37
(Antigen Express) and Stimuvax (Merck KgA). While these development candidates are aimed at a number of different targets, there is no guarantee that any of the these compounds will not in the future be indicated for treatment of low to intermediate
HER2 breast cancer patients and become directly competitive with NeuVax. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are dependent on technologies we license,
and if we lose the right to license such technologies or we fail to license new technologies in the future, our ability to develop new products would be harmed. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently are dependent on licenses from third parties for technologies relating to our product candidates. Our current licenses impose, and any future licenses we enter into are likely to impose,
various development, funding, royalty, diligence, sublicensing, insurance and other obligations on us. If our license with respect to any of these technologies is terminated for any reason, the development of the products contemplated by the
licenses would be delayed, or suspended altogether, while we seek to license similar technology or develop new non-infringing technology. The costs of obtaining new licenses are high. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to protect our intellectual property rights licensed from others parties, our intellectual property rights may be
inadequate to prevent third parties from using our technologies or developing competing products, and we may need to license additional intellectual property from others. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our licenses, we also rely on copyright and trademark protection, trade secrets, know-how, continuing technological
innovation and licensing opportunities. In an effort to maintain the confidentiality and ownership of our trade secrets and proprietary information, we require our employees, consultants, advisors and others to whom we disclose confidential
information to execute confidentiality and proprietary information agreements. However, it is possible that these agreements may be breached, invalidated or rendered unenforceable, and if so, there may not be an adequate corrective remedy available.
Furthermore, like many companies in our industry, we may from time to time hire scientific personnel formerly employed by other companies involved in one or more areas similar to the activities we conduct. In some situations, our confidentiality and
proprietary information agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants or advisors have prior employment or consulting relationships. Although we require our employees and consultants
to maintain the confidentiality of all confidential information of previous employers, we may be subject to allegations of trade secret misappropriation or other similar claims as a result of our employees&#146; or consultants&#146; prior
affiliations. Finally, others may independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets. Our failure to protect our proprietary information and techniques may inhibit or
limit our ability to exclude certain competitors from the market and execute our business strategies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our success
depends upon our ability to obtain and maintain intellectual property protection for our products and technologies. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend on our ability to obtain and maintain adequate protection of our intellectual property covering our product
candidates and technologies. The ultimate degree of patent protection that will be afforded to biotechnology products and processes, including ours, in the United States and in other important markets remains uncertain and is dependent upon the
scope of protection decided upon by the patent offices, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
courts and lawmakers in these countries. There is no certainty that our existing patents, or patent applications if obtained, will afford us substantial protection or commercial benefit.
Similarly, there is no assurance that our pending patent applications or patent applications licensed from third parties will ultimately be granted as patents or that those patents that have been issued or are issued in the future will stand if they
are challenged in court. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a risk that the products incorporating our peptide-based immunotherapy technology or
otherwise marketed by us might infringe the patent, trademark or other intellectual property rights of third parties, and there may be patent or other intellectual property rights belonging to others that require us to alter our products, pay
licensing fees or cease certain activities. For example, in June 2010, we received a letter from Alnylam Pharmaceuticals, Inc. claiming that we require access to Alnylam&#146;s patent and patent applications and demanding that we stop engaging in
unspecified alleged infringing activities unless we obtain a license from Alnylam. If our products infringe patent or other intellectual property rights of others, the owners of those rights could bring legal actions against us claiming damages and
seeking to enjoin manufacture, use, marketing and sales of the affected products. If these legal actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture
or market the affected products. We may not prevail in any action brought against us, and any license required under any rights that we infringe may not be available on acceptable terms or at all. Others may attempt to invalidate our intellectual
property rights or those of our licensors. Even if our rights, or those of our licensors, are not directly challenged, disputes among third parties could lead to the weakening or invalidation of our intellectual property rights. Any attempt by third
parties to undermine or invalidate our intellectual property rights could be costly to defend, require significant time and attention of our management and have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to obtain regulatory exclusivity for NeuVax, our business would be adversely affected and such exclusivity may not
provide sufficient protection to prevent competitors from entering our markets. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because our intellectual property
rights to the composition of matter of NeuVax expire prior to commercialization, we expect to rely substantially on data exclusivity provided under the Federal Food, Drug, and Cosmetic Act and similar laws in other countries and, to a lesser extent,
on orphan drug designation, if granted for NeuVax. We are preparing to apply for Orphan Drug status for NeuVax that, if granted, could provide seven years or ten years of market exclusivity in the United States or the European Union, respectively.
However, there is no assurance that the FDA or the European Medicines Agency, or &#147;EMEA,&#148; will approve our Orphan Drug Application. We also anticipate that NeuVax will qualify for 12 years of data exclusivity, and thus other companies would
be prevented from using our clinical data to support their application for regulatory approval, under the Patient Protection and Affordable Care Act; however, there can be no assurance that the 12 years of exclusivity provided for under the Patient
Protection and Affordable Care Act will remain in effect, or that NeuVax will meet the qualifications of a &#147;biological product&#148; to receive the specified period of exclusivity. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While the orphan drug designation for NeuVax, if granted, will provide seven years of market exclusivity in the United States, we will not
be able to exclude other companies from receiving market approval for the designated orphan indication beyond that timeframe. Even if we have orphan drug designation for a particular drug indication, we cannot guarantee that another company also
holding orphan drug designation will not receive FDA approval for the same indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company&#146;s seven-year period of exclusivity
expired. Even if we are the first to obtain FDA approval for an orphan drug indication, there are circumstances under which a competing product may be approved for the same indication during our seven-year period of marketing exclusivity, such as if
the later product is shown to be clinically superior to the orphan product. Further, the seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same compound for other indications or the use of other types of
drugs for the same use as the orphan drug. In addition, data exclusivity does not prevent another company from completing its own clinical trials with NeuVax and obtaining regulatory approval for the same indication for which NeuVax may be approved.
Consequently, we may not be able to prevent competitors from entering the market prior to the end of any applicable data exclusivity period. If we are not able to prevent competitors from entering the market with a similar product to NeuVax, our
ability to achieve profits from sales of NeuVax will be dramatically limited. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to potential liabilities from clinical testing and future product
liability claims. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our future products are alleged to be defective, they may expose us to claims for personal
injury by patients in clinical trials of our products. If our products are approved by the FDA, users may claim that such products caused unintended adverse effects. We will seek to obtain clinical trial insurance for clinical trials that we
conduct, as well as liability insurance for any products that we market. There can be no assurance that we will be able to obtain insurance in the amounts we seek, or at all. We anticipate that licensees who develop our products will carry liability
insurance covering the clinical testing and marketing of those products. There is no assurance, however, that any insurance maintained by us or our licensees will prove adequate in the event of a claim against us. Even if claims asserted against us
are unsuccessful, they may divert management&#146;s attention from our operations and we may have to incur substantial costs to defend such claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could have a material adverse effect on our
business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to sell our products primarily to hospitals, oncologists and clinics which receive reimbursement
for the health care services they provide to their patients from third-party payors, such as Medicare, Medicaid and other domestic and international government programs, private insurance plans and managed care programs. Most third-party payors may
deny reimbursement if they determine that a medical product was not used in accordance with cost-effective treatment methods, as determined by the third-party payor, was used for an unapproved indication or if they believe the cost of the product
outweighs its benefits. Third-party payors also may refuse to reimburse for experimental procedures and devices. Furthermore, because our programs are still in development, we are unable at this time to determine their cost-effectiveness and the
level or method of reimbursement for them. Increasingly, the third-party payors who reimburse patients are requiring that drug companies provide them with predetermined discounts from list prices, and are challenging the prices charged for medical
products. If the price we are able to charge for any products we develop is inadequate in light of our development and other costs, our profitability could be adversely affected. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently expect that any drugs we develop may need to be administered under the supervision of a physician. Under currently applicable
law, drugs that are not usually self-administered may be eligible for coverage by the Medicare program if: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are &#147;incidental&#148; to a physician&#146;s services; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are &#147;reasonable and necessary&#148; for the diagnosis or treatment of the illness or injury for which they are administered according to
accepted standard of medical practice; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are not excluded as immunizations; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they have been approved by the FDA. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Insurers may refuse to provide insurance coverage for newly approved drugs, or insurance coverage may be delayed or be more limited than the purpose for which the drugs are approved by the FDA. Moreover,
eligibility for insurance coverage does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable,
may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by
mandatory discounts or rebates required by government health care programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United
States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and
private payors for new drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to develop products, and our overall financial condition. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of
reimbursement for medical products and services. Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
adversely affect the demand for and price levels of our products. If our customers are not reimbursed for our products, they may reduce or discontinue purchases of our products, which could have
a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive health care reform
legislation, which was recently adopted by Congress and was subsequently signed into law, could adversely affect our business and financial condition. Among other provisions, the legislation provides that a &#147;biosimilar&#148; product may be
approved by the FDA on the basis of analytical tests and certain clinical studies demonstrating that such product is highly similar to an existing, approved product and that switching between an existing product and the biosimilar product will not
result in diminished safety or efficacy. This abbreviated regulatory approval process may result in increased competition if we are able to bring a product to market. The legislation also includes more stringent compliance programs for companies in
various sectors of the life sciences industry with which we may need to comply and enhanced penalties for non-compliance with the new health care regulations. Complying with new regulations may divert management resources, and inadvertent failure to
comply with new regulations may result in penalties being imposed on us. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some states and localities have established drug
importation programs for their citizens, and federal drug import legislation has been introduced in Congress. The Medicare Prescription Drug Plan legislation, which became law in December 2003, required the Secretary of Health and Human Services to
promulgate regulations for drug reimportation from Canada into the United States under some circumstances, including when the drugs are sold at a lower price than in the United States. The Secretary, however, retained the discretion not to implement
a drug reimportation plan if he finds that the benefits do not outweigh the costs, and has so far declined to approve a reimportation plan. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation
under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for
profitability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If our new management team is not effective or if we fail to attract, hire and retain qualified
personnel, we may not be able to design, develop, market or sell our products or successfully manage our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
business prospects are dependent on our management team. The loss of Dr.&nbsp;Ahn, our President and Chief Executive Officer, or our other executive officers, or our inability to identify, attract, retain and integrate additional qualified key
personnel, could make it difficult for us to manage our business successfully and achieve our business objectives. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Competition
for skilled research, product development, regulatory and technical personnel also is intense, and we may not be able to recruit and retain the personnel we need. The loss of the services of any key research, product development, regulatory, and
technical personnel, or our inability to hire new personnel with the requisite skills, could restrict our ability to develop our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We use biological and hazardous materials, and we may be liable for any contamination or injury we cause. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals and various radioactive compounds. We cannot
completely eliminate the risk of accidental contamination or injury; we may be liable for any damages that result, and any liability could exceed our resources. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of
biohazardous materials. We maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials. State laws mandate the limits of our workers&#146;
compensation insurance, and our workers&#146; compensation liability is capped at these state-mandated limits. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our
storage or disposal of biological, hazardous or radioactive materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial
fines or penalties if we violate any of these laws or regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating To Our Financial Position and Capital Requirements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to obtain sufficient financing, and may not be able to develop our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that our existing cash and cash equivalents and the proceeds from our sales agreement with Cantor should be sufficient to fund
our operations through at least the first quarter of 2013. In the future, we will be dependent on obtaining further financing from third parties in order to maintain our operations and to meet our financial obligations. We cannot assure that
additional funding to maintain our operations and to meet our obligations to our licensors will be available to us in the future on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back,
or terminate, our operations, or to seek to merge with or to be acquired by another company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that we will need
to raise substantial amounts of money to fund a variety of future activities integral to the development of our business, which may include but are not limited to the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to conduct our Phase 3 PRESENT clinical trial of NeuVax , our Phase&nbsp;1/2 clinical trials of FBP and our planned Phase 2 trial of NeuVax in
combination with Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and our other planned NeuVax trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to obtain regulatory approval for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to file and prosecute patent applications and to defend and assess patents to protect our technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to retain qualified employees, particularly in light of intense competition for qualified scientists; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to manufacture products ourselves or through third parties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to market our products, either through building our own sales and distribution capabilities or relying on third parties; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to acquire new technologies, licenses, products or companies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot assure you that any financing needed for the development of our business will be available to us on acceptable terms or at all.
If we cannot obtain additional financing in the future, our operations may be restricted and we may ultimately be unable to continue to develop and potentially commercialize our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to continue to incur significant research and development expenses, which may make it difficult for us to attain
profitability, and may lead to uncertainty about or as to our ability to continue as a going concern. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Substantial
funds were expended to develop our technologies and product candidates, and additional substantial funds will be required for further preclinical testing and clinical trials of our product candidates, and to manufacture and market any products that
are approved for commercial sale. Because the successful development of our products is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to
generate enough revenue, even if we are able to commercialize any of our product candidates, to become profitable. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the
event that we are unable to achieve or sustain profitability or to secure additional financing, we may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such
inability to continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing. Our financial statements contemplate that we will
continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Changes in our operating plans, our existing and anticipated working capital needs, the acceleration or modification
of our expansion plans, increased expenses, potential acquisitions or other events will all affect our ability to continue as a going concern. Future financing may be obtained through, and future development efforts may be paid for by, the issuance
of debt or equity, which may have an adverse effect on our stockholders or may otherwise adversely affect our business. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we
raise funds through the issuance of debt or equity, any debt securities or preferred stock issued will have rights, preferences and privileges senior to those of holders of our common stock in the event of a
liqui-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
dation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the holders of common stock. In addition, if we raise funds
through the issuance of additional equity, whether through private placements or additional public offerings, such an issuance would dilute your ownership in us. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The terms of debt securities may also impose restrictions on our operations, which may include limiting our ability to incur additional indebtedness, to pay dividends on or repurchase our capital stock,
or to make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of our control.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may have difficulty evaluating our business, because we have a limited history and our historical financial information
may not be representative of our future results. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have limited operating experience and may not be able to
effectively operate. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a development-stage company with limited operating history conducting oncology drug
programs. We will focus on developing and, if we obtain regulatory approval, commercializing our product candidates, and there is no assurance that we will be successful. There is no assurance that we will be able to manage our business effectively,
or that we will be able to identify, hire and retain any needed additional management or scientific personnel to develop and implement our product development plans, obtain third-party contracts or any needed financing or achieve our other business
objectives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to comply with our reporting and other requirements under federal securities laws.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a publicly traded company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as
amended, or the &#147;Exchange Act<B>,</B>&#148; and the Sarbanes-Oxley Act of 2002, or the &#147;Sarbanes-Oxley Act.&#148; In addition, the Exchange Act requires that we file annual, quarterly and current reports. Our failure to prepare and
disclose this information in a timely manner could subject us to penalties under federal securities laws, expose us to lawsuits and restrict our ability to access financing. The Sarbanes-Oxley Act requires that we, among other things, establish and
maintain effective internal controls and procedures for financial reporting. From time to time we evaluate our existing internal controls in light of the standards adopted by the Public Company Accounting Oversight Board. It is possible that we or
our independent registered public accounting firm may identify significant deficiencies or material weaknesses in our internal control over financial reporting in the future. Any failure or difficulties in implementing and maintaining these controls
could cause us to fail to meet the periodic reporting obligations or result in material misstatements in our financial statements. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting. Our failure to satisfy the requirements of
Section&nbsp;404 on a timely basis could result in the loss of investor confidence in the reliability of our financial statements, which in turn could have a material adverse effect on our business and our common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We recently reported a material weakness in the effectiveness of our internal controls over financial reporting, and if we cannot
provide reliable financial and other information, investors may lose confidence in our SEC reports. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2011,
our management identified a material weakness in the effectiveness of our internal control over financial reporting related to our accounting for certain outstanding stock options and warrants. As a result, we restated our unaudited condensed
consolidated financial statements as of June&nbsp;30, 2011. Based on this evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, and because of the error described above, our management concluded that
our disclosure controls and procedures over our accounting for stock options modified and for warrants potentially settleable in cash were not effective as of the end of the quarters ended June&nbsp;30, and September&nbsp;30, 2011. Disclosure
controls and procedures generally include controls and procedures designed to ensure that information required to be disclosed by us in the reports we file with the SEC is recorded, processed, summarized and reported accurately and within the time
periods specified in the SEC&#146;s rules and forms. In the fourth quarter of 2011, we implemented additional review procedures to ensure the accuracy of our fair market value calculations to ensure that our accounting for stock options modified and
for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
warrants potentially settleable in cash is in accordance with generally accepted accounting principles. This action was in place in connection with the preparation of our financial statements for
the year ended 2011. As such, we believe that the remediation initiative was sufficient to eliminate the material weakness in internal control over financial reporting as discussed above. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective internal controls over financial reporting and disclosure controls and procedures are necessary for us to provide reliable
financial and other reports and effectively prevent fraud. If we cannot provide reliable financial or SEC reports or prevent fraud, investors may lose confidence in our SEC reports, our operating results and the trading price of our common stock
could suffer materially and we may become subject to litigation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have been sued by some of our warrant holders, and
we could be found liable to repurchase their warrants. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;21, 2011, Hudson Bay Master Fund, Ltd.
(&#147;Hudson Bay&#148;) filed a Complaint against us in the United States District Court for the Southern District of New York (the &#147;Court&#148;), captioned <U>Hudson Bay Master Fund, Ltd. v. Galena Biopharma, Inc., 11 Civ. 8432 (JPO)</U>,
alleging that our plan to partially spin off RXi and related actions taken by us in preparation for the spin-off gives Hudson Bay the right to require us to repurchase the warrants acquired by Hudson Bay in our April 2011 underwritten public
offering. Hudson Bay also seeks related declaratory and injunctive relief. On January&nbsp;12, 2012, three other warrant holders affiliated with each other filed a Complaint in the Court, captioned <U>Tenor Opportunity Fund, Ltd., Aria Opportunity
Fund, Ltd., and Parsoon Opportunity Fund, Ltd. v. Galena Biopharma, Inc., 12 </U><U>CIV 0260</U>, and on January&nbsp;20, 2012 and February&nbsp;2, 2012, respectively, two other warrant holders filed their own Complaints in the Court, captioned
<U>Cranshire Capital Master Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0493</U> and <U>Iroquois Master Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0839</U>, respectively. In these Complaints, which are substantially identical to the previous
Complaints filed in the Court, the various warrant holders also claim that our planned spin-off of RXi and related actions give them the right to require us to repurchase our outstanding warrants held by them. According to the allegations in the
Complaints, the repurchase price of the plaintiffs&#146; warrants would amount to approximately $5.2 million in the aggregate. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;21, 2012, we received letters from each of the plaintiff-warrant holders withdrawing their repurchase demands with respect
to their warrants covering an aggregate of 6,350,000 shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the &#147;Withdrawal Notice<B>s</B>&#148;). After giving effect to the Withdrawal Notices, the
plaintiff-warrant holders continued to demand that we repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based on the plaintiff-warrant holders&#146; claims in their Complaints, we believe that the
repurchase price for these warrants is $0.71 per underlying share, or an aggregate of $355,000. On March 27, 2012, we tendered to the plaintiff-warrant holders an aggregate of $355,000 as payment in full of the repurchase price for those warrants.
We believe that the Withdrawal Notices and our tender of payment as described above render moot the majority of the claims of the plaintiff-warrant holders in their Complaints, although the Withdrawal Notices purport to reserve all rights of the
plaintiff-warrant holders under the Complaints. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we were to become liable to repurchase the plaintiffs&#146; warrants, we
may not have on hand sufficient funds to satisfy the liability and to meet our other obligations as they come due, which could raise doubts as to our ability to continue as a going concern. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Ownership of Our Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The market price and
trading volume of our common stock may be volatile. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The market price of our common stock has exhibited substantial
volatility recently. Between January 1, 2012 and March 27, 2012, the sale price of our common stock as reported on The NASDAQ Capital Market ranged from a low of $0.43 to a high of $2.93. The market price of our common stock could continue to
fluctuate significantly for many reasons, including the following factors: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reports of the results of our clinical trials regarding the safety or efficacy of our product candidates and surrogate markers;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of regulatory developments or technological innovations by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of business or strategic transactions such as our planned partial spin-off of RXi and related transactions and of the progress of the
partial spin-off or other strategic transactions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in our relationship with our licensors and other strategic partners; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our quarterly operating results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments in patent or other technology ownership rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern regarding the safety of our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additional funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stock
holders; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">government regulation of drug pricing; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general changes in the economy, the financial markets or the pharmaceutical or biotechnology industries. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, factors beyond our control may also have an impact on the price of our stock. For example, to the extent that other large
companies within our industry experience declines in their stock price, our stock price may decline as well. In addition, when the market price of a company&#146;s common stock drops significantly, stockholders often institute securities class
action lawsuits against the company. A lawsuit against us could cause us to incur substantial costs and could divert the time and attention of our management and other resources. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Anti-takeover provisions of our certificate of incorporation and by-laws and provisions of Delaware law could delay or prevent a
change of control that you may favor. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-takeover provisions of our certificate of incorporation and by-laws and
provisions of Delaware law may discourage, delay or prevent a merger or other change of control that stockholders may consider favorable, or may impede the ability of the holders of our common stock to change our management. These provisions of our
certificate of incorporation and by-laws, among other things: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">divide our board of directors into three classes, with members of each class to be elected for staggered three-year terms;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limit the right of stockholders to remove directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulate how stockholders may present proposals or nominate directors for election at annual meetings of stockholders; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">authorize our board of directors to issue preferred stock in one or more series, without stockholder approval. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, Section&nbsp;203 of the Delaware General Corporation Law provides that, subject to limited exceptions, persons that acquire,
or are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation such as our company shall not engage in any business combination with that corporation, including by merger, consolidation or
acquisitions of additional shares for a three-year period following the date on which that person or its affiliate crosses the 15% stock ownership threshold. Section&nbsp;203 could operate to delay or prevent a change of control of our company.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may acquire other businesses, including businesses in which our directors or officers may have an interest, or form
joint ventures that may be unsuccessful and could adversely dilute your ownership of our company. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of our
business strategy, we may pursue acquisitions of other complementary businesses and assets and may also pursue strategic alliances. We have limited experience in acquiring other companies and in forming such alliances. Apthera was our first
acquisition. Sanford J. Hillsberg, our Chairman of the Board, was a substantial stockholder of Apthera at the time of the acquisition and had interests in the Apthera acquisition that were different from the interests of our stockholders, generally.
We may not be able to successfully integrate any acquisitions into our existing business, and we could assume unknown or contingent liabilities or become subject </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to possible stockholder claims in connection with any related-party or third-party acquisitions or other transactions. We also could experience adverse effects on our reported results of
operations from acquisition-related charges, amortization of acquired technology and other intangibles and impairment charges relating to write-offs of goodwill and other intangible assets from time to time following the acquisition of Apthera or
other acquisitions. Integration of an acquired company requires management resources that otherwise would be available for ongoing development of our existing business. We may not realize the anticipated benefits of any acquisition, technology
license or strategic alliance. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To finance future acquisitions, we may choose to issue shares of our common stock as
consideration, which would dilute your ownership interest in us. Alternatively, it may be necessary for us to raise additional funds through public or private financings. Additional funds may not be available on terms that are favorable to us and,
in the case of equity financings, may result in dilution to our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to the Partial Spin-Off of RXi
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a number of risks associated with the partial spin-off of RXi, including the following: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The partial spin-off may be delayed or may not be completed. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;27, 2012 we announced, as required by NASDAQ Listing Rule 5250(e)(6), that our board of directors had declared a
conditional dividend on Galena common stock of one share of common stock of RXi for each outstanding share of Galena common stock. The spin-off shares will be payable, subject to certain conditions described below, to our stockholders as of close of
business (Eastern time) on March 8, 2012, the record date for the distribution, in the ratio of one RXi share for each share of Galena common stock held as of the record date. In light of the conditional nature of the partial spin-off of RXi, our
board of directors has not set a payment date for the distribution, and under NASDAQ rules our common stock is not yet trading &#147;ex-dividend.&#148; The distribution of the spin-off shares will be taxable to Galena stockholders who receive RXi
shares in the distribution. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution to Galena stockholders of the spin-off shares is to be made pursuant to the
registration statement filed by RXi with the Securities and Exchange Commission and declared effective on February 14, 2012. Because the RXi registration statement will go &#147;stale&#148; on April 30, 2012, we must complete the distribution of the
spin-off shares by that date, unless we were to cause RXi to amend the registration statement. It is likely that we would abandon the partial spin-off of RXi if the distribution of the spin-off shares has not been made by April&nbsp;30, 2012,
although our board of directors has not made any decision in this regard. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The establishment of a payment date for the
distribution and the payment of the distribution is dependent upon the timing of effectiveness of an application filed with FINRA to permit RXi common stock to be traded in the OTC Markets Group under the symbol &#147;RXII.&#148; The payment of the
distribution also is conditioned upon the closing of the RXi financing, which is subject to certain closing conditions that may or may not be satisfied. In addition, the securities purchase agreement among Galena, RXi and the RXi investors provides
that the agreement may be unilaterally terminated by us or by the RXi investors if the closing of the transactions has not occurred by March&nbsp;31, 2012, and it is not possible for the closing to occur by this date. Accordingly, unless this date
is extended by mutual agreement of the RXi investors and us, either we or the RXi investors generally may terminate the securities purchase agreement at any time after March 31, 2012, unless the failure of the closing to occur was due to the fault
of the party seeking to terminate the securities purchase agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we have no present intention to terminate the
securities purchase agreement or to abandon the partial spin-off of RXi, the RXi investors may choose to do so. We also may decide to do so at any time if our board of directors determines that it is in the best interests of our company. For all of
the foregoing reasons, there is no assurance that the payment and distribution of the spin-off shares will be completed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will no longer control RXi. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently own all of the outstanding shares of common stock of RXi. Upon completion of the RXi financing and the partial spin-off of RXi, assuming they are completed, we will own only approximately 4%
of the as-converted common stock of RXi and our stockholders will own in the aggregate approximately 8% of the as-converted common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will have no management rights in RXi, and the officers, directors and other RXi
stockholders may have interests that are different from ours. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we will own approximately 4% of RXi&#146;s
outstanding common stock upon completion of the spin-off of RXi, we will have no control over its management or operations. RXi will have its own board of directors and management, who will be responsible for the affairs and policies of RXi and its
development plans. Mark J. Ahn, Ph.D., our President and Chief Executive Officer, will resign as a director of RXi in conjunction with the partial spin-off of RXi, and neither we nor our stockholders will have any right to designate or elect
Dr.&nbsp;Ahn or other individual as a director of RXi or any other management rights in RXi. The directors, management and other stockholders of RXi may have interests that are different from ours, and RXi may engage in actions in connection with
its business and operations that we believe are not in our best interests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have agreed to guarantee the bridge loan
to RXi upon the imminent maturity date of the RXi convertible notes, and there is no assurance that the maturity date will be extended; and if the spin-off of RXi is not completed, we will lose control of RXi. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the securities purchase agreement with the RXi, investors, the RXi investors have provided a bridge loan to RXi by purchasing
$1,000,000 of RXi convertible notes and have agreed, in the RXi investors&#146; discretion, to purchase up to an additional $500,000 of RXi convertible notes prior to the closing. The RXi convertible notes accrue interest at a rate of 7%&nbsp;per
annum (or 18%&nbsp;per annum in the case of an event of default) and mature on March&nbsp;31, 2012, or earlier in the case of an event of default. The obligations due under the RXi convertible notes are secured by a first-priority blanket lien on
the assets of RXi and are guaranteed by us. Additionally, we have pledged all of our shares of RXi common stock to further guarantee the timely payment of the amounts due under the RXi convertible notes, if not converted into RXi preferred stock at
the closing of the transactions under the securities purchase agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the closing of the transactions under the
securities purchase agreement has not occurred by the March&nbsp;31, 2012 maturity date of the RXi convertible notes, unless such date is extended by mutual agreement by the RXi investors and us, the permanent financing and the partial spin-off of
RXi will not occur, and one-half of the outstanding principal of and accrued interest on the RXi convertible notes held by the investors will be converted into shares of RXi common stock equal to 51% of the shares of outstanding common stock of RXi
immediately upon such conversion. RXi will be obliged to repay the balance of the principal of and accrued interest on the RXi convertible notes held by the investors, and we have agreed in the securities purchase agreement to guarantee RXi&#146;s
repayment of the RXi convertible notes to the extent they are not converted. In this event, we will own 44% of the outstanding shares of RXi common stock, and RXi will carry on as a stand-alone private company under the investors&#146; control, with
its own management and with whatever funding and other financial resources that may be available to it. Neither the investors in RXi nor Galena will be obliged to provide any funding to RXi in this event, and there is no guarantee that funding will
be available to RXi on acceptable terms, or at all. If RXi fails to obtain additional funding in this event, it would be forced to scale back or terminate its operations, or to seek to merge with or to be acquired by another company. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we will own approximately 4% of RXi&#146;s outstanding common stock upon completion of the spin-off of RXi, we will have no
control over its management or operations. RXi will have its own board of directors and management, who will be responsible for the affairs and policies of RXi and its development plans. Mark J. Ahn, Ph.D., our President and Chief Executive Officer,
will resign as a director of RXi in conjunction with the partial spin-off of RXi, and neither we nor our stockholders will have any right to designate or elect Dr.&nbsp;Ahn or other individual as a director of RXi or any other management rights in
RXi. The directors, management and other stockholders of RXi may have interests that are different from ours, and RXi may engage in actions in connection with its business and operations that we believe are not in our best interests. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are in discussions with the RXi investors to extend the current March 31, 2012 maturity date of the RXi convertible notes, but there
is no assurance that the maturity date will be extended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We retain little discretion over the use of RXi&#146;s funds.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed in the securities purchase agreement to use the proceeds of the RXi convertible notes and the funds
contributed to RXi by us in accordance with budgets agreed or to be agreed upon by the investors and us. We retain no discretion over the use of these funds, and these funds will not be available to us for use in Galena&#146;s oncology business or
operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Risks Associated With Our Ownership Interest in RXi. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the partial spin-off is completed, or if it is not completed and we become a minority stockholder of RXi, the value of our ownership
interest in RXi and of the spin-off shares to be received by our stockholders will depend on RXi&#146;s success in developing and commercializing products developed based upon its RNAi technologies, which activities are subject to significant risks
and uncertainties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi will be dependent on the success of its leading drug candidate, which may not receive regulatory
approval or be successfully commercialized. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXI-109, RXi&#146;s first RNAi-based product candidate, targets connective
tissue growth factor, or &#147;CTGF,&#148; and may have a variety of medical applications. RXi is planning to file an IND application with the FDA and begin a Phase 1 clinical trial in 2012 for RXI-109. The FDA, however, may deny RXi&#146;s
application or require additional information before approving the application, and such information may be costly to provide. There is no assurance that RXi will be able to successfully develop RXI-109 or any other product candidate. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi currently generates no revenue from sales, and may never be able to develop marketable products. The FDA or similar foreign
governmental agencies must approve RXi&#146;s products in development before they can be marketed. The process for obtaining FDA approval is both time-consuming and costly, with no certainty of a successful outcome. Before obtaining regulatory
approval for the sale of any drug candidate, RXi must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. RXi has not shown safety or efficacy in humans for any
RNAi-based product candidates, including RXI-109. A failure of any preclinical study or clinical trial can occur at any stage of testing. The results of preclinical and initial clinical testing of these products may not necessarily indicate the
results that will be obtained from later or more extensive testing. It is also possible to suffer significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A number of different factors could prevent RXi from obtaining regulatory approval or commercializing its product candidates on a
timely basis, or at all. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi, the FDA or other applicable regulatory authorities, or an IRB may suspend clinical
trials of a drug candidate at any time for various reasons, including if RXi or they believe the subjects or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a drug
candidate on subjects or patients in a clinical trial could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing to approve a particular drug candidate for any or all indications of use. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials of a new drug candidate require the enrollment of a sufficient number of patients, including patients who are suffering
from the disease the drug candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, and delays in patient enrollment can result in increased costs and longer development times.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials also require the review and oversight of IRBs, which approve and continually review clinical investigations
and protect the rights and welfare of human subjects. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or information derived
from a clinical investigation not subject to initial and continuing IRB review and approval. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Numerous factors could affect the
timing, cost or outcome of RXi&#146;s drug development efforts, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in filing the initial IND drug application for RXI-109 or other product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulty in securing centers to conduct trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of RXi&#146;s clinical trials;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">problems in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulty in enrolling patients in conformity with required protocols or projected timelines; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third-party contractors failing to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi&#146;s drug candidates having very different chemical and pharmacological properties in humans than in laboratory testing and interacting with
human biological systems in unforeseen, ineffective or harmful ways; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to suspend or terminate clinical trials if the participants are being exposed to unacceptable health risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insufficient or inadequate supply or quality of RXi&#146;s drug candidates or other necessary materials necessary to conduct our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effects of our drug candidates not being the desired effects or including undesirable side effects or the drug candidates having other unexpected
characteristics; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of RXi&#146;s clinical trials may be greater than it anticipates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative or inconclusive results from RXi&#146;s clinical trials or the clinical trials of others for similar drug candidates or inability to generate
statistically significant data confirming the efficacy of the product being tested; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the FDA&#146;s requirements for testing during the course of that testing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reallocation of RXi&#146;s limited financial and other resources to other clinical programs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse results obtained by other companies developing similar drugs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that none of the product candidates that RXi may develop will obtain the appropriate regulatory approvals necessary to
begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses for which RXi may market the product. The time required to obtain FDA and other approvals is unpredictable, but often can take
years following the commencement of clinical trials, depending upon the complexity of the drug candidate. Any analysis RXi performs of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could
delay, limit or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material adverse effect on RXi&#146;s ability to generate revenue from the particular drug candidate. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi also is subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing
authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval described above as well as risks attributable to the satisfaction of local regulations in
foreign jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The approach RXi is taking to discover and develop novel therapeutics using RNAi is unproven and may never lead to marketable
products. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RNA interference is a relatively new scientific discovery. To date, no company has received regulatory
approval to market therapeutics utilizing RNAi, and a number of clinical trials of RNAi technologies by other companies have been unsuccessful. The scientific evidence to support the feasibility of developing drugs based on these discoveries is both
preliminary and limited. To successfully develop RNAi-based products, RXi must solve a number of issues, including stabilizing the RNAi material and delivering it into target cells in the human body. RXi may spend large amounts of money trying to
solve these issues and never succeed in doing so. In addition, any compounds that RXi develops may not demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory studies, and they may interact with human
biological systems in unforeseen, ineffective or even harmful ways. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The FDA could impose a unique regulatory regime for RNAi therapeutics.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The substances RXi intends to develop may represent a new class of drug, and the FDA has not yet established any
definitive policies, practices or guidelines in relation to these drugs. While we expect any product candidates that RXi develops will be regulated as a new drug under the Federal Food, Drug, and Cosmetic Act, the FDA could decide to regulate them
or other products RXi may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder or slow review by the FDA of any regulatory filings that RXi may submit. Moreover, the FDA may respond to
these submissions by defining requirements that RXi may not have anticipated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The FDA approval process may be delayed
for any drugs RXi develops that require the use of specialized drug delivery devices or vehicles. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some drug candidates
that RXi develops may need to be administered using specialized devices, such as an implantable pump that deliver RNAi therapeutics directly to diseased parts of the body. These devices may or may not have been approved by the FDA or other
regulatory agencies. The drug delivery vehicles that RXi may utilize to deliver its drug candidates have not been approved by the FDA or other regulatory agencies. In addition, the FDA may regulate the product as a combination product of a drug and
a device or require additional approvals or clearances for the modified delivery. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If specialized delivery vehicle is owned by
another company, RXi would need that company&#146;s cooperation to implement the necessary changes to the vehicle, or its labeling, and to obtain any additional approvals or clearances. Any delays in finding suitable drug delivery vehicles to
administer RNAi therapeutics directly to diseased parts of the body could negatively affect our ability to successfully develop our RNAi therapeutics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if RXi receives regulatory approval to market its product candidates, its product candidates may not be accepted commercially, which may prevent RXi from becoming profitable.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The RNAi product candidates that RXi is developing are based on new technologies and therapeutic approaches. RNAi
products may be more expensive to manufacture than traditional small molecule drugs, which may make them more costly than competing small molecule drugs. Additionally, for various applications, RNAi products are likely to require injection or
implantation, which will make them less convenient to administer than drugs administered orally. Key participants in the pharmaceutical marketplace, such as physicians, medical professionals working in large reference laboratories, public health
laboratories and hospitals, third-party payors and consumers may not accept products intended to improve therapeutic results based on RNAi technology. As a result, it may be more difficult for RXi to convince the medical community and third-party
payors to accept and use RXi&#146;s products, or to provide favorable reimbursement. If medical professionals working with large reference laboratories, public health laboratories and hospitals choose not to adopt and use RXi&#146;s RNAi technology,
its products may not achieve broader market acceptance. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other factors that we believe will materially affect market acceptance
of RNAi product candidates include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">timing of RXi&#146;s receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safety, efficacy and ease of administration of RXi&#146;s product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advantages of RXi&#146;s product candidates over those of RXi&#146;s competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">willingness of patients to accept relatively new therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">success of RXi&#146;s physician education programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of government and third party payor reimbursement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pricing of RXi&#146;s products, particularly as compared to alternative treatments; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of effective alternative treatments and the relative risks and/or benefits of the treatments. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi will be subject to competition and may not be able to compete successfully.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe numerous companies are investigating or plan to investigate a variety of proposed anti-scarring therapies
in clinical trials. The companies include large and small pharmaceutical, chemical and biotechnology companies, as well as universities, government agencies and other private and public research organizations. Such companies include Renovo Group
plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene,
Derma Sciences, Inc., Healthpoint Biotherapeutics and Pharmaxon. In particular, Excaliard Pharmaceuticals, Inc., which has been acquired by Pfizer, Inc., has successfully advanced an anti-CTGF antisense oligonucleotide through several Phase 1 and
Phase 2 trials, demonstrating improved scar outcome over placebo. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe other companies working in the RNAi area,
generally, include Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira
Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris, as well as a number of large pharmaceutical companies. Many other companies are pursuing non-RNAi-based therapies for one or more fibrotic disease
indications, including ocular scarring or other indications that RXi may seek to pursue. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most of RXi&#146;s competitors have
substantially greater research and development capabilities and financial, scientific, technical, manufacturing, marketing, distribution and other resources than RXi, and RXi may not be able to successfully compete with them. In addition, even if
RXi is successful in developing its product candidates, in order to compete successfully RXi may need to be first to market or to demonstrate that its RNAi-based products are superior to therapies based on different technologies. A number of
RXi&#146;s competitors have already commenced clinical testing of RNAi product candidates and may be more advanced than RXi is in the process of developing products. If RXi is not first to market or are unable to demonstrate superiority, any
products for which RXi is able to obtain approval may not be successful. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi will be dependent on technologies it
licenses, and if it loses the right to license such technologies or fails to license new technologies in the future, its ability to develop new products would be harmed. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many patents in the RNAi field have already been exclusively licensed to third parties, including RXi&#146;s competitors. If any of
RXi&#146;s existing licenses are terminated, the development of the products contemplated by the licenses could be delayed or terminated and RXi may not be able to negotiate additional licenses on acceptable terms, if at all, which would have a
material adverse effect on RXi&#146;s business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi may be unable to protect its intellectual property rights licensed
from others parties, its intellectual property rights may be inadequate to prevent third parties from using its technologies or developing competing products, and RXi may need to license additional intellectual property from others.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Therapeutic applications of gene silencing technologies, delivery methods and other technologies that RXi licenses
from third parties are claimed in a number of pending patent applications, but there is no assurance that these applications will result in any issued patents or that those patents would withstand possible legal challenges or protect RXi&#146;s
technologies from competition. The United States Patent and Trademark Office and patent granting authorities in other countries have upheld stringent standards for the RNAi patents that have been prosecuted so far. Consequently, pending patents that
RXi has licensed or owns may continue to experience long and difficult prosecution challenges and may ultimately issue with much narrower claims than those in the pending applications. Third parties may hold or seek to obtain additional patents that
could make it more difficult or impossible for RXi to develop products based on RNAi technology without obtaining a license to such patents, which licenses may not be available to RXi on attractive terms, or at all. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, others may challenge the patents or patent applications that RXi currently licenses or may license in the future or that RXi
owns and, as a result, these patents could be narrowed, invalidated or rendered unenforceable, which would negatively affect RXi&#146;s ability to exclude others from using RNAi technologies described in these patents. There can be no assurance that
these patent or other pending applications or issued </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
patents RXi licenses or owns will withstand possible legal challenges. Moreover, the laws of some foreign countries may not protect RXi&#146;s proprietary rights to the same extent as the laws of
the United States. Any patents issued to RXi or its licensors may not provide RXi with any competitive advantages, and there can be no assurance that the patents of others will not have an adverse effect on RXi&#146;s ability to do business or to
continue to use its technologies freely. RXi&#146;s efforts to enforce and maintain its intellectual property rights may not be successful and may result in substantial costs and diversion of management time. Even if RXi&#146;s rights are valid,
enforceable and broad in scope, competitors may develop products based on technology that is not covered by RXi&#146;s licenses or patents or patent application that it owns. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2010, we received a letter from Alnylam Pharmaceuticals, Inc. claiming that we require access to Alnylam&#146;s patent and patent applications and demanding that we stop engaging in unspecified
alleged infringing activities unless we obtain a license from Alnylam. We understand that other companies working in the RNAi area have received similar letters from Alnylam. Although we believe that RXi&#146;s current and planned activities do not
infringe any valid patent rights of Alnylam, there is no assurance that RXi will not need to alter its development candidates or products or obtain a license to Alnylam&#146;s rights to avoid any such infringement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is no guarantee that future licenses will be available from third parties for RXi&#146;s product candidates on satisfactory terms,
or at all. To the extent that RXi is required and is able to obtain multiple licenses from third parties to develop or commercialize a product candidate, the aggregate licensing fees and milestones and royalty payments made to these parties may
materially reduce RXi&#146;s economic returns or cause RXi to abandon development or commercialization of a product candidate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi&#146;s success depends upon its ability to obtain and maintain intellectual property protection for its products and
technologies. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The applications based on RNAi technologies claim many different methods, compositions and processes
relating to the discovery, development, delivery and commercialization of RNAi therapeutics. Because this field is so new, very few of these patent applications have been fully processed by government patent offices around the world, and there is a
great deal of uncertainty about which patents will issue, when, to whom, and with what claims. It is likely that there will be significant litigation and other proceedings, such as interference and opposition proceedings in various patent offices,
relating to patent rights in the RNAi field and that RXi may be a party to such proceedings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi will rely upon third
parties for the manufacture of its clinical product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi does not have the facilities or expertise to
manufacture supplies of any of its potential product candidates for clinical trials. Accordingly, RXi will be dependent upon contract manufacturers for these supplies. RXi currently obtains supplies for RXI-109 from a single supplier, Agilent
Technologies, Nucleic Acid Solutions Division. If for any reason RXi is unable to obtain RXI-109 from this supplier, it would have to seek to obtain it from another major oligonucleotide manufacturer. There is no assurance that RXi will be able to
timely secure needed supply arrangements on satisfactory terms, or at all. RXi&#146;s failure to secure these arrangements as needed could have a material adverse effect on its ability to complete the development of its product candidates or, if RXi
obtains regulatory approval for its product candidates, to commercialize them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi may not be able to establish or
maintain the third-party relationships that are necessary to develop or potentially commercialize some or all of its product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect that RXi will be dependent upon collaborators, partners, licensees, clinical research organizations and other third parties to support its discovery efforts, to formulate product candidates, to
manufacture its product candidates and to conduct clinical trials for some or all of its product candidates. We cannot guarantee that RXi will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners,
licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. RXi&#146;s ability to successfully negotiate such agreements will depend on, among other things, potential partners&#146; evaluation of the superiority
of RXi&#146;s technology over competing technologies, the quality of the preclinical and clinical data that RXi has generated and the perceived risks specific to developing its product candidates. If RXi is unable to obtain or maintain these
agreements, it may not be able to clinically develop, formulate, manufacture, obtain </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regulatory approvals for or commercialize its product candidates. RXi cannot necessarily control the amount or timing of resources that its contract partners will devote to RXi&#146;s research
and development programs, product candidates or potential product candidates, and we cannot guarantee that these parties will fulfill their obligations to RXi under these arrangements in a timely fashion. RXi may not be able to readily terminate any
such agreements with contract partners even if such contract partners do not fulfill their obligations to RXi. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If RXi
fails to attract, hire and retain qualified personnel, it may not be able to design, develop, market or sell its products or successfully manage its business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">RXi&#146;s business prospects are dependent on its management team and on RXi&#146;s ability to identify, attract, retain and integrate additional qualified key personnel. RXi will need to recruit and
hire a Chief Executive Officer to replace Mark J. Ahn, Ph.D., who currently serves on a part-time basis as RXi&#146;s President. RXi also is seeking a new Chief Financial Officer, as well as other key employees. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Competition for skilled research, product development, regulatory and technical personnel is intense, and RXi may not be able to recruit
and retain the personnel it needs. The loss of the services of any key research, product development, regulatory and technical personnel, or RXi&#146;s inability to hire new personnel with the requisite skills, could restrict RXi&#146;s ability to
develop its product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>RXi may not be able to obtain sufficient financing and may not be able to develop its
product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With the proceeds to be received in the RXi financing, we believe that RXi will have sufficient
working capital to fund its currently planned expenditures through the first quarter of 2013. However, in the future RXi may need to incur debt or issue equity in order to fund its planned expenditures, as well as to make acquisitions and other
investments. There is no assurance that debt or equity financing will be available to RXi on acceptable terms or at all. If RXi cannot, or is limited in the ability to, incur debt, issue equity or enter in strategic collaborations, RXi may be unable
to fund discovery and development of its product candidates, address gaps in its product offerings or improve its technology. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate that RXi will need to raise substantial amounts of money to fund a variety of future activities integral to the development
of its business, which may include, but are not limited to, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to conduct research and development to successfully develop its RNAi technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to obtain regulatory approval for its products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to file and prosecute patent applications and to defend and assess patents to protect its technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to retain qualified employees, particularly in light of intense competition for qualified scientists; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to manufacture products itself or through third parties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to market its products, either through building its own sales and distribution capabilities or relying on third parties; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to acquire new technologies, licenses or products. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We cannot assure that any needed financing will be available to RXi on acceptable terms or at all. If RXi cannot obtain additional financing in the future, its operations may be restricted, and it may
ultimately be unable to continue to develop and potentially commercialize its product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future financing may
be obtained by RXi through, and future development efforts may be paid for by, RXi&#146;s issuance of debt or equity, which may have an adverse effect on Galena and RXi&#146;s other stockholders or may otherwise adversely affect RXi&#146;s business.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If RXi raises funds through the issuance of debt or equity, any debt securities or preferred stock issued will have
rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the
holders of common stock. In addition, if RXi raises funds through the issuance of additional equity, whether through private placements or public offerings, such an issuance would dilute Galena&#146;s ownership in RXi. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The terms of debt securities may also impose restrictions on RXi&#146;s operations, which
may include limiting its ability to incur additional indebtedness, to pay dividends on or repurchase its capital stock, or to make certain acquisitions or investments. In addition, RXi may be subject to covenants requiring it to satisfy certain
financial tests and ratios, and its ability to satisfy such covenants may be affected by events outside of RXi&#146;s control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect that RXi will incur significant research and development expenses, which may make it difficult for RXi to attain
profitability, and may lead to uncertainty about RXi&#146;s ability to continue as a going concern. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Substantial funds
were expended to develop RXi&#146;s RNAi technologies, and additional substantial funds will be required for further research and development, including preclinical testing and clinical trials of any product candidates, and to manufacture and market
any products that are approved for commercial sale. Because the successful development of its products is uncertain, we are unable to precisely estimate the actual funds RXi will require to develop and potentially commercialize them. In addition,
RXi may not be able to generate enough revenue, even if it is able to commercialize any of its product candidates, to become profitable. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If RXi is unable to achieve or sustain profitability or to secure additional financing, it may not be able to meet its obligations as they come due, raising substantial doubts as to its ability to
continue as a going concern. Any such inability to continue as a going concern may result in RXi&#146;s common stock holders losing their entire investment. There is no guarantee that RXi will become profitable or secure additional financing.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_3"></A>Item&nbsp;1B.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>UNRESOLVED STAFF COMMENTS</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_4"></A>Item&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>PROPERTIES</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On July 18, 2011, we entered into a lease with LO 138, LLC for our facility located at 310 N. State Street, Suite 208, Lake Oswego, Oregon, 97034. The facility is approximately 2,100 square feet and is
used for Galena&#146;s general and administrative offices. The monthly rent is approximately $3,200. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi occupies its facility
located at 60 Prescott Street, Worcester, Massachusetts, pursuant to a lease agreement, dated September&nbsp;25, 2007, with Newgate Properties, LLC (an affiliate of Worcester Polytechnic Institute). The facility is approximately 6,800 square feet,
of which 5,600 square feet is laboratory space used for research and development and the additional 1,200 square feet is used for general and administrative offices. In May 2011, RXi reduced the total space occupied by it to approximately 5,355
square feet. On June&nbsp;9, 2011, the lease was extended through July&nbsp;31, 2012. The monthly rent is approximately $16,000. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that our facilities are suitable for our current needs. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_5"></A>Item&nbsp;3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>LEGAL PROCEEDINGS</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;21, 2011, Hudson Bay Master Fund, Ltd. (&#147;Hudson Bay&#148;) filed a Complaint against us in the United States District Court for the Southern District of New York (the
&#147;Court&#148;), captioned <U>Hudson Bay Master Fund, Ltd. v. Galena Biopharma, Inc., 11 Civ. 8432 (JPO)</U>, alleging that our plan to partially spin off RXi and related actions taken by us in preparation for the spin-off gives Hudson Bay the
right to require us to repurchase the warrants acquired by Hudson Bay in our April 2011 underwritten public offering. Hudson Bay also seeks related declaratory and injunctive relief. On January&nbsp;12, 2012, three other warrant holders affiliated
with each other filed a Complaint in the Court, captioned <U>Tenor Opportunity Fund, Ltd., Aria Opportunity Fund, Ltd., and Parsoon Opportunity Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0260</U>, and on January&nbsp;20, 2012 and February&nbsp;2,
2012, respectively, two other warrant holders filed their own Complaints in the Court, captioned <U>Cranshire Capital Master Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0493</U> and <U>Iroquois Master Fund, Ltd. v. Galena Biopharma, Inc.</U>, 12
CIV 0839, respectively. In these latest Complaints, which are substantially identical to the previous Complaints filed in the Court, the various warrant holders also claim that our planned spin-off of RXi and related actions give them the right to
require us to repurchase our outstanding warrants held by them. According to the allegations in the Complaints, the repurchase price of the plaintiffs&#146; warrants would amount to approximately $5.2 million in the aggregate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;21, 2012, we received letters from each of the plaintiff-warrant holders
withdrawing their repurchase demands with respect to their warrants covering an aggregate of 6,350,000 shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the &#147;Withdrawal Notice<B>s</B>&#148;). After
giving effect to the Withdrawal Notices, the plaintiff-warrant holders continued to demand that we repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based on the plaintiff-warrant holders&#146; claims
in their Complaints, we believe that the repurchase price for these warrants is $0.71 per underlying share, or an aggregate of $355,000. On March 27, 2012, we tendered to the plaintiff-warrant holders an aggregate of $355,000 as payment in full of
the repurchase price for those warrants. We believe that the Withdrawal Notices and our tender of payment as described above render moot the majority of claims of the plaintiff-warrant holders in their Complaints, although the Withdrawal Notices
purport to reserve all rights of the plaintiff-warrant holders under the Complaints. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_6"></A>Item&nbsp;4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>MINE SAFETY DISCLOSURES</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II. </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_7"></A>Item&nbsp;5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Market Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
common stock is listed on The NASDAQ Capital Market under the symbol &#147;GALE<B></B>&#148; The following table shows the high and low per-share sale prices of our common stock for the periods indicated: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2010</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Holders </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;26, 2012, there were approximately 700 holders of record of our common stock. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are
unable to estimate the total number of individual stockholders represented by these holders of record. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dividends </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never paid any cash dividends and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We
expect to retain future earnings, if any, for use in our development activities and the operation of our business. The payment of any future dividends will be subject to the discretion of our board of directors and will depend, among other things,
upon our results of operations, financial condition, cash requirements, prospects and other factors that our board of directors may deem relevant. Additionally, our ability to pay future dividends may be restricted by the terms of any debt
financing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Performance Graph </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Because we are a smaller reporting company, we are not required to provide this information. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Sales of Unregistered Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Set forth below is information regarding any unregistered sales by us of common stock, preferred stock, options and warrants during the period covered by this annual report that were not previously
reported by us in a Quarter Report on Form&nbsp;10-K or Current Report on Form&nbsp;8-K: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preferred Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;8, 2012, the Company issued 1,315,789 restricted shares of common stock in payment of the first milestone under the contingent value rights agreement entered into in connection with our
merger acquisition of Apthera in April 2011. The certificates evidencing the milestone shares have been deposited with the escrow </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
agent under the escrow agreement, dated as of April&nbsp;13, 2011, among the Company, the stockholder representative, and Computershare Trust Company, N.A., as Escrow Agent. The milestone shares
will be released to the former Apthera shareholders from escrow if the issuance of the milestone shares is approved by the stockholders of the Company at the Company&#146;s 2012 annual stockholders meeting. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;3, 2012, the Company issued 100,000 shares of our common stock in payment of $135,000 of accrued legal fees. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;20, 2012, the Company sold 579,710 shares of our common stock for $400,000 to Kwang Dong Pharmaceutical Company as part of
a existing license agreement for NeuVax covering territorial rights for the compound in South Korea that we acquired in our merger acquisition of Apthera. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From January 23, 2012 through March 23, 2012, the Company issued 1,369,944 shares of our common stock subject to the exercise of outstanding warrants from various warrant holders. The Company received
$1,223,464 in total payments at exercise prices ranging from $0.65 to $2.50 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing shares were issued
without registration under the Securities Act of 1933, as amended, in reliance upon the exemptions from registration afforded under Section&nbsp;4(2) of the Act and Regulation&nbsp;D under the Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock Options and Warrants </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;4, 2012, the Company granted warrants to purchase 400,000 shares of common stock at an exercise price of $0.66 per share in exchange for business advisory services to the Company for a
period of up to twelve months. The warrants vested as to 100,000 shares upon issuance, and then will vest at a rate of 100,000 shares per quarter starting on the 90-day anniversary of issuance. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing warrants were issued without registration under the Securities Act of 1933, as amended, in reliance upon the exemption from
registration afforded under Section&nbsp;4(2) of the Act. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_8"></A>Item&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>SELECTED FINANCIAL DATA</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Because we are a smaller reporting company, we are not required to provide the information required by this Item. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_9"></A>Item&nbsp;7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the following discussion in conjunction with the consolidated financial statements and the notes to consolidated financial
statements included elsewhere in this annual report. This &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. For a discussion of indicators of forward-looking statements and specific important factors that could cause actual results to differ materially from those contained in forward-looking statements, see &#147;Risk
Factors&#148; under Part I &#151; Item&nbsp;1A of this annual report. This &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section should be read and interpreted in light of such factors. Our
actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those discussed below and elsewhere in this annual report. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may have difficulty evaluating our business, because we acquired Apthera only in the past year and are undertaking to partially spin
off RXi. There is no assurance, however, that the partial spin-off will be completed. Following the partial spin-off, assuming it is completed, our financial statements will no longer reflect the consolidated financial condition and results of
operations of RXi, and we will account for our partial ownership of RXi based on the equity method of accounting. For these reasons, the historical consolidated financial information included in this annual report do not necessarily reflect the
financial condition, results of operations or cash flows that we will achieve in the future. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Background on the Company and Recent Change in Strategic Focus </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were formed in 2006 by CytRx Corporation (&#147;CytRx&#148;) and four prominent RNAi researchers. We commenced operations in January
2007, after CytRx contributed to us its portfolio of RNAi therapeutic assets consisting primarily of RNAi licenses and related intellectual property and a nominal amount of equipment. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We acquired Apthera and our NeuVax product candidate in April 2011. Prior to that time, we were engaged primarily in conducting discovery
research and preclinical development activities based on RNAi. Our acquisition of Apthera followed from the determination by our board of directors to broaden our strategic direction by giving us access to a late-stage clinical candidate, NeuVax. In
connection with our acquisition of Apthera, we reduced the scope of our RNAi activities to focus primarily on RXI-109, our lead RNAi-product, while maintaining our key development alliances and core RNAi discovery and development capability.
Following the Apthera acquisition, our board of directors undertook to explore strategic alternatives for our RNAi platform that would enable us to commit more resources to our later-stage oncology drug programs. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;27, 2012 we announced, as required by NASDAQ Listing Rule 5250(e)(6), that our board of directors had declared a
conditional dividend on Galena common stock of one share of common stock of RXi for each outstanding share of Galena common stock. The spin-off shares will be payable, subject to certain conditions described below, to our stockholders as of close of
business (Eastern time) on March 8, 2012, the record date for the distribution, in the ratio of one RXi share for each share of Galena common stock held as of the record date. In light of the conditional nature of the partial spin-off of RXi, our
board of directors has not set a payment date for the distribution, and under NASDAQ rules our common stock is not yet trading &#147;ex-dividend.&#148; The distribution of the spin-off shares will be taxable to Galena stockholders who receive RXi
shares in the distribution. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution to Galena stockholders of the spin-off shares is to be made pursuant to the
registration statement filed by RXi with the Securities and Exchange Commission and declared effective on February 14, 2012. Because the RXi registration statement will go &#147;stale&#148; on April 30, 2012, we must complete the distribution of the
spin-off shares by that date, unless we were to cause RXi to amend the registration statement. It is likely that we would abandon the partial spin-off of RXi if the distribution of the spin-off shares has not been made by April&nbsp;30, 2012,
although our board of directors has not made any decision in this regard. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The establishment of a payment date for the
distribution and the payment of the distribution is dependent upon the timing of effectiveness of an application filed with FINRA to permit RXi common stock to be traded in the OTC Markets Group under the symbol &#147;RXII.&#148; The payment of the
distribution also is conditioned upon the closing of the RXi financing, which is subject to certain closing conditions that may or may not be satisfied. In addition, the securities purchase agreement among Galena, RXi and the RXi investors provides
that the agreement may be unilaterally terminated by us or by the RXi investors if the closing of the transactions has not occurred by March&nbsp;31, 2012, and it is not possible for the closing to occur by this date. Accordingly, unless this date
is extended by mutual agreement of the RXi investors and us, either we or the RXi investors generally may terminate the securities purchase agreement at any time after March 31, 2012, unless the failure of the closing to occur was due to the fault
of the party seeking to terminate the securities purchase agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we have no present intention to terminate the
securities purchase agreement or to abandon the partial spin-off of RXi, the RXi investors may choose to do so. We also may decide to do so at any time if our board of directors determines that it is in the best interests of our company. For all of
the foregoing reasons, there is no assurance that the payment and distribution of the spin-off shares will be completed. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If
the closing of the transactions under the securities purchase agreement has not occurred by the March&nbsp;31, 2012 maturity date of the RXi convertible notes, unless such date is extended by mutual agreement by the RXi investors and us, the
permanent financing and the partial spin-off of RXi may not occur, and one-half of the outstanding principal of and accrued interest on the RXi convertible notes held by the investors will be converted into shares of RXi common stock equal to 51% of
the shares of outstanding common stock of RXi immediately upon such conversion. RXi will be obliged to repay the balance of the principal of and accrued interest on the RXi convertible notes held by the investors, and we have agreed in the
securities purchase agreement to guarantee RXi&#146;s repayment of the RXi convertible notes to the extent they are not converted. In this event, we will own 44% of the outstanding shares of RXi common stock, and RXi will carry on as a stand-alone
private company </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
under the investors&#146; control, with its own management and with whatever funding and other financial resources that may be available to it. Neither the investors in RXi nor Galena will be
obliged to provide any funding to RXi in this event, and there is no guarantee that funding will be available to RXi on acceptable terms, or at all. If RXi fails to obtain additional funding in this event, it would be forced to scale back or
terminate its operations, or to seek to merge with or to be acquired by another company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are in discussions with the RXi
investors to extend the current March 31, 2012 maturity date of the RXi convertible notes, but there is no assurance that the maturity date will be extended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Research and Development </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development programs are focused
on developing cancer therapies utilizing peptide-based immunotherapy products, including our main product candidate NeuVax, for the treatment of various cancers. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since we commenced operations, research and development has comprised a significant proportion of our total operating expenses and is expected to comprise the majority of our spending for the foreseeable
future. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are risks in any new field of drug discovery that preclude certainty regarding the successful development of a
product. We cannot reasonably estimate or know the nature, timing and costs of the efforts necessary to complete the development of, or the period in which material net cash inflows are expected to commence from, any product candidate. Our inability
to make these estimates results from the uncertainty of numerous factors, including but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to advance product candidates into preclinical research and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope and rate of progress of our preclinical program and other research and development activities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, rate of progress and cost of any clinical trials we commence; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical trial results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and timing of any collaborative, licensing and other arrangements that we may establish; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost and timing of regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost and timing of establishing sales, marketing and distribution capabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of competing technological and market developments; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of government regulation and insurance industry efforts to control healthcare costs through reimbursement policy and other cost management
strategies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure to complete any stage of the development of our product candidates in a timely manner
could have a material adverse effect on our operations, financial position and liquidity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>License Agreements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into licensing relationships with academic institutions, research foundations and commercial entities, and may seek to
enter into additional licenses with pharmaceutical and biotechnology companies. We also may enter into strategic alliances to expand our intellectual property portfolio and to potentially accelerate our development programs by gaining access to
technology and funding, including equity sales, license fees and other revenues. For each product that we develop that is covered by the patents licensed to us including our material licenses discussed elsewhere in this annual report, we are
obligated to make additional payments upon the attainment of certain specified product development milestones. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">See
&#147;Business &#151; Intellectual Property&#148; under Part I &#151; Item&nbsp;1 of this annual report for information on our material license agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Estimates </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Use of Estimates </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation of our financial statements requires management to make estimates, allocations and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related
disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to impairment of goodwill and long-lived assets, accrued liabilities and certain expenses. We base our estimates about
the carrying values of assets and liabilities that are not readily apparent from other sources on historical experience and on other assumptions believed to be reasonable under the circumstances. Actual results may differ materially from these
estimates under different assumptions or conditions. Additionally, the financial information included here may not necessarily reflect the financial position, operating results, changes in our invested equity and cash flows in the future or what
they would have been had we been a separate, stand-alone entity during the periods presented. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our significant accounting
policies are summarized in the notes to our consolidated financial statements. We believe the following critical accounting policies involve significant judgments and estimates used in the preparation of our financial statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead
related to our research and development departments as well as costs to acquire technology licenses and expenses associated with preparation of clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We follow the provisions of the Financial
Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 718, &#147;Compensation &#151; Stock Compensation&#148; (&#147;ASC 718&#148;), which requires the measurement and recognition of compensation
expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC
718 is recognized as an expense over the requisite service period. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For stock options granted as consideration for services
rendered by non-employees, we recognize compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#147;ASC 505-50&#148;), &#147;Equity Based Payments to Non- Employees.&#148; Non-employee option grants that do not vest
immediately upon grant are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes
option-pricing model, will be re-measured using the fair value of our common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to
change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The fair value of each option grant is estimated using the Black-Scholes option-pricing model, with the following weighted average assumptions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average risk free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.92%&nbsp;-&nbsp;3.16%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.88% - 3.28%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98.61%&nbsp;-&nbsp;113.87%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118.3%&nbsp;-&nbsp;133.62%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected lives (years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.71 - 9.25</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 - 10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s expected common stock price volatility assumption is based upon the volatility of a
basket of companies that we consider comparable to us. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC 718-10, which averages the contractual term of the options
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of ten years with the average vesting term of four years for an average of six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The
dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was also based upon
prevailing short-term interest rates. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has an estimated annualized forfeiture rate of 15.0% for options granted to
employees, and 8.0% for options granted to senior management and no forfeiture rate for the directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the
actual forfeiture rates are higher than estimated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Derivative Financial Instruments </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the normal course of business, from time to time, we issue warrants and options to vendors as consideration to perform services. We
may also issue warrants as part of a debt or equity financing. We do not enter into any derivative contracts for speculative purposes. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We recognize all derivatives as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge
accounting and are accounted for as such. During the years ended December&nbsp;31, 2011 and 2010, we issued warrants to purchase 18,100,000 and 540,000 shares of common stock, respectively, in connection with an equity transaction. In accordance
with ASC Topic 815-40, &#147;Derivatives and Hedging &#151; Contracts in Entity&#146;s Own Stock&#148; (&#147;ASC&nbsp;815-40&#148;), the value of these warrants is required to be recorded as a liability, as the holders have an option to put the
warrants back to us in certain events, as defined. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Goodwill, Other Intangible Assets and Impairment of Long-Lived
Assets </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Business acquisitions typically result in goodwill and other intangible assets, and the recorded values of
those assets may become impaired in the future. The determination of the value of such intangible assets requires us to make estimates and assumptions that affect our consolidated financial statements. Goodwill has an indefinite useful life and is
not amortized but is evaluated for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We record intangible assets acquired at fair value. Our intangible assets consist
primarily of acquired in-process research and development. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill and other intangible assets with indefinite lives are
tested annually for impairment at the reporting unit level utilizing the &#147;fair value&#148; methodology. Factors the Company considers important that could trigger an interim review for impairment include, but are not limited to, the following:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant changes in the manner of its use of acquired assets or the strategy for its overall business; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant negative industry or economic trends; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant decline in stock price for a sustained period; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant decline in market capitalization relative to net book value. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill and other intangible assets with indefinite lives are evaluated for impairment using the two-step process. The first step is to
compare the fair value of the reporting unit to the carrying amount of the reporting unit (the &#147;First Step&#148;). If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment (the &#147;Second
Step&#148;). Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill, the Company determines fair
values of its intangible assets using the Income Approach, or more specifically the Discounted Cash Flow Method. This valuation method requires management to project revenues, operating expenses, working capital investment, capital spending and cash
flows for the reporting units over a multiyear period, as well as determine the weighted average cost of capital to be used as a discount rate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Long-lived assets, held and used are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be entirely recoverable. When such factors and
circumstances exist, we compare the projected undiscounted future cash flows associated with the related asset or group of assets over </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in
the period in which the determination was made. Any resulting impairment losses recorded by the Company could have an adverse impact on our results of operations by either decreasing net income or increasing net loss. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with its annual impairment test, the Company performed its review for impairment. Based upon the valuation approach
described above, the Company determined that the current carrying value of its goodwill had not been impaired. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill
amounted to $5.9 million and $0 as of December&nbsp;31, 2011 and 2010, respectively. There was no amortization of goodwill for the years ended 2011 and 2010. Other intangible assets amounted to $12.9 million and $0 million as of December&nbsp;31,
2011 and 2010, respectively. There was no amortization of other intangible assets for the years ended 2011 and 2010. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purchase Price Allocation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We allocate the purchase price of our acquisitions to the assets and liabilities acquired, including identifiable intangible assets, based on their respective fair values at the date of acquisition. Some
of the items, including property and equipment, other intangible assets, certain accrued liabilities and other reserves require a degree of management judgment. Certain estimates may change as additional information becomes available. Management
finalizes the purchase price allocation within 12 months of the acquisition date as certain initial accounting estimates are resolved. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Acquired In-Process Research and Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2011, we recorded
$12.9 million of acquired in-process research and development related to our acquisition of Apthera. The projects acquired in the acquisition consisted primarily of the clinical development related to its clinical oncology program, primarily the
NeuVax compound for breast cancer patients.&nbsp;We purchased this with the intent of clinically developing the NeuVax compound for market approval. At the date we acquired the NeuVax compound, the program was in the midst of a Phase 2 clinical
trial.&nbsp;In order to commercialize this drug, the Company will need to complete at least one Phase 3 clinical trial.&nbsp;On January&nbsp;19, 2012, we initiated our Phase 3 PRESENT trial for NeuVax&#153; (E75 peptide plus GM-CSF) vaccine in
low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The cost of this Phase 3 clinical trial is expected to exceed $50 million to reach its primary
endpoint. We do not expect to commence commercialization of NeuVax prior to 2017, if at all.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Valuation of Contingent
Earnout Consideration </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisitions may include contingent consideration payments based on the achievement of certain
future financial performance measures of the acquired company. Contingent consideration is required to be recognized at fair value as of the acquisition date. We estimate the fair value of these liabilities based on financial projections of the
acquired companies and estimated probabilities of achievement. We believe our estimates and assumptions are reasonable; however, there is significant judgment involved. We evaluate, on a routine, periodic basis, the estimated fair value of the
contingent consideration and changes in estimated fair value, subsequent to the initial fair value estimate at the time of the acquisition, are reflected in income or expense in the consolidated statements of expenses. Changes in the fair value of
contingent consideration obligations may result from changes in discount periods and rates, changes in the timing of development milestones achieved and changes in probability assumptions with respect to the likelihood of achieving the various
earnout criteria. Any changes in the estimated fair value of contingent consideration may have a material impact on our operating results. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the year ended December&nbsp;31, 2011, our net loss was approximately $11,485,000 compared with a net loss of $11,993,000 for the year ended December&nbsp;31, 2010. The primary reasons for the
variation in the net loss between the years are discussed below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since we are a development-stage biopharmaceutical company, we have not generated any revenue since inception through December&nbsp;31,
2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense (in thousands) </I></B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development employee stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development non-employee stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,538</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense consists primarily of compensation-related costs for our employees
dedicated to research and development activities and for clinical trial related costs, licensing fees, patent prosecution costs, and the cost of lab supplies used in our research and development programs. We expect to continue to devote a
substantial portion of our resources to research and development programs. As a result of the costs expected to be incurred in connection with our recently commenced clinical trials of NeuVax and FBP, we expect that our research and development
expense will increase significantly from historic levels for the foreseeable future. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expenses
for the year ended December&nbsp;31, 2011 was approximately $11,538,000 as compared to $7,873,000 for the year ended December&nbsp;31, 2010. The increase of $3,665,000, or 47%, was due to an increase of $4,696,000 in research and development cash
expenses related to preparation for our Phase 3 PRESENT clinical trial of NeuVax, which was partially offset by a decrease of $218,000 in employee stock-based compensation and a $813,000 decrease in non-employee stock based compensation expense.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Non-Employee Stock-Based Compensation Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We issued options to purchase shares of our common stock as compensation to our Scientific Advisory Board (&#147;SAB&#148;) members and
consultants. For financial statement purposes, we valued these shares at their fair value. Fluctuations in non-employee stock-based compensation expense results from variations in the number of common stock options issued, vesting schedules and the
Black-Scholes fair values of common stock options granted to SAB members. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense (in
thousands) </I></B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock warrants issued for general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock and stock options issued for general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total general and administrative expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense includes compensation-related costs for our employees
dedicated to general and administrative activities, legal fees, audit and tax fees, consultants and professional services, and general corporate expenses. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Total general and administrative expense was $9,249,000 for the year ended December&nbsp;31, 2011 compared with $8,752,000 for the year ended December&nbsp;31, 2010. The increase of $497,000, or 6%, was
primarily due to an increase of $1,370,000 in general and administrative expense related to an increase in legal, audit and other professional services, and an increase of $73,000 for non-cash share-based compensation expense issued in exchange for
services, which increases were partially offset by a decrease of $610,000 from warrants issued for business advisory services and $336,000 in non-cash share based compensation expense. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we expect to issue shares of our common stock or warrants or options to purchase shares of our common stock to
consultants and other service providers in exchange for services. For financial statement purposes, we will value these shares of common stock, common stock options, and warrants at their fair value. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interest Income </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Interest income was negligible for both the year ended December&nbsp;31, 2011, and December&nbsp;31, 2010. The key objectives of our investment policy are to preserve principal and ensure sufficient
liquidity, so our invested cash may not earn as high a level of income as longer-term or higher risk securities, which generally have less liquidity and more volatility. The interest rates available on lower risk, shorter-term investments in
today&#146;s market are lower than rates available in the prior period. We expect to have interest income in future periods based on our current account balances and potentially from additional capital we may receive in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other income (expense) is summarized as follows (in thousands): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on warrant exchange</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of common stock warrants issued</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,886</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduction of potential redemption liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in contingent purchase liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">793</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income was $9,302,000 and $4,632,000 for the years ended December&nbsp;31, 2011 and 2010,
respectively. The overall increase of $4,670,000, or 101%, was due to an increase of $6,837,000 attributable to the change in fair value of common stock warrants outstanding, which was partially offset by $900,000 due to the loss on warrant
exchange, a decrease of $785,000 attributed to a decrease of potential redemption liability and a decrease of $616,000 in other income, representing primarily a decrease in grant income. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There was no income tax expense for the years ended December&nbsp;31, 2011 and 2010 due to the fact that we have incurred significant tax losses since we began operations. A deferred tax benefit would
have been recorded for losses; however, due to the uncertainty of realizing the tax benefit, a valuation allowance was recognized which fully offset the deferred tax benefit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We had cash and cash equivalents of
approximately $11.4 million as of December&nbsp;31, 2011 and approximately $8.2 million as of March&nbsp;26, 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not generated revenue to date and may not generate product revenue in the
foreseeable future, if ever. We expect to incur significant operating losses as we advance our product candidates through the drug development and regulatory process. As a result of the increased research and development expense expected to be
incurred in connection with our recently commenced clinical trials of NeuVax and FBP, we expect that our expenses will increase significantly from historic levels for the foreseeable future. In addition to increasing research and development
expense, we expect general and administrative costs to increase as we conduct future clinical trials. We will need to generate significant revenue to achieve profitability and might never do so. In the absence of product revenue, our potential
sources of operational funding are expected to be the proceeds from the sale of equity, funded research and development payments and payments received under partnership and collaborative agreements. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;17, 2012, we entered into a Controlled Equity Offering</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> sales agreement with Cantor Fitzgerald&nbsp;&amp; Co.
(&#147;Cantor&#148;), pursuant to which we may offer and sell from time to time through Cantor, acting as agent, shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to $10 million. The offer and sale of
our shares through Cantor will be registered pursuant to our Registration Statement on Form S-3 (File No.&nbsp;333-167025) declared effective by the SEC on May&nbsp;21, 2010 and is described in detail in the related prospectus supplement dated
February&nbsp;17, 2012 filed with the SEC and the prospectus dated May&nbsp;21, 2010 included as part of our Registration Statement.<B> </B>The offering pursuant to the sales agreement will terminate upon the sale of all shares subject to the sales
agreement or the earlier termination of the sales agreement as permitted therein. There is no assurance that additional funding will be available to the Company on acceptable terms or at all. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the sales agreement, Cantor may sell shares of our common stock by any method permitted by law deemed to be an
&#147;at-the-market&#148; offering as defined in Rule 415 of the SEC Securities Act of 1933, as amended, including, but not limited to, sales made directly on The NASDAQ Capital Market, on any other existing trading market for our common stock or to
or through a market maker. Cantor may also sell our shares under the sales agreement by any other method permitted by law, including in privately negotiated transactions. Cantor has agreed in the sales agreement to use its commercially reasonable
efforts to sell shares in accordance with our instructions (including any price, time or size limit or other customary parameters or conditions we may impose). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe that our existing cash and cash equivalents and the proceeds from the sales agreement should be sufficient to fund our operations through at least the first quarter of 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Cash Flow from Operating Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities was approximately $14,668,000 for the year ended December&nbsp;31, 2011 compared with $10,257,000 net cash used in operating activities for the year ended
December&nbsp;31, 2010. The increase of approximately $4,411,000 resulted from a net loss of $11,485,000, less non-cash items of $5,738,000, of which $3,074,000 related to stock-based compensation, $108,000 related to stock warrant expense in
exchange for services, $900,000 related to a loss on equity instruments, $163,000 related to depreciation, $109,000 related to a decrease in the fair value of the contingent purchase consideration, $9,881,000 that reflects the fair value of warrants
and mandatorily redeemable stock obligations issued with financings completed by the Company and $2,255,000 related to changes in current assets and liabilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Cash Flow from Investing Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by
investing activities was approximately $14,000 for the year ended December&nbsp;31, 2011, compared with net cash used in investing activities of $106,000 for the year ended December&nbsp;31, 2010. The increase of approximately $121,000 in cash
provided by investing activities was due to $101,000 change in restricted cash, $168,000 of cash received in connection with our acquisition and a decrease of $53,000 in cash paid for equipment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Cash Flow from Financing Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities was approximately $19,196,000 for the year ended December&nbsp;31, 2011, compared with $11,570,000 for the year ended December&nbsp;31, 2010. This increase of
approximately $7,626,000 was primarily due to not purchasing any treasury shares in 2011 compared with the purchase of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
$3,849,000 during 2010, an increase in net proceeds from the issuance of common stock of $3,380,000 and $500,000 of notes payable incurred by RXi during 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Recently Issued Accounting Pronouncements </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In December 2010, the FASB issued ASC Update 2010-29, Business Combinations (Topic 805) &#151;<I> Disclosure of Supplementary Pro Forma Information for Business Combinations</I> (Update No.&nbsp;2010-29).
This Update requires a public entity to disclose pro forma information for business combinations that occurred in the current reporting period. The disclosures include pro forma revenue and earnings of the combined entity for the current reporting
period as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. If comparative financial statements are presented, the pro forma revenue and earnings of
the combined entity for the comparable prior reporting period should be reported as though the acquisition date for all business combinations that occurred during the current year had been as of the beginning of the comparable prior annual reporting
period. This Update affects any public entity that enters into business combinations that are material on an individual or aggregate basis and is effective prospectively for business combinations for which the acquisition date is on or after the
beginning of the first annual reporting period beginning on or after December&nbsp;15, 2010. All disclosures are presented in accordance with the acquisition of Apthera, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Recently Adopted Accounting Pronouncements </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May&nbsp;2011, the FASB
issued Accounting Standards Updated (&#147;ASU&#148;) 2011-04<I>, Fair Value Measurement</I> (Topic 820): <I>Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs</I> , a new accounting standard that
clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on a prospective
basis for annual and interim reporting periods beginning on or after December&nbsp;15, 2011. The Company does not expect that adoption of this new standard will have a material impact on its consolidated financial statements. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June&nbsp;2011, the FASB issued ASU 2011-05, <I>Comprehensive Income</I> (Topic 220): <I>Presentation of Comprehensive Income</I>, a
new accounting standard that eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders&#146; equity, requires the consecutive presentation of the statement of net income and
other comprehensive income and requires an entity to present reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this new standard do not change the items that must be
reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This new standard is required to be applied
retrospectively and is effective for fiscal years and interim periods within those years beginning after December&nbsp;15, 2011. As this new standard only requires enhanced disclosure, the adoption of this standard will not impact the Company&#146;s
consolidated financial statements. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September&nbsp;2011, the FASB issued ASU 2011-08, <I>Intangibles &#151; Goodwill and
Other</I> (Topic 350): Testing Goodwill for Impairment, a new accounting standard to simplify how entities test goodwill for impairment. The amendments in the Update permit an entity to first assess qualitative factors to determine whether it is
more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in Topic 350. The more-likely-than-not
threshold is defined as having a likelihood of more than 50 percent. Previous guidance under Topic 350 required an entity to test goodwill for impairment, on at least an annual basis, by comparing the fair value of a reporting unit with its carrying
amount, including goodwill (step one). If the fair value of a reporting unit is less than its carrying amount, then the second step of the test must be performed to measure the amount of the impairment loss, if any. Under the amendments in this
Update, an entity is not required to calculate the fair value of a reporting unit unless the entity determines that it is more likely than not that its fair value is less than its carrying amount. This new standard is effective for fiscal years
beginning after December&nbsp;15, 2011; however, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
early adoption is permitted. The Company does not expect that adoption of this new standard will have a material impact on its consolidated financial statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with certain license agreements, we are required to indemnify the licensor for certain damages arising in connection with the intellectual property rights licensed under the agreement. In
addition, we are a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate us to indemnify the other parties to such agreements upon the occurrence of certain events. These
indemnification obligations are considered off-balance sheet arrangements in accordance with ASC Topic 460 (&#147;ASC 460&#148;), &#147;Guarantor&#146;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of
Indebtedness of Others.&#148; To date, we have not encountered material costs as a result of such obligations and have not accrued any liabilities related to such obligations in our financial statements. See Note 9 of the notes to consolidated
financial statements included in this annual report for further discussion of these indemnification agreements. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_10"></A>Item&nbsp;7A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because we are a smaller reporting company, we are not required to provide the information required by this Item. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_11"></A>I<A NAME="index"></A>tem&nbsp;8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page&nbsp;No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Index to Financial Statements</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin275067_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin275067_2">Consolidated Balance Sheets as of December&nbsp;31, 2011 and 2010</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin275067_3">Consolidated Statements of Expenses for the years ended December&nbsp;
31, 2011 and 2010 and the cumulative period from inception (January&nbsp;1, 2003)&nbsp;through December&nbsp;31, 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin275067_4">Consolidated Statements of Stockholders&#146; Equity for the period from April&nbsp;
3, 2006 through December&nbsp;31, 2011 and Parent Company&#146;s Net Deficit for the period from December&nbsp;31, 2003 through December&nbsp;31, 2006</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin275067_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;
31, 2011 and 2010 and the cumulative period from inception (January&nbsp;1, 2003)&nbsp;through December&nbsp;31, 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin275067_6">Notes to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin275067_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Board of Directors and Stockholders </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake Oswego, Oregon </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying consolidated balance sheets of Galena Biopharma, Inc., formerly RXi Pharmaceuticals Corporation, (a
development stage company) (the &#147;Company&#148;) as of December&nbsp;31, 2011 and 2010 and the related consolidated statements of expenses, stockholders&#146; equity, and cash flows for the years then ended and for the period from
January&nbsp;1, 2003 (date of inception) to December&nbsp;31, 2011. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our
opinion. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the
consolidated financial position of Galena Biopharma, Inc. as of December&nbsp;31, 2011 and 2010 and the results of its operations and its cash flows for the years then ended and for the period from January&nbsp;1, 2003 (date of inception) to
December&nbsp;31, 2011, in conformity with accounting principles generally accepted in the United States of America. </FONT></P>
<P STYLE="margin-top:36px;margin-bottom:0px; margin-left:50%"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;BDO USA, LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boston, Massachusetts </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin275067_2"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands, except share data) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furnishings, net of accumulated depreciation and amortization of $657 and $491 in 2011 and 2010,
respectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In-process research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expense and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current maturities of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of warrants potentially settleable in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current contingent purchase price consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,782</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital lease obligations, net of current maturities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax liability, non-current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contingent purchase price consideration, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,856</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and contingencies (Note 9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.0001&nbsp;par value; 5,000,000&nbsp;shares authorized; no shares issued and outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.0001&nbsp;par value; 125,000,000&nbsp;shares authorized and 47,811,453 shares issued and 47,136,453 shares
outstanding at December&nbsp;31, 2011; and 50,000,000 shares authorized and 19,047,759&nbsp;shares issued and 18,372,759&nbsp;outstanding at December&nbsp;31, 2010, respectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deficit accumulated during the developmental stage</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(67,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(55,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less treasury shares at cost, 675,000 shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin275067_3"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF EXPENSES </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands, except share and per share data) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December&nbsp;31,<BR>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period from<BR>January&nbsp;1,<BR>2003 (Date of<BR>Inception)
to<BR>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development employee stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development non-employee stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for licensing rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,538</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock warrants issued for general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative employee stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,319</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,787</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(90,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income/(expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on warrant exchange</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(77,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(77,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss per common share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average common shares outstanding: basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,334,413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,883,381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <P STYLE="margin-top:68px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin275067_4"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY FOR THE PERIOD FROM </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APRIL 3, 2006 TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DECEMBER 31, 2011 AND PARENT COMPANY&#146;S NET DEFICIT FOR THE PERIOD </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FROM DECEMBER 31, 2003 TO DECEMBER 31, 2006 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands, except share and per share data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Paid-In</B></FONT>
<br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Deficit</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>During
</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Development</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stage</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Treasury</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock</B></FONT></TD>

<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Parent</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company&#146;s<BR>Net
Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Issued</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Predecessor</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2003</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net transactions with Parent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2004</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,209</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,209</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net transactions with Parent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net transactions with Parent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Successor</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at April&nbsp;3, 2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,624,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,624,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued to CytRx for contribution of RXi and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,040,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued for cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,273,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued to CytRx for reimbursement of expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">188,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses incurred by CytRx for RXi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued to UMMS for additional intellectual properties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">462,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued to directors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued upon exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,045</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation for directors and employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,684,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Paid-In</B></FONT>
<br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Deficit</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>During
</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Development</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stage</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Treasury</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock</B></FONT></TD>

<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Parent</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company&#146;s<BR>Net
Deficit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares<BR>Issued</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock, net of offering costs of $796</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,073,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued upon exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation for directors and employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock warrant expense in exchange for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,763,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock, net of offering costs of $636</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,385,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock warrants issued in connection with the 2009 Offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,863</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued upon exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued as commitment fee in connection with SEDA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for directors and employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock warrant expense in exchange for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,207,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(43,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock, net of offering costs of $965</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,700,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of 675,000&nbsp;shares of treasury stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock warrants issued in connection with 2010 offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued upon exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of restricted stock units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for directors and employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Value of common stock warrants issued in exchange for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,047,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(55,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Paid-In</B></FONT>
<br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Deficit</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>During
</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Development</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stage</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Treasury</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock</B></FONT></TD>

<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Parent</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company&#146;s<BR>Net
Deficit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares<BR>Issued</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock, net of offering costs of $1,890</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,650,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock warrants issued in connection with the 2011 common stock offerings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of stock in lieu of cash bonus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of restricted stock units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock upon exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock in cashless exchange of outstanding warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,151,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock related to acquisition of Apthera, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,974,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock subject to employee termination agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">398,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock in connection with employee stock purchase plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for directors and employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation expense for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Value of common stock warrants issued in exchange for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,811,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(67,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:238px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin275067_5"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December&nbsp;31,<BR>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period from<BR>January&nbsp;1,<BR>2003 (Date
of<BR>Inception)<BR>through<BR>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(77,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustment to reconcile net loss to net cash used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on disposal of equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash rent expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accretion and receipt of bond discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash share based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on exchange of equity instruments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock warrants issued in exchange for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of common stock warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,072</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for licensing rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to former parent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used in operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from investing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash received in acquisition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maturities of short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for purchase of equipment and furnishings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(739</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disposal of equipment and furnishings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash refunded (paid) for lease deposit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by (used in) investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December&nbsp;31,<BR>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period from<BR>January&nbsp;1,<BR>2003 (Date
of<BR>Inception)<BR>through<BR>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from financing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds from issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,982</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for repurchase of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds from exercise of common stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds from exercise of common stock warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued in connection with ESPP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds from issuance of convertible notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash advances from former parent company, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at the beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosure of cash flow information:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash received during the periods for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid during the periods for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosure of non-cash investing and financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlement of corporate formation expenses in exchange for common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of warrants issued in connection with common stock recorded as cost of equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock in exchange of outstanding warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allocation of management expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furnishings exchanged for common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furnishings acquired through capital lease</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">277</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash lease deposit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Value of restricted stock units and common stock issued in lieu of cash bonuses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Apthera Acquisition:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of shares issued to acquire Apthera</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of contingent purchase price consideration in connection with Apthera acquisition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net assets acquired excluding cash of $168</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">See accompanying notes to consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin275067_6"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Nature of Business </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma Inc. (&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Galena&#148; or the &#147;Company&#148;)
is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. Galena is pursuing the development of novel cancer therapeutics using
peptide-based immunotherapy products, including our main product candidate, NeuVax (E75), for the treatment of various cancers. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company was incorporated as Argonaut Pharmaceuticals, Inc., in Delaware, on April&nbsp;3, 2006. The Company changed its name to RXi
Pharmaceuticals Corporation on November&nbsp;28, 2006. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We acquired Apthera and our NeuVax product candidate in April 2011.
Prior to that time, we were engaged primarily in conducting discovery research and preclinical development activities based on RNAi. Our acquisition of Apthera followed from the determination by our board of directors to broaden our strategic
direction by giving us access to a late-stage clinical candidate, NeuVax. In connection with our acquisition of Apthera, we reduced the scope of our RNAi activities to focus primarily on RXI-109, our lead RNAi-product, while maintaining our key
development alliances and core RNAi discovery and development capability. Following the Apthera acquisition, our board of directors undertook to explore strategic alternatives for our RNAi platform that would enable us to commit more resources to
our later-stage oncology drug programs. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;26, 2011, the Company changed its name from RXi Pharmaceuticals
Corporation to Galena Biopharma, Inc. in connection with the Company&#146;s planned separation into two companies: (i)&nbsp;Galena, which will operate as a late-stage oncology drug development company; and (ii)&nbsp;RXi Pharmaceuticals Corporation,
or RXi, which will continue to develop novel RNAi-based therapies utilizing our historical RNAi assets. RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in the
Company&#146;s name to Galena. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the Company has not generated any revenue from inception through December&nbsp;31, 2011, the
Company is considered a development-stage company for accounting purposes. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company had cash and cash
equivalents of approximately $11.4 million as of December&nbsp;31, 2011. On February&nbsp;17, 2012, the Company entered into a Controlled Equity Offering</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> sales agreement with Cantor Fitzgerald&nbsp;&amp; Co. (&#147;Cantor&#148;), pursuant to which the Company may offer
and sell from time to time through Cantor, acting as agent, shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to $10 million. The offer and sale of our shares through Cantor will be registered pursuant
to the Company&#146;s Registration Statement on Form S-3 (File No.&nbsp;333-167025) declared effective by the Securities and Exchange Commission (the &#147;SEC&#148;) on May&nbsp;21, 2010. The offering pursuant to the sales agreement will terminate
upon the sale of all shares subject to the sales agreement or the earlier termination of the sales agreement as permitted therein. There is no assurance that additional funding will be available to the Company on acceptable terms, or at all.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company believes that its existing cash and cash equivalents should be sufficient to fund its operations through at least
the first quarter of 2013. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has not generated revenue to date and may not generate product revenue in the
foreseeable future, if ever. The Company expects to incur significant operating losses as it advances its product candidates through the drug development and regulatory process. The Company expects to continue to devote a substantial portion of its
resources to research and development programs. As a result of the costs expected to be incurred in connection with our recently commenced clinical trials of NeuVax and FBP, the Company expects that their research and development expense will
increase significantly from historic levels for the foreseeable future. The Company will need to generate significant revenue to achieve profitability and might never do so. In the absence of product revenue, our potential sources of operational
funding are expected to be the proceeds from equity financings, funded research and development payments and payments received under partnership and collabo-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
rative agreements. There is no guarantee that additional funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, it
would be forced to scale back or terminate operations or to seek to merge with or to be acquired by another company. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;Basis of Presentation and Summary of Significant Accounting Policies </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Uses of estimates in preparation of financial statements </I>&#151; The preparation of financial statements in
accordance with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Principles of Consolidation </I>&#151;&nbsp;The consolidated financial statements include the accounts of Galena and its wholly owned
subsidiaries. All material intercompany accounts have been eliminated in consolidation.</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cash and Cash Equivalents </I>&#151;
The Company considers all highly-liquid debt instruments with an original maturity of 90&nbsp;days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted Cash </I>&#151; Restricted cash consists of certificates of deposit on hand with the Company&#146;s financial institutions
as collateral for its corporate credit cards. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fair Value of Financial Instruments </I>&#151; The carrying amounts reported
in the balance sheet for cash equivalents, accounts payable, convertible notes payable and capital leases approximate their fair values due to their short-term nature and market rates of interest. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Equipment and Furnishings</I> &#151; Equipment and furnishings are stated at cost and depreciated using the straight-line method based
on the estimated useful lives (generally three to five years for equipment and furniture) of the related assets. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Goodwill
and Intangible Assets </I>&#151; Goodwill has an indefinite useful life and is not amortized but is evaluated for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The In-Process Research&nbsp;&amp; Development (&#147;IPR&amp;D&#148;) asset is considered an indefinite-lived intangible asset and is not
subject to amortization. IPR&amp;D must be tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment test consists of a comparison of the fair value of the
IPR&amp;D with its carrying amount. If the carrying amount of the IPR&amp;D exceeds its fair value, an impairment loss must be recognized in an amount equal to that excess. After an impairment loss is recognized, the adjusted carrying amount of the
IPR&amp;D will be its new accounting basis. Subsequent reversal of a previously recognized impairment loss is prohibited. The initial determination and subsequent evaluation for impairment, of the IPR&amp;D asset requires management to make
significant judgments and estimates. The Company believes no impairment of its IPR&amp;D exists as of December 31, 2011. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company records intangible assets at historical cost or fair value, if acquired through an acquisition. Intangible assets consist primarily of acquired in process research and development and clinical data that has been generated thereof. Goodwill
is tested for impairment annually utilizing the &#147;fair value&#148; methodology. The annual measurement date is December&nbsp;31. Factors the Company considers important that could trigger an interim review for impairment include, but are not
limited to, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant changes in the manner of its use of acquired assets or the strategy for its overall business; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant negative industry or economic trends; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant decline in stock price for a sustained period; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant decline in market capitalization relative to net book value. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill is evaluated for impairment using a two-step process. The first step is to
compare the fair value to the carrying amount (the &#147;First Step&#148;). If the carrying amount exceeds the fair value, a second step must be followed to calculate potential impairment (the &#147;Second Step&#148;). Otherwise, if the fair value
exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill, the Company determines fair value using the Income Approach, or more specifically the
Discounted Cash Flow Method. This valuation method requires management to project revenues, operating expenses, working capital investment, capital spending and cash flows for the reporting unit over a multi-year period, as well as determine the
weighted average cost of capital to be used as a discount rate. The 2011 analysis confirmed that fair values exceeded carrying values and, therefore, no impairment existed.</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Contingent Consideration </I>&#151; Contingent consideration is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is remeasured at each
reporting period with any adjustments in fair value included in our consolidated statement of expenses. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Patents and Patent
Application Costs </I>&#151; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as
incurred. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share-based Compensation </I>&#151; The Company follows the provisions of the Financial Accounting Standards
Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 718, &#147;<I>Compensation&nbsp;&#151; Stock Compensation&#148; </I>(&#147;ASC 718&#148;), which requires the measurement and recognition of compensation expense for
all stock based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&nbsp;718 is
recognized as an expense over the requisite service period. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For stock options granted as consideration for services rendered
by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#147;ASC 505-50&#148;), &#147; <I>Equity Based Payments to Non- Employees</I> .&#148; Non-employee option grants that do not
vest immediately upon grant are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes
option-pricing model, will be re-measured using the fair value of the Company&#146;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to
non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognized ($70,000) and $743,000 of stock based compensation expense related to non-employee stock options for the years
ended December&nbsp;31, 2011 and 2010, respectively. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Derivative Financial Instruments </I>&#151; During the normal course
of business, from time to time, the Company issues warrants and options to vendors as consideration to perform services. It may also issue warrants as part of a debt or equity financing. The Company does not enter into any derivative contracts for
speculative purposes. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognizes all derivatives as assets or liabilities measured at fair value with changes in
fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with FASB ASC Topic 815-40, &#147;<I>Derivatives and Hedging&nbsp;&#151; Contracts
in Entity&#146;s Own Stock,&#148; </I>the value of these warrants is required to be recorded as a liability, as the holders have an option to put the warrants back to the Company upon the occurrence of certain events set forth in the warrant
agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Obligations to Repurchase Shares of the Company&#146;s Equity Securities </I>&#151; In accordance with FASB ASC
Topic 480-10, <I>&#147;Distinguishing Liabilities from Equity,&#148;</I> the Company recognizes all obligations to repurchase shares of its equity securities that require or may require the Company to settle the obligation by transferring assets, as
liabilities or assets in some circumstances measured at fair value with changes in fair value reflected as current period income or loss and are accounted for as such. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development Expenses </I>&#151; Research and development costs are
expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, clinical trial related expenses, facilities, supplies, external services and overhead directly related to the Company&#146;s research and
development departments as well as costs to acquire technology licenses. We recognize expenses for these costs based on a variety of factors, including estimates provided by third parties or the Company&#146;s employees, measuring changes in
activities and reviewing various milestones that may have been achieved. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Income Taxes </I>&#151; The Company recognizes
liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&nbsp;740-10, &#147;<I>Accounting for
Income Taxes&#148; (&#147;ASC 740-10&#148;).</I> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. <I>ASC 740-10</I> requires
that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and
valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax
assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#146;s income tax provision or benefit. The recognition and measurement of benefits related to the Company&#146;s
tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&#146;s assumptions or
changes in the Company&#146;s assumptions in future periods are recorded in the period they become known </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Concentrations of
Credit Risk </I>&#151; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks,
which at times are in excess of federally insured limits. As of December&nbsp;31, 2011, the Company&#146;s cash equivalents were invested in money market mutual funds. The Company&#146;s investment policy disallows investment in any debt securities
rated less than &#147;investment grade&#148; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. All of the non-interest bearing cash balances were fully insured at December&nbsp;31,
2011 due to temporary federal program in effect from December&nbsp;31, 2010 through December&nbsp;31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning in 2013, insurance coverage will revert to
$250,000 per depositor at each financial institution, and the non-interest bearing cash balances may again exceed federally insured limits. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Comprehensive Loss </I>&#151; The Company&#146;s comprehensive loss is equal to its net loss for all periods presented. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Parent Company&#146;s Net Deficit </I>&#151; The Parent Company&#146;s Net Deficit of the Predecessor consists of CytRx&#146;s initial investment in RXi and subsequent changes in RXi&#146;s net
investment resulting from RXi being an integrated part of CytRx. All disbursements for the Predecessor were made by CytRx. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;Recent Accounting Pronouncements </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Recently Adopted Accounting Pronouncements </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In December 2010, the FASB issued ASC Update 2010-29, Business Combinations (Topic 805) &#151;<I> Disclosure of Supplementary Pro Forma Information for Business Combinations</I> (Update No.&nbsp;2010-29).
This Update requires a public entity to disclose pro forma information for business combinations that occurred in the current reporting period. The disclosures include pro forma revenue and earnings of the combined entity for the current reporting
period as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. If comparative financial statements are presented, the pro forma revenue and earnings of
the combined entity for the comparable prior reporting period should be reported as though the acquisition date for all business combinations that occurred during the current year had been as of the beginning of the comparable prior annual reporting
period. This Update affects any public entity that enters into business combi-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
nations that are material on an individual or aggregate basis and is effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first
annual reporting period beginning on or after December&nbsp;15, 2010. All disclosures are presented in accordance with the acquisition of Apthera, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Recently Issued Accounting Pronouncements </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May&nbsp;2011, the FASB
issued Accounting Standards Updated (&#147;ASU&#148;) 2011-04<I>, Fair Value Measurement</I> (Topic 820): <I>Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.</I> <I>GAAP and IFRSs</I> , a new accounting
standard that clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on
a prospective basis for annual and interim reporting periods beginning on or after December&nbsp;15, 2011. The Company does not expect that adoption of this new standard will have a material impact on its consolidated financial statements.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June&nbsp;2011, the FASB issued ASU 2011-05, <I>Comprehensive Income</I> (Topic 220): <I>Presentation of Comprehensive
Income</I>, a new accounting standard that eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders&#146; equity, requires the consecutive presentation of the statement of net
income and other comprehensive income and requires an entity to present reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this new standard do not change the items
that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This new standard is required to be
applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December&nbsp;15, 2011. As this new standard only requires enhanced disclosure, the adoption of this standard will not impact the
Company&#146;s consolidated financial statements. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September&nbsp;2011, the FASB issued ASU 2011-08, <I>Intangibles &#151;
Goodwill and Other</I> (Topic 350): <I>Testing Goodwill for Impairment</I>, a new accounting standard to simplify how entities test goodwill for impairment. The amendments in the Update permit an entity to first assess qualitative factors to
determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in Topic 350. The
more-likely-than-not threshold is defined as having a likelihood of more than 50 percent. Previous guidance under Topic 350 required an entity to test goodwill for impairment, on at least an annual basis, by comparing the fair value of a reporting
unit with its carrying amount, including goodwill (step one). If the fair value of a reporting unit is less than its carrying amount, then the second step of the test must be performed to measure the amount of the impairment loss, if any. Under the
amendments in this Update, an entity is not required to calculate the fair value of a reporting unit unless the entity determines that it is more likely than not that its fair value is less than its carrying amount. This new standard is effective
for fiscal years beginning after December&nbsp;15, 2011; however, early adoption is permitted. The Company adopted this standard for the fiscal year ended December&nbsp;31, 2011. The adoption of this standard had no material impact on the
Company&#146;s consolidated financial statements. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Apthera Acquisition </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;13, 2011, the Company completed its acquisition of Apthera, Inc., a Delaware corporation
(&#147;Apthera&#148;), under an Agreement and Plan of Merger (&#147;Merger Agreement&#148;) entered into on March&nbsp;31, 2011. Subject to the terms and conditions of the Merger Agreement, the Company&#146;s wholly owned subsidiary formed for this
purpose was merged with and into Apthera, with Apthera surviving as a wholly-owned subsidiary of the Company. Under the Merger Agreement, the Company issued to Apthera&#146;s stockholders approximately 5.0&nbsp;million shares of common stock of the
Company (the &#147;Aggregate Stock Consideration&#148;) and agreed to make future contingent payments of up to $32&nbsp;million based on the achievement of certain development and commercial milestones relating to the Company&#146;s NeuVax&#153;
product candidate. The contingent consideration is payable, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
at the election of the Company, in either cash or additional shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it
has first obtained approval of its stockholders in accordance with Rule 5635(a) of the NASDAQ Marketplace Rules. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection
with the Merger Agreement, the Company deposited with a third-party escrow agent certificates representing 10% of the Aggregate Stock Consideration, which shares will be available to compensate the Company and related parties for certain
indemnifiable losses as described in the merger agreement. On October&nbsp;13, 2011, the escrow agent released from the escrow 5% of the Aggregate Stock Consideration, or 248,705 shares. The remaining Aggregate Stock Consideration held with the
escrow agent is expected to be released in April 2012. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s acquisition of Apthera was in concert with the
decision by the Company&#146;s Board of Directors to diversify its development programs and to become a late stage clinical development company. The Company does not expect any of its goodwill to be deductible for tax purposes. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purchase price consideration and allocation of purchase price of Apthera were as follows: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in 000&#146;s)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Calculation of allocable purchase price:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of shares issued at closing including escrowed shares expected to be released</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimated value of earn-out</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total allocable purchase price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Allocation of purchase price:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furnishings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In-process research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax liability, non-current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:13%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The value of the Company&#146;s common stock was based upon a per share value of $1.28, the closing price of the Company&#146;s common stock as of the close of business
on April&nbsp;13, 2011. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The estimated value of the earn-out consideration of $6.5 million originally recorded
was based on the expected probability of achievement in the future of certain development and commercial milestones relating to the Company&#146;s NeuVax product candidate and then applying a discount rate, based on a corporate debt interest rate
index publicly issued, to the expected future payments. The expected timing of the milestones, the probability of success for each milestone and the discount rates applied are updated quarterly using the most current information to measure the
contingent liability as of the reporting date. The decrease in the fair value of the contingent liability from date of issuance to December&nbsp;31, 2011 is $109,000, which was included in other income and expense in the accompanying consolidated
statements of expenses for the twelve months ended December&nbsp;31, 2011. The fair value of the contingent liability at December&nbsp;31, 2011 was $6,351,000. Of this amount $1,782,000 was recorded as a current liability. On January&nbsp;19, 2012,
the first milestone of $1,000,000 of this contingent liability was triggered with the first patient enrolled in our Phase 3 present clinical trial for breast </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
cancer. On March&nbsp;8, 2012, the Company issued 1,315,789 restricted shares of common stock in payment of the first milestone. The certificates evidencing the milestone shares have been
deposited with a third party escrow agent. The milestone shares will be released to the Apthera shareholders from escrow following approval of the issuance of the milestone shares by the stockholders of the Company, which the Company intends to seek
at its 2012 annual stockholders meeting. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If stockholder approval is obtained, the number of milestone shares will be subject
to increase to the extent that $0.76 (<I>i.e</I>., the closing price of the Company&#146;s common stock as reported on The NASDAQ Capital Market on January&nbsp;18, 2012, the day prior to achievement of its first milestone, used for purposes of
determining the number of milestone shares in) is greater than the closing price of common stock as of the most recent trading day prior to the receipt of stockholder approval. Whether or not stockholder approval is obtained, in addition to the
release from escrow of the milestone shares or the payment in cash of the final milestone as the case may be, the Company will pay concurrently to the former Apthera shareholders in cash an interest factor of ten percent (10%)&nbsp;per annum on the
amount of the final milestone from February&nbsp;10, 2012 through the day immediately prior to the release of the milestone shares from escrow or the cash payment, as the case may be, less certain legal fees of the stockholder representative to be
paid or reimbursed by the Company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the fourth quarter of 2011, the Company finalized its purchase price allocation
which resulted in an increase in goodwill and deferred tax liability of $5,053,000. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following presents the pro forma net
loss and pro forma net loss per common share of the Company and twelve months ended December&nbsp;31, 2011 and 2010 as if the Company&#146;s acquisition of Apthera occurred as of January&nbsp;1, 2010: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Twelve Months Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,724,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,857,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;RXi Spin-Out </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Contribution Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;24, 2011, the Company entered into a Contribution Agreement (&#147;Contribution Agreement&#148;) with RXi pursuant to which we assigned and contributed to RXi substantially all of the
Company&#146;s RNAi-related technologies and assets. The contributed assets consist primarily of our novel RNAi compounds and licenses relating to our RNAi technologies, as well as the lease of our Worcester, Massachusetts laboratory facility, fixed
assets and other equipment located at the facility and our employment arrangements with certain scientific, corporate and administrative personnel who have become employees of RXi. The Company also contributed $1.5&nbsp;million of cash to the
capital of RXi. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Contribution Agreement, RXi has agreed to assume certain recent accrued expenses of our
RXI-109 development program and all future obligations under the contributed licenses, employment arrangements and other agreements. RXi has also agreed to make future milestone payments to us of up to $45&nbsp;million, consisting of two one-time
payments of $15&nbsp;million and $30&nbsp;million, respectively, if RXi achieves annual net sales equal to or greater than $500 million and $1&nbsp;billion, respectively, of any covered products that may be developed with the contributed RNAi
technologies. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the Contribution Agreement, the Company made customary representations and warranties to RXi regarding the
contributed assets and other matters, and the parties have agreed to customary covenants regarding the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
conduct of RXi&#146;s business pending the spin-off of RXi. The parties also have agreed to indemnify each other against losses arising from a breach of their respective representations,
warranties and covenants set forth in the Contribution Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Securities Purchase Agreement </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;24, 2011, the Company also entered into a Securities Purchase Agreement (&#147;Securities Purchase Agreement&#148;) with
RXi and two institutional Investors (the &#147;Investors&#148;), pursuant to which the Investors agreed to purchase a total of $9,500,000 of Series&nbsp;A Preferred Stock of RXi (&#147;RXi Preferred Stock&#148;) at the closing of the spin-off of
RXi, and to lend up to $1,500,000 to RXi to fund its operations between signing and closing (the &#147;Bridge Loan&#148;). The outstanding principal and accrued interest from the Bridge Loan will, except under certain circumstances described below,
be converted into RXi Preferred Stock at the closing of the spin-off of RXi and will represent a portion of the $9,500,000 total investment, which is referred to herein as the &#147;RXi financing.&#148; The RXi financing and the spin-off of RXi are
subject to customary closing conditions, including the registration under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), of the distribution by us of the spin-off shares. There is no assurance that the RXi financing and the
spin-off of RXi will be completed. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The RXi Preferred Stock will be convertible by a holder at any time into shares of RXi
common stock, except to the extent that the holder would own more than 9.999% of the shares of RXi common stock outstanding immediately after giving effect to such conversion. Without regard to this conversion limitation, the shares of the Preferred
Stock to be held by the Investors upon completion of the RXi financing and the spin-off of RXi will be convertible into shares of RXi common stock representing approximately 83% of the shares of RXi common stock that would be outstanding, assuming
the conversion in full of the Preferred Stock, which we refer to as the &#147;as-converted common stock.&#148; The Company will own approximately 12% of the as-converted common stock immediately prior to the spin-off of RXi, and Advirna, LLC, a key
licensor of RXi, will be issued the remaining 5% of the as-converted common stock pursuant to the agreement with Advirna, LLC as described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Spin-Off </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has agreed in the Securities Purchase Agreement to
undertake to distribute to our stockholders on a share-for-share basis approximately 8% of the as-converted common stock of RXi, subject to the registration of the distribution of such shares under the Securities Act of 1933 and other conditions.
Assuming the spin-off of RXi is completed, the Company will initially retain 4% of the as-converted common stock, and the Company agreed, in the Securities Purchase Agreement, not to sell or dispose of our shares of RXi common stock for a one-year
period following completion of the spin-off of RXi. The Securities Purchase Agreement provides that the spin-off will be on a share-for-share basis, so that one share of RXi will be distributed as a dividend on each share of Galena that is issued
and outstanding as of the record date for the distribution. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;27, 2012, the Company announced, as required by
NASDAQ Listing Rule 5250(e)(6), that its board of directors had declared a conditional dividend on Galena common stock of one share of common stock of RXi for each outstanding share of Galena common stock. The spin-off shares will be payable,
subject to certain conditions described below, to the Company&#146;s stockholders as of close of business (Eastern time) on March&nbsp;8, 2012, the record date for the distribution, in the ratio of one RXi share for each share of Galena common stock
held as of the record date. In light of the conditional nature of the partial spin-off of RXi, the Company&#146;s board of directors has not set a payment date for the distribution, and under NASDAQ rules Galena common stock is not yet trading
&#147;ex-dividend.&#148; The distribution of the spin-off shares will be taxable to Galena stockholders who receive RXi shares in the distribution. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The distribution to Galena stockholders of the spin-off shares is to be made pursuant to the registration statement filed by RXi with the Securities and Exchange Commission and declared effective on
February&nbsp;14, 2012. Because the RXi registration statement will go &#147;stale&#148; on April&nbsp;30, 2012, the Company must complete the distribution of the spin-off shares by that date, unless the Company were to cause RXi to amend the
registration </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
statement. It is likely that the Company would abandon the partial spin-off of RXi if the distribution of the spin-off shares has not been made by April&nbsp;30, 2012, although the Company&#146;s
board of directors has not made any decision in this regard. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The establishment of a payment date for the distribution and the
payment of the distribution is dependent upon the timing of effectiveness of an application filed with FINRA to permit RXi common stock to be traded in the OTC Markets Group under the symbol &#147;RXII.&#148; The payment of the distribution also is
conditioned upon the closing of the RXi financing, which is subject to certain closing conditions that may or may not be satisfied. In addition, the securities purchase agreement among Galena, RXi and the Investors provides that the agreement may be
unilaterally terminated by the Company or by the Investors if the closing of the transactions has not occurred by March&nbsp;31, 2012, and it is not possible for the closing to occur by this date. Accordingly, unless this date is extended by mutual
agreement of the Investors and the Company, either the Company or the Investors generally may terminate the securities purchase agreement at any time after March&nbsp;31, 2012, unless the failure of the closing to occur was due to the fault of the
party seeking to terminate the securities purchase agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although the Company has no present intention to terminate the
securities purchase agreement or to abandon the partial spin-off of RXi, the Investors may choose to do so. The Company also may decide to do so at any time if its board of directors determines that it is in the best interests of the Company. For
all of the foregoing reasons, there is no assurance that the payment and distribution of the spin-off shares will be completed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Purchase Agreement Terms and Conditions </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the Securities Purchase Agreement, the parties have made customary representations and warranties to the other parties and have agreed to customary covenants regarding the parties&#146; actions in
connection with the spin-off of RXi and other matters, including the filing of a resale registration statement registering a portion of the common stock underlying the conversion of the Preferred Stock. The parties also have agreed to indemnify each
other against losses arising from a breach of their respective representations, warranties and covenants set forth in the Securities Purchase Agreement. RXi has agreed, upon completion of the spin-off of RXi, to reimburse the Company and the
Investors for up to a total of $300,000 and $100,000, respectively, of transaction costs relating to the Contribution Agreement, the Securities Purchase Agreement and the transactions contemplated by the agreements. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Securities Purchase Agreement may be terminated in certain circumstances, including by the Investors or the Company if the spin-off of
RXi has not occurred by March&nbsp;31, 2012. If the Securities Purchase Agreement is terminated without cause due to the fact that the spin-off has not occurred by such date, then a portion of the Bridge Loan will be converted into common stock of
RXi, as described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Bridge Loan </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Securities Purchase Agreement, the Investors agreed to provide the Bridge Loan by purchasing $500,000 of secured convertible promissory notes of RXi (&#147;RXi convertible notes&#148;) and
agreeing to purchase up to an additional $1,000,000 of RXi convertible notes prior to the closing of the spin-off of RXi. The RXi convertible notes will, except as described below, be convertible into shares of RXi Preferred Stock at a conversion
price of $1,000 per share. The proceeds from the Bridge Loan will be used by RXi in accordance with an operating budget approved by the Investors to fund RXi&#146;s business and operations pending completion of the spin-off of RXi. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The RXi convertible notes accrue interest at a rate of 7%&nbsp;per annum (or 18%&nbsp;per annum in the case of an event of default) and
mature on March&nbsp;31, 2012, or earlier in the case of an event of default. The obligations due under the RXi convertible notes are secured by a first-priority blanket lien on the assets of RXi and are guaranteed by Galena. Additionally, Galena
has pledged all of the shares of RXi common stock that it holds to further guaranty the timely repayment of the amounts due under the RXi convertible notes, if not converted into RXi Preferred Stock at the closing under the Securities Purchase
Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the closing under the Securities Purchase Agreement has not occurred by the
March&nbsp;31, 2012 maturity date of the RXi convertible notes, then 50% of the outstanding Bridge Loan balance will be converted into a number of shares of RXi common stock equal to 51% of the post-conversion shares outstanding. RXi will remain
obligated to repay the remaining balance of the principal and accrued interest under the Bridge Loan, and Galena has agreed to guarantee RXi&#146;s repayment of the RXi convertible notes to the extent they are not converted. In this event, Galena
and Advirna, LLC will beneficially own 44% and 5%, respectively, of the outstanding shares of RXi common stock, and RXi will carry on as a stand-alone private company under the Investors&#146; control. Neither the Investors nor Galena will be
obliged to provide any funding to RXi in this event. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of the date of the filing of the Annual Report on Form&nbsp;10-K of
which these Consolidated Financial Statements are a part, the Company was in discussions with the Investors to extend the current March&nbsp;31, 2012 maturity date of the RXi convertible notes, but there is no assurance that the maturity date will
be extended. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The RXi convertible notes will be issued, and the Bridge Loan will be funded, in three tranches of $500,000 each.
The first and second tranches were issued and funded on September&nbsp;24, 2011 and February&nbsp;24, 2012, respectively, and the third tranche is to be issued and funded as needed by RXi prior to the closing under the Securities Purchase Agreement
and following the approval by the Investors, in their discretion, of RXi&#146;s budget for the use of such funds. At December&nbsp;31, 2011, the first tranche of $500,000 had been received and recorded to convertible notes payable as a current
liability. There are additional features of the RXi post spin-off Series A Convertible Preferred Stock which represent contingent beneficial conversion features, to be reevaluated in the future. In the event that the facts and circumstances indicate
that a contingency is removed, at that point the beneficial conversion feature, if any, will be recorded. On February&nbsp;24, 2012, the second tranche of $500,000 was received and recorded to convertible notes payable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Advirna Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of the transactions contemplated by the Contribution Agreement and Securities Purchase Agreement, RXi has entered into an agreement with Advirna, LLC, which the Company refers to as
&#147;Advirna,&#148; a company affiliated with Anastasia Khvorova, Ph.D., the Company&#146;s former Senior Vice President and Chief Scientific Officer. In the agreement, Advirna has agreed to amend its existing patent and technology assignment
agreement with RXi to eliminate all clinical milestone and royalty payments to Advirna under the amended agreement; obligations remain to make an annual $100,000 maintenance fee and a one-time milestone payment of $350,000 to Advirna upon the
issuance of a patent with valid claims covering the assigned technology. Additionally, RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi on the license of the assigned Advirna technology. In exchange, RXi
has agreed to issue to Advirna upon the earlier of the closing under the Securities Purchase Agreement or the partial conversion of the RXi convertible notes, a number of shares of RXi common stock equal to 5% of the as-converted common stock of
RXi. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;Fair Value Measurements </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company follows ASC&nbsp;820, &#147;Fair Value Measurements and Disclosures,&#148; (&#147;ASC 820&#148;) for the
Company&#146;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three
levels. Level inputs are as defined as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;1&nbsp;&#151; quoted prices in active markets for identical assets
or liabilities. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;2&nbsp;&#151; other significant observable inputs for the assets or liabilities through
corroboration with market data at the measurement date. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;3&nbsp;&#151; significant unobservable inputs that reflect
management&#146;s best estimate of what market participants would use to price the assets or liabilities at the measurement date. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company categorized its cash equivalents as Level&nbsp;1 hierarchy. The valuation
for Level&nbsp;1 was determined based on a &#147;market approach&#148; using quoted prices in active markets for identical assets. Valuations of these assets do not require a significant degree of judgment. The Company categorized its warrants
potentially settleable in cash as a Level&nbsp;2 hierarchy. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using the
Black-Scholes method, using assumptions consistent with our application of ASC&nbsp;718. The contingent purchase price consideration is categorized as a Level 3 hierarchy and is measured at its estimated fair value on a recurring basis and is
adjusted at each quarter-end until it is completely settled. The contingent price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and the updated discount rates based on a
corporate debt interest rate index publicly issued. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;In<BR>Active Markets<BR>(Level 1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level 2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unobservable&nbsp;Inputs<BR>(Level 3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants potentially settleable in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contingent purchase price consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,097</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>(Level 1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level 2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unobservable&nbsp;Inputs<BR>(Level 3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants potentially settleable in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has classified its liabilities for contingent earn-out consideration relating to its
acquisitions of Apthera within Level 3 of the fair value hierarchy because the fair values are determined using significant unobservable inputs, which included probability weighted cash flows. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has not transferred any financial instruments into or out of Level 3
classification during 2010 or 2011. A reconciliation of the beginning and ending Level 3 liabilities for the year ended December&nbsp;31, 2011 is as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value<BR>Measurements<BR>Using&nbsp;Significant<BR>Unobservable<BR>Inputs</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Level 3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In Thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at January&nbsp;1, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial fair value of contingent earnout consideration related to Meridian Acquisition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of earnout consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;Capital Lease Obligations </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company acquired equipment under capital leases that is included in equipment and furnishings in the accompanying
consolidated balance sheet. The cost and accumulated amortization of capitalized leased equipment was approximately $272,000 and $95,000 at December&nbsp;31, 2011, respectively, and $196,000 and $56,000 at December&nbsp;31, 2010, respectively.
Amortization expense for capitalized leased equipment was approximately $54,000 in 2011 and $39,000 in 2010. Future minimum lease payments under the capital leases including interest are approximately $38,000, $25,000 and $14,000 for the years
ending December&nbsp;31, 2012, 2013 and 2014, respectively. Interest expense related to the capital leases was $6,000 for each of the years ended December&nbsp;31, 2011 and 2010. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;Accrued Expenses and Other Current Liabilities </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other current liabilities consist of the following (in thousands): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years<BR>Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Professional fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">740</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company acquires assets still in development and enters into research and development arrangements with third
parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain
agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below (see also Note&nbsp;15).
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by
these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the
product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&#146;s contractual obligations that
will require future cash payments as of December&nbsp;31, 2011 are as follows (in thousands): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Operating<BR>Leases(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Non-Cancelable<BR>Employment<BR>Agreements(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Subtotal</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cancelable<BR>License<BR>Agreements(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">578</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,492</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">538</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017 and Thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December&nbsp;31,
2011 and 2010 were approximately $233,000 and $274,000, respectively. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been
revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable. </FONT></TD></TR></TABLE>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements generally relate to the Company&#146;s obligations with The Board of Regents, University of Texas and Henry Jackson Foundation for our oncology
therapies and UMMS associated with RNAi and, for future periods, represent minimum annual royalty and milestone payment obligations, of the total amount due. The Company continually assesses the progress of its licensed technology and the progress
of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, no amounts will be due. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company applies the disclosure provisions FASB ASC Topic 460 (&#147;ASC 460&#148;), &#147; <I>Guarantor&#146;s Accounting and
Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Other</I><I>s</I>&#148;, to its agreements that contain guarantee or indemnification clauses. The Company provides (i)&nbsp;indemnifications of varying scope
and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&nbsp;indemnifications of varying scope and size to officers and
directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&nbsp;460. To date, the Company has not incurred costs as a result of these obligations and
does not expect to incur material costs in the future. Accordingly, the Company has not accrued any liabilities in its financial statements related to these indemnifications. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-22
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;21, 2011, Hudson Bay Master Fund, Ltd. (&#147;Hudson Bay&#148;) filed a
Complaint against the Company in the United States District Court for the Southern District of New York (the &#147;Court&#148;), captioned <U>Hudson Bay Master Fund, Ltd. v. Galena Biopharma, Inc., 11 Civ. 8432 (JPO)</U>, alleging that the
Company&#146;s plan to partially spin off RXi and related actions taken in preparation for the spin-off gives Hudson Bay the right to require us to repurchase the warrants acquired by Hudson Bay in our April 2011 underwritten public offering. Hudson
Bay also seeks related declaratory and injunctive relief. On January&nbsp;12, 2012, three other warrant holders affiliated with each other filed a Complaint in the Court, captioned <U>Tenor Opportunity Fund, Ltd., Aria Opportunity Fund, Ltd., and
</U><U>Parsoon Opportunity Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0260</U>, and on January&nbsp;20, 2012 and February&nbsp;2, 2012, respectively, two other warrant holders filed their own Complaints in the Court, captioned <U>Cranshire Capital
Master Fund, Ltd. v. Galena Biopharma, Inc., 12&nbsp;CIV 0493</U> and <U>Iroquois Master Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0839</U>, respectively. In these latest Complaints, which are substantially identical to the previous Complaints
filed in the Court, the various warrant holders also claim that the planned spin-off of RXi and related actions give them the right to require the Company to repurchase the Company&#146;s outstanding warrants held by them. According to the
allegations in the Complaints, the repurchase price of the plaintiffs&#146; warrants would amount to approximately $5.2 million in the aggregate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;21, 2012, the Company received letters from each of the plaintiff-warrant holders withdrawing their repurchase demands with respect to their warrants covering an aggregate of 6,350,000
shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the &#147;Withdrawal Notice<B>s</B>&#148;). After giving effect to the Withdrawal Notices, the plaintiff-warrant holders continued to demand that the Company
repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based on the plaintiff-warrant holders&#146; claims in their Complaints, the Company believes that the repurchase price for these warrants is $0.71
per underlying share, or an aggregate of $355,000. On March 27, 2012, the Company tendered to the plaintiff-warrant holders an aggregate of $355,000 as payment in full of the repurchase price for those warrants. The Company believes that the
Withdrawal Notices and the Company&#146;s tender of payment as described above render moot the majority of claims of the plaintiff-warrant holders in their Complaints, although the Withdrawal Notices purport to reserve all rights of the
plaintiff-warrant holders under the Complaints. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company were to become liable to repurchase the plaintiffs&#146;
warrants, the Company may not have on hand sufficient funds to satisfy the liability and to meet its other obligations as they come due, which could raise doubts as to the Company&#146;s ability to continue as a going concern. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;Stockholders&#146; Equity </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Preferred Stock </I>&#151; The Company has authorized up to 5,000,000&nbsp;shares of preferred stock,
$0.0001&nbsp;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as
shall be determined by the Company&#146;s board of directors upon its issuance. At December&nbsp;31, 2011, there were no shares of preferred stock outstanding. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Common Stock </I>&#151; The Company has authorized up to 125,000,000&nbsp;shares of common stock, $0.0001&nbsp;par value per share, for issuance. Shares of common stock are reserved as follows:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of<BR>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,120,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,163,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options reserved for future issuance under the Company&#146;s 2007 Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,299,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total reserved for future issuance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,583,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-23
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Common Stock Warrants </I>&#151; On August&nbsp;7, 2008, the Company issued 190,000
warrants to an investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $7.036 per share and expire 5&nbsp;years from the date of issuance, on August&nbsp;7, 2013. The warrants vested as
to 94,000&nbsp;shares upon issuance, and vested at a rate of 32,000&nbsp;shares&nbsp;per month starting on the 90&nbsp;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation cost was
fully recorded at December&nbsp;31, 2009. The Company also agreed to give the holder of the warrants unlimited &#147;piggy back&#148; registration rights with respect to the shares of the Company&#146;s common stock underlying the warrants in any
registration statement the Company files in connection with an underwritten offering of its common stock. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;3,
2008, the Company acquired the rights to license exclusive worldwide technology for the oral delivery of RNAi therapeutics. As consideration for this license, the Company agreed to pay a total license fee of $2,500,000 over a 12&nbsp;month period,
which can be paid in cash, in equity or a combination thereof, provided that a specified amount of the license fee must be made in cash. Payments made in equity may only be made if, at the time of such payment, the shares of common stock issuable
upon conversion of the warrant have been registered for resale under the Securities Act of 1933. No warrants have been issued under this agreement thru the date of this report. The Company continually assesses the progress of its research and
development efforts as it relates to its licensed technology and may terminate with notice to the Licensor at any time. Accordingly, the amounts are being expensed, as payments are made. There was no expense for this license for the years ended
December&nbsp;31, 2011 and 2010. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;29, 2009, the Company issued 142,500 warrants to an investment bank as
consideration for investment and business advisory services. The warrants have an exercise price of $4.273 per share and expire five years from the date of issuance on January&nbsp;29, 2014. The warrants vested as to 71,250&nbsp;shares upon
issuance, and vested at a rate of 23,750&nbsp;shares&nbsp;per month starting on the 90&nbsp;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation expense was fully recorded at
December&nbsp;31, 2009. The Company has also agreed to give the holder of the warrants unlimited &#147;piggy back&#148; registration rights with respect to the shares of Common Stock underlying the warrants in any registration statement the Company
files in connection with an underwritten offering of the common stock. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the 2009 Offering, the Company
issued warrants to purchase 978,142&nbsp;shares of the Company&#146;s common stock. Details of the transaction can be found under the heading &#147;2009 Registered Direct Offering&#148; below. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the 2010 Offering, the Company issued warrants to purchase 540,000&nbsp;shares of the Company&#146;s common stock.
Details of the transaction can be found under the heading &#147;2010 Registered Direct Offering&#148; below. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection
with the March 2011 Offering, the Company issued warrants to purchase 6,000,000&nbsp;shares of the Company&#146;s common stock. Details of the transaction can be found under the heading &#147;March 2011 Registered Direct Offering&#148; below.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the April 2011 Offering, the Company issued warrants to purchase 11,950,000&nbsp;shares of the
Company&#146;s common stock. Details of the transaction can be found under the heading &#147;April 2011 Registered Direct Offering&#148; below. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During 2011, the Company issued 150,000 warrants in exchange for business advisory services. The Company recognizes the total fair value of these warrants as stock compensation expense, over the requisite
service period. The Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants on the date of the award. Total expense related to these warrants was $108,000 in 2011. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Private Investment in Public Equity </I>&#151; On June&nbsp;24, 2008, the Company entered into a Securities Purchase Agreement pursuant
to which RXi issued and sold to certain investors an aggregate of 1,073,299&nbsp;shares of common stock in a private placement at a price of $8.12 per share. Net proceeds to the Company were approximately $7.9&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-24
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2009 Registered Direct Offering </I>&#151; On March&nbsp;17, 2009, the Company
entered into a placement agency agreement, which was subsequently amended on May&nbsp;26, 2009 and July&nbsp;22, 2009, with Rodman&nbsp;&amp; Renshaw, LLC (&#147;Rodman&#148;) as the exclusive placement agent, relating to a proposed offering by the
Company of new securities to potential investors. On July&nbsp;30, 2009, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors of 2,385,715&nbsp;units, with each unit consisting of one share of
the Company&#146;s common stock and a warrant to purchase 0.40 of a share of common stock, at a purchase price of $3.50 per unit (the &#147;2009 Offering&#148;). The 2009 Offering closed on August&nbsp;4, 2009. The warrants have an exercise price of
$4.50 per share and are exercisable for a period beginning on February&nbsp;3, 2010 until their expiration on August&nbsp;3, 2014. The Company raised gross proceeds of approximately $8,350,000 in the 2009 Offering and net cash proceeds, after
deducting the placement agents&#146; fees and other offering expenses payable by the Company, of approximately $7.7&nbsp;million. Total warrants issued in connection with the transaction were 954,285. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the placement agency agreement, the Company issued a warrant to purchase 23,857&nbsp;shares of the Company&#146;s common stock
to Rodman. The warrant has an exercise price of $4.38 per share. The warrant is immediately vested and is exercisable until its expiration on August&nbsp;3, 2014. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain warrants issued in connection with the stock offering on August&nbsp;4, 2009 were determined not to be indexed to the Company&#146;s common stock as they are potentially settleable in cash. The
fair value of the warrants at the dates of issuance totaling $2,863,000 was recorded as a liability and a cost of equity and was determined by the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the
Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publicly traded. The Company used a weighted average expected stock volatility of 122.69%. The
expected life assumption is based on the contract term of five years. The dividend yield of zero is based on the fact that RXi has no present intention to pay cash dividends in the future. The risk free rate of 1.72% used for the warrant is equal to
the zero coupon rate in effect at the time of the grant. The change in the fair value of the warrants during the years ended December&nbsp;31, 2011 and 2010 was $1,879,000 and $1,778,000, respectively. These amounts have been included in other
income and expense in the accompanying consolidated statements of expenses. The fair value of the warrants at December&nbsp;31, 2011 of $64,000 is included as a current liability in the accompanying balance sheet as of that date and was determined
by the Black-Scholes option pricing model. The following assumptions were used to determine the fair value as of December&nbsp;31, 2011: weighted average expected stock volatility of 98.91%; an expected life of 2.6 years and a dividend yield of zero
and a risk free rate of 0.31%. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2010 Registered Direct Offering</I>&nbsp;&#151; On March&nbsp;22, 2010, the Company entered
into a placement agency agreement relating to a proposed offering by the Company of new securities to potential investors. On March&nbsp;23, 2010, the Company entered into definitive agreements for the sale and issuance by the Company to certain
investors of 2,700,000&nbsp;units, with each unit consisting of one share of the Company&#146;s common stock and a warrant to purchase 0.20 of a share of the Company&#146;s common stock, at a purchase price of $6.00 per unit (the &#147;2010
Offering&#148;). The 2010 Offering closed on March&nbsp;26, 2010. The Company issued warrants to purchase 540,000&nbsp;shares of the Company&#146;s common stock at an exercise price of $6.00 per share and that are exercisable beginning on
September&nbsp;26, 2010 until their expiration on March&nbsp;26, 2016. The Company raised gross proceeds of approximately $16.2&nbsp;million in the 2010 Offering and net cash proceeds, after deducting the placement agent fees and other offering
expenses payable by the Company, of approximately $15.2&nbsp;million. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the 2010 Offering, the Company entered in a
stock redemption agreement whereby the Company was required to use 25% of the net proceeds from the 2010 Offering to repurchase from CytRx Corporation (&#147;CytRx&#148;) 675,000 shares of the Company&#146;s common stock held by CytRx (&#147;CytRx
shares&#148;). The Company repurchased such shares on March&nbsp;29, 2010. The values of the shares at the date of repurchase totaling $3,849,000 were recorded at cost and have been included in treasury stock in the accompanying consolidated balance
sheet at December&nbsp;31, 2011 and 2010. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-25
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares of common stock that are mandatorily redeemable under the stock redemption
agreement upon the exercise of warrants issued in the 2010 Offering, were determined to embody an obligation that may require the Company to settle the obligation by transferring assets, and as such, shall be classified as a liability. The fair
value of the common stock potentially redeemable under the stock redemption agreement totaling $785,000 was recorded as a liability and a cost of equity and was determined using the fixed monetary amount of each warrant multiplied by assumptions
regarding the number and timing of warrants to be exercised. On December&nbsp;29, 2010, CytRx sold all of their shares held in Galena, thus reducing the potential redemption liability to zero as December&nbsp;31, 2010. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain warrants issued in connection with the 2010 Offering were determined not to be indexed to the Company&#146;s common stock as they
are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,466,000 was recorded as a liability and a cost of equity and was determined by the Black-Scholes option pricing model. Due to the fact that the
Company has limited trading history, the Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted
average expected stock volatility of 119.49%. The expected life assumption is based on the contract term of 6.5&nbsp;years. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk
free rate of 3.22% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. The change in the fair value of the warrants during the years ended December&nbsp;31, 2011 and 2010 was $1,079,000 and $1,271,000,
respectively. These amounts have been included in other income and expense in the accompanying consolidated statements of expenses. The fair value of the warrants at December&nbsp;31, 2011 of $116,000 is included as a current liability in the
accompanying consolidated balance sheets and was determined by the Black-Scholes option pricing model. In the model, the Company used a weighted average expected stock volatility of 98.91%. The expected life assumption is based on the remaining
contract term of 4.8&nbsp;years. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.83% used for the warrant is equal to the zero coupon rate in effect on the date
of the re-measurement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>March 2011 Registered Direct Offering</I>&nbsp;&#151; On March&nbsp;4, 2011, the Company closed an
underwritten public offering of 6,000,000 units at a price to the public of $1.35 per unit for gross proceeds of $8.1&nbsp;million (the &#147;March&nbsp;2011 Offering&#148;). The offering provided approximately $7.3&nbsp;million to the Company after
deducting the underwriting discounts and commissions and offering expenses. Each unit consists of (i)&nbsp;one share of common stock, (ii)&nbsp;a thirteen-month warrant to purchase 0.50 of a share of common stock at an exercise price of $1.70 per
share (subject to anti-dilution adjustment) and (iii)&nbsp;a five-year warrant to purchase 0.50 of a share of common stock at an exercise price of $1.87 per share (subject to anti-dilution adjustment). On April&nbsp;15, 2011, the holders of
outstanding warrants issued in the March&nbsp;2011 Offering to purchase an aggregate of 3,450,000 shares of common stock agreed to exchange such warrants for warrants exercisable for the same number of shares as those being exchanged, but otherwise
on the same terms of the warrants sold in the Company&#146;s April&nbsp;2011 financing. Prior to the exchange, the Company recorded a decrease in fair value of $1,000,000 related to the exchanged warrants. Upon the exchange, the Company recorded a
loss of $900,000, which represented the difference between the adjusted fair value of the March&nbsp;2011 warrants as compared to the fair value of the April&nbsp;2011 warrants received in the exchange. As a result of a subsequent offering that was
completed on April&nbsp;15, 2011, the exercise price of the remaining 2,550,000 outstanding warrants sold in the March&nbsp;2011 Offering was reduced to $1.00 per share as a result of the anti-dilution adjustment. At December&nbsp;31, 2011, 150,000
warrants from the March&nbsp;2011 Offering had been exercised with a remaining outstanding balance of 5,850,000. As a result of the subsequent offering on September&nbsp;26, 2011, the exercise price of the remaining 5,850,000 warrants sold in the
March&nbsp;4, 2011 Offering were reduced to $0.65 per share as a result of the anti-dilution adjustment.</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The thirteen-month and
five-year warrants issued in connection with the March 2011 Offering were determined not to be indexed to the Company&#146;s common stock as they are potentially settleable in cash. The fair value of the 2,550,000 warrants at the date of issuance
totaling $1,790,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes option pricing model. Due to the fact that the Company </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
has limited trading history, the Company expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose shares or options are publicly traded.
The Company used a weighted average expected stock volatility of 113.25%. The expected life assumption is based on the contract term of 1.08 years used for the thirteen-month warrants and 5 years used for the five-year warrants. The dividend yield
of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.26% used for the thirteen-month warrants and 2.17% used for the five-year warrants is equal to the zero coupon rate in effect at the time
of the grant. In July 2011, 75,000 of the thirteen-month warrants were exercised at $1.00 per common share which resulted in a $34,000 reduction of the warrant liability. In July 2011, 75,000 of the five-year warrants were exercised at $1.00 per
common share which resulted in a $68,000 reduction of the warrant liability. The decrease in the fair value of the warrants from the date of issuance to December&nbsp;31, 2011 of $1,378,000 has been included in other income and expense in the
accompanying consolidated statements of expenses for the year ended December&nbsp;31, 2011. The fair value of the warrants at December&nbsp;31, 2011 of $412,000 is included as a current liability in the accompanying consolidated balance sheets and
was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities
whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 98.91%. The expected life assumption is based on the remaining contract term of 0.3 years used for the thirteen-month warrants and 4.2
years used for the five- year warrants. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.02% used for the thirteen-month warrants and 0.60% used for the
five-year warrants is equal to the zero coupon rate in effect on the date of the re-measurement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>April 2011 Registered
Direct Offering</I>&nbsp;&#151; On April&nbsp;20, 2011, the Company completed an underwritten public offering of 11,950,000 units at a price to the public of $1.00 per unit for gross proceeds of approximately $12&nbsp;million (the
&#147;April&nbsp;2011 Offering&#148;). Each unit consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $1.00 per share (subject to anti-dilution adjustment). The shares of common stock and
warrants were immediately separable and no separate units were issued. The warrants are exercisable beginning one year and one day from the date of issuance, and expire on the sixth anniversary of the date of issuance. Net proceeds, after
underwriting discounts and commissions and other offering expenses, were approximately $10.9&nbsp;million. As a result of the subsequent offering that was completed on September&nbsp;26, 2011, the exercise price of the 11,950,000 outstanding
warrants sold in the April&nbsp;2011 Offering was reduced to $0.65 per share as a result of the anti-dilution adjustment.&nbsp;On December&nbsp;6, 2011, the Company effected a warrant exchange with a ratio of 1.42857 warrants in exchange for one
share of common stock with several of the April 2011 warrant holders. In total, 5,930,000 warrants were exchanged for 4,151,000 shares of common stock in this transaction. At December&nbsp;31, 2011, 6,020,000 warrants sold in the April&nbsp;20, 2011
Offering remained outstanding. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The warrants issued in connection with the April 2011 Offering, including the warrants issued
in exchange for the 3,450,000&nbsp;March 2011 warrants, were determined not to be indexed to the Company&#146;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $11,015,000 was
recorded as a liability and a cost of equity and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#146;s expected stock volatility assumption is based on a
combination of implied volatilities of similar entities whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 99.04%. The expected life assumption is based on the contract term of 6.0 years.
The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 2.81% used for the warrants is equal to the zero coupon rate in effect at the time of the grant. In December 2011, the
Company exchanged 4,151,000 shares of common stock in exchange for 5,930,000 of these April warrants at a ratio of 0.7 common shares for each warrant which resulted in a reduction to warrant liability of $3,120,000. The decrease in the fair value of
the warrants from date of issuance to December&nbsp;31, 2011 is $5,168,000, of which all has been included in other income and expense in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the accompanying consolidated statements of expenses for the twelve months ended December&nbsp;31, 2011. The fair value of the warrants at December&nbsp;31, 2011 of $3,154,000 is included as a
current liability in the accompanying consolidated balance sheets and was determined by the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#146;s expected stock volatility assumption is
based on a combination of implied volatilities of similar entities whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 98.91%. The expected life assumption is based on the remaining contract
term of 5.3 years. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.83% used for the warrants is equal to the zero coupon rate in effect on the date of the
re-measurement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>September 2011 Registered Direct Offering</I>&nbsp;&#151; On September&nbsp;26, 2011, the Company completed
a direct offering of 700,000 shares of common stock for gross proceeds of $455,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Options Modified
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;14, 2011, all of the Company&#146;s directors and certain of the Company&#146;s executive officers
executed agreements with the Company under which they agreed that none of their outstanding stock options will be exercisable unless and until the Company increases the number of authorized shares of common stock to a number that is sufficient to
permit the exercise or conversion in full of all then outstanding options of the Company (including their stock options), warrants and other securities of the Company that are convertible into shares of common stock. An aggregate of 3,498,256 option
shares are covered by these agreements. For accounting purposes, the agreement of all of the Company&#146;s directors and certain executive officers to place restrictions of the exercisability of their options is treated as a modification of their
options resulting in the reclassification of the options from equity to a liability. In connection with the modification, the Company will recognize compensation cost equal to the greater of (a)&nbsp;the grant date fair value of the original equity
award plus an incremental cost associated with the modification or (b)&nbsp;the fair value of the modified award when it is settled. On July&nbsp;15, 2011, the Board of Directors of the Company adopted an amendment to increase the authorized shares
of common stock to 125,000,000, which was presented to and approved by the stockholders of the Company at the 2011 Annual Meeting of Stockholders. This increase in the authorized shares was sufficient to permit the exercise or conversion in full of
all then outstanding options of the Company (including their stock options), warrants and other securities of the Company that are convertible into shares of common stock, as a result, the liability was marked to market through July&nbsp;15, 2011
and, upon settlement, the value of $1,036,000 was reclassified to additional paid in capital. As a result of the modification, the Company recorded additional stock compensation expense of $35,000 during the year ended December&nbsp;31, 2011.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Equity Transactions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;30, 2011, the Company entered into a severance agreement with its former President and Chief Executive Officer whereby, among other things, it agreed to issue shares to the former officer
such that the number of shares issued times the market price of the shares on the day immediately following the separation date equal a value of $300,000. As of December&nbsp;31, 2011, all payments and shares due under this severance agreement have
been issued and recorded to stock compensation expense. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;Development Stage Supplemental Equity Disclosure </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Summarized below are the Company&#146;s equity (common stock and common stock options) transactions since the
Company&#146;s inception through December&nbsp;31, 2011 (in thousands except per share data). </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Type of Security</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date&nbsp;of&nbsp;Issuance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares of<BR>Common<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Dollar<BR>Amount of<BR>Consideration<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Price&nbsp;per<BR>Share or<BR>Exercise<BR>Price per<BR>Share<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Counter</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Party to</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Transaction</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nature of<BR>Non-Cash<BR>Consideration</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Basis of<BR>Assigning Cost</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 3, 2006</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,624,278</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.002</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Founders</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 8, 2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.040,318</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.007</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">CytRx</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contributed<BR>Assets</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Predecessor<BR>Cost</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 30, 2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,273,292</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,348</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.19</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">CytRx</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 30, 2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">462,112</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,311</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">UMMS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual<BR>Properties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Independent<BR>Third Party<BR>Valuation</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 18, 2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 28, 2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">188,387</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.19</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">CytRx</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Independent<BR>Third Party<BR>Valuation</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 21, 2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,045</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">331</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of Stock<BR>Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 26, 2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,073,299</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,918</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.12</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">PIPE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Cash</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">October&nbsp;6,&nbsp;2008&nbsp;and<BR>November 16, 2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,500</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of Stock<BR>Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 30, 2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,398</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market Value</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 1, 2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.19</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of Stock<BR>Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 3, 2009 and<BR>August 4, 2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,385,715</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,714</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.50</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registered&nbsp;Direct</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Cash</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 22, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,700,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,235</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registered Direct</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Various&nbsp;&#151; 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,500</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.75</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of Stock<BR>Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;2,&nbsp;2010&nbsp;and<BR>February 9, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86,634</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">207</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted Stock<BR>Units</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market Value</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 4, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,307</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.35</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registered Direct</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Cash</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 15, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220,729</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted Stock<BR>Units</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market Value</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 13, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,974,090</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,367</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquired Company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market Value</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 20, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,950,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,853</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registered Direct</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 1, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,824</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.83</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ESPP</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 27, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of<BR>Warrants</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 26, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">700,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">455</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.65</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registered Direct</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">December 6, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,151,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,120</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange with<BR>Warrant Holders</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market&nbsp;Value</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Various &#151; 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">599,051</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">594</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock&nbsp;Compensation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market&nbsp;Value</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transactions between related parties are accounted for at the historical cost of CytRx, with the intellectual property which was previously expensed on CytRx&#146;s
books being recorded at zero cost and equipment and furnishings being recorded at $48,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company received gross proceeds of $17.0&nbsp;million for the issuance of the 3,273,292&nbsp;shares of common stock which equals $5.19 per share.
The gross proceeds were reduced by a reimbursement to CytRx of (1)&nbsp;$1.3&nbsp;million for RXi&#146;s pro rata share of offering costs related to the April&nbsp;17, 2007 private placement
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
conducted by CytRx to fund its capital contribution to the Company and (2)&nbsp;$363,000 of expenses incurred on behalf of RXi for the year ended December&nbsp;31, 2006. Net proceeds to RXi after
these charges were $15.3&nbsp;million or $4.69 a share. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;Stock Based Compensation </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Options to Purchase Shares of Common Stock </I>&#151; The Company follows the provisions ASC&nbsp;718 which requires
the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value
estimated in accordance with the provisions of ASC&nbsp;718 is recognized as an expense over the requisite service period. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For
stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50, Non-employee option grants that do not vest immediately upon grant
are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, is being
re-measured using the fair value of the Company&#146;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the
future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company is currently using the Black-Scholes option-pricing model to determine the fair value of all its option grants. For options grants issued for the year ended December&nbsp;31, 2011 and 2010,
the following assumptions were used: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average risk free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.92%&nbsp;-&nbsp;3.16%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.88%&nbsp;-&nbsp;3.28%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98.61%&nbsp;-&nbsp;113.87%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118.3%&nbsp;-&nbsp;133.62%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected lives (years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.71 - 9.25</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 - 10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average fair value of options granted during the years ended December&nbsp;31, 2011 and 2010
was $0.89 and $4.31 per share, respectively. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s expected common stock price volatility assumption is based
upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&nbsp;718-10, which averages the contractual term of the Company&#146;s options of
ten years with the average vesting term of four years for an average of six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that
Galena has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an
annualized forfeiture rate of 15% for options granted to its employees, 8% for options granted to senior management and no forfeiture rate for the directors. The Company will record additional expense if the actual forfeitures are lower than
estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
recorded approximately $3,001,000 and $4,368,000 of stock-based compensation for the years ended December&nbsp;31, 2011 and 2010, respectively. As of December&nbsp;31, 2011, there was $1,012,000 of unrecognized compensation cost related to
outstanding options that is expected to be recognized as a component of the Company&#146;s operating expenses over a weighted average period of 3.3 years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-30
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;4, 2009, as part of a plan succession in leadership, Tod
Woolf,&nbsp;Ph.D., resigned as our President, Chief Executive Officer and a member of our Board of Directors. According to the Separation Agreement between Dr.&nbsp;Woolf and the Company, Dr.&nbsp;Woolf received in one lump sum payment his full
severance equivalent to a six (6)&nbsp;month salary ($187,500), six (6)&nbsp;months acceleration of vesting of all of his outstanding unvested Stock Options as of November&nbsp;4, 2009, and an offer to join the Company&#146;s Scientific Advisory
Board (SAB) for 3&nbsp;years (the &#147;New Position&#148;). In addition, and as part of the Separation Agreement, the Company agreed to extend the exercise period for all of Dr.&nbsp;Woolf&#146;s vested Stock Options as of November&nbsp;4, 2009, to
the later of: (i)&nbsp;a period of two (2)&nbsp;years from his resignation (until November&nbsp;4, 2011), or (ii)&nbsp;ninety (90)&nbsp;days following the end of the term of the SAB&nbsp;Agreement (February&nbsp;4, 2013)&nbsp;or such earlier date as
the SAB&nbsp;Agreement may be terminated pursuant to the terms of the SAB&nbsp;Agreement provided Dr.&nbsp;Woolf has not violated the non-competition provisions of the SAB&nbsp;Agreement prior to the date of exercise (whether or not the
SAB&nbsp;Agreement is still in effect at that time). Notwithstanding any provision of the Company&#146;s 2007 Incentive Plan, the Company also agreed that Dr.&nbsp;Woolf&#146;s previously awarded Stock Options shall continue to vest during his
continuing role in the Company in the New Position. The total expense for 2011 and 2010 was $65,000 and $193,000, respectively. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the fiscal year ended December&nbsp;31, 2011, we granted to our President and Chief Executive Officer 300,000 stock options subject
to performance-based vesting. The aggregate fair market value of the stock option grant was valued using the lattice model and is being amortized to compensation expense over the vesting period. Compensation expense recognized related to this grant
was approximately $23,000 for the year ended December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2011, an aggregate of
8,750,000&nbsp;shares of common stock were reserved for issuance under the Company&#146;s 2007 Incentive Plan, including 6,163,137&nbsp;shares subject to outstanding common stock options granted under this plan and 1,299,717&nbsp;shares available
for future grants. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date include vesting upon grant to vesting at the end of a four year period. The options will expire,
unless previously exercised, no later than ten years from the grant date. The Company is using unissued shares for all shares issued for options, restricted share awards and ESPP issuances. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the options&#146; activity of the Company&#146;s stock option plan: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding&nbsp;&#151; January&nbsp;1, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,582,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">926,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(122,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding&nbsp;&#151; December&nbsp;31, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,333,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,322,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,492,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding&nbsp;&#151; December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,163,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable&nbsp;&#151; December&nbsp;31, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,155,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable&nbsp;&#151; December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,673,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average remaining contractual life of options outstanding and exercisable at
December&nbsp;31, 2011 was 7.87 years and 7.56 years, respectively. The weighted average remaining contractual life of options outstanding and exercisable at December&nbsp;31, 2010 was 7.35 years and 7.09 years, respectively. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate intrinsic value of outstanding options as of December&nbsp;31, 2011 and 2010 is $0 and $137,000, respectively. The aggregate
intrinsic value of exercisable options as of December&nbsp;31, 2011 and 2010 is $0 and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-31
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
$34,000, respectively. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company&#146;s common stock and the exercise price
of the underlying options. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate intrinsic value of options exercised during 2010 was approximately $164,000. There
were no options exercised during 2011. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Employee Stock Purchase Plan</I> &#151;&nbsp;The Company also has an employee stock
purchase plan (&#147;ESPP&#148;) which allows employees to contribute up to 15% of their cash earnings, subject to certain maximums, to be used to purchase shares of our common stock on each semi-annual purchase date. The purchase price is equal to
85% of the market value per share on either the first or last day of the semi-annual period, whichever is lower. Our ESPP is non-compensatory pursuant to the provisions of generally accepted accounting principles for share-based compensation
expense. The ESPP contains an &#147;evergreen provision&#148; with annual increases in the number of shares available for issuance on the first day of each year through January&nbsp;1, 2015 equal to the lesser of: (a)&nbsp;250,000 shares increased
on each anniversary of the adoption of the Plan by one percent (1%)&nbsp;of the total shares of stock then outstanding and (b)&nbsp;1,000,000 shares.&nbsp;As of December&nbsp;31, 2011, an aggregate of 231,176 shares of common stock were authorized
and available for issuance under the ESPP. Under the evergreen provision, on January&nbsp;1, 2012, an additional 250,000 shares were authorized under our ESPP. The Company has issued 18,824 shares under the ESPP through December&nbsp;31, 2011.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted Stock Units </I>&#151; In addition to options to purchase shares of common stock, the Company may grant
restricted stock units (&#147;RSU&#148;) as part of its compensation package. Each RSU is granted at the fair market value based on the date of grant. Vesting is determined on a grant by grant basis. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2011 and 2010, the Company granted a total of 220,728 and 43,541 RSUs, respectively. The RSUs granted in 2011 and 2010 had an aggregate
intrinsic value of $256,000 and $112,000. As of December&nbsp;31, 2011 and 2010, all of the RSUs had vested in full. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.&nbsp;&nbsp;&nbsp;&nbsp;Net Loss Per Share </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#147;
<I>Earnings per Share.&#148;</I> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by
dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding.
Potential common shares consist of shares issuable upon the exercise of stock options and warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as
basic net loss per common share. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the potential common shares excluded from the calculation of
net loss per common share because their inclusion would be anti-dilutive: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options to purchase common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,163,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,333,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants to purchase common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,120,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,100,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,283,779</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,433,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-32
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14.&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The components of federal and state income tax expense are as follows (in thousands): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,853</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The components of net deferred tax assets are as follows (in thousands): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net operating loss carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax credit carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Licensing deduction deferral</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(36,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The components of net deferred tax liabilities are as follows (in thousands):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2010&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In-process research and development not subject to future amortization for tax purposes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross deferred tax liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-33
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provision for income taxes differs from the provision computed by applying the
federal statutory rate to net loss before income taxes as follows (in thousands): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected federal income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-qualified stock compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of change in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax credits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State income taxes after credits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has incurred net operating losses from inception. At December&nbsp;31, 2011, the Company had
domestic federal and state net operating loss carryforwards of approximately $41.6&nbsp;million available to reduce future taxable income, which expire at various dates beginning in 2013 through 2031. The Company also had federal and state research
and development tax credit carryforwards of approximately $2,000,000 and $1,800,000, respectively, available to reduce future tax liabilities and which expire at various dates beginning in 2023 through 2031. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#146;s ownership may result in a limitation
on the amount of net operating loss carryforwards and research and development credit carryforwards which could be utilized annually to offset future taxable income and taxes payable. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on an assessment of all available evidence including, but not limited to the Company&#146;s limited operating history in its core
business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has
concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a 100% deferred income tax valuation allowance has been recorded against these assets. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company adopted certain provisions of the <I>ASC 740,</I> effective January&nbsp;1, 2007 which clarifies the accounting for
uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. The adoption
of <I>ASC 740-10</I> did not have any effect on the Company&#146;s financial position or results of operations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
files income tax returns in the U.S.&nbsp;federal, Massachusetts and Oregon jurisdictions. The Company is subject to tax examinations for the 2007 tax year and beyond. The Company does not believe there will be any material changes in its
unrecognized tax positions over the next 12&nbsp;months. The Company has not incurred any interest or penalties. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial
statements as general and administrative expense. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;License Agreements </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of its business, the Company enters into licensing agreements with third parties that often require milestone
and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to
make royalty payments based upon a percentage of net sales. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expenditures required under these arrangements may be material
individually in the event that the Company develops product candidates covered by the intellectual property licensed under any such arrangement, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-34
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of
operations. In addition, these arrangements often give the Company discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease
development if the compound successfully achieves clinical testing objectives. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended December&nbsp;31, 2007,
the Company entered into a license agreement with Cold Spring Harbor Laboratory (&#147;CSHL&#148;) for small hairpin RNA, or &#147;shRNA&#148;, for which the Company paid $50,000 and agreed to make future milestone and royalty payments upon
successful development and commercialization of products. The Company also entered into four exclusive license agreements and an invention disclosure agreement with the University of Massachusetts Medical School (&#147;UMMS&#148;) for which the
Company paid cash of $453,000 and issued 462,112 shares of its common stock valued at $2.3 million, or $5.00 per share. For each RNAi product developed in connection with the license granted by CSHL, the possible aggregate milestone payments equal
$2,650,000. The invention disclosure agreement has an initial term of three years and provides the option to negotiate licenses to certain RNAi technologies discovered at UMMS. During the year ended December&nbsp;31, 2011, the Company cancelled
several of its licenses with UMMS. Upon the signing of the Contribution Agreement on September&nbsp;24, 2011, one of the remaining UMMS licenses was transferred to RXi and the CSHL license agreement was retained by the Company and not transferred to
RXi. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2007, the Company entered into a license agreement with Dharmacon, Inc. (now part of Thermo Fisher Scientific
Inc.), pursuant to which the Company obtained an exclusive license to certain RNAi sequences to a number of target genes for the development of the Company&#146;s rxRNA compounds. Further, the Company has obtained the right to license additional
RNAi sequences, under the same terms, disclosed by Thermo Fisher Scientific Inc. in its pending patent applications against target genes and has received an option for exclusivity for other siRNA configurations. As consideration for this license,
the Company paid an up-front fee of $150,000 and agreed to pay future clinical milestone payments and royalty payments based on sales of siRNA compositions developed in connection with the licensed technology. In addition, the Company has agreed to
pay future clinical milestone payments in an aggregate amount of up to $2,000,000 and royalty payments of either 0.25% or 0.5% based on the level of any future sales of siRNA compositions developed in connection with the licensed technology. No
amounts were expensed in 2010 and 2011 related to this license. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September, 2009, the Company entered into a Patent and
Technology Assignment Agreement with Advirna, LLC (&#147;Advirna&#148;), a Colorado limited liability company co-founded by the Company&#146;s former Chief Scientific Officer. Pursuant to the terms of the agreement, Advirna assigned to the Company
certain patent and technology rights related to chemically modified polynucleotides (the &#147;Rights&#148;) and the Company granted to Advirna a fully paid-up license to the Rights in a specified field. During the year ended December&nbsp;31, 2011,
the Company paid and expensed $100,000 for the annual maintenance fees under this agreement. There was no expense recorded for the year ended December&nbsp;31, 2010. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of the transactions contemplated by the Contribution Agreement and Securities Purchase Agreement, on September&nbsp;24, 2011, RXi entered into an agreement with Advirna pursuant to which:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advirna assigned to RXi its existing patent and technology rights related to sd-rxRNA technology in exchange for RXi&#146;s agreement to pay Advirna an
annual $100,000 maintenance fee and a one-time $350,000 milestone payment upon the future issuance of the first patent with valid claims covering the assigned patent and technology rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi with respect to future licensing of the assigned Advirna
patent and technology rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi has granted back to Advirna a license under the assigned patent and technology for fields of use outside the fields of human therapeutics and
diagnostics; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi has agreed to issue to Advirna, upon the completion of the spin-off transaction, shares of RXi&#146;s common stock equal to approximately 5% of the
fully diluted shares of RXi common stock assuming the conversion in full of all outstanding Series A Preferred Stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the acquisition of Apthera, the Company assumed the rights and obligations of a certain license agreement, as amended, from The University of Texas M. D. Anderson Cancer Center
(&#147;MDACC&#148;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#147;HJF&#148;) which grants exclusive worldwide rights to a U.S. patent covering the E75 peptide, and several U.S. and foreign patents and
patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to make future annual maintenance fee payments, as well as clinical milestone payments and royalty payments based on sales of
therapeutic products developed from the licensed technologies. As part of the expected payments under the terms of the license, the Company must pay an annual maintenance fee of $200,000. In addition, upon commencing the Phase 3 trial, we will pay a
milestone payment of $200,000. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2011, the Company entered into a subsequent non-exclusive license
agreement with HJF which has since been made exclusive, granting patent rights to the use of the E75 peptide in combination with Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. As part of the expected payments under the terms of the license, the Company paid an issue royalty fee of $100,000. In addition, the Company must pay an annual
maintenance fee of $50,000 ($25,000 for each patent) and royalties based on net sales upon commercialization. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September
2011, the Company licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39 (FBP) targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarconimas. The FBP vaccine was licensed
from The University of Texas M D Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. FBP has been granted Investigational New Drug approval by the U.S. Food and Drug Administration to enter clinical
trials. Institutional Review Board approval has also been received allowing RXi to initiate Phase 1 trials by the end of 2011. As part of the expected payments under the terms of the license, the Company paid an issue royalty fee of $100,000.
Additionally, the Company shall pay the HJF a non-creditable, nonrefundable License issue royalty in the sum of $15,000 for each additional item of follow-on intellectual property. In addition, the Company must pay an annual maintenance fee of
$25,000 in 2012 and $50,000 in 2013. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16.&nbsp;&nbsp;&nbsp;&nbsp;Related Party Transactions </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi and Advirna, LLC, which is 50%-owned by the Company&#146;s former Chief Scientific Officer, or CSO, are parties to
an option agreement whereby the Company paid $5,000 in 2008 for consideration to be granted the exclusive worldwide rights to license certain technology and $75,000 for the initial maintenance in 2009 under a Patent and Technology Assignment
Agreement with Advirna entered into in September 2009 (see also Note&nbsp;15). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;26, 2007, the Company entered
into Scientific Advisory Board Agreements (the &#147;SAB&nbsp;Agreements&#148;), with four of its founders. At the time of the execution of the SAB&nbsp;Agreements, each of the founders were beneficial owners of more than five percent of the
Company&#146;s outstanding stock. Pursuant to the SAB&nbsp;Agreements, on May&nbsp;23, 2007, the Company granted to each of the founders a stock option under the 2007 Plan to purchase 52,832&nbsp;shares of its common stock. In addition, under the
SAB&nbsp;Agreements, the Company will grant each of the founders a stock option under the 2007 Plan to purchase 52,832&nbsp;shares of its common stock on February&nbsp;26, 2008, June&nbsp;5, 2009 and June&nbsp;4, 2010 with a per share exercise price
equal to the closing price of such stock on the public market on the date of grant unless a founder terminates a SAB&nbsp;Agreement without good reason (as defined) or the Company terminates a SAB&nbsp;Agreement with cause (as defined therein) in
which case no further option grants will be made to the founder. If the Company&#146;s common stock is not publicly available on the dates specified above, its Board of Directors will grant the stock options to the founders at the first scheduled
board meeting after such date and the per share exercise price of the options will be determined in good faith by the Company&#146;s board of directors. All options granted pursuant to the SAB&nbsp;Agreements are fully vested on the date of grant
and have a term of ten years. The fair value of stock options granted during 2011 and 2010 under </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-36
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the SAB&nbsp;Agreement for each founder is approximately $0 and $142,000 which was estimated using the Black-Scholes option-pricing model as more fully discussed above under significant
accounting policies and the stock based compensation footnote. Included in the accompanying financial statements for the years ended December&nbsp;31, 2010 is approximately $566,000 of expense related to the granting of these stock options. No
options under the SAB agreements were issued during the year ended December 31, 2011 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, pursuant to a letter
agreement between the Company and each founder dated as of April&nbsp;30, 2007, the &#147;SAB&nbsp;Letters&#148;, in further consideration of the services to be rendered by the founders under the SAB&nbsp;Agreements, the Company granted additional
stock options on May&nbsp;23, 2007 under the 2007 Plan to each of the founders to purchase 26,416&nbsp;shares of its common stock. Unless a founder terminates a SAB&nbsp;Agreement without good reason (as defined) or the Company terminates a
SAB&nbsp;Agreement with cause (as defined therein), the options granted pursuant to the SAB&nbsp;Letters will fully vest from and after April&nbsp;29, 2012 and will have a term of ten years from the date of grant. At December&nbsp;31, 2011 and 2010,
the fair market value of stock options under the SAB&nbsp;Agreement for each founder is approximately $5,000 and $59,000, respectively, which was estimated using the Black-Scholes option-pricing model as more fully discussed above under the summary
of significant accounting policies and the stock based compensation footnote. Included in the accompanying financial statements for the years ended December&nbsp;31, 2011 and 2010 is approximately $159,000 and $60,000 of income, respectively,
related to these stock options. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2012, the Company retained TroyGould PC to be its outside corporate counsel. Sanford J.
Hillsberg, the Chairman of the Company, is a senior lawyer with TroyGould PC. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17.&nbsp;&nbsp;&nbsp;&nbsp;Employee Benefit Plan </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company sponsors a 401(k) retirement savings plan (the &#147;Plan&#148;). Participation in the Plan is available to
full-time employees who meet eligibility requirements. Eligible employees may defer a portion of their salary as defined by Internal Revenue Service regulations. The Company may make matching contributions on behalf of all participants in the 401(k)
Plan in an amount determined by the Company&#146;s board of directors. The Company may also make additional discretionary profit sharing contributions in amounts as determined by the board of directors, subject to statutory limitations. Matching and
profit-sharing contributions, if any, are subject to a vesting schedule; all other contributions are at all times fully vested. The Company intends the 401(k) Plan, and the accompanying trust, to qualify under Sections&nbsp;401(k) and 501 of the
Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that the Company will be able to deduct its
contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, invests the assets of the 401(k) Plan in any of a number of investment options. To date, the Company has not made any matching contributions.
</FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18.&nbsp;&nbsp;&nbsp;&nbsp;Subsequent Events </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company evaluated all events or transactions that occurred after December&nbsp;31, 2011 up through the date these
financial statements were issued. Other than what is disclosed below, or elsewhere in the notes to the consolidated financial statements, the Company did not have any material recognizable or unrecognizable subsequent events. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;12, 2012, the Company granted an option to purchase 50,000&nbsp;shares of common stock to each of the five non-employee
members of the Board of Directors. These options had an exercise price of $0.72 per share, which represented the Company&#146;s closing stock price on that date. The options vest quarterly over a one-year period and expire not later than 10 years
from the grant date. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;12, 2012, the Company granted options to purchase an aggregate of 825,000&nbsp;shares of
common stock to certain employees at a price of $0.72 per share, which represented the Company&#146;s closing stock price on </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-37
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#151; (Continued) </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
that date. The options vest quarterly over four years beginning three months from the date of grant and expire not later than 10 years from the date of grant. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;4, 2012, the Company granted warrants to purchase 400,000&nbsp;shares of common stock at an exercise price of $0.66 per
share in exchange for business advisory services to the Company for a period of up to twelve months. The warrants vested as to 100,000&nbsp;shares upon issuance, and then will vest at a rate of 100,000&nbsp;shares&nbsp;per quarter starting on the
90&nbsp;day anniversary of issuance. The Company has also agreed to give &#147;piggy back&#148; registration rights with respect to the shares of common stock underlying the warrants in any registration statement filed by the company in connection
with an underwritten offering of the common stock. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;20, 2012, the Company sold 579,710 shares of our common
stock for $400,000 to Kwang Dong Pharmaceutical Company as part of a existing license agreement for NeuVax covering territorial rights for the compound in South Korea that the Company acquired in its merger acquisition of Apthera. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;3, 2012, the Company issued 100,000 shares of our common stock in payment of $135,000 of accrued legal fees. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;8, 2012, the Company issued 1,315,789 restricted shares of common stock in payment of the first milestone under the
contingent value rights agreement entered into in connection with our merger acquisition of Apthera in April 2011. The certificates evidencing the milestone shares have been deposited with a third-party escrow agent. The milestone shares will be
released to the former Apthera shareholders from escrow if the issuance of the milestone shares is approved by the stockholders of the Company at the Company&#146;s 2012 annual stockholders meeting. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From January 23, 2012 through March 23, 2012, the Company issued 1,369,944 shares of the Company&#146;s common stock subject to the
exercise of outstanding warrants from various warrant holders. The Company received $1,223,464 in total payments at exercise prices ranging from $0.65 to $2.50 per share. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-38
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_12"></A>Item&nbsp;9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES.</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_13"></A>Item&nbsp;9A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>CONTROLS AND PROCEDURES</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Evaluation of Disclosure Controls and Procedures </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rule 13a-15(e) under the
Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), defines the term &#147;disclosure controls and procedures&#148; as those controls and procedures designed to ensure that information required to be disclosed by a
company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and that such information is
accumulated and communicated to the company&#146;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Chief Executive Officer and Principal Accounting Officer have evaluated the effectiveness of the design and operation of
our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, our Chief
Executive Officer and Principal Accounting Officer have concluded that our disclosure controls and procedures are effective. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been no changes in our internal controls over financial reporting during the fourth quarter of the year ended December&nbsp;31,
2011 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Evaluation of Disclosure Controls and Procedure Management&#146;s report on Internal Control over Financial Reporting </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Accounting Officer, we conducted evaluations of the effectiveness of our internal control over
financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#147;COSO&#148;). Based on our evaluations under the framework in Internal
Control-Integrated Framework issued by the COSO, our management concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This annual report does not include an attestation report of the company&#146;s registered public accounting firm regarding internal control over financial reporting. Management&#146;s report was not
subject to attestation by our registered public accounting firm pursuant to SEC rules that permit us to provide only management&#146;s report in this annual report. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_14"></A>Item&nbsp;9B.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>OTHER INFORMATION</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">None </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART III. </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_15"></A>Item&nbsp;10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will file with the SEC a definitive Proxy Statement, which we refer to herein as the &#147;Proxy Statement,&#148; not later than 120 days after the close of the fiscal year ended December&nbsp;31,
2011. The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_16"></A>Item&nbsp;11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>EXECUTIVE COMPENSATION</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_17"></A>Item&nbsp;12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_18"></A>Item&nbsp;13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</I></B><B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_19"></A>Item&nbsp;14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>PRINCIPAL ACCOUNTANT FEES AND SERVICES</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PART IV. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_20"></A>Item&nbsp;15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) (1)&nbsp;<I>Financial Statements</I> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">See Item&nbsp;8 in Part II of this
annual report on Form 10-K, &#147;Financial Statements and Supplementary Data,&#148; for an index to the financial statements filed in this annual report, which information is incorporated herein by reference. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) <I>Financial Statement Schedules</I> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain schedules are omitted because they are not applicable, or not required by smaller reporting companies. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(3) <I>Exhibits</I> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Exhibits listed in the Exhibit Index immediately
preceding the Exhibits are filed as a part of this annual report. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc275067_21"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="65"></TD>
<TD HEIGHT="65" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Mark J. Ahn</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: March&nbsp;28, 2012 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates
indicated. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Mark J. Ahn</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer and Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Kwang S. Lee</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance and Principal Accounting Officer (Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Sanford J. Hillsberg</I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Richard Chin</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Stephen S. Galliker</I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Steven A. Kriegsman</I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A. Kriegsman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Rudolph Nisi</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Amended and Restated Certificate of Incorporation of Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation).(1)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Amended and Restated Certificate of Incorporation of Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation).(27)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Ownership and Merger.(19)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Amended and Restated By-laws of Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation).(1)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specimen common stock certificate.(3)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annex I to form of Subscription Agreement &#151; Registration Rights Terms between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and Stephen Galliker, Mark Ahn
and Sanford Hillsberg.(1)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant No. A-1 in favor of J.P. Turner Partners, LP, dated August 7, 2008.(5)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Common Stock Purchase Warrant issued in August 2009.(8)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Common Stock Purchase Warrant issued in March 2010.(10)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of 13-Month Common Stock Purchase Warrant issued in March 2011.(12)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Five-Year Common Stock Purchase Warrant issued in March 2011.(12)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Common Stock Purchase Warrant issued in April 2011.(15)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant No. 2012-1 in favor of Legend Securities, Inc. issued in February 2012.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Contingent Value Rights Agreement among Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert
E Kennedy, dated April 13, 2011.(14)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Contingent Value Rights Agreement among Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc.,
and Robert E Kennedy, dated February 15, 2012.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Escrow Agreement entered into among Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., and Robert E. Kennedy, in his
capacity as the Stockholder Representative, on April&nbsp;13, 2011.(14)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Exclusive License Agreement, between CytRx Corporation and the University of Massachusetts Medical School related to UMMS disclosure number 01-36, dated April 15, 2003, as
amended February 1, 2004.+(24)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement between RXi Pharmaceuticals Corporation and Dharmacon, Inc. (now part of Thermo Fisher Scientific Inc.), dated October&nbsp;29, 2007.+(24)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Agreement between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and Mark W. Schwartz, Ph.D., dated April&nbsp;13, 2011.*(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Agreement between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and Mark Ahn, dated March 31, 2011.*(13)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) Amended and Restated 2007 Incentive Plan.*(11)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) Amended and Restated 2007 Incentive Plan.*(26)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option.*(1)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Non-qualified Stock Option.*(1)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease between RXi Pharmaceuticals Corporation and Newgate Properties, LLC for One Gateway Place, Worcester, Massachusetts 01605, dated September 25, 2007.(2)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease between RXi Pharmaceuticals Corporation and Newgate Properties, LLC for One Gateway Place, Worcester, Massachusetts 01605, dated January 23,
2009.(6)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease between RXi Pharmaceuticals Corporation and Newgate Properties, LLC for One Gateway Place, Worcester, Massachusetts 01605, dated March 5,
2009.(7)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease between RXi Pharmaceuticals Corporation and Newgate Properties, LLC for One Gateway Place, Worcester, Massachusetts 01605, dated August&nbsp;28,
2008.(23)</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease between RXi Pharmaceuticals Corporation and Newgate Properties, LLC for One Gateway Place, Worcester, Massachusetts 01605, dated November&nbsp;4,
2008.(23)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease between RXi Pharmaceuticals Corporation and Newgate Properties, LLC for One Gateway Place, Worcester, Massachusetts 01605, dated June&nbsp;9,
2011.(23)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent and Technology Assignment Agreement between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and Advirna, LLC dated September 21, 2009.+(9)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent and Technology License Agreement, dated September&nbsp;11, 2006, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson
Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.).+(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;1 to Patent and Technology License Agreement, dated December&nbsp;21, 2007, by and among the Board of Regents of the University of Texas System, the University of
Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.).(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.21</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;2 to Patent and Technology License Agreement, dated September&nbsp;3, 2008, by and among the Board of Regents of the University of Texas System, the University of
Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.).(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.22</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;3 to Patent and Technology License Agreement, dated July&nbsp;8, 2009, by and among the Board of Regents of the University of Texas System, the University of
Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.).(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.23</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;4 to Patent and Technology License Agreement, dated February&nbsp;11, 2010, by and among the Board of Regents of the University of Texas System, the University of
Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.).+(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;5 to Patent and Technology License Agreement, dated January&nbsp;10, 2011, by and among the Board of Regents of the University of Texas System, the University of
Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.).+(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.25</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scientific Advisory Agreement between RXi Pharmaceuticals Corporation and George E. Peoples, Ph.D., dated April&nbsp;13, 2011.(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.26</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Amendment to Stock Options Granted under Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) 2007 Incentive Plan, entered into in April&nbsp;2011 by Galena
Biopharma, Inc. with all directors of Galena Biopharma, Inc., as of April&nbsp;1, 2011, and Mark J. Ahn, Ph.D., Anastasia Khvorova, Ph.D., and Pamela Pavco, Ph.D.*(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.27</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive License Agreement, dated as of July&nbsp;11, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Galena Biopharma, Inc.
(formerly RXi Pharmaceuticals Corporation) and its wholly-owned subsidiary, Apthera, Inc.+(16)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.28</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separation and Transition Agreement entered into as of September&nbsp;24, 2011 between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and Pamela Pavco,
Ph.D.(17)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.29</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment letter dated 21 September&nbsp;2011 between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and Kwang Lee.*(17)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.30</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;1 to Employment Agreement made as of September&nbsp;23, 2011 between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and Mark W. Schwartz,
Ph.D.*(17)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.31</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger by and among Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), Diamondback Acquisition Corp., Apthera, Inc. and Robert E. Kennedy, in
his capacity as the Stockholder Representative, dated March&nbsp;31, 2011.(13)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.32</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separation Agreement between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and Noah D. Beerman, dated March&nbsp;30,
2011.(13)</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.33</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusive License Agreement, dated effective as of September 16, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Galena Biopharma,
Inc. (formerly RXi Pharmaceuticals Corporation), The Board of Regents of the University of Texas System and The University of Texas M.D. Anderson Cancer Center.+(18)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.34</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contribution Agreement, dated as of September&nbsp;24, 2011, between RXi Pharmaceuticals Corporation (formerly RNCS, Inc.) and Galena Biopharma, Inc. (formerly RXi Pharmaceuticals
Corporation).(19)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.35</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities Purchase Agreement, dated as of September&nbsp;24, 2011, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly RXi Pharmaceuticals
Corporation), Tang Capital Partners, LP and RTW Investments, LLC.(19)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.36</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Omnibus Amendment to Securities Purchase Agreement, dated as of February 6, 2012, among<BR>RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly
RXi Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC.(24)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.37</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Omnibus Amendment to Securities Purchase Agreement, dated as of March 5, 2012, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly
RXi Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.38</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Subscription Agreement, dated September&nbsp;24, 2011, among Galena Biopharma, Inc. (formerly, RXi Pharmaceuticals Corporation), Tang Capital Partners, LP. and RTW
Investments, LLC.(19)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.39</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Investor Subscription Agreement, dated September&nbsp;26, 2011, among Galena Biopharma, Inc., Tang Capital Partners, LP. and RTW Investments,
LLC.(20)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.40</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent and Technology Assignment Agreement between RXi Pharmaceuticals Corporation (formerly RNCS, Inc.) and Advirna, LLC, effective as of September&nbsp;24,
2011.(23)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.41</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Exchange Agreements by and between Galena Biopharma, Inc. and the Investors named therein.(21)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.42</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Controlled Equity Offering</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> Sales Agreement, dated as of February&nbsp;17, 2012, between Galena Biopharma, Inc. and Cantor Fitzgerald &amp; Co.(22)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.43</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and LO 138, LLC for 310 N. State Street, Suite 208, Lake Oswego, Oregon, 97034, entered into as of
July 18, 2011.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.44</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) Employee Stock Purchase Plan.*(25)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.45</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement, effective as of April 30, 2009, between Kwangdong Pharmaceutical Co., Ltd. and Apthera, Inc.+**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.46</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to License Agreement, dated as of January 13, 2012, by and among Apthera, Inc., Kwangdong Pharmaceutical Co., Ltd., and Galena Biopharma, Inc.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.47</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separation and Transition Agreement entered into as of September 24, 2011 between Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corp.) and Anastasia Khvorova, Ph.D.*
**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;14.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Code of Ethics and Conduct.(4)</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of the Registrant.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of BDO USA, LLP, Independent Registered Public Accounting Firm.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sarbanes-Oxley Act Section 302 Certification of Mark J. Ahn.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sarbanes-Oxley Act Section 302 Certification of Kwang S. Lee.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sarbanes-Oxley Act Section 906 Certification of Mark J. Ahn and Kwang S. Lee.**</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.INS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document.</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.SCH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema.</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.CAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation.</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.DEF</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition.</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.LAB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Label.</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.PRE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:13%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Registration Statement on Form S-1 filed on October&nbsp;30, 2007 (File No.&nbsp;333-147009) and incorporated by
reference herein </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to Amendment No.&nbsp;1 to the Company&#146;s Registration Statement on Form S-1 filed on November&nbsp;19, 2007(File
No.&nbsp;333-147009) and incorporated by reference herein. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to Amendment No.&nbsp;2 to the Company&#146;s Registration Statement on Form S-1 filed on January&nbsp;20, 2008 (File
No.&nbsp;333-147009) and incorporated by reference herein. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 10-K filed on April&nbsp;15, 2008 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 10-Q filed on November&nbsp;14, 2008 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on January&nbsp;29, 2009 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 10-Q filed on May&nbsp;15, 2009 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on July&nbsp;31, 2009 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 10-Q filed on November&nbsp;16, 2009 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on March&nbsp;23, 2010 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as Annex A to the Company&#146;s Proxy Statement on Schedule 14A filed on April&nbsp;23, 2010 (File No.&nbsp;001-33958) and incorporated by reference
herein. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on March&nbsp;1, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on April&nbsp;5, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on April&nbsp;14, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on April&nbsp;15, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 10-Q filed on August&nbsp;15, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 10-Q filed on November&nbsp;14, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on September&nbsp;21, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on September&nbsp;26, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on September&nbsp;27, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on December&nbsp;6, 2011 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on February&nbsp;17, 2012 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to RXi Pharmaceuticals Corporation&#146;s Registration Statement on Form S-1 filed on October&nbsp;25, 2011 (File No.&nbsp;333-177498)
and incorporated by reference herein. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to Amendment No.&nbsp;4 to RXi Pharmaceuticals Corporation&#146;s Registration Statement on Form S-1 filed on February&nbsp;7, 2012 (File
No.&nbsp;333-177498) and incorporated by reference herein. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as Annex B to the Company&#146;s Proxy Statement on Schedule 14A filed on April&nbsp;23, 2010 (File No.&nbsp;001-33958) and incorporated by reference
herein. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as Annex A to the Company&#146;s Proxy Statement on Schedule 14A filed on May&nbsp;31, 2011 (File No.&nbsp;001-33958) and incorporated by reference
herein. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(27)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as Annex B to the Company&#146;s Proxy Statement on Schedule 14A filed on May&nbsp;31, 2011 (File No.&nbsp;001-33958) and incorporated by reference
herein. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates a management contract or compensatory plan or arrangement. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This exhibit was filed separately with the Commission pursuant to an application for confidential treatment. The confidential portions of the exhibit have been omitted
and have been marked by an asterisk. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>2
<FILENAME>d275067dex49.htm
<DESCRIPTION>WARRANT NO. 2012-1 IN FAVOR OF LEGEND SECURITIES, INC.
<TEXT>
<HTML><HEAD>
<TITLE>Warrant No. 2012-1 in favor of Legend Securities, Inc.</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 4.9 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NEITHER THESE SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN
RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT
OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WARRANT </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant No.&nbsp;2012-1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective Date: February 4, 2012</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), hereby certifies
that, for value received, Legend Securities, Inc., or its registered Permitted Transferees (together, the &#147;<B><I>Holder</I></B>&#148;), as registered owner of this warrant (the &#147;<B><I>Warrant</I></B>&#148;), is entitled to purchase from
the Company up to a total of 400,000 shares (as adjusted from time to time as provided in <U>Section&nbsp;10</U>) of Common Stock, at an exercise price equal to $0.66 per share (as adjusted from time to time as provided in <U>Section&nbsp;10</U>,
the &#147;<B><I>Exercise Price</I></B>&#148;), upon such shares becoming Vested Shares, at any time and from time to time from and after the date of this Warrant (the &#147;<B><I>Initial Exercise Date</I></B>&#148;) to and including February 4, 2017
(the &#147;<B><I>Expiration Date</I></B>&#148; and the period starting with the Initial Exercise Date and ending on the Expiration Date is referred to as the &#147;<B><I>Term</I></B>&#148;), and subject to the following terms and conditions:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Definitions</U>. The capitalized terms used herein and not otherwise defined shall have the meanings set forth below:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Affiliate</I></B>&#148; of any specified Person means any other person or entity directly or indirectly
controlling, controlled by or under direct or indirect common control with such specified Person. For purposes of this definition, &#147;<B><I>control</I></B>&#148; means the power to direct the management and policies of such Person or firm,
directly or indirectly, whether through the ownership of voting securities, by contract or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Commission</I></B>&#148; means the United States Securities and Exchange Commission. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company, $0.0001 par value per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Eligible Market</I></B>&#148; means any of the New York Stock Exchange, the
American Stock Exchange or Nasdaq (as defined below), and any successor markets thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Exchange
Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Market Price</I></B>&#148; shall mean
(i)&nbsp;if the principal trading market for such securities is an exchange, the average of the last reported sale prices per share for the last ten previous Trading Days in which a sale was reported, as officially reported on any consolidated tape
or (ii)&nbsp;if clause&nbsp;(i) is not applicable, the average of the closing bid price per share for the last ten previous Trading Days as set forth in the National Quotation Bureau sheet listing for such securities. Notwithstanding the foregoing,
if there is no reported sales price or closing bid price, as the case may be, on any of the ten Trading Days preceding the event requiring a determination of Market Price hereunder, then the Market Price shall be determined in good faith after
reasonable investigation by resolution of the Board of Directors of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Nasdaq</I></B>&#148; means the
Nasdaq Global Market or Nasdaq Capital Market, and any successor markets thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Permitted
Transferees</I></B>&#148; means only Persons who are the directors, officers and employees of the Holder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Person</I></B>&#148; means any court or other federal, state, local or other governmental authority or other individual or
corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Trading Day</I></B>&#148; means (a)&nbsp;any day on which the Common Stock is listed or quoted and traded on any Eligible
Market or (b)&nbsp;if the Common Stock is not then quoted and traded on any Eligible Market, then a day on which trading occurs on the Nasdaq Global Market (or any successor thereto). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Vested Shares</I></B>&#148; means Warrant Shares that have become vested as described in and pursuant to
<U>Section&nbsp;4</U> hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Warrant Shares</I></B>&#148; shall initially mean shares of Common Stock and in
addition may include Other Securities and Substituted Property (as defined in <U>Section&nbsp;10(e)(x)</U>) issued or issuable from time to time upon exercise of this Warrant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2. <U>Registration of Warrant</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B><I>Warrant Register</I></B>&#148;), in the name of
the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Registration of Transfers</U>. The Company shall register the transfer of any portion of this Warrant in the Warrant
Register, which transfer shall only be made to a Permitted </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Transferee and in accordance with applicable securities laws, upon surrender of this Warrant, with the Form of Assignment attached hereto as Appendix&nbsp;A duly completed and signed, to the
Company at its address specified herein. Upon any such registration and transfer, a new warrant in substantially the form of a Warrant (any such new warrant, a &#147;<B><I>New Warrant</I></B>&#148;), evidencing the portion of this Warrant so
transferred shall be issued to the Permitted Transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the Permitted
Transferee thereof shall be deemed the acceptance by such Permitted Transferee of all of the rights and obligations of a holder of a Warrant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4. <U>Vesting of Warrant Shares</U>. The Warrant Shares issued hereunder shall vest completely and in favor of Legend in the following installments (the &#147;<B><I>Installments</I></B>&#148;) as
described in this Section&nbsp;4. The first Installment in the amount of 100,000 shares shall vest on the Effective Date of the Investment Banking Agreement, and the three remaining Installments, each in the amount of 100,000 shares, shall vest on
each quarterly anniversary of the Effective Date of the Investment Banking Agreement following unless the letter agreement between Legend Securities and the Company dated February 4, 2012 has been terminated prior to each such date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>Exercise and Duration of Warrant</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The Vested Shares under this Warrant shall be exercisable, either in its entirety or for a portion of the number of Vested Shares, by the registered Holder at any time and from time to time from and
after the Initial Exercise Date to and including the Expiration Date. At 5:00&nbsp;P.M. Boston, Massachusetts time on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value, and the
Holder hereof shall have no right to purchase any additional Warrant Shares hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) A Holder may exercise this Warrant
by delivering to the Company, in accordance with <U>Section&nbsp;13</U>, this Warrant, together with (i)&nbsp;an exercise notice, in the form attached hereto as <U>Appendix&nbsp;B</U> (the &#147;<B><I>Exercise Notice</I></B>&#148;), appropriately
completed and duly signed, and (ii)&nbsp;(A)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised pursuant to a Cash Exercise (as set forth in <U>Section&nbsp;5(c)</U> below) or (B)&nbsp;if
available pursuant to <U>Section&nbsp;5(d)</U> below, by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as set forth in <U>Section&nbsp;5(d)</U> below), and the date such items are received by the Company
is an &#147;<B><I>Exercise Date</I></B>.&#148; Execution and delivery of an Exercise Notice in respect of less than all of the Warrant Shares issuable upon exercise of this Warrant shall result in the cancellation of the original Warrant and
issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <I>Cash Exercise</I>.
In the event the Holder has elected to pay the Exercise Price in cash, it shall pay the Exercise Price by certified bank check payable to the order of the Company or by wire transfer of immediately available funds in accordance with the
Company&#146;s instructions (a &#147;<B><I>Cash Exercise</I></B>&#148;). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <I>Cashless Exercise</I>. Notwithstanding anything contained herein to the contrary, the
Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Exercise Price, elect instead to receive upon
such exercise the &#147;Net Number&#148; of shares of Common Stock determined according to the following formula (a &#147;<B><I>Cashless Exercise</I></B>&#148;): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="middle" ROWSPAN="2" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Net Number</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ROWSPAN="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">=</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>(<I>A*B</I>) &#150; (<I>A*C</I>)</U></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&nbsp;B</I></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the foregoing formula, </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A = the total number of shares with respect to which this Warrant is then being exercised. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">B = the closing price per share of the Common Stock (as reported by Bloomberg) on the Trading Day immediately preceding the date of the Exercise Notice. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">C = the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Except as otherwise provided for herein, this Warrant shall not entitle the Holder to any voting rights or other rights as a
stockholder of the Company by virtue of the ownership hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>Delivery of Warrant Shares</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Upon exercise of this Warrant, the Company shall promptly issue or cause to be issued and deliver or cause to be delivered to the
Holder, in such name or names as the Holder may designate, a certificate for the Warrant Shares issuable upon such exercise (the &#147;<B><I>Certificate</I></B>&#148;) bearing no restrictive legends. The Holder, or any Person so designated by the
Holder to receive the Warrant Shares, shall be deemed to have become holder of record of such Warrant Shares as of the Exercise Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Neither these securities nor the securities for which these securities are exercisable have been registered with the Commission or the securities commission of any state in reliance upon an exemption
from registration under the Securities Act of 1933 (the &#147;<B><I>Securities Act</I></B>&#148;), and, accordingly, may not be offered or sold except pursuant to an effective registration statement under the Securities Act or pursuant to an
available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with applicable state securities laws. The Holder acknowledges and agrees that the Warrant may be sold only pursuant
to an applicable exemption from the registration requirements of the Securities Act and that the Warrant Shares may only be sold pursuant to an effective registration statement under the Securities Act or in accordance with any applicable exemption
from the registration requirements of the Securities Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) This Warrant is exercisable, either in its entirety or, from time to time, for a portion
of the number of Warrant Shares. Upon surrender of this Warrant following one or more partial exercises, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant
Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>Charges, Taxes and Expenses</U>. Issuance and delivery of certificates for shares of Common Stock upon exercise
of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the
Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issue, delivery or registration of any certificates for Warrant Shares or Warrant in a
name other than that of the Holder and that the Holder will be required to pay any tax with respect to cash received in lieu of fractional shares. The Holder shall be responsible for all other tax liability that may arise as a result of holding or
transferring this Warrant or receiving Warrant Shares upon exercise hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <U>Replacement of Warrant</U>. If this Warrant
is mutilated, lost, stolen or destroyed, the Company, at the sole expense of the Holder (such expenses, if any imposed by the Company to be reasonable), shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof,
or in lieu of and in substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested by the Company.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. <U>Reservation of Warrant Shares</U>. The Company covenants that it will at all times reserve and keep available out of
the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable
and deliverable upon the exercise of this entire Warrant, free from all taxes, liens, claims, encumbrances with respect to the issuance of such Warrant Shares and will not be subject to any pre-emptive rights or similar rights (taking into account
the adjustments and restrictions of Section&nbsp;10 hereof). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly
and validly authorized, issued, fully paid and nonassessable. The Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed or quoted, as the case may be; <I>provided, however</I>, that such actions shall only require the Company&#146;s
best efforts (or other specified standard) to the extent specifically provided for in this Warrant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. <U>Certain
Adjustments</U>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section&nbsp;10. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <I>Stock Dividends</I>. If the Company, at any time while this Warrant is outstanding, pays a dividend on its Common Stock payable in
additional shares of Common </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, then in each such case the Exercise Price shall be multiplied by a fraction,
(A)&nbsp;the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to the opening of business on the day after the record date for the determination of stockholders entitled to receive such dividend or
distribution and (B)&nbsp;the denominator of which shall be the number of shares of Common Stock outstanding immediately after the distribution date of such dividend or distribution. Any adjustment made pursuant to this <U>Section&nbsp;10(a)</U>
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution; <I>provided, however</I>, that if following such record date the Company rescinds or modifies such
dividend or distribution, the Exercise Price shall be appropriately adjusted (as of the date that the Company effectively rescinds or modifies such dividend or distribution) to take into account the effect of such rescinded or modified dividend or
distribution on the Exercise Price pursuant to this <U>Section&nbsp;10(a)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <I>Stock Splits</I>. If the Company, at
any time while this Warrant is outstanding, (i)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, or (ii)&nbsp;combines outstanding shares of Common Stock into a smaller number of shares, then in each such case the
Exercise Price shall be multiplied by a fraction, (A)&nbsp;the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and (B)&nbsp;the denominator of which shall be the number of shares of Common
Stock outstanding immediately after such event. Any adjustment pursuant to this <U>Section&nbsp;10(b)</U> shall become effective immediately after the effective date of such subdivision or combination. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <I>Reclassifications</I>. A reclassification of the Common Stock (other than any such reclassification in connection with a merger or
consolidation to which <U>Section&nbsp;10(e)</U> applies) into shares of any other class of stock shall be deemed: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) a
distribution by the Company to the holders of its Common Stock of such shares of such other class of stock for the purposes and within the meaning of this <U>Section&nbsp;10</U>; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) if the outstanding shares of Common Stock shall be changed into a larger or smaller number of shares of Common Stock as part of
such reclassification, such change shall be deemed a subdivision or combination, as the case may be, of the outstanding shares of Common Stock for the purposes and within the meaning of <U>Section&nbsp;10(b</U>). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <I>Other Distributions</I>. If the Company, at any time while this Warrant is outstanding, distributes to holders of Common Stock
(i)&nbsp;evidences of its indebtedness, (ii)&nbsp;shares of any class of capital stock, (iii)&nbsp;rights or warrants to subscribe for or purchase any shares of any class of capital stock or (iv)&nbsp;any other asset, other than a distribution of
Common Stock covered by <U>Section&nbsp;10(a)</U>, (in each case, &#147;<B><I>Distributed Property</I></B>&#148;), then in each such case the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders
entitled to receive such distribution (and the Exercise Price thereafter applicable) shall be adjusted (effective on and after such record date) to equal the product of such Exercise Price multiplied by a fraction, (A)&nbsp;the numerator of which
shall be Market Price on such record date </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
less the then fair market value of the Distributed Property distributed in respect of one outstanding share of Common Stock, which, if the Distributed Property is other than cash or marketable
securities, shall be as determined in good faith by the Board of Directors of the Company whose determination shall be described in a board resolution, and (B)&nbsp;the denominator of which shall be the Market Price on such record date; <I>provided,
however</I>, that if following the record date for such distribution the Company rescinds or modifies such distribution, the Exercise Price shall be appropriately adjusted (as of the date that the Company effectively rescinds or modifies such
distribution) to take into account the effect of such rescinded or modified distribution on the Exercise Price pursuant to this <U>Section&nbsp;10(d)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) <I>Fundamental Transactions.</I> If, at any time following the Initial Exercise Date, (i)&nbsp;the Company effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the
Company effects any sale of all or substantially all of its assets in one or a series of related transactions or (iii)&nbsp;there shall occur any merger of another Person into the Company whereby the Common Stock is cancelled, converted or
reclassified into or exchanged for other securities, cash or property (in any such case, a &#147;<B><I>Fundamental Transaction</I></B>&#148;), then, as a condition to the consummation of such Fundamental Transaction, the Company shall (or, in the
case of any Fundamental Transaction in which the Company is not the surviving entity, the Company shall take all reasonable steps to cause such other Person to) shall, at its election in its sole discretion: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(I) execute and deliver to the Holder of this Warrant a written instrument providing that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(x) so long as this Warrant remains outstanding, upon the exercise hereof at any time on or after the consummation of such Fundamental
Transaction and on such terms and subject to such conditions as shall be nearly equivalent as may be practicable to the provisions set forth in this Warrant, this Warrant shall be exercisable into, in lieu of Common Stock issuable upon such exercise
prior to such consummation, the securities or other property (the &#147;<B><I>Substituted Property</I></B>&#148;) that would have been received in connection with such Fundamental Transaction by a holder of the number of shares of Common Stock into
which this Warrant was exercisable immediately prior to such Fundamental Transaction, assuming such holder of Common Stock: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) is not a Person with which the Company consolidated or into which the Company merged or which merged into the Company or to which
such sale or transfer was made, as the case may be (a &#147;<B><I>Constituent Person</I></B>&#148;), or an Affiliate of a Constituent Person; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:21%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(B) failed to exercise such Holder&#146;s rights of election, if any, as to the kind or amount of securities, cash and other property receivable in connection with such Fundamental Transaction
(<I>provided, however</I>, that if the kind or amount of securities, cash or other property receivable in connection with such Fundamental Transaction is not the same for each share of Common Stock held immediately prior to such Fundamental
Transaction by a Person other than a Constituent Person or an Affiliate thereof and in respect of which such rights of election shall not have been exercised (a &#147;<B><I>Non-Electing Share</I></B>&#148;), then, for the purposes of this
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<U>Section&nbsp;10(e)</U>, the kind and amount of securities, cash and other property receivable in connection with such Fundamental Transaction by each Non-Electing Share shall be deemed to be
the kind and amount so receivable per share by a plurality of the Non-Electing Shares); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(y) the rights and obligations
of the Company (or, in the event of a transaction in which the Company is not the surviving Person, such other Person) and the Holder in respect of Substituted Property shall be as nearly equivalent as may be practicable to the rights and
obligations of the Company and Holder in respect of Common Stock hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such written instrument shall provide for
adjustments which, for events subsequent to the effective date of such written instrument, shall be as nearly equivalent as may be practicable to the adjustments provided for in this <U>Section&nbsp;10</U>. The above provisions of this
<U>Section&nbsp;10(e)</U> shall similarly apply to successive Fundamental Transactions, or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(II) cause to be delivered to the
Holder, as soon as practicable following the closing of the Fundamental Transaction, the Substituted Property less such portion of the Substituted Property with a value (determined in good faith by the Board of Directors of the Company or the other
Person in the Fundamental Transaction) equal to the aggregate Exercise Price of this Warrant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <I>Adjustment of Warrant
Shares.</I> Simultaneously with any adjustment to the Exercise Price pursuant to paragraphs&nbsp;(a) through (d)&nbsp;of this <U>Section&nbsp;10</U>, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased
or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price payable for the Warrant Shares
immediately prior to such adjustment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <I>Calculations.</I> All calculations under this <U>Section&nbsp;10</U> shall be
made to the nearest cent or the nearest 1/100th of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the disposition of any
such shares shall be considered an issue or sale of Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) <I>Adjustments</I>. Notwithstanding any provision of
this <U>Section&nbsp;10</U>, no adjustment of the Exercise Price shall be required if such adjustment is less than $0.01; <I>provided, however</I>, that any adjustments which by reason of this <U>Section&nbsp;10(h)</U> are not required to be made
shall be carried forward and taken into account for purposes of any subsequent adjustment required to be made hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)
<I>Notice of Adjustments.</I> Upon the occurrence of each adjustment pursuant to this <U>Section&nbsp;10</U>, the Company will promptly deliver to the Holder a certificate executed by the Company&#146;s Chief Financial Officer setting forth, in
reasonable detail, the event requiring such adjustment and the method by which such adjustment was calculated, the adjusted Exercise Price and the adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant
(as applicable). The Company will retain at its office copies of all such certificates and cause the same to be available for inspection at said office during normal business hours by the Holder or any prospective purchaser of the Warrant designated
by the Holder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) <I>Notice of Corporate Events. </I>If the Company (i)&nbsp;declares a dividend or any
other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary of the
Company, (ii)&nbsp;authorizes, approves, enters into any agreement contemplating, or solicits stockholder approval for, any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the
Company, then the Company shall deliver to the Holder a notice describing the material terms and conditions of such transaction at least 10 calendar days prior to the applicable record or effective date on which a Person would need to hold Common
Stock in order to participate in or vote with respect to such transaction, and the Company will take all steps reasonably necessary in order to ensure that the Holder is given the practical opportunity to exercise this Warrant prior to such time so
as to participate in or vote with respect to such transaction; <I>provided</I>, <I>however</I>, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such
notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. Registration Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <I>General. </I>If at any time after the date hereof the Company proposes to register any of its Common Stock under the Securities Act in connection with the public offering of such securities for the
accounts of shareholders other than Holder, solely for cash on a form that would also permit the registration of the Warrant Shares, the Company shall, each such time, promptly give Holder written notice of such determination. Upon the written
request of Holder given within fifteen (15)&nbsp;days after the giving of any such notice by the Company, the Company shall, subject to the limitations set forth in <U>Section&nbsp;11(e)</U>, use its best efforts to cause to be registered under the
Securities Act all of the Warrant Shares that Holder has requested be registered; provided, that the Company shall have the right to postpone or withdraw any registration statement relating to an offering in which the Holder is eligible to
participate under this <U>Section&nbsp;11</U> without any liability or obligation to the Holder under this <U>Section&nbsp;11</U>. For the avoidance of doubt, the Company shall not be obligated to effect any registration of Warrant Shares under this
<U>Section&nbsp;11</U> incidental to the registration of any of its securities in connection with the Company&#146;s Registration Statement on Form S-3 (Registration Statement No.&nbsp;333-167025) filed with the SEC by the Company in connection with
the shelf registration of the Company&#146;s Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Other Contractual Obligations of the Company</U>. Each
exercise of all or part of the Warrant by the Holder pursuant to <U>Section&nbsp;5</U> herein shall serve as Holder&#146;s acknowledgment and acceptance that the Holder&#146;s rights under this <U>Section&nbsp;11</U> as to the Warrant Shares
received as the result of such exercise are subject to the contractual obligations of the Company as of the Effective Date, including the Company&#146;s obligations to CytRx Corporation set out in the Contribution Agreement dated as of
April&nbsp;30, 2007 between CytRx Corporation and the Company, as amended on July&nbsp;28, 2008. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <I>Obligations of the Company</I>. Whenever required under this <U>Section&nbsp;11</U>
to use its best efforts to effect the registration of any Warrant Shares, the Company shall, as expeditiously as reasonably possible: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) Prepare and file with the SEC a registration statement with respect to such Warrant Shares and use its best efforts to cause such registration statement to become effective, and, upon the request of
the Holder, keep such registration statement effective for a period of up to one (1)&nbsp;year or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i)&nbsp;such one
(1)&nbsp;year period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Company; and
(ii)&nbsp;in the case of any registration of Warrant Shares on Form&nbsp;S-3 which are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one (1)&nbsp;year period shall be extended for up
to ninety (90)&nbsp;days, if necessary, to keep the registration statement effective until all such Warrant Shares are sold. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Furnish to the Holder such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of such Warrant Shares owned by it. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iv) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably
appropriate for the distribution of the securities covered by the registration statement, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions, and further provided that (anything in this <U>Section&nbsp;11</U> to the contrary notwithstanding with respect to the bearing of expenses) if any jurisdiction in which the securities shall be
qualified shall require that expenses incurred in connection with the qualification of the securities in that jurisdiction be borne by shareholders, then such expenses shall be payable by the Holder to the extent required by such jurisdiction.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) Provide a transfer agent for the Common Stock no later than the effective date of the first registration of any Warrant
Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) Otherwise use its best efforts to comply with all applicable rules and regulations of the SEC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) Use its best efforts&nbsp;to cause all such Warrant Shares to be listed on a national securities exchange (if such securities are
not already so listed) and on each additional national securities exchange on which similar securities issued by the Company are then listed, if the listing of such securities is then permitted under the rules of such exchange. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(viii) Use every reasonable effort to prevent the issuance of any stop order suspending the
effectiveness of such registration statement or of any order preventing or suspending the use of any preliminary prospectus and, if any such order is issued, to obtain the lifting thereof at the earliest reasonable time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <I>Furnish Information</I>. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
<U>Section&nbsp;11</U> with respect to the registration of any of the Holder&#146;s Warrant Shares that the Holder shall take such actions and furnish to the Company such information regarding itself, the Warrant Shares held by it, and the intended
method of disposition of such securities, as the Company shall reasonably request and as shall be required in connection with any registration, qualification or compliance referred to in this agreement, including, without limitation (i)&nbsp;in
connection with an underwritten offering, enter into an appropriate underwriting agreement containing terms and provisions then customary in agreements of that nature, (ii)&nbsp;enter into such custody agreements, powers of attorney and related
documents at such time and on such terms and conditions as may then be customarily required in connection with such offering and (iii)&nbsp;distribute the Warrant Shares only in accordance with and in the manner of the distribution contemplated by
the applicable registration statement and prospectus. In addition, the Holder shall promptly notify the Company of any request by the Commission or any state securities commission or agency for additional information or for such registration
statement or prospectus to be amended or supplemented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <I>Registration Expenses. </I>All expenses (excluding
underwriters&#146; discounts and commissions) incurred in connection with any registration pursuant to this <U>Section&nbsp;11</U> including, without limitation, any additional registration and qualification fees and any additional fees and
disbursements of counsel to the Company that result from the inclusion of securities held by the Holder in such registration, shall be borne by the Company whether or not the registration statement to which such registration expenses relate becomes
effective. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <I>Underwriting Requirements</I>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) In connection with any offering under this <U>Section&nbsp;11</U> involving an underwriting of shares being issued by the Company, the Company shall not be required to include any Warrant Shares in
such underwriting unless the Holder accepts the terms of the underwriting as agreed upon between the Company and the underwriters selected by it, and then only in such quantity as will not, in the sole discretion of the underwriters, jeopardize the
success of the offering by the Company. If the total amount of securities that the Holder requests to be included in an underwritten offering under this <U>Section&nbsp;11</U> exceeds the amount of securities that the underwriters reasonably believe
compatible with the success of the offering, the Company may exclude some or all of the Warrant Shares from such registration and underwriting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) With respect to any underwritings of shares to be registered under this <U>Section&nbsp;11</U>, the Company shall have the right to designate the managing underwriter or underwriters. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <I>Delay of Registration</I>. The Holder shall not have any right to take any action to
restrain, enjoin, or otherwise delay any registration as the result of any controversy that might arise with respect to the interpretation or implementation of this <U>Section&nbsp;11</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <I>Indemnification</I>. In the event any Warrant Shares are included in a registration statement under this <U>Section&nbsp;11</U>:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) To the extent permitted by law, in connection with any registration statement in which Warrant Shares are included, the
Company will indemnify and hold harmless the Holder and its officers, directors and stockholders, legal counsel and accountants for the Holder, any underwriter (as defined in the Securities Act) for the Holder and each person, if any, who controls
the Holder or underwriter within the meaning of the Securities Act or the 1934 Act, against any losses, claims, damages or liabilities, joint or several, to which they may become subject under the Securities Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or are based on (i)&nbsp;any untrue or alleged untrue statement of any material fact contained in such registration statement, including, without limitation, any prospectus
or final prospectus contained therein or any amendments or supplements thereto, (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading or
(iii)&nbsp;any violation by the Company of any rule or regulation promulgated under the Securities Act applicable to the Company and relating to action or inaction required of the Company in connection with any such registration; and will promptly
reimburse the Holder, and any underwriter, controlling person or other aforementioned person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or
action, provided, however, that the indemnity agreement contained in this <U>Section&nbsp;11g(i)</U> shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld or delayed) nor shall the Company be liable to the Holder, or any underwriter, controlling person or other aforementioned person in any such case for any such loss, claim,
damage, liability or action to the extent that it (i)&nbsp;arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in connection with such registration statement, preliminary prospectus,
final prospectus, or amendments or supplements thereto, in reliance upon and in conformity with written information furnished to the Company expressly for use in connection with such registration by or on behalf of the Holder, or any underwriter,
controlling person or other aforementioned person, (ii)&nbsp;is caused by the failure of the Holder to deliver a copy of the final prospectus relating to such Warrant Shares, as then amended or supplemented, in connection with a purchase, if the
Company had previously furnished copies thereof to the Holder or (iii)&nbsp;is caused by the Holder&#146;s disposition of Warrant Shares during any period during which the Holder is obligated to discontinue any disposition of Warrant Shares under
<U>Section&nbsp;11(j)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) To the extent permitted by law, the Holder will indemnify and hold harmless the Company,
each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, and any underwriter (within the meaning of the Securities Act) for the
Company against any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
losses, claims, damages or liabilities to which the Company or any such director, officer, controlling person or underwriter may become subject, under the Securities Act or otherwise, insofar as
such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon (i)&nbsp;any untrue statement or alleged untrue statement of any material fact contained in such registration statement, including any
prospectus or final prospectus contained therein or any amendments or supplements thereto or (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information relating to and furnished to
the Company by the Holder expressly for use in connection with such registration; and will promptly reimburse the Company or any such director, officer, controlling person or underwriter for any legal or other expenses reasonably incurred by them in
connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this <U>Section&nbsp;11(g)(ii)</U> shall not apply to amounts paid in settlement of any such
loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld or delayed) and provided further that the Holder shall not have any liability under this
<U>Section&nbsp;11(g)(ii)</U> in excess of the net proceeds actually received by the Holder in the relevant public offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Promptly after receipt by an indemnified party under this <U>Section&nbsp;11(g)</U> of notice of the commencement of any action,
such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this <U>Section&nbsp;11(g)</U>, notify the indemnifying party in writing of the commencement thereof and the indemnifying party shall have
the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties. The failure to notify an
indemnifying party promptly of the commencement of any such action, if prejudicial to his ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this <U>Section&nbsp;11(g)</U>, but the
omission so to notify the indemnifying party will not relieve him of any liability that he may have to any indemnified party otherwise than under this <U>Section&nbsp;11(g)</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) If the indemnification provided for in this <U>Section&nbsp;11(g)</U> is required by its terms but is for any reason held to be
unavailable to or otherwise insufficient to hold harmless an indemnified party under <U>Section&nbsp;11(g)(i)</U> or <U>Section&nbsp;11(g)(ii)</U> in respect of any losses, claims, damages, liabilities or expenses referred to herein, then each
applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred to herein in such proportion as is appropriate to reflect the
relative fault of the Company and the Holder in connection with the statements or omissions described in such <U>Section&nbsp;11(g)(i)</U> or <U>Section&nbsp;11(g)(ii)</U> which resulted in such losses, claims, damages, liabilities or expenses, as
well as any other relevant equitable considerations. The relative fault of the Company and the Holder shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the Company or the Holder and the parties&#146; relative intent, knowledge, access to information and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be
deemed to include, subject to the limitations set forth in this <U>Section&nbsp;11(g)</U>, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set
forth in <U>Section&nbsp;11(g)(iii)</U> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this <U>Section&nbsp;11(g)(iv)</U>; provided, however, that no additional notice shall be
required with respect to any action for which notice has been given under <U>Section&nbsp;11(g)(iii)</U> for purposes of indemnification. The Company and the Holder agree that it would not be just and equitable if contribution pursuant to this
<U>Section&nbsp;11(g)</U> were determined solely by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this
<U>Section&nbsp;11(g)(iv)</U>, the Holder shall not be required to contribute an amount in excess of the net proceeds actually received by the Holder in the relevant public offering. No person guilty of fraudulent misrepresentation (within the
meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(h) <I>Payment of Expenses</I>. The Company shall pay all reasonable expenses of the Holder (including the reasonable expenses of legal counsel for such Holder) incurred in connection with each
registration of Warrant Shares requested pursuant to this <U>Section&nbsp;11</U>, other than underwriting discount and commission, if any, and applicable transfer taxes, if any. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <I>No Transfer of Registration Rights</I>. The registration rights and obligations of the Holder under this Exhibit with respect to
any Warrant Shares may not be transferred to any third party other than any acquirer of all or substantially all of the assets or outstanding shares of stock of the Holder or any entity that merges with or into the Holder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) <I>Future Events</I>. If the Holder is at the time participating in a registration of Warrant Shares requested pursuant to this
<U>Section&nbsp;11</U>, the Company will notify the Holder of the occurrence of any of the following events of which the Company is actually aware, and when so notified, the Holder will immediately discontinue any disposition of Warrant Shares until
notified by the Company that such event is no longer applicable: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) the issuance by the Commission or any state securities
commission or agency of any stop order suspending the effectiveness of the registration statement or the initiation of any proceedings for that purpose (in which case the Company will make reasonable efforts to obtain the withdrawal of any such
order or the cessation of any such proceedings); or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) the existence of any fact which makes untrue any material statement
made in the registration statement or prospectus or any document incorporated therein by reference or which requires the making of any changes in the registration statement or prospectus or any document incorporated therein by reference in order to
make the statements therein not misleading (in which case the Company will make reasonable efforts to amend the applicable document to correct the deficiency). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) <I>Termination of Rights. </I>The rights of the Holder pursuant to this Section&nbsp;11
shall terminate and be of no further force and effect on the earlier of (i)&nbsp;the date that all Warrant Shares have been sold by the Holder or (ii)&nbsp;the date that all Warrant Shares may be sold in any three month period pursuant to Rule
144(b) promulgated under the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <U>Fractional Shares</U>. The Company shall not be
required to issue or cause to be issued fractional Warrant Shares on the exercise of this Warrant. If any fraction of a Warrant Share would, except for the provisions of this Section&nbsp;12, be issuable upon exercise of this Warrant, the Company
shall make a cash payment to the Holder equal to (a)&nbsp;such fraction multiplied by (b)&nbsp;the Market Price on the Exercise Date of one full Warrant Share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13. Remedies. The Company stipulates that the remedies at law of the Holder of this Warrant in the event of any default or threatened default by the Company in the performance of or compliance with any of
the terms of this Warrant are not and will not be adequate, and that such terms may be specifically enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of the terms
hereof or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. Notices. Any and all notices or other communications or deliveries hereunder (including without
limitation any Exercise Notice) shall be in writing and shall be mailed by certified mail, return receipt requested, or by a nationally recognized courier service or delivered (in person or by facsimile), against receipt to the party to whom such
notice or other communication is to be given. Any notice or other communication given by means permitted by this Section&nbsp;14 shall be deemed given at the time of receipt thereof. The address for such notices or communications shall be as set
forth below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Company:</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">310 N. State Street, Suite 208</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake Oswego, Oregon 97034</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 855-883-7422</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Holder:</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legend Securities, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Salvatore C. Caruso</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 Broadway 32</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> Floor</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10006</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone: 212-344-5747 ext 231</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 212-898-1224</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Or such other address as is provided to such other party in accordance with this <U>Section&nbsp;14</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon a
prompt written notice to the Holder, the Company may appoint a new warrant agent. Any Person into which any new warrant agent may be merged, any Person resulting from any consolidation to which any new warrant agent shall be a party or any Person to
which any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause
notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16. Miscellaneous. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) This Warrant may not be assigned by the Holder except to
a Permitted Transferee. This Warrant may not be assigned by the Company, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective permitted
successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This
Warrant may be amended only in writing signed by the Company and the Holder and their permitted successors and assigns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
The Company will not, by amendment of its governing documents or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder
against impairment. Without limiting the generality of the foregoing, the Company (i)&nbsp;will not increase the par value of any Warrant Shares above the amount payable therefor upon exercise thereof, and (ii)&nbsp;will take all such action as may
be reasonably necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares on the exercise of this Warrant, free from all taxes, liens, claims and encumbrances and (iii)&nbsp;will not
close its shareholder books or records in any manner which interferes with the timely exercise of this Warrant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) This
Warrant shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and Federal courts sitting in the City of
Boston, Massachusetts, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding
that it is not personally subject to the jurisdiction of any such court or that such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall
constitute </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. THE PARTIES
HEREBY WAIVE ALL RIGHTS TO A TRIAL BY JURY. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Neither party shall be deemed in default of any provision of this Warrant, to
the extent that performance of its obligations or attempts to cure a breach hereof are delayed or prevented by any event reasonably beyond the control of such party, including, without limitation, war, hostilities, acts of terrorism, revolution,
riot, civil commotion, national emergency, strike, lockout, unavailability of supplies, epidemic, fire, flood, earthquake, force of nature, explosion, embargo, or any other Act of God, or any law, proclamation, regulation, ordinance, or other act or
order of any court, government or governmental agency, <I>provided</I> that such party gives the other party written notice thereof promptly upon discovery thereof and uses reasonable efforts to cure or mitigate the delay or failure to perform.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) In case any one or more of the provisions of this Warrant shall be deemed invalid
or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and
enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURE PAGE FOLLOWS] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized officer as of the date first indicated above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mark J. Ahn, President and Chief Executive Officer</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acknowledged and Agreed:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Salvatore C. Caruso</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Salvatore C. Caruso, Legend Securities, Inc.</B></FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>APPENDIX A </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">FORM OF ASSIGNMENT </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(to be completed and signed only upon transfer of Warrant)
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto
<U></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the right represented by the within Warrant to purchase <U></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
Common Stock of Galena Biopharma, Inc. to which the within warrant relates and appoints &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;attorney to
transfer said right on the books of Galena Biopharma, Inc. with full power of substitution in the premises. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated:<U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Signature must conform in all respects to name of Holder as specified on face of the Warrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Address of Transferee:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legend Securities, Inc.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Salvatore C. Caruso</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 Broadway, 32</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, NY 10006</FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the presence of:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>APPENDIX B </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NOTICE OF EXERCISE </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">TO: GALENA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) The undersigned hereby elects to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant Shares of
the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) Payment shall take the form of (check applicable box): </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> in lawful money of the United States; or </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> [if permitted] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(3) Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">[SIGNATURE OF HOLDER] </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Name of Investing Entity:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Signature of Authorized Signatory of Investing Entity:</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Name of Authorized Signatory:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Title of Authorized Signatory:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d275067dex102.htm
<DESCRIPTION>FIRST AMENDMENT TO CONTIGENT VALUE RIGHTS AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>First Amendment to Contigent Value Rights Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">FIRST AMENDMENT TO CONTINGENT VALUE RIGHTS AGREEMENT </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS FIRST
AMENDMENT TO CONTINGENT VALUE RIGHTS AGREEMENT (this &#147;<U>Amendment</U>&#148;) is made and entered into as of February&nbsp;15, 2012 by and among the undersigned Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation and herein
&#147;<U>Parent</U>&#148;), Computershare Trust Company, N.A., a national banking association, Computershare Inc., a Delaware corporation, and Robert E. Kennedy, an individual, as the Stockholder Representative (collectively the
&#147;<U>Parties</U>&#148;), in order to amend in certain respects the Contingent Value Rights Agreement dated as of April 13, 2011 among the Parties (the &#147;<U>Original Agreement</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration, the Parties
agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Certain Definitions</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.1 References in the Original Agreement to this &#147;Agreement&#148; shall mean the Original Agreement, as amended by this Amendment. Unless otherwise defined in this Amendment, capitalized terms used
herein shall have the meanings ascribed to them in the Original Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2 When used in this Amendment, the following
capitalized terms shall have the meanings indicated: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Future Milestone Shares</U>&#148; means any and all
&#147;restricted&#148; shares of Parent Common Stock that Parent, in its discretion in accordance with the provisions of the Original Agreement, elects to issue in payment of any of Milestone&nbsp;#2, Milestone&nbsp;#3, Milestone&nbsp;#4 and
Milestone&nbsp;#5. The term &#147;<U>restricted</U>&#148; shares for this purpose and for the purposes of the definition of &#147;Milestone Shares&#148; has the meaning set forth in Rule&nbsp;144 under the Securities Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Milestone Shares</U>&#148; means 1,315,789 &#147;restricted&#148; shares of Parent Common Stock, subject to increase as
provided in Section&nbsp;2.4 of this Amendment; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Payment Date</U>&#148; means February&nbsp;10, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Milestone Payments</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.1 Parent hereby acknowledges that Milestone&nbsp;#1 was achieved on January&nbsp;19, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.2 Notwithstanding any other provision of the Original Agreement, the Parties agree that Milestone&nbsp;#1 shall be payable by Parent&#146;s issuance of the Milestone Shares as
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
provided herein. On or before the Payment Date, Parent shall cause Computershare to issue in the name of each Holder, as reflected in the CVR Register as of the close of business on the last
Business Day prior to the Payment Date, a stock certificate evidencing the number of Milestone Shares to which such holder shall be entitled under the Original Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.3 On the Payment Date, all of the certificates evidencing the Milestone Shares shall be deposited by Parent with the Escrow Agent under the Escrow Agreement, dated as of April&nbsp;13, 2011, among
Parent, the Stockholder Representative, and Computershare Trust Company, N.A., as Escrow Agent (the &#147;<U>Escrow Agent</U>&#148;). The certificates evidencing Milestone Shares shall be released to the Holders from the escrow under the Escrow
Agreement (the &#147;<U>Escrow</U>&#148;) within three (3)&nbsp;Business Days following stockholder approval of the Stockholder Proposal, as contemplated in Section&nbsp;3, below (&#147;<U>Stockholder Approval</U>&#148;). The Milestone Shares shall
be subject to cancellation in the events described in Section&nbsp;3, below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4 The Parties agree that, if Stockholder
Approval is obtained, the number of Milestone Shares shall be subject to increase to the extent that $0.76 (<I>i.e.</I>, the closing price of Parent Common Stock as reported on The NASDAQ Capital Market on January&nbsp;18, 2012, the day prior to
achievement of Milestone&nbsp;#1, used for purposes of determining the number of Milestone Shares in accordance with the Original Agreement) is greater than the closing price of Parent Common Stock as of the most recent trading day prior to the
receipt of Stockholder Approval. In such event, the actual number of Milestone Shares issuable in payment of Milestone #1 shall equal the quotient determined by dividing $1&nbsp;million (<I>i.e.,</I> the amount of Milestone&nbsp;#1) by the lesser of
(1)&nbsp;$0.76 and (2)&nbsp;the closing price of Parent Common Stock as reported on The NASDAQ Capital Market or other principal trading market for Parent Common Stock on the most recent trading day prior to the receipt of Stockholder Approval.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Stockholder Proposal</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.1 Parent shall undertake to seek approval by Parent stockholders of the issuance of the Milestone Shares in payment of Milestone&nbsp;#1 and the issuance of Future Milestone Shares and any related
enabling matters (collectively, the &#147;<U>Stockholder Proposal</U>&#148;) at the 2012 Annual Meeting of Parent stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 If Parent stockholders fail to approve of the Stockholder Proposal, or if Stockholder Approval is not otherwise obtained for any
reason on or before July&nbsp;15, 2012, the Milestone Shares shall be cancelled automatically. In either such event, Parent shall pay Milestone&nbsp;#1, plus interest thereon as provided in Section&nbsp;4, below, in cash to the Holders within three
Business Days after the earlier of the 2012 Annual Meeting of Parent stockholders and July&nbsp;15, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Interest
Factor</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 Whether or not Stockholder Approval is obtained, in addition to the release from Escrow of the Milestone
Shares or the payment in cash of Milestone #1 to the Holders, as the case may be, Parent shall pay concurrently to the Holders in cash an interest </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
factor of ten percent (10%)&nbsp;per annum on the amount of Milestone&nbsp;#1 from the Payment Date through the day immediately prior to the release of the Milestone Shares from Escrow or the
cash payment, as the case may be, less the amount of legal fees incurred by the Stockholder Representative in connection with the negotiation, preparation and implementation of this Amendment, if any, in excess of the $10,000 to be paid or
reimbursed by Parent as provided in Section&nbsp;8, below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>Resale Registration Filings</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1 If Stockholder Approval is obtained, Parent shall, at its own expense (excluding any underwriting commissions and discounts or other
brokerage fees incurred in connection with the resale by the Holders of the Milestone Shares), prepare and file with the Securities and Exchange Commission (&#147;<U>SEC</U>&#148;) within ten (10)&nbsp;Business Days following such approval a
registration statement on Form&nbsp;S-3 or other appropriate form that Parent is then eligible to use under the Securities Act for the purposes of registering the Milestone Shares and a reasonable estimate of the Future Milestone Shares associated
with the achievement of Milestone #2 for resale by the Holders (the &#147;<U>Resale Registration Statement</U>&#148;). Unless Parent has a resale registration statement in effect that covers such Future Milestone Shares, Parent also shall prepare
and file with the SEC within ten (10)&nbsp;days following the achievement of each Milestone to be paid in Future Milestone Shares a registration statement on Form&nbsp;S-3 or other appropriate form that Parent is then eligible to use under the
Securities Act for the purpose of registering the Future Milestone Shares for resale by the Holders (collectively, &#147;<U>Future Resale Registration Statements</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.2 Parent shall use commercially reasonable efforts to have the Resale Registration Statement and any Future Resale Registration Statements declared effective by the SEC. Parent shall respond to any SEC
comments within five (5)&nbsp;Business Days after receipt of such comments until the Resale Registration Statement, or any such Future Resale Registration Statements, as the case may be, is declared effective by the SEC. Parent shall maintain the
effectiveness of the Resale Registration Statement and any Future Resale Registration Statements for a period ending on the earlier of: (i)&nbsp;the date on which the Milestone Shares or Future Milestone Shares covered thereby may be sold without
any volume restrictions under Rule&nbsp;144 under the Securities Act; or (ii)&nbsp;the date on which all Milestone Shares or Future Milestone Shares covered by such Registration Statement have been sold. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 If (i)&nbsp;the Resale Registration Statement or any Future Resale Registration Statements has not been declared effective on or
before the ninetieth (90th)&nbsp;day following the filing thereof with the SEC, or (ii)&nbsp;if counsel has not provided to the transfer agent for Parent Common Stock (the &#147;<U>Transfer Agent</U>&#148;) a &#147;blanket&#148; legal opinion
allowing for removal of the restrictive legend on the corresponding Milestone Shares or the Future Milestone Shares as contemplated in Section&nbsp;6, below (the &#147;<U>Cutoff Date</U>&#148;), Parent shall pay the Holders in the aggregate one
thousand dollars ($1,000) per day for each day following the Cutoff Date that the Resale Registration Statement or any Future Resale Registration Statements, as the case may be, shall not have been declared effective; provided, that the $1,000 per
day penalty shall cease to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
accrue upon the delivery to the Transfer Agent of a legend removal opinion of the type described in Section&nbsp;6, below, sufficient to allow for removal of the restrictive legend from the
applicable Milestone Shares or Future Milestone Shares, as the case may be, covered by such registration statement. The aggregate accrued penalties shall be deposited by Parent with the Escrow Agent on or before the fifth Business Day following the
end of each month and promptly released by the Escrow Agent to the Holders on a pro rata basis in accordance with each Holder&#146;s ownership of Escrow Shares (as defined in the Escrow Agreement). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>Legal Opinions</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.1 Concurrently with the execution and delivery of this Amendment, Parent shall cause its legal counsel to render a &#147;blanket&#148; legal opinion to the Transfer Agent to permit the Holders to have
reissued in the Holders&#146; name, or in street-name, the certificates evidencing the shares of Parent Common Stock currently held by the Holders, including those shares currently held in the Escrow, as and when released from the Escrow, without a
restrictive legend under the Securities Act, subject to obtaining appropriate representations and acknowledgements from the Holders regarding the manner of resale of such shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 Within ten (10)&nbsp;days following (i)&nbsp;the effectiveness of the Resale Registration Statement, (ii)&nbsp;the effectiveness of
any Future Resale Registration Statements and (iii)&nbsp;if the SEC fails to declare a registration statement effective, the sixth (6th)&nbsp;month anniversary of the issuance of the applicable Milestone Shares and Future Milestone Shares, Parent
shall use commercially reasonable efforts to cause its legal counsel to render a &#147;blanket&#148; legal opinion to the Transfer Agent to permit the Holders to have reissued in the Holders&#146; name, or in street-name, the certificates evidencing
the shares of Parent Common Stock then held by the Holders, without a restrictive legend under the Securities Act, subject to obtaining appropriate representations and acknowledgements from the Holders regarding the manner of resale of such shares
in the event a registration statement is not effective. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>Representation</U>. The Stockholder Representative acknowledges
and agrees that the Milestone Shares, as well as any Future Milestone Shares, are or shall be &#147;restricted&#148; shares and, when issued, shall bear an appropriate restrictive legend to such effect. The Milestone Shares and any Future Milestone
Shares shall not be resold publicly by the Holders, except pursuant to an effective registration statement under the Securities Act or in reliance upon the opinion of Parent&#146;s legal counsel to be given pursuant to Section&nbsp;6.2, above,
indicating that such registration is not required. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <U>Legal Fees and Expenses</U>. Parent and the Stockholder
Representative shall bear their own legal fees and other expenses in connection with this Amendment and the consummation of the transactions contemplated hereby, except that Parent shall (i)&nbsp;pay or reimburse the Stockholder Representative for
up to $2,500 of documented legal fees reasonably incurred by him in connection with the negotiation of the Term Sheet, dated January&nbsp;25, 2012, between Parent and the Stockholder Representative (the &#147;<U>Term Sheet</U>&#148;) and up to
$10,000 in the aggregate in connection with the negotiation of the Term Sheet, this Amendment and the consummation of the transactions contemplated hereby, and (ii)&nbsp;shall also pay to or reimburse
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Stockholder Representative the amount of documented legal fees, if any, in excess of $10,000 reasonably incurred by him in these connections. The Parties acknowledge and agree that the amount
referred to in clause (ii), above, if any, shall be deducted from the Interest Factor otherwise payable by Parent to the Holders as provided in Section&nbsp;4, above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9. <U>Miscellaneous</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1 Except as specifically set forth in this Amendment,
the Original Agreement shall remain unchanged and in full force and effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 This Amendment, including the exhibits and
schedules hereto, embodies the entire agreement and understanding of the Parties hereto in respect of the subject matter contained herein and supersedes all prior agreements and the understanding between the Parties with respect to such subject
matter, including, without limitation, the Term Sheet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 This Amendment may be executed in two or more counterparts, each
of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument. A signature to this Amendment transmitted electronically shall have the same authority, effect, and enforceability as an original
signature. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signature page follows] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF<B>, </B>the Parties have caused this Amendment to be executed by their
duly authorized representatives. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rights Agent:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computershare Trust Company, N.A.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Rose Stroud</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rose Stroud</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trust Officer</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computershare Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Rose Stroud</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rose Stroud</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trust Officer</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholder Representative:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Robert E. Kennedy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert E. Kennedy</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page of First Amendment to Contingent Value Rights Agreement] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>4
<FILENAME>d275067dex1037.htm
<DESCRIPTION>SECOND OMNIBUS AMENDMENT TO SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Second Omnibus Amendment to Securities Purchase Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.37 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">SECOND OMNIBUS AMENDMENT </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This SECOND OMNIBUS AMENDMENT (this &#147;<U>Second
Amendment</U>&#148;) is made and entered into as of March&nbsp;5, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September&nbsp;24, 2011 (the
&#147;<U>Securities Purchase Agreement</U>&#148;) and the Ancillary Agreements related thereto, including the Bridge Notes; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into an Omnibus Amendment dated as of February&nbsp;6, 2012 (the &#147;<U>First Amendment</U>&#148;),
amending certain provisions of the Securities Purchase Agreement and the Bridge Notes; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Securities Purchase
Agreement, as amended by the First Amendment, in Section&nbsp;8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on
March&nbsp;5, 2012, which date may be extended from time to time by mutual written consent of the Company and the Investors; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Bridge Notes dated September&nbsp;24, 2011 held by the Investors, as amended by the First Amendment, in Section&nbsp;1.1
thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i)&nbsp;March&nbsp;5, 2012 or (ii)&nbsp;an Event of Default (as defined in the Bridge Notes); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the Bridge Notes, in each case, as amended
by the First Amendment, to extend the March&nbsp;5, 2012 date; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual
covenants herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1. <U>Securities Purchase Agreement Amendment</U>. The Securities Purchase Agreement, as previously amended by the First Amendment, is hereby further amended as follows: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Section&nbsp;8.01(c) is hereby further amended to replace &#147;March 5, 2012&#148; with &#147;March 31, 2012&#148;;
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Section&nbsp;5.11 is hereby amended to add the following new sentence at the end thereof:
&#147;Notwithstanding any other provision of this Agreement, the failure of Anastasia Khvorova to be employed by the Company, by itself of in combination with one or more other events, shall not be deemed to have resulted or to be reasonably
expected to result in a Material Adverse Effect.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The following new sections are hereby added to ARTICLE V: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.14 <U>Trading Market; Ticker Symbol</U>. The Company shall have obtained the approval of the Financial
Industry Regulatory Authority to list the Company Common Stock for trading in a Trading Market and the Company shall have obtained the use of the trading symbol RXII or a derivative thereof (<I>e.g.</I>, RXII.OB or RXII.PK). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.15 <U>Absence of Certain Developments</U>. The Company shall have received confirmation, in a form
satisfactory to the Investors in their sole discretion, that the Advirna Agreement remains in full force and effect and that the Company&#146;s rights arising thereunder remain intact as of the date of such confirmation. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The following new section is hereby added to ARTICLE IV: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.21 <U>Annual Report on Form 10-K</U>. By no later than March&nbsp;30, 2012, the Company shall prepare and
file, if required, an annual report on Form 10-K for the year ended December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Bridge Notes Amendment</U>.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Bridge Notes, as amended by the First Amendment, are hereby further amended to replace: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) references of &#147;March 5, 2012&#148; with &#147;March 31, 2012&#148;; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) references of &#147;RNCS, Inc.&#148; with &#147;RXi Pharmaceuticals Corporation&#148;; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) references of &#147;RXi Pharmaceuticals Corporation&#148; (but only those references contained in the Bridge Notes
prior to giving effect to the change set forth above in Section&nbsp;2(a)(ii)) with &#147;Galena BioPharma, Inc.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.
<U>Miscellaneous</U>. Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, as applicable, in each case as amended by the First Amendment. The terms and
conditions set forth in Article X of the Securities Purchase Agreement are incorporated herein by reference. Nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to
Section&nbsp;10.03 of the Securities Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page Follows] </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Second Amendment as of the date
first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi PHARMACEUTICALS CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TANG CAPITAL PARTNERS, LP</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin C. Tang</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kevin C. Tang</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managing Director</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RTW INVESTMENTS, LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Roderick Wong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roderick Wong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managing Member</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page to Second Omnibus Amendment] </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>5
<FILENAME>d275067dex1043.htm
<DESCRIPTION>LEASE BETWEEN GALENA BIOPHARMA, INC. AND LO 138, LLC
<TEXT>
<HTML><HEAD>
<TITLE>Lease between Galena Biopharma, Inc. and LO 138, LLC</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.43 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>RXi PHARMACEUTICALS CORP.</U> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,136 rentable sq. ft. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#147;LAKE VIEW VILLAGE&#148; </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>COMMERCIAL OFFICE LEASE </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LEASE, dated as of the 30th day of
June, 2011, between LO 138 LLC, an Oregon limited liability company as &#147;Landlord&#148; and RXi PHARMACEUTICALS CORPORATION, a Delaware corporation, as &#147;Tenant&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1 <B><U>PREMISES</U></B>. Landlord hereby leases to Tenant and Tenant hereby leases from Landlord approximately 2,136 rentable Square feet of space shown on the floor plan attached hereto as
Exhibit A-1 (&#147;the &#147;Premises&#148;) on the second floor of the building as shown crosshatched on the site plan attached as Exhibit A-2 (the &#147;Building&#148;) in the development known as Lakeview Village constructed or to be constructed
by Landlord on the real property described in attached Exhibit A-3 (the &#147;Project&#148;). Tenant&#146;s lease of the Premises shall include the appurtenant right to use in common with others all common areas within the Project as Landlord may
from time to time designate. Tenant&#146;s lease of the Premises shall also include the nonexclusive right to use in common with others the City of Lake Oswego public parking garage constructed or to be constructed as shown on the site plan attached
as Exhibit A-2 (the &#147;Garage&#148;). Such use shall be in accordance with the LORA Parking Facility Use, Maintenance and Operation Agreement between the Lake Oswego Redevelopment Agency and Gramor Development, Inc. (the &#147;Parking
Agreement&#148;). Landlord reserves the right to alter or relocate any common area. The Lease is subject to all easements, restrictions, agreements of record, mortgages and deeds of trust, and zoning and building laws. This Lease is subject to that
certain Agreement for the Disposition and Development of Block 138, City of Lake Oswego (&#147;DDA&#148;) dated April&nbsp;17, 2001 between The Lake Oswego Redevelopment Agency (&#147;LORA&#148;) and Gramor Development, Inc. and any amendments
thereto </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2 <B><U>TERM</U></B>. The lease term shall commence on the Date of Commencement described below and continue for
twenty-four (24)&nbsp;full calendar months (plus the partial month, if any, in which the lease commences), unless sooner terminated. &#147;Date of Commencement&#148; shall be August&nbsp;1, 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3 <B><U>RENT</U></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Minimum Rent</U>. Tenant shall pay to Landlord, during the term of this Lease as minimum monthly rent the sum of Three Thousand Two Hundred Four and no/100 Dollars ($3,204.00) per month. Tenant
shall not be required to pay minimum rent during Month 1 of the Lease term. Tenant shall be required to pay additional rent, pursuant to Section 3.2 from the Date of Commencement. Rent will be paid in advance on the first day of each month at such
place as Landlord may designate. Minimum rent is uniformly apportionable day to day. Minimum rent for the partial month (if any) in which the lease term commences shall be prorated and paid at commencement of the lease term. Upon execution hereof,
Tenant shall pay to Landlord the sum of Three Thousand Two Hundred Four and no/100 Dollars ($3,204.00) to be applied to minimum and additional rent as it becomes due. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Additional Rent</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) <U>Operating Expenses</U>. In addition to the minimum rent, Tenant shall pay as additional rent its share of all expenses for the
Project. As used herein &#147;operating expenses&#148; shall mean all costs of ownership, operation, maintenance and repair of the Project as determined by standard real estate accounting practice, including but not limited to: wages, salaries and
benefits of employees engaged in the operation, maintenance and repair of the Project; costs incurred by the Landlord under the Parking Agreement; the cost of all utilities for the Project including water, sewer, lighting, power, heating, air
conditioning and ventilating (excluding utilities separately metered and servicing tenant spaces exclusively); the cost of janitorial service and supplies, waste disposal service, window washing and her services furnished for the benefit of tenants
of the Project; costs of consumable supplies including without limitation cleaning supplies, restroom paper products, light bulbs, tubes and ballasts; costs of Project maintenance and service agreements; the cost of security, repair and replacement;
cost of materials, tools and equipment used in the operation, management and maintenance of the Project; common area utility costs including city or county road maintenance fees; the cost of all insurance relating to the Project, including but not
limited to the cost of casualty, rental abatement, boiler and machinery, earthquake, flood and liability insurance (and all deductibles); all accounting, legal and professional fees incurred in connection with the operation of the Project; the cost
of rental value of the Project office; and a management fee of four percent (4%)&nbsp;of the minimum rent </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) <U>Taxes and
Assessments</U>. In addition to the minimum rent, Tenant shall pay as additional rent its share of all real property taxes and assessments of any public authority against the Project payable during or with respect to the Lease term, including
without limitation, Landlord&#146;s cost incurred under the Parking Agreement and the cost of contesting any tax. Real property taxes and assessments shall include all real property taxes and assessments of any public authority assessed against the
Project and any rent tax, gross receipts tax, tax on Landlord&#146;s interest under this Lease, or any tax in lieu of the foregoing, whether or not such tax is now in effect (excluding any tax based upon Landlord&#146;s net income). If any portion
of the Project is occupied by a tax exempt tenant so that the Project has a partial tax exemption under ORS 307.112 or a similar statute, the real property taxes and assessments shall mean real property taxes and assessments computed as if such
partial exemption did not exist. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3) <U>Tenant&#146;s Share</U>. Tenant&#146;s share of the operating expenses, taxes and
assessments of the Project shall be a percentage thereof equal to the percentage which the rentable square feet of the Premises bears to the total rentable square feet of the Project. Tenant&#146;s share shall be based on the total rentable area of
the Project whether such area is occupied or not and shall not be adjusted to reflect vacancy in the Project, Notwithstanding the foregoing, Landlord shall be permitted to adjust Tenant&#146;s percentage share of any item of operating expense to
allocate such operating expense among tenants in the Project in an equitable manner based upon the usage of and benefits afforded to such tenants, respectively. Landlord shall also be permitted to adjust Tenant&#146;s share of any portion of any
real property taxes and assessments in the event a tenant within the Shopping Center is billed directly or separately assessed for such portion of real property taxes and assessments by the taxing authority. In such
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
event, Landlord shall be permitted to exclude such tenant&#146;s area from the total net rentable area of the Shopping Center for the purposes of determining Tenant&#146;s share of such portion
of real property taxes and assessments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4) <U>Payment</U>. Upon commencement of the Lease term and at the beginning of each
calendar year during the term of the Lease, Landlord may reasonably estimate Tenant&#146;s share of operating expenses and taxes and assessments for the ensuing calendar year or portion thereof, Landlord may revise the estimate during the course of
any year. Tenant will pay one-twelfth of Tenant&#146;s estimated share of operating expenses and taxes and assessments on the first day of each calendar month during the term hereof. If Landlord bills on an estimated basis, Landlord shall, within
120-days (or as soon thereafter as possible) after the end of any calendar year give Tenant written notice of Tenant&#146;s actual share of operating expenses and taxes and assessments. If Tenant&#146;s payments of its estimated share for such
calendar year differ from Tenant&#146;s actual share, an appropriate adjustment shall be made within 30-days after the giving of such notice. Any objections by Tenant to the annual statement shall be made in writing within thirty days after receipt
thereof. Otherwise, the annual statement shall be deemed conclusive and binding on the parties. If Landlord bills on an actual basis Tenant will pay Tenant&#146;s actual share of operating expenses and taxes and assessments on the first day of the
first calendar month after such bill. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5) <U>Parking Facility Agreement. This Lease is subject to the Parking Agreement</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6) <U>Reciprocal Easement</U>. Landlord reserves the right to subject the Project to reciprocal easements, covenants and
restrictions to which this Lease shall automatically be subordinate. In such event, the operating expenses for the Project shall be deemed to include, without limitation, Landlord&#146;s share of such costs under the reciprocal easements, covenants
and restrictions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Interest and Late Charges</U>. All rent and other payments not paid within thirty (30)&nbsp;days
when due shall bear interest from the due date until fully paid at the rate of twelve percent (12%)&nbsp;per annum, but not in any event at a rate greater than the maximum rate of interest permitted by law. In addition, Tenant acknowledges that late
payment of any rent or other payment required by this Lease from Tenant to Landlord will result in collection costs to Landlord, the extent of which additional costs is extremely difficult and economically impractical to ascertain. Tenant therefore
agrees that if Tenant fails to make any rent or other payment required by this Lease to be paid to Landlord within ten (10)&nbsp;days when it is due, Landlord may elect to impose a late charge of five cents (50)&nbsp;per dollar of the overdue
payment, to reimburse Landlord for the costs of collecting the overdue payment. Tenant shall pay the late charge upon demand by Landlord. Tenant agrees that the late charge is a reasonable estimate of the costs to Landlord of collecting the overdue
payment. Landlord may levy and collect a late charge in addition to all other remedies available for Tenant&#146;s default, and collection of a late charge shall not waive the breach caused by the late payment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4 <U>Net Lease Provision</U>. All payments required to be paid by Tenant under this Lease, other than minimum rent, will constitute
additional rent. This is intended to be a net lease, meaning that Tenant shall pay all expenses of every type relating to the Premises after commencement of the lease term, all rent (including minimum and additional rent) shall be received by
Landlord without setoff, offset, abatement, or deduction of any kind. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4 <B><U>BUSINESS PURPOSE</U></B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>Permitted Use</U>. Tenant shall use the Premises only for the purpose of a general office use which may include biotechnological,
pharmaceutical and medical office use and for no other purpose without the Landlord&#146;s express written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2
<U>Compliance with Laws</U>. In connection with its use, Tenant shall comply at its expense with all applicable laws, regulations and requirements of any public authority, including those regarding maintenance, operation and use of the Premises and
any appliances on the Premises (including signs), </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3 <U>Insurance</U>. Tenant shall not conduct or permit any activities on
the Premises which will: increase the fire insurance rate upon the Project or cause a cancellation of the fire insurance policy; or create a nuisance or damage the reputation of the Project or be reasonably offensive to Landlord or other tenants
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4 <U>Supervision</U>. Tenant shall keep the Premises clean and orderly and will cause its employees on the Premises to be
well groomed and dressed in accordance with a first-class, professional operation of Tenant&#146;s business. Tenant will supervise its employees and cause Tenant&#146;s agents, independent contractors, employees, customers, suppliers and invitees to
conduct their activities in such a manner as to comply with the requirements of this Lease and the rules and regulations described herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.5 <U>Common Areas</U>. All common areas within the Project shall be used in strict compliance with Landlord&#146;s reasonable rules, regulations and requirements for such areas. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6 <U>Name of Business</U>. The advertised name of the business operated in the Premises shall be RXi Pharmaceuticals or any other such
name the originally-named Tenant is legally identified as. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7 <U>Parking</U>. Tenant shall comply with the Garage rules,
regulations and requirements as adopted and published by Landlord from time to time and shall cause Tenant&#146;s customers, employees and invitees to abide by such rules, regulations and requirements. Landlord reserves the right to restrict the use
of designated stalls or areas within the Garage. When requested by Landlord, Tenant shall give Landlord written notice of the license number of all vehicles parked in the Project by Tenant&#146;s officers, employees, agents and contractors. If a
vehicle of Tenant&#146;s or its officers, employees, agents or contractors is at any time parked in a part of the Project or Garage other than the designated area, Landlord shall have the right to have the vehicle towed and to collect towing and
storage charges as a condition of releasing the vehicle to its owner or to charge the owner of the vehicle a per diem fee for each vehicle so parked. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the hours of 7:00 am &#151; 5:00 pm Monday through Friday (&#147;Office Hours&#148;), Tenant shall have the exclusive right to use four (4)&nbsp;parking stalls for employee parking. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8 <U>Storage, Trash</U>. Tenant shall not store anything outside except in areas approved
by Landlord. Tenant will use only trash and garbage receptacles approved by Landlord. Tenant shall dispose of trash and other matter in a manner acceptable to Landlord, at Tenant&#146;s expense. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5 <B><U>UTILITIES AND SERVICES</U></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Building Maintenance</U>. Landlord shall maintain the public and common areas of the Project and the Building structure in good condition and repairs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Utility Service</U>. Landlord shall supply the Premises with electricity for lighting and operation of normal office equipment,
heating ventilation and cooling to a standard of comfort customary in other comparable office buildings in the area, janitorial services and such other services as Landlord may elect during the times and in the manner that such services are
customarily furnished in comparable office buildings in the area. Landlord shall not be in default hereunder or be liable for any failure or interruption of utilities or services to the Premises. Landlord shall take reasonable steps to restore
service as soon as practical subject to causes beyond Landlord&#146;s reasonable control. Gas, electricity, water and sewer used in the office portion of the Project shall be separately metered from gas, electricity, water and sewer used in the
retail portion of the Project. Tenant shall pay its proportionate share of all Project utilities including but not limited to parking area lighting, elevator electricity and landscape irrigation pursuant to Section&nbsp;3.2 hereof. Landlord shall
reasonably allocate operating expenses of the Project based on projected and actual costs associated with each. All such costs and services incurred shall be an Operating Expense pursuant to Section&nbsp;3.2 hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6 <B><U>INSURANCE; INDEMNITY</U></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Public Liability Insurance</U>. Tenant shall continuously maintain at its expense comprehensive general liability insurance, with limits of not less than $2,000,000 per person, $2,000,000 per
occurrence for injury to, illness of, or death of persons occurring in, upon or about the Premises or Project, and $200,000 per occurrence for property damage occurring in, upon or about the Project with fire legal liability endorsement with limits
no less than $200,000. All such insurance shall insure the performance by Tenant of the indemnity agreement set forth in Section&nbsp;6.5 hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>Fire Insurance of Tenant</U>. Tenant, at its expense, shall maintain in effect; fire and extended coverage insurance on furnishings, leasehold improvements, fixtures, inventory and equipment
located on the Premises, for the full replacement value. The proceeds of such insurance, so long as this Lease remains in effect, shall be used to repair or replace the leasehold improvements, fixtures, equipment and plate glass so insured.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Insurance Policies</U>. All insurance policies shall name Landlord, its managers and members and any managing agent
and other designee as additional insureds and shall be with companies and with loss-payable clauses satisfactory to Landlord and with ratings no less than A+ by A.M. Best. Copies of all policies or certificates evidencing such insurance shall be
delivered to Landlord by Tenant prior to Tenant&#146;s occupancy of the Premises. All policies shall be primary and noncontributing with any insurance which may be carried by Landlord. All policies shall bear endorsements requiring 30 days written
notice to Landlord prior to any change or cancellation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>Waiver of Subrogation</U>. Neither party shall be liable to the other for any loss or
damage caused by water damage or any of the risks covered by a standard fire insurance policy with extended coverage endorsements, and there shall be no subrogated claim by one party&#146;s insurance carrier against the other party arising out of
any such loss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5 <U>Indemnity of Landlord</U>. Tenant hereby waives all claims against Landlord for damage to any property
or injury, illness or death of any person in, upon, or about the Premises and/or Shopping Center arising at any time and from any cause whatsoever. Tenant shall defend, indemnify and hold harmless Landlord, its managers and members and any managing
agent or other designee from any and all claims or liability for any damage to any property or injury, illness, or death of any person occurring in or on the Premises or occurring elsewhere in the Shopping Center when such damage, injury, illness,
or death shall be caused in whole or in part by the act or failure to act of Tenant, its agents, servants, employees, invitees, contractors, or licensees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7 <B><U>REPAIRS, MAINTENANCE AND ALTERATIONS</U></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1
<U>Condition of Premises</U>. By entry hereunder Tenant accepts the Premises as being in the condition in which Landlord is obligated to deliver the Premises. Tenant shall, at Tenant&#146;s own expense, keep the Premises in good condition and
repair, including without limitation, the maintenance, replacement and repair of any walls, floors, ceilings, interior doors, interior windows and fixtures, interior plumbing (if any), electrical wiring and conduits. Tenant shall be responsible for
all repairs, interior and exterior, structural and non-structural, ordinary and extraordinary, in and to the Premises and the Project and the facilities and systems thereof, the need for which arises out of the performance or existence of the
Tenant&#146;s alterations, the installation, use or operation of Tenant&#146;s property in the Premises, the moving of Tenant&#146;s property in or out of the Project, or the act, omission, misuse or neglect of Tenant, its agents, employees,
contractors or invitees. Tenant shall promptly make, at Tenant&#146;s expense, all repairs in or to the Premises for which Tenant is responsible. Such work shall be performed only by contractor(s) designated or approved in writing by the Landlord.
Tenant shall, upon the termination of this Lease, surrender the Premises to Landlord, in good condition except for ordinary wear and tear and for damage covered by Landlord&#146;s fire and extended coverage insurance. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>Climate Control</U>. Landlord shall maintain and operate the heating, ventilating and air-conditioning systems serving the
Premises for occupancy of the Premises during Business Hours of Business Days, the expense of which shall be included in Operating Expense of the Project as defined in Section&nbsp;3.2 hereof. As used herein, &#147;Business Hours&#148; shall mean
generally customary daytime business hours, but not before 7:30 a.m. or after 6 p.m. on weekdays and not before 7:30 a.m. or after 1 p.m. on Saturdays. &#147;Business Days&#148; shall mean all days except Sundays and days observed by the Federal or
State government as legal holidays. Tenant shall have the right to use and control the HVAC system within the Premises during hours outside Business Hours. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3 <U>Alterations</U>. Tenant shall not make any alterations or improvements to the
Premises without the prior written consent of Landlord. Any alterations or improvements to the Premises (excluding trade fixtures installed by Tenant), shall become part of the Premises and belong to Landlord and shall be surrendered with the
Premises without disturbance upon the termination of the Lease. In the event Landlord consents to the making of any alterations or improvement, the same shall be made at Tenant&#146;s sole expense. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4 <U>Trade Fixtures</U>. Upon expiration or earlier termination of the Lease, Tenant shall remove all trade fixtures, movable furniture
and equipment located on the Premises which belong to the Tenant, and repair at its expense any damage caused to the Premises by such removal. If Tenant fails to remove such property, this shall be an abandonment of the property and Landlord may
retain the property and all rights of Tenant with respect to it shall cease or, by notice in writing given to Tenant within 20 days after removal was required, Landlord may elect to hold Tenant to its obligation of removal. If Landlord elects to
require Tenant to remove, Landlord may effect a removal and place the property in storage for Tenant&#146;s account. Tenant shall be liable to Landlord for the cost or reasonable value of removal, restoration, transportation to storage and storage,
with interest on all such as expenses as provided in paragraph 13.3 below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5 <U>Compliance With The Laws</U>. Tenant should
not use the Premises or permit anything to be done in or about the Premises which will conflict with any law or regulation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6 <U>Entry and Inspection</U>. With reasonable notice except in an emergency, Landlord or its agents may enter the Premises at any time
to determine Tenant&#146;s compliance with this Lease, to make necessary repairs, or to show the Premises to prospective tenants or purchasers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8 <B><U>RECONSTRUCTION AND RESTORATION</U></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.1 <U>Minor Damage</U>. If during the term hereof the Premises are destroyed or damaged by fire or other perils covered by Landlord&#146;s fire and extended coverage insurance and such damage is not
&#147;substantial,&#148; Landlord shall promptly repair such damage to Landlord&#146;s Work in the Premises and this Lease shall continue in full force and effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Substantial Damage</U>. If during the term hereof the Premises are destroyed or damaged by fire or other perils covered by Landlord&#146;s insurance in an amount exceeding twenty-five percent
(25%)&nbsp;of its full construction-replacement cost or other peril not covered by Landlord&#146;s insurance, then Landlord may elect to terminate this Lease by giving Tenant written notice of such termination within 60 days after the date of such
damage. Otherwise, Landlord shall proceed to restore Landlord&#146;s Work in the Premises to a condition comparable to that existing prior to the damage. Tenant shall cooperate with Landlord during the period of repair and vacate all or any part of
the Premises to the extent necessary for the performance of the required work. Landlord need not incur expenses for restoration in excess of the net insurance proceeds available to Landlord after payment of all reasonable costs, expenses and
attorneys&#146; fees incurred by Landlord in connection therewith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3 <U>Abatement of Rent</U>. The minimum rent shall be
abated during the period and to the extent the Premises is not reasonably usable for Tenant&#146;s use. if the damage does not cause any material interference with Tenant&#146;s use, there shall be no rent abatement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4 <U>Repair of Tenant&#146;s Property</U>. Repair, replacement, or restoration of any
fixtures, equipment and personal property owned by Tenant, and Tenant improvements shall be the responsibility of Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9
<B><U>ASSIGNMENT AND SUBLETTING</U></B>. Tenant shall not (voluntarily or by operation of law) assign, mortgage, pledge, hypothecate or encumber the Premises or Tenant&#146;s leasehold estate or sublet any portion of the Premises, or otherwise
transfer any interest in the Premises without Landlord&#146;s prior written consent in each instance which consent shall not be unreasonably withheld or delayed. In determining whether to consent, Landlord may consider any reasonable factor
including without limitation, credit worthiness, business experience, general reputation and ability to perform the terms of this Lease of the proposed transferee. If Tenant is a corporation, transfer of a fifty percent (50%)&nbsp;or greater
interest in cumulative total in any 2-year period in the stock of Tenant shall be deemed an assignment within the meaning of this Section. If Tenant is a partnership, any change in the partners shall be deemed an assignment of this Lease. if Tenant
requests consent to a proposed transfer, Tenant shall pay a review fee of $200 at the time of the request for application to Landlord&#146;s expenses in reviewing the request for consent to transfer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10 <B><U>CONDEMNATION</U></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.1 <U>Entire or Substantial Taking</U>. If more than twenty-five percent (25%)&nbsp;of the Premises (notwithstanding restoration by Landlord as herein provided) shall be taken under the power of eminent
domain, this Lease shall automatically terminate on the date the condemning authority takes possession. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2 <U>Partial
Taking</U>. In the event of any taking under the power of eminent domain which does not so result in a termination of this Lease, the minimum rent payable hereunder shall be reduced, effective on the date the condemning authority takes possession,
in the same proportion as the reduction in rentable floor area of the Premises. Landlord shall promptly, at its sole expense, restore the portion of the Premises not taken to as near its former condition as is reasonably possible, and this Lease
shall continue in full force and effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3 <U>Awards</U>. Any award for taking of all or any part of the Premises under
the power or eminent domain shall be the property of the Landlord, whether such award shall be made as compensation for diminution in value of the leasehold or for taking of the fee. Nothing herein, however, shall be deemed to preclude Tenant from
obtaining, or to give Landlord any interest in, any award to Tenant for loss of or damage to or cost of removal of Tenant&#146;s trade fixtures and removable personal property, or for damages for cessation or interruption of Tenant&#146;s business.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4 <U>Sale Under Threat of Condemnation</U>. A sale by Landlord to any authority with power of eminent domain, either under
threat of condemnation or while condemnation proceedings are pending, shall be deemed a taking under the power of eminent domain under this Section. Landlord need not incur expenses for restoration in excess of the amount of condemnation proceeds
received by Landlord after payment of all reasonable costs, expenses and attorneys&#146; fees paid or incurred by Landlord in connection with the condemnation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11 <B><U>SIGNS</U></B>. Tenant shall not inscribe, post, place or in any manner display any
sign notice, picture, placard, or any advertising matter, anywhere in, on or about the Premises or the Project without first obtaining Landlord&#146;s prior written consent. Tenant shall be permitted to place identification signage to the right of
the interior door to the Premises. Landlord shall produce and install said door signage in accordance with building standards and at Tenant&#146;s expense. Any sign on the Premises will be designed and constructed in compliance with applicable sign
codes. Tenant shall be responsible for the removal of its sign(s) and the repair of any damage to the building as a result of the sign&#146;s presence or removal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;12 <B><U>OTHER OBLIGATIONS OF PARTIES</U></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1 <U>Liens</U>.
Tenant shall pay as due all claims for work done on the Premises or for services rendered or materials furnished to the Premises and shall keep the Premises free from any liens other than liens created by Landlord. If Tenant fails to pay such claim
or to discharge any lien, Landlord may do so and collect such amount as additional rent. Amounts paid by Landlord shall bear interest and be repaid by Tenant as provided in paragraph 13.3 below. Such payment by Landlord shall not constitute a waiver
of any right or remedy Landlord may have because of Tenant&#146;s default. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2 <U>Holding Over</U>. If Tenant does not
vacate the Premises at the time required, Landlord shall have the option to treat Tenant as a tenant from month to month, subject to all of the provisions of this Lease (except that the term will be month to month and the initial minimum monthly
rent will be one hundred fifty percent {150%) of the minimum monthly rent then being paid by Tenant), or to eject Tenant from the Premises and recover damages caused by wrongful hold over. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3 <U>Non merger</U>. The voluntary or other surrender of this Lease by Tenant, or a mutual cancellation thereof, shall not work a
merger, and shall, at the option of the Landlord, terminate all and any existing subtenancies, or may, at the option of Landlord, operate as an assignment to it of any and all such subtenancies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4 <U>Rights of Landlord</U>. Landlord shall have the right to change the name or designation of the Project without notice or
liability to Tenant. Landlord shall also have the right to grant to anyone the exclusive right to conduct a particular business or undertaking in the Project. Landlord has entered into a Declaration of Restrictive Covenants with the Lake Oswego
Redevelopment Agency (the &#147;Restrictive Covenants&#148;) to which this lease is subordinate. Tenant shall not use the Premises for any use which violates such Restrictive Covenants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5 <U>Priority of Lease</U>. This Lease shall be subject and subordinated at all times to the lien of all mortgages and deeds of trust
subsequently placed upon the Project all without the necessity of having further instruments executed on the part of Tenant to effectuate such subordination. If any party providing financing or funding to Landlord requires, as a condition to such
financing or funding, that Tenant send such party written notice of any default by Landlord under this Lease, giving such party the right to cure such default until it has completed foreclosure and preventing Tenant from terminating this Lease
unless such default remains uncured after foreclosure has been completed, Tenant will execute and deliver any agreement required by such party in order to accomplish this purpose. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6 <U>Landlord&#146;s Liability; Sale</U>. The liability of Landlord under this Lease will
be limited to Landlord&#146;s interest in the Project, and any judgment against Landlord will be enforceable solely against Landlord&#146;s interest in the Project. In the event the original Landlord hereunder, or any successor owner of the Project,
shall sell or convey the Project, all liabilities and obligations on the part of the original Landlord, or such successor owner, under this Lease accruing thereafter shall terminate, and thereupon all such liabilities and obligations shall be
binding upon the new owner. Tenant agrees to attorn to such new owner. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.7 <U>Estoppel Certificate</U>. Within 10 days after
Landlord&#146;s written request, Tenant shall deliver a written statement stating the date to which the rent and other charges have been paid, whether the Lease is unmodified and in full force and effect, and any other matters that may reasonably be
requested by Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.8 <U>Rules and Regulations</U>. Tenant agrees to comply with any rules and regulations for the
Project adopted and published by Landlord from time to time and to cause Tenant&#146;s customers, employees and invitees to abide by such rules and regulations. Tenant agrees that Landlord shall not be responsible to Tenant for the noncompliance by
any other tenant or occupancy of the Project with such rules and regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.9 <U>Financial Statements</U>. Upon written
notice from Landlord, Tenant agrees to provide current financial statements for the Tenant and/or Guarantor. Landlord hereby agrees to maintain the confidentiality of all such statements; however Landlord may disclose such to its attorneys,
accountants or other professional advisors and any current or potential mortgagee or purchaser of the Property, and in connection with any proceeding to enforce the terms of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;13 <B><U>DEFAULTS; REMEDIES</U></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1 <U>Default</U>. The
following shall be events of default: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) <U>Payment Default</U>. Failure of Tenant to make any base, percentage or
additional rent or other payment under this Lease for a period of ten (10)&nbsp;days after it becomes due and payable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)
<U>Unauthorized Transfer</U>. Any transfer by Tenant without Landlord&#146;s prior written consent as required under Section&nbsp;9. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(3) <U>Abandonment of Premises</U>. Tenant fails to occupy or use the Premises for the purposes permitted by this Lease for a total of ten (10)&nbsp;consecutive business days or more during the lease
term, unless such failure is excused under other provisions of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4) <U>Default In Other Covenant</U>. Failure of
Tenant to comply with any other term or condition or fulfill any other obligation of this Lease within 20-days after written notice by Landlord specifying the nature of the default with reasonable particularity. No notice and no opportunity to cure
shall be required if Landlord has previously given Tenant notice of failure to comply with such term or condition or fulfill such other obligation of this Lease during the term hereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5) <U>Insolvency Defaults</U>. Dissolution, termination of existence, insolvency on a
balance sheet basis or business failure of Tenant; the commencement by Tenant of a voluntary case under the federal bankruptcy laws or under any other federal or state law relating to insolvency or debtor&#146;s relief; the entry of a decree or
order for relief against Tenant in an involuntary case under the federal bankruptcy laws or under any other applicable federal or state law relating to insolvency or debtor&#146;s relief; the appointment of or the consent by Tenant to the
appointment of a receiver, trustee or custodian of Tenant or of any of Tenant&#146;s property; an assignment for the benefit of creditors by Tenant; Tenant&#146;s failure generally to pay its debts as such debts become due; the making or suffering
by Tenant of a fraudulent transfer under applicable federal or state law; concealment by Tenant of any of its property in fraud of creditors; the making or suffering by Tenant of a preference within the meaning of federal bankruptcy law; or the
imposition of a lien through legal proceedings or distraint upon any of the property of Tenant which is not discharged or bonded. During any period in which there is a Guarantor(s) of this Lease, each reference to &#147;Tenants&#148; in this
paragraph shall be deemed to refer to &#147;Guarantor or Tenant,&#148; separately. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2 <U>Remedies on Default</U>. Upon
default, Landlord may exercise any one or more of the following remedies, or any other remedy available under applicable law: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) <U>Retake Possession</U>. With or without terminating the Lease, to the extent permitted by law, Landlord may re-enter and retake
possession of the Premises and terminate Tenant&#146;s tenancy, without notice, either by summary proceedings, force, any other applicable action or proceeding, or otherwise. Landlord may use the Premises for Landlord&#146;s own purposes or relet it
upon any reasonable terms without prejudice to any other remedies that Landlord may have by reason of Tenant&#146;s default. None of these actions will be deemed an acceptance of surrender by Tenant. To the extent permitted by law, Tenant expressly
waives the service of any notice of intention to terminate Tenant&#146;s tenancy or Tenant&#146;s right to possession or to retake the Premises, and waives service of any demand for payment of rent or for possession, and of any and every other
notice or demand required or permitted under applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) <U>Relet the Premises</U>. Landlord at its option may relet
the whole or any part of the Premises, from time to time, either in the name of Landlord or otherwise, to such tenants, for such terms ending before, on, or after the expiration date of the lease term, at such reasonable rentals and upon such other
reasonable conditions (including concessions and free rent periods) as Landlord, in its sole discretion, may reasonably determine to be appropriate. Landlord shall have no obligation to relet the Premises or any part and shall not be liable for
refusal or failure to relet the Premises, or in the event of any such reletting, for refusal or failure to collect any rent due upon such reletting. No such refusal or failure shall operate to relieve Tenant of any liability under this Lease or
otherwise affecting such liability. Landlord at its option may make such physical changes to the Premises as Landlord, in its sole discretion, considers advisable or necessary in connection with any such reletting or proposed reletting without
relieving Tenant of any liability under this Lease or otherwise affecting Tenant&#146;s liability. If there is other comparable unleased space in the Project, Landlord shall have no obligation to attempt to relet the Premises prior to leasing other
space in the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3) <U>Damages for Default</U>. Whether or not Landlord retakes possession or relets the Premises,
Landlord may recover all damages caused by the default (including but not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
limited to unpaid rent, attorneys&#146; fees relating to the default, and costs of reletting). Landlord may sue periodically to recover damages as they accrue during the remainder of the lease
term without barring a later action for further damages. Landlord may at any time bring an action for accrued damages plus damages for the remaining lease term equal to the difference between the rent specified in this Lease and the reasonable
rental value of the Premises for the remainder of the term, discounted to the time of judgment at the rate of six percent (6%)&nbsp;per annum. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(4) <U>Continuation after Default</U>. Even though Tenant is in default under this Lease, this Lease shall continue in effect so long as Landlord does not terminate this Lease, and Landlord may enforce
all its rights and remedies under this Lease, including the right to recover the rent as it becomes due under the Lease. Upon default, Landlord may terminate this Lease by giving written notice of termination of this Lease to Tenant. Termination of
Tenant&#146;s tenancy or Tenant&#146;s right to possession, acts of maintenance or preservation or efforts to relet the Premises or the appointment of a receiver upon initiative of Landlord to protect Landlord&#146;s interest under this Lease shall
not constitute a termination of this Lease unless written notice of termination of this Lease is given by Landlord to Tenant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <U>Cure of Tenant&#146;s Default</U>. Without prejudice to any other remedy for default, Landlord may perform any obligation or make
any payment required to cure a default by Tenant. The cost of performance, including attorneys&#146; fees and all disbursements, shall immediately be repaid by Tenant upon demand, together with interest from the date of expenditure until fully paid
at the rate of fourteen percent (14%)&nbsp;per annum, but not in any event at a rate greater than the maximum rate of interest permitted by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.4 <U>Cumulative Remedies</U>. The remedies provided for in this Lease are cumulative and not intended to be exclusive of any other remedy to which Landlord may lawfully be entitled at any time, and
Landlord may invoke any such remedy, including, without limitation, termination of the tenancy under ORS 91.090, as if specific remedies were not provided for herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;14 <B><U>SECURITY DEPOSITS</U></B>. Tenant shall upon execution hereof deposit with the Landlord the sum of Three Thousand Two Hundred Four and no/100 Dollars ($3,204.00), as security for the
full and faithful performance by Tenant of every provision of this Lease. If Tenant violates any provision of this Lease, Landlord may, but shall not be obligated to, apply all or any part of this security deposit to remedy such violation. If any
portion of said deposit is so applied, Tenant shall immediately deposit with Landlord cash in an amount sufficient to restore the security deposit to its original amount. Landlord may commingle this deposit with Landlord&#146;s funds and Tenant
shall not be entitled to interest on such deposit. If Tenant shall fully and faithfully perform every provision of this Lease, the security deposit or any balance thereof shall be returned to Tenant within 10 days after the expiration of the lease
term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;15 <B><U>LANDLORD&#146;S AND TENANT&#146;S WORK</U></B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1 <U>By Landlord</U>. Landlord shall perform the work described as Landlord&#146;s Work in attached Exhibit B. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.2 <U>By Tenant</U>. Tenant shall perform all other work required to ready the Premises
for Tenant&#146;s use and occupancy in accordance with attached Exhibit B. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;16 <B><U>MISCELLANEOUS</U></B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1 <U>Waivers</U>. No waiver by Landlord of performance of any provision of this Lease shall be deemed to be a waiver of nor prejudice
Landlord&#146;s right to otherwise require performance of the same provision or any other provision. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2 <U>Recording</U>.
Tenant shall not record this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.3 <U>Notices</U>. All notices under this Lease shall be in writing effective when
delivered in person, or if mailed, upon deposit in the United States Mail, certified and postage prepaid and addressed to the address of Tenant or Landlord shown below or at such other address as may be designated by either party by notice to the
other. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4 <U>Exhibits and Riders</U>. Exhibits and riders, if any, initialed or signed by Landlord and Tenant, and attached
or affixed to this Lease, are a part hereof as if set forth in full herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5 <U>Construction</U>. (a)&nbsp;This Lease
shall be construed and governed by the laws of the State of Oregon; (b)&nbsp;the invalidity or unenforceability of any provision hereof shall not affect or impair any other provisions hereof; (c)&nbsp;this Lease constitutes the entire agreement of
the parties and supersedes all prior agreements or understandings between the parties with respect to the subject matter hereof; (d)&nbsp;this Lease may not be modified or amended except by written agreement signed and acknowledged by both parties;
(e)&nbsp;if there be more than one tenant, the obligations hereunder imposed upon Tenant shall be joint and several; (f)&nbsp;time is of the essence of this Lease in each and every provision hereof; and (g)&nbsp;nothing contained herein shall create
the relationship of principal and agent or of partnership or of joint venture between the parties hereto and no provisions contained herein shall be deemed to create any relationship other than that of landlord and tenant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6 <U>Successor</U>. Subject to any limitations on assignments herein, all of the provisions of this Lease shall inure to the benefit
of and be binding upon the successors and assigns of the parties hereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.7 <U>Attorneys&#146; Fees</U>. In the event suit
or action is instituted to interpret or enforce the terms of this Lease, the prevailing party shall be entitled to recover from the other party such sum as the court may adjudge reasonable as attorneys&#146; fees at trial, on petition for review, or
on appeal, in addition to all other sums provided by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.8 <U>Hazardous Substances</U>. Tenant shall not use, generate
transport, treat, store, dispose of or otherwise handle Hazardous Substances on the Leased Premises without the prior written consent of Landlord, except Hazardous Substances and in quantities commonly used in business offices, provided such
Hazardous Substances are maintained and used in accordance with applicable laws relating thereto, Landlord may withhold such consent in its sole discretion or may condition such consent upon Tenant&#146;s agreement to comply with requirements
designated by Landlord. The term &#147;Hazardous Substances&#148; shall mean any and all hazardous, toxic, infectious or radioactive substances, wastes or materials as defined or listed by any federal, state or local statute, regulation or ordinance
pertaining to the protection of human health or the environment and shall specifically include petroleum oil and its fractions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.9 <U>No Offer</U>. This Lease is submitted to Tenant on the understanding that it will
not be considered an offer and will not bind Landlord in any way until (a)&nbsp;Tenant has duly executed and delivered duplicated originals to Landlord and (b)&nbsp;Landlord has executed and delivered one of such originals to Tenant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.10 <U>Consent</U>. Unless Landlord&#146;s consent or approval is required by the express terms of this Lease not to be unreasonably
withheld, such approval or consent may be withheld, delayed or conditioned by Landlord in its sole and arbitrary discretion. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LO 138 LLC,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RXi PHARMACEUTICALS CORPORATION</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">an Oregon limited liability company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gramor 138 LLC,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">an Oregon limited liability company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manager</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gramor Investments, Inc.,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">an Oregon Corporation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manager</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Barry A. Cain</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Barry A. Cain, President</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, President/CEO</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">7/18/11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">7/18/11</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Landlord Address:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant Address:</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">19767 SW 72nd Avenue, Suite 100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 Prescott Street</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tualatin, OR 97062</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Worcester, MA 01605</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">(503) 245-1976</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">(503) 961-4465</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">and&nbsp;a&nbsp;copy&nbsp;to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thomas R. Page</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stoel Rives</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">900 S.W. Fifth Avenue Suite 2600</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Portland, OR 97204</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">STATE&nbsp;OF&nbsp;OREGON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ss</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">County&nbsp;of&nbsp;Washington</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On this day personally appeared before me MARK J. AHN, to me known to be the PRESIDENT/CEO, of the
corporation described as Tenant in the foregoing instrument, and acknowledged the said instrument to be the free and voluntary act and deed of said corporation for the uses and purposes therein mentioned, and on oath stated that they were authorized
to execute the said instrument on behalf of the corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">GIVEN under my hand and official seal this 18th day of July,
2011. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Official Seal</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kristin Jennifer Woods</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kristin Jennifer Woods</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notary
Public &#150; Oregon</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commission No. 447699</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">My Commission Expires May&nbsp;19, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notary Public in and for the State of Oregon</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">STATE&nbsp;OF&nbsp;OREGON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ss</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">County&nbsp;of&nbsp;Washington</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On this day personally appeared before me BARRY A. CAIN, to me known to be the President of Gramor
Investments, Inc., that executed the foregoing instrument, and acknowledged the said instrument to be the free and voluntary act and deed of said corporation for the uses and purposes therein mentioned, and on oath stated that he was authorized to
execute the said instrument on behalf of the corporation and Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">GIVEN under my hand and official seal this 18th day of
July, 2011. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Official Seal</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kristin Jennifer Woods</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kristin Jennifer Woods</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notary
Public &#150; Oregon</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commission No. 447699</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">My Commission Expires May&nbsp;19, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notary Public in and for the State of Oregon</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIST OF EXHIBITS AND RIDERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ATTACHED HERETO AND MADE A PART HEREOF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>&#147;LAKE VIEW VILLAGE&#148; </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT&nbsp;&#147;A-1&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Premises</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT&nbsp;&#147;A-2&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT&nbsp;&#147;A-3&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal Description of the Project</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT&nbsp;&#147;B&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Construction Exhibit</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT&nbsp;&#147;C&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shopping Center Rules and Regulations</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">RIDER:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option to Extend</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT &#147;A-2&#148; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SITE PLAN </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LAKE VIEW VILLAGE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g275067ex10_4346.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT &#147;A-2&#148; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SITE PLAN </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LAKE VIEW VILLAGE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g275067ex10_4347.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT &#147;A-3&#148; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LEGAL DESCRIPTION OF THE PROJECT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>&#147;LAKE VIEW VILLAGE&#148; </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parcel 2 of PARTITION PLAT NO 2002-076, a duly filed plat,
in the City of Lake Oswego, County of Clackamas, State of Oregon. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT &#147;B&#148; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DESCRIPTION OF LANDLORD&#146;S WORK AND TENANT&#146;S WORK </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>&#147;LAKE VIEW VILLAGE&#148; </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RXi PHARMACEUTICALS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Page 1 of 1 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>CONSTRUCTION OF TENANT&#146;S PREMISES: </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord agrees that it will, at its sole cost and expense, commence and pursue to completion the construction of the improvements as stated in
&#147;Description of Landlord&#146;s Work&#148; herein. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>DESCRIPTION OF LANDLORD&#146;S WORK: </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall paint the interior of the Premises in a color(s) mutually agreeable to Tenant and Landlord. Other than outlined herein, Landlord shall
deliver the Premises to Tenant in &#147;as is&#148; condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>DESCRIPTION OF TENANT&#146;S WORK: </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as provided under &#147;Description of Landlord&#146;s Work&#148;, all work in the Premises shall be provided by or for Tenant at Tenant&#146;s
expense. This work shall include, but not be limited to the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event Tenant plans to make alternations to the Premises which require a building permit, Tenant shall within twenty (20)&nbsp;days after receipt of
Landlord&#146;s floor plan, submit to Landlord two (2)&nbsp;prints and one (1)&nbsp;reproducible set of full dimensioned 1/8 inch scale or larger drawings on 24&#148; x 36&#148; sheets plus specifications prepared by Tenant&#146;s architect or
designed at Tenant&#146;s expense if Landlord&#146;s architect is used, which drawings shall indicate the specific requirement of Tenant&#146;s space showing clearly the storefront, interior partitions, colors, materials, trade fixtures plans,
lighting and electrical outlets all in conformity with the provision of this Exhibit &#147;B&#148; and which shall be suitable for submittal for issuance of required permits. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any special or decorative lighting including any additional service panel capacity that may be required as a result. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Special furred, covered or dropped ceiling areas. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All interior painting, floor covering and other finishes not included in Landlord&#146;s work. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Al partitions and doors not included under Landlord&#146;s work. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Landlord performs any of Tenant&#146;s work, then the cost of said work shall be paid in the following manner: Fifty percent (50%)&nbsp;prior to commencement of
construction and the balance immediately following completion. Payment is due upon receipt of invoice. The entire payment of the invoice must be received by landlord prior to Tenant occupying the Premises and issuance of keys.
</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Tenant penetrates roof membrane, Tenant shall, at its expense, use Landlord&#146;s roofing contractor to repair all such penetrations. Al repairs shall comply with
the requirements under the roof warranty. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant&#146;s licensed general contractor must be approved by Landlord prior to Tenant issuing a contract. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT &#147;C&#148; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TO OFFICE LEASE AGREEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>RULES AND REGULATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#147;LAKE VIEW VILLAGE&#148; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Page 1 of 4 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The entrance, halls, corridors, stairways and elevator shall not be obstructed by any of the tenants or used for any purpose other than for ingress and egress from
their respective premises. The entrances, halls, corridors, stairways, walkways, and the elevator are not intended for use by the general public but for the tenant and its employees, licensees and invitees. Landlord reserves the right to control and
operate the public portions of the building in which the Premises are located (the &#147;Building&#148;), the Project, and the public facilities as well as facilities furnished for the common use of the tenants, in such manner as it in its
reasonable judgment deems best for the benefit of the tenants generally. No tenant shall invite to the tenant&#146;s premises, or permit the visit of persons in such numbers or under such conditions as to interfere with the use and enjoyment of any
of the entrances, corridors, elevator and other facilities of the Building or Project by any other tenants. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No awnings or other projections shall be attached to the outside walls of the Building. No curtains, blinds, shades or screens, if any, which are different from the
standards adopted by Landlord for the Project shall be attached to or hung in any exterior window or door or the premises of any tenant without the prior written consent of Landlord, which consent shall not be unreasonably withheld.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant may mark, drive nails or screw or drill on or into the partitions, woodwork or plaster of the Premises; provided, however, that any damage caused thereby shall
be repaired by Tenant, at Tenant&#146;s expense, prior to the expiration of the lease term. Tenant shall not penetrate the ceiling or floor of the Premises without the prior written consent of Landlord. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No sign, placard, picture, name lettering, advertisement, notice or object visible from the exterior of any tenant&#146;s premises shall be displayed in or on the
exterior windows or doors, or on the outside of any tenant&#146;s premises, or at any point inside any tenant&#146;s premises where the same might be visible outside of such premises, without the prior written consent of Landlord, which consent
shall not be unreasonably withheld. All approved signs or lettering shall be prepared, printed, affixed, or inscribed at the expense of the tenant and shall be of a size, color and style acceptable to Landlord. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The windows that reflect or admit light and air into the halls, passageways or other public places in the Building shall not be covered or obstructed by any tenant, nor
shall any bottles, parcels or other articles be placed on the window sills. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No showcases or other articles shall be put in front of or affixed to any part of the exterior of the Building, nor placed in the halls, corridors or vestibules.
</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit &#147;C&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake View Village</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No bicycles, skateboard, vehicles, animals or birds of any kind shall be brought into or kept in or about the Building; however, bicycles may be kept in a bike rack
installed by the Landlord on the Building exterior. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No noise, including, but not limited to, music or the playing of musical instruments, recordings, radio, television or similar audio or video device which, in the
judgment of Landlord, might disturb other tenants in the Building, shall be made or permitted by any tenant. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No tenant, nor any tenant&#146;s contractors, employees, agents, visitors, invitees, or licensees, shall at any time bring into or keep upon the premises or the
Building any inflammable, combustible, explosive, environmentally hazardous or otherwise dangerous fluid, chemical or substance. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional locks or bolts of any kind which shall not be operable by the grand master key for the Building shall not be placed upon any of the doors or windows by any
tenant, nor shall any changes be made in locks or mechanism thereof which shall make such locks inoperable by such grand master key. Additional keys for a tenant&#146;s premises and toilet rooms shall be procured only from the Landlord who may make
a reasonable charge therefore. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All movement of freight, furniture, packages, boxes, crates or any other object or matter of any description must take place during such hours and in such elevators,
and in such manner as Landlord or its agents may determine from time to time. Any labor and engineering costs incurred by Landlord in connection with any moving herein specified, shall be paid by Tenant to Landlord, on demand.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall have the right to prescribe the weight and position of safes and other objects of excessive weight, and no safe or other object whose weight exceeds the
lawful load for the area upon which it would stand shall be brought into or kept upon any tenant&#146;s premises. If, in the judgment of Landlord, it is necessary to distribute the concentrated weight of any heavy object, the work involved in such
distribution shall be done at the expense of the tenant and in such manner as Landlord shall determine. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No machinery or mechanical equipment other than ordinary portable business machines may be installed or operated in any tenant&#146;s premises without Landlord&#146;s
prior written consent which consent shall not be unreasonably withheld or delayed, and in no case shall any machines or mechanical equipment be so placed or operated as to disturb other tenants. Machines and mechanical equipment which may be
permitted to be installed and used in tenant&#146;s premises shall be equipped, installed and maintained so as to prevent any disturbing noise, vibration or electrical or other interference from being transmitted from such premises to any other area
of the Building. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord, its contractors, and their respective employees, shall have the right to use, without charge therefor, electricity and water in the premises of any tenant
while making repairs or alterations in the premises of such tenant. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit &#147;C&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake View Village</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No premises of any tenant shall be used for lodging or sleeping or for any immoral or illegal purpose. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The requirements of tenants for any services by Landlord will be attended to only upon prior application to the Landlord. Employees of Landlord shall not perform any
work or do anything outside of their regular duties, unless under special instructions from Landlord. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canvassing, soliciting and peddling in the Building are prohibited and each tenant shall cooperate to prevent the same. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Without the prior written consent of Landlord, no tenant shall sell newspapers, magazines, periodicals, theater or travel tickets or other goods or merchandise to the
general public in or on tenant&#146;s premises nor shall any tenant use or permit the use of any sidewalk for any similar purposes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each tenant shall store its trash and garbage within its premises. No material shall be placed in the trash boxes or receptacles if such material is of such nature that
it may not be disposed of in the ordinary and customary manner of removing and disposing of office building trash and garbage in the City of Lake Oswego without being in violation of any law or ordinance governing such disposal. All garbage and
refuse disposal shall be made only through entryways provided for such purposes and at such times as Landlord shall designate. No tenant shall cause or permit any unusual or objectionable odors to emanate from its premises which would annoy other
tenants or create a public or private nuisance. No cooking shall be done in the premises of any tenant except as is expressly permitted in such tenant&#146;s lease; and in any event said cooking shall not cause objectionable odors to permeate from
its premises which would annoy other tenants. Tenant&#146;s operation of an employee kitchen containing a microwave and refrigeration shall not be considered a violation of this regulation. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">20.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No coin vending machine, video game, coin or token operated amusement device or similar machine shall be used or installed in any tenant&#146;s premises without
Landlord&#146;s prior written consent. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No bankruptcy, going out of business, liquidation or other form of distress sale shall be held in any of tenant&#146;s premises. No sales shall be held outside of any
tenant&#146;s premises. No advertisement shall be done by loudspeaker, barkers, flashing lights or displays or other methods not consistent with the character of a high-quality office building. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nothing shall be done or permitted in any tenant&#146;s premises, and nothing shall be brought into or kept in any tenant&#146;s premises, which would impair or
interfere with the economic heating, cleaning or other servicing of the Building or the premises, or the use or enjoyment by any other tenant of any other premises, nor shall there be installed by any tenant any ventilating, air conditioning,
electrical or other equipment of any kind which, in the reasonable judgment of Landlord, might cause any such impairment or interference. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit &#147;C&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake View Village</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No acids, vapors or other similar caustic materials shall be discharged or permitted to be discharged into the waste lines, vents or flues of the Building. The water
and wash closets and other plumbing fixtures in or serving any tenant&#146;s premises shall not be used for any purpose other than the purposes for which they were designed or constructed, and no sweepings, rubbish, rages, acids or other foreign
substances shall be deposited therein. All damages resulting from any misuse of the fixtures shall be borne by the tenant who, or whose employees, agents, invitees, visitors or licensees shall have caused the same. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All entrance doors in each tenant&#146;s premises and windows shall be left locked when the tenant is not occupying the premises. Entrance doors to the tenant&#146;s
premises shall not be blocked open at any time. Each tenant, before closing and leaving its premises at any time, shall turn out all lights. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hand trucks not equipped with rubber tires and side guards shall not be used within the Building. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant&#146;s employees shall park only in those areas of the Project designated in writing by Landlord from time to time for such purpose. If requested, Tenant shall
furnish to Landlord in writing license numbers of vehicle of Tenant and employees. Any vehicle improperly parked by an employee of Tenant may be towed or otherwise removed by Landlord at Tenant&#146;s expense and Tenant shall indemnify Landlord from
any liability in connection with such removal. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall be responsible for the observance of all of the foregoing rules and regulations by Tenant&#146;s employees, agents, clients, customers, invitees, and
guests. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord reserves the right to rescind, modify, alter or waive any rule or regulation at any time prescribed for the Project when, in its reasonable judgment, it deems
it necessary, desirable or proper for the Project&#146; s best interest and for the best interests of the tenants generally, and no alteration or waiver of any rule or regulation in favor of one tenant shall operate as an alteration or waiver in
favor of any other tenant. Landlord shall not be responsible to any tenant for the non-observance or violation by any other tenant of any of the rules and regulations at any time prescribed for the Building. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord reserves the right to add to, modify or otherwise change these Rules and Regulations. Such changes shall become effective when written notice thereof is
provided tenants of the Building. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">These rules and regulations are in addition to, and shall not be construed in any manner to modify or amend, in whole or in part, the terms of any written lease for
space in the Project. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake View Village </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RIDER: OPTION TO EXTEND </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Terms of Option: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall have an option to extend the term of this Lease
for one (1)&nbsp;additional period of one (1)&nbsp;year upon the same terms and conditions set forth herein; provided Tenant shall have delivered written notice to Landlord of the exercise of the option not more than 365 days nor less than 120 days
prior to the end of the initial Lease term and provided further that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant is not in default hereunder in the payment of rent or any other term or condition hereof at the time it gives such notice to Landlord or at the time the extended
term begins; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The minimum monthly rent, as specified in Section&nbsp;3.1 hereof, for such extended term shall be modified as follows: </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 25-36 $3,300.00 per month </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LO 138 LLC,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RXi PHARMACEUTICALS CORPORATION,</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">an Oregon limited liability company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gramor 138 LLC,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">an Oregon
limited liability company</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manager</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gramor Investments, Inc.,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">an Oregon Corporation</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manager</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Barry A. Cain</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Barry A. Cain, President</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, President/CEO</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>6
<FILENAME>d275067dex1045.htm
<DESCRIPTION>LEASE AGREEMENT, EFFECTIVE AS OF APRIL 30, 2009
<TEXT>
<HTML><HEAD>
<TITLE>Lease Agreement, effective as of April 30, 2009</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.45 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>EXT</SMALL> M<SMALL>ARKED</SMALL> B<SMALL>Y</SMALL> [* * *] H<SMALL>AS</SMALL> B<SMALL>EEN</SMALL> O<SMALL>MITTED</SMALL> P<SMALL>URSUANT</SMALL> T<SMALL>O</SMALL> A R<SMALL>EQUEST</SMALL>
F<SMALL>OR</SMALL> C<SMALL>ONFIDENTIAL</SMALL> T<SMALL>REATMENT</SMALL> A<SMALL>ND</SMALL> W<SMALL>AS</SMALL> F<SMALL>ILED</SMALL> S<SMALL>EPARATELY</SMALL> W<SMALL>ITH</SMALL> T<SMALL>HE</SMALL> S<SMALL>ECURITIES</SMALL> A<SMALL>ND</SMALL>
E<SMALL>XCHANGE</SMALL> C<SMALL>OMMISSION</SMALL>. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g275067g36l13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LICENSE AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">THIS LICENSE AGREEMENT (this &#147;<B>Agreement</B>&#148;) is made and entered into by and between Apthera, Inc., a Delaware corporation having its principal offices at 8418 E. Shea Boulevard, Suite 100,
Scottsdale, Arizona 85260 USA (the &#147;<B>Licensor</B>&#148;), and Kwangdong Pharmaceutical Co., Ltd., a company incorporated in Korea having its principal offices at 1577-4 Seocho-Dong, Seoul, Republic of Korea (the &#147;<B>Licensee</B>&#148;),
with such foregoing entities also referred to hereafter individually as a &#147;<B>Party</B>&#148; or collectively as the &#147;<B>Parties.</B>&#148; The Agreement shall be effective as of the Effective Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Licensor is the owner of or otherwise controls the Licensed Intellectual Property (as defined below); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Licensee desires to use, sell, offer for sale, and otherwise commercialize the products using the Licensed Intellectual Property
within the Licensed Fields (as defined below); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Licensee desires to acquire and the Licensor desires to grant to
Licensee a license under the Licensed Intellectual Property; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the mutual promises and
covenants contained in this Agreement and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>1. Definitions. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1 <U>Certain Definitions</U>. The following terms shall
have the following respective meanings: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Affiliates</B>&#148; shall mean, with respect to any specified Person, a
Person that directly or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the Person specified. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Agreement</B>&#148; shall have the meaning set forth in the Introduction hereof. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Bankruptcy</B>&#148; of either Party shall mean any of the following events: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Such Party is unable to pay its debts as they come due or such Party fails to have assets (both tangible and intangible) with a fair salable value in excess of the amount required to pay the probable
liability on its respective existing debts for a period of more than ninety (90)&nbsp;days (&#147;<B>Insolvency</B>&#148;); </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The institution by such Party of proceedings to be adjudicated as bankrupt, or
insolvent or the consent by such Party to the institution of bankruptcy or Insolvency proceedings against such Party or the filing by such Party of a petition or answer or consent seeking reorganization or release under any applicable law, or the
consent by such Party to the filing of any such petition or the appointment of a receiver, liquidator, assignee, trustee, or other similar official of such Party, or of any substantial part of such Party&#146;s property, or the making by such Party
of an assignment for the benefit of creditors, or the taking of action by such Party in furtherance of any such action; or 8418 E. Shea Blvd., Suite 100, Scottsdale, AZ 85260 www.apthera.com </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The institution, consent, or the filing by (or against) such Party of any composition, reorganization, or bankruptcy liquidation
proceedings under applicable law. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Claims</B>&#148; shall mean any claim, action, arbitration, proceeding, review,
audit, hearing, investigation, litigation, or suit (whether civil, criminal, administrative, investigative, informal, or threatened). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Confidential Information</B>&#148; shall have the meaning set forth in the Mutual Confidential Disclosure Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Disclosing Party</B>&#148; shall have the meaning set forth in the Mutual Confidential Disclosure Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Effective Date</B>&#148; shall mean the date on which this Agreement is signed by the last Party to sign it. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>EMEA</B>&#148; shall mean the European Medicines Agency, and any successor thereto. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>FDA</B>&#148; shall mean the United States Food and Drug Administration, and any successor thereto. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Field of Use</B>&#148; shall mean for the treatment of breast cancer. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Indemnified Party</B>&#148; shall mean the Party seeking indemnification. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Indemnifying Party</B>&#148; shall mean the Party indemnifying the Indemnified Party. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Infringes</B>&#148; shall mean impairs, dilutes, misappropriates, or otherwise violates. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Insolvency</B>&#148; shall have the meaning set forth in the definition of Bankruptcy hereof. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Intellectual Property</B>&#148; shall mean all intellectual property rights of any nature or form of protection of a similar
nature or having equivalent or similar effect to any of the foregoing, including, without limitation: (a)&nbsp;inventions, discoveries, processes, designs, techniques, developments, technology, and related improvements, whether or not patentable;
(b)&nbsp;United States patents, patent applications, divisional s, continuations, reissues, renewals, registrations, confirmations, re-examinations, certificates of inventorship, extensions, and the like, and any provision applications of any such
patents or patent applications, and any foreign or international equivalent of any of the foregoing; (c)&nbsp;any word, name, symbol, color, designation, or device or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any combination thereof, including, without limitation, any United States or pending trademark, trade dress, service mark, service name, trade name, brand name, logo, domain name, or business
symbol, and any foreign or international equivalent of any of the foregoing and all goodwill associated therewith; (d)&nbsp;any work, whether or not registered in the United States or elsewhere, that incorporate, is based upon, derived from, or
otherwise uses any intellectual property, including, without limitation, mechanical and electronic design drawings (including, without limitation, computer-aided design files), specification, software (including, without limitation, documentation
and object and source code listing), processes, technical or engineering data, test procedures, schematics, writings, materials, products, artwork, packaging and advertising materials; and (e)&nbsp;technical, scientific, and other know-how and
information, trade secrets, knowledge, technology, means, methods, processed, practices, formulas, assembly procedures, computer programs, apparatuses, specifications, books, records, production data, publications, databases, reports, manuals, data
and results, in written, electronic, or any other form not known or hereafter developed. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>KFDA</B>&#148; shall mean
the Korea Food&nbsp;&amp; Drug Administration and any successor thereto. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Licensee</B>&#148; shall have the meaning
set forth in the Introduction hereof. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Licensee Financial Records</B>&#148; shall have the meaning set forth in
Section&nbsp;3.4 hereof. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Licensee Indemnities</B>&#148; shall mean Licensee and its directors, officers, employees,
Affiliates and agents. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Licensed Intellectual Property</B>&#148; shall mean any and all Intellectual Property related
to the Licensed Products as set forth on Exhibit B attached hereto, as may be amended from time to time by the mutual written agreement of the Parties. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Licensed Products</B>&#148; shall mean any product which: (a)&nbsp;in the absence of the license granted in Section&nbsp;2 hereof would infringe any of the Licensed Intellectual Property; or
(b)&nbsp;is made, at least in part, using any of the Licensed Intellectual Property. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Licensed Territory</B>&#148;
shall mean the Republic of Korea. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Licensor</B>&#148; shall have the meaning set forth in the Introduction hereof.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Licensor Indemnitees</B>&#148; shall mean the Licensor and its directors, officers, employees, Affiliates and
agents. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Losses</B>&#148; shall mean all Claims, losses, liabilities, damages, costs, obligations, assessments,
penalties and interest, demands and expenses (including, without limitation, actual attorneys&#146; fees), whether direct or indirect, known or unknown, absolute or contingent (including, without limitation, settlement costs and any legal,
accounting and other expenses for investigation or defending any Claims). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Mutual Confidential Disclosure
Agreement</B>&#148; shall mean that certain Mutual Confidential Disclosure Agreement entered into by and between the Licensor and Licensee, dated April&nbsp;2, 2009 attached hereto as Exhibit A. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Net Sales</B>&#148; shall mean Licensee&#146;s invoice price for the sale of all
Licensed Products, less those taxes, duties, refunds, exchanges, promotional give-aways and shipping charges actually incurred by Licensee and separately stated on such invoice. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Party</B>&#148; or &#147;<B>Parties</B>&#148; shall have the meaning set forth in the Introduction hereof. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Persons</B>&#148; shall mean any individual, partnership, firm, corporation, association, trust, unincorporated organization, or
other entity, as well as any syndicate or group that would be deemed to be a person under Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Phase III Clinical Trial</B>&#148; shall mean a clinical trial as defined in 21 C.F.R. 312.21(c), as may be amended from time to time, or any foreign equivalent thereto. A Phase III Clinical
Trial shall be deemed to have been initiated when the first patient is dosed in such Phase III Clinical Trial. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Quarterly Net Sales Report</B>&#148; shall have the meaning set forth in Section&nbsp;3.5 hereof. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Receiving Party</B>&#148; shall have the meaning set forth in the Mutual Confidential Disclosure Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Regulatory Authority</B>&#148; shall mean, with respect to any particular country, territory or union, the governmental
authority, body, commission, agency or other instrumentality of such country, territory or union with the primary responsibility for the evaluation or approval of pharmaceutical products before such pharmaceutical product may be tested, marketed,
promoted, distributed or sold in such country, including such governmental bodies that have jurisdiction over the pricing of such pharmaceutical product. The term &#147;Regulatory Authority&#148; includes the KFDA, the FDA, and the European Agency
for the Evaluation of Medicinal Products or EMEA </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Reimbursement approval</B>&#148; shall mean the approval received
for any Licensed Product to be reimbursed by insurance. Once a Licensed Product is approved for reimbursement by insurance, the royalty rate for Reimbursable Net Sales shall apply to the Licensed Product. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Reimbursable Net Sales</B>&#148; shall mean the Net Sales for any Licensed Products that have been approved for reimbursement by
insurance. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Non-reimbursable Net Sales</B>&#148; shall mean the Net Sales for any Licensed Products that have not
been approved for reimbursement by insurance. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Royalties</B>&#148; shall have the meaning set forth in
Section&nbsp;3.3 hereof. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Term</B>&#148; shall have the meaning set forth in Section&nbsp;12.1 hereof. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. License Grant. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>Grant of License</U>. Subject to the terms and conditions of this Agreement, the Licensor grants to Licensee and its Affiliates an exclusive, non-transferable license, limited to the Licensed
Territory and Field of Use, to the Licensed Intellectual Property to use, sell, offer for sale, or otherwise commercially exploit the Licensed Products supplied by Licensee within the Licensed Territory and Field of Use for the Term of this
Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Right to Sub-license</U>. Licensee shall not have the right to sub-license any of the
Licensed Intellectual Property in accordance with Section&nbsp;2.1 hereof without Licensor&#146;s prior written consent and Licensor&#146;s consent shall not be unreasonably withheld. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3 <U>Reservation of Rights</U>. All rights in any Licensed Intellectual Property not granted by the Licensor to Licensee in Sections
2.1 and 2.2 hereof are expressly reserved to the Licensor and no additional licenses are granted or implied hereunder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.
Consideration and Reporting. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Equity Investment</U>. Licensee shall make a <B><U>[***]</U></B> U.S. dollar
($<B><U>[***]</U></B>) equity investment in Licensor payable as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) a <B><U>[***]</U></B> U.S. dollar
($<B><U>[***]</U></B>) investment in Series B-1 Preferred Equity Offering to be paid within fifteen (15)&nbsp;days after the Effective Date of the Agreement, and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) a four hundred thousand U.S. dollar ($400,000.00) investment to be paid within thirty (30)&nbsp;days from the date that the first patient is dosed in a Phase III clinical study with the investment to
be made in Licensor&#146;s then current preferred equity offering; provided that the conditions of the aforesaid preferred equity offering shall be at least senior to or on parity with the conditions of the Licensor&#146;s most senior preferred
equity at that time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Milestone Payments</U>. Licensee agrees to pay Licensor the following milestone payments:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B><U>[***]</U></B> U.S. dollars ($<B><U>[***]</U></B>) to be paid within thirty (30)&nbsp;days of receiving
reimbursement approval in the Licensed Territory, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B><U>[***]</U></B> U.S. dollars ($<B><U>[***]</U></B>) to be paid
within thirty (30)&nbsp;days after Licensee achieves <B><U>[***]</U></B> U.S. dollars ($<B><U>[***]</U></B>) in Net Sales of all Licensed Products, and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <B><U>[***]</U> </B>U.S. dollars ($<B><U>[***]</U></B>) to be paid within thirty (30)&nbsp;days after Licensee achieves <B><U>[***]</U></B> U.S. dollars ($<B><U>[***]</U></B>) in Net Sales of all
Licensed Products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Royalties</U>. Licensee shall pay and the Licensor shall receive the following percents of the Net
Sales of all Licensed Products in the Licensed Territory for the Term of this Agreement (the &#147;<B>Royalties</B>&#148;): </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) for the first <B><U>[***]</U> </B>U.S. dollars ($<B><U>[***]</U></B>) in Net Sales, Licensor shall receive <B><U>[***]</U></B>
(<B><U>[***]</U></B>%) of Reimbursable Net Sales and <B><U>[***]</U></B> (<B><U>[***]</U></B>%) of Non-reimbursable Net Sales, </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) for Net Sales over <B><U>[***]</U></B> U.S. dollars ($<B><U>[***]</U></B>) and up to <B><U>[***]</U></B> U.S. dollars
($<B><U>[***]</U></B>), Licensor shall receive <B><U>[***]</U></B> percent (<B><U>[***]</U></B>%) of Reimbursable Net Sales and <B><U>[***]</U> </B>percent (<B><U>[***]</U></B>%) of Non-reimbursable Net Sales, </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) for Net Sales over <B><U>[***]</U></B> U.S. dollars ($<B><U>[***]</U></B>), Licensor shall receive <B><U>[***]</U> </B>percent
(<B><U>[***]</U></B>%) of Reimbursable Net Sales and <B><U>[***]</U> </B>percent (<B><U>[***]</U></B>%) of Non-reimbursable Net Sales. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Royalties due under this Section&nbsp;3.3 shall be paid within sixty (60)&nbsp;days after the end of the then-current quarter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.4 <U>Financial Records and Auditing</U>. Licensee shall, during the Term of this Agreement and for a period of one (1)&nbsp;fiscal year thereafter, keep and maintain financial statements and records
relating </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
exclusively to the subject matter of this Agreement solely for the purposes of confirming the Net Sales of the Licensed Products to be reported according to Section&nbsp;3.5 hereof (the
&#147;<B>Licensee Financial Records</B>&#148;). The Licensor, through an independent certified public accountant (provided that such independent certified public accountant is not compensated on a contingency basis), subject to a written
non-disclosure agreement with Licensee, shall have the right, during normal business hours and upon ten (10)&nbsp;days advance written notice to Licensee, and no more often than once per calendar year, to inspect the Licensee Financial Records.
Licensee shall have the right to have a representative present at all such inspections. The Licensor warrants that all such audits shall be carried out in a manner calculated not to unreasonably interfere with Licensee&#146;s conduct of business.
Further, such certified public accountant agrees to comply with all of Licensee&#146;s safety and security requirements during any visits to Licensee&#146;s facilities. The cost of such inspection or audit shall be borne by the Licensor, unless such
inspection or audit reflects a discrepancy adverse to the Licensor of five percent (5%)&nbsp;or more in the Net Sales reported by Licensee. In the event that the inspection or audit reveals a discrepancy adverse to the Licensor of five percent
(5%)&nbsp;or more in the Net Sales reported by Licensee in accordance with this Agreement, Licensee shall be responsible for the reasonable costs of such inspection or audit. The Licensor acknowledges that the Licensee&#146;s Financial Records
contain confidential trade information. Neither the Licensor nor its representatives shall at any time communicate to others or use any facts or information obtained as a result of such inspection or audit of the Licensee Financial Records. Under no
circumstances shall such independent certified public accountant provide the Licensor with any information regarding the identity of Licensee&#146;s customers or provide the Licensor with any copies of Licensee&#146;s customer lists. The
Licensor&#146;s right to inspect the Licensee Financial Records shall be limited to the current year for which Net Sales of the Licensed Products are to be reported are payable and the immediately preceding one (1)&nbsp;fiscal year period.
Notwithstanding anything in this Agreement to the contrary, such audit right shall extend only one (1)&nbsp;fiscal year beyond termination of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.5 <U>Quarterly Reports</U>. During the Term of this Agreement and for any calendar quarter in which Licensee or its Affiliates have made any sales of the Licensed Products, Licensee shall, within thirty
(30)&nbsp;days after the end of each such calendar quarter, furnish to the Licensor a written report showing the Net Sales of the Licensed Products during such quarter (the &#147;<B>Quarterly Net Sales Report</B>&#148;) including the following
specific information: (a)&nbsp;total Net Sales of the Licensed Products broken down into Reimbursable Net Sales and Non-reimbursable Net Sales categories as may be reasonably requested by the Licensor, and sufficient documentation to demonstrate the
calculation of such Net Sales; (b)&nbsp;the exchange rates used in determining the Net Sales in United States dollars; and (c)&nbsp;a comparison of forecast to actual sales of the Licensed Products, as customarily done by Licensee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6 <U>Payments</U>. All payments due pursuant to this Agreement shall be made in United States dollars. Any payments due pursuant to
this Agreement unpaid within the time period set forth in the corresponding Section shall bear interest at the rate of one and one-half percent (1.5%)&nbsp;per month or the highest amount permitted by law, whichever is lower, from the date when such
payment was due until payment in full, with interest, is made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.7 <U>Withholding Taxes</U>. Licensee shall make the payment
of the milestone and royalty payments owed to Licensor (defined in Sections 3.2 and 3.3) after deduction of withholding taxes that are imposed on such payments under the laws of the Licensed Territory and any of the bi-lateral tax treaties to which
the government of the Licensed Territory is a party. Licensee shall notify Licensor of any such withholding taxes and the Parties shall cooperate to receive any benefits under any double taxation treaty. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Ownership of Intellectual Property. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>Ownership of Licensed Intellectual Property</U>. Licensee acknowledges and agrees, by and between the Parties, that the Licensor shall own all right, title and interest in and to the Licensed
Intellectual Property and Licensee shall have no rights thereto beyond the licenses granted in Sections 2.1 and 2.2 hereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>Ownership of Improvements to Licensed Intellectual Property</U>. Licensee
acknowledges and agrees, by and between the Parties, that Licensor shall own all right, title and interest in and to any improvements in the Licensed Intellectual Property regardless of which Party contributed to the improvements. Licensor agrees to
grant to Licensee and its Affiliates an exclusive, non-transferable license, limited to the Licensed Territory and Field of Use, to any such improvements in the Licensed Intellectual Property in accordance with the same terms and conditions that
apply to the licensed Intellectual Property. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Prosecution and Maintenance of Intellectual Property. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Prosecution and Maintenance of Licensed Intellectual Property</U>. The Licensor shall prosecute and maintain the Licensed
Intellectual Property. The Licensor shall be responsible for all costs, fees and other expenses related to such prosecution and maintenance (including, without limitation, outside counsel fees, patent, trademark and copyright office fees, annuities
and maintenance fees) with respect to any Licensed Intellectual Property. The Licensor shall file, prosecute and maintain the Licensed Intellectual Property, at the Licensor&#146;s sole cost. The Licensor shall keep Licensee advised as to all
material developments with respect to all registrations and applications filed, prosecuted and maintained under this Section&nbsp;5.1. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>6. Product Development and Clinical Trials. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Costs and
Participation</U>. Licensor shall be responsible for all product development costs and all costs for clinical trials, and recruit enough patients for filing with Regulatory Authorities in the Licensed Territory. Licensee shall advise on regulatory
aspects related to clearance of the sale of any Licensed Product in the Licensed Territory and Licensee shall participate in Phase III clinical trials in the Licensed Territory at sites mutually agreed upon by the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>Information and Data used for Regulatory Purposes</U>. Licensor shall deliver to Licensee documents, information and data which
are and will remain in Licensor&#146;s possession and owned or controlled by Licensor and its Affiliates, which Licensor deems may be reasonably needed by Licensee in developing, registering, and marketing the Licensed Product in the Licensed
Territory. During the term of this Agreement, Licensor shall from time to time inform Licensee of new information which Licensor may deem to be useful for Licensee in the development and sale of the Licensed Product in the Licensed Territory.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Cost and Supply of Licensed Product. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>Cost</U>. Licensor shall supply Licensee with Licensed product known as the commercial product NeuVax (E75 peptide in combination with GM-CSF) as a packaged finished product at a price not to
exceed <B><U>[***]</U></B> U.S. dollars ($<B><U>[***]</U></B>) per dose under the terms of a Supply Agreement to be agreed upon by both Parties after the Licensed Product NeuVax is approved for sale in the Licensed Territory. This price can be
adjusted for inflation on an annual basis based on rates set by the U.S. Bureau of Labor Statistics. If an adjuvant biologically similar to GM-CSF becomes available and approved to be packaged with E75, Licensor will supply such packaged product to
Licensee at Licensor&#146;s cost plus <B><U>[***]</U></B> (<B><U>[***]</U></B>%) of Licensor&#146;s costs, provided that the sale of the commercial product NeuVax has been launched by Licensee in the Licensed Territory for a period of at least five
(5)&nbsp;years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>Supply</U>. Licensor agrees to supply Licensee with the Licensed Product having more than 90% of shelf
life remaining, within 3 months after its acceptance of the orders. Licensor shall guarantee the Licensed Product was manufactured in a qualified GMP facility of Licensor or any of its subcontractors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Representations, Warranties and Covenants. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1 <U>Representations and Warranties</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The Licensor&#146;s Representations and Warranties. The Licensor represents and warrants as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) The Licensor has all necessary legal power, right and authority to enter into and perform its obligations under this Agreement and has taken all necessary corporate action under the laws of the State
of Delaware and its certificate of incorporation and bylaws to authorize the execution of this Agreement and the consummation of the transactions contemplated hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) No Claim has been brought or is threatened by any third party with respect to any Licensed Intellectual Property that alleges that such Licensed Intellectual Property Infringes the rights of any
third party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) The Licensor has not threatened or initiated any Claim against any third party alleging that such third
party Infringes any Licensed Intellectual Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) The Licensor has taken all reasonable measures to protect and
preserve the security, confidentiality and value of all Licensed Intellectual Property, including, without limitation, trade secrets and other Confidential Information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(v) The Licensor has not previously granted any rights to any third party that are inconsistent with the rights granted to Licensee under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Licensee&#146;s Representations and Warranties. Licensee represents and warrants that Licensee has all necessary legal power to
enter into and perform its obligations under this Agreement and has taken all necessary corporate action under all applicable Korean laws and its certificate of incorporation and bylaws to authorize the execution of this Agreement and the
consummation of the transactions contemplated hereunder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Covenants</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Licensor&#146;s Covenants. The Licensor covenants as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The Licensor will comply with all applicable laws and regulations with respect to the Licensed Intellectual Property, the Licensed
Products, and this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) The Licensor will take every reasonable action to preserve the security, confidentiality
and value of all Licensed Intellectual Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) The Licensor will ensure that all of its employees, consultants, or
agents involved in creation of the Licensed Intellectual Property on behalf of the Licensor shall assign to the Licensor all of their right, title and interest in and to such Licensed Intellectual Property. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) The Licensor will not grant for the Term of this Agreement any rights to any third party that are inconsistent with the rights
granted to Licensee under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) The Licensor will collaborate with the Licensee in good faith if the Licensee
requests any supports for the successful marketing of the Licensed Products in the Licensed Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Licensee&#146;s
Covenants. Licensee covenants that it will comply with all applicable laws and regulations with respect to the Licensed Intellectual Property and the Licensed Products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3 <U>DISCLAIMER</U>. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 8 HEREOF, NO PARTY
MAKES ADDITIONAL WARRANTIES, REPRESENTATIONS, OR COVENANTS EXPRESS, IMPLIED, OR STATUTORY AS TO ANY OTHER MATTER WHATSOEVER. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. Infringement. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.1 <U>Notice of Infringement</U>. Each Party shall immediately notify the other Party in writing of any known or alleged infringement(s) of the Licensed Intellectual Property and the Licensed Products
and shall immediately inform the other Party of any evidence of any such infringement(s). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 <U>Enforcement of Licensed
Intellectual Property</U>. The Licensor shall have the first right, but not the obligation, to enforce any of the Licensed Intellectual Property against any third party. Licensee agrees to join as a party plaintiff in any Claim initiated by the
Licensor if requested by the Licensor, at the sole cost of the Licensor, and Licensee shall provide the Licensor all assistance the Licensor may reasonably request in any such Claim, at the sole cost of the Licensor. In the event that the Licensor
fails or decides not to enforce such Licensed Intellectual Property within thirty (30)&nbsp;days after written notice of such possible infringement, the Licensor shall give Licensee written notice of the decision or failure to take action and
Licensee shall have the right, but not the obligation to undertake such Claim in its own name, on its own behalf, and at its own cost; provided, however, that the Licensor shall join as a party plaintiff in any such Claim initiated by Licensee if
requested by Licensee, at the equal share of the cost of Licensor and Licensee, and the Licensor shall provide Licensee all assistance Licensee may reasonably request in any such Claim, at the equal share of the cost of Licensor and Licensee.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 <U>No Settlement</U>. Notwithstanding anything in this Agreement to the contrary, under no circumstances shall either
Party settle or resolve any Claims of or by the Licensed Intellectual Property and/or the Licensed Products without the express written consent of the other Party, of which such consent shall not be unreasonably withheld, delayed, or conditioned.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Indemnification. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.1 <U>Indemnification by Licensor</U>. The Licensor shall defend, indemnify and hold harmless Licensee Indemnitees from and against any and all Losses which any Licensee Indemnitee may suffer or incur
by reason of: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Any breach by the Licensor of any of its representations, warranties, agreements, or covenants contained
in this Agreement or by the willful misconduct of the Licensor, including, without limitation, by way of any misappropriation, willful misstatement, or fraud on any government authority; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Any third party Claim of harm or injury arising out of, related to, or in connection with a product recall or the manufacture of the
Licensed Products that is attributable to any Licensed Product provided by Licensor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2 <U>Indemnification by Licensee</U>.
Licensee shall defend, indemnify and hold harmless the Licensor Indemnitees from and against any and all Losses, which any Licensor Indemnitee may suffer or incur by reason of: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Any breach by Licensee of its representations, warranties, agreements, or covenants contained in this Agreement or by the willful
misconduct of Licensee, including, without limitation, by way of any misappropriation, willful misstatement, or fraud on any government authority. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3 <U>Indemnification Procedures</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Indemnified Party pursuant to this Article 10 shall promptly notify the Indemnifying Party, in writing, of such Claim describing
such Claim in reasonable detail; provided, however, that the failure to provide such written notice shall not affect the obligations of the Indemnifying Party unless and only to the extent it is actually prejudiced thereby. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Indemnifying Party shall have a right within thirty (30)&nbsp;days after receipt of such written notice to take control, through
counsel of its own choosing (but reasonably acceptable to the Indemnified Party) and at its own cost, the settlement, or defense thereof unless: (i)&nbsp;the Indemnifying Party is also a party to the proceeding and the Indemnified Party determines
in good faith that joint representation would be inappropriate; or (ii)&nbsp;the Indemnifying Party fails to provide reasonable assurance to the Indemnified Party of its financial capacity to defend such proceeding, and provide indemnification with
respect thereto. The Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall not be unreasonably withheld, delayed, or conditioned), settle or compromise any Claim, unless such settlement or compromise
includes an unconditional release of the Indemnified Party. If the Indemnifying Party does not notify the Indemnified Party within thirty (30)&nbsp;days after the receipt of written notice of a Claim of indemnity hereunder that it elects to
undertake the defense thereof, the Indemnified Party shall have the right to contest, settle, or compromise the Claim but shall not pay or settle any such Claim without the consent of the Indemnifying Party (which consent shall not be unreasonably
withheld, delayed, or conditioned). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Indemnifying Party and the Indemnified Party shall cooperate fully in all
aspects of any investigation, defense, pre-trial activities, trial, compromise, settlement, or discharge of any Claim in respect of which indemnity is sought pursuant to this Article 10, including, without limitation, providing the other Party with
reasonable access to employees and officers (including, without limitation, as witnesses) and other information. The remedies provided in this Article 10 shall not be exclusive of or limit any other remedies that may be available to the Indemnified
Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Indemnifying Party shall reimburse the Indemnified Party for all Losses within five (5)&nbsp;days of
receipt of written notice from the Indemnified Party setting forth the amount of such Losses. The Indemnified Party shall also have a right to offset such Losses against any payment due to the Indemnifying Party. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Confidential Information. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.1 <U>Confidential Information Generally</U>. The existence and terms and conditions of this Agreement are confidential, and neither Party may make any disclosures regarding this Agreement without the
express prior written consent of the other Party, except: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) As may be required by law or legal process; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) During the course of litigation so long as the disclosure of such terms and conditions are restricted in the same manner as is the
confidential information of other litigating parties and so long as: (i)&nbsp;the restrictions are embodied in a court-entered protective order; and (ii)&nbsp;the Disclosing Party informs the Receiving Party in writing in advance of the disclosure;
or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In confidence to its legal counsel, accountants, banks and financing sources and their advisors solely in connection
with complying with financial transactions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2 <U>Restrictions on Confidential Information</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Receiving Party agrees not to disclose any Confidential Information of the Disclosing Party and to maintain such Confidential
Information in strictest confidence, to take all reasonable precautions to prevent its unauthorized dissemination and to refrain from sharing any or all of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
information with any third party for any reason whatsoever except as required by court order, both during and after the Term of this Agreement. Without limiting the scope of this duty, the
Receiving Party agrees to limit its internal distribution of the Confidential Information of the Disclosing Party only on a &#147;need to know&#148; basis solely in connection with the performance of this Agreement, and to take steps to ensure that
the dissemination is so limited. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Receiving Party agrees not to use the Confidential Information of the Disclosing
Party for its own benefit or for the benefit of any third party other than in accordance with the terms and conditions of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) All the Licensor&#146;s Confidential Information remains the sole property of the Licensor and all Licensee&#146;s Confidential Information remains the sole property of Licensee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Upon written request of the Disclosing Party, or upon the expiration or other termination of this Agreement for any reason
whatsoever, the Receiving Party agrees to return to the Disclosing Party all such provided Confidential Information, including, without limitation, all copies thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.3 <U>Survival</U>. The obligations set forth in this Article 11 shall apply throughout the Term of this Agreement and for a period of five (5)&nbsp;years after the termination or expiration of this
Agreement or any extensions hereof. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Term and Termination. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1 <U>Term</U>. This Agreement shall commence on the Effective Date, and, unless extended by the mutual written agreement of the Parties
(and then only upon the terms and conditions set forth herein) or sooner terminated in accordance with Section&nbsp;12.2 hereof, shall continue for a period of 15 years from the launch of the sale of any Licensed Product in the Licensed Territory or
until the expiration or invalidation of the last valid claim in the Licensed Intellectual Property in the Licensed Territory, whichever occurs later (the &#147;<B>Term</B>&#148;). This Agreement shall be automatically renewed thereafter on a yearly
basis, unless terminated pursuant to the terms of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2 <U>Early Termination</U>. Upon the occurrence of any
of the following, this Agreement may be terminated by: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Either Party immediately upon written notice to the other Party
if the other Party breaches any material provision of this Agreement and such breach is: (i)&nbsp;incapable of cure; or (ii)&nbsp;capable of cure, but not cured within ninety (90)&nbsp;days of the breaching Party&#146;s receipt of written notice of
such default from the non-breaching Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Either Party immediately upon the Bankruptcy of the other Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Licensor immediately if Licensee does not pay the Consideration as described in Article 3 hereof within ninety (90)&nbsp;days of
the Licensor&#146;s written notice of such non-payment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Licensee if no Licensed Product is approved for sale in the
Licensed Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Mutual written agreement of the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3 <U>Effect of Early Termination:</U> Upon expiration or early termination of this Agreement by the Licensor or Licensee pursuant to
Section&nbsp;12.2 hereof, the rights granted hereunder shall immediately terminate; provided, however, that Licensee shall be permitted to use the Licensed Intellectual Property for a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
period of three (3)&nbsp;months to complete deliveries on contracts in force as of the date of termination, to sell and to otherwise dispose of any existing inventory of the Licensed Products
provided under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4 <U>Survival</U>. Expiration or early termination of this Agreement shall not relieve
either Party of its obligations incurred prior to the expiration or early termination. The following provisions shall survive expiration or early termination of this Agreement or of any extensions thereof for a period of five (5)&nbsp;years or for
such period of time as indicated in the surviving provision: Sections 4, 8, 10, 11, 13 hereof, Section&nbsp;12.3 hereof and this Section&nbsp;12.4. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>13. Miscellaneous. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1 <U>Notices</U>. All notices, requests, demands and
other communications required to or permitted to be given under this Agreement shall be in writing and shall be conclusively deemed to have been delivered: (a)&nbsp;when hand delivered to the other Party; (b)&nbsp;when received when sent by
facsimile at the address and number set forth below (provided, however, any notice given by facsimile shall be deemed received on the next business day if such notice is received after 5:00 p.m. recipient&#146;s time, or on a non-business day);
(c)&nbsp;three (3)&nbsp;business days after the same have been deposited in a United States post office with first class or certified mail return receipt requested postage prepaid and addressed to the Parties as set forth below; or (d)&nbsp;the next
business day after the same have been deposited with a nationally recognized overnight delivery service (i.e., Federal Express, DHL, or United Parcel Service) postage prepaid, addressed to the Parties as set forth below with next business-day
delivery guaranteed. For the purposes of this Agreement, the delivery addresses of the Parties are: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Licensor:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Apthera, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8418 E. Shea Boulevard </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 100 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scottsdale, Arizona 85260 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">USA </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Robert E. Kennedy, CFO </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone: (480) 348-9705 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Facsimile: (480) 348-9709 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to Licensee: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwangdong Pharmaceutical Co., Ltd. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1577-4 Seocho-Dong </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Seoul, Republic of Korea </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: [Bo Hyung Lee, Director] </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Phone: [82-2-2025-1360] </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: [82-2-2025-1350] </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Party shall make an ordinary, good faith effort to ensure that it will accept or receive notices that are given in accordance with
this Section&nbsp;11.1, and to ensure that the receiving Party actually receives such notice. A Party may change or supplement the addresses given above, or designate additional addresses by giving the other Party written notice of the new address
in the manner set forth above. Any correctly addressed notice that is refused, unclaimed, or undeliverable because of an act or omission of the Party to be notified shall be deemed effective as of the first date that said notice was refused,
unclaimed, or deemed undeliverable by the postal authorities, messenger, or overnight delivery service. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2 <U>Entire
Agreement</U>. This Agreement, together with any exhibits and schedules attached hereto and incorporated herein by this reference, and any other agreements entered into pursuant to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
this Agreement, constitute the entire agreement between the Parties pertaining to the subject matter contained herein, and supersede all prior or contemporaneous agreements, representations and
understandings of the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or remedy
accruing to either Party upon any breach or default under this Agreement shall impair any such right, power, or remedy of such Party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any
similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent, or approval of any kind or
character on the part of either Party of any breach or default under this Agreement, or any waiver on the part of either Party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent
specifically set forth in such writing or as provided in this Agreement. All remedies, either under this Agreement or by law or otherwise afforded to either Party, shall be cumulative and not alternative. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4 <U>Severability</U>. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision
hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the Parties intend that there shall be added as a part of
this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible to be valid and enforceable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.5 <U>Governing Law</U>. This Agreement shall be governed by, and construed and enforced in accordance with the internal laws of the State of Arizona without regard to its conflict of laws provisions.
The Parties expressly and irrevocably consent to the exclusive personal jurisdiction and venue of the federal courts sitting within the County of Maricopa, Arizona, unless no federal subject matter jurisdiction exists, in which case the Parties
consent to the exclusive jurisdiction and venue in the Superior Court of Maricopa County, Arizona. The Parties expressly waive all defenses of lack of personal jurisdiction and forum non conveniens with respect to the federal and state courts
sitting within the County of Maricopa, Arizona. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6 <U>Commercial Impracticability</U>. No Party shall be liable for any
failure to perform its obligations in connection with any action described in this Agreement, only if such failure directly results from and is caused by any act of God, riot, war, terrorist attack, civil unrest, flood, earthquake, or other causes
beyond such Party&#146;s reasonable control, excluding a Party&#146;s financial condition or negligence. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7 <U>Successors
and Assigns; No Third Party Beneficiaries</U>. Neither this Agreement nor any of the rights or obligations arising under this Agreement may be assigned or transferred by either Party, in whole or in part, without the prior written consent of the
other Party, and any attempted assignment or transfer without such written consent shall be of no force or effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.8
<U>Entire Agreement; Amendment</U>. Neither this Agreement nor any term hereof may be amended, waived, discharged, or terminated other than by a written instrument signed by the Party against whom enforcement of any such amendment, waiver,
discharge, or termination is sought. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.9 <U>Construction; Headings</U>. The article, section and subsection headings in this
Agreement are inserted for convenience only and will not affect in any way the meaning or interpretation of this Agreement. The language of this Agreement shall be construed simply and according to its fair meaning, and shall not be construed for or
against any Party hereto as a result of the source of its draftsmanship. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.10 <U>Counterparts</U>. This Agreement may be
executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one instrument. Signatures transmitted electronically or by facsimile will be deemed original signatures. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.11 <U>Independent Contractor</U>. Each Party is an independent contractor and is not and
shall not be deemed to be the legal representative or agent of the other Party for any purpose whatsoever, and neither Party is authorized by the other Party to transact business, incur obligations (express or implied), bill goods, or otherwise act
in any manner, in the name or on behalf of the other Party, or to make any promise, warranty, or representation in the name or on behalf of the other Party except as permitted in this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.12 <U>Injunctive Relief and Equitable Relief</U>. The Parties acknowledge that a breach of any of the provisions set forth in Article
11 hereof shall result in irreparable and continuing damage for which there shall be no adequate remedy at law, and the non-breaching Party shall be entitled to injunctive relief and/or a decree for specific performance, and such other relief as may
be proper (including, without limitation, monetary damages if appropriate). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.13 <U>Further Assurances</U>. Each Party
hereto shall promptly execute and deliver such further instruments and take such further actions as any other Party hereto may reasonably require or request in order to carry out the intent of this Agreement and to consummate the transactions
contemplated hereby. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[The remainder of this page has been intentionally left blank; signature page follows.] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the Effective
Date. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APTHERA, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Robert E. Kennedy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert E. Kennedy</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 22, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>KWANGDONG</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PHARMACEUTICAL CO., LTD.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Soo Boo Choi</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soo Boo Choi</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 30, 2009</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Non-Disclosure Agreement </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT (hereinafter referred to as &#147;Agreement&#148;), effective as of the 2nd day of April, 2009 (the
&#147;Effective Date&#148;), is made by and between: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Kwangdong Pharmaceutical Co., Ltd.</B>, a Korean corporation having its principal
offices at 1577-4 Seocho-Dong, Seoul, Republic of Korea, hereinafter referred to as &#147;COMPANY&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Apthera, Inc.</B>, a Delaware corporation having its principal place of business at 8418 Shea Blvd., Suite 100, Scottsdale, Arizona 85260-6667,
hereinafter referred to as &#147;Apthera&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hereinafter sometimes individually referred to as &#145;Party&#146; and collectively as
&#145;Parties&#146;. The party disclosing the Information shall hereinafter referred to as the &#145;Disclosing Party&#146; and the party receiving such Information shall be referred to as the &#145;Receiving Party&#146; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESSETH </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, Apthera and COMPANY
wish to discuss a potential business, scientific and/or technical relationship between them (hereinafter referred to as the &#147;Purpose&#148;); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, during the course of such discussions, it may become desirable or necessary for the Parties hereto to disclose to each other certain technical, commercial or business information of a
proprietary or confidential nature (hereinafter referred to as &#147;Confidential Information&#148;); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, Parties hereto are
willing to provide for the conditions of such disclosure of Confidential Information and the rules governing the use and the protection thereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NOW, THEREFORE</B>, Apthera and COMPANY, intending to be legally bound, hereby agree as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">As used in this Agreement the term &#147;Confidential Information&#148; shall mean all information including, where appropriate and without limitation, licenses,
business plans and data (including financial, manufacturing, marketing, operations and strategic information), other data (including engineering, scientific and technical information), patent disclosures, patent applications, unpublished findings,
know how, techniques, processes, structures, methods, models, specifications, designs, drawings, algorithms, formulae, programs, samples, compositions, biological material, and compounds relating to the same disclosed by the Disclosing Party to the
Receiving Party or obtained by the Receiving Party through observation or examination of information or any means of disclosing such Proprietary Information that the Disclosing Party hereto may select to use during the life of this Agreement, but
only to the extent that such information is maintained as confidential by the Disclosing Party and is marked or otherwise identified as &#147;Confidential&#148; when disclosed to the Receiving Party. In the case of information given verbally, such
Confidential Information must be reduced to written form within 30 days of disclosure and likewise marked &#147;Confidential&#148;. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the period in which this Agreement is effective and also during the period stated in Section&nbsp;13 below, each Party is obliged to treat all Confidential
Information supplied or disclosed by the Disclosing Party as strictly confidential and secret. Each Party shall use such Confidential Information only for the Purpose and shall safeguard any such Confidential Information as it safeguards its own
confidential information and shall refrain from unauthorized use by or disclosing it to third parties or disclosing it in any other way. Furthermore, Parties will ensure every reasonable precaution to prevent the unauthorized disclosure of said
Confidential Information. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parties may only disclose or reveal the Confidential Information to the minimum number of employees of Parties who have a need to know and solely for the Purpose or,
with prior written approval of the Disclosing Party, to the minimum of employees of companies associated with the other Party or its advisors who are actually engaged in the execution of activities requiring access to the Confidential Information,
on the condition that the Receiving Party has in force an appropriate confidentiality agreement with such advisors and associated company and their employees have signed appropriate agreements requiring them to treat the Confidential Information as
strictly confidential, and treat such Confidential Information in accordance with this Agreement. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Confidential Information of each Party, or any part thereof, whether capable of being copyrighted, patented, or otherwise registered by law, or not, is for the
purpose of this Agreement acknowledged by the Receiving Party as being the sole property of the Disclosing Party. Upon termination or expiration as set forth in Section&nbsp;13 below, or at such earlier time as it appears that the Confidential
Information is no longer required, each Party shall, at its own expense, return to the other Party the originals and all copies of such Confidential Information within a reasonable time or, if requested by the Disclosing Party, shall destroy or
return the originals and all copies of such Confidential Information and certify to the destruction or return in writing within thirty (30)&nbsp;days of the request thereto. Notwithstanding any contrary foregoing provision, the Receiving Party may
retain one copy of Confidential Information in a secure location with appropriately restricted access for evidentiary purposes. The parties acknowledge that it may not be feasible to remove copies of information in electronic systems, such as email
and system archives and certain electronic media, and their continued presence shall not be a breach of this obligation so long as such copies are treated as confidential. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Receiving Party shall not analyze, copy, reverse engineer, or otherwise attempt to derive the composition or underlying information of any Confidential Information.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Receiving Party shall have no obligations or restrictions with respect to any Confidential Information, which the Receiving Party can prove:
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">is or has become publicly and generally available or ascertainable prior to, or after the disclosure thereof and in such case through no wrongful act of the Receiving
Party; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">is already known to the Receiving Party, as evidenced by written documentation in its files; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">has been lawfully received at any time from a third party that the Receiving Party reasonably believes possesses such information lawfully and has the right to disclose
such information; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">has been or is published without violation of this Agreement; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">e.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">is independently developed in good faith by employees of the Receiving Party who did not have access to, nor had knowledge of the Confidential Information; or
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">f.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">is approved for release or use by written authorization of the Disclosing Party; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">g.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">is required to be disclosed by applicable law, regulations or order of a governmental authority, agency or court of competent jurisdiction provided that the Receiving
Party takes reasonable steps to avoid disclosure or minimize its extent and promptly notifies the other Party of such order to provide that Party sufficient time to seek a protective order or other remedy to protect such Confidential Information.
The Receiving Party may disclose only the minimum Confidential Information required to be disclosed, whether or not a protective order or other remedy is in place. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Confidential Information shall not be deemed to be within one of the foregoing
exceptions merely because it is embraced by more general information within the exception. In addition, any combination of features shall not be deemed to be within one of the foregoing exceptions merely because individual features are within the
exception but only if the combination itself is within the exception. The Receiving Party shall have the burden of proof in establishing any of the above-mentioned exceptions. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nothing contained in this Agreement shall be construed as granting or conferring any rights by license or otherwise to the Receiving Party, expressed or implied, for
any patent, trademark, copyright, know-how, invention or other intellectual property, discovery or improvement prior to or after the date of this Agreement, whether or not related to the subject matter of the Agreement. All Confidential Information
disclosed by one Party to the other shall remain the intellectual property of the Disclosing Party. Furthermore while each Party hereto agrees to act in good faith in disclosing information, which is accurate and adequate for the purpose set forth
herein, neither Party provides any warranty as to the accuracy and completeness of the information disclosed by it hereunder. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nothing in this Agreement may be construed as compelling either Party hereto to disclose any Confidential Information to the other, or to enter into any further
contractual relationship relating to the subject matter of this Agreement. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Party hereto, to the extent of its right to do so, shall disclose to the other Party only such Confidential Information, which the Disclosing Party deems
appropriate to fulfill the objectives of this Agreement. Any information or data in whatever form disclosed by either Party hereto to the other shall be subject to the relevant terms and conditions of this Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Receiving Party shall be liable to Disclosing Party for any and all damages suffered by Disclosing Party arising out of or in relation to any breach of the
Receiving Party undertakings herein. The Receiving Party understands that any violation of this Agreement may cause immediate and irreparable harm to the Disclosing Party, which monetary damages cannot adequately remedy. Without prejudice to rights
and remedies available to the Disclosing Party, Receiving Party agrees that injunctive relief may be sought against it, in order to remedy, or to prevent a violation hereof. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For each and every breach of this Agreement the Disclosing Party shall have the right to seek specific performance and other injunctive and equitable relief.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The execution, existence and performance of this Agreement shall be kept confidential by the Parties hereto and shall not be disclosed by either Party without the prior
written consent of the other. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration of the Purpose, Parties shall exchange Confidential Information within one (1)&nbsp;year of signing this Agreement. That if, on whatever grounds, an
agreement between Parties would not be entered into, this Agreement shall be terminated automatically after one (1)&nbsp;year and the obligations set forth in this Agreement are continuing and shall survive the termination of any discussions,
evaluations, negotiations or this Agreement and remain in full effect for a period of five (5)&nbsp;years from the date of termination. In the event the Parties enter into an agreement related to the Purpose, this Agreement shall continue in full
effect until the longer of one (1)&nbsp;year of signing this Agreement or the expiration of such agreement related to the Purpose, and the obligations set forth in this Agreement are continuing and shall survive the termination of this Agreement and
remain in full effect for a period of five (5)&nbsp;years from the date of termination. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Agreement shall be governed by and construed in accordance with the laws of the State of Arizona, USA, without regard to the conflict of law principles thereof.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the terms of this Agreement shall be amended or modified except in writing and signed by persons authorized to bind Parties. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement shall be binding upon and inure to the benefit of each of the Parties, their successors, legal representatives, and assigns. A Party may assign this
Agreement only to a successor of that Party to that portion of its business relating to the subject matter of this Agreement and only after written approval of the contracting Party under this Agreement. However, such assignment shall not relieve
said Party of any of the obligations of confidentiality set forth above. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement may be rendered effective through facsimile or other electronic transmission and/or may be executed in counterparts, each of which shall be deemed an
original, and all of which together shall constitute one and the same instrument. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF</B>,
the Parties hereto have executed this Agreement as of the Effective Date. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">APTHERA, INC.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwangdong Pharmaceuticals, Co., Ltd.</FONT></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Robert E. Kennedy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Bo-Hyung Lee</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert E. Kennedy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bo-Hyung Lee</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CFO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, Business Development</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT B </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Licensed Intellectual Property </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>PATENTS </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Issued Patents</U> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Patent&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Patent</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jurisdiction</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing&nbsp;<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Date</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,514,942</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods And Compositions For Stimulating T-Lymphocytes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/95</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,096,313</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compositions Containing Immunogenic Molecules and Granulocyte-Macrophage Colony Stimulating Factor, as an Adjuvant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/9/96</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Pending Patent Applications</U> </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:70pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Application Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Patent</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jurisdiction</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing&nbsp;Date</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/507,009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Controlled modulation of amino acid side chain length of peptide antigens</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/28/05</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">60/941,524</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vaccine for the Prevention of Breast Cancer Relapse</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/07</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PCT/US08/60044</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vaccine for the Prevention of Breast Cancer Relapse</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PCT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/11/08</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>TRADEMARKS</U> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">U.S. Serial No. 77/107,771 filed February&nbsp;14, 2007 for the mark &#147;NEUVAX&#148;. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>7
<FILENAME>d275067dex1046.htm
<DESCRIPTION>AMENDMENT NO. 1 TO LICENSE AGREEMENT, DATED JANUARY 13, 2012
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 1 to License Agreement, dated January 13, 2012</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.46 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDMENT NO. 1 TO LICENSE AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Amendment No.&nbsp;1 to License
Agreement (this &#147;<U>Amendment</U>&#148;) is made as of January&nbsp;13, 2012, by and among Apthera, Inc., a Delaware corporation (&#147;<U>Licensor</U>&#148;), Kwangdong Pharmaceutical Co., Ltd., a company incorporated in Korea
(&#147;<U>Licensee</U>&#148;), and Galena Biopharma, Inc., a Delaware corporation (&#147;<U>Galena</U>&#148;), with reference to the following facts: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Licensor and Licensee previously entered into a License Agreement, effective as of April&nbsp;30, 2009 (the &#147;<U>License Agreement</U>&#148;), in connection with Licensor&#146;s grant to
Licensee of a license to the Licensed Intellectual Property; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Licensor is a wholly-owned subsidiary of Galena; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Licensor and Licensee wish to amend the License Agreement in certain respects as provided in this Amendment.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the foregoing and other consideration, the receipt and sufficiency of which hereby are
acknowledged, the parties hereto hereby agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Definitions</U>. Capitalized terms not defined in this
Amendment shall have the meanings attributed to such terms in the License Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Amendment</U>. Section&nbsp;3.1(b)
of the License Agreement is hereby amended and restated in its entirety to read as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;a four
hundred thousand U.S. dollar ($400,000) investment to be paid within thirty (30)&nbsp;days from the date that the first patient is dosed in a Phase III Clinical Trial, with such investment to be made in shares (the &#147;<U>Shares</U>&#148;) of
Galena common stock, par value $0.0001 per share (the &#147;<U>Common Stock</U>&#148;), at a price per share equal to the greater of (i)&nbsp;the closing sale price of the Common Stock as reported on the NASDAQ Capital Market (or if not then trading
on the NASDAQ Capital Market, the closing sale price of the Common Stock on the stock exchange or over-the-counter market on which the Common Stock is principally trading on such date) on the first full trading day after Galena first issues a press
release announcing that the first patient was dosed in a Phase III Clinical Trial, or (ii)&nbsp;$0.65. Notwithstanding anything to the contrary herein, if Galena issues the foregoing press release prior to market open (i.e., 9:30 a.m. EST) on a
trading day, then the closing sale price of the Common Stock on that trading day will apply for purposes of (i)&nbsp;of this Section&nbsp;3.1(b).&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3. <U>Issuance of the Shares</U>. Upon issuance in accordance with the terms of this Amendment, the Shares will be duly authorized, validly issued, fully paid and non-assessable. For its clarity, Galena
shall issue the Shares as afore-mentioned subject to the terms of this Amendment and the License Agreement and it shall cause the certificates representing the Shares to be delivered to Licensee. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Representations, Warranties and Agreements of Licensee</U>. Licensee represents and
warrants to, and agrees with, Licensor and Galena as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Licensee will acquire the Shares for its own account, for
investment purposes only. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Licensee understands that the Shares will not upon issuance thereof be registered under the
Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), or under any state securities laws. Licensee is familiar with the provisions of the Securities Act and Rule 144 thereunder and understands that the restrictions on transfer
placed on Shares may result in Licensee being required to hold the Shares for an indefinite period of time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Licensee
agrees not to sell, assign, transfer or otherwise dispose of, with or without consideration (&#147;<U>Transfer</U>&#148;), any of the Shares except pursuant to an effective registration statement under the Securities Act or an exemption from
registration. As a further condition to any such Transfer, except in the event that such Transfer is made pursuant to an effective registration statement under the Securities Act, if in the reasonable opinion of counsel to Galena any Transfer of the
Shares by the contemplated transferee thereof would not be exempt from the registration and prospectus delivery requirements of the Securities Act, the contemplated transferee may be required to furnish Galena with an investment letter setting forth
such information and agreements as may be reasonably requested by Galena to verify the Transfer&#146;s compliance with the registration provisions of the Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5. <U>Lock-Up</U>. Licensee agrees that, without the prior written consent of Galena, it will not, during the period commencing on the date the Shares are issued to Licensee and ending on the first
anniversary of such date: (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of,
directly or indirectly, any of the Shares or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Shares, whether any such transaction described in
clause&nbsp;(i) or (ii)&nbsp;above is to be settled by delivery of the Common Stock or such other securities, in cash or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6. <U>Compliance and liability of Galena and Licensor</U>. Galena shall have Licensor comply with all of the terms and conditions of this Amendment and License Agreement and Galena and Licensor shall be
jointly and severally liable for the fulfillment of this Amendment as well as License Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>No Other Changes to
the License Agreement</U>. Except as expressly amended by this Amendment, all of the terms of the License Agreement shall remain in full force and effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8. <U>Execution in Counterparts</U>. This Amendment may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute but one and the same
instrument. Counterpart signature pages to this Amendment may be delivered by facsimile or electronic delivery (<I>e.g</I>., by email of a PDF signature page) and each such counterpart signature page will constitute an original for all purposes.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[<I>Signature page follows</I>] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first set
forth above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">APTHERA, INC.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">KWANGDONG PHARMACEUTICAL CO., LTD.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sung Won Choi</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sung Won Choi</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>8
<FILENAME>d275067dex1047.htm
<DESCRIPTION>SEPARATION AND TRANSITION AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Separation and Transition Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.47 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">THIS SEPARATION AND TRANSITION AGREEMENT is entered into as of September&nbsp;24, 2011 by and among the Parties. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>R E C I T A L S </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Employee is currently employed as the Chief
Scientific Officer of RXi pursuant to the Existing Employment Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, it is proposed that Employee be employed in
the same capacity by RNCS, Inc., a Delaware corporation and wholly owned subsidiary of RXi (&#147;<U>RNCS</U>&#148;), in connection with the transactions contemplated by the Definitive Agreements; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, in order to facilitate the transactions contemplated by the Definitive Agreements, the Parties wish to terminate and
Employee&#146;s employment with RXi in conjunction with her new employment by RNCS; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Employee wishes to resign
voluntarily her employment with RXi in order to accept her new employment with RNCS. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>AGREEMENTS </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the foregoing and the mutual promises contained in this Agreement, the Parties agree as follows:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Definitions</U>. Unless otherwise defined herein, capitalized terms used herein shall have the meanings set forth in the Existing Employment Agreement. Certain other
capitalized terms used herein shall have the meanings indicated in paragraph&nbsp;7. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Termination of Employment</U>. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee hereby resigns voluntarily as of the Effective Date; as such, the Term of the Employee&#146;s employment under the Existing Employment Agreement shall
terminate on the Effective Date, except that the provisions of the Existing Employment Agreement that by the terms thereof are to continue beyond the Term of such employment shall not be affected by this Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Transition Arrangements</U>. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration of Employee&#146;s entering into the New Employment Agreement, RXi shall pay Employee the following compensation in lieu of any other compensation or
benefits under the Existing Employment Agreement, or otherwise: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Within three business days following the Effective Date, RXi shall (i)&nbsp;pay Employee $50,000 in cash and (ii)&nbsp;issue to Employee under RXi&#146;s 2007 Incentive
Plan $50,000 of shares of RXi common stock valued for this purpose at the closing price of RXi common stock as reported on The NASDAQ Capital Market on the Effective Date. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 1 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent it shall not have done so previously, within three business days following the Effective Date, RXi shall pay Employee any accrued and unpaid Base Salary
as of the Effective Date. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee acknowledges and agrees that any and all accrued and unpaid vacation pay and other paid time off of Employee shall be assumed by RNCS and honored by RNCS under
the New Employment Agreement. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent it shall not have done so previously, upon presentation by Employee after the Effective Date, RXi shall reimburse Employee for any previously unreimbursed
business expenses incurred by her prior to the Effective Date in accordance with RXi&#146;s usual expense reimbursement policies. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the Spin-off Closing, RXi shall grant to Employee under RXi&#146;s 2007 Incentive Plan an option to purchase up to 50,000 shares of RXi common stock
at an exercise price equal to the closing price of RXi common stock as reported on The NASDAQ Capital Market as of the date of the Spin-off Closing and otherwise on the terms set forth in the form of Option Agreement attached hereto as
<U>Exhibit&nbsp;1</U>. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent it shall not have done so previously, RXi shall reimburse Employee, promptly upon presentation by Employee of invoices therefor, for legal services and
disbursements, not to exceed $10,000 in the aggregate, incurred by her in connection with the negotiation and preparation of this Agreement, the New Employment Agreement and the Definitive Agreements, tax and other legal analysis of the transactions
contemplated hereby and thereby and related matters. Additionally, to the extent it shall not have done so previously, RXi shall, upon presentation by Employee of appropriate documentation, reimburse Employee as provided in the Existing Employment
Agreement for her relocation expenses as follows: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing costs on the sale of Employee&#146;s Colorado home up to a maximum of 7% of $500,000 (<U>i.e</U>., $35,000); and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to $20,000 to cover taxes on non-tax-free components of Employee&#146;s relocation package under the Existing Employment Agreement and the foregoing reimbursement.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent it shall not have done so previously, within three business days following the Effective Date, RXi shall pay Employee $5,000 relating to the recent
release by the FDA of the clinical CMC hold on RXi&#146;s NewVax product candidate. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee acknowledges and agrees that the foregoing compensation is all of the compensation and benefits payable or otherwise to be provided to Employee by RXi on and
after the Effective Date in connection with or as a result of Employee&#146;s employment, or termination of her employment, with RXi, and that Employee is not entitled to any other compensation, benefits or perquisites from RXi.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee agrees that all compensation payable under this paragraph&nbsp;3 shall be paid after withholding for taxes that, in RXi&#146;s reasonable good faith judgment,
are required to be withheld by RXi. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>RXi Property</U>. Employee hereby acknowledges and agrees that, to the extent she has not previously done so, and except as RXi may otherwise agree in light of the
ongoing services to be performed by her under the New Employment Agreement, on the Effective Date Employee shall return to RXi all RXi property, including, but not limited to, all keys, credit cards, documents, equipment (including computer and
telephone equipment) files, data, and records of any kind whatsoever that she has, or has had, in her possession or control. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Transition Agreements</U>. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the terms and provisions of this Agreement and Employee&#146;s compliance herewith: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">From and after the Effective Date until the Spin-Off Closing, Employee shall be entitled to continue, at her election, to participate in all group health plans and
other employee benefit plans, including 401(k) plans, generally made available to employees of RXi. Nothing herein, however, shall affect RXi&#146;s right to modify, amend, change or discontinue any such plans at any time. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Release; Further Assurances</U>. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In further consideration of RXi entering into this Agreement, and its promise to make payments and to provide benefits hereunder to which Employee is otherwise not
entitled, Employee shall, concurrently with her execution and delivery of this Agreement, execute and deliver to RXi the Release. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Parties hereby agree to make, execute and deliver such other instruments or documents, and to do or cause to be done such further or additional acts, as may be
reasonably necessary to effectuate the purposes or to implement the terms of this Agreement. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Definitions</U>. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">As used in this Agreement, the following capitalized terms shall have the meanings indicated: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Agreement</B>&#148; means this Separation and Transition Agreement, as it may be amended as provided herein. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Definitive Agreements</B>&#148; means, collectively, the Contribution Agreement between RXi and RNCS and the Agreement between RNCS and Advirna, LLC, an
affiliate of Employee, each dated the date hereof, as they may be amended as provided therein, together with the SPA. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Effective Date</B>&#148; has the meaning set forth in the RNCS Employment Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Employee</B>&#148; means Anastasia Khvorova, Ph.D. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Existing Employment Agreement</B>&#148; means the Employment Agreement, made as of October&nbsp;17, 2008, between Employee and RXi, as amended to date.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>New Employment Agreement</B>&#148; means the Employment Agreement to be entered into between RNCS and Employee on terms mutually satisfactory to RNCS and
Employee. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Parties</B>&#148; means the Employee and RXi, collectively. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>RXi</B>&#148; means RXi Pharmaceuticals Corporation, a Delaware corporation (to be renamed Galena Biopharma, Inc.). </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Release</B>&#148; means the General Release in the form attached hereto as <U>Exhibit&nbsp;2</U>. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>SPA</B>&#148; means the Securities Purchase Agreement among RXi, RNCS, Tang Capital Partners L.P., and RTW Investments, LLC, dated the date hereof, as it may
be amended as provided therein. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Spin-Off Closing</B>&#148; has the meaning set forth in the SPA. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Miscellaneous</U>. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement shall be governed by and construed in accordance with the substantive laws of the State of Massachusetts without regard to any conflict or choice of law
rules that would result in the application of any other state&#146;s law. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Should any provision of this Agreement or any portion hereof, be declared or be determined by any court to be illegal or invalid, the validity of the remaining parts,
terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be automatically conformed to the law, if possible, or deemed not to be part of this Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Parties to this Agreement acknowledge that they have entered into this Agreement voluntarily, without coercion and based upon their judgment and not in reliance
upon any representation or promises made by the other party other than those contained or referred to herein. This Agreement, including Exhibits, incorporates and constitutes the entire agreement among the Parties regarding the subject matter hereof
and supersedes all prior negotiations, understandings and agreements between the Parties hereto with respect to the subject matter hereof. This Agreement may not be modified or cancelled, nor may any provision with respect to it be waived, except in
a writing signed by the Parties. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement shall be binding upon and inure to the benefit of the Parties and their respective heirs, legal representatives, successors and assigns.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page Follows] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Parties have caused this Separation and Transition Agreement to be
executed as of the date first set forth above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Anastasia Khvorova &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">ANASTASIA KHVOROVA, Ph.D.</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi PHARMACEUTICALS CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ACKNOWLEDGED:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">RNCS, INC.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Treasurer</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>d275067dex211.htm
<DESCRIPTION>SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<HTML><HEAD>
<TITLE>Subsidiaries of the Registrant</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 21.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SUBSIDIARIES OF THE REGISTRANT </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:20pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:77pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ownership&nbsp;Percentage</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:96pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jurisdiction&nbsp;of&nbsp;Organization</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Apthera, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delaware</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi Pharmaceuticals Corporation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delaware</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>d275067dex231.htm
<DESCRIPTION>CONSENT OF BDO USA, LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML><HEAD>
<TITLE>Consent of BDO USA, LLP, Independent Registered Public Accounting Firm</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 23.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake Oswego, OR </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (No.333-167025 and No.&nbsp;333-174076 and Forms S-8 (Nos. 333-174819 and No.&nbsp;333-175763) of Galena Biopharma, Inc. of our report dated March&nbsp;28,
2012, relating to the consolidated financial statements which appear in the Annual Report on Form 10-K. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;BDO USA,
LLP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boston, MA </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;28, 2012
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>d275067dex311.htm
<DESCRIPTION>SARBANES-OXLEY ACT SECTION 302 CERTIFICATION OF MARK J. AHN
<TEXT>
<HTML><HEAD>
<TITLE>Sarbanes-Oxley Act Section 302 Certification of Mark J. Ahn</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 31.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Mark J. Ahn, Ph.D., certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this annual report on Form 10-K of Galena Biopharma, Inc.; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#150;15(f) and 15d&#150;15(f)) for the registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal controls over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: March 28, 2012 </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="45%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Mark J. Ahn</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D., President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>d275067dex312.htm
<DESCRIPTION>SARBANES-OXLEY ACT SECTION 302 CERTIFICATION OF CAITLIN KONTULIS
<TEXT>
<HTML><HEAD>
<TITLE>Sarbanes-Oxley Act Section 302 Certification of Caitlin Kontulis</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 31.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Kwang S. Lee, certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this annual report on Form 10-K of Galena Biopharma, Inc.; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#150;15(f) and 15d&#150;15(f)) for the registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal controls over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: March 28, 2012 </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Kwang S. Lee</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee, Vice President, Finance and Chief</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Accounting Officer (Principal Financial Officer)</FONT></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>d275067dex321.htm
<DESCRIPTION>SARBANES-OXLEY ACT SECTION 906 CERTIFICATION OF MARK J. AHN AND CAITLIN KONTULIS
<TEXT>
<HTML><HEAD>
<TITLE>Sarbanes-Oxley Act Section 906 Certification of Mark J. Ahn and Caitlin Kontulis</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 32.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CODE, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to Section&nbsp;1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002, each of the undersigned, as principal executive officer and principal financial officer of Galena Biopharma, Inc. (the &#147;<B>Company</B>&#148;), does hereby certify that to such officer&#146;s knowledge: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) the Company&#146;s Form 10-K for the period ended December&nbsp;31, 2011 fully complies with the requirements of Section&nbsp;13(a) or
15(d) of the Securities Exchange Act of 1934; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) the information contained in the Company&#146;s Form 10-K for the period
ended December&nbsp;31, 2011 fairly presents, in all material respects, the financial condition and results of operations of the Company. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Mark J. Ahn</I></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President
and Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/&nbsp;&nbsp;&nbsp;&nbsp;Kwang S. Lee</I></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice&nbsp;President,&nbsp;Finance&nbsp;and&nbsp;Principal&nbsp;Accounting&nbsp;Officer</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Financial Officer)</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: March 28, 2012 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>14
<FILENAME>rxii-20111231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:rxii="http://rxipharma.com/20111231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="rxii-20111231.xsd" />
  <!-- Context Section -->
  <context id="TwelveMonthsEnded_31Dec2010_Treasury_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_31Dec2006_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-04-04</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_31Dec2006_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-04-04</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2010_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2008_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_31Dec2006_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-04-04</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Treasury_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010_Treasury_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2009_Successor_Member_Treasury_Stock_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2009_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2009_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2008_Treasury_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2008_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2008_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2007_Treasury_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2007_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2007_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Treasury_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Predecessor_Member_Retained_Earnings_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Predecessor_Member_Additional_Paid_In_Capital_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Predecessor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_03Apr2006_Treasury_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-04-03</instant>
    </period>
  </context>
  <context id="BalanceAsOf_03Apr2006_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-04-03</instant>
    </period>
  </context>
  <context id="BalanceAsOf_03Apr2006_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-04-03</instant>
    </period>
  </context>
  <context id="BalanceAsOf_03Apr2006_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-04-03</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2005_Predecessor_Member_Retained_Earnings_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2005_Predecessor_Member_Additional_Paid_In_Capital_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2005_Predecessor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2004_Predecessor_Member_Retained_Earnings_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2004_Predecessor_Member_Additional_Paid_In_Capital_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2004_Predecessor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2003_Predecessor_Member_Retained_Earnings_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2003_Predecessor_Member_Additional_Paid_In_Capital_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2003_Predecessor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2009_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2008_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2007_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2006_Predecessor_Member_Common_Stock_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_03Apr2006_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-04-03</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2005_Predecessor_Member_Common_Stock_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2004_Predecessor_Member_Common_Stock_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2003_Predecessor_Member_Common_Stock_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2011_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2010_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2009_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2008_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2007_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rxii:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2007_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2009_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2007_Common_Stock_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2006_Predecessor_Member_Retained_Earnings_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2006_Predecessor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2005_Predecessor_Member_Retained_Earnings_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2005_Predecessor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2004_Predecessor_Member_Retained_Earnings_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2004_Predecessor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2011_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2009_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2008_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="TwelveMonthsEnded_31Dec2010_Successor_Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SuccessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_26Mar2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2012-03-26</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="Jan-1-2011_Dec-31-2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="Jan-1-2010_Dec-31-2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="Jan-1-2003_Dec-31-2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="USDEPS">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <!-- Element Section -->
  <!--Document Information-->
  <dei:EntityRegistrantName contextRef="Jan-1-2011_Dec-31-2011">Galena Biopharma, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="Jan-1-2011_Dec-31-2011">0001390478</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="Jan-1-2011_Dec-31-2011">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Jan-1-2011_Dec-31-2011">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers contextRef="Jan-1-2011_Dec-31-2011">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus contextRef="Jan-1-2011_Dec-31-2011">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Jan-1-2011_Dec-31-2011">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentType contextRef="Jan-1-2011_Dec-31-2011">10-K</dei:DocumentType>
  <dei:AmendmentFlag contextRef="Jan-1-2011_Dec-31-2011">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate contextRef="Jan-1-2011_Dec-31-2011">2011-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Jan-1-2011_Dec-31-2011">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Jan-1-2011_Dec-31-2011">2011</dei:DocumentFiscalYearFocus>
  <dei:EntityPublicFloat contextRef="BalanceAsOf_30Jun2011" decimals="0" unitRef="USD">41000064</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_26Mar2012" decimals="INF" unitRef="Shares">50493396</dei:EntityCommonStockSharesOutstanding>
  <!-- Instance Elements for BALANCE_SHEETS -->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">11433000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">6891000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">101000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">276000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">150000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">11810000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">7041000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">393000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">419000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">657000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">491000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <rxii:InProcessResearchDevelopment contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">12864000</rxii:InProcessResearchDevelopment>
  <rxii:InProcessResearchDevelopment contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">0</rxii:InProcessResearchDevelopment>
  <us-gaap:Goodwill contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">5898000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">0</us-gaap:Goodwill>
  <us-gaap:DepositsAssetsNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">3000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:DepositsAssetsNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">16000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:Assets contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">30968000</us-gaap:Assets>
  <us-gaap:Assets contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">7476000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">2155000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">724000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">2168000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1113000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">500000</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">0</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">816000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">0</us-gaap:DeferredRevenueCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">35000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">51000</us-gaap:CapitalLeaseObligationsCurrent>
  <rxii:FairValueOfWarrantsPotentiallySettleableInCash contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">3746000</rxii:FairValueOfWarrantsPotentiallySettleableInCash>
  <rxii:FairValueOfWarrantsPotentiallySettleableInCash contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">3138000</rxii:FairValueOfWarrantsPotentiallySettleableInCash>
  <rxii:CurrentContingentPurchasePriceConsideration contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">1782000</rxii:CurrentContingentPurchasePriceConsideration>
  <rxii:CurrentContingentPurchasePriceConsideration contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">0</rxii:CurrentContingentPurchasePriceConsideration>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">11202000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">5026000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">32000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">20000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">-5053000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
  <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
  <rxii:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">4569000</rxii:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
  <rxii:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">0</rxii:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
  <us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">20856000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">5046000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="USD" xsi:nil="true" contextRef="BalanceAsOf_31Dec2011" />
  <us-gaap:CommitmentsAndContingencies unitRef="USD" xsi:nil="true" contextRef="BalanceAsOf_31Dec2010" />
  <us-gaap:PreferredStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" xsi:nil="true" />
  <us-gaap:PreferredStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" xsi:nil="true" />
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" xsi:nil="true" />
  <us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" xsi:nil="true" />
  <us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" xsi:nil="true" />
  <us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" xsi:nil="true" />
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">5000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">2000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">47811453</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">19047759</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">47136453</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">18372759</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">81184000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">62020000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <rxii:DeficitAccumulatedDuringDevelopmentalStage contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">-67228000</rxii:DeficitAccumulatedDuringDevelopmentalStage>
  <rxii:DeficitAccumulatedDuringDevelopmentalStage contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">-55743000</rxii:DeficitAccumulatedDuringDevelopmentalStage>
  <us-gaap:TreasuryStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">3849000</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">3849000</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockShares contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">675000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockShares contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">675000</us-gaap:TreasuryStockShares>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">10112000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">2430000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">30968000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">7476000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!-- Instance Elements for STMNT_INCOME -->
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">10742000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">6046000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">37425000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">866000</rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense>
  <rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">1084000</rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense>
  <rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">3273000</rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense>
  <rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">-70000</rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense>
  <rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">743000</rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense>
  <rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">5993000</rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense>
  <rxii:FairValueOfCommonStockInExchangeForLicensingRights contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-3954000</rxii:FairValueOfCommonStockInExchangeForLicensingRights>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">11538000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">7873000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">50645000</us-gaap:ResearchAndDevelopmentExpense>
  <rxii:GeneralAndAdministrativeExpenses contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">6863000</rxii:GeneralAndAdministrativeExpenses>
  <rxii:GeneralAndAdministrativeExpenses contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">5493000</rxii:GeneralAndAdministrativeExpenses>
  <rxii:GeneralAndAdministrativeExpenses contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">27973000</rxii:GeneralAndAdministrativeExpenses>
  <rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">108000</rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense>
  <rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">718000</rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense>
  <rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">2402000</rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense>
  <rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">73000</rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses>
  <rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">354000</rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses>
  <rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">2205000</rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation>
  <rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">2541000</rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation>
  <rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">9590000</rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">9249000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">8752000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">40319000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">20787000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">16625000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">90964000</us-gaap:OperatingExpenses>
  <rxii:InterestIncome contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">30000</rxii:InterestIncome>
  <rxii:InterestIncome contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">5000</rxii:InterestIncome>
  <rxii:InterestIncome contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">658000</rxii:InterestIncome>
  <rxii:LossOnWarrantExchange contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">900000</rxii:LossOnWarrantExchange>
  <rxii:LossOnWarrantExchange contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">900000</rxii:LossOnWarrantExchange>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">10172000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">4627000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">13937000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">9302000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">4632000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">13695000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">-11485000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">-11993000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-77269000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">-11485000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">-11993000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-77269000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Jan-1-2011_Dec-31-2011" unitRef="USDEPS" decimals="2">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Jan-1-2010_Dec-31-2010" unitRef="USDEPS" decimals="2">-0.67</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Jan-1-2003_Dec-31-2011" unitRef="USDEPS" decimals="2">0</us-gaap:EarningsPerShareBasicAndDiluted>
  <rxii:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Jan-1-2011_Dec-31-2011" unitRef="Shares" decimals="0">36334413</rxii:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <rxii:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Jan-1-2010_Dec-31-2010" unitRef="Shares" decimals="0">17883381</rxii:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!-- Instance Elements for STMNT_CASH_FLOWS -->
  <rxii:NetIncomeLossIncludingOther contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">-11485000</rxii:NetIncomeLossIncludingOther>
  <rxii:NetIncomeLossIncludingOther contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">-11993000</rxii:NetIncomeLossIncludingOther>
  <rxii:NetIncomeLossIncludingOther contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-77269000</rxii:NetIncomeLossIncludingOther>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">163000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">172000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">664000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">-7000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-19000</us-gaap:GainLossOnDispositionOfAssets>
  <rxii:NonCashRentExpense contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">29000</rxii:NonCashRentExpense>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-35000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:ShareBasedCompensation contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">3001000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">4368000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">18858000</us-gaap:ShareBasedCompensation>
  <rxii:LossOnExchangeOfEquityInstruments contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">900000</rxii:LossOnExchangeOfEquityInstruments>
  <rxii:LossOnExchangeOfEquityInstruments contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">900000</rxii:LossOnExchangeOfEquityInstruments>
  <rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">785000</rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants>
  <rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">785000</rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants>
  <rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">108000</rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
  <rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">718000</rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
  <rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">2402000</rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">73000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">354000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">9881000</rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
  <rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">3049000</rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
  <rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">12072000</rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
  <rxii:FairValueOfCommonStockIssuedInExchangeForLicensingRights contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">3954000</rxii:FairValueOfCommonStockIssuedInExchangeForLicensingRights>
  <rxii:ChangeInFairValueOfContingentPurchaseConsideration contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">109000</rxii:ChangeInFairValueOfContingentPurchaseConsideration>
  <rxii:ChangeInFairValueOfContingentPurchaseConsideration contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">109000</rxii:ChangeInFairValueOfContingentPurchaseConsideration>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">99000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">30000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">249000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">500000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">99000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">1224000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-207000</us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">816000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">816000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">1338000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">243000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">2658000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">-14668000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">-10257000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-58778000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">101000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">101000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <rxii:CashReceivedInAcquisition contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">-168000</rxii:CashReceivedInAcquisition>
  <rxii:CashReceivedInAcquisition contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-168000</rxii:CashReceivedInAcquisition>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">5990000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">37532000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">5990000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">37497000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">53000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">106000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">739000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <rxii:CashRefundedPaidForLeaseDeposit contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-45000</rxii:CashRefundedPaidForLeaseDeposit>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">14000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">-106000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-753000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">18615000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">15235000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">64982000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">3849000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">3849000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">254000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">610000</us-gaap:ProceedsFromStockOptionsExercised>
  <rxii:NetProceedsFromExerciseOfCommonStockWarrants contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">150000</rxii:NetProceedsFromExerciseOfCommonStockWarrants>
  <rxii:NetProceedsFromExerciseOfCommonStockWarrants contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">150000</rxii:NetProceedsFromExerciseOfCommonStockWarrants>
  <rxii:CommonStockIssuedInConnectionWithEspp contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">15000</rxii:CommonStockIssuedInConnectionWithEspp>
  <rxii:CommonStockIssuedInConnectionWithEspp contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">15000</rxii:CommonStockIssuedInConnectionWithEspp>
  <rxii:NetProceedsFromIssuanceOfConvertibleNotesPayable contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">-500000</rxii:NetProceedsFromIssuanceOfConvertibleNotesPayable>
  <rxii:NetProceedsFromIssuanceOfConvertibleNotesPayable contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">-500000</rxii:NetProceedsFromIssuanceOfConvertibleNotesPayable>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">84000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">70000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">210000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">8766000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">19196000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">11570000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">70964000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">4542000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">1207000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">11433000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2009" unitRef="USD" decimals="-3">5684000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ProceedsFromInterestReceived contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">2000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:ProceedsFromInterestReceived contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">726000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:InterestPaid contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">6000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">13000</us-gaap:InterestPaid>
  <us-gaap:StockIssued1 contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">978000</us-gaap:StockIssued1>
  <rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">12709000</rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
  <rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">2466000</rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
  <rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">18038000</rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
  <rxii:IssuanceOfCommonStockInExchangeOfOutstandingWarrants contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">3120000</rxii:IssuanceOfCommonStockInExchangeOfOutstandingWarrants>
  <rxii:IssuanceOfCommonStockInExchangeOfOutstandingWarrants contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">3120000</rxii:IssuanceOfCommonStockInExchangeOfOutstandingWarrants>
  <rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">785000</rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant>
  <rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">785000</rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant>
  <rxii:AllocationOfManagementExpenses contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">551000</rxii:AllocationOfManagementExpenses>
  <rxii:EquipmentAndFurnishingsExchangedForCommonStock contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">48000</rxii:EquipmentAndFurnishingsExchangedForCommonStock>
  <us-gaap:FairValueOfAssetsAcquired contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">80000</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:FairValueOfAssetsAcquired contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">53000</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:FairValueOfAssetsAcquired contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">277000</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:CapitalLeaseObligationsIncurred contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">50000</us-gaap:CapitalLeaseObligationsIncurred>
  <rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">427000</rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses>
  <rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses contextRef="Jan-1-2010_Dec-31-2010" unitRef="USD" decimals="-3">207000</rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses>
  <rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">634000</rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses>
  <rxii:FairValueOfSharesIssuedToAcquire contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">6367000</rxii:FairValueOfSharesIssuedToAcquire>
  <rxii:FairValueOfSharesIssuedToAcquire contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">6367000</rxii:FairValueOfSharesIssuedToAcquire>
  <rxii:FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">6460000</rxii:FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition>
  <rxii:FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">6460000</rxii:FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition>
  <rxii:NetAssetsAcquiredExcludingCash contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">12827000</rxii:NetAssetsAcquiredExcludingCash>
  <rxii:NetAssetsAcquiredExcludingCash contextRef="Jan-1-2003_Dec-31-2011" unitRef="USD" decimals="-3">12827000</rxii:NetAssetsAcquiredExcludingCash>
  <rxii:CashExcludingFromNetAssetsAcquired contextRef="Jan-1-2011_Dec-31-2011" unitRef="USD" decimals="-3">168000</rxii:CashExcludingFromNetAssetsAcquired>
  <!-- Begin Block Tagged Note -->
  <us-gaap:NatureOfOperations contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations--&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;
   &lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Nature of Business &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Galena Biopharma Inc. (&amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; &amp;#8220;our,&amp;#8221; &amp;#8220;Galena&amp;#8221; or the &amp;#8220;Company&amp;#8221;)
   is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. Galena is pursuing the development of novel cancer therapeutics using
   peptide-based immunotherapy products, including our main product candidate, NeuVax (E75), for the treatment of various cancers. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company was incorporated as Argonaut Pharmaceuticals, Inc., in Delaware, on April&amp;#160;3, 2006. The Company changed its name to RXi
   Pharmaceuticals Corporation on November&amp;#160;28, 2006. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We acquired Apthera and our NeuVax product candidate in April 2011.
   Prior to that time, we were engaged primarily in conducting discovery research and preclinical development activities based on RNAi. Our acquisition of Apthera followed from the determination by our board of directors to broaden our strategic
   direction by giving us access to a late-stage clinical candidate, NeuVax. In connection with our acquisition of Apthera, we reduced the scope of our RNAi activities to focus primarily on RXI-109, our lead RNAi-product, while maintaining our key
   development alliances and core RNAi discovery and development capability. Following the Apthera acquisition, our board of directors undertook to explore strategic alternatives for our RNAi platform that would enable us to commit more resources to
   our later-stage oncology drug programs. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On September&amp;#160;26, 2011, the Company changed its name from RXi Pharmaceuticals
   Corporation to Galena Biopharma, Inc. in connection with the Company&amp;#8217;s planned separation into two companies: (i)&amp;#160;Galena, which will operate as a late-stage oncology drug development company; and (ii)&amp;#160;RXi Pharmaceuticals Corporation,
   or RXi, which will continue to develop novel RNAi-based therapies utilizing our historical RNAi assets. RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in the
   Company&amp;#8217;s name to Galena. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As the Company has not generated any revenue from inception through December&amp;#160;31, 2011, the
   Company is considered a development-stage company for accounting purposes. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company had cash and cash
   equivalents of approximately $11.4 million as of December&amp;#160;31, 2011. On February&amp;#160;17, 2012, the Company entered into a Controlled Equity Offering&lt;/font&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;sup&gt;
   SM&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:times new roman" size="2"&gt; sales agreement with Cantor Fitzgerald&amp;#160;&amp;#038; Co. (&amp;#8220;Cantor&amp;#8221;), pursuant to which the Company may offer
   and sell from time to time through Cantor, acting as agent, shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to $10 million. The offer and sale of our shares through Cantor will be registered pursuant
   to the Company&amp;#8217;s Registration Statement on Form S-3 (File No.&amp;#160;333-167025) declared effective by the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) on May&amp;#160;21, 2010. The offering pursuant to the sales agreement will terminate
   upon the sale of all shares subject to the sales agreement or the earlier termination of the sales agreement as permitted therein. There is no assurance that additional funding will be available to the Company on acceptable terms, or at all.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company believes that its existing cash and cash equivalents should be sufficient to fund its operations through at least
   the first quarter of 2013. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has not generated revenue to date and may not generate product revenue in the
   foreseeable future, if ever. The Company expects to incur significant operating losses as it advances its product candidates through the drug development and regulatory process. The Company expects to continue to devote a substantial portion of its
   resources to research and development programs. As a result of the costs expected to be incurred in connection with our recently commenced clinical trials of NeuVax and FBP, the Company expects that their research and development expense will
   increase significantly from historic levels for the foreseeable future. The Company will need to generate significant revenue to achieve profitability and might never do so. In the absence of product revenue, our potential sources of operational
   funding are expected to be the proceeds from equity financings, funded research and development payments and payments received under partnership and collaborative agreements. There is no guarantee that additional funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, it
   would be forced to scale back or terminate operations or to seek to merge with or to be acquired by another company. &lt;/font&gt;&lt;/p&gt;
</us-gaap:NatureOfOperations>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Basis of Presentation and Summary of Significant Accounting Policies &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Uses of estimates in preparation of financial statements &lt;/i&gt;&amp;#8212; The preparation of financial statements in
   accordance with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
   liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Principles of Consolidation &lt;/i&gt;&amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned
   subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Cash and Cash Equivalents &lt;/i&gt;&amp;#8212;
   The Company considers all highly-liquid debt instruments with an original maturity of 90&amp;#160;days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Restricted Cash &lt;/i&gt;&amp;#8212; Restricted cash consists of certificates of deposit on hand with the Company&amp;#8217;s financial institutions
   as collateral for its corporate credit cards. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Fair Value of Financial Instruments &lt;/i&gt;&amp;#8212; The carrying amounts reported
   in the balance sheet for cash equivalents, accounts payable, convertible notes payable and capital leases approximate their fair values due to their short-term nature and market rates of interest. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Equipment and Furnishings&lt;/i&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based
   on the estimated useful lives (generally three to five years for equipment and furniture) of the related assets. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Goodwill
   and Intangible Assets &lt;/i&gt;&amp;#8212; Goodwill has an indefinite useful life and is not amortized but is evaluated for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The In-Process Research&amp;#160;&amp;#038; Development (&amp;#8220;IPR&amp;#038;D&amp;#8221;) asset is considered an indefinite-lived intangible asset and is not
   subject to amortization. IPR&amp;#038;D must be tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment test consists of a comparison of the fair value of the
   IPR&amp;#038;D with its carrying amount. If the carrying amount of the IPR&amp;#038;D exceeds its fair value, an impairment loss must be recognized in an amount equal to that excess. After an impairment loss is recognized, the adjusted carrying amount of the
   IPR&amp;#038;D will be its new accounting basis. Subsequent reversal of a previously recognized impairment loss is prohibited. The initial determination and subsequent evaluation for impairment, of the IPR&amp;#038;D asset requires management to make
   significant judgments and estimates. The Company believes no impairment of its IPR&amp;#038;D exists as of December 31, 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The
   Company records intangible assets at historical cost or fair value, if acquired through an acquisition. Intangible assets consist primarily of acquired in process research and development and clinical data that has been generated thereof. Goodwill
   is tested for impairment annually utilizing the &amp;#8220;fair value&amp;#8221; methodology. The annual measurement date is December&amp;#160;31. Factors the Company considers important that could trigger an interim review for impairment include, but are not
   limited to, the following: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;significant changes in the manner of its use of acquired assets or the strategy for its overall business; &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;significant negative industry or economic trends; &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;significant decline in stock price for a sustained period; and &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;significant decline in market capitalization relative to net book value. &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Goodwill is
   evaluated for impairment using a two-step process. The first step is to compare the fair value to the carrying amount (the &amp;#8220;First Step&amp;#8221;). If the carrying amount exceeds the fair value, a second step must be followed to calculate potential
   impairment (the &amp;#8220;Second Step&amp;#8221;). Otherwise, if the fair value exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill, the Company determines
   fair value using the Income Approach, or more specifically the Discounted Cash Flow Method. This valuation method requires management to project revenues, operating expenses, working capital investment, capital spending and cash flows for the
   reporting unit over a multi-year period, as well as determine the weighted average cost of capital to be used as a discount rate. The 2011 analysis confirmed that fair values exceeded carrying values and, therefore, no impairment existed.&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Contingent Consideration &lt;/i&gt;&amp;#8212; Contingent consideration is recorded at the estimated fair value as of the acquisition date. The
   fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of expenses. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Patents and Patent Application Costs &lt;/i&gt;&amp;#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the
   patents is uncertain. Patent costs are, therefore, expensed as incurred. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Share-based Compensation &lt;/i&gt;&amp;#8212; The Company
   follows the provisions of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 718, &amp;#8220;&lt;i&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&amp;#8221; &lt;/i&gt;(&amp;#8220;ASC 718&amp;#8221;), which requires
   the measurement and recognition of compensation expense for all stock based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value
   estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;For
   stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220; &lt;i&gt;Equity Based Payments to Non-
   Employees&lt;/i&gt; .&amp;#8221; Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of
   these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company&amp;#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the
   fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company recognized ($70,000) and $743,000 of stock based compensation expense related to non-employee stock options for the years
   ended December&amp;#160;31, 2011 and 2010, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Derivative Financial Instruments &lt;/i&gt;&amp;#8212; During the normal course
   of business, from time to time, the Company issues warrants and options to vendors as consideration to perform services. It may also issue warrants as part of a debt or equity financing. The Company does not enter into any derivative contracts for
   speculative purposes. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company recognizes all derivatives as assets or liabilities measured at fair value with changes in
   fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with FASB ASC Topic 815-40, &amp;#8220;&lt;i&gt;Derivatives and Hedging&amp;#160;&amp;#8212; Contracts
   in Entity&amp;#8217;s Own Stock,&amp;#8221; &lt;/i&gt;the value of these warrants is required to be recorded as a liability, as the holders have an option to put the warrants back to the Company upon the occurrence of certain events set forth in the warrant
   agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Obligations to Repurchase Shares of the Company&amp;#8217;s Equity Securities &lt;/i&gt;&amp;#8212; In accordance with FASB ASC
   Topic 480-10, &lt;i&gt;&amp;#8220;Distinguishing Liabilities from Equity,&amp;#8221;&lt;/i&gt; the Company recognizes all obligations to repurchase shares of its equity securities that require or may require the Company to settle the obligation by transferring assets, as
   liabilities or assets in some circumstances measured at fair value with changes in fair value reflected as current period income or loss and are accounted for as such. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Research and
   Development Expenses &lt;/i&gt;&amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, clinical trial related expenses, facilities, supplies, external
   services and overhead directly related to the Company&amp;#8217;s research and development departments as well as costs to acquire technology licenses. We recognize expenses for these costs based on a variety of factors, including estimates provided by
   third parties or the Company&amp;#8217;s employees, measuring changes in activities and reviewing various milestones that may have been achieved. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Income Taxes &lt;/i&gt;&amp;#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts
   in the financial statements in accordance with FASB ASC&amp;#160;740-10, &amp;#8220;&lt;i&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/i&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported
   amounts of the assets or liabilities are recovered or settled. &lt;i&gt;ASC 740-10&lt;/i&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be
   realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other
   positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&amp;#8217;s income tax
   provision or benefit. The recognition and measurement of benefits related to the Company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by
   taxing authorities. Differences between actual results and the Company&amp;#8217;s assumptions or changes in the Company&amp;#8217;s assumptions in future periods are recorded in the period they become known &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Concentrations of Credit Risk &lt;/i&gt;&amp;#8212; Financial instruments that potentially subject the Company to significant concentrations of
   credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of December&amp;#160;31, 2011, the Company&amp;#8217;s cash
   equivalents were invested in money market mutual funds. The Company&amp;#8217;s investment policy disallows investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The Company has not experienced any
   losses on its deposits of cash and cash equivalents. All of the non-interest bearing cash balances were fully insured at December&amp;#160;31, 2011 due to temporary federal program in effect from December&amp;#160;31, 2010 through December&amp;#160;31, 2012.
   Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning in 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and the non-interest bearing cash balances may again
   exceed federally insured limits. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Comprehensive Loss &lt;/i&gt;&amp;#8212; The Company&amp;#8217;s comprehensive loss is equal to its net
   loss for all periods presented. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Parent Company&amp;#8217;s Net Deficit &lt;/i&gt;&amp;#8212; The Parent Company&amp;#8217;s Net Deficit of the
   Predecessor consists of CytRx&amp;#8217;s initial investment in RXi and subsequent changes in RXi&amp;#8217;s net investment resulting from RXi being an integrated part of CytRx. All disbursements for the Predecessor were made by CytRx. &lt;/font&gt;&lt;/p&gt;
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:AccountingChangesAndErrorCorrectionsTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;3.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Recent Accounting Pronouncements &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In December 2010, the FASB issued ASC Update 2010-29, Business Combinations (Topic 805) &amp;#8212;&lt;i&gt; Disclosure of Supplementary Pro Forma Information for Business Combinations&lt;/i&gt; (Update No.&amp;#160;2010-29).
   This Update requires a public entity to disclose pro forma information for business combinations that occurred in the current reporting period. The disclosures include pro forma revenue and earnings of the combined entity for the current reporting
   period as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. If comparative financial statements are presented, the pro forma revenue and earnings of
   the combined entity for the comparable prior reporting period should be reported as though the acquisition date for all business combinations that occurred during the current year had been as of the beginning of the comparable prior annual reporting
   period. This Update affects any public entity that enters into business combinations that are material on an individual or aggregate basis and is effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first
   annual reporting period beginning on or after December&amp;#160;15, 2010. All disclosures are presented in accordance with the acquisition of Apthera, Inc. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Recently Issued Accounting Pronouncements &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In May&amp;#160;2011, the FASB
   issued Accounting Standards Updated (&amp;#8220;ASU&amp;#8221;) 2011-04&lt;i&gt;, Fair Value Measurement&lt;/i&gt; (Topic 820): &lt;i&gt;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.&lt;/i&gt; &lt;i&gt;GAAP and IFRSs&lt;/i&gt; , a new accounting
   standard that clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on
   a prospective basis for annual and interim reporting periods beginning on or after December&amp;#160;15, 2011. The Company does not expect that adoption of this new standard will have a material impact on its consolidated financial statements.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In June&amp;#160;2011, the FASB issued ASU 2011-05, &lt;i&gt;Comprehensive Income&lt;/i&gt; (Topic 220): &lt;i&gt;Presentation of Comprehensive
   Income&lt;/i&gt;, a new accounting standard that eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders&amp;#8217; equity, requires the consecutive presentation of the statement of net
   income and other comprehensive income and requires an entity to present reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this new standard do not change the items
   that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This new standard is required to be
   applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December&amp;#160;15, 2011. As this new standard only requires enhanced disclosure, the adoption of this standard will not impact the
   Company&amp;#8217;s consolidated financial statements. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In September&amp;#160;2011, the FASB issued ASU 2011-08, &lt;i&gt;Intangibles &amp;#8212;
   Goodwill and Other&lt;/i&gt; (Topic 350): &lt;i&gt;Testing Goodwill for Impairment&lt;/i&gt;, a new accounting standard to simplify how entities test goodwill for impairment. The amendments in the Update permit an entity to first assess qualitative factors to
   determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in Topic 350. The
   more-likely-than-not threshold is defined as having a likelihood of more than 50 percent. Previous guidance under Topic 350 required an entity to test goodwill for impairment, on at least an annual basis, by comparing the fair value of a reporting
   unit with its carrying amount, including goodwill (step one). If the fair value of a reporting unit is less than its carrying amount, then the second step of the test must be performed to measure the amount of the impairment loss, if any. Under the
   amendments in this Update, an entity is not required to calculate the fair value of a reporting unit unless the entity determines that it is more likely than not that its fair value is less than its carrying amount. This new standard is effective
   for fiscal years beginning after December&amp;#160;15, 2011; however, early adoption is permitted. The Company adopted this standard for the fiscal year ended December&amp;#160;31, 2011. The adoption of this standard had no material impact on the
   Company&amp;#8217;s consolidated financial statements. &lt;/font&gt;&lt;/p&gt;
</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:BusinessCombinationDisclosureTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;4.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Apthera Acquisition &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On April&amp;#160;13, 2011, the Company completed its acquisition of Apthera, Inc., a Delaware corporation
   (&amp;#8220;Apthera&amp;#8221;), under an Agreement and Plan of Merger (&amp;#8220;Merger Agreement&amp;#8221;) entered into on March&amp;#160;31, 2011. Subject to the terms and conditions of the Merger Agreement, the Company&amp;#8217;s wholly owned subsidiary formed for this
   purpose was merged with and into Apthera, with Apthera surviving as a wholly-owned subsidiary of the Company. Under the Merger Agreement, the Company issued to Apthera&amp;#8217;s stockholders approximately 5.0&amp;#160;million shares of common stock of the
   Company (the &amp;#8220;Aggregate Stock Consideration&amp;#8221;) and agreed to make future contingent payments of up to $32&amp;#160;million based on the achievement of certain development and commercial milestones relating to the Company&amp;#8217;s NeuVax&amp;#8482;
   product candidate. The contingent consideration is payable, at the election of the Company, in either cash or additional shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it
   has first obtained approval of its stockholders in accordance with Rule 5635(a) of the NASDAQ Marketplace Rules. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection
   with the Merger Agreement, the Company deposited with a third-party escrow agent certificates representing 10% of the Aggregate Stock Consideration, which shares will be available to compensate the Company and related parties for certain
   indemnifiable losses as described in the merger agreement. On October&amp;#160;13, 2011, the escrow agent released from the escrow 5% of the Aggregate Stock Consideration, or 248,705 shares. The remaining Aggregate Stock Consideration held with the
   escrow agent is expected to be released in April 2012. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company&amp;#8217;s acquisition of Apthera was in concert with the
   decision by the Company&amp;#8217;s Board of Directors to diversify its development programs and to become a late stage clinical development company. The Company does not expect any of its goodwill to be deductible for tax purposes. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The purchase price consideration and allocation of purchase price of Apthera were as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="89%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="7%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;(in 000&amp;#8217;s)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Calculation of allocable purchase price:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Fair value of shares issued at closing including escrowed shares expected to be released&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,367&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(i)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Estimated value of earn-out&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,460&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total allocable purchase price&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,827&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Allocation of purchase price:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;14&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Equipment and furnishings&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,898&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In-process research and development&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,864&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accounts payable&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(931&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(143&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Notes payable&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(1&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Deferred tax liability, non-current&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(5,053&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,827&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:13%"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="3%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(i)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The value of the Company&amp;#8217;s common stock was based upon a per share value of $1.28, the closing price of the Company&amp;#8217;s common stock as of the close of business
   on April&amp;#160;13, 2011. &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The estimated value of the earn-out consideration of $6.5 million originally recorded
   was based on the expected probability of achievement in the future of certain development and commercial milestones relating to the Company&amp;#8217;s NeuVax product candidate and then applying a discount rate, based on a corporate debt interest rate
   index publicly issued, to the expected future payments. The expected timing of the milestones, the probability of success for each milestone and the discount rates applied are updated quarterly using the most current information to measure the
   contingent liability as of the reporting date. The decrease in the fair value of the contingent liability from date of issuance to December&amp;#160;31, 2011 is $109,000, which was included in other income and expense in the accompanying consolidated
   statements of expenses for the twelve months ended December&amp;#160;31, 2011. The fair value of the contingent liability at December&amp;#160;31, 2011 was $6,351,000. Of this amount $1,782,000 was recorded as a current liability. On January&amp;#160;19, 2012,
   the first milestone of $1,000,000 of this contingent liability was triggered with the first patient enrolled in our Phase 3 present clinical trial for breast cancer. On March&amp;#160;8, 2012, the Company issued 1,315,789 restricted shares of common stock in payment of the first milestone. The certificates evidencing the milestone shares have been
   deposited with a third party escrow agent. The milestone shares will be released to the Apthera shareholders from escrow following approval of the issuance of the milestone shares by the stockholders of the Company, which the Company intends to seek
   at its 2012 annual stockholders meeting. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;If stockholder approval is obtained, the number of milestone shares will be subject
   to increase to the extent that $0.76 (&lt;i&gt;i.e&lt;/i&gt;., the closing price of the Company&amp;#8217;s common stock as reported on The NASDAQ Capital Market on January&amp;#160;18, 2012, the day prior to achievement of its first milestone, used for purposes of
   determining the number of milestone shares in) is greater than the closing price of common stock as of the most recent trading day prior to the receipt of stockholder approval. Whether or not stockholder approval is obtained, in addition to the
   release from escrow of the milestone shares or the payment in cash of the final milestone as the case may be, the Company will pay concurrently to the former Apthera shareholders in cash an interest factor of ten percent (10%)&amp;#160;per annum on the
   amount of the final milestone from February&amp;#160;10, 2012 through the day immediately prior to the release of the milestone shares from escrow or the cash payment, as the case may be, less certain legal fees of the stockholder representative to be
   paid or reimbursed by the Company. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During the fourth quarter of 2011, the Company finalized its purchase price allocation
   which resulted in an increase in goodwill and deferred tax liability of $5,053,000. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following presents the pro forma net
   loss and pro forma net loss per common share of the Company and twelve months ended December&amp;#160;31, 2011 and 2010 as if the Company&amp;#8217;s acquisition of Apthera occurred as of January&amp;#160;1, 2010: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="71%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="9%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="8%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the Twelve Months Ended&lt;br /&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;(unaudited)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Pro forma net loss&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(12,778&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(14,229&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Pro forma net loss per common share&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.34&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.62&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted average shares outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;37,724,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;22,857,471&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <rxii:PartnerCompanyTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - rxii:PartnerCompanyTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;5.&amp;#160;&amp;#160;&amp;#160;&amp;#160;RXi Spin-Out &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Contribution Agreement &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   On September&amp;#160;24, 2011, the Company entered into a Contribution Agreement (&amp;#8220;Contribution Agreement&amp;#8221;) with RXi pursuant to which we assigned and contributed to RXi substantially all of the
   Company&amp;#8217;s RNAi-related technologies and assets. The contributed assets consist primarily of our novel RNAi compounds and licenses relating to our RNAi technologies, as well as the lease of our Worcester, Massachusetts laboratory facility, fixed
   assets and other equipment located at the facility and our employment arrangements with certain scientific, corporate and administrative personnel who have become employees of RXi. The Company also contributed $1.5&amp;#160;million of cash to the
   capital of RXi. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Pursuant to the Contribution Agreement, RXi has agreed to assume certain recent accrued expenses of our
   RXI-109 development program and all future obligations under the contributed licenses, employment arrangements and other agreements. RXi has also agreed to make future milestone payments to us of up to $45&amp;#160;million, consisting of two one-time
   payments of $15&amp;#160;million and $30&amp;#160;million, respectively, if RXi achieves annual net sales equal to or greater than $500 million and $1&amp;#160;billion, respectively, of any covered products that may be developed with the contributed RNAi
   technologies. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In the Contribution Agreement, the Company made customary representations and warranties to RXi regarding the
   contributed assets and other matters, and the parties have agreed to customary covenants regarding the conduct of RXi&amp;#8217;s business pending the spin-off of RXi. The parties also have agreed to indemnify each other against losses arising from a breach of their respective representations,
   warranties and covenants set forth in the Contribution Agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Securities Purchase Agreement &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On September&amp;#160;24, 2011, the Company also entered into a Securities Purchase Agreement (&amp;#8220;Securities Purchase Agreement&amp;#8221;) with
   RXi and two institutional Investors (the &amp;#8220;Investors&amp;#8221;), pursuant to which the Investors agreed to purchase a total of $9,500,000 of Series&amp;#160;A Preferred Stock of RXi (&amp;#8220;RXi Preferred Stock&amp;#8221;) at the closing of the spin-off of
   RXi, and to lend up to $1,500,000 to RXi to fund its operations between signing and closing (the &amp;#8220;Bridge Loan&amp;#8221;). The outstanding principal and accrued interest from the Bridge Loan will, except under certain circumstances described below,
   be converted into RXi Preferred Stock at the closing of the spin-off of RXi and will represent a portion of the $9,500,000 total investment, which is referred to herein as the &amp;#8220;RXi financing.&amp;#8221; The RXi financing and the spin-off of RXi are
   subject to customary closing conditions, including the registration under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), of the distribution by us of the spin-off shares. There is no assurance that the RXi financing and the
   spin-off of RXi will be completed. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The RXi Preferred Stock will be convertible by a holder at any time into shares of RXi
   common stock, except to the extent that the holder would own more than 9.999% of the shares of RXi common stock outstanding immediately after giving effect to such conversion. Without regard to this conversion limitation, the shares of the Preferred
   Stock to be held by the Investors upon completion of the RXi financing and the spin-off of RXi will be convertible into shares of RXi common stock representing approximately 83% of the shares of RXi common stock that would be outstanding, assuming
   the conversion in full of the Preferred Stock, which we refer to as the &amp;#8220;as-converted common stock.&amp;#8221; The Company will own approximately 12% of the as-converted common stock immediately prior to the spin-off of RXi, and Advirna, LLC, a key
   licensor of RXi, will be issued the remaining 5% of the as-converted common stock pursuant to the agreement with Advirna, LLC as described below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Spin-Off &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has agreed in the Securities Purchase Agreement to
   undertake to distribute to our stockholders on a share-for-share basis approximately 8% of the as-converted common stock of RXi, subject to the registration of the distribution of such shares under the Securities Act of 1933 and other conditions.
   Assuming the spin-off of RXi is completed, the Company will initially retain 4% of the as-converted common stock, and the Company agreed, in the Securities Purchase Agreement, not to sell or dispose of our shares of RXi common stock for a one-year
   period following completion of the spin-off of RXi. The Securities Purchase Agreement provides that the spin-off will be on a share-for-share basis, so that one share of RXi will be distributed as a dividend on each share of Galena that is issued
   and outstanding as of the record date for the distribution. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On February&amp;#160;27, 2012, the Company announced, as required by
   NASDAQ Listing Rule 5250(e)(6), that its board of directors had declared a conditional dividend on Galena common stock of one share of common stock of RXi for each outstanding share of Galena common stock. The spin-off shares will be payable,
   subject to certain conditions described below, to the Company&amp;#8217;s stockholders as of close of business (Eastern time) on March&amp;#160;8, 2012, the record date for the distribution, in the ratio of one RXi share for each share of Galena common stock
   held as of the record date. In light of the conditional nature of the partial spin-off of RXi, the Company&amp;#8217;s board of directors has not set a payment date for the distribution, and under NASDAQ rules Galena common stock is not yet trading
   &amp;#8220;ex-dividend.&amp;#8221; The distribution of the spin-off shares will be taxable to Galena stockholders who receive RXi shares in the distribution. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The distribution to Galena stockholders of the spin-off shares is to be made pursuant to the registration statement filed by RXi with the Securities and Exchange Commission and declared effective on
   February&amp;#160;14, 2012. Because the RXi registration statement will go &amp;#8220;stale&amp;#8221; on April&amp;#160;30, 2012, the Company must complete the distribution of the spin-off shares by that date, unless the Company were to cause RXi to amend the
   registration statement. It is likely that the Company would abandon the partial spin-off of RXi if the distribution of the spin-off shares has not been made by April&amp;#160;30, 2012, although the Company&amp;#8217;s
   board of directors has not made any decision in this regard. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The establishment of a payment date for the distribution and the
   payment of the distribution is dependent upon the timing of effectiveness of an application filed with FINRA to permit RXi common stock to be graded in the OTC Markets Group under the symbol &amp;#8220;RXII.&amp;#8221; The payment of the distribution also is conditioned
   upon the closing of the RXi financing, which is subject to certain closing conditions that may or may not be satisfied. In addition, the securities purchase agreement among Galena, RXi and the Investors provides that the agreement may be unilaterally
   terminated by the Company or by the Investors if the closing of the transactions has not occurred by March&amp;#160;31, 2012, and it is not possible for the closing to occur by this date. Accordingly, unless this date is extended by mutual agreement of
   the Investors and the Company, either the Company or the Investors generally may terminate the securities purchase agreement at any time after March&amp;#160;31, 2012, unless the failure of the closing to occur was due to the fault of the party seeking
   to terminate the securities purchase agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Although the Company has no present intention to terminate the securities
   purchase agreement or to abandon the partial spin-off of RXi, the Investors may choose to do so. The Company also may decide to do so at any time if its board of directors determines that it is in the best interests of the Company. For all of the foregoing
   reasons, there is no assurance that the payment and distribution of the spin-off shares will be completed. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Purchase
   Agreement Terms and Conditions &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In the Securities Purchase Agreement, the parties have made customary representations and
   warranties to the other parties and have agreed to customary covenants regarding the parties&amp;#8217; actions in connection with the spin-off of RXi and other matters, including the filing of a resale registration statement registering a portion of the
   common stock underlying the conversion of the Preferred Stock. The parties also have agreed to indemnify each other against losses arising from a breach of their respective representations, warranties and covenants set forth in the Securities
   Purchase Agreement. RXi has agreed, upon completion of the spin-off of RXi, to reimburse the Company and the Investors for up to a total of $300,000 and $100,000, respectively, of transaction costs relating to the Contribution Agreement, the
   Securities Purchase Agreement and the transactions contemplated by the agreements. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Securities Purchase Agreement may be
   terminated in certain circumstances, including by the Investors or the Company if the spin-off of RXi has not occurred by March&amp;#160;31, 2012. If the Securities Purchase Agreement is terminated without cause due to the fact that the spin-off has not
   occurred by such date, then a portion of the Bridge Loan will be converted into common stock of RXi, as described below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Bridge Loan &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   Pursuant to the Securities Purchase Agreement, the Investors agreed to provide the Bridge Loan by purchasing $500,000 of secured convertible promissory notes of RXi (&amp;#8220;RXi convertible notes&amp;#8221;) and
   agreeing to purchase up to an additional $1,000,000 of RXi convertible notes prior to the closing of the spin-off of RXi. The RXi convertible notes will, except as described below, be convertible into shares of RXi Preferred Stock at a conversion
   price of $1,000 per share. The proceeds from the Bridge Loan will be used by RXi in accordance with an operating budget approved by the Investors to fund RXi&amp;#8217;s business and operations pending completion of the spin-off of RXi. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The RXi convertible notes accrue interest at a rate of 7%&amp;#160;per annum (or 18%&amp;#160;per annum in the case of an event of default) and
   mature on March&amp;#160;31, 2012, or earlier in the case of an event of default. The obligations due under the RXi convertible notes are secured by a first-priority blanket lien on the assets of RXi and are guaranteed by Galena. Additionally, Galena
   has pledged all of the shares of RXi common stock that it holds to further guaranty the timely repayment of the amounts due under the RXi convertible notes, if not converted into RXi Preferred Stock at the closing under the Securities Purchase
   Agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;If the closing
   under the Securities Purchase Agreement has not occurred by the March&amp;#160;31, 2012 maturity date of the RXi convertible notes, then 50% of the outstanding Bridge Loan balance will be converted into a number of shares of RXi common stock equal to
   51% of the post-conversion shares outstanding. RXi will remain obligated to repay the remaining balance of the principal and accrued interest under the Bridge Loan, and Galena has agreed to guarantee RXi&amp;#8217;s repayment of the RXi convertible notes
   to the extent they are not converted. In this event, Galena and Advirna, LLC will beneficially own 44% and 5%, respectively, of the outstanding shares of RXi common stock, and RXi will carry on as a stand-alone private company under the
   Investors&amp;#8217; control. Neither the Investors nor Galena will be obliged to provide any funding to RXi in this event. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As of
   the date of the filing of the Annual Report on Form&amp;#160;10-K of which these Consolidated Financial Statements are a part, the Company was in discussions with the Investors to extend the current March&amp;#160;31, 2012 maturity date of the RXi
   convertible notes, but there is no assurance that the maturity date will be extended. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The RXi convertible notes will be
   issued, and the Bridge Loan will be funded, in three tranches of $500,000 each. The first and second tranches were issued and funded on September&amp;#160;24, 2011 and February&amp;#160;24, 2012, respectively, and the third tranche is to be issued and
   funded as needed by RXi prior to the closing under the Securities Purchase Agreement and following the approval by the Investors, in their discretion, of RXi&amp;#8217;s budget for the use of such funds. At December&amp;#160;31, 2011, the first tranche of
   $500,000 had been received and recorded to convertible notes payable as a current liability. There are additional features of the RXi post spin-off Series A Convertible Preferred Stock which represent contingent beneficial conversion features, to be
   reevaluated in the future. In the event that the facts and circumstances indicate that a contingency is removed, at that point the beneficial conversion feature, if any, will be recorded. On February&amp;#160;24, 2012, the second tranche of $500,000 was
   received and recorded to convertible notes payable. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Advirna Agreement &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As part of the transactions contemplated by the Contribution Agreement and Securities Purchase Agreement, RXi has entered into an
   agreement with Advirna, LLC, which the Company refers to as &amp;#8220;Advirna,&amp;#8221; a company affiliated with Anastasia Khvorova, Ph.D., the Company&amp;#8217;s former Senior Vice President and Chief Scientific Officer. In the agreement, Advirna has agreed
   to amend its existing patent and technology assignment agreement with RXi to eliminate all clinical milestone and royalty payments to Advirna under the amended agreement; obligations remain to make an annual $100,000 maintenance fee and a one-time
   milestone payment of $350,000 to Advirna upon the issuance of a patent with valid claims covering the assigned technology. Additionally, RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi on the license of
   the assigned Advirna technology. In exchange, RXi has agreed to issue to Advirna upon the earlier of the closing under the Securities Purchase Agreement or the partial conversion of the RXi convertible notes, a number of shares of RXi common stock
   equal to 5% of the as-converted common stock of RXi. &lt;/font&gt;&lt;/p&gt;
</rxii:PartnerCompanyTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - us-gaap:FinancialInstrumentsDisclosureTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;6.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Fair Value Measurements &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company follows ASC&amp;#160;820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;) for the
   Company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three
   levels. Level inputs are as defined as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets
   or liabilities. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through
   corroboration with market data at the measurement date. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect
   management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company categorized its cash equivalents as Level&amp;#160;1 hierarchy. The valuation
   for Level&amp;#160;1 was determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuations of these assets do not require a significant degree of judgment. The Company categorized its warrants
   potentially settleable in cash as a Level&amp;#160;2 hierarchy. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using the
   Black-Scholes method, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as a Level 3 hierarchy and is measured at its estimated fair value on a recurring basis and is
   adjusted at each quarter-end until it is completely settled. The contingent price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and the updated discount rates based on a
   corporate debt interest rate index publicly issued. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="42%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="10%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="10%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="10%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="10%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;
   &lt;p style="border-bottom:1px solid #000000;width:39pt"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Quoted&amp;#160;Prices&amp;#160;In&lt;br /&gt;Active Markets&lt;br /&gt;(Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Significant&amp;#160;Other&lt;br /&gt;Observable&amp;#160;Inputs&lt;br /&gt;(Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unobservable&amp;#160;Inputs&lt;br /&gt;(Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,746&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,746&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,351&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,351&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,097&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,746&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,351&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="46%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="10%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="10%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="10%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="10%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;
   &lt;p style="border-bottom:1px solid #000000;width:39pt"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;br /&gt;Active Markets&lt;br /&gt;(Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Significant&amp;#160;Other&lt;br /&gt;Observable&amp;#160;Inputs&lt;br /&gt;(Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unobservable&amp;#160;Inputs&lt;br /&gt;(Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,891&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,891&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,891&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,891&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,138&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,138&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,138&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,138&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has classified its liabilities for contingent earn-out consideration relating to its
   acquisitions of Apthera within Level 3 of the fair value hierarchy because the fair values are determined using significant unobservable inputs, which included probability weighted cash flows. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has not
   transferred any financial instruments into or out of Level 3 classification during 2010 or 2011. A reconciliation of the beginning and ending Level 3 liabilities for the year ended December&amp;#160;31, 2011 is as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="83%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="13%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair Value&lt;br /&gt;Measurements&lt;br /&gt;Using&amp;#160;Significant&lt;br /&gt;Unobservable&lt;br /&gt;Inputs&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;(In Thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at January&amp;#160;1, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Initial fair value of contingent earnout consideration related to Meridian Acquisition&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,460&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Change in fair value of earnout consideration&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(109&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Balance at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,351&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:FinancialInstrumentsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 7 - us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;7.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Capital Lease Obligations &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company acquired equipment under capital leases that is included in equipment and furnishings in the accompanying
   consolidated balance sheet. The cost and accumulated amortization of capitalized leased equipment was approximately $272,000 and $95,000 at December&amp;#160;31, 2011, respectively, and $196,000 and $56,000 at December&amp;#160;31, 2010, respectively.
   Amortization expense for capitalized leased equipment was approximately $54,000 in 2011 and $39,000 in 2010. Future minimum lease payments under the capital leases including interest are approximately $38,000, $25,000 and $14,000 for the years
   ending December&amp;#160;31, 2012, 2013 and 2014, respectively. Interest expense related to the capital leases was $6,000 for each of the years ended December&amp;#160;31, 2011 and 2010. &lt;/font&gt;&lt;/p&gt;
</us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 8 - us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;8.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accrued Expenses and Other Current Liabilities &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued expenses and other current liabilities consist of the following (in thousands): &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="82%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the Years&lt;br /&gt;Ended&lt;br /&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Professional fees&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;520&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;313&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Research and development costs&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;755&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;60&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Payroll related costs&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;868&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;740&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;25&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total accrued expenses and other current liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,113&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 9 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;9.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Commitments and Contingencies &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company acquires assets still in development and enters into research and development arrangements with third
   parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain
   agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below (see also Note&amp;#160;15).
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by
   these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the
   product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&amp;#8217;s contractual obligations that
   will require future cash payments as of December&amp;#160;31, 2011 are as follows (in thousands): &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="49%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Operating&lt;br /&gt;Leases(1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Non-Cancelable&lt;br /&gt;Employment&lt;br /&gt;Agreements(2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Cancelable&lt;br /&gt;License&lt;br /&gt;Agreements(3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;139&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,774&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,914&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;578&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,492&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;25&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,006&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,031&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;453&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,484&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;413&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;415&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;463&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;878&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;300&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;303&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;538&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;841&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;100&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;102&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;988&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,090&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2017 and Thereafter&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,173&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,173&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;172&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,593&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,765&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,193&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,958&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="3%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(1)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December&amp;#160;31,
   2011 and 2010 were approximately $233,000 and $274,000, respectively. &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:3px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="3%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(2)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been
   revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable. &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:3px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="3%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(3)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;License agreements generally relate to the Company&amp;#8217;s obligations with The Board of Regents, University of Texas and Henry Jackson Foundation for our oncology
   therapies and UMMS associated with RNAi and, for future periods, represent minimum annual royalty and milestone payment obligations, of the total amount due. The Company continually assesses the progress of its licensed technology and the progress
   of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, no amounts will be due. &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company applies the disclosure provisions FASB ASC Topic 460 (&amp;#8220;ASC 460&amp;#8221;), &amp;#8220; &lt;i&gt;Guarantor&amp;#8217;s Accounting and
   Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Other&lt;/i&gt;&lt;i&gt;s&lt;/i&gt;&amp;#8221;, to its agreements that contain guarantee or indemnification clauses. The Company provides (i)&amp;#160;indemnifications of varying scope
   and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&amp;#160;indemnifications of varying scope and size to officers and
   directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&amp;#160;460. To date, the Company has not incurred costs as a result of these obligations and
   does not expect to incur material costs in the future. Accordingly, the Company has not accrued any liabilities in its financial statements related to these indemnifications. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On
   November&amp;#160;21, 2011, Hudson Bay Master Fund, Ltd. (&amp;#8220;Hudson Bay&amp;#8221;) filed a Complaint against the Company in the United States District Court for the Southern District of New York (the &amp;#8220;Court&amp;#8221;), captioned &lt;u&gt;Hudson Bay Master
   Fund, Ltd. v. Galena Biopharma, Inc., 11 Civ. 8432 (JPO)&lt;/u&gt;, alleging that the Company&amp;#8217;s plan to partially spin off RXi and related actions taken in preparation for the spin-off gives Hudson Bay the right to require us to repurchase the
   warrants acquired by Hudson Bay in our April 2011 underwritten public offering. Hudson Bay also seeks related declaratory and injunctive relief. On January&amp;#160;12, 2012, three other warrant holders affiliated with each other filed a Complaint in
   the Court, captioned &lt;u&gt;Tenor Opportunity Fund, Ltd., Aria Opportunity Fund, Ltd., and &lt;/u&gt;&lt;u&gt;Parsoon Opportunity Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0260&lt;/u&gt;, and on January&amp;#160;20, 2012 and February&amp;#160;2, 2012, respectively, two other
   warrant holders filed their own Complaints in the Court, captioned &lt;u&gt;Cranshire Capital Master Fund, Ltd. v. Galena Biopharma, Inc., 12&amp;#160;CIV 0493&lt;/u&gt; and &lt;u&gt;Iroquois Master Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0839&lt;/u&gt;, respectively. In
   these latest Complaints, which are substantially identical to the previous Complaints filed in the Court, the various warrant holders also claim that the planned spin-off of RXi and related actions give them the right to require the Company to
   repurchase the Company&amp;#8217;s outstanding warrants held by them. According to the allegations in the Complaints, the repurchase price of the plaintiffs&amp;#8217; warrants would amount to approximately $5.2 million in the aggregate. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On March&amp;#160;21, 2012, the Company received letters from each of the plaintiff-warrant holders withdrawing their repurchase demands with
   respect to their warrants covering an aggregate of 6,350,000 shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the &amp;#8220;Withdrawal Notice&lt;b&gt;s&lt;/b&gt;&amp;#8221;). After giving effect to the Withdrawal Notices, the
   plaintiff-warrant holders continued to demand that the Company repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based on the plaintiff-warrant holders&amp;#8217; claims in their Complaints, the Company
   believes that the repurchase price for these warrants is $0.71 per underlying share, or an aggregate of $355,000. On March 27, 2012, the Company tendered to the plaintiff-warrant holders an aggregate of $355,000 as payment in full of the repurchase
   price for those warrants. The Company believes that the Withdrawal Notices and the Company&amp;#8217;s tender of payment as described above render moot the majority of claims of the plaintiff-warrant holders in their Complaints, although the Withdrawal
   Notices purport to reserve all rights of the plaintiff-warrant holders under the Complaints. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;If the Company were to become
   liable to repurchase the plaintiffs&amp;#8217; warrants, the Company may not have on hand sufficient funds to satisfy the liability and to meet its other obligations as they come due, which could raise doubts as to the Company&amp;#8217;s ability to continue
   as a going concern. &lt;/font&gt;&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 10 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;10.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stockholders&amp;#8217; Equity &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Preferred Stock &lt;/i&gt;&amp;#8212; The Company has authorized up to 5,000,000&amp;#160;shares of preferred stock,
   $0.0001&amp;#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as
   shall be determined by the Company&amp;#8217;s board of directors upon its issuance. At December&amp;#160;31, 2011, there were no shares of preferred stock outstanding. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Common Stock &lt;/i&gt;&amp;#8212; The Company has authorized up to 125,000,000&amp;#160;shares of common stock, $0.0001&amp;#160;par value per share, for issuance. Shares of common stock are reserved as follows:
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="86%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;As of&lt;br /&gt;December&amp;#160;31,&lt;br /&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;14,120,642&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock options outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,163,137&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2007 Incentive Plan&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,299,717&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;21,583,496&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Common Stock Warrants &lt;/i&gt;&amp;#8212; On August&amp;#160;7, 2008, the Company issued 190,000
   warrants to an investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $7.036 per share and expire 5&amp;#160;years from the date of issuance, on August&amp;#160;7, 2013. The warrants vested as
   to 94,000&amp;#160;shares upon issuance, and vested at a rate of 32,000&amp;#160;shares&amp;#160;per month starting on the 90&amp;#160;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation cost was
   fully recorded at December&amp;#160;31, 2009. The Company also agreed to give the holder of the warrants unlimited &amp;#8220;piggy back&amp;#8221; registration rights with respect to the shares of the Company&amp;#8217;s common stock underlying the warrants in any
   registration statement the Company files in connection with an underwritten offering of its common stock. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On October&amp;#160;3,
   2008, the Company acquired the rights to license exclusive worldwide technology for the oral delivery of RNAi therapeutics. As consideration for this license, the Company agreed to pay a total license fee of $2,500,000 over a 12&amp;#160;month period,
   which can be paid in cash, in equity or a combination thereof, provided that a specified amount of the license fee must be made in cash. Payments made in equity may only be made if, at the time of such payment, the shares of common stock issuable
   upon conversion of the warrant have been registered for resale under the Securities Act of 1933. No warrants have been issued under this agreement thru the date of this report. The Company continually assesses the progress of its research and
   development efforts as it relates to its licensed technology and may terminate with notice to the Licensor at any time. Accordingly, the amounts are being expensed, as payments are made. There was no expense for this license for the years ended
   December&amp;#160;31, 2011 and 2010. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On January&amp;#160;29, 2009, the Company issued 142,500 warrants to an investment bank as
   consideration for investment and business advisory services. The warrants have an exercise price of $4.273 per share and expire five years from the date of issuance on January&amp;#160;29, 2014. The warrants vested as to 71,250&amp;#160;shares upon
   issuance, and vested at a rate of 23,750&amp;#160;shares&amp;#160;per month starting on the 90&amp;#160;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation expense was fully recorded at
   December&amp;#160;31, 2009. The Company has also agreed to give the holder of the warrants unlimited &amp;#8220;piggy back&amp;#8221; registration rights with respect to the shares of Common Stock underlying the warrants in any registration statement the Company
   files in connection with an underwritten offering of the common stock. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection with the 2009 Offering, the Company
   issued warrants to purchase 978,142&amp;#160;shares of the Company&amp;#8217;s common stock. Details of the transaction can be found under the heading &amp;#8220;2009 Registered Direct Offering&amp;#8221; below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection with the 2010 Offering, the Company issued warrants to purchase 540,000&amp;#160;shares of the Company&amp;#8217;s common stock.
   Details of the transaction can be found under the heading &amp;#8220;2010 Registered Direct Offering&amp;#8221; below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection
   with the March 2011 Offering, the Company issued warrants to purchase 6,000,000&amp;#160;shares of the Company&amp;#8217;s common stock. Details of the transaction can be found under the heading &amp;#8220;March 2011 Registered Direct Offering&amp;#8221; below.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection with the April 2011 Offering, the Company issued warrants to purchase 11,950,000&amp;#160;shares of the
   Company&amp;#8217;s common stock. Details of the transaction can be found under the heading &amp;#8220;April 2011 Registered Direct Offering&amp;#8221; below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   During 2011, the Company issued 150,000 warrants in exchange for business advisory services. The Company recognizes the total fair value of these warrants as stock compensation expense, over the requisite
   service period. The Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants on the date of the award. Total expense related to these warrants was $108,000 in 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Private Investment in Public Equity &lt;/i&gt;&amp;#8212; On June&amp;#160;24, 2008, the Company entered into a Securities Purchase Agreement pursuant
   to which RXi issued and sold to certain investors an aggregate of 1,073,299&amp;#160;shares of common stock in a private placement at a price of $8.12 per share. Net proceeds to the Company were approximately $7.9&amp;#160;million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;2009 Registered
   Direct Offering &lt;/i&gt;&amp;#8212; On March&amp;#160;17, 2009, the Company entered into a placement agency agreement, which was subsequently amended on May&amp;#160;26, 2009 and July&amp;#160;22, 2009, with Rodman&amp;#160;&amp;#038; Renshaw, LLC (&amp;#8220;Rodman&amp;#8221;) as the
   exclusive placement agent, relating to a proposed offering by the Company of new securities to potential investors. On July&amp;#160;30, 2009, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors
   of 2,385,715&amp;#160;units, with each unit consisting of one share of the Company&amp;#8217;s common stock and a warrant to purchase 0.40 of a share of common stock, at a purchase price of $3.50 per unit (the &amp;#8220;2009 Offering&amp;#8221;). The 2009 Offering
   closed on August&amp;#160;4, 2009. The warrants have an exercise price of $4.50 per share and are exercisable for a period beginning on February&amp;#160;3, 2010 until their expiration on August&amp;#160;3, 2014. The Company raised gross proceeds of
   approximately $8,350,000 in the 2009 Offering and net cash proceeds, after deducting the placement agents&amp;#8217; fees and other offering expenses payable by the Company, of approximately $7.7&amp;#160;million. Total warrants issued in connection with the
   transaction were 954,285. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As part of the placement agency agreement, the Company issued a warrant to purchase
   23,857&amp;#160;shares of the Company&amp;#8217;s common stock to Rodman. The warrant has an exercise price of $4.38 per share. The warrant is immediately vested and is exercisable until its expiration on August&amp;#160;3, 2014. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Certain warrants issued in connection with the stock offering on August&amp;#160;4, 2009 were determined not to be indexed to the
   Company&amp;#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,863,000 was recorded as a liability and a cost of equity and was determined by the Black-Scholes option
   pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publicly
   traded. The Company used a weighted average expected stock volatility of 122.69%. The expected life assumption is based on the contract term of five years. The dividend yield of zero is based on the fact that RXi has no present intention to pay cash
   dividends in the future. The risk free rate of 1.72% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. The change in the fair value of the warrants during the years ended December&amp;#160;31, 2011 and 2010 was
   $1,879,000 and $1,778,000, respectively. These amounts have been included in other income and expense in the accompanying consolidated statements of expenses. The fair value of the warrants at December&amp;#160;31, 2011 of $64,000 is included as a
   current liability in the accompanying balance sheet as of that date and was determined by the Black-Scholes option pricing model. The following assumptions were used to determine the fair value as of December&amp;#160;31, 2011: weighted average expected
   stock volatility of 98.91%; an expected life of 2.6 years and a dividend yield of zero and a risk free rate of 0.31%. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;2010
   Registered Direct Offering&lt;/i&gt;&amp;#160;&amp;#8212; On March&amp;#160;22, 2010, the Company entered into a placement agency agreement relating to a proposed offering by the Company of new securities to potential investors. On March&amp;#160;23, 2010, the Company
   entered into definitive agreements for the sale and issuance by the Company to certain investors of 2,700,000&amp;#160;units, with each unit consisting of one share of the Company&amp;#8217;s common stock and a warrant to purchase 0.20 of a share of the
   Company&amp;#8217;s common stock, at a purchase price of $6.00 per unit (the &amp;#8220;2010 Offering&amp;#8221;). The 2010 Offering closed on March&amp;#160;26, 2010. The Company issued warrants to purchase 540,000&amp;#160;shares of the Company&amp;#8217;s common stock at an
   exercise price of $6.00 per share and that are exercisable beginning on September&amp;#160;26, 2010 until their expiration on March&amp;#160;26, 2016. The Company raised gross proceeds of approximately $16.2&amp;#160;million in the 2010 Offering and net cash
   proceeds, after deducting the placement agent fees and other offering expenses payable by the Company, of approximately $15.2&amp;#160;million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   As part of the 2010 Offering, the Company entered in a stock redemption agreement whereby the Company was required to use 25% of the net proceeds from the 2010 Offering to repurchase from CytRx
   Corporation (&amp;#8220;CytRx&amp;#8221;) 675,000 shares of the Company&amp;#8217;s common stock held by CytRx (&amp;#8220;CytRx shares&amp;#8221;). The Company repurchased such shares on March&amp;#160;29, 2010. The values of the shares at the date of repurchase totaling
   $3,849,000 were recorded at cost and have been included in treasury stock in the accompanying consolidated balance sheet at December&amp;#160;31, 2011 and 2010. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Shares of common
   stock that are mandatorily redeemable under the stock redemption agreement upon the exercise of warrants issued in the 2010 Offering, were determined to embody an obligation that may require the Company to settle the obligation by transferring
   assets, and as such, shall be classified as a liability. The fair value of the common stock potentially redeemable under the stock redemption agreement totaling $785,000 was recorded as a liability and a cost of equity and was determined using the
   fixed monetary amount of each warrant multiplied by assumptions regarding the number and timing of warrants to be exercised. On December&amp;#160;29, 2010, CytRx sold all of their shares held in Galena, thus reducing the potential redemption liability
   to zero as December&amp;#160;31, 2010. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Certain warrants issued in connection with the 2010 Offering were determined not to be
   indexed to the Company&amp;#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,466,000 was recorded as a liability and a cost of equity and was determined by the
   Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option
   prices are publically traded. The Company used a weighted average expected stock volatility of 119.49%. The expected life assumption is based on the contract term of 6.5&amp;#160;years. The dividend yield of zero is based on the fact that the Company
   has no present intention to pay cash dividends. The risk free rate of 3.22% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. The change in the fair value of the warrants during the years ended
   December&amp;#160;31, 2011 and 2010 was $1,079,000 and $1,271,000, respectively. These amounts have been included in other income and expense in the accompanying consolidated statements of expenses. The fair value of the warrants at December&amp;#160;31,
   2011 of $116,000 is included as a current liability in the accompanying consolidated balance sheets and was determined by the Black-Scholes option pricing model. In the model, the Company used a weighted average expected stock volatility of 98.91%.
   The expected life assumption is based on the remaining contract term of 4.8&amp;#160;years. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.83% used for the warrant
   is equal to the zero coupon rate in effect on the date of the re-measurement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;March 2011 Registered Direct
   Offering&lt;/i&gt;&amp;#160;&amp;#8212; On March&amp;#160;4, 2011, the Company closed an underwritten public offering of 6,000,000 units at a price to the public of $1.35 per unit for gross proceeds of $8.1&amp;#160;million (the &amp;#8220;March&amp;#160;2011 Offering&amp;#8221;). The
   offering provided approximately $7.3&amp;#160;million to the Company after deducting the underwriting discounts and commissions and offering expenses. Each unit consists of (i)&amp;#160;one share of common stock, (ii)&amp;#160;a thirteen-month warrant to
   purchase 0.50 of a share of common stock at an exercise price of $1.70 per share (subject to anti-dilution adjustment) and (iii)&amp;#160;a five-year warrant to purchase 0.50 of a share of common stock at an exercise price of $1.87 per share (subject to
   anti-dilution adjustment). On April&amp;#160;15, 2011, the holders of outstanding warrants issued in the March&amp;#160;2011 Offering to purchase an aggregate of 3,450,000 shares of common stock agreed to exchange such warrants for warrants exercisable for
   the same number of shares as those being exchanged, but otherwise on the same terms of the warrants sold in the Company&amp;#8217;s April&amp;#160;2011 financing. Prior to the exchange, the Company recorded a decrease in fair value of $1,000,000 related to
   the exchanged warrants. Upon the exchange, the Company recorded a loss of $900,000, which represented the difference between the adjusted fair value of the March&amp;#160;2011 warrants as compared to the fair value of the April&amp;#160;2011 warrants
   received in the exchange. As a result of a subsequent offering that was completed on April&amp;#160;15, 2011, the exercise price of the remaining 2,550,000 outstanding warrants sold in the March&amp;#160;2011 Offering was reduced to $1.00 per share as a
   result of the anti-dilution adjustment. At December&amp;#160;31, 2011, 150,000 warrants from the March&amp;#160;2011 Offering had been exercised with a remaining outstanding balance of 5,850,000. As a result of the subsequent offering on September&amp;#160;26,
   2011, the exercise price of the remaining 5,850,000 warrants sold in the March&amp;#160;4, 2011 Offering were reduced to $0.65 per share as a result of the anti-dilution adjustment.&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The thirteen-month and five-year warrants issued in connection with the March 2011 Offering were determined not to be indexed to the Company&amp;#8217;s common stock as they are potentially settleable in cash.
   The fair value of the 2,550,000 warrants at the date of issuance totaling $1,790,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes option pricing model. Due to the fact that the Company
   has limited trading history, the Company expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose shares or options are publicly traded.
   The Company used a weighted average expected stock volatility of 113.25%. The expected life assumption is based on the contract term of 1.08 years used for the thirteen-month warrants and 5 years used for the five-year warrants. The dividend yield
   of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.26% used for the thirteen-month warrants and 2.17% used for the five-year warrants is equal to the zero coupon rate in effect at the time
   of the grant. In July 2011, 75,000 of the thirteen-month warrants were exercised at $1.00 per common share which resulted in a $34,000 reduction of the warrant liability. In July 2011, 75,000 of the five-year warrants were exercised at $1.00 per
   common share which resulted in a $68,000 reduction of the warrant liability. The decrease in the fair value of the warrants from the date of issuance to December&amp;#160;31, 2011 of $1,378,000 has been included in other income and expense in the
   accompanying consolidated statements of expenses for the year ended December&amp;#160;31, 2011. The fair value of the warrants at December&amp;#160;31, 2011 of $412,000 is included as a current liability in the accompanying consolidated balance sheets and
   was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities
   whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 98.91%. The expected life assumption is based on the remaining contract term of 0.3 years used for the thirteen-month warrants and 4.2
   years used for the five- year warrants. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.02% used for the thirteen-month warrants and 0.60% used for the
   five-year warrants is equal to the zero coupon rate in effect on the date of the re-measurement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;April 2011 Registered
   Direct Offering&lt;/i&gt;&amp;#160;&amp;#8212; On April&amp;#160;20, 2011, the Company completed an underwritten public offering of 11,950,000 units at a price to the public of $1.00 per unit for gross proceeds of approximately $12&amp;#160;million (the
   &amp;#8220;April&amp;#160;2011 Offering&amp;#8221;). Each unit consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $1.00 per share (subject to anti-dilution adjustment). The shares of common stock and
   warrants were immediately separable and no separate units were issued. The warrants are exercisable beginning one year and one day from the date of issuance, and expire on the sixth anniversary of the date of issuance. Net proceeds, after
   underwriting discounts and commissions and other offering expenses, were approximately $10.9&amp;#160;million. As a result of the subsequent offering that was completed on September&amp;#160;26, 2011, the exercise price of the 11,950,000 outstanding
   warrants sold in the April&amp;#160;2011 Offering was reduced to $0.65 per share as a result of the anti-dilution adjustment.&amp;#160;On December&amp;#160;6, 2011, the Company effected a warrant exchange with a ratio of 1.42857 warrants in exchange for one
   share of common stock with several of the April 2011 warrant holders. In total, 5,930,000 warrants were exchanged for 4,151,000 shares of common stock in this transaction. At December&amp;#160;31, 2011, 6,020,000 warrants sold in the April&amp;#160;20, 2011
   Offering remained outstanding. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The warrants issued in connection with the April 2011 Offering, including the warrants issued
   in exchange for the 3,450,000&amp;#160;March 2011 warrants, were determined not to be indexed to the Company&amp;#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $11,015,000 was
   recorded as a liability and a cost of equity and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a
   combination of implied volatilities of similar entities whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 99.04%. The expected life assumption is based on the contract term of 6.0 years.
   The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 2.81% used for the warrants is equal to the zero coupon rate in effect at the time of the grant. In December 2011, the
   Company exchanged 4,151,000 shares of common stock in exchange for 5,930,000 of these April warrants at a ratio of 0.7 common shares for each warrant which resulted in a reduction to warrant liability of $3,120,000. The decrease in the fair value of
   the warrants from date of issuance to December&amp;#160;31, 2011 is $5,168,000, of which all has been included in other income and expense in the accompanying consolidated statements of expenses for the twelve months ended December&amp;#160;31, 2011. The fair value of the warrants at December&amp;#160;31, 2011 of $3,154,000 is included as a
   current liability in the accompanying consolidated balance sheets and was determined by the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is
   based on a combination of implied volatilities of similar entities whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 98.91%. The expected life assumption is based on the remaining contract
   term of 5.3 years. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.83% used for the warrants is equal to the zero coupon rate in effect on the date of the
   re-measurement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;September 2011 Registered Direct Offering&lt;/i&gt;&amp;#160;&amp;#8212; On September&amp;#160;26, 2011, the Company completed
   a direct offering of 700,000 shares of common stock for gross proceeds of $455,000. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Stock Options Modified
   &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On April&amp;#160;14, 2011, all of the Company&amp;#8217;s directors and certain of the Company&amp;#8217;s executive officers
   executed agreements with the Company under which they agreed that none of their outstanding stock options will be exercisable unless and until the Company increases the number of authorized shares of common stock to a number that is sufficient to
   permit the exercise or conversion in full of all then outstanding options of the Company (including their stock options), warrants and other securities of the Company that are convertible into shares of common stock. An aggregate of 3,498,256 option
   shares are covered by these agreements. For accounting purposes, the agreement of all of the Company&amp;#8217;s directors and certain executive officers to place restrictions of the exercisability of their options is treated as a modification of their
   options resulting in the reclassification of the options from equity to a liability. In connection with the modification, the Company will recognize compensation cost equal to the greater of (a)&amp;#160;the grant date fair value of the original equity
   award plus an incremental cost associated with the modification or (b)&amp;#160;the fair value of the modified award when it is settled. On July&amp;#160;15, 2011, the Board of Directors of the Company adopted an amendment to increase the authorized shares
   of common stock to 125,000,000, which was presented to and approved by the stockholders of the Company at the 2011 Annual Meeting of Stockholders. This increase in the authorized shares was sufficient to permit the exercise or conversion in full of
   all then outstanding options of the Company (including their stock options), warrants and other securities of the Company that are convertible into shares of common stock, as a result, the liability was marked to market through July&amp;#160;15, 2011
   and, upon settlement, the value of $1,036,000 was reclassified to additional paid in capital. As a result of the modification, the Company recorded additional stock compensation expense of $35,000 during the year ended December&amp;#160;31, 2011.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Other Equity Transactions &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   On March&amp;#160;30, 2011, the Company entered into a severance agreement with its former President and Chief Executive Officer whereby, among other things, it agreed to issue shares to the former officer
   such that the number of shares issued times the market price of the shares on the day immediately following the separation date equal a value of $300,000. As of December&amp;#160;31, 2011, all payments and shares due under this severance agreement have
   been issued and recorded to stock compensation expense. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 11 - us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;11.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Development Stage Supplemental Equity Disclosure &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Summarized below are the Company&amp;#8217;s equity (common stock and common stock options) transactions since the
   Company&amp;#8217;s inception through December&amp;#160;31, 2011 (in thousands except per share data). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="27%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;
   &lt;p style="border-bottom:1px solid #000000;width:49pt"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Type of Security&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Date&amp;#160;of&amp;#160;Issuance&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Shares of&lt;br /&gt;Common&lt;br /&gt;Stock&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Dollar&lt;br /&gt;Amount of&lt;br /&gt;Consideration&lt;br /&gt;($)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Price&amp;#160;per&lt;br /&gt;Share or&lt;br /&gt;Exercise&lt;br /&gt;Price per&lt;br /&gt;Share&lt;br /&gt;($)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Counter&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Party to&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;b&gt;Transaction&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Nature of&lt;br /&gt;Non-Cash&lt;br /&gt;Consideration&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Basis of&lt;br /&gt;Assigning Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;April 3, 2006&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,624,278&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.002&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Founders&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;January 8, 2007&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7.040,318&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;48&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(A)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.007&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;CytRx&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Contributed&lt;br /&gt;Assets&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Predecessor&lt;br /&gt;Cost&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;April 30, 2007&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,273,292&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;15,348&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(B)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.19&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;CytRx&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;April 30, 2007&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;462,112&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,311&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;UMMS&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Intellectual&lt;br /&gt;Properties&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Independent&lt;br /&gt;Third Party&lt;br /&gt;Valuation&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;August 18, 2007&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;30,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;150&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Directors&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;September 28, 2007&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;188,387&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;978&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.19&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;CytRx&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Independent&lt;br /&gt;Third Party&lt;br /&gt;Valuation&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;November 21, 2007&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;66,045&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;331&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercise of Stock&lt;br /&gt;Options&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;June 26, 2008&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,073,299&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,918&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8.12&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;PIPE&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;October&amp;#160;6,&amp;#160;2008&amp;#160;and&lt;br /&gt;November 16, 2008&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,500&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;26&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercise of Stock&lt;br /&gt;Options&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;January 30, 2009&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;58,398&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Market Value&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;May 1, 2009&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;281&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.19&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercise of Stock&lt;br /&gt;Options&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;August 3, 2009 and&lt;br /&gt;August 4, 2009&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,385,715&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,714&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3.50&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Registered&amp;#160;Direct&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;March 22, 2010&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,700,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;15,235&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Registered Direct&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Various&amp;#160;&amp;#8212; 2010&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;53,500&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;254&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.75&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercise of Stock&lt;br /&gt;Options&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;January&amp;#160;2,&amp;#160;2010&amp;#160;and&lt;br /&gt;February 9, 2010&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;86,634&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;207&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Restricted Stock&lt;br /&gt;Units&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Market Value&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;March 4, 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,000,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,307&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.35&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Registered Direct&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;March 15, 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;220,729&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;256&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.16&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Restricted Stock&lt;br /&gt;Units&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Market Value&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;April 13, 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,974,090&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,367&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Acquired Company&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Market Value&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;April 20, 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,950,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,853&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Registered Direct&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;July 1, 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,824&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;15&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.83&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;ESPP&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;July 27, 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;150,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;150&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercise of&lt;br /&gt;Warrants&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;September 26, 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;700,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;455&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.65&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Registered Direct&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;December 6, 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,151,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,120&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exchange with&lt;br /&gt;Warrant Holders&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Market&amp;#160;Value&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Various &amp;#8212; 2011&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;599,051&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;594&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock&amp;#160;Compensation&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;NA&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Market&amp;#160;Value&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="3%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(A)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Transactions between related parties are accounted for at the historical cost of CytRx, with the intellectual property which was previously expensed on CytRx&amp;#8217;s
   books being recorded at zero cost and equipment and furnishings being recorded at $48,000. &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:3px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="3%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(B)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company received gross proceeds of $17.0&amp;#160;million for the issuance of the 3,273,292&amp;#160;shares of common stock which equals $5.19 per share.
   The gross proceeds were reduced by a reimbursement to CytRx of (1)&amp;#160;$1.3&amp;#160;million for RXi&amp;#8217;s pro rata share of offering costs related to the April&amp;#160;17, 2007 private placement
   conducted by CytRx to fund its capital contribution to the Company and (2)&amp;#160;$363,000 of expenses incurred on behalf of RXi for the year ended December&amp;#160;31, 2006. Net proceeds to RXi after
   these charges were $15.3&amp;#160;million or $4.69 a share. &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
</us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 12 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;12.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock Based Compensation &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Options to Purchase Shares of Common Stock &lt;/i&gt;&amp;#8212; The Company follows the provisions ASC&amp;#160;718 which requires
   the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value
   estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;For
   stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50, Non-employee option grants that do not vest immediately upon grant
   are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, is being
   re-measured using the fair value of the Company&amp;#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the
   future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The Company is currently using the Black-Scholes option-pricing model to determine the fair value of all its option grants. For options grants issued for the year ended December&amp;#160;31, 2011 and 2010,
   the following assumptions were used: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="58%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted average risk free interest rate&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.92%&amp;#160;-&amp;#160;3.16%&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.88%&amp;#160;-&amp;#160;3.28%&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted average volatility&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;98.61%&amp;#160;-&amp;#160;113.87%&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;118.3%&amp;#160;-&amp;#160;133.62%&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expected lives (years)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.71 - 9.25&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6 - 10&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0%&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0%&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The weighted average fair value of options granted during the years ended December&amp;#160;31, 2011 and 2010
   was $0.89 and $4.31 per share, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company&amp;#8217;s expected common stock price volatility assumption is based
   upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&amp;#160;718-10, which averages the contractual term of the Company&amp;#8217;s options of
   ten years with the average vesting term of four years for an average of six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that
   Galena has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an
   annualized forfeiture rate of 15% for options granted to its employees, 8% for options granted to senior management and no forfeiture rate for the directors. The Company will record additional expense if the actual forfeitures are lower than
   estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company
   recorded approximately $3,001,000 and $4,368,000 of stock-based compensation for the years ended December&amp;#160;31, 2011 and 2010, respectively. As of December&amp;#160;31, 2011, there was $1,012,000 of unrecognized compensation cost related to
   outstanding options that is expected to be recognized as a component of the Company&amp;#8217;s operating expenses over a weighted average period of 3.3 years. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On November&amp;#160;4,
   2009, as part of a plan succession in leadership, Tod Woolf,&amp;#160;Ph.D., resigned as our President, Chief Executive Officer and a member of our Board of Directors. According to the Separation Agreement between Dr.&amp;#160;Woolf and the Company,
   Dr.&amp;#160;Woolf received in one lump sum payment his full severance equivalent to a six (6)&amp;#160;month salary ($187,500), six (6)&amp;#160;months acceleration of vesting of all of his outstanding unvested Stock Options as of November&amp;#160;4, 2009, and an
   offer to join the Company&amp;#8217;s Scientific Advisory Board (SAB) for 3&amp;#160;years (the &amp;#8220;New Position&amp;#8221;). In addition, and as part of the Separation Agreement, the Company agreed to extend the exercise period for all of Dr.&amp;#160;Woolf&amp;#8217;s
   vested Stock Options as of November&amp;#160;4, 2009, to the later of: (i)&amp;#160;a period of two (2)&amp;#160;years from his resignation (until November&amp;#160;4, 2011), or (ii)&amp;#160;ninety (90)&amp;#160;days following the end of the term of the SAB&amp;#160;Agreement
   (February&amp;#160;4, 2013)&amp;#160;or such earlier date as the SAB&amp;#160;Agreement may be terminated pursuant to the terms of the SAB&amp;#160;Agreement provided Dr.&amp;#160;Woolf has not violated the non-competition provisions of the SAB&amp;#160;Agreement prior to
   the date of exercise (whether or not the SAB&amp;#160;Agreement is still in effect at that time). Notwithstanding any provision of the Company&amp;#8217;s 2007 Incentive Plan, the Company also agreed that Dr.&amp;#160;Woolf&amp;#8217;s previously awarded Stock
   Options shall continue to vest during his continuing role in the Company in the New Position. The total expense for 2011 and 2010 was $65,000 and $193,000, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   During the fiscal year ended December&amp;#160;31, 2011, we granted to our President and Chief Executive Officer 300,000 stock options subject to performance-based vesting. The aggregate fair market value of
   the stock option grant was valued using the lattice model and is being amortized to compensation expense over the vesting period. Compensation expense recognized related to this grant was approximately $23,000 for the year ended December&amp;#160;31,
   2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As of December&amp;#160;31, 2011, an aggregate of 8,750,000&amp;#160;shares of common stock were reserved for issuance under the
   Company&amp;#8217;s 2007 Incentive Plan, including 6,163,137&amp;#160;shares subject to outstanding common stock options granted under this plan and 1,299,717&amp;#160;shares available for future grants. The administrator of the plan determines the times when an
   option may become exercisable. Vesting periods of options granted to date include vesting upon grant to vesting at the end of a four year period. The options will expire, unless previously exercised, no later than ten years from the grant date. The
   Company is using unissued shares for all shares issued for options, restricted share awards and ESPP issuances. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following
   table summarizes the options&amp;#8217; activity of the Company&amp;#8217;s stock option plan: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="73%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="7%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Stock&lt;br /&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&amp;#160;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Outstanding&amp;#160;&amp;#8212; January&amp;#160;1, 2010&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,582,339&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.16&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;926,768&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.81&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(53,500&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.75&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(122,471&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.85&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Outstanding&amp;#160;&amp;#8212; December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,333,136&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.10&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,322,500&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.21&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(1,492,499&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4.99&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Outstanding&amp;#160;&amp;#8212; December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,163,137&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3.03&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercisable&amp;#160;&amp;#8212; December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,155,900&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.22&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercisable&amp;#160;&amp;#8212; December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,673,768&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3.40&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The weighted average remaining contractual life of options outstanding and exercisable at
   December&amp;#160;31, 2011 was 7.87 years and 7.56 years, respectively. The weighted average remaining contractual life of options outstanding and exercisable at December&amp;#160;31, 2010 was 7.35 years and 7.09 years, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The aggregate intrinsic value of outstanding options as of December&amp;#160;31, 2011 and 2010 is $0 and $137,000, respectively. The aggregate
   intrinsic value of exercisable options as of December&amp;#160;31, 2011 and 2010 is $0 and $34,000, respectively. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company&amp;#8217;s common stock and the exercise price
   of the underlying options. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The aggregate intrinsic value of options exercised during 2010 was approximately $164,000. There
   were no options exercised during 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Employee Stock Purchase Plan&lt;/i&gt; &amp;#8212;&amp;#160;The Company also has an employee stock
   purchase plan (&amp;#8220;ESPP&amp;#8221;) which allows employees to contribute up to 15% of their cash earnings, subject to certain maximums, to be used to purchase shares of our common stock on each semi-annual purchase date. The purchase price is equal to
   85% of the market value per share on either the first or last day of the semi-annual period, whichever is lower. Our ESPP is non-compensatory pursuant to the provisions of generally accepted accounting principles for share-based compensation
   expense. The ESPP contains an &amp;#8220;evergreen provision&amp;#8221; with annual increases in the number of shares available for issuance on the first day of each year through January&amp;#160;1, 2015 equal to the lesser of: (a)&amp;#160;250,000 shares increased
   on each anniversary of the adoption of the Plan by one percent (1%)&amp;#160;of the total shares of stock then outstanding and (b)&amp;#160;1,000,000 shares.&amp;#160;As of December&amp;#160;31, 2011, an aggregate of 231,176 shares of common stock were authorized
   and available for issuance under the ESPP. Under the evergreen provision, on January&amp;#160;1, 2012, an additional 250,000 shares were authorized under our ESPP. The Company has issued 18,824 shares under the ESPP through December&amp;#160;31, 2011.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Restricted Stock Units &lt;/i&gt;&amp;#8212; In addition to options to purchase shares of common stock, the Company may grant
   restricted stock units (&amp;#8220;RSU&amp;#8221;) as part of its compensation package. Each RSU is granted at the fair market value based on the date of grant. Vesting is determined on a grant by grant basis. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In 2011 and 2010, the Company granted a total of 220,728 and 43,541 RSUs, respectively. The RSUs granted in 2011 and 2010 had an aggregate
   intrinsic value of $256,000 and $112,000. As of December&amp;#160;31, 2011 and 2010, all of the RSUs had vested in full. &lt;/font&gt;&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:EarningsPerShareTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 13 - us-gaap:EarningsPerShareTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;13.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net Loss Per Share &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &amp;#8220;
   &lt;i&gt;Earnings per Share.&amp;#8221;&lt;/i&gt; Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by
   dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding.
   Potential common shares consist of shares issuable upon the exercise of stock options and warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as
   basic net loss per common share. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following table sets forth the potential common shares excluded from the calculation of
   net loss per common share because their inclusion would be anti-dilutive: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="75%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Options to purchase common stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,163,137&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,333,136&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;14,120,642&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,100,642&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;20,283,779&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,433,778&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 14 - us-gaap:IncomeTaxDisclosureTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;14.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Income Taxes &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The components of federal and state income tax expense are as follows (in thousands): &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="79%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="9%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="8%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Current&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;State&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total current&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Deferred&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Federal&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,531&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,853&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;State&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,831&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,283&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total deferred&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,362&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,136&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(10,362&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(6,136&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total income tax expense&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The components of net deferred tax assets are as follows (in thousands): &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="77%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,786&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,328&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,160&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,061&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock based compensation&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,885&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,864&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;193&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;104&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Licensing deduction deferral&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,458&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,264&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;36,482&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;23,621&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(36,482&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(23,621&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net deferred tax asset&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The components of net deferred tax liabilities are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2011&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2010&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In-process research and development not subject to future amortization for tax purposes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,053&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Gross deferred tax liability&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,053&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The provision for
   income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows (in thousands): &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="79%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Expected federal income tax benefit&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(3,905&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(4,078&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Non-qualified stock compensation&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(3,189&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(1,236&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Effect of change in valuation allowance&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8,551&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,136&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Income tax credits&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(260&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(231&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;State income taxes after credits&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(1,197&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(994&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;403&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has incurred net operating losses from inception. At December&amp;#160;31, 2011, the Company had
   domestic federal and state net operating loss carryforwards of approximately $41.6&amp;#160;million available to reduce future taxable income, which expire at various dates beginning in 2013 through 2031. The Company also had federal and state research
   and development tax credit carryforwards of approximately $2,000,000 and $1,800,000, respectively, available to reduce future tax liabilities and which expire at various dates beginning in 2023 through 2031. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&amp;#8217;s ownership may result in a limitation
   on the amount of net operating loss carryforwards and research and development credit carryforwards which could be utilized annually to offset future taxable income and taxes payable. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Based on an assessment of all available evidence including, but not limited to the Company&amp;#8217;s limited operating history in its core
   business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has
   concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a 100% deferred income tax valuation allowance has been recorded against these assets. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company adopted certain provisions of the &lt;i&gt;ASC 740,&lt;/i&gt; effective January&amp;#160;1, 2007 which clarifies the accounting for
   uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. The adoption
   of &lt;i&gt;ASC 740-10&lt;/i&gt; did not have any effect on the Company&amp;#8217;s financial position or results of operations. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company
   files income tax returns in the U.S.&amp;#160;federal, Massachusetts and Oregon jurisdictions. The Company is subject to tax examinations for the 2007 tax year and beyond. The Company does not believe there will be any material changes in its
   unrecognized tax positions over the next 12&amp;#160;months. The Company has not incurred any interest or penalties. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial
   statements as general and administrative expense. &lt;/font&gt;&lt;/p&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 15 - us-gaap:IntangibleAssetsDisclosureTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;15.&amp;#160;&amp;#160;&amp;#160;&amp;#160;License Agreements &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As part of its business, the Company enters into licensing agreements with third parties that often require milestone
   and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to
   make royalty payments based upon a percentage of net sales. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The expenditures required under these arrangements may be material
   individually in the event that the Company develops product candidates covered by the intellectual property licensed under any such arrangement, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of
   operations. In addition, these arrangements often give the Company discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease
   development if the compound successfully achieves clinical testing objectives. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During the year ended December&amp;#160;31, 2007,
   the Company entered into a license agreement with Cold Spring Harbor Laboratory (&amp;#8220;CSHL&amp;#8221;) for small hairpin RNA, or &amp;#8220;shRNA&amp;#8221;, for which the Company paid $50,000 and agreed to make future milestone and royalty payments upon
   successful development and commercialization of products. The Company also entered into four exclusive license agreements and an invention disclosure agreement with the University of Massachusetts Medical School (&amp;#8220;UMMS&amp;#8221;) for which the
   Company paid cash of $453,000 and issued 462,112 shares of its common stock valued at $2.3 million, or $5.00 per share. For each RNAi product developed in connection with the license granted by CSHL, the possible aggregate milestone payments equal
   $2,650,000. The invention disclosure agreement has an initial term of three years and provides the option to negotiate licenses to certain RNAi technologies discovered at UMMS. During the year ended December&amp;#160;31, 2011, the Company cancelled
   several of its licenses with UMMS. Upon the signing of the Contribution Agreement on September&amp;#160;24, 2011, one of the remaining UMMS licenses was transferred to RXi and the CSHL license agreement was retained by the Company and not transferred to
   RXi. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In October 2007, the Company entered into a license agreement with Dharmacon, Inc. (now part of Thermo Fisher Scientific
   Inc.), pursuant to which the Company obtained an exclusive license to certain RNAi sequences to a number of target genes for the development of the Company&amp;#8217;s rxRNA compounds. Further, the Company has obtained the right to license additional
   RNAi sequences, under the same terms, disclosed by Thermo Fisher Scientific Inc. in its pending patent applications against target genes and has received an option for exclusivity for other siRNA configurations. As consideration for this license,
   the Company paid an up-front fee of $150,000 and agreed to pay future clinical milestone payments and royalty payments based on sales of siRNA compositions developed in connection with the licensed technology. In addition, the Company has agreed to
   pay future clinical milestone payments in an aggregate amount of up to $2,000,000 and royalty payments of either 0.25% or 0.5% based on the level of any future sales of siRNA compositions developed in connection with the licensed technology. No
   amounts were expensed in 2010 and 2011 related to this license. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In September, 2009, the Company entered into a Patent and
   Technology Assignment Agreement with Advirna, LLC (&amp;#8220;Advirna&amp;#8221;), a Colorado limited liability company co-founded by the Company&amp;#8217;s former Chief Scientific Officer. Pursuant to the terms of the agreement, Advirna assigned to the Company
   certain patent and technology rights related to chemically modified polynucleotides (the &amp;#8220;Rights&amp;#8221;) and the Company granted to Advirna a fully paid-up license to the Rights in a specified field. During the year ended December&amp;#160;31, 2011,
   the Company paid and expensed $100,000 for the annual maintenance fees under this agreement. There was no expense recorded for the year ended December&amp;#160;31, 2010. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   As part of the transactions contemplated by the Contribution Agreement and Securities Purchase Agreement, on September&amp;#160;24, 2011, RXi entered into an agreement with Advirna pursuant to which:
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Advirna assigned to RXi its existing patent and technology rights related to sd-rxRNA technology in exchange for RXi&amp;#8217;s agreement to pay Advirna an
   annual $100,000 maintenance fee and a one-time $350,000 milestone payment upon the future issuance of the first patent with valid claims covering the assigned patent and technology rights; &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi with respect to future licensing of the assigned Advirna
   patent and technology rights; &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;RXi has granted back to Advirna a license under the assigned patent and technology for fields of use outside the fields of human therapeutics and
   diagnostics; and &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:6px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;RXi has agreed to issue to Advirna, upon the completion of the spin-off transaction, shares of RXi&amp;#8217;s common stock equal to approximately 5% of the
   fully diluted shares of RXi common stock assuming the conversion in full of all outstanding Series A Preferred Stock. &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In conjunction with the acquisition of Apthera, the Company assumed the rights and obligations of a certain license agreement, as amended, from The University of Texas M. D. Anderson Cancer Center
   (&amp;#8220;MDACC&amp;#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&amp;#8220;HJF&amp;#8221;) which grants exclusive worldwide rights to a U.S. patent covering the E75 peptide, and several U.S. and foreign patents and
   patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to make future annual maintenance fee payments, as well as clinical milestone payments and royalty payments based on sales of
   therapeutic products developed from the licensed technologies. As part of the expected payments under the terms of the license, the Company must pay an annual maintenance fee of $200,000. In addition, upon commencing the Phase 3 trial, we will pay a
   milestone payment of $200,000. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In July 2011, the Company entered into a subsequent non-exclusive license
   agreement with HJF which has since been made exclusive, granting patent rights to the use of the E75 peptide in combination with Herceptin&lt;font style="font-family:times new roman" size="1"&gt;&lt;sup&gt;
   &amp;reg;&lt;/sup&gt;&lt;/font&gt;. As part of the expected payments under the terms of the license, the Company paid an issue royalty fee of $100,000. In addition, the Company must pay an annual
   maintenance fee of $50,000 ($25,000 for each patent) and royalties based on net sales upon commercialization. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In September
   2011, the Company licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39 (FBP) targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarconimas. The FBP vaccine was licensed
   from The University of Texas M D Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. FBP has been granted Investigational New Drug approval by the U.S. Food and Drug Administration to enter clinical
   trials. Institutional Review Board approval has also been received allowing RXi to initiate Phase 1 trials by the end of 2011. As part of the expected payments under the terms of the license, the Company paid an issue royalty fee of $100,000.
   Additionally, the Company shall pay the HJF a non-creditable, nonrefundable License issue royalty in the sum of $15,000 for each additional item of follow-on intellectual property. In addition, the Company must pay an annual maintenance fee of
   $25,000 in 2012 and $50,000 in 2013. &lt;/font&gt;&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 16 - us-gaap:RelatedPartyTransactionsDisclosureTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;16.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Related Party Transactions &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;RXi and Advirna, LLC, which is 50%-owned by the Company&amp;#8217;s former Chief Scientific Officer, or CSO, are parties to
   an option agreement whereby the Company paid $5,000 in 2008 for consideration to be granted the exclusive worldwide rights to license certain technology and $75,000 for the initial maintenance in 2009 under a Patent and Technology Assignment
   Agreement with Advirna entered into in September 2009 (see also Note&amp;#160;15). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On February&amp;#160;26, 2007, the Company entered
   into Scientific Advisory Board Agreements (the &amp;#8220;SAB&amp;#160;Agreements&amp;#8221;), with four of its founders. At the time of the execution of the SAB&amp;#160;Agreements, each of the founders were beneficial owners of more than five percent of the
   Company&amp;#8217;s outstanding stock. Pursuant to the SAB&amp;#160;Agreements, on May&amp;#160;23, 2007, the Company granted to each of the founders a stock option under the 2007 Plan to purchase 52,832&amp;#160;shares of its common stock. In addition, under the
   SAB&amp;#160;Agreements, the Company will grant each of the founders a stock option under the 2007 Plan to purchase 52,832&amp;#160;shares of its common stock on February&amp;#160;26, 2008, June&amp;#160;5, 2009 and June&amp;#160;4, 2010 with a per share exercise price
   equal to the closing price of such stock on the public market on the date of grant unless a founder terminates a SAB&amp;#160;Agreement without good reason (as defined) or the Company terminates a SAB&amp;#160;Agreement with cause (as defined therein) in
   which case no further option grants will be made to the founder. If the Company&amp;#8217;s common stock is not publicly available on the dates specified above, its Board of Directors will grant the stock options to the founders at the first scheduled
   board meeting after such date and the per share exercise price of the options will be determined in good faith by the Company&amp;#8217;s board of directors. All options granted pursuant to the SAB&amp;#160;Agreements are fully vested on the date of grant
   and have a term of ten years. The fair value of stock options granted during 2011 and 2010 under the SAB&amp;#160;Agreement for each founder is approximately $0 and $142,000 which was estimated using the Black-Scholes option-pricing model as more fully discussed above under significant
   accounting policies and the stock based compensation footnote. Included in the accompanying financial statements for the years ended December&amp;#160;31, 2010 is approximately $566,000 of expense related to the
   granting of these stock options. No options under the SAB agreements were issued during the year ended December &amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Additionally, pursuant to a letter agreement between the Company and each founder dated as of
   April&amp;#160;30, 2007, the &amp;#8220;SAB&amp;#160;Letters&amp;#8221;, in further consideration of the services to be rendered by the founders under the SAB&amp;#160;Agreements, the Company granted additional stock options on May&amp;#160;23, 2007 under the 2007 Plan to
   each of the founders to purchase 26,416&amp;#160;shares of its common stock. Unless a founder terminates a SAB&amp;#160;Agreement without good reason (as defined) or the Company terminates a SAB&amp;#160;Agreement with cause (as defined therein), the options
   granted pursuant to the SAB&amp;#160;Letters will fully vest from and after April&amp;#160;29, 2012 and will have a term of ten years from the date of grant. At December&amp;#160;31, 2011 and 2010 the fair market value of stock options under the SAB&amp;#160;Agreement for
   each founder is approximately $5,000 and $59,000, respectively, which was estimated using the Black-Scholes option-pricing model as more fully discussed above under the summary of significant accounting policies and the stock based compensation footnote. Included in the
   accompanying financial statements for the years ended December&amp;#160;31, 2011 and 2010 is approximately $159,000 and $60,000 of income, respectively, related to these stock options. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During 2012, the Company retained TroyGould PC to be its outside corporate counsel. Sanford J. Hillsberg, the Chairman of the Company, is
   a senior lawyer with TroyGould PC. &lt;/font&gt;&lt;/p&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 17 - us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;17.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Employee Benefit Plan &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company sponsors a 401(k) retirement savings plan (the &amp;#8220;Plan&amp;#8221;). Participation in the Plan is available to
   full-time employees who meet eligibility requirements. Eligible employees may defer a portion of their salary as defined by Internal Revenue Service regulations. The Company may make matching contributions on behalf of all participants in the 401(k)
   Plan in an amount determined by the Company&amp;#8217;s board of directors. The Company may also make additional discretionary profit sharing contributions in amounts as determined by the board of directors, subject to statutory limitations. Matching and
   profit-sharing contributions, if any, are subject to a vesting schedule; all other contributions are at all times fully vested. The Company intends the 401(k) Plan, and the accompanying trust, to qualify under Sections&amp;#160;401(k) and 501 of the
   Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that the Company will be able to deduct its
   contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, invests the assets of the 401(k) Plan in any of a number of investment options. To date, the Company has not made any matching contributions.
   &lt;/font&gt;&lt;/p&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SubsequentEventsTextBlock contextRef="Jan-1-2011_Dec-31-2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 18 - us-gaap:SubsequentEventsTextBlock--&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;18.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subsequent Events &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company evaluated all events or transactions that occurred after December&amp;#160;31, 2011 up through the date these
   financial statements were issued. Other than what is disclosed below, or elsewhere in the notes to the consolidated financial statements, the Company did not have any material recognizable or unrecognizable subsequent events. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On January&amp;#160;12, 2012, the Company granted an option to purchase 50,000&amp;#160;shares of common stock to each of the five non-employee
   members of the Board of Directors. These options had an exercise price of $0.72 per share, which represented the Company&amp;#8217;s closing stock price on that date. The options vest quarterly over a one-year period and expire not later than 10 years
   from the grant date. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On January&amp;#160;12, 2012, the Company granted options to purchase an aggregate of 825,000&amp;#160;shares of
   common stock to certain employees at a price of $0.72 per share, which represented the Company&amp;#8217;s closing stock price on that date. The options vest quarterly over four years beginning three months from the date of grant and expire not later than 10 years from the date of grant. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On February&amp;#160;4, 2012, the Company granted warrants to purchase 400,000&amp;#160;shares of common stock at an exercise price of $0.66 per
   share in exchange for business advisory services to the Company for a period of up to twelve months. The warrants vested as to 100,000&amp;#160;shares upon issuance, and then will vest at a rate of 100,000&amp;#160;shares&amp;#160;per quarter starting on the
   90&amp;#160;day anniversary of issuance. The Company has also agreed to give &amp;#8220;piggy back&amp;#8221; registration rights with respect to the shares of common stock underlying the warrants in any registration statement filed by the company in connection
   with an underwritten offering of the common stock. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On January&amp;#160;20, 2012, the Company sold 579,710 shares of our common
   stock for $400,000 to Kwang Dong Pharmaceutical Company as part of a existing license agreement for NeuVax covering territorial rights for the compound in South Korea that the Company acquired in its merger acquisition of Apthera. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On February&amp;#160;3, 2012, the Company issued 100,000 shares of our common stock in payment of $135,000 of accrued legal fees. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On March&amp;#160;8, 2012, the Company issued 1,315,789 restricted shares of common stock in payment of the first milestone under the
   contingent value rights agreement entered into in connection with our merger acquisition of Apthera in April 2011. The certificates evidencing the milestone shares have been deposited with a third-party escrow agent. The milestone shares will be
   released to the former Apthera shareholders from escrow if the issuance of the milestone shares is approved by the stockholders of the Company at the Company&amp;#8217;s 2012 annual stockholders meeting. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;From January 23, 2012 through March 23, 2012, the Company issued 1,369,944 shares of the Company&amp;#8217;s common stock subject to the
   exercise of outstanding warrants from various warrant holders. The Company received $1,223,464 in total payments at exercise prices ranging from $0.65 to $2.50 per share. &lt;/font&gt;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
  <!-- End Block Tagged Note -->
  <rxii:AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">785000</rxii:AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants>
  <rxii:AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">785000</rxii:AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants>
  <rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices contextRef="TwelveMonthsEnded_31Dec2008_Successor_Member" unitRef="USD" decimals="-3">750000</rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices>
  <rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices contextRef="TwelveMonthsEnded_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">750000</rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices>
  <rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">826000</rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices>
  <rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices contextRef="TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">826000</rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices>
  <rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">718000</rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices>
  <rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">718000</rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices>
  <rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">108000</rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices>
  <rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">108000</rxii:AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices>
  <rxii:NetTransactionsWithParent contextRef="TwelveMonthsEnded_31Dec2004_Predecessor_Member" unitRef="USD" decimals="-3">2393000</rxii:NetTransactionsWithParent>
  <rxii:NetTransactionsWithParent contextRef="TwelveMonthsEnded_31Dec2004_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">2393000</rxii:NetTransactionsWithParent>
  <rxii:NetTransactionsWithParent contextRef="TwelveMonthsEnded_31Dec2005_Predecessor_Member" unitRef="USD" decimals="-3">2727000</rxii:NetTransactionsWithParent>
  <rxii:NetTransactionsWithParent contextRef="TwelveMonthsEnded_31Dec2005_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">2727000</rxii:NetTransactionsWithParent>
  <rxii:NetTransactionsWithParent contextRef="TwelveMonthsEnded_31Dec2006_Predecessor_Member" unitRef="USD" decimals="-3">2587000</rxii:NetTransactionsWithParent>
  <rxii:NetTransactionsWithParent contextRef="TwelveMonthsEnded_31Dec2006_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">2587000</rxii:NetTransactionsWithParent>
  <rxii:StockIssuedDuringPeriodForReimbursementOfExpensesShares contextRef="TwelveMonthsEnded_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">188387</rxii:StockIssuedDuringPeriodForReimbursementOfExpensesShares>
  <rxii:StockIssuedDuringPeriodSharesCashBonus contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">147040</rxii:StockIssuedDuringPeriodSharesCashBonus>
  <rxii:StockIssuedDuringPeriodSharesEmployeeTerminationAgreements contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">398453</rxii:StockIssuedDuringPeriodSharesEmployeeTerminationAgreements>
  <rxii:StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties contextRef="TwelveMonthsEnded_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">462112</rxii:StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties>
  <rxii:StockIssuedDuringPeriodSharesInExchangeOfWarrants contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">4151000</rxii:StockIssuedDuringPeriodSharesInExchangeOfWarrants>
  <rxii:StockIssuedDuringPeriodSharesServices contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">53558</rxii:StockIssuedDuringPeriodSharesServices>
  <rxii:StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement contextRef="TwelveMonthsEnded_31Dec2009_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">58398</rxii:StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement>
  <rxii:StockIssuedDuringPeriodSharesToDirectors contextRef="TwelveMonthsEnded_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">30000</rxii:StockIssuedDuringPeriodSharesToDirectors>
  <rxii:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">150000</rxii:StockIssuedDuringPeriodSharesWarrantsExercised>
  <rxii:StockIssuedDuringPeriodValueCashBonus contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">171000</rxii:StockIssuedDuringPeriodValueCashBonus>
  <rxii:StockIssuedDuringPeriodValueCashBonus contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">171000</rxii:StockIssuedDuringPeriodValueCashBonus>
  <rxii:StockIssuedDuringPeriodValueEmployeeTerminationAgreements contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">350000</rxii:StockIssuedDuringPeriodValueEmployeeTerminationAgreements>
  <rxii:StockIssuedDuringPeriodValueEmployeeTerminationAgreements contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">350000</rxii:StockIssuedDuringPeriodValueEmployeeTerminationAgreements>
  <rxii:StockIssuedDuringPeriodValueForAdditionalIntellectualProperties contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">2311000</rxii:StockIssuedDuringPeriodValueForAdditionalIntellectualProperties>
  <rxii:StockIssuedDuringPeriodValueForAdditionalIntellectualProperties contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">2311000</rxii:StockIssuedDuringPeriodValueForAdditionalIntellectualProperties>
  <rxii:StockIssuedDuringPeriodValueForReimbursementOfExpenses contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">978000</rxii:StockIssuedDuringPeriodValueForReimbursementOfExpenses>
  <rxii:StockIssuedDuringPeriodValueForReimbursementOfExpenses contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">978000</rxii:StockIssuedDuringPeriodValueForReimbursementOfExpenses>
  <rxii:StockIssuedDuringPeriodValueInExchangeOfWarrants contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">3120000</rxii:StockIssuedDuringPeriodValueInExchangeOfWarrants>
  <rxii:StockIssuedDuringPeriodValueInExchangeOfWarrants contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">3120000</rxii:StockIssuedDuringPeriodValueInExchangeOfWarrants>
  <rxii:StockIssuedDuringPeriodValueServices contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">73000</rxii:StockIssuedDuringPeriodValueServices>
  <rxii:StockIssuedDuringPeriodValueServices contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">73000</rxii:StockIssuedDuringPeriodValueServices>
  <rxii:StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">281000</rxii:StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement>
  <rxii:StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement contextRef="TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">281000</rxii:StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement>
  <rxii:StockIssuedDuringPeriodValueToDirectors contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">150000</rxii:StockIssuedDuringPeriodValueToDirectors>
  <rxii:StockIssuedDuringPeriodValueToDirectors contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">150000</rxii:StockIssuedDuringPeriodValueToDirectors>
  <rxii:StockIssuedDuringPeriodValueWarrantsExercised contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">150000</rxii:StockIssuedDuringPeriodValueWarrantsExercised>
  <rxii:StockIssuedDuringPeriodValueWarrantsExercised contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">150000</rxii:StockIssuedDuringPeriodValueWarrantsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">1048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">1048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2008_Successor_Member" unitRef="USD" decimals="-3">2211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">2211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">2906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">2906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">3625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">3625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">2774000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">2774000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2008_Successor_Member" unitRef="USD" decimals="-3">1613000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">1613000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">1296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">1296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">-123000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">-123000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">-2863000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">-2863000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">-2466000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">-2466000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">-12709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">-12709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2004_Predecessor_Member" unitRef="USD" decimals="-3">-3272000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2004_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">-3272000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2005_Predecessor_Member" unitRef="USD" decimals="-3">-2209000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2005_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">-2209000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2006_Predecessor_Member" unitRef="USD" decimals="-3">-2405000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2006_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">-2405000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">-10990000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-10990000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2008_Successor_Member" unitRef="USD" decimals="-3">-14373000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2008_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-14373000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">-18387000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-18387000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">-11993000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-11993000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">-11485000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-11485000</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2008_Successor_Member" unitRef="USD" decimals="-3">796000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">796000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">636000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">636000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2009_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">636000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">965000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">965000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">1890000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">1890000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">1890000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2003_Predecessor_Member_Common_Stock_Member" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2004_Predecessor_Member_Common_Stock_Member" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2005_Predecessor_Member_Common_Stock_Member" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_03Apr2006_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2006_Predecessor_Member_Common_Stock_Member" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2006_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">1624278</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">12684432</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2008_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">13763231</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2009_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">16207625</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2010_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">19047759</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="BalanceAsOf_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">47811453</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2003_Predecessor_Member" unitRef="USD" decimals="-3">-89000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2003_Predecessor_Member_Additional_Paid_In_Capital_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2003_Predecessor_Member_Common_Stock_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2003_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">-89000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2004_Predecessor_Member" unitRef="USD" decimals="-3">-968000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2004_Predecessor_Member_Additional_Paid_In_Capital_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2004_Predecessor_Member_Common_Stock_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2004_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">-968000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2005_Predecessor_Member" unitRef="USD" decimals="-3">-450000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2005_Predecessor_Member_Additional_Paid_In_Capital_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2005_Predecessor_Member_Common_Stock_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2005_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">-450000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_03Apr2006_Successor_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_03Apr2006_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_03Apr2006_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_03Apr2006_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_03Apr2006_Treasury_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Predecessor_Member" unitRef="USD" decimals="-3">-268000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Successor_Member" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Predecessor_Member_Additional_Paid_In_Capital_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Predecessor_Member_Common_Stock_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Predecessor_Member_Retained_Earnings_Member" unitRef="USD" decimals="-3">-268000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2006_Treasury_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">10823000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2007_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-10990000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">21812000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2007_Treasury_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2008_Successor_Member" unitRef="USD" decimals="-3">8968000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2008_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-25363000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">34330000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2008_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2008_Treasury_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">741000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2009_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-43750000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">44489000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2009_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2009_Successor_Member_Treasury_Stock_Member" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">2430000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-55743000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">62020000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010_Treasury_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">-3849000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">10112000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011_Successor_Member_Deficit_Accumulated_During_Development_Stage_Member" unitRef="USD" decimals="-3">-67228000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">81184000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">5000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011_Treasury_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">-3849000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">4974090</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">18824</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="NineMonthsEnded_31Dec2006_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">1624278</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="TwelveMonthsEnded_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">3273292</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="TwelveMonthsEnded_31Dec2008_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">1073299</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="TwelveMonthsEnded_31Dec2009_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">2385715</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="TwelveMonthsEnded_31Dec2010_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">2700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">18650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="TwelveMonthsEnded_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">7040318</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="TwelveMonthsEnded_31Dec2010_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">86634</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">220729</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">66045</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2008_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">5500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2009_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">281</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2010_Common_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">53500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">6367000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">6366000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">15000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">15000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="NineMonthsEnded_31Dec2006_Successor_Member" unitRef="USD" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="NineMonthsEnded_31Dec2006_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">15348000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">15348000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2008_Successor_Member" unitRef="USD" decimals="-3">7918000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">7918000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2009_Successor_Member" unitRef="USD" decimals="-3">7714000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2009_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">7713000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2009_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">15235000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">15235000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">18615000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">18613000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="TwelveMonthsEnded_31Dec2011_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">48000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">47000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="TwelveMonthsEnded_31Dec2007_Common_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">207000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">207000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="TwelveMonthsEnded_31Dec2011_Successor_Member" unitRef="USD" decimals="-3">256000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="TwelveMonthsEnded_31Dec2011_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">256000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2007_Successor_Member" unitRef="USD" decimals="-3">331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2007_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2008_Successor_Member" unitRef="USD" decimals="-3">26000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2008_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">26000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">254000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="TwelveMonthsEnded_31Dec2010_Additional_Paid_In_Capital_Member_Successor_Member" unitRef="USD" decimals="-3">254000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:TreasuryStockSharesAcquired contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="Shares" decimals="INF">675000</us-gaap:TreasuryStockSharesAcquired>
  <us-gaap:TreasuryStockSharesAcquired contextRef="TwelveMonthsEnded_31Dec2010_Treasury_Stock_Member_Successor_Member" unitRef="Shares" decimals="INF">675000</us-gaap:TreasuryStockSharesAcquired>
  <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="TwelveMonthsEnded_31Dec2010_Successor_Member" unitRef="USD" decimals="-3">3849000</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="TwelveMonthsEnded_31Dec2010_Treasury_Stock_Member_Successor_Member" unitRef="USD" decimals="-3">3849000</us-gaap:TreasuryStockValueAcquiredCostMethod>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>rxii-20111231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://rxipharma.com/20111231" xmlns:rxii="http://rxipharma.com/20111231" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://xbrl.sec.gov/us-types/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://rxipharma.com/role/LicenseAgreements" id="LicenseAgreements">
        <link:definition>0215 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StatementsOfStockholderEquity" id="StatementsOfStockholderEquity">
        <link:definition>0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
        <link:definition>0130 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>00 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>0110 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0111 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StatementsOfIncome" id="StatementsOfIncome">
        <link:definition>0120 - Statement - Consolidated Statements of Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0140 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
        <link:definition>0141 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/NatureOfBusiness" id="NatureOfBusiness">
        <link:definition>0201 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
        <link:definition>0203 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/SubsidiaryAcquisition" id="SubsidiaryAcquisition">
        <link:definition>0204 - Disclosure - Apthera Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/SpinOut" id="SpinOut">
        <link:definition>0205 - Disclosure - RXi Spin-Out</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>0206 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/CapitalLeaseObligations" id="CapitalLeaseObligations">
        <link:definition>0207 - Disclosure - Capital Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>0208 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>0209 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>0210 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/DevelopmentStageSupplementalEquityDisclosure" id="DevelopmentStageSupplementalEquityDisclosure">
        <link:definition>0211 - Disclosure - Development Stage Supplemental Equity Disclosure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>0212 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>0213 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0214 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>0216 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
        <link:definition>0217 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0218 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="rxii-20111231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rxii-20111231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rxii-20111231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rxii-20111231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <!-- elements -->
  <element name="DocumentAndEntityInformationAbstract" id="rxii_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true" />
  <element name="InProcessResearchDevelopment" id="rxii_InProcessResearchDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="FairValueOfWarrantsPotentiallySettleableInCash" id="rxii_FairValueOfWarrantsPotentiallySettleableInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="CurrentContingentPurchasePriceConsideration" id="rxii_CurrentContingentPurchasePriceConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" id="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="DeficitAccumulatedDuringDevelopmentalStage" id="rxii_DeficitAccumulatedDuringDevelopmentalStage" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" id="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" id="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfCommonStockInExchangeForLicensingRights" id="rxii_FairValueOfCommonStockInExchangeForLicensingRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="GeneralAndAdministrativeExpenses" id="rxii_GeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" id="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" id="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="GeneralAndAdministrativeEmployeeStockBasedCompensation" id="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="InterestIncome" id="rxii_InterestIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="LossOnWarrantExchange" id="rxii_LossOnWarrantExchange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" id="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" id="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="NetIncomeLossIncludingOther" id="rxii_NetIncomeLossIncludingOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="NonCashRentExpense" id="rxii_NonCashRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="LossOnExchangeOfEquityInstruments" id="rxii_LossOnExchangeOfEquityInstruments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" id="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" id="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FairValueOfCommonStockIssuedInExchangeForLicensingRights" id="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ChangeInFairValueOfContingentPurchaseConsideration" id="rxii_ChangeInFairValueOfContingentPurchaseConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="CashReceivedInAcquisition" id="rxii_CashReceivedInAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="CashRefundedPaidForLeaseDeposit" id="rxii_CashRefundedPaidForLeaseDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="NetProceedsFromExerciseOfCommonStockWarrants" id="rxii_NetProceedsFromExerciseOfCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="NetProceedsFromIssuanceOfConvertibleNotesPayable" id="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" id="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" id="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="AllocationOfManagementExpenses" id="rxii_AllocationOfManagementExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="EquipmentAndFurnishingsExchangedForCommonStock" id="rxii_EquipmentAndFurnishingsExchangedForCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" id="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FairValueOfSharesIssuedToAcquire" id="rxii_FairValueOfSharesIssuedToAcquire" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition" id="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="NetAssetsAcquiredExcludingCash" id="rxii_NetAssetsAcquiredExcludingCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="CashExcludingFromNetAssetsAcquired" id="rxii_CashExcludingFromNetAssetsAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_NetTransactionsWithParent" name="NetTransactionsWithParent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" name="StockIssuedDuringPeriodForReimbursementOfExpensesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" name="StockIssuedDuringPeriodValueForReimbursementOfExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_StockIssuedDuringPeriodSharesToDirectors" name="StockIssuedDuringPeriodSharesToDirectors" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodValueToDirectors" name="StockIssuedDuringPeriodValueToDirectors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" name="AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" name="StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" name="StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_StockIssuedDuringPeriodValueCashBonus" name="StockIssuedDuringPeriodValueCashBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_StockIssuedDuringPeriodSharesCashBonus" name="StockIssuedDuringPeriodSharesCashBonus" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodValueServices" name="StockIssuedDuringPeriodValueServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_StockIssuedDuringPeriodSharesServices" name="StockIssuedDuringPeriodSharesServices" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="rxii_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" name="StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" name="StockIssuedDuringPeriodValueEmployeeTerminationAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" name="StockIssuedDuringPeriodSharesInExchangeOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" name="AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="rxii_DeficitAccumulatedDuringDevelopmentStageMember" name="DeficitAccumulatedDuringDevelopmentStageMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" name="StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" name="StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" name="StockIssuedDuringPeriodValueInExchangeOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="rxii_SubsidiaryAcquisitionAbstract" name="SubsidiaryAcquisitionAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_PartnerCompanyTextBlock" name="PartnerCompanyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="rxii_CommonStockIssuedInConnectionWithEspp" name="CommonStockIssuedInConnectionWithEspp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" name="IssuanceOfCommonStockInExchangeOfOutstandingWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>rxii-20111231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#DocumentAndEntityInformation" roleURI="http://rxipharma.com/role/DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfStockholdersEquity" roleURI="http://rxipharma.com/role/StatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfStockholderEquity" roleURI="http://rxipharma.com/role/StatementsOfStockholderEquity" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#LicenseAgreements" roleURI="http://rxipharma.com/role/LicenseAgreements" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
  <roleRef roleURI="http://rxipharma.com/role/BalanceSheets" xlink:href="rxii-20111231.xsd#BalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://rxipharma.com/role/BalanceSheetsParenthetical" xlink:href="rxii-20111231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://rxipharma.com/role/StatementsOfIncome" xlink:href="rxii-20111231.xsd#StatementsOfIncome" xlink:type="simple" />
  <roleRef roleURI="http://rxipharma.com/role/StatementsOfCashFlows" xlink:href="rxii-20111231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://rxipharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="rxii-20111231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <calculationLink xlink:role="http://rxipharma.com/role/BalanceSheets" xlink:title="0110 - Statement - Consolidated Balance Sheets" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_InProcessResearchDevelopment" xlink:label="rxii_InProcessResearchDevelopment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="rxii_InProcessResearchDevelopment" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_Goodwill" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_Goodwill" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_DepositsAssetsNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_DepositsAssetsNoncurrent" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableCurrent" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccruedLiabilitiesCurrent" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_ConvertibleNotesPayableCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_ConvertibleNotesPayableCurrent" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_DeferredRevenueCurrent" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_CapitalLeaseObligationsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_CapitalLeaseObligationsCurrent" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="rxii_FairValueOfWarrantsPotentiallySettleableInCash" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CurrentContingentPurchasePriceConsideration" xlink:label="rxii_CurrentContingentPurchasePriceConsideration" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="rxii_CurrentContingentPurchasePriceConsideration" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_LiabilitiesCurrent" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_CapitalLeaseObligationsNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_CapitalLeaseObligationsNoncurrent" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_Liabilities" order="18" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_PreferredStockValue" order="19" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="21" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentalStage" order="22" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_TreasuryStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_TreasuryStockValue" order="23" use="optional" weight="-1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="24" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" order="0.5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_DeferredTaxAssetsLiabilitiesNetNoncurrent" order="7.5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://rxipharma.com/role/StatementsOfIncome" xlink:title="0120 - Statement - Consolidated Statements of Expenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_InterestIncome" xlink:label="rxii_InterestIncome" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_LossOnWarrantExchange" xlink:label="rxii_LossOnWarrantExchange" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_IncomeTaxExpenseBenefit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeTaxExpenseBenefit" order="17.5" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_NonoperatingIncomeExpense" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_ResearchAndDevelopmentExpense" order="29" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ResearchAndDevelopmentExpense" xlink:to="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="25" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ResearchAndDevelopmentExpense" xlink:to="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" order="26" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ResearchAndDevelopmentExpense" xlink:to="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" order="27" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockInExchangeForLicensingRights" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ResearchAndDevelopmentExpense" xlink:to="rxii_FairValueOfCommonStockInExchangeForLicensingRights" order="28" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_GeneralAndAdministrativeExpense" order="34" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_GeneralAndAdministrativeExpenses" xlink:label="rxii_GeneralAndAdministrativeExpenses" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GeneralAndAdministrativeExpense" xlink:to="rxii_GeneralAndAdministrativeExpenses" order="30" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GeneralAndAdministrativeExpense" xlink:to="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" order="31" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GeneralAndAdministrativeExpense" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" order="32" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GeneralAndAdministrativeExpense" xlink:to="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" order="33" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_OperatingExpenses" order="10" use="optional" weight="-1" priority="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="8.75" use="optional" weight="1" priority="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="rxii_InterestIncome" order="20" use="optional" weight="1" priority="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="rxii_LossOnWarrantExchange" order="40" use="optional" weight="-1" priority="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_OtherNonoperatingIncomeExpense" order="60" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://rxipharma.com/role/StatementsOfCashFlows" xlink:title="0140 - Statement - Consolidated Statements of Cash Flows" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetIncomeLossIncludingOther" xlink:label="rxii_NetIncomeLossIncludingOther" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_NetIncomeLossIncludingOther" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_DepreciationDepletionAndAmortization" order="41" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_GainLossOnDispositionOfAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GainLossOnDispositionOfAssets" order="42" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NonCashRentExpense" xlink:label="rxii_NonCashRentExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_NonCashRentExpense" order="43" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="44" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ShareBasedCompensation" order="45" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_LossOnExchangeOfEquityInstruments" xlink:label="rxii_LossOnExchangeOfEquityInstruments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_LossOnExchangeOfEquityInstruments" order="46" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" order="47" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" order="48" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IssuanceOfStockAndWarrantsForServicesOrClaims" order="49" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" order="50" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" order="51" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_ChangeInFairValueOfContingentPurchaseConsideration" order="52" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="54" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="loc_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" order="55" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="56" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccruedLiabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccruedLiabilities" order="57" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="58" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CashReceivedInAcquisition" xlink:label="rxii_CashReceivedInAcquisition" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="rxii_CashReceivedInAcquisition" order="59" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_PaymentsToAcquireShortTermInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquireShortTermInvestments" order="60" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="61" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="62" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" order="63" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CashRefundedPaidForLeaseDeposit" xlink:label="rxii_CashRefundedPaidForLeaseDeposit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="rxii_CashRefundedPaidForLeaseDeposit" order="64" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="65" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="66" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_PaymentsForRepurchaseOfCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PaymentsForRepurchaseOfCommonStock" order="67" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromStockOptionsExercised" order="68" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxii_NetProceedsFromExerciseOfCommonStockWarrants" order="69" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" order="70" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations" order="71" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_ProceedsFromRelatedPartyDebt" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromRelatedPartyDebt" order="72" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="73" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="20" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CommonStockIssuedInConnectionWithEspp" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxii_CommonStockIssuedInConnectionWithEspp" order="33" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_IncreaseDecreaseInRestrictedCash" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_IncreaseDecreaseInRestrictedCash" order="29.5" use="optional" weight="-1" />
  </calculationLink>
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#NatureOfBusiness" roleURI="http://rxipharma.com/role/NatureOfBusiness" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/NatureOfBusiness" xlink:title="0201 - Disclosure - Nature of Business" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://rxipharma.com/role/SummaryOfSignificantAccountingPolicies" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#RecentAccountingPronouncements" roleURI="http://rxipharma.com/role/RecentAccountingPronouncements" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/RecentAccountingPronouncements" xlink:title="0203 - Disclosure - Recent Accounting Pronouncements" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#SubsidiaryAcquisition" roleURI="http://rxipharma.com/role/SubsidiaryAcquisition" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SubsidiaryAcquisition" xlink:title="0204 - Disclosure - Apthera Acquisition" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#SpinOut" roleURI="http://rxipharma.com/role/SpinOut" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SpinOut" xlink:title="0205 - Disclosure - RXi Spin-Out" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#FairValueMeasurements" roleURI="http://rxipharma.com/role/FairValueMeasurements" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/FairValueMeasurements" xlink:title="0206 - Disclosure - Fair Value Measurements" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#CapitalLeaseObligations" roleURI="http://rxipharma.com/role/CapitalLeaseObligations" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/CapitalLeaseObligations" xlink:title="0207 - Disclosure - Capital Lease Obligations" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://rxipharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="0208 - Disclosure - Accrued Expenses and Other Current Liabilities" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#CommitmentsAndContingencies" roleURI="http://rxipharma.com/role/CommitmentsAndContingencies" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/CommitmentsAndContingencies" xlink:title="0209 - Disclosure - Commitments and Contingencies" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StockholdersEquity" roleURI="http://rxipharma.com/role/StockholdersEquity" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StockholdersEquity" xlink:title="0210 - Disclosure - Stockholders' Equity" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#DevelopmentStageSupplementalEquityDisclosure" roleURI="http://rxipharma.com/role/DevelopmentStageSupplementalEquityDisclosure" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/DevelopmentStageSupplementalEquityDisclosure" xlink:title="0211 - Disclosure - Development Stage Supplemental Equity Disclosure" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StockBasedCompensation" roleURI="http://rxipharma.com/role/StockBasedCompensation" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StockBasedCompensation" xlink:title="0212 - Disclosure - Stock Based Compensation" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#NetLossPerShare" roleURI="http://rxipharma.com/role/NetLossPerShare" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/NetLossPerShare" xlink:title="0213 - Disclosure - Net Loss Per Share" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#IncomeTaxes" roleURI="http://rxipharma.com/role/IncomeTaxes" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/IncomeTaxes" xlink:title="0214 - Disclosure - Income Taxes" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#RelatedPartyTransactions" roleURI="http://rxipharma.com/role/RelatedPartyTransactions" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/RelatedPartyTransactions" xlink:title="0216 - Disclosure - Related Party Transactions" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#EmployeeBenefitPlan" roleURI="http://rxipharma.com/role/EmployeeBenefitPlan" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/EmployeeBenefitPlan" xlink:title="0217 - Disclosure - Employee Benefit Plan" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#SubsequentEvents" roleURI="http://rxipharma.com/role/SubsequentEvents" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SubsequentEvents" xlink:title="0218 - Disclosure - Subsequent Events" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)" />
  <calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/LicenseAgreements" xlink:title="0215 - Disclosure - License Agreements" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>rxii-20111231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.176; Copyright (C) RR Donnelley-->
<!--Based on XBRL 2.1-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfStockholdersEquity" roleURI="http://rxipharma.com/role/StatementsOfStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfStockholderEquity" roleURI="http://rxipharma.com/role/StatementsOfStockholderEquity" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_DeficitAccumulatedDuringDevelopmentStageMember" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentStageMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentStageMember" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="5" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="2" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PredecessorMember" xlink:label="us-gaap_PredecessorMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SuccessorMember" xlink:label="us-gaap_SuccessorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PredecessorMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_SuccessorMember" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="3" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:StatementLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" xlink:label="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" xlink:label="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" xlink:label="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" xlink:label="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesToDirectors" xlink:label="rxii_StockIssuedDuringPeriodSharesToDirectors" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueToDirectors" xlink:label="rxii_StockIssuedDuringPeriodValueToDirectors" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" xlink:label="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" xlink:label="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesCashBonus" xlink:label="rxii_StockIssuedDuringPeriodSharesCashBonus" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueCashBonus" xlink:label="rxii_StockIssuedDuringPeriodValueCashBonus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesServices" xlink:label="rxii_StockIssuedDuringPeriodSharesServices" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueServices" xlink:label="rxii_StockIssuedDuringPeriodValueServices" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="rxii_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="rxii_StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" xlink:label="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" xlink:label="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" xlink:label="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" xlink:label="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetTransactionsWithParent" xlink:label="rxii_NetTransactionsWithParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" order="7" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" order="8" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="9" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" order="10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" order="11" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesToDirectors" order="12" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="13" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="14" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueToDirectors" order="15" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" order="16" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="18" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" order="19" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" order="20" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesCashBonus" order="21" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueCashBonus" order="22" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="23" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="24" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesServices" order="25" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueServices" order="26" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesWarrantsExercised" order="27" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueWarrantsExercised" order="28" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" order="29" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" order="30" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="31" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="32" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" order="33" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" order="34" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="35" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="36" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" order="37" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="38" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" order="39" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="40" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rxii_NetTransactionsWithParent" order="41" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="2" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="3" />
  </link:definitionLink>
  <!-- Hypercube Definition (Line Items to Hypercube)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="2" />
  </link:definitionLink>
  <!-- Domain Members -->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SuccessorMember" xlink:label="us-gaap_SuccessorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_SuccessorMember" order="1" />
  </link:definitionLink>
  <!-- Hypercube Definition (All)-->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="3" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <!-- Inheritance for Line Items:  us-gaap:StatementLineItems-->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="2" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1" />
  </link:definitionLink>
  <!-- Dimension Defaults -->
  <link:definitionLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="2" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>rxii-20111231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="rxii_DocumentAndEntityInformationAbstract" xlink:href="rxii-20111231.xsd#rxii_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="rxii_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:label="rxii_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement, Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment and furnishings, net of accumulated depreciation and amortization of $657 and $491 in 2011 and 2010, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization of equipment and furnishings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_InProcessResearchDevelopment" xlink:label="rxii_InProcessResearchDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_InProcessResearchDevelopment" xlink:to="rxii_InProcessResearchDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_InProcessResearchDevelopment_lbl" xml:lang="en-US">In Process Research Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_InProcessResearchDevelopment_lbl" xml:lang="en-US">In-process research &amp; development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_InProcessResearchDevelopment_lbl" xml:lang="en-US">In-process research &amp; development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expense and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Current maturities of capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital Lease Obligations, Current</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfWarrantsPotentiallySettleableInCash" xlink:to="rxii_FairValueOfWarrantsPotentiallySettleableInCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US">Fair Value of Warrants Potentially Settleable in Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US">Fair value of warrants potentially settleable in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US">Fair value of warrants potentially settleable in cash (Note 8)</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CurrentContingentPurchasePriceConsideration" xlink:label="rxii_CurrentContingentPurchasePriceConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CurrentContingentPurchasePriceConsideration" xlink:to="rxii_CurrentContingentPurchasePriceConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CurrentContingentPurchasePriceConsideration_lbl" xml:lang="en-US">Current Contingent Purchase Price Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CurrentContingentPurchasePriceConsideration_lbl" xml:lang="en-US">Current contingent purchase price consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CurrentContingentPurchasePriceConsideration_lbl" xml:lang="en-US">Current contingent purchase price consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital lease obligations, net of current maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital Lease Obligations, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:to="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US">Contingent Purchase Price Consideration Net of Current Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US">Contingent purchase price consideration, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US">Contingent purchase price consideration, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 9)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 125,000,000 shares authorized and 47,811,453 shares issued and 47,136,453 shares outstanding at December 31, 2011; and 50,000,000 shares authorized and 19,047,759 shares issued and 18,372,759 outstanding at December 31, 2010, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_DeficitAccumulatedDuringDevelopmentalStage" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentalStage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage_lbl" xml:lang="en-US">Deficit Accumulated During Developmental Stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage_lbl" xml:lang="en-US">Deficit accumulated during the developmental stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage_lbl" xml:lang="en-US">Deficit accumulated during the developmental stage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Less treasury shares at cost, 675,000 shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Less treasury shares at cost, 675,000 and 0 shares at December 31, 2011 and December 31, 2010, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury Stock, Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury Stock, Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" xlink:to="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and Development Employee Stock Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and development employee stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and development employee stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" xlink:to="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and Development Non Employee Stock Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and development non-employee stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and development non-employee stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockInExchangeForLicensingRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfCommonStockInExchangeForLicensingRights" xlink:to="rxii_FairValueOfCommonStockInExchangeForLicensingRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfCommonStockInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair Value of Common Stock in Exchange for Licensing Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfCommonStockInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for licensing rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfCommonStockInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for licensing rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_FairValueOfCommonStockInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for licensing rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total research and development expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_GeneralAndAdministrativeExpenses" xlink:label="rxii_GeneralAndAdministrativeExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_GeneralAndAdministrativeExpenses" xlink:to="rxii_GeneralAndAdministrativeExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administration</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" xlink:to="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Fair Value of Common Stock Warrants Issued for General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Fair value of common stock warrants issued for general and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Fair value of common stock warrants issued for general and administrative expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair Value of Common Stock Issued in Exchange for General and Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for general and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" xlink:to="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation_lbl" xml:lang="en-US">General and Administrative Employee Stock Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation_lbl" xml:lang="en-US">General and administrative employee stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation_lbl" xml:lang="en-US">General and administration employee stock based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses, Total</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_InterestIncome" xlink:label="rxii_InterestIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_InterestIncome" xlink:to="rxii_InterestIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_InterestIncome_lbl" xml:lang="en-US">Interest Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_InterestIncome_lbl" xml:lang="en-US">Interest income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_InterestIncome_lbl" xml:lang="en-US">Interest income (expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense), Total</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_LossOnWarrantExchange" xlink:label="rxii_LossOnWarrantExchange" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_LossOnWarrantExchange" xlink:to="rxii_LossOnWarrantExchange_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_LossOnWarrantExchange_lbl" xml:lang="en-US">Loss on Warrant Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_LossOnWarrantExchange_lbl" xml:lang="en-US">Loss on warrant exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_LossOnWarrantExchange_lbl" xml:lang="en-US">Loss on warrant exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_LossOnWarrantExchange_lbl" xml:lang="en-US">Loss on warrant exchange</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per common share:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Share Outstanding Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares outstanding: basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares outstanding: basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" xml:lang="en-US">Fair Value of Shares Mandatorily Redeemable for Cash Upon Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetIncomeLossIncludingOther" xlink:label="rxii_NetIncomeLossIncludingOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NetIncomeLossIncludingOther" xlink:to="rxii_NetIncomeLossIncludingOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NetIncomeLossIncludingOther_lbl" xml:lang="en-US">Net Income Loss Including Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NetIncomeLossIncludingOther_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NetIncomeLossIncludingOther_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of equipment</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NonCashRentExpense" xlink:label="rxii_NonCashRentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NonCashRentExpense" xlink:to="rxii_NonCashRentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NonCashRentExpense_lbl" xml:lang="en-US">Non Cash Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NonCashRentExpense_lbl" xml:lang="en-US">Non-cash rent expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NonCashRentExpense_lbl" xml:lang="en-US">Non-cash rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion and receipt of bond discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion and receipt of bond discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Non-cash share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_LossOnExchangeOfEquityInstruments" xlink:label="rxii_LossOnExchangeOfEquityInstruments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_LossOnExchangeOfEquityInstruments" xlink:to="rxii_LossOnExchangeOfEquityInstruments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_LossOnExchangeOfEquityInstruments_lbl" xml:lang="en-US">Loss on Exchange of Equity Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_LossOnExchangeOfEquityInstruments_lbl" xml:lang="en-US">Loss on exchange of equity instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_LossOnExchangeOfEquityInstruments_lbl" xml:lang="en-US">Loss on exchange of equity instruments</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:to="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_lbl" xml:lang="en-US">Fair Value of Parent Company Common Stock Issued in Exchange for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_lbl" xml:lang="en-US">Fair value of common stock warrants issued in exchange for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_lbl" xml:lang="en-US">Fair value of common stock warrants issued in exchange for services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:to="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" xml:lang="en-US">Change in Fair Value of Common Stock Warrants Issued in Connection with Various Equity Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" xml:lang="en-US">Change in fair value of common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair Value of Common Stock Issued in Exchange for Licensing Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for licensing rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for licensing rights</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ChangeInFairValueOfContingentPurchaseConsideration" xlink:to="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" xml:lang="en-US">Change in Fair Value of Contingent Purchase Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" xml:lang="en-US">Change in fair value of contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" xml:lang="en-US">Change in fair value of contingent purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" xml:lang="en-US">Change in fair value of contingent purchase consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to former parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Increase (Decrease) in Due to Other Related Parties, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CashReceivedInAcquisition" xlink:label="rxii_CashReceivedInAcquisition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CashReceivedInAcquisition" xlink:to="rxii_CashReceivedInAcquisition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CashReceivedInAcquisition_lbl" xml:lang="en-US">Cash Received in Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CashReceivedInAcquisition_lbl" xml:lang="en-US">Cash received in acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CashReceivedInAcquisition_lbl" xml:lang="en-US">Cash received in acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_CashReceivedInAcquisition_lbl" xml:lang="en-US">Cash received in acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US">Maturities of short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Cash paid for purchase of equipment and furnishings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Cash paid for purchase of equipment and furnishings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Disposal of equipment and furnishings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CashRefundedPaidForLeaseDeposit" xlink:label="rxii_CashRefundedPaidForLeaseDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CashRefundedPaidForLeaseDeposit" xlink:to="rxii_CashRefundedPaidForLeaseDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CashRefundedPaidForLeaseDeposit_lbl" xml:lang="en-US">Cash Refunded Paid for Lease Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CashRefundedPaidForLeaseDeposit_lbl" xml:lang="en-US">Cash refunded (paid) for lease deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CashRefundedPaidForLeaseDeposit_lbl" xml:lang="en-US">Cash refunded (paid) for lease deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Cash paid for repurchase of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Cash paid for repurchase of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Net proceeds from exercise of common stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NetProceedsFromExerciseOfCommonStockWarrants" xlink:to="rxii_NetProceedsFromExerciseOfCommonStockWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Net Proceeds from Exercise of Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Net proceeds from exercise of common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Net proceeds from exercise of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:to="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US">Net Proceeds from Issuance of Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US">Net proceeds from issuance of convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US">Net proceeds from issuance of convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US">Net proceeds from issuance of convertible notes payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of capital lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Cash advances from former parent company, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Cash received during the periods for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Proceeds from Interest Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Cash received during the periods for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid during the periods for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid during the periods for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Settlement of corporate formation expenses in exchange for common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock Issued</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:to="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_lbl" xml:lang="en-US">Fair Value of Warrants Issued in Connection with Common Stock Recorded As Cost of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_lbl" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as cost of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_lbl" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as cost of equity</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant_lbl" xml:lang="en-US">Fair Value of Shares Mandatorily Redeemable for Cash Upon Exercise of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_AllocationOfManagementExpenses" xlink:label="rxii_AllocationOfManagementExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_AllocationOfManagementExpenses" xlink:to="rxii_AllocationOfManagementExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_AllocationOfManagementExpenses_lbl" xml:lang="en-US">Allocation of Management Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_AllocationOfManagementExpenses_lbl" xml:lang="en-US">Allocation of management expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_AllocationOfManagementExpenses_lbl" xml:lang="en-US">Allocation of management expenses</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_EquipmentAndFurnishingsExchangedForCommonStock" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_EquipmentAndFurnishingsExchangedForCommonStock" xlink:to="rxii_EquipmentAndFurnishingsExchangedForCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock_lbl" xml:lang="en-US">Equipment and Furnishings Exchanged for Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock_lbl" xml:lang="en-US">Equipment and furnishings exchanged for common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock_lbl" xml:lang="en-US">Equipment and furnishings exchanged for common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Equipment and furnishings acquired through capital lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Non-cash lease deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Capital Lease Obligations Incurred</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" xlink:to="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses_lbl" xml:lang="en-US">Value of Restricted Stock Units and Common Stock Issued in Lieu of Cash Bonuses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses_lbl" xml:lang="en-US">Value of restricted stock units and common stock issued in lieu of cash bonuses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses_lbl" xml:lang="en-US">Value of restricted stock units and common stock issued in lieu of cash bonuses</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfSharesIssuedToAcquire" xlink:label="rxii_FairValueOfSharesIssuedToAcquire" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfSharesIssuedToAcquire" xlink:to="rxii_FairValueOfSharesIssuedToAcquire_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfSharesIssuedToAcquire_lbl" xml:lang="en-US">Fair Value of Shares Issued to Acquire</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfSharesIssuedToAcquire_lbl" xml:lang="en-US">Fair value of shares issued to acquire Apthera</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfSharesIssuedToAcquire_lbl" xml:lang="en-US">Fair value of shares issued to acquire Apthera</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition" xlink:label="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition" xlink:to="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition_lbl" xml:lang="en-US">Fair Value of Contingent Purchase Price Consideration in Connection with Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition_lbl" xml:lang="en-US">Fair value of contingent purchase price consideration in connection with Apthera acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition_lbl" xml:lang="en-US">Fair value of contingent purchase price consideration in connection with Apthera acquisition</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetAssetsAcquiredExcludingCash" xlink:label="rxii_NetAssetsAcquiredExcludingCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NetAssetsAcquiredExcludingCash" xlink:to="rxii_NetAssetsAcquiredExcludingCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NetAssetsAcquiredExcludingCash_lbl" xml:lang="en-US">Net Assets Acquired Excluding Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NetAssetsAcquiredExcludingCash_lbl" xml:lang="en-US">Net assets acquired excluding cash of $168</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NetAssetsAcquiredExcludingCash_lbl" xml:lang="en-US">Net assets acquired excluding cash of $168</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CashExcludingFromNetAssetsAcquired" xlink:label="rxii_CashExcludingFromNetAssetsAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CashExcludingFromNetAssetsAcquired" xlink:to="rxii_CashExcludingFromNetAssetsAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CashExcludingFromNetAssetsAcquired_lbl" xml:lang="en-US">Cash Excluding from Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CashExcludingFromNetAssetsAcquired_lbl" xml:lang="en-US">Cash excluding from net assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CashExcludingFromNetAssetsAcquired_lbl" xml:lang="en-US">Cash excluding from net assets acquired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Business [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Apthera Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Apthera Acquisition [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xlink:label="us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xlink:to="us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Capital Leases in Financial Statements of Lessee Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Capital Lease Obligations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">RXi Spin-Out and Related Party Transactions [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="lab_SharesIssued" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_SharesIssued" xml:lang="en-US">Ending balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_SharesIssued" xml:lang="en-US">Beginning balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_SharesIssued" xml:lang="en-US">Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetTransactionsWithParent" xlink:label="rxii_NetTransactionsWithParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NetTransactionsWithParent" xlink:to="rxii_NetTransactionsWithParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NetTransactionsWithParent_lbl" xml:lang="en-US">Net Transactions With Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NetTransactionsWithParent_lbl" xml:lang="en-US">Net transactions with Parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NetTransactionsWithParent_lbl" xml:lang="en-US">Net transactions with Parent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="lab_CommonStockMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CommonStockMember" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_AdditionalPaidInCapitalMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="lab_RetainedEarningsMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RetainedEarningsMember" xml:lang="en-US">Parent Company's Net Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="lab_TreasuryStockMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_TreasuryStockMember" xml:lang="en-US">Treasury Stock</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" xlink:label="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" xlink:to="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares_lbl" xml:lang="en-US">Stock Issued During Period For Reimbursement of Expenses Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares_lbl" xml:lang="en-US">Common stock issued to CytRx for reimbursement of expenses, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares_lbl" xml:lang="en-US">Stock issued during period for reimbursement of expenses shares.</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" xlink:label="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" xlink:to="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses_lbl" xml:lang="en-US">Stock Issued During Period Value For Reimbursement of Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses_lbl" xml:lang="en-US">Common stock issued to CytRx for reimbursement of expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses_lbl" xml:lang="en-US">Stock issued during period value for reimbursement of expenses.</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesToDirectors" xlink:label="rxii_StockIssuedDuringPeriodSharesToDirectors" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodSharesToDirectors" xlink:to="rxii_StockIssuedDuringPeriodSharesToDirectors_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodSharesToDirectors_lbl" xml:lang="en-US">Stock Issued During Period Shares to Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodSharesToDirectors_lbl" xml:lang="en-US">Common stock issued to directors, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodSharesToDirectors_lbl" xml:lang="en-US">Stock issued during period shares to directors.</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueToDirectors" xlink:label="rxii_StockIssuedDuringPeriodValueToDirectors" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueToDirectors" xlink:to="rxii_StockIssuedDuringPeriodValueToDirectors_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueToDirectors_lbl" xml:lang="en-US">Stock Issued During Period Value to Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueToDirectors_lbl" xml:lang="en-US">Common stock issued to directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueToDirectors_lbl" xml:lang="en-US">Stock issued during period value to directors.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Stock issuance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Expenses incurred by CytRx for RXi</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Common stock issued to CytRx for contribution of RXi and other assets, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Common stock issued to CytRx for contribution of RXi and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Common stock issued upon exercise of stock options, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Common stock issued upon exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SuccessorMember" xlink:label="us-gaap_SuccessorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SuccessorMember" xlink:to="lab_SuccessorMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_SuccessorMember" xml:lang="en-US">Successor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_SuccessorMember" xml:lang="en-US">Successor</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PredecessorMember" xlink:label="us-gaap_PredecessorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PredecessorMember" xlink:to="lab_PredecessorMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PredecessorMember" xml:lang="en-US">Predecessor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PredecessorMember" xml:lang="en-US">Predecessor</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Common stock warrants issued in connection with the 2009, 2010 and 2011 offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="lab_StatementScenarioAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StatementScenarioAxis" xml:lang="en-US">Statement, Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_ScenarioUnspecifiedDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" xlink:to="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital Warrant Expense in Exchange for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices_lbl" xml:lang="en-US">Value of common stock warrants issued (expense) in exchange for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices_lbl" xml:lang="en-US">Adjustments to additional paid in capital warrant expense in exchange for services.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_TreasuryStockValueAcquiredCostMethod" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Purchase of 675,000 shares of treasury stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock units, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" xlink:label="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" xlink:to="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Commitment Fee Under Standby Equity Distribution Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement_lbl" xml:lang="en-US">Common stock issued as commitment fee in connection with SEDA, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement_lbl" xml:lang="en-US">Stock issued during period shares stock commitment fee under standby equity distribution agreement</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" xlink:label="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" xlink:to="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement_lbl" xml:lang="en-US">Stock Issued During Period Value Stock Commitment Fee Under Standby Equity Distribution Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement_lbl" xml:lang="en-US">Common stock issued as commitment fee in connection with SEDA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement_lbl" xml:lang="en-US">Stock issued during period value stock commitment fee under standby equity distribution agreement</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueCashBonus" xlink:label="rxii_StockIssuedDuringPeriodValueCashBonus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueCashBonus" xlink:to="rxii_StockIssuedDuringPeriodValueCashBonus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueCashBonus_lbl" xml:lang="en-US">Stock Issued During Period Value Cash Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueCashBonus_lbl" xml:lang="en-US">Issuance of stock in lieu of cash bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueCashBonus_lbl" xml:lang="en-US">Stock issued during period value cash bonus</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesCashBonus" xlink:label="rxii_StockIssuedDuringPeriodSharesCashBonus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodSharesCashBonus" xlink:to="rxii_StockIssuedDuringPeriodSharesCashBonus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodSharesCashBonus_lbl" xml:lang="en-US">Stock Issued During Period Shares Cash Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodSharesCashBonus_lbl" xml:lang="en-US">Issuance of stock in lieu of cash bonus, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodSharesCashBonus_lbl" xml:lang="en-US">Stock issued during period shares cash bonus</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueServices" xlink:label="rxii_StockIssuedDuringPeriodValueServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueServices" xlink:to="rxii_StockIssuedDuringPeriodValueServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueServices_lbl" xml:lang="en-US">Stock Issued During Period Value Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueServices_lbl" xml:lang="en-US">Issuance of common stock for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueServices_lbl" xml:lang="en-US">Stock issued during period value services</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesServices" xlink:label="rxii_StockIssuedDuringPeriodSharesServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodSharesServices" xlink:to="rxii_StockIssuedDuringPeriodSharesServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodSharesServices_lbl" xml:lang="en-US">Stock Issued During Period Shares Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodSharesServices_lbl" xml:lang="en-US">Issuance of common stock for services, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodSharesServices_lbl" xml:lang="en-US">Stock issued during period shares services</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="rxii_StockIssuedDuringPeriodValueWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="rxii_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock issued during period value warrants exercised</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="rxii_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="rxii_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrant, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock issued during period shares warrants exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_StockIssuedDuringPeriodSharesAcquisitions" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Issuance of common stock related to acquisition of Apthera Inc., shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_StockIssuedDuringPeriodValueAcquisitions" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issuance of common stock related to acquisition of Apthera Inc.</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" xlink:label="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" xlink:to="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements_lbl" xml:lang="en-US">Stock Issued During Period Shares Employee Termination Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements_lbl" xml:lang="en-US">Issuance of common stock subject to employee termination agreements, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements_lbl" xml:lang="en-US">Stock issued during period shares employee termination agreements</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" xlink:label="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" xlink:to="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements_lbl" xml:lang="en-US">Stock Issued During Period Value Employee Termination Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements_lbl" xml:lang="en-US">Issuance of common stock subject to employee termination agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements_lbl" xml:lang="en-US">Stock issued during period value employee termination agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Issuance of common stock subject to Employee Stock Purchase Plan, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Issuance of common stock subject to Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" xlink:label="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" xlink:to="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period Shares in Exchange of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants_lbl" xml:lang="en-US">Issuance of common stock in cashless exchange of outstanding warrants, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants_lbl" xml:lang="en-US">Stock issued during period shares in exchange of warrants</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" xlink:to="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital Shares to be Redeemed for Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants_lbl" xml:lang="en-US">Adjustments to additional paid in capital shares to be redeemed for exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_TreasuryStockSharesAcquired" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_TreasuryStockSharesAcquired" xml:lang="en-US">Treasury Stock, Shares, Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_TreasuryStockSharesAcquired" xml:lang="en-US">Treasury stock, shares</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_DeficitAccumulatedDuringDevelopmentStageMember" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentStageMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_DeficitAccumulatedDuringDevelopmentStageMember" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentStageMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xml:lang="en-US">Deficit Accumulated During Development Stage [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xml:lang="en-US">Deficit Accumulated During Development Stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xml:lang="en-US">Deficit Accumulated During Development Stage.</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" xlink:label="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" xlink:to="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties_lbl" xml:lang="en-US">Stock Issued During Period Shares For Additional Intellectual Properties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties_lbl" xml:lang="en-US">Common stock issued to UMMS for additional intellectual properties, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties_lbl" xml:lang="en-US">Stock issued during period shares for additional intellectual properties</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" xlink:label="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" xlink:to="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties_lbl" xml:lang="en-US">Stock Issued During Period Value For Additional Intellectual Properties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties_lbl" xml:lang="en-US">Common stock issued to UMMS for additional intellectual properties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties_lbl" xml:lang="en-US">Stock issued during period value for additional intellectual properties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" xml:lang="en-US">Stock based compensation expense for directors and employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Nonvested Shares, Requisite Service Period Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Stock based compensation expense for services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_PaymentsOfStockIssuanceCosts" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Stock issuance cost</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" xlink:label="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" xlink:to="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period Value in Exchange of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants_lbl" xml:lang="en-US">Issuance of common stock in cashless exchange of outstanding warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants_lbl" xml:lang="en-US">Stock issued during period value in exchange of warrants</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_SubsidiaryAcquisitionAbstract" xlink:label="rxii_SubsidiaryAcquisitionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_SubsidiaryAcquisitionAbstract" xlink:to="rxii_SubsidiaryAcquisitionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_SubsidiaryAcquisitionAbstract_lbl" xml:lang="en-US">Subsidiary Acquisition Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_SubsidiaryAcquisitionAbstract_lbl" xml:lang="en-US">Apthera Acquisition:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_SubsidiaryAcquisitionAbstract_lbl" xml:lang="en-US">Subsidiary acquisition.</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_PartnerCompanyTextBlock" xlink:label="rxii_PartnerCompanyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_PartnerCompanyTextBlock" xlink:to="rxii_PartnerCompanyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_PartnerCompanyTextBlock_lbl" xml:lang="en-US">Partner Company Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_PartnerCompanyTextBlock_lbl" xml:lang="en-US">RXi Spin-Out</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_PartnerCompanyTextBlock_lbl" xml:lang="en-US">Partner company.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterprisesAbstract" xlink:label="us-gaap_DevelopmentStageEnterprisesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentStageEnterprisesAbstract" xlink:to="us-gaap_DevelopmentStageEnterprisesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentStageEnterprisesAbstract_lbl" xml:lang="en-US">Development Stage Supplemental Equity Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DevelopmentStageEnterprisesAbstract_lbl" xml:lang="en-US">Development Stage Supplemental Equity Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock" xlink:label="us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock" xlink:to="us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock_lbl" xml:lang="en-US">Development Stage Enterprise General Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock_lbl" xml:lang="en-US">Development Stage Supplemental Equity Disclosure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">License Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">License Agreements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">License Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="lab_NonoperatingIncomeExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_NonoperatingIncomeExpense" xml:lang="en-US">Total other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_NonoperatingIncomeExpense" xml:lang="en-US">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" xml:lang="en-US">Deferred Tax Assets (Liabilities), Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" xml:lang="en-US">Deferred tax liability, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" xml:lang="en-US">Deferred tax liability, non-current</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CommonStockIssuedInConnectionWithEspp" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CommonStockIssuedInConnectionWithEspp" xlink:to="rxii_CommonStockIssuedInConnectionWithEspp_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp_lbl" xml:lang="en-US">Common Stock Issued In Connection With Espp</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp_lbl" xml:lang="en-US">Common stock issued in connection with Espp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp_lbl" xml:lang="en-US">Common stock issued in connection with ESPP</label>
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" xlink:to="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_lbl" xml:lang="en-US">Issuance of common stock in exchange of outstanding warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_lbl" xml:lang="en-US">Issuance of common stock in exchange of outstanding warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_lbl" xml:lang="en-US">Issuance of common stock in exchange of outstanding warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_NonoperatingIncomeExpenseAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income/(expense):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="lab_IncreaseDecreaseInRestrictedCash" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">Change in restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">Increase (Decrease) in Restricted Cash, Total</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>rxii-20111231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://rxipharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="rxii-20111231.xsd#DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#NatureOfBusiness" roleURI="http://rxipharma.com/role/NatureOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://rxipharma.com/role/SummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#RecentAccountingPronouncements" roleURI="http://rxipharma.com/role/RecentAccountingPronouncements" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#SubsidiaryAcquisition" roleURI="http://rxipharma.com/role/SubsidiaryAcquisition" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#SpinOut" roleURI="http://rxipharma.com/role/SpinOut" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#FairValueMeasurements" roleURI="http://rxipharma.com/role/FairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#CapitalLeaseObligations" roleURI="http://rxipharma.com/role/CapitalLeaseObligations" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://rxipharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#CommitmentsAndContingencies" roleURI="http://rxipharma.com/role/CommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StockholdersEquity" roleURI="http://rxipharma.com/role/StockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#DevelopmentStageSupplementalEquityDisclosure" roleURI="http://rxipharma.com/role/DevelopmentStageSupplementalEquityDisclosure" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StockBasedCompensation" roleURI="http://rxipharma.com/role/StockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#NetLossPerShare" roleURI="http://rxipharma.com/role/NetLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#IncomeTaxes" roleURI="http://rxipharma.com/role/IncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#RelatedPartyTransactions" roleURI="http://rxipharma.com/role/RelatedPartyTransactions" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#EmployeeBenefitPlan" roleURI="http://rxipharma.com/role/EmployeeBenefitPlan" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#SubsequentEvents" roleURI="http://rxipharma.com/role/SubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfStockholdersEquity" roleURI="http://rxipharma.com/role/StatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfStockholderEquity" roleURI="http://rxipharma.com/role/StatementsOfStockholderEquity" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#LicenseAgreements" roleURI="http://rxipharma.com/role/LicenseAgreements" />
  <presentationLink xlink:role="http://rxipharma.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_DocumentAndEntityInformationAbstract" xlink:label="rxii_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="5.03" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="5.05" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="5.04" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="5.01" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="5.02" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="5.08" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="5.09" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="5.10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="5.11" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="5.12" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5.14" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="5.13" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="5.07" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="5.06" use="optional" />
  </presentationLink>
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#BalanceSheets" roleURI="http://rxipharma.com/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#BalanceSheetsParenthetical" roleURI="http://rxipharma.com/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfIncome" roleURI="http://rxipharma.com/role/StatementsOfIncome" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfCashFlows" roleURI="http://rxipharma.com/role/StatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="rxii-20111231.xsd#StatementsOfCashFlowsParenthetical" roleURI="http://rxipharma.com/role/StatementsOfCashFlowsParenthetical" />
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/BalanceSheets" xlink:title="0110 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_AssetsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsAbstract" order="1." use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AssetsCurrentAbstract" order="2.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_InProcessResearchDevelopment" xlink:label="rxii_InProcessResearchDevelopment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="rxii_InProcessResearchDevelopment" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_Goodwill" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Goodwill" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_DepositsAssetsNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_DepositsAssetsNoncurrent" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Assets" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="11.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="12.2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableCurrent" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_ConvertibleNotesPayableCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_ConvertibleNotesPayableCurrent" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_DeferredRevenueCurrent" order="16.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_CapitalLeaseObligationsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_CapitalLeaseObligationsCurrent" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="rxii_FairValueOfWarrantsPotentiallySettleableInCash" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CurrentContingentPurchasePriceConsideration" xlink:label="rxii_CurrentContingentPurchasePriceConsideration" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="rxii_CurrentContingentPurchasePriceConsideration" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_CapitalLeaseObligationsNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CapitalLeaseObligationsNoncurrent" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_Liabilities" order="23.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_CommitmentsAndContingencies" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CommitmentsAndContingencies" order="24.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="25.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockValue" order="26.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="27.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="28.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentalStage" order="29.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_TreasuryStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_TreasuryStockValue" order="30.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="31.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="32.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" order="3.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredTaxAssetsLiabilitiesNetNoncurrent" order="21.5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/BalanceSheetsParenthetical" xlink:title="0111 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="6.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_PreferredStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockParOrStatedValuePerShare" order="26.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_PreferredStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesAuthorized" order="26.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_PreferredStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesIssued" order="26.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_PreferredStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesOutstanding" order="26.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="27.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="27.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesIssued" order="27.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="27.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_TreasuryStockShares" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_TreasuryStockShares" order="30.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfIncome" xlink:title="0120 - Statement - Consolidated Statements of Expenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_OperatingExpensesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OperatingExpensesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockInExchangeForLicensingRights" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_FairValueOfCommonStockInExchangeForLicensingRights" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpense" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_GeneralAndAdministrativeExpenses" xlink:label="rxii_GeneralAndAdministrativeExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_GeneralAndAdministrativeExpenses" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_GeneralAndAdministrativeExpense" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NetIncomeLoss" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_EarningsPerShareAbstract" order="19.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_EarningsPerShareBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_EarningsPerShareBasicAndDiluted" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_IncomeTaxExpenseBenefit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_IncomeTaxExpenseBenefit" order="17.5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_OperatingExpenses" order="11.5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="17.1875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_LossOnWarrantExchange" xlink:label="rxii_LossOnWarrantExchange" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="rxii_LossOnWarrantExchange" order="13.0367225" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OtherNonoperatingIncomeExpense" order="15.02617625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_NonoperatingIncomeExpenseAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NonoperatingIncomeExpenseAbstract" order="5.0789075" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_InterestIncome" xlink:label="rxii_InterestIncome" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="rxii_InterestIncome" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="rxii_LossOnWarrantExchange" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_OtherNonoperatingIncomeExpense" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_NonoperatingIncomeExpense" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfCashFlows" xlink:title="0140 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetIncomeLossIncludingOther" xlink:label="rxii_NetIncomeLossIncludingOther" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_NetIncomeLossIncludingOther" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="3.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_DepreciationDepletionAndAmortization" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_GainLossOnDispositionOfAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GainLossOnDispositionOfAssets" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NonCashRentExpense" xlink:label="rxii_NonCashRentExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_NonCashRentExpense" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ShareBasedCompensation" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_LossOnExchangeOfEquityInstruments" xlink:label="rxii_LossOnExchangeOfEquityInstruments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_LossOnExchangeOfEquityInstruments" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" order="10" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IssuanceOfStockAndWarrantsForServicesOrClaims" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_ChangeInFairValueOfContingentPurchaseConsideration" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="16.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="loc_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccruedLiabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccruedLiabilities" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="23.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CashReceivedInAcquisition" xlink:label="rxii_CashReceivedInAcquisition" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="rxii_CashReceivedInAcquisition" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_PaymentsToAcquireShortTermInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireShortTermInvestments" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="26.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="27.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" order="28.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CashRefundedPaidForLeaseDeposit" xlink:label="rxii_CashRefundedPaidForLeaseDeposit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="rxii_CashRefundedPaidForLeaseDeposit" order="29.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="30.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="40.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="41.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="42.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_SupplementalCashFlowInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_SupplementalCashFlowInformationAbstract" order="43.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_ProceedsFromInterestReceived" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_ProceedsFromInterestReceived" order="44.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_InterestPaid" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_InterestPaid" order="45.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="46.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_StockIssued1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_StockIssued1" order="47.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" order="48.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" order="49.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_AllocationOfManagementExpenses" xlink:label="rxii_AllocationOfManagementExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_AllocationOfManagementExpenses" order="51.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_EquipmentAndFurnishingsExchangedForCommonStock" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_EquipmentAndFurnishingsExchangedForCommonStock" order="52.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_FairValueOfAssetsAcquired" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_FairValueOfAssetsAcquired" order="53.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_CapitalLeaseObligationsIncurred" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CapitalLeaseObligationsIncurred" order="54.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" order="55.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_SubsidiaryAcquisitionAbstract" xlink:label="rxii_SubsidiaryAcquisitionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_SubsidiaryAcquisitionAbstract" order="76.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfSharesIssuedToAcquire" xlink:label="rxii_FairValueOfSharesIssuedToAcquire" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_SubsidiaryAcquisitionAbstract" xlink:to="rxii_FairValueOfSharesIssuedToAcquire" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition" xlink:label="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_SubsidiaryAcquisitionAbstract" xlink:to="rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetAssetsAcquiredExcludingCash" xlink:label="rxii_NetAssetsAcquiredExcludingCash" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_SubsidiaryAcquisitionAbstract" xlink:to="rxii_NetAssetsAcquiredExcludingCash" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" order="48.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="25.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_PaymentsForRepurchaseOfCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PaymentsForRepurchaseOfCommonStock" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromStockOptionsExercised" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxii_NetProceedsFromExerciseOfCommonStockWarrants" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CommonStockIssuedInConnectionWithEspp" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxii_CommonStockIssuedInConnectionWithEspp" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" order="120" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations" order="140" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_ProceedsFromRelatedPartyDebt" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromRelatedPartyDebt" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="165" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_IncreaseDecreaseInRestrictedCash" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInRestrictedCash" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="0141 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_CashExcludingFromNetAssetsAcquired" xlink:label="rxii_CashExcludingFromNetAssetsAcquired" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="rxii_CashExcludingFromNetAssetsAcquired" order="59.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/NatureOfBusiness" xlink:title="0201 - Disclosure - Nature of Business">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_NatureOfOperations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_NatureOfOperations" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/RecentAccountingPronouncements" xlink:title="0203 - Disclosure - Recent Accounting Pronouncements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_AccountingChangesAndErrorCorrectionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_AccountingChangesAndErrorCorrectionsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_AccountingChangesAndErrorCorrectionsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SubsidiaryAcquisition" xlink:title="0204 - Disclosure - Apthera Acquisition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_BusinessCombinationDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BusinessCombinationsAbstract" xlink:to="loc_BusinessCombinationDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SpinOut" xlink:title="0205 - Disclosure - RXi Spin-Out">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_PartnerCompanyTextBlock" xlink:label="rxii_PartnerCompanyTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RelatedPartyTransactionsAbstract" xlink:to="rxii_PartnerCompanyTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/FairValueMeasurements" xlink:title="0206 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_InvestmentsAllOtherInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_FinancialInstrumentsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_FinancialInstrumentsDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/CapitalLeaseObligations" xlink:title="0207 - Disclosure - Capital Lease Obligations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xlink:label="loc_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LeasesAbstract" xlink:to="loc_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="0208 - Disclosure - Accrued Expenses and Other Current Liabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PayablesAndAccrualsAbstract" xlink:to="loc_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/CommitmentsAndContingencies" xlink:title="0209 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StockholdersEquity" xlink:title="0210 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/DevelopmentStageSupplementalEquityDisclosure" xlink:title="0211 - Disclosure - Development Stage Supplemental Equity Disclosure">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterprisesAbstract" xlink:label="loc_DevelopmentStageEnterprisesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock" xlink:label="loc_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DevelopmentStageEnterprisesAbstract" xlink:to="loc_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StockBasedCompensation" xlink:title="0212 - Disclosure - Stock Based Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/NetLossPerShare" xlink:title="0213 - Disclosure - Net Loss Per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_EarningsPerShareTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_EarningsPerShareTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/IncomeTaxes" xlink:title="0214 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_IncomeTaxDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeTaxDisclosureAbstract" xlink:to="loc_IncomeTaxDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/RelatedPartyTransactions" xlink:title="0216 - Disclosure - Related Party Transactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_RelatedPartyTransactionsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RelatedPartyTransactionsAbstract" xlink:to="loc_RelatedPartyTransactionsDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/EmployeeBenefitPlan" xlink:title="0217 - Disclosure - Employee Benefit Plan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CompensationAndRetirementDisclosureAbstract" xlink:to="loc_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SubsequentEvents" xlink:title="0218 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_SubsequentEventsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SubsequentEventsAbstract" xlink:to="loc_SubsequentEventsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholdersEquity" xlink:title="0130 - Statement - Consolidated Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_StatementTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfStockholdersEquityAbstract" xlink:to="loc_StatementTable" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_StatementEquityComponentsAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementTable" xlink:to="loc_StatementEquityComponentsAxis" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_EquityComponentDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementEquityComponentsAxis" xlink:to="loc_EquityComponentDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_CommonStockMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityComponentDomain" xlink:to="loc_CommonStockMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_AdditionalPaidInCapitalMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityComponentDomain" xlink:to="loc_AdditionalPaidInCapitalMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_TreasuryStockMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityComponentDomain" xlink:to="loc_TreasuryStockMember" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_StatementLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementTable" xlink:to="loc_StatementLineItems" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_StatementScenarioAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementTable" xlink:to="loc_StatementScenarioAxis" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_ScenarioUnspecifiedDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementScenarioAxis" xlink:to="loc_ScenarioUnspecifiedDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_PredecessorMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScenarioUnspecifiedDomain" xlink:to="loc_PredecessorMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SuccessorMember" xlink:label="loc_SuccessorMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScenarioUnspecifiedDomain" xlink:to="loc_SuccessorMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockholdersEquity" order="37.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_SharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_SharesIssued" order="37.499845" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="36.875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodValuePurchaseOfAssets" order="37.1875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" xlink:label="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares" order="37.34375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" xlink:label="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses" order="37.421875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesToDirectors" xlink:label="rxii_StockIssuedDuringPeriodSharesToDirectors" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesToDirectors" order="37.4609375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueToDirectors" xlink:label="rxii_StockIssuedDuringPeriodValueToDirectors" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueToDirectors" order="37.48046875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="37.44140625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised" order="37.490234375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised" order="37.4951171875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_NetIncomeLoss" order="37.4997675" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_NetTransactionsWithParent" xlink:label="rxii_NetTransactionsWithParent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_NetTransactionsWithParent" order="37.49980625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices" order="37.49954" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="37.470705" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_TreasuryStockValueAcquiredCostMethod" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_TreasuryStockValueAcquiredCostMethod" order="37.46826" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="37.49832" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="37.49855" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" xlink:label="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement" order="37.497405" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" xlink:label="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement" order="37.49809" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueCashBonus" xlink:label="rxii_StockIssuedDuringPeriodValueCashBonus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueCashBonus" order="37.498205" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesCashBonus" xlink:label="rxii_StockIssuedDuringPeriodSharesCashBonus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesCashBonus" order="37.4981475" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueServices" xlink:label="rxii_StockIssuedDuringPeriodValueServices" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueServices" order="37.498665" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesServices" xlink:label="rxii_StockIssuedDuringPeriodSharesServices" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesServices" order="37.4986075" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="rxii_StockIssuedDuringPeriodValueWarrantsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueWarrantsExercised" order="37.4987225" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="rxii_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesWarrantsExercised" order="37.49869375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_StockIssuedDuringPeriodSharesAcquisitions" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodSharesAcquisitions" order="37.49875125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_StockIssuedDuringPeriodValueAcquisitions" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodValueAcquisitions" order="37.498765625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" xlink:label="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements" order="37.4987728125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" xlink:label="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements" order="37.49877640625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="37.498778203125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="37.4987791015625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" xlink:label="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants" order="37.4987275" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" xlink:label="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants" order="37.48535" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_3" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="us-gaap_SharesIssued_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_RetainedEarningsMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityComponentDomain" xlink:to="loc_RetainedEarningsMember" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_DeficitAccumulatedDuringDevelopmentStageMember" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentStageMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityComponentDomain" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentStageMember" order="45" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" xlink:label="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties" order="37.44873" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" xlink:label="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties" order="37.44995" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition" order="37.499065" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="37.4991125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rxii-20111231.xsd#rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" xlink:label="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants" order="37.49874" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues" order="37.265625" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_StockIssuedDuringPeriodValueNewIssues" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues" order="37.3046875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfStockholderEquity" xlink:title="0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_StatementTable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfStockholdersEquityAbstract" xlink:to="loc_StatementTable" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_StatementEquityComponentsAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementTable" xlink:to="loc_StatementEquityComponentsAxis" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_EquityComponentDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementEquityComponentsAxis" xlink:to="loc_EquityComponentDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_CommonStockMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityComponentDomain" xlink:to="loc_CommonStockMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_AdditionalPaidInCapitalMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityComponentDomain" xlink:to="loc_AdditionalPaidInCapitalMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_TreasuryStockMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityComponentDomain" xlink:to="loc_TreasuryStockMember" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_StatementScenarioAxis" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementTable" xlink:to="loc_StatementScenarioAxis" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_ScenarioUnspecifiedDomain" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementScenarioAxis" xlink:to="loc_ScenarioUnspecifiedDomain" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SuccessorMember" xlink:label="loc_SuccessorMember" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ScenarioUnspecifiedDomain" xlink:to="loc_SuccessorMember" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_StatementLineItems" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementTable" xlink:to="loc_StatementLineItems" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_TreasuryStockSharesAcquired" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_TreasuryStockSharesAcquired" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_PaymentsOfStockIssuanceCosts" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementLineItems" xlink:to="loc_PaymentsOfStockIssuanceCosts" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/LicenseAgreements" xlink:title="0215 - Disclosure - License Agreements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_IntangibleAssetsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_IntangibleAssetsDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g275067ex10_4346.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g275067ex10_4346.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"P`)M`P$1``(1`0,1`?_$`)D``0`"`04!`0$`````
M```````)"@@$!08'"P,"`0$!`````````````````````!```00"`@$$`@$#
M`@0"`@`G!`(#!08!!P@)`!$2$PH4%2$Q(A8C%T$R)!A1&7$S)1IA@4)BUK<X
M4G6UU28V)UAX\$-3DS0UE7:65Y<H*3F1TY1%55E:$0$`````````````````
M````_]H`#`,!``(1`Q$`/P"_QX#P'@83Z9[!N,6]N5G)'A32+?*,\C>+"H-_
M9U`LM>D:\43!ST7!28UKIQ)R,,6BL#9LH3#Y+.4Y;>):S[,LO,.NAFQX#P'@
M/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\#`7L7[!=(=<.CH'=.]2K,W
M6[7M.@ZH`%HC<%)WI)EXF$`%S]>K$T]\MI;J48EV0,#"8+,4,RKXV5J]/`SR
M#)0:(*8TA]MHL=@EMLIAX4E"'VDNH00*0AM\9]*5^BVUI2M"O7&<8SC./`U'
M@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`
M\!X'P9*&)R^D<AA]0SRAR4LO-NY'(1A*E,/X0I66GDI5C.4J]%8QG'\>!]_`
M>`\!X#P'@/`>!^''&V6W'GG$---(4XZZXI*&VVT)RI;CBU9PE"$)QG.<YSC&
M,8\#YBE#&C#FA$,%AEL-%"%BNMD#%#$-I=8('?:4MIYAYI>%(6G.4J3G&<9S
MC/@??P'@/`>`\"G?UA/H/^TIW4GCR@<JPSK&LQ3A$00S,@MD"9TB(['%2<I,
M?O0)*$?BW`R11A7PF"V'A_>,AD9MT+B'@/`>`\!X#P'@/`>`\!X#P'@/`>`\
M!X#P'@/`>`\!X'\4I*4Y4K.$I3C*E*5G&$I3C'KG.<Y_C&,8\"A3]EWLGX$<
MX=$<5]=<:.24;N2:U;S/J]KV>'KRLW`R+J](B(&Q0-BM$C996HC5[+$03),I
M'4.4\A_\C"\8<:]%>!<DXL<WN*',J!FYCC!O&E[GBJ?9)FBV&2I[DJ['AVJK
M!0!<]%CERD7%HDTA!V4!Y)`V'!WF2FW&UJ3G.<!EGX#P'@/`>`\!X#P'@/`>
M`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`VR:^+$/+9?^;X<1A_
MS?CD9$(^+\5WY/@*2I*AGO9Z^US&<90KTSZ_QX%0OZWDAR?W%UB<L;#H[:4'
M";NOG.O;SN-P;[_?[?F,MHK.K@G).5/2:@BT6<&N,--L&G.%L.D?WN,J1_S!
M;N@`9"-BF09,QN0)'?/2@IO]AG*P52!3D6V^Y*2,J<0:/&+9;(>6^K#SZ%N)
M2VE26T!O/@/`>`\!X#P'@1O=P14B%U=<\2HAOYI-GC-M!0+6;-+T]#A.8`A+
M2')^"FJ_)BLJ4KT6T@I""T^H[B'FG5LN!U7T,%KD.H7@K(..%K4?J(@W"#$F
M)<&05=+4^T"UDX85Y84>TM+`ZDIRRIEM.6E+:]B\A+KX#P'@/`>!31ZU;0Q2
M?LQ=UAAM?DHJL.5."_-.K='L10#LC.W#1L0,;,%$X-G\$'2YKA/N&8<`(6\:
M6UEH)MO.`N7>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@5E>PE^R
M]DO*K8G&J(Y';JXF\*NMB)D;/V5RM7G9FASVZ"-EZ^AMAZ>KNOB:.!+VZ;HM
M?JT++OV1]1<:ET0Y3+0[KWXY"`C1XA?:'ZTM$B)J'_ES3_%K1<W/2L?8=O:-
MK54MM"LMLB!3XV`D90**H6MY&T6"R0E=:<>>)]9)MO\`N6TO#:_8''Y[E?Q/
M[2^<IVFNL'05/X[<W-7RFV.1FG^9NLK[6JY3]^AZPN#<K-Z^WA%ZR!K%BD:K
MR3/K,=^>B0-(.%BC&G75X0X2.H+C7#?D$;R?XXZUW#.U^(IUUFXZ0A]D4J#M
M$)<HJG;*I\S(U&^5^-L4!(20,I#BV>$)5'O*<2^]'N,..MMN*4VD,GO`>`\!
MX#P'@/`>`\!X#P-(6<,#^-^2M2/RRV01_:R\][R2/=AI"OA;<^-*O;GU6KVH
M3_QSCP/T86P`(4<4M38H0SY9+B6W7E(8&:4\\M++"''G5);1G.$H2I2OZ8QG
M/\>!J$YPK&%8]?16,9QZXSC/IG'KCUQG&,XS_P"TS_/@?WP-L_;@?MOTGRN_
MLOP_S_A_$,^+\7#F&OD_,^#\+W>_/I[/D]__`+3P-S\!X&R!66NR4I)0<=.Q
M!TS#.?%+Q(DB(1(Q;N&0R?CD`FG5D!K_`!Y$=?HXE.?8^WG^BT^H;WX#P'@;
M,;8H"./%BI";B@I,W(^`X\L\4<TK);[@PN!Q774O/9)(:4A'MQGW+3G&/7./
M`WGP/DZ^PQ\?SO-,_,ZAAGY7$-_*^YZ_&RW[\X][J_;GT3CUSGT\`A]AQUYA
MMYI;P_Q_.RAQ"G6/E3E37S-XSE;?RIQG*?=C'NQC^/`^O@/`>`\!X#P-GL-A
M@*E!3-IM4Y#UFL5R+.F[#8[#)A0L%!0L6,X;)R\S+R3XT?%Q<<&RMU\A]Q#3
M+2,J6K"<9SX%5*S;QO/.L"F\Q.6_8W-]7/`:S[X+!XK:(KVR%:6M7)+7>MH2
MTQ-VO%IY#P9&H[F_!;CAAUV&IM0\K,0[,:M@K"3%*9\#K6)XF=5?&"AZ`V%U
MS=S$9PZ_8["G-I5TJ[\O#-@ZJY-3<(V!!RC%]UY9MFUNIS%0Q8:#(KEB6(E;
M94KET9:L-LH#2$V/4_V$/\VM6W.@[+K,_2N57%K.NZ3R2KTG!R4;7IB2O=1_
MRS7>TM=RDIADZQ:^VS3V<2\:44+&F.MKRZL(=ET?+@2O>`\!X#P'@/`>!&QW
M$_B?^5OSO4=,`0(J.-NQG'I.3+CP1&\-Q*G$C*(E'&PL/R*TX&90K#BG7G4H
M0TZM26EAP/HO:0SU*<'$()D2<9U"MQ6)AZ*(EA'';=9W78R3>A1`8UV0B75Y
M&>RVTC_4:S[L>[U\"6/P'@/`>`\"GEU;,N@_9P[N#)0@T1@.FU$$-@QB89'R
MY:YS4I,=AM+A0P+63\I2L?+@KWY"'<N,.H1E670N&^`\!X#P'@/`>`\!X#P'
M@/`>`\!X#P'@/`>`\!X#P'@5>-ATV7XU]H'8'IW:Y-;UUJ+NVT_4Z?IKE3:H
MQPFD5/D'4M8R>EZWQI,K<E.1PMZN%F@9N4L3;.3(L8Q*V`F<NNY?P@*\NK.K
M_OR)IE=ZF;/IRO4OAY5=\;/<C>3%GI.IMH`UZDV^LS=$O[^J3+,\I^OUN\#3
M4E885QH&%L(YTCEM,DRK'Q>!J>L?@QV-=/G,2Z<N>6M-B=%:,XH\=[:?MJWG
M6^)73N2[VWZ]D_3O%K5UC9`EJH=?)7<XT2#(NUP=:0)!G_J7",OB(+"V!TR3
M>FM.\*JI>-B[;J]`V)R1VSN;D1=*-?-Q:X?36K[R/O&=B/4H*7A#XV'O1<5#
M9C_Q2W\F2;"7WF,K:QE8S83##;RTF;E>`]PZL+RW)#PSF!M@U)_*)@LPB.%B
MEX:EU^V2)D!'6&V,_P"JMYI:,)RI.<8#?F]D:[>8:)9OM+=&?)C0F2&[3!K8
M>,F%.(B!&G4G9;<)E5M+P,WC.5/Y3G",*],^!R-F8B"1VC!Y2.($(9;)8*9.
M&='>'=1AUI]I]#JFG&7&E84E>,Y3E.?7&?3P`TQ$&#L%ARD<4(4RT0*4,<,^
M.2.^A+C+[#S3JFWF7FU84E2<Y2I.<9QGT\#8K-?Z+2X2Q66WW*K5BO5&OGVR
MU3<_/1<3%URKQ8Y)<E8IPXXI@>+A`!@GG'2GE(9;2TO.58PG/H&+$#V2=>EG
M+;`K_.7B1+FO-03S0H7(?4[I#C5FA7+%`+2U_E>%YQ+0C2B6?X]5-X]?Z_QX
M&&=@^PSTXU64*B+!S;I4<^+)RD2DI=&V\1#R)$++2\%*$P<Z'KTB&L$6'+P;
MXZC`7R!<N83C#F?=CP,2=S_:XZG-0RL$!$7;9.^`K1#2TI"SVAZ/F?CFCP9)
M(`E4G@+Y)ZYLT/93FW&WO3]>\![7,);*=6EQ+8=>E?;FZTGVW(N!UQRX>NIX
MY8=5K]GU'`5:*F[=F,>+A*R98TWR:3%YES4M#Y?:%,6UAW"TLN^F$*#``K[D
MDLJIVB5DNMVP1K5;&/@9^5A^4\"X##7`"0'BY%O$X9I/]5D0-\MA+61<R6%D
MFBLK6A3O@8>G_;:Y[DV68N-2IO%7_9JSW&5*UO#W37NR`[76H>4L]I=I6M=D
MW)O9-9JRYU$!#!#2$S#,20;.#77/_6AEX'##?D=]H_M4VYKJO4@'8NB>..Q8
MVPB6.;/T3'D5RX'0#=?GZX15INP[-F=D:_#:(E$B6#*`TJ,(P8RVPX.@9YMT
M,0X?["/;?'B2BR>R>VR4A6'``D.-5O6.8^T9ER(Q@"4KH]@T4LN4;K0RC5RS
M$BW'X=RRRIE]WY<HP'!K/VB]H6*O(HD.87*O4>N-O3VQ]@PFZK9N??T(/M6*
M'AE'/5^EI1ZBXL\*[?F,9#K.8F`R_D,5261AVB,AWT5S^[C(V_/KI.P^<D^%
M#L3-3%"MCG-<1ZZF&3!TO8+=/Q35G&;BW)2X2HT(U%MFX=#;D1FFL,H0C*0Z
MXKW8_P!UKLD:F;W9V/$P<DL0DXU^X\F(NF59BUP_JN.RY`TJ6NC#(>)5*`7\
M9-4I]IE:$OHSEYX-@K?;)W/-R`YPN].PRP@0<4JJ35;8O&WI>/E[3"5R26=)
MREB'CQY>M2T"[*Q11T4*UCY?:I3[C:%I0L/O'=MG;M/VUI<KS>Y[:KHLT:W*
M-21YUZMF:Q5)DZ)'1(#!BUIV4M,)2WI/#"S,DH>F,/"_P(\][%!KVNX?MH<G
MP9&,Y>\[YV&R&"Y-"6(C8<170K++L$.O0#<C27B9Y45737`PPR<#I(E5.NON
MC,X2TPX&USG=_P!HJ(>J@1G+[G'!SM@"*BIZQV&]$38Y5@&EVVY1%&CA(&C@
M"Q$772Q))."!W95LHG(K[^!,LO>!U^YWE=SA$)5RHGG=R?-7@"3#F$C(][N6
MXN2:;0=D]VO%!'+5'R(K:WT+^9M['^NGW+2Z\'8,IWJ]G,;[*_5^;W,PDU1$
MN/',&6F*+NI;*[.R8VBVP$S7[<B$DE57\H$/`!SJF5A-FN-.8)6V@.*']\_;
MP')Q+!78AO\`#8"ED@RD2ZN"=F8R"&.6MEJ2(1K$`62G(\<!2#R5X>6\MU./
MC4G#S:0WNG=ZG=K;(YDNN<\=^SGZZQ1T98HH2O:\6N"@I@^'B8"7DK9)TI$0
MPN;F))P)"R?8AIYG"W580XG&`_0W?5W2Q-MC@S^P/81[K4Q&/UX.6C-+NA3;
MKDF.F$<FF#XF.#A8*795[WGGRV_C%<]RL_$OY/`S^C_M/]N)5NCV(K;G$<N+
MFLA33\X]Q_D?:"(:]#P$/6KG%UV1F)\/*9Q#C>4`*DS6U&.N-O.C*$]H=G:%
M^VYV3C[6K2]QQNB-HZCK]XAGK^!3*?":LF)FCBP]O;?%_P!P)*R7:!II$_(A
MC$E.+C"D-_CI98*&^?&5!,Q*_<#UQ%2JJU_V#;%D;:^75@8BO0O)[C[/D3)-
MS@C;!76@%U\N6=.7(A"H;PD1HI;);R!7\,EN,,/AF1I?[1?"FSZCHNP.0NIN
M0?'BVWF/M]C'H<=1)K=XP%+K<QLF-!MA5HHD.(\,#*-ZODOG;+C`UQY#+OR9
M4$TH_(943WV&NKBF2-*C=@[DMVOE7Z=+A*\9:M5WEJ,(;#9.>>L"9")BI<8V
MK(R%AI<@'DD=@IY`SV6R$NM-!R\+[`73I(LL%!\Z]8.A$R"(D>0S7]G-1SLL
MXEM;<4B1>HC8.9-QIW"TC_)\RF_5>$Y2E6<!)?K3=NLMJ01UBIE_J=FB!+%=
MH#]C%'(9&P319YV`L;'M-?P\_F`D$I'*(1C`ZG,X6C/Q.-J4$;W>7':YO/5G
MR+A-AS$J)J:U.Z;B-A6ZF0!-TF:MKR:W;K<6VW.#"AXZP$9*KU9)?-:(;!.2
MC#>,J:RVI2TA5/[SH/44!W!\"*YSAC9^Y<#J+Q[U75\3=HI=@JM4F:VQ`W,'
M8#]4_P!N1H#-WO2)]5>*S$PK2OQW36QF!VF67L8"KSNG/%<Z)FZGQE$O3NF"
MTUZ2HEFY(%:_K.XL@U>AR$K?A!JG3(>P"IKHVU9>30&87.MM'DDC--MEX#.P
MT'H^<)+G1+;V5\8;*?1+QI[D)?.G5<ELK6]F-ESUE:]K6\=:PFA;=:':G_\`
M.T1>)RKIF"2!R7"3HIHC`"5X4RI3@6-_`>`\!X#P'@<%O^T-::GB@9W:6PZ-
MK:#DY9B!CIF_6R!I\2?.%"F'"PP<E83XX,F5)#CB'6QT+RZMMA:L)SA"LX"*
M?M3Y,<;-C]<?-RC4+D/QCNMREM`[#B(JH%;)UW=LS<S_`(_B0:KK=5`N0<C)
MS<D,M"0F6'$E))>9<:PI>$)4',NCN1BC^JOA;F%B$1$>YJ%N29'"A9*$@T_M
M+C;WW&H4:4D9HA(:'FU+0C\X]*67&LI)(0M#RPE@\!X#P'@/`IT]8_ZRU?9V
M[H"8G\^._3U&K?M3HZ1_`68=79;4L2N+_$62T4]!R)(;N9)I3);9)++3B'!4
M>QMT+BW@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X&#?8+PIXM\Y=
M`GZYY:MO":YI!LELR)N#=[EM?(UE;HJG6FOQFSU38,S#Q22:(%9"9`;,I\\<
MP4RV^ZVK#?@1IPW`;LJX\9ID?Q;[:JW=..,5KUBCZCH?,30D#NF>BY6=KAKS
M&RG][TZP5:RW>S11Y!$G"/E-H#P&IL$C!`Z/>Z':>LNI39NP;WH/='8_S&OW
M,_9VA)_-HKE/8K]=UOQR_P`PIMUNDCJJ_ITC"QO^*G7&/J]N5DTV39D),229
M&_7'CLB)^</*[YBZWO=JYO<A*E!:WDSYV3YF;^H,4+#M92JRV0G<,M^-7?1G
M*@F9I#DPRS\N%I2MMYI/ICXO7P.WY'J:[(6(B+6YUN\T,-P8^7Y.>@-.WIO,
MXRW(,RIA;F1ZW81)$D!E\\8`X;.$O#_BN9:5E"TO`B^NSL_J@$A!S_6AR>G6
M[+"EX%/+XU[78GH]B/%AB@C8N7A:\TB/)B&X#"F_<W\KGY17\Y<(4K`<;G.!
M_-!QHZ/C."78-7)E'H",Y_L1O!ZL1I*+0\EY1<6JE3<R^(-4_:U_HG+5DM'N
MPE2/^8-B=X%\[1&`/AX4<ZGWQ\.96/'\?^0*HTE`<@2TP&8/(:\C20D2(:&U
MX=&>=PRSE.,M?+E>$!SJ)XP<\80TN53UT\P(=!T`7#S#"./O((^KM+R%*"!V
MARM354+`,D89MYEU3!+BH\KY#VWF<L&?&R&PO\<.?K)==9;X!<D96O4M5C"K
M5;LG$[8TQ6T%V>$Q!&%F0TEK<M1!1,@&9(M#.ONM@FK_`.BP-^,WG`=IIT9R
MRH-1'I<+QYY]%MHB![)^P%XY;,C0YFRD4^H!0.LID>0KP:Q-=0DY-6MF5%&:
M?:+?(;6C\M2\$-!E;Q_T'QS&I,&9R>USWB:VW$Y-2[,5KS0W$'7=LU70(%F[
MC6FGQ&N)+9LK6[`W,LR0P<D46+$QBUR3N590XO*WGP[,B^+_`%:R-MC3M[:I
M^P'M:L0M;8H4'5P>'FH-8'0#E9R$%"Q\6;'7*Q1++,<*X[^>)B,226>4HMQW
MYWGE.AV\?Q3Z0_VDW!O<:/LA"0D@2$;/K*TOKQR.GBGL/"U>=E`7XI,B\Y-3
MDDA8"B1LN9?-PWC*?>K/@9E:[J/UJ*?1(:I;"ZW^U7:L]&+6U([1VMHW=3-^
M/AI/)LC%2%A>HFQJS6?P89LO$0)^'&L*4R`WGXW,)R\X&4FA>3GUN^(%KE-A
MZ)ZW.9TK92JL)0;#4[9Q'O\`M8&0C)B5I,BN7*C=X3UBBXBP5U,6X1^2&0$\
M0SDU&$D_,+C(9ZSG<YTE!"0([77/NJ?$<(L+3(@O6/'L,P21`)*20]\4W7XT
M=6+0;&M,,)#R\M+I"'"\#M-O.-!N5W[R.GZ0B:%%D=?_`"3V'`5*$E0ZU!?^
M6Z&7%Z_00TY+BU"(%MP$8!`NV"82OXVXG#@2BFUN/.(1_J^!WDG[/'7T,J/&
M)T]SQC4D2(43Z/\`$2ZMM".&11YP:<-MFJ<>6LH%`*6&4+?42\E2$*'0Z^V'
MW(^S]UR,%Q(;-!YO&+/PVY(9'XC["1_C@R@,2+I4PP4X,4\P*,XVIS(+9G]C
MB5I]R,^[P/F[]G;K(801+QP7,(T86-,D2XR+XB[(2R<AXX$+$P^69#B);6*4
MW^,EU9;(^5OY0Y[G,->P`_V<^I)OY,9-Y$QYIWY;Z@'.(^WD''_ACQC7SY2-
M6'6B/F0R.RE2EY]GXZ,.?&C#6<A\ROLQ]1[)[<HRCD/(R;:GA&Y$3A[MM)S0
M@KKF!74%G58,A(9F"''&$85[TI4KY$-JSZ9#86_LB=)Y3#`C^-ELE/)*R=7R
M>&>T'9&+%AWX:/;*E`AZ,2RD+XB$996VIU+;8:D*^-Q++;@<$Y!?96ZN8O4V
MS2-4[)I5XW/"TW_+M*Z<VKQIW;4A4['@*_8+$_3+?+RE8:";MK$O5DAM8#P#
M@.2D(]G#[WRK>9#F"?LA=-Q&JZ?9)C;.OM>[CL=4K.)2CFZ+VOLH72EG-05`
MY@=E'UC6M>*Q"Z]D)IX*1>$4SCXB7$@X?^;"7`YO#?81Z`6BY$!G?M#@T8.G
M&3S"^,.YPP'C"2"&#DNN(TXZ]A5A<D3/C;<0E3^$DI6G&<+3D*N_>/R]ZV^=
M_*?KO<U+L[_N%X_Q%=W&C=,'J%J&T?;JB/,7<.0`E5?YE%ZQJ%9L)D-7&0E/
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M/<-OSFRHZ&=AK`V]L4F[T6.EZY+6N8R^2*F#2.2"ZAG!.5NI)\#@NU^HW1^@
MS++1FN['KXL_(437D14Z+J-R.T]K6:OEZG=@F9?;VQM.RV3:;T>9>JU:91V:
MD'AD2TB_D,1Y7X#:5+#&2_\`3MS[K-9NLH_N?K!@*;0(@2@6W+W-&!C(SC=9
MQ*:#,(J\O)6N6BH&#V%>@[N_(2*0L.QTM(SY&7T-@O8&P$<)7`7E!J7<]DUS
M,\?JMMT;35MCJP_<]7'VJ^:AV/>MET:!MFH:?#JA;%7Q]AU"^6&6"RA\1MM!
M*916'"41S###(=QP6Q><7#?1>S==V"V<IN$^A)Y[:M7G-1$V0ZEU'>>X+O10
M:=?H!(%NAIZ)M-0JU?FX8$@0<*5Q^ECOF8=%+,=,&#K8#FSNZ`B==TV;Y"ZM
MY/ZWXX5'%[TOJOD'+V':W'NHU:;I<OIUJ"INB-A--Y)VYKVOV-,B-"R"BVQL
M_.ZIHMH%!#H996#MLFU1-!G)/B%UP[`!X[55B+UL3'<?DP)6GI2/LCVSX*IZ
M<B87:]7L%*PC8CKEGF)44R4%"_:+C@VV',/A/!VGK#[)?.76&Y.37)\#;N@Y
M38/)&$UV,]2+;HN9MD9'N:KI#Q-`I]79KVTH:5HL"_.7B:$-=D)J6:')4E:&
M,8PM#09CU7[1?:K>)R$I3TOP7-D9>#G9>SP<1J*=F%X@(6(L\Y/)K4BSR6Q$
M6`IB!I\DPH<IV-(S)K#'0TZR6DI`9:]>G?9VJ<S>4G'?B[5;!P;ID5N*Y7RL
MQD58-+;D@KE2=;:=0B1FYDM05ZMM/D)6R4V,/9K3L6;,PKDU'NB2!8><LY?"
MQC;N54PS*Y`H?<;UOG&LWZA@259MH.H@)B(HV+)%Q6UFER$/R-,6=?F8QXIR
M!;7&!AHD$,B&)6EQ3Z`Z_JV]>1=LU%.N[-[:>LN/VK%.[%*R-I>L4.RUN.AP
MB[A&ZUFX>Q7?D9%$P-L(CP@BCW3P"H\&026,A+[36'\A2THW=MW54J`MELNG
M,&V2E`9TJ#?HHY>..UI3'V28DU5N$!L=R_V1D55Z3>L9[/I576F)D])8.6C&
M(Y[,DT'`)_G1RSW;/36P>47,G8$ELL"E*B*TZ!N/<]`JE156CJM5+P+9'^.F
MP:=JS7\A%PAC\TX[&A3QA[K[)9C#XQ>,8#HN+U3SMY6?N63)T[D\-IZW%-R-
M<W1R^UWL*(3>&Q)#5%/@)J0W/L[5[BA!ZP$;+8,B/SU1,:=%EN+RT4[AL.81
M_!+=G%L"-V#NGBB5HK7M,KE;M%O(JG)?B[L=XZKY?R>UMM;-BO9UTF)TM,0B
M89(K3K<0H(8=J(2$3)8)2'HA=#39+'4/P6$,*-.,`T^N,+-.FP+&X65&6ZS1
MY)`LS&(0$;%.OC*R%E&7?8'\2,NO93EU82Y^`\!X#P'@4P>J)XB=^R_W:,BV
M\FNR:@2TFQ5>_3G1\I%5;9.GF(]_)4G$3;JY%P44H.592Z#^$H]:6OE=]B@P
MN?>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X&E;"':+*.0ES!)C0K)"E
M/OK;4V'\^1\-CK=4.PI/Y*_<I"$J7ZX]V<^U/H&J\#CUMJ-5OU6L5'O-;@KC
M3+="R5;M53L\4#.URR5^9$=`EH2=A9-@F.E8F3!?6R^.^VMIUM>4J3G&<X\#
M4UZO0E2K\'5:U%APE<K,/&5ZOPL>RD>/B(2&"8C8J+!'3_:P&``,VTTC'\)0
MC&/^'@;QX'C6[>CKS:^P'>VM-)PU^NV\[7S[W$O7E<V"#K@^BVF[?[['Q(D.
M?1]E25RH%OE)`R5';+0_'9RV*VO#OSB.$H2'L1:\C"X6@4:&/8'%.B:?68PT
M8/,6H0<L"%"%(8%S!QT/"Y'9>:RE&0Q!1?;C'Q,M-^U"0YAX#P'@/`>`\!X#
MP'@/`>`\!X#P'@/`^2F65.MD*::4^RAUMIY3:,NM-OY;4\VVYG'O0A[+*,JQ
MC.,*RC'K_3'@?7P-M5#0ZR'BUQ,:LHD4@$@E0(JB'PC%H=+#>>RUEQT4IQM*
MG&U9RA:DXRK&<XQX''Y#76OI:19F)2BTV2EQG2GQY20K$(9(L/G>W\UYDX@%
MPEITSV8^5258RYZ8]WKZ>!5TZ3>#&D[ERX[)N=4N%;9K=#'8USYXZV^0D;%"
MVC6=_P!6(O\`KRZU>"G*G-P<B*J4IMNCV20SXHD8M@H93)2G&_:T@+02]6ZR
M=62ZYKJB..&E,'&.+J-?6LLT4LR0&,)6J/RI\H<^1(?;<7ZK0\^XO&<*6K.0
MJQ_9.X?\?=@5?CY_\ZZ(A[1#ZHYKS%,)UB7':PM;MMI6H8JZZ[`.E1!&(`G7
MC6QV`R)84U*<.$J%6A>/:M#@:KZNNMZ;M7@INUG9E&UOLR"JW-;D+685%SCJ
MOM1J!8$J.H*T/$T:PK@(VK%49V`C%#I7&PD$*0.AA+8:6<>J@L3W+A%Q%OC<
M`BP<<]/>ZM6>IVV))AZ#6JZ<W*4J[Q6R((8B0@(Z..-@<7>#$D"XQUQ<?(/,
MXP4R\A2DJ#C5OZ\>#U\LU>M5JXKZ,E3*Y'VN+9B7-;51JI385S$APYMNXTQB
M+:JMV7AJ`$R&Y+"&.1[C/O%RRI2\J#A%LZJ>N&U4^Z4UOA)Q?I[%YIEKHLE8
M]=Z*U=1+M%PMR@3ZW-/5FX5NJ`3E>EE1<DZEHH9U#C:E>N,YQZXR&M"ZL^ML
M4<!DC@=Q!F'@(**KR#IOCAIV3,>CXC):Q_FR_3/Q\$ODR#[S[C;;>7WGE*7Z
MY]/0.,7KJ0ZY;PK6N<</>/--:U=L*.V-"@Z_TSK&HQ,W(A!2L:1!W2'BJDU&
M6ZKR04T1\@1K3B&R?B*9RT2PTZ@,$]V?6$Z=]Z;)F]GS_'>7I4G.A@A/5G4=
M[G-7:^CT1E?9KH+L+1ZCF/@(=]E@9HA>6&D8(,1EU[#F7'<.!Q*__58Z>=D3
MTK9I[3^PXZ:EFFV%N4[9\K1H@!D2.'B8MF(J=1"AJ=&-Q(`;26\-1Z?G6C+I
M/SNK=6L.&F_4BZ:RV8X=.NMZB#QY"R,#C[_NSK)7R_!^0T\T>HU#""<#IPXH
M;##BL8Q_=_"?0.P=7_5GZ>-3;:J.W8#25WFY"ES(T]&TJ^;.G[WK60-$+62T
MS9*A9VY$:RQ2D*^%P(UQX-YG'HXTK/JK(9)5_H!ZE8+9NW=EN<--/SB=PM55
MJ2U[/4VM':SIBJH9^T;*UK6,0[3E)+GI9:WY10A*6SD*P,M&!&VF$!V5)](_
M4C+(<;,Z]>+J6W66QW4`:RAXE+C;68+V85^J2%ZKQBMBX]W_`#93\V,YS@DG
M#H55?LD\?>&/$VR:/UGQ"XCT+0N^8_6=TY'O;)T[KRHUTN\Z[HC+.L);6;LD
M2,?#CDQB95BQR#Y<0<0:+%Y':('(,6MX,-/K>\/N,?-WGYOASDAI&L[(J=4X
MNJN6HB)VNV"EC6B81NV(@S]S)K5=LX\53+:4\00TX`,D%E#1:'QQFL.K=="P
MF5]/+J8/L")TV4Y1+0\-(YE88;;-=#BI"6D)>,D\2K>&=>_G1V!&!"1&AF7\
M#X'-7E25.MLNH#0S'TXNI.0DFC8^:Y60(:2@GW8@#;U;*#=''R]DH+!$OKF1
MDFVI##B<+7A[+B/9CV*3ZY]0V+5?U?.GJVWO9@VNK=O.]%:5>N?'K9E'V7<`
M+M"5G8%HU1$2L580ACZG`&`VZF538%>D(8P-]48ER/';6R[ELA.0C5Z<>IG@
MWR,[`^S#2.XM?R>S=)\)=JN:[TYJNYV915:FJU+3VP-?L6*\1<./%,3]WK8N
MK`!HVU0SX9)@B'6I/YGW%(;"?2T?5[Z9K/L2K7/_`+6&8&MP%1L5<D]:5W8N
MU(FK6N6E2:HN"M\T:+>$65J;J@4`8PP@8UD8O]L\Z4V\ZAI20Q"[0N@KK8T3
MP3Y![XX\Z%?H&X]':^%V'3+@;>-F;2+9&U?&&8K]+*9VKL.P1$-K)67AT3K;
M:$(_0".L8]C?IE`2>]%4YD?K$X+TLI^MXDG.,T%?7(Z/."BY",CK-<+/F+#B
MJ4V`,:FAA,)R+%S*G'6Y!L;UPZ0OW$.!,;X#P'@/`>!YF^Z>VEWJN[Q.U/>1
MNE:;R*9V%N9O6,?1_P#>.2H)]7=U]+:SLCMH6,#2K"Z>0^NK`LI_):0P.>P^
MAI1*&WL+#)\;[Q5ZPJ&R9UVU)Q#11JK`D;D;,,J-"4"^B/9AE.ZA?Q&%,R66
MG'G'\%H<82IM*$+5AQ`:YW[O&PI"36;$]>U)BJF#'.(DDS/(F>DI7,T[A]^-
MP.;&ZB#;0(8D18^&_P`%WVO.)<6\VVE6,AO[GW/MR0-0C9^V\)='"RTR`-(Q
M5?"Y`W;$R\$B)^9\TV*1JN2<B$34NXAD%DAY#B&DJ>7EP;+)+H:^&^[+99AW
M+PG7_0UC9D94!B,EN6K=1FWVT#D2\=*N/SFFE5L&/%B@'!G\.'9=*D7F4#IQ
ME6&U!-KNGN4Y9<?^M&![3KEQ.T';-&WZJ::V!3:!2.06TD;%AJKNAJL!P`UP
MD)CCDBO_`+`26G/>04TD<5M+S0Z<.*Q^0Z'%>J7O(Y7]N4;NF6T=P4U)K*/T
MHBAIEB]N<J+D(/8R=A+L*X=J`76^,<RXID<*JFO.O.(PC.4MH1[LK5E`0_<C
MON%;CTQO^>HCG$.L1<?JJ]VS5.PJ@C99=B$N$G0-T1D/9+Y2;A):ZIDV+"SU
M#KLU&1*2(W"!Y,I!1"'\,9'\#A:ON@;C@!MJR$_P7B5$WT6`D..]?7OB"/?U
M\^77A(8T:ZA16MHVSVR#.GXXB:$2X*`;G\O`F7_@<&?0&'8/W1^QI>(84W1O
M#X=]+K(LR<14]O(%SA(Z&'I!Q@/9AI0S2BG,O*:9;><0EKV)PO*L>@<UC_NB
M]AB\0;CW$7B\2S(M8CF2EL;9C@IF7'D&"2WP3'[S@9A.(E]#"F/>Y\:W,/97
MZ9PWX'&R_NM=@:\0WX?&GB8SD88/$U[X_:[^)0IHM3AC@^,[#9S&(*#]K6$8
MR_\`&OU7A6?7"$AS&(^YSS[-&?G%\=N&CP(H!ALA`I5MH28BV(=\5C!C[I^P
M0Q#46DZ;&%&8#=*,8P,\^IC+>,>X.VM3?=/Y`5ZQV-OD]Q%U*5#B4`@BKP.G
M)VUQ%EE+],##R].,EY>T3EK@`J1B,)2F20VG,BUEQM;*'%)=92$N&YNZOM"Z
M^=+Z$Y7=@W$GB=.<9=U3=5KT8'QMVOL9?(9PG8=`D+W4'<5/8%;CZB@^-""R
MW*CN.B^Y]M;;>&?<VK(.,G?7SR[*BKM:NM/K^K<MJ+4D5(E[2M'+O9\A0\GV
MYMY@IS7VKK3K:JR],S)U^MG@'OC2[CLDX@_UPC+3?R+"*>[_`'6[U53(D"@<
M/PKN^[!U\F^N;1V`Q5\US83++X5]J]`#H]1>4;KEHX1MZ$+F'GIK"7W<&>[T
M;0V&TL_=SWK^/EMWKUUH_(3+`F:Q^'O.TK;R]E9T>3^8$C7[Y1WY$JRC#+3:
MQG$H0I.<KRM"TAS07[JN[C0#I-CK7KJ0@9!N$6ZK>5P=RN=8849*Q0^6M.?C
M/28,<PZ4X*IUEYD=&7%>Y*<Y\#F%;^ZU-VAV79%Z^XH)XDBU?X0P1R+6Z]--
MPU;DY<./DLKU8"P))I+:#0Y\:UY+_)^$5I;V,>H<LJ_W339.O+L4OU>;#_7,
M'Q/Y,G7M]MR,1^HL)K\'7WQCC]*1WY4A+V.,-#8;0G+;C@RTI7EQ#B4!H<_=
MH@(UT6/F.O0XR7?R0(H2I<H(J?2J2R`._')9]=,BN_C&FG-,Y0XE!C*D/H<8
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MG,>Q$J9+,-Y994Z^EQ)#><)6,1\08LS'W0N.]50Y_E_!/D!#OX.<`;&#V?J.
M8>22,TZHX<YD<UDF.+"(]C+C2V\Y0Y\J%Y2ZRIO(4^JG>&]@<TZMN>>IFHJ=
M5=E\\I?D(.-S+8)<JLCKW8VR&&W*]?FX^1"@I_4,'&6#\J;D(.-:*(60\H93
MJA&$9#V+*4(8!3JF#(AUJ.D`JS!"'`4QIYBG@F#18K)(=49(9'(9K8SR%(!0
MMM"TBI1A2<9]<>!R;P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P-MEY4:$C2
MI0MF2(&$2A;K,1$2L](KPMU#6,"Q,(&?*&*PIS&58997E*<95GT3C.<!!5T*
M*%_P_L_:'P\&MGN0YX8>A2)A4BY%Y79ZLXEW\1P<9Z-1+95DI.%8SAY+F%)S
ME/IG(3S^!6L^R!EY[25=!<S(M1R^+'9::\5'1DF:EB0%XI%BQ[<L2&I`HT*:
M/(DL.I7ZO9=<:=2G([!7H'7?U2KU$S77=:+"'2!J<C:',O;+H-&U[3;(!2-<
MC#:JUQ(`-/L$_L`ZM7I6(A&R&"G2G&3#9%I/R+)(RGP+2_@/`>`\!X#P'@/`
M>`\!X%#_`.UQ7)":YO\`#=,91[/;"Y#C'LN(`'HT?:;'89^><VA#$0%4/IT2
M='QEM#40AR1CXCY6CY8\+XAG$$-CX4'#?JE-+;[!^31\>[%QM6M'%6>LU?I+
M5ADI*T4D&5W9K*<CX.]P\O>;@?$V$>+L3.<9]K`[B5*PC.'T%#"A?R\!X'#8
M^B5Z'M)ELAF'H8R4'D\349$.XC:_/2LL1#NEVJ>A0D,AS-OPQ!#C-R9.'"VQ
M,*92O"%JQD*J7USF9G'89]@U^9)KKSZ.9\!'8:K1PSD6PD*]\D'6FX^.1,3)
M(D<A@Q.$KRZIE3_RI0KW(<0@+;_@1C=SRH__`,K+G`W,2XL%#%:,G@)J1,5&
MI93"R)T8!+AX_<DAQ*B)2.)=%922ZAE;KR4KSZ9SX'#NDF4BD=9O!VMBPMC%
M/&XR4Z6+D#X9W]("DB<L(3E2#L@C'Z%),!(C$(:AQWG%QH&&<*3A"D+6$M7@
M/`>`\!X%"_3?6/QL[).^SMXH/+[16SM@ZHUY,%R-,V;&*M5,A(O9L[)5*;.K
MTMLS7;T=$ES;-.MK*82(F##3L1,=AW#3*6W!VPE;DOJ*]-9P30@FO]Z0SB)9
MF1=D(_>MG?.?$:#EALP:OVXTH$U&//R+1"U(827ET%G&'\-Y?0\&@3]0CIQP
M*X/FJ<AU.K(9>2:K>DG^4RVTV0A8K:4P:0\CDJ>2M>5LJ=PII'L6E.5I6$!O
M/?I3X*\5NV?K1X):KIVRV]'\PWQVMQO6^>M]NG;(TS;)T'(E5MP3<<#`O5EB
M.$>(_'9^01)+3Y*LBJ<0X$R>[_J==..K=,;(VC(Q7*=H+55"G]DSV:ON:.>F
MYB(UW!D6NP1<6)8JN5#-&V6.AGQD_)EM#*R/5"VO:E20Z(X&=(74)V?\5P]S
M\<]D]F-'X\2+EGU`FC;"WJ#$"6PBID4N1Q*DU+];;X54%6)X)P849M38#Q;"
MW<CXRP.I(1:]\76AH3I-K_&B4X`[.Y?:MN>["-Z25IE8';5RD"'2-2Q5*L5.
ME2'*B30`XH&JC6*4_).]YI0@><O8%=_O7X$8O4YP8T#V7\ZJOQYY1;-Y`A$[
M(U)?;$5&U:JC8NF-BQP4H=+VK%WGSK2)"T\"SN$2[*'HIS\U*O0D4?#RWW`M
ME._2NZYDG-'1O)+FG$K'_"6/@2V:;RX.4(RPE1C)+NF5$-OO%-9?QZ*QAM:O
M1'HG&,8#2)^E-UU)=P]CDUS1RZES#N%KL6D',Y<PKW^Y6'-)J2OU5_.?=C.,
M_P#'P/E(_2IZ_#E`YQRHYGY2*\VAQ)L[I<W'ZS"B770`$IU`*B.4LE_Y$KPE
MQM']W^EG*_7`:"0^DYU]NH1B+Y2\PPEX07AQ1TCIB22MQ8CS82DH9U1&90@8
MY3;KB?<K+S25-XRWE6'$AQ:6^DEPT=9-;@>8?)(!Q]L7`A$W7-:SC@+K4S^2
M4O"(Z+K3)*"H#_I,)6GU;*_ZG"LH_P"FR$>O9C]7K@OUN\%=W\H[=S-W1-W&
MG4,Z+UG!6&N4V%@KOO"6EXUZ@P`XT+%RTHS'2L<">$2*MUS*LOX+_,%0,IMT
M.F>K*.XP\]^+FP-S=M7:'OW96H.$<<Y?=J<*]CV*WQU0!KSU9FM>:4O&K+='
MWF,N\K8X@\A@086!C\.8F'A`,Y<P<CY@PUXZ;GLNN>P4#C/Q_P"57,7J?X&<
ML+[5=@\>:B5>!3BHNH[EA*^+0-M[,<NEUAZPU3+W`!.$Y*=D92092\&*ELM*
M<D^!94Y&?2]XA;'M]9F-`\D-G:+J$91BXBQP-@@4;?LEVOBS+-)C;`E;K,VJ
M"9#R6[*QXQ0`D6T/D2/SEO*'WUNX#&=CZ/E3<)5DCGY8@P\QM!2C#&DHV1):
MF&(4-O:#ZE+O,4T_&RMBP0]`-8PV['A*;9+<,=2I]0?EOZ2IRX.&JQ79)/YK
MPTV78)&(;T:\N#1*'!TF.)DH:NN;82"+-N@Q\LTZ:XXIQ]E$:UE*4LO96&FD
M_I`1@RC\5SL&D"&BI&#''_<Z""$<&KZIOY+.Z_D78LE@N81!MH_`2U^*VHOU
M^5Q+6?3(;3,?2)FCVY#(_88SC\")EA*H%(:)>('_`#6#2_\`'U2#XNQ0VXN.
MD0\-/'M##/NL%..^UPGT^1P.!*^D3NA@.3!!["*`@<Z1PK+*])VAL8@$0R(S
M%DGCMWU6'I`8,J55EO"L(P\@?"7,)>=4R':O'GZ4A,=L*9(Y2\VI":UIF-<,
M@D<<J]_@%Y<N0$DAFOGRW^=PUTK@\8/"/DNJR.E13):\-MK4A2W<A&#VS<(^
M-OU]MY<9[?UW<M-CSO,TPZX2TO';NA=*7UG5M)7'OPD)?H51^J8R`@[$98Q)
M`$4G*"B&E#/92H=2,?,$QU(^N]PN[9(6L<T[7V1<D-L;OY/:_J%^V==:Q7-/
M1M9GIJ#CZA3[B`S%P&L*[#,MPL_3)$!M"G,NY<2*2XDC+"W#0X^-PNWGSFX[
M[QZV:7M'G'R&XG\*=VN<2I:O-L]<&H086\\?@J\31K+59N5`A=FS=8CQ7U%%
M`2.6R)-4@PQ^Q2H%\DH.F..WU2>+G*K34;R8B^8'*/3&OYVS7T/-'W76]$6V
MR"SU(O\`-ZRLUB.O]!NLK0CH^R3E7)4$^@'#^&5M8<PO*<9<"#OEYU;;VX/<
MG[I8:9*U;;O&GC_N"/I=:MV[7X*[S5BA*+?--Z9M-:G]<CCQLM.5O%WW<$'^
M@!2A!<=A2F/=EC+O@>AYV`ZK[J+)/:XDNMGDQQRU]66:2<!>:GNO6,9D#]U7
M"H>5KTU&SO\`C5VFRIW827R8PL-`D?$PX`GN1\A)"76`BDY+\#?LV\Q-:6+0
M^Y>2_73$4J3./"$V!00MN4J\QX[;?ZA-H@I"M5`8B,-GX.1,:<9<9<PRTZO&
M$(=RTM`8-]1G.#[&O+:VQO'*I[`X^Q.L./R7:99=_;OU!9K$ULH+7MP%J-V$
MI]^CV0839=QJ#AXP\DPP\`4&,IE3J%$>_P!X7S88.0`CF1928>GCD.%K=E"!
M`077T/F/OC-*%CF1Q$)"&=0PG*484M+>%+]5Y5G(;IX#P'@/`>`\!X#P'@/`
M>`\!X#P'@/`^;K2'D?&Y[LI]S:_[5K;S[FW$N(_N;4A7I[T8]<>OIG'\9]<9
MSCP((>A)1S^O.RXTV2)._*[DN?Z6FB<-K6+@6YUD;.,%YQDHE+J4)],.J5\2
M4X0CT1C&/`GB\"L?]D242#K>MCIB0Y<DOA%VE9;08R\EJ.&3HG78ADK^8V(\
MV0^/@]"!P5/"?(2MLKY',!9'>#@7U9Y2K5_KXE:)8A9UXO\`[S=QKK*WH\J5
M@HR2@(+642ADF5KPCM5K$^J0*SAT#+Z,$EJ)(%0L5*W&PM6^`\#B=]O51U?2
M+?LF_3@=8HU!K4W<;C9)##V0("L5N.(EYR9-_&:??_$C(T1QYS*$*5A",^F,
M^!6&F/MJ<"I6^66J:5UMM7;]<K$;B9,V&]/:TU9`D1@;/R3K@,)LJUP=R+)!
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MI95IR.IHEZ,PR8EL+3U;G0[178&S1S1C,?8H6+G069$5P&0:#EP6)`9HX)W_
M`%0S&V2$X=:5_<VO&4Y_G'@;UX#P*1_V<*6S:N<G$B5,4A@"E\5]G2Y97^!X
MV&8,P=MVIL%2,9%CQ4Y(P)$,&&X[^X&'2:,0X.*&K)1K?L#KCZPB:LYV$[JE
MZD]NE4+;^#3-RAQ=JYGFH$&NG;@UA7*[&ZP<N=;K]YM=1K4;4\06+%(9(1(K
MAO@9=7@-?H%[?P'@/`JO](D1=XWG/WYR;3@W^1S'+:+5!&O!!VIX=$5LWD=%
M$B20[%UA&T*?/'(-:C2'(EYIHO#Z,J'>9QX%J#P(G^]$0X[J)Y]A1RGD%%<?
M["QAUKW80PP[(Q*"R35I:>PU%#"96X8M2%-H$2XI>/9C/@<AZ5PU`=4'`,;!
MY4F)CC3KIZ),.88&/=@B8S\F`2<T)/64+!C4,ZPAW+!:F,K3G+;;"/:PV$G_
M`(#P'@/`>!4-ZHJ;<W/L>=UUSS!6L/5\:ER+CC1X"[P6MO\`<2:D=3$36<M9
M0!1W-A2$)'H*>()8=DY$(C)PCB@R5O/A;R\!X%07N`JMCLWV+^BQRMAR\WFN
MCRMFL0</`V:=_P`:K$3LM2#[1-?I(XQB*A"7C6Q%G.J2,*[A"C%M,92K(68.
M:S+9'#;EJ.\4T$R_QEWRRZ:^V0ZP(V[JRU(64\T(T^4XT.E65J2TA;F<8]$I
MSGTQX$!7U&8LZ+ZF:HE\B"CVG-W[Z%-@@L#E3)\[&VF*&)G9>01,F."DB@X9
M!_!P,PE([;#_`//S86X$>/W;6A2-7]?#!;SHC+MYY')S(-I(4W&Y57-1-Y,.
M0($>6Y'8:6IMU#3?O5\F,>[&/7&0A;^JG:"[3VV<>,SDU'RLO7]/\D86/A!D
MSN9&)KYE*S-BS\G)MF*@#L9*?=BVAG/>8RRVUAU"D-#*9#U0?`>`\!X#P*T?
MV2^J7D+V<\>*5)\<C,)VMQE*N=CIFOL6"'B4[JB]@P49'V^LLR$D"!B#LD>F
MM#,Q[1,L+%R#1Q/Y*L+:'2H*N_&[ZI_;!=N/][G[/=*AQUW*=>(J@M:GV]LU
MFST6_:1JCK=K2[9!:!7-H12QD;-@H<J'#*=(%>'8>=>%'6AC)`=Y\B?JL=U7
M*C:8^XMZ<M.'EWV#&Q5:I4190I6XT?\`54G7\.S&T0.$K]"X^U:NP8\(,.V*
M*,*,S^,VA*L.9],8P%YGKFX^[@XK<(^.7'_?>WYC>FV=9Z[CH.X;"FTMY+>,
M6^3(#548M)!3TK#:^`,:@8\U]Q1!H,:T\[A*UY0D,V/`>`\!X#P-*<\2."80
M&&J0,8%(>$`2^T,HXEIE:V`TD$92P.HEU.$86O.$(]WKG^,9\#SG?LG]4O8_
MMOL+=Y4Z3XHR?(76^]]5:TBI.!U#5)7;)E&L>MH:IQ]LK=T_$@H^<JY<U(Q3
M:@YJ*6&N2BUNLI(;7@IG`6B_K^<![)P+X'ZBUQM+7]NK^WY%.P-B7)RWYI65
M4"Q;'EJP'8=?5]4`ZQ8"(67#H$5,-KDF'BF$N8%?>0ZQ\"`ZPTGQ&[G.'&TN
M9LUQM<ZV[QJ7E#S`VQR=A:GN2S\D(*YU/_/5+$Q'O3%$IRJLEZ6BZ_#J(;9C
MEY&,40M3Y?KA7@29=<?'W:^A^$>LM#<D8BB(V=6Y/:)=W'UY.RUHU\<9<]P7
MC8PQE5E+"#&V)Z&RS:&L-(D6$&-Y;REWWJQ[U!2BYOW?9&WN8/;9Q@>L8$Q6
MM.;_`-$,:L=#IEF)D2+;O_EIP\M]MK]Q)J52L,Q*R%AG:$AJ('B81TA2AY!;
M:E"L-IR'H84;-BS3JRJVEQY]E7"@.3!<5!258`?,<80M:V*]+R$K)PV?:K&%
MCOD..-+PK&<X]/;@.4K]WM5[?3"O;GVY5C*L85Z9]/5*<X4K'K_PQ_.?`@Q^
MNHIM?6;7G/<$LQSDMS,<E<@_GMH_:.<H=HK+R\#)-I*BGEYSA7XN5O991E.,
MN*5[O`G0\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`XQ=I%413+=+(?+%7&5B?D
M4%`*:2<,H**+)2^$I^,FV4ELY:]S>5A%IPO&/5EW']B@KL?5KO9&VNOW>.Y#
M&;,V;N+L!Y6[.-?MLS"ST[(%W"5J<N^?)2D!6J;&&R>5D99,>:BHYH@QAUUH
M49A;3#863O`K.=[Y.O-P[/TQQ9D+2"):K5QMY.B76K?D--6!O4N[;/H'4(EY
MC63!9"#4W#VIUY^/4<UA2IB'1^/_`*K?NP&^?6^T[KO2/&W?VF:Y-S1C>@N?
MG-/5M''N1,,->9VK5VT4ZLMW2T`193C$C,R@-=92LH-D2.]J\X2RI?J\H+(_
M@/`Z[VYJRF[QU=L'3>Q`C9.@[1J$_0[I&1TO)P)DG5K1&D1$[&L3,*4#+QF9
M",+<9R\,\T^A*\Y0M*O3.`H#]Q'1WQXZT<<<MP<;46.&UKN3E6-J3=L#(TPC
M9^O:QHBZ72NW2NN;#(V%8+3#*Q2I^';A!3#A6PC@2V<$HR6PIXL)_.5'4KSM
MLUXXQT/KMYJP/6_PUHU(W)`;%U5H2',%E*I9+])RMG$MNO71(J%=O85EEG`&
M,Q\A(PB:BTR^Y#NJ_(RA(0-<X^,O-G@OLCLHLMGWOM[F?93^J^IT,WD[R%TG
MKRM:IF*7*<B*0?LO0!5BL%O9JUIG#-2YE)`A]4BW9E/O)0**>4MCP(DH71_)
MZ3KE*V.=PMW!.4?>]5IFV=+#<5.,`P,2!$V&RP&EI\C;6@=6%1VM`M?3LM1Y
MF6@H20EU(LY6`9(AK(D@25X%D;I`X*]:'8!Q'FM*[UT'/\C'N)>^]K35:V-9
M@+U0]#NG[RD(6P3-=TDB@W2.ILHW5(ZGQ$?8`75%D,FCH>=PALQ+*`N>1,5'
MP45&0D2*V#%0\>'%1@3/KAD./CQFQ`A6L*RI7QCC,I0GUSG/ICP-P\!X%(3[
M0M78M7,+C*/(.VM$/&\89H^2%KM.C;F-.EYY)ZX16ZK+1,K'3:I(>QV!MEH,
M.-BIZ4?L"(K+<:^A"LI#A?ULQE:S[`N3]$KNO+O'R;O$?6\I'UK80;,1;:11
MYR]4=_7AUJF*\=7]<W`NYQ\T1/STK"0!9"6G0T8(4:B4&\"]?X#P'@57N@EZ
MU%]A7?`=9B;`G\SE37G@X:RL%`&0SO\`NCRA1*M1H3P\>&7`/2R'OQ9`,09@
MO*5X<;20A['@6H?`BX[K&R7NJ[FNT%7Q;:>YJ):(^IFQ:YH6UR*K/7<1]8>C
M&XR646FPF90'[?B1C&7O=E\;&,D-!N?3)'JBNJ;@''.)6V0)QBUBR8,Z'@!X
M"0Q"-9D(Q\1)IZ&7XH[+@R\)6E.5M9SAIC&?A;"33P'@/`>`\"G=UB2DD_\`
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M_"EGC*^_DK_V(!DLX]G@63></_P%?+[_`.E=W_\`^^GMO@0,_4@`R_U%:MFS
M)6;?="VOOZ!BHXZ4C"X080J["29.(6/8&2=&.I(%6MU#J\N+<==<S[FUM?&$
M<_W;B&Q]:=>"7A#3VC;YR3CE@@'N1KY;AM2U4T$VHAM@G+C#4E\+RV<HSA_#
M7L]4^N%I"'/ZQAE8V?VZ:PJ4J--B`5OAYM2B4NTZU3&4119$0$*5*6"6GHC7
MU-M[YS8,@0"J00^U,*/:;P[($"K6.Z'J6>`\!X#P'@/`>`\!X#P'@/`>`\!X
M&@D@G3Q5C,21\4XI2%8,C?PORD83GURE'[`(\;VK_IGU;SGT_IG'@:[&/3&,
M>N<^F,8]<^GKGT_XY],8QZY_]'@?WP-ELD:#,UZ=B),T^,C92'DXZ0DHN8-K
MTG'A&A/#E&QT_&DA2,(<(PXIQHMAYIX9Q.'$+2I.,X#SB-YVI=&[P>V$&U;'
MD]%TLGD3P%F+99:%'L';A>K4'O[CP@*R:P]&;(5)6T`66_R0MH>#FCWW0_GR
MTC##_N"W+SR[R.(?6=LZC:*Y"16Z[5:[EK/_`#>H6:C0NNK)'V42`-F(>UN6
M)/\`G=;E*H;"K@UE%O%10H9"5.I"^98[K*`E,N&XZO7])R&_(?$O=*/'T-O:
M$>S3V8=4U<*H]"(GP&ZZQ;)6L1F39F-?;6,V46'E:U)1[DJ5Z>!$#];ZW#7C
MJUHUE!CI6-`E.0/+PT!B:^5N24%(<E]FR8RC`'%NIB"6VCL-.B(6XAEYM6,*
MSZY\"=[P'@/`>`\!X#P'@/`>`\!X#P'@/`>!AMO_`+#>#O%6Q3-/Y&\J-*Z9
MML!4X&\R=7OMWBH.Q-U2SR<U#5^8%A"'?V<DS+2==-990,T\\I0ZL^S&,ISD
M.WMA6$2T<?-C63#%B@XV6U7?3F%#!1DK9&HI=:F?Q9:(CHZ5-CY$LX!*3`6/
MR<*=PZTAWXG,K0@*Z7U"QFL]5UHF/V6)@V:Y7[64;)('D0T$_J*5JF#"4X,<
MEEK)Z0(]O!3K+2$N/^["E.+1E>0M,>!3F^P)NC6.DNP/1EA,5)B[CG^`VW:]
MKK*X">OM1NEFB=X5/8NL-7S=4U_43+Y7C[7L;7Z4-SJI7]:V"DUA0R'/5;P8
M7=0G7_SLW9MGDOVD<0>8/&;6&Z;WNKD+IB[US8>D9S>=(A&)RRP.Y9=.JKX9
M?BILZISUIL`HHDB\R))*@$)6ZRTYA0'@3WKTA]BX!<<&[S_Z["4OA.CID3>*
M=V%(*FF:PR6,(L9FX,-NYD;0A\9;@[>/CCVOS4L?(K]>@-6[HK[&V'',,\\^
MN5QG!D6VTMSBGL9IQ<>](@M313C2;6\ALR/B7"7Q6,+6@PAEIA;PR'5$,ALM
MEU=]B"J0P\K(=@?6,&\].$Q.46OC9L2M0/XIKR0JR\U.XM13KL[+%/(2H'(Z
M&VG\I0V^5[O3(<2M>MOLCM!`XCN6G4O?:Q/2(L0S)6K2FV*^^A$BRG`<E&1G
MY$G"2T^Y*K4$("HG+3^<M+4K&5N);#[&T+[2@[T@B-WOU&2(;699<80=KWD!
M&F%LQ)2QH=LD(>/-&`+MH:DDNIP0^T"O&6OE_P".0Z<WGQ@^QCR4UM8]&<BV
M>E'=.F[?*B/VFM7:D<D9.`-"KTA_E\"\[#"A"'.JC[!`A-BK84@UIYUM[*_]
M->?`QAJ_+'[2D/I6=NA7%3B!KV)IVD9K9-2TSGC]NHJU2<53;BWK2+TM4:W0
M[).A1NQY\-D>8AH4W\1O,$2EQQP=++J&@W[CH#]BC1#.MM$:*XZ=:.B*3L[-
M<VQ,,P?'OD=6]=ZWN6_8G9VU+R!L>2C"'1Q+70Y:I-Q,]@;!8P4C.0\>,[EC
M&,,!R75?+;[3>R(^`?D>-O"K64S)V*HP<A5]FZGY#0TE`B36Q[5K(^RS<C#S
MLS7?\9C\P#=A+>#-)(3"&#/-,^US./`RGQ8OM5!X')_P'J%FO<,LDF,;LN_!
M'1B,F`N)BGGUD#M**2&XXG#C;F6<HPM65^_XO<&D_P`I^U@(V$_C5O4K))6H
MS+P#EOW8DUE"HU`@R#BDD1X;BFC\Y+2H?U]RL9;7_I^F,A5?[DN2?-Z^\NV-
M-<^I'CCK;D;HGC3L`+%CXK6S:J*!"5B\T0B[10MF!/L(-JG[_:)(P18RA4X'
MKP@ZB6P99TA+(X2>_5OL[A_/_DY716]?UZ(@N&-,B(RK4^RV"U''0<+NQT^O
MV>>L\U[TWZ7-+N$J218TN(7+,28KJ@8GW?A)"]MX#P'@5>NE65LQG-OOB,HY
MF+C*1W+Z+#&#N,T=%4D2P%;%WY8)*/JAXD-.359KTE7YL<YX#(I61)MXGW97
M\JW/`M"^!%-WB/R0O4WSB+A\*S+!Z=69&92`-));/$M5;(%=>%+4D?\`%9?;
M2MYQ6?\`0:2IW'\HQX&MZ5)AF0ZMN#8[R6&9O_MRHDU.#"M$X9;.G7IEPLA9
M#L1#LNFF2P9:R$X;4XEWU4I;N%H?>"4SP'@/`>`\"GYUAR!$%]H3NRK;H*WG
M9_7M$ELJ$;C6&0PV6-02+)I/MEE)7AQN;:2O#:'B777?>XVSG#J$AB7]J7C;
M_F7+[BOO?D(/L5?`*#U_(Z[V\9I2R9E]CP.UR1;X;19EG7\F')5X,@Z2GH<5
MAU+7YLH$V8A>&V!<$M!`%U@QLQP_YV]6E,JNE]ETKGA!<N+F?R8'F*/;)>65
MQ>W-2M+Q=`"1#.8E:X)7%:NMELDSY$`7!\8/(_D/O_Z;"&PLS]H>P&;5]@;H
M&N3OY`BI1*8,\9N&L\,@Z0E+,R6F6A`+?'U69D**>?96T!2#K2%.J%(PIC+H
MZF5!:KYP_P#P%?+[_P"E=W__`.^GMO@0*?4DC8@WJ`U$7^F@)(J)WMR(.S+J
M&$S*5N>>FPHM&&<NX+(3)2E</6VX0TH56`E)94A:%Y4H(W?NV)&?I/7D)()E
M<A/VOD>RPI$>@B$'E"H'4PXYA10Q`DH@L!E3A&&TK=:4AG^YE>/=X$1?U7G&
M\=W\<ZB5IXHAO'G>R`1J%F(&IDDL=J$#>C*]'-_D?@C_`"13IGQL+R^_^-DG
M#KHSN7'`]2/P'@/`>`\##?F9SPXW<`-53&Z.5%X9H%&'/'A*PD`*4M-IO5H,
M@YF9C:G7*Q"`$&?NYI4"2,&HA;(2W\)PZ0QA6,^!6=U'WF=UG/"T:^LW!?JT
MK54X[SN[A]$6W:V\S;3;P*O-#WVON3-PM4959C7]GI];K&O)A*)W+8,T,(9\
MRARWGF,BJ#F]Y[=^_+A@;NV]\U>JW4^P^..C(IX:U[FX_P"PY"BUA6?\L9#:
MV;6WK].V^TW:G_J2TL)C6((`S+F$/NO,)5E/@32\*>VGC=V.PLM.<+9$#92J
MI6TR-_IMRFW]:;-U[9)&8DHZM5FUTZ0@)D5MFQA09Q;,@'(&,MH'^-2/?E6$
M!*6WE:FT*<1AMS*$Y6WA7OPA><8RI&%^B??A*OX]?3'KX&"_8EV"Z6ZT>.4C
MR4WK&W69J3%FAJ3&Q=$@ESTJ9;+,+*+K@\AA+B,0T&:=&?C/'J2[AAQYM.&W
M7%H;4%;**^USL+6="OF_>7G7K>=+Z-V;18*Y]?V8^?E#)7DH\N9@`+1"D[`D
MH-%&6S!0-G'FC3@1VL1;#2Q%CDEO,8R'7U:^YE7;6WL78<'UP[LF-%:KH]0+
MO]KA]AU\^1I-]N=Z(K->8M<DFOHKT32;$'EE@`I><&O3'O'PQEO*7<!VO2/M
MQ"3VH[AR%E>KKF#(Z$C+=+141MJB-0]@U_#14!"45$Z)>KJ\./`Q=BC+9:%-
MK]%,C?A%@_T>6ZG`<&V5]KW9U+TKJJI/<";NSS\W3<'G*UQE)8O\(F,U5+3M
M;+U?-F)D:N/=IRP;DI4VM4.F$$+84^.ZY\K2L-LY#;-J?;RD--ZBUK7D=9G*
M&'Y#RVN*W+'0&\RI2E4D@N*E'JQ<Y:`L)T),;!O=;'/BW&QY5V.&=?-<RT5\
M;S3GO"PMTZ=A>R.SGB&WRBV1H`GCH_+[!L%;JE1>.LDN-8:=&0];D8F\14Y8
MJO5$S43/O3+R6"`F7@U)8]$NJ7A>$A*QX&U3@@1L1(C24>N5!6(ZLF-:;^5T
MYME/S_BM,_(UAYUY3>$I1E6,*SG&,Y],^!Y[E="D93[`O8I/S(1+(XW,_K=#
M&CY\UEB3AX^X\IM!68(!EI&#B8I[*XS"WL"D-8:=]67/=AY7H$CGV#K+PVI'
M-_C(+S'ZN+!R@@]U5JC:SU_RPE=]7^D4"J7!5BV2#!Z9<J,-',U[#34O94R\
MRE,O'D$B&,%*]?PD>X,!^M/L_P":-"YS:FX/<[N4G%3</$VTW?DMPFMF@ARJ
M)<F-6#Z,"=I-*$M&+#3*WL2P5W8D^"!`4XV8)FEVF-4<DT11:VW6PL:?6\'8
M#ZLJ$$!!M5Z%"WYRV$KT6)D9,<-`C\D=E-QC,4*+[VH^+%8Q\#`^'7_B0UZ8
M<5CT\">#P'@/`>`\!X#P'@/`>`\!X#P'@/`>!1P^W#Q71)7OB%O&CU^MU:4W
M03<./&YM\;3M]DBM2U-2'*4OCT/:9>4M0M2UNFJSDW9IL$P49&&U-R![[!BV
M/3`28TW0'<[6=B*8W)VUZ:L>DX2OZINC.JX?C=J*NW3>^M(FE*EMU56GOQ4W
M.7>CA,#5MP`66;S)E2>2BRT+"RTWX''_`*DA,<5U:VUVOQ\_'5#_`+Q=]IIC
M-F<9(F'*XF-U[\1!AHP80AA3TCDG)"F<+:;)^1I*LX;],!E-SA^Q#UT\%]QN
M\>[Q=;-?]RPNP-<T^[4W6M9EK/\`XA%7&:<CK1/$3,8&;$RDMK80=;LG7QG5
M3BB%-#MC^]S.4!7W^PIS2X\6?<?'_=^G]4:8Y;:_E>'6Y*C;G+!LR(&"U_%[
M9V#-UBVLV_39KSMGUO>8B5BI#"[#B)8G8RQ,)"=4V0VG"`FA^L]*$JX([0,%
MUJ!16+)SAW?,M:XJ&S:?M2#U76;?7J/;:]'YOX5GD';>''PT@(VZ6IU^4+?)
MPZMGTRXI`6/%M-N9;RXVA>6EX=:RM"59;<PE2,.-Y5C/L7A"\X]<?SZ9SC_C
MX'[\#XD##ELJ'*89)87E.5L$-(>97E"TN(RIMQ*D*RAQ&%8]<?QG&,_U\`^,
M.3AM)+#)"6GF26DOM(=PT0.O#K#[>'$JPAYAQ.%(7CT4E6/7&<9\#[>`\!X#
MP'@:=D04993@XPX[AI&"C'&66VEEE888%P24M"4J((P*,VW[U^JOC;2GU]$X
MQ@-1X%%3[->H]>6/L&XDULEJ8H,;N33CP>RL:SKU(3*<AYLG?&O:M4J%>1I0
MB-_RDW)>01@#9'!JX]3K6!V"$8>;;#2?5MU/LRC\_>5,_M"#])X_BM'PSU_D
MI6K2LQ?2Q=TQ3I0R%420L%9")U^,T-!R@RS_`,H50H0^&&D,*;;"]MX#P'@5
M=.A"<=D^?/?8V3+`2K[_`#7:EL+!GQ93"!E[`Y!PS&7(N%L5DK\"M:X5SU:2
MX.6YZ>];/Q99=<"T7X$6?=JRX_U1<YL-PQ-BPQI"5.?KX64H.G`XZ8A3SH@%
MY3[/XITD$,XRR^E)"V'5I<2,4I.!G0UG2U*RDWU8<)).9CF(>3(TQ'H+A!@X
MN/'@EC3<V(B!9#A(Z)B6&X1IA(F,#BCM9^'UPVGU]/`E`\!X#P'@/`IP]99<
MH3]HKNK,B!*O+8:UY3P"W7K`,24*PQ*:*CC<1TJP/+%MDA!CD*+CD(2ADT=L
M)]8^6\*0&;7;ETD\(N=/('3^T9G>A/"[E`;!;5LP^P]9O1E=MVUP]<5,(QVS
M2[Q1,>"Z5JHB6CS)*6]R)14'_P!)@EEI#3PP1J1_8+S%X<[.AMT7^/XJ=R'%
MG66MJ5IJ%W7P=D`;%R&TMI'8D!M#Y6+EK^!>D$,S6TW-&UZ7N4O+.XKHZ(I#
M`3C;CRDL!DYV46'8,[]@#IAD-?Q^BL.R>DY>:F0][C:\,S%U2Q[>K2+43JTR
MW$`%&;NBHWXW*[B&?<EFWFGW`V5I62AT+&/.'_X"OE]_]*[O_P#]]/;?`@K^
MI=83R^GS3$$/!2RP8S:.^4GV$XZ*3#MJ=V!+F-@0HXBG99TM#A36762F64)P
MXXZDA>/8SX$??W6[&J)T-PCAE6B[")FMH;7D`*1"*Q_B5MF(.L56-&E+(^S*
M1\G$3-4$MCZXMT9DU!>"R1WD-8RV[@(:/JA5(;_S?!986`,LT77=);%&@+!B
M[T6-*H@*8(ZLO.SM*;C'3+:N0?#R`X3#+&<#((;)???9)=PZ'J(^`\!X#P,3
M><G+W7/`_BKN;E3M!Z.<KNIJ@?.AU\ZQQM6(O-GRC\>K4"#EY5MX1FQ7.<=9
MCP4Y;<]7WT_VYQC/@5UNI+@Y5^:^SR^U+L\H-BVUS$W[9X;8^B]7[.TA?JO0
M>).O=<S%U`U8)4R7W5ZZLS%BK42!*1I9K*W/0<,Q*GC"\DO!T-]BCL'WWP=Y
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M'*%5+5G#D95C;,`2E+H^76D%-/AK=6^(]A(8Q]Y_5KR;[&H[B[=.+^\Z?J38
MG$*\V#<--AK="$R`-NV&T92YFHE+.PV;&MN0)%,6V,*:*H-\D]*WW6FFEX<"
M!KE)T8=P_.O0FP=X<ZY+36Z>1`'&RH4;B5QRU38*SK%OCALB5WA1IZ^J-@HT
M*JZ`D&CM;!RJ9:5&GCBGE*;:&;(4P+[`Y/RG^JWI?5/`S3+^G=-[4V5S"?O?
M%VN<D&-3;ALTI79ZI9M@,=OJU4NM71$=&,LN1QKAXZ2@W\Q664*:1E#3RG@[
MQ[#.B[DSQ&X-7_B_THT"NWO7')^?L,7R^K>T[/%S/("<J)$E%SVN(W6]VODS
M6Z3!T"@*BS0B0QFVIDQV722XHMS#CS`<4U+P&^R59]A,\V9MOK+KNZ=E<>-,
MZ9?UQNJE6*:FM4UK5=J&GZ<5B)&J%H@8O9]<+F333"FI>2%7D?*&TJ<0%[`B
M9Y[=-/?ARVYD:QFN0K[NVK[LZG['7+;%@`IR8XW\7(NU6G;$]'Z8KMW'9E)_
M,.J*82Y'_P#08&AW)T(!PG.&UOI"WM]>;4/,_2?7?IZ@<S-;8U=;J=%R-!I5
M+)EI6+F*_J>IRCQE%S:=>..R$/&;!F)FR3ZI:0;4"26"-%X=:?PE"V@G@\#9
M+)/"U>!E[$<),'!PH!$B4'7X63L<V0P*WEQUN+@H44V6EC,HQGV,#,NO.9_A
M*<Y_CP/-TY:\AM3\6NZ+N$VKLB8#FO\`;;=G`;>4%2K/8@Z-==HN:?WUQMNM
MDU;JU!C#S\M.#Q+SIP+GRL@JBH93Y6<,Y]R`X#SJ^S#-\Y-K637\_P`>J9<.
MO^1I[E6NO%_<R60G%SL1-U6T#[BLNTM>GYLS=PB9V+)C*X+7I^+&)QEI+V4J
M)=P^&57UQN-&KN4W,K8O8+0MDV77.L^./(B^?]NO%*%*J>PY6H:@W?';)KY-
M2V95R)R;V51(BN!RE>*C+1AXR'<S'EL((4^VZMD+*'ULB1"^K"COA$CDC.<@
M^7:VLM,+9)90[R3V2\VU)N+]<F27Q.)6X]ZJ]V%XQ[LYQZ^!/5X#P'@/`>`\
M!X#P'@/`>`\!X#P'@/`ZTV9IG4NYQ*L#MO6E'V6)1KI`['I@]WK,196ZK?JL
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MT^VO0<9?6M8QA=TK$O+G0%,FR2-<2#[\-%8?"":(&;:?SE#J?`GS\!X%(CD-
MR][FNQVP<JN0?%';U2ZXN`?`BQ<F::_MU$^]*6#D#-:7K,@45(>^P1Y-,N<(
MJ]TG$>.6`F*'BV)Y3#W[$H9U&`KJ[#[^>TBW[:F[R[SKV+0@IZ6KIDM0./44
M/9]4ZADIX(&/:AQ%V^I6=%I*&FLK.>A!SUQYF&#`A)-KT'\#<Z]W5]OMKWG`
M:'UQV<;=F['>MNC\>=<RU_TSK[70$JHFTQ%%HESNL?9:E-DT1^2DI9XB<]')
M27%PVVV]A3V/<D)@:CR<[].*>P=W;FY!<R@N0VA^LC;>D(CG3J:`>UX/.;';
MN-6JLA$4K4\DUJ40N89L$1>8V-DUE%@EMV%L@S*5M_$XH,QKI=_LV5<*[<^[
M5M33M#X?084GRMMW&.-F:%(;%J^E(RC!WPWC_6S+7Q[58X_85<A2S:^6F6>1
M[K)'Y?<]&O8I81[\#NV;M/W[SNX[<1MF]C,]0`K#)6:;V6F3XY\?+T2%)Z;A
MM@SU\K)4]!5:$%EZK8"=?M`J1%2I+@WYY*&BGW@\+<#T3_`>`\"AS]L4YY'*
M?2D8["4<R*?XAREA+M]U(M`R=2&TK>XUA@=CQ:@#&Z\\N2L+(E-<:>PR0M=N
M:2VK+JAR`0?5GM.W-C=BG+W96YA88>UW'AWKF?9EJW17*'5+S6I/;.8VGV^E
MM&U6'D+?4UURL,L#3JB7%2*L*6^LLCWNLA?&\#&>0+Y%;/K]0EZ@)_VUS=8W
M5-*M]9V;%4W9RMEZCK8UTKX(P;]$N1XM6%V%)OP\X(2DUN6`#'RP2.TZXXU@
M,DA\$8'8P4IE16&6L$J'0ML=1'L3\RF$.+<<0SESU]N%*4K"?3USG/\`/@5;
M/K_N"JYY]]Z!3@O]+FK$LEP(:5+;AS1K3O81UUHIF:/!+9DVAVWO=\2R4KRI
M#Q9.4XPT%IGP(IN\E(:NHKL!_/(6**CCG<7G'VS9`!:%,*!?:]A$9$39.5K>
M;2G#>6,,OYS\;SP[*W"&@_'1D*^+U#]?6"5@+>+XW4J5S^L<;<#;1,X,EVF&
M_BQAMEP=HU+;C6/7#+J5-^N?;Z^!*YX#P'@/`_#B5+;<0AQ32UH4E#J,(4II
M2DYPEQ*7$K;4I&<^N,*QG&<X_G&<>!2CZMI2M\<OL+=YL[LG83L5J_4^EXZP
MWS:F\+HJ3GXNOQLCK*??M5DNT_\`BJ9@4`/%$OJ5\088:1VF\(8993@,"?M5
M4_;W-[EEP<M'!O7^RN1%6M?$ZW6BF;&T(-;;]5]AP[UDF9J<9HQU8=.KTWFN
MU#"2Y/$6E9*1)%'YGJWEE*0PPZON)_-O@=O7K-W17..O*W5NQ"N8&PJGS*;N
M&H]M3>L:EHZR2.E=05"?NM`"BQVH20?K&Y[0T)+K3GXL/I);7C\1SVA/5W&"
M-/\`V-.AZ)AA6WV0IAH_"F'"'?1(VW9@^82X22^X(ZN/<!?<6A"L/-Y]R5)_
M]5C(6F.<'_P%G+[_`.E=W_\`^^GMO@5]_J/R!['5OK.'(F?9&%WWD0?$0QTY
M%.%2S\;L:$%E)NOP2DLSK5>BT'#,NK4C+3)I:\KSC)#2<!'A]WAAYW7_`%]O
M"!P&"@KGOXO$V\:,#88Y(U:U\=B/'61,C)?CI7`*W$(_$<<46&AMEW"W<M.A
M&?\`4L7K$CLN.N-IV/M=Z>B-(3=(U&./0K3,UN[3UAE2G[1#7Z8""OL?KJ-@
MXR065&Y</@HPTE'_`*Q9'R,.AZ=/@/`>`\"EG]K'956L/(GJ=XD;GO#&D..N
MR]V2FR]E<@PV5LV36S59EJY3')$20DT/5?%?A1[BB5/;(:>4VZ$,ZK+:$XRL
M)YH+O"Z?<P5+6'V&\60@["``Q#"$[&@H@N-:_2N2++%CAW/QW:-E@(3+:FY1
MH%#)/L%_A];;2@J8]X/:KP!K'*_BWNC6W'3A!V2;"J]5O\-+[W,W%5;;"VB'
MD8>$J055W3KC62,04LJ*$D"38QVP@M,`/JPJ)PG#)F5AO_6IJ'AR/V?5CL:Y
M=\P>G?CZ?#PMC8UMPAXX;"TT]"Z[G@Q,Q^MK$U8X*2`J.)@*O^^<S,-O$S3I
M"VQB<,YRXTV%RL;LGZW3)IML7G#P^=GBHT?#;J-_ZF2<[%O.S[HS7YF;.E?X
MN7Z[(+2WE?IA;"L^F,J3E00#])5[.H_<)VK\;M97?1D[Q,O^#^6NEXW2=BI>
MQ(%8TYL<+6H2Q;;1IN3BZEF(8ACDG5YY#9?YAGY3N/5:5N!V5]B2B[3WSR-Z
MB.+]=Y.[/XGZEW-OO=96U]KT:QDTB-@4:^UF!:@CWK<+(PV!+C_B`]A#A4%$
MY!9>.<?>:6E'MR%73E9S1Z\*+N->A^&FU^[GF!:DWBU:T>G(SL0M&OH^:L4<
M<!#5V2U$,/JC9TGL2.L$FZ6D?\F/CU9_%;6A!+)"5)#C]TYO]5U<T+J2_1/+
M_O8M.\K/`P$C>M'P'.R/17J@4F^R5?N<9+;6E=:M..V2/KX+LE%L-P`8\F'^
M)\B@U$+=2'*M0\@.,NY='2%@C=X=[%*Y37O:5)HG$#B0WV'_`"B<AA]N64RH
MQ-LH^W;/HNNA-52M6&MR`,Z3@$X8`D81EPE3IB\L!R"[S<W;."W-3DII/L0[
M7-5\@>&VV=2:NG]!\@N9\=?JV9&[/W%&ZV#M05RUG#0*K8)+I"FW$+CT*A67
MOA^"3-0GT6'I?ZTG8>QT:N2$&8Z>`P#F%R2\/)C.*/KC[M?E6U(F!Q9%S#$I
M&/(PZM'H^E.'$*6A:5J#G7@/`V*S1#\[!G18T_-5=\C`[C4]7E@-R\>L0I@S
M"Q<RD?*QZT/?C_&ZAT=U#C*UI]/Y]<!YWFXQ]6-]V';M;=UHH@.B0-\];I>W
MW-DQ<(=K(O3]GW_QN>MI]X*EDB"!0,E!)PX6T][4.LN.9?RO+7M<#X]Q?2QJ
M0WGYQII'6_7>(^G(G=],(V#:-;['Y00VK"=P-6*XVL^371-6DV42S@Z5BM:1
M!#"'J<.PIT!9332,O#)5D).^E[L"Z4=$';BTOQ#TQ>J#NNPWFJQ<UFOQB;52
MM[[<FI6)UT-K/C3M:<MY]CM&M(ZVV>0DJTU;SAG(^LEE2KSS`K1'XX2?_6R^
M575S5GG!6@&R.27,,@6,1.Q=E<BQG>2FQU(C2IJ(-D!)`D1?N2I[YE_/CT=2
MI2%H5D)[/`>`\!X#P'@;;,S$578>5L$[("1,)!1ITQ,RI[R!P8R*C!739"0,
M(<SAM@0,1A;CBU9QA*$YSG^G@5N=V_8,A=R3C>ENH+4AG-O;\S#2!N-JV&)M
M]%X]:[0!9M:Q)5DE\ST76+AMFO0$?<CGIT6K9<EHA$?\^6'ALNNLAUBWQM^U
M)O0R4OEHYW<0>'.9*]&)&TI0M7P>R8FLU(8ZL!,G0UGEJ7=)&9#.!@7C&19"
M6_,4H\I#JQOF;;&#A^MNP#O-ZTJ+39[MFXO5?D7QU@8RV&[7Y+<>)>OV#;-)
M:DK;3E0EFV%`U9%<U\Q5JBQ=%Q"(^.C<3$MD-;PZGT"NN/!8ZXB\P-"\X]*5
M[?W'2VD6O7]A*EXS&96$EJO8X2<KTF3#3]>LE9GA0I>%F8:5#='?:=;]OR(S
M[5*Q_/@9.>`\!X#P'@4Z?LWW;=7'"9J&U]/=@?/#2VS]Q:RF8#17&_CPV.SI
M(Z8T?+1%GVQ<]ES`UV@;)#NR5,NH[R2(V.D"&40[CCB'&$JP@,G^`//X>WF[
M#XA<O^&.@=,[3EN.D?RKTG,T<<'<W&GDAHVIZLCG\;?N>](N%F8NTS8N"@L%
MOH$+.;`D6L>U;V5-Y#G?UC;;`;%X9\L-G5H*FQ<+LGLPY?W:+B-=E2!M#AHJ
MP'4>1B(FEER5:IA)52!C2&DQCJHB,6L#+.5BC.>]AL+'G@4,OM)S<AKOM!ZX
M]KBQ<;)C4O7=.LTB+<+S-5>A%0FO^4<%<YI^?;KU>+F8R%@%CAF34JR23@*.
MQ@A8J/Q4K>"P'T*[LUMO'BEM;95,V5JVWEW[E[R(L\_7M9/;35!Z^L5DM+=G
M50FC]I3Q85E*!@9H$_$A5(FN5LL:09=;C&BU%O/A.5X'P(*%#0ATLE@5MQ\8
M5MPAYMA"RC2&A`QD+=4E*GRRGD--(Q_<XXM*4XSG.,>!22VGQSZ%;3NV[2LA
MW76BCZ?N_)([:^Y>"%@Y+-IXV64@K8T+8-F:RMVL[0H*SP?^:;8K)<E+E%G8
M*&;+4MMMEA#1'@9"=<T+T!=;?)/E1M/C[V><:S]<<BFX/&-`VC:=%EZ-J==4
ME)2Y5]=0M4A-F%3$7`#2I@HY$BHHD?Y&V<EY(RI+H=Q<:N0O5!Q[U9RJUM(]
MLG"S8]CY8\CN4O(@C<^-BZCJEMT;.\C(X<L=BE1J[+/.SQ=.M8V2@RD%QRL.
M+2YEM.4?R$1LWUQ=1\_%[+@9'[,^RIY7)*<@+!L&-?Y/:;EA]N2D.1`PU1DM
MA1KTPG-VF(*3KSJ6"C7D+:;;%]OQ_BY6^&1W`?HJK/,X?:[?-#MHF.R;3-4G
M9%FG5+C]RDMMFK$3-72+4)B\7_`4^257=A_K87X6VB'9$*2&>)0XVKX4/+"2
M;@+]?[8'`;;W'S8-6[)]^;1H&D3;?$%:&O5-B&-83>MK'"WR/`JE?!C;4HJG
MGP\Q;&);)*5&#.R31+R16EE>YH+)2$);0AM&/1"$I0G'KG/HE.,)3CUSG.<^
MF,?\?`_7@1]<P^S+BOP8VSQCU#R%N+E,F.45NF:W6K+(A&#42DQL,&TTNU[$
MN"QE0=5A#[;+1,(,LIYK"RY/#J\MC#DO-A4P^T?M#7:>7/&VTR-F@92HR?`C
M8%LURY&6*L8@=GS,QL%V8I+)TP59:^;(49^4C8PA.:Y)B29C167D-S`C#\8\
M'8GUIGAO_,#Y<R":/7U76*XNU^&LTIK-4XU1"*\C:-7_`-ME0>+Y8CS`IJY1
M#4C+R(J'`!`U-)9:%90EEO`7D/`\]/L0Y#=I'6OS[E+SLKG%NZ9XG7OD[KV_
MZ=)M6]PM;Z;DJ;,;'-MEYT:5K@6N;OW/,ZSKU#<:A"+$'&1$>`L$WXV#'OQV
M%A<MXD=HG!#G#9C-?\9^2VL-L[(AJDFYV*DTZ5DC9**@VDUMJ1DD9DX:&<+C
M0)*TB"J=RTTYE_*T*:0MIY#80@?7>ECYKGAWZ/&QDE"(C.;(\2)$R-4$A2F6
M?]P^1<JX_+3K*52%AFGB)-7K@Y\E\4'`R$+2QEIM`6OO`BD[R5#-]2'/5\LP
M@!D30DZ;@H(M`)Z'P9.(,%1'%K?9PS)O%,(0-G&'U9?4C"1R<YP.Z&Y])BGE
M=3?`9+X\H(ICCG2@V@IR5&F9H$0)LH,$"7.$%!83)@AL-M/CX884(ZA3"FT*
M:RG`2D>`\!X#P'@4S>L*BOV[[!/?`>Y4:'LBKV4V/UG-QUY-AC8<N!?O6N&]
MD0,O!.0TO+D`LU,AU+`Q,7B(EBPTAN&9]JWTA./R'Y0\0>OC>];LW);E9QMT
M#HRL:.K]1TAQE7K&`:V)4+1/VRS-67:U(-J$?(7^*UY(U6O-0A<;&1/Z0?`/
MY!3[&4MI=#OGC)V4<!^<TBS6N+'*O6^W[,AF;GW*I39N0C;L-$4>0JS<[*RE
M2F0(BT1]:09:XYC))(C09WY*FV5N^QW"`KG=Q$$8/]B7H=&8JI$=4,VZ9DHQ
M\)49#0DK:'=CJL=KE!WE,9$<F&2B1BI)E6,&FY4CVY^0AIS(6?\`G$Q)D\*^
M7@T*!B4ER>,.^QXV-R\Z/^<:_JRU-#BI>9%.=0M]Q>$I]K+F<JSC'I_/@0)_
M4@:5_P"49J9YH8*=:3N+DF@N;<4RQ(4=]=MK&6*F*R\PX4<-8VFLR+SK+K33
M2FVT+0M64Y2$=?W7392/J_7"8S6XJ<$#V!O\H;\@G\DTL]J`U?@B%=K[\$8(
M>$6PMIU#N"O>EQI2,CKPK#C81F_3O=O^O^?VR8)K)T.#?=2@BVZ/5K\6VBR=
M49$LMBC1"[H+<XDW5,R/9@XDQ.'8N7Q(">YAUH3Y&"?`]-;P'@/`>!3R^U5J
MFCZ_F^O7L3V1KRQ;OU_QKY"U2@[)T]_C=1.UI,:LN<RJT7C.RIFSP%H';1;W
M*M'P$8R0'D)MXQU2E9=<:Q@)2M>],/1/R0I=<WCK'A3QEO5%V5$@VFMVJCBS
MP%8F(R3%:?&+BX^%G(F/`:<:5C.6DBCJ2K.?>A*LY\".KN%ZU.JS@1PLL^T]
M#]<?'2T\EM@7"G:(XSTR:`O<V1:MW[:D%URG"URM8S<(FVV6#4MZ7%B)09J+
ME<QV1"'F\/)PH*RG7[J'B9OOE7U<:,Y"5?B9KW.ZXK;6.0=.!T%$VJWW_;M"
MY.;)U_5]$&A4::.-U`Y=Z=7PQF9]W,6(@8=XO"5O*2MP+S<ST"=)->C9.RV#
M@CH:#A((`N9FIF7E[E%PD1%1811$A)RI1EU8C08T$'Y'GW7LI:0E'R+SCXTJ
M2$(WUU./NO(WMA[1^1_$6OUAO@8:`C56C[#4&[/%T\D0RT5Z>CQ:+BWT^.)M
MT)&E5.7CSB@Y#.09`/T=22T4*3D,]N^W;>@]+<NNFN\<FK\)K;2(VV>9D!LF
MWO8D7B(&KW_B\=KEV19'A(^8FF_63MHS"261'DBO/-N+QA./7P*(6H--:[TM
MMG;)^H.>O`'3VN]LR\[K>%VY(;!W-M7>O'O2-T/*BYR1H#<?J[7J)RU$T2>7
M$2IR(YN2?;;?=C\`+RE_`<RVEQ@XEZMWK3V^%?.KA1MG1='UWJFRSH')/:^T
M:=6=N<BH>@2%8N^RA=<HI0QE2&@[=.DR$+$2$H]EI#6,?(4(ZH;(=[\HM+\:
M]QT30>YK-VR\/^7_`"QK5]%(V5IW:$SL+2?'@'1[H57DF]3:]C:G4ZY5=??I
M=B@3#4LJMOP[4^-/+DV$BN,D/DAQ(0_C5J?@SV#WH[?O$:!WMR6G>(^M-:<0
MN,FT-@W:*K.N=:;NU[?KQ.1DO;"CY"(>957_`,H9#5L-"Q[B\9:&^(3WAZRM
M?<2]`0CJ<JREV(C7$Y4YEU64K"95C*G<N/9<5G&?Y5[U>O\`7US_`%\#=_`>
M!QVVV$.JUN8L!Q8P(\:&IW)9K)Q`;+SBD#BJ+:C!RCU#9*=1A?Q-J5A.<Y_X
M>O@>;GRM`UM=>UCO#_S77FP]I:HD=M\"(N\ZTTD"N9V#MJN%\@N/69^D:]9B
MS#9$Z\W)(#I8##"D()4,ZE>&E^QO`65^ZSJ+V/S:K?'7E7P/LYFF>8^B81FN
MUFXDLR4+;I;2E@J<K%DU/),S+`O5*7K$789)8H3,>DLD^4=:=4PK'RMA6'Z3
M>H_LIX_=I?&^R<@^+VS=04_CWG-LV1=Z/:M0PY\-![7US>:UKQ<]+5&RMGVB
MJ31^O"XVP#(>F7AQWG\OL#O%I<>"WC];M[+_`%4ZS<S@5/NWARR5\8DB1*I9
M^3DKLYW++IQ19[Y#S>7/3*U/O*6GT7E:\JRK(3O>`\!X#P'@?E:TMI4M:DH0
MA.5K6O.$I0E.,Y4I2LYQA*4XQZYSG^,8\"GIVQ<_H_M.W+QYZANL_?\`-V!W
M>EP-3S2VMJIYO%(IVB8MB83<M96V<*KZ9V.L)>(-PDQN/-']H;#H!+)>3,C(
M"Q'P&X&:1X$\>*'H/5U!KD&!09JT2P4NU(2-HE9:<G4MP4A?GY2?"$<@+=?:
MS%AO3HD2P'%-'./M"MY']N5A6>[Z?L`U5S5QO%'K3Y.Z7>V'?]8["N^S^0$+
MMF>IL_JROZ](%)7K;6%A!`C(A&[]D(`/$`'_`&GYS"!7F,#LEE`.J"?+J5W#
MH3D9P#U`'J_=3W*$JKT'78.Y['?;Y<MUE`[SG*-5MCW"LV.Z;$>FI.1.@+)/
MI=R#@DG$)ZMBHPSEA#2`@A[,N*C'3%RBKW<]PWNUBH&G9S:U&H_8YQ5T^NFO
M.7J&OE@%LLE,4./OKDA&,G72UNBJD8S`XQ@J#<2(+XC62EI"R[P!Y_\`'+L@
MX]UWD+QPND;9(8I(,3>:PV\5BQZOOZH6,F9G7UO!/CXHT>9A6Y1O&'\#X%-:
MRE\9;K*TKR&;7@/`>!\W7/B:<=PVX[EMM;GQ-8PIUSV)RKXVTYRG"G%^GIC&
M<X]<^!6I^PCHS5W+'C!I&07O+4O'[DW73<;<T7I7E==J11:MO.'KCU7M-[TO
M?Z'>[$Q7IA_,B)"NOMX06M)PC8*G&Q2R74A4>XF7!&Y^>/#*3U1LRRPW%W3$
MSM/4G^T5JV'HL2=XRO[\JMZ;W'HC0[!&\5;FY%ZKI5BM08]9):;D(^P!*2P.
MPUEH@=T+;'U/XF!@NK:=B*FW8EU(#ESR$&J<Q:XZN0U@LM6:?J:*]/3,)5Y>
MPQL),DQ"66CP_P!@=D:09?;0^XREI7@68_`H5?:.#V!,\\N%%,;G;%36]MZ6
M)T??[EJA@4F:K=!VOR78K(3@[%GM5+"L0T]4738V8ABCXV)DGC<"F$*'?9RT
M$]W0'HS7-,Z^-;P/^+W&QOZXVWM?_$;AN?2NFM>3;1@=D5"/6#7"-8LR03L.
M8W#I01(/R1\QB408&44Y@5"$!//X'6.Y';TWK:X)UP\/'VQZM69J*L+H94T7
M4I#_`!F9=AK3$U,.OV-Z\2L/8&@UM0V&49.QE2<+RK"6G`HK\1=?<1J=TA\T
M.R+E!PETMS0Y+:YY6<H31KAN?2%>IUFV7<K+NFF0,+)W6LL?ARE:KH]U.;(/
M@&G/FC&&S8X5*?E=2X$-%7IF^K?N'>?(BZZ)ZUM,5/16O)DG5>N7M":/@M2[
M3NEQ:IFUH_A_J:A2\<Q.[=W1;*S?(]F'L,GF:FX:$4@T4C+1@[BPT^]=\0-4
MTU:-6-=7G$*#YH!;ZV$+9;[9=(::AM?<=*6%)42?;T9`13-IKM7GKUK+:49:
M:E*/7B`E5D,D-@L2!)3:F?`R.Z7>/$#(=AFC>'W/OB-PTL5*Y1B[]M_^V]\U
MOK,'D-KJ7"U;%[-%S8Z[6;:5L/12BYRE!CPM3L(H241Y\DN.$&&=QA03>?7Q
MUK#:1[L>\K3]#K0%%UM3;<U&UK7]=A`ZS5J9`A;0FET8&*@@BDA#!$UV1=;#
MR.T[G(X>5OK:4ZTET+I?@/`>!2K^U!H6U<D.37`'6=4MFD*`MS1O-"\V2\\C
M7S8#4]6JNJP=5W^1FI&S1J9$PN8BW89LD2(S''#&OM(P2R\/\K*PIEW.P<D6
M+;JR$V]MBYVO4FC-;RE-U-N<$*7LE+AM(7V>E4;$N6H3[;K+74Q=-5S+=ALW
M^,1K.<)CSHU(+;J1A<86%K;ZA=4U_L39//.YM;JV=89T6H:3K4;$9NZZ>-<:
MA=(^0L%FF9>C1Q1,H;/ZON5>3$1]A'D/G""DW0G<I2\VTD+Z7@1D\VN`_#79
M-AM?.S:NC*%>N26@]!W!G6.QM@_FST)31J/`WVUUTA^E34@_KN31#SEC+*^2
M1C"<84I*E9_TF\I"'KZQNEM5;PX-:1Y@6K6]53OK6FYM[UFD[=8UW5=;WF5U
M_+@KC#8.Q%:P#J<?=HE9MME'F,2V)8=DI]QU+:2$-J9#C?UKE-QG+3NWARLQ
M8#\IS$E)VO1Q(E8C+/)P`&W^1L1)S`^((@E=FJH4ZO(B93WN-I/^87/M6SZ9
M"V_X$3O>F7(!=1'/LF,7&MDMZ!GTJ7,(=<C,!.R<0S)_F-,Q$XMQE4:X[CVY
M82A6<XPMX9'N):#=NDCV9ZF^!BFR%&X7Q^J[JI+(;P#4NZZ1(./S00Q+0YF(
MR:>4HL1;[:"'1GFUNI2XI6,!*9X#P'@/`>!3.ZH:V_8OLM]Y)\O(3D8=%1D,
MT+F.-B!27HU.QM92<<AR0B1/R&P2H^NBLK'0ZVMX)]QDY+CWNRD,8/M7Z*MY
M_/#@CR)V3;)30W%!FN_[&S_(<"D1NV6*W=53=AV&T+9-9JD&XNP5$QW\$5P.
MP."`R6%%H4A\9A[.`C<T5S[V?I+LBX![3IM!K?'_`)N\B]PJXR\V2M?ZRB(3
MAORKXVRVTM;4?5.Y]800C\?`N6JS(CI14A+U@P6-=-B`BD8;<?-%6$\O=@S$
MI^P3T`O-./?NGKX4D]C+#:1<1K&S(']40DG",.O%+)=+2I&59PVA",XQCW9]
M0M(<KV1R.+7)0<M9#0K^@=QLDNB);66V.[KNQH>6*AX<MI1"&U9RC"FG4Y5Z
M>J%8_C(5XOJ(13!G4#13W7I-IV'Y*[\+$:$E9,`(I928>-<1+1X93`4V,VT4
MI;;1;;S3)"4/(2EUM"TA@/\`==0<)K_KEF87(H$TQM;>@XT_B:*A96+3BK:[
M?Q@0L.4#*#C,XPMXPEII2FLL,XRZW[DH="%/ZJ-@DZ'VM:VHT7K*EWVGWG7-
MU#OVQ+!45;",U+<8*D[%M=>G-:7EN%CP]73=LQ7FXPC*'"U2,=EYC+ZE^K;`
M>I_X#P'@/`Z9Y$:(H?)[1FU^/FSV)!^A;AH=FU]:<PYGZZ:&B+3$E0YAD))?
M$\J-EQ&"U+'?PE66W,8SZ9QZXR%.+@1V![%Z%]O1/5_SETI>*3P4F]TWRL<-
M>85LJ,#2/@K4GL^U,2]JW,_!S,U`DU^;FG<RC17RMR@,4:P62U^"MM;(2X<Z
MNF[C[W+;UTGRONG./;,UH#6]5EX+6.N..ULI;=$9M#$P4`]L6D[/#S9F!;;_
M`)G'*;D#!Q2'",Q(8C;C'XKF7@PYXN_4MXH<2>9^KN7=5Y9;UF(G26S1=J4_
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M\9(QZ/YP[G^_^GH'7!/4=U=%OH)?Z^>'ZWD)%0E2=`:U:QA(3]=(&QEMJO(;
M5\;U4`SZYQG*L,JPKUPZ]AP.*M]+/4NT_@EOKNXDH?Q*M36'$Z8I^,ID6%K<
M:=3C]?[4LH6YG/P8Q\'_`+I_&/`DN`$6$QEA1*R4)?(6/[F!1TBBN/+6+'LM
MAL#M8'CQU)9;SE.7%(1C*U*5ZJR&L\!X'Q(:R0.^QAYX?+S+K6"!U)00QEQ"
MD8>84M#B$O->[W)SE*L85C'KC/@>>5=XBVUSO?[0W]1!Z[LFSF.4O7-.U(38
ML_;:U`8MQ._>.\A!15AM,16Y>3`K-FG3$MR[X<.:Z&\@=(RU-*4]D/0AK<B7
M+UZ"E)!@$60D8B.-D!8LYV4C13R1&731H^3?"CGI$(<E2D-/K'84\WC"\MHS
MGVX#1W5ZTCTZV$48"O2EU8K4X]4(RVR)L159"SMQA2X$&RRL:!*R$9`%2F&D
M&$,"D/,CJ6M#2U8PG(0._6:F+C)]7D`+;X:EQ3L%R)Y010+]#C["#7I9:]TV
MN7GS(TB;82!/1`MJE3@X^1BWGP7P1FFU904R2A(6"/`>`\##;L'Y6Q_"#A=R
M*Y3'"NFOZBUM-3M?#36IFVAEW0W#<'1`YN%@3XJ3<KIMRE`69%Y!8B10W''E
MO-)1E>`II]0OV..6VX>?%0UKS\Y,<;*?QLL&GYA^R3=SCM?:O!B-CCLO+K<?
M6+6&96ADS=DLDBRPR.;F1P]#BY]J,/?(5D.^_LO=[NV..ER;X$\:(^Y:KG;%
M3URVR-XVG5$;)1=RK5R1F"#K6H"MA2<57)"J2$5F7$FK#^!)AO\`RI8!=:6R
M0^D(2^@;F])]:.Y>0MN@.+6]^6D%::=3=0#NZ5S5XA59APMLVYZN6&]`L?M:
M89.VXTUIL%]=C/QAPM(H1;XSS?L"R%3OM;:PWB57:SK+K$[!-CVF>JDCM:!K
ME*I=&M,I(Z\@+'_B&-CP3`<A*EG0$;>&G@52`XZ6A9$5*/FRI648"N#L+4W5
MWO>F<@9?3/37V_G;_GZO?7*I=23)?8M9KF[+U%73-0L-\KM9FX]Q@`>YQA);
MHR6EX5B/(3\"\-*:R$TO5)WL]4_#"N:BX:1G#OD'Q-W=9F:7`<L5LZP9Q383
M:^M-:&U39.V[7$1]QF+DD(=O7S1DNX+`-FM,E/$%M9=$)6L)<MN=YW0KO_5&
MT=0W;FQK)RL[AUU9*U:E-4S:<3,N`7NHRU(/("E5:T>(CKA'P):V6GL)46'C
M+?MQZ8QCP*''6]VF[UZO-V0V]=?O(E]+SP]&U3O[7MMEVY4G8FLJ&S7`H65K
MM60P++05NIM6E6'8*6P1AEULM8YJTLECL-A<FW-]@RP0?*NMU7CK2[IR`U5R
M?ZX8'DCP[I]5T%=[K.M[P?N%\!GO]ZF=>/R6S(^BP$52G0I-B$BY1T*19>QE
M>$>UWP);^ISL:H_9=QXF]PU&L[#JT[2[GC6VU8NZ1/ZNO@[9C:S`35UB=7JD
M'V[;(:]B39I+8+\V!&2JF\XP0,V[A:4A))6;*#:XY<K'!SP0J32PD(L5=G*N
M<]D1SXEDM1=B`C9/\%Y7\M.J92AU/]R?7'\^!R'P,+N:'7EP[["*E6Z3R]TM
M#[>@:?*%3=627-VJL2<'*E@$1KI0<W3)VNS"F_QRE9_'=?<%RYA*U-96A.<!
M'I4/K]]7O%B0N&]..'&FLU?;M?UYLAFG%W^UV[8U'CI:7H`L-&%'P.QI6W@Q
MS</,03,HR>(AF2#+(*6T_AIW+.`Q%^H"TTSU'E-I<<<)1ROWJB03AU;@+1B`
MZ(CXXE"D(0Q'9%2TO"$>J<NJ6K_F5G&`M+>!0%^T3K'4MVYQ=:]"VE8+1/V6
M\ES6IK74(^`(H[QU-V%O2KR4]LO7UXNY&Q*X06\S9I&$C8C.!\QLAADIIY(S
M6!DA:,Z2*+0--<!ZMQZU]89&9C>.^Y.2^H"HZQ'1!MTJW^,\A-E*A(&\*A8Z
M)!:L^:J6`6]A(S65(*0K*<95Z8"6[P.M-P5"Q7G7-LKE/G_\6N!T'+M5.P+,
MG@Q8BQOQ1P<1(F+K<I$2JF0"RDO(4VZI0[[;;Z$*<:1CP//SUQQ5[UM(<*]E
M=?$GU70N^M)[KW,9=;MM4'=R:-MB\UJ5W57MB&UB7M2]EB7NOU"R#U(YHC,L
MWF7&1/?DON8?2IMP,4]4];_8YJK9`6S;QT+[0W%7]3;#@[WQZU9:.6TU.T;4
M%7J30I8>OG*T_;[0_LX`R<"5(OJ=;8<(*(=;:80PM#"`Z_Y*=:/9-R?MMQVT
M?TD\C:;L_<;VYK?9[&%R=F#XPG;.YKU$V"8O3E*L9/P5*+$)-DVG()2A1CV#
MD//.?$$K*PS-X>[9YP=7VPMJ[XJ?U[MM6W<,D],1-NW/L[>FP-T;6CHJ'5K2
MFV^OU6V+H]DGI(.;FK1!+5^)DW)>7G<#96*,5@<)-OKU07*V6Y[<_.<^_N"V
MY.,]<YKDL35/BEUAURO@SA&Y28Z]!3LE96*U:HDBK2J5G/8DAF7317"R0QL-
M(0AP+H'@/`TY98H`I)QI#(@00[Q991#B61QA1FU/$$/NKRE#3++2,J4K.<82
MG&<Y\#SX_M.<@==[4YUZ$U\Y*ZQR!Q!U#9[,0;/6>"M(<U>]],DIJH-EH-@>
MB8:#8I$IKB.+P\ZF;0>B9$<='P)A:7`A$Y:<U-J=@!W&.1VE#ZNF)'B=HQ/&
MN[634%<HLCKVZL6G;<VWKS-$U_@J&U;4;Z?6Z^WG]8S(HBY@*/6M`X8+JQ4A
M8&^IUK_;%=Y1<HS9"E4&:U]7JGKNKVVQ;&US7JWR@T]L,NEYQ0("NSJ#\!.Z
MCO>MJR02<B#+FE%O9BR'DH3D@QT+X-A/5%P,U)-E@`.@Q1Y;)THR01&!O,"N
MN,DR#`CC);X++J<*=0TM#BD8SA*L9SC/@5H>>78)V3:PY5F\>ZX#T]D<;=RQ
M](9H4'R=WE)Q^W+-IR^0P=1M][N>GY"\5R1N5/D[7(22FHB)B#R28V+?!2DM
M]U+F0[GZA.;O4D#`;$XM\&[TB(OC^Y+W?K!HPV$GZ?/7>_64PH;85VX_4*XR
M9DG,Z?=S22)=AB++.'@(C*$/_CJ3\"0CS^O,)&W'G=WDU&37'0Y`/*N+EWW]
M=6>=JEF,<BMC[^C4'S,_4%U!Z7_;/'O)E$MBBQI!HC:VFW,I4M(7&_`B1[WR
M/QNH?G8][%.9QIU#:64'BQ+CZWKC5F4#M2IC;C48\0IS"$$)PEUA2L+:4AU*
M%I#?.D$9P/J8X&BNEM&J8T'7FDNLFNR"6VD'RF&`U%/O$NK>CF?:.XE3CF6W
M&LH]RO;ZY"5+P'@/`>`\"H[U,U:1`^QUWL32&9<^,;"I`A\Q^G*:@P#K"71K
M%#0ZYC+3(^95\1)F&QU(2M;(*G6UO(RI:0L><VM(Z3Y$<4M[:IY$4:-V+J&;
MUW89*VU:3+?C$%LU<%VS!%A30DO7SX&4CI"):?&.'D`'Q7486DAGT]^`HI_6
M,XB<;^Q`7>UGW;4[:J]\/-R<?KYQC+'O4G)1/'BL1.S=K;5J^FJ#B?".NT33
M2[F`018PWYP[,L&\SEH@4IX]U\)/.W^.LL]]CCHU&K04I:#:D"+:K<!#0`4T
M-5*J5MHB%D;9)-"PYDQ#PKKSOQK,/+=$$<2VH?([WRN/!:&YD.A,<0N53TFG
M"XUGC?O%V02H)B2PH)O6-H66G,<4ML4_&6,*Q\#BDMN_\JLXQG.?`K^?3^#%
M'Z>H<EAAMI\_DEN]\UU&,X42\TY5Q&G'/7.<>Y`HZ$8]/3^U./`C%^[=$SPV
MJ.OL=V25/`L;"Y*'X,D?;FRY6=&ZZD'!DAP=;C*^S6JS&Y9%;>==P:M'Q?)A
M]:7R%!!S]8&5GF^U_5M+'M]BK5"W3HC<#.T(PZ/8JE1N(M9I]FEH8?Y(:QP)
M>8>NVFNADC2L>^)(_L1G6?:AATG*P]9/P'@/`>`\#$SF[P_H'.GC3M;C/L2;
ML-/@]J5&2IY-XI0U:5>*U'R[@BI/_'#[1`V$(%$NP&D8U*64J)#6MKWH]V%)
M#R@>R#ASV`]+W(ZL5^<NE\KVLGITJT<8+"%L:3O%.?IU,V-)V6AU^7%(!B:D
M9=*.>-'S<C%)C5QXDB6P3A&?F3G(=/Z6([`NT;FQ6]:4+D#M"Y[TY'7H:[7"
MWA3E_I]%I5@M%=Q"WFX6^$I\2+'UH*(A'\1Q<B"&R"Z.K`S>5-/HQX'JK]47
M5UI3JDXRQFBM5/E6*U6!439]U;(/68DG8^RV8<:+D[`'&FF2&:U7T(8^("+8
M=_'%:QE?HHAXAYT).O`>`\!X#P'@/`>`\#\?(W\F6OD1\N$8<RU[D_)AM2E)
M2YE'K[L(4I.<8SZ>F<XSX%`>=#0#W\=D,@Y9*]((?YN=3K2XZH?BQQ(SA/(;
M038K,H^3&PX*)H%;N1C_`&_D.E$*>]SKCJDK="_WX&-_*CE5ISASJP?;^\;1
M$5.EE[`UMK=F1F9VO5\;,[LVZ0].CGE&V65B`,@P34H]+264N+>8AXXLA+;G
MPY3D(??K6VJ&D^MAB4S/QC@]LY9<NI2MM?DC-,$`&[NL*V18`AXW\B>C&GG,
MI'(_%!4M"DH_&1A.%N!8/2XA2EH2M"E-9PEQ*58RIM2DX6E*\8SZHRI"L9QC
M/]<9]?`_?@/`Z-Y*\<M2<MM%[*XZ[RK`MNUAM2M&UJRQ3[0BR&$OX2['3D,\
M:*:Q'V2MRC+)\87\2U!GC-/)QE2,>!$6CZT_3YC1C.@7N+T:56A[T+=V;R[*
M*;W<AMB08D2*6K=X@@VSGZ-(N-NMO!N2:W4L$K;:>:2AC#(=Q]G73GQK[".'
M$/QN9I54I-ITA0I2`XE6?")$*+T_+-U$>JP$6K,9@D]ZF9!C`F2!U-EI;R*P
M3AAYT="%!5OZ9-0\GNM#O%O'!/EMKG7NP,\B=46^)'Y`S3P\76[O1J`,C9L!
M8J%&Y'=AK"=,R8H$<5#F(;DXS"QE*0QAM220O#62#JIE:IUYU-@:I.UVQ0,2
M-9Z'KFC'3KVN47^+?O=%B\6Z,'3%T>WO17_L1>C<?E+'1^5'8<*P*YX%)+M]
M[<(G5/<IPC"T-,V2M:(XO7R/D]SB<?YMFN6+:UXO;E?C[90+-KJ\56DU&3O=
M3K]_<"?1@^5P[$6<YM18!&#D,!-QT+Q-ZVY2.>P7+K89'++8NC^>N]^,4+?M
MO5:FG2P]!UM$PD#D`.%0'(9KK%J=FCR),;)!*"G"5X6Z_CW+4&6/:QL;BMUO
M\+]P<N6^+FEI*_U](=?UC*`Z:T^\N+W5>R'(/5UJM!,^]45?XM"WPL(N7?'-
MR:V&VXXVG.4J4D*D'UP^E*M<SMA!\]>5^H92#T?JXO!&BZC(&#YB=X[/_P`M
ML4R=?;='+DS)0&+UJ1^,PU&K1^-(F-LJ7[1A\CDA9#[#OKJ\>^:?(K3?)[7^
MT-D<<-@T2?IE?NL=JB9'HT/-Z5&LMKGM@0M`-JL2%*:_V98S[W)R7[QS,FR4
M8K++PZ&WEOMAPBI_6GTWK.Z:3K^I.4_(;6_%_4D_8=LS6IJY/C1]_P!M\A9.
MV!3L'L;9^SHUB/!M$)7X*OP\/^I?A,Y)#CDJ_(:>6XXL+,G@/`>!UWMY8[>I
M]H.%@%R@K>N[JLF,CRB@3Y$=-:DU/`!&@,%'!EF-XRVVZRTXZVM6%(2I6,8R
M%;GZACB5]1:/9[$-(Y3;Y2R/\BG7Q&LKJ+B1BW'#RW%D)]^5>Y3(6<H4G.6<
M_P#KWPM%>!32^R7/A4OGGUBS59CZG7MH7<DS2Z-E7E&N]D1,=4]B;/JH<8Y7
M=)3$J-<`[CK^^L@3`=OS@2*!((8%4LO"RF6`L*=54?.1O#V-'M$[FU6;.^^7
MR[!;<1#T&U:Y;/+'=&#+"/%OOOY$%E'$_(VVC#;*$YPEM"483ZA(SX#P'@/`
M>!MI(!+\E&'MS$D&,`@]),.,B*5&S*C&V6V')-9483*H7&*:RMC\0D5.5.*^
M;#J?:E(;EX#P'@?S.,*QE*L8SC.,XSC./7&<9_C.,XS_`!G&<>!&/SDZ?^!_
M8Q>Z/L;ECJ@S8%EUU4IZF55X&SS%68$B+"S(H*48FO/`$2I01)Z20\E..MB$
MC-.-HQG#F'`I4_8-XD:.X+<E^#7'/BWIF4%TA0M!;%V$)IX"0V-+XM-FM>]+
M'83)*2L<<0?L"_M4Z2>7,.COS(F:Y$Q_N#*%<<&0L.W_`*O=[C:?R9Y":B:V
M;R#<%V!=*=%0<Q0]*0&V=6'WI45LZWA;#M_(.9HMSB]*V%S7D*17LA/R"U3S
M<TL3WO$1X[[`>A41@A0[Z1'&6BE,NX&=(960.T1E"L,N/L-/C./LH<],J0EQ
MM2DXSC"DYSZX"O1VT<(NNOG7*6JC<\>0/$G2.YJM6A_^UW8K6R*[JS?5!AIX
M!F$5*;$8LVPX8^_UX#9IQ#L)&I4Q"(>(QAYEXK.59#"_Z]/%JK<6[[R#`Y6.
M\6Y#>TA;:19^)]_!WIH#<&R[MIR@:>?U#9-C:X)JEVL]\IU+L]?CF)5V*2V'
M'Q\9.#CH;]C*L-AP/H"HEUG^R3OUD2KI=JX6OEG76XVX.UV.!M$NW$\@-UVB
M3'*6?`%UHZ.DQ8C]0:VXVHO$:8K`ZF5>UUL+E/@10]X\[(UOJBYGS$41)"F#
MZZ@&,/PH#<I-('D-C4J-._31KQ0(\A+K!+<2*RZ^PRX_E"7'$(RI6`Y)TP8/
MQU8\($2RG%3#>CH-J:2\'D$AF;:D)1N8&)'4VA?Y0LFEUMUQ2GU/.(RYE\C*
MOG<"3KP'@/`>`\"L-P/676N[7NTLCP-KI]=F+UHFAPVQC-DU]_2,;MBSZ4U(
MFN5Z?THB5KUAG=C6Y)(YD7*_`ECX1Y./P=AU_"G0X?VT]WG+;K_FB[`[PUUS
M)Z+J06O)2*D=C<LZ/J+=^S;!<8QR-(>7QHCLV_8TWJB+F)5X,U+`[[&3HQY:
MR\-#.HR'?'U^=?=:<W4^1W+;KUVG>;I8^15[B2N5-<N,L:M%1VR-FR7YZ%KU
M5L%-I5A@:B$?M(X>,.6'\<H,(GVO.*8>]`CD[4?PW?LA]%\!1GR:I5(F)_7`
MLQ(\E#POX]9VS?T3U:"A18F)P.&216OQ'LX((%>;6VM32&$X60%JKG#_`/`5
M\OO_`*5W?_\`[Z>V^!`_]0IEMKIPJ*T%CDJ(Y";T>=:923AP%S$K"L8$*R0.
MPVHA33*7L994ZU\;J,>_WX6A`1*?=R,'`@>"P44.<,_+W#?LA/GK1-(9+,&J
M6F8I@44@LO$9^+F'<;PZT(SAI:\*RXK+F',>!!Y]7R!D<]UND(NO.M%1S>N-
MZG,AV-F1_5RM<DM03Y0K$L*X#'O$L+2<P0A6!L,.DM-.H]S?M7X'K8>`\!X#
MP'@/`AT[SH+@1+\!-FKY_P!KAM8:_?1'URB;F%J"+CM;5.P;%-0^(*TZ=C(T
M8BYE6021CAWC18CT49&#O(,_Z+#^4ACW]=[A'P:X_</8OD%Q&OQ?($GD.3,2
MLER#N58@JOL@NOQYXT*'K2:KT),6`2EYIZZVRP=&-E84LX?+Y#;;ZE-H"P?X
M#P'@/`>`\!X#P.-7.Y577=1M%]O-@BZI3*579RVVRS39;0,17ZS6HLN;GYN4
M,>SAL:.B(@!XE]S/\-LM*5G^,9\"J1RE^W=PTT[MV1TUH336P.5,K'O2T&JY
MT"XT@6F2MK<LYM:IL=0C&29M.RP;0S^#)?/'.H2P(=AK/N*9(9:#-:`)[]^7
M/%H:3_=<%^`^U=I1@T_#'QL1LS8^X=25[%E3+5X4R*ER[=KJ5D+%5&1\E).9
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M&_;GLV[.:9XY[\N5TXK0[-F&MNO.-]@T5S`Q&;AT%<==V<F?:M$OOBCQ`LK$
M28IOX\$X)DQY);[S.5!Z$:6T)4M:4(2IW.%.*2G&%.*2G"$J7G&/5>4H3C&,
MY_IC'IX'[\!X#P'@/`BR[6.KO4G9=H<NN204'3.2.O,,VOC1R$1%(=M.JMB0
M9"I2"P24/E@J=H<H=[FI2&)6Z$\AW+Z6TE-,/-A$GP_[_HW3\]:>$G=)79#C
M+R,XR0-5A]A\E#'\S^E-W7)19$E62%":YIP7^`S^PJ(@*PQT4^)EF3%0<YEH
M+X$#+#3TKZUW4'+Z.V!8Q;ZW9+QNJQ6Z\:DY5E7>2A+CK!K;;P,[11:Y!)NT
M;2Y6=HSQ:'81\Z-9DOF=3^2EQ>/3(=_\>V^!/UM]"[HHFZ>=I6T!]J;#7R-@
M*?L!ZC2?)^TF6O\`QW7UOD*_7*_("6K<31]EA%GO&)%R\-A!25>_+2UK#!*B
M\8>4GV).1U"YM\C9"Q\=>K&EEB,\=>,$Q(P=J/Y14?,A+XMMYEDP4Q#2=$*M
M4G5XO!G[0(AX<7"&05*PT0XL+B-7KD94*Y!5>';^*,K\/%P@.,M"LN*$B(\:
M-$4\@$8,3#WXHJ,9^-IMO'IZ)2E.,)P&_>`\!X#P'@=5[U%4=I'<820WI%1F
MJ]A"ICQUBM/G*(J,NU@-EPTL`)MXK*_8E3S[+6,JQE;B$^JL!6O^H%,PF>J`
MVMC'0N9*$Y5[N`(8#?2@TMU<'KB<<<(&>=26Z0"-,M#K7\+:/8RGVX6CVNN!
M:D\"B3]F.Q.C=P/5'7C9V`8@32N/ZI"$4#-GVM0CW+=4O*R<>,&\+7C(YU-/
M%'4/)O-K>7ZX$2XK#ZV`L<=2=\L%VXSGLOZVVW31]<\V>:=&:D)$>`BJUM&"
M)WYMV?9VG'+FYIV6L&MVS++^O2\)ADW,_'.X0,H5I:O`E^\!X#P'@/`>`\!X
M#P'@/`H2_:/OAD%SPXX6*(L.1H=KBG:JK<:1,5.2KH=ZI0'(R-9V,U)["<(K
M=JK$5566!YX"7AEDNC*BLDBK0R\XZZ&4OU#ZBY40.PD=R)ML+F0LW'B2PBXQ
MUACY*S#&-;U(C;\TN?CPWI)%F`=0T67E2G7Y4(OU0AO#2G`N:^!@UR.ZT.`_
M+R_1FT>37%34.ZK]#595+C;+>J]F4-%K:I94Y@%#6"6@UO-22UK;)4VHIM#K
MC:'$M.N(4'`-'=0'6AQHV?1MTZ#X>:GU1M76ZI15.O=.&G8VP1?[J)LL%+(?
M+Q-N8F&Y"'MIPSJ3DDI4TII/I_TPWPA`WT0C$1/;[]A^(J.`E2+')NNO,CSN
M7,A-BO;>W5F26[(,)+F5.)#<>R.C'HRX]C&%^W"<*P%PCP(?._E$:YT]\Z&Y
M@%J2BW-7P+<@"ZZ:.HD1>RJ.EY`I4=&39@<A[,YR*^@,OX",(<4RXE.49#F7
M2,'%C=4?!1^/B8V)*+X\Z_;G4@#%,$&3<'#,5<LJ:7(0\#)$S[;4"VP6L@9#
MN'6<H]5)0E60E1\!X#P'@/`J^];.U;<COU[J-,1TY.2%).L^KMAVZO'ZLK0[
M8,V%IS3]>I-A(VHY:8:UH!:81+1T?"MUP\(@;XSU2"'',9)"!S[I.N-S8Y0\
M6M^16HIZ.U'3=0XHS>]0@A#8HW86+U)VEJMRY`:""(=,$+(B*`5)?$T:042@
M;"\LO>H8L]=79)<);MDZRN0.->R.C=U\IY2#XX\J:AK?69NH=4<F==6V2$U]
MK#>J&#YF2J=APB5=''?&AHD`5HJG?DM$_DG.ML!8_P"P2`J^^/L=]20T,X_*
M':PT5;-ML/C7Z(UP1$(K.ZY6+++?B[55I<B^,&-QAX>8(5<68>PIU\<O_0PT
M\%B#G:8-'\(>8IICOPBC\6M_N/._&Z[[$?[4VS'N^-AMUY?IG/\`1*<Y_P#:
M>!!Q]1810W33KUU3`3.#MZ[V+2L1PA;Q*4V84/YY)+Y#[;1ON$RC"6DM-_CH
M:S[/?E:UA&Y]U&LWHFA<$]A0>N9*V436MNVX_?IT@23Q30W[;C6<'5JO8)")
M/AY1+]H>:,:::#+:*RVEQ6%-_P!J_`@=^J9K3;-R[:Z';X*K6\*&H=!VX1?-
MH1U2G)P:DHN6O+#$U8*S%EE?XQ!!V"0B20P'9`5]+SZG&D)4]AAP</5X\!X#
MP'@/`>!1L^T5U^=PG8!R!TE5>-VJI#<7$>HU0B5J]'IMKJ$#BO[8PIT*SW/9
MF+A/5D`B8EHN00'!+;(+;$CF2,8P.Z40ET.^OKSZH[I.)]KU'Q+Y#ZXUMK#@
M%KG2Y5S6N9UD14+W,;!W&[)W]NK-6Q8`!\OMFCWNUIBI\<W&!%A#*2(LM3/Y
M&0N,^`\!X#P'@/`>!CGRTY2:JX6\>]E<FMV%RH>L=4P[4Y:7($8$^=6$\>)'
MH;AHL^3B42\@IXQ.4"M/?D.XQG#2%K]$Y"`KA!IGDKW$[%J78GSNDHH/@J4U
M=+;P:X-I=JM@CF:Q?HMJB'63D;F/JP<%LIR4J8,@E$5+-R#T<]+.8')80VXV
M2$=O/_@!S6K._+A'N\F.AO1&G("/L+/$#4?(?4/'^@;5J&@FYB0CZ10ZU:9O
MC]"SL&W&"L/C(D8F?<(CC48<04R\M)&`AQU)PL[6K`5MO=Y_:!-%\SP-646I
MZ%>TKV0<==@R%U$L.Q*/63-0[(V._P`KH.YU!MMZSM+CAAH^4#++CG&\/9>_
M"9*#T'^K*"Y%5[KVXMUWEX7L*4Y)Q&N51NYR]LR3\[?2;F+8IUH_-AFBY.:>
MG,X:2VD8W)+N"P\-/)]J5X2D(IOL8<%.4')JJ<8>0G$+46CMK;.X@6?8&R)V
MN;BJ%'O+%S@B8&-CX.F#4NY5*9C;HA$L01(('D)`"*CUL++7C)"676@A(^OE
MS[[&MC<V-BZ;VCO<R&TC%MP%SVAQXWU2]PVNW:BU3,N&C:OJ_':`/B6Q-:PO
M^8;2@X4Y@\XQ3\!@0EEI8H.26PL#?64P"GJ\`0$<&?EOE-R\04[%`_JX)+^-
M[V[+.*_&(6^-'0KX&67V6&'R6F?ERC#JLX5C`6#/`>`\!X#P'@/`QYY(<;-+
M<G]?N:OW?I;7FYJ3,2^'I*&O<>`^B"=,KM@JC]UKA!$1)DA72%@;(8Q'E#*$
M,'P6YEDEE7\Y"$2X?58ZAK#9];2<#I.P4^KU:QWJ5OE,C-H;9>#V;#VJG2,%
M7H$F45?F)"J?[>658,O%E1^4O+6,ZR3\_P"2MU`9J\6>C3K!X=7P?9FF>,D`
MN[1?^,/U:P[-G+)N66H,G5'Y<J/F]<2NTY2VRNOY<PN<)>-<B'PTFO+^1U*E
MXQG`2HQ=9KD(,"%"U^$B`XQ^0)C1(N*`CQH\F7()+E2`6!&&FA'Y,HQYTA;>
M$J><=6I>594K.0WOP'@/`>`\!X'6&[LYQI?;N<.X'SC6%^SA_.$JPSG%4ELX
M=RE?HC.&\_SZ9_C^/Y\"M']/=3A75#.%/N1Q"F>5NY`&EL0N(^1'2-`:[5\$
MC)XD"T3JOA?;RT^ED7XF<I'RE?PX=6%JE?O]B_CPG+GM5\>%YSA&5^F?;A>4
MX4K"<J_KG&,Y]/`HK?9"0:WVY]8<HJUQU:EHBGZ(G9>,?E@\D6`N(YE0;4?$
M:<AE5F;L<[L')$N<MQIM`:G@&V<I>1ALEE\+1O5*RRQPYC4L>F$JY!\S'%(Q
M',1JFW'.8&\E+0[AA*?SGDYS_>4OU=(5ZK7G*LY\"1[P'@/`>`\!X#P'@/`>
M`\"@A]JVL29'/'CN>)8+U#0AG%ER#O1L;M36E%C'*,?MN\6::#?@[3^-.WBK
M1A%58>F&B?RX"&:<&*>_%=]JW@Y9]17%N$W?RL-N6I;?;R+O2*M*?]RZK<7=
MHREV6MS,E"RFF;J8:6F<CI:V5=R)E8O$RQ^PPN,D,?Z?S.--A?#\!X#P*F'2
MS*71GM![MFA&2I2FHYMXN,+'@D5;`TG%[`V=O;7%BN31T?19&W20-?D:6,C,
M>7/C@L?CEE-#8RMQ>0MG^!$%WY$`"=/G.XF3.EHP-C48+KDA`LB/S(3B+Y3\
MCDQK1SC+&2VB?9E.<.,NISCU:=:<PAQ(=E=,WRJZK>!SI`9P!!7'&@FD#2DF
M3,2V'S@EF//2\B8I9;\N4Z_ETO#BE+;(6M&<YRGU\"3/P'@/`>`\"IMUVU+5
M5G[].[.*G[3/V;D.Q;=`SOSKCJT!J+_96LQFD+="Q+=<C+N!=CMGU*SPXT7F
M11@N+9P+@D]C#Q.`W0[.^P5J?M4Y!3.G>.O$71.B>0/$O>D6W4=N0FZ*-'VV
M,U[MH":.D*IL*5F1$B6B@P00SPGXLP.\ZT/(,J2^EL9QW#P0(</OK[]PNA^8
MW`';W)F"H^X=3<4]D:\BZ5!TWE#4`K%KNHQ=YL>Q(X>J#;'KST415J'<"")Z
M1@HP9)TP&2^,*OY'%NBA*CV+D1-Z^R?TYE7&7DJB#3Z;;0:&!-594O,[!V#5
M=K["K\LR1#!R`X]-KTK&L(FHJ><;6R2RQC"6L.)2EL+-?/$U,=P?YBFK4,A(
M_%O?R\K,-:CA$?\`SJK6GWD'O)4T(RG*O53BL9PG'\^!")]1X3\;IDUB[^R2
M?^=NO?!?XZ6THS$^EQP'^M6K#SN75*R)^3[LX;SC!.$^WT3A2@BO^YS$U"J5
MG@RB&T36;/8+ILW;<C_F"W[['&Q\YE%`)-KX`E6N$'6RBMDK=4Y(N$1[TDM4
M<TXP4RK#GO")7ZF!>WY3LM,J]4UW<Y[5TYK&4B^0.RH.X;"!CJ7"5J%N$Y3U
M2Y%4GJ]5C(J];-C@!F6Y<62>PXRI(CK?R$Y6'J1^`\!X#P'@/`>!H3XN,E4#
M-R<<#(H".#E`T'B,%I$DX]Y)($B,DAMS#!P)",.,NI]'&UXPI.<9_GP-=X#P
M'@/`>`\#3*-#00D198R"EXQE`RGVDD+QG&<XREG*\.*QG"<_TQ_P\"L/+:8C
M.Y3LZMK>\5-[)Z_.L.\V36-.K<A%FPH6Y>:3\Q"6G:,9L&-'9JIK];T<`'7X
M0(0Z/-A)QG#K[19;I3^4!9W$;"&'%$`0*P(P.A@(41+30[(HJ4,(9%99PEIL
M<9/M1A*,82C'IC^/X\"H?]CCK%VGN;8^A.QRMU",Y=:[XD@B"[+X9FP<\NZ[
M3US+W\J>M2*U9:WB1CB(.N!2C:L!NQ""6!FGGG2S/1H?`5]>IKCKQ+ZR^5\Q
MJ;OFXP,Z7V#:WM-;XXE;:O$C.RD-0+30;Y*-H@GI_4-GEH_!DU./Q9JQ"VEB
ML!QJW)'XV'QTNAZ9]$M#MHKL+)2#*(Z7EX8.R.0N3(,\B.B9Q\QV&2Z=69RR
M5^1Q@5GX_P`H(XD4E3:G&U>U6,8#?)^&_?194;B3F(9Q]@EMF3@CW(^2">?$
M($04.ZG"V7'1<D?*VEY#K/RH0I2%>W&/`IL?62K+QG+#NKMFW;#.;FVU4^2,
M?0:_R#V>S^RW'>:M6[)N^G3F2K*>&*"4$ZNGQ7S!",,A,&,H1\#;;0[;022?
M5_2`CJJKZ(X*4"'3R4Y4+1^W5'X+)8)W'82X\A8T3EJ(!6F)(':=:$'$&P0V
MXIME*584L+#G@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X&''.'E1H#BWQ]VI;=Y
M[AK.J8[-%E`!#I(B5+FFCK<EZGU@P.OU5!5O?&*M,DP,DD5E*&GE?R\UZ96D
M*^WU-[E3]/=7]BIFT[E6:1;G.:N](=^"M4\#$3(DN/7M<A$`RXDF2V3&EID8
MYT?/Y.4X47E#&%*><0A06FP]E:ZD&X]T"_4HYJ6("%BG`[5!$MR94FZ.Q&C1
MZV3UI,(D'RVD,(;RI3JW483C.58]0I&?8A@6*EW!]1XS6P&M95]^(I-<J+;,
MC<IV5ML@_P`N==.6.HV$B-AC9J"B9R,GW%LF*/);7^"MO.!L^S#P6E>K#Y,<
M/(A*TM(PC?',)#26E`+]K".76[TLI=S'OD)P^E&,87A[*2,*Q_JI2OUQX$B?
M@/`>`\!X#P'@/`>`\!X%`W[1M)$E^R#BC%C6N8KOX/%.=LX(TQ^FG*C(3>.0
M9MR?;E7+E&%QH<#&YKKTM)#.GY>=8CQ1XD7YO5IT.U_J=(V#GD5SA5'52#D]
M?S%+T_*;@V`?+3PFS:?NAJ3LA=/HYD1,V:01*5FXU)V0+</!<DA74Q`JL_@(
M,2$V%YOP'@/`JO='&M*W)\].^&TW2^ZIMEGV!S8N%)LVALLIS>ZM6]<7Z^2D
M->+'7LR1D/*4:^/[!6/'FNCN/8-AB&</^U&6TA:A\")+O=<^/J/YO>AQ$<Z[
MK"'&&+$!/DRD&%[#I@H30T=%3,#)FODEO(:0T.3\ZU+QA#1"O0=T.9]+<8S#
M]3G7Q&LAH`P+Q7U.EX9`^!<X,77!G3WGA_1.62BC7''7DJ_OPZM7N_N]?`DZ
M\!X#P'@/`J2=;E8?,^S3W-;(811BF&:?1-?%A#WAA-VKR6Z7HJ21-HIOZ5#T
MO!68B&PP^4@AM(!P[C*_F5[5J"VWX&E)!",6(X6&*4L`K!P*R1VGUA&I9?&2
M8(IU"LC%)')<;PXCVKPAQ2?7T5G&0IL]KB7L?99Z0DRI47*,EIEY2(GF08*/
M):C';9=&HNIO$EGO"2K,))!K=8?RAHU;IZT#X6_AG&`LY]@ALC'<$.:!\2A#
MDB)Q6W^^(VX*Z:AQUO5=J5AM8K#C+SR7$XSC.$+2KTS_`!G&?`A2^HZW((Z9
M=9*-3[1W=V;X<BL_C&L>Z/Q<,-+5EPO_`$2__8FV3CY!O]#^/9G_`%4.^!&3
M]THFB"Z]X1S%KC-B![%C=G[4B]6&0=@J\?KR1J3]>UC(;"F;B4W&DW^,GQ)%
M8042P$XV.IM)1+ZE9PPTL(OOJ)P^L9+L8V7!SVQ;M7BV^/Q"]90D+N<VL1^P
M)4*WYFY&B3,=5Y2*(OP49"I*L#$;EH+#*HMPLD/&/>G(>FP68(`QDDXH8(9+
MC#2B"WVAV,.DOMC#-Y=>4AO#A!+R&T8]?5:U83CUSG&/`U/@/`>`\"&KN^[2
MJ)U=\.K3>$W^,JO)'94-983BQ7)"D&[`8MNQ:Z/&R!?[B#'/APPZE&,2`[4B
M>48R@/\`-:4VV2[[!G0@,Z\ON%:5(T])B]EX=H!Y!/WB6>@F>..CG7-?IUZ]
M$UK_`!@%Y4GM2;ES;69*NR#KRL-L,I9RTWZ>].5+"1K8GVPNL_4%CEJ=MG7/
M-W6%RC$BDHJ&PN-)-*M!T3(0@DO&3;<%9K?%2`D7*.D+%'62AE3KK*G,)_&4
MA]03M<0.5.M>;7'+6?*'3X%SCM:[9CI67J0^P*T]4K4N,B[%,5S!I\&\07^.
M-)/0RR1'$/.MD".M.H5G"\>!DIX#P'@/`Z;Y%;!L>I>/^\=JU")BI^U:SU#L
MC8-<@YQP]F'F9NF4^8L<9%RCL4T])H`/,C4-.Y'3E[V+S[/[O3P/*QN%[%[4
MN7VON5&Z^<XNKKI-ZTF-Y<P-E`2T7K.C\3];4&4E,Z\T=QB:D)V+O]KW0/2*
MR0(X$S%FX/GI(=QE\EHIXG(8XZ$Y8\A=<<-=]<?SMX7+CMK+<XEDV-06:QKY
MQ_<'/C8UCOD9KBL)LFV;Q+(@`Z%J*QU;.9*3ABP)0+&"4M).=:=_&#*>6MW)
M;I>8X[;MX@<]"^0W*NT<;M@S/+;3-,?#Y&Z1XG:[OY]3A(8>V7RL6:VZ_=FG
M]A$"E8RK(F(Z>CPT.Y)8?94>'2_"ODCRLX"<D.&?-7>O,&1719;<-0+MNH:=
MO>K[OVM,\<=G.@7[:5@<H3=ALU`I=4MXL8[&S0A\C#V:,DO:IT(9?P/Y"2/M
M_P"S'0/:OO\`N&X6]D:[-XS]:5^UD5JGB;M>?I=*EN<,7(W.TYY%VK7U^CW)
MBS)C;5%46MQ<?$`LRCAD6:T<ZT&IMW*0E4T]N[LLZ\=#Z5[`^'$/M;G-U8\@
MZ1?MPO<(K0&7*;IXAPQM->MD>T5NHJ#M5FE-:T^6AC1D26&,A,1(3+#8"5$M
M/H#;^Q'L2XC\^(KBERIX^0_9E<-ASVUKSQ+F=$<6>5/_`&C[3IFP]85TO;0Y
M$OJHNHW4K8,Q^'82ECRH_P"*V$`E31F62%MC8#@_U^>WC?=YY#ZKXM27$_7M
M:X3[VL6[*/H;<E<J8\3M&3W9HB@0-UE[MOW8`\I,1.V=TG:J;C_\FE,B1!)\
ME*L'I>^#"V\A-_\`6/>29U?C2F9$F3)F>4O*^8/)-+%*-R=(;BGGWDF8`E9@
M$<Q6%)6ZAEWXU.+RYCW>_P"186$_`>`\!X#P'@/`Z'Y.\CM8\1=";/Y([E.E
MX[6>I:T_9[43`04E9)E0J'QP0PXV'BV7B239.3,8&:RKXQVW'L+>=:92MQ(0
M,@?:,X@&FZ<BU\-.S0>5Y`@FR&E(O_M<AS)+:PL9+M1TJ[K<&/V@45>FXP3+
MAC^8M!6$,-93G_54AM0=E6?[&G'>DPTY8[IP.[9*A7:W$3<Y.3]HX-6N`A8F
M-AYC`"2Y24EK,(#%BFQ6%2>'R7&AV!490^MHGT8R$\NOK@/L.A4B_B1,Q`"W
MBH5JX#05A:#8GX4>S0P4TS$SC$<;)1[,Q'-FX9)0P20REY"L(<6GT5D.7^`\
M!X#P'@5[NW'OB=ZI-E5NC3_"[9NY:S?]<YME`VU$W^N4>@R]MCI*<#MM#/>G
M8,XX:1IL8&!)FN#I)4F-.R_EM#+#KF`VKLTZI>*';Y0]7\X=F[2W7`UW7O%:
M<FJA6-*S>NXH.WU2<;:VJ:S*6R9J4^1/"R@P20Q<MEIBL)7^6Q_ZQ3BPIQ=.
MG1I>^VQ!&S][@S6I.))K>RJ]0MD\=)'32)VH[2K\IK^811ME5ZRGS5[=ICU.
M>PB#0MJ0_!>PQ[5,,N+6X%A"N_2^XEU*;@[)6.<?,:NS]:E8Z<KTW!+UE$R\
M%,Q!3)T7+0TB%5&BHR3C3!FW1WV5)<9=0E2<XRG&?`[\[M>BCF'V0<A>)&TN
M.7(+4&I(KB=JF)K=5NNRC]AR&YS]AQ=WC;`-:I*<@JY+`G8C1XL4X0C+B"<2
MB"5N8S@E*F@^/$CA!]COAX.-J.K\X.!.X]40NW"-KV56SJWLZ6V'*QFPK21>
M-C5QE$;1</52#M$\_*K%9$S[VWRWG!'&?X;0'?.ENV;L_P!>;$J%?['>I;96
MI]5W^='K4#O'C*J0WM7JNK]N43*77:U,JLI<KYK^EQ5.='>]KX;D@^0R1GXF
M_13#`3*\=.<O$OEY7CK%Q>WSKK>J(H5DZ9@:!8X\VYU\1Z>D:VA^S4F1?C+5
M5D9EH<I"<20@JG$L94WA:5(RH,I1"5%(=6H4H3+918V&RT-H6ZD4AP=)36&G
M7DY%+2W\C6<YPI3:L94E.?7&`U7@/`>`\!X#P'@/`H!?::M5)GN=&IJY+0;8
M4O(\1;5K6#L%JB3YNMF3S^U).8"P.#4\%VB+GHJ9'!)A)04N/=:,PX,2RM@I
MMU`9"?5O*;/M_9M5-L2L$%$76X<:[J@.B6*P1-9R1)`VXJL_CFL.,7.D3X`X
MP03H)$H*R\VAE`XN6?5U\+O/@/`>!5$Z026XCL;[PKYB,V78%VSFJ92IZ7JD
M;FWZA9.1NC9$=4H:).Q&1EIKMKI8%B.D[.TZ@Z(%A9,([\@9Q3C#@6N_`B@[
MRY4:'ZEN=!!\:]*11.DI.)F1V)V*K:D0TU,0\5*$9EI<.20TED(Q>?C&&?D7
M\^C0:/REM9P'->F]`3755U]MQRG%@-\4M.H#><4:K\H=-1CTM&LYD8Z)D,"&
MIQ\K.'QVW4LK3A?JK&59"2KP'@/`>`\"HOU?4BV$?98[I=D8@2LT\2M0E1DK
M.JJ!.10]F=;TV?"UR-N<HX581CS*TSDTT(50XCZD)4IM;3`BD!;H\!X'GQ]L
MO9%PGIGV%>O;9:;0NN:UX!REPU9R,D8;5]K2Y4;-#S]Q+(!A1(6()3=X5AZS
M-9:S#M$*9>=(RM/JI/J$H_++[-G4SM/BUR+UG6>215DLU_X_;LI<#`?]L6^!
MTSERM%',AZ/'?+<Z.[4AHE^2*>;D,R>%#J0XU_*$)=SD(U>@GOKZU.O/K(U_
MQYW]LNRUK=45L#:UOG:]':GV9,19(UGO6'HMY5KJ]/GXLR0<K.4.HQC*\8P-
MAAQ;2O9X&$OV8^T;A)VBZJXJ27%/?XM^G=#VK8!ERUM8-9[QUQ:Y@+9HM=R%
M)P`MDJC5",`J`E+4/+/)EOV&7"VEC(6Q\V6@QG^M]V;\2>N[E?<9C?R=E5.A
M;=I0&NHVX0=&!M%7B9F,M=PLPMOND=%*G;R&]'0,D-##?IAY4S.#2%%$($1Z
M9"W<G[:G5DU1N0EME)B_BRVFK<95M?T,.'"FK3R19$-2,S;-39CBG(.,JAS;
MS+[)%E+@WL-J<][*%,K3X'3#_P!SOJZ;E&A&=5\O2(U:%9<EL:\URTEI>'81
M"4?A.;7_`"E^YL\Q?KC^GX&<?U>:\#G.?N,=1?XICV(_E7D@=1R1@_\`9JOX
M</P,IW`BV'O]Q_@93(I0G*/F4WEOW^CF$^F?`UJ?N(=064ISG'*9.<XQG*5:
M4B?<G.<>N4J]NP5)]4_TSZ9SC_PSX&;7'?[''43R.KHLO!\H@-=V$Q^99&UG
MM>LSU;V67^FS_P#VRMPXMD9G2I=O/NCPP"2CS?\`E;8RYC*,!"K]B3EYTK]C
MG"*ZIKO-&CW;D[QIKUCOW'2L4FUVZ-3.6NP/U,&P5J2B"*H77K.N3B06T_$K
M"#`ULN>A`J/REI""_JLXU=/NR.O;D87O_L#K_%+DMR#B3=1)I^T+-K*832AZ
M5?*#LG6VQ(`,W7ZK/7V)FUT]X61(%)09F(<6AH@7+GR/!T;H76^F.<W9Y'1O
M9-RKX_T31_$VFZATW=MS/;_@;5$<CO\`;(Z)I=7<!V):=GS,G<YK9HN3#Y6?
M@L2D+%K;2LMIL1:R%!Z,O_G']0E!HN787GEQ!`J5)JY&(FK4S:E%>?"K]2K0
MLD-`52EP!V375"P>&1X^-"%RMUU.!!VU/(RTD..1/>QU73M]%UI$\N=:D6N0
M5N?`*2I<2'KBV]$9?S>"I.\3I$92*J"6R&0]"OS,C',SHXSCH*GF_8I09$1W
M9]UT'L@97SFXC@'')&2J(-Y(:85(A&DD0X2HPO`-W-"R<-(SP@SF&7GFOF?1
MA"U84E60_>Q^SCKTU32[9?;AS/XU-0%*K8MKG$0FY*#9YO\`2GDR@48[%UVN
MSTG.S9,L="EL"L"#O/$/#K0A.5)SCP.0;/[#N#&G:%-[,OW++0D=3J^]&"2!
MT3LRK6P]9\T_'#Q,;&P%3D9NP3$G(N2PRFAQ!7G<M.X=RG#6,KP'2<YVG=9%
M[@]GU&:Y2:<L=-CHBFU6^N8L"2Z[+`;OV-9M"0\"`4%G+]@_/NT&='260$O(
MBQ\I+*6P*XV^H*]NHJ_]1/0@=`@Y7:O&*[;2TG:6)2.VK-1NR8^[%66E6:6F
MH(ZQ?X5!153GRZV\0AEUS\-0YS83#A*7<H2KP(IMV<.^G_E0-2@-L_9#A;4Y
MJZA%ZXUH)8=`P`$92J)(6QZRIJ8,J8N'F)@,2>EEK04::1))9RM2GL,I7C`=
MF:>XZ\"..VE+[QVXZ?9MT+4M9;1@-BT>VUFV\8-%V[!]#VL%^'L."1;;.0?<
MH=%@'@H5U7XLD*..8"HEIM!"67&@Z4U+U9\(^/\`3-^UO07V1N"4%";LU3,:
MZW*/<M1:4N!<QK<Z%DPK$#5#K/M*6LE=L#[,L2TP16W199;+V4H4IS"/:&:!
MO'J+L&IB=-,_99ZCB-2S6O"=;,@2/#W@2':G=>R]955OQ3;&FRA6L2PO5HCX
MWCL$LR*2,Y=^5#W]V`KZ:X[I.R+B'=J=HW2/*21V1Q?XX[(CM+UV`_P2D-ZF
MV/KG7EP1#U&M2]IBHR8GY:E[#JM1R:\TU*,.J8EI/`J_0EY]T)UOLK<*9X;E
M10-X\.N`_).[\L[94]<<B]D<FN/E>N%RTH&;`LET27HEHU)%:_L4*R7D>C"2
M^3ER;1AG[$A$BV8R\CV!@AM/M4Y0:\1PUIU<ZQ)_A]VC<>MTRA^D:Y4-`.T#
M2FVJMO71D+I6SSMEXV2->B)&S[VOF*>$+%OQ(XX3(POL$]BD*&4$D/UVN[&"
MTM0-&]9^.'O(_8^TI??\TSNW<-1$?EZ;K6>W=L]S,G:+G61(`F>JT142#W&I
M1I;(@[1`)&6E+3G+G@7\O`>`\!X#P'@/`AQ^P2MUKIIY^O,'8CW&-+MO)>4T
M*\EW+5TJB\!Y;,0XSG!N<?%_3W_W_P!O]WIX%`;MHD;,;PBZ!SO\PB89D'K^
MN,T!8?S9-,C!3JK[`-&%0KU-;08S.AAL#,AC8RE+;@SS*TI6A6/`[`XW=P?-
MW:G7#V1<(K+3=E<N='B\9E(HV_+'(!UPCC=JR@@TJA7`:<?LDF>S>($6*EX;
M]1&M'?Y(HQW)3_SX*=_$#TU>,*H]?&KCRN)CVXF*7HW4RHR*:&BPVHR/508#
M(4>V)!GRL**V$-E+>&PRB1483[6G7&\)7D.\O`>`\!X#P(4N['K@N_/[3>HC
M]&5W1&>0W'K;(VYZ-:]R4:$M_P"Q%H]+N\S%ZBPU,@O1Q]/VGL5,''S8$D\F
M)R"MPIUMQT9K'@53.HG>/</OWD'V(2U_Y*P5>%U744F\M>+FY566P"5Z@/57
M<<5,17'FC8S-433DI"3%?&3^O%8$&)')&RIY;",M/!-5]/D>`A>JJ5'0L,.P
M6'E+MN3D`WT-#2[Y`E+U$.]@G&!1$D--I?;>&PWE[#89+6,J]_O2D+6W@<$K
M&T-;W:SW^E4^^5&T6_5,M$P.SJQ`6"+EIW7TW/0HUCA(>Y18)+YE<DY:OFLG
M#L%H:==$>0ZE.4+2K(<Z],>N<^F/7/IC.?\`CGT]?3US_P"T]?`9QA6,I5C"
MDJQG"DYQC.,XSCTSC.,_QG&<>!!ESNZIK&;<K7S=ZT+:7QH[!\5J*J[Q4-*0
MD9J7?%-`DZ"H?6VSX6R5ZU1=.K\>U1QR,'5H6-D'T*.'=4YF1==0&5?7=SH`
MY5UJ^:UVE2J]H+FKH2SGUOE1QA!G&IHG7]GE2GIN`MM>E\,#)M](V15I$"<$
MD6<.*9S(_C%Y02A6%!)'X#P'@/`>`\!X#P//D^U%:;%CL%XU,ZWKMY=DR>,-
ML:/@*^U#4J7FRJ]NR?LF;H+*2D/*VP9JKV'5@,NB0BH]XX@6*:=9>;&4TLD,
MSOJM#V.;VQSZ/DT1]%+B1^-0AL'K*MTL36=@1G&V[/)Y=G(ROC_O[6+.VDN,
MEC$J(=<4`A;,@0VKW8"Z;X#P'@52.A6TA3W8UWN1<'7-?,L1W.6U6!NT!`$)
MV`U#VBZ;$B)&L3DI$F%5<R`;E]?LE1`>?:4(X4>_E:D/):\"UOX$2/=%<(>1
MZN^P6'A[<W!SU,U*T+8,CD1"#HG]H?6)8!F5Q)8);A8*T1I&1G)%QK"AQ5OO
ML>KK&,X#M3J$^/\`\KO@1EH@(M"N+.GU_DQY#)8CZUU&/6ZXT6.48R8I3BL^
M]["\?*OU7E#><Y;2$C7@/`>`\!X%0KK,%3#_`&>NYN.P.ZRY*:WK4T\XIX=U
M]Y+G^S)C"C`51<R?$#91-YR,I4M'-FM>UU(;Z?CP$%O7P'@4[^[0`!OOJZ%8
MT$<.N?MK].'3,]'0D&N0E&1KS$(5"EE2,:E)$=("E$CELI(=<=:-5G#.7DCY
M6%B;L+K4!$<"^:4G#5"L9DP.*^_"A$XCA(U2ELZNM"UH1(@AJ,`<6UA6$O-8
MRMI6<*Q_./`A!^IYK>EW#I]UU(VZIQ]D&3M[<X(T7=*U7YZ*:+"NY13T]7")
M>$>E&F9!DL<9YI)+@2"(Y2VFVGED*<#MKOIZ6<=J-2T=0]'[&H6DMK:3BMAV
MJJU60UL;'5"^1=BD-?UDK%EV?5XTW-.`I+*G"1(Q,=(/RRR'6V4C(2^4T%7T
M/Z9_:!%'@'1O)3B:R1!,DN09*;GM["A'FR"G1PV&5ZH<;%%-R\I;N,>YO&7E
MI4A>,J]P;99OIF]FQ;Q*XW:W!]]QXH1[\T6Y;?K^?C;CT#OL-1K&I"XH9APE
MOY5X2SAQ3JLJ2I"/]/P./`?3"[.$&QV9W;7$Q$0Y-0(DNY5[SL":G0X0^:!!
MG9B-BI_6E-B9,F`B"'CL".R0F2\#Y90XEQ:?4->KZ:7/5_6DO*Q/(7C1([RA
M%CDR.C%25K&2%$RLEEF`>,V,F()A1Y62AAB2UC_AJ&:6Q\*"GO=\B0A4[3^I
M[:_5#L?3^J=T;,U]<+MM+1<1N@^(J:91I=-(/L<C5SZ2822V^#-R4=*11&$&
M".Y$);8<4C.,)3[PE+Z`>H+:W-R'V]R)UT%Q@?=U3;Z)3!*UR'E>1L;-0\N]
M!Q5X;N.N;_QFVEKRRU&5D6UI;><*;*4@=S+#'LRIUQ(=L<[?KF3G6W0-N<[^
M0VU^$UEU?!%V<V`X@AVOD'51+@5='2H&O4#5UTFK1';+G+)3G)YF3"P\>8\Y
M^MRLSY1\/)R&*?`/HPMG<GI&J;5XK;9X?Z(LFI*K$:PW1J.2MNW)O9$C9HF0
MFTQN\+W%.1UM8KQ.V1$+^(8!8\8G$9E3+3>5J0D,ZO\`V2=Y\?\`T4W$[_[9
MMG_W@/`?^R3O/C_Z*;B=_P#;-L_^\!X&B)^E+V$(]^!^3/$DE*'&4M?));98
MPII;:UON>G^V[OQJ:>PE.$_S[\9]WKCT],A\7_I2]AJ#4,L<D^(SP.764K-7
M+;99=0TMT=+[F`_]M'/>IEIQU6$_)CWY;QCUQ[_5(;2/]*_LD61'H)W]P]''
M?QG,B0W:ML/K`S\PB,898_VF:_.]677E^ON:_EI*?_<_5(;7(_3-[,V_C@XO
M<W"B0('_`/8L2^]=]N1TBEB099&::6_G3!;9`2"0'\-HQG"D*PI><8PXG&`T
M#/TR.U<92W!MO<,V7%,OL*4QM+;;2UL$LK')8RI.CT>K1([JFUISGVK0K*<_
MQG/@;!%?3I[<VS4(S=^)\".Z$2@B55N6]_".S(1:DR03[<9JH@YQ!"'5AOX0
MVMMWUSZY4UGW9"*.O=>58LP>`(_L9ZHH@BR@R@BV+;M+:%.D8A4+^K1())-N
M6A(W%3E&92MH:&6MP=R0P>0L?+XCSJDAO<[U;,LA1SD!V8]1!IP[!($H/6^6
MDE7#QU$Q5?!)#.D++KB#CYX<L$QY3CP+Q(JUMF(RO*UH:6'7!75;=$*RN,YJ
M]8\Z%\A;2)*/YVZ<"%<6&8*&OVLV(V#DDX<Q("NH]S"?5LE/]%MOH:#FH_3W
MMB6=#C0^676*/+QUDBZ?8@!N?>DRC(U4L[*$CV^:?_R,N%>BF\#."*;BWWRO
M^F3G`><K^5T,<+UO&TM4&J<7;#?(.51HK>4G%P.-05^@0FH+Y7')^Q/S=LM&
MPJJ/!SNV#PK">MNJER0+[`$`>6EDA+3K8Z0]6+EWV=[?X07RBZH@>`/,OG$U
M<=<#;-:V)QLH($W4J:W8;/8HV#U?+'"!I#)E*_%PJ%?F96E\@5UAUQO*W%*R
M%?OM`[?>1_,_4M+U7KOIAYYQHK%_CC-KQ&X>*T;/&6S44U3+Y$6VO:RV&30=
M@6#16SWD*4J(MT-'.2L8E+[C"F'_`(O>'3OUR>T/C5H0"D<583KQWPQR#L^Z
M)FE[5WUK_7N;!`:HU9N[<)E@HS.^+T7G%ZQ6]=CDH87(3`V<J#C<NI=3C#J4
M!Z`D?(1\N`#*Q1P<G%R88TA&R4>2R:!(`&LH)#.!,&6Z.6&6.XEQIUM2D.(5
MA2<YQG&?`UG@/`>`\!X#P(8OL,LR)'3+ST'BWB&BW]3Q3.$"PKLZ^8R]L"G-
MOQR`V&G7&,R#2LM?DXQ_TF%_-ZX]GKX%`#<W,GAUOC2/7A$6B&V?NN8ZSN(\
MYJB<UO(U@1C2NWML!2L,96R+"5,6>%FVM#5I0HHUD<?`@#Y,)8X@YHY:Q$/!
MD[O#N)X=<[^J#97"&[4F,X1[<TA7I+>NN4\9&1:=Q_W;:ZNS-ZUIFB9-B<*L
MFSK/)2M,M<0N2)*0<[.D0[A)18;#"B$!Z2_&]LAKCOH5HM+Z2FM+ZM;)23@M
M)*2$4>"2\DA)\C,')?PYC/OP\64]A7K[WG5>JU!W1X#P'@/`>!_,^OIGT_KZ
M9]/_`$^!3TZ.-';+HNL.]*(Y&TZV!\V#=S;>B+[8-K$P4QLVQ4.U:FDY769!
M%^RPU.VVE3QBC"HZ3<>S"&XRIZ/2WC!"<!W=]0`=H?J:E0F@G&A0.5^XT"DF
MQ:8N1.6JL:S<(+-9208T^\V^\MAI]#F<9&;;1G&%(5ZA:>\#8X^LUN(EIZ?B
MJ_!QD[:G8]^T34?$@!2UD?B0DQL4]/20P[9DP[&1R,#CJ(6YEEG&$(]$_P`>
M!U]:>0.A:/.%UFZ[NU%3[(!E[!U>M.R:;7YP/(\,%8B,%Q,M-"'CY8K\D.>O
MWMX]H;[;V?1M:59#L")M%9GCIN,@[%!3,E62Q8^R1\3+Q\B=7SSHX67!"FQ`
MR'GXDLR)-9*:;?2VMP=Y#B<90I*LAQ\G9%4%LT;6G)J!PY)9*#;-5::LSA%B
M:,$%"JN(IZ:;GRIR5P\^ME#`CK:<".)<6A>6TK"#SM-J`'`+<5*[J=7Y:AWM
M:NT727..G@Q50?<V_P`3+W>8N(E#ZX%+,0YAFY*5=SX0V-?1.1#;P`S^#5F-
MC"B>!/A$R8<U%1DS'O-D`2T>')@OM/#D-/!GC-E#/-D"O$"OMN,NISA;;BVU
M8SZI5G&<9R&X>`\!X#P'@/`I[]U7?]R+XB<K7.*O%F'UW4GM(-5:[;TV+;Q:
MCN0BXAWB-4]2]:5?7D-?8&RPQKX/YI\LPX@>>0L,+#&6@R\/D!5P[(.<&R^P
M"V\1KON!C7%UWE3]=2.N;AMFL4*".K4K:U[/V1L*@PE(@8NRRD;%R(4.>S#3
M5:LL8P9F3A'?<\@4U!:PL`?36>85.=CWXA4>Q'GS''N5CXNI0L%#4(YI8&S@
M"9^!4U6Z]-R*7#05M)RRTQ$#+R\EAG&5^[(7E_`>`\"JET2#S,7SZ[Z=HS46
M`97K9SE7584W75C<N@`<C5K_`+(K9\$71Z^=F2C70A)J*,_9NUX=/Z]UQUPU
M;#2OC"U;X$3O>.&,GJ5Y]G>T(?+&A9:8DG7V0LID@:Y)Q$L_&F)+8?&D&SP@
MW!<,/MO-NX>RWE"TKRC(:WH^S&JZEN!:HN+%B&%<?JI^2(#.+L`#DJA9K<S(
M`%.2TPJ."EI9#Q349\C/ZA#V`?QA/Q_Q60E5\!X#P'@/`JZ]96CR<=_W=IOU
M*+`PS!R6M]3E#+"UZ77&\7/7VG=BQQ#LQ'V<.]!S<IF((>'8S`/1Z@T+21(_
MFL_&X%HKP'@5,NWZI3UW[^>C(&JGC`FU!G9-_L[\[=J_4(=FFPESK;AV(51E
MUJLX?9CU-+'_``AL..2:5M,M,2+:3!,!8'[$66".`O-A@E12&'>*'()+J@A3
M32L(SJJU>OP"1Q(9K[F?Z>UMU"O_`&O@0S_4G=6YTOZB0K\OT8W!OII'Y(CP
MS7L5?2W_`/H775K0<)[WL^KK>$HP]\C?I[FU9R%E[P'@/`>!^'76V&G'GEI;
M:9;6ZZXO.$H;;;3E:UJSG^,)2G&<YS_X>!YHOW.2RG^Q'C%+0`XLNC'",.10
MXH`67#Q%D;4W`EV4PP4R0-E`PA/S-/93G+*\(=3G"DIS@)2/I?$PK7&SE!%E
MA.F$&<AX&2K!\)`64RK!&U_343&3KCUC=(-%AI)X2P8RH>19CLDOE/9#R4VG
M.!@R9^U7P<WGV$\<-7N<3HN)V_>>(UWL-EV)IZH*-GMQ28NS6JE5XAJJ5:,B
MREG-Q[8))IZ%E,O8881EIA_^]3(8=_4MZMN;'$K=G([DERBT9.<>*O,:?C]&
M56K;"CI&O[!N]@-N-;V#(6QBNFNDO#5V%C(EH-XMW`C1))#;8S;BQS%-A>@\
M!X#P'@/`>!^5JRA"UX0IS*4J5AM'M]Z\IQG.$(]ZD(]RO3TQZYQCU_KG'@5.
M>X?OZSH.N[ET?QRT/:=G[/TK6OQ.5D[9;6?0M+:,-NQ]2I`&O++:Z^16;KL6
M[R*+^I\(>C3L=*!DBL2#*SH]LK"0J?\`$WDUU#S6O;=K7GOT^LD\CZI5*!#Z
MD&T??.1NO+5R$M<2F`I$R/=HTBW9`HUIG)020FI*6]!`7G%X'_#4]G+R@ZV8
MO'$'&X-]AR7U_8`+3'$Z]O/\H&!^3/+\O9VF]4Q^S8C7LJ)8IDC>D?16]EM&
MR&0V,8;R&1)+QE+/XS+KF`Y/M'7&JP-%\6-UD=)FD=`:DYE[ZIVL]2W&>Y0<
MIYS8UEAH&\Q15N:8H5VVH*?#P-_K!#(P-A&0RTTVYEYDEQ#[:<AGAVUZ+Z!N
MM'E#J[BI!\2']U24V=7S^5<@#R/Y,15WXOP$F32'8\VI$`R$M4[<_+4XF5EE
MPA@Y$DE>&%*>8:)81@+?W"[I-Z>]?:CUW>M.\0=>W.OW,FO;XU[;]UPC6Q]A
MP8]I"@;9510K%;L24]%QD0TR,\.`Z^YD9U;N',J4MSU"%S[+]T['N._(7A#"
M<%N1]FXJZ1V]3YO2S#PF]:YI;5I6Y6)ZPV8&/G)"T6:.B*\856C6VF)0ML0-
MM>66<E85A"6PR_XA?8(TKOC0V_.+E!L4Y`<\>+/$.SIJ)>Q;C2=]B\E=_P"J
MM5V%%@>TA9:5:"\\F"$7"K8D?<+^&78P"?RAF/@P^MD/G]4;2NMI'K\?Y6V&
M@U3')[;NUN0M.W#L1NK"P%RFX@?;$A-+IES2*1\4ND":=<):P4(.\(R^@1#>
M&64*<"TV$$'&AB1T<(,!'@#,!`@A,-"AA!BM(8%$$%80VP,,,PVE#;:$I0A"
M<8QC&,>!J?`>`\!X#P'@1Q=NNE=N\B>MWEGI;0]87<=N7W6R(ZD5UJQ#U0B1
ME0++`S:DB3Q+XJ0#F0XMUP?*76W7'TH0VI*U)5@*:%;ZUJ;<.%FLM!;K^O1S
MI%Y'Q$#00=O<LM,V?154V%:[9$37[2]3,&[=+G/1!@=BCHF.%4Z1&I>-3(2'
M^H&^VI\P,2=-=26Q],\)N0-(/Z=.P[9_,#?VC+'K^,VE>*_H"5U[I*^0MU)L
M$;,ZJAFYPRUQ<18ZU!AM2$B4`J>4^RX)$$(:D??D/26XTQUBB..6@(FWQTI#
MVR+TGJJ.M$3-MH9FHNQ!42!&FXZ79;6ZVU*!233K1"4J4E+J58QG./Y\#NSP
M'@/`>`\"JW]F*;H==@>*\BO77*?D!M^6O1&MJ?H#1V\=Z:)H\]![;7BC?OYZ
MU:JIT_7'MG.7HZ%!K(4R8-^?[R6TL&,)(&="'KA5VY<OZE":XU_:>-U&BN*7
M,NK;6X;:EEYMVQ&[[TI+<:*;,5EZ$Y);ID=9"N;LV-'Q)!8\-'21`1*!$+??
M8&2XY[@ER^H(+8Y3JPS9)>TR$FSGE#O!*A"CTS/['&*GJ&,B7W"BB'Y.%3`-
M1Y@[8.,,-.I(^93:DX'=R%K?P(:N^[D1N?C%UI[8V1HW84AJ6U2-TU!K><VC
M7ZS)VV[:^H6T=CU^BW2V:\B(TH#*KY$0TVMR-6X^Q[7?X9=;*R.M(4`Y_BUQ
M`OY]WY<;TVQM^R:BW$WM"N\.:-+RR^3'-_F38J]HFXU&R\A]BG55W_<O4=03
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M11AW3#L#`>\C+B&AV&?1*@G$\!X#P'@/`>!!YV&]`'!CLDW;"[_V^YLG6VQH
MBI?XL7-Z%D*5KF2MKF2Y(C%@O<W_`(/+SMNG!QS&A1W2B58'$'PTC'M<7ZA3
M.^P)P>XZ]<V_^)NC]+:4I,S27>(%/C+_`'^R1A]2(G-@P=ZV'4XC<VU9&AB1
M]`E[],1N,J67)Q+(7RBN.O\`N2K&60E6^G^$&7'<S#PY.6O3=^FN.%DE<,6!
M(X]2$J[^YHZ-/G9):`I*>MR2:Q'8D@PW%QV,&I4S\PSJT-A>>\!X#P*H/0U"
MJ1VG]]TNLR)+)`Y)1\.<*6.]+W*O/26Y^2TD+!'74E3R9&.4&$DS\<526$8)
M92YC+K.<X"U]X$3?>H3&"=1_.LB8D5Q,<WIASYY!MPAK(V5VJMML9RZ&R\<T
MVX2I"%+'PDA*59RTMMS"5I#6=':R7>IK@P429'2"C])1DDP;%H*P,0#)3$R=
M&J<(/&%D9*01'D-(+,)PX4:4EQ]YUUUQ3JPE8\!X#P'@/`K-=61<K%=R?=ZR
M/6]EL4"7Y"4@)-PB;-!?[($;%<U709!^K3&O5"(N(^U/P4G&MSS?K$.AY)'?
M7A_(F70LR^`\"G#W?APYOV`NA4>Q+CA(E=BDU,%2<-'BB$3;.Q@7X,!ZS'XR
MB141.-AM,A?PX"\_AUG.'2TYP%D'LN-B8[KNYRG3K0CT0)Q,Y`/GLGA8D@G6
M&]76=66R@,A2."V5J],*1\+GKC_A_P`<!$%]2IG+72[IU?MSC!&W-]O)SG)6
M?=C&PI!C*O0DXMI./<QG'HP@9K^/7XLN96ZZ%EKP'@/`>`\#S5ON00L;+]E6
M@69MV;.#QPJKK@(`2@8U]@]W>6Q8X0:&*(BE#R&9`HS"7_R7EI8PXM:,Y4V@
M=P)4OI90*ZAQ7YG"22B,E'\GZO"#E-8F5PA9L7J861)`"46,,`B4CFE._F^U
MM#R<?"A[.<?!CP+J_@/`>`\!X#P'@/`>!2R[+OKP<M]S<HM]\O-6\XZTQ%[(
MW<+RAUSQ&EM7GRU<N>_=,ZUF?]HJ\_"SVP6=<6NV&U^O$QCLG)B,-8!+*2XC
M+&5HR$;&T.BN^\I.9>Z.&')/;.CZUV"[-L,=S0?YK3L3M/,KR)UML=@%>PJ!
MI[0E6FH+6].B]$6:$DV9"6D%.9E'3!@PVQ$LD/-AG[Q$^M+RTD8&_<>N4_+#
M_:_A_7)T:D2NL^-M.CM82_-6$JMDHNP(2X<AY2`E%O7ZM/O24_&B%S+O^5`2
M"5O,.-"?!A82)?8_ZRMZ<]]%\.:]QOG@*<O0N^8TN6/;B9<LRE5NRQT/5@]D
MH)@L)D(RJZH8`7)RZQL.FI#;PL5A]]M#2@PMJWUL]_[6T7R-F]M=I/(6[\H.
M06MIC77((F.LK-CUKO2T:[7*N\=V+A<MAZ__`-S8:A`40Z%!F(IA!K[27"6V
M3G&?^GR$^W4GI;=?$;AUI_AMR2(X_L[7T53`(2(#X_R=TDH2<UV,T(,%=;,[
M=H&O&.7>>M+DBN56,SD5UY27L92IY3:`[3YF\)."?)*ED6+F3IW6U]K&N@;[
M:`[%L,!N68HK]F@H<6V6F'9DL&@L2^8NI!9;S^,_Z*%3[&E94K"@IC=1O$T7
M1FO>USL!X7V:B6?B;J'C]S%UGQ2VMLW7E'8Y?0>X=(:\B9NC;8'E?\9AX^C1
M%EC+').AO/@YDSHYH?\`/$%=?=PZ$_?U75F%]-VE9B0(GR"[!M?D9.$_Y&>+
M*'M$G[FMN3/_`&(-`A&F8)-;<(=<-R\6LEYW*EX1EMML+%G@/`>`\!X#P(].
MR+LMXY=8>AS]T[YER3)61_)C-6ZL@4/NW3;US;PRH:G53"`R@A#GT/9=608I
MH=IAMQ>59]F<>!"%6_MW\$W>/^[=H;'U!NK5.Y]4VJMP%:XLV=B/SLW:499<
M-,)LU=EE,!UZ*C*V>'))FL&J0J.;%'S_`*KQP[&0XMQN^XWP#W1=9*G[+U%N
M/CVVN"2]4)^T+C[Q&6VYF3T)"1%(^&A@2DA`.R*99PI4B4U@$<<-WY%87EM*
MPV?1?W$.*FU+I78*\<4-YZBI#WYA%^VF?9*M=:WKJ)BHV5.E9N0B:J$]:)B/
M8=AWF6L#AI>?5CUPC'\XP$Z/&CM!U/RQY@7;C'INKGV6E5KBSI[E37.0@=DA
MB:;?JGN<O#%=B8.N,M9G`R!&TNX(=*6VMLD5]E;#>4H6X$G'@/`>`\!X%![[
M&W8'ORD]ANK^(VZ(G7,]PDK&=&<E3M3P9`-DV3/Q-1NUH"LEQ58XUN@VC7&Q
MYRNC2[5:BVY>19&=!'D,NLN$X4$'?G<MM>O35$XX\?.K+C+Q?M]AJM&E-R:E
MV[4=Z:5I]GX@[0DVF3;XXG5`VQ\1>Q=JV[54,0P4N4#D"A#'<DI4>2\GV!'E
M]?CMGY`\9=#6?@AQ!Z[[%S7V1%VK;'(^UC5CDA2*C)5R$DV=<T(43\.:I&%3
MF,66'R02H;U?:#D!_B9>]CJ\!8O:[=>W49`JYGZ]?(=O"61<2?Z;DUJ^74T6
M\7^*[B.::J3:S1F\COJ]^?CRE'Q+7A#;J5^!'S]E/;?.39FY>._"W2F@]8\@
M-<7/CIN+DEN#C+?9(-<62-JBXD1$1M2PVV*V#I^U"L42$>8E`@AI5@/$C\V'
MFI'`V<-A7-Z=X2TU+69V]-$=I/%?B9N7-\E3YJD[5XT2^]M@4M-<UO(QC6S:
M_<&M4V4W7B;75IRUA'"#X''7%1KCRB"6_?E@,VMNTRP[R`F8?;/>SUR%Q.P[
M)8]EW`Z,X-S\;(6ZU;,UY+:^E-K2/Z_3,2Q:;PO7UK*3#39#N3`,D)?!)'7E
M+N`Z^XJ<<(+@_7[0+H7ONZK=?.6R&L-?LT_>]%J/V19:5<(Z&B)^F.36R:25
M=CZ0>!`"-.18RU!,.,YSA"'<K5D,PJYMC=>H-**XW5C[`G47K_CO)Q-TC<:3
M_P"U>':U856[D7,$W>K`52?UX;$MUN=/F3'WH<9*!,J-4MMA*7T^X)-NE[F%
MPYZ]M+[IT_O7MAX'[R7<^0CUYU-`:8V)3-9:]HM?O8\(BTP59HM@AJ)7:!%C
MW!Z1/Q'@'F1ZPVTJ$;9>6IET)J@>Z+JG=94X9V'</6\N.&OBJ'WA45,NQK39
MIHSRW"C1O0K]:'E3[:<*PV]_IXRK.4>X-T;[E.J-W*4I[#>(V,K)P(CY-WT=
MKWO*P6I.$Y=ED84VO`+OM<Q_IY]G\*_G'J'(\]L_6'@\&,SS^XC),DSY*+`0
MK?.N4M%'Q!YD9)#M%9G\"Y4*<`ZWG.5X3GVXSC.4J3E0;F'VG=:IY*@Q>>O$
M91:(X.5<&<W_`*R&>:`/RK`CSS9-C:6TIW*,X^-6,.)SC^Y./`^I7:1ULA,*
M)*YZ<1&6$R3L1EQ7(/5V4_L6(L*:>&Q[;-G.<MQDBR[E6/[,8<]/7W8SC`:X
MCLRZ\Q)/$:9S>XECK>*CH\)]7(O3[K9TG(S),`F/9;8N+I+3S$J.EM:G4-M9
M^5.4K4G"\I#D+O89P&8>='=YM\2D/,/QHSK>>16HO<A^7>PQ&M9]+?GU66[G
MT3Z>OI_7/IC^?`HT_:-WIJ#9_/3BE=-(;@<VR'#\2MGU^>+XY;`UO?`A,$VZ
MP8DX@H@FS352$E7ZI+FOD-?A*D&V4C$I2]AIO+`2(?5I8'UG,]D5ZN&QJ673
MHT_5$C=]B,Q\#0=>135.KU_#?`RV'`4&N0#FOZI`L8EBEQP+"VL?E?$G#RGE
M!9<VMV$\9ZSK*]VC4V_^*NV-A5FOYE(#7)O*O3-`9GI%TD00.-EK7,3YX53;
M(>+2G#Q;&4_)E+?IA2\>!W0CEOQ46PHC')KCWEEO\+#KR=T:X4RVJ1/#B@$J
M=Q9/8G)TI(CC,^N<?*^^VVGU6M.,AM6R>8_&35FO-A;,L6ZM<'5[6-3D[E:1
M:S=*O8I]J'BT%^]`,'&S#IQIYQ(3@PK"4X405CXD>J_7'@5^>BO96B+1<^P[
MD1K=^*.WMRZ[)-P(C@V)YHF\6CC]%3E6M=9NEYT>C8(R:K%:W'V++AORPJ7U
M"/'IPZHG*TC*"T_X$3O>C&.2W4?SN%:8ERW&-)ERN`8-A1$I(8@K)7IM4:.T
ME:%^R13'Y8=4GU4VRXI6,*SC"<AO72H!(A]6G"AZ7C'(63D-&T]\B&7BQ")B
MQPP4PT.'F#L6<9KL@W!18N9$4).(]<IDDAA;Z7_R7@E(\!X#P'@/`J?=0VN;
M&SWH]VVW"(79Z8,O<-GUJJ?C6ZY(:'6:(K5UK"BI$X"TBS\1MYJ*+:>^-Z%+
M$(!=?;R8.4,ZV0'5_P!B3=7==0-[4)CKNMENUUQQKU-B96[;/'MFB=?UEG;\
M\NPQY&M"+%M&9@F)C/\`BL8!*M1Y:"G4%FJ<'<PG/QMAGCT_]K&GI_CGQRXS
M<S.8E5G.Q@B"M9>Y:AL&6CHVU@3I]Z=.K<;,6`(46@./2E;NL"W"-AFJQ),O
MH;$0O++J6PPP[=ZM>+!]BKHX-H(,)(2==@[;89EJ2GJV$L>HQEY('LYBX^QS
M,2TIQJ)E7<!_C9=/*)SE(C)#["6LA8?['<O8Z_.;GP$RH:\\4M_)R7!Q3DY+
MC-*U?9TD/QT.U*0JY(MIC*E(9P6-[\X],N)Q_/@1#_4Y90UTJZ&6A0:E$[*W
MZ\[^+(H.=2M.U;"/A)["'7,Q1F&V$_\`3JPA66?C>]OH[A2@LD>`\!X#P/D^
M^R,R\22\T...TX^^^^XAIEAEI&7'7GG7,I0TTTA.5*4K.,)QCUSX'FO_`'!9
M%V*[2.-[5=)!R?=N'55JTLW@^)AVB&9;<VS&(YJ7EI0X"$:"6^R.YEZ4<_`9
M:3[GL9:3GP)-OIDUA@[0_,^8)E)MV2J?*B)RU*P5PE3JA8QY'4Z8PB$,;?.R
MU:1(U:FRDDD")7EYL1UDA>$K3@+M_@/`>`\!X#P'@/`>`\"';L^X.7_9)=/Y
ML\/;K':,YR<;HZ3D(;;&:Q-WA=YTY$1DM/6K2EBUY!)P5L^.M:F%AQ\,^Z@5
MHB3(*:1F00$\R'8W6OV3ZQYM:QJ-?LC6=+\O(.I?F;YXG;#D)*"W%J^VQRP<
M6=A=*OK<+L>5IS2IL`H*8_7*CUAR0S7Y&2$/,M!*'X#P'@0Z]F79_H_AQ.Q.
MA-N<1>8W)IK9U"Q9B<<=M%G;*J8,#)2TY5UBR5I'G87,):Q)&-;RVV.I!@V#
M!GVG$+4G.`C!XJU;B=H[IH[7-'<8]S`;%AR=2<SM\.:Q6+"4NPZ"'VKHXJ93
MH/-:8O=MOI2]-@D1@,A.%YR*_('8;')=4VXAD,F?JM'JDNF[2A:BI%["]G;Y
M2D0]93K<2E&SYU.8T(DB&A6C$)7C+Q3K"7F5R3Q.<.>[WMMA8O\``>`\!X#P
M'@5J.ZK@ORWVURFXP<S^,G'WBARLSHK3^V=93>E>3TQ&5.O#DWF4B3@=COV&
M:L59'*55%X](]D4Z.+#(<>=P3Z.X:4$)/.KK_P"QOFQ,TWG'V6:TJL;>9GD_
MQ3XD53BWQ$$J>QZY%<6"K'-V?D++;)V15I:XV"L1YI!3CHLHY92)`222Z*IH
M89V.6@.[>T#H`X3\2.!'(2S]<&FMA[EY-WTS3&OZW'F/C<@)BHP<IO.K3EDM
MM)?*K)Y^NY".@PLQY\^(6/@*+4E!3B<DK=="$^B]"?/[5NV.-45S%XPRQ>J-
MH\O^.^@[3O?3F\`+A9M;:CD)8L.]1$7#4TR<"KE8<A6UN$W`D!*8@Z-4EU_/
MY)"7@L1]1W59S%ZB>T[DM)0^M5;\Z_\`9&JE154Y.O'5RQ;3K-0BVCK?K'7U
M:K(]G5L"=/8)'&@YM,;$OQI;@XA;:&&4HRV%NG6&TZ5N"L9MM%FH^9BV9J?K
M4C@*5A)0B&LU4EB8&T5J:_12DL-&6*MS83P<@"ZZDH$II;+Z&W4J1@.P&GFG
MVTNLN(=;5[O:M&<*2KVJRE7IG'\9]%)SC_VW@?3P'@/`H:?:4XLVQOE1K;D(
MFF;:Y(TW8O&ZQ4&>TSJZQ0>LIBK[8IMAFZKQEV6`5$JG;]MXJ%V3OEI3U<BX
M1QWX(_&7"D-DK^,,6=Y]9USXF\6>*5PX@=,>SI;FL5PSU;L'9G+$N_[?:9X]
M;W_3V*M[G&MNE[1<!]7&V<6-"5)"K>9?"%60I9`2VECJP'1_0#V[2W&JL3.C
M-$]3YW-KDA'&7#8$SLS1D53:7MNOZELA5!ACZ@$/!ZYN<^718&_GH4M:#&`U
M9/0ZXPUZJRD+%$S]B3GG%J,"Q]>'L-_:,L8RRE8][)!^=X=#XWS%QW'<MM3/
MM=3E?QJ4I/\`*<^BL9Q@,$_L-<\]_<0^P7@WO'3^I=>SULVAU][0U9)4_D!5
MR7-85].^K/E^QPECG9@O7\18)J.`JJV7H:>>R$TRVM3T>A1>?<$7G5#IG3NS
M.,NSMG3_`&P<)^+LCR3M5QA]N<:;GLS9W%@($>-<NM?);SKG0/*KC7!V"G7>
MO7-+[#,C"/"@LL-AAY2'A]AT)2A::S&AQK=$^P9P:*K;T(RP`R?V*\L:#BKL
M5F#<BJ#"U>MPO,&0A0X5IEQ#!*5##)%:%97@8K/O:R&*FZ.`.F.54I2B]\=H
M_47R%NU>@G:S`6+:W99RWN]E@!\$2'X4?6BIK>\F-AHI)C)+ZFQ1,*+`8RMI
M_*BG"0W[:76QJOE&[JR)Y)=O'6MR"5K]S]-5([:/8+R(V.N%+"0,)8ZQ!)F=
MYBOX#L(L3'-2;@JHTM>`FE-98<PXM\/OJGZP9>YJ--7?1MHZU]V:KG;*.W!K
MUORIYHSFLI*5K$39H*4**LE3+M;*9JK6,]*%!9<D'G6UO)P7'_W,OAS"M_4A
MW=%(2/)TKA4X,206_+JJW+7FK633F7$+8"C6'3-+V,)B.$%(>2K#PQ)#JG<^
MKN$>J%!\3?J)[4'(6L/77"(P%O\``RO+/*#FC%RSK`""%E?JDNZKF@XZ7ELX
M80XZ1DX;"T.K:88P\VV,'&(?ZOF_[]6*]>B.+.B*J98Z-B<CZ':.??)V,LNO
M)JT1SD@;4)P<KC]86F2`"2W!9$=@UQI]Y:\X)RC.<^!K/_95O>=D0@BS<8-+
M!0T*YC,72D]EFZ9(\^6G2WC;-8V;%(</9B,C02,`L(?$P(@I]]W#WY"_8I.`
MTX7U==RUM\A^#X-ZS4O$N@MM\3M,M`LC@>(FH8V(_5R17!!1\.Y\L6X0A]AY
M@G"2<H=SG+:4>!Q^8^K-N$>5)<QP,H=LP01@IZ38[5K$'@ES#_H2I[$KPC$.
M4_)?"I]:LIS[/R/3&?<G^`V5_P"K%NIS)IK/7_1QFWWR61(?':M(NO@MO)<<
M'+06YPFRR0R'G*6\)<<RXXK'JI/IZY\"&OL=X`7WJONH]%V!6]=:4$VS0,;B
MI-!B=J;-Y(;`J\MK[!E1AI=O9=?USJ*HAEVF]'EB@E+'%5`!2"7'E%D)90X$
M_'U6M;:FY'TKLJT-?JC##UC;=$U9KW;,36O\RA):0@[+"[B"OE4B+J[=;'<@
M&VF+,J'D3R#!'CFQ&6VO<ME]2@G<>^K'TB$2+<B]Q+F59P(^P^"SOO?X4<62
M^Z*[^R<%`V4+@8MG\=24-C98%2EY>/A_AO*`TK7U6ND=B9'EV>*]C2D<T4Q,
M0[OS>YD,Y@9V-<4&0*?L(IT@(K`"TNH6YG*DEO>BDY^++0;M_P"RM_2%F<,G
M'.'YKF2BQ2VXG_??D&S!@K&QCW,AQPVT&4?B%*QZNM.J=;S_`$3A*<YQD(X^
MB#ACI<;G+RNY6<?9C7M4*XU<@>:'!YO0841'BQ6>/0FS*I:]176G3L7*2]EB
MK!!SSLS%29<VW)JF1&FF&U#8%2ZZ%R?P(J.\1#[G4KSP;%<^(A>B9E+/K''2
MK;SF9:&PD-\..5^5^,=G_1==]C[0[;BG76"&D+9<#^='34.WU+<$7H$6,"C)
M'1</,M"0[A+P`[TW+3$L8RVX5&P[JW6C#%I=]!6&OEPK#:,-^WP)6/`>`\!X
M#P*R'5EL-52[$^^^<M5LT_3-)T[F&/<[?89*YRT'L0*:@-:QL>0]/1$[$C0:
M-4`0[93KIRBVU8ET*0/AP;&'%!'C]S&&V)M/B1Q1O.N*]>SM9T?=FQXW94@W
MDR&@%%R0$+!Z[-)KAL@$5:QK`=&2I$!(#`&LN`(()9>0.[E;@58-9\0>07&+
MC)R'V96^*M]:YE<.>1G%O;V>2PDYK,RI<=J!/Z\/ND3"2%*M%MDG;]*;!?V+
M3)$07-6*6$0C.'GVEM*%?"V#R4Y(;!3W)_7OV#N'CS5&=C\EN+T15-J:MW;"
M.W.8TW<MG7^(GIZPU-V4'$<K.Q]>6B+2]&&(%;2$C#K*&FDN>Y`6ENP\ID'@
M-S7+(88)88XH<@W'&"GB1AW4XU3:L92\^&T\4TC^?YRVG*O_``\");ZK-B)L
M_3/H0\D"KQF1+OMZ#8!J=0CJ@$V+7[N=#,$23<8*,W8K%)("_+/EG<NDG$OJ
M4\XMU*L^!8N\!X#P'@?AQMMYMQIUM#K3J%-NM.)2MMQM:<I6VXA6,I6A:<YQ
MG&<>F<>!YEGW+H&0LG9QH"'A!*ZL]SB-1A6D#E,14F2X;M_9X0_[LJ7S'1SF
M!UD)]CC3SC0H2<N/J:0A>4A+[]*>HL"</.5DW*1<@/-B\E@APW3F4C-,!R.I
M:40O(:$E_D/_`)XN6'%*>80CX\M*94O"U9P%UGP'@/`>`\!X#P/XI6$I4I7]
M$XRK/IC.?XQCUS_&,9SG^/\`P\#AL)L*FV).5Q$Z.0W@)$CEUY@P!K`;DW)U
MQMW+L@,*WC+DW#DCI3Z^]2V_7&/:I.5!S/P'@1%=CW4_1N9JU;STO?+-Q2YY
M4R*";U9RRU*<W6K\ENNPE[C(37MOGV`#Y7_;>75L`Y$DF/\`@-7[F'%J(2(P
M/X&",GW`=B_"V+<K'/GJ]W)M-8VT#M64OD)PH@Y*[Z]V="58XJ.F]J26L9>4
MG-IT`*5!%Q(QHA[642;*L_`1_/\`:$C^FNZ;J[WO-;"KU'YDZGBYC5TO&05Q
MCMHFRFD3@I65DI6);"#!W)&44Z6?CCX9]$@D9IW,9Z)R7AG"TYR'!9GO8ZK1
MMB.Z:8YO::AMJL[-#U=^AEPK?-QI=@(FVHH;`%CK4:_4C(6=0ZVL*9;E%Q:$
MOMJ>=3G"VTA@-]BCBGR9Y2RO!:)U9`\AMCZ9`VY;!=E4SB9$$5W;E:(F]>64
M*(V5-;E-LSU4A-?!33L6R5&E0677V4DK8-P\IIGP(<].=;L[U#\S.N/DMSJ?
MH.J-<FTSDMK/FQO*H;$V)?\`C9L.QCTN8FM17#>5@M=!K!96VMVVN]2C#D/.
M,R<08_6PG1\Y(RI#86!_K/(9SU54HR,F9F?JTIR$Y8'T:6E6DC#'4I?(&]CU
M\ZOA,QD0$!!20P^2D,C#LC)(?>^-#:<_&@)_/`>`\!X#P'@5%/L%R).]N=W`
M_@+LSFN?PBXJ[HU'N:X;CON)B.I,!;7<%?XJUK&QW25M4!`K`V'$Y=!;%EV#
M@ASD#.ML.+<7\85#.>6OJ-<-U%<6NJ;<._M@\#Y7<FN*B53+_9+54=,:9Y97
M>[3.JX8ZP;6E98B@;$3LU="D2X*WR!)3#8!RQF5X;`;]`UG*;IPY]:9V?P3X
MC5_C`]J[D[NVIW84N9I?+5>V@]L'P5DKL7*W^VQH_P"#`:#@83]R*V\I!;T4
M^R0WE3V'V'4^!(!R=X9U0M'2SP(WCS-3Q<<#.Y7Z`Y1ZL@N06NMD0G&_94'=
M)R^F;0N]C:M%6AL6;<I-KC65-2@XR$1`H@K))#K*LJ#M"@<;=:=@NMN3/*KL
M2[78NG:@XY!\G-8\;-8:WG<(/U<C5;$A78VR:VT_&[1=MM@@XVL4*LVR+K<"
M3-PDV+,+%&('=2X]D,$>0=;Y'\\ML;%@.!?-6W<CN,?%^/H`U9V1R7Y95OC;
MM*7V+N'3,8G?MDIS6[K)0;DJF7BTUN3DYB,>42(&T*[A+GL>=<(#T2NI2@NZ
MXX#<::_)5ZPUVR_[1T]^RB3.[@N0X6)%AHZ*:1#;7@)`JF69A8<8V2X]"LC!
MN9*2XI*WUNN*"2;P'@/`IH?:OX?:,QCC3S]V3R.WCQM+UM89[6H=LTY6KSN"
MXO;)EH46U:?(J-6,W-K:EZ?CH<F@R69&<BG1)`HTD/Y$O+2EUD/KQU^RWJ/E
MFG<G$E7'+:M6UO-:ON>F^/?($0DV^C["DBZ!98RGR>W802*2/IYRQPL.IYU#
MTS-D-R"UC*]V1RGF@Y/]1K6VM8?@G4K03IJD2&XE[7Y+CF;M#U^"JZT6$C7M
M01^-6V/9XE('6N1L*Y=R0:BGIMYUL%G&,(5\3K(@7`_`PKYNZZX*6'61&UN>
M^L=)W?5.@8>>V$JU;UU[$WJJZY!2_!(F9<-4Y"S`<?)21`@+:6649+-RTE#:
M'/;G&`\]3;^Q]B<GM_Z)JW`+@QU20-4Y7S=SK>@^/\OP]U1=]J8T_KG8L@'7
M^5.T8>W:J+G=3:\V;7I`J4^)XXM+8]6.4A.5*:8=#H;0^_X6]RV_J],Z%ZL-
MH[4U9Q/YW;ENE5K_`%NZ>$J&O;AQJQ(*ITM"7J%!@D;&Q<HN#D)ME*`FH@`)
MP-139>''QV`GIY/4?@7K#@1PBJ.F.#'6?=NU?F9QKJNV*]2[MQOHL#&!0K''
MBV[AV3M__#XZG/5R$:$,J;@<#'2N!8V4D7L,(][+3ZF@D[ZQ>%_39V)\,M%\
MIL==O"2*MLW65_YW4J_4-23KM8L\:43$2&;K$T+"H&$D+$U%IF&H>0:R3%"G
MMLN)2XE?J'P^K;QPU3J?@#:-T:^!DHFP<A-Z[I1>8I,PX94!E:6W3M/6-1?J
M,,M"D5]HJK`L?EM-.K9=>;2IM+:?1'@66_`>`\!X#P'@/`H'?:0G)HGLGXNU
MRMT\2P3DKP[V?!3E>(-K0+]W@E7B?-@86J/V5G$;<[O#FNHGPZ^^RZXT<$(]
M'N8/]BD!DU]4'8Q<A.]G&P=BRP;Y;DYQ1&M=E:K,!&C(N^:QL@N\PC;U$@XN
M`4J)NUK='^%#+A&<J3ZN.);_`+`NK^`\!X$`/1N0BSK[561#YJ)`JW=-S`.%
M'"E5.HDFR(37KS\=*N$E362XUTB2RXMM#^%*<9:S[L>W*?`G^\");O9,_!ZB
M>>#ZL>YA>E'Q#49<6TAZ-D+/7`),=YQ)\8RD<B/)=0[^0^V'\:L_DY_'^3&0
M_/1IB?,ZLN%5@DS!QH.P\?M?&U.G"5"$J8M-AD!EMM"L8AF!OVK<LUELI)#R
M,NK2O"U./+6M]P):_`>`\!X#P*G?51&2E_[?.^74-ITAK'9'&BR[IL)5VV';
MJ;"VR95?9P>M5J1T9+SDZ*&Y-4.QU+!AST&['G`"."9;P_GWK64%JQFO0`XC
M0#$)$L@LA`1K0;<<(D9N.BD*1%@H9PS\>`XY"U88;]/8UA6?;C'KGP*CG"_5
MU@@_M@]FDY=Z9/1$1?.(\):J"_.A("A+C2GW^/M++GXX"0&RY.0V;/2Y`!HA
MKT:0^"]C/N2I&?`V+N)A)*8^Q_T-1T&VRA\1!4JIO)HL8TB'KE^GIV:2VZ2^
M,RK*(.,?]@Z59<)5C##2%N.)0H+&/9V2@3KDYVDN1X<JVSQ'Y!.*CCT$+#+Q
MC5MG_P!$A`LG"D*;5_[H4PK_`-VQX$2'U:(Q^Q=&_'^(CY>?I12M@;Q3_D5>
M2#B74H7>-ED77P?\ICK+"*8.'1^"_E`?Q_%\GLPV1ZO8"RMX#P'@/`>!YC?W
M/2'F>S+1OO-F!&%\.*V/[V/>IM3!&RMM-OBAHR6PA0IN5?&1CUPG^Y7JE?\`
M3(33_3(<@:[Q1Y:U!9\8-./<EQ2HV-)D&7K)+P+6LZR8!*$H`E)&O%X%CCF6
MGOURG5".X4T2YG/PH0%SWP'@/`>`\"L)]F[GGM'BQI7B]HS2&Z+=QHV+R?WE
M'1$GR0KDR+%0>H];5\B(K]Q-OZL@%RC59D6K^V7AX-T8AMR(5E"\YQE.0JI<
M^ME[OTHDQ/4)VZ]@O-:G5K76N"^7EN!Y`V2VUK4INPKM4Z/J&%I%S'-K=MDC
M+ILA;H9#<7'I=C_R@`BG\J+4QX'#+92N_32/">^<K^17*+LFHN3-BT#4NI`&
MN9UGB9H399^W[/K&\T*_:6L-O:VM.VE2:Y\T.S#_``,_&0V4XZ\QAU#(=L[*
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MEI3&LM6Q^J`J;HG8,/5J[-PL;.SD\Q*S&96NS9SDZX]-?$Z^ES&'&1FL9QZI
M]?`BZW;]7+A;K34^V=D;+Y@\W=A4"CTB8M9]*VCR,:K.O"(NKB,3SK=_M,-J
M6^RT?6QB(UQX@T6%)4"/GY4C.N,X4H(YOKK=0,QOB?@N9\]O?9K7%W7NV`K+
MQ_K.M-QR@-8/V+H?>4N)<*+L+6DA208&Z:NOT#"@%#RXC@1)33KF26FRWG6F
M`]!!W\S\D7X/QOQ/]?\`-^7Y?R?_`%>/QOQ?9_I?^M_Y_?\`^X_T_GP-3X#P
M'@/`>!7K[BN?_'#C_O;CYQBV[U@7/LJV!L;7]QVQK^IT[4]'W+*52-K\LF#L
M1(-3LU=LLHRYAEA+I!0K*6T,^F%J_GP(G]N?8&XC<7:+IV@[TZ!>17'_`%M`
M71JVZ%I^T=#:TUG38G8%,DSK`Q8-6P5GJ$/#BVJK3%W(-01&-8)"(E5NXRA9
M&5+#E?(/O9X_1ENH7,;E/T%<Y(:X:\;J5>U3OS=>GH^+8I4B9.R$Y68NH7*Y
MQP<55"I6P$MNL/!Y;)D'EX2O"_A92H.@]@=S?4SO2+N','=GU]>0^SZS<Y$F
MT7+DC;^+^J-A52RS-?AW-6(,LFS;`=_CQ@-<$C6HAG+QCC$83\N&FVR4YRX'
M8FG^P?HGY6\JM`ZSWETT3VE['S!R#5]6<@>2''FC2,)L)P%U%(U635K7!E6Z
M>M@]FD!685,_'N."@OI&2\:L5O!#`6;=H]1_67NN]739NVN#W'/8.P-@KKKE
MLM]HUU$2<[(YJL?"Q$%@8YYOY(9L2)KP8BT@_C)(%:RT]AQM;B5AF+IS3VL^
M/VN*IIC2]"K>L]3:_B40](I=4'_!A8(!PLTXH,./PWG#"%FEK?6YEUQQ]YYQ
M:\^[.<J#L_P'@/`X-LK7%&V[0[5K7952A+S1KG"2,!9*K81DE14Q&20KHA(K
M^,I4Z.I;3N?8^U[7V%^CC:DK2G.`I=])E9TNN([O=\\>ZN=J/24_$[(T/3.-
M5G16)2U56\Z<HVS+O.Q^K;:)7Z6S)Z\""OKK($84G,J)AO#\D\XMQ+W@9S?3
MZD,&]/D>Q\@JU1G)K=X+GXZ&$OI6ZU393VR"VHL!QXS*9+"L*=>.<^!3:</I
M1A`PX6E_`Q;YL\9`N9W%#>W%>2N)%`B][4*1U[*W$.N15K.@8F9>&Q*%Q\'-
MNLQI$BL!IQL=U:TJ$>6E]O/R-(\"I54OJE<L]=7V_P!+U]V@G53C=LK\ABQW
M*!UHJ!Y4.1#E'LD-_BC]NBC&LFTB9G["I,_",SP$78!L8*(82:VUE(2-V'ZX
M507(2X6O^6$Y0->(X(7;@72Z*-H37;I,#0]CTF%K-RNEPN]8FJ/9]L7"2FHY
MZ3;=G''5M?(R-EQ;3*\OABL]]4$2_;PUQN;D=SGG-X@5^JZPU5?];0VF9'14
M+;=*ZVU]7-90M!@[)K3=;<M5$P$!6!#`76F%H)DVU+-;?9?<:\#J38?`G6_2
M/P=Y4<(=>;BK&\M^]PNPV=)<==3S)M6TL]K\NS`6ZM,F1ULMNP9J>GHZDUB<
M83'R4BH,(BU,1X1!`JY5+J0MB\+N/^.*O$_CUQSS+CV)_3&I:1KLJRLP**T[
M9B:K`A0[EADH1N9L209F8_$P^:G!YF,E+7G#RT^F?`R=\"MS]C'M\MO6_P`<
M9+6.F*_MB$Y";UHQK>N-^0&OHJRZLT^\]9(^$(S9+#,V*&%B;]8(1$K_`(_A
M`TCD4H;!;H[C;7MR&%_0CWKTNX:^BN,_.OF_';PY/WCD6'K#CY@O7TT'?;/5
MK95*K:6'=@62%`*J+282V621B/RS"V4-JBU#L/FH2RXL+A@1P4F$)(QI8LA'
MGC,&@'A$-%A&AE-)?&+$*86XP2,0RM*VW$*4A:<XSC.<9\#5>`\!X%!'[2>P
MPHWG[Q1AK*N0N>MR>+NW8NPLTILU-E,D#]E6FO2M-A;"W7=C4RGV&)#-&9=/
M)@EO!+90Z6ZAW(;@X9=?4@B:R"7V.!P)TD6S"VOC;6R(B8BR!%5J1K86[0#X
MN,4[#0XF(]B2&5GVMH6[DM#K[RL+=PE`7-/`>`\"`KH5)8E0.U^QCO,FMV'N
M+YC&)E!94"2"DTB#:YBDD!ICXR-:$::_`^%2<I7\CC:EXSC"O;@)]?`BC[Q4
MQ;O5)S-'FE-LQ9NO*_'FF/.+:9C&I'8]*!_<.K;?'<^.%61@M24JRI6&?;A#
MF<^Q0<JZ;S8TCK`X/"QY;YOX7'37J"'7F9IG"25`O-%,-M3<7%$!($.'>9P$
MA+C4>EO`[3KS*&GW0DR\!X#P'@/`JD]:>S*+I/L:[_M[;HU-%UO7.NN3<J5*
M<U!XF(+BX>/9B**(;QZ;"KL&Y?9FQ-LNQDL0.`P?AXY?M=1@Q]M98=&]Y7*'
M07)OB%K[F5U[\\^0B-KVK9%,XRZVA^+V\K7KB`MUJN]PE`*D1M36MDDZV='T
MZ"LE=EQ7)`"+%DS3CA_>4Z*(EG(0]<%N[#M"XR2E9V5R?M-9L/$#C/N"F<'^
M7-%MTK)[BWK&W%=LL&P=F\A65YFIK9\Y8HZ.K<E%X(;GO\'%/)&88`Q\F%8"
M6KL?L<%RI[Y.@S<^C,V;9.KI?6C.YQ[12:U8RRP-=$;#4^'<9B'5'C3L!"!%
M3@&)%9HS60&W\Y);2E*D^!9H[+/R/_+OYS_B?O/R?^TGD)\7^-%.!3ON_P!J
MK3_][2V2!76"/3U_NPXC^WU_GP(E_J>HC$]*F@,Q[Q;I"]B[\7,))90TTQ)_
M[LV5.&05H2E1`GZQ(R_>KU5\RG$^OHG&,!9#\!X#P'@;?+FJC8J3D4-*>7'Q
MYIJ64,'E*>4*,Z^EI(T6%)29"G,M^F$##D/KSGT;;6O.$Y#S1?M_GW,CM#X\
MDZ_G#0IR?X55H81D>7Q`F1\9*WW;B)4*13,&1[M?9D8YUSYFC6@E*0K.%I]<
M^!,/],N4)JW$7DK0+E+QX$R3RADVJE7WC\$NEDQ.J:&Y;G*^0+-'U\X7\%B/
M<=_`89<<PSEYUPE'Q*9"Z'X#P'@/`>!7Y^P?RMX+Z1XZZ]TMS>XK;@Y=PF_K
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M<K+K#TQL^\W>T!AWO79K$E^++@"C,G/"@H6I]+V'77`L2<@/J_=0?)"TQ=U7
MHR9TD.+16JN'4^/,W$:KJBBW98N:Q=9&,CJ[(KEKCAD[`7RDO/!_AM(3^/E:
M<.>!,7Q/XJZUX::4U_Q_T^=<EZVUG1ZC1*K%6ZQKL#@0-3C5`.2B%9%$8&F+
M04ZX=*J';9&?-<4MMEE.?9@,E?`>!YXL.'^9W;=N&9J.R=(N]AG5W&PC;`8+
M,0$8YS:TS(1,T9+G2?S`2`D'"K^-E#JL&+>=S\.%MM-H#/WNU'[Z:ESHI\#U
MB;NWJ5JO9-`B[S,T$4OCB-"ZQLI]ZMFMY9R*BY&/7<9F@C1!P<W)&DL2>(K)
M?YA3K2A&LB!*=Q8[>..G,+6V[>'>K^1TS!\\>.NF3J-?9>T!:NKT[9MM46OR
M-/V)LG5!=_,D]2[$B*_>J\0:82ZA<4V,4P^XU^,[C.`TGUHPSX[JVKL=*21,
MS)Q_)GF$#(2YC48P5*G"\C-@,ER1+$)C$,P0<0A3JT!_]*E2\X:_L]O@3]>`
M\!X#P'@/`J`=YFT]J\<>U+C;RFU3-(A)WCGUC\SMN.,N@0)>+?$U.9"%G:2+
M(3T)9A:Q)3`]C8P-)8CR5M$?&C"%I<<3X%.O9-BY"]A-9K'*OL2YL7BR&7A&
MQ*WQ6T-7:\G<FVKML&5,G`XJ(U?I6D6$>$U7")V?.P8;)EF_12$S7TNJADR.
M(L490<PY6;NYV[BW>KAEV0<OA]<P'&:NU>H;%78YRR[8HD7=:G6(,R+E1SJ6
MU=&K-MS8+`+T:2X\,N&CYD)/YOP.C(='#+G675'W'\EN'0&U:5RA=I?6EH_&
MXS-'USE?L>TZYD#N+L:<):I^T6[2FN879$<BD6>+I@SIU9.D2DY.#>2R/EI2
M2'@[AXHS=KGK#]9DB8V8`2X/S&YF"Q>QG)HMV-+I`6_];1=/K%1HLI^NSJ^*
ML,8"B-CH0`2.-CH<\5+@3(F!FU!Z746N3<C@5S0X`DNL5A4D-%F$2$<.;EM.
M2603BP8PDL5MWUPAQP=A:T^F<H3G^,!K_`>`\!X$4W9IV2*ZV82&VM:>-W)'
M>NFU4>V26R[9J&'IN==Z<6%/5&NU&5V-8+`Y&3`9%TLEN8`9_#*?0"`R6<\(
MXECWI"#'K%V3U25'7'/'27$SD>+8]N[@FN1&_970^QSZ=L*7KUX#XZW$BT9X
M];1KZY@:]:\@:_/K0W8DGOGEM!$HR]G"RV_`R3^HNJQ174_"5:4B%X:B>1&_
MASS<3$63^A-0[K^2!A2HUEY1;+LLQ.OE(]OOPA+7O7[</M>H6E/`V"UVNLT2
ML6&ZW2?B*K4*E"R=DM%FGY`:*@Z_`0H;TA+3,O)F.,B`1L:".MYYYQ24-MHR
MK.<8QX&GI-VI^R:?6-@Z]M$!=Z+=8&+M%/N%5E@9ZM6>MS@;,C#SL#-1KQ,?
M*14F"0AYA]EQ;;C:\*3G.,^!R?P,9N5O,'CWPCU-.[QY.;``U=JVO--I+M4L
MR00P;+DJ7B.JT$``V3*V"W2S;+K@D:&P^42VPYE",^S/@0F=>VH=X]C?,R6[
M=^76NH"IZ7K$)<-5==7'Z_56;D[!3]:N343A/)X9-G77":G<MK*A"7\8D:_D
MI^+,#6-D5`K#I(63/`>!%KS"B=)-<;^2\CVS1W&+9G'T&\;!M.EJ@\$F)FE:
MMB-?(+@:>"Y>IN*/F.1QX\7/9;<K18Q);9N!@\)Q[TJ"(WJ,Y/\`1AS`V'J"
MVZ\XK:<XE\Q(NFLZRUSHF]TJOMX83J::D),:8U+;B:M$5R\;1B![&VB0D,I'
MNC2<98=:6PPDAP+6PXXXC#`HK#(PHS+8XPP[2&6!V&48;9989;2EMIEIM.$I
M2G&,)QCTQCT\#[>`\!X'GF?9%J&C]*]E6@FJMKK0^O-=[*XL;NG-OE3%+56$
M2=T*VE8+-9]GV!=7?H5[L%UKTR%'V*$="ELGRLF&A`.</D)<=#*WZFER"M9'
M-6^E[`G[?+3&T>.PK<R[8)R9DY+\NF[E&S6K8F^A!KPV=\1D]B:):"E"GE)#
M046\]AAT+PW@5N>9W:3VXZ0Y:[CTIQVZF;'OS052D*;%4;DL,!NDR`*S(URH
M6*YSDM7*E0I><N$?6ER\@"D:N,D/O%"8P.LMS"F%!F]I[N@Z[[H2Q3KGS6XP
MPFT'2J?'HK>+V%5AY:<NL-$R`=7IX]OEFIRV3,++22HF00V.P2++M.!/BL%-
M.-8#&7H"<JV*MV?`Q)H)UEC.W'F4+:W1Y!4Z0E*YJN$P2,VAU]UZQQZ0GW,,
MO>UM##^"!_3WLN*R%@+P(H.\A1:.J7F,\$FM.$CTBHE('N%@EJM7#4";4H1+
MT=)6&$G*Q(Q29)AI0[3B9*.;^9Q&'2AVLK=0'..GA#K/6!PB'?BZY#.B:&J8
M*H^ISD/9()O`/Y0:7Q9N!)-BY`DU#&'RE(>>6DMQU+JUNX6K(23^`\!X#P.E
M=\Z%I?(NE#T*]S6SX&&%L$19V#M2[=V7I6THEH)U;\9G-PU5:*C9U@LD+PXH
M1161G7$(4XVK*$9P%87I=!@]=]L_<]I>GZIW#9JZ+R#5'E[:L^_I^VU=44''
M5:,F("X5C8%XFY>]["'DB79/-ASDZ80&6X*\MA*FV<AFKV)_7JX-<DN(VT-6
M<7N)?%72G(F5#&(U1M1=<F-="5NSN2XO["8M5BUC%EVR?&9A2#'60RF)`1\]
M(_Y#2FDJ]`KOQ'T^N3>LXZH1#?.K4VO-8['U_%P/.*Q9E;6@R1_"OTC:SH+5
M(+U!J[$SKL2'AX(EX:Q3D=F2EPG7GDLM-#)0&9O/?0%/T%WE?7*T-1RO?KO2
M&LX3758,M,O'-2!,91Y2Q,5?\P@7,.B3FC$UQ'QY::]I!OQI4A:G4H<"SIVB
M.!,];_.TB0%;,&$XF;Z-RPZ4V$GYPM:V(L1W!;HA[8[@Q;*'$*RRYZ+1C^/`
MBY^J40"_TF\;4""OCNBW;?X\BX\@9"##O]ZKH1@H?([KCCC&`GV6O<]A#OO:
M5CV^S"%*"QIX#P'@/`>!YIWW`9"O"=GNG0S&68T^P<1Z-6I$^9'.CZN;6Y'9
M6UWSY21L0?Y,N.9%F""LI1'BN)6/EU+KB<^K;@2K_30+@X;AWR`@<%U/,JGF
M.>"5(24T>K,XTG2H"X%6NAWPD01TXG\<W).12'2U12G5/X0A#"5A=62UA+KC
MOO<SEQ#2,MJ7G+2/BRYG"FV_^5"U_+_=G'\JPG'K_3'@?3P'@/`>!78[12_D
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M#J6SH>\TV8!UQ-5!([,%-9=<E7#V#B11D,CI6@,IKYHFRZ>X7=X7&FR;:O\`
MO@W0/9=U_:SUC?=EER5FLD'&%[@'3'+K(MWM%X9@I#`-C6&^MIU.9!K'_4*4
MVYEAH/29`:6P`$PZI2W&1!FG%+2VA2EMLH0M2D-)2TA658]<X3C"<9_ICT\#
M4..):;<=7[O8TA3B_:A;BO:A.5*]K;:5.+5Z8_C"<9SG_ACP(I^P3N*X3=<#
MNN8_E%<-FT__`'2A@[/5)*G:TF;3E0"37W&`)0?`;I<45*M1)+;C+HN'&FD.
M84IAW+><A(3IO:L;NO7]=V=7Z]:(&I7.%K=HIC]L#CXV2L=3M=4@+9"V%N)#
ME)(V('?8G?QE#'I%.:)%=PMA*/C6L*"50CYT?O:[4;#+%&I&ANPOKB%DVH0?
M)P*8VR\PM5"U\XYL^9B7&'PX[#3"G<.>P91+RFLYREEEX)G._+A=R.E[9QCY
M<<$=<R\_R)TA4MBZLVFN2MMF<HUUX2!T^R2=YH&V[5<+-"4QB#GF):0',9><
M-M,H\>TL-U:A7"!PIR=4?%O;=SV;M?F#$::Q3.&0/'#G4/*[(SK>`MW&_7]H
MB=0;`LM;U++6?=-@GPK/50I<Z%'<>O3Z<&I5^&2MUG_J%A>*^JF:1)=->F9$
MM,:@L_;_`"5-+1#B@`Q""2MVW`AY$6#%-,1@4<EQS/P-#(0PVU[4MIPC&,>!
M8T\!X#P'@/`>!#AS]ZL;[S(Y&T?D?K?E)#\>;13N.6R>-;C)G'N/W*7)53:M
MBCIZRRXDG,[3IPU=G`DQ++,82($DP%3I#N"%+<9_'#!YGH)Y"UK;TCR+UMS^
MU9KS?<G5)6CRU^IG`Z&JJ[)4%4ZM4FC5Z:BH[D<1`AITU'4J%+ITG&@A3L-)
MQ(Y.37UY>PZ&)EB^KWRUL&R]7[OE.X*S6/<FF;E;=JZWO-JXF4.7E(':&P["
M_=[Y*%$EW\M5BA9V\N*/R%)(+$;=**6@=M1#V'`R!5U#][`]>CM>B=[48=K:
M*B1:^-79OA[K:1'+KS1C(BH*8C3<GAS$0Q7$9:0.0MQIS.,#J3AG^[`8`<,N
MC;MPK_.#A+LGD'(<8M>Z+X4W:ZW*KS-,?<NIEHLMINLA:MG7U6O1IJM*@K=R
M&?6E\A22W(RND_CJ&BV6F5B^!>A\!X#P'@/`@$[V>MSD%S^A>(1^DYYFZ0.G
M.1--,V_Q4O5WLVO=%;SU;;9^$C[E*[2LE(,9M[(M)B`584D$<XO]0?(_BCN%
M9:;6%8O>_729U0G=:/('=TUQ*USKS5[O/&D;!O>GKQ+?Y-<([=F-FDZBD(F6
M,(K>P=TU:J1VW(J!'PQ&+DHQA!#DF.Y%*4YX$XGU)(]T/K%JI4'-#-4PK=._
M!VX%V/+D9>3F<IU:0]-F6*,'K4&'F,+9.%2P;'R1SH[C.&I!#3.1L!:K\"*G
ME[V-</\`@KR4BHKE_P`RA]5UG8FAH[_%>/D]J2>GJT=*,7VT#R6UE;%K-*L4
MF_+3@3:8)-?=*:&2T#DCX7''DJ0'2,)W^='M`!148'F;J*CQ\,ZZ&FJ`:_V;
M6QH)]E>6B([]"QKD-J(>$=1EMP?XF\LK3E.4XSC./`Q^V!W]O[)V?-Z*X$=?
M'+/E'NV/(:FM13.PXMKB]H3<-+%B1#[I>JE>MC&#V.>AXBN2V7H\1RNJ(E,*
M;+&;_'3@C`<]U#UD\A.6>RH??G;CMD[8LI5]M@;UTYPEI-S2UH7CI-U.?O==
MJ<-)"5W\>#W]`3])>ASGY"<`%.'F!"V&\9$,.9?"?J,C(Z%C8^'AP`XN)B01
M(R+C(\9D./CHX!AL4(`$,=#8XH88S26VFT)2A"$X2G&,8QCP-=X&$O.CL/XF
M]<NI']R<J]FB4JO9D8F'AJ_%BO6.^VJ5FGR60@ZO3(S+DQ*X2V"2\\_[$"L,
MC.J<=3[?3(49>32N[+O]WB[R5XD:EL-2X>:4N\TCB]5[Y;Z_0*&7;ZQ/R&N)
MK9RQ-@@BG6._$5>2?6\XZQ$$P7Y+J(M2"A2E/ABIM3H^[Z]=&USD0[H`<;9^
MOK?7#==F\1MLP(VWH.5GB[+8W9`+$-.2``D+49QJ0(,D'<Y/:/M&$MK+$4I`
M`7`>HGO"U]RSH,)Q\Y5VBIZ^[%:1:K;JNV:8';,A9G<DGKPB2!D-C:VC)40*
MN'"2R8(_)`,=*GY9*CB,H]B7&6,!8;:<PZTVZE+B<.-H<PEUM;3J<+3A6$N-
M.82MMS&,_P`I5C&<9_C/@?OP(!.R/N"H76=S@X]1^Z)+<UOX];>TE=8:;JVG
M*92KG`ZZV%7MPZ^A9#;FR"R1HV\C1M:K=L_#=!B9(YQ67$^Z,P^H=;X5@_L:
M[CJG*#EUH[<U`DM$[[TE8=&W&IZ$LFJ+]#3=GL]=H6R7ZWLJ/M(=TDHVJC3V
M=U?*W6[!2Y9$E&QF<O$@RJT.!L!F9]5-AM1_/375;J^TP8XFS\4[%FY6BZZ6
MVM%Q+,(01/:_J,Q7::!,ST=//0EAD'SI)U)<4,H;Y'5Q4DU\*0O5^!5>[A(3
MJ=X\\H:'L7GAK3EFW;>7SM]CX._Z?Y3;ZJM<E9S2.LJ$U6H7.M-=;KIT1"$7
M-4D-6XQ2`6DJEVD.&?&,0LQ`0(];W7SU2<]4;"X2Z=_[]J!MZ1LM-Y`PW(S<
MVCM8$3>I*R(Z4J3U9$3NOKS=`8Z!V<$T<RWBXI<`8FZ]^8VEPYX-MP+'?UB-
M4OZ-XN<V]/NRD_/M:N[,N3VN1+%;<LYMUB'I(&O:]^_M61)V9`58)EP%11*F
M$#(4X[E64N+RI]P+*G@1&=\<4Y-]2'-6)0AUQL[7]49,::'))0[&?[IT)4LR
M8D..EBF(QV,2\DM]`SN1A<N.^W^SUP':/3[#UZO]8/!V#JZZ>Y%1/'NC1V7:
M(.2+6W94,)8\^ZPT8XX4J3<GFR<R+CGL4[(Y?7\;?N^-(21>`\!X#P'@5R^G
MG6>J&>P+O%W`]1JHO;X'8%8=<A;2_P`7?1:6:%9Z-K^SET`*WRF$R2XAVV1J
M3#(]EIH5)B4/(<?9<8RV%C3P/@2**8UE@P8<MA6<9RR2RV^UG./Z9RVZE2,Y
MQ_P_CP*@W;TZY_[,<=&H#1!`&"XB>><-CUU]B3^*+M=ND<18Y5G=;B6`I=]A
MMHK"/^N<9Q[`\_DY;2L+"G:%*DP?6[SRE@\$*)!XB<A'F4BMNND95_M;9T?Z
M3;"''EJ]%9_A*<Y\"++ZHP\@QTG\<EFCO,L$WO?Q$6MU\%Y)4?\`[RW!C)#"
M`Q!G1F<2#)#?QDJ??][:E?)\:FVT!8Y\!X#P'@/`\T/[A>*!_P"930F+Y!W4
MTLCAQK@VI3$5<8JN1<9F-VSL]=@$1$RU;LB+%F6BOE:90R[&K8D,(4K+S?O3
MD)?/IK.UI[B%R*1"4JTN5^4Y5S4S7)B6`A).(IYL)IW6(9(#\W@K$JU-2/\`
MD!+0Q"6/:0,R[[OQ_=\2@N@>`\!X#P'@0<=K?`7F]RHY#\&^1W"C;7'_`%3>
M>&:MZ6&,)WM"W*QQ\O;]J053J\-^+#58%\=Z.C8F*/R2LIS.$+?:4A@CV*;R
M$&<QT)]K+<L],B:8Z#[';)*U3UL,V5(<==@,7(6PR4BS:QK'A\NE$!G&AV0I
MY+#;P[C>4-8_)2^TK",`W3T7]Q&_K;.[2W3K_I)VWL:<"AW925M6N-U,DR:X
M2-)KT77`W(R`CH^J1,?%PH3W_L(9`;?=.7\N',L^!E9H#B+]E_BMK:(U/QZ;
MZ9M5T&`A/_856:O5MPCM-E*EC3$0A,D362922;#_`&I#C))3[^&D*^)'HGT]
M`Q/W%U#=[]RK6\JX13>LIZ*Y8\B=+<AN3,KI:Z;TJ^SKO?=2;-'OD?98F3VO
M^XIM<=?+2MPA@,9@=#.?C8']<83D+R;.%I::2Y_+F&T8<S[_`)/5>$XPK_4^
M-KW_`-W_`!]J?7_PQ_3P/IX%!;[LFJZ)$_\`8KO$E^S*O=DLFPM=DE.V6>E8
M>`HU0"KUB=:J6O"WV:2)*RDO9_GD3<N#&G9$#96MQAKU8#I'K?[O>U;6]\ZU
MF]U[7X\<B.'_`"0VZOA%6J9"150H%SK4M5(K0]?<LMFGZS18[,1*4-O8\4H+
M"W"V)C'[%AQEK*Q260_%>-C!^\3M,:1+DUPQSL9ZZ3DC&@6!\E9$5SNU5'OM
M-2L`0I\6/FA#,/-Y4RM/PEMMN92TV_E07<N6/+?A%1*O;-%<B.7.C="S>WM3
M6`0$&_[.H]0M+M/O<7-U-NV0,+;)(5<F,@C!*6%_"XRLD=3:L9RE2?`@9X"\
M-=I\(^@GLSTUL^F?K*A.5;G#?]$_C[`IU^L%\T#<M!L8H5PF;5K14U6')>TM
M!D/(P`-C&&%-Y0PO"DY6&4WU8$O#]-FD(QPG!34'M3D="!N?KB8G_HX[=EQ:
M9Q^`>RQ*#>N?7/L,QDI/K[7,^['I@+%'@/`>`\!X#P'@/`>`\!X#P'@/`>`\
M#:Y:;A8(99DY+Q<,&VT\\X5+2`D<,AD9OY2'5OF.LM):8:_N6K.?1*?YSZ8\
M"#7M;Z?."W8-7KER#WHK8EGM/'?0MZK%!K=&VP96M>4TRGQ=HNZFUU&"96`-
M8#I*09Q(J<5AUT4<5O*4I;3ZA69Z#NB3COV/\7_^\GD[N?DF-8+G>-M5FQZA
MH=NC=75PBQP]AK[T5LF&*KL>U*,CNPA2A7Q'!\L/$N9<0I*&VD*"=M'U0>LY
M"DK3L3F_A:,I4E6.3)B<X6G.,I5C*:@E6,X5CU_C.,X\"&3[6<?JEGL"X2QF
MZ+%LH[645QNJ3MYI5!`$58+E1(;DP/(7>+"DR92IQ@<W8*O#D$"N8DQ"$2D0
M$P,TXLS*F@L&](W&3AEM3JPXT6O''#7-R@+PYMNXLD;KU75+;<Y-R;V3=*M^
M[M;]KC9YLJVSE,B`AYHL5YT>3(2\[EU_+RW'`GI!C(V,!CHR-CP8^-AQAPXF
M/!$'$!BPPQOPA!(X0=MM@(84/_1;;:2E*&O[4XPG^/`U6&6L.J?PTWA]3:65
M/80GY5-(4M:&E.>GORVA;BLX3Z^F,JSG_CGP/IX&'G.[FMI'K_XT;!Y([YN0
ME-J]9C3P*YEZ-)FCK5L`F$F)&I4F!A120%R\]8RXE;8XZB@VE^U7R$,(PIU(
M5^NI/J_&YM+_`/-?[9]/!;7Y?;LL41>]9Q5Y'4_JBL:57KB1J%2K8NAIX9,'
M$".1-B=^>.F(^3;_`"HP&8CSGEENOK#(SO*Y[\D^',UQ(X]<?I6L<0M6<C-B
M1=8V/V"W&GAVW66A`VD6(Y=``HKXT9"'7&TQ%?=*:<7(,+:#96AO\9QQLU@(
M/.I?G!N?5/,OCSH#6?<98N4O%[<ST[-[$N?/KC?M35U>EKF#+:OB([36B;_M
MZ_E6\G;%KH$K@V'8'G2(=)*DK>C7U%86L++_`&J=+W'OL=K4#?0%%:5Y=:6J
MY(G&KD+1Y&4K!VN9\:U0MW@BIP"LX9798J&G8=Y0;;B%O1N9,QX/+1#WR8#A
M_1WV-;7YR:EV?0.5@(=-YC\6K].ZEV[3B&@:5:;?"`%LDU3<\WH\AMNTZK39
MQ#,`9:*QD(LT`IP17Q^K3(3H>!12^S)H_@O&<N.(,!R'&V-J+3A6C><F^+G:
MM`A!%WR?W!(RE)LM="`'DPK##Q5HVUL@$6(5,2XXD<I^08'64VG.%BA6TW_Q
MGV-P1W#K6`G./QNL8[8@+FW]'PG*%K5&\+]!:LD($FIZ47LO3VMVW).K[9C!
MPYU<H&\T,*%,23$OZCEAY2H+*/TX()J@4SG.FV97#V&.O_'(<H.(`D9HY29J
M"W3AEBP,1D(_^L'((?\`CRN0PB7'(%4DAQ#"Q\.!>G\#"OL(U;QJV3P]Y(KY
M4ZF%VWJ.M:'VI/W2"#C@'+NY4:[6W;G."T&<)>!,K]I=>J8I`#[)8OQR(@KJ
MG$Y:2I(0-?4RT)2H?@[<.5$$)7VG=^;5N,9781W6]/A;7KNHZN+'UA"02+_"
M8_<V$&S5.F0QTFT3C_6FVR#7''WR775!W?T#ZWO,5$]D]D_RO9D0-GM8Y8UF
M/J4]<8R=UY)UZ)V!&S,M;*]!EU0MV"LYI5AD`#B176D2GZX9#F6\LX=0%DKP
M(@^^\6/*Z@N<G[2=<K(8>L8*75/-),<5&/P>R:1,A$Y'`')*-;P:"WA8Z4?]
M2G.6E*0E>5)#D_2O%0+W6IPZO`+$R5-VGC]1X^3M=C@9*L3%NBX*2M)<).-P
M4I)2)`5>F7[";)1*E?"X_'2+3JVF<JPRT$JO@/`>`\!X$"O3H2[GECWH`%NO
MK.'[-9@S*"I4Z3(1&GZAH:(G./[E0HP>1@LI';9_ZMAI.&"<8PPQCP)ZO`>!
M4:[:"91[[%O2)`@0M:DAI.-DI*4.G(2+.+BP(*SWS).(N9/%>?ALG#23B<M-
M+1@TM`J<^KK;.4A/UV@L9*ZWN>(^""A?EXB\@T_D!"B'%-8_VML^<J8$/DH<
M1]?ICT]'"64_^[?\,A&!]5*.8`Z2>,#[*EJ7+6S?TB1A2!TX0_C>5]CO:C++
M#*UH^&/1GU=RXYZYSCW>S"4I"Q5X#P'@/`>!YD/W)EFX[1-'L0XYT@6;Q`IP
M)T6`SA+\D&1LW:F"8U#@+2CGD&B8RE65>Y:?7^S^,8\"<_Z7Q"'^NO?;8@Q\
M>@;EW9\%#E?O2(QQEW6E!=93%N'V(N+:DV<NMME+%CPO<TPUA[#[JL.MA</\
M!X#P'@/`P=YP]CW#7KDJ-.NO,#<T3JJ'O]B=K50$S%3MILL\:((HV3,C:C4H
MV;LYD+"L_%@XUH18P;A(Z'5I4^UA01D._:;Z3&1?G=Y46%LC#[P[L8YH3>[<
MD.I@-)2LD,.:\0TWA3V<CXQ[_?@A.<9QA&/?X&]\T?L=\`^'>F^+&_6#K%R#
MUKRO@K'8Z:C2LI2"[]78>&#$4#(VO7UPLU6F8D(V;47$E9?4R]'28#X[K2G4
M+0@)5.%/,72W/7C5K#E#H6PBS=&V1`!GOQV#0B9RCVA`HZK+KVXCA//HB[A3
MY)U0AH^<^F5)2ZWE;+K3BPRJ\#2FF#QXKQA2G$L,)PMS+3#Y+F,95A./8P,V
M\^ZK*E8_A*<Y\")V[]W/7=KSEB#PZM.]ZJ%M`O9%1U(22U,Q#\%!7^YQ5\+C
M(*R.X.0?$?#-4IB(?(4PL=B0GXK#BT,DY>;"0/<?'?1/(,&!8W3IG46X<U(@
MR4I6=L:YJ^Q@:O+G-#I=DH@2QA%?AJ)R&Q\_X[C"WT,I3E>/1.<!!5Q,T!H?
M<W:WV7ZFV5H'0U[U5PEN?#NZ\6HI[C5K:!@]%;*VGHB+LFS2*/88NO`J5-24
M[58L]33R7WQ7AF"VW\J4C*`K]1)C(W=CVO6-HE4O)1W9IU7PPQ",R$8ZV-)<
MS]<Q<F"F+:$5'%IB\AML9)>SA[.!_>U[DOO+2$SG?/U0<E.1;.F>1W7]J[3D
M/R.XU\C4[S@)EU$?(;(O6%@-7^1D2IR\+&KT%`P>SXP@O_$6F)4.=D3<&8PR
M\24TL*[74[S+[`N4U2[<:7N_FOODJ0`XR\JME;BXY[0U79+<"[&,Z7VQ5R,4
M;:SR3">-UZJ&R;#%,LU"/B8P>9"!6RSC"P$#H"U)]5YDYOIET&_(MJ9,D=@;
MWDWVGI%4F;A9VU[*]E^1?===+;-/SG\G+;^<.)0\G^/;E.<A8H\!X#P'@/`>
M`\!X#P'@/`>`\!X#P'@52?L`=3=1[(N1G%L`OG!H;CU?R*7<*;3=0<@K/8)`
MG9#\E8ZLP%G2FO0;]3A&K`F6+2S($1PY,S*NDBCN.*&':8P&V<4?L)\<^9L7
MR7X(OTDFC;:I/%W=P6O;+&FN-U3?TGK:B6Z%LL=3*K9L#6NAV)49!9.%A[":
MZ<\PEST?=2A#SP=+_6RW-2.+_1<CDC,TI^=*I6Z>12K?;0JJ9,2M6U[$KKMM
MN#BW*U%RMUF8UZ(J@Z`8\`8QPZ?6$PXE@?#I8H7&X"9$L<%"V$!!+8,]$QTR
M$V:PL4Q`DH&R<,@L5?\`>,2EE].'&\_RA7KC/]/`I!_:'I\_?N<?$*FP>O:3
ML(JV:BH5+CHJT[1,UNAZ5OW*>'HXD>5+11#,A67),JP,,1TVK*4`^\UUO*WF
M$-J"Q]TDU5VB=7_%RCO595&>I@.UZF[2561JYYIKM<WKL^'<JG^8,,#,VS%=
M4%D/$FEMO!^&?G]J?D],!*IX#P'@5-?M:<BIC4&J>!=$D9Q2-([.Y90TKO6F
M`T:%OLIL:#U!*42]0M+$CY$0@UE<@2X][F1W&4F>Y##_`,C*\MJ#G-,^U-U(
MTFN1],@]=\J]:5*FM,U&F5H3C$[$P0]8KX8@,4W68F"L#P41`ACIP..(I`[@
MZ&<)RRA/M]0@T[A>\3BIRAVYPFY0\<:QL_?#W'.=MF)#A7R7TUM>I:<N$A<8
M61&$W!.%U>\/U"TR%-='S".Q#X)B)`22(;<6\/[FT!BE_P":YK3L'VSKH?M9
M9M&AN(/%J[5K8G&7BOQ(XYV`D($F'J:==CQCM_BYJK62KP%5?K&)2,`D(];R
M'))*4N8CV,1[X6K`/M?]3+KT6,1(\H@!2U$#DR\AQNMZPHI0N!,-KD\1SYAC
MJCD$*4W@,<G*<-+^1+?JWAP(]>*_81PZY1_9!HF_>.'(#:&:9R*XR6B@WND;
M#KEETI59#:>LA8^D::A(^O61V*=V=-2L%,2\@%\C12P\R.,(88=:?R@+LJUH
M;0IQQ24(0G*EK6K"4(2G'KE2E*SC"4XQ_7.?`\R#[0^\.1TUV)UFA\E:3;=1
M:_J\;.(XL7K7Q\*&_-:@.DFF79JP%0\=,R-M<E-Q42*F78<XO\B(%#0X.TP[
M)HP,$9>Q[;S,W=`Z_%YUQFU;G>-8:-CK'QJL.]1IT&V6;3_(:\3%OLV\S;*3
M*+D+G7A[&?@0>;D390'(Q@D;AA3GPC+"T]]-E,0C/9HB$CUQP3=TXL-O)=+D
M3GCY=-(VEF=G"2I6R6TU9<_,J?,=2J0>2A3_`+4I;QC#:`N[^!7N[$><G,_4
MM\V]IF_\).+UJX0V\:1I'^>;DYC:]U-?]_:J-HU0/W?5M8:9M,S7B+W=$5FU
MS8,<`S-@?F/`9P\L52VDO!V3T<[UZRIK2-[XO=;][N<O6]&W&:NMWHVQ*_.U
MRQ4J:W-9;%9I"(B&IB`@@#ZU!3PQD>TB.4<Q'88;9<(<4M#CH<.Z"YVE2=0[
M*D5^0K3T\[VU\U"K"Q&S\@;/%9_R&MC14K88"5-<=K[[\8.VRPD84,4@8=#W
ML4\IYUP)^?`B*[YX^S2?4+SH&IV1O\C1J>..CVRQB3&",15^ITF:'D<5IY2W
M#H\-UEO*\882XO"GE)9PM6`Y-TI,RHW5MP2&?%K`T,SQ8T\@)-?/D#2,3J84
ME%J9DDEJ?&8R.:AI.$LOK]A/Y#>6V4-MH\"4_P`!X#P'@/`@>Z:G1T\CN\,%
MK!F'&>UG8IKF2`7QFLXD-2ZN_ADG*5!DYP^,Y_:AQ3J6LMN.(;P\W[@GA\#^
M9SZ8SGTSGTQG/IC^<Y]/^&,?^/@4O>=O,&I[:^QOU_P^E=^15-A.&]-NL5S2
M_P`MVF%IJF4>&D)K]M)UJW24_9JW"W9TE<C$-E0P3LBY@W#+)3*,LN_$$U_8
M;SFX,;*X'<T-=U;F7Q7GK3;N(F]?T5?C>06JWI671*:<GI>,R`*U8C"2/SX\
MMEYG#;+BG$.I]J<Y5CP,-/KU[GX^\5>J;CIJ+=?(C4^K[*&-+W(&K;>W!QUK
M%E#B=J'$;#0Z(-4=M6I1%=D)^9E'8UR7Q%SB!D_CF@,/#J]X3H#\QN(A;#)0
MO*CCB2,2TV^.0QO#63K+[#R,.,O,NHLZD.-.MJPI*L9SC.,^N/`_C?,CB&\\
M2,SRIXWND!*908PWO'6*WA5$-8?822TFT96QEYA6%H]V,>Y.?7'\>!]_^[[B
M9_\`10\=O_TV:U_]Z;P-_P#^Y/CK\?S?[^:5^'\^0B_E_P!TZ-\?[.(:">E8
M[W_O?;^?&,R0ZR&?7Y&4D-Y7C&%I]0^V>17'W&#,YWKIO&(X-$C(9SLZDXP#
M'N/Y%;.,S^[]!@W"DY;2ZOVHRYCVXSZ_QX'GF_;1-Q9.Q36L_2+$F3))X-TF
MQUR8KDVQ)BIHXEGWU:[+,,Q);QE4M%6DX`1MYHM)(*QS%BN#)*<<RI(31?3L
M9=K/`SDG#&.",0C/+ZRE0IR5UQN.>>.UCK8H^+#,3-FW`TJ$%<#07B48::8?
M<RV,\3E)"TA;C_<1/_\`E([_`/K1O_YO@?1J2CGE>QD\)U?]O]K13#BO[UI;
M1_:ES.?[G%X3C_QSG&/ZY\#48?8SGVX>:RKT1GVX<1G/HYE.&\^F,^OHO*\>
MG_CZX\#]I6A7\)6E7_'^U6,_\$J_X9_^%7C/_HSC_P`?`_7@0]]T755J/M)X
MJSM.LT`8YNS5T;.W+C[;(!R'C[(+=&(]1":*N;EQ"&@*EL9\-@"2]<I:97^.
M8I+BPVD>!Y[?5MUR;JYHW?D7UX1'%_4M3VC5.1=$O_(KD;R0C%VFX\==0:_5
M97@=9TR,$8J]TDC-M6V/_"E#0"F42P#K&$H$'=>-:#NG[1/74GCER#TWR/UM
M)56!T-R#KB-5:PTR"._"YTXKC'KZAZ\F8S]B9-S4!(Q5ES&YD!5H-Q(*<7EL
MAM9&<K6%W_Z^O"W<W!#KVKVF-Q2FJ9K,]L"T;@H$IJ@BX.@%T/:H$#9XG_(!
M;I!0$I$SK#K[C7XGQO?`.AK"W5.>]*0G`\#JC>M3MEZTSM6G46;/KUPL^M[]
M7JQ*1LI^A,%L,]3IR&@2&+`@,XNOO!3)[!#9P[>7Q7&4K3A7IE*@\7-/!CDZ
M%SM_[&-H4^9C.7UEW[6*-^UD[5(RWP6V4G'%24Q(6FO#6I1D?9G)L.2_R!;9
M&!$(P0_[&UOK;#VG=/TR5UUJC6E!GKC;=ASE+HE4JTQ?+\>'*7BY2D%!@QI]
MGMTE',#`'6.<*&628ZRVAIPAQ64X],X\"%WG;T;Q'*'<E]Y+:&YE<M^'^[=B
MU6UHV/G2NZ+A5*EN2]!T!%*TO)7Y@4TUJ%K^MPPQX]QJ+`^<B%RXTTIDK."O
M`I9Z]M?)+B/V7<\:WN&6UWR@VS7.9_`X_:D9K*R2%)Y%;ZNU+W;$W>HQO%6E
M6`:2!M94G)L,,6S,FG),?'KP6V4AW*G5!;ZXB_8@XD66^3/'OFG.W#@_R(A!
MK39[#KGEQ6`=)Q^K:T+*QRJ54;)LJYV0&-N-LM51GP)2-=9&;>.`4MUS&5H4
MM8=T]K5JX'\/NO[L&WV_*T;1EKYCZELU!+VY1H%1=LWEM[8.IY:%U/B',BA"
MW;P\3''LNN%@J6P+%,O$NO-)'4XV'2?U00#@>D_CMDX(P/!U_P"0!X62QGQL
M&`O;EMZ&31,O(1@D-U;2TI=1[D*4A6,9]<9]`L>^`\!X#P'@/`>`\!X#P'@/
M`>`\!X#P(B^V'K!IW8_1:05#7:;T1R?XYGD[/XU\D*S61I25HUQ:6T^W`2!H
MK";095)<R)8=.`C"1R</-#EM_(\PVVL*/O6-Q<YJ\I]UW;D"ND:4J_&7CGM;
MF7N/8-QIFB*CIJSQ&UIKBZ7`1L$-5,QD-=/\.GXZ:"*K09G["/CCA3EOM,N/
M.X)"S3]04HLWJ"CRC3FS'7>2VZ4H0@IU[(+(XM*%;#6(IY8T4O.&/F^!AMAM
M>'</J1EUYQUP+1O@4>OL+5=4]WA]1$E^N@I)%=F^+YRH]\4(FP3*"N8DC%NQ
MH"9;":Z^RWD]#R1I$^$0]Z..L+/4.X@(+.O50\.1P:U>0)\_XK]ZY(NC?DF/
MR!'P.<GMR*:R^>4I1)KN49Q[G7,Y6YG^Y6?7.?`D0\!X#P*PGV;=!G$:"XL<
MXX6M779$AP!Y;T;D!9:+`)A@P3=5"NPDW?\`]K8T1R+!6XYI[6\8.P4P\[\1
M,EE2V2%8'2R$^?&G=&N>6?'S3W(:G!P<E5]L4:%N<;^.G]S'A%2PJ%S4;'3!
MT1$YFQHN:;?%P>T,TP=\'S-XRVM.?`QJ[1>;NK^MKAILCDY:JY!6.?K;,?5=
M0Z[6PTQ(;(VG:C<B5&BPB1&\R37YQCCI9CHC;KH0`Y)?Q.?#E*@H\Z/[(Y?=
M'%+I\@P^8LKQ=V?JKG=NFM<@]P;6WL'L4^R5&2IC6[(^9V!$6*2D2']:SX]O
M;J\:'+,GAQDHTKV#?.VT/X'I$H@*\ME&,0L,MG/H\GTC@5-94M"<?*G&&,(S
ME:,8_NQC^<>!6[XT["![!.]"[\D-*1D&5Q7X$<>[;QBB]CKKEOQ7MP[7V);6
M)F^%:TER8]%!*-UC-U0-IX^/<4N0B905]+SK*A_:%EQ:$.(4VXE*T+3E*T+3
MA2%I5CTRE258SA2<X_KC/@=:;)U!KC:P`8MZIL)9G8F<J-HB'S4NA'BSM!M4
M9=ZDZW-QWQ2PX8-GAV'G6$K4.0U\C+[3K+KK2PH!?:IM@5*[*--1*8-]@6,X
M75X^&/4#7%5:B(>O>Y:S'72$CKQ*-UYRVTZ8E$*@%QJ(Q<><\X1C#Y:6ELA(
M']0<6\,']I)5T9D`B)7=&F)!R*DF8Z-/AYA`.X(R4CYVN1)A@-8M#0T<)DL3
M'LSAA0ZTIPTMK&`NC^!54[E.J+>G(?EY7>8.K=-ZIYK5^K\?=G:H)X9WZQ.5
M9P"R7J@;*CZ7OE4ILV^%ZTF'J9L&50^/'1,=`2N5-I^,AUW&"!@P\Z3.)7-C
M4W.WBH!R@XGR-$M/#WC!NC0VV-]"WW55OD+0!N9N$V=QAJU\C]=RN#FA=7ZN
M@I"O-2AK1F7)$A`N7,90U[0EH^OS4BH>@]DDY)P<0&1-]MO-K$5*"LP2Y(V(
MC;)6XY;)14,VSAM@689+PTSEIA.,*RXE&?DRXL+`W@0Z?8!2(KIXYQ_F-1A#
M:-=U)YD.8#LI\;(GL;8U\]%Q98E06W87FY62;:'QAA6,84[C+O\`I8<\#M'I
M;%D0^I_K\9E1H,0[/%W5I#H]=R-F,0V9`LEC*_Z4P[&)%T5]"SL.N8*2:IW!
M"&G\.-H"3KP'@/`>`\"![IJ2I[D=WAR#[Y9!3O:QL2.4LDTPAM(<5J;5[<>P
MR.\^X,/@9E_+>%-H2K+2&T*SE#324!/#X#P*FG)+J_X$[9^PGQ\JURXQ:NFJ
M_;^'&_.5NU(4L-I^,VCNG.^H\)NU[*KI)A(EX4;_`)@?\S,F,\.XCXDM^B14
M(;#*[F1T<]3&I^%G*ZWZ[Z_]*#VVGZ(W-?ZO)!PMBF[1'6F!UE:7HHR#//L!
M<JVJ/>_Z@<)#R0ORVFG5-X6VA:0Z#Z?>L_IUYI];O$G>1W!S2UXN)>GZO4-G
M6VXZ>DJ;-V':M5I\-2=D2I#!*8X&QH+G(MU]F8!R2$46MPQA[!;CZ\!(?-]!
M?3S,2+#CW7;QZP.2"2">1&!S];P(TED!`RA8R"E@A7C'\@IPHE*F2&\_(O"U
M*?>]P;:[]>7I=>8%'7U_:=PV(EY+2FI'8;#Z\/NY>7DHIFZMDFJ2M7HC+RW,
MMH_M3Z)QC'@:?_V7;Z6?_H`=2_\`X<V=_P"]WX'&"/K9]*)!*"5<&J<U\?Y_
MH.QL'<C(BLG_`+#WJ4,C8F&O</\`L/\`1SC&,M_`SZ?PTGP..RGUC^DV4AAH
M;/#("/0-)+DOV,5MG=@$P1E>4YR"7(M[$R\3&8RG'HPK^Q.<>N/Y]?`I;?;>
MH,#J'G[Q^TY1:Q*0U&H_`K16KM=LYL,I*Y75J7=KQ#0<?E@D99A_ZT&%9$SA
M\@IPA]"2%*P[C"?`QLZA.FO8W8-KS<VT0-=;8V?5*';0M89AM2\HM1:-NU<V
M-'$1MDL<O;:YN#7\ZHB"GJ82U'Q;>%#O-'Y(>><<2QAC`=M7'ZKW=$J?LIU#
MT_&ATUVR$8IL';.4>I)6[AU61G3!H5NT2<+-15:/G(6%2P[*OB(''<4I2AFL
M_P`M(#00WU;^^"*D&R8F@UF!+;*>^*3"Y/T<!QM4/)BO`F((`M'Y3:72V&RQ
M,^F',99PO*4.)3CP-]<^M1]A*.EXTH2"><D'UP`&)J/Y>5)M<2+$LF/0RRC7
M+R,8V#6LU0%#*6,.J'6^#AA&?C=R,&A$^NA]B2)R(@*KVN.=?;L8P[8'+NII
MPTR+7FFR67R8[8RP@&;)'P8D:/AUUM)"D#M.>QEOW-A^#NA'[(\:V&\-7]P'
MI>DQB!TQO,6M))9DRE(BW9!81FUP3A<AH?RV^:IM+2&/56',M*2I0;1.=)OV
M4:W@DB<@]]QD1'#+/F+$5S6IC5<@XMOW9=EI>95N_`8<8*AIQPEW*LX"8;4^
M3\+'HYD(K^,ND^>F_>2-ZT]QSE]Q7SE)9<7=<HK7F^DP<_?,:R()C[.[(VY^
M::;MC$0:E!;3I<HPR0&.YEE:E+;6D.7<\^)?9QQ@B-:M=C+.Y`8B7E)-5%IN
MRN04-L*>B3"8Y0S$Z'7$WB^D5>-G<0;C#!ZA&F3OU)`Z7/>/G"`S0C.MK[)`
M]1A+15Z;SDDZE,5>M3\&52>295@%*JUJKY)$"4$'6=O'N?B.P;KK*VDMX6'[
MLLO):4K",ANDCP6^S?&RRG!]<]ED<^M0ZFQH+<NU)847#S+HK:L$,[.F'&VE
MH;<PI3KV<)]<^N<8],>!M;O$C[.C)&!G*AVGX>48>`TE.QMSN(()C2G!"T"N
MM7);)3:5LK6AQM2FWF$Y>;4IK'O\#"RE:*[4Y+F/=M34!&\,\^X@J<,OH-=V
MY@7DN^\/7Q1YN,FK0->&;1+K"@&&L.A8,==PAU*,HSE:$>!F&=IC[.5;CD.D
MP?;>*`0H=S"1K)R*,SE84.&4,IQ@&;)?:RQ%&MIQ[DI]%>YO_P!8VM*0XA-5
M+[(LM$VJN6`'MM-ABT(K-GAY4[DTL.7;.CTO?IOQ"2_9.MD1AF5+:'P_C+7R
M>['HASVAT[9*QQ_J=(X^:`,XW<E:GVM:WY>1T#RILMWD)>QQ-HK)]LL45`ZV
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M`W'P'@/`>`\!X#P'@/`>`\!X#P'@/`A([(>^3B#UF[;J^B]RT7DG=+]<:^]+
MQI&IM/+LM4$+<"R7'P7^16.R4F*LEC>9>'>?`AWSG0F"V%%*'^5/@8,=2_$K
M7?%?K`[)I[5^\A=_-;L(Y&[!D_DKAT;=:;*CZCEPQJ+L[5.9]RSZUV4($ZUB
M9ILF@::B#U.L.DDMJ'=0&X_4-+DL]0%*">%*?CL;SWP0+)J'<#$"5BQ0Z/TR
M<&J:?EG777'BORPVW04>]0ZG<$M.MI"T;X%'?[`[@8W>_P!2+I,TNLJ=A]$&
M8/?S&$14RU6N82Y4N&F6I(@*-C8@"->)-=7)9+$-,0&RRQAYO+F`LN=06<*Z
M]=&K_-9D<N3F^75FCR"Y9DAUWD;MMQY3<JN&KV93"75Y3^3@`-+^<>]++:58
M3@)+/`>`\#:+!`P]J@9NL6&/8EH"QQ$E`SD65A61I*'EPWH^3`(PA2%Y8,"(
M6VOTSC/M5GTSCP*B^E-B\GOKE[`N6J>5@4YN3J)N"MB;0U5N;6%8V/L*4X5/
M#SL!7:;I*Q/3LQ/3J=>2;4Y`P<;@XEUTF9?R0(E#6))?@9:V+2_7)]DPO1O(
M6)Y/[+VKQQT8+8XR_P##,6>D*1`?YW:8"]Q%3NU\AZ]+05WH6V8+$C^9&G8,
M+:>C!,,H:0A]]:@^)'UT^I/AM9-<<LM8Q#?'.0X[[*J6T+9L7:NUK==]?.ZW
MB"W0K[4;3&[4M<I2(Z+M]>DG0EGECN9$RYA3?L7G"TAT#R;[F]X]CYM[X&=+
M.N-EE;'GKP-J79/.:3'C8?4>@*JEVRA[$L-;G`9<@IVTLBUYS,%*"?D#G@?D
MDPZR3V&6TA-[U;\#*/UW<.-3Z#@*10ZOL,>MP\SONQ4.0F;`+LK=!<>SBZWH
M^W6>,A[19UR4CA21'#QV5B`(9%:;;88:0D)$?`>!YW?VR;5^C[`:\BLT82ZW
M9[@(@,XV?CK'.P,)3,;>L9$G'"Q,>T6V)/))*;*;/')B&FFB5B'X/'/P,H,W
MOJ$UF3J%7[`K!7T66\@WRV<8;U"3\Z+7:0U:PKJ%LUJPS"(J*)F!8YB#(!,,
M#8>=&,6`\VG,>&M_&%A=F\!X'XPTVEQ;V&T8=<0VVX[A"<.+0UEQ32%KQCW*
M0WEU64XSGTQE6?3^N?`@%^O-&"1NA>=^17)1]9G:]SJ()+(#;8@3'6[]%B-O
M5,S]>"7)Q2!AFVWW7\N+0>V^VG*4(2G`3^^!#[WZ2.8CJ%YK2>'QQL!4>D/N
M/DR`D8AEE&X-=?.XV7($BQWY:6?=\#1.7!B'_8TZT^VM3+@=[=2V`$]9'`]N
M-D(V4"8XM:=%9-BHD>%%<R+3HP9YMP(5UUA<@,^TIHPE.4_FEH<(RA&7<H2$
MAG@/`>`\!X%?'HMG96U;:[I[/.U"P:_F9?M9VKF0I=F,C2Y:`<%UIK5A#!BH
M,^3@E$%-XP]\@S[J7&7&\97GVX]`L'>`\"O-R+V]#:N^QQP?AI'7]ULI6WNO
M;<FKHR?IE17:L5N1D-VPME'GK8J(41*UVD18U8>8/EBVFP@EFM>JLH6\IH)*
MNT=(:^MKGJB08/*#5Q"Y"X?8BULMR#B,ZLL_HD59!@#*7<*],_W/-_QC^OKX
M&$'UP=A*V?U!<5K2P5?'(4:&FJ-7(W85JKENE8"'U3)N:K5$PYU9HU""CJ?F
M6I9141'/#FE@`E-LO'$K3E6`G.\!X#P'@/`\Q/[ADTR[VGT>)"M2HMT/ASKO
M,WEJ*/>(C$IV/L66!$:+0`.K*3%LLD84.0ZA#B$X7E"_[<!.C],3Y">$7*R6
M87+&1,ERF8RS,RN)/"YN;8U-1L6:2S^<V4U@DN2=P\[\<@4O.'4*<:&RK"%!
M<;\!X%63[(G=WL/K)K^GM2<7+=3(/DQ=CVMA6%FZ5"7M#06I1&9Z/BV0822J
M+M2FPKO:HI\(DUF=#/A\@X]&7<$Y6R$@71[V+178!P=TO<]@<@=;[8Y5$UFQ
M3>[:S6(J*H=AK9@]SD(_#2]:MI"D6*_71S08K]PR+^MD2VE+:=7E?KD)%=R<
M5M#<@+MI/8VVJ)BTW;CK<'KYINPM62WUTRFV<EV(?*,0W5Y^%%G`RWH$)3P4
MFV8"ZH9&5LY]/`A0^QN!V5;?XOQ/$7KUXSV?<0G(4*?"WSLFOW"%J1.NZ=7)
M.KR$-6HE^2N%+?7,7J2]Z7U_.4'F)$+&(%<P6A;04WN,W4IV\<3-?"V"D]6>
M]X;FE2=^:_W!H#E31-ZZ]B4UB$@`VL6O3NU=>A6Z5CKGK6S#QSC_`/H&0923
MGLLD$DCN(%4&._V!=,]@MUY=5[E9RHT#L:@8Y#ZYJ(--A#$_F1<?9]4:U@/]
M]JOK^CM6VZVJF42K7W,Q*#M&Y2DD`S]KAQQLS+R@O#?6'XU<_P#B_P`#X.C\
MNQJ96-933AEXT?KTMZYRN[ZJ#:Y0@DEJ\2)]DE:#"4\R,$&,A8B(&8)8P<ZL
MS"'%8PL+*W@='\G%75'&WD&YK55B1L9O2.UG=?JJ"2EVQ-V;HD\NJ9K*`4.&
M.6#$\D?\-+25.*(]F$XSG.,>!XQ=!T'R['Y53E,!INWR^>6N=M6C8U\K`\#;
M9O;E%G==?K[U.;#L,M"O*D0,,2\@8?+R(SATF-D)!#;>,JPIT/:+T05MX[3F
MMCM^-Z]9W*94HDO8K.J'K(1KIFRD#X>,:J)%P8%LQ$2VE:4I<-::>6K"LY0G
M&<)P';/@><12J%42N\CL9N;6O8DFUZJ[.N#>*78C8IN3+ILIM#G3`+L[M;GJ
M^PG,&J]Q1#V3L..J,6UEY&<*::(:P%NK>_?5U<\5MD6C27(_E#6J%N:@,P+=
M\J%?J.U-B1<3)SD!$V!H:*M51U^?$S(OXLNC"5?Z!&,X4EYAEU*VDAWCV26N
M"OO4]S:O-6E9!ZL7/@EO:VUV6#"=!-/@+#I&Q3,2\Y&S<?@H5F3CBV\$#DCM
MOH9=6A26UX_M"('ZM'''6*.M72W*^MQC-8Y"[=G[]%[NVC%?@R5@V[4J#MO8
MX5:IEUQ)M2`"`XE@YM+)(S(LNRT*PU^3\*?CR%IK&,8QZ8QZ8Q_3&/XQX#P'
M@/`>`\!X#P'@8Z\M>3%#X<\<=N<F=F#31U+U#4BK/*QM=CBY2:ER/G'CH:#C
MAQ!R/B+G9PX8-#[V$"#*?PZ0XTRAQQ(16=:W?%I7LJW]/<>:EI/9&A+M`:ZD
M-F-Q.\I^F`66X5Z.L3E6-=H=<I\E:5RZ(6787^Q681'_``,Y0XPDE*EY:"=W
MP'@/`>`\"&[O#ZQG>T?AJ_J6J3(]3W-K>UM[0TS;OQ6LGBVF/@)N(?JZ9-4O
M!JBH:Z#R:1)!U3[C3324D?COOCL)P%/'I4X(21<)V;6/DG_W'Z:VMPDKLCL4
M,`JZ;9UY5MY[$K,?R7CKK>]Q5&>7;*U>U()"_49/CD_EA(:^=C/Y+[ZW@L7_
M`%0(VPPG5'JV&LL-<`"@]@;K+BB#&SHJJ9KECGZK;X9YB"-Q$O8*G!;'@P(E
MP!Q3X^2'FR/QR&OE"SAX%(3ORM476N_;IWC)>+<F(F\O\;(2:!*FPQX1R/A>
M99$PVHZ#9%)DC2$O.*PTX3[`\+SA3277&G<("Q#U!6BSRG"71,:S2WFZQAG<
M,H5?C'1:Z+)2I'(_>()L.+2")2>MH-F8_6#'2*3<#@HS)90.^ZXTXRV$K7@/
M`>`\#B-]H5,VC3+/KO8=;B;A2+G"R%=M%9G!4&1<S#2@ZQ30BV%^F?:ZRYGT
M6G*7&U>BD*2K&%8"'O9/UX^IN^U^.@JWQH:T2_'R(DAFT<>+K<-2W&23'U@V
MK`1LS8X*74=+1(HQ:2OQW\K0Z>RE]WY%+?P\'4%5^LGUBU^QPDY/#\F-H1,3
M(CGFZ_VKR0OERUU:D"K^5N+N%5(6,//0RWDI6X,XO#;F48PKU3ZIR$P?&7B+
MQLX:T>0UKQ@U!4],T24L!]H,K-19,;CES<FAA!I+6)`PY\9AS\?"DC-K0,TM
M2U(;2IQS*@R.\!X#P//P^U?0#I+L.T!9@:_;YM[_`+9XDMZ[M3#4-3M5A538
M-[GFXR/_`,;JEHN6+Q<Y0!EQTUK#<DF,9PS&-N.X6ZP&7'U5[GC;5'YU[)K^
MKV9F.MFX.*L0;&16TSY2>C!=?5VZ@IF)"Q6G,,7*Q-9/B6'X\13[!142\AIX
M=UQ"WSPNK^!H9(',B&^(DTZ.<=:=0T=&OI8,$=<9<:02QEUI\9QUC+GO0EYI
MUG*TX]R%8QZ>!TWH/31VD*8S49'95IVX?A##TKL+8$331-BV^;4LIZ5L=WEZ
M-7*C!STQ(N$(0E;<:+AEAA"/1>?<M00S?7_V=K"=J78CJBN6L25V;0^R[EQ=
M=@UQ"9!)\/7-F[1GDZWGBOD`!A\#6F.IQN1\"8QGVB94\A*\^JPL%^!$;WOV
MLVB]3',>Y1AGX,G6*E09J->4B&=9<D0-QZY?!#+8LD=+ULF/D2D('(:D12(]
MUAU:"6U,97CP.T^I*."QUV<.[1^*MN?N'&C0LK83\RLS,LRN&M5U=BMDA&R\
M/7O?'LU/\)D=#(32!V6TC*6\MA3J@D?\!X#P'@/`@AZ9\9QR"[OO7&<?_M9=
MIY_G_P`,ZGU1G&?_`&^,^!.]X#P*J'/+;NT=>?9RZKJYJN=JD"SM3C!>]8;3
M1+$P>2+3K(NYW6]6"LN-$^PT:88=IHAD/G+F'7"4J2/C/O=0Z$UG:^%(R761
MS]CX@T>.DS>(>_Q032WOQQAR7]:6)MI;S_P$X91E2O3W9;4G'K_/\>N?`C=^
MK<<=(=.'%Y\6/CH6M_-NKX8@0*36VU+XWUL@0E^-FI*?DB7PR4`J()'?:4XV
M:4O+3R1_C'9"Q+X'6.Z-A2&IM4W[9473)S8A])K4C8AZ164NKL%F5'-_,N*A
MVV`Y!YT]]O"OC2EAQ2E8],8_GP.S$+2XA*TY]4K2E:<^F<>J58QG&?3.,9QZ
MXS_Q\#]>`\#R]OMYSQ$;VX1["9"5$8-X::TA2F(^>;.8/C)&V;!=E0I*$=D0
MFHH-`3;A+0Z_<@DY@=_*%>OK@)[/I<0A,5P+Y1OX9%=B2N7,N+#S0^!E9F68
MK6](%>>R^V[^0XPTI2<MX=::],.9RG&<*_@+CO@/`KT]X767U9\BHRM<T.PZ
MTWC60VEH0:ED;$K^WH>EPQ%603-V2'J4G5[IB1C[-DF>?)2-&5QD:P2;YRD(
M4YC'N9#I+H5T3T\P9^UN?G6P1:X@'D,%BC;`H.R]ATE$CQ*'*N39\1IZ5I2+
M,?/5Q.RK,",]#Y(*G<ECQK"6#/3*L.A:#\"#/NL[<I+K7K>CM4ZETM<-]<J.
M8,G>Z)H2DU9HW.`)R(K[$=&69U@./->M!86Q+;7!TP++@9,B(42MLAK+']P5
M<-X]T?>WU`Q5PKW/U_6.T-V\I6:AM/CU"S15*FH'1T-7K@-*;*K]EJ^KS:I+
MP\=.0,P/$Q\42\M;2TN._D*P/E#P8B:Z^UCVM$5_=.Z+J7PSV1!PLC#UFNZW
MNM1J]6O5"&V0=+Y?D=1P,+)1-WO-;C8Z'3'2Y$@],LB?*"LO"\N^K@=MZW[F
M?L<YZ_[!S9A)?5A/'**O]0A&-[3-6X^""Q6("4A=).Z;@M0CQ@\LLVRVVR1T
MLX\+&MNMLA$N-+0PI2<!F_7>R[[#NNX>N]7&F]#,[UY^:BUG'V_<6VCFM8W(
M>B5*>L#U@U2<];SK>K7,S%VO3Q00ZDVEF)L&)CT<2X6E:65!TMV=_8,[I>$M
MCXS5"\,Z9T!MZ\\9(N^;2TTS0*CLYN,NPNWMJ40:Q'V,K\L`2/V!2JP#,LMP
MLK*QZ7?CPRMIM;J,A/7T%Z*.Y*Z2K/:9S,XP:AI_.O<=^MFP:3ORH:WIU"ME
MNTY;JB'"P%FRBHRQV"AKQ"3\NT0]*##R!8SS2E(4VP`\@++7@/`\\/CY"A/=
MS7;%%+2AQR1[7^OLD)D^<*B)LAT'FN_8I-N."G,N3)H`JF\.J6T^@;`[;:&6
MUL/-8:#+C[">GN`U@YW0="Y5:8VGJN1Y`\2[>'H+DAK;:=:U[JS:/*6@?YC*
M:^U+N'7(=&;)GQS+%:X5I^VR4L]D,LF*#4L,'!;[81X==?<]R2YC5CL=Z[.>
M%BOLO%[:XN[2KNJA-$:=JM_+T.1KVG2U9V%6*7082;CYFZ1KL`TAV)BA#)%Q
MT\138ZTH?;RD)G^EGG]3N#/1=QJV3L_6&Q[+IC6#]Y9VW>Z!!A2,]KB'FMZ;
M]BY:X3FOD?B34E4J?.5>+"DCD/9+R].MX;8<R,YA036]?/;YQ"[.HK:TWQ6<
MVY,0NH9^M5BTS-IU?+UX1<E;8JV3,0Y&92]*._AXCZ>0IYXQL1#+A`S2O]1]
M*/`JN\DNZO9_)SMPX&4"M[]VMQBZ[HK9U)L#6XIO6UOXU64C8$KK#)\G1-ZG
M[3<EM-[4A6IS`!3*$PC48H"=QD5>/5!:@G[Y&?92ZJN*N\]E<=]R[/V9";'U
M7)MQ-C:B=.72QP!99,?&RH2X"?A1"P)@&0C95E]@E&<#N-9]V%^GIZAFLUV]
M]6KS3;J>P7B*E+K:'4I=WMKUIS"7$X6G#C3DXEQI>,9_E*L84G/\9QZ^!QP;
MN0ZU'IXF,?YI\5PXAG_U%H=Y(:2=CC/[7L_Z4<->7[`U_+:<?ZHB/Y<Q_P`,
M*RD.;"]L76*:TM\;L`X@+:;PZI2E<@M9-9QAE0R7/1#MC0M7MR6W_3&?7W?Q
M_17H&V3';+UYQ1TT$QS`XPS.(>,5((*C.2F@?QY1YMP5+L.!^=LD)[$M\3SK
MC:'D-,N)'7C#GN4WA8<RC^SCKGD11"FN=G$%G\MAI[#!')#3K;[.7$ISEE[&
M+DI"76E*]JO16<>N/XSG'\^`>[.^N`=EY][GIP]0T/#"V!Y7_<=J17LB#5N-
MC%>U-L4M2G%M9Q\6,9>3_P"Y)QC./4(@.\W<G7%S<Z_-MZZA.9?#RW;5U_#1
MN^M65_/*:L`/3)&MY"/N=E@(@.G6R0&F+7=M?Q$G#0[$C&3##4C(,K_#4O&,
MX"OY]<79_$+77-?=>_M[[^CM"V_1&@Q=>1%8WWM+0</C8TONV?D[K/U_6[?O
MKK%+IFJ`:L.*'7HMTIUDZ7<P:8*VEJ.R%Z)CL1X`DND,#<X>(9+PK93Q+8W)
M#3I"V&`8Y4L:2XEFXKRD42-0IYQW/^FA"<^N<>F?`W)7/G@NVZL=_F=Q2%*:
MB8N=?",Y#:D".&A9QF-(AY0L$NW,EB`2C,P(IAUU"$.X*:]N<_(CU#?<\TN'
M6/7UY9<:,>GIZ^N]]6_QZ_T]?_EJ_CU\#]"\S^'AT=F7"Y7\:C(E*`'%2@N]
M=7$1R6Y5IU^+7DUJTK&PB2986L?/N]'DH5E'KC&?`^P_,?B(8Y\(G*GC>4[C
M*<9:'WCK%]S&5Y5A&/8U:%*]5Y1GT_C^?3/_`(>!KV^67%=YD0AGDOQ_=8/`
M'E07V]RZZ6R;%EAGR(LD(XFQY00`3'Q13[;R,Y;6R,ZO&<I;7G`1A]O?8GH+
M1/![E38:);FMT[.K>D+%!#Z]T_<PYEN"1O.(MNMJS=ME9@Y$B(B*A'2\<:IH
MHQ+SB#1TM#LK(>:2H-+TR<F.-E!ZG^%U=MV^M6U2;U=JBF:=V/$7;850K\]2
MMM0<G&4RP:^LT=(3#)$58XJY3@D;^*[C#N'2AT9Q[G4XR$F%(YE\3MDF5P"A
M\C=-6DVW:];VM5QHC8-;(=GM<N6$JI*M\6G]@G\N'%M`3L<0M/KD8U'PNX0O
M.$Y"E']F:R421[4.`]^(V^C5^MZ+KK2!^Q>0^L+_``N;WJ*,1RFM!34]6(Z#
M:F[BBP1@3)A<<1'!R"6S6VR"!LLB*=;"SOU9[@U#JCK.XHR5[VY#1D%8#):L
MU.U;"FF(N9NTGL?=%JSKI#I$M&UJ4LMIO`=FC2<$O1H,A*9.2<2(,X^XV@,X
M(SFCQ*FZ5$;'A>1FGIBAS[=Q=@[=$WN!DH&8;U[8(2J7E<9(A&/CG)J=FLL>
M`?\`'E7XQ9K#2_1;B,9#XS'-SAS79J+K=@Y2Z`@;!-QUUEXF$FMM4>*E9")U
MN7:@+_*"@'S0Y3D=3#Z--,2;_M^(-Z*+;=4E;#F$AVO%[EU'-68:EQ&S]?R=
MN-'BC(^L!6^`)GI,.=KIEOA3(N*:/4;*"2M5CR)(=T=#C;H([KZ<Y;;6I(<D
MMUTJ-`@3K3>+-!5&M1F!E24]8Y0.'B(]!D@%%#.FR![S`HK+LC(L,X6M248<
M>1C.<>['@<F\!X#P-C`L]<E)N>K4;/1!]BJR8E=E@A)$0B7@$3PSQD(Y,1S3
MJBXYN7%'<<&4ZA&'T-JRCUPE7H&^>`\#\)<2IQQO'O\`<WA&5>K;B49PY[O;
M['%)PVY_RY]?;G/M_P"/IX'G]?9`E[S.=I=-;G:#4ZI1M8\9E3%?V*\?F]Q+
MDK,@;(A=?7?:M">KLC7HRX9VM+MQ]08'_:S;(4:](N#*1\"`@SY^I+(0CU`[
M&+(P5>5C2&]]83)4Q?`$Q@S0SVM9"2D6&R$``Q."V9TF1/)2(M8K01P:_1M;
MCGN"X<E6%8PI.<*2K&%)SC/KC.,X]<9QG']<9QX']\#H/DUR9T[Q"TS;-][W
MLZ:EK:F(!S,2N!UF$J>D3&00Q``FU)=,,?>>]<-ISZ^Q*E?T3GP(G^A&?AS^
M,/+^X(E@5ULWLLYX3\;-.QD?68UJI&;4>L()Z!T);0#"OBR+AZ%ONN8^,G+G
MOPA6,)"=AEYDAEH@=UM]A]M#S#[*TNLO,NIPMMUIQ&5(<;<0K&4JQG.,XSZX
M\"&3["7Z7'4)RZS.M/E`I#T\O,:.EI]^86WOS5KBHAJ.+*%BYAV1'0XV@0W*
MPGUYQA]"F_7'@9/]4<6-#]9/`$(+$Z@3/#_CX<.S93R9*:$:EM85J50`824E
M"TXC\&_`TRA#;(S+:&6D(:0A"0D`\!X#P(Z^P+M)X?\`6WK:?O/(?9,:)9`Z
MU8)JHZIA"6#-@;#FH0(`P2F5\)2TQ\=9+$F3:R`F3?"9(92^^E>6!B7&@@'#
M[:NV#M7O5=I?63QTSH#@_M3;HNN(WL;N55F+%>J;%51NJ7:\SHE!DE%TZ`FX
M8,*5@,HE0)BNS$FXD%N2&>5AS`34=176-(=86F]Q4:T[_G>2>Q]\;WM.^]D;
M+F*H)26C[-9(N%AULQ]>&EY]P5*AH5+SZUFNX60ZKXT--80W@(YNXG[&4EU'
M<J8#C].<.W]YU>UZJJ>QX.^P^X2*(\V;-2EZA):KR$<7JVU1O[$$NN@D-89,
M6O(9"E+0G*V_0)J^!7,:#YL<6M`<@G8>OZZMN[M406UR-0CW@*WSM3A9]QY(
M*B2,Q=<DBQ76D(5E]4<PTEQSXTJ7[<+4%>KG%8ZRC[5G6+7GZ]KWYI/C19XV
MQ2DM6:?=9\XD%6W;E1BD8M%<+>UQ.15FA1D1DU%E-S3B?D'0ZVR[\;H3M=MK
M48_U=]A#,S*/PD6YP[Y"),E1HU4N^$UG6%D_UFXU!D>HS/O],>S#S?KC/]?`
MP0^L(Y57.E?B8NFBV,*%_,W2G(]I/BY*5Q+(W=L!$^ZDN'CHH/,61.)(<!;R
MSAYD-;3;JW'4K<4$_G@/`>`\#Y/I>4P\D9QMDA33B6'G6E$--/91G#3CK"7A
MU/-H7Z94C#B,JQCT]V/7UP'EV_<!(GX3MGJ3J#\+1/<.]8Q!Z(=H5!I,25:=
MEA3PRAW07%BX-0A>6\./EJ0C.,X6G&/;@)^?IL3)>.%V_P"'?_3SCDER2N\F
M?9(R1JADH(Y`5C7,4`';BAH^+M,^;/L2CKT:1\LN&."#GW.@_D"L$!<>\###
MGOS6T%P*XP['Y#<@K>#7*C789\2'C_64*F+C;9/"(^M52`C:^EV>,-EYDP=I
MQP=.$AL+40\XTRVMQ(>6=S*Y*=KW?IR%E[G`Z+WM=M?,5UV7U7QTU!%W:2UC
M3*)&3(T`Q.Q`I(Z8NYV)=BD&5S$W\"RR',+3C`P8R&A0V?ACN_LCZ%>3K<_;
MN,FRZ5%V*O5TWD3I[95%DWX'9^G5SZ92',-R8%)P=8L%;+B3G829;]CP)2GD
M/86PM]AP/5>X=\W>/W.C3%#WUQ[N(5JH.Q(<:2B$)?9S9X200@UFP5J\5L=1
M!E.GZQ,1I`!+9><,O$->H[KS;C2W`A=^PMQ\X4;T:XS3O('G)4>N_DQH^P';
M'XC<A+7:05H_8CSM=E]@``ZX:LT',S1=:)IT`:/))4+D4X@9H=YU;CS'@0:$
M<'^KY_1=K_.[PN''+CE[LO:G&(ZZ;PY>[0UT<*-KOCY<"=CWG6U++M4GL.UQ
M4/L7YV&W7C3EL%MA,QY!2AE/LK#+CFSQ7Z&.1D=K8/C?RSZ:>+UFH.^=<[2V
ML*!'Z.(A-T4N"MB9<FEC7"/OHTM5J^?6EECGQ@@RA)4U'Q&--C*%>;#:>Q#A
M9P%Y'`::T7P4[0N!/`WAQ)L66W\F=%:SWQ5*]';B'/M^GMH"WY[7B+:S69"W
M4+5U0%EPCI/&%L/B,,-_CCO*4D.BS>L/7-#VMG9W$;[,%*B)GD_:X2&YA;4N
M'(G5@=^O]+=!'E8*(J`]0M);]PMTLVU-/!#2,A'`,A-I8RI>,*^0-XE?II![
M+W!0U"\Q[8/QL@-/$0LC?;+!3$UO*T;$C[C8<P4?%Z[LS$56Z!KZ*J$@&)C"
M9(E3A$:Z\R*V@Y*F0MQ=9O".Q=>/%"I\5IKD)=>245KZ:G$4*Y7N&8@I:LZ]
M)R&BKZX#`'F)QI,+4!QEMC92\E&$NY0VTTVE#:0S_P#`V2>FQ8$00DHB/&_-
MFH&$&S)%N!,/%SDP%%#C-/-"&K6>0LOVC->S"7R,H;4MM*LN)#SI.-]F%L?=
M-V56N/E(60@$=M_"O,="GPM7M4_<I^%YA7"I@R>MK%'6FH&0Y$#%%GK>R`))
MH=AB'L'NHPGW$!<,[?.%G';EQPLW]9>16OA+XO36B=L[<U;'S38,:?KZ_5#3
MFRR!I,.R5[`MC6P49*"D'`*DGHQXN'"=^//Q*RX%.[H,X(:(HO!_:G=CR"V-
MLS$!IRA;^US_`+/:`)C=7SRZ'`:YS2KL=F[U,NC7<'94PI3$D#*1\['$-_ZB
MGE/./+=4$]?3CK('='UOU:\:FD4*%V!5>7N1)]^+IFUUQD&_N;:$HR_-1NSZ
M_8:/<G'@1O@,<-">8)0I3Z%-NJ2X@*6_3MJ7<=NVMJ;C%2>;N_N,0_*0G8=N
ML`O%W=-L@K9J]O0-78V!<ISD7H$409TY=UU[%&QE(=9,"5(/._F$9)#&2&0'
M?]9V!PZY(<R^%'6Q<]CW'<?7%$[Q@YL;>?)D;/'??<@7>./:-6%T6R3[,742
M'*MK^XU.+%KK^775!#H&`R0^/EE#0=5=ANR]!<'.X_L/1)<?:UON+I>I0=)<
M8Z1<L5^]:JH9DCI/4^OJS=;M!ST5(?OV:'K%9Q$+AM:70[`D$AQ3J6U*\"1?
M@S]9&K\C^-?#'DJ-N?C;.M7G7#FQKWJW:/\`O#0[);9/8PK4C"UVZR-'VG+N
M@`ZK$PSD!J$#@WIU"UK-<;2\CXP[-K'TZMG1M)L=7E-\\/KW:\L;!5%[1?N.
M^*[*0O[J/K0%-?+I,&&76%IU\5#F2/\`JN.)/=G'!R?>T&.XX'5K7TI^9*&3
MF8_FYQ<4,4I09:&XO:3;9+(LT(K#):68!Y.5LL,+(4UGW808PAGU]JLOMAMI
M?TJ.=K_L&1S%XE%@1WY#4;^2YN!M3(3A;K^,_C)U^4T'E]Y_+BVTN+2EQ>?[
ME?\`-D-GD?I0<_V`ED17*7B'+DX4C#8GYVWPDNIRO"7%8*<UFZTG+>/7/IG'
M\^GI_7P/U-_3>["Y8JF2-3N'$37#L1$PL!8PS=L;3OJ)VP5]@%B4V@M4CI@4
M6/&O!KCQ:(!MMYN+0UACY'?=[\AR.4^HASO*'V`+$5'B-!Q]RJE5%HXF.2.S
MY64U)<HB/K15DGS9\W0:2]A1]L.A#QLQ:L`B@.RZ76G%($]'@W`CZFW..PW^
M%L).HN/472DS5ZE+Q4+;S4V!;+!=QS`K,3KP(;8D;QR%EZL]5DN@@$$(&+_:
MFJ420VV-Z,LAL&LOJ5<V:Y1A(_:/'SCULV[-7,`XRRPW.:[Z^052FIFOR$I7
MFZVSQMLD8/(&0<>?',27YJE#OR&"5B/8'0VH.9@_5K[#5ZZ8TQ.TW2P6CHJ6
M@MGMU1SE[7A+$YNW%3:J6P[VUL+_`+)YZPCU.?@P1FQ:ZIQ``*1$ONK)?5E;
M8<(=^I;S!/N4"U'5'2-MU=E1\_?@:[R]B`=F!V&2%$E(NK@[$7Q/_1PP@]>G
MAL8'Q5S`RS0W3$."BEBM(#BT5]1WL%%BH=$]K;3UDL$G>R92[20'*:#J@:]:
MR]7BY,6EUP1?':SM5FYU:[1Y+)-B89*&D!RVV&(QD?#S_@;J3]2[EX[841H/
M&O\`$C(Z,E)&1G#>PO69<%879-2&:Y!UQT?AH/98V?K+@+[LKD^*Q''L&BX%
M):<;(3@/O7_JJ\P8*\MRU@XGV*RQ`C-1EJXU`\[.,RP(LJM5LR0GX.WAW3BF
M]'W!=BL+0`$>U^I2"E#1"9)TAHC!;8=@;O\`KH<L]U7B8V/=^N#:XT^9`Q\<
MU':,YJ=;6E*R2Y"!`0T>>51J1Q>IM''L)F'_`,DUP,,-HU`;JEN)?<1A8=0R
M7U;^1HK3!HO7YRMD4$C1;JHD/LBX(9D@'RD/.',&$GZ)C0'70LB^QW#*G$)6
M2U\2WTI<RD.;T3ZUW+#7&R:K=(+KLW-9PZI*I%$JVX.</`7;>OS1I..,9DSI
MNHR^G8F.F(!I1[B\,*'02T;A#K:5*1AS`8=;AZV>RC@M=]KR$OU>ZNW7)<LJ
M+R1K^M]<UC2M:Y#SW'&J[#VEK`$2[ST?INIVK5]2LT9%,IB:4B,E6WX1R5->
M$4QAO#:@M`=574SJ+F#TF<?.(_.W3]HUC>*?LRZ;F1!CQU?HNWJ6-8-KSSL3
M.!$IKZS*M)7:$K+L0:22*B<8&9(%PL=2$^P.PYWZE/65`4J7:B)?FY:UQ$7;
MW*[483D-78Y_+]BDG9-T2OL3M7AZN-(*;0*QZF/LBF9#:<,RXY[W,AM"OIX]
M9L@\(58MO\U;(4*%(@-/R^XJ<Z0V')S.95\1IW&L,K8&4T8<PXTC.&WLR#SJ
M\*=S[_`UQ/U$N`_[BHRL3R;Y\P2:^BJN3(H&[ZJM5JDJM#.UQJ7(/)UL](09
MQ%?.-!;R`XP@(0YYD7#32O9X&WD_4PX8RA\K6YWE7V23L'*A/EDFR>]Z`367
MHQZQP,F/1R17**Y*'+"(KK16,O!*85GXGLOY(89PV'Y/^K)QW<LTK58/F?VG
M5FL%KBY^.FX_D#0GZ9%Y%=:S*0"&C(I^S&S4P0`"5DEZ+^)A\%M2'?;A+20Y
M!,?5(XXR#\\U'=@7957X*R3#LE-0$?ON'*$EV&3Y(^%9FG)BFR2I@Z$6<GXB
MGTJ4I>'7/8E;WJ@.0+^KKH"2/-F2>>W9X#+?DQC<;(/<GF)"8%3#1+,:3)IE
M<U9:WG;-/0\=.>U26\@O"MC(3AMM'L#:0OJZU"(E9:R0/;)VO0MLF40;4A9@
MN0\:/+2+-<S*.P;,N<)5Q)&4:A2Y<AP)+C^,"9(>^/TR\I7@?=CZN6O!F;`*
M-VJ]L(XL['OPKHS'(^(:8)@#8"'KLC"3K2*7AN=CCXN%8%<:5AEE0`XXRD*0
MPG.0U\I]8*B339J97M>[<)1Q^+<@AURO)R+D4-03AD3+_I26R:0K)D5F?A!#
M5#X4TTI\5A7MPME"_`_>?K+@!R)\M`=P';K#24M+'S$O(8Y,M.R$H=*`)C9(
M\\T2O1KQ<L>&VAE\IS*ENL)PVK&<8QZ!4N[T.)+/73S"I>J+9R!Y(<Z#I_BH
M+)ZUL7**X3.R;I69FU6#8^M3]<4_$A7+177Z\.')#6!0>!1G$I%6VP6V0YEM
MT,^^E+K)V[SR?YDGL]C7-;A^YJ_:-"B):H<7-IS%(H5JF9^IR*ESPU5BXF@Q
ME9@8VOP,;&0T0Z"S)Q4>'@<EIMM`V,A/$CZ[&[FVPFD=[';9A$>4Z8+C.]YE
M64D/9&RYEU2I[*R6\Y$;]&W<K;3Z9]$X]RO4-^A?K\[]A"\DC=[/;+G#I!CY
M*%[I<)4Y^PR+DS#.9(R1'&RO\-OV>C64,^F?8G'N5[@ZSWU]>CE5M&F/Z[?[
MH.P+:-$V?:8FN[VIFW-DBD529TW+Y<1?VXR&9BYD&0L>1!F,1X+[#4>\YE27
MEM(4I>`B9ZG^M+G%?7[O5M=]BG+C0G`^*Y(\P>/MAB]$VL'_`"6/V7JC:E#H
M@4[90)S$D0.]R!ARY5]<@&!*-5HB)^0LSX"D-)"[?MS?FAN$6CDV_?NW@*I1
M]=5!UAJ<N,F]+WBU@4NO+*=:C8<3!EJV/>7H6+60^Q&"$G&NI<=2QC&<XP%2
MOD3VD<MN\2>?X2=>O#N>)XLV#840QN+DWL2-%<@U5?5VVH`ER?KLC,&0U9;A
MR6I^GSQ<0AYJZ@A8*9P&MMW#F`ME<']7[(TCPYXOZ9V^Q3Q]FZFT3K#6MT:H
M$I,35-Q-T>HQ59(77Y2?#CY<P%U$8E>%/,MYPM2L)QE.$YR&4O@/`Z\VS3;%
ML/6MUHU3V/9]06*V5\^"C-G4H2`-N%(>D6_QW)^L,6F+FZ\F>#'6O(KI89+3
M#V4N?&O*,8\"AKOGH\YT]8W,>-YS\=]<D]NX1D^##T.%W@;?+QO73D@BP1KE
M=M,OD>PMQ>QY&)UY!2$7F5EF1J_&.R;6?PEO(&]`F3ZV?LC\!]^72*XGWK5R
M.`&T6KP9K/6NHY9<1)ZWF)U=UKM$B*M6+52JQ7JL'8[+?K`>,R&R'^"C]62\
MZ8G*VTJ"S+#3<580$RD*:U(1ZRI$)!;&%_$X3$R)43((;RXA&5I8D`G6_=C&
M4+]GJG.4YQG(4+?N\S:XS/72&(4H$HHGD4<HM@F*44,D`C1SC1P(*W$SC$@(
M^A&4'#_&EM&<LY=Q\OM4$!W#'DGL?A[1*3VBZ>VU:2=MZTY9Z;X2P^FW[?9I
MRA;-X[-\<Y*<D*]+P4H7*V>;";L(0SZHU!#8T.2\EJ/^->!W!PNT3FO-7\K_
M`+"W"[>UDJ.PZQ*U#JC8Y#ZZCYL>R:_N]5M+V^9"#$A=DP`Y./P'@J_>Y,"0
MA9#W-9=(<;7A2TX\"6CMG_(_\L+L"_%G8FLO8X?\@<XGYW)F(F*1C6=CRZ49
MF/CI8SV)9]V$X0.YZKSC&<8QZJP&%?UJ:<51>FGB7!E5?8E/4\WM2>9A=HUQ
M58M/XMFVY=I\63;`6VQ^76)MB1P9"G8;;Q(1#XY&$X^3P)W/`>`\!X#P/+_^
MVJ(.?W-TH!"*_@X[BMJ%`)#I%@??'EQ;3L>0BOVPX<Q%M`K/?$2$E;2_B;#)
M4^M*G4X5@)[/IPY?#X#;4;A(?7$V\?RYV8WL>VQ%B+'N(0XFO*(NK'R$6H:6
M8G`YT]MQD%G_`-@61@D+)4@C+B/>%B_L=YTT?K@X@[2Y;WZI3M^BM?8KD;%T
M>MR,1$2]KM=SL<94JM#-RDT\@.,!?FI=E9I6&RG0P4//I'?RW\:@@2Z_NI3<
MW-/?E:[7NTU4$?;KI/3%HU[P$L=3!L>GM*Z^=@1&=0M)"8G8L039-&;;9')1
M-1)ZW`T/C',+*6@A@,-N^GFOS,X9]BG$[A3P!Y2:MZ_-+6?CFNXG-6\/4>N>
M-\%:9/8>X)B4GYP^8H%E15QY?$4@7XF!TM/R#S?L9][JW,A(KT9;]W_R8<Y;
M\?>?O/?A]V/.6*GT[%+K7'ZVZZVC51=8$_YU`[91L&&JFN:03%QT^1884/.)
MP7X#6UH9&RI2"$X#'KL-ZW'>H.[R_;MUS"PNN=::O)/F.6_#Z%+;A*?M^F6B
MTK<C[I4LRP\K2JW9]6V.R,$5R&37BQ@GPAG&%YPHD=X.*\E^2W#/GWRGZ3^4
M&YZ=#[7XO37#;M!W%LZG[UI58F7V(>B:NI!DOB8J7ZUBMER\1.5XQJ(3AIC)
M.&V26O;\[+BPK0WCL4JO,[<U<U_UK=3'7WQ9J\._+3ENL&T=`Z)VG$-P4=-Q
M0]9V'M78-_UF%3=-5.K/2;+$@6^M$2P1((669AKV^T.%;@[?>*5OUIK#5G&?
MIIX/UGD`S!ZS@KIM6T:*U!M-S8FTF1I&%V$+5-75S7D;7$0%UG2`B(5`+B2F
M'<*:2E;2DI4'-)CL=X:\?=6[RX\<I.G'@I?N:T).3H%0VEIZ)I\/I>AMRM*@
M9:F"3]>JI<Y(6B;H-P9::F8Y$T,\0C\L$]UDE!C1`9T1M+ZW^074_$\E=3:5
MX=,<]*IRYX;52].<7-?;QUD#K.+V3NW6LP-58.E;5L-B<M<\S&3+L)-2L>TB
M)66ZX*,\O`['Y`>E9X#P'@?`EM;HQ#33SHSCC#K;9#*&7'AUK;4E#S39#3PZ
MW6E9]R<.(6C.<>BDYQZX\#RO.LUZYUWMUMZ-]!:"'V'8NQWC^S-5#;+450N5
M%9L]?Y`33396F-94:+B*35RQP)3#5O!^..'8AU>P5"O8ME06PNS/M+[$N*^Z
MH_4]ATKUU:;T-M>%L*:9.<IN7%5AK'LVMZ]ME:B]IBALSK,93P/]PJ?=&&H@
M*7BGF1$(*66IYQ*1%!B[5.P#IPMG4YV6\/\`KEM>-72\;QTY3;-5H>S2]@B9
M-VQWG7]RG[\C4TO,.6U%SIU65#/-O9A7"HL4)3&&W&AB&WL!D#TC0NQ9?ZTV
MN6M2;6N6DK]&U#?5JA=CZPUW"[*V!$?X?NF\6N3CZE0IL:7C+79K3$PST4.R
MX*0XXX;CXV'',(0H(,NL+N:W'HWG)S/W?W!W2&TEL'6NE*[59[7D'Q<U-1>0
M5[V#9K11J_6:X=`UVI538EJ&H=4?5-E1[YN$"!LX?<RAIKV*";'M6CN%_:UM
MKI6J+=PIVY>*VY>5N]J5?7=9[`B7(J1M,1QVD+-%U=-QH<H06[.P$^PTP]@%
M]T-#SJV'W<?(G"@ZK[8^G7HNXWZ=WERHY5#[KKM[!UM5Z=3K%G9]O)F=B[&&
MU4SK34T#0*8"7#PUTM;"Z**::(VD>/9<2Z^<IB/]^&@H<V'@MM[5^YE4G9D%
MN,>GTRI0.W>0;FHJR3MG8O%C4,]*R,6G'("N1)4/':SV55`XU+DU$2Y(*0&7
M$+ROT5A'@9)ZQX`ZQW#MJ)KFL]X;ALFE[_R'YT:JU+NB.:IJ$[)HO%W08>ZJ
MI9<4>4M,)9Z[,2H<@$[*I,:_#*"-2V&MHP=UG(1+'D6&$*A6I.Y2C0TFQ&GF
MIBI_]R?'A2(X1ZR7&`I7`#A+HIOR-,9*0YZX]C_PN86E(6\;Q]9N*HW7[/\`
M8J_V57RD:5?XRHY"MTRUZ->,N1$',UV,M]$I,\92=^S%>(E;-(D1XZO@R0,(
M<\U_+F&LNX"Y]T94Z>U%UK<0=1[!JMRUWLN*T369ZP4:X/`K^)R4(?E9*R03
M`1TAED:R'SZ)`[+RT/+D#7/<G"\+2D-P[J>>U_ZY.)5,Y!Z^-I<80=R9T7K"
MWRU_IT]=*S#:YO<Z>/>YHH&MV"`E8\J'KX#I(Y3?YG^NTAC`SBGTJ0&,.D>\
MC1N\.>')NOT_DGQZG>O3COP=JO(>8W+'QM@BI&$V0=L$JN6F`M5LG99EDAF)
M@AV7QXT*$0:^\<TRC+K^/C6$,=J^U;R7D.,/,W=M#U#QX@Y#1^[=&UO1;UW7
M?!<[7USR%3MYR'PQ19::J=NLA=+B:4++-3X:`!96.1E1$:`MW",!96Y\\R]F
M<5.KN1YLUV%H=HW!3:!H6T"@VF-FHRD%V3:UHUS1[(O$(W9(J:"9<%O9GX(B
MS7B&GLM(RE]>,H6$I*!!C41QAP8KY@S.7&'GAFENB.EB_"7^,IU*W!LOLK4V
MO"<XRI&<ISZX\#6-,,,>_P"!EIGY%)4Y\3:&_>I#:&4*7[,8]RDM-)3C.?Z)
M3C'],8\#Z^`\!X#P'@/`>!M<G($1_P"N^"(D9;\Z4%CW\QWX/_L,'(P[ER7/
M_.-"_P#8<'EO&'?A^9_^_'M;5_/H&Z>`\!X&V/RB&):.B,A2;JY(.3-0>P`^
M]$AIBW(UM8\C)(3D<$PW,EC(K2\X40EE[*?7XE>`BI1$JR4\@*3!P+)R<7EN
M5`?CWGUQ9SX"S16G\)41&&J8RZ*^G^PAA27$^J58\#<_`>`\!X#P.`[3V+#Z
MBUO>-H6"(N$]"4*LR]JE(37U/L&P+O*A0P;IC\?5:3509*Q6>=*0U[!PPV'7
MGG,XQC'_`!P%'7[$D/8-K]A`<)'3]YA*99.N"O*LE7/1-U@:!-L]TWB/%WN7
MAJBRW<[NK5D"9)2QU7_ZR6<?'SAB/(&02X.&67U)H>#%A.?DM4:/==3P1MXT
M.%.ZDO,#:*XYK^]BU2]24Y&4Z%L4Y-/PE,DAIMF2'#(>+.%_/2.X42T.R0^%
MQ;P'@/`J?<'0N;DOUV<PWNM.XTB@[TI_:1V!7LV-W)3VMA@;2A*]LJZF-ZBK
M!6$5>O5R;V%81HP')Q)+3L>SEQWYQ\.MNMA7LXU;-XQZB[*M@0/V'-8V7;FS
MB!P*75-V[KS.[5TAFR4*%5JJU(BCYG,]%[3K,S:EM-,R8XH,=43H)Q6'F?>8
MCP/2#TS%:>B=:TT?0R*,K53%:@8JD&ZY,B96IF5BM1(E:KZ(B;AB#`Y@&,AX
MAD-E[#[V<-#I1[\^WP.T?`>`\!X#P,%^1O6EP4Y71]@'W;QCU+9IFQP<16R[
MR)38*$V/'P<+:S+J*!6]@10(MKJOS6&4,>>>CBA2'?S7_5SU<SGP*L$[TN=Z
MG6[L*?5U3\\";[QAG$.G.:QW%>'%2=-BXW\"US<4!3[O5-@56,+L,TR2"&?6
M4_MR!LIP6I*G%9R'>7_LQMUC\D]J4?BCVB<!['I[9<>=1HZ5C.3^L=/;7UAK
M79-W`IZ7T2,G;#,R=&@&$6A9#LN?&A8&BAOE.2,YG+"`QUZO8;C]R`[F.U[B
M/"4S2F_>OLZ5@]O5'3,!1>/EDU%"7#$KK6O5W:&M9:'!3@:H5BO1`P^<5\X=
MS.7F/F$*>8R_X$[,D;%C?8PJ4<\6H8MSJ`GD1PJ,AH05E/+2/RXR0I0[YKR6
M6&_>WCY&,)7Z^W+GJM/@91=Q;AS/5/V(NQIK<<4UP\WXY^6ZPLA+8R-=SJCD
M)0@D3*'7P<.-H<RO*6EJPM2',)RVH,:OKL3=]L/4;Q;D=DU$*@V?\6]!_P"%
MQ],E:&+!0<=?+`#6740,T27(YS9*^.-,?E97@<O]C\HJ&Q%,-H";GP'@/`>!
M^'$)=0MM?KE#B%(5[5*1GVKQE*O1:,I6G/IG^N,XSC_AX'E'_:GU[1]!=I%(
MU_KL'\6H4_B#K,&(B;898-C/C(EK%N`\C,G-7^3LDY8I`R1F'GVB3"GW!WEH
M4E2<-(PD+/?TU6#E]>6Z904J5_Q<[E#=\C"S$%`)>-E\5NGJ7,LVJ'+:D3S'
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M/?#33/,VC5-^#U,>F5/4;RS_`$\Q7)K<][098W7GP+2B4F$D"MN2:4$,,>X+
M7MA[.NJ7:T-:M>77FAPMGJ!8ZX*-)JLW)?C\NKVR,GAW<DQ3(*]D+L#!L:A*
M<O?E!!J8=4A3*U+3G*`H)5N6,TWV%;YU'QLHNW>5_7_HE_G?2-=;FX%\>Q.0
M+5!E>Q720()3XC5*M9^O;*+KG]0&!%B.S(6$BP:EJ:PK#C.`Z#T!Q\XT:/G(
M*G;8U[W1;7T.%*JN.UM`0W"5W2Y-FLMBHK\(WEFU1VX)N0#BSX`KVR(9PZ@Y
MN`;?;]$N*8>:#F7(+6G'N0YC;-Y*<1M,]D_`7#X:`JQIVC]:"Y&,U5%R^IA8
M*:90]*;H><BYJ?+$E)8DQ@01#`A?R@(94SZI#L;EE`=7?('B=I30NJN.7:KI
M'9''FHFP53V%.</J]<JUL6ZWZXU&S[<V]M=F&L4#LBV7:?'BBQ`T.S;44$RI
M'P@(RE/@:/38O#O4.D0^+?&3C;S[5R/WKRDZ]H*0WKM70*82N[(CZ#L:@6K:
M$37(*2=)QKJK2FQJRF:BX:3(L)#I+;:7'V14N82'J;>`\!X&BDEH:CCW''B1
MVVPBEK(#;4\6PA##BE/"M('+6Z2UC'N0G#3N5*QC&$*_ID/'JZSS3]A=ZO$&
MY60@F6F+/S\ECR86TRQO^2!Y%V'*6-HRS69`8LQ+SW[63>]7#!FB"7Q?:[A+
M2\)0'J&]C_5[Q:[1=31NJ^2<%+?_`"M&2<K3;O3R`(:[UB4/A)&-:2)/NQQ<
M@Y7VY,D63(BL.-A2!T6'DI+K;7QY"J)QZZ<M@=8?4UW6+Y+ZLU9.;1@*)N<7
MCKR/C`*C)6"QZRG=*JIUK?J9TLZ+<Z;7I@AUUAT*0R&HE3BW&&7L90IP)NOK
M!PD:9TD\06CV1I5I$QMF;8;)?(DTA206\KP8"\TD["L`%1Y;"7&T,^C;*\84
MCTSG/@0?_99ZCN+&E'-(\L=)RVNM/[!O]B$XT5S4-YGIBD:UV):[M'W4I%FE
MMFI?#C:U8(!,N3,%2-NF0H<YH1P>2+?&RP#D,T:EQN$XW[%^L)K5_4%7U%L3
M_,MIF;?@H;_'W`2]DT_ALY&VVQ!!5'\BFK)LLDTZ43+1CS7[9U+!A'YCBD.M
MA(]WX=;/)7L?T9H>H\5K1I&C[#U#OZL[D.LNWHTUW/PTR%L+5<;C3AH"V`&`
M1LO.//DQ<A%EBG>].,Y;0EU#X4"NM??$EO;D1JKKUY.[^JW'32>R^1M_VQRD
MY#4Q\NG[0W1*U<>SSF=:[\V)8G'Z#8J&7,U=I49F<C"(B%$(7C.,9((:R%@>
MH<'<1.W:U=8KF)U@U^LQW+CM)WJ=5*-S&UGANO:^YJ<<Z]J[0\A&LOU4<!JP
MQLQ%LJ<=#'`&CXTAE3(KZ\YRD(VN./&#L*>U1<."<AP2ZA-9:EO%%&J]RWUN
M>VT5Z:LD[KV,+K<?M-C:4!O*X7,':,K.3`]DBUHC8Z-)?C/B2*V*X0,Z$^^]
M*CI+B+U%Z;Z?(#E7`\M=F\OKE!:/F;H[M[44C8*#2K'8H2W[YV/6L6`^.@WJ
M;IZL@%.UZ-FI9J0'0^(TT6ZV'Z-A9BU?N'C=K_7>LM=!<D]0V-%6IE;I$1-'
M;4H;DI:4TV$`@7))6&K`Y@N0)_"PZ1AK*_8ZYG&?`P([4-/:T[$]!Z<TGK_D
M+Q8PN,Y8<>MOR<5L?84++UG8M:UM:)*7/UR!'P;UA'FI2]D,8CFQRX^1"=:R
M_A0[CB$>T(G>P#I"9Y=\P):W<8.3'$CCAPNVSJ;4.A>6&D=3#:]JNP;-2];[
M1G;I9YFH.`:WN5&@;@$<<'D1UQD-YTB.2P20AK/I@,&^7WU'*7LH>A"<-.?J
M;IM$,0*&DBN6&QX:=?C]*56HB52G5JDBZ>UXJ1,'BECNL+?*:0*S'ML#,I3\
M;F7`ZPL?U;^[&ZTIW6=N[7:';==OQL#$/4"Q;XY5SM-=B:E)"SE9CG*O)5(J
M%6#6Y:/8+":RQ[!'V$.-X2I"<X"5WJ=Z:^T[A?S'B=\\O^PI/*#6,;KJZ0(5
M(:Y)<GI]@2YR:(L6NS$U4KJ/$U6UPH<6J1:_'-R^@<AUDAMOY6D+0%M#P'@8
M/=C'-VE=>7$+<'*:Y"Q4ZO7E;)*JU(.MU9J)]]MC^,,0U9@B+/*Q+4H>Z^Y\
M[H8>7Y%T-A[(S#[R4-*#"3I8[F:KVVZ+M%\_VIL6K=@:RLE7I&Q(O"&#J5(6
M^WLV&;&!UU)?M3IR<C*U68P=V3),'"<0I[+OPH9]/:$WG@/`>`\"AM]AZ_IK
M?-7?6P]H['V?LK6?'SCMIV*HFA=.<FKAQQM6A;=OAR9CW=\6042DCQ^VZ)8)
M>L#1I4%!S[D_\SR%J89$R^0P$:?'[G)OM745VEUW0_$OEG;>-NS=BW&T5SEE
M8.4H5WD>,<*!4=9C0>M-@2,NN&G["76`!1OB=COQW769)C_1>(97E0<![+^Y
MBC[HX2\!^)?#_9-AUE6-<:^KNV=XI(N6Q+-M2IWE"9JI&5`?=DM:H*8OMID(
MV[S$U,13@S#`BA@F0#G?;AO`95=C?,[4=UYD"[/NTAV/8XN7K@KP)M](7PYY
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MZ^DHRP)*B335+<_,;)%#>4"T*C(6F/`>`\!X&*5DYN\7J=R?C.'=LV_4*UOZ
M:U]7MD1%,GIB.B52D1;;OC7M4A8XP\MA@VZV>R>J8^%:]\B6.A3[;2FL95X%
M,+[1>P-3Z_YH4^S9"V'!\AW>.U1KD"[`'/`4^TTEO8>S)4$:U7`F5)IE5,'L
M84<1!8)B)$IJ9>:4:W@)36"`RX^JCL*OB:Z[`+(?*:_<OCNY..D7>?2REUE$
M<24Q:]7QH=^D)..359;:\Q8822D3I6.4M=JDI-I"&AFU!LH"YEX#P'@03]%,
M)&3/$KE_49<12ARNR?L.KUD9$+8$_,;E-V3GY.!)JN%-&.97%2#;>"DD8):6
MG*4.)2VW[0DSY*<)>)O,2IQ-'Y.Z$UWNJLP)<>;#`W6'_-)C7XMHUD'`LNP\
M+,M#LHD7LY9P1\+BU^]:5*PG.`KC[CZ4.;/!C9(/(+J#Y*3]7UW256*RSO$6
MWSUHF(RTQDI;IG:5MH]%AD'B48>E$_IHJ`@Z<&%#EDK>>(<L0A+^2V@[[UY]
MBBK:.M--T3VI\8-Z<)MZS;%;C6Y9=9#V?K6P&E59F1-L1$KKJ0G'JL599EHC
M$95@T6"7&&R/EUUW\AI:@L5:ZV50=MU*+O6M+?7KO4YEAE\&<K4L#,`*R\,.
M7^*^\`^^@6089*1\P[F4O,J5[5I3G^/`YQX#P'@/`Q-Y'<[N'/$1N8SR6Y'Z
MHTX=!T;.RBJ]<+2&-<3*-^X?KZ;#7Z2+DNWVH5R;&<%0B,",>6^VI*49RG/H
M'G,=WG<!&\T=MT_9O'_2>O++PT<8V3I>AW+DEQ5ILW7SM[IG9**VS;Z9=3EF
M3C>9O7=DJMFP<,E$Q&NHC4/"LOI>PL.V_KMSW"KA7S"R=<.0'(2RR5^MFT>/
M%JW_`*PRWK#K@>*A:N=M?6C\MM$R<J=_LTG8*K3Y(AF-F(2(8C2G4.K1E#*G
M5!9QV/%5.?\`LC:/S=.0;]7,B>M_-FJ<!4+O0J&+LV1+Y5SI]+U7>Z_-MR,W
ML.&=BG$R(044\D\LR%P=C#`Z'D.!)1W&?B?^5/V'X.S))$SQ`WNE]R)&<+-9
M0O7\TG\C`S1@#CPHZLX<(3AW'_3I7ZI7C^Q0=0="]%@-7]57$K7L'N2,W>J'
MU\W/G6B.FD3;T'_N+(';&BM?S#P]RO8(,UKR#M(T*2&+(9$#=!RTPR.TA+*`
MF$\!X#P'@:"5?D!HT\B)`:E)-@0AV/C7S<1K)YB&E*'$=D,CEX";(=QA.7<M
M.>S&?7VY]/3P/+?^XL&]CM?BSA7A3\KXC:>S,BBQF'7JZWFY;"8&_9GY&RG"
MSG\HRR][DJPAS#6,X]WMR%B7Z8,I-+ZW]O0ZP#?THW*FWGL&EP040)AV0H%$
M9(7$S8\H>3;T*=BFVWL$"Q[D>YC*$Y(;4C*`[.^P67H'7?-/J>Y#<Q-$Q>X^
M'U7MG('0^UTWD^AQVOHNV\@8&F5BBR=EC;D2"?+050!C9BQ'$I23'B"17R84
MR3EI3@2`5_IVZN=EQLM:$=8?%Q84A:'@:<^32ZG"Q\M18IR*$BK\Q::C8;.W
M9H6_0B%3,2\T$*5EHA`AS+3J7B%!'7VS\1>E;K1X13N^ICKXX8@;PDL043I/
M2.P8Z>,-VE>FY**)EZ7'/4B97/2#L?7<$O/R#:L@-.X:24YZ$(0Z$1?%&K<.
M>1'91U[<:K=U2\&:%K7F!P1_[A[;56ZY>PI.,LEF!O=U&+J\Q*IQ.#R\2)KQ
MP$4=]Y48\">XM/HXV,OP+,P?1-U(Q]JLAMYX(<3JIKZO5^4?K<3*`6"/N"(:
ML/#-V*_VBR8VW)0,K4G&'FWD.E1PAT>AY&"W4J5E.0C(^O[K?6:>7W9AO+BW
MQJMFM^-,AR6A=1:%NVM$U]C68M/ITC#U_;U1CR;5NFV0MIK<I,U4"9D#(F!_
M-P-AMZ.-9R4Q',!<5\!X#/KZ9]/Z_P##U_IZ_P##U\#2"M$9$$3)Y$(.;:84
M4Z*.MD11J&\8>>$8(>*>':RYE64)4XM:4Y],JSG^<AIH6'`K\6%#1:'VH^/9
M^`1LDXZ2?;:PI2\(6;)$EG/^W*LXQEQQ><8],8SZ8QCP-T\#^*4E"5+6I*4)
M3E2E*SA*4I3CU4I2L^F,)QC'\Y\#!#9W9[UYZ>V'<-/;-YH\9J!MRC.#AVC7
M-ZW%3ZE9(*2D&(Q^,`FP94]LJ,<.;FPU)]S:E8:(2Y[<I\#S#.'>U>'T=W6Q
M&X+)<-=Z\A(+G;JJQZ2-TG!"Q/$0:CD[7/D]F2<Y:-NN4_8L)7H*!=9772U@
MJ?-)SEM;;`OP-9#T..9/<I6>'N]XW4D[PS["]K,#4=N]&S_'WC&)MBG2\?*2
M=GA61"+0Q?8?-=/@LUC$BMOX7U$!2`^58:]WID('>YGO"VKRKX%;1T+Q0ZZN
M?U/5LZ.)#W;?.2W%J1INOZ[Q[CX.R6&_DBR8,O:&QI"6"K#C'YSKD=^N#:))
M8)22VQX']^N+W:\<:'P_XT\`&-'<K[AL>@2-N'V=LV@:<A)S16K(J[7Z]WIB
MU7VY`7IZ=AZG`U?+Y!AQ49^4ZD)]+#+ZVTX6'>'9Z;J3[&FA=)<7^M?EUH/;
M^]]"[%AN0^U46JO[BHT`Q2F*G8Z8X4-(N:GEXJ(FB;18A6F1"7AG5(ROTSC&
M%8\"2/L.%D?^_3Z^L?:4D"28_(K>#TR$&X$_AJRQO$^P*4A:!&"OE&'DTK0M
MUE[`Z&U9SGU]R%H"?(H=!8Q(CF5I;*8>'<4VKVN)0\VIM66U>F?:O"5?QGTS
MZ9\"HWK+Z@?!2B\PD;ALENV)M+CK%P$1*P^E;[,Q,M+S6S1)9IZQO;.G\59D
M.WT*V199"<!`,0IH+[2%I)<ROU0$FA'UQ>DXE3JW.`VN$Y>2M*\#W?<PB<8<
M(P2K+2!=E,H85AQ/HG*,)REO_3QG",Y3X'5NVN@WH"T5K6\;@VUPVUA1M;ZX
MK$W<;G:IO:.^6(^%KU=C29:6.=]NU%OOJ'!#<6EII"WG<X]J$J5G&,A&9UN]
M-?45V%6WDCREJ'$RD2O`JRJHVO>&\:H3D]JZ\%KKT!DS=FPI^2L6U7/\C>SL
MR5+K83K24)816U*^).'OE("6YGZUW2:PV4TWP8J&4%R3$DYAW9.[2%(RPC#:
M01UD;+=<&CEIRKW-MY3[LKSG.?7"<I"&[L'Z3^L/1?/KI]U%IKB/5X"L<E^2
MVW(K<=;Q?=GS;%PI-(U3'3F89YBR;+9)B(J&]CTD@F/-9*;,1C"62_D_'R%<
M'MCU9QPM6X4:`ZN>M0*CZXL^\[-KG47+"J77D'.V7>%TTRP?%[RHM7B-D6W_
M`!P&D5J3L<4W(?/&8?$/B7'V3G1"4Y\#I)NZ<4.%VL]J<3>3W7A1]J\S-);F
M1K"S\@P-L[G147J5-1L\H^68LE`W92#92_Q\_*`F5^-B84<=R"BG6R_>ZX0\
MR'[U_$R'%[3FP]!<N>N&5@.36Q=);(V'QSWGMW8&]=<[`)Q-2U=8#L.(!&^*
M+!"4NK:PC[,S7VA8N378[84`&\IQ"W4NAO\`6M,<9)OI<YI[AEHH*2YG<6>1
M>D:+5MLT?<&T6IB>U_N>T0I!!VQM8RMM8J[,?#@@2U="(&@@TY-8RO#KZ\*?
M4'JB<'/ASPLXBJ'<C765\9-$.-N0SACT2M#FKZNYA4:[(R,N>X#GW?Z67BB'
M<H]/<XO/JK(92>!"]WO=9=^[5>#RN/NK+U7J3L>J;1I^UZ>W<\DC4>SR4`+-
M5\R!M<O%Q,U/P8&8.TEDM$`CN.J*';95C#;JG&PARZP>CO7FD]HT'97`ON+-
MV37N/_(ZH[0W#HVAQE)LU%>Q(#HI6S]:VZ:J]R-G(6=M]>J$K"M/FLJ5@$?"
M'1,K]Q&0N7>`\!X#P*@?>C/]947R^U[5+7UB&=F_/?:C^LZ;:=;578>U*7/T
MG5.<K%UU:9*3J(LS5(IVQV2<_4@#&XC%'?&XMUWX4>Y8887GNOXJ\)-3;HXY
M[!Z5BM.7;=FWCKCRQX-W#<<(+5`8*T437YU#VJ/&3-!)JB$[/+_7A-5R/#`R
M+F&<*^''O:^4(^]!=R?3K3*@:+1>@;CX)70)\U3H.Q-\4;85YD;#=!8D$N/I
MV=OZTLUE/8*8JHB5"-ECC#+PE;3:<ND+\#.C6^\N%&JKH%H>,^L9RI$MW(G5
MRX8_7$HO.R(;96J]12H1LI>1*X6!-Q-M>UA:;&P-B>%`_/'&6-G!.'%-C8#H
M:CC].?(TRX@\;OKH<[N2]"UA?;3KF'V'IO8>\YVI%B4Z9/\`QI*.9DM@@2%3
M3<(^<&F"(XD85]#Y>,+2IUMU2@QV@.2'0%==FNZ8JO0'R<L>ZI.R$Z:#UFYO
MBYLVX;8T(.J'>KQ<$+M0J>B;,DV/=2^ZL-UY939&4MNNMK1@/0UX6<7M9<-]
M&U[C[HS6]:U5HZF)9)UO4HB3M,U8FF[&(/8K>??IBW(Q+R=J-N\G(9R\ZMQU
M0J6?DRA?JRT&6G@/`>`\#SC?LL\?=C[L[BX(+A];!;IR-B..]-VW?X%4]6=1
M3G'F&T4(=8:_8*_N6ZW*K1L:FV1$_F0=^-0[`Q30N$/ND.+;8"";DSS.Y';O
MMSZ^76S(6P[=U[JR2XZV>?!E;'L3=R:_1]D7Q,U7K5<:"=&:XF+':K;9S8EN
M87(DAN0*X[###Q(S:G`M[?3M0UFH=BU=<BF(Z-KNV](1H=>L9T/+;&A\P<3L
MR,CA]@_J8B(C,S80$*'CYVV5_*<T0OY,JQZ("ZKX#P'@0B=$`RQ.//+YC(S(
M;&.T3G^L(=MK##B1%;MD,)4^RZ'&R#;BB$.83^4.R]EO"?1/Q_&K(3=^`\#"
M+GGIW@=L[2DS-=@M5U!*Z5HT?)%G6O;Q:(.-H0L^1#Q<G.1%Q9.BIFE'$N,B
M,N20!8A33?\`;\R&U+]0H]Z(V5LW76[<:W^N':>='('5M6VW(73<=;G)'7`7
M"FNE;3V+*+I]%CM46>#A+0-00/\`#&H>9OP,\ITJ#RZ4R<I8JVR@N^?Y9SE_
M\OS_`#/_`&XHW_F$_P"P?[G_`&K_`"(;_;/_`+B?TGS?X?\`L?\`.OUG^`_Y
M/_TWYG[SYOUO^O[OG_TO`SE\!X'\4I*4Y4K.$I3C*E*5G&$I3C'KG.<Y_C&,
M8\"F_P`).IK@UV1<Y.SKE=R/;N&[I?2O8MN/66HPH_>5E(H4;5Q(77]YA3AA
M8"6Q,ADURV3D@['8&E&8[*7LIR,I+2/:&9'>SU7[/WW3^)G(/@?KK7_^^/!7
M=1^\ZEJ,UL*KZFLD:@B.V/<72-=U6KOD[`V#;+=KB`"%%:<$<*:()3ES+CN,
MX"H]2>K[M%/UPUQ<V3P9W#/S/(O?^H.<VK=@TURPU746G-H7,V2K%\I?)MZR
MTH]4?(P-2!(!'CDD1Z(*2-28<<6"MO*0N,7/6T=<OLQZ;MCV(J,E*#U3R=Z)
M$36-9V*66:_OVPTAH<B8GZ[*VBJ+R+9UMIDX0H61?:&R'@A(#I;+X2"]P>!L
M]5?8@DN1#B6'.'/()I4A(+(;$'6[K6P-L_*L0<LG&77E)0GV-K5E:L8]/`^W
M5'1:17.O+A%.5K7%4U[(3O%74,Q(`5JO5ZOX27<ZO&7FQOE,UFL4V)<D+#:I
MHF4D'FHT/!<B4Z0IOWN9SD)%_`>`\!X#P/+Q^W976K;W'46O*.`AFY/B[IX0
MB3DPV8,#Y7K3LW(@KUC1@ULHB1=;2*.0:V.*(^ZA+SC8Z%OH"P_]-AU*.O+?
ML6&9(/P45RXNK$"+*2)Q1H,>Y4*?E"'PTC_XT*Z_A&''78H@A@A_+GO]JD?W
M!-QVT]=U)[*.']YTG,PP9VS(,*5N''N<D[1*5:*I>ZAH<V.JEGDS@(NQ-(CF
M,FN#EN9C#26@"","X;?6ES`1$=*G;KLZ!_:]=?;-DO1'+71\?91J3L_<;LQ4
MX/?>O:'8QZ?(3YE]O;XM<G;@S82\B"N1II+$NR*\MI#*V?B4'&NT/HNYO]Q7
M+F^%<B>45&TCPYTK^N5PSAZ71H[85Q*?N4#`(VR7?8\@RGR4*>3,5T1#2\2Q
M8SHXK.4#-.9==6'4'5O];S>G`3L$TYRFO7),^U:UX[0/(2O0;LR<+)IGJ))8
M+I^KJZ!"O2C:M90TQ7[A/6F5901(BQYJ6A$)4MQ\I0=\=T_-NR\Q['`]4'6/
M8ZWNKD3OFI62O[^O%/F[%*:YT7J"TUP2TQC]EV-KV.DH*%LML<@6$!Y,E10&
M&R6VBT.(.2H<,*Y+M@>Z.K+KGJWXI]=NX>45.TO8H[4<+NFZ"*U'8=D\@;Y8
M;"7/5VNG5'5$Q3]C&V($T'](>T2B4-&7^*2TIT53BPFMUGWY<,+'IB9DN6@V
MZ.#NXJWKFKRNVM([>U)NRJWRM66^2:*R#3-4FD:]AIW;=L=(D1#06ZV$0?F/
M-8+^%"6R/@"%\S[?=3T1+HK%PZ\^0V*+/G7&R:OO%^WO^)<-BZQBME6^B1=V
MCJYLVBAS.%2"JHME48DUS`\J,:*VXI+&5X"1OJR^S5Q\[->34-Q3&XZ;;T/L
M:PU6T2T(;8I(:^5H^SU7$E,'5!^3K-?#7`9<I<05()/EFX\?)0S@*<*>RPM\
M+,W@;'8K`)6HQZ4,%ESD-)=^,*"AI*>E2W6AB"_QPXV*&**??<:&7A&/;C"E
M^B?7W*3C(02\V.YNQ:OY(2/!K@1QUN/.'EZT.1)6R*A2X^&U7IEH`>'7.1]K
MM92H=J3E(2&.5(_@@OF.+.8(C7GAB$J2.%5[DORHY);"V3R;JW+;O$XC;.TH
M'^)KS>7#/6EAWKHF;M$?K<\;-FK.ER;UH:Q":_W&%,U3\U!3,L8%)3JG(PHQ
M$>[E*`ZH@.RGZ_A"[8=OGI*VZ;IV;=K@.@-U_LI*R;9VK#U@(>#N4SMFV6/<
M%?"=M[%OB%M./0TS*H(;4MHG+:TJ2X%VJ(Z0NIRV;,KG*5OAS34;1D[56]RA
MSY-@O>&\3Z!?SX\:0J:+>[3"8##)J6B(903D2^VTAM;"VT)QX$'/;9?^SOC?
MRWM-W`[2^/'`_COL*7,<U%H7<G(MUVQ;:J.O\UP61+U^Q#\4K>SH$.P"%X&]
M2"I1(ISBGG27\9^)L,X>4'8WQ7Y>]379#JO3?*2EVS:FLN*N\*/,Q9FSM9W2
MVVB/UI0HZ%O.S*R77UDRM\US:Y.2>#&L)4/%NRSN'2&A1$K;4D.`?6GXZ:RB
M>J2#Y1TO58ETWQOC5=_U3L^-.LYM=K/(>*TWLK;->U.'=AIHNR5^-D&:U+J@
M$RRP$.,0RTM.C+PW[5A5TXL$=H/,WD4[JJMZ9W'H"A5^]6;6#_+OB[J*+XQS
M.EH28D':[23ML[]TOQ]UU>-PZMHT;G]C)04HX+_D3X@)3ZXO#2W?`D8ZM>3'
M(_D?MKINK7*ZW%VN[Z*Y]\G-2T,R]XF('8<AJ:D<'5SM&LEPH4OE<DW-V`FU
M/Y:GS`FS)7##.7BG76W7E!?EGMEZYJLN'7[/?Z37)Z0=A68^$GK5!0\N<]8Y
M$B'KS0<;('CF$NSTL(Z*$E"%9*(:6VU[EIRG`?>S;!H5*6PW<KO4*DLIKYAD
M6:RPT"LAG\H<'Y6$RIHF7FOS2VF?<GUQ\KJ$?\RL8R$/7+7O\Z\N*D]%41N_
M2_(#95DD=G5&`I?&T>'W$>+L[7.0XH;6UW13)B9EM?V6[W<]$#$(D`/5XYI]
MQ:$"L+?\"/FB\;N</>%_N!:NSBG7CCWUIS]@IEOXX\/H5VOT_<]B>'CR8>)M
M&YBZW$3E\&-KLX]B1,C94Z-:'/;<S^LP&I&6`M)TREU'755@*/0JS!TZG5:*
M`@ZY6*W&"0\'"1$8*T%'QT;&@M,BB"""L(;0A*<8PE./`Y/X%='O*E]@:0Y!
M]5'-P#CUL??VF^)F_-ORFWXS4=;:V5L2+<V3JU-<HRJUJO$G#F2I[LQ'/.-S
M2'TLPCS*%.X5\R&W`IW8UYPLCKYMK8]0T;]BVC6'>)G(=G8PL%Q/T(3`G53D
M)'6B$G:E$Q,V9)_JVFZ_9E@'G_(Z;(C8<PPN/4M&60YM=:!U@SEGUQ=--<&^
M\3B6O3`%$BJ3'ZGX=:RFIJX[#UXJ'M4=?;]<+O;;.NT;0:G8E$KEYT<1AAHY
M3*&,"94A09>Z<Y2<<*#.<FMYF:_^P+%\Z^3I<7B<YE0?$C7=3V-5J\)*4N6D
MM<5+6E6LKFG,05VEZ.8Z[@F*<_%9(RV/AMT93SX8.<I[=H^4X*\WM6ZCT]V:
M<@.9?-3D9I_:-XWOR#X99U3,RIM(FP['>8*>_P!NIJSP!4=_D\5,'Q<4P$R\
M`Y)K;R\XD=S*P]'[@U8H:=XD\<A(9EYE%=T)HN'-2BO&0,1^8_IVBSF$5_+D
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MB3<M$*]`HD2[,P1&NCQ0P4RJ2%_Q[];)K22XO`Y2B4(^+_3QG*_`KT\V^'?8
M-4NP'8O-G@KRBT#J:?W7KWBSQYN5$N6K/]TKH#0H799(,SL^3B9^ZP,0B$@,
MV,@AU$>&2>0#'*;'RT[EYSP(Q-Z?7<V;M7D%Q"W/S)=L7,/96Y>1&WI7L;WI
MJ7<8&EZG0]/MUQ#/'F+H$#8'ZY*P]+I<T"*>8*!'2$HIYAP$<YAC]=A`=DVG
MZP'%39?-V(U):-'7RI<"M2<*(&!UCNFB77654V!=^1;NXIR=M;>UI^)8D+IL
M6=33K.E`LA+0P;38H6!FUK2RVIP.,<T.M3N4_P"]C358X92^B]8<4(G3?(+B
MQINZ:BJ[.N`^%W&_;TM28F0D["Y6IZEV>U[5E$Q;$L&_!ME.`EB/$/8SCWD+
M#F^H.`GV#.-&BT]=&B^:_'2LZMH6L:[(T/DJ?J"U1)@Q6P>0E@5+T>O;9<L<
MQ._[F5*M(5).#E5H@1V/E!HUE]QY7YC00!1_67WMZXVOJ6_0O`ZRW9/$[?EA
MVY7KH3):@G3=GVV#NXLI9;:15ITVOG6BMVFWUY<I7(7\`5L*%,^`-*7WW9%T
M/3EI%ED[5%F24E`YK^&Y4@,`9V3#D#2`6&!5?DRHH>,X@)AHQUX8J.<6\X(^
M.I.7%XSA60YEX#P'@/`\MS["N[=2;L[;=UVFM0=N`1K:MQO%K<E:O:&X1J]S
MFN28V7FXR+?AS8A-6HUCK[J6X^<))F3$Y6_(+8%;&!;P'1?/'F?J;DSL[6MQ
MXT\687CQ2="<(J-HW8E*O-43NUS6#U`VI;X.)(UH;59!H/;DE"4R[PMK#E+%
M^O#,DXK,DMQ[(393P6,/IY7-A$=SHH,E7=O.W>9L.G]FVN\6:G!"T:4R;4R6
M!2B[F',S:2K[;#YLUQL7))/YT9$_LU*:?)?;R%V?P.,3]VIE4?!%M-NK%:*D
MT$.1HT_/Q4._(-B*'06X"S(EC.%H%66UAS+>%81EU&,^GNQZANL1,1%@C`IJ
M!E8V;AY%A),?+1!PTE&'CJSG"2`CPG7A2F%9QGT6A:DY]/Z^!"=T,B1S''KF
M*3&P8<*P?VD<_"/4$K,D/)?%N4D))K<QEM&)=#:1?Q\/)RI*?@^/U]49Q@)P
M_`BH[@^>]_Z\>*#NY-:4*LWBT3]I'H0Y-BND)!KHB)V'EU-;#B:$9ARR[J+J
MT@.P\]6H1'YCHGRE/.,!#$OMA%KH+IFO7/.N:>Y,]D'-_DKROK]BO=^W-!Z&
MN44=IC4HM4NOL=UF?%Z3:8#F-7RB8,(5F6JDJ7/P3T44^(L=*UJ7X%E_5NI]
M::2HE6UCJ.CUO7FOZ1!`UBI5*JQ@\5"P%>C%/JCH:-%83C#$>$LIW+;?KE*,
MN*SC^59]0["\!X#P-BM+8[M8L;1;3CXKD#+MDL-%E`.O#KCR$O--G@NL'!..
M-YSC#S*T.MYS[D*PK&,^!5"^H/*0=FXA<TKG6Z#":M@K5SKNY\3KRHYF'J-3
MHUG6FM1PJ]4#;19K5;SHR-83A"G),E9&7/7/O7C/K@+;7@/`KA;KU]8K;]FS
MB[9(NA*M4=KSK<L-HEK%C:$GK-G7\45N2^U8RS$P,(@IW>Z#)"P!1;59D,#1
MX#YR9;*UN!H3@)"NYTQ`/4SV,/.%#!X7P\WP&AXI+BVLO2-`FH\<?&&LX5\Y
M;Y26FLY_MPZM.58RG&<>!K>I79=1V)U_\26M>%5N=HU/XUZ1H\?;JI<8JW0L
MO;J12`:7LZ`%(C3I1/S4.\UXJ,(?;++$((2KX7E>Q:4A)-X#P'@/`>!Y;?W%
M)1`?:@S&1TK+AO3/%O1V+!$AXD!(::'C[/M(B/>F5+EUARI4:^IO(J4!H;:]
MR\Y5\J?506,/IL-VD3K7N3;M>D&:I(<D=K$8L)ULC909R8`K^L!&8Z(J[8XD
MM5F/B<)R2V[DILA]K!"'&LNJ:\"WIX$'W9'TLU'L]I>S:KOG;K$=*`3U1FN(
M>P:MK40;9/&YB&K^`[37[5=2[43,;QK5RM+Q$K^*:J*<C%/9:%>3ZY<\"A+R
MCY+=S?0EO[=G#"L<O[W'5"?V7,[<KNPW/]N]I'[4$M,3&1M=NDW,;'@;[-U:
M=E*Y#@JE85]P5YDMM3J</,.L%OAI]'\EN^#O;V%%\/X#D)=;X#1C+%?;=;8@
MJ+U-4:R!BO3L++#7?<&HZ?EL*"O83Q,9&`%9(ACSWV4ML?&GW-AZ*W5EU*\3
MNJC6%JJ_'&!LCEDVN;$3VS;]>[(#;[K8U1+9^:S729^*A*W$NUZG,3!+02!`
M!&''2'R<MI<)<\#'WNMJ6TKM9.J&,U=KG86S%UOM2XZ;$O,=KZD?YHNL4*F0
M]Z,G[S:5O,F1U:J]98?R\0>6PIIM.,X0MM[XU>!UWW2Z]L^U>6/3#71./.P=
MW:ZIO-LG:FTY:$KDJ7KRFAUNKC1]*:N]G;0-7H24E[?*,E1*)$P8-Y^*4@A:
M&UXSD,8NT3JG@.PSMAZ_X3=6BZ?9-%F:#Y"VSDC=-<'V+6^R\FUD2G0M':MU
MN#_;`GPM?NEDC<0,6Q(J)?P7,K5A;2/>H.?M=8%2Z#M+\G>975UKV];ZV6_J
MR(#O6BMX;"9F8ZY5^JW95OF+77IN&KL7:?\`.8:L$G!1T0"EU,N\ZRG++I/H
MI83O<7[?R-M''FC7WE70J10MVV2NC6NT:MU038IJ/I"9<)B3!HY,A:_Q#I>Y
M0+#_`.+*.-H9#R>AQ#'O:2EUP(W>??,?>=YWW%]6'!F9S2>96Q:@#M?86Z)>
MNE/4SCEQ2*,-AI[:$7)314$Q:=O3$N-B)K\7&CR@;!A7SE%"J&S[0SZX3\)]
M(<#-$U31&DXN1=CH-LTZRWJUF8F]A[)N4\8N7M]\O5C<;0])V&V3[SII.&TM
M"MNN>UEIM"4IP%//[#_+_DCQ-Y+;(XOZDVSPTU9K+9W!O;FS,P).E2ZQL:2S
M<IR;IV:Y'3U&@MFR1^ZXJL0$MFK3$DBJ0V&9V3<>=0I"7$A'OT0\`;;V94VK
M:Z<$T_:^OWC]O:U17)(38=;O,=L[=LQ9]1R[NN+O%Q<5<&1ZS.:R`(S781$3
M81QX?,N_,$@'%//_`#AZ6%5A%UJMPE>6=F2_2QPT8T8H5@++HP3>&!$_BC?Z
M+7PBH0W_`!_7V^N?YSGP(C.X;@'Q"Y;<&]LZZWE7+K60-7:NM^Y:MLW4]:1+
M;#HXNEXZ3MSPP,S//QM;L83^)<I6*M-3`C,OAUYP93!`Z31`JB]3/%.F4CZ]
M_;QRA(I-/GHW9=2Y+!<>MFIJ4,/N0/753UP?KN9;+(EA+?,40.Q28CCIL4+,
M'LJ:<?3A[_E=R$[_`$;<D=4<./KM<<^0NX;:*SKO75?V'*6$P0LXXA!$WO>V
MQP-3B&CHJ,;<LI$E+,@CB85^#^P<PVLU#7R$-AE#Q%[?..G<!";+U/PMW-N7
MBYN^(HS]BC6]N:0ICEZ73IQ04>!M^B5Z6GKG2[+7H23=R*EUXG+?YCR/E'6W
M\>5A7TYA\`N?/!3MLX9\_@N1>O.PGF]R#D]]P=3I6P=,C<>]7K&TAQ*LC2(U
M*ZM?KL^S83:>SE,-'18`>#)I&<Y)&4]A60@4Y&ZJW-V`]M?)6[;8G]J\<-K5
MG4\ARGEQ(*>*VY+:9G:!QUKN]HJA0$O*V'7=CI&0+7),AQT9',R!=7)*0&Q^
M>^RI]877@OK$=?>\*5IJX<HK;S$WWMV*I-1(MEWVUR1V'.3,_+DB#3UFCS(2
MSI-:J\)*6,LAUR+":#R/ES*<YPY[EY"<[3W#7BEQ]L&P;1H_CWJ?5,UM4F#,
MV$11*9#UP:U%UMN1;A"I&,CAF(O!,>F6)]JVF6U*R^O*LJSGU\#);P'@/`>!
MQNPU]^>`F0A[+9*V[+01D*S)5XF.9/A'BL.8;GX;]G%RH3<Z$IS&65D,D#^J
M<86RO'KC(<B3C*4I3E2EY2G&,K5Z>Y6<8],J5[<)3[E?USZ8QCP-D9"GTV(P
M]Z<$=K3L8*.%7DPN&C0Y1MYU9<D[/_L7,EL%,*0A(WXK?QY3E7R*]?3`?UD&
M:18SY)Z>P]7B(>+"`K.(H9K,?+"F2KTI-KFL.J,,_:B%BL8&4A#0_P")E:<J
M4ZKVANSKC`@[CSBD,##,K<<5GT2VRPRC*EJSC&/1*&VT_P#ML8\"F3N#L>Y+
M=^')?D)U>=<R8_5G".$BAZOR2YTEQQ\K:3*K'6?$7<&=8L#F-UK$3LEQ"P(,
M5PAF3EHH4B022&TIP=`;GS+X:=;_`-=3C%J?D)K#K_H'-7:\_=)?CW-R>X[M
M8%[`MU-N58O-M/G$U(FM["UM*SL3%U8<.3+`KT1E,=\SB,M)>=;R'0W7/V*<
M1.YCD;-=?]WZ6^/.@*YM'1UYG=E;&ABZ/&WJ!H<=0X*`A"Z5@;2=#M$:^?@L
M$,`N+D6B00G62!LXPPIS(<\VCTO\D^D.[7GL-ZRMA&[VT[$'6RT\G^!-RKI(
ML#=="9+M,[)UJD.17^9%6<ZC5AX2.B?SX\F4$]A,ADMQ#A`C@6MN$?,S2O/O
MC3K/E'H29=DJ+L>'R4N+D<-,62G6(`AZ,LU*M@#3CN`+%6)P-\1_"5*9>RUA
MYA;C#C;B@RP\!X%%?77`?C%VZ=\?;A7^:#VV+8]I0BD0FMZW#WR4UZY4J_2%
MP52!3'%5&:>(D:^<,ZT8,V4R%EMU]3R,/.O/J:#0]HW4+TK]6M'UK>=@TKL!
MW];-O726I6K]!43D#)N.[#F"C(A3@1$OBLCEA,U;]N(P&RT8DXW\K"<H,=3[
MD!6RWI&\5=,6G:50F>+]D.MFL[([#7@"B=F6PKG`U`.-BJ=--2@#V.-C!)PU
MJ?V*U$M-/G$'!2\.^&6.&0VK\T)]>F[J)ZM^WG5N_=TUZN\S-0:ZUCO).J]=
M#&<K1)O8%H@@Z-6[(7.[#!&J1\+7Y8PZP^U`P2$L_$UA2'%8RKP)!N(/"71/
M4SW@P?&/1]]W99]6;EZ[+!M2?I6ZMG5NZ2VS]JU/>$:-41*7!R53I,?/V:I1
MT$3*C#1#I,@'C))2TCCHQ[@MW5R)8@:_"0@P0T</$Q,?',QX911H82!!6F,"
M"&')084,/[/8VXZE+BT8QE6,9SG'@;UX#P'@/`>!6N[$_K#\*^PSDD;R6F+_
M`+)T!9YR&C`;=#:2B:5%QMRFFI24,G[A8'9R&EE/66QA2.&'R&FVLJ<0I]_\
MA;F<8"MQW%<5-=];W(RA\>^/<LQ1:?KWKCT6_"(3%P`-GV/;ZGRPMME(WK;I
MZN'TB1*V#1;!$Y*_*6DPHL`E<9@P!DEMS`2[?4S#+I=>Y]P9PK))SV[^/==*
MB:\)6WR(5#6BY27;NT\95;+9JP?6+-_ZH65#E9AZ0+2MUU]U3N5I"Y%X%0K[
M7W'G6=QU1Q@W?LA6X;'9J]>]EZ2U#5M0QFJ&D+LVU]>.7,1JYF[.`FUR$3)'
M:=3&_C1B1B2L2F<9P[EEMMP.G^E_OC.M^Q.)O6S5-#:M"U0]5ZYJ[2-Z*V&=
MKZ[5W7>NP+`PE_;5;-J1-6M.Y9&D41Y\N,J;K@*["6TV\4.A_*T!,[T-?J%\
M7>3+\/\`(TV3V5]@+I<>[(D2;D48GD#8A_PUOOBB(1ET1AHGV-)RWZ$>N<^]
M2\8";CP*D_V5]30>K-!ZHVPJ4V!M2[[$YGSX$0JV;!!"LNKZ)M7C#>J1?M1Z
M5L#84$70]%3[%+%DK/$Y+4DUMT[\@K`SZVTA:)TGK*C:6T]J_4FLJL)2->ZV
MH55I=,J`+[Q0M;KE>A0XR*AVS"#)$DW(0@Z4*?=((=?7C+BW7%*RO(=G^`\!
MX#P./6YMQVJ6=IHE0;KE>FFVRTL-E*%<7&DI02D5Y2625,*SA6&U9PE?IZ9S
MZ9\"HG].F5A8+@-R.20?*D.R_.JWP8V<U,AEE9Q.N->Y`5@Z+CB,O,E,#J6^
MZ00X."OT:RZC&4XR%PWP'@5?]LR5L<^S3QGKUDW?0]"2LEUP0;KL4-6&+4_R
ME>B=X[!LLKHBFF;%04#1CX?,"5/NR<&TS..Q(:V%+]5I6R$JG<J/DKJ@[$VO
MR'Q4XX?;X?<>'2,IW#0NOYHEYO"2QBFE(?:94A>,)2YE"LX;<:<]KJ`W;J5J
M=3K76SP@(JU)I]%38N,>H;?*PU)J\=4(%%ANU,A[9:S8^`C%N@Q*9RRRI)[[
M3*L-N%$..^F%K5X$BW@/`>`\!X'EE_<+`=E>W:(&BVY$@MOBOI1HY13@S44&
MX;;-AC`*9+<<;8CQ7W'T)<<)6VCYU?U],X\"RW].>=)+ZT;[#!PZOT0?*#9I
MF)XJP1!DH\<33M6X=;D881I$@)DXU!;K2WLJ]&FTIPIS^%Y"VSG.,?USZ?SZ
M?S_XY_IC_P!.?`XW8;E3ZCD'%KM=;K&9/)28W%AG8N%S(*`8_*.2#B2*&R7D
M,;_4=PW[OC;_`+E>F/Y\"%CO-U!U\\DN$1,%S%VC1]35RZRH(FC.0DM.%P=1
MAMN%P\U_@;,IL&"!EX[-</PL@AX8M!@;@XJRDC$.AM82'?G3OPRX9<-.$>M*
MUPGFH/8^MMDQS.PI?>H,A'6*6W;-2?S-.6:8M`,3")E0XO"5@`C8$$:`89RW
M@=IS+V%!*4PPR,RT.,RT..PVAEAAAM#3+++:<(;:::;PE#;;:,8PE.,8QC&/
M3'@?O"$86IS"$X<6E"%.83C"U(;RM3:%*]/=E*%.JSC&?XQE6?3^N?`TSHB7
M2Q#,OEH4(@E"6&B76Q'\%8:PI18R<X:)6S\7^EE6,Y;RI7I_7/@=?;;O%GUY
M1+/:J=JVV[BLD-7+',0]"IAU8C)FS2<'"'2T?7!)"V3<)%AGV4L1(`;CB\M)
M+(;^7+;7O<2&.')GG]QWX3<:('DWS%M#.A*Y*Q=+<,J$VI5@O(MKMOZ9HBDP
MM:@629NXS=7-E\XD<1HK_P".**^4M*66U*P%36R_<$W%';+G@8WJ_P!D/ZWA
MA"=F1CQM\GH?8SW'%R)1-`;GMU#?U2>B*JY];EH^2#DD2+4&\A:\?GJ1[5>!
MA)Q\^QK2N,NPM_<R!>+DQRIVYRVF\6[:]LA[:;K76?'[-<3;('C_`*CB6+!1
M+6-5]GV/6L5,'W(&,DS1)HIE@N.((6X<.*$Q?&/[2G&&P57D-M'FWIN7XC<F
M];5],+K+C0N0V?8-D;KJ<=&JL`4=$ILU#I-&BK#*W<X@$%LCV&J1A>?<I/M;
M6'<^DH/C9W\\,ZWO?F+P*E:!LF#W`5!TZNC[`&O&Y@-3G;<JZ[-?I`Z6C*?;
MA-23MAHL_420WPGCFHB$E@8I3.5+6D(*.-_-PWB=VX\L*+T<1\9R%XK6QO4]
MKM7"D2ORE9(V-/PTK64;6%X?P`\8,Q6IN@:\!,:E)JTI#0QA$AEY@TA,:VH+
MB_6CVZ<6.S:@NG:MFO\`#=[5.%D9/<O&*S%J?VMJ(B(L1%7/:F!DQX#4W%_M
MV6T,G"-Y;7^0TAQ#3JOBP$:/8?W^<*0%<J>O15?Y,QV_[!4YOCHV.9QWEEP9
M=WWSKF0@*C'"*F[E2Y,9]UZS-DL9,:&3(M!/)$^5*VWO`Z]SPBLO69]:?F7Q
M;V7?*MLLL+C[R6V'&6/-#G*V*/`[#;$E(&&L=$E#8^XQ=O&.FLI7\V7T1QJ/
M1]S*&4M.!WIT"4^LVOZ[NEZC<0)ZPU&VZCY+1EJA-3D&YV#*0$SL+:P4S"5A
M<$+#R[.PI"-<<9#2.XLO!;C/QD97E.4A5"ZJ[1R.@]F<Z.8O5=?]':BVEJ7T
ML>X.L)G55X&EMA\6]+3`)DNQK>Z;9#OY<+.V]^/+43'#J1.@2IF6DY;^1IK(
M2#]6G8[RH[$MZ=36WN6VS(':%SKW9!S1UW!@@U."UZFJUM'`@"4AQGQJ!!5R
M-FRA)"U&O,.OI=<7AW#3ZE-YRGP,6MF4X&2[P.V.[2Y5*D&D4SLLAFX86<L3
MUSE&8KC'KNND0EN7&3IKD32R6[VS^J=9>:=&E&#4*90*PX&T'H^TB+:A*74(
M5CY?AB*O`1;/SJ%4_P#$!$B"-_,H$4$)3OL:Q[LLL,M9S_R(0GT3@.4>`\!X
M#P'@/`>`\!X$)/V%.4URXH=7VZK)K>VU^G['VY)5KCG3#YTV:C"G#=V/&5"<
M(JTI7BPYF+MU8IY$E.A$L96IA42I>6W$IRA096]6_#2M<%N#_'[1`-!@:/?8
M37-8,W2N'DQK,18]R244*9LFP'W1#+9=K;D;8Z4L1]Y6?B"^%EO"&FT(2&>4
MX&@L!>5,O$K#6DYH89B,?(,R+ZN.1K6)9AX1"95C"A7%>K2\-O*]KC><X6D*
MP#]&_P``^U;0K_.P>*P1OOKVO`-=_P`CNM'*$F<:\<JL0A.N(*%B@K&(8T-#
M&8,!DW'RG6F"2QWL"-8&:"TJI.%I4E7\I5C*58]<X]<9QZ9_G&<9Q_&?`JM<
M+=*YZG>[.U\(=7`6YWAYS]U;L#DQJ&'MELH-E(IN]Z4@$K<\C'RQ$.%LH>N)
M@&`(H&*(),=)PY^4Z\]@92TA:F\!X%%#BYV#<5.L[O:[G+7SFV!9]"1V[;$"
M;K<NT:OVL<S;XJM6*;>$.@HRO424)=C9*'C_`)0)).7`IK#S:17%+3G"PX%W
ML]AO5WV>UOB7,:9[+M/Z^C]4R.Y"K35MDZ8YF$KMZ+0J@-0$?,0^J=;@6V`%
MC)JC?L&GB7A\..(&<;2\WE:%!'-,5CKTY`:_LDKO#NQXXZPW%&"3VP>,.O\`
MC)H/D7J_C7HK;4U/ZDEJYL6(@P=?4^0KUIV.S6)%J_,GA2I\:=(JE!E./"K:
M\";/H^[#>M_K2XU;*UIR5[3.,NVKI>-DB["BYK645O,V.`K(NN*=5FH$QBU:
MC@[#^^9EZZ:ZYAS#ZB?G0[CXU.990'?=*W9P6[-?L8\;MN:)W"+ND'C%U^V:
M_P!%M^L&F7*R%M`C:\Y5)JM[!?GH\>4P@376PWW6!VQVW6##6%X>3E+C>0MK
M^`\!X#P'@/`>!0:^QLY9JSV.Q$;&V*RP%4L''CC:99[R[#1.*S%,A;2WW``5
M&WWZ?KL],C'S1MAR1'L1KC,>M/O(E$K9BT90&=7UL:U9+L]V!$VN(K,PJ$YE
MTJV'/V.JC*;M#;=-LS8AU.G&)&/8:)IEU*.>9L0]92//9%<89-(2XMX`+??@
M11=MO5K#]K6G=3ZBF=ZVS0;6J]P,;=%M%-JD1:YB1.&H]PIH\:PU,RD:+$.C
MJMGY;1J,.OLN#XPWA"U8=0%9_K4ZX^/N].1NQ.'EWO6W8^R=2'9??M]SP$S7
M1)9SDM5KVG7VO],6R_;:J-E,FZQ>LV?4)LG)1K;F02QG?7`@0RG?A"?/Z_\`
M(FR_$/D'*'(F@WI#L=Y^'?I)MM;+U;R;R$LQ3\$,SEAIAEH8MYQQY#*G6TFN
MOX]V%>Y"`G*\"N']F*.>-XB:#>%+JP90/)0UUEVUX90%E)'&[D$$_EDO*EGB
M$B,$**0H)@L[#@Z5,,K=2GT"=7CO2)+7.C=14N:GY^SS59UCKRO3$[9;Y-[.
MEI63KU,@X,R3,OMBBX.:MYDF_'Y)(E"@0R9(AUPIYEMUU:<!W/X#P'@/`XY<
M4AKJ-I1(K-:CUUR<2<Y&XDU2+8:HPK!*P$PJ5S"C4,95EK`B<DY<]/BQE?M\
M"JS]0F/`B.#O*B+AR&R8,#FYL`:")2)8`ERD,WKW6J8RR*'MJQK2RW:`L-G-
MH/CHU]"'O13.,^N$A;)\!X%=+8]0O=J^S-K`NC[2BJ"!4.K*+M&Q8+_`!]C2
M.Q::/RBLP/\`A#A\_P"L9IQTV3.9)'GXWTDBV1R`\XREQ&4AG+W;O%,]1G8H
ML,[$>\KB=MUA1&5MMX6,362AS0O<ZAQ'_L2#=<&]/3US\OIC.,YQG`<QZO-G
MTFR=<G7R?6K*J\1U@XO:/K8=@K$?,6B+:G*UK"!CI^-L$M##2P58*@Y2,(!)
MQ)OC?":PH=6</8RWX$BJ5H7E:4K2K+:O8YA*L9RVO*$N80O&,YRE7L6E7IG^
M?3.,_P#'P/UX#P-JG)N.KD49-2[KS$<`A#A3HX1TB\A#CK;"<H"C1BS7_P#4
M=3ZX;;5G&/YSZ8QG.`^^)$=R,Q+"X=.%<!_8#8$:4X^6PH?\EK`S*O8MQY]O
M./8G/IG*LXQ_'@>71]N>QGP7<`G,4(%B3F.)VDP!CI1UQI$<T=*[1"?_`-)\
MP>&]R\EI5ETQ#J!UM86GV9QE7@68?IT1APG5E:7S7(HIAOE!M,"*+CY!LMY`
M[<!0GY`$IAB)`::0Q*.+6TZL@]Q]+F5)=2Q\+:0LU;9_<SM9+J-)Q%CWVR0U
MD)UQ;[+2";]KZDW^MQV9*HV6Y1PIL8E0D39$#OLLI,$((<84AEYMW&%)#SB/
MME[WY;W/E?ISCQM&0IY.H=?:<K=WK=<AZR6W5;3L8:BRC.\MU5:XGUD2<=K(
M\])R%?1#B3Y>6G*PC)8"2L)RX&#V@^('=OV^]>>BM1:&C*?L#AIQ/OUKUW2]
M>`7?6FHS&+>>B+MY5LO<9892LG7K+`=U_P#89)$J)R.V\5AM*5K>6X%ZWHOK
M/:GHW6%1XD\X.*^J]'Z$X[\=-=4K3U^J6T8/85UOEXC3W,3J+4B'NL\R`PJ"
M.1GX&H\8<,D1:$/O(=;2V%@-2T(],K4E.%*2A/N5A/JM6?1*<>N<>JE9_C&/
MZY\#9X*R5VT#$&UF?A;$&&>5%EEP4J#+C"R8.4I-CB'X]\AI@\-2\8=95G#C
M><X]V,>O@:I^6BQ3@8LJ2CQI.4^?];'/F#LG2/XK+A!/X(CCB2"_QQVE.+^-
M*O8A.59],8SGP/JR>"0\2..8(^^'E*3&&2&77A,J]WMP2VA:EL95[%>GNQCU
M],_^'@5>_M"<">4'8YH3AUI[B9K478M@:Y%GSMGLK^8D2`H-2*U_+QB;-8+:
M^R0?#5EV0-9P^@%+[A>4(S\#V6D>T*Q6N^!W:)I/B!O*G[3X^[?XU4*)T7$/
M\R.96R)9ZX\@IG3,:1>XW77&CB0RF^0P9.D#*UB#'L]"?_\`8FHUYU+R6<_K
M0L!#[Q=Y"XTE_LC1+U9-&;AUP?(5C<FGM!W+8=C$XN:WWK.WJ"B#[OS?KD#!
MQ$UL1FJ5:B/E_I2I@Y,8B7&R*EP=T^/6&6W.33&M-C577_-2'[<]'<I.9(<?
ML2\\NZA.;CLE9<C2X:VFW#7>O^*3-RJT%*V2-BHO#T2-"!+=`1(#,$1ZD`E,
M(0&]:*W''G6.\<MM=\^AN%6]-EZH#O4_J_3V^%QP'[37X<9!3&TMGS^[[_+'
M;EW->I\ZX2[VK,,1\L9.3K<Q$'?C*SGP.\-'ZYUKP3M_$/F/K7MJX)\GK)H'
M:U-NE9T30[;GCKM[9U;W3L%<CL.O;SW18*^[;HJOB*<2[+@64>79C12"FWF`
MQU*>>"QAS(KW3ISGM+TQUV<[..?%GMCO9+45J/9^@=P6.GYO&QK7(W*;GM?6
M>2ULL2JVQG:UJE'69>;R#)2)'P!>SUPZPAT(&>UG:';#M?F[JOBQS?V=7^#@
MM`U':Z?4-SSVQXRE\<-[6JH:ELHLWNM_8#T77:U.7G>=,LJ:TH4X\<2NESJA
M<(CO<6PH.S-F\/\`?W7-K"[1,G9*C5='<T.FVW,;P!*VZ_L&F6+DOJS7;UE>
MC)+<]W_.K@MCVY82I0ROP--F&<F(2V.RA7M:P\%LSZVL9B4Z3N#2Y\=^0^.(
MO\K%8EY)$W^+B,W9L-$(Y'J4PTN-&BT"H0*.K+BQDMXQ[\_QZ!@/WW0,QP_C
MM(\I.LS2!-%Y4V?F+'#\CKKH33,T]<[O5[)2;O,2+FZ(2M5HAK959EIZ/8/;
M%GA).*/D<,/99?6M"7`R^Y>ZMH&INQSH8@:7!P%,BIKD%S=N=A5'0'ZTFR["
MMG%V>FI>=EA(40,#]M8YDUY.5+8;:!PXVRP@<1K#*0K_`&V*N<;V/=NUN(AF
M)RNCV_L`U^B1KU(I+0$4T7PHI]QF85[:+\_F[1!A$F[@@Z*RPP!B;2J2',!=
M:.4V%_&AEQI5.KF(HS!HH40%%*7F71/$CF1#"(T\"1ED2,ODV6CC17&"UK*(
M=_(;7[W%K]59#EW@/`>`\!X#P'@/`>!5N^V=5IFV]=5&/CKO"5&`T[R=TEN7
M8GJY+Q]Z55,3Y&IPI?7LX(&?$Q,O79[:#)KRS&G/1ECWMI4M&$.!V!7.E*[[
M-@H7:.E^][M:DM=[(B(NS5B=:W[!7&.LE$M,0F04?$S3->A!C$V-R16:%(-L
M)::&?0E#3GM2[D.*;%Z:^5>N0R-B77[$_891]>4NL62:M,_;;'&C"PL5!BLV
M2Q3LE8W+;'0L7!1E/@9!TETP9SX%H0_\OM0MET*_6EGHCF5M&A;9TWVI]NZM
MH'\KZ_UTZ/Y`WA_2EE_QB4VS2)39=SD$R-<V$%9K%JDC.MLN.YCWP%J:D`B,
MM*PT]A\+`SW1CV6?M&EC_8@YVXA<2$>IX9Z"+S*+BDE#*E6&CD;:P(U(/A8>
M2.[D=;;3JD*6VXE*D*#"RA\=.5G$'OBX!:K7SXFNQ_:)&E.1TSL=KD_9/T,_
MH+1-CG=>M3CM;&K!UXL2[E/5$-1L6#*K&C)$P/*V_P`9IQQSP+IW@/`Z0N_&
M;C?LVPGV[9''[26P;5*QP41)V6\:JHMLGY"*CAI(./C#9>?@I"0*CP@Y@MII
ME;BFVVBG4IQA+B\9#K8O@OQ*$"=9I7&'B_2#C#J]F3D8[C?J(C,C!1-FAK#)
M01`W^,B-+;E41&&VWEY7D(C+93:,NLM^@?M_@+P4)0MLCA9Q,>0[GU<2YQST
M^O"\^["_57K3L^N??CU]?_'P-K3UU=?R0EQZ>#W$;`3C0[*V,<<]0^U38G_W
M.E2O\0]^?B_X9]?7_P`?`Y]J?B#Q3T-:2+OI#C=HW3UP,KI-2-LNL-6TNB31
MM9+-B9(F"-D*Q#1A!D8](00;^6G5*3\HZ%?UQZ^!D7X#P'@/`>`\!X%"'[+E
M=';[!)V]2.PI;7,S6^`]2%H\+6:*;LF1W01<[EOVJ#TQV&K::Y+P1\44W)GI
M/,(L`"6Q&6B@?P""L(#/+ZKL'%5VI=A%!4X#-!QW*+7BH0BE*DR-<"5L'3=7
MF*@_7GY:?M-HB&"ADX6L.0E"4#OX_%0E#C9"5!;L\"%/N'[4]H=6,!JW95=X
M]ZSWWK2W#W")MH5CY,4S1&Q(ZZ@N5PNE1&OJQ9(:RR^T79^%5-ND!Q8#I0^0
M$+RK"5>U88=])FQ.NW9_(W?VW-,U_?.C.=W*FBU+DAR\XT[U9G`UUN3LM@L=
MJI%@J14S2:='RD69#W\PN*7#>C$A7)$8PP5M[V+P&3'U\''W^'G(`IQF.:',
M[&>>14?^L=D7QEB/;VG%*]")-##Y&&3?F:0O#+&%LMHRIO#F5J4$['@5R_LY
MTVWV+K^KEHK=3>G0M8;XUI:CYX78Y52>J<G9YAG4$$033!Z/9$[+C9G_`'-*
M$4/B6K#T26L:0;D$_`M/@6(H9M]J'BFB??\`DMQH+9'RY]SGSH%:2[\BOE>]
MR_DQGUS[U^N?_<L_U\#<O`>`\!X'&+L04'3+<6",LPT6L3Y`8;3SXSA13$46
MZ.,V0*^,2PM]U.$X6VXVXG.?5*DYQC.`JB_3L?*D^!7*&POX?%:G^;^R#QH=
MV2DI5N%2NB:Y4X`P=+O%R926E.>W+Q#[[[V4^YQ>5YSG(6X?`>!18MO75S<C
M?L2[>IG'GL'W#0[IOOC7-<G=Z[M:KM3@)"C:1N>W;!4J=J76-7F1=I1ETAZ#
M9Z[!,I8-<KBB6AW,MNLN)^;(9&=BG6AVBZ<Z^>7VS-F=X/(;=U0H^@MKV>ZZ
MD3QZUY%1^PJQ%4J3>?JY4^S;\RT'&2:_<B2*:]^6(_Y'4MNK1A"@UO#+J;[7
MYKB%QCMVB^[6RZ,HEXTO1=EQ&KZ5Q.UM`TZLD;&J2[L^(%%Q2ZNDEQ4Q,B9.
M)*#R1(/Y-,<SEXC"?`R@:ZB^ZF,EB).%^P%L3#KK"D*(D>*.MB"9%P`!&8/$
MUZV%Q$FAJ2>?;=6]EQS`7QH1G^WVX`7U;=]8RU)B>_N3,':GV3Q?VW$G7#!2
MX_!"!5H,>8+.;<PU%>KOX>$8&>*QZ96WA7RI#8C.M'[%JS!DB][5,4`T6*ZX
M0YQ7IXQ>6L1&5E>H3$4ZP0A,VM3"&5/I2L7"7U+PYC\?P/F]UL?8Y3(,-L=Z
M.OG(I3"U$F/<6JFQ(-$X2_EMIB,1!$#$,*4EK&7%%M*3A:LX1GV8PL.%']<W
MV?D#95&=U&BBR_RG$89.TQ'QS'X.&U9;)_*'TS*.8+4[Z8RS\/L2G.<X=5G'
MMR%5S[0,5?Z'VBU.&ML_#7;:IO!3C)`WL\ZLQ5J"O=[':E:Y95P3+]4$<&?G
MY6%6:R8H8(M*5+;;4PE:!TA@]U]=DG8_QFI=LUKQ.Y3Z/XJTQ6R7-D3=7ORM
M-4-F?M6Q8T>*=F1FK]7#S[!`P-?AQT-BX4Z)'#Y94RUEQ2%>!GK#]XG>0/A,
M:QV:<3``A$&OMF$S_$I([[L9+3:?B^(6B/&K?G7&/G1E;"4/L$L9=4A65)0'
M1NXN17.+LX3#4+L0WWKW;M,UW4C[CKDC1VV^N:@7-V\G#5S]*5<+1+6BD+M]
M=!JER.:?BDR*SX\V1]<CH<;+0D,HJEV-=M7#^+3QRZ^>46D('B5J=IBJ:>#W
MC?>K%C<:89*GRLQ%\-C]FW(69GD60H]D-QJ6.:=#^%25,I7AI`=EA]Y7V-`L
M!'8Y#\)K$)(1`GXZ/]R^N)YE*V4OBN&$HC=G1QP<N0]C+CS#N4(PI*?:RAO/
MM4&ZF]V_V*#XP4>7V/P-EQ?RZX[&V&2V#U\%#15BCD1TJ*>,:K<R8(6R#+8P
M\2EQI607'U92VQG#7QAKX'O&^Q&$'B1B+7P''@V430RP6=@\%HR'C2Y_)#\9
M^8,'OD%8<G'_`*<A<6EY6,E)RO+Z2\93Z!S.A=W_`-@&_;*KZ,Q'`2<F5JJP
M7^1UT_B5=+I4*J8Y'JM!%6""Y/11\D]+#+SF1CEFMI48M(S2P7%M^P)2:'V'
M=D3@5BE)??7'O7>T)B0E6[E7J]US56PR:&Q9>P"U#%WL,1S\CRU6BPPP#Y2(
M\AAUX4M1`:<NN#O*R'.<\Z.X*N3L;5*YL[5;-`C*A,&)G1.M@F,:@RX63A8Z
MN4P2G`<X,(<=DX(HDS#P1+@@^!4CI1E:\^P.4YYJ]HUL`DJC;>06@3HB<9+B
MYZ,LW65L_(!;&(:0.D*.<W`<S9!3CMJA5?\`KFO<RSE3;:BAWEJ3@,'FM=2%
MDDI::;Z^.G)9($B7-8:V'U9;TH[0,F*O!DK'2*Q-F3LW*H%BXP1B/P[%K:DU
MOK<=:$<^5+@<2M&C9]<?`NO=7O1W-5^5L`$2:Y6>'/,ABP#15H`$!F;P]&52
M*)L8$?66B'G,1X^2'\MI4\SEDMIEIP-;;.($E.`RL\'U6=.]@G:=33VXJCU_
MAMV64RR6$L!NSQ;->:C`JA#U*3E3INJ_KQYH@PEEM]_YG2FD*:<)#H^UZBO]
M9TS<.46P^E/J/U\73=227(B\ZWMW$?LJJYU5@XN!E+L?"RTPG5;/',*69#^9
M"QVI[,0ES#;:W4M-MY0%>;B/2XG6\'P=Y^:WGSJ-O^3[0&-+1-?9KE>L.MXJ
MM04=K6]"W&-@IP$Q";'"26Q\`H%(=_"<%9'6RTAUIYU8>B]V?](-J[99&-1O
M7F[N#5&L(HB`D8WCMK6$J]LU1'6ZG&['BH;9(9ELCXJ?9M]@I-T98D6T80.T
M0VZC"B&\#K:"H]VO].7,S@5JG3^O*QRLA-U<"M1[,V%:Z+2]EGZ\USLRM&CT
MUJ>WOL"&JR`\V*]M/`S$N,D6&>GK*@:,P:,!@?#*T!)7]<[CGV8[QU4Q>R^7
M_+OCQP3JC8,YQDH36=17*M[AH5S>VE";1IM:LLP;)6:DV#6]^!PN,E3@_P`5
M3ZVR5QJ?<MA`1*<=N\OFW3.46_\`6?$N=Y#\K>5'(38E(U9JO8W*W9.M(X,K
M7VJU8-15)70,-$_[41NSU$!ST?'SPUI2.L*<<^09TIL=>`GYTQV"-]IO+CH"
MY),/P-?LK7('L.@-IZ@K*;19:]J2W5_BL))P]0(M\U1*Z%/V%JIH1*N/H9<_
M%<FE,LE*0,IU(0L<DD3+_;=VZ5ZJOR4Z#)[`Y5-RM9U0R*QR!=%F>+4JFTEV
MRF;!)#H,KQ!'=3EJZ2$2PNY.I8&.CG/C0EU(>D+INJ#TC6%)K0H4!&L@0`"_
MP*M%D0\`(\8RDTIF-#.>)E%L8*(7GYSG7CR59RZ2XX^MQ>0[,\!X#P'@/`>`
M\!X#P,2>=7$?7W.CBCN;BYLL*.?KNTZH1%#R,A"(L+E6L0KC<A6KG#13LC$L
M/V6I30S)\;EU_#"#6&\O(=:PMI80'=&79Q9]=,PO4?V*+A=+<N./D56-<:""
MM4L2BV;JU6!)S5,H,#*@,QS\(/L&NU^N`.#K8D74V*!D`CQVO["7%!D7]@FA
M\_N5/&$'A#POXR2-Y&Y"WV!K6X-PV"R:^!UYK_5<9/TLE$F<V3:A+T(9*6>4
M;<><CP#'AH2%D\NC.((8]0@;XM=6G;UQ7[-M!5NX<;]*3/$.*YNZGY:[*O'$
M.OA4G2E$M:M7V#4S8E`A[C8=>7<.F4VLVI3LT&'&$-/$>]3F9#XE#N!=CYA<
MO-'<&N/]^Y'<@;?'U6BT6&D3F1'3XD>Q76>%C#I*-HM#BY61BTV:\6)(#B`(
M]IW#CV4J7G*&FW'$!`UT@\1-L[YVUL[N1YX5.6(Y/;PDS@N,-F)L&:RW"<4Y
M*#%BJ<&=IF"&:!HTL1"LK3D<Z3EG'A3,9?99+:R\L+07@/`>`\!X#P'@/`>`
M\!X#P'@/`\[G[35@M<?V,CCQ-OS7*C*<.]5NFS$/LJX4LJ&L<5LW>$8+,GQ^
MO[@DZ='JL85+&ON&P![;+8ZP\/!Y*PMT),?J5;?&V)!=A[DJ57:[,3_(.A2]
M=H41+2S,=B!AM5Q4*7.TZMV5J,E1(`MML)]:1P!!!6RAVFF6!OQ6DA<5\"N-
M]DCC=M?>G&+2,MI?B].\G9;7N_Q[WLRHTT:+&L+.OJYIW<(0%D,DPQ7]BR(-
M*MEB$.9B:WAR5E7/<$TE."EJP%5C0^Y]N;2YT]=NTJ7M_5V\;II+;^M-3UOD
M$Q)TZN[#V+Q9V(V9/Q.O=QZR>K&JH:8W=QYI%4E'LN&6>3K46>`/'#I-.%]Q
M(7%_K]0K41POW,^WD)]4WV#<]Y1Z3B5C?HYIP?D;<8%,I`L,BCD!PSS,(A##
M1*GG\8;SGWX;4VV@)R?`K4?9_E))CAUH6!8MUKAH2T\F0P+%2Z=*B1<OM%,;
MI[;$]5*KG]]7K/3I-D'8,7$2;(<H([AZ0"&R,G!*&G&PG]T'F:5HW3F;));%
MF+#G5]#S.RVWX&`JVUY.7_QB,_8G[+K55&#K%?OI1?O7+A1S38(QZG6V$I:2
MG'@=M>`\!X#P..7$A(E1M):QR#$"UR<(4(&L=HLI+,84XH<5PQQH1LA_"?:A
M3JDMX5G&59PGUSX%4GZ=SRW.O[D>T-$247!L<TM@)B%2\B+(21#BM?:TS*H*
M_`C``6EB'^Y&/B4\E6/Y]<?TR&$M@^X%MZ$Y/W/C.)PYT--E5W?EFT3$[#QR
M&O,53)<EG82-?5JZJRG3LQ.8JK!`[QTDM@)\C(3B%L->Y&4NA=>@-I1\S5H6
M<$&1:CG\CQ5D8UF8W>8FNVP=T`&QP+LJRF.=RJORA:T/?..,2AIA:G6&EXRW
M@(>13HB:^P\--0,G^QBI_IX@B$62O&5=V)6(+S-4;#H5+L.KD)8"Q+2\.A&/
MR$93[_Q\M^YY?@9(=W8C9O45V*,.84I*>*&VB<82.^3GY`JX0:UGXQWQUHPE
MT?&<NY5EMG'^HXE:$J0H.<]2^RJ9M'K?X:RU(O4;L4*L<?\`6.M9ZS1,=:HL
M%RZZTJ$/2KI&,BW/W6!6(:QPQ`OS.K<;(^+Y65J96C/@2)>`\!X#P-OEERS<
M7(.00T>;-(#(5%"2QQ,9%DR"6E9$8D)$..ERP0W7_3#CK8I"T(SG*6UYQ[<A
MY@'VN["35NWW8P;HBVPK]PITW!G14#8<P?\`F+SMBFLQ7^4._JVC)-J-G(=E
MS\(9]M9(\:/[R,-?,-X$_P#]/^(AMB=<5Y388^JV*+J?)S9((L-:ZD-99^-C
MY6FZX)C`A;1+1PS:8L4Q@MY*&/R6UN$+1E`RFLY?"UH9H[2J!27F]2:H%>;(
M,FFC'=<5-]`LRZ&^,Y.+93&-*>._'=6EQS"TNN-*4C*_16?`\Q/[5O)>;-Y?
MQ/!*#U]I*G:DXWQE7V3&3FLM6T^AS=\O^YZ'!V2?M$FJOR,L9$1O^/F1T>F.
M=6P\0Y'),(0O"A<M!8I^L&[Q<YM=>-"U-N;AMQFOLWQD(MM)_P`RV'JF)V':
M)F,(M#EL@)$V0O\`J1RNE/G2]YL"<M1<^8[%#C#H?';R8EQ06;%\!^"KC@KK
MG"WB8XZ#*YG07%\<]/+<#F\E.G9F15JIV5#RN37UO9(1G#WRK4OW>[.<^!LY
MG7-U[2)94A(<$.&AQYQ+YAQIG&#2)19A93JGR2BB7Z.MX@DA]:EK6M65+7G.
M<YSG/@<:ENK?K8G9(J8E>!'$`J5-&D@C)'_MXU6R84),(<:E!R"!ZNRX\T:P
MZII>%9SC+2LM_P#)_;X&V2W4[U@3C:&I/KSX7D(00^6G".->HA?1\@<H5Y?J
M'4V%9PI@QS&$YS[4Y5C.,8RE.<!LC?3YU5-$+*1UV<-</..$.K5GCSK):<N%
MR(\J_GXEUU36,9.%0I.,)]$)Q[$^B,Y3D.$RW3UU$4"O2%L?ZZ>(2`:0&?<'
M7']+ZWRYA$"&5).J(.L8XL8XRAII6?;($H!3Z8RZI"$^Y(5N^PCF7]7[CSKS
M=6MM,<:N#.S^2>NM=D'Z6$K_`!=%VSJ&ZW*2CG[%"5R2V5JTV%C7P79.5="D
M%$6($B,>SE7HM+#2%A78V)V<C\?@ZA`;?Z`.MC6,];:W4]H4-O9O&_<40W;-
M?66-CG0+8S'V_8O[:UQ%F3"#/"&9,<&]?GRI#KCSJU!LT5VY:N$H[NRYOH;Z
MQ7J%,7'_``8B\5K4NU:?7WIV#%A;2!3(N:8O\D/&V0*'88*.PRY\D@RYAQ]K
M*%N8=#LW2_/"C[N(E)K4'URM"[G1`,UT6?(U$_R]M;,%'24M^Z#%>S`6>S!5
M[,Y98-Y3/JVC#H#3@+B7A\.X6&]4CG-`[OCK=#T[Z[5(V-'5N7EZ-LQJB63G
M=;8RFS\X.2%.04[6J];)+_'#P&T/J$C'?B?C<L^@V&5MX5@.S^IOIG["^3UP
MXQG;"J&Q-,\1*OS;M>[[[HR_U#9>H!*(7KD'6[A%^I\K;:!-AR\O:`97$'""
MNK<R1FNEM$.LIQAY039=O'.&(XY]AP?&6@=C/9SQKL,I1M7TJ&U?IC1SF\]:
M/S.SI^Z)L>P&9_:ENE=AW68A@KDV4XW5863>]H0X,6^@\-M(@;1VU]-/+NV<
M![AOWESVVW_F)KWB?J2R\@JKK2X\9=:Z^7/WZ#U^U$0*V;Q&S;UMB*],"+PF
M5$-086?[O>XX@[/Y6`XC]834_;3L.F:7LNR>0VWM+<(M!%5B:TYI.8UQ52M8
M<C-6V`[D36MA0C5X`4Q:HBR4?8Z17<QYB_[&\,OO#J]`G?`G^L?7+PYZT.*_
M(S:O$C@=&\@]M18$AM.J:V-CI?9.RKYMO]4Y58[-(L)4)<KA2)R9$ELMDE0+
M`ZD-X<?SA*LNNY"GWQ&LVX.%78?Q:Y!\C^O#>W6)U3:KY!SUKCX+8--M5UA-
M0;WW?QF)T,]:IW=6R*E%7\FEWNVP(!<DTM?ZV';SAQ"4+:;<R$:O*KE81:>Q
MGLBYE<3+0>3I&5O]Z,V/?HH",7^;H[:&T-=ZYE&()Z4:D'+(_MXR.(C8[&1A
M&(X>32Z@]I&5.>!ZM'%C;M$W]QRTMN[5\U;[%KK:^O*W?J5-WX#$7<I&M6<%
MN5B7[%'X&$2)(_B$I2I"6\)QA./3*L>BLAW[X#P'@/`>`\!X#P'@/`BK[!NH
M_CESV<#V(^1,Z)Y557-==UGRPU;\X6T:"36Y9$H$X,AJ2C0)9M?MPV[\F6R'
MVV!V77EBL)'R$4*-G_9(Z]!?V^P=.:6[.]`5>3M5"J-3UU;K.'S*N,2=/S=E
MI^U]@S@FNG:X=,0M3BOU\@%'`986X6RAIIQU*7<ALD_VR=_FXDB:VTSTJ2/&
M2ZVG8E.UQ&;LY#7"SW34]$D<&(:ND[<(6"IE3EBZ+(9/$1'6`-U^,'3A_.%G
M+QZ-!R+0_1EN/FK97]]=W^X+QR"M:I28C&>,$#:9&C:&K>*C?=W@P0H`^OYB
M/(OU!1%7U$U3ILQR+MH(IF03<_`A3"@M%U:JU^E0,76:Q&M14+#Q\?&`BMK?
M?<P)%1XD4#^4:6Z0=(E-QX++:GR'77W,-XRM:L_SX'(/`>`\!X#P'@/`>!IG
MQ&"7!'7D94L$C)0V<..HPV_D8@3*U);6E+N/@*7CVKPI/KGU]/=C&<!J?`>`
M\!X#P/.F^T7%,H[)+7(XI9!@L?PAUH?)AL:FC+]$6B!78.1*YJU3DP)).S58
M:H4S^O-84X"Z(HX-LLAO_I&7O`EQ^K5,AED]AC4]8F9RTS6]=:7$8B1=JZ%$
M3=RTY"VB_CTL2KS<I6AH6ONRD?&.,PZ&F<`!1[SZ&<OM"C!;H\")+M!X[\R^
M8M?C.//'_?DMPQU`W`$7W;/(Z%1%62=V)*#2'ZNN<=(NLQE@@[U5:](.+Q-V
M"QCD#96,*/&,))08=\`1`<4_K6;IXT<SM2\CI?E=HC<6K*6/$4ZXZ8M?%B'2
M-.ZXA["]:A6*;)6BP;$7KNULVT<&<P;'*:,_9"^S!B!\X1@))^@-<P[Q`WV]
M/$BORC_8OS]=,9%2_C\(M7(NV?GC/..%%#/.+D<//)4/\;/Q/(Q[<KPMQ83B
M^!5Q^UE*,Q'#SB^6J+A)<Q'+@7,8-*"%RAK1O^P6\48D("$BSH2:FYR)8<66
M(*))!+?+891E2_=A/@6!>(R`QN+?'6-#G-@V5$3H[4T8Y.[;C9>'VM+.B4&O
MMJDMG1$])3,U%;"/QC#TR,6840Q(K>;<=<6G*LAD3X#P'@/`V&TI(76+&@,?
M!9:X&72*+DD</!)"H\C#`^2RUMBBX>=SA/R.*2VCU]RLXQC.?`K*_55U!=N/
MG$WF9HG8+D:3:]1]@>XJ-.'5R3#G*<9,0]+UJU)O5.<'&%?EXK+ZOX(<3A+G
MKC+?]F<>!"?WY69>G>R>Y:*T-L;COQ.-BN-U?WEI,>9TYJ&OA3V]+/&;AK^S
M"8S=3M.B2M.VX[7MEE)>,->-/EC+NF)=CG!3"&GF`Z8Z.N1>R-,]C76]9JAR
M6Y*<B-4=C6N]YQFY=6[9N%H^6B<AARB7]U[$+CGTRM)ML.?LRI)E0)1EW$Z2
M"MQ<DZT^KVOA8UVMO/4FM/LOZ6H-L3;+./R4ZW->5'7-<BJZB]47&Q*_R,ON
MRZE>%(>D'0Z,'5X"AF&8EQ1_["<,91Z9<>=P$CG=\0@7J)[$G%M3#V%\5-K"
MI1!O,,&X=-@7@V7'ED+;;5$,O/I7((QG*W`$O(1A2U)3D.4=0V\*%O?K=X96
MFA/6[$=&\>=<4MX>_0\A7[6](:TAF]8V"5<C);"9`F!.M5./Q''^F6#Q4(>:
M5E*L>!)-X#P'@/`VV9C$S,3)1*S9*-1)!$A*/AC78V6"22TIK),;(,?ZP1K.
M%>YMU']R%XQG'\X\#S!_MP1L0?VBVZOI,BV;`;QPXX3M=B!Z41.W6V3[<GL>
MND#!6L0);T+#(A4MJ+&=(P@HA@53;*E)6O`6)?IORY[?6A;H"17!C`F\CMJ2
M]-CH]))L^Y$Q</KH*QR=PDF77XX$M<Y+-#@AN-@$+%'R^AEU"E/9"W+X$#G:
ME]>[ACVL7^E[8V1,7?2>SJQ&S\;8+MI6.HD9,[.1*#UH2$(V018*K-/6,RG!
M5M(T<\I:'FQ'UL*7EM#*6PD7X!<)-7=>7%C6_%;4KV96N:_'/_,MYM<J=:LU
M[F#S'%N6FZ,TR'@X>7M2XMH0)^04Q^48T$TM];CGN5D,S/`>`\!X#P*L_P!J
M[;%LU=Q)T*,UOBYZATCLO<Y>KN5M:UO::9%[#V9QXN5?Q%W"-J=4M9(YMW(B
M37A,$CQWN=:#,=R_Z"K=5@*//&_0O'/9FNK2CBQI)CF3S-YD,[/UIJ[A8*/=
MYR"X&Z\FIH(.O[@O6T[+5Z?^_P!IP)PPP]<EVIT."2-(_+*X4IQ(R@V35LUK
M_EU8=MZW[+MLT_2-MI$1.3NT>6>TRI'8_)*0DN+E.=UCK?C%Q@HL"JNT8;!`
MY@4?*1,H;D.;Q'X,8D&"0T-K#N+8W!O%JU.<?!\A0N"'6%(<EK&;QEJ7.1W8
M\9M+D/L6G:R#9O>WJW5J[I^8`BYDZE1XD=[),^/K@\H4Q'-&NK6LA89D\<NS
MV?Z\>%?*SB-P]U[L7E/1N9%BF(;B#<MC<>#=0[/DXR_Z.>+Y26J3JU`O5TE)
MZ-U1(3$,-7(V,0+%$ND'R:"OA0X/X',?KE<[-O<,^>]`T3==#\EZ=IGG-)U*
MAV=B]2*S8Z4Y'3I]B:!WF5*[`U_4)$J+D6XHP5T`:6<,8&!,>]\J0C+*0]-Q
M*DK2E2584E6,*2I.<92I.<>N%)SCUQG&<9_C/@4I_LG\/M6\?[]1NQFH<`9W
ME;<K9<`0-S[0,Y+\MZO.ZTF8D:MQNIA-8U;1NR8EZB@.CQDFZ3))%&BPSDC^
MSW&F^QT,).,O9KV=<W.I3M7<Y`Q="W'Q8HO'_8VMHKD!"$0U.O&O;2#2*NL/
M7T?3U0,#-;8AI:`G%,XFC_62;DD_,40ZV[A&0LJ?6OCB:]TG\.<D1AZ"_P!+
MM^0>!4>Y(R11"=W;+0XW\)K("8TYUP;+>0\K4AES'I\F?7/H$Z488N1C8^0<
M!.BW#P1#%QDFAAN2CEE,-OJ!D&Q2"QFSA%+^-U+;KK>'$YPE:L>F<AQG86O*
M1M:H3&O]D4ZH[!HMD0,-9:;>ZY&VVJSX`Y@YV!)6`F&B(L]"216W&\/MN(0Z
MA*O;G*<>!Y/W:CK+7^O^4O;SK66XOS-N_P!GKE#2NBMBZMU%6M,ZUX]0$QMV
M@DR9UOB*CB"1-469`V.FKQJD8?\`86L$O*EI*]&0],GJ]?%*ZW^!Y839389?
M$?C\6+@TY4D6XP5J^M/M$$EKEIQ2WRD.8<4G)3GQ97[/1'M]B0SL\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`\]W[--9D7>Q:4D)
M*0UV.!CAKQXEK#,SMDL6LI%,2!N7=@$E5J];@:_<I.J-WE*,L2,L"H;+<8PH
M)\UI@@I#H2M_5AID?!UGL2LD;4]9UR)M7)+7AU:SJYDV)JB8'&GX9]J.KE6F
MS#K-%UD(PY]04E)K0=8$O+-<1C"DYR%L?P'@/`A)Z%F5-\3>0:U)?2DCL?[!
MWF\NNO.-K1CDK<V,J%2X>8AEC"V5)REML5&7<+5\65*4\Z$VW@5BOM*1,?,\
M1N/`,K)S$?'O\@K8V_\`J'99+JWL<9=\/Q?H,.&?7#"C9H<:.:9F6OP'_P!B
MIA:D8=4K`3V<1JY/5'BWQYK-IHH>L;+"Z8UH!8=<@PU,@&J/8&*=#IGJPY$Z
MX<<U\&5$37SM.H@_;$X<3G`N/A]F<AD3X#P'@/`X=L1I+^O[TRM#3B'J=9VE
MMOQS<NPXER$.0I#T2Z!*-2;2L9]%#J%)2]C^S+3F%>S(5,/I[NVASK=Y+EP3
M4`N7)YG[`>AQ)*(77()MY=&UEDQ#S\-A]]0B4J7\334>(D7.$LI1E/\`=@.)
M=NO75VI[8V%L?8ERI?';LVXO,1^V-NTS0^SX^7T^5QC,CXBKFURIZPLNH[C5
M]U[IL9$=!RT=&Q9*%Q3KYN'WFG##EY%#'WAKR0Z1]=]CJ]T<ON$%TZXN=N&/
M\WK0V]KR9<].MDVZFCW$79E>AGC'JOKNVN-?'%56*`8).;8.%_%92M6'&0F0
ML)]OCOLV@/5>BN7:/*ZD:1%W,AFTP%>>H]:D>6=W;_SA$;.A.KMK<9*-CL/`
MA%!G(8)6^W^1\61G`S5[N#G8[J/[#26FB'O=Q9VB(^V*L5#^09"$<`D,H49G
M#']@)+BLXSA2LIQG"4J5[4Y#BO191-Z:LZN>)FN.1,?9`=EUK7Q;IG^76@.U
M3V(&<N5KFZ5'DGBR$FI+$11#8IAMM;N%#8QD;+3*AU-I"73P'@/`>`\#RLOM
MSQ8C_<#=SE2+K"`N+NB"R_U<8.\Y@LDV8B41LL\WF*4A3\>[\Z2'EF*RGX6/
M<EO*4L!9Z^G<)%177/N:!$:0Q*5_EA?XJ984/"+-8=:K-0<%:E)J#4^/-R"6
M%^BEY=5AEK#;:,8;PE2PMI^`\!X#P'@/`>`\#8IZK5FTL,C6>N05C&'<4Z./
M/1$?+L,.K3[%N,M2`Y#;3BT?QG*<8SG'\>!LL5K37,%*LSL%0J9!SH\:7#C3
MD+6(2*F18D]8;AT:+*@`CGC@ENQXZW&D.);6IAO.<9RA.<!6_P!-R&B.#79]
MO?@!R1X\Z1J/&SG%L)S>_`JU3T!JZ1I9=SBM-4F.Y$4FUO78QVX9M5SN#/Y8
M3BQGP")`MT=LA99RF4A84L5!T?N$=^BW_7VJMDXI(PH,A4[34:W=(FKIG(U&
M$QXX-@AR1`V#XX5*?C2TW[V$)PM.,>F/`W%_1VE"K1`W<G3^KB+I518,*L6]
MZ@51VT5P*L,R(U;#@;`N)5+0XE?'ERVP6QWFT"H*>2UA.'5X4&IONF]2[3S5
ME;*UE0KZY1K$/;J4];ZG!V$BGVH9>5LV.KD2@)+\!-8QE25$B*:>6VM:%*RA
M:DY#GL='`1$>#$Q00D;%Q88L=&QP`[0@(``3"!@P@Q6$-L#""CM);;;0G"$(
M3C&,8QCP,6.<UTL%.X7\PK1K^WE5'8-)XV;HGJQ8X$EC_(:I;`-9V.3JTG'H
MR%*K&F&I-EET/W#.J4[[,H3G/IX%1[C-#@6OZJG/GD-D:%$VER+K')J_;MD*
M?"@5>#N%KJ\^7K<$G.MH<(&J:V*!KU9"24)"A`))>%_*?][A#OJ$YWUM?_W)
MG!#_`/$?8?\`[^W9G@3C>`\#Q^>?FYQ[MR+[@[!>^2NQQAMI[*AH6EU;6FI)
MK6^L>1DY0]]QX-HC+/4+.";@&*T^B,+DOR23X\XZ=902XK#SZV/`]0SJMR*K
MK8X*9"D2987/%7266)`N3"F'B&_\"A?3_P!B,<MP`AIK_D;PS[6T-I2C"483
M[$AGUX#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>!0"
M^QY;KO$]ES-:I5AJ\#(3VA>-+Y\NNF4C83$3;8#8_(>PTJ0F:W=+\@8":@:2
M#)R`CYL$5&'985&J4.N48>4$A?UFY.WPD'S7E)B,KH=FOW*O4%:EK!.G!.GV
M`:-U3(S!;#]F%MKT!:[>FNI6ZP#"YD%A$N/+PW^F6`XT%O+P'@/`@\Z`!)$;
MA?N%P\:2::,[`^?!,89(Y.])<%').[!+D@D3!I<\T-F2$(86F0PR;^4P]EQ&
M<YPZX$X?@5G_`+.)V(SCCQ.-5:JS2%/<FK97HNS7QZ1!U^'9+IQ5Y#TV`$N,
MQ'J;3!@GDSRTBEOK;8:D$C^]6,9SX$R?7M!1D7PKXJ2D7,6":9LG&;CO)9)F
MY>9,'RVQIBE1XCL3"2-ON\?563`Q4/$"`2)3"RW''5/D.N+?<#,WP'@/`>!U
MYMTM^/U1L\\9*5DA:\NI8Z%/-C)4^-6Y)YI*B'0Y!IA*G$8QE:AWTI_KEM>,
M>W(55_IHI2KK:WD3\3"'B>8^PEOJ;4I3JU8U_K/TP^O\4=M?LQGT3E&58RG_
M`()_Y?`Q'[^NUOLOX_<_-J\-N'&\Y&,@9CBY2[)6=+430<=LO9]DG;L#:8S8
M#U3N]-K$ULFBS58J@^;$.>Z6%@/`V'&%)QA"EA&9UHZV:T7SUZZ.)_(J-G^1
M&B^7NGI\.P<5^=VI)6E;(XX[K!A(V=M]DH=%V%59V0K=>L6S*$B.J5AC2([_
M`"<&,<:-?':"],A;YJQ>'_L?W19L2Z%*%]+>N"E(>.;==B,_]X=M4?%/-AJ?
M`-=4^^WC+R'5)1D?/LRI+F<X#(_N^3[NHKL1_P#5Y]O%;::_1W!64?Z<&XY_
M/X:VWDY_M_A6<_&G/IES&6\*QD.K/K\4:L47J9X?0L(9,3<E%4*=CYR>LVL+
MGJFQN21^P;?:Y*&(K]_8:L9,;#2MD?:%D$95'RJ/^M$PEE]*4A-#X#P'@/`>
M!Y=7VOWIF6[=9[,#(50,2`X]:KL+MIC/T!-E@Y"GQ%Y.9B)DTF=P1'"ESX;;
M#;3B14K+6RAMA\C"4OA9+^G2.X_U6RYA\2<EUKD_N(J*F2!26026).$U\-(L
MQS[Y&6BG4%1?H_EAI+"/1"?<IW#N$A;*\!X#P'@/`@Z[D>S;>/#-G2'&WA7I
MM&\.<W*Z9.B-25RQPMA_V_IM.`PN(LVU;'/,M1]6>9IUCE8EEX4Z5"'%3(-E
M&*P-C"'0K;\A_L%=V'6[LLGC=SIJ?!TG<.UJ'49K7MCC9I.8KCW(V0BOOE6/
M=%5U=)W2>F(",`)+8S'8'`)+=:<+!)-%0TAT,?[7]JKL8IJJ[3(W>W6]MBX;
M+V)50H[8-,UEOZ)U7INH-,%P=D_W&:O8%$L:AY>5EHZ3:-"1*J"$CI#"T?Z@
MS20[7WM]@'O7TGJ;37(".F>MS=>@]Z[4LND:)N'3M&VC)51[:E2.4),U0X*Z
MW"C6U&$-(40S(CQI$42PG.6R5+Q[,A(CJ[MM[R]_\A%\'...D."NU>1_%R/M
M4IS:VX38;R+Q\(GEWF5C*SK&I-"RD;;->V&"BXM<4:N2P4_)S#!3S#0P;++Q
M01^]K',3E=MW<-2X=<TZETYPFUX;BJWM`?:6WK9?J$/I_;5QE]J:Y+7I#>L=
M;)+*[C1`)>/F8\)Q:&V96._-0E90V$#A+UUP]OFP]0S?&+@EV/0^M:7N+D)K
M6HWC0G.K6NQ*M>-`\R?\KD4157GG;$TP($UL>?A(I$?(F2$C@R9GFD?C"(;,
M$]0M`TJ^4S9$`/:J!9X6Y5<QTED"R5P]B6@9)0CZQB5Q<P&IV/E!V26EMY='
M<<:^1"D^[U3G&`Y9X#P*,'?/SPYX=;'-35.N]<=A4Y-<9=]PB[+:]'5_5.CM
MV\E./%2JX4)$6&;'@[G58\BT525C0URE>)L<WAX^2&E?RG\(:_)4'$ZKVR:K
MY%]37-GK]C>(YW";?#G7WN'D_7HFMU:JZWTUL_4UA'C;8C;<&W`'B,5N>VA3
M)]N:-$(:;&.*+4P"^9\S2,A8%^MK_P#N3."'_P")&Q/_`&^,;NV;Z9_]OCP)
MQO`TAY+@011;(14DX,RX\@`'\?\`,+RVGW?`+^60(-DAS&/1&%NMIRK^,JQ_
M7P/).YP42&_W?[]F]7W:ZZKUUK*]T^S?[7!["U]9"-PM[)Y3Z[:-AK_+0EDN
M8L]3-?W`TV<BA(IU,E&/EMB2I#;N'!?`],#JGC\QG65U_"Y?P2M7#GCF:X^E
MC`V''9/5%6DG<Y92Z]A*L.%YQG/N_NSCW>F/7TP&?G@/`X#L^@HV?1)^BN7"
M^T%$^V"WFW:PLS].O4/^#*`RF'(&R#L$NQKA2@<,/^C:L.BNNM9QZ+SX'47)
M[F3QBX8UNM7+E'NS7FCZI;)PJO0<]L.PBP`<G*A0YLT^!%I?PI^5D$B!YS@<
M="WLX5ZX3G&,^@84`=]'3I(GYC1^PSCFV1@+,A\A]I,BP/@25^'EO$K)Q8<7
MDWY?YP-\WY.6O]7#?Q_W^!I.3G>1U^<7]9<?MJR][NFWX3E`#+3VEH'0]#D[
M]>[92X-!6)/8**46]7I\.CL%C8'0>ZRE+SSJ/B2M'O6D,]^*/*/3O-'CYK#D
MWH2PKLFK-LU],_7#"6F!98%;)1,;+U^Q1PY1J8BSUN9"(!D0\NK4,8.XWG.?
M;ZY#(;P'@/`>`\!X#P'@/`X#;MK:NU^8)'7S9-!I,A("K.`!MUQKU;,-";):
M"<,$%F9$)\D5!CZ&LN(2I&'5I3G/NSC'@;2UO329`B3A=P:L)$<+9CV26-A5
M%P9Z1*1'N"Q[9"9?+*C"DRPF6V_=[UX*:SC&<.(]0Q*WGVK<`N->U]9Z-W;R
M-K%-VSM^.K,EKVG#0-WN+UA8M]V3KJ`2S,4:KV2O".G7)60\((+94G"5/*PD
M?&7?`D)\!X#P'@/`>`\!X#P'@>?C]B.R(C^XNNLY!:E0HOC%QXL$D&?+$4ZI
MC/UC:FT)L*1OTK0I\;84O6!7GV,*<_Q^V$_.MD*-"S(.@8\#/GZP`9QE;Y<5
MZ2KWY]DUOS`A&SA"XHZCJI1;&LY:KRQMOHXAI($0L6)@W`:S%_D3;$,\O+"'
MF$)PXD+BO@/`>!!]T#M,#\/MZ"I+!).$[$N?PTPB/'8%%$DV^2-R]P[0Z2C3
MFFEA99>;28ZX2AIU*?<IO#:LA.#X%8_[/5AK<!Q_X=.62(A["VYRK/7&0DZ7
M&AQ14IG0VVXP8F0<L+P%82"#B64M:BB'2&U>Q0H$B[CX,!96KD3#P-?@X6O1
M$37X&)B8^/AH*`&$"@X:+$%:8!BX<,!@8$6+!&0EIAMEMMI#24X0E*<8Q@-Z
M\!X#P'@<+V1DE.N[[D-QMHO%+M.177C(Z/:;)Q!G98<=/E_2)!;0[Z94\5_T
M[6/[G/[,*\"K3]/S$B%U_P#)*OS1H<C.U[G)MJ/FSXZ2A+!'&RF*?KK\TR/M
MD`2;&VH(HA"EM',//#/H5A;"U-JQG(3[;CM7&[3<U:-B[_V5K31-DMUF'I^K
M-T;:1HBJ2%<F7=:$!QK&M[M/!O$O$"C/33XS%D<<*<?7(--LKCLH0L/WKF/X
M<<GI>%VS2K=QLY1[DT@I%1`Y$UR.T;M#9.N)++\B<F."M=7C))-'+?2<4I(P
MF0VU?*ZM"/52\Y")S%YG9C[,THK4;FM[K7(#J^I>NN0DT;=W$$ZN%5R:V'(`
M0$9&UZ+G$&[9E+F_`L)A94B*2S"F$FY4M2&&W`SP[L9S-=ZENPB506.$ZUQ;
MVD..^2F'<1@@^!>`9;0S.JQ'D/O.$X2VWZ+?6YG"6$+?RVG(<+Z(!=DB]4O$
M#&W*%,:XOCVNTD'UV9-L4@LB!7(%IH5BCR;-<KR>J,M&O411[6$&-#IR0K#8
MHN/5A`2\>`\!X#P-NF!Y$R*D18B21#2A(9#$?+.`MR:8TMUI2&#LQ[SS#)N1
MG,X7AM:\(7G'HK^/7'@>3M]HW6='T;W`7VNZ.I5=UVS;-4Z]OEL37XN,BFK3
ML#94K8[5>;G8"W9610?)V>9*^0XHQ`&,IQEM3'P)2^0%KGZ@$/*277'8;?+0
MX1,@1RMWJ7,6QRPRB9&3ES:]KP=US].S%JA)S_4_(PHO!F6V<+Q\.5N+?2V%
MN'P'@/`>`\"O?W1\#JARIVIQ8W%0.QJK==W,#CP5+RVN-@62XPK3A^LIAY__
M`"4..H,C?:&Y(XDK:/&8).><,`=&$4$\.XE[/H$35KZ0^($Y3:IMBX=B_$#D
MQV)37*;4^[MZ<H^25^@)BCW.BTG8,A8IZAUS3D'MQN(B@YNMN@A'C$$/CR8T
M?D5O,>AY+HX9K\K.L[J^Y'\GN&VYZ)LOAEJS3G':R6J];%XN:?)XKPEBY#;"
M/&@!:0[/R#MB31I>*CWJJ(Q+1LE^0W,Q9!#?S,OY]70Z/[;^G76W.M>K-0\/
M.<7"SAIQHU(P=N%7'^`:UZ/#N[[M^)B2SMF-!H;]>DJD'/4,T;W$8.*&?;;2
M^R&WAO#KP=?,=,/,;CK.O\@.OOMQU;IS;O*+5^KJIRWVKN^YUO;4WO+DS-RT
MU.V.<H-]50G?T8$W)2^4P8K+!$C(^]3B\(>;:<P&-&W/J!<AA+H6;QVY(\>#
MZG;=40T)LTGD[5IO:%RM&XIZ%`<VYLJ!D%ZWDGZ9^XN0F#(58IRI(%M'^H0K
M+SZ%A83XJ].%;F."VCN*_:G$Z3YIW?CNU9ZIJ6YQ=:7$P5"UJ7&PL#4(2IB#
M5JCO@3%=@81AC)CXY1:W6OF42M3BL8#IV8ZI^;O#VFQ/_E!\V;Q0J]5]E55^
MK\..6$B+;>)L!J"I,3YEIH,(X50;KN:)D-DWEQ)A<G'3D8MX61*4E;:DB*:#
MCMYYH_8^U;<2Z:YU@\/M[A1YL=#1NP]8\CO]O8+8AR*N)(3<E3ZKLZYMW<:-
M#EB'<J24%AQH<)_'^HW[2O`CMX5?9\YF\J.7_%SC39^&W'_7</N+D*[HF\3\
M7M>Q6ZRCO0\:23:[!3ZR`YA]J$ALC+>1).XD8E_",LX)Q_+Z0T7V`=U=4W&3
MLXT_N3D3)\J9WD+*<3]SZMW+K?C]$TXF$L6D=H:UNVMJ+$6&P[!DZ^/2Y>?S
M<K"V/(0*Y`UI*,++0.AL93@5S.5W9!UU$R\'<.N_3>^X&_VW@O;>M.^4WD,+
M4$1TAJTW7U<UYK;=C=VJ%NFGC]DUZ!C&8@@/,>$P8,`T^\0E67$/!9G^NGW7
M<0*EI+B/U.W<79VOM^T'6^PV)6T7VJ,0%$E+TN\S.P&M?P/P2DI9ERBJM9RR
M/RCP8\/V0[V??C+S"5!<]8?9*89)'<2Z.0TV^PZC/JAUEY&'&G$Y_P"*5H5C
M./\`VF?`^1K+Y`SK(QCH#Z\)PV6RT.^XSG"TJSE+133PZ_<G&4Y]R<_QG^/Y
M],^!Y'/('C7N79T=V^V6.X@:7LLOK+E))W'9>YM>68:Y;.IE9$O9)4E#:5UM
M6+%:#HVG6:-M459[19I5LF-!C8Z0;_*:->^$8+K'`/[`74]JKA)P]U7N#FY1
MHS9U`XT:,I.PF7X#:DMB,NU?U[`0E@AS#\U.2+,+B3@EH)*1EP)2\9^)U2?1
M.`R]Q]B7IS,E(=4?S_TFS"+$/>FVI2N[9%E_F<;#S$)CG7*2P"Q\:U/?E-O)
M4YG'M]GMRE?@<F`^PETPR7R_C]@6EF_A:$>7^>Q>8KW(-+2&REK$G4`\ONH>
M7C+J$>Y;#7JZ[A#6,KP&N=^P%TT,R:8E?8-HC)2G&&L.M&6A^,PHA#;C>533
M-:<AD-I2YCWKR_A#2L92O*<I5C`1==N7+3H*[4N/06A]G=C6DZU=*3.N;)TS
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M#"PEM#/2,M(X>;;?`.4D+"`W=+U+ER#48SV)\1ORGB1A6\O;KI@PF72XO$RP
MI4B3),Q[8_X.?[WE.X:;?_T%J2__`*?@;V#W"=5,BZ4P+V*<-?D#5E#_`.1R
M%UD$WZX*-"S\#QMB'9*3\\>[_+2EX]GL<]?8XVI8?<;MVZORGXYA'/SB,WB8
M&",B''N06JT9D!3HLJ:01^)_E69&.88C0U...&LC-IQE.,*SE6,>!O?_`)K'
M61\KC'_F#\,?E:CFY=QO_N4U#[D1KPK!K1JL?Y;_``PL0EMS&?\`X56,^!J)
MSM&ZXX7$H.YSRX:8EHM9P[L89R;T_'YP?'FBQA`1!#EJ=2*MN2.986K*<X0X
MZGU\#E49V+=?TTPX3%<X.(YX[+!1+KPW(O4;B&QPI9^"+?<5BW>B&F)D5P92
ML_Q\R?;_`%]/`W`;G]P8)>('1S'XN-D#&.`+9?W[JEEU1+4T37%(:;7;,*<Q
M^^">#QG&/Y?;RG_P]0W8;G'PK,4X@/E[QA*6RQ/%/)'WWJMY30U71\MD)=PW
M:E9;8@6L>\Q>?1(Z/[EY3C^?`U#O-;ARR0"*OE=QNP])$&B!)QO'6.</DQPS
M!AP[>?\`*/13PHQ+:UIQZY1AQ.<XQ[L>H4B_LO\`$KC!8=O43L6TWL[0>W:V
M5@JA\MZMC>%?VW=H6'L2,1-/V=KO6DILJ)!S'TTDE[.0H^0:S^R=!0@3(?Y.
M,!'[UO\`##CAS)OO'&O3>J>$FH=<\1=[6:V<P^0>V-I62C9Y9-6C8*)V)T7J
MK55DL>O;;58/6.J;+^.F0-`'P5+Q+.<%.-MN-NA@WV=ZKWVUV3\C-O/V0O,G
MN/>%QD^/RD["KYZ;]KM>YPJ9H.;!V55MK62)@(**F(X/(+MCEH;\%N%80+A*
MVD-!AZ7_`%V["V[1N*^GJ?S5WSI&V[DJ^K=?1NP+8/N*%LMPD-E&Q,W8;4W=
M#5C0T,K+M?P`='.#YRZZ*I_+B<H900^$@D/L6@SXHI\)=:G*@'G2,;&G1MDA
M#PY,Z(66U*BQI09S[!I$:_'D-D-MJ4MAP9U*\)4VO&`WANRUQTEX-J?A'#!D
M#ND"MRH*R1VR\O8%<>82_EUI!.1W/CRK&,+]BO3U],^@:MR6BF5>UZ3CVE9Q
MG/M<-&0KTPI2,Y]%.8SZ84G./_3C/@?O$G'*2E29`)25XRI"L%L92K&,.*SE
M.<.>BL82RO/\?\$Y_P##/@?C,K'X+%"_*1D@QLMP;"<+6R[^"\RP2U@I*<BI
M)0Z]C&&LKPZO"5Y2G.&W,I#7>Y/\X]R?5/\`S8]<?V^F,*SZ_P#AZ85C/_HS
MX'Z]<9]?3/\`3/IG_P!IGTQGTS_X9],^`\!X'GE_9$*D4]G5EOSVHH52-;<>
M-&-LV+8<N`&B0@(J;W7:9&\5B#(W&-`3,/&`@RN`WS89DL*=AV5-AE*<2DP)
M&?J[4NU:MXE\T`Z<7:#[##;IU[M8R)KQ>K[RS=B#=55^6L&KZK8V)#$+(35A
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MG?4<QE@A*?E95[593A+B?12<Y2K&<A6&^TU".37%KB<C$>+(#"\MXLJ1;%`@
M2;?^L'U3LDN034C)]0P\:4D05;KF67EE$*9:':%)6[C#86>(]*$@!);2^AM(
M@R6T$IPDA",,HPE)"4^B4OI3_"\8_C"O7P-7X#P'@/`V2S"BFUNP!G9-2$7"
M2PIBHU24R&!7P"&B,@*4E24FX97GXLYQG&%^G\>!68^J'%:R"X)<F3]00%W@
M-<2?81R1_P`"'V%D)=M1K\$2BBT2/LKP+SK3]JB*Q@<>55C&&\G)<]GJGTSX
M%9C[1E'VI*]S9EIKU)JEPI,%Q_U[L)^#V=9XV`U)=\Z0J4I9KY7IIVPW.FQD
MW8XJMV!AM<)&',V$D>6'0$TI\UG+H9M=$_/[06L^?'%_3_#653K;C-V.T_9=
MHWMPN0F*N97&7F-KF!.';36[S82!M@(U;;JU7V7X9UY;Z'X[#3"T/%C%O("P
M]3Z]`U[[+6U'H""AH)VT=.]+L=F=AHH&*<LMB5R_G(Q5@L#@`XZIR=S&@,#?
MF%9=(_'8;:]_QMH3@,IN[I.%=1G8CC(Y96,\4]L>K82@DD)3FND84_C)\G$C
MY9%1G+CJ<.J=4TA6&F2'<H'=#=NHC;.P-K\!N,AU[U?7-;M0.CM7UFH$5+<]
M0W?`W"JUFLL5>)G&[/4(Z)8CIM$?!L(F(X@9EZ.F,E"8PM(V'7`DU\!X#P'@
M/`\IW[<JC,]R5UQ#,%,NHXTZ63-+B5.)?+`_3SBSWI/(J,*P/B.4VTY\WO3\
M+:/=_;Z8P%I'Z?<V^/UA$0P-*V$B"EN4&\BA+-)OQI54!#`AJ"H1+996(,YU
M\Y9&0U8CA31%&AOK6H9:EM)"VCX#P'@/`>!2\[OG.(&\^Y;C%J?F+IVW[1T!
MQXX%<H]Q[PC68J^1!#M?'B,WF-G]3R%*DJQ-WFQU=-5SDP<<Y\85MUWU9R^W
ME*PI07O5M(['N1-A"ZWN%S?%[2VM]43=XN(DO?\`9FS(NGP])HLG<[I<-N;8
MLS\Y$P8<E(UXX.O8_#BTDK>&#7\I"\*2'*>05ZX!;8T[KO6O`#KMMK6\B],Q
M<AOK9DOM;D#M^TU:ZP>:C.V^>UI0P9<.L"UD$,`P63E96+=#PN2?0*.RR*P6
M2'0,WH^S:RII&B[!QAA-T[;N;]%ND7N35MBV[9=@ZA$-@8N>N.B9*O5,YS6S
MM_AH(1*)B.F(21D*V\^_CUSC*,MA(AP2XH\5[9Q=KFSYV9:M_(6H]O/"W2D>
M2%/33*QN/]WDP`+9*?[5V.2CZZ9%2]N0Z,"?+@BDJRRIM>1TJ<:2'KRH0AI"
M&VTX2AM*4(3C^B4(QA*4X_\`:8QCP/UX#P,4>1/%+7_(J]\?+Y;9G;=6L?'.
MZ3>Q*)9M3[,E=;/-R$E&!PLW6+<[!DCRMCJ%PA?>(='ISA@D7#K+ZOC=RE8>
M6GU%/2^.XCA8P4/`.&0O/AZ,'%DJ@/&;$D8.7B[7*!VDLMR3>L9T(FO$,^C2
MVG`(MD<%:'?:Y_J!.9V6<K>R[2';W#V?<&P2M+]5FV>76M*3`S>]M?Z*DJ;-
MZ<K`-%K^ZBPX>U5&V;;8U3*9@I56))(S4>6/(C/M.X_8#*=#.W8'/7JO[+NH
MSM1OO$[C7K?5^Q=#\>=EQT_`VW2VK:9?(R/GJR<Q6K_69*@#S4@FN3CS1#(A
M&7!2$F"N-OM-HQ[U!DC]7S@/Q;HG7#H/ES&:\8GMY\@AW;[=;7=#,W1,'<M:
M7/:^MJ[/ZZ%GVC4Z^E?\7.)'+?C5-$$_D+0M>6DMMMA:0\!X'DM:\O\`0^.H
M7:CORO6$^L\X:YSDN>KJ:RMMFR:OG=`;0V%9]><B*/RBJLP!<]7DZ<MD=:DL
MQF;(P[&G6,=OXEE$",H2&<''[J=[R[]IO5^\M5<4NO&Q0NX-CA<X]96:9BM/
MCN5R4W/J.N`CBIT_($AZ.&I#])$&:8KA]7/8AY,MP@9(Y'N?:#MB2Z@^]_8D
MAM^3W-UU=>E_L>\=31O'B2LH,CI_26*-0HFRE;'!F:O`<>+CK:HQTXU=Z]&O
M/S:HPF<*&;9C5NN1[KK+8<CMG6!WP;-V&;L+:W5[U\7=LW1DUQ:8J($YJK5=
M<AH>YUE]C;&YHJ,TOLC7<:WL/9QYI+F9U]HDN%*6RF*8!0PAS(=;/]:'>M$R
MFDK9<NG[A%LZ9TGI:5TY!O59W0M#E[:/>:FQ3):];2.I&VJ:==MC5_6#2*_'
MR+Q"?TL@TF5%1F2]Y;@=?:5Z?.[C63.D:)9^H[ACMS7F@K]:MGT."V'+:13B
M6N5D79)L+_=?8<#MN.V9MBFUIUEL4>O34@3#OJ_7()8?0VI2`YU)]4O<:SK[
MD9$P_2_PKJ5)W/?U7Z6IL':-52MTI<0FFUUS<M"T=,$;*G;#4*ONPFOB-0K`
MI"BJ9(-D(KZH[#ZWE!\;IUC]OEJGN5D+4.C+AIKFN[_KE59D8-N6U-8\:UE8
M`NJ0-OMO&?85GV,<YKRW[(@3QW7,-ON8BC(LR3C60S,NX(#E%CZZ>U1K9NO[
MC1/KR<#(&0UYJ\C2$E#3TCK;8M$V*!4:?$R%#OUB%LVU0AL;1@9@QAYRWB/A
MR%D(`>BY!]\7"V5AU.9U+=H0>FM+U*@="''B)V#J/=P>R[AMVX;)T+L:S[VF
MA8BS0E_KUVJ=^MPL.G0ULDY$<V!K;:$@PN065(27\N7\AK;5U3=EUJ9WI,*^
MO#H"`V)LC9E2OVJ['6-QZ`@Z3I&&U]9DS53U\+J$6_9I=PJ\S&$%@VYIQ("+
M7A8^7T,,C8'<#8;SU2\[[HYR$-V+]<ZHQ6PMTUNNUG2TCQ[Y$:[UCJWCU8,'
M-RJK4B@05NN`,^J1NPJW3LD2T0P-6R%1:G&F,,%-A^4\!.7<18ME2FR/K%15
MDFWM.,ZIUI':WV=(0>NZ?LF6@RQ[EO"T1%:F+6C:$W)WP5<C#C@R<+$UR'6F
M.8]^%L'8#&30'5QV0:UOVB[#O+H,<WIJK64//15SUK"S-PUG-;U+-@L1D'8=
MJVL/:-T<_<5:?&_:CI#B0`R'7GF7&5#K80R'+'>N/F"\`57)'ZYNPT:W*WX[
MLTJ5A+=:P^0A&FVG)>T+T0G8GQGU:.:7+OC,_NHNEQY:XD7]6T.EY[)&`X?L
M?0^K^/-FO6K.2W2ML7BY7N;VQ1XCA]L"WV#8G(#?W'>`9CJR%MH:IZ9KEEH3
MV])QR2GHO%0CSQH/,/(RSC#QLG^/EKP/AK?1W'?=?(!RW\!.DK?_`#5XG:FJ
M[^HMJCVO8>TEW&Z;(AZVP71=BNB:]5`DZ,M,U.A#EV>(-S8!9(5PX4#(:<I<
M2&V"]97*-"M*6%_H2Y3-VT78=^E.3T*H#8LIJ+8.M[.OXZO6=,T["HF^ZED]
M?AR1"@7E6N0?(*!$6622VX^S@/A:>M;D>;2HJ?J?0US-J^V([E(]L"*I!H6R
MK1QS.XZ(@W`V-,S\*7%C[M*L[KT/'J-G';-E!2TF/#MA9+PPV'9:^'S=[H/)
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M?&L("F<;*-NZ3VG5[;6>8P"K$;.5BI6&O3)J]EZLQK`$FRML&`F6!V6B%LH2
M)&NO+:#IW=S'71H/=L52K=Q.["YV>@>,\ZO8^H^:-[(T+LD;?"(AN4U;8JK(
M57:+1AU6V1+SZWYL10.7_@9:7#1ZW'GDY#30%BZRM7WSC]5=R\?NS*7E*77K
M'KSG!JEN=;HQ5)V#)G6\Z(M6HL16R3Y5^5B";8Q5_P!))-5F.*`%<,<;_,*)
M#R'!&]M\(CM6\A-A4VH=BE.W7KC</^>:KH],V$=,ZATMHD&RIUS/0FX;W);8
M>VA3Y7;LSLC'[F3S&H*&G'\`1Q/Q'NN(#FUUY==6EJA^9EA@)WL[JEEG8^8K
M_"BDS7($ZP5T:4738HA_;G(.S.W&:GEVNPW*(0(N'!:D(M,>V&EQ:E(<)8#D
M.L>;?`&;FM%,;6NW9UH**`T:,;R4O=)Y";,V`?M/>CZ(:@T^'H58D-DP.(?5
ME4IS1%D8DBI-LU]Z-Q%-!Y%2CY@Y;J#EEP8V)<^+.N7]O=HL%&PVP-Q3?*V[
M:NVYMVTHG]'ZE'L,Q07-;:/@;8T3K2/V?1QLRML=$DIG%#Q&*P(@D/Y5(#BE
M1Y':2CN..E,\@=C]JVG]J2&^):)VWOL#=&Y;3K27X_DU,/<VNY#75)ES8"%/
MVULZ@VD"%$CW9X9B)84)9'%DC$+%\#HG8MLT3L[E!M;D'H?9VP,\?:]8*S3M
M'WOE8W$<@=Y:Q3$5JFW/%ZV;7M@W,UTFN`W4"1#CE`ID`FE%O)4-G"LH?"VU
M]=3B[8-[<3NRGC3L#9E_T3BR[PTV/L6S\7++$ZVV.]8)W1<#+7T,"UMUBQ0$
M+"VT*1#;*7#M_E.$X-6T7@=]C.0D[S]:/B?DPV4_[TNU/]W)NF.2D]_WK2O[
MF43(-1K1K,B;_@WN+:*Q#BY<]^,K<R.UA2LX;1A(;BGZY.C(V(/BJIV(=O%4
M1(-MLO?K><4OD1;6#@SW4.@?X0TP[AYX)O.<^J<X6E*O7^/3(=6[9^M-PNE=
M36B/WISO[-[)JBO!)M]P&V=R_'L5"C*O0BUVE)LI`V/79\$,-58F/<4T6IOW
MA^Q3R/3/JGP([.E_@9R2W/ODC?CVYN0](X9ZUY*;SE-5DZ;Y-XIE.V=>=/\`
M)-2#9/?/&Z.J%:JIL)R`UQ&Q03RJ\P$VZ_"%'E(8P<.*D+O`+13`@[)I:3BV
MVDI(,2.D1)#N/^9W`R%N(9PK_P"%PK.,>!69^S_F"%XY<2Y64:='-$Y.S8L;
M/BL#FR$$V=Q[W(H]Z-!+C)(=9RD"-O-/IR(^(L;#K98OM4^@+,<;G"HX!6'7
M'\*"%SA]W.,NO8RPWG#KN<+=QEQS^JO[E?SG^N?Z^!K?`>`\!X''+B*\=4;2
M$.2\&^97)P5@L<AP0@5XB,*:;)8*9($>&>86O"DN(=;4A6,9PM.<>N`JW?4B
MAK4[UD63\FSO1[$'SJWZ5),1^(Z7?MK3=1ID8?%6*7DVIK+@BYLMH]!48^R0
MZX(VE3ZVG'DNAC5]BS66P.4^^935%AZCN0')[76KM6T5VH<R^/&QU0-\HT?9
M[/%72[U&&KEGHMYUZ*HL^K_@FR;X1)3$:^_Z>Q'KG`1R=$7`)FI]A^H-HZOX
M1=AG'=JN5C:LDQMGE6C3VV-$KEH&MO,!5R8,%XSZ_E:K+2EB=&0.;"S`,YAK
M*DC._"M[*@LX4GXD_93V:@E\0N=STSZSS-+CEEM!AR2.6$TDIE(1I)ZVD%M9
M9>92A;6&V<X]Z7'%*<R&77=-(Q<7U*]BQ<NII(N>(6[PV<O"NF(5*25(E(V#
M1AEE@A:7')HL=*'?;A+*\X<4I"4Y6D.S.MS76HM=<-N.C&J*'KK62+/HG3=H
MN-.U<-#1-2#N<CKR"=LQ8T!6WO\`'@Y(F=<)_.)':2Z<4E3CZW7?5?@9W>`\
M!X#P'@>6_P#;&$JTCV\W>-(+BHB;)XPZP*F)FT/?/%,5R(B29L,6E@E@`N)V
M<>1$%C"I0=F/,;);'^1DATC*`LF?3SC8)KK'/EXFQG)6[R%W!"'P#S]>0Q,R
M+</K&6Q+E1[8!%@CSZ\.^L49E,FZ*X(4LIQE+A"$,!;4\!X#P'@/`IE=X$7S
M/.[,-5;3QUU\B>8O#2H\,M[Z7)@..=G/$M%D`WZ'BH[)(/G*M7-B2.MY92G`
MD"N1;(,U+1;6,9<PPR0UD*ZFGN&S>HI2:B(_JA^P69IZ\?X\G<VFA+=,5+7V
M_(6`=7("479D'KSCE298RM!2QKSH;ZI8H@7*?<A'O>7E`<EL/&IQ7(/9G*.O
M=;7?=P\G%2U?"U,#Q,UZ/11=?ZXCZ1KG70]8>M)NOQ[6)+AAP\J\2>T4^BPN
M/#MO,AJ>(?2';"]J:NU9JCCMI_3W%3OEX>250DIO<,UL/3FCJ")N#=FR]I52
M<@;ALBP[&E6XZX6:%DZ.M0X,1DA(*!3BO=GV"#X<#]5+=G$35^F.,?$WC%P=
M[,]9Y_\`,7X/<D]];DY4ZH>FJU+?[-2+0]YLRZ_5Y.Q$PA5IB5N2[\2(PH5Q
M+3GHO#;3>,!Z:H"RW!4.&+$<><6^M*P<.I&4,M]U064X>6MS+GX66_DSZ^W+
MGNRGT3Z8\#6>`\#\.?RVYC_W17]<>['_`"Y_JG_C_P"CP/)+ZFCCX;M\X1Q8
MESJ-AC+ISC-LMF"H<0B#O,(>.;<XVMUC834W7HVPAP41B-40&$"^_$LQQ9*,
M.9RMCT"R1]@+JRW3M'>NFN8E'U_K>Q4MC0^V=(;G'Y$VM4#QCXWU6O:@V2=5
M=M)HVLJQ9"J/"TI,"_8\S9\W(!8G_P!!'?A84G.,!";HO2_(*3XE<W]ZR6IJ
M;?-2\?>M7DYQBO',[6%N><U%RGM#MDUC`ZE,UM^OJ^N1[B!H+6T,B#>_(94A
M"PRS%J(D''!W@OH](^U`=S]4W"&]@5""I"'-,1U2,A:T_&%0Y<MK:8F-;S5I
M'(AHJ$C77[O+5-Z9(RV,CT(/7C.5JQEQ02H>`\#Q_P"_#5.'T7VV[%`Y*7J@
M;%V-V$@:JL^GQJA2;C#;HUI%[JL>S1+'8)H)3TIIB8I-X'&E6;%^4Q#F+#<B
MQG7WBU89#U%>KUA8W6WP&9<D2Y9>.'/&]69(U8[A)GRZBJ3N'7%BMML*3G"_
M1/M]W]F,>JEY]5J#.OP'@/`>`\!X#P'@/`>`\!X#P*<OV<RZX[S%Z;*O=N2]
MXXDZ_N>T]PUS8F]M?;%=U=8=>T\J1TT618V;IF1;`KC<;+`".X/+%6,$XA#[
MCB<->G@;C]/"93-\9N<I$A)+E[2%RZ:AIN3`BHU=:DQ8;6U<CHN8`O-><_QW
M8=AGG6"CI>2;;286^2@PAQ[!K+F0N$^`\#3"AAA(<;"%&$;>)),>0*PT.ATL
MQY9)93B6DHPX240XIQQ>?52UJRI6<YSG/@!PPQ5ENBBC#.'D_F'.#L-,K-,_
M''$_*+6VE*B"?Q1&FO>OU5\;2$^OHG&,!I9>%A[``[%3T3&S<6^X*\_&RX(L
MD`\Z$4R<&ZZ&8T\.XX(:,V\UG*<Y;=;2M/HI.,X#<DI2E.$IQA*4XPE*4XQA
M*4XQZ8QC&/XQC&/`T9<;''N@$'`!&/Q1>3XQXL5@AV..R,0'DP!QYM:PR\B%
M.M?(WE*_C<6GU]JLXR'#[;0:Q/"S1ZJ92Y>T$QI"09"PUR(D<O2+`GLB?V!)
M03Y#HHY#+6/3.<^U",>G],>!XX?/W8?)#_ODYA)Y3VB.NW+^K[C%JTYL"A5*
M&JH"YW6[^8#7K>E*5+0]$G(^"_?AA9P6Q&F%E1R&#$M*?5DM8>N5I+5FIMC<
M>M83%SU)1;`1L_4^O+-?6;MKVL'2EKF;#$5^[2QE\$DHLK,O/&6WVR1N3/F<
M5*(^=><O)POP.SF^/&@&GT%-:-T\T4V65(-DMZSI2'T'G-*9.-0\F$PXDLQE
M64.N8S[W$YSA6<X\#^E\>M!'B-@':/T^:"S(1LLT&7K2ED"-2D-\V8>2;'>A
M5LHD(K)#GXSV,8<8]ZO9E/NSZA\A>.?'P%]!06B=-!E-L/BMDBZPI([Z!26I
M!@D9#S,&AQ+!#,L4A:,9]JTDNXSC.'%^H;>=Q@XY244Q`':,U237Q`5Q@->7
M1:YBOQH*Z[&5!3$7!ICTQ47C_%80*.PH=EI6`@V&<9PVRVE(4#_LA1VMB^UZ
MDZB@86K5&H7OAUK%[UKC.I=;_P"0707<NPXZ(=@=B25?E7Z98`F9!Q+4C@(@
M_+PR1LI4"XOVA*K]1IF3L^H.;6RVI(V1`FN1-/CESLY)V>:EIL]O6(4Y:@Y1
M-M(C;8W/QQ<_&L.2$NP:^^D56&2B67,*;"XAX#P,1N=L>V1PXY;Y5B9)S)<7
MM[0KH<7.%1;V17=7VY\@B,2TY[43"&<*]CC2,D93CTQZXQZ>!$]]7\NQF]4-
M))MTH;,6-S>._LRQTG$APTHX5F^E*5B2#$CHY6#?16,N?+AU:,Y^-+JV4-9P
M%AKP*R_V<#C8/0G$*Q1,,N3E`^2-WBGBQ4-ID8BM6#B_O0*TF#%9DH=\4?,>
MA.'_`(B4/*3C'QI<<PA"@LLQ7LQ&1V&D8:;P`'\;>/=Z-H_';]B,>];B_1"?
MX_E2L_\`CG/@:_P'@/`>!L]B5A%?G5*5A"4P\FI2\LH(PG&`G\Y5D=S^Q_"<
M8]?8K^%?TS_7P*LWU!3X@SK?W8B/DX:0,9YN;K<D6XZ+5#GCI+KNNWX]V5CF
MBGHX'\X3.'1AQFVFAV<X1_=Z>[P)O.;A@'(7A=R2U9I'9NHIJU;BTENG4E6;
M+NL&['V2TW6@W+7L)5HF>`L(XD1.EWV0$#^=Q)B67$.LJ'4[G&6PC#^KY0>1
M&E>LR+T'R3XT[+XY735&VM@LQJ-EQDK"R&S8"\G,[`%NL9%3"$EAA"O6-<4O
M"<Y:6Z`I2<)SE2<!VO7LME_91V2ZP0.K]3TUZ]CS6%OH9*02?S`M4@Q@<5[+
M;YK"14X4ZZPEQIE3B$N*2M:4Y#+?N*QE75)V+HPO+>5\,N0[?OQG*<IPYK&Q
M(SGU3_./X5_7P-)U#5^/A^O;B^4UQMK7&&5D-451R4I-<L6N+J///YBQG'=C
M9NNL238&Q)V82M<[EYQW)F5GJR3C#V5YR$EW@/`>`\!X'ES_`&I78D/N<M7^
M6QYZXZ3T/Q[3%2=:@7?\DK;<6)-2+EQ$=_3,(LQ0J!Y,=`_YV67/B3@CW(#0
MVT%D/Z>D=$276+(3;00:7X3DMN1D%)<#)$GQ:YRJZE&D<QMNF`!AU9DGZ^X\
M6Q$K<'^-\=LC.'F?3P+:O@:0LX4'(N"G<MY-+:!&]&W7/D*>2XMMK/Q(7\>%
M):5_<KT3CT_G/]/`U?@/`_F<8SC.,XQG&<>F<9_G&<9_KC./^.,^!\1AA@AA
MPPQV!!!&&AA11FFV!AAV$):8''8:2AIEAEM.$H0G&$I3C&,8]/`B;W;V^Z-T
M_P!A_&_K6"H]UV!O7?4K(,SY58,KY$#IVOXB9:8K=BNRQ#I)]/\`E05=DGV8
M]7XT@,$'^4^TAEYA3@=G<2.>A')+EIV`\49/7!=?D^$FRJ#61MAQ:BS:9?J[
MLNH8M$,+@MYM28Z\UE0SS4J)ES",I=96RGVX<S@(S.<7V)7>"')Z?XU[$ZWN
M6UW='NL/2J)L#6SM<L=<VO(V:$18:P%0DL"Y:FK)+Q2_>J(8)>.&<;=:<3AY
MIQM(?/;'VA>#VOY&H:_H6IN27)/?,C5-=VK8VF^.5'C=F&:@_P`VCJR5+URT
MV\":8KLO:*5*VH6(.&BU%H1-+P$ZXP_GVX#E](^R)Q6(D.)S.^=!\GN)D)RW
MV-M_5U3MG(&D1E.KM-L>KI.@10)MV*)ET.A5BW'7UMA,DPAX>,(%=P9EMI+C
MS09X:@YD`;@[,.7?#`/7$S$+XF:\T%LJ3V<]MBV.1]PE=RU"8<#@P-5*%!@1
M(J%A#/<X0V\:&49E+SB$%LLK2$E,@2Z$$46R&3(.C,./(!#^'\HK+:<J^$?#
M[K+675^G]N%*QZY_CP.+0UI/L<'!3(E2L$2Q-AI,+!M;3=<F8)K)"&'A9.)<
M64<W*(:4IU#6$_&I*/3+J,Y3ZAY-'5%LD>S=RG79`MS4:MB$Y97YXVN.5B`@
MAZV^_,V(6!K2I*#`!D+Z8N/A@C`I:1<2XJ8/?]PZ7<$%&AZ`7-;LIZ^MRZSY
M(=>L_P`NJOH'E1N*C2'&9G6M^I=FD;[3=J[_`*J'5*;"D5@6JV:$N.1Y:\!-
M&OPS\K&L_P"KG!6,-*=0$7)'#O;W7E]73F+Q)Y3QU?5L"CZWW_,(S5)<FWU6
M0@+-LL.5J4Q%3$>BOY"?</EFG_Q2%Y?&<3EQUEUOU9R$J7UOD#-])_`U(I*R
MF\Z_O*UN.#9%4@ES<FQW"QL-Y>?]Z!"E+:2[ZX^9*,+]J/=[<!-]X#P/(EME
MBO\`7.&O=`S5X/61>O\`<O8#6].3;TL1$:^W@+-#[FLFV:P9'SQ`34ALJJAL
MT=X0REMJ$:`<D'IE2<H$<Q@/3MZN76GNM3K\<9=;>;SPNXQXPXTM#B,Y1IFF
MH6G"T94GW(6G*58_KA6,XS_./`SM\!X#P'@/`>`\!X#P'@/`>!2`^S+SPY#]
M?W8/Q(VOHG>!FJ7)OB=>:],Q#P$S.1EG#7N2,:FF(B++#N]%B[VJMR!.(Z;-
MK:W8QM#V/G(4\.RP$.'+#NYKW;3LWK/GK["<?^*.[]4[CW7"VJ];BA#]F<?-
M45JU2NIY+7^WY:N6Z.:B;U`D0L%+1$A$2[Y0'YHSA*QD8<%RR$^'TP%+5PHY
MG96;%22\\WK"I4A!"L`P9ZU:FUGE1L,$*,$*'%%9_O':;99;;94E*4)QC"<!
MWMW)W7L(Y?\`85Q[ZI>#.XC.(;4!IISF]MOE16MB6VL6&/J+$O<]4PU5D(>L
MG5PF0@6K5AK*A&BBW#2C1R,I';CW<NAA%J'E)V5<&]G0O5'7.PCC1S>Y7<F-
M^8_%Y+[DV8_/?]GS=.E:Y#;EUUL:D72>8V#?-@7AB4AV:E76))AUU]\S`#:G
M\Y6@(\>17/'MFZ3KL-I*.[5]%\U[/L:?N2]@UB38N'(@SC-;Z'(@Q$'K25<N
M,O+VG7+&Q)2X?!EDO#>4.Q2\^U3C+F7@ZNYI?9NYWW'D.;>]&1=PXE66B:'L
M_''D%Q,OUIMNQ:\+LO.P;B19=FZZKM?BZ2_6=C4FL18@[TY(*`-AW\+'0M:/
M]18<8@N9/>!5N)RKW8^4/.^H6BW<Y=2<?J;JB2JMOV'R*O29GC?M`T9>K+1<
M9)D":K%OL596T\"'"'XS+?#(H,=("4V2'5VQ>ZONMT5JUW36WMA<H]1Q%LVG
M,;2JNS=VUJ4IG,>7I,#(1L)"U#7:K.)5:U/T6.R,R[/H56UCDOF&91_ICKPV
M&]:C[>N_?9_%FTE4W<NV]UT&G[]H88V]=-QL$3O8R[[*UUL)%.U(QB0I4J+:
M=;M$TQZ4FHK$!F8BRD,NO$-BDM8R&4O"[N>[[..VX9&N;3T)N_E!`S-?D.0]
MVAN4^JYK4FYY#C'H.O);V\+I9R3D:9`M%U5!Q#[F0HJ;*-D,MOJ%6HE;>0[1
MXG=S^XN:^P+WHK1M+I&R^6?,;F_NDGB=?N90^LTQ_'#CE"Z['MM6JW^6:FHD
MAM].S`1V9$:*G/@*$@5144VEUYAM2/`[KY@[L[F.MOB'58/D-V!5;:6^YSFY
M7A_\VX[;7Q=MLC5VS:-LV;YJ2UT^\:FEJY6("*L'^*N0@350+8;D)-I_"1WY
M1I6`EH^M1RPYU\N=;<F+?S#VA=[<+3+S0*K6:=NF@QM3W+6):2U32;3,R[IM
M>KFOH0G7=DDI4U^(:7`8*]F<9_-?0C&,!9Y\!X#P//&^R-%QLEVTVN"F+_:J
MH+<N`VO8`V8*?FQJA#5,S;!QUL@X[`X14<;8&8"K'S,>,3ET(J74RE#"#&DO
M+"7WZK+=L8UWV%CWB.FHFQ#\J:8TV!-UIFGD(K"M'4DFG&L5MD*.;A0YBND,
M&,"MM+888(0EM\A/^JH+7G@/`P#Y[RMAJ.C>3EMFKS$C:O7PLY%P4?KLZFY*
M3*;-31;%.MSYUN8FLGD,_P"(Q9(K,*S&_P![6"R%%8SA#60CC^KS+,2O4/J7
MVG"21L?MC?H$N:&FNN-DR6-H3IKCRY&L35@CIA3@QK2DD_E.*RWE*$_Z3;?@
M6&/`J]_:"G)B'TUP8`@,L/G7;ER=K66BR3G!4R](V'I#9M5NX@K):VJ\Y)-0
MDDIX=XA:#1E-Y4%GY<JQX%GL,5L$,4)G+BF0QF!6E.KRZ[EL=I+2,NN*_N<<
MRE&/<K/\YS_/@:GP'@/`>!L5H_\`F9L7_P`0I?\`^-Y'@5>_J"")9ZL[X5AX
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M7RK#,ON,0ISJC[&&T>GO7PRY#H1[OZ>Y6L;&E/K_`.T]<^!RWJYW+5M[]?'$
M:^5$>PA@,Z,U]29,.T4><UU*B6K6]=!H-P&Q5+`!&FA1K-GKA:0W6VU!EB8;
M>&<<8<;6H,]_`>`\!X'\SG"<94K.$XQ_.<YSC&,8_P#'.<_QCP/+8^T'B6E^
MY;D17*);9<:?G=`<;*T77!90?!LM:3H:'DH^(B!YQT8F-AVJR.@DMZ#RI:72
MEMN^J#34^!:'^GU'Q['4FJ1CG99");DAMA9,=(-U_(H9H(%0!?(CCHF%BY21
M;D?B2XM4DZ40SG&&&UX8:;QD+4/@/`>`\!X'4V][-M>F::V9:M%:S!W+N2!I
MTW(ZSU9*6Z,H49>KFP&YF"KTC<IG&8RN@&G93AXE[T2AO&?3.,YQGP*'SO2'
M]@D>H[8V.S*<&Q-D[;Y30_89<&DE)L.^U;VJ#4G9JOJR-OQ]-)K;E1AY63)!
M8A<2ZH-2S"&_S,A%$_*&=/'387:;Q1YS=E.]M&=85HY74_DYN+30NP"@=Y:_
MTI(TO9.HM)1SFSFAZ)>+#<Y-)<]9=CLJCGD$KABP1,+`==&<95@.&[?VOWA[
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MT)=MF:IX_P`YL9ZI:R-FI46PCS#Z*W<(Y,KB7BSR!\Q_X&27Q$Y;>"666ZF.
M4%1AV)&#[P>S\?\`7FK>FWITK2>Q,/PQTTAPU`,8[J8<P,H:*(<3@I2S$B*Q
MA]#&&FL#Y""GJ=YR;,J_?%OSC-4N7&X^5?$/:=,V9<K/N'>\C2Y-&V=QZZJD
M(U9MB:>*@6JG!5BBAW<0R`@X"$0>(+'XPTH?WI_($"N3TIU25QW6<%=H.#PI
M-=N?*6XQL:RW'R#2!3XROWC#R"&@X0R.:F014,&9]KF5)??:=>6RA2WT!<P^
MS!U#[QYBU[5?-;A80)6^3'%:+MT[/HJ+<M7ML[`JL<`#-P:]?3FO:C)W^S;.
MJLA!8;@@LG,X0DEQL3&'W?Y"N5P,V7L?>/4QV\[*VGS7Y"3NV=;<;[3JS9'$
M;<=\MVRJB?K6QUVBBZTW-6_]R)RT7JFVD6^C2`IZX]3,:\RX@9;+:%LYP%T#
MZXS#@_2EP*0Y'+C%+UQ<7\#K6^YEYLG;FPR&I'"B%*7A$JV[@E*<?V)2[C",
M81C&/`FW\!X'D<;)TQ;%</.XW84/QQU_L:,@>;=7<V[NZ9V\U%;GT=79;?EE
M,J;<)J"1DK9`ICK-(PIL*=*H=%MXY$V\,Z.5&L$K\#TV^KMH5CK7X`-ACMB#
M?]F7&=QH=M+:4MI>TY3G<^[XFF6UNJ4O.5KPA/O7G*LXQG/@9V>`\!X#P'@/
M`>`\!X#P'@/`H^?:'O,AH7FUPUWJUL_CUKMF3X][$T\`;N?55#Y'LQ$G)7\2
MXG62R:/GJCLFZ1E'3"0[H0UIKT)^R&G"6!4NJ%=,^$(<=@]8^D]`[%Z4;UQ-
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M*2%>]UM"DAVK6]M?4DC>/;VB*WR:VA66[3>ZGL2[;?35=^`;[V&33MH$[1KL
M#L^\OZBRU:8F(L0WL'0:"L@47#"FG4$801X&U=H^VOK7]I=ZAMR3/8%8M4[7
MAJ;2*8(/$:\VW5=>3%4C]KXO=\>LT8)HXZ8+V%;*],24>Q)//$-"&9%)>%(P
M.I"PSLY$[^Z6NX"3X2\)('LAEPA=<;2"`TY6]6TW<=$W'/V)S2!^I-:@16U9
M>M9K$=:XBXGXEUG%QJ!S&,_@_&UGWOO!DCIKZR?'_1G+K0/):/Y*\GMVQFJH
MC9<+/5OD5LB,OLID&XU%Z`BPJ5*LTD3$-#OFST\]*#X^`K+TNDL`P,D1/SAR
MN^?6:XLRQL_%Z8Y4<V>*NI)NW0&P0M&\?-IUFM:[J5ZK-;D*?%VBE-3U'LDU
M5Y9=;ES632Q"FSY5T\EPXDG#B$-!N'%/H)B>#_-G17+;7W*SDWR1B-?4W?51
MO=1Y4[,!V/.("VG6@@8E>J$"U"O1<:2;8$O/SOYYK39+.&U)PMW&?`V+9WU>
MN">P]K;XW+7KON#1-YVS<J?;J#.\?3X#74QQ\571)ENR`ZMEGHJ?+&SM&1GR
M2;"\_E67?]-H-(;*5(<#&7:/U3]:$TG706L.0EVLF[0.4%;W'MGEAN:TWIKD
MK=M.1,'48P_1D3?J%+A1@B\S5?<EXN>.BS38DAL5EM"\,_/X$N?79U)1777M
MS;FQ:US%Y;<B:YM.H0U7'HG)K86-D(I1$/./2Z)>O3B&8I.'2!W?Q5)6#AW+
M2<94\K^G@2]>`\!X'FQ?8!AY.M]M$ZS6[(5MB9QQYTT[K:O%Z]HR;MQ\B838
MV;5!RL;>Y&Q!DH%BK/'.K;D=D$-%2;TZD%EAT%,2\L)W/JT7F0D]7\T`9Z&C
M0$.<FZ74:S+@5*PL62RMTWCC0042FPK$FNPD(1-%5N#$**?=&%6[-E&J6\0X
M4SE06P?`>!BKSH*9CN%W+&8>-C(W]'QPW=-M2,V\4S"@OQ>M+.6R7,_B.M.N
MQ;*V_<^WGWI6WC.,H7C^W(1'_5O!%&Z<=$F!XC\,RVP]]$I7%!PP,>\B,VW:
M*RP0PQ!L#"+<(&@$+?>4G#A)"G'O^5Q/@6&O`K._97@(6Q:TX,"2+163P^4E
MEF@'1;4NM96S!:&V9,D`.LL$_D3PY)P`;K@7XZFB6QU,N/,I=]KP68O`>`\!
MX#P-BM'_`,S-B_\`B%+_`/QO(\"IM]0"T"@]>6QH`J>A"&9?F9NX805<L@*1
MAK&S3=920=6Q%R,T^N8DK'`#GRS68\0=+(<>[E[#BO1S`9G=DGU_:5S[Y4R7
M+VI<KML\6MKV#1Q6AK:=KVO1MJ8M-/EX6R4^QAG(G9V/Q'1\[1;`J*?'!P-E
MQK+RW'%J=]$!B)P&^ME)\,.>U*W%;]XRF_.,G'/7XL-Q#B;=^A>V7K*^S-G$
MOUOG)&)568VKUZ"8M!4O^&]%/F'O9DW%.--J<R\T&:]">S_[,R[^8'D'?BSU
M$ZJ7(1ZB#,-.&-<ESOPW4"N#,"N_B"$*S[D*>PWDG/\`?A2W&T!FIW(O?C]4
M'8R[AIQ[V<-.0G^FTG"U9]VM;`GW9QE2?]-'N]R\_P!<)QG/IGT]/`Y?UD:R
M9U[P5XDJ-NVS]GV.7XX:FE3+]NNP@V[:#T79ZV/>8^HS5G"@J[^QB*4_:G@(
MU+HV'V@VD)=6ZYA;B@SY\!X#P'@?`D48T=X0P=@L4A"FGQB66WQWVU?PIMYE
MU*VW$*Q_7"L9QGP/)V^UW(6".[K=^.?F_BL$Z6T<!'_E-8RT]`':BA!Y`(;!
M`RVG<$22R_:I'N]CV<^BTK3_`&A;<^GO')B.I\=Q,REYJS<B=S3"HDU$:DL<
M\1BE1#B8985BD"%P[8,<VZ\DL$(K\HA2L(R/\+SX6M/`>`\#B=JOE)HP@I]S
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MCIAI8N*>*$'DF<!'D1I"DI0:*R8CY7`WE(5C#J$J2K.,X]V/`WGP(JNYWG#7
MN!O7WOW9V=B/:XVY;J!==<<;Y,$#!\P9OBP4^==I*()DN*E8-Z7A5ANRK;!Z
M4,%I`4RG*G%H0H*UG)SA!4.O7K^ZK.:&QM7T&61P'Y.U':W(/851;E[O8=WU
M3?<Y$2B[A28.3.:%@*Y9=BVL(\^(+(C&(N1&6L`%YMUIMX*N?6;7=K?^<EQ3
MA./,OIR?M0._[R_IVT[%@-IHTN9:A8:U2R9NU`BL0&PWI'(C`ISX"5L%`DK'
M%)2-\3K+0>@;1H7[+FNJZS`Q=8ZDK*"@^:6.W==P<W;=8A!B&X]83TA=K8Q8
M)F><>.44Y\:_A;81E+2$I0E./`CT[%]9=V-1Z^NP0O9&B.I'5VK=G:8E[/R'
MM>@KWRA:V7(Q=)I$'7")*I0TW6A:NN?S2J;'Q@@KJAP/C8Q\N%>YQ2@[.ZD;
M;W,C]<G$17"[C3UB5SC$3KE^5UQ$;8W[RN,V0N+E[!8I&7?LKS-&G1`)4^X&
M&EJ::*,&:9<2RSE+>$>T)(G=B?8G""D27>-'4]-$,A_+'Q\/R+Y-`E$%-$,.
MN#X5,:D:`<66$AUEK#A`J$/N(<6Y[$*0L-$9N_["PSM?88X)==4C@Y$BN:,$
MY=[.:$B,HDY?$<P2V=JX0Q"UQ7X6,J%;D4N.I<<5\'RX8&"D]R1^OOWNNS.X
M]1U71D!;=/[*VL/NLRKZFV[K,;3`ULFU%F@/,'7>7UA<K+<*%&SSD,](GPRF
MGV$O+2ZXM+:\!Z1'!?5UST?PJXBZ8V,`+%;!U-QHT;K:\18,B++AQUNI&M*U
M6[&")*@K<"DQQ)>->;00RI33R4X4C.4YQGP,J/`>`\!X#P'@/`>`\!X#P/PX
MA+K:VU97A+B%(5EMQ;2\)6G*<Y0ZVI#C:\8S_"DYPK&?YQGU\#S^^[#ZY?-6
MX\G9+E9PW2)RBG=]SFQB]K:_<C:1J@B@1T@:/*1#-8/G9%-?.(=%?(:)F#I5
M,N=(N)=2*XG).4A&%R"Z@>0/6OO#J+A[W#!<[MT<A+U;KG;^%T]*1=5U0/;(
M*P5HQG4-0N4N:V-'CW,&W+1*D?AAQO[,-"ELO,(:]0LV?3W:($X*<JHY^D&4
M+,9SDV.`Y`%RR3_UIPNO=9CR<.@)H0,:*S!&M*&6AM&$+4CUQC&,8\#BO9/O
MS5'$KNSWYR:WO2*AM[6FH^D%%G5K.\QM$,$G[07RN<K=$K4&FUP4EE+T]<Y$
M=HHIA)$@*,4\IIHEM*1%A5/O_,#E1RL%V?N?3W+'15(CH6@3?)KD'JN,T=KZ
MH:&XZU4\NK5O6&H->C6.B7+9FQ]@!7*P$P17X\41'!NEAD_L/QB27V0Y!M7L
M+Y?[Z@=%\6=4Z;XJ<8>0=)O6LM4RD#9=%Z]IO*78MFA-)B'WS96[+-L36T7I
MU.N[1;DO2(@J!P91*W6&\LEMN)=>#N*J;;F;9%[125V1\?Q^,W'S_;N1EN2&
MK>OK3-SW]NC=&_:I3SK)J&G:QV-6=68NNO-#E0-G(05%N`/C"LY=0&6X:&AD
M)5.,`VP=BZ_Z*-E;=U7IV.V'(]M@<53=N:[U%K'4ESW)Q_K^@)F[:ZV/M7-;
M,G/P+9<`Y9V5<A5,AO,H0D;X1"V6WG`ON>`\#3O%B#O"COE#L/GNN,`L//-M
MO&/M#O%NLBMK4E9#K8H[CJDHQG.&T*5G^,9S@-1X#P'@/`>`\#SAOM+^KG95
ML*-(CD+J9O#;0<C>SIN[0U?".CXFZ;HDV*X&X3;:]-IC5@PQ,D-#@MF.2EBC
MQLY$=<=&=8"5?ZDJHL70?)B6I,C#N5&Q<DVBWX[5L7@"E&'AZTK,8IAR$M5D
ML]A@E.&3!)#C0H]?RTS`,$922')"M)"Y%X#P,:.:$Q(5SB#RGL\0\Z/,UGCC
MO*P0[[3#!N692*U;:R@7EQQB'8Z30R0C"OQR6W1W<XQA:%8\"'OZNLZ]9>H?
M5,\16`:F]+[?Y"RKT='O2A;#Y$KM>P2A4AD^5+->.4468OT4VXIIM"4LX]%-
M*QX%AOP*OGV=LM,ZRX#E/ECN-IY;RHWZ15@.K!)"W]*;">38LR,8')%G1=70
M(I148ZQ@"2R4TR4^.WG#N`M!8SA6,*3G"DJQC*58SC.,XSCUQG&<?QG&<>!_
M?`>`\!X&Q6C_`.9FQ?\`Q"E__C>1X%3WZ=DC*XZY]WBS67&(=OFSL\>H+._-
M:'+?(HFO295F(6:O\$AY+[;F7$AX]<>U7R>JL9\"V_X#P()Z*-[/L@;^(5'O
M+4YU(:64U)%Q9N,BMJY/7=I8T1*X*+!Q'R#@V,OH4D5;I`OHAI?P.NK#*KN8
M)8$ZF^QITAYMA"N&O($="W%^Q*B3-<3P@;*5?Q_JDEOH;1C^N5JQC'\Y\#OG
M@_($C\.^&D1,!RS,X3Q0T.4=ET"6*%&,#U52VI$61FG4EL#2*27_`.U!1'SO
M^U:DY<RA><!E48<P"EE;Z2E)?)8$1^*":?G#Q"\-M9>2".0H<?WY_N><PEIO
M'\J5C'\^!J_`>`\!X'E._:@=DU]UV\8$AJ5>KUHTIQW$F$PPYDW(L0(U,@2E
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MCOM(C8#3]RLL`X/8!JQ&VFEB5NR-M.*+7'A.DE2&&BE,_&X$F/?1P%Y3<`A>
M/&D;/.;NO7`?4&OM>T'7EJL5HL9&LG.2MMI-@L^R2*%4[1>K(S%2QZX)YU_`
M#+<0"PEP<5L?&<-9"YA]6K67-;3O7-$PW,Q[8B0;U>7;5QAK]ZF9&SGT_C^_
M1ZJ_7P,?)D[_``NM34I^8?#1[Y"4?AOH^)MK"DM8"RN0<&(Z&R44P.[(DJ#`
M;>=0VLPM(I)JAATJSC+K^!`W7/:GUS[&U9_IC/@?L<D8MK#XA#!3"E.(2\.Z
MV\TI;+BV7DX<;4I&5-/-J0K'KZI4G.,_SC/@4_/L_P#-KE&SUM0\)HG2FS:5
MJ3?VQMI:AY"3.R]02P5QK6OZ,0J#%7)0EB@I2.K-;V9+"'2,/)LK1(O1L<'(
M"$L(<>;2&!/TW>6^_P`W9>].$%@%J<GH.KTF[[LK=K,I,E'[`3L%5_IT'8HQ
M5QCPF!9)N9'M+9DB'8W7I<3\<-`OQL8=1X%O?L.FN6=3TX3MO@K4:!N7D/HJ
M48MJ=&76;L<<QL.HR$1*"6BIQ[=2G(-XFY3<6ZA<*-+NYBOR6<$X:=*8%QX%
M6?9_;WQI[6>6'!?66]=D5GA=J'A]9(SDWS%U/R+V<SHV7;Y3Z\L%IUY4M=:J
MNWZ7]A8[/J"RDYL1@A)08<O!$8&]!SFRFT!F%SH[=>FGM)X@[XZ^=8<JM+U2
M_P"R-;2$=JF>Y$4;8>J-#T6[5(UQ=8F2]AS=0`JE=(KF8=)44\TZMK*W!L#I
M>7G+'@4P^BG)4?W0]=E?;G(JRP%2W5;:M"6",Q:#(:3;;!V2800.S+.I'",D
M<2*#&TAH9';8*'>?0IY3V5!ZR>[>7G%+C5(043R)Y+:%T1*6@0P^M1NX-MT/
M6Y]@!CGF!SS842WST0_)BA/DMH=<92M#:UIPK.,YQX$*OV6^;^G^.O7%?=+7
MN,V',&<XJ+=M/ZKM&N(.$M$-'6EENIRK#=AR;/12\!S<%*$/AY%P]DG`;C>%
M-*6VY@.<_79WQQZ-ZSN%G&^F[@H5@W'4]!RUYL.KH^9@4["@:J?M6XB)L5II
M\26437TE2AB4.?/E2LD+SC+KRO5Q03\^!HY$\&+CSI.4,'CHR.#).D9`PAL4
M0$$1E9!9A13JD-##C,-J6MQ6<)0E.<YSC&/`K)=&T=+T[FEW&Z_HOO/U/3^<
M0=8AA;3L:YW.:IFM1J#:IREIJC5DD;%A==M4S+MF!$_LGDD".O9RTSE#.%A9
MY\!X#P'@/`B`V;W=\&Z5.;GU[4[E*[$V]J#=M'XQKI(<)+UFOSO(7:=0N%EU
MM12=FS\:U3*E`3$G19.*D[#(O-QL$2$\Z7G`^&W'0R"ZT>><%V/\6(7DO!T!
MS5ZB[YLK74W25WNM;*:B9_6=ODJG(N@72J-C1$[%2GX*"Q"$,,X>&?0XC"V5
MM/.!AQSO[U^&W!'=T7J&T6ZP[.OX%OU?3=N:OU["?L7])5._'3LE.;INLJQ&
M&G/#T>IP>2R8`;WR)8I0KS#.6WLO(#&C37VC.#G(OF;0.&FB=5[^V--;/W`/
MJ.D[1'`UU5Z-++SCYY"Z.PUVOM<V/%5>,!9?>RDR$8D"/QU-L#.O*0VH++?@
M/`>`\!X%'O[94%+6?EKU-5ZM:RGMRVZ8)WL!5=6TW84YJV^WF9)M>B6FZY1;
MU`CE$5ZR2@ZG&FR'&UI0UE?QI4_\2<AD5]-7!L;P&Y,UV23*Q;\9S/OOXM7F
M9]B8,@F6=?ZU`-'_`!VUM+&=9DAELDOY&&260TI>$_\`@&[]TW"CM*D^<MGY
MR<'-/:`W729?@_"</I^D[2!>V/;#<W':DY)S,M4]88A`@13:L78`)+$D4>6.
M.((4ZMOT3AG(0.<?.BKM8U=N^X[\MO73P_V7FA;E+J^I-5V2W6:M:]I&W9NR
MT,FH\@ZI5*ZIEC:/'RK3Y8I4E&S[AL,N%#DFT!BY9RK`?:W=&7=]RKY0[1Y<
M;3XG<:IT6S\D[Y?;9Q^W%N.952[-.PY:-<S+<%(2-C_W!=U?88F/257'4SR&
M$1(0BQL(:;&8<#,?:G3AVI[`C>)FJP.MKB_KGBAPWFMMW/7VCM2\WI:"V1>9
MS;$(#FR16U>0<JO-MM,?+V>`#P0X,Q&R&8#_`-A;9[.$-E,AA=M^8YE=5.YN
MNZH;(X%T+4VN>.=EV5V#3?&W5._G-LF;GV;7@+"/O/=[5YDR+Y)ZJKFN=5L!
M`B1,J<:&*EA3K#A[[CF6`ML=</;GL?F+R0VS0]R5W1>D=55WBKPNW]KUINQF
M.723LO*[6!.Q3JH7=)2X*J-GCZ>U7I1#:A(F.->:PA;C2/@>]X2/<K^PSB)P
MHUQ7]L<@]LL0%&M-UKVNX*4I]9M^UBY"XVV,EY>L0S4)JV!N$YAV?!@2E"+R
M/AM]3?L0K*U)QD,!-)\^^3'81Q4Y/6F@ZGENNRVO:\E1>)EXY`Y8GY/:#]EB
M#CZ?N^O04Q`U;(M(9&';8_$6!($N%&XS\C2AL-D!7>TW]B'F;PYX]=56GK=6
M-=\I)7D1J&AR^P]P;*F]C*V50Q93DOM?12@]A&Q6"XF9E_UM-&;#D"CW94DR
M--=/94LEE*`OX>`\!X#P'@>=M]D:J2UB[4[V@4.2;FP>.O$JUU(B,T\18C&X
MZ#V;=XX^RQ=SK`VQ\+L@4I*O1\>#9X6-CY#YWT,I(*!C698)/OJ>T6P#\9N6
ML//DWIMN!YETS!T#^>YKPBOW2GZNIY5[_80-?#J[#D&9<T*9>CBAQCI".9'1
M)QHJDY&P%POP'@8I\[L&9X0<Q\1_XGYV>+'(+`OY_P`V0OFSJ:VX1^5@;_7R
MSZ_\WL_N]/Z>!$?]65<>_P!+'&DN/R5E)=MWPX2LX9EDIPEC=-V!RIYYEAK!
MW^@(WA+N5O*PC&&_?C",-H"PYX%7[[-+DAFE]?8[=5A9V"QRNF#K+*24\3%%
M0T2+J^PC&LB0\=+1YEV$D8R0)<*@BVWH*90(D*3RVR0A60L_H0AM"6VTI0VA
M*4(0A.$H0A.,)2E*4XPE*4IQZ8QC^,8\#]>`\!X#P-DLK:W:Y/M-X]SCD)*M
MMI_C^Y:P7TIQ_.<8_E6?_''@51_I\-QJ>O7?\8I41^VAN;FTT'Q"'!RYF#-:
MH^N!\9E'D31_JZ^E2\L+2&!C#*LXQE_&?ER%M/P'@43[WT5T/;/>?MK0<%S@
MYQ4.$>X=0W+6X6ZLW[YK@-,7KD=L&*!TW7[LX@)-3U]6C$QLM!A.B2ZDJ$)Q
M\B'?:\V'<O8A]?,;0O`[F'NO/:3V=;+SJGC?N"__`.WNQ>0#D[0;OFJT>9F?
M\6N<*H!O$I69W\3\8UC*L?(.XK'\_P!/`Y%H;ZQ^L-_\<=(;1ENR/LCBH_<V
M@-4VV6I;FYH>7AP(^V4:LV>,J:,%5Y#)=>JZB\,##N-9;]C3?MPCVX\#(4GZ
MM]2(6IW_`,U_M,R0I@17SD;Z%)7^T'>C5NR*LKATY5AQH8A*&\Y]6E/(5[U?
M%Z.!NX'UHIV)6*B'[E^U>*!$EK+,-"Q^\6PUX,LK3>#"\OBLL(<D"'F&U%/.
M-N?D)1A*4M9_N\#?([ZX%MA\LN17=1VX!O#G*DFEIY#J<2DWU8?:(RVZ(K"U
MI.;4ZO&?[7,*PGTQZ94H/J']=K<`7ROL=XO;`V>M$4A!"=U+^%.85]EV-^05
MPEW+B1DB,8QC#B<J4WG*LJPKVX#;C/KK;S_7FBQ7>;VFLN.QJQQ4R6VSS0\'
M(B)&,&<-;#GXPQ^.3^U?PMEIYAY3+F4I>2YA+J0I\?9^@AJ_W';\P3D<D^FZ
M'XUD01=@L;(AMS"CM25"`/D)DP]Y<C9[2IQQS/M02.80V)G.$/93G*PU7$#D
MCJF@4O6=,F^_KG/Q2J-:XOT\IJ@T@'==XK-5Y&$S5ZAY/65532,R%7K^I-:P
M30:WD(P^\:F98=#<PGWM#!]])=BM_P!BQO&^DSW?)SUT+=I<FV9Y)6K:>P-F
ME:?UW6J1)R$=&":T(JD+8;[:;%M"-<`,A$R`8[4?ALMB1RVI([CH;W$]BNTC
MJU5-=#?8)YG16[3N5AVL[WM"SV#86.+L+H.H0\M,$<AJH>(+,[IG(JU_,S'0
ML$3&QA1\ECUD6!&$M/(#?.07:1R!U1N_8NMM*_8!Y';AH1$KIH[C'N1NNR!]
M">3;[!%Q.Z7N4ZYBL15WHPNLA`B#XZ/@*Y;QY01;>$X86Z^CP.W]O=F>Z*%M
M*ZZRU_\`9%VOMO6LII'-ATCLZOZB>C4JW3`PHHI&O]]2EIH<%/:]KL[8'R<Q
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MV);BF-_2U7^Q/QOKVGJC`7E7'2U<DZ)QKU+M7<^QJJ!!+JL+)Z3MD.U8=&PM
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M("V2Y27"1$V:"=`/CWW&,+3@,+;#;:U;>-ND)78>Y^O0V7Y$ZYY9P.UMK&<<
MK#)<J-:7^MR%&WF-G:EBAX1N:N.TMFRC`55K%P'CR!1OW\L,\6OX731PY^_O
M[D5#=857J6T.?'&39>M]ID3=/@.%M^+MMNVOKFN5&5B].0=Q@K3KJ#DZ]60:
M2++JL$9`2\J@#\87,JW'''#"8;#O;JGH6D>._9KU@2-0(M]AJ[?*';P=EYGW
M:"L6LN.FUO\`'X^V4D(#0,S>9**KUBHN8R/%-R6<%$VAJ4D'021E80(VD/1<
MY*].G6YS(V^1OSE%Q=J>Y=ME!0\2[:[#:=FA-KA:XC(]?BU5V$O4=5U#@!)2
MVYC\/T*SC*G<*]V<>!TK;/KW]05NK6:R;PRI`[(HGQP$DQ:-EJF:Y(-B2`C$
MM'2[UV7*D$(_-0MQDE]\0A8@^76E991G`1O=5_0)QYX9\@=^Q=[1IS85QUYR
M`C=D<;I],[:O^X$/0\Q0P`+`%M$6!V6NNKI\E-61V)CXD^&RXX@)V0+<>_9C
MLC!:X>^5H9W\-IIQ]MA?XK#CF6&5NH;S\#3CR6WE,M*7C&,JPA64X_GTS_3P
M.O:1:0=DUN79-D*@3*Q$Y+U.X1NO;YBV!UV>B24Y(KTA/1@T(='SS`+P[A@3
MS`[X_P`_L6G*<X4H*OO5-RET'I+M\[E^-MQOC$5LK=_,B7M-%K3CHH\1"4K4
M>K9"=M5DL+S0T%6JM7Q&Y5F-#?\`:X64^REDA3BFOR'`M!G[(AUDC"U64IEH
M>;-CFIUI%[A07X0`Y\-:CUL(1(.$+3$NO%-,Y^++^&<)2K&%^](<IQ:ZNI7L
MQ9(#*_1:O;B8CLJ]K:<+7GVX(]?1"58SG_PQGP/W_D]:_L_^6&#_`-3_`-7_
M`.Q8#^_^[*/[/^H_N_OQG'\?\<>G@:=RVUY)#0Z):.?PI3R27V)&.6/'?$PX
M_C,@O):5CX>PTK"/[<^JL9]?3&,Y\#<\2\3G"E8E([*48]5JP:-G",>Y2/56
M?E]$X]Z,X_G_`(XSC_AX%*SGOQRVK<^R'E5.%\<9'9FK+7V=],5YDY*PZ1G=
MG:XO>GJ1QPVG7-G%&UZ(#)1>*9KH\S#=B4E[X6'"4-O)]ZOB6&>G.CINW_NP
MG1T3UK\O1^JK1&NX2=&LW'S29D]0XBPWBS;*R=9;R3'Z7O0%'S,/5S"\,KRT
M00Z0TTP^XA'\#!$7S`N7:/PIN>Z.)_`K@?R#Y&"6<N'IW*_L@V1IPZ]<AN:#
MML@;Q$`CO;/J+2!EPU.JFU(^)K4NPMF6AWXEQO*TM+4C`3O=5/7#PQ9T9Q3W
M1.<$]:T78VK=;:D.UGLO<U!I\/S,'V#6$6:.F9;=35:IE5C(NV0I8XS83^'3
MBI)YITPCV.I:SX$^N),91B1$>YQ*F%O*,0IE03:TOLCH$=>P][D%OJ>]6T>W
MT4E*OY]<>G@:Q+["_3*'FE8SE2<92XA7JI*TMJQCTSGUREQ>$Y_\,YQC^N?`
M^OK_`/5_Z/Z__P`/`>`\"E;]J"T3=`Y@=0FQP;EMVB`:[F>2UY(N&@=9UO<.
MX:*[5@M5R6;_`%37-Q=CJK8V*QZ-N&)D#6!F1E+<5_<E&?`[.^GK$3<=QJYW
M9E&+"Z*#S,DZK'35MID=4K3+XJ])AFB<6!$*W)0K<P%^P0DJ-&FI=$64MQ.%
M(0ZAT@+>7[F'_<8KW[6-_?YC53&(/\X7]QF(22D)4KB,^7\W]:DQ:6LO^SXL
M.YPGW>[/IX&Y>`\!X%<#NBX`\P.7_(/6-YXZ:MIMQK=-X%]@.CR+!:-E1E6=
M&V?R7UHQ2:1$B5\^9B\N-*R!E#AZTN"-H.5E_P!N6&E8#B)GUX^/O*/KAXEZ
M'Y'1-MXK[YUKIW3$#OFW:%M-.5-;"LFJ:-'U-,7M.QNQ]E@=I5ZON1[A,$X4
MMS]+AW.!5,I4XUD(E>9WUJ.3.B@>-%/Z?SMC3055E1]Q[JW5LOE%#T-=HW)3
M3Y"/XU7FBP<<2,]5+=HN%M4\:D^+&%`+8D&$);)=2XW@([(_HPY1VSBI>>>O
M+??E2X$Z49UI4W-R5+8-\V=L.P[XCH$V#M-NV->"TSV9:O[#V;LT9W`E<9CO
MDQ8,#8#&<9>QET+`OU3>+FGJOQ/W=MN@5N.1`[$Y17-RES5OL6L=H;;D-`UR
M!C8FB:IW._3''HBA7FD["'E9IZ,0(&^A1J#&4I&D_586Y?`>`\!X#P/.#^Q-
M+17_`)I-EL.XH+;NO7*_J_C\<U4!*%K,JK<@M7U*XW"M%7R*LE!OHNS+%1VM
MFRT.\BN3"3)A_$43\S+8T>!EH)FOJU/:'8X]\N0M:Y*#K,=RQU20)+5]S80!
M-GF+%J#7I4(=8%K4S)$Y/EI-UN2CW\DQ8_L5\SYP_I(E!/\`=D-(Y(;%X:;I
MJ'$R5L47O28@&AZE_C%WA=;2LF.HME,]#-WJ8J%W=K6)."40VDB/"3*9<]B!
M21'%X):"I]]=7G9+ZTY;;KXY<O>3!^NI_8-(U=!4CCCN?=]NW18)7?R[M<HT
MYFKVO8ENMEFI=FAJPVS'2]=7B/4^XMA\EM;HJ7G`L`2W8MQY[`>N'L5W/QVG
M+JSJ_2E)Y<:5F+M::A'"5:^2U+TW-+-M=$?Q.+_RRAE#6$4P%]HZ*,?5A+;R
M&/=[5!BW]3N5:D>ES1HK2E>V%V9OF-RTINS_`/3J<VA/2:F<DSXHT86I2Y'+
MF<PV78UO#F&UJ_.08E(62?`K&?9@(#$H'!9]X>+++5R1MH(8DZ./.1YF)+45
MG!?;AZH_"S62[Q'_`#HD(R71^&N`8!+)P4SE7JH+.?@/`>`\!X&Q6C_YF;%_
M\0I?_P"-Y'@5+_IOMQ?_`&`\D%@N3+CZ.95X;)1)N-K"%=7KC6*GVH-M$4(D
M8-Y]&5.8P47E:L)4KXE?V>!;M\!X%;OC9R&A]U?9;YMU*JP=@@FM"==VO-);
M%Q9\`(7-WBO;X:OT)/U)M,B82FI'5':K6$Y;0SA9"%*?;2O+>5A(AW/^S_RE
M^QOY)!4:G_LXWYZ$H=$:RXO_`&]F_C`RLUE]G*95ST%4G"<.K2]E+2D.Y0K`
M=_<`_P#X!+A3_P`/_P!4GCA_'_A_\YVF_P#C_/@9;>`\!X#P'@>4I]K`T,7N
M1W_D%0(4K'ZET%-*GF'0!I&/DEZNKL>Q'99BG')"1)D04LMX6=A+K#+Z5>S`
MR&75!:<^H]4]'7KJND"X_2,;&E1O(J\Q=HD[O.06T"+E<1:-JK][<(=LRHPS
MM"A))8PS3,%_UGXV0\/?E/Y>]V`VG[//913.N?1=6T=QYH^L8+E=R.C950=K
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M\K3A*583@,P#.)G%>0^'\_C1Q^._'PK`_P"9IK7)/P862":O#/S5Q?Q869&#
M/9]OIZNCM*_YFT9P'$S^"'""4;:9D>''%DUIC\CX6R./VIW$M?E@%196&\*J
M>?;A^.-=97Z?U;<4G^F?`XC(=:777+$A&27!'A^:5'?CX!?(XXZB6X+@0/,>
M-AE6:CZH^`)66D_^",^G@;,9U8=9\@V0T;U^\,RFRC&9`A#W&O4"TO&CBJ"9
M)7C-1_EUH166\9_X)SZ>!CSR,XD])_&2A/6ODAQ3X-ZJURT_70/W5UT/K*!I
MR3WY@-FM029<JKCUP(N5F@6<-B./LX)4UA3J5-I4K`4WN;?>GTTE4'=6LN+?
M4=KVO;4FJ08G46Y[_P`:^.@8E:NUC`AK-#2MBUA:*M-K,@8R<?\`E6`]@L`G
M\=IUIIUIU.4A#WS!Y.<N^(MM@=5;JXV=4L/LJP4+6NQTC:^X3\)+I9]>P=FI
MK#K=0N\3%ZZE8>IVJTC$#R\Q$S4>N0%)4TX%D0)[#3H96\#=>=HW9-"6#<_&
M?B#U7G:LHEL`U[L":L'#S@%1X#5A+D15E2MZFZ]8:1&VH^*8KQQ$LZ_Z'CJP
M*>D5G#C3+&`R+X$\6.:G8W<-KT_CO`=3,Q4--V78,!MO;QW7-QF<I3LC3YY<
M)KUVO2==U3*2U^%WA%1!LH,NG#EA1`S"$D+&>,80Z'</77PBY4=C*.1%CXZ4
MCI$MM&X_[E%U9(V#:G7:7K^/VA8A:[%6!^0B(N/U+#7*"K4#(%+9:9*1&2!*
MVLX-$2PXAK(?S0W2ER3ZO.S7J1B.5^W-$[LUONCE3L@"CZKIQ-ZL-%I1T'KX
M^?DRQX7955B(:+_92EA86..(*M;YHS2W'?D2A20F+[//L52M0YHZJZ]."\YK
M2!M3^X8'7')+DCN2I"["U-KINRV,V@-U./K8ETJ0T@8S+DBF%'F20@'P/CL?
M(C+A"QP^?5)MRQ]+/$^O.=SO+'86E)#D9R%O?^R6H]F0D_?`J4S"L/A3L9,W
M:HQNV@Q:M/"6*(L+1+,V%'A/>K&7%X8*PZ&_<WOLY:V/H^THWJNBJ9R`L-$T
M*#NS87)'8DNG7^K]'P9FV:GK=+4AJZYQT%M3;=H%:E''28.-%%+98)$)9_+1
M\K:`C.X`]U?8KQSUU4MT=L6SZ[-\*>2'**_:4LDW=XVZU;E5KH>QZOF)G%UU
M]4->P3-GK.G*<?`(P@7]7^WP1,,+#6PPMLC`87ZOVISK)H>QJCT-F[?L=HT?
MSW[`;AL8*C5LDNSQ?'#?]@TB;Q[-V/7]_CXEY>8L`VEI%D)1HDA8<*CSL$.L
MJ><;>#/KI[ZG.&'*C=G9IJ'LHK:.4V[].;ZU=KEC:UK-M.KK25;+S0YRVW:L
MCR^M=C9&+M=>GZJ7&Y#2>0_&!17L2V*V\H9L)\W_`*Q'2LZEW#'$V;C''R<%
M.DQ'(GDK%E..8`9CU)<)#VVTZXTZTS[UI5G.%NK6O/JI:LY#CH/U:NET-UMY
M?'38ASB(YD!:B>3G)!I3[N$K0;).KC]H`N?FRK7L00A.4BY0TC#;+?\`=[@W
M!WZO/2ZXU\;?&F^C+0VI`Q#/*/E#ET)>5+<0\+A_;SS"'&GUY<3ZH4CW_P`Y
M3G^?4.,X^JYT[)*DB6M2;H83)N,./C-<FMWI9Q\48U'.(RYFX*+*24Y\Y+F2
M'7E8>,>2C*!\ML-A\Y/ZLW4^<R6R%7^2T!@P/`JUQ/*3;3BD.8+?+_-2B:F9
MAEXGU(RGVO(<8]/[OC^3*EJ#CYOU4NL$PW)F+)S(%2@1X<$5CE!:76(LEY3:
MU2<>Z?%&G(.PMI.?1QYP?.<8RIK/ICT#2!?5#ZM`V!F?W7+\AP<U!KA3O)>Q
M,OEYQ)KE7V"$@PP8R&C"'%?(MEMI_P!<Y6EQ+V<N>!\)+ZI/6J:ZPX%LCG!"
MMM*$^0:/Y.23S#[;#*&BFUYE*M(OH_9K3EQ[*%I]KB\_'\:/1&`^N/JG];F'
M/EQM+G7AWU$5\N.44A\GN`P[@%7O_P`1]WJ%A]?PY]?]/WJ]OIZY\#2A_5'Z
MWQ/R/7;/.UU3Y:B<*_[G"&,M(2_@@5C'XU-:^1(3B<9;6OW.>['NRK.?`T17
MU2>`>2`5Q/(3L`A0QIQN3)CA>2^'1SH_*0'3(=2WJ5E\9)TI&M%K);5@C#J$
M^BO1#?M#;R?JG<.7I0]YKF'V-C0)D\F416D<CPW1&(QP1EHZ$R8_2'"R<'&8
M>?44[E1&,O91ZYQC'@<9(^IWQA6\`\+SU[(Q%#2(9A64[W@'7#60D/(9&PXN
MCX4(M'S?V/(_U&\>N$^GNSX&1.M/K_&:9VC7]T:M[1^P&L[)KNI8[3`<^?*:
M+N`RJA&UN.J3+KE?N&H)NN.6',##B-_LW!')'Y1\/Y?R]E2\A5A[S>(N]FNQ
MWA_5^;6Y^15VU5R#J^Q=#ZOVC+W#7%FVK#DP4J6P#NNRZCT+JFI4F%U[6YC9
M\/(2E?!8+L$K!0YB'I%E[\=#`<G^N5U&T_FGK3?.T('F5RHX[7SCGR$D]:AQ
MNF+!`A4*Y-KJ`BF;E<=97ZHS317^1"DOB%`&.*;>%94,ZTCV94L+$S7UM7P-
MM1>]8?M3YY@[1&J8U&DYEU_4ST(;56-7IT]^O`IXE*CJU&%8HV5M-EN#EE-F
MJP?[U'XR4H,B-#].W*;CC;MAWK6W<'RF79]LM:__`-PC;MI/C9L8:6=UQ#%5
MZOC0P-ZI$^S38)F%=;8R'$_B?)EO+CSCSN4+;#KZV]&O)6W<BXOEJ5W(<OX[
M>L58(2UM8AZ/KZ(T@78*G6("L5DB2X]Q1P&N#8[(440W+B99PU+CDI2K++R'
M2"0ZGM'U\>7,ULMS941WN<\84F0V$3LN9K3D8V52G[">4.;(CQ-"B]DU_7D1
M77W?G81$JAR8I$>XV(H9;+:L.A]JUT-<ZJ=L.%V#1^_#G_'2-6N#5N<A=AQ3
ME^H5IL:Y1NTR3Y%"QN>)J!='EY,YUDF%,`6PM.'FLIRSE&<AE39>M7L_LU%V
M!KY_NPN47$;#MLW<S)>%X=5$.Z5:2F]@-;!_64.Z/;S+L-6J<,ZPB&`AVGUQ
MP]>3^%EI>%+<4'=".,/;XS*Q^6^U'1Y$'&K4TILOKIK29"=%D&L8,>G,!\B!
MF&38)U&/U>(]03*TJ5^8DC.$^@=+[HZY^R?D/KZ,UEO7L)XG;LH\>16)&2IF
MV.KW7ESJ-SGX*6@Y%NS6^`EMZ$Q2YF$5'DNQV(X>/#^<C.'F%(]F&0X)H/K)
M[*>(]+L5&XJ<P>O?1U<MT@/:;!7M>=9+5(@R;SFJ!UN0LR0J[R,;%(.,1`QV
M/>0R\A*$+REK"<)94'?/_;MWBCK==8[+.'!^%Q<;A`LGU]3C334L/'(3(?$_
M'<EQWL"'2BEYRM>'%):2G*&F\^Y&0W<#0G=@TXT;)=B/#8MZ/<:^*%&X%V<.
M&L+3!0YV,3)J^2Q,Q$N&>]X(C(2U8_#;:6UAHA2W?`U*>/\`W2MCM._^8]P_
M).0H13@KW7S8F(Y[TD'_`,UO+[/*M1B&\Q6&LMYQCW9(RO&<X1[<X##'8?6C
MWBW:NC5R-[L(^G.-S59+5;*OQV,B;,/%5X.UAF1[.&-AJCC\6S%J87(X+0ZO
M#M>`<8=:4^=\P;GI7KW[V-+OP;Y'<'JW=CL%9;=.JSO+C9<[&)80;/6X:NA5
MRPQM=W%6$.P]5=B7).-PP\TZU)'/+<6ZWA#>`I_\Z1.R#7_,K>(7*XK<-AN,
M?3I"FZNV78Z-$DR4SQOE-XSLU59&DU1G9%LD*WK^.WF`*'2B;#BQ2;/Y3#IA
M"$!?KLA8_P#JHVI6W*!SENQUML>P'B.4](DG)#9),+89N-A:WHNO5'7.(.?C
M\L2EK*'A0OPL6HUL=$U&10Y+0C9!I6!0M5[DV/!:>U)LW:]G#L,A6];4*V7F
M>`J0J#;4;#U:#-F9$6M!.&1Z39Y\0-:1&?G:RZ1E"<*QG./`HD=1G%K2_8;U
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M-+#Q,:2ZV8(6X^,EI7M#.<6VQD+./@/`>`\!X&PVK*L5>R92A3BL0,QE+:/;
M[W%8CR/1"?>I*/<K/\8]<XQZ_P!<^!4C^G`=)9X(<BXML1DF#8YA;+?<F,$H
M8<'E<TW6"&(MJ-5$L$ECE`J43DI92_B5C#7QISG/H%OKP-,:4D$,LU;1+Z`Q
MGREL!#.F&/)':6ZIH00=*WRB7,(]&VT)RM:LX3C&<YQX%6C@?>Z[L'[+/9.3
M6XJI1RJ=PZIM.M3</K8G64ZU9L;8K,[C-ER]9)M>S;2;#2PRY6Q.CQRV\MC1
M^!6_Q%./A+3W1_C?^4MV+_F%Y"8_[0-Y>YY(XQ2EK_P66^$5+98Q;*5'O^UC
M#F$8<9RY\C:FW$I6D.==5PVVA.N?ABSNN8U[.W?''?5RF9#6$58(>I+I*ZI&
M*UHTV+9SY"8<G6=>9C$RSRLM-/2F"%LLM,Y0C`9^^`\!X#P'@>5/]IZ(%E>Z
M;=)F*G8+215M.Z7M%AC<P9BJP[1XC4L&YDV0-K&:[9,`YGB/Q2I)1KJ1<+2C
M#_\`HI%;"TC]0!J=9ZN6`',2(84+R<Y"`3`H0D"F-?/Q&ZO4(FQ%'HQ/OR(C
MJR<!KBU+%RWAQ!:O<AA/@6:]BZ.T3LR1CK3MG4>J=@2E7CSQXFP;$HM3M1E>
MBBACFI1B/DK)%GN1(!09SZ24MK;;<;<5\GKCP*W&\^VGZWE0),U[':5TKRAO
M$%;I?7O^T7'SA54MJV-O_`T6^'D9>NN&4Z"I$O2H"*@#'F#(N5(9S'%-D#I4
MRXM:0P.V#V&?5FY2<@*%L[D+Q,VGKS98+6N*_%[4VAH_8=`I%/@=?1[1&NGK
M57Z5?)&H'5V,`BPX]E+\#)8*$<''<:=$3GXPMJ<-^</$7G#KAV]<1=MU+95'
M@):;J>6(,<NO'Q6*E)NU]3N:=-@PUABZZ0H5*HXEP)D8H52%LYRG/I@,ODJ2
MM*5H4E:%IPI*DYPI*DJQZI4E6/7"DJQGUQG']?`_7@/`>!4Z^UGJ#:>X]0\)
M8NA\1MT\QZG5-]7:W;3UEI\+9B%D5MO7CT%%,6"S:YK\^]6&R;#-L/BO.MY>
M=6&M#25(R^I`5VN(G6UV#;MXY[#TYKGA7N"L<O-P5^-T1S$Y*]@%(AX6)U7Q
MBBZQBM:?UYQ,C[L5$S:AY-RALM3<NS&D2T`Y"1C3+[0J\.^!'YU^ZZVO<[S$
MP'*'BMOWDOJ.H[)L0]*9U=KG,]KOE)RRUU8(#6NFM=\JN4DD\94\<==86*;7
M'/2;SDEB+A9M\5E&1GV_@"8MGZ]7V";A_OCLVC<@]$\60.8$C;[[MGC3K[>F
MV-?TZ`,V7;096:U\95ZC0INH!`Q<:RREUP$PWW#Q[8J72$^U60Z1X(B]AG$G
MKGWCP6U#%<F[AR4YW<A]H\<=`4>J2UPTA4.,O^Q@M<GMJ[N%O.PF(".@&=ZM
M7`6/'`*%KDI)@A.+;?P\I#*@R$Z>=/=GW4[SZXZ6CF'PWL^G^->_HZL\+9TO
M3PM$L<%([)FXL5R@;=VE#5:]65EBQ3=@`'S9[D^V&2XP,XGY?9A0A02\=[^[
MJ'QSYJ]._(#E$-6-?:TUGOSF@?.DUJ]6.QV>5U4K4<0$(0H`:#JSD98[N42A
MID,5]UH0TP<;)_M4X\V'1MEZBNGC<.EN!<OI#<O7E`YIN]:_NW8DWM62UP!L
M7DCI68D9"Q!\<]B&4;:;`O\`D(52NL?&RY:FI%]^1C1WTI8R\ZEP)]=QZHZB
M.2A^OX'<\QQ*W$;IBZR$E0J9==X5NQ1-<OHD>T*<,?2W[X3$RDB)'07QO!R0
M)>&1VGL99PE3V%!6:Y[_`%^*[S)Y32/(WC5RJZN.(-.@R*Z-KW6NGJR+*P%G
MEJA+#F0EFVP`Y/JU_)W`B2FVPRV0(%,:\(V&T\(0ZXXM8<OW%T]DZ6XM=@?-
M_MWY9-]A^[:YIIZ1U!*4B>1%SVE*[6S@I^P*T:BYM.4[6-TGGF$!QCD?7W8R
MO(1@D4)YQ3H[H=2?5>@=,[6Y0\R>0]'V+(:'KL'7=;:^CN,M+EG:Y!VBM0,S
M`3=)W)N"Z9V1.XO>V+,Q6',6$:*%9A,FR\LE:1VC$!)#/#JHYJZ8I/=UVR<0
MY.3MO^Y/)3F'*;%URH2'F!*L_#ZXT].'3B+&9*?&&%^R;6K,:EIO#T@Z.A>%
M?"EA*@MY>`\!X#P'@/`>`\!X#P'@/`>`\"E_]H<HN/YJ=.LS"\DWN(-@KEZV
M])B\ECJX+9:KI(,^P:;@G=D6,0G(@C($"?(C-.8.+9`?27\:_3USGP.6_3Z(
MB)C2'/>T14XU9B9GDU5QK3961I%8]MNL70\XLUY!F)<N1DY$&^%&IF,,N/X2
M(^:ZEMAAI:$Y"XGX#P'@/`>`\!X#P'@/`>`\#X$NN,#$/LC/&NLL.NM!CJ'0
M06XVVI:!F%EOC"H>?5C"4Y=<;;PK./<I./7.`^J%94A*E(4VI24JRVK*<J1G
M.,9RA64*6C*DY_C/IG./_#.?`\^#[2E8M5D[0-7QM6J]5MTX9P9K+<9!':HN
ME_E"HN7VEO2`GY1VRUL:6:UVFIM.I/9EGF$B!+2DK*'71O102%?4U386]-\T
M:M9-I5V7M[.]]01`UHK*:<45-AZOU'4:]-U:OD)DK1'6*G0$-&"QN216FL"Y
M,(6S^.ZM&6PMO[%7--50Q^O3`\%,,%Q2P9(JG3=]'9?7)B,(0_5ZZ?&2YS#^
M7?8XXT\G`K:E/K_L;5G`4$NP3GATB;VK^PJIL/JKW?#35*F>1>M--7CCS693
M3CUT-A]P4:C6K;E0EJ-7XO5-TGX5V/78V%3[L^)&%A-1Y'J](X5@)$NIW9.Y
MN5G7UVA%`[PWG?>+$7HC9FB=(:LY\_J9O=NH=AXU3>+ALXW<VVHND50'9%;N
M7^Y4<<,1@A_,%#-,@K;3ECWN!(#]82/EX7J;UY7K%,1\[8:SN??U<FY$$F74
MXZ="[&DP4I-C9;+?Z5:`VFL"M#L"L%1WXQN6OE+=<<"PEX%9'[-E1>N.G^#`
MS)4C&MUWF"J[2,BU-1<)%IBZII;9L@[&E/3I#<6=)S1_XPXH;;;DD6THAH+*
M75^B@LW>`\!X#P'@<1O[7Y%#NS'XHYOS5&R-?AF-D/"%_)#&H_%*:$0X4Z._
M[O8M+25.*3G.$XSGTQX%1+Z>]<L*>`&X+)`"0`YS?-J^PYI4VJQ*811B*7JH
MFT@P0(L@T$F=69%BX%=?92AKVJ^3W>N4J##':?)K[,O%[GW-:I.V59^1_'2E
M;C!+;_!KG#C5MLW!I)FV/SAO^)Q5X`?M\.])PKI<6,7\#RG\!X_'<4E+;F`M
MX<8>T;K^YF7D_6/&7E-K#;6Q(N$_R$^F0$@>//,1B<>I"VA9>.CDGD@XPK)#
M`RGGATMK4XE*4*S@(5>O.SZ]L?V4NW476U$D*,BI<?=:5G:#\I8S[+_GFU$7
M2"EY*_0K1JG&:?$2<)*""_JALI8^4)1'I\CJ\8"6'NO(*%ZD.Q5T/*,/9XD[
ME9S[Y/,1C(Y-2/&,Q@S"D^]:A'5X2/Z^A:O1C_ZYX&5?"[W_`/9UQ.^1SYE_
M]M&B?>[^0\7\J_\`:VJ^YS\HC.7R??G^?D7_`'K]?7/\YSX&2_@/`>`\#:YN
M8`KT/)SDH0R+'Q(1!Y;Y!(8;2&1FU.*PHJ0($!8ROV^W"G76V\*SCW*3C^?`
M\I_[1\Q+"]R7(IR)I&#)FTZ9T(`V3+Q;4I+UYF=UO3ZTXPU&L2]@@'2)!H!;
M`CKHS10[TAEUC"7T#$8"TU]2:^5>@=/UJO5_E8RI5MKE)O&<LMJ.AAJU5:\`
M'7J.7)35BFQVAX2*K\>P.KWG$?B@A-H^#*D(9QX'!;SL_F9W]<P9[4G%'==Y
MU)TPZGV+09*[<CM?U6YZ8V/O6>IL?-MVRNZ/VR6*\W=J_&[(K[>$/-H`2$LA
M@IX<QL=#:@RXVOJSJ4^NEQEUOLY?'R(O&VHJ<?3KZ[,1M(G>2FR-SJH#E:7:
M!S):9BK;'1-VD6PXR9;JH;L/&/32778]IAU:O`X9PCY9<Y^RO?&XN.W:KUZ:
M'X[<+[MK>M8J>F=P6$'.S[5LQF?A+O5:R56[1("3^S$D0D&3(D"MP$*B-&$8
M6]A[Y?:Z&Z<QNB*%T/8KWSHZB)9[BOR<J-2)F?\`MTJK1#?%_D:X#)EGV.@;
M*U6.MZ()@[;233(,"&CF`8U@IYHA*$/_`.M@,X^H[M;H/8%K.ZZ_+TS==#<E
MN)#%8UARJT8JFR0]5U9LH66L=%?JM'D6E&)-AV)2B'+;C\Y49#AH2R5G*F\N
M+"7N6M%9@'PQ9VQ04*5(8>4`-+2\?'/G)'^/\A0;)A#+A.&/E3[\HPKV^['K
MZ>N/`T#%[IA47^Y%M$`7&YD?TS98LQ'$LOS*DX6S#CN,$N-D2Q+:TJ:&1G+S
MJ5IRE.?=CU#?0Y2,D$-.`2()J'_S/@6(6.2E[]<3@*0^)3+BTN?@F9^%[V^O
MQ._VJ]%?QX'YDI4*(8R5(N*&#;;>?*.<;7@$`8=&'""Y$S./QP`V&O5:W75(
M;0A*E9SC&,YP&M9>9(9:('=;?8?;0\P^RM+K+S+J<+;=:<1E2'&W$*QE*L9S
MC.,^N/`K,FF\@>K?LWOMNW]?XV-ZBN8FP7+G3YFDUP/7VON+_+"W8K,)5X?;
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M56?`V]WZOO22]^;AWAYZI+-R8VEK<V\A?P$Y&%'R"$X)L8=[\++@RGO:ZIU>
M'7E^BL(]J$!H%_5NZ1W,HRKB3,>B$/(RC_N!Y$_&[\R,)]SR,[2REU;6<>Y&
M<_\`*K^<?SX'"-S_`%<>I:7U5LH#27$^`K.XI&B6F.U?/V3>'(8>K0%]-K4A
M%U.>L+0-WG7BHF%FR6#GV<!%8>4QC&6U>O@10]&E5XT]"&Q>;=`[%M\Z;U9L
M'8-ZK,)HK;M@=L($;O#5.LV;`!;[!17"(XEQ-;C;Z<H+V$X:+=-&=^)*V?8M
M8638OO$ZCI<V*CA.P#CDR?-F10,:'*7/]&2^_.)'<BEK9F@X]P80UDMIQ)#N
M$,8;=0M2\)5C.0E/9(')PO([[+^&U(2YEEU#N$*<9:);2O*%*]JECOH<QC/]
M4+2K'\9QGP/MX#P'@/`>`\!X#P'@8V<O^5.L.$?&[:?*?<[=E<UAI^'C)RWH
MI\2S.63($I8X:L,*BHD@^,9->1(3C.5)4^WZ-X5GU]<>F0Q6X:=O/"[G%1+Q
MLW5=LM%,H&O)JFUNS7'=E=9U75QK#?5'-5F#'LD[*J@"90\H-`Z6L$^Y9)8S
M+?O<>2GP(DME]Z-MVUVX<?.)/"FU520X^ZXM>S*CSZL^P:S%_P".5`>F6J.A
MBK55MA?Y1&5TV`:CLYP"?'R12&R#FWC!5-L*'<#$;[1]TK=;Y8]0VT6[!H&:
M`BRMR6*N5?D"Z2?QUV=C%JT!*@1^X)6/?;BAM1D@84<2:IPI#C@S#:6%)>P\
MT&]_3#((/X^]@<L0W2P<RW*Z$D%0]$R.BMQ3QE%_->'KP@)!$>'4V\%)9C$-
M*SA++"D>[.$)]`NC^`\!X#P'@/`>`\!X#P'@:!F5C")$Z'8/#>E8P<$N1CFR
M&EF@BRBC$QQ!0R59=89.5'OX:4K&,.997Z>OMSZ!K_`HM=I_?IR>ZM^Y':U2
MD;7,;EXZ5ZK4%<3Q-911X.N/@7#0R)!VTD[*_P`7EKK5+&#M5R/):%3DU@F.
M4=\C3.<C9=")'O&Y\:=[!^27'CDIQ^Q"15*L_%#7D/M<;:9Y-<M,016]F6>_
MD4J*3=K1!ZPEJ4_8)&%`=DF!'R5GOO*P.XL8H=L)_OJ*-6]/&'EVAJ(IM4E'
M^558GINI,?Y27'U>/L.N*%+E)C4R.<N.2MJIQ"'6GT'E,I=9'?>^7YEH0%O6
MUVFO4>L6&YVV5%@JM5(63L5BFCE+2'%0D,&](2<@3EM#CGPB!CK6K"4J5G"?
M3&,Y],>!%-%=T72V8R/$1_.OB$.,TA<.+'OVV`B16F)\L=LL)@<\,-AH(XIA
MI1>,8PUCXTK>]$IPK`=E7[E;Q/Y+<(>==ZXM[=HNZ*S4M.[VBMC6+0<W`S1@
M]R;TI(G$LMS0;XT49<$UQ0:F'G"%8PE#*<N8PC&$A@Y]8D?`W5+1FP<VI=93
MN3=3=/>N$N/-2QD(+:4!&2+9@&"8I,?)V@:1)8;$/EF$)=_@QU?O2V%A+P*S
MOV2G"5UCKRB17P7'K/R[E*B-`2691#5OE+1I^[0<#5HI\2,/"&M<K.G#)CG'
M%CO(7A:DN(8P4ZV%F+P'@/`>`\#B]W<>9I=O>'<%9(:J\^XP\<AYP%IY$46I
MIPQ`ZVB%BH7C&7,-J2O*,9]N<9],^!5'^G8VZGKZWY@:0DWHUGF-LM*Q9..D
M1$+,(H>J7TE1F"),V/"&;SAY+C0V%Y=RM#CJTN8RGP(YOL#])W,OG#V?6?DY
M5XF@ZCX>0FNM&P&T>3U_N>O:U`Z]@(,,C&Q-BR%<*LD+;K4!KV+(R^2KVH<<
M2PEAMY*$X4V&DZAN&V_F>9G6YSHX$QFG-F<9Q=+RW&WF-R)UEK].N:+:H2A7
M*SZ[=<"U;NU^`VU$[:EZO4:\;9)V)$;_`&,F^Z;C+H[Y`[H2T\!ZUKRN?9)[
M)I6@P&V*D_M/AIK?9EZA-K0EJ@C"]C&;2B(6VGUO_)!'QYRGQ[L:.&`;%FN0
MN%I(9`42RW\C82B=Y*GT=0?8BH=)"G/^UO9>%X%P]EW\=47A)>5882I?X^!<
MKR]Z_P!GQ>[W^B/=GP,O^%F0\\..)F8]##0&>,^B,@MBLI'&;#SJVJ_C(''2
M'')880S[<(1@=C"4^F/C1Z>W`9,>`\!X#P-AL\W"5R`E)RQJ4W!1HJB)5U,:
M;+)9#]R4///`1PAQ3HS.%^]U6&E)::PIQ?M0E2L!Y1OVB9BP@=U&W)<>#)A=
M@KU%Q[,CI"F6644RU.-ZPA%-3M=F!HJ"F9E#44T@9I7Q".8)85CT6A.$K"3S
MKNNK^A_JQ<SMMU\:IE6F)V_N#0Q4D34IN:#FM;<@YS0>MMGQ-BAVK+62'I#]
M!,NN1Q4K^L1'D#,>F$X5\[H6G>J[7_"OK@XE:LXXQ',S0%M52JHR(=/O;YJT
M<S,3]BE9*[WF:?II.V[=4J^?*7FR'K1^L<7E`.!QEDD(';7X%;W[,_)R1JW)
M?@)>].\@=9[%T7J.,M5?*G<:9K?*.K:+E=O#N4*P[8O.T)&Y6XF[[377@7CJ
MU!)'C9&)(K[<D.6HU]EQH(,-:<>J=R>WWIL'KMW7RSV!R1D[J$SR6[1MM;AD
M=+ZMK35B3L&'O#F8FVU./VC4)4_7$6')CG/WN2DST%O1K8RWW4(0'JGZ_P!V
MZ=>KL!!?[L43,[#P`(LI$2NRZ#+6D)R*&9!,<G\P=KGQ%GH>:]27&RB&_E5G
M_45G^?`K%KITQU__`&+M"2G%:M0,=Q-[4-;6:+VFG&RU2>O[/O.FQU@O]HOM
M+IM6E),MF\0=8KT>K!IX"HTIRU&NN&8>+4ZV&!OV]Z1K;:?+OK[H^Q>0-=XO
MP[>DN1<W([9OT7M2TU!G$?,4HZ%@0ZOJRKV^=_?3A8)`[9+0B4.N+9:?<3A#
M/J%94?8ULT+I?>W!G2I4=S[XR[#WKPUV7:MO:(5R`J%3Q>(,^ZBQE&K@-XJ<
M9*T_8^WSC$P+DLW%,E%?X\TV*V5\>,MAP7:\A3HO5>\7Z!+3G`"[:U+"U[?N
M).X=V<@]A<@-\KF+W6K;@*N0Q&G*O3M?1E&D8(20DW94T`PDA#BD>J,I9="4
M'J$[">L+0&U=T\F=S:MW1K,C37'6XLTK7EHY-6+><?R(N5^E<4,O6T51Y^B4
MZ&=>?I<]DHI)LEEI&!WW\)PRG+:0ZVU=V3\R[?LKL2D.1&C[T6!VLZ0MK.J2
M-J/V/7M=J\IKX/.QM/5JC;9M-TT77H[2-1UX,^(XS&$?/*##1;:6BLJRR2'&
M^M0G7/-BX<9>*/;SOSF;5]`6&I3^FN&HD''OTG7SQ=CO]8O$.W_N$7$3DAMA
MFTW]Q,,.`N'E51Y3\6X@Y@45#8P7%=)<G^:/41R/H?#/E:,1R.ZLFX.>K6E>
M?L7%6N<MO'4.+F+R16]8\K+JW^?7IDS7$+5E1$@4@<!<;#M#2+SF66"QV`L`
MZ4YE\6^1^K&=U:'WA1-L:Q4&S(&V>D23DXB`#?1).-O6^)%'5.TK'LB"<J3+
MBA*1\*O=C'@9)C$CF#L%AD,%"%,MD#%#.MOCD,/(PXT\P\TI3;K+J%84E2<Y
MPK&?7&?`KG]ML0"]VT?7\E%K5F3_`.XOD."(E<>0*,P(/J^#E37'+%'Q!4@^
M^3^,AMF.R2T*M?\`>^GXO>X@+&W@/`>!QJ>E78-YB8/FJU"4^+BYV1M9<\XH
M-X8<$8<H>1'EGI`2+C(R,8:)</62VXGX_8K"F\)5E059=D\V.>?<OR*W%QDZ
MJ=DS'%CAYH0R+J.V>=9]2D<D[=V%";;IZKA`\==BP9IPT4F+H4>65#NML%,6
M((A[!R@1BX]Y09F<5?KM]=''W4LY6>0&N*YS%O=KD"['LC;G(>/79")>QO2\
MO(2%MKT?8I:><UU(V=DT=R;P!(89.-&P]_9CT3@,1B1>DKF5VJW/K?E^O_6.
MV-T:IU0%`2_(!Z2JMJJ$=1]":WU]!U:EA2D;9I2POW2E.V!RMR$::TV6&F$:
M4:X_C*&6`ZBVUUJ=F_3A7+SM'J8WK/\`(OB>"FTW?:/";>5DEB+C&UEQ[73U
MH7IJUQF0Y(V\G56GR*7)MHX&9!&<2W%!.EY][H6).O/GKH;L<XW57DIQ^M>)
M>KV+#0,W3I-O`UVU5;(\`(>Q:_O8JB7GG)N+E4NN-F82D:0#>:?&4ZPM#RPS
ME\!X#P'@/`>`\!X&*O-FO,VOBWO&`DM9TS;L`5JZ_&2U&O`#$_$2YD'5):>J
M#?\`B)SD9&6U2+O&1JG`WY6']&4J=:*2^VTA8>6CUM;EVBWQCYAT6CW'@CBO
M1<M&\DMA<$N6&AJY<,;>HF@AOSSW]:W/9,@$J9LE%J[$MD"#5+XF'&HPO&2Q
MWRF5&AF_S;TSQ%[*^8/392N!7'K4W%?7W+74DM*IA#M1.:DB2;-6-F7`C92+
M!'56$FC;Q$9=IAL)#2"AWH?!8Y.$&$BJ<4P$A_VX:;6Z-;NL#7,#7I:4KE$T
MIR'H(=9H#\7`2\?5'XK4%!C&6:]$B)R-5"XUER/)2"*A@$1:UMHSAI+"PL!=
M#'"'3/!32.\Z%HT?9<K`V3E%OZ"LMBM]M@K!$I-TIL&5UU4RT#CCP3S,].5+
M`X9CL:&\"Z_!J4]^*][4/!/1X#P'@/`>`\!X#P'@/`>`\!X%!OM-W/L_4/<O
MS-UM2JCP,)7R=TIQGM%1V9V&UW34MJ2A)TM"(J-PN.N;;LXA<:NYP+,]*`FU
M1892S!F2#,+0\$T.0$<?9/QCIG%'EE4Z'H.6U5:=97_A[H[D!M>RUJ2I-KT[
M8^0^S-A;"P;?]>:U<"DJ_'Q]N6Z0_5:]$1L;'Q0/Q2C2!0QRG'PL1_4P,"D-
M1=@D@!(N3+$KRKIDXB6=BRX);^)_0M`F5AM09,=$-Q($62:XP,PR*TPVPE*&
M<K82TK(6W?`I6]]N@M#<&[/Q7M^G^*'7)!4SDIM<[3EZHUPXDT>^;&N<]-7J
M"MK]KA[?*1D:+#`E0Y)`I[#&6Y`8TYIP9PE&59&"Q-MGB=QSX@=>?-?7G%+0
M5!T[5I_C[R&M$C3-5UV&K`]CM9VFIV(5)%X4\`.9*/`1HPZ7"'TX2TRE.%)3
MCP,!_JU?B)Z?]1-A/Q#[+&UM]#>D$8U)Q3&1MES+"6@YAL(%<PTIIM+F'W$J
M<QA?QY6K#>/`L2>!67^RRN+9UYP2=E5$*:=Y06Z/%&&7\CCQYF@=F*"=4&T$
M25E@8D9*GB<.,,#L97AU?HXG'@6:/`>`\!X#P.&;&<^'7M[>P^H7+5,M#F"4
M%M`+']D(<KYT'/OBL!*:]/=AU;K:&\X]V5)QCUP%4SZ;<H1)==G(+);D@22S
MS+OWS'G$BF8-RYKO6/L6T4V6461\32$H4I[VXSZ8^/*D>F?`E-[+><7"ZS\6
M.;_%2,Y:<3&^1,OHG<6J0]0[$WY0Z2>G8MBJ5IK$34;*S*62*?BRWIT=3#PY
M"FD8SC"2/:R[ZJ#$+ZQ?!+D'U^\1MZ:KY.Z&=TILBV<BI*\11Z;O1KU%7NAF
MTJL1=8?B):G66P.MMP144>C+1R!B,I?2YA.<+5A`<@XKP4='?8\[`"HS:TOM
M,9W@=ITI;!]WB;K_`+5R4QNR>*FM3/XB4H?J+%?DQ'#(Z$D?>:"%(>J%8'<:
M3@,Y.\,,@_J&[$QQDEK=3Q5VF5G`90P;WP@PCAQ"EO%H6SD1`XZLOMXQAQYC
M"VV\X<4G.`R^X9?-_P!GO%'\C(JB/^VO1?SJ"-<D@E/?[7U;Y<B2+OHZ>+E?
MK\;RO[G4>BL_SGP,E/`>`\!X&U3I4.#!S)MA4(B`#BI$J<4>TE\%,..&\])J
M,84AU+PF`D+RXC*584CUQZ9_IX'E(_:=$;N'=!R0&CP9P\JJZ#T1)PH]<CB)
M!M0,9J6K624DI/`@A#D7"PT#($EO/*2AIIL;U6XVG/K@)A-5L;)L/U)]P:QC
MX>[2-WDQZA8:O1*IQQ9TY?;-ID:]:.L%VLS,/6I`DKD-0@XB6,(+V(,PZX<$
MM"9!ML@1]20DDXQ?7*Z$.;7&_3O);3>C-W5NA;9JXUQ@$G[YV*/:%1T@*8(P
M'98TFY7&.C"VG5)+PRRXAY*T-8<SA&7&%!RS9'U2^DW5NO;ULRW5CD5&4[75
M,G;S;"`-V6(]]JOTH`BSSAC4>U#D$G&+B(QYK#+6,J6E><,I2]E"TA3'UE%]
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M]PPXJ\<IRZ6R`V/N)4M8IJ@6Q&X#K<%*#-5';,D\\<AT@@-`<JV6"P9ZOLLA
MWUS7Y?ZHVCLRD5_[$W37`<=&S=+\CK7QXV/2^19K<A<KU58FG6BRTO\`^=_8
M(H,&>OA-<!C(V4EI%U34@8*PE/Q/OO)#'(7F(=PGXF.;B#^M%_L/Q`M>PN/_
M`"ES=9WEW?$56R6>&EH!S1DB23;*#,3TM#RA;HCSU7S\@IS!#KI8>6''E>!E
M'R!^QMUQ\RNKIG86Y]$4V&Y7Z<VB;!ZAX12IAUIJDM-'4>TTF%L6;7`0=0EP
M=)(UK<"_S"1,P1\?8(\=@?/N;#=>"V?PZTC1[QQ!X@.;PXG\>Z);M8ZIJ`5(
MU[`,5W<E-U*!%CQ":VYJJ\V*!S*C1\M$UV)E$.)S@QI[#27WR'Q_R%AGD?$Q
M4I&R,/)QD?(Q$N*:#+11X8Q<;*!233C$B'(@D-N"FBGL/+0^VZE2'4+SA6,X
MSGP(%.3WUZ>,VY+QL?:?'W>W)W@KLK<EPKMHVM,<8-HSM/JEN$J]9+K<57O]
MLPY`"BQ8#.'VR<.-!Y>;=0O#>4)((PX&.O,RG=YG"#C7OOD!&=IW'^QZ6XSZ
MVLUY@@KOP^JLAMVX5&@1JB:]7;99,R+-?DKW;&`F(\LYIIE))I2G6TMK6G"0
MKY<!NPGLAYX]DW3Q<N?$[[*$%N?9-OXY7*=XYQ6LZSL]B\:CN=.O+%8N%4CL
M5NQGUV>JH\?'L?B,D)4=@YQYI/P>@>DEX&'NZNP+A/QVO54U?NCE#I2A;*N5
M[JVMX?7TO?Z^JZCVFZ`/RE;;L56#-)G*E!R(#&'/VLHP'%M)>9^0A'SL^\,K
MY6;AH*&D;'-RT9#UZ'C#)N7G94\6/AHJ&CQ7#CY:1E"W6008P$%E;SQ#JTM-
M-)RM2L)QG/@4"^_ONL_[OIFQ=:/#[:>LPZ')7FF:=WCMR!LDMB>V59;7;2:-
M8==ZS<36Y*-M&EH29D`'K&>*2*_+9BGV!G7`E864%SWK]XD1'!GB)ICC%#3T
MY96=;UUQH^7L4L'8)%R<G#RK!/!-6`:O5<B:@XB7DW@XIXL-LM$4P,TY_P"K
MPE(80]T.W^SBOZ(E=+]8/%:W;6VWM*GS3<YR`"OFO*=#:+@E/IC2E5..M%PK
MT[:-M2+#RE1B&6\!@-Y_*4HAQ&!LA3JZ4./_`"TXJ=Z%)T/%\?9+3^T&./\`
M&3/+ZMW39U5VI+@ZCO&I]<2-TOIMJ"LD%+,66Z;P+BY)0$>^>_`CRF&T#D*'
M<?4'HP2DW`0L$'K`F9*B[&77(&J@DJ@+/=`QSK`"?"0Y!)\V)+L3;62HI[+R
MI0MQ2THPHUS'S86L*`W,[8_)SZ]G=Q=-I\>U1FT=!<L:$/R&W%J"0-I5!KUK
MHT85=ZO)(L!<+0J=3M5%:]MA9JZPW%X>2_C\-HI13YK@R@M_;+[F^!>MN$NM
M.?A6VVIKCWMFX5:@U2=KL:[.3+=MGYAV(G822@0WT/(F-<H`D2YH)#WY'P19
M"1/R7E#MO!)G$W"K34D5`QEE@I&PQL=&2LK`B20:IR,CYAA)$6=)P>"%RD4+
M),J][&2&T86G^F<^!R7P'@/`>`\!X'0/)O-B`TQ<[35+[?-;3='CL7+_`"G6
MFMT;CNZ8.M$C3-JA*UJ@B-G!;Q-VBM`E1HPWZ\XIITO#PK624-9\#R;^3M(N
M>Z(KD9:^(W7UNYSC7?\`>M_W!.;DV_HD>V;HJ.T*J[9J_LC7D9OMVK$RT?J.
M&5-"3TA&23$60U-LD(+2EQMI*0F`X?4R[Z/[#?KA0LY5YN*VA$\;MF5.^UC8
M%(O>M3:O9S=P<Q)IRH8K]L@HR9K)TF+<706"FH@2O'DB))&+-"]S[09@_;CE
M'I/;'6458)&N:SO.=7[\EIR#F"8BT"PO[V1TH!8JJY*D2];AY%)2'3HL8EU.
M&3L8>4/AE_#2TA:^ZU/BQIW=*$MJ&?;YI<QT&1^<D^V/)3ORY8PPUAST"0P0
M-\9*,!I2+A+^/;[U^]Q82'^`\!X#P'@/`>`\!X#P'@/`>!YS?:%]<+MHY"<V
M.86T-/PFJ]B\?=S<@I7=58",VE1*A:SDSD"V<XQ'8LT(LZKR0*25P)"L.-LR
M#XK3SS;XZ6WDA&YRVXGV'K^Y`SU6E-CZ:1:%<==>@\I8GBIJ*+L0^O*W;92Q
MN[(U19D$3@4!#7B'H&M9!4Q*BR%:D[/@YL#\']<4=@D+/_U#DJ"XV<X#I);I
M$D!RA_8O)A*2W2A92&E-54PR$(8HX;#$P*[D&-RN-%+$8,2"4VO#><DYQ@+3
MG(-/(`O3UL8XN.:P"WA(BQX-)D]TKLK6OX!R1D0Q96Q3H56C9*<E":Y"OD&B
M1R4--GF,-C//#M.+>;"GQ1>R'BKR@TDM'?5LSA;N2HB[*WKJO6,?JS2VT1^0
M>BMHZGF9>BVN]$0VNYG8%ZI51V-781R9KUG'`KQ81`K:7/\`4;;6P%C0CESQ
MUYX=:?);;7%F^Q^T:#*\=N0M6&0-(B"6<,Z/UY<8@2/M4))$.35,E9X-ED\0
M><8$-5'F#DO,(2[Z>!@/]4XUP_IBT41F1#)&5LG?B@HD,1D7%78<VO8WB()Q
M;$?'H*PY)N$'LJS\^6ACFV/E5\/M2%C?P*P?V5I2&K\7UW34XH,,4CDO>*JW
M-F-EE_IC;!J:8+AS(^/C(HJ1*FV9^##>`RHR/!26RVDMW#2_>V%GSP'@/`>`
M\#@^SG&&=;;"=*6ML9JCVQPA;8SYCB&$0)ZGEH#&*!)+6EO&<X;;?96YG^U*
MT9SA6`JM_3<$):ZU-TF+2O`1W,G9B@'%Q#(&'4,4;6;3V<'X$05)YPYGTSAX
MDK(^?]/&4X_CP*]7;ANJ[4?MWYG5:*X6]>VMYB(39]M@W+E=I@#Y]I5G658L
M]N;W%7+G>)"*07=]M/QS<;'`1K3N)Z=;'P.I67%.>!/5PUK/?KV94+B!R_<[
M%M"Z9T&MLG98]<I?'7:%`M<[-OPLA`YK-\UY9J_3X_:=(@Y9"VV'1YT>$E1W
M7"P2'O\`I7T!EKPMT?3]'_8R[,$U8:0%)V[PWT3N^UOFGGDM3MUN^R)5BT3$
M6(M3H<3$(+AFV&1<K4MG*5>Q2\*<SX&??>3@3/4)V(X-="98SQ;V7A*Y!J0>
M'R5^KQ^`VE,8P02@IX[XT#K4G##3ZD+?4AE+BTAEWPF`Q%<,^(\6EED9,;QC
MT(`D<=]1([&`]550?#+!*WRED,M8;]J5Y=<RM.,9RI7KZY#)SP'@/`>!H9.4
MC82..F)F1!B(F+$(/DY23+'`CHX$5I3Q1IQQ3C0P@@S*,K<<<4E"$XSG.<8Q
MX'E0?9OV7,UKM7Y-1KERCYJ2M.H..0!"HVGAP>947.I7X:1C3<NY(LD1"I:D
M\GK`?D7PY![\%]T8A+`;P@6V/KF42J;IZ98GCML[1^[Z+5]T5W>,19)NU6.>
MFJ/L.G['@H"&LEITM8@%,PVI*G8XV^.B1U;C/Q/QI&,EGDI6\@M>0PHZXN3]
ME^O_`,JK[U+<Y[1*Q/$":M#-UX0;TF*+#L1!\)M:]*!/F=D[1`D:]5ZG`!RR
MW79=LM$F]'RI"AVGT,)'00$IG>SPWYR]DVK=2\5>)EMJT!HO:6P4R6[]N.7I
MZ)C];`4*O6)^'B;!6ZQ(!V38]=V'9Y5H4P-"),:,(C1B'!FU8^9(5SA_K'<V
M^"7+#@E8]'7FY<DN-[NY-#[>Y3!4BY1&H937M[TD65;+#8ALS-F@HQV)CH4J
M9'JLLDE$FE\E8B\LNF-?(%S3L`[*>,G!70T_M/8%BI]]O#5<J]OU+Q\!ML$#
MM/=4I89QH&AA:\K9K4C,FORTX/G\<QH!]MAT?.?X6G&/`C&Z..O+?5&W!R6[
M3.7Z9,+>?/9N4FZMJ3:'YUGV_P`;-/SE^EKI5-9RM[?>B1/BE*J3"#RD+B#C
M_P`!VO`IPAA2716@^_<?UR4KFCS&XTV[;>^^)^GM'"\>=RZ*W(%N"3A<[R,J
M&RID"7_RG2$;=I<&F0-I@3(!(D/9,-O%0A\B\^X*>VAMAH(/@NA^0XX?Y_(<
M)>Z;0U"G*%LTS:O"LM_<M#IA>KSMAFS^N-N0.QYN%/G96>F)C0K\,PBQ1^64
MO$QQ(BHA+9+9#0;?:OKYSO-.L6K8'.ONVTCM?FR0)1*KI2T1FSZ9>Z17X2OV
MJQ?NX*YBR4K!6^^$6"!)"<AB@G(LB/*=<;)9,0VVGP,GM.].G-WD9=]=$]L?
M:UHOEIHK4MO,MU0XT,WZ+N]7V%:&]?&P%3'F)68!K`L(#DS+C98K01JU-,.$
M,N8?=6XD.LYSZG6E-O\`$70^)GESJS3_`"]HNKCJ]?K-3,5NX:OVAMJP;2FK
M>]9=ESY\RBZSEDCX2U#5=:PS?Q<.QXSPS.$K6P\%Y+5E7E*/K'7-+G)06;FJ
MA0ZA5YB:!%_!"EY2`K\?$R$H(%ZY_#%/+$6ZVU_];0O"?^'@<\\!X&%78UI^
MT\@>"_*31]+$L!MEVOJ&ST*.'J\S4("84FRLMQASC4K?7QJDP$Q'$/.&(,<0
ME\-+K2,_*M'@>;)TPF<;8SM+Z6H;2)NT:QMR#<W+"\JW[;^UD-?R^T5,;PAX
M%K7*RY28&8_R760\4*=B/':C&_R6E8>^9)/QAZN'@>>YW`](_=US1YW[LW*%
MKK2W(S6DN\95],SYVU*53P*CH\IV=*KVNF*A;;-5S8ZU5M$L(L^;:!9((F([
M#[#ZV''/F":_7W![M;Y;<`MO\;N4UA$X1WVD5ZIT#APYK;=P5R%$JD3Q]A]/
MW:L<@`M4QK52VWJN^NFS3B6)?!,H"LU*OQEK"%)?#STMJZ>Y+\4^18G#G=D1
M8]/W[&ZH37T%:)>F8AZ+!ET[8U/KE2WAIJ96J'?/C4S,,:8\]'/HB"4.87GW
MONO.("^WCI#[LEXPM/V,][J2K&%)4G45B]JDYQZX4GV[S]OIG'_A_'@<,M/3
M5W)ZVIMMO]R^R)N:O0%<B92VVF5EJ#-`0L:%$QV'2R7IJQ;\C8J)!;#!3ZJ>
M6,*WGU4K*?52LA6MU'MWG5NK:'&G9^K.S;FY8>5'*B0G=&:J!!T?J?.S;%I>
MB)L\^9:)_8[/(Q=.*KT;9IF90U6Y&5S:4X#0:@'(R8AQP+38G4U]A*(!2%&]
M_P`^8E>)%UY<UQUB3RFGY:0BY<M#,A(F2QCC#!L4AL7URC`8CCS#"&F"'FEA
M4E^P_ICGAQ:Y.<>7.<7/IKE!NX#0<?9-3W6EZN;UK(UR#C=KVE`T`LJOA04>
M64)/AKE?V1"W#,JSEK*,8:'RZ'YU=Q`YE:XZ5^7?+2UJV=.:"YKBZIJ.K-+.
MUUN=_(OC?(6J3X^_CHZR'RTS`-2*H67C8,Z!%<.G%V5"LN($4ZI`<]X";BA-
M1<D:)SFXVU7L`MVU.%NF*/L7L<NN\]G0AL#MC7:-<5^BVK36MJY+Z_G[I%&3
M=V<'`K3-@F2!WXR*SD=4<IL;X@]*KAAR)M'*SCEKS>UPTA<./,Y>PBI/.LKK
M,PEED`8EPMURN3L9:*XK]+9:]:ZZX+(AF#I0VMLGVXQGV>]09,@R,?)LJ(C3
M@Y`=!!`JWP262V4%"/+'+&4ZPMQ"2!2&U-N(SGW(6G*<XQG&<>!\@)B*E'Y4
M:-D@3R(*1_3S3`93)#L3*YCP);$;(MM+4H,[]9*C$?$YA*_A(;7Z>U:<Y#^B
M2T8>.X6$>(2*R64"Z2R^VMA!@)3@)8RG<*]F'AS&E-+3Z^N%ISC^O@;AX#P.
M.7"X537M4L=ZO=D@Z=2Z?"25DM=LLTH%"5VMU^&$=/EIJ;F)%X<",BXT)A;K
MS[RT-MMIRI6<8QX%1_MLII/(WMOZ7]N<;8NR[=TUIK=TM$\DKMI&NOWW7NM3
M/]V=7R(\3LZ5JHJXB*E7G"RG)<*1+40!'K_)?':;=]Q`?+LQ2PK[2W36"9)Q
MP096GI:66*9*6#.2Y"/.Y`-PB'06&QXQAY9C2VXY*'7L+)6]DA"$+3\@8H?<
M1C[#9MM\#ZQ"%MB1+&M.0%BNQ9MGDZU5XF!C;SHXJ.EKV\.-^I(BQYF/1F*8
M-?0V1,I92E*G<-M/!9EZI=BQNP]'6JR:W%B+/IRV<E.8=BK>RJ];F)JJR3:^
M0]L;B?\`"DX+E\6&K6-APDYJ2$*0&AS"FT-?W9]@2I>`\!X#P'@/`>`\!X#P
M'@/`>`\#S?NYLG5$IVE\F:-7M=.[_P!D`56P6>?E?\^L$BQHXHF+8+M8,T+>
M:77I&7/@-9R?[V'IT$59:E#.OBRJ677W)1#83=?5)J3U'UEV,UERZVBZ-1G-
M1Q`9=PF86=LS8!>MJW)1;ELD((!R/<N^8<X8:82U)EM,%B99P,`MI;;@6Q_`
MI/=F'"/@ZY9K!RMZ]^1W#.6ODM`E:3WGQ2-Y&<<]25K:&NH:1E*Q=YR'VD[/
MP5KA-X0UE9FO\CFYPZ5E[2`=)11!*4J:1X$P7#ZA\5ZQU([IK7'IOC:BU&\.
M&QN30_&K%:;BT[M?X>5X>;5>T:XFY)M-Y.AEC$NK;4.:X.^TO/O=5\[@<;^L
MG59RE=3&J:S/CP3143M'>0S!-3=!+I\B,G8TOE9U3E(F8G(.:AEG9?1DP%_(
MKY3;RDXSGW+4%@/P*U?V-YZ7B:UP8CHJ:E:PS9-Y[5B9N;"^-`<A`8T/<3).
MBE+(KTR,^7<FAL8'&R1'+)2(ZE)+>,*6@+*G@/`>`\!X'"]D91C7=]RY\OLQ
M2[3E?P%/@O\`LQ!G95\)HHIQ0;OI_P`KK;+SC>?[DH7G&$Y"JC].6UAD]<NV
MZ<MQ*3X_EKMF9$'2$8I:HLBKZP9>?*EU,X$)=28YA"4+RV1[?57Q^W^[P)JN
MPCJ$X-=FR-?E<H-9/GVC6MC9GJ]?:.>+4KN2'[!&I"HV*;1&GXLE-F&0!T/@
MF-._'AE.1UL*]RLAG=JG3^MM'4JKZXU/5`J10Z358*CU&IQ!$AF#KE3K*I#,
M#!Q`)AA300<:F4>0W[,85\7L;SG*&FDH"#OCUKX:F?8RYIF+L&Q9XNQ]<NE+
M4P1L"QD3@[+-GY`W9TR(HC+(P@450J\[%,B!A/)<<#?0^EE?QK7X&6G>;E..
MH'L1]_\`*<\7MCI_Y6U?RJ/0E/\`ZS^Q/HK./[OZI_KC^<8\#,;ACC">'O%%
M.&F&,)XUZ*QAD5;#HS.,:OJV,-#N##!C.,-X_A"FV6D93C&4H3CT3@,E/`>`
M\!X&P6FNB6VO2U:/)D`P9H-P$Q^+)P(=@5[*</M-/J;>2E!#6,MN)4A25MK4
MG.,XSGP/*'^TW5HNK=SVQH:.-:=&>TOQQ8+3)R^!G9++>O(.!?'FIA6,#1I<
MB``E\DES##><+R\K^Y?N4%U_ZN].>I'5IJ`.)9VW_AMI9<NX^-JAPZ1HNYS@
MX+ET%U7,QDO_`.Q[3\T;\<A$XS%BNQY[LB.024]CU;":3EIQ)T1S<T9=N/'(
MFD@7775YC'P2VGAP?W=?/6P\T#:*A+&!G.5RW03CV7H^181\XA&$N(SA6,>!
MYYO+&J=WOUIXR4F>._(^8GN!.S]B6:JZ=,NJX/;+-!0[9;-9*M#7/7.RJD-%
M:UVA>89PB3.>@`<@R3C3_O?RMGV8#$Z(^REW?7^#BM?Q6T*);CMXNS6OZO&5
M73^N:C:+%/[0"EZ:,_`SNNRZ9?:SL.NVY.78`@)0:W)3"7'%DLY'9<"U_P!.
MG1?MFFV&&YV=L&PY#D_S'LT-KV8I\/MH^6V=<./A5&G@+=1BXW:MAF7YABUL
MBN.`344TPZ"C'JR@AUO+F'`M0S\?(2L)*QL3/'5>3.!)&`L4:)$GGPI;K:DL
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ME:4X<4&^^`\#!CLSJNRKOP!Y:573EJV!2-JS.EK:/KVTZL$NAM_B;:V,@F$<
MK8VO#XVWK*).80RYD1WT0PXXIY#H^'6EAYN75%3]@W7FKU"16H-Z\F:^2/L+
M9G_RZ[CUK9]C:@U#N&-3N6Z774FDX22F(FCW:$LFFAXK-JDF\1Q$>;+O2##R
M4IPPR'JYXQG&,8SGW9QC&,Y]/3USZ?SGTQ_3USX']\!X$9':CUA:<[0>-EDU
M!<L1-&VQ'M!S&E.0`=5AY:^:DN<+(L3425#S#S+-@'K<D>*EF5#!-#64*XOV
MN)<PE6`P:Z?N>NS:V?\`^4WSVHW^T_/CC)22XZ@K00"U1N7^F*2V^)![1TW,
MN#Q8$C)"P8C:9(9Q67WT,/'J5\K4J/&AL7V$7>>VY:1QEX(\&PY:LRO,VS;#
MJFX=AJC(:<JL+K&$J8@5GJM\:;#LUBB:9*`6QQV3D0XHA#>!V&L.IR]GP(->
MN'J&[;^(//?B#K;8>BZ!:>(W$SE'L7>Y_(O4LI3J"N=M&W>.=<I=O;P%.SL!
M;+K45YK\3%JQFMYP@QLML<QH53J6PNH\RN9VD>!VA;7R/Y%V4"GZWJD28K*'
M3Q?\GM5T<$R35M:T>%<RVQ8KA<'1R&16_P`EEII3/R.K2/AU]D*M_`7JBV[V
M8<M;CVP]C($'?>.6]<;@A=.<(>2[)&W;KK#3UHQ'KUB7'S;0U>J6LIJOO"J2
MR'%QZ3&!<Y<=)_-==5@+F$=#1$/%QD)$14;%PL(&#'PT1'`B@Q<0!%L-C1H,
M9'C--"`!QPS*&V&FD(0RA&$HQC&,8\#[8CX].2,I!#3DOX\E9P,SC)/PYSEG
M\C.$?ZWQ9SGV^[U]OK_'@4FOM_[TV9H"=Z\9_7FS[UK",*:Y*"6!.O-F['UU
M(SN&A=/B0([[%`L\$B1'@3Y#![:WV7_Q_P`=6,)>0M89(52.+&XN26JJCHB1
MX.;SY`W[G)NGDO;]B4O2^B-IER6OF==ZC*-)D,[>T*`F+G);8FQ90!\QE^PL
MR`,E367D/,)7Z*2&=UFY80&P^"V\.74;R:Y.ZGYI[1[,MJ4>ZZWXP[TN=<I1
M8W(N)K-QU85OH78L@B>M6NJ%7=4ST)7/U@P!I.!G`#'6&AF\L!TYV^ZKM_6)
MR`M'`;CSM;DCMC2D;IS4NV9*.V;LJ1M!M7VQ;I"0O<_L^@4>I!#4>D"NI`C0
M2W3XPQ66<F)01\I33[(9$<78_L[UGUW']M^I.VB[R^DN+5MJX6=&M["V7M6Y
ML.O26O-</UW8.J[K,6'4D%*QL!="!6HV4'?C<1(8AC2G?R6W6@N2]%G$*^:P
MT75.:.T^5&\^5FT>=FGM7[GN5@V];+,.+2F;K5HFY1]4A:-_EEAI9`<,F1;'
M"):%#+CDJ,;:<4(4@48)!>RS48.^.$'(W4DIK:\[DC[QJVWQF=54&=*J\K>9
M4&%+L-:A2K#$939XV-)LT(&V[B,RX05\F!UL$,NN,J#ST^#&PN>_`?@OL/L]
MXS<H9&W_`(L[N+4/83Q;W;M0&/G=:[J/BO\`!-`;;`JFP`)LZW78)TL67+%4
MVU8#$1F`VOGC%/K&#KC7';3R&VOV*=5//#L$U5M5G_9:)F*W";`J5*4%:.0]
M5GK3M&>_RO5-`>JU2JUO@JZQ<FZXL>&>,+>2AK/YCT@ZRUD)I/ME6^BS\OP.
MV9/SE@H\58N/&X[Q5XFS,R-"M@Y"KGQYEG(-^O+%C;85=9*K64N-+JY[[0K>
M5ND$M)=C_P"0FHZ9^S/@)M'0.QX6F[CHFJI4/D?N6X8UGM"=J>M;>Q7-W;/+
MV!KR3CZF[*8B5`24!?XIM]N&*DA8TQ_`Y+S1.5LH"PEX&E"-'D!T%"K6MA:W
MD)4MEYA65,/.#N_Z1#;3N$X=:5C&<I]%8_N3ZISC.0U7@/`>`\!X#P'@/`>`
M\!X#P/-Y[S]?!/\`:!RG@=#T&]4G9D[3M<;'MS.R;)B)B>0%TD)4"N"VF&!M
M\FF!MFD1<QU>"177%%PLZ_5'QU1C+S:BB0G,^K"168S07)R8JM[1?*1N?D:-
M?:E('[*A[+<JT8C5E2K,Y5]H4@R;=MFL+B=8:C).QL24T4Z]"BMJ044..@IT
M+77@1RR74#U831I\I.=>?#R=F)8HH^7G)S0&MYF>EY$YU9!TI+SLG`%2\I+'
MDNJ=?*(><(>=4I:UJ7G.<AQ_97#;B[PWX"\WZ7Q8T=0=%U:V<;MW2]B@-?1.
M86*FIN*T5/UH.9D14/J;(F%P\<RT07G_`*@M2/E?6XZI3F0Q&^M.(\'U3ZU9
M=B)ZOI1MW?P[$'8:XW4BHEF/VC.Q>`!:^$ZJ%C01G`5)0W'MLBH7A:?:IW#K
MK@3Y^!6S^QF4('3^%"U.23<D1NS:$?&?J(*:G7\(D='VP.9?G$5MMN:C:4'!
M.D.R!:WEQC!"!,G"D,_WCA9,\!X#P'@/`Z_VSE>-6;+RVWEYS&O[EEMI+@K.
M75_XY)>QO#IV,A-96K^/<]C+2?7U7_;Z^!59^GLK_P#9Y7]+]DBH]..4^Y&X
MBDQ4N`^]+I8I&DFI^R30A(2I4HD"1PW\#@A.`V$2"D*1Z*9P@+<W@?E:T-(6
MZZM#;;:%+<<6K"$(0C&5+6M:LX2E"4X]<YS_`!C'@59.MW]V?]BWM\DI)G5\
M;%`Z7UU$UAG7%MQ:'+%#JV.2\_.7%I-HMZZ_?X^>&.%F8QQ<,H)Q;/QQJ&G4
M.J"0?OXN?Z'J9YQU\2M6"T'6?C_>8TM4#!5ZPB4^)5"24DY<+>-8;35DQE9;
M=A,A)/#4<>%(%#O#A$K1\>0D'X<*PKB)Q74G#>$JXX:/4G#6"DM8QG658SC#
M23F1C4MXQ_RX>;;=QC_G2E7KC`9'^`\!X#P'@>4_]G^*LX_<;LVZWA,2-!5[
M7_':'L4NQ'28U<G98[5#,FNH1[3<[(V@N&L,(,0,2MI+#3"EN)=0GUP0^%O#
MZI5`F8CJ\HMWF]+U74$99KE=3]?*K\I8YTC9$+)L54*T[BE)&P6NR?KC[U8*
MLW'NQ`B1`H[%=1EIEI;[R?`LX>!T1R2XS:-Y=Z?N&B.0^NJ]LS65WC7(Z8@)
M\)I]3"\J0Z)+0IV4_F0D]%%M-OB&C+;?'?;2I*OX]/`@'ZVOK$\6>O?D)LGD
M!G84SN*QFBR(O'\Z8K3$).\>4S^;`#,F0KY\U;8.UV0:O20P<=+F`-DAJ;?>
MPA3CS:F`LW8QZ8QCUSGTQC'KG/KG/I_QSG_CG/@?WP*&/;1K^0UKWM;6WKO'
MCUS>G.(.^^"-LXTV+:?%#4+.P;"3(WS6&=<S9$$^]!!1[#<`JQC,N9*<D25E
MI1AO+HN'&!PBPXX:GX:<>:[+:(W'M'MXO7"J_;(@[1?N.E9Z]IO1IF_+M6TU
MF3I0-DO`5HF)VT5M@/!39M<*-90@658*`RV7CY_`T5EK'7_CEMG<FAN3G,7C
MCQE'E"8?6_&>+X!;]MN-*5&YA5DK<U%TCM6W76\$ZHY();CR+0Q/P<"EN+GL
M#$CR*T(^?`9?Z9B/JRP&MI6L7#C+V$[AO\5(V)LC<&W](;FD=F&SEEDY:>^"
M7$U?,PFNI*6HRW14^V4BDN$#E#I>R8E1/QAUW*[OX=UK6W!+JPZS=2\FMI0$
MCV3:*Y*W'<&S-6;$H$I=;E1KC,8L%5M\)-`(EGKK5M;0\3A]ZHBQHQ;$<\\@
M(8A*F2`](:F`'QE>$!DJ_6:N2.3*X3"5`\B2@!1%RQSH+PI14!67?R3PEMD%
M-_AH2R4ZXVE;R4X><#E/@/`Z6Y$RNP(?2FQR]4NZZ;V1FLR#-.3M>;G*[0WI
M5UK/RM3DM6A3)\=.(W#ZV<"-Y=4^E&/5"<J6D/-TZPI:LS_/7H`AXODC2-Z3
M:C-S6:YZ5)D,FVOBA-1).[&HRDQUDB36H2-H-PCAV[5%ULPPB>1/%FE$MN"R
M0K'@7%N77>M2>''**W\2[=PQY:[GV?!:LA]MP@O%RM5G>KLG69N1L\6$Y:(:
M"G0)W7B5EP@?^I(CY1[))M?_`")2IT.NM&_:.ZA]R1$&Y-[IMFEKG8+8=4@M
M9[3UQ:F+:.2BPN0,*9*&4\&VT^+%G_5I]'S2B5"MN>A/Q>U6?`GUHE_HNTJG
M#WW6ERJVP:/8F7R("X4J?B[16)I@4LB/)>BIV%*-C)!L<\1UES+3JL(=:4C/
MHI.<8#EW@11=HO51Q_[&*/$6*WCS%&Y`Z>@KR1I+>5!F9ZG7>J2MCJ<K"M@3
MD[2`W+I9J*(<8U(/08SC;ACPV&6G&L/O?($)"M0?:_X>:XLE&U)N/BIRPUEI
M*"M`M`MEZB#)7?\`N>N1?XE@KK^:Y+J=_$MC<0'FOQT:[*Y1A2E?.LEW+4AX
M&3NTN>'V#]JG5.O<?^K37O$&5J+,W=MB7GEGONC[0U!L"MUL.'431HR8UJW6
MR*%8)1^1R^P8:<R*X,R2C#R'&?=@./\`#[I#VIO?=D)R^[D.4)_,7<U873;1
M!\38R7C<\;]*7.)1:?PZ_<Z9&F3$)LLB@O39@L24]D=@MI\M![1ON4I06E4I
M2A*4(2E"$)PE"$XPE*4IQZ)2E./3"4IQCTQC']/`_7@/`@0[B=\\:-=;UX+Z
MUV[UOWOL5W'<\\C;]H*D4"IZ^NDA$E:UU]%"WZ(FZU?EX!L%:G*M<E'O#>PE
M#9D,*0@=TID;VA&&C;7&>/WCI[>U=^K[V`:PVOH"V25[J$SK7BQJ77T+_EUG
MBO8U)R[T#)PT5:'H!X'!,6K*L*BSDI4WAIQSV*#==W7SCSO#5FT]:VKZR?85
M"0^[9J.MUYL^M]$:?J^Q";[7+1:+I$;!5;("X.3L?L&,L=YF'DR!/N*?:DR1
MGOE%=<8R&2<'R_$A]_;@WZ_TB]LX&WN0&@=>Z,V$DG7FLK31;M4:P+/F4>#E
M1!MPQT%#NCU@XULV522(TRX3D`WV%)&1X&-G^?\`5[/"W3A_L7IB[&N%&G>Q
M_=^E=3[`MQ_&Z=TAJBPVV-#C&^/D6Y+ZVN)+4"W+6&/PO]:`*IU@XDLL]/I@
MA386KN/.E(#CAIC7>AJ:6\10-1U:%U]KD8O!3DC#:_JD8+"U*!DY$V1D2)HZ
M&APFV%&JRUE_",9RTC.,^H8;=L\+OJ=X9;5"XR[3EM*[O35Y^1U]M$>S,U."
MI$E6`/\`-[#8)^98A)J>#PUKRJ3@PRA$H0MPI3+^<I>3Z!4%^OWR/XD:2XO\
MB`NU3;FA+3`]B>Y-+UVMCV:RTK;#]@=NNOMI5J1_WJ'J1\_-:?4PL"0%.,LS
M$,F+((6M3[>2,+\#<^?''CKXY'=IO39QEXR#ZSO?`#8U-V5`ATWCS?)5NAQ*
M[/N6XR]^)9L-:N!;D85B]PSI;,>RV".S)1*FW4E(2Z*T$S_9KQ-TMR`[@.E_
MCOMC6-,V'QX&T+S?`/U5:(QR>AB(FE4+7(L`/@(Z:">'Q!F+C'QS0\NGC?B+
M6[A;.,J;#.E/U\^F1.&,)Z_-)8_&4I3>?==/=G*U"KS\R_\`+/<1C"@T>W#F
M583C*\8],.N86'6.PNGO=&MJZ#7^N/L6Y0\16)G<!>P[O$[!MY/)/78M=DAC
MW9FK46@WYIJ4A<R4BU%M-*Q8&1P@@G,):<>)><6&T:Q[1[YPL2?JGM^TZ=QP
MLX@B+8QRQU7$73;/%+;$47)AU^8V)9YVK"6LKC?-2-PE8T%ZMS.?P!SY1A`)
M;K#K>$!.36+U4+HH[_$K!'6-F/'@RWSX=W)T2X+980.R0)(,PPE<5*,2<!)#
M&-K&>>3^.0TO.<)<1E0<L\!X#P'@/`>!IR\%9%)P"H=)V1WL!J+2XL5)7QJ_
M'42AE;;RQ\/>GOPA2593Z^F<9_GP/LCW>U/O]OO]N/?[/7"?=Z8]WMQG.<X3
MZ_T]?Y]/`_7@/`>!YA7<8LR_=F?9F/8875!-%T?;Z##6AZ>"N9\V=7=A42!G
M8%YJB4R$G";5:476VYQ_D)J91$1'Q`S8X0;B&7"0LD_5KH#M"T7ROU5*ZQ%I
M\7I?D)4(*HD6;3[&MMF3A$GJB.O#MOO[A\'7IRR6)(6QL@1,L3'`/O5=`/M;
M2AW*<!:L\!X&,_-/X?\`LXY9_D-,/C_]L^]_G9*(>$&>9_VMM7RM$%#+;(&8
M<1ZX6XVI*T)SG*<XSC'@1*?64.%ENI[6LQ%J`=@I3;^_GX`B)/L\M#%Q8NSI
MJ+29%2MV?7<9$8HV/><<<E&13<$*=0XUGVX>="P'X%;'[%P\#F%X#2<L$AV2
M@N2-HEJE(N%RH+,=;QM;R.:V+(*A0'Y":BK)-_CQ;L/^0RW)NF-)]JW6VE-!
M9.\!X#P'@/`X3LI*%ZYOZ'0691M=)M27(PAMQYB10J"/PL%]EK&7762TY^-2
M4XRI259QC^?`JH_3N)A1^N[;83R4@39',/;V`(M]\IUD<4:BZD<D&*^@R3/P
MR*TEX=1:66Q\9<4C+GR*]%8"W)X&F,##D0RX^0$&/`/&?#.!,8:*#,#*:4P2
M(6,^E;)`Q#*U(<;6G*5ISG&<9QGP*Q_7MLJ-VW]B?MS=@]91.L@=%\?]%Z&D
MT1"XL;-\EHVW25B:V),`14)&I7)S@AN6&UOO%D-!BM84[E+B61PD0[WGFV.G
MKL-6XZ(RG/&RYLI6:C+C/RD+!'90E*<XRDIUYU*&%?\`N#ZD*_X>!FOPU6^Y
MQ`XIN$Y>R2OC;HQ9&2#')`C+ZM85=3N7SWA@WCGLN9S[GELM*=5ZJRA.<^W`
M9)>`\!X#P-MEY!R*CB3VHR2F'!\-Y3&Q#8SLB3\CS;6<#-F%!#*RWASWJ]SJ
M/1"<^GKGTQD/*,^U&5F1[LMT?CS\3%BJU;QXBWI\Y$XVU6P)?3\=^4*>P.*4
M42V>$>XZY^(*3G#3R$8]KWRX\"Q3TE_8>ZP>-_6=Q;X]<D=UR&G]MZDC;%09
M^LEZOV3/`YBFKE+S,3;@9BEU>T1C\$5#SJ$)PX_^S<($>]['JIM3H2\1_P!F
M?I+,1(K(YL0D7@!+I#6#M5;Q6N3CT/#,,G1[<?K4]S*R7"?5(;N&I)"$+6X.
MA"?=X')0_L9],%B'+9@N>VLA34#1Y"56&L[:IR$L2(9DCEP8FSZM2P^<)'1[
MV<L89=4DO+`SN$.DLI6'8:._3IN<98?3V$\?<()1[VTKFYEMY./^C_A\9R#0
M0*O_`*Y']KJ$*_M<_C_2=]@<3D^_/J3=D1R8?L7XZ#0:XJ58D\&R%@=D`9)E
MV-Q$'P\6FH)?D<O*D%I)0Z2A'Q-84RA7L(4@.S$=Y_3^XA#B>Q+B[A*TI6G"
M]CQ[:\85C"L86VXA+C:L8S_*58PK&?XSC&?`V>Q]U73Y;821KKW9-QTAFY0=
M3"Y2N[F$K4X&G&<.+<C)T-T<N,*4A&48<:6AST5G"<^N<>!N,?W==0HHS(ZN
MR#C$<AQS`[3DEM6`<(3[&F&E8(=RAESXW%*]^77_`.,J4KT5[4^U(<A$[I>H
MXU7N&[#^(:U)>ROU5N6FLKP^IE:<NX^8]M7O4S[D^_\`XX]<>O\`P\#D`';W
MU7$_E*"Y^\26T_.TMYU6Z:*$V4Z2&*6DEAU^58;D$*'?0E3K67$I<2II2L.-
MK0D/F;VO]6I60LM\_P#APUD23:DLY>W/K0K*EIRO+JF<N3J<BENY7_Z]/JXG
M^?Z^O@=E:![!.(7*79A>O>/W*70VU[!&UFR39U!HMNB+3=%!0%H$@%VU@V&L
M)(&*SA+R,Y8_$60M)@[_`,J&\^Q85%NU'NO[6.#/87R7XYZ9W#I2]:FX_P!0
MI>YC,;CK6B*9/2U+L$)7KY9*#7I/$E5CIVXQ8EF%B8J)!"E+";'87(+:6K*'
M/`[AZC^R7NB[7F@]@ZVY:\)JA!T?=L&UNW1MVX_7N(V#!Z;E;>@P+_#;XQ6W
M:+?)&P5*(G@QD`DM%AN1*%&.L.D?(@.I./\`W==F$SR@X%4S?4WH7=&@.<>P
M>350CZD%IE%9N5$CM)[EV#IUN8+LL*[(,2]NB_\`$DRS+(T>..L<EMMY2<N9
M>;".CJ*B-7U'F!T0URA;UU]LD3<6Y.6_)?;.B@`ZB9M7CWO!Z@W;5H+=BF8[
M\=P/7ENK=`BSX>%DTXFHPL4UU"GDD#X0%J+0T;"POV/=TXJ,PB<JL_U-Z_,"
MF_\`*K9?C+#^IY%,Q2Y*2M4TP]'J*$(84`E#4C)9<9";]SK;J'!V@EZV5P.X
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MYV-.AIN-`F8B3&="DHJ5#'D(V0#?1EM\0X$MMX4L9Y&<I6VXE2%8SZ9QX'S!
MA8:,)D#(V)C(\R6>P1*E@@"B$R9"5O.)?D'V&FW3'DN$N*PIS*E8RXK/K_=G
MU#<_`>`\"O)V=$/M=QO1@]!0]BM=HAG>?MF8JL2#&E#/PL-HFLN2,HUF8ME=
MCESS+SC0H;:OCS[B\KR2VVA;;@0)_8!Y/6V\]CVQ^(NX+ELBU:HIFNN,MRT?
MQP7NBF:+XN2LY;F9RS[;DN7$WF]ZNLL_/5Z'$6;3\Q-@:>P<".%ES*#5X<")
MBK<AMD\':[0N/.JN9/,34G7CS.J4Q/[XYE+TUL5A/(:_ZGF+5-7&?X%`6\`+
M8%1-VG15UNDR#LD\&*7+N*>D74Q3;2VPQ)"!JQ]0NFR=%E<H6;R]![EK^_Z?
MIBQ;0N>FN*G#-RH&T7%=MMQV+^5=)2;,FXDATIPTIZK.L23@;;X)4=Z+"V?,
M0&\XOK5^N/';,Y&)N+">P7B3"RL'+4#8T3-7GUMUYGM;-2,KMP>!V)'OZ>I8
M.890Y`3<;*M,-%AKR,V)EX+F-?@/TA5G+SF-4[8[$Y.N+CXUV.=4G,5$Q3*9
M1;LB>F2DFF(I*5$H2,A;6&T?#C*,K6&]'`A281D;)!BR$=("D`G@'#M%A'!%
MM+8*#,%?0XP2*2PXI#C:TJ0M"LXSC.,^!YO??CT^<2M+<L./+'#FHUV(VAR$
MV3+RQ?%VU6W>Q&S^2%O*VI3823I^CH60UK+:SJE/:&ER'U3$W:1&9#!1.!,.
MY$3\@28]D6I*!H#O6Z*:5K'5<;KO76NZAJ.A4:`I0ZHM$8`-N]-/_`R9&ELQ
M.8J%!M+>#%S.%/'HR0@;+IA+?R!*GRG"C(;OIZ7*]"Y:1$1G'3L3)`'_`'"Y
M0EMN0U]4<J>=07@B3P._EC_2(=*>0_E*D(2CXE96%@$,P20%8.`)'-#*:0^,
M6*\V0,0RYCW(=8?:4IMUM:<^N%)SG&<>!J?`Z=Y!:$U;RCTGLWCUNRM(M^J=
MNU*3I5XKRBRXYR0A)1O"7,AR<>\/(Q4D&^A#XI8[C9`I+3;K2TK0E6`KG\19
MKD)T[\Z*AU_[@I4[LCKOW_,1VG.O;DDR`1;[_JN1=/D+K4N..]-@/?B)S6`I
M2UV,6M,E9R8S@7*A6U!.);%"TEX#P'@/`>`\!X#P'@/`>!YV?;YH@F1Y\<^I
MJZ6X2(@W8X#;T"[D#9-3IE)#C@*\M<A>[`S&Q5S)E;9$:>EHU<Y3X"Q`%@2N
M(U,KC,1(ADA,W]5Z1*F=4\Z9DH*S!XE>0VLY`9FV7JV[2E00I#C_`$*2!B$;
M*MS(1%V`%"-;(9-$$$C<X,RD)O(B6'%A:Q\!X&-_,?XL<0^5.7W$LL?]M^\?
MF=6U&OI::_VQM'R.*9F5(AWDH1ZYRDO.!E8QZ.YPCW>!$O\`68E#)GJ)T<?+
M/`FV!%[W=#3TK#H!57Y@FI[1L=0BI&NR$,!'5V:AE5B``:;-CF\C$J:4I:W"
M?G<4$_'@5E/LBJ`RQUH,D/.X>_[T&S31DQ\U/,*J(%'D7KF<[7H,=#KCD7%J
M2ZB1*,'C8S'N68ET=Q>6@LU^`\!X#P'@<!VN2X'JW9);(R#'A:#<26@W4RZV
MBW&*[(NH&<17V2)Y:'U)PG.`FW"\XS_HI4Y[<9"K_P#3V(^;K0VHT@.-$9'Y
M<;#;]`1[$*_DW.OM69DVI%B?*?Q@L8["T94PAE+F<94I"59],!:^\!X%2SJI
MBI`'[(/>L2?$SX:#J[J8V.,?2X'#$QQ+\`P@A0Q`Z%R+AA`#F`R6E_$A(Q2/
M[LJ_M"2W["Q-M:Z@>:X=;H\'<XR3U)-CW0B;V.%KC_#:P&WB71<8E9\-*,7.
M8C;%&@-,U_#T>]*?D9;:(^7V,O!)#Q'-?DN*7&.1*2P@D_CUI<TA`J6D#(?*
MUO6GWDCH92AE#"7',X1A&,)PGT],8QX&0O@/`>`\#9[!*O0<-(2P\-)V!T!C
MYTP\.[#,21N,+2E:!7K#+P,*VIM"LK5D@MA&$)S_`'>OIC(>7=]F$V)ENXWD
MM-.5^6FW:_H+C&T/,IA7S1*!,35&BRF1#BJS^P5(Q\O#2RU_*A#SSQ><#L'!
M-HP0@+CG0IK.F6#JYX92&T=+:C6U>=/SEIB6%ZWIZ@8=$YM?9LZW"-I,C#I;
M$656Y<)\;)SN4X:SA"77W%+5X%6#[+O*_DB%R-E>*=4X4N<<.(>NI;6!DS<J
M9JFFNR^\8B*N(1]5FCKQ2@)6J5^OEV6.856HG)[4DTG+6"4C.'%`^!P#7FO-
MR\_.S!WE=Q#HLI6,%\X(.(:Y7<KCM&4]O0^LP=<TS$QQ7O\`PPFV[([+EZ[+
MDR(.&L8J,D2J&AV6L#+:>6,%I[A#]?6JZ,Y5\L^6/)W=VL.:%GY(AE0CVO+3
MQ8U-`:;KY:I6&FD3$KK1#L_!KL59,@V1H_$9F(;;"=?P^EUYWY4A"_\`8SX(
MPVW.=O6[U\\3M1Z(TQ5-\I+MMP@M6:=TUJ:0DK0#+V6(59V;15ZEF]RF`Z''
M2Z'`W$/0$>XT,2=E&%X?9#6*^CM6\ES"D=ATZ@!4:C]`VYQWCUFLR^6L?)F9
M<1MI([\?A_U],,);<]O_`!]?`XW)?2`F4BO#1G8;"O#LS3Q<>V?QLP":]'$$
M1K.1CYL7:IA>"?UPSF&TX;=&:)5A:&O[W/<&\?6>X6Z`GM_=MW!;D9IG0G)^
MA<1]X1]6H5LVOH?7<U=/S2+/NO5%ID&K!+1<Q8XN(M$)00W\1/Y[PH!?R.CY
M2ZMQQ09*=T\;PMZ_>17$;3VKNJGK&V=0MM:LW!L&X-;.UO6:'=Q('32(:8L,
M+K6Q-6.GUF?NMOIK3P=;B24$'2=@2PRRI67_`&9"`7C7V*\/MU;XTMKO8?1Q
MU^CPNUS9A<M_LQIC=U\V..W%#V9:`H'5L!/E&JD9HRN9^+`Z3&1`G%E*PY@=
MUK`6UNJ_K6ZKNP'KYX_<K-G=;O#FNV[>%8L4O/5_6-%LD%7JZY&W&R59,5%E
M2EQF["DP=F$2ITG!B%_,O/L2C&,>!'#K/2O'?B)]M:$UKQ^X_P`#K765+X1S
MDTS2]-T614,'-/Z8E9N4M68!LDEV1FI,%"0,.0XZW3"76&<LN&.$O+#@GVH-
M!\1N,^U],\\KIQ@F.2NR^2]U)1:Z_==G;*HFOZ\+IO7.KH>K1\M6*4T,T;%R
MP(&6YD=\@.0)2O+;9+2&\>P(I^(-CI<ARLXF%T^(BN%HL;#-<Z--6^Z<GN2.
MN-!<?]>;DW$D78.B:H7L70)U2B`+I68"6"BY@N2S4Y5XC`;4R_*.I1D+<NG_
M`*U/`KC+N>&Y<ZZMN^+WLG7<'M&X5*-V5=X"TTM&SKE%$'1^S8>'@:A7_P!5
M8(.86LP-L92@5NNX4L=Q3;*D!5*ZQK7.:FY??7_UQ.:2T8MS9.Q]Q\@DWW43
MMCK.V+RY=#=L<8Q3MW%W0H>HGV&F8UEF5<3!.#MRHR/QEC9/SEPH+@]#J4#!
M?9&VD1!!"QC>>HZC?.!$SQ+H#"W>3#H3&"*HQAJ+K.<BQ*?@92C.'L?(0CVJ
M>>]P3[^`\"L_WW=>>_[C.ZS[8>"M\N=<YN\&JBU'U:B5*N5B77M76)UEDO\`
M-8=EZ7AI1:IR+K=REG4,G,R$:]'Y):_&2ZYASP)9>MOGUKGLCXU0O)+50)(5
M2-DLU$MJ2?RB;#NU=AH?_/868B?Q&FXEZ%LQKS(N6B#&3H[(QB7$9?4.P&??
M@/`>`\!X#P(INQ#@5O?D[N#B!R5XN\BJAQ\WWQ!G-LN54_8^I6]R:_L->W74
M0*;<AY>JKL==<3+`Q4=C\!]EYIU"WEYP\WZ8]0BAVWT^]IFZ=FHNVUKMTL;F
MD9P.NCVW9NV>O,NU;)^.M!LQ$+'C#3QMD_>QT%#Q8;0R7YH)*L84E3>/;E;H
M:B_=7/;WL6/U94]BWOI0W+"Z#K!U;T-0MH<.=@.US6=4+!JT&MFI0P!A.(($
M8*NAL);0T0QEL%EA><MOO)2&LK?6KW-5#2,]QOK<;T-P^C+/&6&&G=6QG&;?
MT?29.+L\W%V.6CS8`138A,<5.QF2W15?],20\IQYM:D-Y2'9LYUY]OG(.?X4
MZOY-[9ZVM<<4^)VX=$;D:B>+&K-S(V"N4XWE#JHE;JXFU2BJM`QEC`7F->0S
MEL>/$;PIIIW.$LK"QW6X95=@(>"7,3=@5$QXH"IRR&-R$_+*&:2VJ0F#61PV
M2I`K./>ZM#3:,JSGT2G'IC`=<[\WSJSC)J*[;RW597:AK+7T5F7M-@&@K#9R
M@0U/M"MY$K]4B9VPRI+I)"$):%$?<]<^N4X3A6<!63V`#P.[6^8W"[F?QR[1
M]16P_K8ND/:9NH;DJ,9$.WH>^6R'LK@9-NEFM1E"('B*80T$AB(D,1<@G#KW
MLR1Z+#ISN;*K6?L2=)T*1#14W_G84%&6%Z7D-@MLJ@W-NR68%F&*CY#_`!8)
MQL\8ES#4>RE\MQ_*)92@W1,H"0+D!'P];[T^D*E1%'%H3%1XD\[(L.`")%.#
M@:\#K"IPM?J(IPN,H*$K(\,M+><*4CVO8]/3.<YR&*?9I]GW7/$:2VEJ/AOK
M-ODG>-.EO4ZV;9LQ\U,:'K-F<CXQV/=+M=2D9"Q7$^)L@,Q7)6*6J+>3*MM/
M8D,,(=PL/UQ5^S76-O\`!KFIO_DKJ0_2>Y^.\CK&M4G1-0E0*Y?-KR>\*>,+
MK:'U:[L4F9E;)<YJX1$Q*K]E>>:BZ\L1S`TEEIUT@,!8S[DVS3=Q1!4_P+(U
MWQ>!D]=UO9EA(L-@V7MG7);]T@7K_8)!N+CJ'6C,26N9)UB!B"Q8EU4Y['5&
M$-(=#2'[YM=OTKSYJ-CU=R)Z]=SZ<ZZ.0&Y(&M\.^7HMNL>F-U@\@:9*G5ZK
M[*5&E+Q6;5>(>?BWS@*NI3.`V(];CI!JQ$9\#/'3GV&8KCXO@-PTWMJJY[IY
M5[)$)U3MJQ:LVA59[5%,F(?D;8^-<#.S6P-@2&+39[1DBAJ/F423D>^$@WY'
MED*):4@+9H4D@TJ5%0+(,9BBV1%OE@OBB'*?CPY'!$22ZG#4D&V@W#2W6LY0
MDAMQO.?<A6/`W'P'@/`>`\!X#P'@/`\VWN#*JT7V#=B]@DJILR2AH>:MC$[9
MF==Q.QAJ_/-<==2E4BJ0[>T+`9$L:HV&?8K'$V-,(L5Y@JQC)6+\3@Z$A/7]
M4S7\W2.+_)`X^#*@8.Y;=I$Q5Q<E4!8)`M>U?"Z]GBDQE"L4DFOGMVZFGC9$
MDXV(E51PP1!+9+CZBG`M3^`\#'+F(0`)Q'Y3%2H@1\8-QRW>1(@R29)<<:`S
MK.SN&"2"(8H&74$2.E2'<"OLDY;5GXEH7[58"(_ZS,8%$]3.J1(^7N]@&_W2
MWL]F<V+5E4ZXR1;VS)M<DJ:@77CGQB@I/+PJE.&'*<R/E6'O;E+;83^^!6N^
MQ5$04S'<$`YHYF'^;=VQ1@Y7(DG+%>AFNDC2\8/%A2H\>'@FO.&%?N)0-^*B
MG`6_R'Q</I^8+*/@/`>`\!X'!=H$.":TV(4T2R$Z-1;:0V800\(.(XS`2#B"
M7RQVWGQ66%)PM3B$+6A.,YQC.<8QX%5OZ=DY[NM_8\/@>>D,E\M-RR14S\(S
MM=CS&*SJU.8])N;*>>X1)CF-D-+<C8_YLI>Q[7/BP\X%M[P'@5"^N2X;FM/V
M6^W>+C[35)*GT>O42L6*.V!FY6"W`:W]S,_$P^H3D'.0M1%C;W/-N&@N99CG
MF"ENH&<*]7T!+GW]+<1TV=@ZFGH\=7^P<GC+DFTP\,I"K#7DNLMH(&+;P>2W
MG+8BL(PM!2FU(6VO"7$AGQQ!C\Q/$SB]%*7AQ4;QVTI'J<Q^!Z+R'K6LCY7C
M]4,%%^BLM^O_`$S+0_\`]C0E'HG`9$^`\!X#P-HG@<R<-)1V(^(EL'"N"N1D
M\WEV&.8?Q\;XLDU^,9AT5YA2L*3EI>%>OIG'IG/@>51]IN4+IG<]L?,<$$T@
M#7&BY5JOL1'Y\81$NZ3K5>F%J6VB&+3#NQL*H)V);=4!D<;Y5.)6\\TV$L'4
M/]<[B)SVX&:5WUN^S<F-4[`V+6R#Z](:=Y$PDU2[15J^5&0[EN*I=RT^//T*
M9+L&)**=B$DR,>AR+42(8X.^PGP.C>\/J+X/]-W$H6RUW;G/S;=SY!VEW7^J
M:R9ONGUG5],N-:AB+GF^;&AXW7'Y=X!CYF+AR!HQG\-U9`25I,'4A"\!&)T2
M<!N)?:WO6XZ"Y'VKEIKCE&J"MW(FD[YUQ<ZL3"VV!B[%21))ZSLW>O2MC%M\
M/8RBB1)4,@K,F](/9?6.X"U\X6SH[ZDVFXJ)BW:5V-=B6OIMPQ%@G76]BU-3
MAMF=D"I-^;=%KX`0XDYDIQA67VS"E?,QESY%*7ZI"`WLNZP=/]?/9)U]:7W/
MV)\H4ZEVI4+!9;AR;V]=6D7#20$#9+*VI[6-U8&+D*(VP\D9QU@12UG%$^Q:
MFTO8RD,SJUPGZL;E9X"DU7[1'*VPVRR2D958""A>01QTC8K7*3`<,!'Q#+,@
M]@XB8D9H0<,=GWJ>5AQ2%NX2YEH.U)[J9XITJ!J+]Z^RAS,B0+KKS8>^J/@G
M9=DBFY35%#'(%M&QQ8DBZ''9@:W(5DE1)ZOA;*:%^-A*5-Y=4$='4)UL[!YP
M\S.T.D:.[0>3^CEZ#Y`HE8;?FIKJ;:Y7D`-)7K;E88V1L2:J]GJ0=MFK5$`O
M'!2:)9;2UGF+0R^AQ2T!+[MCZA]UWFS6E[_[>N3F\1M<M&#Z_&V)02+695(2
M4-'EK+&P,E;MSV7,2[+G,9=PIAM#7R);RM"_9X%%C5ULQIC?&Q0=;;AO^B:-
M4MM8D8.\MR,/CDQ")I4I8:-#JK1U4/"AQ++'0-].(FB63(Z+=C!#<MDY4AL9
MX+XW&KH*YM*XUZ$1Q,^P5RLHW&TF@0]ET_6Z;JV]ZMA!*)?Y$G8#98E;CM[0
M1R7)+-H(+:R>SA_'S(;QE#"6TH"(.Y=>7*^E?8/AN+LEVL\B`]X6OBH]99/G
M9(C#P&T(6&9T[:I-^MMLS.TXR2F*("%2%CD'QTI^2,A>?>A+S3K_`(&7W:QT
M=\E=:<.+YR/Y>=V&SN4NNM"T.]6^GT;=U.CY@BQS5IK\8"[!:WF]F;GM,<U;
MK0,-EN.6.AP_"FVOP<H><RI(56N`;[6^=I+X=WWE#=N,-+YBT?5G'@FRFU4_
M>\%8XV(V;"V_7]*E@FYV/L%.KBKM6@6XH.+%(5^S4PRM08;Q)"0O(3?4UVL<
M*>/STL7]A2_:]T#H'6:JX&+(\;DW("NT(!U\2,ATPI%IM4S8CF4N`@QV,-&R
M2$+P&*K#26F\A60Z===%!]JG4+$WR*W]!6*YU?;>S1+GLG9$7-ZWO?'^2I.\
MGJN;HRJ5^*BK%J^HRA5=GVC!")1YUH]Q]6&6LX5[PNO\6Z<:5WX<O-G3FT&+
M7&5#K[XI:JIQ<F=`P\I<&-IV>V[(!.1`UPJ$#-0(%17_`,9PJ,)<<RLI8KS"
M<%-K"PWX#P/F\RT0TZP^TV^P^VMEYEY"7&GFG$Y0XTZVO"D.-N(5G"DYQG&<
M9],^!5@ZL]%V'@;V_<ZN#4O,FGZWW%7P^PC0(58O\O6JY0ZL3;;5J69H)^GJ
MV'$Z["AI:4N!+P$>/@C`L=!1CA.72F&5L!:C\!X#P'@/`>`\!X&V_IH?]Q_D
M/ZJ-_?\`ZW]-^\_!%_<?I_ROSOU7[+XOS?UOYO\`K?![_B^7^_V^[^?`W+P-
MOQ$QF!OPU`BN"_G9DOQWF4/M8D,R.9?!F$/8<3@AN4S^0A6/Y0[C"D^F<8]`
MW#P.HN0*;<K0N[4T`.4D+XK46R4TD"##BY&;-MV:;-8K8D/'SCP\(?*$S.64
M#LF.(%==4E+JL-Y5GP/.KU]T%\R-MZ,V]NG?7$MUPRP\=]UQU_J%OFS97F?5
MN7^JX:R[!J.R]0!1%.J52<H6^]F+CH8:N1C]EB558PA_#[9ZDNX#(W@\W?\`
M?7,_I\TSR%V:+<N7/7!I_D;<.1D7?K5)0NP]"&ZJY,4MK-+O(15"FQMCR@>C
M0UAQ[,:;A\_#J9)<HIMIM186$^3<GFU]ZO3G+MSC3]=,XM]B-BJ,H1'-0[<T
M9.TVEMNPZ`Y$L*78D8:N.BO$LJ8<);P.K+C#7J^I@*.EVT'K'@ES!CP-];(X
M/<G9,/D+N30D;I_=VQ-I4X/C+9X#<8]XB.0^X:C18X&PUBG3TS%$N,#Y>L(<
MU#264'H$^=O+8?WGK9M;T*^ZXY@4;G/Q>Y+<N=][/WPC8`>EXO7+>GN.=1K>
MBZ1J_66MHJJW&O8E@XN#$(D8ROS;$TU!L*B8Z0AW$$)4=X&6'$'9#7)CA!6^
M.4ES=X-]>?!O9EE/CN3V+[M>G6'F'RFMU>W-6[C:+GLA-L`DMAZXM%WCAY"4
M@0TFRL$^,E^/60RPZPI8:RG]BO)?L.W7%\X-T7'K?GM9<6]GVVA\6N-/+3EU
M%<?:IK"_2L:Y8=<;D%UF.+!2>YZ]33AHIK!]D8)?DEMK&RMO#3Q00<*TUUD\
M@^Q21YD4^A\L.O#;>_`M]PVU=B_XM5+%8J1NS8VT=9;9W!0[;I;D*?%DUZP3
M4M#;4M0DC!9BHP>/?IX'YB\.M*+0'HP\#R-^$\,N,F>4T"]5^1P^F*+'[K@'
M@JS'9C-CQD*-&V@=H*F%&U1@3,D*M3'Z]S(N65)RWA.,^W`99^`\!X#P'@/`
M>`\!X'G'=P(&O*AVD\_(J/O&LMBE;:8T];=OB_L[Q'M:WJ=:U]'!7;7NU:=6
M@Y2#G(.FU:%C+>>:P&;89IY41%Q0W[7+9"`F=^JI4ZH!JOFDB"DT&"U3DC0!
M8=D&#EM?S3+#O'*D)4C:4(%7:5&VN]_)-E8EGCF)//[AMU])+ZDL%K"VIX#P
M.@^5B&7.+O))LAP%D=S0>X4/O2<<Y+QK3*M>6)+KDA$M/C.R@*$9SET=+C:G
MV\91A2<J]<!"]]7%N.3U`ZA<!DY^9()VQR"(F92Q2@L^4;,*VO8D$DC6.-EY
MF&L(CS*&E?E!K;9^;+C:DJ>;=>="P[X%<?[#H4N9`\`OP_C5##<K9&4M#7^1
MU6$6N*JFKK3?QGR0[;%EQTW$QDQ31C'F/F:_UQF,9;<]^'&`L<>`\!X#P'@<
M!VL+^;J[9(7YZXO\N@W$7]FVI"%QWY%=D6OST*<4A"5A^_Y,9SG&,93_`#G'
M@>:/TL?8STIU)\6;=QKV'QWVCMHZQ;\LNTXN:I=FU]'B1M5L\%3X,UN0/-RB
M2F+$F0K)1+8S[`R&V76FOF3_`"YX%B?D#W6=H.FN'Q/9BGA5P]$X57"/J]XT
M\9<M_6H3D$5J7:DU"":H!N-*KD7.5K_<.?#F!RS0X^46*+EQ2%93EA2EAT;Q
M&^R#RW[3MNW;0G!SA#HZ6OU/D+IN*)!Y#;6/J$-_V_U9W7M?JC)<O&1]A:=W
M89=;*8HY`PR8EF+>9P._A]ITC(0;!=R?)'K-[GNR*\[`XY:[L6XN2=RUO0]A
MZPH&ZR45.C7>H/U,^-%@MKR>LI8J>B74N/1LNVJ%%^3!CWQ.MK'9=R$PO?1V
M2]C>C>`5WT=SQX7<7*W4.:E<MFH*3==`\I+1;IFK6B+%@+:#-2U/G]<1CTI$
M@_C96O(YWPN.80TZIK"T8(#"JA_=*VGKZG4;68/`C7LWFJ5;7]2BYA_D7-*S
M(!1=;`C'2Y3(>KR66)0M3;*G&T+5@1WY6E_(I'KX$NO//[!G8-UJU+7UOY;]
M;/'^FC[)M-GA:?!UCG1"WBVVF(`$49#66,JL#J]Z;C*TAH5?Y4B:RVUE9(S6
M6AR%J9P'$>/WV8>6W([1D_R-U[UW\;2M95$2Y9LHUD[.=$:YV&,11@WIJREC
MZUOM7AKFJ.A:^Z(0O&0\O&X+:R'A_"_1(=+<8/M\[-Y6;%8U1K+K=IY=U=AY
M*PJQ<>=NK],5=J'A?PU2;KMSW#KZI59HS."/8.-DO)#[BTX0VK"5YP&HY"?<
M-LW&';=@TWMWK3;B[?76J^>6Q4^;&M-H0;\18XROS\8;%WG6FL[129QLZ"D7
MG$+#->PTZMIMW"7&WD8#O69^S!R*C>+K?-\GK#I[&BQJ[&6`:75V/<>BK:95
MK?9BJL"^SJ4&(SM!4V+8D0Z"0EUUPP<9PI]7P,XQE85)N6-EY'_8"YM;LYI<
M1N/(M$/CX32.OYZGWKDKID!=?),HD_2`/T!FR%ZEQ/*GTUA\G"8]M]R-=0I3
MOKDEK*`FHZY?L?R7!?5W&7K,ENN/9.V]]Z=E'>**)NO;LU\/8K=L<?8IT3(4
MFJQL=K@^+);#N4PB.%9Q-OM$*0VXLA2EY7X':_=5W;438G&27X[<\>GC:.L+
MCMO5U[F>,5[V9?=37INC;BAHH:+8O5,E:^&D\2/I=]?%'/?#+'(/`1EDD-3;
MSHG@=+]+UTM_4%UFN]C$QP#U9RD8V.J>M)>^-1\@*I%[NUQHTIHH;_&[_1YG
M6TBFOQ%>NM6(Q(&#S*RWL30(JQW<B-MH"9_@I]G`'L+GKS5]`\!]F'V+7+%-
ME+3$26[J"R>BMWFZP&OHZPPT:W6US%@#K]@GTDSB!17%QL.RLO'SJQ\'@0&=
MM_8EUL]E',O6E+Y/:6[6./\`R%T,MWCY6M=:Q*XO55<5>;7<<.OD6,B_V.P$
MA2!1\B(/ZHP![!V\9>SG^,-AB7SYZCN!75L+J^S\KJ7VP:T9V?-30.M+!4[?
MP)OR'9RA)I\Q/NO%4NY./P9.!;!C`'S*'>^="W4?*@56'@X-H/KLX-\J..'(
M;FOK*R]JDGQBXEU\^+VS,V8CB/%6L&MB`RERM53J#1&SB'IQ@ZMRK.,CL1WX
MC)A#CKR7$$9::"1+ZZ_-_@'Q7Y0;`TEP1U%S]Y%;6Y8PD3'PE#VA$\6*7,")
MT]"76Z2F%WO_`'BK]2>BG($H\Q#;K0+J'1/9E;^7&TX"PWR_^S)Q0X,[+;T'
MRWXZ\C]=[;-H\3;9JCU.7X];8*JT=9#)V,%B+1,:YW;.0T%9_AALE9`=>_(2
M&4,_E.$O)\"FAM/K2A-%WVE]FNT>+>P-0]*EZMFI"<045OJD;CY![@T]LJ/)
MF*O*OBAW.$GJS*;/+``59`%&!*@\RCH[&"V6G$>!<MZ\^^;C[R@H2M:\%>`G
M-'95"T.]1=8MQ.M:1JB/J^KZE.HFXW5,3+&77><<H$`.MU)UHEY+CHXN!<YS
ME+:F_4*]+O:7I?>_V;M2\HJSH3?Q4?#T%[AB=IFU5#6(^S3^0DI$[)UNU2AF
MIG9X5+@F2)286*LPB6]ZLL$M)94EU*_`F![G.W_A2GB_?.'_`#WX9<U=$RV^
M-7WU.IAK9K;0)$R+,UW$E78ZR4Z>3>]IQ].5^UPT(W,MQCY+`!ZW1D*SC^`K
MO]!G&/7%.&B^R7:G$SG5OJ$U!/QQFIK3QVTOQOO&G<QFNJ78V-TU;:-&N-B5
M:)24A9F5">!L@S0<T2^#@H3X'DJPH++\S]BC@QV.Z\W'Q4XK\7N;/+/:5WT[
M<S&M,TZNQ^H9.9`#3'!J_-V5$[4$L%*CAY24&_(DHU)9(R/5267<>J<A4QXT
M[^LW5QV(]?DMS[A=OP$APIJA%3V7K$/7(@]AT'KW:4!R'L>KZ)%8B;P5#;E&
MEW]SB3:YI;`QX67WH[URL9*'PM9=8/89#\YN\[FO>=<:4GJAINT<0=2!4BQ[
M/_'J>SM@QNEMN6>D1&XZKK6V14#:8VB3IMXG0#U-+)>`S$A(*2V43D1@+9/@
M/`>!5*[R>0^E^`W:'T_\W-JT&>)KD,]R6UU=K;KJD.'7.4%L]5J=4K`$]80"
MZT1/UZDJN1TJU"D2$E[<+)>%BWGE95D,D8G[2_3[.A01T-MC=4JU,X*9)3%\
M8MYR>:_+"ICW<P$P]'4PH1Z:='/^7#<>X<A#;2E.+1[V?E#ZM?:=Z6,M,&%\
MC[Y&1)KDHQ&SLAQPY`-0\L_$'8#,8C#&==/_`)CS;3K!*DI3ZM,$M8=^-U66
MTAPX;[7_`$ZO[7D*`[N6[C4P>HUVQ1NY7-4W]=*F)>:S(.251;AFH!=[BY>K
MAAMK,<.BAAG'26V1EONX4E(9.6KO^Z]:!7&M@WR6Y&U+4TFN`)@]OV;AUR<K
M&KBXFS0:)>!+1>)W6HL2<[/):=_`;9]'BUK;9;:4[G/@?>C=_O7#N>$F9/05
MYW?NC,4D``@[77#SEW>("%LT]'%'5^`M,E4-)S/Z0\M`JEN,+3^0AI"E81GT
MQZAQ^K?8_P"GVWE14%7>51-DNLJ0%&!T2LZ,Y#3=TD9HJ,D9)V+BJD%JMZPG
M&#9BW67&D#Y=:(4VTM.%N)QX'*+?]@OJFH03J[WR0E-:3#D26?%P6W-#\D]7
MG21P0TFZ7"LL6G3@QSLE%D1Z&3V1V"7PG#!4K;RHEA+@?JN_8$ZKY<&:E#.2
MX[5=KJ0OVNQH/4/(VP:;RM^,&,.Q';:QI6.IYZ(<UY0A2L/)_'?]B'L-O+RT
M@-_A>_?J`LSI(]9YOZ[LIHS0KN8VO5;:4W*D*.-7&@C`Q4;0B9&0/.D<('9'
M8:<>=>?90A.5/M86&I-[\>GB-*(`D^?.DXP\1Q3)<?)KML<>(\G_`)F2@C:N
MP4,ZG_BE:$JQ_P"'@?66[Z.H>!&@SIKG%JZ*CK,XZB`E)"(V$)%RZ6`FY!XB
M/DR*8V"4&T(0PI3Z'%-)_)8QE7J^SA8;4OO]Z@5D`M1O.+5<VP0_E$A(0T;L
M"4C(,?.6QV2IB0CJ68%&I*E3!1&4ON-9=>*1A/KX'(E=[W3RE+*L]A_&KT(6
M^AO";M[E)4.D=3F7D)"RH9"L%)^-3F$)=SA>$95EMSVA5RY6?8,Y#<Y].\O=
M<:,V]P+XLZLC;`/3Z9?9?E)M;77)YV$CI%J6DC*P:#KDZ*G8R[P$&9#O2D.U
M%,,*FF6`I)16$..A7>L&V(BD;EO<W6.2$RF^PFU]$ZUV3L[7?)"Q%TC<$N)9
MXB(Y'WG&\8BF2$M8]8;J<%B)=J=O#CHY"XV1)?&EBQQTMA/[WT\M>MSFYR9Z
M^Y4;D/9)'1E`U[R4<Y,["X6VT"4V#Q]=LULU(.W/R\9,1H(:H26M9Q8A+ZXQ
M1T\@[U#8*)6.TL.!?7-V-T]TWCYR87V/VCAW,[!N7*":&UX_S1K.I+;M4ZEU
MR@4-)\F7(7V$EK/#P9]B<<RVP<H8?\L=W+25/?/GP+&5@O'U:E5ETF4*Z:FX
M>>C71LNQ4!Q9:FOPY".?=4H=$%%)LD28D3*LH<0EDAA[TPG*'?;CP/B%GZQ%
MDB,R4[&]*0X")&?KL*7'G<6EK/B(8H#/SGD%0U=-:E%(0.X^CT*;:]_^F6^A
MS*U!JE0GU;[M98^'0STW35@EEJ5%@1Y'%MI/K&X#:<%'1&NC@AX4M2%*8SE&
M2%Y<5[5YPYG`95:&VCT=<2I:TR7&G:W6[H.;NOZFKVO&JMHZ!U^JSOP;=CGH
M.+FF8"P`#&OQ[;DF^TXZA2VT*=_N]/X\#,]GG'PS_4@RYW+3C"`.;"1U@PX]
MR`U.H9,7*-#N"'M&8M:6"8XA1*$LDHS\+WN3E&<^['@:J*YM<-)R)`GH?EKQ
MHDH64:">CY0/>NL'P3&Y&+;FP,CDHM&6W,EPSJ2F\8SZJ'5AS&/;_/@:QCF7
MQ`*+9`&Y6<;2#B&FWQPF-YZP=+?8>8?*9>9&;M"GG6G11G'$J2G.%-MJ5C^$
MYS@-]EN4?&:!3'JG.16BH9,L_@:*5+;<H$<F3(4-@Q(\?DRP,X-?4)G#N$-^
MY66_[O3V_P`^!J6.2W'(IL5X;?\`I,ADY120G6-JT1YLQ0++9)R15MSRDD*#
M'=0X[A&<_&A6%*],9QGP-;!\A-!V=HQ^M;PU!868_",GO0>RZ9+-`X<%D3F\
MF.`31"!L.!1!;R??E/JT*\O']K:\I#6YWEI-)PL9G<.K,21JHY`<?G8-2P<6
MN74`B)0*)F7_`"'U2BY47`^$)SE_)+6$>[Y$>H<LG;K3:NX,S9K;6:Z\:)+R
M`;4[/140X6!7Q4'3QHR)`L=3XD($XEXMQ.,H&:5A;F4ISZ^!]VK75GV<$,V2
M`>'4U\Z7VIB.<9RQAN/=R]AU!.49:PU+"J]WKZ>TEK/]'$>H:T>9B"WW!196
M-)):P1ET<<X5Y]O`A60BLN--NJ<1@8W&67/7']CO]F?17\>!YTG<EK)BN]IW
M)VQ0;LS29'8=>)V'8*)N+:T+39K9.:=7X0"KWWCS"U6FIL:M>6O-.D8=A_,T
M+8L2C4F^^\Q!--+("S9]?+2!FKN`-$VR#"1_^Z/(?8.S[=R7FK3>[':9N_VN
MM;>M>N*SLF-N.#K#57AA]5U,-H6-AXT&%E/>T^,4,QC'RA/]\C><9SAQ&<8]
M/7/N3Z8]?Z>N?7^/7P&'&\_T6C/]OO\`X5C_`),9],J_K_R^O_'^G@8S\SMA
MU75W$OD5>+A)PD9!1FG[V%AZP,-&Q!\U8(`VMUB`(`=',;E7K/9Y8.-8#^%[
M)I);;"6UJ<PC(1C?73@INA=7&I-=W(J(9ME-V'OVOR40+&UJ!DHI<#MZR`EQ
M\S&UBU7&(=E8LA]#1!#$@4A>'&L_(OW)6L)O_P!R"Y%8F@5N2H*QT$L+B6ER
M+A;*\X2A0C0V%K(]W_NN,_TS_P"'@5Y/L%OD@C<"9'%?3-1SG(2\ULDS*(P%
M^'D+7JF8B8@F$M4JSD:!N?RN+=@6,N)_:3#`XWIC*DOL!8P\!X#P'@/`ZWW*
M\X/J#:K[25+=9UM>7FD(844M;C=8E%H2@5$M`K)4I2<8PW@X+*\_QA]GU^1(
M4J_J]]=W!+F9UQV^U\H>,VE-\W.I<I]K0D5-W>G#R-AK\))5/5TNF#<E/PA3
M'1,%>YU#*SY%(ZUNX0MOY'$K"R)$]'/4A"*%R%P&X^NMA%LFBBRM9+G0&2!_
M;EC*8^<DY$'X6%(QE#66\M)5CUPG&?Y\#9Q^AOI]$(>+#X`Z%#)(0^VZ\'$S
M@B\H)SZO(1^/.MX:3G/\IPCV^S.,>WT],>@?:1Z(^H27*=/E>`VB9$]YP=QR
M0,BYT@__`*,9L(-I!SLZHIL8,1I#3+*5X::;;0E*<80G&`^A?13U%R`H(4GP
M0TG*B1A#Y4:-+BV669CW2F7V2\!-R-B)2,P9@C*WFD82T\\VTZM*G66EH#CQ
M?U_NF@UYM][KYT0A;1;IB4B!V<!G+SQ2#%H<&!LHX[PF'D8PEA:5,(:]6DHP
MWG*,AR.U]&75-?G(9_87$"J;%)KL2FOU\O8E\W#?3(.`;4RL>!B#+=L29)C8
M0-;/N'$96@<=3CN6D(R\[[PX-_[+R=+GHWC_`,O_`$]Z-.MO)_\`8EL3URMM
M3JDI<5_FWN>:SE[/N;7[FUXPG"L9PE/H&B7]=7I67C.%<`M5X]<8QGV63:K>
M?3&?7'IEO8"<IS_XYQ_.?`TQ'UR^E0GX\*X$:T:2A[Y5I'MFV6/F_P#NM6&G
M%M[!2ZEG#AF5>B%(]?C;3G.6T)1@-,;]<#I/.PCW\"]>CY0\$]A05YW*%E7X
M+K#B6EI'V0A"V2$L>Q_&<?ZJ5*]V<Y5G/@<8DOK>=-D6TR37^O\`UW8S'Y*$
M!("G=L[KAP@($B6%:G949\6XR:S)**AUNOL,.-X4:\TAE1#&'%/)#63?UI^E
M&:QE2.$T#!D?CO,MFUW:N\HDUAUU*_8>P2SLM2VY$9:_>T]_SH6G&?Y]/`X;
M_P"RO/2RX>"63Q2,?%BL1[4?%8W/O)$<I@)D?Y\R;"MCN_L#)8U#CI;V/AR[
MAQ*/;CV85D-I!^K-TR1TF^<)Q^V&R`6UD<RM-\A]WLULT56&,N"&1S%W:64(
M\^.AY;:W5(4[C"LX_C'H&D3]5WIK$G5V"`T?M&I&_)EP7%4Y$;DA<1ZU(0AW
M\$L>V9E&D.I;3ZH40M"<XSE&$Y4OW!P62^I9T_RL_+60JI\B52DH8L]LA?(:
MXEDQ9:HY@-HD&2D&C)D@@4UG\]MPTDMS\M6<*4H?"6$AN]D^J3U*6U`[5@@N
M2TJP*.K#(\GR6V#,,MRI!62Y2QMHFGI+XIN;<4K!64>T9?NRI+*%_P!_@;;6
M_JA]6U-=L**A.\PJK#69,D-*5FM\E[!!P3\5+(("D8,AJ+A!9"4B3((TB,=0
M<04MX`EU#BUK7ESP.(U[ZC_6)3)U%GU_<^6NLK5%EI-J5YUQO4NLW^I/XP,V
MMZ*LBX.1&0^0-@EAQQ(;:\LDYPG*5)]R@X?L'Z>?6;L.<*M$MM_FJ1:9<@Z2
MM%HGMR5&WV.US9SD,MZ9GIBRZQ/++/=R$8XZO*O>\_(*4I7M::;2'8D_]5OB
M%8];2>F)3FEV7R>G2H:NQD;JF>Y*P%@UW%/U-XDFMD-T^4U@]`*%@'U#J"':
M''P+\&<(7C#F<)#2Z>^K#QEXYXLR>.W/'LNT2U8;#'3GP:JY"5NDC>T&N.0"
MFYH2O:XC1+'(YS('J9,(;2X,P9EA*<X3A>0R6TE];#JEU!5Z0B4TE8=E;DIL
MDNQ.\E;'M7;$#NRPW+_(#+"S=I&?I-YKL<#:&"B4X22"*+[5-)<3A+G]W@=L
M;6Z#^M'?LI6I;D#J[:>^BJ7`FUFF9W#R6Y#WQ=4@Y*6S/'Q\&7-[+?D1ARYA
MQTA:5/K3\C[GIC&%>F`V:&Z'^'FN*4+J7C[=>4?'K1LQ<;;/[1TCK3E+OV.U
MOLJO7G7EOH-GJ9,(K8OMK3<E_D09BS`5)?6J*;97A:'7,^!UCJWZX'7[QKMM
M?V'Q`-W_`,7MD`DC1MDV'K?D%N%JV6G7V9-$[.:_(+<NS(H49:9..`9.?PRX
M]^N8<:9^$A;9;`8/\B_K^\=+[O\`U[$7'AWMWF%9[L)K>Z\M^?\`O#F!M2N%
M3D=5XP^GVNNZ[I-;V#8[O*[?D!HB-,C8P\1BLL1ZDCJE$N,-^!(7P#Z,]&==
M7*W=7*CC)LZ_U.$WK7D5E[0-DB09^DT"G/72L79NO5Z7E9,RZ?G@_J31$D&2
M!>6\R2W,I6IK'O"='P'@/`AH[9NF73?;&=QLDME;!MU!*T-L1,A--PA-A+C+
M_INPIPG:.JLQ47;ZJ)7YB^(!`;18\?EEQK`RVT,.(>7C`86C?4HZ@0H5B)"J
MO(,5]@5AG$RSOFQ-23I;4D*>]+.M,`-1*9,X<;(3SC0K6/PG5H;PVO#;C8=<
M&_3RZGR666F9;DZ.AIZ7(2&YMT,J+%<E*RN(9:C1'*HDH46.GL,RZ/D(??>?
M:PP^ZX-GXL!T#+?3QX-!;,OW^+[,W,71973[0E6U>3(V2LELWI=Y?F'+)/[X
M:!M%6DXE,>VS&CUS-;=)'8"&->6^_EPEP)+-D?7XUSMW2M'XU[)[#.R.W<?-
M>,ZT9JFJY/;.FD14*G5`9`=,5&S`&A`K".Y7TM`*`6HIU8J@<*RIQ2L*;#^:
M"Z$6.)\1>(GC)V>]D.J&KU,,V"6;7?\`2E]"*FHV,BZ]!2$F%?\`2-A_8/1-
M6C$1W]C@^'6&V,9QC`S6,!BE1/J:<4M2;5I>_=0\SN;U`WS0;$FU5K:0UFT]
M-2T3./-N*E38^-F-2$Q(^9,^1D'E-+:=83@Y2,H5C'JH.U>3?UMZES-DJY;.
M4_8WSGWI?:13K53Z'/7:0TR/!TT:V.#-RA<%2JGJ^M0`Q4K%L9#DG5(63(-*
M0I;R7!QE,AS6'Z#+;&<=E<.E=I7,@?B652W=:2^CJSK_`(ITZ)EM>%12(^2K
MQ5A@M'LSZS)AW"UFR2G5G&I<7\[CCJW'UAUEQT^M1"<-KH;L3B1V9<Y=,W*5
MIU8UG+RI&-);#9+UE7I*#DTTIB+NNM)*.CP!B8Q]R+4RVG$2X1CXT.-)<:?#
MI7;WU*=&<A-S6'D9OCG)R7VEO:ZW0&[WC84[3]*#M6$^+1&,`!JI8-*:IK$:
MT%$,CJ'4(Z*IC&499]G]O@9$\A_KS7/EQ7==17)7M<YG[#D=6'SLA1"(*IZ&
MU;`TQVPU(VL2+%/@-;T&NEPD>^EB+3D54@2.D`)X9M#>2\OM!HN*GU]MR\':
M?>*#Q8[6MZ:^J>T;7*W;9D;8^.N@=FDV^RRD-(U?]H3,W@"4FAGQZX^)Z)P0
MMI4K'LG91A>,-8#"\SZ;VA9>7".G>>G)$N/C`5P(C8M)UB%.M5,^J-UR?@&;
M#D)]0HDR\7).J;0/^*AD_+2F''$K(>##[ZX?'3D#NBK<_JKQRY_7?2%)U)RE
M)I_ZZ0XW<>-OPFT(_-'G*I6[/8F[I5_S!B\-5X%\ED`]E@Q(`^5,L.>UW`:4
M?ZC]NIO*RCZQJ?(;?96I@-5R6VP^6\34-.5*+H'(BM;6B937M#;J*;-)[`,&
M9JSLU)NEC84+B6(C_8II+#J4A+1R9^OGRQYD2VIIGD5VR2]JD-2UC-;A96&X
M5:6K]@,Q+3L%8;+)2\J!:6`92;<.K$<@`]8+9`R`TJ5A:W'\N!T1:NA#G1QU
MX5VW@[Q*[%=&V"C[OKD[K^RZTV[Q&U10;;;8R[3T,1MF]Q6X*[8)F_62YU_7
MHY0@;<BQ(J3'O*8P2&KX#!@Q_P!&_6?YB=9&X`=I\'N3NF-NIONOMJ47<UAY
M#Z#H+X%-J(X]1N]"CZQ3+?:+3$'$VNZT]4?-R^36%@11/N:'SE*UJ#0["^KI
MMWESR(SO"R\_-?SM#VO0K1<-A[#UOQTTZQ"1F[68NAZQ8HU&I-(MX-7?KC$/
M3WLG2+2V667XM3.!</FD.)#(7?\`TJ]I_,ZP0E1WER%X6Z"HVL=^;.NU,W!H
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M,N2H`Q;I:5GI=6EQ*$AV]MWIY[9>0&CZGQLM'#?IOHE!V7J;6M$N^S:!H.N:
MWW?Q>LL=<H=VSV>DV"O6*WJV$5#5RL,^]X4T5,VR1\:6`7<+4H,6^*O0/VL\
M%9B9N<!PZZWN=DWMJG('N,'RMA:7(1&KT5;9,J9$5^GMIL$>&9<=@P+4;+2L
MAEAT8%0Z`FS'OB6H@,<;G]?+N7N7(I&_D<!>#5/:1R<QR.QKRB[)UE6ZLV`N
MS0EG>TD..U-/QS6IVRX=:!QLA+,9;,?;4^XPI+*`R)YG=+/;SS9G:`2OJ^ZV
M>(T/1"K9*S">+EQUI0BK^)8F=>`D14XE:[?&2=C%`J!#4:49&N"CC2!36<(R
MOW/!ONO^I/MTJ'#BX\8K)TX]:-PM5EKVTJ]!<BAMA:PK^_Z81MB3F25R\796
M[%+`L8I+DPRW%-AN!9CXH!H<933C;;B`X#QDZ+>W#B=L&*V)-==G`'FF+;-$
MP=;F-;[VO]<.J^J;8%<X]TEL1<Q;@4SE],C]?LGR$L+^6&8BR9'62^D=;>`_
M>SOKR=F>S;%8=E5SB?Q5TM';FO5XVC-<>*'LNOQ,=IB"U2Y7FJWQKS<@VD1M
MFHW)-VG19,89$N"LU\I9;\EA&',IR':7*SJ9[-]WU/31NK>FS@1H(^`-L]WV
MO5M%[BAZ-*7(9W-OJ\7I78LA)6>/8M]=+6&!;%O0DA_+Q(K31(,B)DE(;7%=
M,_8IK;C\O6T?U#\6=O;-O\#?;D=NQ[F'=-?6G3T]M^",H[%"CJE&;DBJK,W#
M4<(4ZE,Z+E49)PI+(:A\.,&**#B]4Z*NQJE3S%^O/`?0O(Q=-TAH*K_[)R/*
MB]4^NW^>&#K$PU(9-C]D5YN-N.@XJAJJ4RY*.2]?MK4JZN.80W[OA#8]U=$W
M9UO2327K;KLXJ<(:U/T>U5TRGT/?DUN!R(D:V]>;U`3LVU<[R7%G7G9E@L05
M;C9D20=16HT-7R#ABK1Z!WIR+ZM.?'*FCTRF:_Z6./'`BP:T1+[%F=AU?E1$
MWG&\VJS7+`AGC>J%U\]7Y"FP.TIB4#=:<))7"1\@*\^_A/RX4D,?-0]1?:=1
M:[9(*Z=/E+N`9.H)NI0;U4Y^CZPEH_=9$ZJ6UYNR3&C]D3U7N<3K)Z+C3F:P
M;&I#*L(O[5Y]3RFVV@S!XZ<(N<NKM61]8Y'?76UMRXV1B;L)4EL&T]AM!BX)
MN*L-D?DXRLU/6DVS=HBG5:O,/,_(RR2\LPMA4@0ITM>7/`R3D>/'("HSV8>K
M_5PU*\.N(8BW9J@]E-5J];6%<J\W(V&OO-8IU:(?CXI^Q&1QZ<B*$R:DI0^7
MF7,/NAA]R:K^T->-:4>V;U#4;K&JTYM:=J85U7RD?WX1L&:NVNYRLRT;#.4V
M$+JFL;%'UJ!;.9G+"-^,6T`.,HL)E+KF`OM>`\!X#P'@=.\B&VGN/^\V7_3X
M7=.[-;>]1<G8^)=*FTN>H6!R\F8]F<_Z7Q._)_R^Q7KZ9"L[].:,R!U:WY]L
M5+(I?+79J&R%,QZ""BPJ-JX64PXZ"0ZI\8<]*TC_`"(;REGTQCW8_GP+8G@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\#
M8[#98"IQJI>R2P4+&I(&$_,/>PRTHLQU(X@K><^JG22GUX0VVG&5K7G&,8SG
M/@;H(6,<,R8&^T4*2VEU@AA:7&7FE8]4N-N)SE*T*Q_3./`X5(;1UY$2\E`2
MEP@HZ9AFQWI6/.-0*1'LEX#R&Z4E[V)::,_8-895G/H[E6<(SG*5>@<]\!X&
MUMSD*]+D5]J7C'9X01!Y4*V>*N6&!<6A#9A$>EW);(KBW$X2XI&$YRK'IG^?
M`W3P'@/`>!7N[<>ZO>75KMFHQ0O7?M+D3Q_LU0#>>WK6+<Y6H@+93Y4J\91F
MQA:;<DX:CZ\.*5DLM027WGG66<.9&=5@,`?JXV&P:YTISVW_`,C1Z#HG7&T-
MLZWV54+!:K[KR+8149^/OQ3!-_-;N9A4)9A'SD"%NSS$?($%M.(<4\ZRZE@+
MAJ5)6E*T*PI"TX4E2<XRE258]4J3G'\9QG&?XSX'Z\#\Y2G.4JRE.5)]?:K.
M,9RGW8],^W/]<>N/Z^!^LXQG&<9QZXS_`!G&?YQG&?ZXSCP/RA"&TX0VA*$8
M]?1*$X2G'KG*L^B4XQC'KG/K_P"GP/R\RR2RZ.0TT^.^TXR^P\VEUEYEU.4.
MM.M+PI#C3B%9PI.<9QG&?3/@?I"$-H2VVE*&T)2A"$)PE"$)QA*4I2G&$I2E
M./3&,?QC'@?KP'@/`>`\!X#P'@/`TI@0<B/D4X9DL93@[RF"&TNM9=%(:*&<
MRA6,IRI@EE"TY_X*3C/_``\#5>!\<#CI(<+2PS@IUEH=TG#2,$.#L+><88<>
MPGY%LLN$.*0G.?:E2U9QCU5GU#[>`\!X#P'@5MOL0O0H(_`60E6,NO8W[>@H
MXA91[(\4^C7BK$[)Y:@*W.VC+WQ5K\7+XC\2R,(60H@\=&<+\"R3X#P'@/`>
M!TWR+<*:X^[U="(P(8UIO9S@A2GE#8&*129Q0Y&2$#EJ8PR[C"O?AIW*?3U]
MBO3TR%:/Z=KCB>KB\(+>&9,.Y;;AD4Q`V)5MN/9;K>M07_C%-,(!#94:RO"4
M#M,*]$^KF%J_N\"V!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\
M!X#P'@/`>`\!X#P'@8*=E_-0+KQX/;_Y?E4]=_)U!5@3(*F_L/U(]@M-EL$/
M3ZL#(RF&2'`(?]_/CN&N-MK>2*ASXTJ<]N,A2%T?_P"?_JGBAQ^[=Z'NGD+N
MJH0=GVON7<_&?=7(!B:U!*\=FM=M[0KVWJTP=;A6S]<S.O"C*^]$F?E3T58P
M&B@QU9<3^(&]538/=3RJX>\G.[+8W+78_&C38NSZ-M75/&BO[AV!2]`[!TK4
M)./K5Z@4UZL)F[?6*K*NP\7!"23)S+TB6N5-+2RE*7GPB[3V(<CK+Q%Y>[!V
M#V\\Q-/\M8#;\?-:#X75K9MVGZ!M/5NS;K5["216[K$+9<'#@AK;).,,,FC+
M_`!;]@J6<K2@.X^-O8?REWU.<PI/DMW=;.X'[7=A)6_:-U/&7V\`Z1!O=TL]
MU)NVNI]O,#<).EYJ:4,$A1T8VX>TI_(^2!R?9GP,0K[WC]E9]^8(O7-#EWK8
M22HM)]:G63K!4FP+97J51\UVV15<NA\S^=%[A#A`9U1#DD,P@R8,,0)@9UML
MD+1FSNQ/EYT1;CW)J7D5R-C^<NO=T\/[+R\XTW+E#:S83>T#N*!17*GCC]8/
M\3/G*M_B\O-Y?.##CD"L$MI6@,W#Z'&E!BAN_FMVX=?FA^/?.;:^Z^3=\!YY
MZGWS!;2TKNN)&UQI3@_9MECIQI^P4"_#N7\]BUQMB-%EZ<.<*2>JKQI8IS#+
MI.7F`PEI_;MR[T=Q5XM\^1.Y&4Y,\AP=L.E[OZWME3M<CVYK3T5<K-KP?#43
M3A)`]R9GH`6.E'F)%<><(R4N40R5\/N6'I"<?MF2VXM*:JV=8Z]%4VS7[75(
MN]@I,38W;6/3SKE6(NSHKZIPJ#K)D@L(.5;Q\KT<$MS&?=\2<9QX'<7@4K>Y
MWJPY(;>Y[7'DYM?LKA..G&386MJ?JWC8)L$QT>LQ?(*;:M54@>/+E+#PN%EX
M:?@IJRRC-B*R-+LR%DP.%AU0ZW$!6+@.O.0W5QXYGQ=,YL:ZD.;G'W=VK#'=
M)4GDBU.:_P"6E6JFK[1:53NIX5N*K4E8]O:OR2F.C\."HS"XAY`$E(YKV7G`
M],#JTXN6_AUP9T9HO8NQ;WL_9$-`DV?8]BV-<6;_`&<+8%_.?NMQJCEP&*+&
ML$53Y^<?C0"VU^T@,9MWTQ[_``)!O`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'
M@/`>`\!X#P*UGV'C:XBR=5458@A)?$KSHB6XJ'G15G50B<S7<1]<+E00SP3#
M)!BTRD>P,V6L>!<8*)1)%#MK:PZ%E/P'@/`>`\#I/DM^)_VX[_\`S\)4#_LG
MM7\U*\EX3D3_``2>_(PK('_783EGU]?A_P!7T_Y/[O3P*T7TYY$)KJNG(;)Q
M[QQO*+=,V,$L$C,:+&BP6K(UU8\HB.;'2^^4ZG*F""G"58]5H1AO&<X"V3X#
MP'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@81
M]CW&[3?+/A'R(T?R`F)RNZBGJ`?9+E/UQDLJ6A`M=/C[#%EV08T"1EY-B,D:
MNR^^&$W^:8PA;#"D.N)5@/-AXF]PUF9T'QQZ[[OR)DM-<9]-[HV6YL;E3N%G
M<^ZM=[GXORT'.4V/XU2?%VJ5<T^2K,A5CV78N'(EA!HUYE2L/!JSE>`X/&]J
MEYXR<9>1_2Y0=_Z4Y)\*]EW2%@=.<L+Y3=AHA==::V6^/9K>EJCC1*K9$NQT
M].C2Q8!`9ZX"8!EF1VS?R!\H#B7%H?B+JS@UR"V13>7/&'4W9CH_DQ&[KX?W
MZL*VU7KA8J3K*,L5)V!2%R=RU4=345O:E<0[8*E%)<;=-E2QV)#`./:*@._Z
M/$\3.0B^QWEGR>YV\*:CR\VLC5?*/B[8]?R-BJ\M3^2<?1YG;$CK,:&LVH+"
MX)0FK7<X^"FWAW,R$G.U=31"%#NJ==##3FELO7/*Z9V/SH.Y$Z&Q=I'6/#R6
M=TH_=-B!\CB+#&ZX`U/L^GPJZ_K2I:XFSV+'K,&6FD*RV-%Q1P[L8L=>'&'@
MDEO',#C]W9;:V=O[F%N?A]PIU?K_`(G;'T%Q]H^Q+?<+9R(H-\A8S7%_J=[<
M0-58=C>,'(V2#F!04&2+3[3)Y@BV2"5C_DAPODEVQ;$[8..'`+AI:;GQOXE6
M/CL%(;='Y)[6V19XV)O.T..VLBZIK5U^#SJR3SKY^_2+Q>`49?F&9"22IKWM
MY:2T\&7>B^M3E)HWCCP/[3]`<'+7M?GAIC>G(JM<L.-EMILQ$$W:OV6T;68"
MO4Q1#@(VQ3EN36;:SF-/%RB#_!;#]0"L^C;P>A'H2T72\Z9UI?-B0)E2NE]I
M\->IZDR<.N#E]?D7(5%D'US.`.%%N+GM=@R;4(<2K+>3"P'"/A8^7X&P[<\"
M##[!/"WD-S]X00W'3CKJFO;5L!VXJ]>K)'6;:<=JD".@Z94KLZ"X/+G"%N2$
MF=99(%H<='QMY7_+[C;'O6D*NVB.D'N$X@\9=3KTYQ<U2QR^U/V1PW)JC[)K
ME\T1;CX;3KVCI.B6*%*=VE8!XY$0-8/PEBQ*RR7R2,J)=2TZ(P0L/0YK<,W#
M1J493ZR)ZD24Z5[$,KD9T@49N2D'6&771AW2G6,9RVSGX4?T1_'@;_X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>!6Q^QRZ6BG\#6FI"2C!C.4TA'
M$+C8N!,3.O2FM[!%#4Z8+G`#O;6YQ)[A$B".G)4F(`MIA"R4L8P%D[P'@/`>
M`\#I+DN^V-QPY`$N_P#JA]);6?=]5$I_TVJ)/.+_`+@GQ3$_VIS_`"TZV[C_
M`-Q4E7IG`5Q?IYC/A]2T\(4RH8D7EYNY@@=6?53#S=<U@EQI6?>YZY;5CT_Y
ML_\`ISX%J?P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>
M`\!X#P'@/`CP[6.4FN>'W`/DWNC:E)LVPZ9':OG*Q)U*MUTZP8EL["<#UR$Q
M.)%GJD@*N8D[>PJ1<_;QQ"0$OK'=PZC&<!0JX3?7JY#SFM^!/9)7*WI7?-?W
MAR*I-\EN$ID5>#M,0>C]D.L2=1E;):B8O91S51IRB"&[*/,@.8"!';;P<<]G
MY'@ZMY@]6AO4G:ZQS4Y]3W!2RR^P.5$0+!];^JH+8EVT]/Z&N(-D?VE9ZY3S
M[3K2RP4=K!XQM5>`<)=CVSQV,OG*<4VPH,)MS:-IUNIX_<'":=T!CC?N?L-=
MT5J'A()3+;2Z<-JFHUBP"5YNU(UO?XNRUY<@%!AMEP]>=D29(]LDW!#33>1B
M`S$[DNL/A]J#M`TK0:#M#46AN.V]H:ESDG!5[+&O]=:BU_KN)9H.S6)K<=IL
M%RA!MW6J_:ZM38PLC"QD9B24"V2[AT@E307'-,_72Z3-DZSU]L9CA_$6-JRT
MBG2$+=UWS9\(%L.(:"%-@]L#4R'V*JN02-H1*V95<:Z&/^.P7AAX,=U+B,!V
M`5]8_I1)#9$;X;@!_!#XA4%"[2W!^8IG+B'2#GGB;V3\\P3GWXR6O"GVDN9P
MRIK"&L-AN=6^M=T[4>VU*[5'BPF$GJ1/0EEK[N-B;"EAV9>`LS-G!=D![!8Y
M=$T*M]M0CXQGSC$1[F6'&U82WEL)K8VG"1-JE+.!('L-R\+$Q)D"EJ*_5.$P
MRGFQ)M968W-A=DL1RT"8;6<H)MEKW(82\X\ZX'+_``'@/`>`\!X#P'@/`>`\
M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>!6A^R#FSLP/79(QWZF2J4/S%%E[I5
MC3@F3YMD&HF.0CD;&+L%0EIO+9_N!_'"D7W'"I,=O,5*_(EEL++W@/`>`\!X
M'2_)`?!?'??0JLX2DG2^TAU*4R.2E.'J/.MYSD<PL`0C&,*_Y'7V6U_T4XA.
M<JP%<3Z>;(C/401@9QYQU7*S=V3L.K#RELI,1KQIM#+8KKRV&U`M,KRA[/R>
M]2E8]6E-JR%J/P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X#P'@/`ZCWGH73G)C6LSIW?FNZWM;5MB.KTC/T2WB*D*W-DU6PQEJ@
M<2T=AQMJ0&!GX88C+#OO8>RUA+J%HRI.0BC[&-0<T:71.&/&SJ?G)7C'66M@
M6.$V:5KK55$L6O==\>(JJ%.R+80UK&%`@K%%SLB*NO1$=(Q!,BU@U`KV'AAT
M>!2P'X]]W&_.QV)Y3<\>K[8G)PS8%CK.NT`;7U]L(S3VD=66*W`P5A>U[7ZE
M=H\.LHK=,D9+]6Y(%DIB##%RZT.R"4E>!NERZVNURT2FJ>IDC@Y(:HXC:M[(
M;5M;5_)B-UYL_;57I\+L4ZP,Q[EHMH<^(QL'4\+47A5$R"QPY!"0<((*0XK*
M,AE;SYF._P!["*_8^L[;?"0.PZ@LW+8VJ@<O:?HZ^T>LX'U]M:V&Q\M4)"U2
M=2@0=.P4!'.C1#\TRHN6#%97F5*(,;=<"_!QVHL_JS16GM4V?]8].:LU;K?7
M,E*02R\P$X?3:+7H*1F(!J4,.FQ84J2">2,V>ZLU+:,9=4O.?>H.YO`>`\!X
M#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`K@?8EE8:)@
M^O,^T2-&$JD%S%$M<['VXU^/D[*/%46<B<UJH$"1\E(?N)0:QO86D)O!F6DY
MSA:!\$JP%C_P/XKU],^W.,*],^W*L95C&?3^,Y3A2<JQC/\`P]<>O_CX''_Q
MK5_C'XG[F"_S']1\'[[_`!X[_'?WOXWL_8_XO_DG[']7^7_?^'^V^7X_[/R/
M7^_P.0^`\#I?D@[ACCOOI]39;R6=+[2=RU'E?@GNX;H\ZO+81OHK\,M>,>C;
MOIGXUYPK_AX%=7ZB*DJZK9S#9<]*,-\I-O-B3$_+"DDR0J8BC?&ZJ"8DY)ZK
M/M*RI"QWLY<?1ALC"\H=2VT%I+P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P
M'@/`>!A)V#<\-4];_&R<Y1[IK.PK70*]::;5)*+UA#Q,[:TEW::9@HPMB-F9
MRO"/B,'/HP[Z$?)C"L>U*OY]`@.C_N2]52P<ES="Y>PS[LD<,''HU32#R7(\
M-H'")0EW&U!0ATEG/D,(80Z\ZC(BE.81A;>%!J\?<GZD\YQC%4YBYSG/IC&-
M-T+.<YS_`$QC'^\G]?`W%[[AW56.6='D:^YKL2$6\X/)@/:-I;1D<0RZIEX<
M\9>X$O"/M/)RA2',)4E6,XSCUQX$XO`+L$U'V+ZMM>VM.T+>6O(.FWC%!EH3
M?FNDZTMKDL[4*K>PI`&$3.3WY,%)U>Z1Q0Q/RIP\T0E:4^Q25*#.OP'@/`>`
M\!X#P'@/`^)+""AR!7%/H;)8=86L8A\0A"'FU-J4.4*XT2,^E*O5#C:TK0KT
MRG.,XQGP/VVC#3;;:<K4EM"4)RXXMUS.$)PG&7'75+<<7G&/Y4K.59S_`#G/
MKX'[\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`T4E)1T-''R\N>%
M%1,4$5)2DI)%,`QT;'`L.%&GGFE.-#!A!C-*<==<4E#:$Y4K.,8SGP.@Q^7W
M$PM#+HG*'CL4V0X:R.X/NO6KR'W8P1L^1:96W9E)=<CP74//I3ZY::5A:O1.
M<9\#;_\`O5X;^N$_]VG&;W9QE6,?[\:L]<IQ_7.,?Y5ZYQCU\#?1.5G%T\#$
MJ#R2T&9%Y9>(Q)";AUX0!D<=;C9#^#&;$L?++#C2TK5[O:E2<XSG&<9\#F-3
MW1IV^RK,%1=L:TNDV3%ES@\/4[W5K'*OPH!`09\NS'P\J86[%A%R8S3Q"49:
M;<(;2I6%.)QD.R_`>`\!X%;+[%<34+'%]?5>N@1!4,5RDDY0QYA^/%R+&0=)
M(,GW4'&%1SL.4Q`+)(9/0\\T(L?U>#+0KT;"R;X#P'@/`>!T9R@0.YQHY$-E
MON#"KT9MM!)+(Z3'AQU4&P)>?:$60(@IQIO.5);RZWA><>W*T^OK@*]/U#6H
MW'41&DQT.)$X>Y&;G9)4VDE1T@^&NM-9,DB29$W+COMSA"&T-"-LH1A/QK5[
MGW@M$^`\#^84E658PI.<HSA*\8SC.4JRG"L85C'_`"YRE6,_S_PSX']\#X+*
M&;>0.LAA!#GMRVPMYM+R_?\`)[/8UE6%J]WPK]/3'\^W/_AGP.&;"O;%!H5L
MO;%:MVP,U6NR=A9IFM8=%IO=LS',.NM0=/@4EA-RT[*/-_`,VM]AG+JL?(ZV
MC"EI#D\5*-RD;&2*A3(MR3CPS\14LTV)+@9,8;?R#(AI=>P/("*7EMYO"UX0
MZE2?7/IZ^!N?@/`>`\!X#P'@/`>`\!X#P'@/`>!7^^S-L.Y:BZIK[M76_P`8
M>R=<;RXVW+7=F6"'(KI%T@]OULN!MPP\H#(0^2HPM.$(R:W^+ZO>B_7UPE04
M\-=_79K_`"GX#T7GY4=T6#7+Q^L]C;?W)I"1H;ERN$'`ZPK=ZK]UO,=L7!,&
M%:K+8=HT-N5_Q)B-C<#PTFZV$IU]ME1(2G:SZJM$V#J:I/8=/<2^ND&*!XF.
M<E[36)KCWR>#MY8-;HDC:'XIZ98YH@QRQ\O1C9?[+++:9,3'N=80V^MOP.G.
M!'UB=>;!TAQUYWVGD'0-I:#V;I@+DW?./EET98:F@N7MVH[@;_@HEUC-G&S"
M:=KV<FPB(Y;PRG'W@G'%MXPXG"@L8?7LVY,;TXQ[NV=/-5<&4F-SZSA"(.FG
M&34!!8I'"SBC21@!I\\.(+E"U!0#3IC;@(Z@37'A?>4EE)3H3Z^`\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P.'[#`:E:
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M#=I$6?,2Y1HLJY%K?0E.9"1;<"8;ZTNK9;57979&+'`ZBJ4M9."^V6&ZOK/6
M$MK9(Y5%Y'ZKI5PDGT6C(5OECHZZ0QM9FDR(8+X,_6RVF@_Q%#2LN%]?P'@/
M`>!73^P?-+KT)P//4P`.*;R><AG)V8R*N#"-;KC=PAH:88.`DPVH^S2U-:8)
M+=9<;##0^M2'<9RRX%BSP'@/`>`\#HKE$A#G&;D2ASY?C7HK;B%_`WAY_P!B
MJ!8,*^%G*VL.N^W/]J?<GW9_CUQ_7P//;Z2>+>YM[\!@;1KKC/S&WC'S6U=J
M#72=XM]MD1Q`ISDEDJ/#3`['T9(7*.1&WAN+0EQ3Z`61CH4H)[&7%NNY\"5"
MP<+NT2,N%B=U[P6[!1Z`-K>9JM0,F^_J0%V,47*`8G7(6TL1^Q)B$9J^+L\L
M;)$>5F47$CCNXRDO+B/`Z<E>-O=M$Q2)*0Z_N>$Y^XAA8T@*N?8'V,Y)L0+2
M8MS,20'F>*>`E,E"!*_(;4E["!7T+ROY%J\#B4EH[O-/R1+E\!NR!V4E0S<I
M(8[V[`*['RDB*TYB1_6Q_P"()E(L?)_A8&(0\A.!4>F</MOO/A\R-3]W1$Y,
M0!'![MV"-KYK$ED^%[PXMZJV&R/?J:D.O$[*4$Q,G57?R!I`IN->&>80(ZZA
MQIG!"%AP:<XK]F.RKG5=@W?JR[6[7LW6!$V=K[;]P[@=2E;,U7(RMDCI&6BM
M82$SIIRORE?+FK">0T_+BR1S`I3V0R6F@&4M!B-:NI'DH0ZY#HZ>>UJL?KR'
MC"F:7V8<;["$\1,X=0^U'7&9XV3<U*0J4B9S^&X>\@=QS+JD)<)6M8;7`]0/
M),=[X\]4W<@AF96BK+1CLRXW`.C?EIS+,2#_`,?&6/!S$@/QV'?>60D%):6D
M.^CBFO4./O=6?(]3(PA'5GWG.QD?"ESS(_\`Y@.CB$AX?RE)P\>#CBJIK,B6
M<PCW"-Y3(O-)P[^/G&,8\#=P^O'FF!'YCW^!'V`X.KBR*1W(*`YWZPG&OU`<
M;"3`T*)%LZ!B&WFW%1SKF#FV%,,%('&0RX0W[?`Z^8X/<Y1V*^#2^(WV*==R
MIDBW6@9-K=X%AC@50LS5Y_\`$>CA]9:X3#0,99PVBP9`J0$CWR1F3&EX6(YA
M`;VUPYYRMQY(-)X__9:J\H6Z7/?FF;#:5%YJ\*(Z,N&*CF(6J_D6)&8=K`JE
M&(?(;::;8!<^1G.0W4;B_P!B(4^2VSKG[+_N3E]B6BXS<C6)YV(:B(_Y@R#A
M%$90T\MX%3;K@BV'66OQT-K6GY&@Y-ICB'V,;%M8E7#D?L%:[,@#*!6QX'8^
MY9+3YAS^W#9B,`D6+=-*1&0=%(LE#RB5D26WV89O(2'OE]R'<!F!#]2G=VHH
MZ5G]I]PJ9-+R8;W1O8[QZ1^3)2$>EMV8"$=W@5&/5P1IU2'<NOAN84K_`$W,
MN-YPH-`CJP[V8B,_9US;_<'&/QL@Y#,!G\Z^/=DEOU9;$\E$RU$JY'Q@)[([
M\R[[VLR'RJPOTPMK"&'<!I+GU[=VVLH4^P*V]W:LUT6M&7"XEPO+OCOL(T:(
M9J]WFID$:+:Y)P,BS80RG24*%%07ZY6PTPIYP@90P<;9XL=\]KC(JPTC>/>8
M5&6*,!N-4DC;YQR?CR&]@UF5G@I`S/\`WIP:F4/04XA)(:FV_P!6<I0W]KZ6
M?:&-C$UWC2UEL-6@^8/<6B5JW(&$X^R$)+1FGAY5K>-F9*+BZ:*Z]S)$$GP2
M6A#7UF`Y?@A1PB''GFT#N92';3.N/L;O764UZWR#[FO\N@ZW!V^5`=JNAF@`
M*[9):QPD))D3SW-1%>PR=)U*11A'Y67$(%4XM"6LI6H-9KD3[%VVZ-&[<IW)
MCMQF-56B)`FX&YP&EN/4VN?K\D?*!9FJO3P>6(=@F`W&99TH1P%A621$,NMY
MPVR&M(<D:S]C!MZ8.MG(_NAJ(LM#-2B2@NO^@7U#A*K"C!<:+`Z]W_*E5-]G
M(JEM_CL,NN,-Y1\2`R&UN!R)5L[^(\D8=OF5W0NKQF.+QEWIW9.;PMZ'#CV$
M+>QM`\5YO$:]E;S+J\8P<GY7T)+^1UL-LONN^R_EK7;=HGL:W%W;[KXQ2X;Q
M=@UOJCJ;@->VFQ7>)*B"*<\S/CGS<#(5RLV>-:D7Q5D,LF#C*^%Y#C^?4.VJ
MK3.7NNM9V?159VM]CZ.X@)@VJ37*%.]>^N9V^0&A7*E:,;MJUAL]F,E9.>LT
M_:+"&W6#1_U^86MLO@LM&9:8P,'9=?H&R8?C5_V3UJQ?9+$XJV;1K^H1],F=
M<7%`W#FLYFM0%5MT2/;92*Q:XN#EXRS.M89P2P8!^?GU(4Z(0YX'8%;+YL:T
MU55=%T7;7V'HG3];U8UI*O4J6ZH.'ENP!!9KYM.@&,S^91BP-Q4%6716$+*)
M4ZAX7#SIN/?E"0V'5!/)W3XL[`Z/W7]CC4,?:"Z=*6(BW]0_'S88DG/5FDT#
M4`4JIQ=8D)49B/US08D;`[.4H2/&9<]7R5YP^&1\!O3GD(^&R[S![WG6,MH.
MEW[-TAZ=-_*P**&EV(B'8?73;L,9($H)4A;C)C",/-)4O_14MT/G,<TN?M24
MT'(\I>W-*I=.(J#=E.@2DE$KDFI###9SK@\G&M%CR!$X*REK#3#N$L_W*1E6
M%8#;9CL?Y(..+"OO8QSWT4RX.(_&BRWU_;<):Y`AZ.(1(H1*"(V97GP0'#AW
M<MX"8=;=^/"7GD>_U#D`G/OD%+U\24.[0.>T;D3-?LA)4-]?R]A^Z)E,%PL&
MP:.]1;<([#6<T9Q[U9>4MTI'^DXRUC+/@;T;V*[WAT#LR'9?S`%6G++ZGY?Z
M]N[\/E1:XE,TW[E"0H`N)-V'0LM;Z&TCX:]<X&1A.<>!\(SL8Y!RY3H$=V7\
MKCCFS3AUB"?7CW^ZZQAYQYZ%$(PH='L.'`6SDK.?:DE>%K:2PE:$H#5Q_89O
MU\14W*=JG(."K:XXLP*2F_KX\@(EN04VF'^!V/*6@QD\=IR02AQ"6T+<6>&E
M"L>CF7`WL7L0W04Z./']SM,8((9%>4#=>C[E%"RH\;'B%))E716K/%Y'3(RC
M6$F$+3D,=*V&FOB>>1E0:2N]F&[GHENQM=UW#^V5R`_*<GIQKJ#Y8K@WFB(<
M`X;,U,P>YV0(E(01C,@A3;C&'&2D+7ZLJ;\#D,/VN[``%".D.X/@W8`HP']G
M)FE]4W-`,21C2`\MCR1Q45R`%8``^1A9"'F5-M+SA6/=E"?3`:%_NJ?;><=C
M^WSK2D52KX\9"QIW73S=!'S.J7D`*(!("Y'FF&DS$EA3:F_1Y]#J,(:;5G.4
MX#6D]UCF'(ED+MQZPTN311\?&N3O7US=@0S9&/:%?,$$/)Y,."/JCV2T.%_W
MIR*TM"W,82O&?`U^.YMYL0(XSN&ZF1Q"VQG/D3PLY9K6Y^:)^R!9`8=Y7LO&
ME&QCK+S+.$I>=2Y_8G./;E0;Y&]RI@4DH"4[7.H>1=/%.#!:LG'GE)J/`$N$
M:*R42DNP<A9X29'"$,9=R/[A,NX>0K#J6E)=R&_J[DB$J+BQNSOIFEI$Y0ST
M`='5WD*40VP*R'F3$+JL7MV7>D##C)X%#&6Y%E;#+)+GPD9;>2*&DL'>#6@7
M63QNR3IW`BS8R-FP(Q0W)*T'YC$R@D9*_G2D/:0%`RA!+F<#A.1R"VF7<OK;
M6RPM;@;I(]V=>2^ZB-[(NEKYDG*^".+N&\G,.1A'SBMJ<EQ;*M.2(MYUI_"V
MQ,M27Q*8QD/Y<$-!_!N[:LRQ;GZOLBZ9&!7(MDX8>2L.^1R&4ES0\<.0069:
M8IIW"?RD,N#?"T\A7N(5E#2%I2'(`^Z:JY&DRR>Q7I3($84R0P]_O-M*$*%#
M(COV>!U1)LL>5-GCB.LJ]!U,K=<4XSEIEUK.,AJF^ZNBNQX.!>Q#I6(EBXIL
M]"93?NQZN&YG#8^',ELG/GF0+[KQ"5(")]Q:6_=_"_C6KP/X-W3U-]1^/_,&
MZ0O4-G#3*%\H;\-@J6PK#JQL/$B(3F*4(ZWE)K"2L?-E;?QYRVKP.(7GO$NU
M/O<?'T_8/4KOO6:ZW*6:QW>A]B50HL[4W'J]-S-)K3E)OX.)&QE6XH`,=L\)
MSX&\G^[+&/@7C(=G$]TZVWK7'!W?K+DB8\+5S55GFNPZECU2T3^P3%$WF-CB
MW*JX:0]QUI1\78+,T^V`F4CY-M,8\M_&6_`W[3'</*;;K:IFPW'J[T?.`6:V
M"G4R_P#9-4;/(RE*KUS=K$;=J_/:\US.U@B+G<"/LIS^2ZH>1;<8=1C+*L*#
MX&=QU\C:.N\D4GK[+:D*)KF\5F`:[2-51LC,%WBROPL]1!Y:2U:FMF3^M:X)
MFRRAK9202(LP9@7Y"\J1X&30G8D3,,FR=:V)UB6*N!Q@17^1`]CPWX7[215\
M@,*4E''LA("BX[_J&GW'/:O']N$>N,YP'#*%V7[`N%9IL].QO77KF5LRF%3=
M)M79K5C+32&2%XPAN836]"S$-)2B6E84L4,MSVYS[/DRKU]`Y%9>P#>D&,.N
M)U=PCNYCEMJE27%4_L7@3)MPVSG994S%1$IH"(7*3($/G]LF.^5DHN/8(RSA
M3C:$.AA=:^\3DK!V6&J]0ZWZGNP^:KC4LTK3W8QQ@EW&)Q4_-0;M/S$VF.J4
M\?8,"Q3,HEH,4E7ZT]I:L)<;(0T'!\=^O*X`22_R7J"ND)*0[CX,L'GGMQ`6
M)%S(2QQI&+E#)&:B"8UX$\X9EU+HR7FU$(PMM*E(2H-ZB^]WES)QP$H/TV[@
MD@I:11&Q1U9YF<4K/&G$+:*<2AJ0CIK#/O1B/*4Y_5MIL=:U+QA*_:'(H#NR
MYO6?!"X#HTY9S382(I\_,5OC0Y[H@LXV"1$DNL,D>]+4F!(LE#J5[4/"+P^E
M7P8RY@-:KNFYT,OO-$=#/.=+:2$-,N#;`U28IQO(D7)K6XEI&&6W$Q<PRO"4
MN.)41AP?*\.,O_&&Y']T'-.$-*!G>B;GPPZ)AC#RX6V:?L@^7?P/VYJ6#(R5
MR"4TS%)4II;3J_F*Q@;.&WL^WP.$2?=IR_MT-/UZ+Z+NR./(D:_,`KEL-4Z/
M1%/E1LMA!(L@X\`TM\<853K7L(:?61[6F\?(MK*PAVZGJ[V&=(<UMXK;_7/R
M,Y8QW)/5/'"UU&1XU!U>4QK46/@-F3]EH>P\6$>(LP.SXVS3:TS<9\7M9+4H
MAQ2UDC?.&47%+GAS2XI\G>>VYYCI>[$+5!\]=Z47=NO*M6J/502J5"US4L12
MI`>W-!3$T");IZ4B5$.)6MA93:</*QAQ66DAI^"G8WRCXGV#F+:)3I;[2;MG
MEGRRV#R>%1"Z-A@\4\6]-1`"*45**B1)JV$03,,[E,D4<2TZGV,#C`--J:P&
M+O`E'85UO\C?^^+;_7IR^Y`43D_K[E!%Z[TYH]V7V9M3CO&;!Y,PV[1:ANND
M76ML/:PL&733G'5BSKI,\\XI^02\X,TIL)L1>^3>3KN,$=&O;@AC"'EN.":/
MAC7D?&TM>,X8_>#IRCWIQA:LK3AM'JK/KZ>F0W!_OFV;$"O%V?I-[AH-OUC6
M`<XXSBGI,/)86](BK4U9&?Q$@I97EMQ6,X)0C*O1']/`T\-WX[%D94(,WI2[
MA(^/(R(\5)M\9QC?PHYT`P@P[(W^1C)=_$*`=0E&748>91E["L?PC(;*-]B)
MX;\HRU=/_;_5X&'>>%LTX[Q2=D6($S#%C'$'<'%L2'2_RK#6GP<K1G"&L(6\
MK/L1C"PCP[)>S8?E\=Q?@,<-.7?%Z=UCN:2G)5SFKQO;U_6++#W&IL5J.BZ5
M89%V>%>L?ZJTCSQ_L>8<A(45^1RP80&TT@+IO@/`>`\!X'1_)QUUCC9R$?9+
M<CWF='[8=:/96^V\"ZW0I];9;2Q?^I0X,K&%IRW_`*F,I_M_GT\"H-]938G8
M*#UAZZ!XEZ2X3[.U;"[MV[';!,VCR&W'K/<#US,FY*9DG)B/@M!;`J48TU"3
M%=R$MDF04\`PO+B$O/\`M%"P:7N[N28='0/U_P#"PYMUEMQYYKL$OS*17%N.
M(6.M!/#1IQQ;2$87E2,91G"\8QG.<9Q@-4K='<6EQM">!G"=:%L8=6[CG]L;
M"6G<EO#Y&4E7"_#BEX';2_[DXRCV.83Z^_"DX#Y+W7W'I6TE/`7A4M*WTM..
M8[`=A82RUE3R<DKPKACA:VTI;2KVIQE><.8QZ>N%>@:.$Y-]I&)YZN6?@[PW
MQ.CB0\@77*UV)21=DC09.5=!;?D8F8XI1;[3<@RPK\%Q.%-$$9PW[L9PKT#F
M1>]NT[\EUL#KVX\9&RHET<D[GF0W[1V`TK9'*:&XOOKP><;G*$?'A;"$8]RU
MI_IX'$2>1W937/FN-YZ_-(UQD2(4*<:1V.Q85)&9>-4W%@N,3/'^.CFK5)S3
MC##9:V4M99(0U\_N_P!+P.6XY,=D[@BR!^LBFO.*-"P(A'/'6JF28D@ME+Y^
M2$ZF]C9(X"EO89QA:'%82E+N?=E20_!')[LH:QG+/5O"DY^=UOT;YV:@;]6D
M(94V1ZO:];Q['E.*3A/_`#XRC/KC&,ISD-M_[G^R"-4T(UU;Q+F3''B&DO\`
M/O43KSI16')$T=C]A1E$+P(XXYCV(_TFD(]&\8:2GT#80N4?:L;:C#D=8VO,
M:XS2%YAQ1N;NKS[>=L7$Q_IN%3+=:8KPE'S`_P!N<-BD'_F8SGU^/T3D,;:A
MR#^Q7D6\XOG7[P328JF'YUJJI\DIG`S.P<2\/F,3=T2TXXZ74%P7[!+_`."I
M@S!?XZDYRWAQ&0Z[3R-^SLH,<A77=UX-E$/?'D!7(JQ+=$;P(<0M\TA%[R*G
M'S"M,H2RI_*G"4YSE"$K5@/WGDY]FGT8D<=:/`G\-Q3B7*]_W1GYGV?@!(5E
MQR4_RO$+A!9H^/BPA+BDI>;0O&/1;J0W)KF7]BW#9`[O3WQE>+C'LBDR#7.&
MJ#1TXI1,A&MG003[3A@P*"!VC5))<RYD):4^F'5YRT&RY[(N_<$DX4OZ_P!%
MRGPF/(&,B.PO1XX:Q4^W#7MR97WWB5>["L_+[6<*QG'^FGTSZA\'NS;OG8=$
M97]>HA2C7UCM*8["M'$--N(&(+RHQYBI.-`L9:&4G#KV4-J=RAO&?>M"5!K1
M>R[O94='@'?7^5&X.R;ZE?\`?WI^1"!8"8:<^8Q^+I!33.277DMLM>ORN*PK
M*4Y2E6<!\D=H_=$5G()_UZ]AEN.C,9P0+S5TRS'OH/:>RA27I6I@O"86"2CY
M&WL-D#+6XT\AM:%8\#YE]MG;O#Y<_8_7IWV0`@2,;QF#Y1ZOFB/RR&,$&#9%
M!I1#CH@@Y@Z,.IPK'SX?0KV_$KP/P9W+]EXCAL7%_7IYF9*C(V0RE+NU*4U$
M_GY;R[6AA)$&DE1YX#X^$X.4*XXX$O.6TMNJ3Z9#]H[N>?64)ROZ^O86E>4I
MRM*92"6E*\XQ[DI6JGMJ4G"OZ9RE.<X_X8_IX'Z_\[CGQ_\`\^W8;_\`A*!_
M]Y'P-_1W><LQ7&VYKH=[/F,(&GC3'8:GUR9:2%%D138#X'Y&8=\QT\<LA;C#
MB!B&5--);01\KJA@VR.[Y.0A\R@;/17VQ-P:``9,Z13J&)S+L@F2!,=\@D&4
M:$&>\EQ#6<,XD&WO1;F5I0VWAQP/V#]A"<99EE6KIE[EH,B*LF*PMJ,XF,6)
MI<@H93J&E/HN,8O*UNC$)][+;XN$-I5E_P!7$HP&Y!?808D7R1@NGWNG??$>
M0.2WGA>.Q\3RUN-I1\A.Q66G/5;*L>Y"E)QZ>N<^F<>H<P%[U+`1ZNKZ;^Z!
M@-IUE)AB^(M<6D1EUW#:B%#-[8482EK&<JREEMQ><8_C&<^!L,AW^?A-N>WJ
M#[GW"'7'F8QMSACAMD]Q<>X?$J6^S?BE@L2OM2CW.-^X?*O]5*<XSCP-B!^P
MT$MZ5;E^HGN8BD12`DOO,\+SY-*37V64F`N)9MC*OD#D\O,)<:^9EU#6'<+3
MA>$X#<W/L,4]4JW'!=57<X>R\.(ID]O@M.,,.&DX9PJ.^(NWL$H=8=<RA3BD
M89SE.<X5G&<9R'8.>\H?_%6;:WU:=M!`JMD3&JC8(7BS!D72$M<&!4I(UZPT
MYO9N9V$J[XMT#_#F2&D19SB"$,/KR,][`Z_3]A:H+B0)Q/59W++BI1U_]><U
MP>E"!R@6LDX;DVUCW-W.!24L)4CW8PO*74Y]/3"LX#=*Y]@_5EJM%;I<1UW=
MJ*;):K6FI10\MQ6BX&)R86,T]"N&6J9V4#58UV;(+&':&(-:*;>*:2ZVWE>/
M`X'$_9@XT621Q$U3@IVI6J1>QD@`&O\`#>3DSI&,2<['YEA`A;@X4L+\D9U'
MNRG&<.-+1_SIRGP-&U]G7B<0L%`O"[L^+2<\M+:Q^(1[F/Q1ULI/.;2FY>\E
MB.2M:GL-86M.&LX]/7*<9#?WOLD<8!*.]L%SA?V18J+=YMFMG#!N,D484/;]
M?JHR+Q%2T(#L4B9@DU@7841\KYPXX[KI&!F5N$)6TD-(1]FOA6'Z8/XN=DD>
M,6^2%#$&<.;&PQ/.AULNVE,1F%V/W.N#UL;!RVU82I`+N"58PPE;B0_`_P!F
MSKZ+0*H;0_/TAPH$>P1X['#BUO/%PCKEAPS90OBEUM/1&":M))P2E?MRX"1[
M<Y_'?RV&AD/M"=:D=*L0\KK'FR"^D<R0<7(<1[6+@`$9N77)R+X9,@B42&(/
M7S%D.MCK2AL1[*L_Z+OL#29^T;U:_P#7Y72^7F!X5P',J2OB=;/QH=!8Y[\<
M3(Y_)RL!HB/ARGF<N)2M;`CN48SAI?H&GD/M"]3Z2A"9JH\J!Y1M$DF-_;<2
M[:F2_7)2`Y.&`N/96M,<PPRRX9[%X5A#",K3GT;QD/H!]I/J,*D)`$1GDC^=
M!^CDVVSQ5O+I$`S\C[2RI=@05XR/9:4.[A65HQG_`$UXQC.4YQX''9?[6?4'
M#GYCUQ?)8I]LXP$SX>,DP(H!P!EDLETP>8D8LU"6XTELI2$M+?;&<2I;:?=C
M&0XZK[/?2D"8Z?)T/=T"=#L,13Y\IQ%(&+BHT7\.4BQGB6E//@QREN-/C,YR
MGVJPESV(]4*R'P>^T]T8!DN9(1LP4MP)H!W+W%L]@E<<V<Y)LA.96TEU02))
MQ1"6\_Z>'U9<QCWYSGP..D?:`Z!#,N9+@[45ETQ,B[DCB4V_ER00*@%!SF7!
M5968D)M+.'<^J\-)PCU]N,8\#CEA^R?]=6W&FR-KUT_9Y"2('+D3[#PNB)HV
M0*$:(8$)-*DHLE\H@5DIU#:W%*4A+B\8SC"L^H;Q7._[ZSY#1TRS6-<5>0@A
M@Y$%H_@P2+,'%.M+>R+!.P^MI!O]D`XCV.96\PW[\XRVXM/]W@<Z<^P1];D-
M<K&LSFLUB14/76&5"<,+;B.E0!`U3L5"Q",ZG:RXFLGDN-88=;99&.RO+.<I
MS\F0VJO]V_U?)I;#J\<<:\X:E+;RYW@I8!7&4,(+?92:H'2!ZO8AQ*L(PG*\
M86]C^GN5G`;B!W5_6!D7',.%\901VU0R5F2/"*;;;R_+QDT=A"!FM)$2;WZI
M,'@<QU#"F6""QF_>K#OJD-5"]OOU;"6D&QLCP^CSY08=\@,OA',0AN,+8%;4
M,>6?H<.,0\(.RA*T9)SC.&O:CWJ]N,AR&#[2/JT6>7;CQ++P/&.R>,,V5/\`
M$!ZL1WY36<E#$*FK%HF+BFQAUPR,X(6^EEM:6<>_&5MX4&ZK[`/JR"R!\?BQ
M=;7Y,?$/OD.L<:JH^`['Q["YE0@,JQJ!R+DS,^[.61!GG2GR,_"VVM[_`$_`
MY$QS3^KP^>JO-7'J]0\U'A$Y6[J35XL5^,Z,\V(EN?(H+,*N0'&0I"FDDY+'
M]<)6E&5)QD/X5RZ^K@)\H[EIZJ\?B#`OY4#JO3Q'HTZ0V$*D4F/HSOS$,K!1
MEQMI:G6&DI<<2EM6%9#12?,_ZM>`)%,A:.KTL..4*R6PUIG6DD\1E<FJ-94&
M*'KLDN;P@P/#CC@R7\('P@ES.&%(=R&G8YA?5E;6R(/9NK]C"ILJ":0WJ'7(
MXK<@*TXMXG+N*`V*/#+0I6&Y-2DQS^592V^O*O3(;H5RF^KDLZ,P]<^K3):'
M?R@'V*9J?X1W8U+"VED&"UC\05324HPPE]:??[?:WA7MSC`?->_?JUO#.EKM
MW52MGW(`=QF%T]\V?G+-F$H_&_48)4RHUQYW+F$>S#BO3*L9SC&01._?JUM2
M#>8RW=5(YQ+JTH=5"Z>&3EPEX=]?O?*B&QVL./BMJ]5*3CU3CP-_B-I?6(G0
MI%J.MW56V!.9_%E@"B=*0+$IAU,8RWD^+DDQR2F5H-&RTZXUE&4Y]R%>B59P
M'+"R?K4-C/!'6'J5(&)AY(]YHRV\<)!"XL1</:9)SU?EB/8\X\:(0M&,X?(<
MQ[<86II:4!S>,G_KRGR!SD9?NJ[]H$3%2A)B=F<<0S1BR`_RH<P.1>L;#S9`
MH+^4LJ'<PH1"U-8^/U4CP-2.=]?%/SQ`6PNK<-D$>/:5'@;@X[1H`HR5R;X#
M(;`MN&!9:;=D#%X0QC&$K)=RK&,NKRH-M"KOUUXU9SD?9.J$)<FJ17(K%VMQ
MI'4>[,,N#RSQF6K:G)+\FPZI!#B_<MY*LX7G.,Y\#ET#J?H6-;-<J[/6H4RQ
M&_+(N5^^:&=;:AYR-DB,K-7&V5241DS#@F+SEST:)&9>SGW(2OT#?+-K;I2D
M9^&$L5MX6AV-RPLQ\9&HY!TVO2,U9!,C.-PQ<5';'C7+.>AIU#:@2FBO<.0M
MI3>6GW$+#YYT+TM;"DTRK$WQ.M3<D1"0[\%%<C8X^DSSPQL5`04)+4"+V@JC
M6)+AP(D>V&7'$(?5A(V4+]^4*#EHVG^I>UV-W]3==`REAUH*SB5BZ[RB,2JL
MBPD@^[E=LKT'MAL-+8QK*VB%R8Z_>AKX7LJ;1A"0A6[B-*\:/R>MD;B+4M:[
M;BC.8<0%?V(W8]LVM1(FD/2]6HY]QV'F%V4863#5*\FQXJ5D.NMMRQ'X^<9?
M(4T\%OKP'@/`>`\#H_DYEC'&SD)DE]L4;&C]L9(*=%R<T,QBA3_RON`I_N,;
M9;]59:Q_+F,>W_CX%<GZ@U6*@NK*1=EHZV1\N/R-VY"O(L*A1(W#+#=6D4MU
MJ+#]JOUJ<GI4\29\A2CUDM(5@=II/@6IO`>`\#:9F`@[$,.'/PT7-B!RD1."
M#2P`LBP+,P$D-,P4L.T6TZAF2AI<)DH5].,.CD-(<0I*DXS@-V\#12,;'2X3
M\;+`!2<<4G""@)$5@T(E"5I<2A\4EMUAY*7$85C"DYQC.,9_KCP-4VVVRVVT
MTVAIII"6VFFTI0VVVA.$H;;0G&$H0A.,8QC&/3&/`_?@?%8[#KC#SC++CPRE
MK&=6VA;@ZW&U-.*86I.5-*<:7E*LISC.4YSC/\9\`P.P*RV.*PR,.TGVM,,-
MH99;3ZYS[6VFTI0A/KG^F,8\#CUBIM;M9E5/GX[)Q=)LC=NK#N#9`3]986HF
M6@D2'Q@EC-&^D5.EL_$0EYC.'O=E'N2E20Y/X'\SC"L92K&,I5C.,XSCUQG&
M<>F<9Q_QQG'@?`048$48((=D0,-AD404=M#(XPP[:6F!V&6\);:99:1A*4IQ
MC"4XQC'@?TH9HP8D-_#F6"F'AGL-//#NY:?;4TYAL@=QHAAS*%9]%MJ2M.?Y
M3G&<8SX&D<B078UJ)<0\H%AL-IM&3#?G]@"V7!O>;@C!KJTK'3E2E.*4YZ9]
M^5>N?4-R\#YO-8>:<:4IQ"7$*1E3+BV74X5CTSEMUI27&UX_X93G&<>!]/`>
M`\!X#P/FZWAYIQI2G$)=;6WE33BVG4X6G*<J;=;REQIS&,^N%)SC*<_SC^?`
M_C#26&66$J=6EEIMI*WW7'WEI;1A&%//NJ6Z\ZK&/52U9RI6?YSGU\#Z^`\!
MX#P'@/`>`\!X#P/FAEIM;JVVFVUD+PZ^M"$I6\XEIMA+CJDXQEQ:66D(QG/K
MG"4XQ_3&/`+::=]GRMMN?&XEUOWH2OXW4^N$N(]V,^QQ.,Y],X_G'KX'X<&&
M=^;Y1V'/R6,#$?(TVO\`(&3\WM'>]R<_*PG\AST0KU3CWJ_C^<^H?AX$(E2E
M$!BOJ6GV+4\.RZI2,-$,80K*T*RI.&3'4>F?X]KJ\?T4KU#2E0D*<M]TV(BR
MW"L"8)<*CQ"%D8`4^H##ZW6EJ>P$HIW+/N]?CRXKV^GNSZAJ"8Z/,<:>,!#*
M>89*'9=)%8?<9'.0ALUAI;J%*;9,;;2EU.,X2XE.,*QG&,>!HAZ[7Q"I,X6"
MAACIM&&IDP>,"9*EVTK(<PW)D-L)>/1APMU6,.Y7CU=7G_W+/J&D(IU0,(?,
M+JM;*+*>)))*(@XQ\@D@P(>.+???=%4Z\\5'B-,.+5G*ELM(0K.4IQC`?HZG
MU*4_-_95>NR/[+X\R/YT)&%_GY99:&9R;^0,Y^5\0["&T^_W>U"$IQ_&,8\#
MCA>H-32#WY!^KM=&D93A&7RZ36B7LH3G.4H^5Z,6OVIRK/ICU],>O@:;_9/3
M/_YH]8__`)!57_Y$^`_V3TS_`/FCUC_^055_^1/@:<G1&CS&T-&::U26TV0,
M6VV3KRHOMH*"(:+#)0AV'4E)`A;*'6EX_N;<0E2<XSC&?`V0[C'QLDU/+DN/
M6CI!9+4P.0L[4U"+40Q816P9]EY3\`YEUJ<!:2R8E7K@EI.$.84G&,>!L,MP
MXXB3\@F6G>*W'":E4Q"H!,E+:/UE(R"8)8B@%0N##*P\1B)4"O+.1O=\.6LY
M1[?;GT\#CS7`S@\..T*)PZXN`,CPV:Z+B-T'JR-<#@<N2;V88)\&JCOA1N79
MHQ7PM*0W[BWL^GJZOW!N#W"+AD03&%/\2^-3KT,SD>*]VC=9Y:`:]H:&\##_
M`.,_CMJ';CV4LJPGW,H1[6\IQG.,AH!.!_"0*,DH5KB)QI<B)=9ZI&,,TCK>
M1!);DU$K-"R*?7"66HQS\U["1$82*VAU:4-I2K.,APTCK*ZX2G`GG^`O#)3D
M>5DP7*>,FF&\((R*4%E:T-4Q""$?CF.8]CF%H]<X5Z>Y*<X#0.]6_6J\EU#G
M`'ALI+TD[+.8QQMU"CU/?#6`Z[C**DG*&U"N9QAK'HUA7]V$X5C"O`VP;J>Z
MQ1$*;8Z_.':4*]_KA?'C5KV?]1T%]?\`<]67%8]7(UG/\9_C"<XQ_"UX4']Q
MU0=8V)!N4QU^\.\&MMR32'/^WC5OQX1+(?;.QD;_`!G\5674$KPG.49RUZXR
MWE.<8]`XDYTT=43D5(PRNO/B4D"5CFHDU#6E:8R2H)G\3XDCR#,8W(`D(_!:
MSA]AUM_U3G/O_N5ZAQ\GI`ZBB_P?GZ[^+/I'-R3(J6M7PPR<-RSI#YF"$#(:
M2;G#I2\LY>PYD7&<89RWA*<8#ZF](W4;(`XC2.N_BJD1+A;N,":J@`'\.'9C
M<DKP8`R,9C*OU#&$_P"I_IXPO"/;AUW"PVC_`,BKI]_"_`_\N[C%\'KZ^_\`
MV^%_-]?DP[_]\OG_`&&,>['IZ?+Z>W^W_E_CP/V]T7=01+XQ)'7IQI>>$!3'
M,J=HK2T_B-LY'90\VHK+1+K#'HAMUS"W6TI3A*L>U/H&UC]"W3H*^,0UUZ<=
M%."/_DM8?K!Q3*G/=A?H2.5*O#F,XSC^&GDK;QC^/;Z>!^6NA3IS:]WLZ\^.
MN?<EM.?EK)[WIAM&&T^WYI9SV*RG']V<>F5J_N5ZYSZ^!^!>A#IQ#:2RSUZ<
M>%H2EM.,E5V3.=]&VTM)RI\V8(?4K*48RK.59RM7JI6<JSG.0_:^A3IS6OWJ
MZ\^.N%?$XSZ(K!S:/8[E&5*^-N52W\N,HQ[7/3Y$8]<)SC&<^H:+_P`@3IK]
M59_\O?07][+C&?\`V%V#TPAU;+BE)Q_D'HA["F$^UQ/HXA.5)2K&%KPH/@GZ
M_G30D?(V.OG1/QJ^3U4H6TJ(_P!5K+2O0M5FR4GT1GU3Z+Q[%?W)]%8]?`_)
M7U^NF<L=\9WKYT6ALAMEMQ0H]L"(2EA3RD98+"LXY0KBLOJ]ZVEH4YC"<*SG
M"$>T-/GZ^'3%E[Y\]?FD_?[\+]N'+MAGUPGV8Q^/BVX']GI_5/M]N<_SG'K_
M`#X$/7:AUL\`."MNZ_)SBEQLK6@+I9^5\.9/7O7<I;43Y5-HV8JVST*8B7L$
MHU;&!<(1,#0[R"E&$1"&AQW7<H3@+B_@/`>`\!X'2')IPAKC=R#=$;:=*;TA
MM=P9I]D4EAPA%#GU,MO#FH<"?:6YC&%(>2II6,^B\93G./`KO_4$8CV.H03\
M`G!BW>3.ZGCWV_RT,9.<#I'N;8&+$$_#;8%PTC*&L+:RM*EX5ZKRE(6C_`>`
M\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P
M'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>
M`\!X%</[`[LL#8^LN8C)V\Q345RX)>/'J$,^4*L95=!6N;F+"Y/0D/56ZVTR
MMYTHC!*V8ER1*;9>2*\,0%CSP'@/`>`\#HCE*TZ_QDY&,,-N///:(VZTRTRV
MIYYUUS7]A0VVTRA*ENN+7G&$IQC.59SZ8QX%?OZD=7D:OU0(:D(,ZJKD>1FW
MC7JK*Q4M&RT.>PW6(M]1[LRAHN05(@QXKZ7,-MMHPO+:4X]F?4+/?@/`TY;I
M#+&7!1OS'L+93ACYD#^Y"WFT/.?*YC*,?`RI2_3^JO;Z8_G./`ZSTQ9=HVZA
M#3NXM;"ZEO)%CO8KM&%M43<\`5B*O-CBJ#+%3T$Z1$NR5JH@4;+%#LN.8!(-
M6-E65,JSX':G@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>
M`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#
MP'@/`VP,PUXJ59-CT@#"'-"Q9>3AR?VXZP!"7"\,-8PX`IHUYT?XG/5:OA^3
M']JT^!^UEF)E1@4Q9+@#T><6_-)(!2((8,3'LBQ;HJR4R3A,BR6\ZVXVRIA"
M15X<6E:VDK#</`>!7_[XGXQMC@"S-D"IB2^6/X;P\C^D)B17I&B3<2NUS<1*
MS$*]+P5*B9$R0-'2M\4H9M8A;*V2O5`6`/`>`\!X'$7=@4)@V0C7KO4&9&(+
MP!+`.V6&;-C#LC#F8#D!5FX?"+R(6T[\;B4K^-U"O3VJQG(?S&P*(XZ,,W<J
ML00<8)'B"C3L84248>2T((,P,.2Z\\Z^0\E.,)3GT]?7/IC&<X#EV,8Q_3&,
M?SG/\?Q_.<^N<_\`ISG/@?WP'@<`VIM/7ND==V_;6U[5&4;6]!AB;%=+A-*>
M;AJU`AY1^;,2SP[+ZQHT%"_>^]E/L9:PI:\I0E2L!TPUS?XB/:FH.^&N16J5
MZ6VDJV)U]M--LC_\#M>:)$VV>N>8JS>_]4XBL0M"FRC5*=2D=B)*6K.$L.92
M'6--[1NNG8M>V9:Z#S5XVV^O:;I@&PMI34'M:KGQ5"I<H0$%'66TFC&O-Q,.
M5(20XV'5_P#*0^AK./D5A&0R_P!;7B'V;KVC;&KTC!2\!?:E7KC"2U7FDV2M
M2<19(D28C9&OV%(<<F<AC0S$.#%X'9P0RI*\(3[O3`<U\#CENN%2H%;E[E?+
M37*34*^+DZ>M5NFXRMUN$"PXAK)DO.3)047&BX==2GY'G4(]RL8]?7./`Z,H
MO,_A]M"S`4K6O*SC?L"Y2L@5$Q52I>[]:6>S2LD$.X88#%P,+9C961*&$96Z
MM#+2\I;0I6?[4YS@,EO`Q^VGRRXM:-EW:_NGDEH;4MA9C!9IRO[)V[0*3/IB
M#7GAPI3$+9)^-E%1YCX[B&GL-9;<6VK"<YRG/H'/];;5UWM^EQFQ]:76HWJ@
MSCI28"Z4VUUVVU6=8&.<CORHNP5N3E(DE#A;66\MX>^9IW&6W$(<PI&`X0UR
MGXQOV"W5)KD5HQ5JU_-8KEZK.=L4-%@IL^J0:B$0MIAESR9&!DW)9]`J6"FV
MG%$JPUC&5Y]O@<MCMU:;F(ZMS$3MK6<I$W(F&"J$I'7RK&QUK,L;C;5>$K9H
MTJZ-.$SSKJ$A-BJ=64I6,-85G./`[,\!X'$(B^5&;P?^#.!85&RDE$%-F+S'
M._EQ):`3%L-'X'<*!_(=1ALEK"QWL+2IM:DJ3G(;RU/0;^%Y9FHE[#:U(<RU
M(AN8;6A:VUH7['L^Q:%MJ3G&?YQE.<?\/`ZZVCOS26DL4G_>#;.O=9YV5>H7
M6.OD7:V0M=<NNP[$8B/A*96&I,P=R:L4B8XEM`H^%N^N?YQC'\^!VWX#P-,4
M4V&VAUQ!+B5D"C82*(28YA99+0K:UM"-/.H';<>PIUW.,-LMX4XM24)4K`:G
MP'@;?+2T5`Q<E.3DG'PL)#`&2LO,2Q@T=%Q47'CN%GR4E(&.,B`@`BM+=>>=
M6EMIM.5*SC&,Y\#9*7>Z/LB`'M>N[E5+[5BR9`(6RTNQ1%I@"3(DY^,E1!YF
M#,.CGB8R2%='(;2YE;+[:FUXPI.<8#DR,O>][Y$M8;PM/X^4*6I:F_B1E>7D
MJ0E*%X>]V,83E6,I],^OKZXP'U\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\
M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P/.;YT;&O6@NQCE1N?7>WIHB
M]ZFYE[EO]'@J#LG;DQ$ZON0T!HXJN2VRM`D_I=.)I+S-@*C[S:G9`R.#KMF<
M3(8!D/U+9(28<9^55XYA]W/&#?!$CR:JFL]J4.Z8UQ4C@=B:MU_.N:FUG;]?
M;CUZF&QNYW36R=8:RV]7B[&FS@AS<G8)&;9CT(6-%Y<0%S3P'@=![^XQ:/Y/
MQNO8G>%#BKV!JW9U8V]2AY1&5-Q5WJ:36(\MQO'^F='&1\F2(:&^EP8P5]:'
M$9_MRD._/`>`\"%[MBZ]N6_8-.Z-HFD.9NP.(FCH"'OCN^?]M[!9XR=VD2?:
M]4F56I$Q];FJXXJ-_P`>A+!C]@HSW`DO,XR.2R\\WX&)'([JNZ-^MWAO9^0/
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MUXM6$/L^];3K:VR&''1GF7G`RQ\",#NGM*J9U1\];#A_#"!N.=X"(]W['#!0
M<TPQ"'1ACT.T]*B1\N'(K%)(&PEX=AY;J%(4C"TA0LXE7CZV>BM$Z9E.:<YS
M`Y&;2VW08O:%AT]5]@WJPZ<X\3$E<+]7Y[7(0%#NVJ"R3#APEN2(U@S+E%1!
M;#F?1)SR'0E>#J?39,]0_;%RVZS^->U./Y%[XO[4T^Y([4F=B1N-EUI<W6#I
MPK7M3OFS+;596O5&Y)!8,+B,NNQKOM%]R'7<C*"X7P5"?CN$O#^/*CBH@D'B
M_H01^*.DAYDR-<'U956E@E2PC3`LF^+E'L4^VA"'<I]R<8QGP.J.T'G7#];G
M"/=/+R7IQU]<UO%Q@E>JHKF1PYBYVN6#K%*C[!(MJ47#UR1M,H(,8:PR4Z(V
M]\N&5I2KT"KSQ-ZW.='>A;Y[EWVO[:VGJ#AULZU?[J:8Z_X>YS\:=_A)HTS4
MHAB4`<&JLUKJD.#P,:=%'H9=*LJALG$-(4XT0L.Z>6GU@NO;B)Q9Y"<G^+UU
MY,ZDY"<>]6V3>.J-IM[1?L<O2[1J`?&QFG8*,!8IC&#[$+6G(A9)#[R0ACW'
MVV5/-M^@8N4ON1[!N0?5CU[<1N'L!=;9V?<R*YL&OA;4D)N86?$:GT9<+34+
M=O8C9.P$N5<FW6AVFE9/??DV403GR90.I*@T*#OCBU]3[7=]QL*7[6-R[5Y*
M[ZL^:S9@]@T:_7Z-'K+O^3[33:J_'7FTM2$?<X:WX-C)A3#\6%)Q92W$^UMM
M["R`V2_<!V^BSLPX'6KBIL/93G!/F9;T</+EQ^M^][$D"C[-V+F3-D]G/-VF
MO6&FST5&0XK<U#@K2/*+LD9E+;V6G?B4%>KB]3?K-[`(Y,V#FWOCEMKVTF<L
M-M_[(L1I6V+I.3?'(:4B7->V6\2T-H>S(>O=L7B0?EU&%+-^5_URVRK"<Y#O
M78NJ/J:TG6=AOO'SFMS@8W968J45JDZ*A]C-V.L[-45#,T;9K$1,:AU1B0:U
MK/2;$Q^*+/PY!PX!*67\/MI5@+H/UXO]^3^K3C[,\EI39-KV4IV_MUJ[[>;+
M5>[)IJ5N1\]J:1?*DSY675&G4@T!:&2BGWQG$J8=6I;.<^!)WRF83*:/V+6"
M:]N.9`ME/L<`\=H'`R]NUPT^.<:BIRA)?D(Y3%ICCE)?CRL+RT*8RVM['Q>[
M.`\H705)ZM`A=LC\]*_VLZHD8C;>Y`D\E-/V"D7.@S9(NS1HJ!I$Y&S%#,;S
M=L!11&9B4_>2""Y<=S.,8PIC#(=O.1?UI0&UDP7++N0*(&(5)/03U<TX$W:_
MA=,><@$2(4"A<07.D>F,'+0]AC!'ORVI?OPD+!NN*_R+JO#;ITUWROKFZAIN
MJ=[''ZPZ,5R.S`S.T83BA;U['(T0K8=HU^Y/KC++)EC%,?ARQ&#'36$L+PB-
M_$]@7EO`>!";W+\_L\;-60_$S7>H+IN?EKSNAM@Z?XR:^K\*7*5PQS$76X>\
M[#O4U&MED5BLZ[B[QF0<S@8EU7X2G7$M")=(;#!?ZW<M.\;2.6?5YR(AFAN9
MG%F]N6"[7J,9V?+QFZ=06!X62H6R2KE>A1@)%W,K<#HV*2PT*Z3"A,+^)2&<
MKP$87<65S0X+]Y$IS'X8[&V1L<:O<6Z[S7WOQG*L-OCZ1*:EHDW!<?MAU"*@
MQUVP&VQEABX9N8E'AHMIRM,Y?D,J8_&9?\">68[`M)=L723RYW)QSDJH9*VC
MBYN'6>PZ/L>U0>MXK4.XYG4!/[2K;$MUYG*=7H*M04A8!R$SKDBP"1&Y24T]
MG.%-I#5_6;`1&=+W$H)`(<>D<S>C668_##@"UM\@MH-N$`R(TE*LS@A#B,J:
MD$NX28C.'<)QA6/`GG\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`
M>`\!X#P'@/`>`\!X#P'@/`>`\!X#P(GN0?<3Q@T[OF(XGZMKVU.8G*BP:]L6
MQHO2'%2#KFP)<&$A`1CA%VVSRUKK5/JS4XP3EQE;IKJFV6U+=0GWCI?"OGLS
MCOV<Z"VGR:[8T<?..&L-`;:U?9=S[RXY<H=C[(WIL73@=MJ0T1O>(C=?Z!KN
MDX'8YEQJ,8'G-7G)*0!8D8X=:C62F4FM!UKUT:2VSQ%E=3=FEBXR<E]\\>[S
M3&]H<>ZEQ7NM?G:SH?24)5-I9NLAO37O(::/V^VPN)VO-V:B0L5=K$:VLPF,
M)>R]AA"@M:</.T'A;SFD`ZGH3;@$AM?%!5LBTZ-LPRJ]N37%>;E@(1]K8M+=
M<(=J\R-(R@R7`W'EO(0^VYG'QK2K(2!^`\!X#P'@/`C0[DX"+L'5;S_1)5&J
MW1Z'XG;TL4'%7""B+#%BV*%US8C(>;'#FFUBC3$*2G\@,I&4/C$(2XTI*\8S
MX&*WUIZK.4WI6X6PU@%K8ISD+M*<9Q5;!7;/%DQ-GW5L6QP9STM5YJ>BOW!T
M/*L.GCY?24$8IT<ED<AIUEL)P+#7H"VP4O5[5"1%EK5@CRXB=K\]'!R\+,Q1
M[*QS8V5BY!D@*0`,8<4AUEU"VUHSG&<9QX%,M^B@?73[7M5E5*T;+JW5IV"S
M]YB)/6V+#)RVH-(;ZD5LOPRV(E%<OMWM<\Y%Q8[$4)'A116!2AQ'I,YD-[.0
MNEI5A24JQA6,*3A6,*2I"L8SCUQA258PI*O_`!QG&,X\")KO9_'QT_=A"B66
M'V4<<+>[E!`<?(-H<:=CW&'T"RDC%!N$"OI2ZUG+JG$.H2IMDAQ*&'`B2Z+>
MF7J_VWUO<->3.T.'^HMJ;>V3I>7<O]AV%"2-QBK+*'7N5SF3*J-Q)DJS'S<*
MW"H#&,C@A,Y&4XG"G&UIS@,J.[#7/#W@1TM<S:OJO3E&T'6;GJBS:OIXFH-6
MPD6$Q;-MSL)',PQ#D5%('AXFXV%8R#E94G.4^XA./>SEQL,2:;]H#KUTGPZT
ML%"JWW<-HZGT_I6'DM3!:-O\0O:/XE*IU5D`Z7L:ZQ`E:'C4$2ZY@.1->:<D
MPX=UM"4J+86L.@]Z]K%?^P1PSYE<8^*7&O=>O-P:$I>HN5FOP-CUV#ODOM*9
MU3NBG3(E`JVLJ9,E3DU(V23CU1F7U?-%C()RLUP=.4^H=N\1_L_<-JC!7F2[
M+]9V/AWS6#NEBU[L"MUK1=_GH:8K6O;#)5Z"C*W9H]JSS)4=39!HT`X4U]K#
M$LR4ME"D.8SX'0?)/LE[+.]BBSO&/J;X_P!RU?QAOJH^A[WY;[!$9HBG0&Y=
M^K;KUS7)&;DBHXFM?X[<X"2+:8_`MS\8HP7$?EIQ2_`_7-36,Y]?OD'U#\D:
M)I&4W/PUXPZ0N/$_=>RX(0>-DQ=@;SM)$G=MD,:XKA/XU:NEP:_*D&7_`&D`
MR9#JH]QS!"1EN!G_`+D^V%U@PE!+7QVF=Q\BMVV1@R#U=JJJZ.OD:5+W:3CY
M$>CYL#MP:IB<527MJ`@'U1CQLGG\Q'XXKJO=[0Z!X+\/^QSLYYU:A[*NU/4E
M!T=IO0,7;[3Q-X_&P8;VS3(S;:B9FBQEQ,C"(@Z#=T8XAHL8R8!#LJY%WV.C
M(2MQ;818<</KT<:NR;6'8W9J%##Z)WKH[LCW[HW6CM&*N8NG'=5:;5&LQ="J
M\-;YBQMBRUG))P.9.FD3.8TA:UJ'<RG+:@Z%TQQ\WOT[\AM.1_95TL\>>3VD
MZ\'*1PW)C06I['LJ>K]?KKD+B[;>LS%>5-4BY_X_7K$2M`EPK$"<6^SA\0UA
M`F59"^_P>YR:GY\ZT@]X\:?U\WQVFHV7&K=JD39.NWG]U7+&_42H>7U5*UH$
M^MQK4I`RK;)CASB"4!-J90M#JLM!G'X%*+ZVNLJURAUYV^\<M]P%:WKQ[C^=
MR"(?6^TWI^[:Q40U>[A;9=<3J^?9%KT*@V2A@I')#64OE'X968/Z#-_*%B@#
MI@ZGHJ7C9^*Z].)\5,P\G&3$5(QFG:G'DQ\G#O\`Y4<:(L,!G#+PQ.,.?VXQ
MA2TIRK&<I3Z!'9]AS?D7H"I=:F[=GQI-<T9J7M3XN[&V%<T*S,34+!4</;1M
MD4[01@239D=<.&@N/<#=(?6K"O5IEQ+.7`^BOMA=*F'VF?\`?[8RDNIQG+Z=
M!;9^!K.9!8/M=SFM8<2K"$?D?PG./Q\XS_S?V>!V!9OLD];)O&ODQOW4VQ+=
M;%\>H:L-?I+)JN[T95IN.R$65C6T1`)O0U,8GF)<FK&DNMLELD+"$<^#"WU,
MMK"LKQ9Y#=V%E[`E\O=I=1]EY%\F]DSR(7C=L_=,SM/6^E>/>M9&@6F:DJ#J
M*7S*-:>AAKK56GGOWA)#CA3F7&$>]12&L!Q+F[.=XG&WGWK7LKY`<8]6\5D[
M@V9`\>I&^ZN$HNS3(>C;`L5,B(^(V58J,;*D24C6(*);B("P208IRD.Y%2MU
MYU*<A9KM$:S+?9PU]&V%`\]&8Z@[W"M,2L6\R&<T;R$0_-AE./Q#,%9R7@)9
M#1`3.5H$"4TMY65D9;\"%GN3ZKM]]7%@W!S8ZLZ>B2XC;FIUK@N9_"8T`VWZ
M#15)&D'A3DR]IB,_7?EZX@PXTV=(*4;AVO'/XR'D8!M;&0F^^KEN:L;:Z;N.
MD1`R+YTKI^<VEK"Y"KC#X\.#L#>PK!=PX.+=.1A$C'!56Z1JD.L*<91\F6O=
ME;:_0+#'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X
M#P'@/`>`\!X#P'@/`@N[1N5')>V[FU5UE]>VP:%0.5>ZJC9]C[7VM.R\/)S^
M@N/L>@>L'V*HTC,F.9*;&L$I8VE1[C^$?JQ6%'-H5CT+##.G@SUT\6.OK5M9
MUYH36L$!8(N%*C[7M^:C0)?<.QY.9*"E+3,W;89(N;'+9L,V`T4X)E](+*F6
MDM,H2TWA(<'[@96QP?5YSNF:FTVY88KC5LR0CG'9%V(2"H.#>?(ED28QT:8`
M_#"-N%MNCOM$H<93EE7R^SP.,]*)`I?5+P6)$,(DF7]$0#JI,IP%UZ5(6?*9
M,E5+C6!PLHE"\K(1A"<XPAS&,K<SC*U!C[V-=8,CL!BR<G^O6"A^,O8OK-N=
MV9JS?5'_`,>@F=V6ZVR"W-@ZEWI"E81$WR`ND7%,)0=/LFMQI3[+P^/^G6VH
M,U>OKF]!\U=0'2<W!#ZRY$:CLDGJ+E'H8N=A9:?U!O.DMA@7ZN^Z+/+S)U1,
MXZY^IE4XP-(B^BVE*],Y\#//P'@/`>!$CV7<O.Q3C#:M)@<&.`:^<<+=H;89
M&T61[:Y0B=>24*JM!43/^3'+5`+'L9\\0MX=;2R<#1SJTY0G.7&PARVYV6=S
MW(35NQ]+;;^N7?+;J/;=,/HMSJC_`"$D((B=JEG#;C+9#FR$578J9CTR,202
MVTX,X.0RI2,YS_"O`VO279+W%<;Z'3]1Z=^MI8M;Z/I<6["UBA4K:9`I$,ZD
MV:)++42JK'.RSLP2ZT26:6Q^468L@AX@APA*_`[3"[J^[L5!+M@^O)NUQ.8L
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M*7KGHXU[3M;0*CO\=I-+XG[[IM6K&3YJ3E)AF!K5<V@$)'BR$Q).O?`PPAE&
M59RTA*,^!^-Q=J'V&MW5Q&O-^?7[TYN6F9D`Y]NG;3X>;ZV14,R\<V4V!+HB
M+)L69@LR@#1+R6GL(^9K#JL)SCWY]0YCKON-^QC4J#3ZG"=$T?\`X-3X<2#A
MH470G)D%J/K-?BP!ZI&`@REYDC8YJNH`Q[5.(=2I&&FFTLJ;PI8;FGN_[^K2
M5(`:_P"D^E*V+!0I(PAE:J^U+',5<E1<I&GE3%<@;BQ(D0*)E;R<QY3C;")!
ME?R+6\C^P,0>2O+7MWY+7@RZ\E/K;<5]GVH2O1D6U,;EXS[GL=F@JAB5G\Q8
M^)28VW'.1<278+%(92\RR*T4<]GURMYM/M#*FG]RGV#]/0`U9J/0E7Z'5!W@
M!86'@./_`"*KP>(X$*)B8:.4H>TX1,S#<'$?B-D>WY7L)9]K><,^QP-1(_8"
M[_"8]0\UT52\Z\I[,C!F#Z!Y434**0,HW$:;EH=,LP<^"9\*\.,E#J5AIS",
MHRXE;0;7$=[G<^%+QQQWUWIIX,-HT1YJ)XY<DH>7R"S8D2-6#CIAV@2C4<S`
MPN7&'DY%>03(+P8TD5&,B*#LA[[(O='%*)S/="NYA&W8^8*C4_X'R:%6C,>E
M9:B2ED:J7@@*+CLI43[$MY7E&584TE7H@,=^/_>/SHXD#[2#U/\`7CW'KW.]
M=UVW=EW<CA^5KZ+=?[<0?_N#;I$&U:QL?K9I.:B5J6D%X()#0_X_Q8^%+F0[
ML*^SGV:2E<D(V[]"VVYJ$DL(A+&(1#;Y>@)6#+R9"VF*.C)70D@,^B1<<P,D
M=_+S.4J<;=PYC/\`(?#6'V@MVZ;@(Z`=Z&=NZT;-7:YRR1>L(RVZ^@'Y-NWF
MR,M)1L0KCXRDI04"?ER5+?SA;DPXX\O#3;OMP'/GON%V);*FP>HCDVLY\@J+
MCVW[^=EEZ;8:?5^N7AG2&7ED-+85\K2,9>2E"L^W^,^!BEQ>^Q]HKAY'78?C
M;T=[]HS6W-H6*_[9L6-G3]CM=SOML/DIDO\`:W2=TS)V.<?38YIU88)9:F06
MRWD"M-X<]G@9I&?;NL`RH[#74%RX(22&,08YFR2@Z&"'E*4\,!\VE<+D6Q6<
MHQEW.&$K?]Z4XRVE#S@8D<H_L@Z8YHUO5X>Y.FWEEL2KZ0WH]O*LLLWZ7@8J
M$NVJ738.E3,R5$:QE(ZQ-"(EIMN?A9%C]<*0PTPYDQ&7L-AT-/\`>7TI@S\!
M$6#Z[-:BB[(]%M&"'ZDT/#3:[4MR5;LL+5X+.O!LV%J(L$BR*)Z.`N&I(S\H
MP:F&6'`[^OGVC.LN[ZMHVHMB=2VXYW3^JX34T]6*S8"J`N&IE\U@T3C6L.&I
M]:'':I49>/:%BY0DA+S["G\JC,90H=T.X]@_=?X\)J5L"USQ"WE5]@,RU6Q0
M2=@(HUBJ9M3)L<2_892V0L'L&FS43+/:_62]%BA%FC+D7&,.$_C84M8;'M/[
M>_`/?EFL.H=J\6=W3_#S8&F8Z&M(,G7JN)MX3:\G?T@3RV38/;;T,%3*_K)W
M]B"9'K:F\3C'M9>9QE#J`Z8H7V>^LASF'!<W-T:(YHS')6FZ\V3QC@K3K\R@
M*TJ_Q^E-PS]LITVUKNP;'A)L>W2%;5'$RF'D.+:.PXTA3R6F%I#-Z2^YWUCW
M"N6"N6[B]R^.@I^+DX"9KLO3])RL;8(26A99B3C3QO\`>-T1\"23A`+S+N/:
MM)GJK&6TN9P'1G&K[*W19PQAL5+AYP]Y9:MK$LFV76=H5+BZ;"TQVWV6/K+L
MT1)0-JY`NP1T\RQ30PPRFD92(REUL;V-ON)6&6L9]S3K7QD\>X:,YCTF3".2
M'^K/I&J)4M:?PG"G7W$Q&X2?Q,,N_$U['<)4I;O\>N&W/:'#-H_<\X!LTV\-
M:8U'R-DMBBMR8E`(V!1*4#19`MD8IR.G+$F)VVW8F8)YYE"7!F$XD/1W'M1_
M:KT#M\/[B/4D(\6`U$\N"A1_G+8D2]55TE9KA1=B+)'9_*V9^4TR$@(;#27,
M(2EHYEM&/1E[#81_5K[A6L:#!3#"N/FNH8<J7V38J;7]8M6*2<L<1BG7\^A&
M;`8=*@XK5URV%LP6`;EA!R;0J%C2"W7%$N9:RD.#U?[I&T9YLE#G"_C^.>F(
M&F!!C^3]HK++SBA91PZO.GV34(<>S/`K88<SG+WXCR<Y99==><3A`;;:/NZ7
M"/\`='U_@/0Y23S^H^"4QR-FGJX1AUZ;S*K2IW443)L)P.J-2RDAMA;;B2LN
M8RC+.?`YK_[.R+B((!^P<$JI(SJS"TGC5/DZ^<)^+&..QAC8R'],*<:*-DWV
M"0ENN_COQK3ZL+^3XDK#<I#[P-&%*(;:Z\[*Z.L1LF.4CDG7R5^I0L40*V>H
M34[K+#K672\/MXSEQI>&T9QA6'/0.1QGW:=6FSL$#-<!+B#7)N2;:/)C.1]-
MD+#&U]T,7Y3L`F4"`A/VOY3C_P`(I$H$I:6TI6MC*T+4'&`?NB\>HJW$S$?P
M:W(^^YBOU0)HGD!#/00U;&=KS4Y+(;DZZEEZ;*2P1AETAMO"FH\52W&%FG*0
M':`WW/>,6:>U$$<-MZ14C^HEV)LF'W9J@I$88-7H@LEZI3<G**EI]_\`R>6?
M8%PZPRZL-ALAM+CN7PA@^\Y]T[A:HFK33?#?DU)'QS=B)!4N_P"MXQ(R7Y*3
M@0OVL9$60D$PJ4@!6BW63&,I`(?]HWS(2@MP-\S]T3CWFF3-S1PKV&EF%L,!
M!NP)/(733%J-9EW9))LO$U?#3UAEXZ*:C%86\**\,EYQM#[PZ7$.*#F<+]PG
M19416IN0X8[8CP[A"ILP#\QR!XUQ@@(+;DP#)#8699XN1:8'DH%YD/\`8"B&
MF/*RA3+7^E\H=JX^WYU\NUB-/%J-O<N,GK345UQ3")MD-B.M5_V/*5&]ZUE[
M<[7<P`<]I^F-Q]HD24*=$."+>%&5DP1;3@=XL_:8ZW#K\95T7-AN@OU#;<I$
M;7CIY9R';50[;=X6EU&1H^*NNWU]W:U/IBK''2I(CD5'"F#,2#C+[[*'0XY>
M_M5\&:>5K>,A=<[2ODKL8-4P.+'V'5E'%@JO*UK7D_1K=-3^W[EK>MI@;D9<
MI"-][);CH!]=-2^WAO++BPW>J_:AZ_;(758UR#OP,M:XV%D!(E@B`E3&7#*7
MI.UV"/=>$+3%H,IY.U980OY"6VWD4N4('4ZVL3#P;?LK[8/6[1']IM5RN;PW
M"-K2^P5="E-5PE*EHO9&O96&FY.7W7KXJ=NU>5)T&D2$2U&32"D!R8D@>.E(
MSC67'6PV+'VU^M7(.I9!JO\`(4J8VS#/R9U+;JNNTKU`%&;#+JA,OLZPKV&W
M"!#EU9*[(M4>7*,BQ`GL<RV=EP9(=A3WV?\`KFB<VZ[L@<@)>E:_OE8UO)V.
M%@J>=6I"K;"LLY'0>]V8(2\$6!K6"6*J(0S('B`R2AIT=I@%YYQY#(=Z:[^P
MGU7W[>\[04\IH:L_BL6*%BIZQ6NHKU?:WJK;HV`KQ%,S"R4Q,R4SLM%I=/CL
M8:0Z[&1>,OH8<]C*P[(V']@;J+HM1.L\9S:TCL$X,ZMA-5"EW&,)LYW^0V.(
M@'"A1)1R,&P-`LRJCS\N.HR.$*\O.,J1[<AP_;/V-NHO55JU15V>552VDC:4
MT1%DV;4)<3<:IJX`>3@X=5GVS,+EXO%5KZSI]KVJ:;,+R.P21\'P#NN)#)0'
MN<ZI9'*L"\_^,"E(#$D%H>VC!"+;CCG1F1)!QLMYA:(\A1C2DOYQAKXW$K]W
MLSA7@;B-W$=6)26W,<_>*XK;RL)9=E-O52'9>]<1JDJ9>EC@FG4+;EQG$J3G
M*5-.X<QGV8RK`?=/<#U7K:R\GL*X@J;3D3&58WSKS.?4UZ/8'3A/[SW94IR3
M9]V,8]6T^]2O:EIW*`ZJE>]WJ8C)K]$CF]HV4)QL"I:Z<-BKK"/P;<A;H1NP
M,6+$^^<+#$T:"!<PW+3++[H,<;_TCJ\%^C.0[B:[<NKAX9)C?83PZ4.I[(Z5
M9Y":Q2O+V'1F?9\*K&E[&<K+1Z?V^F4^Y6/5*%Y2'$:%W%=9MI&O3I_/;B-%
MD4N_VFG'?L-]:]B`#TP61'PY*J*GI>(-LT&3$G#^\\1L@!Z326T*^^TRES(=
MEJ[3NLY&?1?8-PM1G.,9QA?)O32,YQG^BL85<L9SC/\`PS_3/@?G':CUEYSZ
M8[">%6<^[V^F.3VF,Y]V<>["?3%R_P";*?Y]/Z^G@;K%]FG7)-$*$B>>O#F1
M)0PHI3`G)33KSF!DN--*?RE-PSGXL./H3[OZ>JL?^/@:R#[).O.SL2I-<YS\
M1)YB#`<E9=</R,U'(_KXYD8DUPPI`EM=6VPD0-USW>G_`"-JS_3&?`_,AV3]
M>$2]D>4YV</XXC!80"F#N2&H!7TFR((\F"(MIZWH<025'E-O(1G&%9;7C/I_
M/@<P$YS<*3P(:4!Y>\83(VQ3BJQ`'B[YU:^)-6-#J65P,60U:5-'2Z'5X3D=
MK*G<95C^W^<>H<9"[%.!LC+F0P?,+C@\X%5*Y=ERO^[]';JQ-<M;MV;A"XVY
M.32*G+%/HUU,NNB"FO&"CA9>?:;:6VM8<F3SEX4K=D&$<ON,"WHF-+F91M&^
M]5J5'1($A^I-DSL)M6?Q`193_IW'7/:A+_\`9G/N_CP(;>MS??'6L<ENUCE#
MR)Y3Z1C;WLOF;_L[0K7>-BZZIE=E^.VF==UK&H<ZS/FK,0U+5-T^V3S.28\\
MD<HH-Q+V<OC90R$UXO+_`(F&AB2`?*#CN4!($&B`&C[JULZ(<5&RB8.0'#(1
M95-%/`S*L".I1E66R<X;5Z+SC'@88=G^]^/5HZ]^8E.%Y$:C!E;CQWVO7X94
M;L^J$R;IIE-EEJR'%Q5D8EYUH01IT@H(3#SY033R,,O8SEI8=8]0W)OCO3^M
M?B#2;SR7TP%=J'HBN@W*+MVUZ5"V^#Q&SD]6,.7*$F+&F0@))J4A'PBFW?\`
M0:/&>8:6M+>,^!)F=R5XXL,J<)Y#Z5CVF,H)>?7M>@,)0R.O#SN'EDS:FT#N
M-M*2YG^,X1G/HI.?YP$3>B9CCKQ[[:>1Q>K-E:J8UES>T7&;MV),.6?4_P"L
M=Y/:9NE=TV76J/;H^SA31*"J'*-ER]=4"6H2:^8[)*5G.,H"7<+D+H*3CER\
M=O#3\A$ML?E.2@6RZ67'(&_;MU_\A9K$TX,EC]\ZD+WY5[?RU89]?DSA/@;L
MUN;3[ZVFV-KZU><?8D2F6VKU5W%O#0YBXZ7(:2B4RIQB+D&U,$KQZI8>3E"\
MI5C./`Y?%V6N3CSH\)/PDP^P%&R3S$7*@R#S,=,,K(B#W6Q'WEMA2H[:EC.Y
MQAM]"<J1E6,>O@;WX#P*N7V"NTG:O&BMZ[X?Z*WQI?BIR`Y"W5T%S=%DV_&M
MV/3^FHR/FY1.QIRN_P"`S:Z9%WTZ%_3CGNO(,&?=5^'E;B<O,A&CTL\U^6O*
M+G/PKK6YNQS?)M(V-PKF.4MPU+9[YI"2C+SO:'WM=],NZIS^7K&L6%%0M5,J
M3=C:K8#;TK'Y4XZ.9D?'Y/@7N_`H_=TDK8NPCN4X,]=?'L*R#+T3MN&Y#[NV
MJW2K7LF'U_L;])#FUH61.BIZ9C*E0':;KH!LIMMB-'"D#W#"67W/E\"\#X'7
M6W=LZ\T1K"^;EVS:(VE:UUE5I>YW>U2[F6H^"KL&(X;(GD*3A2U?&RWZ)0G"
MEN+SA*<95G&/`\SC9WV,G[IW4Z7YU-UM<)Q?UZ98M:CT:%V3?80*XZ\>C-QZ
M[H^Z=K5&,3?4HV12*=N<F4P*+7&WO>VN.9^7V8-6&472UW"\\]":EY*&:EZ_
M^9O9YJ64WQ,!U/=`VR+^</KJLUNKQ$/K;5;56QKW:$95U,Q101AS01`WQMR&
M,Y9>RVC*@VGLN[DNP/E?KFQT">B=E=5IG&.V4Z;#HN+F5,<N]T\L;S+2I6F-
M983&/Z/L\!I`+7Y<J>?+L5XV.`+`'&D\$E$1^%!%U:=%\F>`SY?'CC#?=M[I
MY=[RIE8,[%)OC1(N6IWC>8/ON%NVKZ=JO?VHIIX(&W6+,:2S:<R<D3&OFO?"
MZ(VMEMU`:#DNJ_ZHV#SDH'([FGRV-M$IH!B<X^*KO-W7G*I,O!Z8W*-'4W0_
M*V6U*Q;HH6UUV^5]J1;;'.KH<-(`.E(R2X0/D@,U[UQ]Y+[LXN]L!!_9'S$V
M^YQPW'Q4H5=I6R-_BR6M=J6O;<CK.7V+?]@M3?[ING0&N+:ZY*M'!$!,146&
MK!I;;;!;RPGL^JIS1Y)62+Y']:W(4YG:\QPDE1TPFYH?:M1V55:_1SEA5.K:
MJKMG@)N?;OL,%*5Z4?C3P'EQX`#21U.>[+*,!<1\!X#P'@/`^:F65I]BVFE(
M]5J]JFTJ3[G<+2[GVYQG'JXEU6%?^.%9]?ZY\#1G@?E1IL>*2[%.%"$#CG`M
MC?DQS[K2FV3Q&R&'Q<E!N92XW\C:T>]&/<G./X\"EI2^PG;W71PN[IKW:=O[
M.Y+[XA^T[<_%3CG:+R-8K^^9L8ZDUS%,'D:Q5CZ3$TR+>=06I0=3_'!`FG6V
MVP6T+:;="!7EZKN8U%8ZSUR\5-X;UW%6]/U'7F_K\9QVO^PIW8\9LBPP[;4]
M-[OD<6RRVO2DQ,R6Q!_R*61-,1LDLD*9?CF9&1=;0$OW";57*CN4Y)==W,\;
MD["7O8_6',!@<PI78M,F-6!O[8MVYK3=YK3&NZ5!09;;UKH&HL`Q,M8%-)BI
MLT9GXS%J0ZX@+&O==S^C.K;@];.2E3T91-QW'-YH.N8:H6)(T?6(^1N#TP3'
MV"YIC0W)4B$CV(8KX1V5,./E.H2EUO&5KP$:O23VT;U[:=G&`;BXM\(M<Z95
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M*<K*A!1%5@S/]Z>/,Q6;QK3_`#W7>FJL^L/5Y,L9'7DF1<D9I4I,AM9$_M]5
M!?#X]\,-/T;36IHC:>AN/LYNF)U'J^H[;NH6NZG9"[C<*=3H*$F)0RY3M2C[
M/:V'I:*4ZR5(MI(<Q[5J2E7\8#O@?CUH$08<(31VGQ0Q!F`Q!!]9TM@88,9I
M#`PH[#<*EID8=EM*$(3C"4)3C&,8QC'@:22X[:+D$-BNZ1TH3'$$RJYD.2U7
M3SD'CS3,PN52VE48AA!,K(S#KA:W4/)(001A:<J>4O`;<UQ4XOCQK<,/QOT,
M-$LQSL.S&#Z@U\.`Q$O?E_+&,",UY##(#F3W\Y92G#><O+_C^]7J'%T<'>%C
M>!TIXA\8L($'`%$;SH75BFQ1XL=`D<V,VJJY0Q@(5M#3?LQC*6T(3C^U*<8#
M;D<*N-B7!!S>/7&FQ1I9D^_:G;'QYU6[,RXISJ7H"/#?B*W$1##$"V.,+E9(
M1;I(@;/O5\Z5/*#:D<`>&),C)YF.'O$,Z%P"J,KHJ..&M$R4?&R2,/6$&1-*
MA2Q2Q3CT)6P@<<5+#6/9G"_^;P-2WUZ\"6ES"T<*.)R53[@CLQ_^KSJ7*3U@
M`BQH>749J648P,$$TVC"<)PG",9]/7USD.$S?6GP7-D(X<#@[PK56I9VSL[!
M9E>.FNG9>3C)YPV?RQ!/"5Y@5@HNZ.LE%+)PZG`Z5H:2E64*0''Y'JLZ_6A5
MA0?!'A?^'(6V*L,P*5H*CQ?S,00Y4A$H05%P;SI)C=F2PXXEU.`W1%NH<8<]
MJ<*#;Y3JFZ_3JS,2>.OO@V]LV7@DF$H*T51DT\F[,PPS`J"31J:W+IKC<D&T
MC+K0J"<C(]WQ8<SE/@:P/J)ZPVP5CE]?_$)2S1C42(S6C*([&I?F06PIO$<.
M5"K2$R>VCT5\:6U*QC"L_P!_\^!L2NESJ<5_7KTXH>[,X'8LNXT_54OJE0'3
M70UK?2%AY80^9%U*1,JR)AO*6_B]B&TI#9D]'W45A>77.O+BZ6\J4_;K?D-:
M14F^LO\`&P)AIQ^0_)=<C$LXQ[0E9R$E6,+PUA>/=X&^$],'4X8IQ9?7?Q(*
M6Z=)2"E$Z5IC^4DRYKLB?\.78U?P#.&/K4AA'M89QGVMH0G^/`TW_DI]2'_^
MN7A__P#H.H__`,BO`TI'21U%E9'4YUS\24Y&>6^W^/INJ"84M8I`F4D)$"92
M6SAHI6<-NX6VEW"',)PXVVI(;)*=%'3Y,`,1Q?7?QD9'&`=CFW(N@CP9ZAWF
M6V%N/RL*1'R91^$-8R@IUY93:\Y6ES"U*5D/V7T6=/IA3YCW7=QA0Z3@+#B!
M->A@"IQ'MD-,?`""\.$+EQ)*LOY:;1DE6$*>^13:,I#B:_K\=,SCN7E=?6C<
M+SDO/HAJW-M?]:*R&]Z,-VA+.,(:83EGT3_T[N5.M>QQ:UJ#A2OK<])*W%.Y
MX$T+"E+RYG"=B;S0WA2E>[.$LHVDEE"/7/\`"<)PG&/XQCT\#<R/KI=+1+Q)
M+G!#7Z"2C!#?RAKYNH,D1X!#K82(HD39C#T*&*V[[4#AJ8'2EMK&$>C+7L#C
M*OK5]*#\:Z$7P8I6"2!GQW)&/V+O8!]M3R%H20&G.URL#$,)7C*,YRO&%I]?
M3_AX&UG_`%D^DDY;J\<*8D'Y%FKP@#;>]&$-_F!B!X2UA6RW<I0'D3Y6<9SG
MV/.N*SZX5Z8#@COU>.GN%%DI6!X[;$D+*Q$.CP[CG)K>T6>XT)72X,"N,3R+
MLZ[%PY(;B!\XRAUIEM",81EM'QY#1"?5DZ>G,_/(:3VRH(\.)3)TXCDKN<^L
MJ<B8=,5%L/,YM33YR8!G^`U*<PEGVXPVE#?HW@-H:^J'TY#?JF0=7[LCHZ.>
MR65$`<BMH#QTY(H=(4'*RZ$S&2/V4:.6X.PZ*X*I+"\I5[L_W>!QBN_51Z?C
MW#L2G';;U.)$9)CC0HWDAL62K\VS+-/E8>CIK,F+8#QHYLMME:"&0F\/C83E
MI]&%//!R]WZIG3GEMH8/5.Y8F/8=A36(N)Y#[1"CFYF#CL1PUA^!$TK+E@>]
MSKRREJ4XEQ]S#7QM92VD.`-?4FZ=UD$Q#VG=SLQXL7"K$MZ>1ES=EY:3R08F
M7'*AO@3&A9;8$86IY#?QO?F+2TVSEK"LAM87U/NIR]$NS=LU[RJC<CC9CHD2
MV\C3)>0<BRHN"(CV\_BHFB(MNFE-E`AC9+6A6%.K=P0C(V6@Y:+]3[J%&KP%
M(:I7(Q&(M299VTIWS:&#98EQ);`C921V6J^@R(._ZYG\:.&6VZK'JM33CC2P
MVF>^HYU(V&?B94T;D[F&B%M8'ISN_I>1@<!,BQ@J(=@J8A9*R`13F(]2W$CG
MMO>Y_.&W6VT-(0&U6/ZA74Q9"5E/'<K(]PE\1^00'O(8IF16"$2"'^2B=I,R
MO&!6B/\`2]BD?"E&$-^QO*D9#C)GTX^HXEYAUB7Y81[;0P3+@XNXZRXT2Z+A
MK!!;JCM9EOH?DOCSEU*%H:3E>?B0WC"<)#>`/J#=6</-1<U!7;F#"+A4*7%A
M@;DJ/XHAR`$CA2?J3JP@@@H"1>,.2EY;C#CI[S+C:Q/C&0'!YKZ:?5M-RALN
M1M;F@V7(NX*-RWL_5*L$'NH1D\Y7RZ.<REZ1,]Y#B4^UI#CN4MI0WA*$AOU:
M^H!URU`(N+KN^^;P$1(28<U(0KNQ=*2<(?,1T'9ZW'29T/+<?SHTLV/@KI*C
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M6N`B;"B9D))N8T@S*F`NF@$R4(Y)-Z4Q*.A&-0<;AK#Y#[8+XBW1FV\EEI>#
M&L7Z\7`S'/&Q\`(7=O+`6&L'%"M<H=NVX:^Z:FK!;KQ7-SQ%2U_#O-26B93&
MN;#68Z/+ETE@OBDR0TQEO#214/8(#,"L_40Z_:M5;'5([D+S30+/"H':(1?]
M3M9C,X&FH@E#8*=,YC)$*1KLQ^(\R6R_[7&L%,*8(S\F`U%L^ICQ`NA4X;/\
MON;<@7:FS6K043/:$_)E4OEU61'=8?$T2$Y$%+DJB(^>\+EMR4=3E1&<Y<?R
M\$@74QU#\?NJZX\F1]%;KW;MDG:[&I(W8(FY680UZNRU%%NLK`JKMD@JE503
M&9"%O_\`U`C>"4BX:9S[F\K]G@34^`\"%':'0]POY*\L-I\M.9O^8<P;-L*L
MQ%,K='V_FMQ-)U%5:W/G35:A=>-ZM@M?SB&8H>2?$6[)&2#YK;JG"%N/*4O(
M<%X2_7<X)\">8<AS*TH1L`^X%#[.:B:)>F==6*A4<C8=DS+@'ZX9;H0%BHQ]
M'K[CT%'/!'I=7$DO-/J<PZOU#D'9]SCYHUF2)X<\`.)^_P"9Y$[-GJY08?ES
M:-6V%KBAI06VP\!+$[*<V&#%62*L1]1Q8F!7!SAAHL60^112B&!2F?`YWU,=
M06E^LJ*VE?JKLN\;MW?R9S6+7N[<%LFB<AW*>0!^YE2H.M@$MUL6&D+Q-S,L
M$0L9R50/*_COED);2K(3&^!T?R3X]:WY7Z*V;QRW`--G:OV]6WJA>H^O3TA6
M9:2KA9(Q$A%CSL4XS(Q[,FT-\#^65H6L=Q:,9Q[O7P,)MB=+_6KLK1I&AY;B
MAIZ%AS*A6Z0;L.IZWU[`;K+A*[+1$VIUW;`U37;435AD(C#DI(-OH-+40^K+
MJ5NY5X&1'$[@IQPX1D[M_P"VVGDZ]@]^[+5MZ\4T23>(IP5^*B!8:7EZA!NH
M^*IB38P#"GP!%)CVW&L9'883[DY".+F!]>C@MS]W9<-_\L9CD?>[[8)F.S7P
MQ>0=M33M>T^&6^EFF:[K$@`2#2ZW8\.8*E`AO>A)^5O!N#Y==RL-UJ7U\NOJ
MK\&+IU^#UW8(>D;[N&+W)9I:&N0<1M.;G*W(#DUF-L>QHFL1<C:H>*'86TRS
M(CD*%9)6VPM'QLN(#B.O?K7=8>IM(\@=&ZVJ.U*A&\D8[-9OFPX^_B%;?CM=
M/S5/L4EJFJ;!EJU(R<5KF=F*+'.R`#R2G#,(<0Z\IMUQ"@Q[OOU'NH^]&R,J
MS"[XHTK+2;4@6]0-G@0,8.*W!MPZX")KC]2D:_&03S[6#%)2.LK)"E8^?X59
M:\"6_KEZR^-'5]J.?TYQMC)A4%8KE-6^1LERS!RE\D%2JF?Q8F;M,5"0A$X#
M!CL)8$R^C*T,(2G/JK&5*"0SP'@/`>`\#K6(IMLC]KWF]F[$EI:EV>F:^KU>
MU>0`(U"TF?J<G>S+-;HR2;7DTPZ^!VB-'*:=3A#"81G*,YRXOT#F\S$`S\4?
M"R:25Q\F,Z&8D,\^+*4P\GVKPQ(Q9(4B&YG']'&76W$_\%8\"OG<NAR(FNPN
MM<N&-XQI_'2M;IW1RY*XG6[2U0O0DMREW96!*M>+*3;I$@61GZ3+CPX,BQ&2
M6"BHB4'5^J(!:=3AD.LN67U^M-<YN1>R]S63D-R^U!KW=EJX_P!YY+<9Z\NS
M1FCM]7ZMQ44J6L,M"E7:1=!)>K`D=%*6,M3=4."<6RZ^I.$LA-%P;X$\:NN[
M2H6B.,=*15Z@P>9)R4O)(BS[O:SB3#"ARKK;0XJ,DK<7$#F9#"?/R^^."VVQ
MA>4(3CP.)=@G6]QL[*]++T1R,"MXM.?NE3O9TCK6="IUKDYBDA6$"NC2DZ["
MS"I")CV;09E`[K:L(6Y[D93GU]0W7C=UN<(>)%JAMA\?N..L-9[/C-:CZHDM
MFT^J0M4N5RJ2&ZWDYN\DU,&!B;1(S4A4@3BR"`\J6<UEY&$*4KU#J",ZH]$Q
M'9O,]IX6Q-Y(W=/4%Z@R-`7>FG=0NAD5."I;I7^/NQ*YE(ZH6N".?KL2&(S$
M@R@O#&'4IS@,XK!Q]T/:ID^RV326H;#9I-Y),A8I_6E-F9HXMMIMEDHZ3D(9
M\\Q]IME"<*<<RK"48QC.,8QX%3&H_4KF(.\[P,E>R"]IU1R6V/!6[?>M*/H:
ML4TC8%=BKN/L#]''VDJ\V9^AR\=.R<NF-D(\9:A6'FT.-O-+(96%C#KKZY]&
M]:NE9#3FF)&Y6TBR6N<NM_V?LF3%F=D[*LLS,2DDU-7F7C@8J/F9>*!DTQK)
M?XK9*X\0=MY;F64*P&?O@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!
MX#P'@/`>`\!X#P'@/`>`\!X#P'@/`K1\Y2+9U'\_]>=CM-G[?(<.N7EGINB>
M?VL0:-3DZZT[!5"LNQ6J>0D/)5P:-MX)U+*.D#I;Y!)1#T.F64\^UG(;:`LB
MU^P0-L@XFS5:;B;)6Y^.$EX*P0,B'+PLU%'LH)!DXJ4CWB`9"/,'<2XT\RM;
M;B%8RG.<9\"-'N=CYY[K)YL2-8KNOIB3$XQ;U`EI.^FRT>JO4F4UM8/\I.J[
ML'5+7(R=E<R$+@6,6D(,]Y*$D%,H1C/@9E\7XQ^,X^:<P0=+R#TAK/7\LZ[-
M.R&3&WI"EP+Q`Z`))2GH(5DCWX:CT^C8:?\`3QC&<9\#J/GES=UMP4T7/;/M
MJ@K%L*5CYR)T/I=J0+#MV_\`;0T4\;6]449F.B)Z0)G[$9AMO*VPWD",*60]
M[&&G%I##[J%X&7_C/`[XY/<C`?T/+[G#LZ<W'O"I5[8M_ME)HL$?(D':NU2V
M#9YLV&DIK4=?D'HM$PT*T6X.\H9;CJ&DJR$R_@/`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\
M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P.)WRBU#9]*MF
MN=@5Z-ME'O->EZI;:S+LY?C)VO3H+T=+19K:5(7E@L,A:,Y0I*T^ON2I*L8S
M@(Z.(/5Q0N#G(38FT>/N\MWUS0VPJD[`M<)3IB"-XRZWG&BZXN(MVI:PQ#!2
M5)DP(Z#(8(PD@E<F[)DD%NNO*2I(=G=D/!&%['>,LKQ<M.VKWIVG6>X5.P7"
M=UT+#$V&P5^LDDG/TM>)]DR)1#SYBF/S,/C%-NL,J96TM#BO0,L-04,G5FJ-
M9ZR+LIMR)UW0:A1WK;)`AQDC9E52``@OWI\?'8P`&;*X`^=UMG&&D.+SA.,8
M]/`CMK/5O$+YRW7G+N'DEN;=5H)N49<=)ZRFUQ58USQR*@P"ZO',ZWC*YAGY
@7Y374H;79TDM*WK!'E9R7E3S;:TA*OX#P'@/`>!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g275067ex10_4347.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g275067ex10_4347.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@##@)J`P$1``(1`0,1`?_$`)4``0`"`@,!`0$!````
M```````'"`8)`P0%"@(!"P$!`````````````````````!```00#``$$`@$#
M`@4!``$E!`(#!08!!P@`$1(3"105(2(6%S$C05$R)!@*87$S)1E"4I'5)B=7
MEUB!H=&2TS1$EM8HF/#!0U-CE%4V5C?7V"D1`0````````````````````#_
MV@`,`P$``A$#$0`_`/OX\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X#P'@/`>`\!X#P'@/`>`\".]L[6HNC]=VG:VRY=^!H]-!:D)^4%AYJ
MP%#L$FBQHK8D)7(^6G)4LN0-99:8%&>><<<QC"<^!#!?86M@7AQRM?\`4*'B
M_7\=#?('3Y.%^U\8;/N<$U0^TS_OF-I_K4G_`*O7_I2K.`\%GNG3#[R!T4[J
M3#B_@_EWB_K5EI"2%K;:6X\]IA#3;>5-J]V5*QA&,>JO3'@>`1]BO-P19`!\
M?TH"8)E>"V"N+.PT9'SA[\9CY'4Z,6QG\TC"D,>U:OF4A7M]<8SGP/,:^S/D
MEU]P;,KOAAYIV08=25QOV,*E#L:OV$)RZ_H9MK.'5?PPK"LI)],_%E>/`_:?
MLUX[42V#_>.UD'._#A`#O*_5S1WO($?.:;6(YI-)"'E!BNN>S*<*PAI>?3^G
M/H'X#^S_`(D*+%%(VO9(!DFSB4UR;N.C>@:-4XJR&$L"-1UCN=RU9!5*K?&^
M0C#STD:(..E7N=6A.,YP%R&-C:]*3E8M\IA*<93C*F+1"/)QE>/5&,Y;.5C&
M58_G'_/P.PW>Z.\YEEFY51UY+:7E--V&(6XEI;J&$.Y;29E6&UON)1A7IZ96
MK&/]<^![@,I&2;;KL;(@2#3#V1WG`3!RVV2,-MNY8=6PXXEM[#3J5>W.<*]J
ML9]/3./`[WN3G_12<^G\Y_G'^G_/P/[ZX_Y_Z_SC_P!G'_/_`.CX#P'@/`>`
M\#7ILK['M/PVR8;2_/,";V]N,F/OTQ;]6\K[5YML5RU9"ZXEZE7K#*[+!V%N
MW70E89Q8[D)'M,K?46HO#B,LX^->4ACSG>703;I+*OJB[[4H5327%-S7#[K3
MF71W2DY%>;[%4T6E+;64JRWE6$.Y2A7HM2<9#'`_M+KM7V?JW773?+G0?%L5
MN&5L]?IFT>F;1RQ7-;E6&KP+T^_!OR-,Z/O,VV=)LMH9$RD!;3CSR/<M#?O<
M2&T..D8^8CP9:).#E(J4#%D8R3CBF#8^1CS6$$A'`FC+=&+#+&=2XTZVI2'$
M*PI.<XSC/@=SP'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@=9:"LEL.((:0&A@E!`JA\K>?(<6+
MD1]LKYTX8;&;;>2M&6U_+EU.?<CV>BP[/@/`>`\!X#P'@/`>`\!X$,;7Z)T=
MHPZJ16W=HU"@2UZ:LK],B+#*M"R]I'I@(<I;R8*+1AV0DQ:O&R#!$@ZTVIL-
MEU*W<I2K&?`UQ?8;V?RG9.,MT`1F[=?R*WAJ*ZX.]*K"9_!8V'29<XU]XU@=
MML`&$;<->=]?:@1I;O\`TISGP-O0)P4F$')1I8TA'2`HYP!X3[109H1;2"!2
MQ"65+9(&)8<2MM:,Y2M*L9QG.,^!VO`>`\!X&";&C]93]9>INW`J)-4V^F!T
MTBJ;&&K\C6;F?,.?^X^J/0=F0]%6(R5>'_V05-/+?4C^E"LX\"(6N+..A\)2
M/RCS<.E&,X2D?1^LV$IPKV>N,8:K*,8QGXD__4X_Y8\#HKX8XJ<^;*^1.9E9
M)RU^0K.B]8^]_P"!3*V,/+Q6/<XEE8[:DXSG.$J0G./YQCT"J..1.8(_NR%J
MD9SSH6,I+G)MMLA=.C]7TX"+,MJ]P4B+8M#L()76HHJ2&AF%"?F.*R2VTYAM
M/]"L^@6R>XUXY.)0*YS9H)XN,>&D?QF]:4I)`KBTD-B$/L,Q27,-NI^3",.8
MRA?MS_&<I_@/-*X,XM,=+?(Y<T<MTTH8PE:==5MK*R1&GF1W$89!;PS\;9"\
M>B/:G.<^N<9SC&<!QJX(XO4XIQ7,VGU+7@G"LYIT;G&<EI2EYSVY;]N'O1&,
MI7C'O;SCU1E.?Y\#''?K?X6=:<'<YFUE\1`YP:FTQYK>%,2"OF+:;^.01E'R
M91ZXRGT4WC']&4X\#S<_6/P7^026CF>@LOF.'N$*&<L(J7%2GQ?L?]H:<:90
M@W#",.)2G"580G&<>F,>!SK^M/AQ02H]'/M;&%4SEA*`)Z[QSC+2L9QZ"D`6
M@8D16/7^%-+0I.?],X\#SVOK"X79<PZC1(OO2M#B??L#:SJ<*;(!*3_MNWI;
M?M^6/;QE/I[5-J=;SC+;[R7`L-I7FC0'.<$#7-'ZAHFM8R.&E@A55N!$'E,`
MSMA.M<J"1/OI(GC0B[%)/%99>)<;0XK'M2E*4X2$X^!A%ZUIKK:$6B$V10Z;
M?HEK+RF(ZYUB$M`0SA#7PO/#"S@)[##RVOZ<K2G"LXQZ>!6#7W%0>JZ96M=T
M#I?JF`I-,@8*KU2OJOM(FQX"N5J%CJ]!PL>78]:2\HF/CHJ+9;;0M]?IG&5?
M]2E9R'/S(;?([;O6>M+3?MB;&K>L[UJT&D3NR'JR]*L"VG3-0MT]&QSU;I--
M;-BV)J66Y@AW)N<ONN,I=1\"FD!<_P`!X#P'@/`>`\!X#P'@/`>`\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P(RW&YN5K6]F7S\)K(W;WXX:::QN.1M
M47K?\I4B&D]RS%TF+F+/@=F(R0IE`K/N<)PVE2T(RI>`TS:P[L^SB[Z^ZCV_
M):*X<;H/'UXZJU=LF*@MN[]*OUZN/-,#.F/'ZYC3M1#5\:$L<P,&TRQ)'I(6
MSEW*G&%Y1A(9G8OMY@4<U?7KLR@.Z#V!O'L;;_%NM;]I.#W+$GS.L`>D&HHK
M9$E&PX#I%LD)+6;!3Z$C&B"Y0M'J5[,MJ;4$87[[BMNQ\O,56@Z1TJN?1]JF
M[?K<A9C;.Z;#K>A"QVJ]*/[6"VW<;%C7TT9!K./%=!?C6!"T.,I2\,^[\B4^
M!TK5]RNY]0R_5E6V]H?F^<FN=N!;IW7"SO//5[VWZ;:(ND7]JDNZYM1+^IZO
M-T:8M22D/QAOXAPWHR[EW"4XQGP)L)^RKJC3]SYMENM>)Z3J_F;J+85!U;6-
M\ZLZFA-MNZNN^W!B'-6`[9J$QK/6J&(*S2*A@'I:*D#1127OXP[[F4/!:SNS
MLZT\B,\Z1-$TY![GO726[G]*52$M6Y(;154A#Q-6[%VJ7/6&^3E3N0@PB8G7
M)`S+&`\N/E$-)2KUSZ9"'P/L&W95RN?P]Y\MZ]H2^B.MJ7RQ42];]9UO=\0$
M[:-7[(V2?=I&4A]559AIV"SKY,?B&7ALDMV1:=0\E"<X4$T=T]M.\A0>K*Y0
M=*WGICI+H:YG:^Y[Y]H!`L-(7>>A85ZR6VPVFZ2K#\#K[6]!KC&3IN:,2ZD1
ME2/:TOW9R@*B:X^UG:^N-IEZ?^S/CPGA*5D-+;NW_KW9D7NNJ=!::O\`1=!"
MAV;9\,U9Z5"1<A5[Q2*'*,R)0,@,C!:&EJ&5GY6&UA#;?W4=-P.H*MV!M'ZE
M=[4'@FP05<V+)=%A=":,O%]I^D;2*Q)QNY+-SA7GO[]&K`L"4W*&CM%O&BQR
M\.Y;4O\`V_`LQ;OLIWS)]";VT;S#]?.PNI8G08.H)"Q;1KG17.^LZU-L;IUC
M%[2J6:[&[,M4)*R>,PLCEMS+6',86VE>?1#S65!:#C_MVC=D<B0_6U(IUOK<
M80'LD2Q:WL>8C-MK-XU%8[+3;]27)$(]VLR[\?:JF6,*>,6H$QKXWL+0E2DH
M"AE-^X_9,I0>>-W["^M7IW6/.71MRYVJE8WD9LOFJW0$$%T_:JM3=6VV?JM4
MVJ??&*](SMVBD.Y1&Y(907C*VTKQ[,ALVY3Z0CNJ-6R6SHVBVK7"8G:^[-1R
M%5N9%?)G19W1VV+?J.PENN5F6FHO`DC-TTA\=.'\NI96G"\85X%?5_9=I1'V
M'M?7-BK;'(V`[2&)Q6W0H6/-TD#L<FK3FQAM!2]J8E%&Q.XRM3UPRU,QKPF$
MNPS7R)<]V?;X'4TA]GW/V[N]NH_KICPK/4=^\PQE:GC$VEVKHKVU(";@X&<F
M)/6C\38I.4.726;7%(EAC10BA_V#2\-J;PM2`L'QOU!7^S.<J!TA5J1==<P>
MP";N,'3=B,0PURAW*-L&UZ\.Q,CP$M-Q3*CI"INDLI;)<5@=YOY,(<]R$A9W
MP'@/`>!2?90<85WYR>22&.1)QG/'7S\<4\(8Z\`DRU<MB%K$*0AF/&<(:_VU
M>]QYU3><X0VVG*UJ"X<Y!0EHA9:MV6'BK%79^--AIV`G(\26A9J'DAG`Y&*E
MHL]D@&2C9`1Y;3[#S:VG6UY2I.4YSCP.^...&.P((PR***RT.,,.TA@<<=A"
M6F6&&6DI;999;3A*4IQA*4XQC&/3P.;P'@/`A+H3HG4G+6LS]O;ML,A5Z%&S
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MJSM+G'BCN+6]EZ;VDO5M7V5RK>:[2'':K:K4S;[-4MIU>P6`,$"DP-FL;LA5
MJY(8+=]HJ1F0R''7G,>U'H&?:F[^^LV]TSI;LC46Z-5S,/K6.K,7U)M"%KMB
M%O%:BZ8'(JIT3L2",K0FQ$`P3,X=B.'<`4VV\^6EI/RX)Q@+/4GK7G+8N_-D
M<N4O:U?G.@=0U:MW;8^JVF9<6SU6IV^.@9:N3QK4A&B!D1TD#:`%86.\]\:B
MDH<]CGN3@(SF/L;X=K^@)/J.9Z6UK':&BKK/:V<V$5(F-A26Q*S.%UJ9HE<B
M,@_W':[@/.`/#MQL8&660II666W$)RKP/*YVZ@X3^P2;@]K<_P"SJ9N:X\\R
M<VD!0JK/6;QK(S8%==@)(F8H5F%K-F`CK97EN,C$GQJ@RDH4H9>5MJRD,YZB
M[LY!XL%K)/4G0&O=-N7-XIFIQ-FDB"+)8D@HRN0-B*K""2ME.B8W^E))J!,B
M#..-H<<2MQ"5!.6J]L:QWC0*UM73>P*?M'6MQ!_95:]T.P1EHJL^%AYP=Q^+
MFX<DL`K#!+*VG4I7E33S:D+PE:58P$@^!'&O=4T_5Y6QC:FW.H(VKL>8VM<%
M3EKLUH0[<)R&KT`<Y"-6.5E&JO!8C*N&EF*C<"Q@ZTK<:80X\ZI82/X&,76H
MPNP*=:Z)9$R"Z]=*W.52=3$S$M7I54/88PF)DL1D_`F1TY"2&0RU_"6&0P4,
MYZ.-.(6E*L!Z,##"UR"A:\"Z:^#!1,=#!O29Q,G(O"Q8;(0[LA)&N/&2!KC+
M&,NONK4ZZYG*E9RK.<^!3W4T3/4_M_KV)??BRJMM"@\W;MB$L-229B+L*8:[
MZ2LH,D^4ZZ`0$5&:?B"!4"X:2RI3V7$96[E:@NQX#P'@/`>`\!X#P'@/`Q*Z
M7VDZYA'[)?K97J=`C(?4[*V26"B`\Y&$(/>:9=->9P22D,1US#3?O=4EM64I
MSZ>!3B:^P373F:2-K'4'2.XI'99TG':[:K^GYG7D3<28>I$WP_\`2VC?#^I:
MT4/_`&@$^:.X@I2#$LK2/EQ:%X2&:M]4W%&%_L.,NN0,M.$8>]E?TI*H;'9=
M<P@E'Z;>4@Z7AX9&'<-#H=>_J^/",N8]O@910^MM+7J^NZH<E;)K_:K<<%+L
M:XVW2;7J^T2T5)/DC@'5ENXQ47&6]HET-W&4Q))KK.6U8=0WE.<>!9?P'@/`
M>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@:GM:<1;9K7,'VA:8EB*&#<.S=Y]R[
M#UM+`SDN=!-0?2M35#Z_?NA*J^-(1,E#+?0/)LC#&)90/E3*W\93ZA6.X_5?
M-8Y(^LBDZTT%S;4^E.<-Y<!W??>PXR*K55G0Z]H+$(3NZ7KVPJ_5\V&XS4Z[
M#NL-,D9_]RR3%J?RA><K2$07+ZI-X[?VA'Q^YM.:2V'SU+?=;OWM#8-`OMKQ
M?X:U<UW3G!.M:3-2=<G!?U[MF>O;KI:ZVAO\4-"&5+^?VK4X&'[_`/IZWAI*
M6[KTO]<6I]+0W$_V"<A;(@+_`*<E[.!2&=/==`4R7K>O+;J]A<.66/0[NC]>
MB6BUE_K`7\/$L,M)0V.Z$SQ?/OVM=NSO,>G^T]+<R<N<F\T;.TIMK9HE/W/8
M-[[1Z?M&D!1K%082"3"5&B4^C4+%\C@S9AL_&3VB@FE!X=;2E60N9]G?&SO:
M5DX$I-DTS7MXZ+HW8*K]T75+5FL.00>LD<^;RJ@<W(1UAE(PJ69"O=GA\88C
M?G.PM:7$M+2VKT"NW9_`$WS]J/BV-^K3DBF&M\T][UOJR>Y_JVPZ_I6JVB,#
MU%M6I6XTBSV]4D$Q.2ZIJ/"']&WLJ<<3A24-?(ZV&&;-AOM3ZO"TYU=!\;TS
MDCK_`(0W;-R^K-&[>W[0-K:IZHT[MS6R:-NRO_Y"UP"Z7K>RN1[BVX$XQEE`
MQ33;CZ7&W%I;#!+SR+WA]N6V0;+W'SI3.!N9Z%SCU?I&EZY%W!6MY=(VRZ]3
MZ\B=9SEXGYFB!+UM!4VF`Q&#HT!DY)A1*&LDX<:<R@<,7V+%?=%N?DR8^J.2
MX[U#3[)-:C`YUV;]B6=LUTWE^:TB;$"4FTW;7FFW(3_*CNTIW71N&/T1(#``
M<Q^8ZV\@9H?'@>5/?1]SYV1U)]D54Z.T)L&J5FN:]XLT_P`9].9+.CIF-KU.
MY?C*A9IS5IF)AZ$M9-+M$&PS(-34<4.DSUPG&<N+4D+V?6PQND;ZQ+5SIT3R
M!*Z2OW-M0VQS0?0J[3(BMT?HB$IM;D`HO:NFZ[`EO-$P>Z8^1PZ1C#8^'["\
M=EE.6%M+4$%_7)]+W.<#S7POL'H*G=($[5UCJW0^RW.>-Q]';WLFHM*]&5FL
MT^2D[)7]*S]_D*Q`62O66NC-L`NX)C(Y(+;8PS6,*]P0;Q3W!T[QO$7/G6Y_
M49]@EF@9+LGJZWQ^Y=<ZCB7:`12=U],;+V35;5B`7:)*WH&'K5I845A2'E84
MG.$K7ZI]0K&1]:WV(3?!]I[V7NC;M8[EE.CY;[9X_BE6H=>D1[735:(/C-?Z
M</GGHMW?A$,US^*/4,5C%E;'1@IT+#265J8R$[T[D+H3J2$[DZHI>G[SS)VO
MKKMFE=N\)R.UJ;,TBUJM4[Q%R_7]F:/MITFW"B6/3NV#J=*T&R!)D%"?.RZ\
M_AK++2UAM&^C.B[-UI]5_*='W)K:WZ@V9`1FU&K;K>]09=>LE4/-WELV39`)
MCCBBS%`N@FM/`E.KPLX%UDC*4?+[$AMF\!X#P'@4VOHJ5=X\UF*.A05-\W]5
ML-#%+2W.3V7+QS`MT:)PIQQ1(L.E&'R4I;:^/Y6U9<5C/LP$C]+=(4[EW78>
MP[A6-DWG$Q<:M0*S1]0TTO8&Q[=;;><H.(AZO4@2!294C#;3Q+_M6G#(@[KJ
MOZ49\"FHGVI5MY)3QG"GV@PP03!)!1\MQ!L5@5E`K6'G?=\!9)&<?%GUPK#>
M4>F,^JL>F?`OCH;=M"Z1TWKC>^KBY([7^TZM'6^JD340;`3'ZN21E2&):$D6
MVCHF3$=0MI\=U.%M.H4G/^G@2WX#P-/OWF6"&K/`TC,SMZO.L(T#HSD60+V3
MK&%F;)LC7P$/TIK.<F+U1:_!0-K-F+/38*,*DQF<Q<DUG(F<K&=3CV^!H-J<
MY,=76+M^-Y&ZFZ&^TEC8/U+]1ZON>Y>A-`V?7J-070N1KDCJ70-!+I^M=4A2
M=BVVB>E)*4@?[6EIE]R)C7&"Q6'24^!?6\?9#SEWC"_6QR]RM,35VZ2ANQ^-
M[YNW1ZM>[-K=JYUHN@B577=TYLX*>`J+<%$ZREZNNNE.Y+)'S.K0&C#SW\8"
M`)OH?2W/VX(S<F[-[T37-'UM_P"I`Z[C;;.6*3L+E>@!9[C*X0R(NU.#QY8L
M=)B,3`>1E/MB!AK*;5A;N,+(6$G=,_:E]?\`9/M5^K[H>$[#TK*<WZ[U9WI4
M[OM0>SPA%!K%\LU,U$-"UV0G3H@AT&Q3(Y+/L8$?9+<95C.?^W^?#@1YUWN?
M3G3$%]T777-D19&>>"OK&UYI69Z5%JEMH6L^C-KA7G:DH](Z\M[X<([M"/HE
M2G!8(N8$;*&_[C([*B6%Y0Z'XN6E-E2W<?V9]I<=MLRW;?"6S.'[/$UB)D9B
M7F-\\P3O$>LR]Q\?3E9=:A(]43L.*C'YFL>\/,@BW`#+;*&4O.!@@7BG?.IH
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M@)\(-4W5.1,^/`6[?.OJN)(FA5.B;&L44^X`.VQ'9)^!9:PVE$>YP-E_@/`>
M`\!X%48-:4]Q;/;7C+:WN5-&+8RM*D?E(&VWT*DO\9:G<I)_!R6S\V$(QEC\
MAKWYS\K>/`M=X#P'@/`>`\!X#P'@5VW)N"R0$]!:ATY$URW[UN4:9,Q\99))
M\>IZYIPR3&'=H[/1$*786ZCF8%Q'1X@B$ES<HO\`&9<8::,,#"F+N*[`;RA:
M[JW7,AVIV17Q+7#7CI;9SPP6H^92C@`+6;5;'<0(V<CM1&6)N:!Q&4:DQ)E@
M(CUC.RRFAE8E'`Q+KG3?1I&N]3;1W7UW<JG(43?.FRI<?E:@U?6];I(>RIXK
M2%JG8N2O<3N2_3*(&!VR\I+YIF`_B84\\!_/M0%D8'B[9M92R['?8=W'+&BJ
M%<&7=)/F2T1[CHAA!B4R<=GF6-S("D_D_"^WAYI3C"$)PM.4X5X&-[YAMS5Z
MH6N-WYJ&I=W\V.B0)4O5*-KM@?HB%)"DL$FSH^LSI4FD;9'@'V!I`=$"_!60
M;+"\@!21>&&E!B%3VDQHVAQ^]=&7ZW]*<4%3#P=\JAA\Q>MJ<S`A.Q=>DY:F
M/2@BMCS5'UJ:&^Y;ZA95%V:N,?DD".?&'F)\#9K$2\58(F+GH*2`F82;C@I>
M&F(LM@^,E8J2&:,CY*..%<=&-`.$>0ZRZVI3;C:L*3G.,XSX'H^`\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P,=MUMKE#
MJ\_=+?+#057JT2=.S\R9\GXL9$QK"R337\,MNNY;88;RK.$I4K/I_&,Y\#7!
M6?M@TE;(R"L,7S]WG_:5HAU3U=NCO$^^7*E-1*@OSPS(Z;"JQ@Y*)-E2,#83
M_+BG$_QC'NS@,N/^SKGJ$AR+!9J'UG584-32#I2P<=](!1X3CTR+`H:*.;UR
M0&T[^P+0GVY7Z_ZX_P"K^GP.>L_9YS#<H6$LM6B>EIVM64,&0KUBC>/NHBH2
M:`E04R,2;&236IE#%A2H;B'!WTJRRXE:<X5Z9QGP/[??M.XGU:Q7R=BW_9]+
M&M=HC*36R;#RUU='#3=PFBD@P]8CGWM)8:(G94U6&1A<9^9][^A"5*_CP-;6
M\OM'U?L#IWGC87#T5:.F;S`57=NE)"FDZ3W54Q\R6R8^"V)'.14M<:Y03%&B
MM<]'-E?@BSB/B?1AQL;.4/*"'>V.X.X;!K+6HNR.<R.5+)G;^LMQ:8L-IB:5
M/3AY6HMW:O"L4=-UV0V';@ZFLRJWO.<O&!O+3ESV-X0M7SLA3JK?=QU_&6#M
M+7NRMDZGVY68#1&N9774^3186FJJ]FNVM]DJLT2TG72[(S/S*[!`#*RB06H=
MI"L.--Y8<PC(?2Y]6T)'5GZ_>7*Y$LL#1D!KG]*`,,EA(PPL78)L)D<?\92V
M5L,(8]B%8S_6G&%9QC.<XP%^_`>`\#KCB"B8<P*,.-AU>'7<#LMLX=<PVAK#
MCF&TI]Z\--I3ZY]<^U.,?Z8QX'3&A(4,]^4$B(L63*94.3(C1XC!Y`ZRR)!;
M#YC322'F5'ENOY2I64Y><6OT]RLYR'DGT6DRK)`\I3JK)#F2CDV6P?7H@QDJ
M:>82,[+D-$".(?E'1DX;40K&75(QA.5>G\>!2$S7&NW/L%KT-_CFH9B1>,K>
M6H?->!5$8*,WE2DL^V(_"S"-&XP&ZKY_9@E:5>WURA.?0+U'56KR=;>ILE6X
M&0J!$6F#?JIT/'EUM^$0PD5$.]!OCN1CD6D9&&\#J:RSAO&$^WTQZ>!RQ=<K
MT(3)FPL##1!DTL%V8+BXL&/)EG(R/'B8UR3?$8:=/7'Q8C0S&7<KRT.VAM/H
MA.,8#S!*%1@*V=3@:94PJA)KE')*JB5V'&K<@N<*?.FUG0;(:(PM<P:4Z\5E
MQI62'7%+<]RE9SD/Q3M?4+7@)$90*14*-&F$K-+CZ=6H:L@E&.J6MPL@2%""
M8?)<6XK*G%)RO.59SG/\Y\#@O.M-<;.CQHC95`I.PHH(K\T.,O-5@K9'B&>S
M+?Y8P4^!(#,%?'G*?D0G"_3/IZ^G@9-$Q,5`Q@,+!QD?#0\6*R%&1,2$-'1D
M<$.C#;`@(`;;(H@K#>,)0VVA*$XQZ8QCP/0\!X#P'@/`I?JL>?L?:W5MRDY)
MI,)1J-H32-9KZ(5E'M:9A+!N.8LZY]PYPU\R6D-J8`>%0.T*EB*&7A;CORX0
M%T/`>`\!X#P'@/`>!&FY=FQFF=57_:<L`7,"T>L2D\S`QRV6Y2RR@PZDPE5A
MU$J0/F:M,RX/'AX7G"5%$MXSG&,^!0W-6V=2(.$T=6+:4UV3UTS-;%W_`+X$
MBQ)5[3]1B@0HZPV"`!(D'P8^,U\B9"IVMXM;CP:#%YDGFS%,2N2@V`ZTUE2=
M0TV'H>OX,>"KL,PAMMI"W2I"2,^)M!DY8)<M;TG8K++N-_,?)&NOFFD*4Z\X
MMQ659"+NOJE)7CEO?]:@WW!+"7J>ZFU@ME;31`=K@X0N=JQHI+S)"`BP[#&#
M.-$80I8[B4NHQ[D8\"4]7W@/9VM-=[)CQG@P-A46I7@$,A+B"!0[9`1\\,,^
MAU#3J'F&3TI5A24JPK&?7&,_QX&=>!1?>]5E.>[;*=<:N9<17&V!7.KM6QS,
M<-$;&H`#HHY^ZA&W6,8'VUIVLI(+4\VMI=D@1E1Q:UK&BUBAR:3?C=%[CSH.
M"+CE:+W!5IG<O,RF91M8-9*")BR-HZ>K3+S;3:ZHTFQ"VBLB".D?AQY<H,AL
M:/CPF\!>3P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P/$S$F_P!R)G/[AEL1
MV(143FJ?'$_HE&J/09BPY=_6?O?VR&$Y&PG!F!/A5G.6<N>B\![?@/`>`\!X
M#P'@/`>`\!X#P'@/`J?W6@]SCWHI,8VATW_%UC4TAPI8:%(0.E9'N?;4A>/0
M9*\^W&?5ST]G\^[T\#5!N+=_,^T./>5N&-H4W:5Q#VV)P7I6S6W6!4-58C4^
MRMHL4RRTF`)N!4DW9X:\?VO`DRSP,3&DE,P>5I(("R0A?@7!W5SK4^5_K8E]
M#T.;LTQ"4Z:H;S-GL[H!]IF)BT='52VS4[,KBXD"+>+*G)Q]U26A&6$M^B?1
M"<95@.?7W.+76'U$Z%YRE+_>=2M;+Y#YOA2K_KXAF/OM2_54[7L]@RMEG-N-
MQ\MA4-AE#JD*RSA>58QG*<8\"FW-MQHV[OKOBN..?;%M&P;#ADR<W2YWH0]N
MOV?:E4T[V<!#[LM86T@"9>&ODU1K>*5$R,HK(SDI*NC$+92.<AW(=7[L;5M:
M"VSQOGGR[5'7F\X&7N=UJ]NN-MKVM(>`@E#"ZNFYV4V/;M-;RK437QCMJ!1I
M;!D&L/YIH9Y\@3XFGO`H7W-*]/W&B?7O3KKLJH=,]#0D=1Q>J1A+EJF#J.KI
M+86QM/CQ5L@]A:ZJ]6II+%WOVI91T!N1+B750`)+C:!CFFD.A3,KZ\_L19O'
M55RL'*EJ@*E)Z7TK!JMA&PQIFM62O4#3.T*W:0JA7`]T6!<H"R?8AI!6)=LM
MS!3&,I2]A][#H?7]];\@W+\/<Y2[+XY3,O152S!8I+90YC$K.S$@.:RMLHWX
M$&L$I=PPIYUP;W_"M2EH5GP+N>`\!X#P'@/`H^3Z_P#NR6%_J?PG/#]G_HPZ
M]@=64[YJ7]2F,/8'6^C"O1*\MY6E.<XPK&%9PH+P>`\!X#P.@5*1@*TM&R(`
M;BD^]+918XZU(SG*<+2AUQ"LI]R<X]?]/7'@=QMQ#J$.M+0XVXA+C;C:L+0X
MA>,*0M"TYRE2%)SZXSC^,X\#]^!07B#>FT]T3G3K>R+#!6&*JFZCA]7IAJJY
M4GZSKJ0&>9BJ=-C$O/'S4O"'0Y*URA&!W34$)SD=E*<84%^O`Q6]&3<=2+C(
M5HV)C;&#5K`;`2,_%FS<$!-"Q);\69-0T9)PLE+10QK:%D##F"/OLI4A#S2E
M86D*B\\[GZQW+HC3FX']6\ZJ1M;5U`V2%D7=&SH).8^]5&&M`>7H4G0=B<B"
M<LRF/D%_/-P/G_;P0][?D4&=\\T3<T%?NC=A;CB-=UTG;-[I4Q4:]KRS25P9
MBJY4=75.BNXL%BE:+K\N1F9*<@2S$9R&Y\`1##'RJ^'VI"U/@/`>`\!X#P'@
M/`IWUBT18++R-KI.$)CKKU73I6;==)`0RH#3]'V'O4$-P(KY"I')UDUH`A*!
MVUY:5_N+4A",KP'[T,#BU]`=;;9D7B")&.O%.Y^K8A;2,)K]-UA182XDL1ZL
M)QG#=DNVTI,Y]?KZNI2.A7KAA'H%P?`XGVV767FB$MK'=:<;?0[C&6ELK1E+
MJ7,*_IRVI&<XSZ_QZ>!3/BR<BJ9R=KR%M<U$006K%WW5"Y&7L`F8YN)T_L&T
MZ[C"E3QLB2&6S^CK8RUO)+(;0I64_*K*<Y\#U-B]\<=ZM+C(RT;^HYLY-$1X
MT/6*$Y*;7M\J]*2;D,&F-I^K(VY6<U"I-E33BVQ%(85CU<RC&<9\#I6'JQ^8
MJJ3=<\J=0[E;L$>>P)".:QB=4#%_)AP!`5D;Z+LNIWX>./+SEAW+PKJD,>YY
M3*F/:M8:\ZC9-ZCZ-YNFK]5-<UYCC_LNH:R+O=EW2FZ;&Q#KV[/<OR<&;&PN
MLA*^).D:MV4TP1[IC""%*;<;]R5-KP&];P'@/`>`\!X#P'@/`>`\!X#P'@/`
M>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>!4GODY49PYV'((#"D5!\R;R?P!
M(AQ4@"9\>M;)G\8H&<#D(4IE['].4&#OBJ]?]UM:/<G(1J#]<?,@O)5;Y4I%
M5?T]4X8_5-]A[QJ8.J4_:L+N'5*Z9(53=P=F_MF3CG=NMG4D%1<P4$4X:WAQ
ME_#C+JV\A7D3@"C;PBKE2V?M0[MW%#19XD+>:U']!\WVENOS<5,M28`LXW7>
M?,GUV>C)ROX<:PXM@AIX97IC&4*]`FRC?7E):UJE7HE([O[P@J728.!J]1K:
M;WH>3#@:S5XC,#`0(Q<USK)2Q0,=$I::PHHE]]SX&UN.+6G*LA[L?P[PS1-<
M\[Z'V/1=87Q&K2)\?2Q6[!Z/([`F[1/VJ(OMYG07OUD`FPV^XW<(&9GG`PTY
MDI-#1)+:W?:KP-9?7D2;Q1VY4NK-F7=.VX&V@;C$J*=CV_85QLVK=#;!VMRX
MGHVH434*VGJ'-"4FL&$D1(L/^)(D0F/:0)(/QRW"PK3NCN;[$]8HV'J_D'B?
M6,?5C[Y?Y:)A-3\?7&QQ&GZ!#RMM#T[8=O9:OU-H&WW.M:9!`S4/(4YK+\&.
MA0Q8SY+P[&`XN5+3]QEYHLIR6V3K&@:@(V)=.3:KLDCE_:4#.UVC&5O85YM&
M^`+%!;?L--K],K-.`<K%+!;6+EJSO0C#V4BX?]P;4*=KKLSZ[=%T.&B+S5>N
M]*Z?JA-(>UQKSE^4HVZQ8M0<FBH7:+9I.TK;%W)JN3[H+,S"Q%<`=7"J(*!1
M\PR!'@FFL4S[+9RH5B>/Z<YC@):9IT#,RD%,\;7YHR"L4B($9)PAWLZP9REF
M*P^ZRI64(=^9O'N0G'KC`>M):X^R]#ZLPW5G))`Z5F9;3+<>[('=6A,:,N.2
M[D'K!Y*,O3'S((RGU]@F$*1ZN94G`=0ZH?:</EO$3OKA60QC",.9FN9-Y@Y5
MG*W5NK3B,Z@?QC*4X0A./],XRI6?YQCU#'B:]]P*%IR%MOZWGF\$B^Y)G/\`
MTRRI0F2C\&Y]P_2+GM(2$D7+6/\`IRZI["LX2E&<A1_'`'VRMY<_8=N:ON![
MSSY9]D.V'WS17Y4TYYPPMY%.H'3$;2ZT&T0^IH<.,'8$8'0A*$)QCTP'Z`X;
M^X2NVBF6>J=BZ$#+JMIB+*4Q:;[WUL6M6$*)+9=+IUEHMYZ&FZ]/5RT@K>&*
M5G(Q0GJAX=?R)QZ!.[^D/M]3N3.]PMC?6CBZYU:C49()&H^G?T9]=9N"KF)(
M)<;V]F7CI`0XI]KXOG)8=1G"_1"L^B`E6/!^YMMG"I6T_6(:1EW"LLQ]"ZJC
M&4,)%*PIK!).R)9;KKQKC*L.?"C#332T^QQ3J5,ADR2?MJ2Y*+7"?74^TK(B
M(0=-HZ6$<:QA(>3R90S-0,21E:D$)9898:]N'6U*=5\2DNADT9+_`&<MCNIF
M-><(&E9,-6R[&;DZ"C!T1ZR%JCQW6"M$RSCI@XN4H>>PXA#SF,K2TUC.$8#T
M/W?V1_\`R,>(/_EZ;Y__`-=O`U^QG/>ANGNW=YU'[.^<N1KOO`VE:4"YUBI*
M+D]DQDWK*#K]XGK6)KFU;.HE/,//C;89(D2L:`QEUEM&'G,+:Q[TA\T^[#*W
MIKJS8-#K'UY;;V'K'7_0O0M/K$QIL1>-17"HP%YJ\)4JG2?V^\*)F,BZG7:X
M359L+#*1G4NE`!+;PIET8-GWT>:NYI[/(ZDA=_\`+6R*M=J*[J"9IE=W3;[V
M-+LZBV=JBM1\E$B08.XK8VB,,O\`KR1DW\FX;))9EQE.8SC.66`V_?4_%1M9
M<ZTH5<KA4#5]3[M<U&&TT'(-UH"8HCMB%E:K6966:'D+&/7XXV/=?+4WA+;I
M_P"+E2W1G<^!M]\#'K<VAVIV=IS&%(<KTTVM*FGWTY0N-)2K"F1EMDO8SC/\
MI;4E:O\`1.<9],^!7?A5AH7B3CL9E*4,C<L\^CLH0.6&A#3.IJDVVA`D@Z_(
M"H2A.,8:?<6^WC^EQ2EXSG(6I\!X#P'@/`>`\#I24@+$1Q\J<MUL&,"*D#%L
MC$F/(%"8<)(6T&$R086ZEEK.4MM-K=<S_2E*E9QC(4ZH7<^L]H=`$<\T+6_0
M\]-1$.S,V_8)6E+75-54)J0&G#(`*Y6B[-UJ0B96U!P2B(H=(#RSA21B&_5A
MY+O@1']G^R[SH'5NFND]7:&F^F-DZ4W[77:?I6KV0.LVJ[2FVZ1?]#CAULHX
M,]DZ0#-V<P4Z-AE2W`F'U)]N4^Y(:3>7^I/_`%!>][UOROZHX8YEX]/GKS$;
M"O3/4=MG[,=1K9?-<0D`#)Y%K5V$MDW3I@FA)DF6F:PVZ*A]X5+Y:F/>H)HE
M>$O_`%'N]YF'E=T?:SSKH>O-$*DR:%S#J*SB#,)D(D59-<)L*@Z-<CPHV9&0
MEIY4Z\_\>75)>PEW+7@2U,_^GX!VZA3/5OV<_9#T8!*DB/W*OG[>J]!K=P$B
M7G#8"!.#K%,5)1=>A)*3E7&A@#!?5N3<1[L>QM20F3CSZL^`=27/;VB?_%RA
M72)YMV!4YS19NYV);<TM4J'LVA0%I;9KIVV#K4Z&.-L02Q,I?#2VRMMAL;.5
M+#SA`;I(2!@JU&!0M<A8F`AXT9@*/B82.#BHP`,5EL<80(`%E@448<=E#:&T
M(2E"$83C&,8QCP/6\#3N84Q;N4)Z0"=DFI3JC["@_P"V9")FW3"C8\7KR&BX
M"<#<CAYK]:$!J34#910R/>E@<1Y2U(_JPD-Q'@/`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\",-V5?6EYT]M*D;G?C!M1W
M/7]NJ6S7IF?558I%$LL$="VG!]E0=&.0`RX4YY*C$$L+'QGWI<0I.%8#YLM&
M_61Q+O;JANPZIL^_M:\XRNI)B1JNK#-_=F:SONU9$&Y9B5[JUW>B]V%EW>BC
MEPJ<94P8,X**<*X3'I;-!,>"U1GT=_5WS:+-3=#HW3U7L5UD1I$^!U!V%U+6
M[CL:9'>1&-F$-0VYX!-CF`FIU:$.FO\`R>A"FD+RM["%A,H7TO\`$=I`BYV&
MV'W%^M,%9,%6#]A7:XJ"6"6L/-_EC%[I_*8>PAW'N;<2VZVK'M6G&<9QX&MN
MI?25I`'=?0%A[JD=Q[*UCJ&Q`[>Y<O5>Z?Z]M=FTY6HBP74R(ACK-.VD2P8V
M"?71H%T>/@')Z2)FFBE9+2DF-#2'?.X'XJVE=,4KH"F=L$`2I]K@:7I0C;VS
M=SW84RR5F"+CY:Y6LFYV:[4>^O:F<E2I6M1"F*]!P\UE,H\[*+%=="/JM]?&
M]K%KA[7]`UI#YK1$7;-.1UF@.@K,FQS.H"[73Y>F;6$W"_'1!]:O^=%V1D,.
MMHE#_P!JO)DI^W&)0/[`N!S9PEQ.J3D=/:(Z?^R30Z#G2K;!0L%W#L6H5+:@
ML?&0M.,N.JT1ENE8+8-?CV1XP9R7AFG!'7164J><3E6'0N*_]3D`[GU;^P/[
M7A<?,EWVL=Y[,5CX\+PO(W_="$J^%2<>S.?7Y/;G^%X5Z*P&)6WZ9=;;`AEU
M?8/</V;;`IZK9"7)5,O?7TI<JL_)5F8`GZZ#)Q%DI\FQ8(&)EXQA](,E^8,^
MMK&7TO9]?`\DWZQZMJEC6-)AOL#^V"H4])?]K5E%=Z>CGJ-2X6NU25Q`U:PF
M2.MC6X&LX!9P-'/D>]QTUD4=9&59:0L)6'^M&^!GY.$^TO[1&\IER9ED4K;O
M/DL$R^2XZY^'D68Y@D&R(EG#V4MAO8<&0G"?1']./0*_W3ZP*'U',9USL'[*
M?LLM-EYRN5<L0T#);'T/2K+6IMW`DU4;PR["<OUR7M-=FUP[C04H\X=&G.!G
MB86M;1S*0L)=N-;_`$FMFV&?^U7[%(:/:(BHM,IE[D250')6*7`KD(XZ"#QD
MZ^\QF:E1TN9SA+3:,Y6ZM#:5K2'3B^&=_P`S`C2%8^W[M^7&*0@N)L(\/Q5/
MQI3S?RLK=RL/EU`<I&*>3_4RAQ']2,X^3_7T"NUMY0^RC_R!K>I]??9KT^O2
MBJ^U8+SLN3HW$D]>ZR=)`75+`KK2]/PY8H^)>(BV`150)")%F1*(06WF)<:>
M#Q('Z?.F=<[1V!T3$_<[V!"[+O$2X)?+',:\YVDJ%_;P1\3/OO!:SL%*,UK4
M3E$P+>#9,(`8AP!'P>YMOWY6$J43D_M;8<.9,T3[Q]XVV)`GIROF2,=R[Q@8
MV/-0\@Z/)1SBTZG;],#.93EA6,9;?$6R^TIQEUMU85;L.OOL^UCN:0I>]/M#
MW[JS3-AMHE%U!O\`7SUP_8JU:K1*P@TE7H^V1$?K9$K4%SYH<N*WDIL=EAX(
M9"GE9/1ED/,MW`G4NSNC^>[8?]T?6^-X0=3E+3K^/I6D^?GZG6JI*QLXV5-[
MNHVN<Q&O[33)(\`Z.AY*P0K@F9A6!QB5$82G`6!N'U8_8%?;;2+3:_NPWY+-
MT>8KMIC:XOE/F(6L*MU0EDS=:GLP(,(-&Y?#D%+^7+K;S[['M94[AO&<9#7A
MJ#Z:_L"Z(,WGL3>?=^W><[I=;Y:F2XHOE?D&U!7*%M=?KCTI+PCD?'.'UR%<
MDV7`W`L.-87D)IYO.,Y]W@7(T%]-W<O+MALMJTM]O$_'S%JJ%/I<RW:^'.?9
MR+.B**)^'6?RPHN;KJRRX8=QYH8AYQQ]EAY3>%Y2I7N#*I;C3[,N6]4;XV36
M_MHC3@0T[9Z,M\09P=I12YFVO0<M;[8-$R$GL50M>BI4^+9P,TK"V0T*=RI2
MO=A2`['-6L/M9Z:YYU'O*/\`MMK=7$VS08:TN1D5P;HNR-13THCVFYKUE<M<
M8S+`(PA:P"G@&\N)RVXXSZ94UX&3;2UE]FFD:C$BVK[3*3L20M2(W7-/HPWU
MV:XG=F[-LLC$NQA>*]$![ZK$=+SC+.5S![SR6(:."%(*.2V`T[[0VX:&UA_A
M+1NF=,?N_P"YO\1ZHUWK'-D_4B0.+!FA5"'JN9O$$`XZ!"8E<Q7SX#84ID;Y
M/C1G*4X\"6/`>`\!X#P'@/`_#B,.(6WE2TX6A2,J;5E"TX5C*?<A:<X4A>/7
M^,X_G&?`I=I[Z]>3=&7=6S*+KN:)V(Y/S5L>N5ZVAM;9LRY:[&E]$_:$XV%=
M;+'C6&724XEXQEAI]2%Y1A6$>B<!,G2.KY'<6D=@42OGYA[F7$LSNN)[!;H/
M]N;3IDB%<M7V-PAE#BOQH*_0,<4^TM#K)##2V7FW67%MJ"DS^T8]M&M?L#@H
M*<9)@:F5HKM[6]78"EK%4(V(/05)R5KB&B\NE37+FR5'.$?CIR0NISDF:UE]
MA`R'0V<Q,M%3T5&3L%)Q\U"34>'+0\Q$F#2,5+14B,V9'R<9(!N/"'QYXCR'
M67FEK;=;7A2<Y3G&?`]#P*>.9;IW>`ZEE)'%WOS$Z,R(HHE*#+'SSL;\E3C8
MF7,AN&.UW?"O5>$I=PR%Z>JDXS[0N'X%5^I-HS]=K\)I_593;F_-[%N4O73*
M!#)'^RX1]P8?8&ZI\<%M>`JOJ2KF/2*5EK%$D9K$?$X?;(D6?`A&F:Z@[%O/
M36DJ;_\`V+^O6EUO)2A)%@@:>Z"FM?/TR@U69'6LXYTS5^H)DJP'X(>^1R0M
M421E2W&%Y\#8MX#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P
M'@/`>`\!X#P'@/`QNXB09U3L8MFKC=OKZX625,59R#9LV+"`R*Z^1$(KQ#)#
M,V\>AOXVQ5(7\[BL(],YSX$52U.U=O\`UW5"*W**CXZ!.B9O7ELHI#$+/Z]L
M%9(90./%?$RI,,5%.!JC96%*8RPXQA^/.&4WEQGP(QT#LRL&7ZWZZN=OK-HW
M[&%2`$Y9Z^X/FMW/%8"KX5D!J7X:G8Z#FJ>ZH)$_6%.KEX5;PSI?S-$#%O!V
M-SMAZ$7+[<K]\B-94VR2CYFU:P-3P[#8+S:2XDP*`DM2PX3"3)/=ELGVXJ.<
M')8EVI@)A++0K)?M*\#!]4\K15A*KVQ[_/V^9$AA7YS4=0LKT&NR:_M%H@HQ
M%AV#L\R&,GJO>>@8&59=CXZ02HB+JX`3`T:W\N"#"0\2L\MQVM+'L(<2!$9@
M3_QC@=U7J\OV0FMU%"IBY2@<;6)2%8CZBS`7N+B9"3^*62Y=90DR9FWG,CM"
MN!BEE+H\CKV.DC#+-3N/8^P1YL<*XU<;!N[L"_R\X+F$J`@-J95LO-4E9P-^
M-Q'.,O2-QCU,H8=%KS>?SPC"]:Y#WC*BU>X%VRI[I'APB]#:@UU8H*D1/($$
MP=`.2>Q&]D"?M%%6P&PYQ5IB:@%$"MB2+U=AH]YMD\ET+-Z7Z]CL6V6T/N^0
MAPMG4=)44O957$E'-.[-75*Y7Y2Z2U=L)4<()"R].S-(_N:-4IX.NNN-MO&Y
M4XE"0O@E6%8PI.<*2K&%)4G.,X5C./7&<9Q_&<9QX'G3$-$6&,,A9^*C9R&D
M6<CR$3+@C24:<QE2598,!,:>%):RI.,^U:58]<8\"&G+?9=86IN)OY3DYKJT
MR[8=.OS49A)U7FY0B#!C*-?6XXDEPW]W+'GO1TXQ'1\4"",V(>M)/Q$F!R;?
MU"]>/P;Q09<2C[MJ(16*'L#`+)3#[+K)2E4N\C):4_9=:S9!.<F`95AQAWVE
MAK8,::>2&-<][?FKZ/::+M,<&K[JI<M(IL^NGX]<8>'5"#5LUJR1#I,O*M;!
MI4LTE30MH!2*%(O-.-NAQIS14<,&:V&'NU3'9CM7!BK`LE@CHY(V(JN)A=4`
MO@GNRML%@,2U-S98-^3%8_)CFBL2&"9!\MM;R4X%P'H:GUM':YK^1FK)/7:<
MEOUY=DN=FFI"=E)^6!@8:OOEM/R1\FY&Q[R(-#B0FGE,M.K<5ZJ<6XM81%T+
MJI_=EJHNL;;LLF`TW98BR%6[5]=A#1[)M&6KYD$<+%SEX2\9&A:S1%D$-R\.
MX(TN56ZRWDA;67&<AF<UIM5<FH&YZ1_1T2>AXZNU26J26/UFN;M0*Z+(1D+6
M9>(B@"4P)5/$E5OPTA&#LDMY&9"?RZ!_LH#!8^HZ8ZRI-I!VE5ZQ:[)D2Q:Y
MO$&9'EQ%NH0SY<V*)&+CI!;=JH,Z5#2&312T*9)=:*20*0Z,MEU04CE;WL[Z
M[IJV"W:`DML42^W67O$3T/-'V6RV^VI/>+%A-&[.M5QNTJ%KF6AS9()N)G77
M(ZGM1S2QPXE!C[ZFPVRTR\5R^Q"9>O&I>PW^(U*Q9'M&GJY(&1H,PW"VB%6O
M]A7)]N,DQWG03$,E,H>1E;:?=CP,N\!X$#]3AN2',?18#0S1KINBMMBMAO/?
MC,E+(H,^TD9TCUQ\#;V5>U2_7'MQGU\"L?&VQ1]>\#:1L3D5<-B6%=%?EH^F
M5`1%HO=J/FKR4"VS$1HSS08L2W.6$9EXUUP6$A`W$N$/BALY6@+':BUK/NR+
M.Z-V05/_`,_3,,=`N.5A^P2,+KNAD6*6FX+7E<>GYJ5"Q*@1QXP]DFXL:);M
M$@$@AP9L=@(<8+#>`\!X#P'@/`>`\!X#P'@4KV?KJ^ZBVP?T9HVIYO,/>@HV
M$Z<T?'OBC36Q08M4?%5C;FM?W$C'UMK:>OH%90\E'D+83;H%+0OS8.CXW"P@
M72LC,ZZJDY<.$2XGH[G`>>G@YCE22LH-"V5H&\LRP#EHH&IY*UB@@U`:"_)*
M4_KFX?I\0YF<-A2(0JT!("QM:[MYLE;#)4FXW&0T=L"&%;,EJ-T)6YO2TRR,
MO#N5%1,G>@XJH7*.94SE*S8&3E0<9RC_`'LX<;RL(4Z(Z6YVC-F\G[7@]W:4
MGFJEMZS4^VE16S*'(/Q.OMB:LN,?.2KQ`DH80/&1-LC*^03A.4)7E+:<Y]ZF
M\9"4(GKF;W6S!+Y)U%9]JUV>)FQ"MT[#$F=,Z9JV(C\T%PW.+G#![-V"XJ;'
M2RRQ`0+X92/<YF08;PEQ0057RI*H[`V!KO3EMA]Y_8)LFMQB][[VG(:TRVE>
M>8H`*1&KL>;"CS1D+1ZE7Y=3BZ[JV-F1K!.$/N2<H_Z/'3?@7TT9IV!T5K:#
MU]"''SI(BC9>UW*<RAZS["O,\4Y*7"_6PW'N6?8[7-D.E$.*4KV84EI&<--M
MI2$N^`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>
M`\!X#P'@55W_`*HV!*U^P%Z4LEHJ4I<,`0U\BJ5.QM<GI.$+D7VY&ST"8L;,
MC6J5L*(8F2C'3&Q67YMMI(SI0[Z`S10Q^XZ6YLU+IJB:?:<&U>.JU-0ND9F#
ME8P#:;>[)Z*FTQTUKNQ6'\AZ0VO,AKD%.OD9=;*"44V;A4?DAOP.ESUK#:TW
M/R^Q>L8T>P[4K\\(3K9A8-+DM;ZXBVHVU0T;8-1X%?EK-7]DV*DV?]?>SG7!
M!S)-MQJ+:3%X;6^%G9^,G`#FINJBXD737(V*GH0B<>B1GHE1[;+DS&O/"R@H
M,I7@3"R$#L-"_LW,I;??3[&EH"B>C>-]BZDNEHU?*V:I;"XT>@$9CJGLI,_?
M]BVB=E+)9+25$V-N>+=IL=!UF9D&"&B!A?EE%N.I):]N!\"AAF\:9T-K:].V
MFB:NO/5.T1ZA'P6H-IV>2IH-)U'$6.Q)I%JAS*BNTUN1$N:ZO(IG;!9X3\"1
MLC8S<:S^M"0_ED,8#FK:`#&Z^J?,?8H\'LBPNV[?^][51-62&X+Y/0`D+F#_
M`!G#]DM,5<M90(8XQJHQ;$/&1JA8L-AY;!XP8Q>+A<[="KUR3PKO:NZDI;<J
M'I_5=<HL#^J:BHP81J.OUV"5BTZWFKHW/)056:D5ZPR@'RW;`6LEQ4:P%H>,
M-M=%3ZW:-OO76TFSR(V6MH-_LU&'K$+%,J,BWW*O+2K@5,;-.,.L#S,*`%`H
M>!CHEW!KJLY86X%[9_-@Q%O9JZ(9R:^8'\=$^Z:S%Y'R>-B2R\Y',OEX>3&?
M-EC"4Y3E_",+]$95G`=J4BXR<C)&$FHX&7AI@`R+EHF3$8/C92,D!W!#XZ0!
M*;=&,!-%>6VZTXE3;C:LI5C.,YQX$6U6,NE$LO\`:N69&X:YF'Y(^!LA4E'O
M3]$.+,L,X=6K`,]^I21106%AQ]=6`V8:,C_MBT?$T@I0=/<.G?\`(K4;9*G9
M"M<;@J+)F=?[.B@VCR8G)GQK,KUGA771P[IK^=<8;Q(PQ:L-.Y0V0.L8Y@8M
MD,JUC9[19JN,J]UI%3OT.D.)O$/'_N2ZNU9TQ4>=)N4BQ34/!O6VH..G>@<@
M@=OW^U33J6R&GFD!^`:P_0T5Z"U?4:7%4XBRV"4MT;@PRNJC4V4V2L$K-UB/
MC(63CCY0^T2#I!(KV0FG?R'',/)7CVK"1O`\$`NQO3M@$DH2,!KH:(C-:FA9
MYX^2G%DC/KFT2D$N$!9KZ8HI#;;&4&G?F(7E><,93[%!`.[=9V!B5`W%I9Y^
M`W1'/Q404.,'DBI[9KSQX#6:9MJ/:=:3F(80QA(-F0V_+5-+CSXJ7Q738\T,
M^C_[2Z%U27'7S7<DU7;:)(P%QUOLNNN"&#%1YSH,I%2<>:WD8YD:2"RX(>*M
MT4IM+10KRT*;<\"C6M(F0^OZRN:OLTF"QRE:I/`^GM@Y&88/H=EETVZ17KO:
MTG(2B0E1P6`@68.<^)<A-'2&6#5*^)"D!*$/N*S%0,Q=K%T;KNITFL3%W+O\
MQ(5RJX!I,;3P,K(I<?8\6!ZNV^=KQLHEJPS<<Z=&"2$.5&ML)(4MQD.S";MN
MLM*Q!35GL&(JTN0^(ZI2NOZ[&WJM,J4-DC^XX2+D;#;![%:*_9XZ?!@S8.*>
MCH<`T@\QM/HVV%3>H^QQ!]1;E+5>XJT:*LNC=T4BDS,*!#R^P^@MIR^MMFG`
M1NG*;6I`2<'I-/&UY+LD6$A#H\H:V]\#34<"1*Y"2OJOTK7P^?M0='S,G:[5
MLB^Z6A*=!&WJ#@ZW+ZUU2+/GS@FMXVKU\@^)K4E(3.&SK0H<E[$I-CH7G*61
MA660VI>`\!X#P'@/`>`\!X#P'@/`>!6':_)6K]H64W8<9(7C36X9`6#CCMTZ
M,M#FOMC2L372UE14+:26A)*M7^$%0\ZRV)8HR6'89?7AE#:LX5@(=N=-^QBG
ME(;UIL+E3I&H88;2Y6NC:=<]+WMPKT::P^_M#38E^HQ+3"DY)4VC7@V7E9^%
M*V<?[O@1IM[7??\`M_4A=%9TCP[KJ\/3^N;1$W,7?.Y;97*]8->WBG["".>K
ML?S3KVQ6`!4]5,-J#;E8S)0JL(<?;]R_0)_SSQO#9D57Q^ANF[&ZV&:S+S]-
MYBAI'G:GSY&!%-9@)2SXM=[W056!GWW%9;#L\3D[VM_DI4C"F5!937>M*!J2
MK"4K6E0@:35@GRRVH:OQ[(`SLA(/**DI4Y3:?GDIF5+6IXLTA;I1;ZE./.+6
MK*LAG'@/`>`\!X#P'@/`P.2VIK"'O43JZ7V/0HK9D_%IG(+7<E<*\#>IJ%60
M:&B8B:B5(M3\C%K+C2&L$,CK:RXPXGW>Y"L8#//`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X#P'@/`>`\!X#P'@/`>`\".=H;`>US6QY8&I6F\S<Q/P=3KE9J<8Z>
M6=/V0Y$?'/2QOHF/K56CE+43*2QKC8H`3+CF<K7AMIP,9IVJTD6*O;@VA&PD
MAO!FDQE</?@YBPS5$I3^6R7+"-JX"QH&5#LS!)SC1<G^&+)R@S;2",I:0VPV
M$V>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@>=+1$3/QIL-.Q<=-0\DPL61B98(
M:2C3QG/3WCF@F-/"E,+]/Y0M"DY_Y>!B:]5ZP<;9:7KBA+:'64L=I=/KRFV%
MG$9*-6RC,=E+2S"LY<=RG&,N.9]RO7/\^!&NS(C45-`)6#JO5MLVG,P-Q/UE
MK<@&BU^S;3LE6J;DJNKP,C-`_&.LH.*%%(-<2H4!E32W\X;2G'@89I#F[$76
M)&4W[`ZCN^P+B>B=D8&"U5KZ/HNL!"Z\/#*UE0RV:H%9++5X1IPMO]E./%2!
M^2WU9P.PXD1H+/URM5ZH0P==JL)%UR!C\DY!AH4$:-C`\FEOGE_C!"-M#L?D
M&E..K]J<>YQQ2L_SG/@>WX#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/
M`>`\!X&)7YVZ,T6Z/:X&A#-AM5.QNT,2S.DL5LJYMPYBJN-8'@\X+9A'YS#"
M2U-9PXEC*LI_J]/`^+"SYWU9NW8J>V.')5[9R+EH,#9%RL-,HD_U7IO9MH70
MY8*H4JXQ>OK`W$/"7Z2$B:2U!1$Q!JIUD,PRU+Q1%G/C@^E?6VP/LN;UOKAZ
MRZ#T=/6&0U_0'9U^R;?EJI;PK2N!@F;C_?D-%Z_-KT?*+EUFDJ1#.%CM>Q+*
M4Y]?<D).<V5W8/\`CE.<O:=-:QB6R7$QG0Y&3%Y9+4S$MC2\GK>-$0DD7'S*
M<6-G.<80E2&5.+^`.,G<?;[)ZA6>+*04$D49[$JUU/7D_(2Z:PT^&F-(UJ,\
MC\4-Q3N7<N^U>4*2G&<^W"P\LG>7=;1#S(O!]:,1@AX9@ESK"BAB+PP4AM,@
MM?\`8Y9J8XP/"W6O^V_*2Y\;;C*<+6XR&2';A[%#>$:9XVAI9LJ0BV7"8WHR
MD(:CXXH*/?DC9%$M`13Z7XHXE\?X14&?,@7Y4+_W4M)#S,[O[-:>BQ'N)HY3
MYBI+\\X3HVDDPD0V,DW$>LHA=='E7_V:H_*DX&"(4V@@?#F$+4XAL.L=T!V"
M$$86UPR;*$"FGBL14=O[7Z2Y,<5I1(LH*5(Q8$<.">RWEI"'W$%I,6VA3&&,
MN$M!Y\CTCV0`\^*+]?-DG"&SU-#N1G1.H1X\J(P.AS]W^=-?J\#>TU?XWX*T
M9/4K"G4M9'QAU0=HGI?JGYS!XO@'9$BH-M:L/D;FTS#AG.(D6P<,@/R$ZEUQ
M9([1)K2G&VF\")'PZMHHA0HX<[O2'52"6VD<$WK+*V&G</.;MU)ZY7@5I9;/
ML$+,;;4DY[X6/D<;^9#:W5X93A&'`ZHW375"S`QB^!-A!M/M?(47C<NJRV0G
M\%.I<BU?BD.9?DF8W#9"G$>L8M:\L-&NNISCP.@GJ?K!+<@X]]=>U\Y#RY^*
M,+NG1KQ4NVTU)96\!^190PF$)?";1[#'Q'G$E-J:;<QAS"`_CO771HZAUK^N
MWH<H8@;Y??&WO1#Q0[V(A<MA@H20V+%X;P4ZTH!A27%Y3(XQ@E(HJT%J#NHZ
M\WHZMWV?7=U:TTR/E3GY=BYG:?\`S!AY,@\1EMC?)8Y+7J**V(\T\M!;IR<?
M[>&2%-A_'.U-B1ZGT3/`';3:1GW1W38&N:+LH#CC(39:_P`-L/?#$Z6W\BLL
M)=P!AEQY&?8M2<X5D.HWW3;<?JUE\`]\`C2I;HC9"M;:>/R'A@1HU\N3"A][
MR4E'!H9>PE"G64J?>2III+CB<I\#C<[VEVTL9SPC]@.7"((2;2RWI*EN*:64
M.T^J%(=;VPH=F;%R^VVZSE?M2XI6,*SAI[+89*KME2$C_)R+VZAUV68BBF$Z
M';?S'8)0I;$H0^-;G@BHE2?9[W1'25#Y<QAY+:D.X;#KM]S!X0PH[DWN6.R2
MRIYI#G-L])+Q\9>1G&G_`.WY:82(^AOT>PE[*/D:S_M^]>,HP'<<[RU8,L!J
M1UAU-#$RA0P<>'.\O;GA#RGRPLGCX0!*U00QM*V$+QG*T)PAUM;:O1:%)P'X
M;[ZTV\AE;5(Z.S@Q)BHM;W.&W@A9O`;QPWI!21]6%BIE1Y4:\V'@9]S)V4>X
M?Y&\X7D.@S]A^BUCO&$TSIZ)#$;@79`F;Y-Z'A\1:;0T6_`YE6)#7;!D<W)C
M`NK;<>;0SG"<)]_O6A"@]#/V`:&_(=&;B-XD.#'KCCDC<_;??6`1@H8!G\H=
M%1R6G!9Y6&&DI;6XIU*D^W'MSX'19^Q7G!X%,EC&WFP58=5^0]HS:S2/8APK
M##V,*JN%N"R`X+SXSZ<*8>9:6I*_5.<8#TG?L`YV:$*/43LE8@0)$D:2QJ38
M1(PD>,X"VHTDL>`=$9&=R=CXEJ7C#OQ.^SW9;SX'D'?9%RM&I4HV?V*/AIZ9
M:,4YI/;Z68U->@HBRSA<J5FEX#BX^.@YX-]1#[C;#GSX;;4MW"D)#RK-]FO+
M%=B%R`TCLJR2GR0JAZG$:EOD;9CHV9G`H'-@CQKC#56.-KL409EPHQLI36$L
M.-M?*3A#"PB#5/6?+VLYR>N>S-J;0V/O+8&9`6QWEKFOHP.O-UVN?L).(I&L
MJ\!1;)"5O7<"`.Z^.@8TUR0+<?.++?((4K`3GG[+..D1^)1_8EL$!4+)%MNF
MZ3WD(MU$-^-F699&(UPV4\6`@M"ELI1EQ6/=[,*]N?0.*0^SGB*,:*>,W*6A
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M,-6SG]GC*VVF$YSA6,>U:OZ4Y4K^/`]?/6?+V'0F%=$:5;?D5X;"9=V93VG7
MUY-1'>S#;DNE:%?G.(:SA6,>BUIQ_P"])]0]8WI?G..;,=.WUIL1J/C'IHYU
M_9E,0T)$CO-COR#[F9GV-BM$/(1E><^GO5C'^N<>!Z!70.A@6'B3=VZB#&'6
MTV005LFFCL,./O.CL(>=>FD-M+>(96A&%9QE2T*3C^<9QX#_`,@="_,R/_FW
M47SD.L,#L_Y)IOS/O$IPH9EEO]U[W72$JQE"4XSE>,_QZ^!VO\YZ3]J5_P"8
M=6>Q>24I7_D&I>U60_R?R\)5^W],Y%_">^3T_P"CX5^[T]JO0.;_`#7IOT'5
M_EK67M*5A`N?[\JOH2M2QFTH'S^U]'E*<-93C"?7.<O(Q_JI/J#&ZM-Y?6+C
M;6LLE-LX(<&Q?*KE]#&6WW</+9_:_(EG+0SBL*SCT]K:L^OHG/H'9SM[4V/;
MC.T-=XRM:&D>MUK6/>XZI"&VT^LG_4MQ;B<)QC^<Y5C&/]<>!SM;5U>^S^0Q
MLBA/#_+\'SM7"O.,_-\2W_A^5$CE'R_`VI?M]?7V)SG_`$QGP.4;9VMC4I6'
ML*CEH4VMU*AK9`OI4TV[@=QQ*FCUXRVV_GV*S_IA?\9_G^/`[#.PJ"0S^0Q>
M*>^/[AD?.S985QGWF9RD1/RH-4CW%*3G#>/7U7G']/KX$9;<Z0UKJ>J)G79@
M"WSTM/C4FDT>K3,(38+ML*2$(,AZ9'.D2#$5%%E#BK?)+D'Q08X)MPHIUIAM
M2\!C='K^IVKH1O\`N,]32]OVBK1T;@X[8,+<HK5M:=CZZ+8=?ZFG"08+,329
M>SQ+9TF\R,.],R:D.%94AD-@8)[&NE.-=?9#ME9+>%PO)30T]%ONC8;6IMS+
M[;12E,X;<1E*O=C'HK&<9_G'@=]NP0+JO8U-Q#B_]K^AN2"6K_?4I+']*7LY
M_P!Y2,X1_P"_9QGT_P!/`[0\E'&*RD0\(I6$^[*1RF'U83E?QX5G#3BLX3ES
M^GU_]^_C_7P.9LD=YM+K)##K2_7V.MNMK;7[<*RKVK2K*5>F$YSGTS_IC/@?
MI#[#GIA#S2\J6\WCV.(5ZN#K4V^C'IG/JMAQ.4KQ_JE6,XSZ9\#E\!X#P'@/
M`>`\!X#P'@/`>`\"#=U]%ZJT"+`.[#FR6)"TR.(RNUZ%CBIRPRCJ6G7R3$1@
M25+#AP6F<_.<2I@-I:D-9=^5UIM89CJW:-)W+2(C86OY94O6YG)K#:R`C(N2
MCI**.(BYJ#G(>28%DX6>@Y8-X4P0EIMX=]I25)_CUR$@^`\!X#P'@/`>`\"'
MICGK0]@VQ!;XGM,ZOFMV5>/;BJWMJ5HM:/V+`QS2)!ID.(N!4:[/1S++,J4A
M&&GT^Q!#J<>B5JQD)A\!X#P'@/`>`\!X#P'@/`>`\!X'6*-#!;PZ:6,&TI6$
M8=*?:';RO/KG"<+>6A.59QC_`$]?7P.DB>@W,JPW,Q*\IQ[E81(AJRE/_ORL
M8>SZ8_C_`%\#MMG@NYSAHT1S*<8RK#9+*\IPK&5)SGVKSZ84G'KC_GCP.TE2
M5XPI"DJ3G_12<X5C/IGTSZ9QZXSZ9QX%:]V]E\C\TS<36NA^G-":,L4]%?OH
M2"VUMFC:^EY>$_-?C?V\;'6F;BRS(W]@,XQ\[:%-_,VI'K[L9QX$11_VF?6C
M*E#`QOV`\:'&%N8:%&%Z4U`\Z0ZK_I0TA%NSE:L^G\8QX&:!?8-P;(_-^#VI
MRB5^,ZEE_P"'H34Z_B>6RV0AM?I;/X6IAY*\8_\`?58SX%F*;=:=L6LQ%UU_
M;*U>:=8!UEP5LI\[&66M30K;[PKA$5.0Q1L9(,-E#N-*4RZM*7$*3G/N3G&`
MR;P'@<2F65Y1E;32\MY2I&5-H5E&49]R,HSG&<IRA7\X]/\`3/@5]WMM^6IT
M)8*EJ46J7+H-VOQ4Q3=?V*;`B0!@9RS"5?\`OBT.FRL&A-6J[;ILJ0*V:-(2
MPD06.!E3Z<Y0'HZNIU5H+3DM/[''VALV5`3%6/;%L:H$?<IN':GI^S1=30Y4
M(2O"!TBK3%JD<PL7['<`,E+3EUYU3CS@2RW.UGT]&IB"],>_'HW(1_ICY%XR
MY_"7O3'R..8]W_-2OY_G/@?M!M>7E26RX5:O7#JDH?!5GUS[64N*PE><^N?7
M"<9_]ICP.TR1$N82IAZ/7A;GJE3+@RL*=RES/JG*%9]SF4Y7_P"SZ>O_`+/@
M=G#8N<)PE`^<(2GV8PEO.$H]%(3[?3'\)]OKC'I_'IZX\"$][;LT;H2N0UDW
MC/1E;@K)+DTJ#6569JTD2TF]7YJWR$*'$5N#GI5]G%;IQQY/HQ\"!@%N.YQA
M&,^!K]L?W)?5'6G1G#M]5,EQJ:D*NM^/U/L<K$1-PHJ9<^(.(SK]M(!H*9!I
M:V<JPXTX8S[DIR^WE88Y%_<)]1<S)J@X_9]9>..@9^QN-9T#LI`9<!66XV#L
MIRY%6M,19*(5N5"#*9^93[2"66U-X0XC&0S=7V1?4U60"YB?VAIC6T2.</&$
M3%YUA*:^B<GOPJ36`U2EAI$4#E]4$0C*4J<QG++R$X]??A.0\6-^RSZ5RYJ*
MQ`=%\>2UGF@1A8$2M1U<F[/,`!2$FZ(%"Q\)7C)J2;$DU&+;8';7E#N7583C
M/OSX'LM==?4:V6](,F:10<7'HB"#FN?K$DLF-;:2PF/=)1J_#SPR64I1[,JS
MCVI3CT]$I]`Z[?67U`R@\K\YV@QXAAEHBS2DYH>8@JM'`10YX^).XS\WK6/K
ML5#P@,>2MPV3(:%"%96\MQMI&5X#Q?\`RT^CFNQM=FG]R<"P4/8%6*;J<Q)R
M.K(N+M.5DN5VT25=D9%E@.T8>,;6$6X,LG#CN%-K]5>N/`]XC?\`]/63WZZ6
MCF9B5?"<CGX8G2K8<DF/>P7,.`*">H#)8HJ\'O$_%[4)]'5+]/Y]?`QYSI?Z
M54.NG$3'*JW7L.)=(+U:P]ES!#IA#B,J)I2\92Z0>^Y[?],NO.+QCW+5G(>E
M6^B_H[ML_#4>J[S^NB2N%P=A*#7J?$[+T8Q=)$^0EV1X&H0U?8FF+().OV$I
MIMD)AEHW!^4)]F'DIQ@)(V(/]26JK+/4S:DOPUK2W4MZ`G;34KS:]/TJ>@7&
M(`NT5N1L5?FI:,-8;56<OFC+*9]C@>5N8]S><YR&,N"_2_;HMR<=L'UY6*&D
M&SHYV4=O>B)*,*8?%R27&K)7/.BN#LB1WS)'SGV#I&PXA*/BPI(3#6M"_7'N
M60DHBD4WF#9<A"+;L\Q"TF1I-I=BB9F2+=;M,K$5R2,P'(2\H(0G]D\TE\E;
M;J/E5Z+3X$FN\1\C/OR9+O.VJ%NS);I\IZU*-^,XQ];3I!1#.&\,N/$D,)==
M5[?5Q['R*]7,Y5D(BW5IWZ_M7&TW.R]*ZT+MVPK'(U[7=,A=?/W'8-ZFI8?"
M;6Q4:+6P9*QST>#"DJ,L#S`JP@(Q"RCUM,(RY@/$T?\`7-I&$UY/![[U;JC8
METV5(Q\]?ZT'5X]6G*LW%1`T#7-::QJ#T7'BCZXI<*$R.*N0'>DI,AO\TUQ3
MWPMC!+CGU^<2/$M&N\MZ5=,8P`D<IRC0ZR!DQ:/CC$BO*8RX,F.1C&&,-Y3A
MGVX]GIZ8]`_AGU^\4GQ7Z(OF?4SD/G]?EV-Q61VA"51;<HV"X8RRIM)KK6)P
M[.5N^]3BS'U+RI3SF5!XF?K;X3R0.7GE[5?Y8D6J$#+_`$S^"@X7.7,IB`R,
M&?,)%M8?<2V.VI+32'%I0E*5JQD/Y_[K<X:^%0O_`(VZ]R'^1&E-@99EOP!B
M8@842.>$#Q*8&%<$8`8PC+:4YQEAO/\`JA.<!X)7U=\'EQ'Z7//5:&$RF8;>
M=CYFVQIQ0\^Z0_+!&G@V`<HR/+(+><_'=4MA#CSBT(2IUS*@Z:?JTX>QA/KJ
M`U2UK`6>^K8^SORYG,95F*:&F:.Q<,&2;;<&.G"TN.92\3G)#F%OYRYX`SZL
M^'#(LJ'SI\\0`MC\=QN,V?MF*<0VTKUC\L/Q]X&='<A4>B`%(SA0;6/8UE*?
M7&0[8?UA<6AISC&L;&0M98<@0\7N'<[[Q<H"X\X/+&+SL#'Y,K_NX2X2O&7G
MTMM_(I>6TYP'K1GUS\O0?PO0<3M*'D1G91X>8!W[O#$FRJ6%E!"6L/OW]]IP
M-#4R3\8ZT*'1\RL>SVJ4G(9%_P"#^H4#.B"VC>8361#F@\C;VV;\L8<=,Q<X
MJ9`>?L+[F#ARH0-IIIW+H*1!T#Y'RSZHR'F0_#%'APOPF]V]7E)42&0Z\3T1
M>FG'<#'2LB0.EJ.(`##9F2I92I'(S3+DA\36"%.>W/N#FD^(JE)D-/?YWZXC
M1\1QH!,="]'WV)`+>-BQ([,M\893;T9*!OBJ,&4`X(T.8\XM#>$92A`>65P?
M52$'(;Z-[0#Q(8DL/Y'Z<OJ\-8DW4ON9!;-=+9C7`WVVU"+'2TL-*/C9RAI;
MK;@93%\>5^-68Z]O+I^8=+?.?;5+;KG<M`?GB+&6T"%&BQD=^,.\ZX0RR\R^
MRV\XK^C*,X1@.JQQM%#$LD-]#]8N(PD-LH<[>4U)L%L@_`A#269`$AB/_('0
MZT\X*AAY:7\K2M#S0SK`<3G'3KZA<D=2=</-L,A#/MHVZQ&?F#ADMFK2ZN!K
M4.I!,@0W[2"D^A:ALY80ZAK.4^!U_P#PV+;>4L3JOKD1EP-L18G^61I-MO."
MHLDE\$N?K<Q+1[Q^(S+;BVB<+:;)?P.IC*D9;#C;XQ*2Y6UD]7]@2.*V8R7E
M!6X4A-V)+;$TET2U#5VOP(,L,29-?DK]K+"U.!C(RK+*'&G0ZIW$S\BDO)/6
M_:"'2_>I*H_>9D.T$^H\L]#X(\1#`H:_'2^T*AE?R#9#'0E;2WUO/N!I7^T3
M@GHIA*TT67N6Y-5[`LM?F):_%:ZL.^NC*+/4O7A50B*K;"*LU%WBY:CMV90A
M]#()8;,6<TM;S1#YJ'DAL&^I+DG;W/\`3+5LK;+PE6<VW1-0P58TZ+2XRBSE
M*@];8O30=BVK&Q&71R]L6^*M(2"V7B9(J`CH\2&<D9+(/YCH;A/`>`\!X#P'
M@/`>`\!X#P'@/`>`\!X#P'@:JK#]KM`D=E6C7G./,O6'9P5)3;AK1L_FJB4N
M:U`'8*')0\-;:G$;(OVP]?UFWV2&F9C\%8\.^?E9P1PZ,J="(2V'AR7VG;#@
MUJ&FOJ>^U!H[X%/ML06E--W$5SU>90RU^VJF_P"6BFWW1W<NY2MY.6\(RA7H
MYZ)\#Q)K[@'*M7IJU6OZQ/ME@8.OL&GRIF>3X296-$A9SER3_"KNU9:0>9RS
MCY,H;96\A&,Y4G&,9]`E?3VP_LYW!K2I[0=I'+&H47F`9GP=8[;JN\HC:%'P
M8:2L2(V!&QMF,CAIYB+PU@D8=SVM$95Z.*3Z8P$AS+OV>,,,*KX7!TJ2LKV$
M,S$GT%`L,!_C$K_(:)#BK&X21^6AEOX<LMI^-Q;GR>K>&W`A*8T!W%T;M?0J
M.P:1PF?SUJZ]W&\7*GT:3VOL*>NQ1FJ;I2*@$N"V=KF-J*HX"P6Y)Q*'E9<3
MD1M;2_>GVJ"UQO!O$L@*P$5R3SDL48MPYIEO3=!'0DIY/M<=5^-!-*<RM/\`
M&<*SE/\`['@85._67]?5E(9+FN.]`&DCI(0T_P#XZ@AG<(*=<>?0I8@S&7$+
M<=5Z85ZX3A64I],9SCP/&A/K.Y9I;-GC=6C[ITK5[@>Y*SU"TGTEOW5.O'I0
MB)#A#9`"C4O8D16H,F2CH]I).01AL/N)RZO&75+6H).USQ7HG7%OLE]0#>=C
M6RU52LT>3F=X[.O^\RFJK3YR=LE>AHG.UK!;,0H@$[9#"O07XOD>=]R_=E*<
MX"<4ZGU8@?`B-::_2)A*48%33:ZD?"4YQE*<,8C<-X2G*<>F/3TQZ>!U"=+:
M<,_&R7J;6960U*4)DFB59_\`%4M+R5J&^6*5\"E)(<QG*?3UPM7_`+]GU#7W
MJ*N;HXIVSSSS6N_ZPV+HO>VV>I"*U%A:>E=:W;7C$HSM;IEEERUB;0L5,M98
MDR>Y%(CPJ]!M+CLN%#,#M!K8P&T_P'@0?N;8UVJ?]KT_5E%+NNS=A$R`=;?E
M`I@;65+CX?`"[!=MH6R/%=:B(.#%DF\BQC*\2L^:ML0-*$9),##7OT[RWI":
MZBX$KUTU]"7H"\=/[]W3>A[=B2L@%JV9#\R;3,KLK+BS\A*?L(:HX)6-!Q!2
MR(V)`;;''92VVGP+W$\@\FF#D"%<P<]/#%,.C$,KTQKC*'6'VU-.M+QBMXSE
M+C:LXS_[&?`\.8X;XNL&6\S/)G-Y^66ULM9>TKKK_;:7&S$0IM'LKJ/:C]=8
M#&L8_P!,8?SG'\X3G`1OCZP?KS;/K\D+QOS]'%5B0E)2(Q%:Z@HD5)TQ#+KY
MS\@#&C"@S6?U;F4,I-;(2,Y_NLX;=QA?@4"^TOC'E#3')$[?--<G:4C]J?Y$
MT-1-?,1&NX2*B).Q7?==(JU:J]NDHX/']M:[L-@F6`Y^099=*8B2"<#MN$+;
M0H-5=,U93]16R'^M7?6H>7HWN>Z;)#8L_<4_7]>F\Q5'4^Q4VF>H<;KBJQ`N
MO4PG1$Y"UY\&FZFM*VI1Q+SM@1(3$>U^*^%S-J<8<ESW7>J.&N$M*)I^VM24
M8J>Z9[)&F-DVPCDO5\R'6(]BNU>Q3LK,566[BWE7O>'7Y*0(5.TZO2,E/)0O
M\EMH@)@OVW)SZ.-,Q]%V?IL+HSARL0I]4Y?M6IZU#KZ/A-GN0]HML7IG<FO5
M8;$V$+98ZO$9:V-$)7((P*LBR!N+R1+K"5-1<RZ8V)P[M'I#['+OJ.Q2/2]<
MAN@=N[0U[L0:M:BYVH=;'38M05;GC;],G045F!T9`8&RS;X8]@NR3:291YUW
M\O#?@:U-#V;=5CO/+7<?=45MV=^M;7"[!)<<;/"K05'VR#BTR#\=2.F/L_H5
M`"AW7J)+T*/2Y7I,%"J^$(:-(V8%)D@IY@-X/UPQU&V7S-8;,[#Z\MU3M?3W
M8TY42HL:#ME=-IA75FW"*F\!,I&)C9L147AIUE]AQ]CVJ3AMS*4X]`O$UIW4
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M-JQQ2XM-KHE6@:/?ZZK!3$@+*5&\5N.`L=:EX^1%:(9($?;6EQO'KZXSG&0Q
M+3GU^<WZJ@9(2RUDOH>[6?%?)ONWNGBF=Z[2O<S`5&LTU$K,VB^BRSL>R7&U
M(-Q4;'("B6'TJ6P*U[L^H2([Q?QX^6X>_P`G\TO'/)RETUW1.KG"W4J=R^I+
MA*ZMEY:5/YRO.,JSZKSZ_P"O@5[V5]>&O(DZ?VCQ\W&\J[X548.LP!>L?R=<
MZ>FVX"YHN@[.SM8ZZ9A82XL21BG1S"765'O!J2/EW+"?BR&:_']EF'R5Y*X:
M6-EO'X8_X&_&GTNX3CU_)+_9/-K;6K&?3VL)RG&?_>O3^0Z_$996\J'`==;;
MU[6*ETE=8>RZJO<=6K;-7VGT5.GMI[#HLG7-72MA$`<B8"=FH9TV1>%#"=F'
MDCJ+^7`8F&0O;X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P
M'@/`>`\!X#P'@/`>`\!X#P/RM:&T+<<6EMMM*EK6M6$H0A.,J4M:E9PE*4IQ
MZYSG^,8\#459-P;.^R"ZS.H.4+Q.ZSXII\W+5;H3LNEE.QEOW78(0TF+L>A>
M.[*V\R]&QD>:/D>T;/$:)$'2IP"N/+D4O2$>&S[6FL]?::H55U=JJG5[7^O*
M1$L0=4IU6C1XF"@XQC*UI'""%0AM*GGW5O/.J]SI#[BW75+<6M60^:/L3[1N
MH-8=J=XZHA>[^`^1=6\F`Z3D*K4.G],738%\V*!?='5G9,_)PA%%VS5K%)#C
MV63>"RR-$$O8;6GX/D6V[A(7`Y6^S#=?3>X/JK`)K=-H5-[1XAZ$Z3VW50(T
MZP*#N&M9/5,%68ZD7(Z2CC8Z'47<S"WV"8\A[+&&6LNY5[G/`CO>OV6=7U`K
MON*H@&M!SN;?L<X?Y7UPY+TV4L"G-6=(`Z$:NI]CP#:XH-^Q"F[.-?CBG7!6
M&$8:9>;6O*<Y#8IP+T?M3HTWMY6S%5?`.B.^-^<V:S;K$*7%^[6VK@*.Y"%3
MQA<D=B;L;YMA*060TV,RE;7QI;SE"EJ#6$%UG]T5]=ZVWQIJ-XDONB^1.L>D
M=3+YP+KFQJ/O[;])Y^L)$41$B;FE;E8M7UZP3<"7@YHE4,PC)02&<^Q+RTX#
MN=%_<MMN%H6QMP\[U/6I=$8^G2@?9+K>"VC7;IBVINUSW*Y4!ZI:D"V*HY+J
M4A4$N-,9#&0\W),?D//H&>':)"5J%]PMCV;IGAVT0FKJW4]X;9[_`-=\"]G:
M/N9\HW8.;-DFT_8D]L>.`;%*8=)/2NECG5U\E3X9\2>A?JZYA7M#CA?L4^PO
MI>H;6Z%XCY3YGDN7Z#?[MKK59W2_0-DUSM/JZ0U9=9BF7NQZQ&K=+FZ+K:LR
M,S`'1\`NR2#CYQ02WGD#L+3Z!<#:G=5SI/U;;!^P1.CY6@;`IW,MEWF3S_MX
MPV(DJS;*W`&2)^OK=*B1X1?L$E07!_S&1FL$M>QY"$I<QC`4'Y^^SWMVY]'\
ME<_[XUUP_'"=7RLK+UR[\E=0_P"<Y2@PFO-=RVU[;5=K:XM5;J\F&Y=Z[&KC
MXV8AY`IF.D6EY6V2C*<9#Z'/`I7O,7+_`%_PJ^T(0MX,SI5Y\_#S38@T:YJ,
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MV5I37.\OK89Y`H/V@=<=&;IZ5M.+5*XHL<NT+UG7]`7!&[-N4C>&UI^<L9&K
MS=SJC*H.'8(T<=%4:B8W$<.)E]L/*Y![ZG/JST[M"R6G5>_=F<NQW7E?TITM
M'[OA*>'W_P`V]@[,CJ$9:9S;-FH9<_4>WM<7>LSL6;"6&$=_NX9E(\>ZR<-D
M1P8++:'[&$W9UD_V7T5JV9V*X_Q_TIU9PQK2N7_5MKUYS=S)H<VKPLA:)=A%
MLD*Z)VGT7)6S\>9/2^V138M#<`^Z,A!^7`H7ITT_[$>H&(WE?GZ?I_#D'S=J
M7["U_63NRS%UG1'8]GLT[MFH-Y@P,+D*+S[`@;@A$$QL$=7R*C>9Z$S/ELC"
MY'-6&X+:/_J!>8M+V/9&M;)R5W)*&Z*UWKVP[RB:/HBMG!:9(O5@FJ,%1K9'
M6:_TL@E8\]#H$",B!Y*&F6BFG8\A]A2%J#Q?K6^Q'15<X\Y'8I>G;E5QNF._
M>C.88S3D)`U>H2',%_L>SMZ[F%HVU*D;-QC5-76=?QK;[\>$RIY.2VOC'QAQ
M.,A<+2GW$\A[YYJ[`Z=I:MB,5OAF8VQ"]`:]F86K,;6A"M01!<U.$0U;C[G)
M1,K&6`6/(1#$JD6&3GQW6\J;6VO"0RG=7VI<[Z@N5&U3`TGH?H?>=YUM5]P)
MT5S+IN9V[LJF:QN.$HK]RV2V`9'5"@QDD8K`[")*78))=_EAIUO_`'/`G_D+
ML_1O;FOI_8&DS[:PJD765UILR@[(I%DUIM+56R((4`Z8HFQ*%;08^:K]@`"E
M1WO3VNC/-/)6R\XG/KX%:ML_;[QSJ2Y[CIC_`/Y`[,5SQ+%5W?%OT1R_OK=V
MM]166,B1YZ=K-YV'K:AV"IQ=AJ\*6T3*AI*<?C&U^A*6UX4C`;"]:[)H6X]?
M4O:VK;9"WO7&Q*U#W&D7&N&(/@[+69\%F1B)>-+;],.#&!OI5C&<)6C.<I6E
M*L9Q@,W\!X#P'@/`I)P$<&UHZQTC$*;79_5_0'1]-N4*:&L;\6RR&Z;GL')@
MKV23&)$.>@KT#)()9<4TYDS.,81E*FT!=OP'@/`>`\!X#P'@/`>`\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@:B?MQF-E3\!QIS+1;
MP;KNL]F=B53GW<MCAG9,2POZD5J[:NS[15X23@#(ZPPSMPSKEF-(*$(8]`R'
M6GUX'==PH-J%+I=1US4:U0:!68*F4BF0<96:E4JQ%APE=K=>A1&@(F%A(B/9
M8!C8R."80TRRTA*&T)QC&/3P,F\#2Q;^+N_*3U7W'OGFC8/#SU0[`E-.S#54
MZ0U)MJ\3U5D-4:!B-.Y<?DZ5=*K&&QT\^*2I03@Y*&!GE*^1>7G6/`K-$?4G
MV7R;K_Z_[QQ5N_GJV]'\4:UW_JJVUG=.L9&F:2W93.E=@$[6O,3'ET=^;O\`
M0%U>[)"Q#K:,=PL813I'N<??9>#UQOJAZ^OFB]_'[IVQH$GJ/K+[`>8>RMH#
M5"-NC&D]84_G6Y:L)BM;Z[*F(>2MMLG$T'5S`B3)(4-E\\A65Y2A&7G0EW6'
M.OVU<P;0ZI=T.-]>%XT_T/V+MWIJ-7M6Z].16T8:)V417`D0$T]"U*<K+DF'
M7ZP,AI(N<!AK_P!EM*V6T9R$)R7'/W+:VIG9.B^:+#P76=<]8]%=0;2"W3>+
M9OJ4W;KF&Z3LY[Y=@&K`U+=H1=LI\$>E8`^'7!/F&1AS"\Y4K(<6_?IMW%(Z
MZV=J#2-OH,O4G?I?US];VK[3LJ9FHRZ9V/K/;,M;XR7L#,'73XX&BSE;-9_*
M(:=>.9+%90EEU/O>\#.^J/J#OVQ^[^&>Z=$VZJZ_GJ)MO1=N[GUL9+2P55W>
MSI>$L$)3]G1/X$$4Y.;9I$%=9R%8(/R+B0BRQT..-Y'SAP*I7WZINY=9:=OO
M!E&T1P[WOP0_N>U[JYNB>I=G;1T]<^=Y:_FV6?D:K8JSKFHS-?V'4J'9KS,O
M0?XQ0;^&BO<I"%)9;&#82']<FW:Y]%,G]9`L_KJ;W9CB^T\^BV.,(F*[K:0O
M,U`2H;$BH\F'+G&8=R1D,*)+6#^00KY'LLH4Y[$A1+37UD=;1_3_``'L>)X2
M^O3AB/Y7O3%EW;O'EW:4@1LW?-,QK&<H4UK%V%@M`:\>*KMMD9K]C),S1QB2
M71V/]U"DK<6'U)^!2/?`XB^QN#"GSW62!SNF6@8YAT5*C7B-/-9=)+9?4EYV
M-`%87A66<*<22\QZX^/*\X"[G@/`H]S*@-73'V(E#O/O$+WWJ`0S\D9ME;#@
M?)NBE-CL/H)<64"ALGW-Y4TUE*U.8QE>/ZL!9:_;IT[JDN'`VCMC6FMSK"/(
MEP`=^O=7IY4X+#N`-2Q,0Q892.=DF(MV5%20MG"TLJ):PO.,N)]0P@/K3E61
M.%C(_IGGTZ2.*8""CP]S:Y).,,*>2.,(*(Q9%OD%$$+2AMM"<K6O.$XQG.?3
MP+!>`\!X'Q,;TY4W)4>]+CU$/K'L#M?5ZNR^U(?I:8YQVF%S=M;6L$YHSE=K
M5)T;;M?;%TM*/UFD1;;\"S$O3+0!D9"DR!.<FEY0@(`Y+T'O#?6LMU]H_7;"
M[0O/!FONZN<NG=$</[$O6J]D=";6O&J;=JX_IZV;!L]LLMJN+E\A`M=KQKV#
MMMD>,6,:V:/G.2!UD!*.Z>8-I?99T'O/?7U_\?;,X]T[5.<=X53I+7^]J@WJ
MJL]K=$R.RJQ(;,T"S4]9V*TO5J9DG]=-,VV?C&DKM4G&L0\NAT5PAS(3/P]U
M;:>3>F==36V>/.YER6I?IGY2YTVQKJO:6A?[CU9<-#;2VBBZ78^J2FP8;$GJ
M*>"(9,#ML;^3#(1G+#CR'TDM#A7V\V^Q?85]CED^PVR\$_:W`\X0V@M&.<$7
MO3.DV[(?:-P:HNTML&F[^ONI+G,CT25`CR;7)#UP*3_8Q)$82X;E:'BV'QPL
MSQYI7HVYUOE'HZV:FV`3+[W_`/4*;Q[!LM>AJ29FPZ<UB;I;:NAYN;WU78LN
M>"U%*BWZJ8R='.2)C43^:VPX0XM.?0(*VW]:O3H'UG2W6?+6G[C#=>-:X^P?
MF?J+G&=UM9:[-=:<S;VZ&WI*U:9<H[XS,Y.[$U4';@;;2W\"O&R(^4#?*YAD
M9A07\FI_<WUX=!=/;9MFD^H#=+][\?\`+,=7^KN?]02._P"Y<F;CT/I20U-^
M@V'I2&AQ;9&Q:3[7''PJ'&C&7))EY!6%(46H0+E_1]*=)6G7_5E\Z+_S[,?W
MQT0%-:AV-TGS1KKEG:VUM4XU)KT8"[VG7>OH6*PY(KM#4H"T3(K?-5%A!)]&
M48PTD*D:'[`S]:E.[2Y?Z$XIZGL.T+1UIUGM+1C>I.:]G[<TWV8+T);Y[8U`
MKU1V!5*G,U>$L9XTRU7YD&?>89!0+A[+[C2E-,!OFXW>O9/+&A2=F:.I',]V
M*UG6BIGGO7+J7*=IA)0:7XO6\6EJ#K8PS]3AW!Q#!V`F1ACFGFF,N-(0XL++
M>`\!X#P'@4SX]8'9D>NUL-I;63V9M=\I20W1<ND?VMKAGY%..*4DY7P,MI^9
M'HCT3A'I[D*\"YG@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X#P'@/`>`\!X#P'@/`U%?99DK'2WTYX1EG`.?L1*_*]T:\^_\`D?\`
MB9TI@/X99+2AXU'IEWWM+6A17\>W"OC5Z!MU\!X#P'@/`>`\!X#P'@/`\B=L
M$#5HDR>LTW$5R"CD-KD)J=D@XB)!0\\V,TLR1D'APQD.D/(;3E:TX4M>$X_G
M.,>!&'_D;SU_\GC3/_RT*1_\//`J)M[H/0SG77&[[.]M1X':ANEVR<L[(JKK
M;F7*92W&V"5#3"AV&O5C+F%D*PW[VDIQC+BD>@7C'VKJXMQUD39%!)>8]?F:
M'N%>><9]$M+S\J&Y%2F_1#R,_P`XQ_"TY_XX\#W\VJKI0AQ5D@$MNNK9:7F8
MCL(<>:2E;C2%9(]JW6T+QE2<?SC&<9S_`*^!H@V)]GO/'`G9/9U/W92]US=@
MVELS45PK,]K.!JMPK<G6Q.=M?4UN.=%)M-<DJ],UN?HTJU(J*2MI:7A%8<3\
MK:,A4#?_`-L>AM@=9Z)W/`<E67=-0@^?]^ZLLU*WD-K"D6:K6.R[)YOM==E8
M.`F3MBYR=+14":VAN0:A<$IRW@<EY2\M^!63;/V%\7=M\=SM7(X/IVA-E;*Z
M.1KN*DF=?:O/#"KFG.C8\\M*[[$1D#;8?9-AC*)D=\-F-0U'2$@C_O4M929@
M/M4:QA+324I4A*6T82A>?<M&,)QC"5JRI>5*3C^,Y]<^N?\`CGP.3P'@?'_T
M)MJ?W#U-TMSIL$>[TGZFV.\SD]X=&TB$M1]?V)<B=-TB$8YAO%RJY^2*)SOB
M6H0X6RK6*L<.(,]L%*.").4XL+.]^4J"W]TYIO17U36<G478>P--,(WEUOH&
M7>:TEJ;B)^MS`=5@-QMU,>4U[=[?L8B19;UNC"6K+!MLYF8XU@89ADP+^?7A
MM[6VBH:B?6]>M+L<@[ZU%11%UG63MC.N6L=Z0>?SY.;V3SSO&=BJX5ODXQ[#
MTE:VR@@[5%21!"Y(/X_0MT*G]3:AB_NJWML/G"!!9J/%/.\/9Z%MOL37Y,2G
M:FX-_P`I`'!*YVTI:'(J5AI31VJ#IQN0V&MUTZ.E[3%HKA(66QY!?@29?_L1
MV+]6>M#*Y]CM)KI],B'C:-RYTEH<$2#UOO-Z$B01M=ZPVU3Y!0$7S+NRT"MJ
MRI2W'-?K:%,?&/"9%R-@+B_5\=99GC^O6.XPN*Y9K7N+J6U3$&V_'GB1A=@Z
M?V_)J"C9N)2Q&6B*'21A`LN..&S+#X06@=I+V$^!L&\!X#P'@/`>`\!X#P'@
M4CX6P5,4S>FRW(Q$1&;?ZNWY=*Z"J2;DCL04#9F-3C&RJAUN!@G2Y.M'C,"M
M*5@9A]M#F<O8=\"[G@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P
M'@/`>`\!X#P'@/`>`\!X#P(7WKT-IOFFHQM[W?=A:)5)>T1%*C)4J+GYG\ZT
MSS1S\1##@UN*F9)PHYJ-?RC/P^S_`&\^JL9SCU"M@/VC\#2+;KH_2520EE]P
M96#H2[1BU.-X0I2F6I*KB.D#YPO'M=;PII>?7"59SC/H&N#M_L;3>[>IOJ9'
MYSGY7H&4I?<Q5BNM3U+1USUEA:G)\][EIKMPD[!:7JQ$56H5TRS(?D\J(^4M
MA/HPEPAMIAX/H.-CPI%#+9XK!;8Q@<@PA]M+B630"&RPBF\*QG"7Q26DK0K_
M`%2I.,X\#N>`\!X#P,%E[\!#7^E:[>@+H;(WB&N,V%88JI3,E1X-BE9KJ3@[
M?<11UPE6E9G-E:_4C%NMNR?XY/P85^.[[0SKP'@/`>`\#4_]KD)4[?6^2Z)>
M:O'7>K7'L'3<;*5&QA0TU2IMIB=9+=:N%9G6BXVS1C033ZF171B$?F_"YE*<
MHPM(:^>_N3M<[2V[JSG_`.L2"^L?7N\HX?<2]X:]N'*_,5],8KM/QJ$8F81'
M&ZTE):J3E++V:)A9:5OH00:V.J/*5A_(P2UW)P1QK0+[PO$5GE3FF(BY3=M+
MKET?C.?=#`%7AMN_:<C!V[5'?V&*)8!C@WC4D-)PTTC!+BTHSGV-Y#O_`&(<
M0ZYU,/I>^<Y<@?7%3-/1=WB6>M[OO+5&C:A`534LCLO4@TG.QTY.5EI2)U-2
MS/BBX4^*(D@EEXAY.1F&W`]_8_UF?7'L[IWEJPU'DG0%VTUL.@='P5TGZ/41
MI?74I-UZ-I2*+@J6J!BJI&30K:K,T,7[4$N.,NM8?PZPVCP-;MBVQKSZY>]M
MWZWY]XDKV\89R9T)KFC:EK&N=GF"ZG#D[`6?,[%3?J%H[?T?`*2_LLZ1/=L3
ML(4X,$O`[KZ?@;R%9NZK_LFS?9YLH+<&EY>@;%&UQ3Y\RIZJ9W'T/'XJ#-%U
M7%N2'^0M-:3+DX8L$^?2-)"?K67!&BQW'UY$/$60$#T/C_JU''=4Z(VIJ+6%
M5H%=ZIL,*>3:8"XZYZ&JQ5Y[JG!ZM*+@BJ+K8J_TJ7_NZ,"8:G7Y`DJ,ELG8
M+2T"-'-A_H(^`\!X'S1;E[R7P[-]&\RT/6NOHF_]5]&]%R&D=@;.N-.#Y[HF
MR[18M=`WJ>Z$JRY(.PU#3\3!W%Z[2<VI3\9-R+I,-EP63*:&\#-^;_K[Z@^J
M*,BKMPO(5;K+4E^J;VR>P=!R\E4]:6+=.]2QH03_`"IQZ>-!HHVIV"H!+F!:
M9)S*:DJ,CP@`E@/+4?X$B]$;KI7VOQ=-X^YIJ$LZ>>7&7GI?=FP:<[1-G_79
M#Q$]+Q<>B)K-P##O=`[6N<K69(*DH'8;<AA&7;$X\Y'8!_8!E]5O-L^F34HM
M&Z!:C+Q]<FK6!8/7'3%%J*0=D\]4_`S:`8CJ_7E0C<HO[L]:S<M8V!6`,/24
MB6IZ<CQR2/S"`BWGBC-]IV6Q_;?]B<;6Z%S0'I^>C>.>7]MV*`GM:Z5YZLT(
M>Q?NBM]1Y2G]?2.Z=Y5@UUM32LE,UVJDIC5N/D+6IH+R?4O/1UFX5UI,UZ-#
MCJ49L'I->M_UV$LQDAK#_P`F=OYUS+1<;@*.=@8N1IN0G!HYUAIT%C*&5I3E
M'I@-D'@/`P*OV6Y2=YV#79K6\C6JC6?[5S2MAD66L2D=LO$S$.&V),?7HP]Z
MS5=RG2B,!/8E!V$F97AT93C?N]H9[X#P(PW7LX+2NG]H;=D8@^P":TH5KNZZ
M[%+;;E;&Y6H0V5&KL4X]C+")2>)&0(/E?]&'GDY5_'KX&-<S[K5T9H?6>[':
M-/ZS)V#7L3!^OK45'&V.FR;!QD9)UV:*B77HU^1BY`!UIQ3*LI]R?^&?7&`G
M3P(PW)N"C:&US/[4V.9+A5&N.0HYRX"M6*XSI)UCGHNL04;#5:IQDS8YV4EI
M^9&%8'#%>><<>QZ)]/7.`JC)?9%H2$!*E)R@]=0\:".\26:5Q-U:^VPV.(\8
M[C+,=J0XMQQ+;"D^U#:\Y7Z)QZYSCP.[]9DH[/<2Z;L+E>N%2;LI>U+.#6-@
M4J2UW=J_$67<VPYV%B+13I>.BI&&F0(B08;?PX.W\ZT_,G&4.)5D+X>!1G?W
M1^\-4=#<YZ8J.L-1VB`Z2M5QJE:M5HVQ<ZI-5\O7^KK#M&RD2M;B-/6\$Q!(
M%;>%!0U)(][BTK=4TG&4^!KYK_WH5.X:L!M%;YTV*ULP/1'0^Y[QKVZ1^RM?
M52N/Z2C8I^$J];W+:]/Q]#VBF\S,TP!DVNK/3'K2Z]EIX=OY,A-NF/M71M3L
MR#Y-F-.`:^5;+5OJO5B;LFQ#1+!.1.FQ7#JW=Z:(=K^.UEN.N;7C(X\YANC6
M^QGUL,=&9E@5U;K0X1=>/NA_L+;6_=:37.+H2=-.[^;A?W6TEUBQ;`C]*5L>
MR0=Q@69_7`5"L=*VLWAX8%VJ6.URL&0L;$V!'I<(4($B;W^RK?G/;N\,W7E7
M5I$?S_`\^VB_R49U),/-C0O3>W+?J?6F1!D<YO%O&1Y-3S(3B5H;;#&?Q@=9
M>4^J@DTK[&,P7(7176L[4-33<#H5*,*B]8[OLEJA9,A"H=N38L]JMFCM=%4S
M]/B<8?(4W%RN$B>Y>/5:?BR&*\B_:=#=2[N#TBSK&&C'CG]JJB=J:[VFWMG3
M-OC]<533-J'72;FU1J<9)S)S&VG&9*..`CB81Z)4AWY5D(0V'C[7^X;4&N]L
M]A:7@Z!,7JZ\KZO*N\(T#;JW$`[KN]6D:#%[/TW573</%0%RH)NX::RX4<SF
M*?=GU860PF/.6T%@]$?85K#HBJ[7N>OJO:%0NI-'4[;MD%E\BQMBC;+.%[IA
M[GI2RP#O_<U3:.JK/I*0C)L0E2D()(:4VI3.4N+"ONLOMJC=D]1U'F]OFN_5
MP:S#ZGPY>[!L754(:P_MO24%N**FZ[K"R6"O;!V)KJ",G,5J2GJ^+(H$G!GT
M+'2VRXM`9#N3[']MZ/W1M?6MSX>O:*1JS1^Z.DR-OB[PTQF"GM*:<:+9(LX%
M<>EVI\68LDQD$1B)>3@T7\]#I&$-H5G(18C[F8.HQ&N[;N[GB0HM!ONTH;7I
M]UUEOW1W2\9K:OFZ^N^P;!M3:`^D[%8BZ=0J-'5%K]L^0GY1QC,E80ID9_T"
M8)S[)KH]=ZA2=6<9;8V^YL*_=!:\I$]`[1T16H*>FN:MAVVD['7\MROD*<&-
M^LJF9<!Q;&636"V64.?-AS"`[L;]I>N;U/\`7%/TGI[:&X;CQY:XF'NL!$RN
ML:=_?-.RQ81KEM;5\ML"]5J(MM`U_<:9-UJ0);>2ZJ?BW1VD*1G#O@=2B_:/
M`S<EJT+8W-&]-21^U(O0]C!LDP?JBU5^HU#IRT7"F:.N5_*I^PY4JLURWV>H
M9CGW5,..19TB$T4VW\_O2''8OMEU#'V\ZJ574FTKNPW8-M5^!M;=SYGUU5KR
MK2-]'U7L&4HIVY=_ZW+LD7&;*_+AFU-,8==(`><PW@=3#SP6IW_V)J/FC_!*
M-J-6P`G?VPX'75<%AH1F<S4GID9IV0N>Q3`Y#,95-;T\DP,::G%/NA@OR`R<
MY7AY*O`K:/\`;AR04_M6+9)V&FTZ7Z1E^9K_`$LZICP]IC[)&(V,L+8$;'3,
MU'MV#4EI7JB>&B)H%PC)\C'N@I9P8TZRV$\<_=LZTZ$N\AK:,I>WM9WH;4E'
MWO$UW;U*&JKUMU)L`HZ.A+I4I&,G+%"2X8DL`H21&_*;.C2'&<$L-I(84X$5
M5;[2^5;I<Z+1ZZ3LLZ4OR]4-1A"M<38K$>O=13H.OWI0`K+-A5$GF-I;+DPP
M3(J+4YC\PEC"7,H"3]C=\<SZJVEM33%UN$I&[(T_JRH;FM-=:K$X6Z=0+E9T
M5$:4JA+`BQ+05!3106)<01;A,6S)AO/H2T2VO(8VS]B?/YTU`1,-&;=G@+Q>
M]B:MU=<HO55H5K_;6RM7)L2K72]>W<Q@.NRDDXJH2R(HDE\2-GW(Y]$826I.
M,9"=-$=#U+H:.LTS2JSL:'AJO8IJJ/2]XIY56CYBPU:SV6DW",KSY)#W[5ZG
MW&HR$;(93A*6B6<91EQIQMQ83WX#P'@/`>`\!X#P'@/`>`\"BO;HRB9CB3""
M!!\L]U:A)S^62@;YDL4;;#BQQO?_`.WRW48S[&L?U+_GP+U>!_$J2K'JE6%8
M]<X]4YQG'KC/IG'KC_CC./`_O@/`>`\!X%,.H=L=#538W/6IN<X_4?\`<VXC
M]GO3EAW/&W.3JL#":YJ0<_AD-BCST+*JG)@V0;::PY[V/A0ZM2DJ0A#H0O*O
M_<N.G'Z.+^LB87^5G&?VL]U17$X"]GJE6/PZY:LJ*PYCVY3_``CTS[O7^/;D
M.LQ+?=$E'H3K_P"K]YSW9SA;&X.K1D>STQZ)^-S1Q2LJQGU_GW>F?^6/`A#;
M78OV:\RV36H.[.?>++M&;<DKC3:,%I7;W31DZ;L*'I4A;*O7B<R'-<ZVV5<"
MXQR.`'P/_P!T7E*5/CISEQ(20U=/O`>BPCDZ$^LELPH2/)>B2>C.FF"@72VF
M7"PR'T<[D"J?C%.*0O*%*0XIO/LSG&<9\#(XN[?<JS(1[T[SU]=)L,PVXB9"
M@^GNA0YD\C++ZFGX0R2YH(C@14O.LX6@EMQS.&G<XS_6W[0CGIW2O>?84%HZ
MCVO56F]!CT;H'4VSK9M#6/5]AL]LCJG5YE2+V#2(:;Y1B\-6,^N&OKB2%&C*
M%DV!G''%-)=:<#T[I]?VR]);:YZZ#X9>U9.;/T]H+;7,MGB>K+?L%B+O=&VW
MLVF;IFMBR-VUY5;+/%;8=V952S))Y^-RS,YG2'7'&'&$)>#`MS:#^VO?$]J>
MVV%/UZ42<T7=XK8E1$K6P.GK+'W21`GJY+%52QDF:ZJCE/CI)JO(;5,!L2AS
M3"WAD,?`61[@R'H_0'V5=D\X;5Y=WE7N&J53-T1L74;5<-4[AZ$D;-`U%=KJ
MTE82J_%6/1L4,395UZ.D&@5J/%;9.=&=RKVM+2L++D\E;`U5LS?70'/>ZKDS
M/;"K%@M,+S!8XS6H'-UCWZUJJL:_@+]=2X*C0VWRB)E='`<D4-VH<593SY/L
MPXKU\#3=J*SZZE=F==WCJVY;YU#T3L.'V)OJYV'1,3=>:Y?0%)YITSRS';!J
MM5R5L&_$3LQL%JTP(LI$.'S\89*0:SF\H;)BR7PJ_P!E_8+`:+LVCX#F/D39
ME:Z+J$3M*3W3M3<G1D;1]^ZL7!,TW>TAF]2T;:[S1NEQ]TZ_TP+(6,23FU!O
MQ#4="K+C",I;CPN3O+OB^_:=SM;^<.7^%>A96]70#66XJM.7>_Z7H6LF*KK?
MH*K34#:[#L6(V-8AF8*R6K6$S%L@C,F'EG0,H"\,UD=U>`VYJZ?ZP;2.I7UJ
M;[=4\HO#R!=[\8K4+@<AUAA3N2NA`T+P<TA+S?QY7E+:\8<]CF%(P$#679O>
M\;L2I=*D:.W\;K$.[VG4+_"]()Y?+MRJC+5*,7$]$7>[';(5$RIX>SH<@0<2
M-MC8P==,9)6"X\X2M`2HCM3HPF,>/$^L+L/#V'2A1P9*X\CQQ#I3`S3[2GD?
M^2!3P\<^M]+>",-N8PI*_1*LH],AJOX=UKT?1I_J;=_97U7;=VETMU[=;^)L
M)Z,L_(MMU33^=KP17V`>;:()==ZQYG^,\*&R9912Q?;99K)<H6E7S(:9"(%7
M_P"R'AA-WJWUU<$=I7K0=WS</T?,71\=HW^V>/I\VN'R@-JY<V55-\6V9LFJ
M!K'+#/.:UEQG!_E:='A)&-0EUC(>K%:LB-:U2$D-$\%_;OHOL6KS9%GLW;L+
MK;G:Z[,Z$NILQ^[N2>GTO=,?K>@-97Z<6M3\+(9:3%A(9;@R(O++"D!@MIZB
M[5[`Z5T3`]]_5_U]7N=>?*NG9\[S!JC2])W34.K=[NFSM9JNS-@EW#8<%"UK
M4VJ'E`ST'55&RTB%8W6URCQ+#(KV0JQNJ/V1OGK!MGGGZN^](GZR:/L&,MO6
M/#L[JVM5;6W2_4U+GT''M16KW]I?VEKRO5&.FXJP.JAG_P"T[W9XME$F+_LO
M2&`W=\E]MW;1VF:YJ^?^KW[+J^X%?]MR3`\%H35\E`0D'L'==^O%>3C,;O5T
MAL>/KUH&R2VPPM(SB5MMX7A"?4+AA_8O"D%`C$\:_8G&)+?>:?*,X^OY`L8T
MV0AIDLY40_)NN,%L+^="1D$/(;QE+B&WL9:\#+G>]J(RL=M?/O<F5%/98:^/
MB?HQY&'$LNOYR^XS0G&Q&OC95Z..Y0WE7HG&?<I*<AX4GV9:]B%URA:#T1T)
M"7^V7&*KV;?T#RQO_7^IZ+7F5.R=OM]DF)FN5422_7U\!]N,$Q)@-R4J^,Q@
ME&%*\"@T$)T!)\RS/9'1WV^[VY6I;MKV2JU-C:MXSKNH]9`0^[K9KNO``N;#
MYZN%KCH=X&,"'91*S4@9@A[&72759],A5_9G>FFM4ZIOEJUG_P"I,U[M6[PT
M3B6AH&Z(X`M[!+HQ8K!(@\;K[4=;DWW70"UY9&POY"3$M)2XA.58R$J:OM'5
M'6/UK6#K$W[*`]K5^R4*XR4_3=0:.Y]#UQ)IJ\O-QDO1V+3(T\^X1;<P$RVV
M6X\L>3CLKQC.$/-JRH-Q?"#Z".6-;N-#J&:Q([+:91E+"$K9'VO>6&26$,%F
MI0*8VWAUG"G/EPTM/R)0Y[D)"WG@4U[VP>KG`Y$7&-2\BYN'F-L(![(ZD.$+
MZ7U(E#GXIA08DBH;U^3`KKF$$Y1\><*]WMR%RO`>`\#4%U?]B?!FD>N=':\Z
M2$V56-DZZW-3-<ZUVXJ&DQ]15'9/3FJK>+$!6FPPUH89_33-.8($,>EXQZ.C
MB2&"59;0RX6,%5=O[D^ORJ575'(2N!^\MO:SK@O0?-&FE:@US=;C6R3XFY;*
MUMO#5E:OC.Y8NS&V:*C-(S4SE1#WS@5T%L@=]EUQL?(>-0]]?5'H^QWWM*'Y
M/ZZUE5M32NR-NF[7M.JM[YYFH5LN>T`-"[4V;JRMR]TEM$5:]7(Z\R1,O+5N
M,&E#(-N9=><RO)+#P=G<D3]2H&P=U:M9U%U3*RNP?\O5H^O\O5KHK:5$B)O<
M>C:/L?<&Y=+ZLT[(W>L:^G]@:NZC#;D[5'5T!$@Z>6TXISY7E%!FUMV?]='4
MQNW8*L"=UWPKJ*G\5QNT-BZ'TAU`L2/C]6.9VWHE)U]JFMU16H[0$FW+S:6U
MN1I<<MMQ@]`3["_:'O<DR?#N_M;6WDN.W;]ANR([JV`9VQ4+%VR7TM!V?9%-
MIB:C)$E\W[(W13ZO$2D%!,XC),MBN+==^$W!B_<VOY$!F?>5K^NK=U\V>7N'
ML+<6@-L?5]0I:][7E.=]NW73E^H5`Z.@JA(K9/)K$047L`.XMU.(88CHW!I"
M)1X8=3:22QD.!%^MN&?K)[2YESH^L%]#5M[EK:MDL6PKQLG^^]-=:CVW9B);
M<%D5O6Q[.I\%<=A:]VB+L!,N4S,"EP$XP*-[L._@XPV%KM1D?7]9]0]C]Z:/
MV?&_X)ZOI9I_0-^I4:<S`,R^GJ]>-?7C8R*LFL?W/'WUZ$+RU+)<!<4<J+&+
M2.M;[KQ(4'UY#_4_4=K4;;\7V'T=+0VFK/I:;B>87A=SB4-KH"+TA:8ZD]$3
MFBXS4`.S'[M?-2TR2(=-:PQ53_U)*_Q5/8(PH)_Z2WS]9>YKW:";YTK<:%=.
MA.*;'S&[Z:NV2"%$:5W[=)!F,O4FW;]0&PU*G%V2M2+$:9/J&"3AEU;S*TM)
M6D*\\\C<!U&XXGMI_:STYV&'I:M[>L\93.J&X@ND"4N#US=]);F%J0<+SWKW
M.Q`VJ[>7$'"Q9,J0M(S*VFU,J=RZ'K:3%^L[FK3/-L3JOM7;%#I7.]N[/"T.
M1;J!;7+<J=W[3[+L&WCKA[IIYBVWR%T%6+F_+!$N"$#,#BMYF""?Q7/0.A0*
M-].&H=H<ZTO476=5HV\([GJ?T58+#K>'J8ESZZIG5VL:5;*]=MW6:H:U;KUV
MLTQ[HZ]PTPCX,)D#G'\KR.00TX$NWN1^LU[1[ELV#VO77-`[]X%TKS;1;(E$
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MK\M:#M76RO06L(2(`M35MFP#\M6*0+.-+;$4VEW"<*RH-9<)RK]?TO9:P:1]
MNFO+I`\2M:%V1M:-5(<[R5GU!)\N6V+KS]HUQM5UR2NW*]!V-<!X^.N\;$EO
M`2I+KS&'1W)`GY0OGL7E?C_[4H7;>PM-]<0-^_8[;T7<8&^Z0LU5NF=,6[3X
M$4!9JF@B"FE8)@=W4P!$798PY3*3XY>,9^3#+&6@F2@?7';*EM&CEV7KO:>Q
M>9]0;NL70.D^9;#3Z.`UKRZ2@MI'JM5=V[!C@72V:BU8[=#WJW7CFLY#4D-#
MY1+`([20NGSQIC.A=?RE#Q8U6EH[:V\=E#R2XM,2Z.UN7<EZVY^D='0:<A]=
M><NR@<$84W^2D?#N6V\JRC`3GX#P'@/`>`\!X#P'@/`>`\"B?:S;KMMX30TP
MZ5G'<=`=<81Z(:2RQJ/=SSAC[R%M$-)!]F'$X0KVNKQAMQ*VU*3D+V>!@&L]
M7433M512-;P"*U5T3MLLR8IL^5DTXG+S:9BZVH[\J9.D3O65LT^65EOY?B9R
M]\;26VDH0D,_\".LU*X*VRB]_P"3YW%!;UZJJ8TRF!JN*TNWN6/$NO9CMGS$
MYNRYK$,A,6@#\[$6ACW._#E]65^!(O@8#M*N76W:]ME:UQL4G4=YF8AX*L[*
M$J\!=2:;*+6VIJ99JEI;=KTZME*5)_'+3EI6%?S_`#C'@9XC"DH0E2\N*2E.
M%+SA*<K5C&,97E*<82G*L_SZ8_C'@4=WD*M[MW@\A&`\X#@^LG'?FPQ@S#3U
M!H;'J&MUQ#N4?*XC#J&TK4K&4JSC"49S@/GNZEUONVJ?>3<=0\S]KW_0>WNJ
MM!479,2$M\RUT^1=E+?L)%HAY2J6%_8<'6(ZKTS0;.(XN.AX#))<FYA3KSN7
MLO!<C9/*?W):LU=>]DR7VC9/%UI1[)>90*)U[0G#K#&4F$F;$7$LXF]-2@X1
MLJ./\'Y#>,+]4HS_`,_`S'FCG#M7H'EG1W2+WW#=9:[`VUI&D[;D(.7U3QM.
M#TQRWTT:RR($C8RM$0V"PJVY*OH<<>;94E(Z,J7C+7NR'M4_D7[6;'L:;'C_
M`+<]@F<YETB%L6K-Q1.E^/K7:;5991N!>F&)BMLZ<'BGZB8$^^J)?$._[?\`
M$RZI9&#L)'#M2GUR=R$;]J^RC/O.ZC8V2'4)"+AJ$%I+0P6J3X`+!@ITY,Z*
M`BV]63$TPY8_;B7-BW#?DP/[7?<.S[`F>5Y#^Q2#C3IB:^Z;8,3$Q@SILC)R
M/%W%X0`(C",N/$EED4=M@=AI&,Y4I2L8QCP*_:GYS^X'>,3N^N;A^QF[Z4JH
M-D-I.H[G2.?>5Y68VMK(H*->&VN-8:D-#62BVR0PT\W^.@>&(BG"7$(;<=9;
M)P$U4?F[OG04#K[4Y_V^0MZEI-Z6A:?+]$<>4F[;"MY[CSTXL61L5<W3KHFP
M%14<RZR)EQ."%-Y]KKA"DMX0$AW34/VJUJG6RQUKN+1^Q;'`5J=FZ_KZ,X0C
MZU)7J;BHLHZ*IL=8Y_L#]%7SK.<PV$R<;_V@CC^'7O\`;0KP*":PKWV,3KLY
MT>?]NNJ=0[#L8]IJ5PY)W]I?3]\TWJ:7K&Q2Z4Z:$G7/0T7*1E@2BGY0S@>8
M6VH@U]DE*B/>EL*?=:\9[<*8OO5NS/L'Y]OG3VD;I9.D=<4G0^G+9-.7"R:U
MHM2IUD'B.;)G>&PZ859+UK<B(@;!ZUBS+QF+A"\*<<(=9\"HFON3=O;'N^N]
M)!;6TUKR&)@;RK5MUL7"^M(RDUO3\D.9:KA`VI=3HNKVN>[;MN<E#`/U<R^9
M=_[=G09.+0*T24D0-YG-?+WV&ZFA8LOG#<WU0S,=7*?7]&N7V*Y[Z`D;%8:3
MJFTV>:A:S<Y*J=,M0;MKB[)=;$7*D(806_+SA3Y&,NXQZA:HP7[AHYP!H_</
MU=A.RIR8R,;+T=U&.N1D5#$F)`!2]TFC)1BA`GG<-(]R\MM+5Z>B<YP$/[6T
M3]X.Q;#KRPU_LKB?4XNOI$F8/IFM-%;?"KVV'W)2M'#PFRI&\[$V)--5I@"%
M,"^.%5&DY1+/.Y>RMECVA*3Z/NW'0Z.')?57.D8`?<P<_$];5=#,IEU_`8;L
M.U.7%;H"AL-+61^:VY[E*0ECT3A:@\%P[[W6,$NY@OJ1?:::4ZRA5K["`]RE
M$/I^)\M51-0.V('AMU3N&E_,OW-X0UCT<\"$VJS_`.H6D]XPNX8C9WUD.:7?
MHZ8HCG<2T;JD:)/2Q`[[T9L*.V6GGI6R0C5*,0YD=F2=CB&6V\81CURK(3@]
M:ON]'+#`?HWU-L'2"25`!/;HZQ;+.2&A#AB@QEZ92\2D5MQ*G,H2KV85C*O3
M&<>![($]]W3;J\RFK_JT+8RWG#:`-W=7Q[J7O=CT6MTC0DFA;>$>N/;A"<^N
M?7W?QZ9"J6I>WON-WAL+<VK:EQ_Q579K3<H1`3EAN6]=_P!?@I,I5@MU0:DJ
ML\_S^>J4':F*:44AM]IE1,8\(2G'Q%(S@,QTQ)_^H6U=6#XS=M)^N3J"?>F5
M20UOB=T;2T0F,KZ("#B1Z]^BCN=K"`2:W+Q9DN9(.+]K[LFIAAD9AAEM(2X7
MNO[J0@R3GN'^#UCB#/%NX%[=VV40MD=I3SF!AVN3,N$/J0C/L0G^5J],8_U\
M"OVCOL'^U#HFMDV36_%?&0F0$D/RM:V'UYMZA6V(CPY<J%+ECXXKEB3BE1+1
ML>2G!`QY+>5CN-*RAY#C:`]+7&[OOLD+KL.Q&\T_7_L?5T@\7'4.J@=![6UQ
M,T6?B9-EN01(WV5TG-M[1J,C'H<3&R(4)')>=4EWWK9S_`4=W/KC[>M80_2E
MRA.*>)=4Z*V+'W2V[.J<'VMT+9X^1L$CLR"V8-L)529UK*Q4?8W'QY827$K<
M+&,SN)Q?SXRV,TCP*:ZHX8^SG9.CM?7K47*7/\S&73^PYT:5+ZX/J]0LFNZ/
MF\V&NAE5:=YSJ^R(^RVG9VP3I6Q*/4WAT.(AQ14C9'=<6&SWEC5OVM:*Y/W7
MR[=_KVT/:PMK.;7+'FZMV[6Q(E@W<L"6'<\2];EM'B`BA$V(TB0PQ'H0.O!C
MJ,M)5CWNA/U!Z1ZRX-YRT+JN\_7CK[7]!HU?UOH2IR$7VI6)L"0N*8)N$@0V
M8\33A4J!$2\G'.DF'/\`JQ$Q^'S"LI8'=5@+2JZ<^R%A+V7_`*NXHE368];:
M8CN?3Q."&"#%#R"&U2U#@LH.CQ_:1AM>$,O-^J</)<QA"@A#=N[>^-ZP]!TG
MGZNMMT8:Q[_YX=VELF8Z0Y2F=:4_4M5VQ1;YL:SQ),#M)_8=JD`XJOOB#QZ*
MZ&\1[\N)6A24MK#<_P"`\!X&H+>/(/)5HZOV=OW>N_\`7.(),=38O=VC=A'T
MZ*J[-9VII38',-+B;I+F6:'D8D+8[MM(S#9D&UME2(SC(*?R%?,T'%H;CC07
M/G_A!4HOKR.M[7%.]NGJ'6&-@3M%EKULG9_1E8O4F'JFWV!,V&63NFB4F_\`
MY"G$BNV&<";602RC!;ZU!0'4?UH\VT:Z[2UY&_8[RK-7R<FGKE>!8;4^EX?H
MA@K5_6M:ZTV&[>Y9C=TFHV(%FJA,Q,[A^NB*C@S/FRXQD!*%A)VHN!]=4.X;
M3W7P%]GNEJ77:[LK<&P5(D*;KGIZF<\:_P!RZTTU2Q]809SF]H&)H5.H"-)_
ME5Q1"61@XU],;^.L(3.'P\N`^FS5FN-U53:S/7.CK;(:]IVD=GV(K?FH"-@[
M'=B]:?LBK-N5JXQ/3VNZ]4:]M"Y2DU,/O9K;]>".*]$M/I&PE03+RMK/7.EM
MF\_.;8^UCFK=,%ROIN?Y^YMU;5(W2VHWHW^Y`J=2)F7V`[_EW8=AOETBXBFQ
M$<%@)V''0Z45AT1;A#?L"%]D?5A68>)EYZ>^QN*U3TD;&;K([8VM<8NK7[6N
MR]8]+7%4\U`6?1>Y;O)ZSU'4['?*_5&@QG<^ID9!O10#_P`>%/-!FFF.-J_4
M^-NH^6-7=K\\,V7KFW!@2B>>8ZPAZITG2TT*@U'>]9U964;HVM:M=KGM;04H
M0W)%3+,3!R\T*XD5I&6F'0DV/^O>/U]H7OG0.HNN:ZG0G;^EI.Z:KSLZ<&NU
MFUO>IRF'4;<NV%[!S-,/W?5%@K!-0PPEK#3,#^%C#+N$DHSD*>;"^HBF2TG<
MHCDCJ'G8_3).PJ/TC9=;[NV'NC9EEK%GJ6IMFZ?M[&-]ZSW_`$O>L3IH:)ND
M7+P4>Y/LC5Z98D,^YT226,V%H>5?K8TZ98+B;OC:VJ-LM6JJ<TUN$U1H/?'1
MH^LY1//DEL*SUUS9=9NG05_DMU,&RI>"V$61Z43\,>2RO#K&%X\"ODC]0LG1
M:9JMS7_0^E4;)E=*]4:,WR;M[9.W[3J^4E^AK*W+LW?0=+>O;6=26P:[1[D/
M(CUYV"4_$2!@C;R"617$!ZEZ^JGM&UTJHQLE;./";O0=B;"O>MJK/;9[QEQ,
M3-KUUKJ``V+7MZ6';,WT5KBYT6TTW'NAXHTZIS$,7E!@:#%))0&<U?ZQ.TZ)
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MU_76RX]H0O5\9?MB*GJM\KKCX.)(F/RA(@HN/`H38/K4^PS<&HM(:.V;4^/=
M7PO*VLZWI*E;,T;L2W*O^X:X;<--PEKNKPEFT@/':L(A]>4*0L;$6X].C'W+
M\'#S>1VE.)#:;Q=R=MGF#>G49EVMKN[:5M5O5<U0.@[S8VWM^2P5:C;#%EZB
MVS6Z[7ZOKHN.UP<>^97[!$QP)4@'./#2#:WPT$/ALD\!X#P'@/`>`\!X#P'@
M/`>`\!X&OW[%H^3"UCI/:D%/D0\[H_K?FV]Q,8Q%QL@S<EVG80.DI2H2),EE
M'Z6/DJ]MHUU1;*VWFW!V\85[5*PH-@7@/`>`\!X#P'@4@W:A2^W>&,I4QZM5
MCK1Y:'"!6G\M?V=K5C+@X[I3))*4.OHPOXFW?9A>,JPE/]6`T?\`66P]>ZQ_
M]23H^^[:V/3-=TBG<*ZS>=G[U.5ZMUJ"Q8]H=-0#I\M/6`9H6%27)%@BM%Y-
M%2E9/P*<]I.67@V[=*=Q<677F?I:`I77G,=SL!?/6Y\!U^G[_P!23]@-6O7D
M^.VV!&QMHDB7GW22&VT?[+B?D<3C*<^N,9"*N<>;)/>7`_`6MYG8B*YS`-R+
MS>SL;6<6S)NW#;#[VH(H0BGV;8F9L!$;37)`L+\L$>/RZ>MI]A664K:PR&SV
M2K$W"5]^-U:17ZT^-7EPU;B96)2_2X,P:.P)"2;D/$8C9<L>,_%'9R"P>&PX
M,E6,90YZ+\"'N=N;F-1.V'8=]L"-G]$[)0*[M+;A8"073VA&0QXRFT^,RX\F
MKZ_K@<>.P*&TKY"U#X*+4Z2K*DABV^>8K%TILBM0^V;36)KDN!`_;3VAFZ_+
M*)VS=<9RR'';;,,G2:I;=70Z,?F-PKL4K!$CAEUQ2?Q49<"PDZ#9*R]`'TM$
M(/3((&?;LU'%@7$%R#9;D<<!,U@B(;>>:DX+\,W&(M`BTRRY#_V\PXRCY0C&
M-TO';7U7`L[^!B+C?I>N/.FVL.NDU&>J!$](P]I8%HSYB<6NC&5:8@XM\5U+
MK!K4E%LE*2T^C"6PC8/8&Z]/3E&T5L"1@[4Y=YN7JFL>D;0X6`S+M_J+A,UB
MN7NLP<%F(D=T1<9`BM/I_.K\3;,Y=+!6(3[XEL(EWCQE-5H^`VUH0C$[8H38
M/^1=F:UMH8LU#;--/N7]VSMVJT=\L9#5C<T"0\Z]!G_`0PPM"<H&47G+CP8W
MS788G;<&5:=,RV&=IGQR:?N[=]KU>3K(GGNI5Z8(*QH36VI[$')QU/DX!@;V
M(A2"LL`+<;FY=<D3EH0@)(C<T&H:OD)1NS6.'YLEA55\!!!4C;-@]"6*Q%./
MPY->7/&6Z;N2-JMVDL<]]Q3$U-E!#Y;2%&L+R4$)0Q_2%-VH7L+5U#C6[I?C
M<S-^Y?:F#0-?5:E1]5JS<)*W"SU\.;A4;KNL=#%*1=(N--K114+FK#-ED,DS
M&`V*#2^J.E*-9*VHEF9C\//0-N@&)A$?<*+91?3+L=(OUZ45+TF]UD['_4R0
MR?&'L*3A39#*\(##J5<[1J2P0.GMRS!4Z!,D-0FG]URBQ&\7QUME?X%!V*\W
M^,R!N9`8BW$/ML,Q]E:1ET;XS,/A("Q(T'#!2LI.!Q4>+,SC4>S,R@XC#)\L
MU$H?:C$R13:$O&_KVB7$,_)E66T*RE/IC^/`]12<*QE*L84E6,I4E6,9PK&<
M>F<9QG^,XSCP,7%CT5*/'BZY!"-UV,BUC1%?AFP(QN-_!&1B/B(H/XP(L&*4
MTPI"/>\A#"U(3C"6OY0$$WG0L?O*%A;=;)"Q4_98,2U+Z[G(:6!>D-+V@IH`
MT62K94*D,>2/$>86+(^\D@>6CBS8YYQZ/)4WD/`HF_[S'6*"TCMZBE";M2_@
M)5BB'(:)UGL>LA-NC9W!3B)6?64%'RY@Z?S:FTY)V*ODDI:<06'AF2)"=8&@
MQ50G;1=P%V+,E9XP54W509Z1+J.9<22GIHR:K]5*>&A@+/-DSJF#3VVF'Y!D
M47#^<Y9QGP*X6&`W_O3=R(:8;;U9RSKB6&.,8CIF(F;=TC-@_P!P1,E5+*W&
M2!@=8U$T4MO,A$E-+-F$CX:(PVP^ZPV%MK(?(5RJS<E6ZP3:I2%@SBH.G1!4
M5$E3QH`3CD=7X\V7)`AHUR0>;0PVZ0ZT.S[L95G"<9\#73=^/]ZW5NR]`M[2
MCH+KTAF,S4(MJ1N6-&@T.LSI5IB^<;7$!3[1,Q0;F;\(MGF16!BC5)_*:$0M
M&&UA.'+^RZ#+U>U2,]'$ZZVM!V!5/W#&W]04;-`ST1.$!P\%&69ZLT:.O>O:
MV9:$0M<EX\/,<^S[!FG72$NYR%R/`>`\#53]P`L41S+2'9A#Y0H&_M?'-Q30
MDD<S,FM0ET;!CY`.*>')D(S!;R'WPO>E,DAG(6<+R1A"@VJI_P"G'_M,?Z8R
MG'^G_#&?YQ_[3P/[X#P'@/`TR?8;]94OV]OFHNRY<63S-L;1UNUSU+3%V^S5
M&P3]MU<JRW+CRT5Y5>2H61<H&U]ARTJ4HM*EL.@@*;][."A2@U93GT[_`&7[
MHU[J5B];AU1JC<_/]&E.I(S9,?!Q.R'-R_8]N#9L+LJZ3CQ>92MS6IF=20VH
MJ[5PK,$X65)!V"6RSEL-YT)(>@U]0W;4I6=:;WM%;I,]NJ:OGV*S>Z>9;'?=
M;%5NBS_8,?T!$4;;NA]_5_6\%;$,5079:$2%/L9$S&FBS3ZTK')CQ_4/2N_T
ML]94Z^;"U/HB;HDYI?L/6N@-9;EZ#VG`ZD79M':OTR;8;]L33-VT/J*NZ!J'
M2L3N^^/A@-SK?X$P!7SI2/,?(84(XV$<W?Z;?L9LM(V`>U<*CGH3GSB$GB+F
MW8X,E6:YKSJ+0"=J]%AV;3>U=4+FK*+5A+[HVRTA<2;+'%,5BQQ##R4+^%YS
M(;;HWZJ^>KSTKUS9=P<:Z!.T]N_EW0&N(LQ%(U:-892^(+Z+=WV5'R-8A@+C
M5+/*#;`AL%V'#K9TB_\`&MHG/XB4M!(?UW\"P.K.+HVA]74!O;^]]X@P5JZ\
ME^A7Z9NZV;/NU??'148&_P!J4'*PEWJVLXB(CP:Z,M*Q0!!4+2RT0X1C(4<U
M9]8.W*#'\E5W2SU<Y(MFNN..GZCT-,Z;U]S-+/VW96W]A\^R5;K&QJW.5\^-
MLH=\@]6S+6+*""V\M49Z.*%0M(Z`K75/K2^R%NV\J;SE:'HP6H<@Z7Y=Y(SQ
M[/D#6>Q[?YSC]5`:_P"OHV"NC5[3J"J0VUL[%EGR("8%F4R[]'A5.G,H0VTL
M-L?"WUI<_:'CNPP9_D+0-#9W;N[H.G`BU_6&K0!KER3=S81-9U[*)J82ORM?
M3$>$I3\+(I;5\V%_,/\`]*UA4RG_`%=V'5A7.1O,FF=?\9;0%[-ZIN.P=Z:>
MU%S=+3%/T<5#]3QVCD2E<DVBX.4JL]6]@Q40+$AMF'1&9-+SBF7!W\J#7&]]
M=G;M&V5JFQ2_'0^^0(P:+>MUDF-%\&;"LC4K7NV^HML%SPY&R]L4PF@VFTU.
M[UZ?:56<%`@I*P,PVP4(C"`V*?;'Q]T7O[I:G;+U%SM*[(DJ5K#6,1KV[$3F
MK;+2,R8>]!;#;:P_$6NU:LV?S/?X$8D>P)V%49>:<EH6.<BU@8-8!]P0UL#Z
M_/LQ/JT&]5MCJ*!@YC[-SM(:FK4+3-,7/0<MO5K??^*K03TA#7.=DI%^V.V<
M!$1@""`<A1YC""?A4)\S(8I:/KCV)LP"<H/.O!LCQMI"Y1/$\'>];;ML5*VW
MKB[[6J^^8'9&T-FW[3-'WFTUL6(U5K0.0@9V>*L$9-W9TMEEA#S`Z'_`SJQ?
M3!O63GM::3!VGK(>`I^BMU(QO)[0-V"J.O)/:G1KEVBM><N5FH=.UBY<\V'5
ME2?%;@RGYVR!J#CA$(8;2,XVL,-(XX^P>G;&WWN'0D!>WMIZMH'7(5$'VA)A
ML5WJZ%V'T_L52]2VV21(P"'[W8M.0=9L5/N3KR!(N:D'4.LJ8<+8:#"J-HKK
MB%F=*PNP^>.F)[?P^T^0'ZWMH2R=*"Z\B>6X&IZ58CZ1&V'7>T(C7FI9G4LE
M7K8/L""V!&EO3[Q11;'S+EV$,!]<_@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X%
M)_L"8">YT94:][,"[[Y-,%8P6P"[('#]2:?6+'#E/,ON-/E.?PGX4Y?5Z>U'
MIG/KX%V/`>`\!X#P'@/`I'NS!'_FSPWEIHI;&*WUA^4XR'\X[*/[,US\63"O
MQ7OP4+=]$H5\C/R+SA'JKU]N0TS]9"4N;^_&B5S95*@+[2"N4^:9B3KLWJMC
M:():8JX=U"K</!C(JQ6-L@=,K[@1%@.`%D8P\MQ+HC*'0VU-Z>^M[\:<@1>5
MM'("%*<%FXN/X]2T(4^:<T&6RZ.#J9#$RP0>9ALG",/M96I6'?\`17H$]A](
M<^5R+:BXZ=7!Q4(VJ.&AP==WJ.'BQXXY4-^(+$#5%G\400QG+2<-M8;3A/JG
M^C^?`\2]V?<N[-,_G<S%1>O)2ZG5X6&V!LZ,E@#X.E%SQL?=[/%4EV,7)(M8
M$`#E^!'D4-#E/E,+?RPA*_0,MU_J8?GS64#5=:8L=O358F-C7P[=<)`R0M*O
MV"'9JPGR\F--?B3:\R$A)+:#'':.+<^'.&T9;4T$9T#2-ZM'0\CU!M/8DE)!
MQ,59:CH#4D&B7A:C0*':&:PW,V"U#2T-7)VP["MS]9000T<-AB)0]^,WDC++
M#[82!TI4][W^FQM%T9<8#6S]KF416P-C2."RK%4Z`Z(1^Z=H,8,/EHBY2J?0
M40ETD7$=EW\E"\N-H]`EBM5'%4'A@(Z;G#X^+KT/77\6.5E+!('M5\!N/C)%
M9IQ^6F98A&%N2!.&%/2+JDK=5[D8SD/U?:'4MGTZP4"]PS%@J-I`7&3D00\6
M,DL52VWD9;+`($/!*&(:0ZP0.ZT^P\A+C:TK2E6`J)?&^DZIJ>Y:"HE@V!8M
MLDZIM96E>F"86FRI$C8HP[_M8"\-R<+B@5S8D9"R0S<<=,#_`*JP+'?)6A#K
M3HR@I_6:/T%T;$6S=&*K80<P6P!TN:MLV9;6%)ZGJ]>FF1LN;#UYB:C<QNPM
M>YC7_P!><@IF`L^&XX<QQ3+!&4!R@=>4&Y;FB[41,3D':SJ7B#B:MO\`ND'J
M8#E>8(@&<R(\O54'C3Q,I.6]\**FYV1>+/FG9$",KK3@>)=UH+`:YV]S/$ZL
MB*I!=-U&KR$H,N3MUPD=A:Q7L^V,5`PJ:M\-"Q$!-2L?%1)D*.9EI-<PX-`1
MQ#J`$"$I2ZR%;;5MH76VS:M>.49"G#LO5VCTQO4(,<*_6MFTCX8^7I\YMN\.
MV,:RQ%_DJ+=43U9/>:4Q!0SAI%H6XX6`RD-BVJ]IZ4[@T6:8Q&9EZG:X[,!?
M]=V938EGJ<D^.R6[`V,>*/<?B95A#C)L>>&1[7F5#G@D*0IE[P/7A[_,:MLM
M?UEM5Z0.B)UQ,5K[=!WZT6$LDT08I$-KFV-H-49$["=CUX0$2IM0<^H1Y>%C
M%N-!O!8KP.-IU+R<K1A>,86ZW_N-.-*]S+JV5_T.H0O*,K1GVJ]/:M/HI.<I
MSC.0\ESYXPF5E39,XJ-=:CD"Q+,8V2F+6QEYHET3$8"Y+FJD5OMY<2YEU+6&
ML91A"<K]0P[:.J:IMF%C8VQCN,2M9FV+;1+9'92/9J!=@09"-CK?4Y/VY>C)
M@:/EBA7,IS\98!9`A"7!B'FEA@>M=J68*=`U#O;%?A=QDM31U=D:R/(BT+;%
M;C"'R$SE%=E'BBQIZ'A%L?OH0ES!D>7AQUC\B.6.6Z$NRK"Z^Q.V*"A'YJ9D
M%Q;IL?B5(8P8T&M@)QT5!.2Q!7`8Q;COQ,,H44MO"<^KB\*\#L5>UP5QB6IB
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MUV)T=JM<T[E(PJ'$L)Q5CE-0U$*,A#I.6C!"RG9/9CA"7R<0[I:!LLI(P`IM
MYQ#?RMI4%`._>CJMM7EF#/B!Y&FMG=$ZX@Z[(VN;K0L->@HN<6/89FDRU8F[
M.)<*JELK\-DYCUCCSW,-,/N(2IY(;JO`>`\!X#P/F\^SB#/F]^[R"WMI?O/;
MB(_3.J[I]:MCXF_RQ#(U]O2#?N+-[C`+51DRE*I_1+=H;!L/[JX14I!JI@;;
M+0[S@A84@%);#SYV5FO=LV=A.\HW:]DFNXXZF,UX/['F.B1BK9>;A`:\F]76
MM%O?XVEAT:^=:+@)Z-K\:Y@,O"`@F#$*<>":]K:7[5V%J3M.N[V_\C[)M;CB
M!Y4U+RSN+1FUM\UF.W]#C["OC%FZ`$#UC8:8#*[EE]07<*#V?`J;)_7S4"02
MTXP,:&IH)'L6D-B:V^P>9J,7,;0CN=Z7L+0\#17=@[=^UF[7:4C9#7%`D'W=
M;62@76TZ#N#;NTI<ID_-X41[2DD-R"E@Y0EL.C]0\-VSK;HK1</T2+ND;6VW
M/KW_`,@Q4RYL_IK<^N]C;I!M^NV+;([R%Z+.6?SGT948!;*$P<4*-"S8\R8I
MC"'8YQOP(7C]Q2%W7K/979VZN]*]I+8G->^=GRG_`(MRG08(50[['Z:L<%=]
M*2Y>ER9V_5N_:&I[=9J>M:;*-8KDFL0YQ\0LY;F'0PEN;^TZOQU?WWLMWH:K
M)KG2'"M4Z+V#$;*WR=:=34`S1'+$]NF8F.+J]57M0[CH9]G*,C;`;4ELGQLQ
M+S))0^6`GTLAL*[*Z"[OKW8=.V?JRI;5DN:N"3]:8ZEK.L0)3^V]_P!=Z-0(
MG:<V-KV5%1:-G`\TZ?DHVR0;]9*DWV+`U*COL96TEG(58Y8+^QK<<-S)RGL[
M?G4U:JNY><=X;MUGVU7XV8KUSBK!)QT&X)J'>C5L@6)3_)_.^UG4K@PY5`PU
MOI):FB'%/"DH\"_NG-S=.ZQX$W3WGO*?L6U.H-XUN!'H/.%8S.Q&H=9[+3)J
MT?I+2^KZM,AXEJ\Y=]J38A=MG)+#Y*Y"3>4IW]='B)0&LP#I_;>M[%I?DK[(
M>GNP>.U\WS&[S;GT_([)K50)Z-I]EH-%ONCK';=F4BK7W4EMFZ]-S,]`9KPI
M:B'7H<=3K+KC[XJ0F:)^RS?<KH_G75NO[1NR[=M5?1_16]IF'N6E?[>EMWZ,
MA-$;/E='[ZL%$`CQ(R;$M)AM>4#&C.0ZI"\#J`<''1G"?`BZK=RRL?L9NO\`
M+GV/[V[5T_9I#C>U7'8]YBJ,>[KR_P"S]QSL=9-/Q%BI>F:7&5Z8V9K6/*??
MIA8[Q$"L-+BUQ3+#B"0Z^I^X>\(#6&L];;LO>Q";K!\4Z)Z$IO0C4*%%U_H:
MD]#],\6PU3E;($TP2Q&;TUG$W2WTJQQJE-ME-+9E6V$I/3AD.O5/L0^P6K4N
MM'V.R6>UARNA_L*ZFTCMN&H,?=H#:VH:7LJJUVO:TL5"A%9L,YOOER#D"Y8!
M+><Q%B@7@EN/F/\`Y:$A<7Z_^NAM@[IZET-0>_MC];42O\L@[PH^S-@R?-]Y
MGV).R'R4=(72K36AJ]5;'K^-@5/B-.TBX5I4R`3\9#:\,NX86%&ZWM_[>#]3
M<O6,'=W3D9JSH61Y2@'MF7V<^OTK9=ZOVX(]-B+9YH/@]=NU<"C2=.C',NL7
MX$>2:DC6!<>KZ2W&@D'4W>W0U[>_P=TCWQ.<+5R*O/5L,UNO;U,YYB^A1K?H
MNU:Z:K7-NX9*<HC7/E>V&'K>2)O3JX<-3UHJ<]&9C2GLLFD8#%>>>^/M0ZQV
MK'VC31FSI.'>HW*A[[$7KGGL;D"!KMPC2+#M3:.W2+VY"=*U`S9FN(/%GJ$?
M`$2RQOVXX933;OR-,!V=?=5]_7WFJ@VZ'Z]VI9=E[OLG(P$?FL7?ZRIL^'%W
M!>ZQ#["C-95*#JBY"LV<9D]N.&:O+:P!WG2,/$I)PVG`6-H_1'=FR-85]U/8
MUMT[=*7W+0N,KM3]@:&YWD.@8FO;#.I`-<MW0=`#@RZ36=JS1TFLV(36)%=<
ME*;+`RR/D?4X/@+-EW3[-(S8NV^:!][Z><:YPIJ>C9;K:V:YJ+,QM?7M[B[N
M[J31]LU+$2L7!:]E(B^:]G6+5:(\9P8NH"!*!_"ER2'&0VS:(V7C=&D=/[?Q
M&N0W^4]84/8?ZEUHUA4;FY5>+L.0<-R(XA^&QLR'L1EYIMQ2<8RI*<Y]/`E;
MP'@/`>`\!X#P'@/`>`\!X&E+['^Y=7!0=^YYC*7T)/WO5^W^<)^VV&C:5O\`
M9*="C4[8FI-^V5(5E@1ULSLG%ZL%69^&,R;^22I`26G274,9#+E?>7P0AQ]E
MQ76S+PS3+SK!'U_]PC$9000((SAAA_0#;Q3CCYS6,(:2M?M5[O3V)4K`9$[]
MU_UY#1[<@9L7<@27!$F9#,Y!Z]&DVD*99?4R_'.:,24R6RA_'R-*3A:%8SC.
M/7&?`YW/NJ^NME[`[VU]F,NY00YC#_*W5["?C$RE)+F7'M)H;2VRI7HK.<XQ
MC/@>4C[T/JR1\ZI3J-FLLCH4MXRX:@WS4HYM"<95[E2=BU?&QR?>C&<HQEWU
M7A*LI]<)5Z!Z3/W@_500V\\/V30'V1U_&2\Q6]E.LC.?$V_\9#K=(4VPOX'D
M+]%YQGV+2K_16,Y#U([[J_JMDRLA,]M:=$+P6,%EB:)L5>7^26<F.:;_`/<_
M`1N/:DQ6$N*_Z&<?U.92G&5>!FH/VV?67(8&4/W/S4G!7KEK)FT*['>UM+I#
M+I!'[`H7\009T5S#SSOL:9RG/O4GP(N_\J^9NF>\^.X;G3?NE]\2-'UYU9:[
MHSJ/9U,V"]3Z^;!ZJK<?*3[55DYA<8/*3<HT*QEY3/RKRKVY5[<X\#7#8>B]
M?["_]07:AJO9BWHCGW3G/>I]O,.UF8AWJQLB.,[2MOZ616_#B2-@$,J=ICY.
M/?:49'O#$?*QGW)6I(?18)N[4Q@PQ;5\@&F3$/NC8-)7&ONM#%8">=P+(-"E
M8;05G"/=E&,9SG'IZXSCP.P_N75`N"5%[#J(C87I^8Z7-@C,"X5[O11+[[K;
M+"?1.?Y4K&,8QX&:04_!VB+$G*W+QL]"R#+9`$M$&#R$:<.\VAUD@,T5QT8H
M=YIQ*D+0I2%I5C.,YQGP/7\!X#P'@/`A#?\`L>^ZOH)MFU]KIK8<NTDUI;!M
M@9@8B"5^L-=C).8RV)(S,B"5--C!?"",XYA9*7'ECC(>)9"OW)/2N_=Z..$;
M"Y^:J]+))L>([:4!<:HN"9(B$PC8=9DJ039Y2_#S3Y1!R7B'!V66'!<-.M-+
M5X%X78J+?>R0]&@/$*]GN?=#'<>5\:L+1ZNK;RO/L7C&<?S_`!G'KX'E+IU0
M<9_&<JM;6/@9\+#"X.,4S@,E25DB?%D7*/QB%HQE;?I[5YQC.<9\#\*I--6P
M.,JI5A0PBLJ$'5`Q2F!E90EO*AVLB9;95E"$X]4XQ_&,8_X>![8L>`!DA0((
M8:BW&WBE"C,CY)=9&8#:=(RRA&7G&@QFVDJ5ZY2VVE./Z4XQ@.TM"',>U:$K
M3A2%X2M.%8PMM:7&U>F<9Q[D.)PK&?\`7&<8SCP/UX#P'@/`ZSX093H;Y(@Q
M#\<0LN/>?8:>=!+<%)!64&XXA2Q2%A&/,Y6C*59:=6CU]JE8R'9\#JL!!"N%
M/"B"C/'/8)-=8':9<,(PTAG#Y2VT)40]AEI*,+7G*O:G&/7TQCP.UX#P(@V;
MI:L;2-AY24F;M69B&B;)76YBB6R3JDB;6+>R"W8J](N@JRV0$:[%BO-/X0@X
M$@=+@A`ZE.Y<"OF]M0ZKI]`BK/M"\;UE*%KF>K$V#$PYG]P14%(QSJ8Z-L,[
M"QE7?8+A(I1.7RRY?#T9&>F3G%#J9P0V%5M/;&YIZED9?GNNWWK$B(N;<Y8T
M%RT%^NIU_`KID6Y='9Z_P-!<K4@Y(SK3@)8<Y(N%6!EDG#;907R>!CGV5:79
MUUSW2)$78=HLBV=VZP0[&WG.O@8:2-BX*P1<5*K'JM`K:6)*&B`V!T-B-I:Q
M&#K;;8P[[74!NNQ_[/\`K_Q]/`>`\!X#P-"WV-]==V\];_G]%<P3-(M^PNB-
M',;9Y1K&Q-=J,J5,>YD9NUP[`B)F=K&!I6?.N%&8J85;;DR&\-3]D2E&<BM/
M.#!"FI?M9WUMIG3&]R;I1=;<W]`6C7>SZI&W:IUFK2]1YRL7;E1YG"3/W&RV
M1L(DRXUVQH/<.>'`(&PO.!65JRRZL-KVDNJJ5<>E^B=;$;QU%,5EL_3)>A:[
M#V'70\A8`[?KM4K;C*Z9%68N<V+B1M8KZLD_BI;84VIAI;N6W?8&E_>_VR=@
MZIW3T+'U:VZ3FJ92ND^H=`UFOWZ-U95HNL":SYBNVS-;SA3D5O([>DQ(L[8K
MXX4R?(U*-JV85HI[)XROBSD-AO/O7.T;+HOIW<,UOFM;/(H?.\EM^E"O:^TE
M5ZE4CHVK7F;_`#)&PZRZ$V0W+PA9D$POX)U^NOMQR4/_`"*0^MUD-?T;]D^V
MM1/5RCT:_<R;)ENA:EQ5T/:MEZ4T+&P@NM[KUON:O:HO<%LV%"W/%TZ>V#=X
MPMF6K)T_-0LL</%R626B6Q$N("U]W^QCH71D9")N2=>7PW<^IMAU#FUJV4K_
M``K<+AW!`;MK&OZ/INQTV&VOM*-9K-SINUX6=%;"E'IDV$KTO)MM-#XPE`=F
M1^Q#J"'UYT9=_P"U8661H&9Z+K*9M/-^PLZ7L!>A;A/T7$E([W9WL&"&3*F0
M:C"P6ZXU^.\A\+Y6DHP9@+%=%]/;TF>H*URUS=L_F_3K..=[%TA8]U;IAI/9
MX-@;J=X'KI6M*73X+8>LP&&8@1A)MLF7I4MV(AI0=QH1MU;;_@:V]/?=;TSO
MR1@X_6'/P-GLY>>;9(JBQ6A][3&OO[0V%K6NW?<-_LG7,99B-0:IK]>^26F*
MIB6BRB)N`&#]J'2#V5I"=Z+]C_5MUU'HZW2]2HT%9]\D<C1<2->.1>C*'JVN
MR/3.S*=5<'1>RIW;TE`;3$BHFQK;%#CG`3W"5#G+2D#YTMA9O7O?$]3M)=U[
M/ZNA=6QUOX<VI8]5ST[HK-HL5-V8W_CO7&P==Q%18G$%VU-ZL4IM`*`,@/<2
MH.Q*4*VZ_P#PZH*$SWW`](@\\TJ[T[G_`$TYM.M+ZM`ZDB:0#M/>M/UMLCG[
M$+,TIF-JNK`8_<`FJ=RU"=8F7]AEPY<56!"ALDCEN$L-NA:SM'[&MOZ8U!RY
MM+2-&U5?(7=FF++N.V2@</M/H+%;#`UW5[O1E5VBZ#!(O$AJ>Y3,JX`=L7++
MD!5V\"$F,N9+&8=",:1]R:Y"Q0VN9'2LPJZ']'\YZE`D]<ZHW7:^?Q*'NC7F
MF[O8#V^E,U"&T_\`WF%_D<I<2+DYAJ0';`QEOY#,92&$2WV8]<:NT]1NDYKD
MKE5C5G5&KMD;NTI3];;BFIW;PM?H>OG=YEA[?:S18"H6R9LVCH.7D7R*^61B
M(G\#1CS9;:UG^!CFW/N\EH*J;3;U5RS0;_)TB>F=J\SQMCOQT%3=Q<9:R@+L
M/-=1PDY!:]MHU16)M77Q57B(SX<+RX='E+?99)1C(7CUOW#I3?U`Z)O%UT)7
M\P'/FB:;O3>5%D(8#8%ZJ&]JV3NZ*VAI2TU[^U/B,V'J0S233,<9A*BI,:0%
M+'8:$>$<>"ME^^R/K3FBG4JU;+X7T;+W3IH+5MBY[U_SUOW$_*VZOF7K4%$L
M&KM@VVSZPI5>1L^J4G:PQD`:$LJKRK[.(U!0WN9=?"T.H-P5#H/6NXMO<1<R
M\UWZ2J.RM30.I92?D(36D-?(>3I.F-G6R6MMC@=;VJQ:\N>JCKO*`+B'(XLT
M6=@$LNX'=4OX0K-2/M5K4)!T?9/8_*&O-#%;QI>[-L4"R46TV#H9Z?L/*L]2
MJC'PMR+IG/PL]`614M<#6H>3<:*9%2%E`ZENDH;\#FKG<UR[KG)31$AR!K.#
MU'N`+5NIMN3T]VN-KK=G^--U:-UGNF6_M2HUK58-DM\4-4]T*#&9B[&-^Q<9
M*]CH^'\>@;V("!A:K!0M7K<6#!UVMQ$;`P$)&#MAQL/"PX;,?%1<>(RE+(H,
M>".VTTVC&$H;1A.,>F/`];P'@/`>`\!X#P'@/`>`\!X%(N0\%IV;]@."?R/;
MGM1U8F'\NY3^*KE;EK"5#X<SZ8'4XA7I[?Z?=C/_`!]?`N[X#P/YG&%8RE6,
M9QG&<9QG'KC.,_QG&<9_C.,X\#KK##<94.X(,L=2?:IA;#2F5)],X]JFE)RC
M*?16?X]/^/@$!!MH<;;$&0V]GW.MH8:2AU64(;]SB4HPE>?C;2GUSZ_TIQC_
M`$QX'C&U"IR:TNR-7KL@XC&4I<-A8TI:4JQC&4I6^,XK&,X3CUQ_['@='.O:
M#G_6CT_/_'^:U"_\/XQ_]I?\,8\"ENS:]7X/OSBI$)`PL3\VH^Q7GTQD4#'^
M];3>@&F25Y!&PMUYE!#C2/DPAM*'W/1S"E8;<#4UM.E!TK_U!(!FJ*I`UB=O
M^D.;KE<CAP`82I7&^%5[['X@&>V:3$98LL_8GV8*/;%6RA]3H\;[7U(2PRI`
M;X*WK#<Q\24QMK?QTQ)&K=6IK45)B-4P@#3X$E'.A`KE3]B6_++:3&2&GLRZ
M2$&#X<POXU892$BQ>K:3&,L-NQA$^\P^P7^?<9>8N4BZ:,87(C&.FV<Z5>R\
M(><ZZ/[<I0,I6,,I;2A"4AG[333#3;++;;+++:&FFFD);:::;3A#;;;:,82A
MM"<8QC&,8QC&/`_?@<!1+`0Q!A3J&!1&'227W,^C;+##:G7G5Y_X(;;1G.<_
M\L>!5_&\-LS]9<O](T='MZ_7`6*PQTSMO8Q^J)\V,C!FC(*5,I?^-[A-UJ&L
M@GROY_9_B2@#"$Y?`PXO+2`R72VS=D;4(G9V?UU%4K7S):T4"Q1U]&MRMCPK
MHP1<;<`Q6*K'#C52P`'I)CGFS,D92C*7VD*S[4AGNP-A#4G-<C!H::LMKN<N
MF$JM=@P%$NE/MI01+RTI(/N"0\'7JU$_(<:282/A;37P#8?->&%>#V**%<X^
MJ1`VPYV&L=T^(A^P2M=AGJ_7UFF&$%X!@XHH^4-'B8AA]`@ZB"'B7FF$NO*R
MZM?@8I(6"1V%@R+U5=A:^93K[51;C.R5"EK%$2T**B*LMCJM4D3C*[`R1DU"
M&M@.RX!$HQ#D.O-+:R:PMIH)8\".J#9;3<FCY^7JQ](@LG%#5>)G,>EBL,"X
M#!F1ULFHMX8(^DFNF.G#9A2D.EM-M-NOJ:<7D=H/`VGME5)=CJG3Z^O86VK.
MPZY5-?`2@4<ML-*EC.7.Z2+V7WJIK6(D,MM'RV!BW$N.(9%&**<;'6$IQ'[;
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M;:H&Z\4,5--')&Q(!N#L(>]CCB`E_P`!X'X==:8:<>><;999;6ZZZZM+;333
M:<K<<<<7G"4-H3C.<YSG&,8QX&&;&O49K6ESMVF0;-(QD$,V^6-4*?8[[/X0
M^2R(D@2IU(*1L,LR*X1APC`[*LM#H6ZO*&T+6D*3ZXWSNV[1,^;.[9YGI4M2
M`,3>T(,RGR,LSK=HH-Q8%?DYN)Z$+%DI..RPP],.MH3'L+D<"BFOO#N>H>RK
M:W1-RJ6OK;KDN@6RK7FG'V\YVR<R;_IR%U`4F,:E)%^O6&YXM@-@*ACEOP56
M)CTR-ESG.$O"CMJ?6$-W;>1')3"(],ARM3+3LEARQU_6-4U#>:=/SSE>K,0N
M2+M[<;=B18,Z%A2@OE8_&*E,`,+2"))/I0+X%1.S^H;=MG0])@;C!_J#S]V4
MWY4T*K[-8_3QX]SM]$%L5I_NT2#%C(YUL/,R7&S+"&(B+=8)/=9>RPVL/H4\
M!X#P'@/`U!]A_8R-SAU#3-4/Z&IEF;8&UC'1VW-B7QW7469)[JNKE:MVMM?[
M#DM:3^HZQ?*W5H<&=,AK=<:@18AR`F`6R,K0ZD*[V3M/;&VY'GC74;]7O/>X
M:/T_C9="H";_`+ZH,3%O1F@+Y;WKO$2U-L>C;$PQ7JY&T4"P`"86Y^00[A+;
M+;XV58#U/KNZ"U?V1MZ.-'^N/DK4%:UA3IB<UKL^M6_5UWVE36JI>?TU6B0*
M*!I"HRVO1R2S3C$+"EUHCR?Z<)4I_+F`J9H[[:^7M^;6K$G-?6WH9W8&_).B
M4\[8=,N6F=KVAF/WMN#6G/LU$[UF4ZF@9NHR$A6MLN%/Q$@4;F<&C#X["L^G
MNR&Q#;_17!/!W6NCN3Z_S-HZF2O8[<33-T6R@5'4VO@J=7+M*R6N.?0-FU&.
M@@;!M"!W3M4@ZK@,CM$C1/M+*/RR&E:E!7WF_JS@'>.QZ%R/3_KQU#1K;NW;
M>UX/>^HYC6NG(42AP^B==SEVTUN^S5L.FM@[.J.U:*6/BJR(C6<19,B6&IYL
M@0I&0V$]$T^A\>Z"$N7.'`.N=TM:JV(;N0+4^O$:<TYFESC-2LC=HW;6Y"W1
MP-<'ND9`)6`IT;+<L0,9EII>48RC(:W(+J_AN9KFZ=P=,\`Z'YRW.=R]"=6Q
M].VI8=#GV_H:O;Z$W>`+7(VX1T3^JL-FO$+K+*9;"%R2\(L+3!J,.I?;R'IT
M^;XXZ%WTKA22^J+G,S5%"W9LN#EI"<N7(CB:C=X6E13UIN<3SR]("[6-$M$;
M&B#$D!QWN.A61358?#]GL"R6P.^>,N5-P=8:`JFB&X:UZ1Y0G=UVLNG5"C47
M7VV!M`ZLA;'+<\5ZR?-&B2&P]6:0ME<D,QY#&`(JN3;&4N(:9?0V%$ZKUC]8
MT#3KV*7]=.MHX6$>YW^.,TI;>--JZDLR]S;$-C]78C]K5G<4)J.HV6LWNNID
M%#39L*8$VX*<'EW#R<X"W-9Z@X)I]4XRU3GCEO6U&Z-Z&>N&N*U7ZQH6Z:YU
M5=J#:HP"B=*;$M.B=A;&UC7VK-O-V!@*],IE29)^RFCX5AMYE6$!Y7?]?X1+
MW[<#=V_6QLCI&V:]U94-^;OZ%TY%:N"+J.KFP]BTL<39I[6\]8;BV/7A:;2)
MI!M18BK`),Q+*!_P#59:8P&'['Z!^M[IRRQFLK=Q[<[A1>,X793]2V'3);4U
M-=UA0M;:L"MTW"T76VNM_P!5ZK.UM=J'%1(>:Z'3GHB43D,>1"^(?.6`S76?
M>/UP2NO(<F3T-G2&NC-C,;M:-D873[^MDV#3>@W-YP>Y@;SIG8UVU]:9&LTK
M3*(3\6*D)"=CY2&;`,`9'0VZH(6C-D?5AR.%=NC)/@[HO1<:[J(*;$A[AJJ=
M*A('5^[=DT74=VCM3Z1QLNU0>C)JQO;+B3[37(^$J\]*0GO>4"6MEYK`3!L&
MS?3E1-=2\W.:A@3]:Z0JU,^N.+D:15[%:(1W1VVZ+K/HI-6J[U-FSLR^CXBA
MF@V:;L1&4-1<?&2)+A&&</J?#+KCV%PSSWN3L4N8Y&Z,@K+>:*1?NJ-AQ'.<
M_*Z\VUJW5=8L-+AMG2)@LR3!VFFRU?%*AP9IH)*99M*&7W%H:3EH*6Z>`^JC
M48];/JG!O?\`,SYFQZO":4I-YUOT!M.\T#_#)X'0,%5.?:_/;)LQ^KM3:XG:
MK&R1,3#K`CG'4A,E,DCMMMM!N\XJ:Y@G]53VZN5*-BA4WHS95UW!>H]VLSU(
MEY'<+YK5%V1)6JDSV&7ZI=6IRCY"F1&QQL?LA'G'49(6\XL/9IG&VAJ`95#Z
MM`6*-*I6J]LZ9KSB+U<LX"H6[+S";'V"!AO]WAO,K)6VO"$,26,8D`DM8;8>
M0W_3X$)4'ZR.?]56&LV#6=_ZLH;=:+UT:NK5CK+?$=0+2_JVF4;7E0_O>@)N
MJZA;&6*1KF(C"FS`W&SA!?80ESW*SD-B7@/`>`\!X#P'@/`>`\!X#P'@4BY$
M999V=]@'PF,&?-VDX^]AA!*,AO+Y6Y;2H)_\EAC"R&DH2M2FOD:RE>/1><X5
MC`7=\!X#P'@/`>`\"A^\E>SO+@M7KA&7:7V&/E7KA.7,9J>IB/@SE7\.8SD?
MWX1C^K^CW?Z)5X&KS>0L@O[]J7*QD2_,FU_GKDJ0``;E$18Q!Y>?LQAL-2)!
M2%`L"XCI(EQ+N,/%8?;;:0SEIU]Y@-UU?!ZAL#:G[M.:<UJT^V1E,+08RT[*
ME@'4EB*!];K;5T>)-2Z$AY)"/[:;]CBTX;<5A/O4'J5W2:A/R7KWM#9^UBI`
M!N/E!;;-QD74S!G!4L2H:Z'2(:JU$F-F',N*>9,%,SAIW+.%_#_1X$H52IUJ
MC5Z,J=/A(ZMUF%96-$040,@.,C!G'W2<C`B-8PT*,EY]64MHQA",9]$XQC&,
M>!D/@11O=HEW26WT!($<,_QE>5B(.B3IX3)+=9DW&/GA8P@22EDX=1C.!QW6
MWGL^B4*PK.,^!'$35M@;%ME5GKT9',ZGKD+3;-3JZ)C*W[9:7P*K/,SFP&)L
M9RPQ5FH-QA<NPF`C\"+&,>P>T41EA8@>]L[;`VOWHG4^KH`"V[HL%=?,H6M0
M%B1\37ZZ$:#7_P"_KVZT^&W5-55>3DATEO->XXM"%C18QAF,,>!E>N]<_P!H
MD3EPL\I_<NR;>T-BV6H@>-8P+%`'3,O"T6ON!1<4\U0:078CFXALS#YWQ/K=
M*(?(<<=4$ADM(EA%LMDD,"D8('?<&68"6MK*'A\J!-8=%*$7A[T6V^WG/N3C
MU1GT5A>`_'LBZW$$*%`2#%Q@YIR@H6*>>4EM/S'F?@Q$.*\484^XI:\-#LN/
M/NJ]$I4M7ID/,%:DYO\`,(D<OQL60RX-&`B/'`R?QKS),9F"#V7PBAER,<6P
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M@M'RXA`R10BL`?,E.)`H?([:L+SG*0XZU71J;&R$E-S:Y69,;;E+;;)5Y8K)
M1(44$&66.(4:4#5H%H>-PZD`5;80ZU..^W+CCSBPCR:"DMY#PZ82S35:U*HP
M*<>L51F&`I+;D-D9IX:'C)-D=<G"T*2?=7DDX5P8N4&;;R$]@1_YW`G`,,..
M$%`CQ1@0`AV1`P@V&A1!!1VTM,#"C,)0RP.PTG"4(0G"4IQC&,8QX'9\#`;'
M/L3.;+0JA;(\'8@\&,4^U'F19,Y309UY84=9C`#HJP@!$90T01%M20:QI)X-
MQ&$K;;?4V%-.AN;[EUGJ[_'%GG6JA>M=6D.-7/'(_N*I;"K3Y-<DWK"5'!Q=
M6"Q,3$$)C.<?K$C1,\V^TRV0$E#CX23I"Z3&N]@#\D7R8G+9/5'4];M=&V;.
MB@1SFQ:Y&*&K5B&*R_:)29F[97)'([IQ2`QQ'&S$^WT6AQ.`DK>>BZ_N2O+:
M_&K<==HTBORM8M,U482U#M2E+LH%YJ,;98V2821/4P*\PH$F_'()%4HD1MYE
MY@EMI]`4SVG$VBD])<_Z\VKOK<6=<;[E;;&Q$U!6]R@QANWX.OQEJ%U&:]#/
M"9B*K<8>M2QL0(PZ[+D/)(#;-;9:P@H)Q3K/B'EDAO9$I&:OHLV;)$Q(-WND
MQFQ6\N4)--LV*_!3=KD9RROEMEQCSXL>$O*FO@SAAO'M]/`U/]T:<JE;UY%V
M37L0LZNVKKW7VZV-KV^"1`0U>@;@=-S#M?/E,QT).SU%IUWAPLC0IV#VBW)8
M;"FLC"/)4'T8^`\!X#P'@:.>V-6_67;M@='[?Z`QN.JV+6LIS#K+JF,UQ=]K
M:[JN^(NW6FBR^@Z_LZH5>?AZON:JA3%@#!>,RTIP0)9811&!6EMH#IQFU>%=
M/D:TN;-![852_K[,ZUGZ;M@K3.Y9?4\E*VF0MM2W(0JYIKN(C9)<M.R4B!6A
MF%?&04\A`#2\);]@89S;MKB7D23+@M:WK[,Y>;>D+!K.+X[V!7.BME3]!*M=
M6FM[CR-4T!.5(R;KD0NOU^3_`$TJSA<:WAD@)I?HGV)#W[%??KXG>=^=N!+K
MM/J[3435-T\A:2U?,6AB_:@WI6=UR%),Z(YMJ,[L-RL1AE2M+T!1!T.9RV(M
M@I8D:\IM\I+:PCBT\@_5X?R1TGV9T9LO=FZ(:LRULBCNR.G(T&_],Z$,Y:V?
M-ZW$CM"S9&KAIZ`"JVZJF>9#LAQ9:)N2-RXK!0Q#;?@8GN>E_4YKZR<R;..Z
M\WSJW=NO.0["UKKHW5(-CG]APG,_6\_*-U&^;6L,9IB[5+6T6BQVJ1,JTG/!
M0S8.&#%+][`[R4AM!ZNZYY&@6KOQ?NW9VVZ3;MOZ])U6F5J6EMWV*2):V]49
MF`%.IVQ*EJ2VZ]=N8T:\^9C'S/?@.L_*0PEM"L>!K\+VW]5D1J[J^8*ZUW'5
M]>6;D'3?)E_VA:=7;0BJ-K#7>D3[[HNG7?7-PM.@@Z*?=B;EOI]$@4R_+`/%
MH9>0*T,T2I031'U;G7E#:6QNFK?]H_0T-JFF;LBIK9NF[Q+Z8&YWQL;J*+CY
MFF0[34)H"(N4BW;%;(CI0%V-GB,I^3&2'OB01A(5JWG];_U7WN?Z:BIK?]IH
MG9=1VX-/]!=%4Y<2]TA`C=S24Y4:/JFZ1)E#GZS8M5;3I&P6:7'LMPRVR8\$
M)M9*2`_>D(VL<U],?1>W9*L<V_8BCF79>Q92CWF[4'0]>I])KUFV[S@LO:T+
MO2Y:XVAI.9U[7+C"TJOR&)TY^/`#F8)#.9##Z!A%)#CJ?)GU-]C:LZ:W)L;O
M61ZWN^B=0Q(973Q[.O=16[AO7<./;MF5"W:YIFD=9Z<JE<!%M39MN&./A9-B
M0DHMMW&7,#Y3D/<WMM3ZX^G#=@=.5_[H[SJG3=EU[I3D+I6.U*_KR/CMA10;
MFT[-5XJQVRR:BG=C:_E-CQL[9&'96"?C&W&FWVV7VW6_1(8M,%?695[,[.1_
MW#':TT9V#$W2RZ^U908'3%9R[7+6P;HZ/5K3HN-TZ1T16S-;W:K#(8:?M?O!
M+A<"&C?K\NCY"0=8<+?7/!5RQ;+V5W3`[PI.U>D[9SALR4<J^@-50&Q=[V_4
MUZY*>TU,A:+U]00P]Q&E7)XPV32.F;E9<01];N!O7#H>/7N;^%X3HW7%MVE]
MLH&RM^]'TWG)_5+5VA^;:C<^A]=ZUWGKO8.NR-B%UFB5B<WE8[7)Z&CZN&<0
M\&_D`,AED9PAQY:P\#4W+OT>;#(WD$#W=0=N\_4&:Z!Z&L>C(WHINCT_0@F[
MH#6VG9Z5=M6O[?3[B-KZB4:JDTR!BCS'(J-A[&_%ML^U33:@N1&:+Y3W'RCB
MSQG>D#L_3FTN,8[ZR@-TPN*#;:]8Y29O955HLZ08V_-#2NRT3=C;@G(<IU3$
MJ6^G!+:G74X\"+-!\I4:T;D+BN4_LAY$&WAS'8[5+3--YNX\Y9KSU>E[A2IG
M4MP+W11=>65@V8E'2,"-H.9>B5A$1N`\^K3CK*@V<\\"<^\,\[%:GL_3D%9Q
M=%V9Y&[-J[;N]&B;(QM#?]Y?V)@[9;45^DK])F-AVO:+3T7'X&":6P>,@="D
MJ2I07.CK-79>7L,!%3D3)3E2(CA+1$@GC%2-=+EXUB9BQ9H1EQ;\:3(1!313
M*'DH4X.ZAQ.,H4G.0]SP'@/`>`\!X#P'@/`>`\!X#P'@4GY((=?V=WYAT@9_
M\?LU0S6!AVA\CLHY8Y>6D<G+0HOY!2%.Y4IU?RK4E2<9<SA.,)"['@/`>`\!
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MJ<REM.?:G"4XQC`>YX$8[KRRG3VTUDOJ%&:UY<7R2D3,G75B#L5\]Y\M$["_
M^Y:)6*TWES#XWH\WE/JG.,_SX$!Z#MO7%HN%CA=^:ZH$1KE$79BZG?*,8/@>
M9=&OCHNO51V"=D6JS'9G=:Y&EC"#(>#4!*X6RVES'MRD)$UW!Z=TG9&-<"W)
M<WM[9.7K!*R5TGV++N'8(\($=^+,6:0;'9DBH"KPX2@`7%M,1P32&QVO:Z[A
M+H99O9S9;&H;^9IR!BK5M&.KIDK1:I.R#T3#6JR17MD8RM2LDS+P61(Z=)&2
M*^I9;+*FG5)<5AM2O`Z7/4SN"?T_3Y7?5-@-?[5?1.,V2IUA0_Z2-&"LDP#6
M7Q!Q;-<QXY<M4Q@3'@T2TA@)\A;'SKRWZ^!*HHTDU(2A!4FV5'DY"_51R`$#
M+BTLC^PS#IN'W5R*S2<Y<QG*&L-)]$8QG^59"!.IK5T53]3F2W+NO*[LS:BY
MN("'@;.>*%'"01"G\S$RVT;8JD/)'!I;;0RPN1&3[GOE5E:6U-K#Q>;\5RCQ
ML3JFRS31O2TAKVK;;WX$_-N6ZP.VNT,MQ\Y,S5E#BXV$;C'K0,8)#B#L1H:`
M1,ICP6!&O8V$K;2UB+M>.BJU8)V3%HGYQ3]ZJ`"!F!=C0ZXLT82L3LQA&)J+
M@6)9]@]],<^*\:H1`SSB@W"6'@KGN#H+<5<D^9E<M:%C>@-5;0NJJWL.W1EC
M(JT?K>E#SM<@&K-#(;@CP"P1@3I.12X1D4!X2&RRP\IXL7"PML_818:4$B[!
M*1C)EDF'@ZA'B,EY/,%&C!RB<%-842I;@I#;ZG24I:%:;<80K.'%8]X>I,C2
M9D1*"0TFW"RY0!8\9,.@-RK<6>\PML607&.OC-'X#>5ASX5N(2Y[?;G/IG/@
M4IU]MZ[QW6<US[6]`V"QZB<H!]^M/8*;KB8@"MH?W3.BV/6TB$Y&'BCR<;-/
M.,CP[,RV1!MH6TB+'CDCN9"T]UHKUY,B09::_P#B#;%E6K71_P!8R\->%F?A
M-!`ST@\0K#M79$06T;%J'<9DTE82\K#;>6W`S<!L%H$-J,:&9CFA1V@&0VVV
M1&0FVD(%:%9:2AIH=MA*<(2G&$I3C&,8]/`HARCU#>-W;6W_`%'9_/.TM'2F
MMKW/T:DVRYLVV-HFY*O`WC8D9$3&OHVT1,(.J79JU=!E95V.Q(@NC3`3C1[B
M5X88"Z=O$MQT&^+2)R$KM@=(`2U+S\"59010<FL?ME-Q(DW`*=D<QGRX$6LC
M++9/L4ZVZWA3:@K+T#N#.A^<-X;.T!68K<VP=<JD,(I;=@LMG?+NTC;VAY&(
MM\A6@KS=XV/KID^042,R&2[&1S"VQQD,M(;2$,?7[OK:O2Q.U-H[4H<=K25$
M5'4$:&@8NPB5NY1M0O&T!8/94&3L2I4O:2!)Z&>:94-)`M!LOCNI$4]['7W0
MNV5J&BF;@B-ZD1KSFQH/7TMK*-E%&D*$'JDU/1UC-81&J5D1!RI*-3Z$I2EW
MXEK;SG*<XQ@)-\"$[)HJM7MBV1VQ9ZY7J`MDM@]RL2D^]%5^(C6OU2@Z[$!5
M=J"=;BAGXK#JEO./&$*?>2\\XTO#:0RVN4#66LJ_&1]:JE0IE=JD:P''?A1D
M9%"0T:"TZAO_`+Q3;:F4-(><RMU;GN4IQ:E*RI:LY#23]A5L:B],DTZ'N,/:
MXZ:[PTTQ#RPEP%MLHW7-B9D<6I$,-B0L9$?98.PHE(\.(RRC\YT9*!TLNEJ=
M:#?KX#P'@/`>!ISZL^MCES<NRMRV#;=ZU#%;NZ]O>BO\)S>R]?Z_L]XI)/.D
M/59R4I6H1;9."2UM<LT72##I$<3+2!!S'EK8=0A2G`I#.<#<:R>T>NQU=_<=
M1KNTA^H3MO5W^P-2B[LIM3VQL@_86RH?9%[;WF"5+U>D2'M!,7+0`[C`@:$.
MO,9PYE01CNCZROJ^LU58SJ+O'D+3O-TIT8'MFG:WN!FLMMZP8VE':3L>KKW4
M4725WO3K?/QTE'6T.PC1"YO']NG-94*E(1KC'@6(K/UW\:ZP5KJH;TZSYGM=
M#W=)`!U?7I1%:T_![$JX?,-@Y<@8G14,UN":(,FHF4L\=(QLHT5-FQIJ?^Q<
M',>21X'OU;AG2\)PORIR3>OL>KUCT;IOJK:UWW!LQC8-4J=[Z+ME,V%M_=U>
MHTGM%N[DIA]AZPVJ7%V*W^U)I<J]6RLD-AI6O*`K%:OIL`D(\T:K_8%H831^
MG[VK2VFI&S5DN0V?R/6R]VSEOK>L*7T)2]]:_LINS(%S8X\(/!75R?B)`H*'
M^:+]^'$$AO4Z0"KTWM7FB^&=":JUK7>4=T'[(VS6[K/10+\TSL70FX=04J',
MD'K)#LTZ3(SL8J2!6>R\W(M!N---_P`Y<0&D_G#ZJQ*S$247$=+<0;$J<E/Z
MTV)MRR55S>-KFMD5O4O4>K>AMC05NKU\ZJVOHBO4F5(K#\:8]'5(++'SBI=6
MVVLA#P253OJ-TU=!@M)Q_;+5EX>LFYN@MHZKU5JB[UP'8.3[-J>DZIKNCXO8
MB#+@BYZST1J<B\1R4H1F=3&V('Y2&513#R@_D)]1-\=HFJ=H/=940G8^IMS<
M?W,S>]>(D1ZQO/F#F>%YV@;QK#=;[Q4BQ+C6+/.X%D!)2<0D&S!-/_EM-$'8
M6%^YKGT)R/[SDYW=6DZ<%V5;!]G<[;++<@+L_1FO_$[6FD#;616=CH>U]+.`
MN5<TI+D5AT<V$DO0AW"EY]H5/T!]?.]M,<O]MZ4M.R^7J4]T1SHQK72M`H=Y
MZ"LFM-?'BZ^N5(=V%,7O>ESN6U8RL3A-HBQVX6"RQ"0(<0VH)M991#BPF3;O
MU::\V3)Z:FXR^73^^A]B:8E.A=B'].[]#V+)Z]TIJS==6I\#J.R0=FP;59.$
MV#MS,@VAK]4.<TX0HY3Z\I96%**=]6/V`:LN;7]B7[FBR5Z.A)O7$]>+'O;J
MS6&X]I0;W26Q=UPVV-JD:HA78FT;9NT%L-;5F&.?(BSIMMPH?#(Y#@V0]2,^
MF'=`%^D[(+L_7,#4SNJ$=PR%&9E;2^ROK)'7I5FSN,FPJCURY$E.\=#"0"8Y
MY/X0=GRMT=2&5N/Y".=:_5EW=0"M!"Q%3YF'38JSRU6N@=HLW^SQ]OH<5H:U
MM&3D&7K(FKW74'5E=,C8Y1]4(FAX"?K94HL5,@ZRC+J0Q:C?7A]L4?H^X:'N
MFLN<KA48S7%2B*&!=NR=N6"L2<_K'<57V?7DQ%?J6FM>6O2UJFH..?`B[)$6
M<YVK2H[!33!#:WLK#8KHOCGJVK\8(INSP*29O.P]P:5Z5EJ_&WF&M1\;0Z%T
M1I>ZR$7<MU#ZWU>-N+8@U(UR67F8+@`'BOE&C5+=P,@EP(A^O7@GL[FSIN1O
MFPJ/S]3M-Z_UOO*KU^KZ[V$??@]BWS9&RQ;A%W'2T%?M9)O7)=/GXV'^:R57
M%VGH1V3/:P(*P.$U[0KU(?4KVA9AA)S=$EK7H^*[;N=&-^QG1=U)JE3A:95*
M_P!+5KHT.)UW=ZO6QY+:0M+BVYZF1V2W`#18F0%R(\W^,TL<-NOU^<L[9Y>F
M.JXC9MG<O,%:=R5)6DKI(20\E9YW1U)TKKBBT02\NM^PE=RJ"(,B")(>;0N0
M'BV#%96X^XM0;'?`>`\!X#P'@/`>`\!X#P'@/`>!27D52E[+[\4O)*E8[1(;
M3E]I+;7QM\M\OX0D-:?Y>'3_`#C*L_SAWWI_TQX%VO`P/6=;N52ID7`[`V,=
MMBUB$3+LC>Y&LUNGE2S!\W(R$4*NO5,0*""1!0Y0\>E33>%D)%P\[G+KB\^!
MGG@/`>`\!X%$MV5BK67NOBQRP5R&F3*[K+JNPP9LY'`RC<9)@'<]Y#?A63`C
M51]C&+4@H<UK([K#8[F$N^J\(6&ERPREWUY][UUMO15CC96*@-=Z9ONOW*VH
MB9-AM*`Q/V8(J,:S5JE3JW9)6R1+);K!(&&K*2240A:2'LN,ML!]!$CNJ[RK
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MF<=6Y)6:6;R^H8,$7*OQH6M0;9*F`0V$IQAK'R/9=(6XZH+">!XT_."5Z-7)
M&()>3^2``,.&,\407(RQXT7%AMH90O#63)$QIK+SN4#L87\CRVVDK6D,2HXM
MRDLIM]WR_!R4D%[`*(.IMH>J11[,4<F)M.0++:X&R7B&DF26'9:.?8!='7AM
MEGT3EUT,$V'L:UR\X5JC2;,=)7SVH&N5W,)%(J^D0)*-<)%F)X-+9N9^]K:?
M&)BJRI+"C67D$E/#A^CCH9_4*/4-81,T8&S'!FRKSMFV!<RV``92V3C0F,RE
MKM<BTV.TZ1EEG.<8S[!@ADI8'0R.TVV@.ZT/*V21;+.2D*JBX')CHWWC.'2\
MB,<3G\J9;R&4VQ'BN!BEQJPS4K>PXK\A'IC"/`\38^S(_7[<%#@Q;]IOEP)-
MC-?T",('!D;1(1D:3,2*/V1F$Q%?B(F'!>()..<9&;2A+2,N$O#L.AY^N]7N
MU^5.V!>9`"W[>L$>U'35L'`>#C(.'^&*P[2]>QT@7*'U:C.'0[)KP?Y3JS9+
M*RR%K<4C#88I:)VT;=F)#7NN)0VMTF.>*BMF[6`3*!22G,B0SQ%!U><AR$>_
M>2\+85.+M\866/7B@UC-H7)>_P#!";*O5J]2X("M56("@X.-2]@2/`9PTUAT
MHATPXMY7\NER$D>0Z042ZI;Y1+JWG5K<6I60]_P/)E3BV!36X8<"4G6`\%"0
MYDI^J01[W%-M9)+;"DWPAG%MJ3AW`SN/<G.,8SGU]`[#<8"U)%3#8Z4R1H04
M<47A2_>\%&O'D`CJ3E66\('?DR%)],8SZNY]<Y_CT#O>!@DU%U>O2>;ME.(2
M8,<AH`^2`%D2<RXTC88]H4.3B(S*AY)]1I7Q,G$,.NQK93ZTN--./^X/"@CO
MR-U[("^4-?ZW7VJ?1ML,IDYC!TUM1[T*,<(<$.'=RS[F<--M*9S\F%^_W)S@
M)8\!X$/6S7U[N15E!)V[.U2G3M<D(4&-U]"QU=N4!)DEQKH=FCK](/S[Z9$`
M41]O#6`4,K45E2L>C:4Y#\Q.B=?"1I4=8QIC9>9%`R)8K:DY(W_,I@(R0.#_
M`"8V?=)K["17Y)?L0.&PC"4-)RG.&&?8&G7ORMR%1U#4-83<!ZU"M_8!IB0U
MDW8#(5^,=JLI596X$&QD<PT\IJI4.W23P46,T`([%OCLM,(^%A@A8;[?`>`\
M!X#P-'?=?UZ]5]F]!S>[*]N*O:3QRU4J7(<&Q&8>NWX:P=`0T[%[9L.UMB/3
ML"3(:MBIJR5N'HI"8%Q4J=4OW27W<LR#8^`K?LOZ6M@[6T?OVX6ZWGG](7"U
M=H6K3NJV2-0C:MU[,=2[2V@^><G8;NJC-C66/7K:]Y6%$S\I)PT2:^\G(3^%
M>W`97MOZ/IBS;2KDY2M]6B-D+K`=#3^VMZ+UYS,!+U_:<WKO3&LM$-P6BP]'
M,ZAF=;`5.BF#3L:Q&@2L@I&'%S#>'?B\"HVO?JM["UEI2?T5,<,\D[U5LOF:
MC\[5C:.PMSBF3W)EKUJ3;:.3L2F/3E.EY]_6U\+L#^W8R.JKT'8(2TRQ46\M
MQ3`LB@,DV-]4G9-GD-S;A!TKI2;M/25#W[HU_3ENV0(6YSM"D:OBJ50>H*Q<
M6!V:F?TAU#*4`'&W3($.)63&28B&'EDQQQ,D&/;(^J3O%TG959H5$J#.D=P]
M;V_N/;NN@MG55,K>]^ZQ[3LMOTH2*98\XBQJEM3G^=KLO88HOW*3+4`,1PP9
MXTEUP+`:1^LKKT#;UJW5U#7>?>CZEW'3MH67J?0EPUE5GW-"[J:*M.W^;)$V
M?G[_`&Z&Z)#T'(RI>KX$D?$(9&P<B*\T\D03.6P\Z8^K3;%9YDYHUGJSES5X
M;.L>2^77=\Z+B;70]95_I_:VL=I:WMNX>>MI7NN1Q0$O#;`B($PB0D)$*1A[
M`<*,P:]@7+^70\""^L#?VRN@8C;="YNKWUP42L[6L^R=$TG7FP*!)-Z3VU1^
M?CZ54^@K'K_5DJG7A*-_6F='K]NJL/\`.S*56N)3)D?,6VZV%H(3C/H$'Z[?
MK^U=N#GVL[TL//=QBY_J+CN.NE5CZ5M])K-^@32XF9M<U_8UN#UO:;>-<XR"
MG#DQ4SF/0P\MHI(SC053JOU.;DWANB4DKGK[7?-6C)*'Z-+U1I2<HO.'7E6Y
M39LMDYU8KVHW:7L",LU&IW^7A:C.W8N-IZ$`02)EZ-:/]SOR^!LX[(^NK3'1
MF_\`@^V6GE[3^V*IJZT6NG[>D[12Z2>+%Z6B]$;;&UY5B(R=;<(.J,5N":BR
M08T-M[`9ZFW_`&H;0XOP-,\/]66UU:]Z[K17),F'?MV*WU`Q)@6H>6JM;`H+
M8?8<5<:](U/L6"W2;LHY$?I+"G@69JN-%!/LLYPZT^`.P\$B;"^O#[0MLD[8
MYLN,U$'B[-Z(H^Q[[VO_`'S)4VM[@TUS/H.H57G>'LU1UY<X/;%4WQ([).#D
M)R4C`LPK\Q0T&?#D,M`R@Z]2Y@^T2WV':G2FP]366H;(WGOWA[476?.<S=-?
MVZEW74>@4\Y"E];:(GX.7E85$I!72JW`PB">'A3#JM,?UM-R$>*V0%Y:O]95
M&CK5VW9XS3.Q*;,UG>M6V)R=`ZMVQ+:W@INNTW0&M'8&J4!ZR6JW:]I,79MM
MAS2)1Q4'&MB2#V7?9EIMI?@8=POSEU3KVH]M5F?JFV08"U\M4*DZFE=F/$4?
M8,QMF*INV826@IRLQ&]=JZRM%\A`SH#$KLV`&JK%OD2LJ6*O\)+J`_.T`;KM
MFI<'5[:W+'=]ATKSS5?[8Z/U?1V9ZCS-DVC)Z>J]=U=;9./INR:Y-;FUQ1YV
M'L;$@B+DRV@)8Z.-)&>']CZ`J\K0?2`>KF`MY<T?8-LAEW1T%&<)435/3%JC
M+[H&QG[SVQ+0M?WULJ)OCC-/W/6]?677[,I=K$FT")C8LX=:W\`DH)"SM&UO
MVA>^I93:W0FJ+Y*\J=K6ZU\\W'5.=P[;C+KH*B:=CY&4YSVY):\K$'!":RS:
MK7J^7<G)J%L27I/%\BG2_@2&EG`5T8Y^ZLI/*6CY[0M'ZWKVXK?R+TM9=ZS2
M=DW^:V@3>86WZ)$"I#1.PMAE@4'?=[U3#68.J&BMLH"F?>\G*'\(<\#WDZHZ
MDFMD1%3X[:[WYRTU9MLZ&V+5I;JJR;8LRHO?%"UCT[LNRU.8B-@V2[W>O<T7
M8BM46JW1LA\B&,?,=;CA_P`[+92PV[?698=R6SF^>L>_]7W?2VVIKHOIV3M>
MKKU*E6$NFK/WG=RXN*K=F(6L>ST+$,\.Y!2`GH$3%K94QC#?IX&PCP'@/`>`
M\!X#P'@/`>`\!X&HCH"=W9P),[9Z4(WGS;"\P;8ZMTI;-G1FV=8W@"ST"O[(
MSI#G^YEB[2K^TA:_E,0!7,2P3AM>RVAUS+#R\MIPOP+*P?V9?7C9,/9A>V^7
MC?QUE-O8_P`UT`?*%A-//DXRDN<85G#;(ZU>N/7"L8_CU]<>H2*/VUQF6(P>
M/UKS.X&0.V6R1C>VKTMK&=;P\A[U7:$Y2C+2L9_GT],?Z^`SVUQEA>$9ZYYB
MPM6<X2C.^]5>_.4X4I6,)_NOUSE*49SG_EC&?^7@?P?MSC`Q]D43KKF$HDAU
MME@<??FJ7WWWGG$LLM,M-6Q3CCKKJ\)2E.,Y4K.,8_G/@07TMV^#%ZXKC'%E
M\Y@WQO?86V=<ZHH]<L.Y(\JAA&W*P/@RLU;S-:/VBV#QL-$1)ZDI##?=46TE
M"DX1AQ2`ICL'JS[E=,W/1]*V;I+ZT7);HO9I.G]7,5C>?1V$$78*@W+:1")X
MJ8U*PL**73M=RJ4K%8-?25EE66OBPYG`8AUK]EWV+\,CPTGOSF/C23A;%$6*
MR1LE0NG;D"P'`4\RB05D<EG-CZTIV$FL6'9<6EE`V'\+$;?7_P!>4(P$)UW[
M">^MP[\AMO0G#.IY07F+3MPL%_!JN\VK5,V/3FW+G56K'+:S+CH1F4L5NB6]
M#R:(^(;"*"DC<MX>='4D9QP.:O;*JN__`+QZAOVMV2GGZBQ0--:TU-9:S8HJ
MUQVR\U36/:=MD;H[)L0/NKK6'=HO@A""2+C1#0;KIBL.Y9'9#Z&F]X:YD&I1
MRKRQU^5#2.(F1:UY!3=X_&DOQFC5B.%5P`^/;<9$>0M>5/)2GWH3G/N6A*@P
M;9_1L#J*D`;+V<32=-:^+KP\X?9MVWZ-HJJX7^$W.R-=G(UD.8;1-1E;&.?>
M2P6\A#P:F\JRC.74A,]%=M!%4B";E+52=L!;3Y9,M2(V2B*N:&4601#N10,O
M-6$]*,0S@Z7'%EN8>>PMQ&&T+2V@*517$T1"]FM="QH4(Q3ATV/8`PSTF458
MP=SVZ-E*K92H:,_1L`155G*[,DEF>X\EYZ5<][:&$_)\@;`O`X6V&&5/N-,M
M-+*=P04MII"%DOI89&P\^I"<*>>P..VWA2O57L0E/^F,8P$;:ZM-ZMY=ME;'
M3$TNH-RS<?KQB5?+1=YV,`R4/*V6TP3HK3%7#ES4(7%!*<<._"QATQ`[SGXS
M(9O/FRD?$E%0D.[/2J<CM!QC10(?RNE%,"Y)()D2PAVP8YM[))'M6I_+#2\,
MMNO9;:6'+"IF4P\4FQ.1CT^F."Q-NPK)0T.[+8';Q(N10YQ!1K$<LOWY90\Z
MXZEOTPI65>N?`\:S9F9,0R`K[I488:RX`?86O<$76PI:+EFA[#6W)&%E(2>F
MXJ2985@1S_:1A7O>_CV-.AYE$H=5U)4,0%:$D/P`U'S,M(%.'V&TV>;+]Q<U
M9+!(905,V>T39"<N/.JPX\\OVMMIPA+;:0\/6UFM&RHO-OL%.LVM85Z2G`Z[
M3K5^.+9YN!&,$9A+E:8EEI!U2)FFAB7&8(EYU]H`EE1[;!F7`Q0]795GME:A
M!6*!44W.Z3L@/#P,85)B0L#&9?SZ%V>TR9#F"&*Q7!_^X*;":*D2,82R,PMQ
M>,I#S=<:O8IIDW;IZ2>MFS;DR(W;;E(,@I(_7`GS$M$4FO8$`!7':_IYUA.1
M$!N_,2AI]3A+Y)+CKZPQ^WHV1?KN_0(@>2I&K(V)6J\[!8*.A;C9)B18'+A*
M[J63C9-E^(9B<(RN<ER!UHRAY`8/_<?DOAA(Y#U)U12G'DBP]+HE.B\JP)$1
M2`8:"B1O_P!&%$PXGL'&:]_\-L,_\?XQX&8)SA6,*3GUPK&,XS_SQG'KC/\`
M\#P(EOVU&:O9JEKVN1#MPV1<WV#0ZP&6R%B#HH4U%1EQV18Y`AM8T=7*F/*)
M4AM7_<2ARF@A4J<=4MH)/%&4TVPX4H<F22&.,7(-"I&42IK'N<4EOY'EL#K?
M4M:6OD7A'N]/7/\`KD,0K5L)M\G>8AZEW>L1M5G4UT&QV,8&%`O"T@L$R,O2
MFA9EZR+@8XM[(F#3!(]!;[:UA_D#^Q]89'.S+$%&/R#S:R'$Y:'""9]<D2,D
M6ZD:/CAL82O_`'S2W$-XSG'M1[LJ5G"$JS@*O@6+:4A9XFV6WEZ[2=DB2V8R
MOF9M&@U0M-CYLB7;D[!`+)V9(V,&19KLLQ'SCS*\+E,!JR,(EOV-N!+&OH2]
M$VBU;"O#DA77K%&5^NQ6LV)^(L5<KL=6WYDQ-B_8!U^+,<M=E?GUMFHR24&R
M.&,AG^KY7'`F#P'@1D.O;\A,RS!H>OZS6DLV-F%D@I6>M=C?(2<T/5#Y"()A
M*Q$!,/1V'"C1T&$J0]EMAMQ2<+>\#HAZK)<EK'*VC9>R[6S8'/\`8K[L\+5J
MU6@\CL,*C:^%18VL2*A5_$I:G)$R1+RIU?J]Z>W"0TP]KCRR-:4^F2]2;>F:
MY]G&OJM5)%^"+8E[3!VR$M-OKA<^3#TH7.8J.387`6I).2V5@`,O&'9)P1G`
M;^?`>`\!X#P-'W?\Q]A4[T+%["Y*H>U'M;</5JN[)LE+"M\C18GL>UW&TU.7
MO.K:O5$0#XNZHNJ:$@9X4%MV8BFA+]+1J4ME8'>3X&NV^U/[;JNQ*`Q#_8&S
M=7[ENOVF;6JTB/8K76MM\X69G5/55/YQTE.PU?$8)G]2[%>E:#8M>$9*2W7K
M0.8,M>&7H_X0VB<^N[KE;KUW,T2+[1KNDT\J:XAJ-%=.'[4<L[W3C$3M&0MQ
M^AX[:TC*;3:C@X*0@`I4I?P1Y4^.W^K2]A!#V0U^/6'L@:L:Z/UN)]FP=-3S
M5R>KO"1V*%N[^[XJ91MK4!V[RN61=P$-6QC;0>KB+UBYNU%HY?Z\<5N!;3+8
M#6L(WL-DZF9/D!.3+WV3!\BSG04T=I^>Z<&[OF7EZWB.3A#K=#P"=8QY_:,5
MJ@;861CZJ_9V&PLEBG)P\I#XJ'0Y2MK],N=G<HP\+L;L^>%D]B\;5>*I&8[J
M>GD6#78VM:*3N?=-?L5KAK;H397,U^9E2I.[A;3C*]M2'DP'V6702/UZ,!:O
MIK9G>](ZTZ2L6J+#N*[<Z3?1W&'.EBH#$-.@#<^#6D'G2SM=$ZBF@HT.?MU"
MFY6SS]=V!%PJI-EA!;)3^&VPS\)"$=,;"W-LW<NHM<N;U[Z9[>V/T+N"J]WZ
M:*)V54>?=%<_BL;,`D[EK3)M1F=6:VJ$.;5*YG5EAKTN9+V$LO(Y1A27Y3\4
M+YZR5LG5GUS=5;N.W;U#>=CHJ74P$`5M^QVBQV*I$ZMV#N"G:XFZS!"4*M6B
MOEOPL9&$$/B1SBBV6FRT-O>N%N!J[VSMWOG3TEMO45_VYMW2\@)OW09U+3/;
M7W7N>NR//LII+?C5RW`GJFB\\3$Y%4'8.TXR,`8KK%5Q-UJ9@6E2/_:2C+B@
MLAIBP]?=(;IIL7I[JB<F]54?F#D+8-^E*QNPJM,62SW;:^\A]UWN#D[?R-*6
M3=[^*Q0QH,5$LJJI"P&.T^(E2T.("--F?:'_`)!X]X'$H/7EDUSMR3LM-@.L
M;&825J>?"#5H?:TF0U=;98^9>@&:LW;]BTX5H,L.$:+++<;9;4P\]\;884UW
M@P9*):V=]IV_M.NT_4_.9_*)FIJ11^AJMUC9K98['7]H/K>_\:J?.=67H+8$
M8Y4Y*(C(BDX@A4,%*!;?P])9#:ARK&;6J/5O9>=N=Y]#;&U;RG*ZZ!;IVWQ^
M?(>D9KNQ^?:_M"<L5[F:ASYKF7:)K$U/O.`N!32110PT)+2ZM3F?`UGN_;1U
M&+1MLSFRL[3T5J7J*:#VSQST#<M5:Q>,UMRP]T!6*-M6ZT&-@K':57L?7G--
M_K6Q8Y5VA8B0`?D)7\AB2CXE#:PL:+MO8!FA;A8^8OM8W;O&C:VZEY^TR+N2
MPZ7T=80#JUT9L;3E/N4(5N:4U-&TG=%DUP/L0Z2C)NO"@Q\$HH*,D&3'!',J
M"43/L@A]*S<]J;>O5E1!VEKKO&TT:TPD]$5(38$CRU2=0F;<D+$93:Q"C/(@
M&Z*!^V*FXX%7HO&1<+P2Y\.`@W4GVP]%"_ID]11X^AF=I]*Z%V3K.?V;K)6J
M*G&<6[UV!F@.:R-E[I*C%3]^UH?^L>E+8H6/"<8M(.,(:=9?1@/HIJ-RJ&P*
M]'VVAVJMW:J2R7U15GJ,Y%V2O2:127@B51\U#%&QIJ1S!G&7,MNJ]CK:DY]%
M)SC`9)X#P'@/`>`\!X#P'@/`>`\!X#P'@/`ZQ08AS6&#11C&4NLOX9*8:(:P
M^,ZA\=[#;J5HPZP^VE:%>GJE:<9QZ9QX&)OZUUT4OY":#2B'/:A'O?JL$ZOV
M-)PAM/N<`4KVMI3C"<?Z8QC^/`Z;FIM5NI6AW6>OG$.I6AQ#E,KBTN(7C*5I
M6E4;G"TK3G.,XS_&<9\#IJTKIM3B7E:EUDIU&5*0ZJAU7+B5+0M"\I7F*]R<
MK0XK&?3/\X5G'_'/@=5&AM&MY]S>F-4-J],8]4:ZJ"<^F%87C'JF'QGTPM.,
M_P#M<>O@=J,TKIN$F`[##:EUE$3\<ZE^/G(RAU4"8`?1\WM>#DQ8IHT5U/Y+
MGHI"TYQ\BO\`W[/J&L#[6ML430NROK6WCN.RLT;1VINN[=;MG7XF/5(@5`=W
MEW>U7KA\NV*-(2R(@^<LJ`W%!#K(2\0TK*L,I=0X&HW[>?LT^O7?*.7)32'7
M&S):[1]ZFJ],SF@7MFPT/2-46ID(ZU3UT($IB06I?^]J96OQ1I)S*$QZ"ROQ
M7OB;SX&&?4KW3PYS[9NLMHV'HK<T_LJ8`UMJ_6VKMPR\MF<W-B&C17Z]!:N3
M>J+4##[9)[/LLA'`CYD5#)9DTJ^)L=+?PA=FM[959_N3U]K&[UG56NK]K"E4
MV&VQ4J#8"R:/#SEUUQTWMJOQK&96$J4A;IJW@7XA;THF+;`+)@GUO?&[D='@
M;T;5TYSKK:*(05LBI$(@2VZYFL4)?][3T?(L+_"8@DU*B,3<M'NL.MX9]C@[
M33&<>B\H3C.<!3'IG9%3Z(I8K\'JC>$P%J1=AOMN:EG(C2<%&KBM<RTJU1-@
MRU\/3+5&P/V,F,^)"H0LP,AA!:48!4DIP-CNNH\F&JD?7EU1%-CJSERM5N%1
M8EVCTJD'G$=6C')1U/Y.'S(AAI;C+JWW6'/5"GGO3Y5!G'@/`>`\!X&#;%.N
MP%6+=U]68*V6-PJ/&3%6.TE4Z)3%$&LMSI[TX#"SYC90$/EYP9EL?'Y)6&VE
M/#H4LAH/BZY5W+V!SCK?67V%WR!V/2N6^>-`R6P=DS$[W1O?H1?>MTWO%3E'
MU!KBI:DV&98]6TJVSVXI>/F'&X=3LK$FN"Q6'?\`NE9;#`=C[][EY@TSLCC+
MI;=71)'3G1FYOK[Z@T5,[3W.7I*VWR9W7O37>N>O.8*5?]=W:T2>M]&4FV>@
MD>H`P*1!B)IU[$=@81QQP/<L73_>],WM+:WHUELFM^@Z3]HW)>H*7]?6Z>U]
MJ;(BSX^2Y=W]85;7DNB-A`C7R_<U='7$J-QB":BG8U+]2_VDC'%X(0$^1'8]
MP3R]KJ;(ZYWZGI8'3?VH6#O.+VC=[#5[;K#K;3?+"\2.M1-70DM'P.M*/JB=
MM.9>B!0S882HR.#DD.K-<?(\#S]G]X=]:DB]Q<XW#<&RXG>7(_`-ZEY/<X5;
M))7N[1NQ>AN/*SJG[!8NHD1ML@):_P"LM,3UU9MR4I.7"ST5(NY5A!./A#8Y
MQ_OME_[+JCHG5'7V[MZZ6D.5KK/N/W'?_-75VOMU2>M)36T>C<(DY0MF2>X=
M`VLH[9>67P3*]'0L]D)[`[+.&$^!3'H[KO84?$]\;>M/;W2.N-W:N[!O>K*;
MS[J/8O-=?:Y.T?H5PBPTG84YSUMN^:K)Z%K_`$C4H<4Y]22SY2219QA(Q*'!
MGEY"09#[6=OD_:%5+JS;]J!?7*SM-KZ^K)*OZ@LT#SO)[9(@I!BR=*RN\)>O
M(K%!G*[T^3&ZU#A'YYW\X3"S&%9PYZNA7[DSL[L^M[7^OBX=#;\ZCUGJ_<%-
MVGO7:FS.IM@\QVGD[=6F]9:@L=FN53TY$ZLU)7MHU7;9)*,6*&BK%*Q9P%;A
MRRW42*FUCY#]0GW(]/T?4?7$_<YW>E7NW2.FG^K^1Y3>?,UDUY6N3JB;M^$U
MQMBHUPS8-;JD1O\`I_-^G=CUC9(\@D90\J,W(,/NY1AK&0R?K+K7?W($-TGK
MC7GV!]<;:NKG#=EOFLK=N76'-;E%V5?JC9=/31707-6]J$^'$5V#%KNXPHHB
M%GJN1`2&?=EB1;>&=(P&Y/Z\(?I"%O6XL;TO/?MK"C:O5U5^-Z[=XIGJ7,2D
MG)39LI*Z=M/)(`"3R8P8`9@T>84AEILX?\?US\N4A)NXNY-B:YLE,KM:Y>OM
MKGKG(HB(ZA2L_4*_=WRSY1Z.@3<(B)RWQ\=#R[`1Q;A)OX[(`X'J0XE13*4A
ML,AY!<M$QDH[&R,.Y(QX9SD1,-CLRT6LL=M]<=)M"$FB-2`2G/C>2T\ZWAQ.
M<)6I/HK(>CX#P(0G-B[.=N`E<H6EY"=KS)DE'678-NM<;18.)+&0R@-4#!N@
MS5JN(KI+WJZ^V*&)AAM2F'R'/1K(>I)5?:]@_,03LH"F"JR2V$U2*J$5(?"M
MH;`[Q\M;W)MI;S;V'O<D<,;.4*1[7$J3G.0U2]FV1B5U;S]#6/#D3:ZG]C^L
MZ)(R!L@')V.9L4*):I.@E2@,1<I0B3G;/6#HU8L9*.D-FB.HRL!L=X=AL-VO
M@/`>`\!X'SL]@=V]-Z.W7V1=:CUYSA"TOE/8O/U<J/%M_P!:UUV][^9V;KC6
MDU(4>`V)&;!1LZ,O=RL]W='KSP=;D!\%_"RIE]M+^4A%>?MOZEU3O'<,7LA-
M)O>I6-7[YHNFV@Z["PEG/[*B^ONP-3\R:^('C)Q)$[7MNT7GG,*ZOWB>ED!2
MVSE3IV$I">M+]4]N[>M%3LTKO.M5:DT^I<:3FT:O1-&:5V'%3Y&P>;->[@VX
M63/6#HNB[/J5?N-HN)`4<:'6C6`F,!*%R0K!B<!"-%^VCKF=9K^BK\/H;5'5
MT7RIC:EI.M<C"QVH[F-N#=G(-,YPWMKR8MUJHU>,`L="W/:145<J>`;.O\,J
M&48PC+#K@=I_[<^J82+O`!A?/RKK3I2\Z<?3M74FT=#P%`VP_P!4<DZ$I-WZ
M"P[L_8P5<IE%JO0!T]8$P$T=!S#3`WX4V'DC#;(25NO[+NTN8MFV+2\I4])=
M:V_5^X-/6'9#^BJ!?*K8I+EZY:$WQN_;%<JU)/V=<11^HM=PVDB9>`AE2AK%
MDK9H7_;M%DX<P$<6S[E^A$:<@NDZ:+H4W10U7E-K6:R1^N+SL>51I\_JS:NL
MJE?[C4JCO(#:.E]5%:0UPV:Q>7ZM98>7LA;WJ-&A`D(P'TM#$L&#L%BNH?&)
M:;?8>;SZH=:=3A:%IS_R4G/@<_@/`>`\#B6.PXZR^XRRX\/ES([RVT*=8RZC
MXW<LN*3E;67$?TJ]N<>N/XSX'(I.%8RE6,*2K&<92K&,XSC/\9QG&?XSC/@<
M"Q!7&T,N##N,MH4TVTMEM3:&UM*'6VA"DY2E"F%Y1G&,>F49SC_3/IX'"W%Q
MC(3$:U'`M1POP?B@-B#H"&_%<0\+\`J6\,,_C/-I6W[4X]BDXSCTSC'@>:?4
MZK*R:)J4K-?DIEN,?A6Y8^&CC)-$.4Y\Q42@\@9PI,82]_6XQA?Q+5_.4YSX
M'/+UVOV!I`\]!0TVPWA26V9>,"DFFTK]GO2ALQAY",+^-/KC&/Y],?\`+P.U
M%Q47"`L1<+&Q\1&BX7@:.BPQX\$?#CBW7,,""-M#M8<=<4I7M3CU4K.<_P`Y
M\#O^`\!X#P'@/`>`\!X#P'@/`>!U31<&CY'R04+ZNCN_,$_D<C'XY#1'QX=3
MC.<-/?%['$_^]MJ4G_CX':\!X#P'@/`>`\!X'`2**8W\)8S!3/N2OXB66WV_
M>C/JE7L=2I/N3G_3/IZX\"C7"\+`DZ[W0O,`*W[>S^UF?;(`Q[Q'^QTWLQK*
MVUMQP:4A.*1E0R/9G+8^4(RMS*?D4%OS:#1)(N.D)&E5(\^(?;*B33:Y#E%Q
MA3+K;[1,<2^&X\$^T^TE:5MJ2I*TXSC/KC'@:_?L$U5KB_R>CV9"2UM0-FSM
MIL\%6=GV)-8;MH`,?K^TV-N("!L@PT;=JDJ?BPB9Z'+D@$KAF2UB.).P.I(0
M5S[`Z2HI\Y!!S<OK&[D'B_NZS2)/5;D-8/[P$-&AYB"N$%7#1+D/>(RJ2#H5
MD21$"#C-,0TQ^,>%EO(9-T9&5C6E)VE8:?LV4.CI>F1%%DGW8FJ[CA!CK99:
MW3Q:W;=)TB(K/]_24#%QP,-4#ORY8N%.*6P4W^O<5AT-O+#:FF66EO.$K::;
M;60]AK#SZD(PE3SN&&V6<..YQ[E>Q"$^N?XQC'\>!R^`\!X#P,3B1K@+8)1$
MI(1<E551X:H9[#2QK`S)Y.DEG,2++(R(]\5`3@Z6WVUH4OV^W+"5(4Z^'#?H
M:WSU7/CJ'<T4"UJ=!)B+,17(^VQXSH1PQ;P4O79!\+$G#RXS*Q2D,%!&)9>4
MH<EAY*'4A%VIYNM7JJDZZM.HXO6TU0)&-C9G4<E$1IU4C2()<-8J_8=>%XAX
MV!N%(9+?#)C98$5I(I[66'6Q)`5X=D,8WG#@Q]B@K[LW7>O]MZ:KA.)V;+MM
M;JQ\[SPJK1$E._Y6KC4S#29EI!?D@&&Y!`KPTI%80R4&V2E)"$!*TSK+6-V*
MQL$.HZWD;N?%0Y%9VB32ZM:)H-R(2;(T>;!FR!5&2`U;.E7#(]*"DH;4\M32
MD?*I60B?7>E`9]%K(W_S_P`\'7F0^>*L6PZW4J])L;E1-5-NJVNRR\%.5Q^:
MK@]BKZ4Q9,8?)S*U@X4*LAX9",N!)ETUZ"S)@['J%/JYMYJM3FZTD-NMTX6>
MO=(S$R9`&H,7B7C79"J50NV*#/PVR\V'@H5&749:4YZAX&E.=><]+NSU@TKS
M[I+2=EN/XJ]@.ZJUW0*?*2,JAILIV-LTM2X:-7-/1K[^?3Y5K1A2LK3C'O\`
M7(1=M+EO0FTN@*)?MR\?Z(W9,QH+[E.WY<-9:[MNPM83\&^J2@ZT\[/U8N?"
MKBADD$1\L/(+_%DO]A;#67VGE!-$WH[7+>J)C5=,U?IV+K+I!%@A:1-:YAS-
M7-W1-B3=0;#,4F)3#B&%)O+2)9TAI3)>9%/Y27<$8POP(,J='YCZ.U[GGO;'
M,VI!LZ0/B6YOFF^4"FV^GZWD"8>2&KM@HT?(5QJJS50G("5,1%3D6(TTZR\4
M(ZD<QHT-D)%W;4-/18M,O.S=.:]N5&U'"7$,>P3%1KD]):@K%JJ)%-NLM%#3
M0_MCZ!(:[>,C;$P!ET@F-<2UD4AC#B4A#-%^L#ZUJ@#=2*!Q-RO&1>WH#,/<
MG(;4-$?C;A39)J">S6EYQ%OB*HQR:^`]B*&]D4XME+N&<K4I2@\W3&J.2^1]
MMVW7VAN/J'JW9EAI"+.?,:+U-K77K%]H0EAD&H^-$DU3T(9./ULI8[1XZU)2
MT8\A_P")MAUE?@37LCJJHZ=C<6C:^M=VTREB`BGS%\3K8N]5FIB%+0V83;']
M7'7N5K49#85A<@>4*W'",84\X1AIM:TA96+DXV;C8^9AI`*5B)8$23BI2.)9
M-CY*./8;*"/!,&6X.6&8,ZEQIUM2D.(5A2<YQG&?`[W@/`JA:>N:,%4]M6/7
MT%/;4,TY.$5FTPT$57:\IF9`DAHF:6Z9<IF"_&@:V<X0@^1^)8R51Y3;'Y#[
M6&E!#971N^]F,7H*DBZ6Y[K^OI&P15WW+LZRO[4AJZ=5XP>RSL+#U^">U_5Y
MR6AJJ>EV8D46(F(KL@&6(]^<XTKVA0GK2J[-C+QSQ-7^XS<X;;NO=1&NHJE5
MDHJ&GR`(21J;&P9AJ&E#J_0K(N+C1@ZX"F;F$O0WODRQQG'2VV@^@GP'@/`>
M`\"O=@Y)Y9MNU1]Z6OG'1MHW2(9$R`>V;'JND3NQ@S8`)N.@B@[G*0A5A$>A
M0F4MB*;(3D;&/5OVY_GP.4;E+F0,YF3%Y]TV-(L3D79V36=<5-LINR0=WM^R
MX6?0^B*PYB9B-A;`G9L4GU^8>3F324*2Z4\I81U-_7MPI9+I7]C3_(/.4S?J
MG#U&OU>Y2.H:079:]`T"+$A*-#0LR]#*/C8JH0X#(T:.RM#0;+24-)3C'IX&
M:W/CWE/8RXI5_P"<M+71$)J_&DXL:T:XJLX")J%N6@IX76J8Z2C"`7*7&SE9
M`-#CUMJ&"+%0\PEMSU5D/.K_`!-Q]4X3^V*SS#HF!JZJ#8=6/U:*U?3PJP;K
MJV3\3:K)39*N,1*(63@)JRP8IS[!##J5E,X<_P"K*LY#]43BODK5I%,*UGSI
MJ+7CVOKR9LRH9I%)A:JW$;`.H$YJMZW_``P0P+,A/(US93H9D@I+ZQP"%-->
MS&$^@1)9/JV^O*W$T0JQ\BZ9E'-:3YUBIC3U;RT%&$'W^9VH]#%1XY+($[26
M-B6(Z7&KL@T5`!F%NJ8#;PO./`MOK356O].P$C5M:UP>JU^5N-XOQL4*9)%C
M+MNR+9+WBZRK.),TY8>)RUSI9BAV5-BLK?4EEMMO&$8"0O`>`\!X#P'@/`>`
M\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\"CF\^A^@H#H.K<\\Z:<U3LFQR&
MF9[=%HF=L[DL^J(F$AXZ\P-&BHF,36-0;4*F)"6+E"'\J6D9MAL/.%9SEQ'J
M'4`V%]D.,M9EN6^2\H003@A$3V#LMUQT3(2,A*$R?R.&C!.)+*DO)<]$8'QA
M2%*7GV8#RMC]&]I:MUY;MD3_`!70K!%TF"*LDQ":]Z=L-SMYL3%,N%S.*W6`
MN9F).Q2PX;:G!P1TJ(+RG*$8^3VI4'0L?V<<WQ>M9:[0(^V[19A*<_9(C6S&
M@>@8FQS<UB)_8`T[!$GJAH*+ES#5)$4LCVMCNYSESTPG/@9Y);M[+%,%9B^)
MJ]8H\H$0S$S&=3TX4%I9+KR%".#S>OXJ4R^.PVAU:DCJ:RAU.$K4O"TI#OC[
MEZ_4A62^+(YIQ*D92@7IBAE(6UEQIM7M<>J@2L/H2M2_;E.$90C^%^[.$^!D
MF@NA;3MF[[BUI?\`3TEIJ]Z=_P`?%2<,9>*K?!9F$V1$S,G`3`$K559'&3AR
MOEL.,/I0\E;/N]/8I"E!H<YQYX^QKH;9W>L[H3[,KGR=0-7_`&1]:42J:HQH
M74FXJZH9RSQ.Q'9<QRWQ,?.X&EIR_%/Y$S(NX6.I'M6RE24("X7*VKOL(U9]
MA<I3^COL>)WOJ0+GTW:*-/R&IM159NSR]NO=JJS+\<=!QE<M]<!UHU`!$^X;
M]J,]B2_'*4QG\=P@,_VW>M:[0^R'C2=IUKU]LRJP-5W70;"1!G52[PPLU8J_
M>$EA.SL.5+OPDI7)'73@IX#^&AGGBFDOYP0.PG`;/G=?ZBD/C^>DZX.]B<(9
M^6MU@GV)"2I&$-^\)?M2(GUQZ8_]MX]<?QX%0NN*=.T76\2]S1S)IZ_VAM4S
M%##OZZI$@/3<MUF6=KDJB+)EJ<P/!"3CC6#G62\.CBK5AEEUUU"<A;726'L:
M8U%@F.&AR,:PH.'XD++N0XM[%4B?ECA,OO$/Y&"7ZM-^]Q:_8G'JI6?YR$G^
M!'VUMD0>H=>6K8]B&D3HNK1V"U1<,V&[,S1Y1(\=#0$,W(FQL<J7GYDT<(7\
MDD8?YWT?*ZVW[EI#QX^G6*T-R$EL*:L`&3IIB4@*I5K7*UMBH186!,!Q9DW3
M7Z_(60V14$DF206^:&V0\\,.I8G]3H1CLO5&QJL##W/G2QV!=SI@20!M77C8
M]G.UALJ!2T1_\2]C>LR[@NHR#IRAW6[*`*[*AML*3E!;3C@KP2'H_>--WW3W
M;55&IJ',BYB6K-NI=LC_`-)=J-:8*0)C)2OVJ"4Z\L$I+XN71GD+<%/#<:*&
M=='=;<4$R>!'%WUK!V^4J]L^)P"\T,LH^GV0$PR++9_+:PB0K<T1&N,DS-&L
M2FF<2<4]E8Q.6&7L)22.,\T';IMS>L+LK$3<(?5;1!2)L>3$RSL4E4\%'X";
MS=:FV#*R)1U%EB#,)#*(2,3A:5-$,,O(4W@(:9JLWSW/9.U_$-R&@IPV8E+=
M1`/U@9>IK#/3\=*2E\IGYTG"QX^L5(,FY6QQ+:39%![K;T6S\:GQL!8FO6"#
MMD#"VFLRT?/5RQQ0$Y`SD44T;&2\/*BM'1LG'F,*6R4$<&^AQIQ&<I6A6,X\
M#V/`B[8\'?/U[,]J<R(%N<9(!$N0EC+D1JG;X7)PSE@@)/\`";.:AY>3!8]`
MYE`1!0;[:$9]PSC[:PR*F72+ND:Z4&EX.2C2R(JQ09K)0TC`SL>0\#)QI+1@
MPCA3#!XKJ!S6D*"/:1A\9QUA:'%!X#$E+4B7CH.607)TN0;9`@[0ZY,S<Z!.
MNO,);BK:]G]D^^+)_,^XQ*.8&$$0.E@A?R.M*6&/[AU(;?/TUNH]E50-PTAL
MM5%O"`OV(#@Q94;)25&O4.AX1^S:SMIL*&F6`:($,RAE+H90I3;;Z0]'6&TF
M[J_-U&QQR:KM:CLQF+[2ED)*0&B54<U#V>NGI_IFZ1:E11#L89Z(>]C:F2FA
MRVGQVPXJ?KL3414_FJG3KFOYF0,G,4-Q3TQ'461+P;(3#]"':#-GV8>=DUI7
MF#;<6"&\ZM838[>5,*#N[1U?5MSU46,/D#HR1B9#^Y*%?:J6*S9Z!<A@)&+C
M+I4))UDT%N7C1Y,AK+;[)(18[SHQ3+XSKK2PZNI+!LLT:<JNV*TL*VTTM@)=
MXB!!!*#LR+.<.>A[+3V$S<K+QA:(T=IN9CCFQU@2F7$#Y(#4.2Z'3J`TS5-J
M6ZF,NBKU_)5>!N-1C4-L"YJ![9#U<L-:BAF25^ZNDJ!&D64_`.@4DI]MO+J%
M80P$U^`\"N>T.3.;]SRS5DOFI:A(W6/R3B/V%#"*JNR84DH-T59$7L&J/0UQ
MC3$#%J^-;9J5(]_JGT]?Y"+9[CVP,D5A&M^A]E5&M52=KDW$Z]M8X&S**/FN
MICP&PVA9A^,LV1#(!DL9YAV5>#6^9DM3"BD8=4&K+[!JSL_9O(O6\++UCE.2
MUIH&7V;?)J^0(4E:)N5V=6*-:!E&6.G2SW[>K[1C,34?EB<0>6\U,94C+&(\
M-M\X-BD;]4_!XU>-@!=,SH<!/)DR)>!%WET&/"G+L.'')I#\4QM5$?EB0R0O
M#C6&\-92KVX3A/\`'@</UR:R@=/1G7.N*>'98VAT_L.Z5W7\38[9=K@W"5"*
MU-I=D*%KTE>IZQ2K5>`D%%8;::(^!)"GO1.%^_U#8[X#P'@/`>`\!X#P'@/`
M>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P**(0&O[-"
M'/D/;/'X3#1AK$46Y%F!F[_/4IQ<XVEL$0^->`QA(CV772&RE.,X:2R_\P7K
M\!X#P'@/`U?]%\#[XVAO>X;QT%WWMWDLG8%0HM8N=6H>M-;7F+G2M>JF&Z].
MND7UB06(6P#/F,*;8;;0XE[W.96IMG+85.J_TO[;H%BM%HH/V&;>JTQLFS77
M8&W2J_7;73,;'VKL./R/;-NR(>O]TU.+B-A'R+;!*'@1V(YA([8Z`OQ4)9P%
M3MN?4);;!VC3!+CW-M9S>6]N:>E:W.]*-UB%*M$-S56-DZM2=R[$U78DWL"L
MR$#,L;R?88GR%YL(8$1A*W2G"27O`P[FW40>LON_V%RGG9$[OK5-+K5+V')C
M[#8TTF(A+GNK1F\Y6U5L_6^MZ%KF`_+)A:=!E113`#C,.'@AK+6,2*<I#Z9F
M>:N>!WVB1]&ZE8(8RE3#[.OJLTZRI"4(3EI;<6E2,^QM./X]/7&/Y\#SO_%/
MF7\7\+_Q^TY^'^L)AOQ?\<U3\?\`4&I927&9:_5^S()21F\.->GL7AM.,XS[
M<>@3E'1X$1'@Q44$+&QD8&-'QL<"PT*$``$R@8,(,9E*&1A11VDH;;1C"4(3
MC&,8QCP.YX&#[$B96;K2(Z'"9/*<LM')?8?-"`;3%1UUK\E-DY?D(F;'6L.&
M$?=2S\'R/J1AMMUAQ:7VPUV<84+["==[6Z'N?9FWCK[JLT":D]94X23U?-PU
M:.>V;L.Q?%2$TO4>O+MFNQ>K':[&L(L9IQ^3F"?3&4Y2ZH-B=,V+4=@Z\KVT
MZC)XF:7::N%<(23'9=PLN$/CTR3#F15I20R4EA7M<86E+K;N,H5C"L9QX$#;
M&J^'ZY(=3:#I81N]7-7ERU;BI*97KF&VTQ(U=#U3K&["1P279>-K676B`'"D
M*-AWD.-BO,M$%-O!C^N=J]86;6M9MULTQ3H.PS%?AI4V+KUBC;!$-ID\+,5)
M`'R%SKY3HK<3EE:Q'6FWFGWE(0Z^EKWN!EC.Q.CWHS,LG3T%D9]T9T-I%GKG
MN3$>P!U^6,*?N0PB$$MD/J:;;4M333&%N9RMS#20A':6S^QY6EPUKT/S;0;O
M<S'0%1-LDMC4J"BQJL7!&S1ID.=(%3Q1\?,388L7A/L95D.04=A.%CX94$D1
M&Y.I9P*"E(;G:C3D--0`TLS88O>,`1#$$/Q3);>(\@2*/P=$2$D2ED<MK+F/
MPD.%Y1E>&PW0C:BRG758FY&7I?.&N(36<E6P'TZR:W'!QK(FQSIZ<L&P+-!K
MAZ'(C`9GYV?)0\TX:Z.2V$,2EL8@DMM(9A*[K[11*U!BJ<CT6WP1TSF-NU@9
MZ+@X9FLC).3&'%`@R%06;+D0!.'7"QT)SEQ`ZVV%K<4C&0R2*W9TG)MX?9Y?
MBSAWK&[#"EQ>[:\0)D2.^!B>*->>K;&0"HR1%DA<-+3EMP@-I'R8R3C+05VD
M=V;8.V=5MF`\9[DQ<(0:V5*S3&N[W79*J6>"@<3XS5(M_P"7"MM3/Z^U%8?C
ME):$,C9-E]"R61E$L%AD4CU]TT9-3T=CZ[-CV'66-7/3C=G&VGK^3DIJ^XD9
M&!G]2F4!N/()&S&%C9&)-<*<RI67,X#4.CYUAZ&.KMU4\$V*C.&>A)P:&?B,
MAMXF&)0LL&88+-F%!RDFRZ@K]!+E,"#B?+C&`TNKQEE##++P1OM7<M[V\]!R
MU:Y3Z*INU==7F:@:+M*OQ]7F7Z)*X*%BYAVPPY,@T'.TBRUTKWFQI:/:0&O_
M`&UCE?COI#/-3=W;<O;=K:NO`?4>MY2LW$FK8`4%6K0V:*Q"ES:)Q1PY\0VP
M,0*.QAMMM)&5YD1/8I7R.X9#NB=H244\0?'<I=9,0K<8G,G6UZ=EU$P4FC++
MD<+%1,0DI\%HR+?446A;.5*5G&482I"L/!X2>SJ=K>`OENK_`#!UILBV#+K@
M]Q73=#2]CV/9IY)`42'#VC]'"Q+>9*GQ,JES#3R?R!X1MM_+6$NMX<";N>=X
MPN][6Q=G=7;(T];YK5C;Q%$W)K,^C[-C*W#[,N5?CS99\R8=<%AYR1!()``>
M`'(4PK!65Y0ZE"0N+X#P-;5!)LFS.NMR-V;14WIT1B"+AZ;N"N-S\!>;@%4S
M)"L?O[G*A3;5>>@YMN2;?JXTE#EX*3'/K4XX@0?"0LS$T#?E),GRH;=C&TXL
MUA;L)6-O5:#BRX<Y##:D,LWG6T1!$.1I93:DJP5#FNCH=]R<N?'\;@:<^Y-D
MSW-G"G3-%EM4BL6OHO9VPJ98KG+;WJ<O269S8D-*3]AD9JYO4ZM3I)$128GW
M8@'(<+\M3B@V#PTXRX*'T)#IPAAA./;G"66TX]G_`$>F$)QCV?RK^G^/X_G/
M\>!1;B#(7]P=RX&EPY=]7=FU7#UC2<8>X$1_CG3S#<88)&,LXA2(T5AMC\=_
MWDK2WA]Q65/>F`O?X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!
MX#P'@/`>`\!X#P'@/`>`\!X#P*-MQC"/LJ+F,@%H)*X;CXQ,HVRVL`A@#?DF
M4L`I_#:W6"Q')%+@Z,J:2ZA][.,.Y;SEH+R>`\!X#P'@/`>!H2^WKGO9W2V_
M.4J%J>I5V_62,TOU382J=8;P%1$R$+BX\NQQ,B!*RT!.QN7XN1*$PY\:@C4M
MD9RVX\Q^2,\&H#ZQ^8]A:A^X7HW3&Z=9.ZI(F!^?ILB"`V&1/9M%7<Y:Z`0F
MPQ-UJ**07*&E6"-R.LX'&&0,`N1[B%9QGV!]<#'*FG!61AQ6MH#,B`$QK2!^
M@=_L>X8L/`+RR%-;.0HLW\9.,()=RLEM>,+0XE>/=X'7?Y4UJXP^,-9=[QK#
MP:`D(C^D]^M+$0TQD=M\-]W8SQ#!:$JRKY??E:EY]RLYSC&<!82)C6(:*C(@
M5TU\:*CPXT=Z2D#9:1>8!&;%9=D)22?*D9(UQMK&72'W''GG,Y6M2E9SG(>A
MX$:;B@Y*QZSMT3"3X]6GW8YLNM3YKX@P,;:(LT65K+TBZ<(>)F-7/!#H(0MA
MW#C"E(]BLJQCP,3B]FP.S-&6NX-/@"?A5W8%>NP.52AH55NE)3-UG8E9((_!
MBY"49JEJAS@E$CLH0:@?YA\J;<;5D(^T1#_'POJB"3@16?\`Q=J49E#4G^&)
M[UZP"&4W^XK.910;:5JRE1`.25M?RMK+BL8RH)%U?^E1S3KS%2?CVZ\C1M2Q
M6280F6-BD0R:#'XAGX@R6CA)PN/2#AM0[I(C93C7M4XRES.48#U-/+))T'JY
MQ*ABC']14I2%@2:IL,DARFQN4+#F98*,5*COKSC+9)(X^7DYPMQM'KE.`]NM
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MVA<)(G\`N3)*-;!9)*6VV.K*$BX1\+:&VT(1@/SH)(B-?EX!*;,"5LG<[HY"
M)HB?4M+^WKP0YAZ0*&%>0ZA]U:?QLIS@-.,,84O#>%J#CT&K']G6)IO\]8@^
MV=SLA/R5N#NI9#/^4K8X^K,J)CU!&8D''F!XU[U(BQFFQ7,Y4UZ^!^]$OH(K
M%N4@IXKV;EW>RI3TI&2V&5L[6MK:A6"(L81D<8?V^U`SJ/R1<8^)Y3CB%.*#
M,-?BMC1LZML*2!P9>;T9EN3,C3G'U.VF43D\1Z,4MIN,D/C^89IW.2&&5I;=
MPEQ*DX#$=1-M,R^[64HBF7\;FEGRF(V7S)OH672Z*0P[+C_AA8A),T-QM_(F
M$KQ\+C;WR.9>RM0=+390)-JZ+;"<?=4'O/(ISCTO)RB?S_\`#^HB'&AV)$A]
MN&889(;1@05+0V%)4[A/R.N*4'L:[Q&9O&\E@GDE&9V!`IFA29PB51&2*-74
M'#`P0#B<"UT-Z(R*_P#BM>N5O.N$+_J>],!$W,>$JO/8K^4E,O+ZDD&7AGEG
M8';_`!]+Z82.\$*1ZB#MG"*;?6H;.4/.K4XOT<4O&`E^OC%$[)GSU60FP,0L
M&]`E8%+K347%2<G8"+&Q`2D3&+S-HGH6ND@):>+2EM0;_O3ZNOO9R$K^`\#6
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ML-9/L8MQ5&B?I'13"FF5/M&E@I9&)9(=?&#P.+&9`:4[.%DA?PWV>WMNNLL)
M8$;:S'25/UA,Q9++XWQNFXD(^2;)<6^TTZV^\XS_`+K;2"'@N_X#P'@/`>`\
M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P-
M;?!>C:%`V?IC?SU!(AMT7KI;IVB3]VE[+.6"=L&NJST'>3*7&JQ(%8"CH(-M
MWY0!&QT9#87AI"U-X3ZA>>\4%B\DT8IZUWVK*HMYBKTPU1[9(5<:TNQ8,J!_
M:EY'"]6K31I%,KETJ+(Q\+SX[#F<XRUCP,]\!X&*7RKO7>D7"F#6FU48BVU>
M>K3%THQX<7=:B].1948W9JC)R$?+`1UF@EDX*`?>%)::*:0I33B<93D/5@(I
M4%!0L&N4EIQ4-$QL4J:GBD&SDNJ.#9$S*3)K;(S9<M(99^4AU+;:7'EJ5A*<
M9],!ZW@/`I->T"Y^PSFA;C[2#$<F]@)%'5^5\S[*]I<=9+<:^,=P3V#Y0UA?
MRNMK_P!Q/QX7_7[`T!4+GC987_J&NM&CMUWTH:^UW5L[$['$66UL74T-?-4=
M,6>N:VUE)6;%QHS='JX%76*H.3BS?5TIUT%(*4Y:\#Z,0>>=BQ<<S'!]@](/
M999::_8S`G/\U)O+9BB(]LA\@S1?Q+=44^DUST;2APEI.,I^'W-*#O/:'V-F
M7>D`^M=_A`+6`XQ`_JM`FQPN1"HH@I"29#2)4P^U*-QBV7DNDK]C1;_P_&K+
M:FPL-#@O1<3%QA$G(39$='!`OS,M^'F4EWA!FAW9.2S'B1X'[`];>77O@889
M^1>?8VA/HG`>CX'E3<%"66,)A+'#14_#&_!DR(FX\25C"_QB&3!OR0#F7Q7_
M`,<L=MU'N1GV.(2K'HK&,X")+WI"'L;MCG:E+S.N;E:77#+3/U!T$%R^O#Z_
MG=?0D;?4%`'9F8B%CIAI\7XLC%BE@#.-/HPA:'`@2+XVGJM7:Q&4/HG>%*"H
M],JM:J.OH2UQS&N(_%8I\57<BF!%0$E+'"RDA&9,6MPAS#+Q+OM;6U\;*`_&
M.5-O'"0,])=6;G&GD0@A-JUHB3JM@TU-6,BE0D+.P'XT_3'+@]1'K'#K-'8=
M/^7"32T/?*T\AE@/Q#<D;0B@80ICJK<@Q$7&U%I="0[4B=:J8@(2&%FJ8B&*
MK2TXJ=ID8?"'U^W!@@3SS(;@WRKSD.L#R/MQ<3"%_P#E1MBC2[`U*))HE&D`
M'-65M5>K(,;*T2G@S$4N1Q1"Y1M[XEF)=-P)EO&<_(C"O`\R(XZW@%_:TR'V
MENBD$Q\?K3,KJRG16N#=*0SE4C*^%;Z?0X:;I:+5'4.S8BB&QD&RA,@"DO*F
MR,82VVV';JW+W0T8%K@JM]5773,)!5_4P<GHB!INJKWKJLB42*A`YRC5FQ3-
M,C;:]!6O`QK<@8^2Z?A;[:@GQ&AVV5!^BN7^GH\FMO:Q[)F-7PHK3[ECI[^G
MM<7J+/EI*R6.<L$_'D&#0;8DK/-V'_>3D=0:#!VR$,I]SS;H>V[S_P!5,28!
MM1ZV8H<.!5KA$?V:C357N$*;;[/M@R\KV)(R$U*C31<BBJI9AF`$O-!"(),>
M3A;RVE,AUC>>^L6")O\`Q_UQ#ZM@R0K:_#52*Y]H%DBPK?)[!M]JBK$81+F,
MO/1$G$SPP\Q'#I&((6PIQ@T=U>7?`Z</SWU=`0L'%TGI2J:Z3&2.U[3.L-Z:
MK5M!O=ZN]]OMAAYFQ"9+K3H,*N/MS)4N)'DC/F2P;*QWPV4D-%AV6=/]=0]8
M4)K/;.E]:$?)<#2*O&:F((K<A;9:_P!QFEVIR3DWG),15GCY,$N590&ZA1V"
MDC.80^T2V'.G7_?S,8(J&WCSU"S`]3FPS!)_5EQOM>F+\99I:2%N#F0[?KF<
MB(1Z&=%93"CDJ;CUY=3@@O"6U^!XXNL^YG)&%(J^]]74YC.T#[#MW%ATJ5/M
MW&.74JU$YCM;,(O+!-?J6)<0E]C\XEZ3<]K2,E-MMN((#W(FH=FB/33]8V-J
MMJ3?V0<3=/\`(6M9_P#4V"+1J6@QD8?K8BO6H<N+B4W6*(6ZT>DYQ0[S[*'F
MUL-J4'I5[7'7L"WB8QL;2+MJLU@`EME-#:]DP8>6P'0J96UF5Z08D$R;!^9:
MOE*:_8,F*0$^RTIQ>!DX6&+:%U9TY3[5MT>S':;@@MB[*G[W=KK4(2WJM)LU
M)T?5\?6\51JQA)@9V/$:B)`0PPU>5B_&R..QA#./:%ZHF(!A1E"`8*^)PA\I
MQ9LC(2I3KY+F7'5NG2A1AKN/7/HG"G,I;1C"4XPG&,8#T_`>!J%?Y>KNX^CM
MDQ$GR53-,UJ03;'YCH;7Y]EUWMBV5JQ8D,MH:EH&-CHJ2DKE:Y23S,19R3P3
MH];SQ.4NLAX-"?I#EG>=5BZFY2NB#=V2]&E19>N1_6D#&6@(:95*2&#+:Q/:
MFC=;'AVL&NS#XH*_PWAADMH;&0&ETA:PJXX+O306R_\`.G3=&GC*MK@>Y;@V
MUN_4<N#L<&\@Q=3V(Q`T(NIYKL-M82IZK:V*P!4*M!0BD''8+DCS2'V%+-#V
M*5]]7U97>H;DN(_2XM78T2S,E7JN;#HNP->WIT."@&[&<54Z1;JU$V:Z>X%:
MDLLQ@Q)+SR/8EK.5M9<"4_K`Z,UIUI1.G>@M,63%QU+L/KZ_EZ]M7ZNT02IZ
MOPVL=.5S)ZH*YQ\38XC"I.()0AI\0;"FT)<;1\3B%*#9IX#P'@/`>`\!X#P'
M@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P*/<`"@
MC:<V8X`0\4V=V)W(:^Z[^<A.#%]<;C9*98'/,.<%8'>8RWA+:TLK4G+C:$)7
MA.`O#X#P'@/`>`\!X%*;F:G'V%\]1RV5*RODGJLP=]EYK.&LM[7Y-9*0<.Z'
MEU*'<+:_'6R1CW*2[AUOTPVKP-1.6)B5_P#4&;TBZO9XFM6=C4_+LA%&6*+1
M9&&OCT#UJ+(JB:\Y*P&31<CG,I-P,8V8VMQI>?1C*O<&\V$KG34>I[,WM?3]
ME3AAML5#.F+16E*?0T[AP@MQK<4YC*7GO8KXVTIPA.%8]V?7&<!FC(NX$.*R
M_-:X(:_'C6DH17+**YDEIQS,N8IS^YB4X;-;6G##&$_]NI'JIUW"O1(2,/\`
M/AAG!665$_"W^0H=*TL9?]B?FRREQ2W$LY<]?;A6<YQCT]<YSX'+X#P'@/`>
M`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`T[VK2UCH/14_2H[>NP=/(VI>+-N&
M@[/E)F:)CG6WHFJF6?4M:5+34^'L>U&2U0$>,AIPJ,;"JD0RF%!(:<F%("T,
MA=>F:#906(V9UAN&$L$S.UT>GV,U-#V-&R,7'[,EHXVHR$,%(05X&D!J_&I?
MC#6X\P5EHTE1F$H2U@*'?9)9K#MSF$IS<^K;;JZT:*P9M^U4ZNN.[FUY9;&7
M$S5%UWK*NWBJNP*YC:<[+7R+<C@RZT1AL]QU([3F&6I-(5OX>^P:FZ$YC%UG
MM[A?[.+K,TFQWK^ZK](\$[6L(T\W(V^0.@1W_P!PTU-'&UNK2,5%NM#QS`8R
M!VT,(2RG&<!?SZ8R9F3Y0ML[/T+9U`D[!T'M"4<"W!1)W65]E1L#5>/CCI*A
MST/7WZW'0\<`U"1S30;2'8Z)8><<+(<?-)#;9X#P'@/`>`\"EHO8LK.V78T#
M1N2^H]A1>M=@VC6LC=JV+SZ#4+!8:<T-F==JCUQZ"JT])18QQ"@L//1XV<G,
M/,Y3A3:O0(JW3]FVO.;['KVO[ZYQ[`U\ULB1F`8B?BM.Q&YHB,'KWX29R>L(
MG/-YV[9XRMQ;TH&V\=B.<92LT?&<_P"ZGP.A"_</]>LE*5*'G-V6#6)EXL0-
M3K9&[M%]`Z/KY5CD@3Y$"(+N.V-6U"F1!98D44IO\N082K\=S&,Y]N?`F:[?
M8OP?K^M2%KGNN=`G1T<Y'L9CZ7LNM;)MLD9+20D1&1M<H>NCK5>+5+R$D<TR
MR'&1Q93BE_TMYQC.<!#.?N%^O_#*2,[1VA\*W5L)<_\`$KL'T4ZTAMQQO'_Q
MA?7W)0ZG/_M,^!ED7]J/"\Q^3^'MZQM_B-@NN_LM$]#0WN3(`M2`^!_W&J0?
MS'$#O8P\AGWJ'>]67<(>2I&`M5I3?VG.C:K*W;2%_A-C56$M]DH,O-0.3/QH
M^XU`M`-EKY*3A0WVSX@IQ*'<>SV_U8RG.<9QGP)@\!X#P'@/`>`\!X#P'@/`
M>`\!X#P'@/`>`\!X#P'@/`>`\#77]=&Q]<SE'W7K>OWBKRM_HG6W:I=WH@M@
MB"[I3V)WL#>!,039JT*4N6@PYA"5.!.$LMI(:QA2,J_GP-BG@/`>`\!X#P'@
M49N/NS]D//\`\GIE">-^I,B>S_J0ZK</*>#<O^W#6<H6WACX_=E['KA?M2UG
MU4X&H36NP8[8WWP]%3>LYR.DTP)6D]9GA3^'HN/'O5"YTZZAK4VV$[&-SYYU
M?,`*"6Z,\D3"'E*RA["FG4!]";"MS8%=R2UK%9N&4Y90P1:FQ5D8!<RM#KK@
MSKS;*I/V8PK"%*PQZY]N5^F/`AJZ;KVM4-DT#4N:93)"W[5#LIM&-:D[E_9C
M6*17TSMI$N=E8J93]9(>]^&HQ381K9?]67<L.?&R\%I8M<DY&1RYE@$686"(
MN6%C"GSHT:24.WDYB/-*#CR3`62LK2TZX.PXXWC"E-HSG*<!WO`>`\!X#P'@
M/`>`\!X#P'@/`>`\!X#P'@5(ZCZH7S8)'9:UE);"D9VO6F<@V1;YKJE1N%4T
M1$G8$SA=SL,=+!QH$2ZAY14?'RRL*4E&6<95C.0L=1K)FY4FGV_(XPF;55J_
M9,BA&N208V9R)$D\CB2+P4:Z>,S^5[6WE##J=3C"LMHSGVX#*?`>!@^Q==57
M:=3DJ9<`R28J02EQDN,D3H.P0<FQZJC[#5K)$$!S=7L\,_G#P,D`^P8&^G#C
M3B%8]?`B"S:KWP@J>>UIT%$U@68#RT.-<-01%S.A2W+#(S!!<+(Q=IID8R\N
M/E'!&EG1DEE+B&B",%^S+*PU*[L!HW^,=U4D::7-/T_:7/2C@9)%B)-AF;+T
MII80[8)04GLB>GK1?[07(%,-7.5E(^28BPL`ML,"!H44'T`^`\!X#P'@/`J'
MUG=;K7">:*A2+G8**3N/I2!UE8)NJ8H2K&BJOZMVU<I%,9C8M5N4)ZM'TT1Y
M[#0*C%L-+0TM'N5GP,J"T5L4>*="*ZWZ%D)%P=YI,T[$<XCD,NK>4ZR4T$)S
M^S&_(.WZ-X2MI;:TX]5)RK/KX'R%[_\`L6Z;X7F?LPKNFNC#6R:ET)T_:*DS
MLZ!U=(O-WY%-H9KI1$9-T'`[(#=C;6>.-%DM14FF26I`[!JW!,!?7ZX^Y]B]
M&=\Z>8WGLN6OCD?SYOZJ4>P8K&L8N`?LERLVA+&$V^_K4>JV&%Q:JW0#7A1[
M37Q$Y(%^)K\4Q>!70VM]$V[:VX.V-4<9P5/T:O2T'J,?JS==AV_5H_:\GL*!
M!O<OJ\/3-&US*,"QU/E7#BVI=VY/OR/X:6DAMQR\D+=P&MKZW8G<])Z8YKK'
M6E6YQM<QU!RKL;H2C5NN<+T+GC<7+&U=(;"UW$6*L64NNQ*9Q^#DXC:*1QYZ
M5!@4.2<.TT(G+I64J#Z6_`ZHQP1N24AF"EJ"*<!,2,0T_D0UI#;CHA.&EKRP
M4VVZA2FU^B\85C.<?SCP-8G%G1.HB^J^^^4E;*'*W[6.D+3N![4YV#T2L3J2
M<UAS^$);8/#D>S&N58JS3>6W<M/K5B3?>RI/N5E2@VB^`\!X#P'@/`>`\!X#
MP'@/`>`\!X#P'@/`>`\!X#P'@/`>!0"KB1XWVB[D<%;99**X.YV?-:9$:8^3
M*NA.HOC,>(;5A1+[Z_>E7N1C*<(QGW*]WHD+_P#@/`>`\!X#P'@49N*OD^R+
M0",X^+\;C;J-U"WO3"#,E[BY4;<:!_E>5.@X%2HC^$>B7VOY7Z^B0T_Q=857
M/OHZ2C-3UN"K=JFJMH.TQ<J9%F!41BYVOF_K4NTS,SB(<^(RS6(M69`EE(V7
MCG65D.N>Y3J\AN]8C>PFAVW2[!IXHUYL`AP8)B9;`CRU?F,S,<APJ%:+DXQE
MM+#X+^<C$.NJ6T^EM"<.+".9+270%@W5K?<UDL%:)EM9UW8%?@0X*;/AHE8]
MVB:^R0N5KY,%)A23Y$B"1[U_D(^!H<!6,.N(=SD)U=K_`$NU&2*`MIZ=)EU!
MEMP[\MIBV?A#F+4\L(B58C=T!NG('3EM#B65#8<]JE8PC*L)2'JZ.VC);5JD
MO(3U6)J%GJ5SM&OK1%K(8-BRIRHG_@%3E8.:=4^95IUI2"@LE-C&-MN?$^RA
MUM6,AF=<N*;'8;_`(@IF,Q0;#%UY<M(*B%1EE=DZA7+<HZ`_7RIQZ`X]%C2$
M^DY@)_\`+'=RAM;&6GG0[.+8$J[.47`<EF1:JS-L<D/QL8ATA$2S\.R'@S+F
M,KDEOC.+RTE&<(:3A2LX]R<*#`MF[;?H-FH5-BZF7:['L5-A3!#M2@T4$,[7
M'JX@I<L2X,<4,`MFP8SDAH=]+2VTX<PE#GR("(KKUBC7E7L]JLU,"<&JD34[
M)(Q<!9Y:6G'*M?K"U5*5/L@%46*2,Q.3S$@UE@QP4D9N-==<;]F4YR%M90M\
M",D3A@7Y0D(`LL>,&=%8(D7QAW'F@1WSGA@F7RW$8;0MYQMI*E8RM24^N<!P
MP<DN9A(>8<!)BW)6*CY)R,,6,X7'+.$9*6"4X&\0(X2(IWXUJ:<<;RI.<I4I
M/IG(=6MV$*T16)<!B0%8_8S<6X/*!.QYS)M?FI"`D6W17OZDH3(1COQKQG*'
M6_:M.<I5C.0],0U@W\GX</8_$+?">P^.\/GYQ\IPO+>'T(RZRK"L90XGU0M.
M?5.<X\#&(V\0LK>;70!'F')JGPE4G)AM!\<X\PQ;WK"W%MO1K12Y03"T5UU:
M77F4,O85Z-K6I#F$!V3+8`%<H"E.IQ^RL-?LUB#7DL!O.!*L=603D8"<)1)$
M^YRT,9^1EE;37IZ.*0I;>%AE/@8Y6K1&VL:4*BT'(:B+'8:N5^>$^$I<E694
MF&DEC)>3C\D%1@B_A?1ZH=1_.,^!D?@>"FS0JK0[34DNYL3,`Q9G`_P9#X$P
MI,B3%,$_L_Q?U>75G".(^#YOR/1/O]GL_J\#AE+;!0U@J]8D"26IFY.3#5>8
M;C),H8IV!CLRTFV3)"AO1L6IH!.5M_ENL?/E.4M>]6,I\#T)6:C(1H1Z4)_%
M:.E(V&%7EE]W#DE+EM`1PV?@:=RU^48\AO"U^UM.58]RL8\!-3,?7HH^;EGE
MC1D6(0?(%(')*P*$(RL@HIQH1I]_+([#:EJRE.?3&/`@?>_-VM^DH>%_NAZ:
MCC8X0QB+L5</<CSB*]/MC.2]=E17D.Q\W7)A0@S[@9C#K:2A6'DX2XTG/@2W
MKV5K\U1ZI(U6P+M===@HYF)LCSB77YL0,=`29(IQ`P:%EDJ'RIW.&6L?)E7H
MA./XP$0TO?4ELV)L-AUG0VKO`0-BL%2Q*1URBXYN2L58M']MSD:(U.Q\6M/Z
MO#;K[SR_:SG#*FV5/KRGU#VC=D;>&]/QN=+-(_\`N,;-5^-L35[./SG6G%?I
MT?FV07*BF'D80Z[G"1\85A3;CG]6,!_9+9.V@?VN!.=+;,*"?98CL@;`U2RW
M,H<1A3I;"I6VQK@8K&5X3GYT-O*RE7HWZ83E8<1.R]KI?2-GFRZEB.N#,.DC
MW[3_`+$MOL968^I@N\B.K%%7G#>/3_==5ZYPC"<84H-;&X-;JHM#GC3M9W>F
M1E\W'RQKZK0ELEM!0+%;I[/0NFY)%+@Y_6\^9LRT`ECA+96T6<:ZT,+\61U,
MCJ?=#=!X#P'@<;3J74Y4E+B<8<=;]'6G&E9RRZMI2L)<2E66U*1ZH5C^E:<X
M5C.<9QGP.3P'@:/>R?L'T,[=.;DQ59WG;<:>[*L,E/$5K0FUK(!*(T]![PTA
M>E5`B&BV@[$1';1DFX8-S*EBE'>[+/R_$M2`NQ1?L1Y\V6+8SJ-"]"V8.J.J
M9FWHCEWH(]T-;2Y`<CY8\37;\JU\$C#G">BV$9=)"?2SAS"/=D/E&[RYXZ3V
M#5/M'N-)Y4Z\=;VQLG?-]H1<EH/4:1+?23->ZU@X^T#V:\:G_P`V4@:.D(HS
M(T3@QHUX)AUQO+:&U8<"6N4]E4C07:^AMB;IM\9J'41Y"8JM7W=]<U%SM&3K
M>*U?&HM(\]_C73@-_7@.T`%.FNN_,G+2UK8;=6,RX&X/[1:63;=I:SNNI]4?
M9!7.AZ#K.43K[L?@2O:=M`<'3KM,EEV'3>QJKMO8D#6MJUJ0E*7'2C\&9$%(
M9>?"*$*9>^7VA6'ZMNB-#;3^QW>M0GKSWEU%V[3--R%-N^YND=8:5I&I>>-7
M5J>HTA)Z>I,3HR932*18=B7><&(F&/Q7Y:5D*YZDK;9#9RX'TR>!CT%4JM5R
M+$76ZY!P!5OGWK5:R8:*!C'[+9R(Z-B'[#.NAL,KEIM^*AA!EE/Y6\I@9I&5
M92A.,!2%NBP4G]I#^QE1\NU8:+P6-4!))I]IJO$QFU^@C)F4%+$P'EXJ;')T
MZ&MEW\A.&F''$Y;7ES"D!?\`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X
M#P'@/`>`\"C<`XO/V5;6:<>*]C?#N@'!!_Q`<`XR[OGI1)SV#TNXDEEJRRPG
M+*V\L)1C"D*PM3F/`O)X#P'@/`>`\!X%'+'^:K[(M0^B_='-<6;^RII:BL8;
M-?W9SOA+HZ,G("RMQ@?*7<X'<=QA*/5Q"<X2L-'-I@=TVC_U&>^?\)7>@Z^M
MD#HGG45J<OU`LVSHA47.:5W<3*K*J$'M/70N/Q78L9ID]Q>"&G"LL-N(;>>0
M^&VSH>W=Z\V\][BWK,[TY@N;&H]76F]&Q;?,-^KC1BZU&2\J4:\4_P!5$,B1
MPPWPK>;4XG_:#<S\J<O8RT&Q*ASY=KH],M)X>(XZRU2NSYL>E+J$@ES$0'(D
MAI0_G+Z,#/$J1C"_Z\>W^?Y\#*_`J'R$,<+&[Y1(LE-&+Z0V0X[DFJ1M4;=Q
MD:O80\&T#,S1,PP1A/RJ-+4R\\^XY\;6!L,*4$CZFC#1+]T=(%KAW&I?;4(Z
M(J-!>!.0R'IK5@.&)[*S"V#Y)I#*<MD-?$E8BF4J;2XA7@?H4QQ72TW'Y<C?
MB9T95C$M)0=^WPX1?K@PMQYQ3^8S];E(N,-80UA_Y<.96K*/CPD(CZ%:B2MY
M:-`#E).H;2E=<]#0NH]CB5-BY15%N$^!KJOBR=C@%OCN30C:9;)+`3KC(#RP
MUJ*=;0A*L!63M+7<;S_QC<JV!9)I\>^V>4:V-8BXHZQVG;%\V))*;AC[S<G9
MT&4J4<]-NLXR0"M/X*!PHZ/;8#0@;(;/K\[ABBW1[(2I+#-3L;N8Y(;D@J0P
MW#F+R$F/96T\<HKT^/#*%)4[[O;C.,Y]?`_.OQWQ*'212F6!R1JC6QR&!HAV
M`&8?9A@FW61X)]\E^%8;<3E*!%N.+&3C#>5*RGUR'%0'2'JWA9;JGR,3UP;6
MZITQ_*L-6^=:;]'CJ[57W4I;1C&,X#^/.,?[;Y;?M+>#'=6(*2K9*WXQR+9=
MVK;%@(76XVMX,%0U%L.2;>(]:W)QN0D&7W/V1.?R2\YSG.,(PC'@8Q46<N]&
M;J/6[,YRSKW2L*R.5!Y$A$-#&[2EED14_P"]S$N60[-^PIG^C\7X6_1.?DRK
M(=FRX<ST3J/*?W'QIU=NSY/QX.,)@O54_IGX_P!I8G/_`',Q,EC.,_AB,_\`
M;&H^=;W]8S/@3GX$?Z[P.H.TOC627LK9&P+OE;DM)?LOTI`L\5'%5N-7^('D
M2(A"0EM,#>B_@_E'R.>GNR&6`Q^1#9DM2D9S*&#D)PA9.<I;'C@@4X<0\^ZR
MASW#9S_LI;1E.<9RG*_<K(1N`3%JWO:A&%#?N6]34,B31A!F#/USUOV(W#*<
M<6O\!0OY#)WL2VGY<+]^5YRG+>,!Q75MU6V-)NX:DG!VWMB(<6&++.A,/.U1
M.6')8H3.(H453;;B&\&>OR$+1AK'OQG.`\[?3P;,#K_\XL0-MW>.DV65EV`B
MO*>,7L>`_"$$='2K,J864E#:8]>/C-2I3:O3&?7P);GXM<Y!34*U(F0[LO%2
M$8W+1WX^9"+<.$>%1(`X+9)$R6$IW#C>'6W&\K3CW)4GUQD/2';4RPRRMU3Z
MVF6VUO*0TVIY2$)2IU3;*&V4*<SCUSA"4IQZ^F,8Q_'@0IS<X0YH[7CIDI)S
M1"X9]QZ6FK:/>9(]2Y205DHFTB-LAR6',9]48:3AH=OVLH_I;QGP(%Y!KDA8
M]3R$FNT;.K6,[3VBAH`BR0<JM\478$JZ*4T>[$R+ST6<*A*!4*<][,?EMG^,
MHPKP+:XIY6&W6_[VNN<NF9+PYDZ(RXTG*14_AM9_1X3@/'XV<^W.,K]75_U?
MRGVA_&Z><R\`\W>KHK\(D=YUI\F"(8D66BF'WA#FW(#.<LEM-*96IK+3J4.*
MRA:5>U6`S;P-!W0%8WWN';%GV_;^@D26D>?/L+T+J*J\V,:#@7<MQUAM_.E>
MDYAK:8$['6^4D'U[**)<>?8*`%84ZWEG*F<.-AOQ\!X#P'@/`>!\BW._;_&^
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M>S8Y>`N6I:BBP1,A+652IJ=.DR)%1Q#2GE/.D95@-GV].M+IJ';N^*8%5:G-
MUG4'!-LZTC,OR,H-8YRY5BSW.*7597+;;@$55BX^L,?"2VV\2M]Y_.<)2PG#
M@>%K'M2X[`WQQIJLJB56*@NH.%+?UK.R@=B/F)"I6BM27/XC5,@2F`6X>Q5U
M]G<[^5'KR.ZK\%I2$*2\K"`DV.F@1_L$M]>=L@C<E*\=ZZF0*@4^,V>4%!;I
MV@%*V*#&<S@PP*/>L(8TFMK"FAG"0<.YPI]KU"Y'@/`>`\!X#P'@/`>`\!X#
MP'@/`>`\!X#P'@/`>`\!X#P*,_9O9;)3?KQ[3ME.LEAJ%IK?->W)J`L]3F3*
MY98.4CJ=*%"R$)/QY`DA"R+#C>,ME#O,OL*_K;<;7A*TAZ7*G%VDN<I*<VG0
M2MQV&^[1HE%KEGM.Y^@MT;]F\5FL/3EA@J[#26WKY>'(*("FKA(DY9`6TVZ\
M2I:O=_3Z!:2SUN9G9*F'15ZLE0&K-F_>3D3!"5<H"_1/Z:6C<U&S+L->FCPH
M7\^08/\`FBGHZ0P0"TC\CX%O-.!F'@/`Q:\0]BL-/LT%4;@5KZT2T+(`5^\!
M0L-8RZG+$C+:!GAH&Q#EP4N]&/JPZD<MIP=W*?:M.4YSX'MQ8Q8<;'"2$@Y+
MGB@B#&RKPXPCLF6P.VT3(.B!MM!BN&O)4XIMI*6T95Z)QA.,8\#O>`\"E1X#
M:OL6JTGG,KAUKBN^!)QA]*81:']Y:Y?7[QDE^]V3;4PGT6ICT;:5G"7,Y4I.
M`T2V'=6CM,_?ST;T-L[;U*K&IJUKK0.OINQIGL2R8C8[//N^"28:;C:X.>0"
M`%7TJR\07[L,GY;8SC"U)P@+E][_`&<?7KO#B/J_4M"ZKH]EN>PM";'J-:JU
M8:E3+79)NPQ!%=C*[`PDK`8:FI69ECVQ$A*3GYTN+POVMX<<0&VC2VQZ(]I[
M5JWKG01R$:\I#!@L9:8!R/`.Q6HM+\>*MF4):PT,]ZMHQAQ?].,>F<_Z^!7^
MT?9IR%4]HV[4QU\F#IS6T18;%MB;AJ=8Y*H:HK-8EZW`2]KOD^T"EJ/J0<W:
M11GY49!<>%G#CI;P[#>7?`KGH?<73KC&U(_26I-:2`8>_2V)D?=%[V)K>TX3
M<!JM>4&`5:TUC$DR-G5%Q@BPDMMI;-D7B4.?$MM65A/=<D>X*LY8):#T%I4Z
M5OFQIJQW0>2Z#L)+<:P-6]8U6$(JC#E),:;C#&(:4?)%60-D1YEOXV5Y)7E(
M8+J/H'=.^YVR[\TAK6EW>&:K$#JEV(.VD=7:V-8(&SW&V3Q<4=-:TCY^9(Q6
MK17\,E8%:BI%+[CK#R4LIP^$IQ\;O39O0VL+CL74MAT[":]!V%"#S%6O=2M;
M5N"L95'MH(M@,CW&)&`JC+U+'!-'0A;\O(+RG+3836'EAX_VBG1T1QSL.>G"
MXF.KU=.K,W+2)U:LECE15ASH28-BIJK#B#(*R3-E>#CFSG4NCH',>;<0K#O\
M!ZU4Z8O6_=81]CJ?.MTF]7[7JTVJ`V;0]H:OE8D^HS=/+.@;K7/RI8"S/@SK
MCJ1AD+B42@A*T9?!Q[5I2$BU[9F^H<2KU]_E^S/`M!IB_P!S_EFA2CP042?"
MQ0,C85F.1)KALQ!ENGY2PR^XAT5UEW"%Y;4L)BTXNV.Z^BG[O$J@[&3*6TLJ
M*6@1MT0$JXSY,&DA`(H8J2G8)T9;OM;Q_N*5ZY4KU5D.;7$"[!*OZG\$_+-[
M)LL][B&99I*VCF8QH7(JY<DMP@9(8S:<+84D3"TJ2RA"$X1@//K-6+CMO[6M
M;P3K0EFKVL@`CU2,J0V9FNMW%)0[<<1E,1'?A+E$YSD;&77LO>YY6?\`;2D.
MK.5R2+WSK>U,PL<_$PFL-M0IU@>#/7*1IUAL>I"XZ*!D&Y!J-'#EV:^0Z0RZ
M,\\ZH-I3;C26W$NA,?@1MJ_`Z8>QH'8+8PG8NQE._F5Z5KCKQ#]RF"'2$BRR
M4N2##RGO5L]G&!3D>CS/HA>,>!#MSW'>M?6NP@UWG?>FT1Y*P/NKE(23JKE>
M'&BHG6X"\5QJQ6.-7&-2:9\MX<5261'R8>0=6^TMUO#@1R+NS9[-\DK^YRCT
M.I,Q5:M3!*\QC5><-N1CFSK4;+2#SU@"+&R&0D&,SER2>%45*-Y&:RU@@M0>
MK*="WA,E$7.3Y-Z:`"J]=MY),,'%T2=L,H0>33Q8^/AH&L7N8#E)-YMY][/Y
M9H+8[`[GLR\ZK+;889/]2)VLBI1-=T-O(D`;:NKB7K*%5]97NO-&5^[1LK8`
MR/[=V!9).O?HQH[WJD"A`LI4M*AEK6E?M"2:)U\J['KC3N;NG]=.9KA4^U*;
M#U8Z#`M/!1)QQD)($5B4MDT++#'@*#^)N/?60ZZTH?#R5_P';9[!KW]W2U1E
MM)],5_$5=1Z,NW2VF)U%%+)?)!8=M(MC&((2/K\$<MPLF;-:#!'$%><=4C.$
M)6$(Z$[$H,#J?6%:1K'>DS$1U,$$_OND:`DLZU/:B7(J(69#-TV3M`@R94^3
M0D2,&62>XO#B,-*6A6/`G;C`&N1^G26:K!,UN%(O]WEF(D>)L4*..[.RV9PK
M+4?:FV)QA2R)%67$O-L^Q[WI2TRE.&D!:PDH8-E9!9#`H[?IEQ\EUMAE'KG"
M<>]UU24)]59QC'KG_7P.9*L*QA2<X4E6,*2I.<9PK&<>N,XSC^,XSCP/[X&F
M2[%@!T78E>/L49'2>Q_M^T[&Q*3)9\LR6(A-VZ'LF8F.:'E#)`0P>#I:O5CV
M)0R.RI2F6QU>_`;F_`>`\!X#P'@:Z.(Z)H^S<HZ%L5LI.EIRR&4(19DR34J&
M^:1ZR,FZVITG$8A"W\X?4IU32&65OK<6VTVE>$8#/M@C</4V_P"N=?WO5N@A
MI79T=>3Z[,2]$U.BOCHUN#!2<P)*R<JT.\*6X#,H=$2VT\E21GLK4W[$^X*_
MZ^B-*;`[2IA'/6M=*ZWJ?-C]^"M=^JF-3U^;W'.W/7*8DBF42GU!#]P.I](>
MG&"Y.=D6HT5R0%P-'Y+:P4YX$]<W?&OJ7[#7$-%MJ3N31XSRG'G7@B'&>5-.
M.X?%PX6^D9_#)*&WFD-LI_VT.>BLN95D*)]RV+L?H'OJC\'<F[>TIR_&QO*\
M?U%N7>]\T-3>@-GR]?.W%/:FKU)U93=@OJIB<02!Y4HPX\8E`3\J,CVY22XE
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MTC]=U+4L1==<VB,+HWZ**B+!79AVR51?[)$J7,J+6I3C>!,*PW@-L'@/`>`\
M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P-?GVN-I>^M3N=E65^Y[F';S
M+"6G5LNNEO5"2;#'96WZJ4\26I#:$>BOD4K",I5A7MR&-U[[`OQX"$'8XD^P
M>29'A8!MF0#YT"<$D&28X=0Y8CF;R/\`*RXWZ*7_`+:,M>OHM*,_TX"3Q^V0
M76OD>Y:[8"S\#;^&B.<K$\[G"T$K4U_[CY`U&'V?QLI4C*L9RI2,)]WO3ZA[
M8_8]9<P^X7HKKJ+'&:">=),Y@VP\G#9;I"'U-L14%)&OJC$#_(0E#2E^QQ/Q
MX<5G*<!T7>ZM-LDNAN4CJC!#$D9$.H3QAU@M"9"/2PHMI)#>G5#.,MX*1[7T
MK4.[ZY^-:O:KVA[B.R-7J0\XJC=,M(8QE3F7N2>EVU>U+;SJLMH5JSWN^U+&
M?^G&<^[*<?ZJ3C(>$?WCHF+'?*D(+I(=D7'J1E/'/61;C6?@DBD)^`'3!3[J
MG!8@AQ.$)5ZI2G'_`%.M)6'BC?8OS$4Z^TA70[61_B]RRN+>RQ6G/E^3T_'=
M?T(VV3[/C_K]F5>SU3Z^GNQZA^C?L8Y9C1'SY&3WD"$,CY"2R^0.OAQF&\9Q
MC+CSSNBDMMHQG./YSG&/`HO:OLJXDJ':E4W9=]KS6O=;R7*%YU['WS8^G-ZZ
M\KTE9P-PTFPEP$<7==.P"3C`8SW$/9:.=0VC_J91G&5K"NFK]K?0_JZ[;CO`
MW85LN9.YMF26W).OWS9_0DU5*1=9LZ<-G3=8PP,+$?V>)-)FDL$#H<>:R,"*
MA&$_&O+@2W<^C/KCG[-9!*C7K!OO45$J5!O&^-EP6[>AK$%0*WLO:35`%E#*
M\9+&C61BL3DLQ/6'&3FB(^$R4?EIU;&4.!RIU']%/1&(JCZKV=SI7=BV<J)@
M-?35/VC%#795AFS(DB+B*O7]@R<M7[5.VI+38^(TB,D'I(=QU"6E9PI2`LCK
M+Z7.!=<4_%6LU%L.W91;D^PK8&S+H?'WYZLS[P3CU#<EM7XUI'+H@#,:.PS&
M_A_"MIA'S_.YC+F0QFZ_1+]6UXL1=N?T,1`6V30,B8M58VQLX"T37X;*QA7)
M:QE7&0G#'Q1/B9:<41[V611VV\I0RWA(0/>OH5^MW7JU;<.N&^-7:SUG!%VN
M\1D/OF\C1Y\?6P;K*RTW,V_)A^Q1,O+GAS"L1LBP^0[`QZ&\X3@ALD-:'7WU
MI\7:RG]<W73%*Z7U;$N/",2U,V?M3=^A87=91&P-0LQ_]I;)EPGHVMV`+7;4
M[B1&E):J2[`#_P"W9=^>$)2D-@?//U1?7QU9JW.S=7[%[QUVO,Q/T*XU!SN7
M:5HLNM]E:[N)\5;Z[,E.['VO4W9R,DA"0U.`2!\.=&D-D,?)ZBOMA,&?H(Y;
M][B<],?8$K\AAT<D9_JF1+%+"(*P26,1'F50@)YDA6,HPK+7R,)],LK:6AM2
M`ZL;]!>C*_$QU<J/;/V64>K1,<)&1=3I?2U5K=7BQAA01G$14#':?:C8EHQ<
M>V\XP*VR,EW.?B:;1Z(P!?T(ZA=<:=<[[^U!;K/NPTO/6,)ZMX4XRZKV^FI<
M8_EP=&?Y]?Y3CP,SJGU`R.N3V0JG]E?V"A4I#$GAV!L6V*7-V9!,N`2V88#?
M,T2,DQE%2K,:\XAT<AM0T<D=.$>_#K805QWIN,Z2AIQRG]R?:KKZ1J4G/,P7
M^>MPZ>M!>SM?`7:UT:/V;#.0,':XN5KDC9ZE-`"_L5Q\Z+^&W^4&VE(SCH93
M):.MMVVU/<VZB[][KI=[9JMGF*]ORZN:AN^EI*>UA:M:0FS-?U^LK?I]RNEO
MK,3<!VC7V6F8>/*><RX6^6P^(L/5Y]TU9-URMEHT?]D'<AEGH=4H%J,M\K"Z
M/J%6VQ5]A+M`<%M75\0S7+))LZ_L\Y299`*#LL/):82IKYQ7!R7@L!;OK5VU
M;X1$#C[1._:>AH@`C,KKZU:>J]C6@#$@ED-Z93J4XE8#ZI!:GT9Q[GU-M>]6
M<-(Q@,7_`/=:_2H%PI(D3]F/5)>I8FC.0-V3:;?<97=MLMC29_\`!M@5[B;S
M7]:P.,KD`U$CHICF7OP_1*T)7Z)#--8_6YM#6CASI?V4=X;:<,?`=:<W'LR.
MFOUS0(_XZ@01*'$ZWB5AG?\`61D@8@EQ>?7#V/X]`\*?^MKH4VQR=C@/M0[<
MB`GX\_,9KLR9ILCKX2P/Q[PH4F46Q!1^UR8L8MQ)"P&[2PRMQ/HC+:/1&`\'
M7'UT]>HH00NV_LRZ"QLQ3B_VL]J,^RQM3PTR;\XGZF!VA<MC$M.NL^Y+_P`S
MKJ<H7A"<?[:7,AY=4^H2>UJ`F,TQWWU7HH8I$.FRNZJ_Q^P9<55V-!AX#-A7
M?ZWL()IN+C`E#MHCAP$X:?<QCVYPVIL(IWCQEWOIMFOWF*^W/8D1H6LO.RW0
M%LV[7PW]A0-1#?AG1S]78JL#(5@^SI*>D&T#24:X(8VX"*L=]UMU\@/>"X-Z
MTWSJ^>9A?MXZ+L%(O#]JI=RKNT^:]:C9EHZ)_P#C:WZA3L$.+K:SUT9R0@98
M<G\)R/+RX6M67G,H2XH//J/U8=L:5@(JA:7^X?8^K*"P[*D1-*=YCTU-`C3,
MS-3MKL9$(Y*6%@@9B2DYH@E8R/>EK/\`*<X1C&,!5N^<B?=]IZCO7FX?;7)2
MPXFPI$0PF@<^05RJU$U,)6I>9$V3>XW,-'VTAJ*FHQH65`BAI!L4-_#Z5/I2
MXA`63V7]:G:O9FFV*IMK[:'=J:/V0]2]DBUXC@_3E7;DV0UU^V5!U?K9A946
M-;(!:*5'F#8_W'LX=;2M&/0,@@>.ONAUE6XBF:S^T/0E@@:<-"U&DP6P./ZJ
M,@.B5W$;!Q:YR3@I0ZP2UA8JS#JUXR0E+A[#6%OJ;<>5@).9Y_\`NO`]X[7V
M&<J3K#+)3(TA-\</!2)3A)C1+1D@-!["%CVW8]C"QF6V,(;4UG"G?D<_J\"`
M]H\'?<'L*PUBQ-]H\6QTCKFX#[/I1<'R];:@J8V4RH`1V8V("!=IH*QB%@QH
MS[OKCYU%",MX4D?Y&UAL)^O^W]/RL#T/KSK?9VN]P;7TAT&_KM-\UE0\ZYKD
MC6I73&F]HQ0+E;5)22TR403L4@=U]2F\O)0C/LQCT4H+_P#@/`>`\!X'RR:"
M_P#3Q</=$Z@HN_+C;MX1=IW/#XV=8(F`B.<(Z"BIJZDD3\J!#@VCG*SV<2.8
MD#G,,M2,D>:TCT0\0ZM.5J"3]2?2WQGQ9VYS8#5*9/[QJNY-7]*U"YP_0-%T
MC=:3"LUF,UA9H*1#<K.D*8&W;RBAW1QVCWB'B`%FN,8Q@<C.0R5.A-9<&?8S
M#W3EW@"B3DQOF1V3656YFCU?3MV"/`T09M(ZE:"VF)/"ZZL]+FHS6"1&JU,Q
M$2:#(M'.YE?P4(0T&PS@[=5!Z!OW9>TM:&.2=4M&VM-2@IK\I\D@"4=R7H4H
MZJ6"L_LI#^S[94B7<BR@>4LJ07[D+3E;2EJ#U>I/J^XZ[&VI$;MWA3+\7M6"
MH4?J^*NVO=Y[LTY-#4".G[!:4559&I;]3,&1)5BLCQA#;^'/G?9'4KU_':]H
M5;Y_XLYYXC^P_4=3TA5-C21.Q.0^EYF=O.V-S]`;PL4$W5MM\P##1$-,[9VG
M:ZU70;'FQ>I+(<8D\G,:SE1"&FU(<"_'6F[]@:!A=27&F0--ML99MXZUU#:*
MI9ITRKRTNK<UA$UM32*I8APYED`J`O-BCY"2;7&2+C\,,6EEM+N$K2'D.;E[
M!;;?7GB^$5\4O(!)PGIVE8P[%".*0+.I6[26DH8DD8PXVPOVOMH_]NI0K^GP
M-4WU3_8]?.D.Y>PN;3-1U>CZF8#E.F]=W$*_15ZFK/(7E6HDVBOBR%>?Q!$Q
ME7.N.'"W6TO*08:AE+J4-X1X'T1>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`
M>`\!X#P'@/`UP?;_`"X,)]8'<QLB(HX9[G/8,1^.@<@I7Y-@C,P(+V&!0)-]
M?XILDV[ZX87[<(]<^W&,J2%_ZG__`"K6?7#F/_B?AOX=3E+N/_<<-_#B<H;R
MES'_`!QE*?3/_#'@9!X#P'@/`>`\!X%$/LX((%X/Z0=%(?&=S38YC+H[SC#F
M6"K;712F<N-*0OXB1GEMN)]?1;:U)SZXSG'@7O\``>!J,^Z$(5'%YV&$QX+B
MKY&):)S"1TL4*8W0]@M0\I&!&!OLJDJV>MH]ESW,Y80*M6'4)QGU#7GVSPQK
M;A_D"T=$2S5MV#MAG9FAHJ3F=#5B?K<$#KT28H]':@U48VQWR,)$(B0C5%S4
MHZ^23)SJT(RVG(3#0:N^/MSV;??1W,VD9RE==52$O^U!8B^Q[7/)E=%3KA>O
MYAR0GI+9#-;.FJ^)$[+M<0N2+]1_Q0"QV77\A`_(H-I7VC\N4?6]BY8TGK2U
M7^HM]`[>H5>G[65:R)>3A$1FZ-2#P[@)CN(Z1@(/Y[(4F5RB0#%,#=4R[G*L
MMY\"A7W#\.=+<W\G]$REL^QNY=/:9L04%!M\FW*FW.S3-0D$U,V41:8?\_J+
M$?B*!D8#-DDW9J,D`P!_RS/B4&UD18;+-9_7W8:+TI9*Y6]@S>@]Y.Z[VIL[
MD:X:#J^A=.<]R6K8O;FC[;*5/:VJ-'P%"O\`9E11T[6JA+1UF198LR("(D8^
M4:*D'06`N;S;PV)MD+H>Y_85S?JZ?W==^GMIV2)EW)4?8HJ=1FPT)"ZIC*9?
MTQ]<L6:U7J$YB)0P^#%$#D#OX6/[L)?="LFJN)./[+]DO3>F#=0T\S7FMM+:
MY'KNO`R9\2%@"#H+74L6M\4>6:=<D5(M#CGR*<4AUB0]N<*6A64A,^V.,K)S
M;T_RELOZ]^;*HRVQ"]%0.X1W=AS-!HF<6:G4N'UQ*;%E3QKL^;`P4TD@Q`<=
M%O2I+HB$L+0VEW"@P[F70,%(_8+U!KSH5R"ZCL57TSJ!^RWW<%"HL^_.6N2I
M>J"I<N#AEUUV/IU<5*ME$!0J'7T1[1",-Y_E;KX;4%<?\E*=6^KESG53SJ6T
M./*TEK3+KB&??\*%N9K/O6EKY5>W&<^B?=GT_P!<^!5S[%]&:<COKZZ1CH'4
M.LHMNAZ%W`YKL6*HE4C&J0;8X@HV:?IJ1HL=JK$3DDE+Q;@7X^2'L86YE2L>
MO@7.F>?M#V=R++LFE-2SQD/6XZHQ!<OKFGR)<158I#N(NM1114.Z_&P$7@AS
M\8-A38['O5\:$^N?`B(W@?C8^/%BR.=M;I#"&)#%2)%/1[[(I<?&Q3["3`"A
MC,MJCX@=K&,N9]F&_5/IE2LJ#I_^Z^>,OB,9_P#'^E?&>Z0^6GWSGJXX46Z<
M^K"OV_O:PLIY2L81E.$XS[<8PG&,8#'B?K/X5,)(+(YSISA!;[Q+Z\2-L;PM
MY]Q3KJ\-MV)#;>%.+SGVIQA./],8QCP.PGZWN+68TF)C]*LP@)7QY>16[[M"
ML/YRT_\`D(RV;7KM&',*^7U]V6W$Y4E2DY]4J5C(88']7?'9"I!4SJRU,YP6
M6+&+`Z:ZB+6]"K`8!8>,R_M,#(,BZA*E+::R\AM]*2$NJ?S[TAV6_JRXJ97E
MP>C;7%<RE2?>)U?UN(O&5-NM8=2H?>;64D--/N);=QZ.-X<7A"D^]7J')&_5
MQQA&357G?[,V[,%4^<KUDA0;9UIUU=:XN:JD^-::\=.U&X;TG*K;%1D^$P2A
M$J$:VI;#>%I4EM"4AEJ?KRY<&M5QN<+!;:JDU?KG9-AVIFD].].TJN'W.X3*
M[%:)X6FU7<$13X4F=GG5F$H!`&9<(<6O*/<XO*@K/N_ZI8R^[.BMFZIWW8=<
MELT5BBS\+N37]<[:C)@0&P2-@C3X;/64GLE[7Y8SLL^V]^AR!@]"D?EY>^%C
M#0:YN5N:9G;/'W9X%FNE;G*K5LWQB7T9`:YC(2"V%LNH\D:\KM"O%T@QA3!8
MN*/+9_?CU82#P*S.*:?]"$C#,H#1!5M0[&V4@)0G"/,TJ-M+:.M-75`2N[DJ
MXS=<%MFZ;/6,5X&P-:"BH^7_`+H?R%&C$-N(C8B/"_(PIE]\7&0^ISL[F+GK
MGXSAMO26CM;:B>ENL]45R7=HU5A8*;)@G5M)(@S+!##L6(D%/XK:E_&7AK*V
M4N.^[&/`WG>`\"F7+AS9NW^^4-I;3F/ZR@H]WXU95E3K?)?,!65.>H8GM<]A
M:<9QC+^/3&/]S/\`T("YO@/`>`\!X'QZZ>^P'LB,A>=N8]0[^U/38S8.[*AS
MQ7"$<L!2EYT50+9M;8=-I$ZER7WZ9%;`DJR!1Q8>85*U.!:$+.PTZUDQ;:DA
MN[H?.?VL4BQB6>S_`&4ZDW?&1B)=:]8VOAJIZZK=H43"R`<4/)W&@;;_`+N@
MU1\P0P7AX3WI7\'QK:6VM2<A.%*T_P!)7S8/.FYNCI_1D+8]0P-_,E-=ZDJE
MNF0&[ELBI1]8,Q$[)NEB8.<CJZ,@M"7FX,-TY!.4*PVA.?D"W-;I=.IO[C^T
M*G6:I_<4R;8[!_;<#%P?[VPR2\.2,],?JQ1?V<R>O'N>*?\`>^[G^5*SX'S%
M?='7N89KK*KHWOGZC1)56H*"^.]W=V%T3HS=3]:%N&Q%+)J=1U0ZU`,400_Y
M4M/9S@F9,R2T1C+0C/@>C](FCM(PO1%OVEH6F?5')UR!TS8*%/[3X1[-Z5Z&
MVH!(V6X4J<#IEOI6Y'SXR-I<DBLN%*E7R%%J,#8:%QAM1/@;AOLZAYX_D^2G
MZM,2L/9-<;EYJVG`Y@M>C[5F928U_P!":UL,7"Q>OLF1<K;I"2/$;0S&19H$
MK)N>@8Q+2R/=X$M\4;(V/N#F76FS-KSE4L%TN+5GE##J?5RZ5',Q2;C8`JW%
MRM0/LUP-JUTAZZ(*+88QV0(<CIUHL564J9RG`5NX_K=,@NU?L0&@M?0%+DH^
MR:)0AV*@8R+3*Q4CKTYS$M'D#"CN.AR#@*&B$C_]LDD/*%^I"'/0-G7@/`>`
M\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P*._990;QM/@CJW7.M:G8KS
M>[KIRSUVLU*I/@#62<DI-MH=(<.[*'Q8.#/B6I>$K(:]^$Y2E7NSC'@1Y;?L
M+>H-#D;'(\7]L@.QC<="P@ELUO4HD6=M$T7'5RE0)=E8V).#1"KA;I8*+;/+
M1@<8@G#Q661TK>2&QX5QUX8=Y\=0C[K#3CPJW&W5#.K;2IP=3K65-.*97G*<
MJ3G*<YQZX_CP-8/27W#\2<I;LM_/6UYS=)&U*)7JG:;1!ZVYIWWMT**@[M%R
M$S7#2I[6>OK1!CH.`BB5>CA"/;EAS&?Y;<]H6'U#WARMONQ:7K6G]I"WLOH7
M2UJZ"U`?#P%GQ!6_5M(M$)2[7-LS1D,+'QA\%9K"((1'&K'D$.N9QEG^A?M#
MS-B_8'RMJ@G?P=\V"?"/\Q7'1-$W0E5,N92:K8NDWX$73K++@D$^B=`M!%E$
M0HL')`H:EJP0MK+:_:$R:>Z(U+OF6W+":NLCUAD-`[;G=&;4:=A)N'36]H5J
M*A9N:K2')J/`3*_AQ5C!?P4)\X;K9*,MNKQG/H&O2X??!]5&OMDW+4UYZLB:
MK=->[(M&I[PS+ZYVZS`5:[4R71!68";N3="=IX`$1)Y6AXU9V`VT-..+=2TG
M*_`N)L?NGE'4L](UV^;C@(DV(YFN/8TF4(#.ST*)S30Y"+C+'M?,_7XJ4AB(
M%DR892.VR^X6:G*E#LN)3G/@4^^Q#JCGJ^?6=8]I5+:E>F]<]&LZIIFD;F$Q
M-/06P[1L^U5LNC0\(2W%+<P1-X;6SG+R&D"E-.#D99?:<;2$V=#?:W]=W*6Q
MSM1[]ZLUM0=D0\2#.V.I*Q8K-)4^(DGFV(\^]*IT%81*(P9EU"V\S#@.5,K2
M[C'Q*PO(7JJEKJ][K,#=*38X.WT^U1($_6;3694&=KUA@Y09LR-F(29C'R8^
M4C#Q74N,OLN+:<0K"DYSC/@:W.NX[3_V#Q>R>,=2;WU9)[BT3>Z!.[\UZU9#
M%VBD5>VP%FAUQ\HJOH/,J]CE*[/$%1KA(<@%DD=#)HKH[SB,AY&VN+>J]O:Y
ME-66_JNP6>DSY-:S-0,Q':/AQW`ZM/Q=IC&8\RJ<JQI8BOW$$(EU"_E8=$^1
MK*/Z\9P%7=2_4IOK16Q8#9VL^C[/'VFGU"6IU1+GK[4+H'%QYE>#KP"51EVY
M6L7PLAQH26G$!D"?EON$'$9>,+?7D)-VA];._P#J;8&K3NO]U5C:6LZ)..+,
MK$.RFJRSE9<$%GE-"&TJA49)-T_R;4ZY(,RR7`&!XT0T+(;S9J\)"K?V"?11
MIT_F#<[_`!UKB7E.G;WBFUD.RVR:KUQ,3392\U>.V$48)>?UK%F>A-7_`+)L
M!A4D%(MJ2W^"8.4AEQ(2#J;:7VC;IZ0_RP-R+S12;AS!KG8G--TUU?NB;'`F
M'D[@B.9M]1EE!-IM'VN)%B$"4T:/`&(>>(RDQPHOX$-LMD!<^.WO]LK8;:9C
MZ\N9"Y')K"WG8KOV5"!3&J;840.VT;RD82Y(,NY<0AW*DM.IPE>4(]<HP%&P
MY+[.-#=-]8]NRG!&LC:9;=:1I5FH;W;=1:?:Q0*518\NQ4^XXU*5^;#Q\#K)
MYUR/DH."(65)Y4E]]+>$-A9S4'=/V4;AUO3MLPOU0UT2F;!U_6]BT[#GV`ZH
M>L$S"W"%BY^ML_JW-2!@1Y94;+MN/X)-92/A#F/5:\(0L)>Y"U+N8WJ#JSJG
M?>GI32]AV6)K*C:WJ3VUZKLB+8I57JL8':)%C%-4T(*5/62!$(SD]E)32,>Q
MK"4Y>RZ&RSP*;?8:RT1PYU4P^0&(P_I*],O%2`@<@`,TY#OH<(.`D"!`#0V4
M*RIUE]UIEQ&,I6M*<YS@+@/DC`B.F&$L"!B,+()+)=;'&''9;RMU]]YU26F6
M6FTY4I2LX2G&/7.?3P/(AK95K$X\S7[+7YUX9M+I#4-,QTFXPTM64(<>0$2^
MIIM2\>F,JQC&<_QX'=;FX9V/>EVI>,=BAL$9(DVSQ5QX^`U+07EXU+N1FL"K
M;5ASW*Q[,ISA7IZ>!V/SP/\`<_[T3_:;9>=_[EG_`&VB,^@[KG]?]#;^?^A6
M?X5_P]?`[#CK3*,N/.-M(QG&,K<6E",9SGTQC*E9QC&<YSX'ZQG&<8SC.,XS
MCUQG'\XSC/\`IG&?^.,^!_?`>`\!X&L6I_4/Q3`0EVBYVHWJ]R.P;1(V6SVF
M=VML.OV0QI]H2-AJZV5KFPT<0:O5FM1@L6(RVPE:Q&<_D+><=>6L.*,^F;ZU
MH?(BX_FD-DB/):.CC,[1W8X=%R+!^)1F5B37-DJ*BI=LWU7@L931&,*4GW^U
M:TJ#(YGZN>9W+-JNVTHG;6OY?5>QJQ?PV1=P;&OL'8FJT0(4W5IJM[<LFP($
M6++>`9S^9'#@RXOM7@<MI#Y"70V.>`\"A7"=ESLO/5N[8ZK7*KTO</5-FE:#
MF\)BAY6QP.M]8:HT5+VF/C(R1DG(BMRMXU3+ICF2E-E/"M))4VA)"$X"^O@/
M`>`\!X'QI\]=\6*>;X+XSL5'U7&5.,^P*@P];FJ=8K@JRR[5*WCM*8!;EZ$3
M3&H9G#,[!CR2'42"PT,-_EMY2H=*O`^RSP'@/`U>=7]+4+6>_6=<VCZV^E.J
M'D:@&V,7N#3_`#_JS;<`$-FUNUL"B(*M-R@;*98AW,/EN!L,N*8'4AQ*%H<4
MM`5EY,JLMNO[-97JO7W#MPXKT_J[ER_\\7&V7J!T93;MT3L*P[+UI9H:L35"
MUI:[E,PD!IEJJ2RQ9$QYI\PF0RTC.!DX2X%R?LJ@6+=K#GNE22S':W<NX^/H
M&W0PA_X";-6%;D@I&1KQ^,E!(,BS%QS:R&?DPY\;65L_[Z&O`N7K35NNM&4=
MJD:SK;%4IT6;89YN(%+DI'.9.QS$A9K')/FRYLA)&GS,Y)$EONO/+6X^\I6<
M^N?`T._4CW&'TMW?WS`HTO=M7D[`KNK-]BOW.WTJRD/UT-C%"@4#XIUGL<>R
M'*"%X6VTSEM0;PA""DI=<;4X'T5^`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`
M>`\!X#P'@/`>!1O[$VVB.9U!OJ<2R=OGDD5W#3&"'7$KZJTTO#;;:EJ3A2U(
MQ_.6#,)Q_/P.?\`O)X'QY=L7+6^L_MA^P.P[K[V[3X#J\QHKC4FJ2G)^O[/:
M6]S)K%(V>W:_WQL9HW;X*I6C)G&&PFV\A%LX.<<]Z\>W#01SR%LZQ<"*^I[M
MWKG4.Q-9\U9XSZIXZM6P&=&79A_0T3)],0VR.>-J[Y@6%6:T45&Z]9PJ)"9D
M\#,"9D7WWEM"L92R@.IN_>%1Z3T+]N_:FIJG<G=";:^P7ZM8_4VS;=2YF'K&
M\H/GZ_\`/]-NLS'1%IA1B,:PBYV+-PY)$!BMJ;4K#I.%-+:8"Y/$/VA_7KQA
MO'[9==]/]4:LTOL*?^UKH2SAU:S?W,'(GUTREZE@HV?9$;CI7+@+Y\"4,Z4G
M+8ZRA7EIPEI3>5!`.B/M8^M/E7G;[&-)]'[4KFQ=I;(^P+[$RX?EB-H<]?;[
M?0-F;=LHU'J(M;CZ:6"\'L!A3#@[\@^XQC)WM4]CV?`T%6+[KVW<X<\R&CML
MBMP^RM?_`/I,=Z15RB)N2/<FZ;,D;9AW0Z@4V3E[*7Q'9)$6MI:\88<#PT-A
M2,8Q@(M[,U'LKBBC<'\ZU2LN6?ZV.W^QOKOZ5T$P!8W9Z+Y3WD3:ZY8]]:=B
MQ)$D*=D-1[48LRIZO#J=8%%,<)2AQMY3V7`M_H_K#77!VJ>V.:=Y[OYBY#^P
M`SK_`'KM3JJ]=\:9NVSX+KS06R[Y:DZOV%J^/HDE4I+;51L-4GXV.%C6Y"37
M$)"E$+CVV7%9:#:C]<'7]%YR^@?6_96QM:TO1]'U3I/;]]QJZF)N-?J#`T!L
M[8,71:W4Q=A2]FM44O99K,<@%@DA[_O)=&&DX;4A&`T^:"JW5/UL[LX8^PSI
MO1=6HE=W[?Y[5/?74]:Z#+MD1N('N^Y8V%IS86W:!/TJO637PG,=QD8JM,GS
M!YXXD:C(B7<9<9<=#[?4J2M*5H4E:%IPI"TYPI*DJQZI4E6/7"DJQGUQG'^O
M@?KP'@/`I1S;D572WV'?$\RLI&_-.-ELML/M.L>G'?/#@^"'5LML$K=;<]R5
M(4YE*,X2K./;A.`NOX%;^R/E_P#$+JKX'\#/_P#C=O+X2<YDDX'=_P`8VCXW
M\YAG6)C&&E^BO41:"?X_VE87[<^!T.(\BJXOY$4#E:@E<P:"R&IQP5UQ0N=4
MU/(^7'0FF`W%Y:]/53*$-9S_`"E.$^F/`L_X#P*9?8D8Y'<+]72#3HP[H.CK
MZ8T^8TP0(RX-"D/(=*8)=8&>&;4C&5H<6A"DXSA2L8SG/@=+[*'\#?71WB3D
MAP7#'&G3#V261F2W6/CTO<U_,T(\MMA]QOT]4H4K"59QZ9SCP/D\YTY:N_'&
MX_IMW@3PYSKR!3[[MW0VHK7TSR5TM<MA;*Z*>W'HEP6JTS:&NK<-KB*8U9L6
MZF-'6)S*[,<Q)1C"Q\J0I#I@7[U7*Z^!_P#3-=M1"5"MO5#7'V<TJ^1%H=K8
M,O`;43NG?S7Z.RL*;BXJ/L[,K*QRQ!O:E]/RBH8PM>6<9"MW8D8HISOEI,21
M8(V<^KWZ3(:7"K\JW%$6%^9ZPN<65'&RCXL>VN1EH5.&O9A]THH#V--OM9RE
M#0;E?O%I55O_`"USOK>WA$25/OGV*?7]K^QUL8E0`]GJMPZ/IE7LU5/.#-CI
MT.+FJQ)ECNJC'VS5)5A&%894]G`5DDN7=,?7!]E_UWT;C.S;3US`=2QO5%5Z
M(Y^5LK;&WJ3<=;ZMT;*WVH;3(@;];[:FAS=*V2'&Q;$L/^/^8W,K&_JRC./`
MU.ZB#['LVMOIYM7(>P[4SNK2GUL=!=;0U'MD_<IB-Z?G:-T!K@*X<_WY+\L2
M+"QVQ:/?)D.*ES!<+1).@-()PTUZ(#V@OLDF.GK+V!MWF7>^T-0:R[@[O^HW
MF&U;&_<S@ENY-H.S>;#$;PKE0P<FRU?6NQ1;Y7BJJ_,!@#H'G)+)677'&QG4
M!LH*UKK[AONWC^B:/UY]A^BH>;Z!A]"S&S;+LHG?_,7:L==]/WBW&QFR$[0Z
M<F+-5['1G8@R2`LF:^Q*MGQSXPHQ3+R,)"0?N$`M]R[#X#UU6M9]8;J%D-4=
MH6F0U1R=TV]RW:;*9`M\^C0\E8;TC;&IFB(2O*DWU9868ZXIPA/QM.?UI\"_
MGUFZ?+U=I6SRDG1NP]42M\V!,2A6J.S>C5=+WNDL0;;->!15;G_?6QVXZES@
MX/Y@XG[8AS*W%.KPG*_Y#8YX#P'@/`UK<%Z[-TCM;N'1@%_VA>-=T7=5,LFN
M@MDR`$FQ1@]O:P@=IVRG4DF+AH,-JI"7:S'DL,*:=)8R3[7GWE>B_`V4^`\!
MX#P'@?Y^/)&W,E[Z^O*"DWXB.>L7=&L#/R(\U(J4FR>RMR3)L+*RSE24X//2
MDS.I;_'P86HE0SD>E]AE].6@_P!`[P'@/`^2+[U[Q#@],;?BM@S/:9*H#ZSI
M<CBBJ<]P'6^:$/WM8[WMT>JV@B1T2$Q0)6[C1(D#[?[@(>#"$%]748]R$.!*
M'U""\85[N8&/XDK>_M<PTW]?$>'TW`[#U5T-K:I[(Z#I>U:2[&;$LDAO2J0!
M5^W:U&W&QIEIEMTAPH8Q"LN.*]_M#8KWQN*.M/2'#W,M;MU;JI$;UOI?:6V;
MU;FFW:%!+JJ)RW:TT"_+LNM.1F^-_O11!-2C\NM?(+#O+(QG!8#)H;=\XPK&
M4JQC*58SC.,X]<9QG'IG&<?\<9QX&FSZE^=M$ZTDNU[OKK5NN*C8A^Z.H=<P
MDW3=;P]$)A]5@35(+K^NHXB-@X1V2IT6N.8+'1[714E.NJ:5G*EK4&Y3P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P-=_VH6&JTOBZZ7^^X-_
ML'7&T.9]BWIV,`D)60$I](Z7U'8[!("143%3,I)+BX^/62I@=G+SC;2L(SA7
MIX&3-_9U]>C@K9JNR^>1A775L-NG[,KD;A3R,9RMG"9`P9?R)PG.?;Z>OIC/
M_+/@=)?VE_6UA+WR]S\K);9^1!.7=V4%+;'L<PPZDG*YK"&<-O*]B_?Z>U6?
M;G^?X\"W&O=@T/=5`AK]1)-JV:_N81KL)+O1,F#'V.'289%+/$"GH\`D^!E<
MBK6(5\*A)$);9(ZWAGFG5A^[SJ[7.S:#9M5[`I%8N&MKI$F05LHT]#!'U>Q0
MTACT/C)>&>9R$:$9C_VZVM&4K_X^O@=U[7U"(=6012:D00YG"G""*Y#OON*Q
MC"<+<>=#6ZXOT3C^<YSG^/`YTTBEH/3*HJ-71*(*2<B23`123TFH<PZDM)F!
M,$)*2[C"L.85[\*QZ^OKX':DZK5YLATN9K<#+E/PYM>?)DX>//(>@)-;;DC!
MNO%CNN.0\@XRA3XV<Y9=RG&5)SG&/`H]]FT;'?\`@GNL)((+3`0%"9B_48=H
M>"=QL>F`!R8;RF_@@OTC3_R(,QA*0$(R[GT2C/@3[$\I<X1*K(O&FJ)-NVR]
M6_9,T]<X=N_/KN-]DBY>UR$:1=U6!Z`!E9(\AW]>`H:.'40[\+#>'%X4$R3=
M6K%F@"ZG9*Y`V"K2`C8!]:FXB/E8`T%K+:F@BX8\=^.)$;RRC*6UMJ1C*<>F
M/XQX'3MM%I%^K[M2O=.JMUJK[@3S]9MM>B+'7WGHTAHN.==AI@,R.<<CRF$.
ML*RWG+3B$J3Z9QC/@92E*4IPE.,)2G&$I2G&,)2G&/3&,8Q_&,8QX']\".+;
MJJGW>Z:OOT^S,N6/3\Q8IZDK`LD_$1C,C::O(4^67.P<7(B0]J8S"2CV&&9)
MDIH5_*7VDH>0A>`D?P*8<XQ[HW1_V#'+9;;;DM^ZB6RXG#N''TB<?<["K4[E
M8K+6?8M&<)]CCV/3'\Y3G^G`7/\``K+VL64!QMUJ<"\0.<%S+ODL,@5UH<I@
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M&QQ11#J/";:V!=X&JRT8P(E(1H(K)86%*PPXWA6?`P+>?TU_4W:KU?\`I/=7
M/M&KRYN<B=E[<,,V9?-;:3LM@JLH-.,7?:6N(J]5S3<Z7@X7#IQ<M&.(+RMQ
M9.7%N+4H)'V5S+]</7]LW:/;K-0-IVKI;4FJM9[2@ZIOXK]G9-7:7N96R-:C
MP\92[N-(5P:O6VQO'I/B\"NOK,]775I4CP*[V;ZA?K"8IVR=82UMV2+B_#UU
MR39O7<O1-MD:_.U6S1%^I5F@A+KO(XJO3T#;X*-DF2PE"&.?B-MY>^)2DJ#,
M>'_KE^N_A%V:MM&OS.R=_P!QIQ%%O73.Z-[$[`W=::^9)'2)(@MBG;44+2VS
MC3/D)1`#QC99#2'74K<2G.`LQJ'@_D'E61T#<:1#F5,SF[2UOYJU!-V[9=FE
MT1&LMEW&!N\W5S2[9/%MV"0-L=;%4(06IXL=E&6&5):S[/`PESZSOK[FX7LM
M@[6D#/4;NB9J%DZ:K[M\L"J989ZH+,-K\U"#QUA%9U])?M)9P];\.Z"X\8M+
MOKZX1Z!@>I_I?X/U?M34^\`(;>>Q[MH]R./T>=N+JOHO;\%JYZ.=*)BC*5`7
M79DQ!#_BXDRTM?,R0W\)KR/3*'/;@+U6SG#5UUZ`U!TU/Q\R_M?1E/V=1M=R
M(]BEPH2.K^WTUE-Y9D:V*4W#S94@FH`?"\4TZL7XLY:RG*E9R&8:MJ]_J-=/
MB]D;0?VW.OVVXR\?:":=7J00!5)FQR$E4:>]%5C"(LYREU\D>,S(^QI^2_&_
M)>0AQQ2<!(_@8%?X78,TQ5<:[O4112HN]5B9M3DS2TW8:UT(`M>;92!A_P"X
M:X[792Q1[GL%F&W2%1Q"$.9%)1[V5!GO@/`I-SV3EWK#[`!LK?5@787/^<(<
M$CVF&_GYOH2\_CECNKD"\K]OJO!*$8;SZ8;]4YSGP+L^`\!X#P*B=_4Z_;"X
M<Z\H^JCR8K9=KYPW'!4&5"MQU"+B[=(4.<'@)(:Z1C)$A6'P)-;;J3&49<8R
MCW8],_S@-1>F.6.Y?[9Y(VB+H_Z]]@:_T;I;20FH*8:5L2;N_P":]"P:)?=H
M#DM`4*D`;F_M98N$$21\F@)P4A4:6PZ:0HH-J^I+;WV;L6K@;NU#SS!ZPD`)
M;%HGM=[#M,M:J])CPSQ<.L>*G(X<.4!D)A"!'$-JRXRES+ONRE/HH+L>`\"G
M>[=Q;VKG0.C=):TIE)`K&VH+8,H=N:[*E[8%#6&BQ&9A-&;UM69>J3+>9:,5
M^5^])EF@&5-X$^%P@AK.`\;:&H^X-ACQL=6>M-9:4%2+8H^;E=><Z%S=D,8L
M$5F)&DX8G8>W;/"1%BJ7S.FQ3KX!P/[##2S!"V&U#.A@W+W`D#I>UWBW;3(H
MVZ;"_*U<?7MRL%/=/OBH^G2\A:0-F;,G+%)S04]T!9;/)ME3$[%"10RB(L5X
M(<)O*1!@PKOC>DWL7]_]?_*\I*6#L'9E3BYJ8=@'B&=?\^:R+GHI4A<>G;I#
MI?E-=5#8%=9D0(>+`RU:K3E+[43\&$.R`H>?]1GU^W+Z^^?;%4-A;9NVQ=@;
M8O<WMC8T//R]5G*I6=@3Y9*)XVE'P-,J1>&;**T(Z6RI*(]A;*&PQ!4I<^4-
MK?@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`Z)\7&2K:&9.
M.`D6FW,.MM'B#F-H=PA;>'$((;<2ES"'%)]<8]?16<?\?`P&RZSHA==LPS&O
MZ<21(P\RA0_]JP3N3R2V77_8\VL'*"5DG82M7O\`7WN>BL^N?Y\#63QWW3I[
M7_+O/^K+!3^MCKAJ?1FL*/=\8XMZQ(R#/4RG5VLSS;A2M2NMDM"2S7Q8<;<=
M2M.<*3G*?YP$YR_VE<?UXP&/L$MOB$-DC7HT`8_C[KG#A,@.3@4@1&1](OH2
M\PXK&5>[*4^W/KC.<>!XG_NW?@;_`.2KL3_\5SK'_P#P?X$![R^S:G;L_P`2
M:3X'W7)1&_\`;&\:71$S]TY+W[-5RKTIT.;E[W.28EXHU!KS"HB'B\+2M^01
M\;BD84G"%*<0$IF<X?;&R\E,3]FVDB!/F=<6N=^OV"<-^-:L*;80J(Z$C1<(
M9QZIQG+>5*3Z>N<Y_GP(=VKQ=]M>YJ+):SV%]AW)TY1[,)&,V^*$X(L4'(R"
MXV;#FVTP\VQU,?\`I<((C6,M.K&*6VO&59PO^,8"1]8]0?9K3M?5^`W3]:VQ
M-K[,B7S(FS[`UGOSCVK4^W.*L)HL38X2KSV[`YB"CGX1P5U]DA"76,I<SE/\
M>G@9GCL_N/+ZV/\`W47T5C*'DL_-GI7B+`ZLJ?2Q\K;N=]_UL8RKWY5Z?PWC
M*O\`AZ>!DL;UYU\[\*IKZL^CHIM3"'",B;WXOFG&'5NOIPPAH;H-C)"DLI96
MI6,XPG+JD_ZMYSD($Y@WQVGI/2VO-8['^L[I"5L4&U<7YV;J6X>2+!#-8,M]
MBGQF0EG=!`R+^<`2;++#:D(RM2<I3_2G&<A9Z,[+VR2"P]*?79VU%'+PY\X"
M$\KR*1\I=6EO&#&.GVVGOD:2E?\`&,>W*O;_`*X\#MN=D;(;PC.?KY[@7[W6
MF?1J-Y><RG+SB6\.+QCJ+^EEO*O5:O\`WE.,Y_X>!7WE+Z^-$7+G.G3?3/,,
M(WN*[2%^N=_%V%AV0V$,9<;U?):+$N<S&V"3&=M(E6L[3)_X1:P4%XS^+[6F
MA\-AL+TWH'3//<%*5K2NN:SKF%G9,*:G`ZX&IA4U,1U:@:<%*2Y;SCYLG(#U
MBKQX6'GW'',LBHQG.<^N<A+_`(&)WVFQ.Q:-=-?3SAK,'>ZG8J;,NQKS0\BU
M$V>',A)%P`A]@IE@U`9R\M+6TXE+F,9RE6,>F0U2B_1GPLR*",09U21^KC%1
M$<[']E],4W`8?ZD&):0R#KS95/BL?AH#4Z.G(^6QU/N-MI2-AIAL*9Z%Z@KG
MU?;5ZNT58M$?9=N74;FXX9S3MAJ^@=V=)#5VLUK6-$J,VN<OQ8HLC-/6FW`$
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M.(]TT^6UF99OK\&W.#2RV3;%5[GOGDZ;UW>Y2OZAD=9P$F?3Y/35?!I+`[<J
M0:AJ#92F3FU-GR;>7\_D,!6/=/&W;%T[ET9T53/J5HM<YSIAM"-VKH:(Z!Y2
MC#KH56J'T-59J/=I8Y\;JVWU26+VS`&8S)G"D).K+:LBKQ@=UD+.7[0^^K;?
M7KE3OJ_Z'T=%)A=7L`T73F[OK8K==9LVIK-<K+7K">X;L"3*D8:37;&AI:!3
M^/&RPT6*V5\K:,(2&*;0T9T^;H2I4;37U!6"L[NH!?/*QMX7+I+CVCG6<;2>
MPM<7>UGST]K;9]MLL7*;*AJ46&2\($2I1$BM#_O'R]A8;#N=/N;X`WCIR@[+
MLW36@=/VBX-LBS&KKCN2I#VJFV`@]T)BNS@\FN!D19-U&&G<M$!BNL_-A#J$
M+2K&`LNC[#."W/?[>T.6?5L0L]U.=\ZP2MH($(B1-*=0JS)4VP("(XXZI6,8
M0E/\^F<XQD(AWY]J_%FG=5VR_4_?^A=[6V`(JT;":@UIT+I5V^W6>M]OK=+A
MJ_`-2=T&CT2C\K:!O7!+K+:$^N5J1C&<X#K*Z\[D3E>/_=36]5>QKY?<CJ'B
M7.%_]7^TWZ[S3E3V?;_IG&,?SC^?`XV>Q>W%,%.O_4OT*PMD=;HK">DN)'UE
MNM.#_(/ZHWYC#"LBN.+;4KUPXMOX\>F58SX&<\;L[<L&R.MMO;8T5<N?'-I[
M'ULY5:3?)G7UBL)<-2-,TRH%SZYC6=^OE8>`.F0'VV&\.#$-89S\B%>Y.<!?
M7P'@/`>!67M+;4!H;D'J#=-J!DI.N:MT%MJ\S<=#N1K4J?'5RC3<D2''.3!T
M9%H,);8RAO+Y#3>%9QZJ\"'^9>LN4(KG3GV"*Z8YZCY*-TAJ4`F()W5K1L\$
M@;7M<]X9`W]T*<;?8;RGU3_/\9QG^<9QG(6(3T_S4MUYA'0VC5OC_P`D,IVU
M05.L?[V1_P#>;Q8,K:_W\>S^K&/Z_P"/]?X\",KQ]@7$&M[(%3KKU;H>$M<C
M`-VL*N*V363YE^LNG/1C4^F.BSS2DQ#DB.MA)"DX:4ZG*<9]?X\#&?\`W9AP
M)_\`-9:8_P#NK'_^M^!2G>GVA<&N=+<8RM*Z1T]MJ3`OW0-(GJAJN6:VEMNO
M..:'EK*46UK^FE2=QCP1WX<$<Q:HQS/_`'S/IE",/*P%C9/[=>%($9!=CV1=
MJZRYEQ#?[71V[$.N/CMFO&#)&%H)1'SQXX#CA&,HQAE'MRK./=C'@:R]O_>Y
M;]B="B<X<'ZBF-JGW]E-'UQ<9G6U^%-)M#A>LK!:MPQ\?8D56*F*%K?5]O//
M1`K3B1EGPGB2B8L81#$F&\'E;E6C\LU*U`0<O:KUL+:5RE-G;JV_L:8$LVR=
MI[$G?9^9+66Q"0U?&5#P0J$1T%%B!`Q<'$#LA@BCL-X;\"T/@/`>`\!X#P'@
M/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\
M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X'E+@H1><J7#Q2\JQG"LKCQ%9S
MA7KZXSG+.<YQGU_GP,:(U?K,IXLDK7=%)(/$D0#GR*C`//&@R^6LRP9;KD>I
M9(DGEA'Y#:\J0][$^_"O3'@8XSS]H4<M9X^D=1,'.R2IEPUG6U-:+<F%D)+5
M*K)1"I>7)**0ES+^5?+ES&%>[UQZ^!+O@/`>`\!X#P'@8Q=:33MDU"RZ_P!A
M56O7BBW.$D:U;J=;(<"P5BSUZ8%<"E8.?@Y1@J-EHF2#>6T^.^VMIUM64J3G
M&?3P*DUGZT/KJIL7,P=5X2Y"@8:PRL5.3<3'<Z:E8CI.7@_9^GD"@L5/([A,
M8I'N95[?]M:E*Q_4M6<AX+GU3_6,\*L%WZ]>+%B.,LCN#JYETYEI;`YQDFPT
MM/\`9_\`4VU(R#[R<9_C#CJE?ZY\#..>?KZXBY+MLW>^9>6M*Z*M]D@B:Q/S
M^L*-#U(^7KQ<J%./0T@N*8'03')E8YAYMI2<I94WC#?M3G.,A<#XV_\`]6C_
M`.I3_P#2\".EZ;U"[<E;%<U5K=S8*W</KO:Z/6%W);^`E1N'E6=47F;4[B.7
MECW9?]?ASE'_`$Y]/`S5N%AF5Y<:B8QIS.%8RML`5"\X7GU7C*DM85Z*SC^?
M^?@>2Y1J4[:HB].U&M.76OPL_7(*W+@XQ5EAJ_:S8*2L\'%3>1LR4?$V*0K$
M:^<.TXAHIX`=;J5*9;RD,I\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P
M'@/`>!\PGV]:8VANKMJD65G24Y]B'.6D.>8T79?#&D>PY/GK?FI;W?-A21:>
MB&];5R=JQNX8VYTJ,8A00#Y!EE*8TS\;*'%.96&MRP7NNM_77):8T]8?L@D:
M_7/M[Y5UK+<6;;)MND.O-`:WVRL.97Q]2-E%[78G+-"6B/DGC8&;,LH0J1Y)
MA*W4-C_.L+5Z4/KO,L9TOTMI;Z^/N0TML_G3C+I#<M/L7=^\]G7O0DW<ZC0C
M5AZ__L\O?VV`;7-R1!"7P%JCL9RR(^ZA33C:%9"7^9OJ$UGU+PGJWLS<77G3
MC?=6_-0UGI]_MH/?URB1M,W^[1`VSHA=/U=6]@!:1`UCK']@F/7#_"@0B.'?
M3EX7+B<CADY47>/LT[P&XDV5V-=+;R'RIQ)SON:]6/E^[8TN_P!R[NVXNT5T
MC9<OL#3]C>D0].QO]N.F,P=?E606YK*4*??;:]/`K'V4%NKZN3>[^9>>>NM[
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M:SE:!5K[1C-B@P[2`WKW#0D^V/)G96XZ:3E7RJ4ZVXM8:9]]=1;5F>Z>_P"H
MV3M#[DM<TW2O2L/2M7U/A/ET'?>HH6ND:7TY<)Z#F[*C3VQ#8RTIML])Y3''
MEH'9#*%<9:RTIQ"@V>\7;5WW$?:K)\N7#H3=NW-30?U-\_[S%C-UQ5>@K>?M
M&V;HL-?DKW<82'C!<0M],K++(DH(-D8)HI"TX'QE",X#.NU]M]&]$?8-JKZO
M.<N@K+R5%+YCM/7_`$3O77M9J5CVX70@]B0VJ*9K'5YUOQ,P=,+L<[*&$R,N
MY&/'")$'R-ZI4YA85XO.WNG?J%ZOUAK[872FZ.WN/>C]$]36VM(Z$>K%KZ"T
M[MKE35%CWJ<#'WJBT>F_W10K]4!%B//3;2D@$MM_]P,VVE)(=G2G-_V:]K\I
M4GML/[7]M:.WKT;JZ+WKJK2FK-9:6.Y+U)%;!@H:YZVU--5JT:_L.PKXQ6X]
MQD";G'IM$@8^X^MM&4IRD@-=ROMMZ3Z`V+]=X^U.VF/KKUYMSBCH*^]&V[7-
M.U5L2`?Z"YWZ`LFD+#^B*O&O]EBPT'+F50LU2%O-@BB_[:"7'&\9?#8W]/?7
M/0W1O674=<K'7%F^PWZ_*=K6E/T;K2Y:%@=%OP?1SMA)$LVE*>97ZI1XS;L2
M)3<?LY.7%CD#1[^1&4^WY\.$!BWV0=H[&U9]CA.@9S[4J7]9&F&>0]9[9J<S
M>]7Z1V7&;,V7,;:VA5K1&BIV>.!*12HRL0(2UMCENM.J]J\X;RGVNA!.@OLN
M[#LU#,0+U;6>EM=0GW$\:\K:T[3K6A*U0*GT9HO<`T*5N>H!0HS2Z(@:L6<D
MNOL3T2^ES\GX\,DO.K8;<#ZAMS;;H^@]1[.W?LV7;@=>:BH=KV/=IAS&5XCJ
MQ380V?FB4-X_J>>0``OXVT_U..9PG'\YQX&C?ZE.Z>TMM;NOVE^_Y&LPEAZ'
MT!KCNKAV)BHNH0<K&\W[&FK5&36L9Q4+"Q+-EV7J)EVNN3"U(+<2B22ZOVMJ
M3E85Y^L#[<NJMA4#86IN[#ZR%O?:&C=U=1\%[?B:S!U^L[UU1KUZ[5^QT4J*
MAXR,JKFX=.S=-3)246.U\Q,'((?<;]C"GG@WC_7'N78W1/`_'6^=O&"2.S]P
M\Y:EV/>Y`"#8K84A9K=38J:E#A8(5:Q(Q@P@S+B6V?:SC"O5M*$92C`72\!X
M#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@03TINM'/6GY[:JX%BQXB)NA0*8XV
MP@5.+:=ONP*O069B;LLFT^%"P%>=LV#SGUH6K`@SF$)4YE*<A\LFC?M'Z%UC
MT5NB_P!WN]^W]%Q8%XE;O0BKH8#KBT1^O)^CZV?K/.VJR]?!F:JMHUOMC<M'
M.ONN-2\>Z1"2[F)\/+N`^CF6[YTA!R<O$R5?WFT7#OR`[JA]#[0D`SG(V<Q7
M2&X:1CJZ7'S!/[-2<X''=<)P*M):FTBK2]D.7'>VA_R10W`-Q,E2*"\Q"'='
M;10/,.A1I$R0)'27]LYBGC6H<?\`*<94^AQAAUE;V&\/L^\-4W7&MN4NI^B(
M7K'0?37:?)'7%)U_%ZO3O#G74]M/J-]UVY8"#8N$V/2+QK:6H.WX"**LY&0R
M4NX;"64T\XZI`S.&P@_/(?UUQW--SUQ+](?8P3;KUU/K#JC9'94Q$VR9Z6DN
M@=9@(@]?3!EQE--3$7`1=7Q!K;C@T0J&H]8[V&7$X'>^(),TYKG4VK]MU38$
MW]GGVS[UU_6S9^LW[2'5$1*WO2VX`;W7I^B!U6<BL:'HKY+"399LX=Q#KS!"
M\A9Q[FRF,O!4L3D;G2%H%KYYTY]JOV/ZE^N:^!62O3?'$7S!<K.:!6]B3!;M
M@UCJG<]HY[F-G:\UM*C6X9M,&T,2:B.((<?(6T4MU`6*WQI;Z^Y5/.^U.2.A
M^A>'^A>.]/UO0&DMM:ZYRW=?ZC(ZNKZ92-J&O]YZWD=6GP&[M>QD^"\X\ZDM
MA_\`)D<N_G864.[@(U$YMXQM55[`8Z;[XZBWQUAWMHT[GNZ=$WGE/9U3B=8Z
MFF$NST93](:N8TZB!U=1<_G$EY'<DE,&_&XZZM+K65X#W/L&UO\`4S]@W&>@
MN:-D]-6"D6+F,+7"=5='5_F;9[<K7<4ZOU*#M0`L/(ZT9@FJ_?*Z$,X?%C%-
MC!E#B.KSE(7Q+".KY8M3PW0_2&^^;?O,V]R=CI>4IMKN.MO_``%,N5.#M&N]
M3U33L7+F2&T-5KFPB7:A315Y9:?CE.EX^5.%H2AO`;"_K3MGUP<!Z'-U72NP
M3]T7?9%]+W)N3=VS8^W/W_<VU-JR(\4[=)-UVM8=R!-G`-#Q[6'24I0I*\O.
MK(R\Z&0\L]`<3<^[F[@VS)]WZBMT1U=T0%NB+AL,/UL.E?C:CUAK%5?S-ON$
M1]WPR+K\5UJ0$0.EMPIX5W#KS7OP%2.DI:-N_>TIVQQQ]P7+O.L_>^::ESE,
M4>_\WL[T3(UO76Q[#=43H4P9LREY#_93EZ1D92!D-%B_UM*(;3AU`>+M6LQ&
MXG.8M\-_<[S/3?LWYMD-D5FN;[JE"AZMJ#;FHMAV6*_8Z)W5SD_L]QQX%)"8
MY"?2524+*H^9`ZG\(4R$I:%U?3MS;KENI_L.^T'E_I:XUS2.V]!Z@UCH1=5T
MWI/4]`W:R+";:MR8"R76Y6JY7ZXPX8T>X:>ZL,,-C#?QOY0AQL(HIW+?;O+V
ML[3PMQ1]P'$];Y=!<M%9U(;OJH#7CKGG&C6J/R2+KVIVBM[3KM-N*ZH3/N/1
M1LO%I-#:6-[<):PTR@)DYFX+Y3Y"Z/XCVGK[LS1)FH^..$]J\LR52EK93%VC
M8ETNUP*VGL;<TM(B65^'B?WDF)*2,J/AI3B7<J3\V6T9QD)WT#SE0N/N]][;
MYY\ZVYWJ_'74(0EJWURU/6Z'2[3NCAQC6AMK:5D0+,Q7:@-=1'`6IJ(($PV5
MA2W6U_[0C;038YJ'1]D^P/8W6-TW-S)>=>7+DS5NA8S6<Z;1YRPQ-FH>U]C7
MQ^X$GRAY\>3$28=O_%8;0AMUIX5><^_&<>P/"[[U>!O70VG*1QSNOCS5&Q=#
M](:;Z!UJG99PAFH(\O4DA)VI,054];34.>L62Q(X6MH=P9.1W'',+;5E#F`I
M5OG1'V2]KZ+NO*_7/:OUF5_5>T;EIMG8Q/,\?MZGWJ2TI#6QFZ;9I:';QLNS
ML/E[#K<2$"-[5!L*`?,P^M3;J?0/)N'U"\#Z1W9RITO]<EOYWYUWCSIO^%M]
ML_O_`']LN[TVZ:"EJ;;(#9FG(N%F=I6H2D.RM=LS1L0X&$T($X(TM3:F$^S(
M>+>_JMJ6T?J0U/Q1-].Z)IG9G,;VPKKHCHO65^?`#UWLB=V#;+*4V-*%R3%Y
MB:M=:I940UD8:]B,9=]Z6GFF&F5AN'X,A(CG#B?DW0&Q-K:FFKQIO0NI]266
M5J=UAC*O(V2DU"*JYC=<,(1#D&@?E1JFQ\K%9><2G&5(PKUQX%NF-B:_*RE(
MUZIQ"E.K82EBS0CN5/MN*96RG#9RLY=0ZG*<I_UPK&<?Z^!W'+G3VEK;=ME:
M;6WC"G$.3L6A:$J:??3E:5%8RG&61G%X]?\`WEM6?]$Y]`[*;-6UX1E%A@UX
M=5A#>4RP"L.+SZ9PA&<$9PM6<*Q_&/Y_GP/18/!*;0\,:(0TYA&4.L$LO-KP
MXI*6\H6VM258<4O&$^F?YSG'I_KX';\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P,:GKG3ZL7!@6>UUJN'6
M:11$5L*>G8N(+L,LZI"&HN#&D"AWI:1<4ZG"6!TN.9RK'HG^<>!DO@/`>`\!
MX#P'@/`Z$I%QDY&R$--1P$Q#RP9,=*14H(/(1LE'FLK',`D`2VWA3`RQW%(=
M:<0I#B%92K&<9SCP->6A_J[YJY]W0?N>KO7FROCI-_Q[KR]R%5G]<:<<*>@F
M@B=9Q+%/CIJ-,J]>K$=!P;YTA(/0L&(D,1;3>5>X-CG@/`>!^<H1E25Y0G*T
M_P`I5E.,J3_"D_TJSCUQ_2M6/_:9S_S\#^YQC./3.,9QZ>GIG&/3TS_&<>G^
MGIG'@/:G&<JQC'NSZ>N?3'KGT_C'KG_7/ICP/RAMMM.$-H0A.,83A*$X2G"4
MI2A.,83C&,82A.,8_P"6,8QX'0+AH<]W#YT5&FOX'?$P\6"*0[@4E+B"1L./
M-+7@<A#JL+1Z^U>%9QG&?7/@`X6'CW?G`B8P%_\`%9!^8,`49W\(9#;8XGR,
MM(7^*PVTE*&_7V)PG&,8QC&/`_3T3%$"/@$1D>^"4\LDD)X,9T0@ATG\QQ]\
M9;:F7GG#/]U2E)RK+G]6<^[^?`[(PPP8[`8@[`H@K+0XHHS3;`XP["$M,,,,
M-)2TRRRVC"4)3C"4IQC&,>F/`Z9$)#%@,Q145'$1@[X!+$<Z$.L%DB+-'DHU
MYH53>6&W0)`1I]G.$XRVZVE2?3.,9\#Q;%0:-;GHTFU4ZL6,J&)9-ARIN"C)
M,J),&;+9'+C"3!GGX\D=H]]*'&E(6A+R\8SCW*]0\1G3>H1TMI8U5K=E++J'
MVDM4>L-X:?;]OL>;PF+Q['D>W'HK']6/3_7P,1,Y;YGD)1,V=SSI`N926&?B
M6?U51G)/\V.$D0(\K)RH+)2GP0Y<IME659RTDES"?3WJ]0X,\I\QY`L\9GGO
M2^0;I($2]O8SK.G^EFERV@6"I>=7^H^64E2&8P9*R7E+?4D=K&5?[:/0/RUR
MES(/@3`O/VG`D@82D%`&NJH`V$VAA8J6!6PXMA`XV&'G4_$C&&_]]W/IZO.Y
M6'48Y%Y<']<-<^:@PC+0C2F54&N.C*P",P&$XL9T!8ZR!!`QVFG<IRZAL9A.
M%8PPSA`?F.Y"Y=B!OQ8S06J@6<F$R"LCTV';><+-"5'&N.DX&_)>28"M33J%
M+RAQ"LX5C/KGP.!KCCE(<@<P/G;3T<>&MEP*1BJ#78J3"='PZEET*2C@13A'
M6VR'$84VXE7QNK1Z^U:\9#]L<><K#23,TQSUJ)N8'S:LLRR:+`9DV\7C)O\`
M=Z$GY"R5\5CQ)$)+1[_8\A]Q.<>U:L9#QPN'^1(X/\"/YVU4$-D9\17XM5!8
M?<:,=_(D5/&-)28\3+$8PX:\MQ3QKF,*?4XK&,^!UW>%..B'LO$\X:G+]Q`Q
MBQBZH"6`X<%*HG0Y!Z,)2['/20LVVDMLA367T$X^7"L+_GP.@Y]?G#SOXV%\
MG:"]@GID=A&L:JV,A>(QR'^7(K<:@9Q_(#F<9<4G*\N>CN<_*E*\!XC?UM\#
M#RT9.B<AZ#`EX;X?UAT;KJ`C'@\#%NGCX:P`*,CVLG/+>3C.,X2ZK*L?SGU\
M#])^N'A5N*(A6>7-2,1Y+3[*VF:VVVZVA]EP?/XQ27<%"J89>=2SEM:<L8?>
M^/V_,[[P\TCZS>$BEG//\UZ]=*DWW23CG1I!Z0(?>CAXY3BCWY!PM"T8#8(1
ME*TY0:R@A.</)POP/35]='%26FD!:`J,,\-$!P8)\"588.3CH^,3(IB4@2,9
M,BEBD0ZI5]8CR58=&<7A3:DJ2G.`Z0_UN<7!.!K`TL(`@)F10R,'<-@,BJ*D
MQA`WI<AC%JRDF;9#%RRR8Y[GVVWGL85_N*]0QO'U=\<L/I(BZ+:X-;!A)`3<
M/M'8P@@(1KXQ9D`T`JRN@$UXHQAQUP0EI]"E$.X_Z?8E`>H-];G,0Y"2E"[8
M>?%C*U%0JD[TVY'XK(]44([$/5A$-;XQ$&<V0`RM3[&$N92TAK&4L(0TD/R/
M]<NAV3Y,YVX]*EMRYTZ69&O=/;N9CELS;XY*(SXP;F&2N-@WQ&51Z%NK6/EE
MOU6OV)]`RU?#^LDDA/@[)Z<BVA51'SB!=-[G6B48@R#BX\&3-/MILN]'))-R
MI8Z"6VG4HPVI.6E.H<#M0W%6M8D*.%(V5U)/%`HEL%2TYU?T"_(33LP.ZT^_
M+(!V!'QBOPR'UD!-#CCCQ[^<?C-M(0A"0.\7T-8J@F]L=1CCXA_U`ZFNE]NJ
M.&6XE6"YG,P197YH^>-RXO*R3""5(RK'Q8;]C7QAX@_#=5&<2ZC?_7#KB)8&
M31DCH.UO-I8%*?)*ADLY;2RF)E<NI2^G"?FPEI'Q.-YRYE8<.>'HS"D.M=-=
M@_-A\5U]TW>!4M@IJ.2M$:$Z-*P1@30HS;KB7<LM-/FY7\A3KSR&G6P](GC$
M(KW^[I3K0;"S"RO:!N)(B$,F)']\:WC^W'%?AC.B-*'=5E1S*<*:_)RRZ\VX
M'!CBUG*,8<Z=ZW6YB/=`]V-NCL-J4HN1(&E%#BUAAE$P(S)*:RMK#0Y/Q-+)
M9>6TA6`]9SD(!+3C8>^^F&<JD"#VG2MT6V1('P6Y(9?CD&$&8.>B\,2K[;+;
MSKJQL(&RRM"A!\H#'#.)GS&Y)C/6/8PXYPH@0J`MVR`+L.T`*H05Z.-$C635
MR#R%J6402X0X4]GWKSZI1[`"<3EB$EDYZ^[5+P>IILP8W=R71L@#S<9.#B!-
MM5EE4.\VY&8%44&H<L@%UUA]QU+KGN`OBV:6E_\`_#([-0Z^U&,I>;VS$8_#
MQ%.GNH?"853UB_ER>7Q<'*(;):?2"E*&VDOEX(#S2.&9-YI3;/9O;@CGY4\8
M@EK=V''T+ERW2P!<H(KKP3D=6L.89":RS[UL(PDE9"\J6H,>_P#`R^M/D*&[
M][<RP1-N3?\`W^Q*L86&HPUI9\6`ZS3`H]$*W&,X8"&?$(2(\I;ROF]V&TAW
M7N']E9+2L+O;L&/"<'-R6VFUT^0D'I,WW+_/'*F*C(QH`XKGMPR(T#@=MOW)
MQCW92M`<">(]T@>\F%^Q[LQ,@XZ`E>;(GGVR1*0`$2#/X#,5_A"+RTHQB0]'
MROGR8ZX.RYEWW)5E89(!RGT$(*\'G[!.B&F4F'ICGQ*/SX7(!P>1?A@HXDVW
M:IM^963BRE+?)D'TY=D,N>Q:$-H92V'&KE[J/-</CL?8INS^XEQ;;<1/9TWS
M1^"'.H3.9R?)PJ-6((EH=UV1$]P39PC_`,8"4X+QEUQ>0YH;FKJF/DPR)'[!
M-K38#4?71#Q"=,\\#9->"BU#64P?(>NFLQYLY+LM%C.94^V"TM\=3)'O:>9#
MJ0_-G7\7$AM&?85>;!.8F&S9$Z1T#HH2)<B\F+>=B8J*CZ\V<"E(ZDM)<)./
M<RA'IZI6O+J0]0'0W8H+$R/CNLLSXA9N-IQ<QSGJR0,99DDMD1LY?51Y,"+:
M;1!'J=0SF*:KL8X#AMIT);R5DN!Z2]0=GLMC-"]DU`M/ZW(A[LIS#7<&.'O-
MF+)E8]Z,V*"((IDG(Z`F'1R&QV,._D9,<4A:`R]K7?4@X2$YZ2J,C(N3@KC[
MI&BHT($>M*:2V<$*,+=G2'IQMS*G6"G'L#Y]$H6/Z>Y60\;.KNP?E7G_`,L:
M&IEV->&QC',H#3@LGEH-0\JVK.V7TDCMDC.I6(K"/<R3GT>2MI"LAU!-9]I)
M1C,AU-K)Y>+`LE6`.<6Q$JJOX<NAF'0HG9Y^6I])K@"UR.<.#K2R_C`2/E1A
MH.9ZD=IMO@8"WMIYUADEDH]<GJ*16LP=;*L&P[8X%I"P/AMU[/XIN'LJ;RRV
MMT=["G&LA^AJ?VFR:C+NX]/%Q_[5WY?R->26"LP>`Y]#*6$B%B-M3*CW8QU2
MUJ<82RR0UAM2EH>2'6Q3.YE/E*_SIH%H8@.<;'9SI*TDOQ\DIMK%=-01C9@:
M#8Q+B5_EA+:0]CWIR@Q6$92X'&Y4NZ_BS[-R<]9<$2RXVWC4MN9S-J90C#P9
M!:[P6BNX.7E2OR6QI'\?&,8PP[_.?`_CE0[I;<=R+N30CZ%"96U^PU=9?:U(
MML!*;86R%91G'HXDQLCY%X>0\V.ZA*<9<1EU8?AV`[V;"(0-L/F@F06TG`KY
M5(OHX8K@L9(-H4^(Q-./'*EI9P5Q[*7ATCLM.);2K+B<MAXZ:]]C0S#HV-F\
MARQ2DLMLS3NK]K08K27'(<D@ARKL[!G'R"@\,2`J,8F&FB$%C$92TH1Y@X,F
MS%=Y--1C+-TY3)7AB33-'FT#:S*W2W4@_JGHB/$OWQBB"+R5\K3[[[CJ?A]'
M4YPYE0>#(1'V-$8?S&7OC&+RHH7(R"]9;KF<,AI(*;-0\XWM&%R^0Z*XRZTK
M"6TMN-*95A>',/MA^!`_L:'17VY*R<;R*F9B039"HFD[CC\RD-A3OZER.%D-
M@EIK;ZVT)_*]SDQEM;F,-I<PC*EAZ4(C["QY`?\`N-_C64BOG$P5B&'W9!R/
MXV5Q"SU,.&D3XN'FVT'MLI4C.%9='<4I.&G6W@^;G[`);KVW;J/5?ZJJ8V=7
MHNPQIVN;+&4-6OHJF#WZ\3%1EM)IGHJ.F;E2;1J.NSTK(24-*JL6#H,1N1=C
M94:.C5!](7")F]#-*%+W>?<9EEJW$,:<L.SXIB#V_9-+IJM276YO;L.W'01<
M=?"[(N82ZT=&QDJD)`WYXZ3/G6L+H^`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`PVZ
M.W\<(0K7XE3E#QWRG)"&MA<K$L2PN8TU(8H%@BAI3,$2F8R,MUYV/D$*&2XA
M+6%J2M(>:QLVMIMN:--)D:O9GAGY")$L`+H<?88QNP/UP8J`L3?SUJ4-,+;9
M=_6M&*E1QS!ED#,_.C&0]BX$W40&.(H\97Y@UN>B/W4=/R1D3\U641[)]<(8
M(&:UBR#B*^4)HE*!'W$?$ZZRE?S("%K1N>U5Z:IC#5?@R#K:B=8'TY,3<%4M
MSR\K!482XR45KIR>M3%$V6="MNJ_8X!-;$&9RI?Y*L#OYP'FN=`SL5:[E#D5
M4*["0C<++A5;7IS[F[HBOR5@CJE*'6+4\\@-<S"UN;_/<=F8.2.8,8#4V,,X
M^G"7`LI'S,5*K?:CSQB7Q$L++%0YA)H:2L.*%4:$Y["P\%(:4IOY$)^1*<Y3
MZX_GP(MD;]>*G;9,"UZ_D96B&2(2*K>:&T[/O1X;E<L$M*L7NHI=780%1LE7
MVPQS(UN0;/?EQ&_QQ_8\OP,^J-UJ5]B7)VEV.'M$0Q*S4"1(0IS!XXLY7)0J
M$GX8M3"U9%E867!>&*'<PEUA]M2%IPK&<>!D_@/`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X'5;&^,LDK\@I?Y+0S7XSCON$8_&R_GY!F?;CXG7_G_P!W/KGW^Q/^
MGIX':\!X&`W#5.KMAR$#+7_6U!O$K5GGB*Q)W"G5VS2%<()PE)#\";-1QI,0
M\^E&,+4.IM2L8QZYSX&?>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P
M'@:-/N;G]LRLKQYH_3NRI=,_M>^[,D+!RY0^AY[D#<?4U0I%.CG3HO573D?'
MNPM*F=82U@"F"H20-C\6<5:AV7?D:QCP-/-EU9?;/]97V%;_`)[M?[.M4[C^
MO^3Z6K=6U!.=-*%L.F;5"T2H[3KNJ]E[2I-YN%?ZP@H%5N`?@[+DJ(,=B)!(
M!`Z2V7%9"U7?,F=Q!ROH'A_4G9G;D;L'MC8#FQ[;T[99?:/5/0?/>J]?U:KV
M"P3]<&U_4)2^@U2W;*'K55&;0M"!G[&4IMQ:/E1@(MZ&W=?NS?JGYO\`L7H'
M7_8',>]:U8^9^4MS:\TEN21UY4*_LFP]5Z\T5O8K8U,L%3CI0S9<:#;I!\)^
M24,@=M\1Q;+C:<96'<Z,T7OW6G=E9XTI?7/WD[MU[3>):GNDV1YIZCT*C="K
M/<.D=OUMV?V5([LS1H:T5\&!BQ(P%,0.R2,T"T@I3WR)5X'TO<AUZ7J?-FHJ
MY/']&2DO$5C(ITAUO/4VS](%.XDY!:7-M3^OCY.F2EF^-:<8=`(=9R-AK&5>
M_"O`^9?[`=[]JU[?G9_0%?WKUU`\_<Z7(&K:RWOQ9L[0^W>5.6VM<4NGRNPX
M'N;C-P)S==\MT!L"?.?M_P`63'QJ>:*4,RVV!C+P6)W1ICI_8_7_`"+5=)_;
M+V-3-9=YZ/ZDWVW)T-_5=MU[2R*_"\_W*IM:@C;+K(FRQ&L)3&RI%V.1,'./
M@`.AAA'#.)RV0&OO=78G>VKC^JKW#]C=U1=\J/V![>Y6Y>K[NC.9[AP=/VY[
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M%OC%Y_&PEI32EK]@?0>_.,Z]UV]9-F6J/4/1Z6Y.;`NSH&(6*4S68/)]KM3D
M8PZ8F)C\H"(+RPA;N&&_Z,*5[?7(1USSU%SMUI2C-C\S[GU[O*AQ\V[6C[;K
M6R`6B"!L0\=&RQ4"6?'..LC3(<=,"O/#+SAYE+Z/>E.58QX&OC:^Q.WNE^U=
MW<O\M]$:QY)UWRMKC5-BV%>9/30>^-K[.V!OB!M,U2XV+KEQ.@:+5M:5`"L*
M6<^T\3+2)CF64*%;3\F0U`[B^U[NF/M&EM(V/HNI\SVZAWOO[2O2^^=?<,7O
MK2I["LW)%NTW%4C9M4TW5ILRZZ\J]SK&QE/2GRE$`Q$LEUA;CC'XZ_`_<U]M
MG;<OS!S]>(GI;6%5@]I]T[;T!2^TH_AK:MPK6\N>*7R\?M^L;E!Y0B[)8]GQ
M#TOLN,,@77(Y[#30P>35#I92YCP)_HG?_;5IH>EM1ZS[&T#O3??8O5LIHG5V
M^+=PQOSG>B:.J.L]"3VY=M2+NEM@'UZQ;8M;@42`U#OYD18;)DJXAY?L!<:R
M'HC_`&P]+:AB]^Z]1NWB7O79$)*\^:]T9>Z(S/\`.V87H/?/00_/.-.=)Z?S
M:MES5*@*S*K=FFK$R>&DL85\+#"BL)4D)TO?1OVD<3[!UW7^IK]RWT1KGH;7
M713</L+46HK1IZ:YSW/IG06P-\Q#1U6L>T+DG<NL;#!T(\=*6UQTTDD9'O\`
M:AS/J'@<E_:GO7>NN>+*/L:&I^LNPG^G=4::[1U43&BF-RNN-F\\[8W/0=QZ
MBPJ:`PU0]PP%8BIN,/%_:)C\MR$6ZE3HSCR0F;[4>\>A>1=DZ/J]"GM8Z'TK
M=*9L&S[#ZLW#SKOOIS7U8NM;F*F#2]23=7Y^GZ[,:VQ=8Z5D34V*:>S'O)`4
M*/C!&%*P%:Y+LS[=MFZ$T?T[H[8_U416M]J[#UEHI8;$?N?H2$G-B77HA_0#
MNQ-=[/UOMRM04IK:524#/BQ18;4_',Y)CS?0MC/J&=]C_8[V?PA3>?*7?H_F
MC?/1D+#;&ZF[9:UI#7V@T:I\&:DM4?`7NYZEKELMTW9'MF_%;HYN+%)D)')I
MD;(92(MKVX;#/.Y>EOLSU_L[G*5Y&V!P(5H'L79NL-*Z+1NC6'04]L")L]VU
M/>-LF7FU3E%V-"5J7JKL5KLI`8@X83_QG-*6[E;*DO!`5[^R7O>A;TZ-T+;=
MW_4+IZ=YNJ_-"+5-]$VC>>NPYRV;:T3&7N[3%3'%M1;LG2HVXL22@,O)'(:`
MPR.2KY<Y(R&S3LOL>T\:<L:8WYL-[5,<9+;;Y7U[O"5*=M$CK>MP>X+U4Z5M
M*SU*8CGF#&8RJ-SI4A&FR2OQ,B"XR1A2EX3D-<?0_P!UFM+I+[\3QY)\J=<Z
MPYZYPT=OY5H*GC;+'Q.X[=U[#:;#BSG(PE08S=.JS3T^*^PVR6)(I#<R0VR\
MA7@3*9UWUV_>^F$<C4;F2)Y=YEODMH-%O['Z$L5,?V'ON@C-2=[HNL1XVFFR
M=,AES5C3#MRUKG)`<DH1+H`C(*?5X/$L/VM\Z3NX3^?OL!&TAR/J:_<3Z9Z(
MK6=X[RIT1=#+;M2Z;#U_L#7</;JK9WJA+8HSU0:6/-5N7R0^T8V0CXT9S\85
MNTY]HCUMJHNZ]_:SU7,:!K_'W0W2>A[37K!:M@7G9%IY=[-LVJR(2D['L`&9
M])TK2Q*3)@13^3)$@V=;P8YZ,+6^$H:"[ALG2VQN'J);M4@:KZ2N%DZ`B=]A
MKV-,P.W.;9[CT.P4C:.;S;XFJ0&ON@A[)8+)5@HR$)B,13PDT65E*L!8>2$A
M<^_:WO\`W7K[HN,HO,+>SMQ:RUFG?/,D:NYM4USKKF0QJ:BM;;K)KO\`;QD_
MKR8W59==60(6'CH^:_4R;D8P0E#!K!+H>_H?NNK=P;SU8'P[JBP1!A>JS-C=
MD[BG9Z0H$?RU8;LZJ%C-&W_4K]<EH#;_`%*=;:,6T=&2+(3M>BHE9:I!O!PS
M;X3ETY]HE6Y@Z>YMY1L^NE6"]]#;Q@:`19X2U$.4#4>KK+#V24KFQ-K6!NJ$
MXJ-RM[]2DAH2L%(;;DT1AQ:9-L41Y:0Q2@_:3;YKMV@<C[(Y<>U>!NBT;>K&
MIYI[?.L[?N88+45:LEM;V-N+GFN(>G-9:FVK"58M=6FV)>90\\A#!S03S[2,
MAN!\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!
MX#P'@/`>`\!X#P'@/`>!7#I?D'F/L>HQ%$ZATAK_`';5J]-MV6NQUYA&Y%VN
MV!H=T1,Q7I-I0\M!2.1GU-J=$?94M&?16<XQCT#!ZY]>_%-/YJN?'M4YNUE6
MN:=C9E'+[J6"B'8JOW$J:(!)E)*R%A%,SDQ,F.Q@ON-?+67A`S*,.80TA*0F
M*%Y]U!7MOKWU$TT<;;*M0U_0S=N7)S93XNI:S8I"V1-.!CBY-^'!$389)9+[
M[(Z"RUH:P^ZXEEK"`A.:^O3C^?K6ZZ;):>"75.B=]U7I[<=>'M%U"B;GO>FV
M:G7"(V(\()8V6XF6?L=`B"3FP/Q19%82<%-.I4O"@B_K+ZE^%>WMM1.\NC]7
M6VW;1@J('K*(M5;W?O'5Y(5$!FY2R,5M`VK=BTT)T!4],DEN8<;6IQY>%*SG
MV(]H6SYUYWU3RIJ"J:)TE#3-?UI2LS.:[$S]SN>P987,_.R5DE/RK;L&?L]M
ME/FEY=]:/RC7OA0K#3?M:0A"0IMN_P"GW@7H3;]KW9L34<\BV[*;CV=SP]+V
MOM;7FN]]#Q9$.2&QO'65)N,%1-H(]U?"01F4`?6<R*TT4IYMMM"0M7+<LZEE
M-Q\];N:#GH2T<PT/9>M=3P==GS(>B1U/VI%TN&L47*4X;TB93`0%`C$1RU)2
MH+X<^WUQG&,!![7UQ<X2>A>N^;+I`6&ZZL[0VQN#;NX(NY6URX&$VS<)<9)R
MTO6"I.%&:J*Z[+PX9<$.TT3^F*!'<:>6IM'M"J$I]&'/1MCEK7$=9?9E2)NQ
M15`CK65K_N_<5.Q;S=;ZXJ6J:_9[4B&*'Q.VUZG4B.9,D'_<^2MGWJSCU],!
MD>QOI?TY?]B6[:,5U[]C^I;7L"#UM#WMS3'8MRU]'W(K56MJYJRJV:Q@Q\4\
MF2M:JU5AEFG*5APPK+CCG]*_9@+LR'(5$E]X\O=!3%TVE,7_`)1U?L_5-(=E
MK0#(`7"&VY"T6&N4YLM!$&LZR6PS_'D<5@UA\+/Y:5K4E25Y1X%J"A13A203
MAAS`C!WA3`RF6R!2A2&U,D#$CO)6T^.^TO*5H5C*5)SG&<9QGP/%K-2JE+C<
MP].K->J<0HETQ45686-@HW);Z6T/%9!BQA1LDO(91A2_;[E83C&<_P`8\"@'
M3WUD:AZ-W7&=+5O;G2/+'10])SK&Q;EY7VHK6]IV#K1I]XV,H]_CI>$ME3LD
M3`2A"RXY]<<@\-]><MD8QA&$AVM&?65H7G78'.6P-967;`QG..MM\Z_CHZQ7
M%JTM;.E.D[94+[M[:&V)68BB+#9=EVR[T]J5(,8+#$480\K`V$Y0E`54N?T;
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MUA!S$;&T+7V#3I?Y&+!,6`R6EC?C%=..?]5H]J&TH#HZ^^LJR:_T[P]I47I:
M;F:[PCU*SO#6\O*T-K^X+/JF.@-EU&MZ(LI8UO9''%J]/VD7&#RP[?L<&C04
MY!0A#C:PPW>GUX]H2/2?1._>2.[:#H"*Z=,U6?LW76Q.1JAOL,E_5&I@]4Q8
M@LY8K[!YQ"S`(WYA8WX:5?D(;PEWV8<2Z%D-[<F[NZ#YLYJU5>]XU(K;FJ-T
M\K;FVULX36Q<95]IRF@;[7+_`&X*'UY&6T02JCW^4@/09E\F1$C,.85\+RFV
M\I"NG:GU<W/IS8FUK/K[<U+T_3K_`,I:VT!#49G4X\@-!7>A=85GI)S9<C(1
M$[7R)8(V/KV8AN+:_%6TZ0LG!.%9]O@8?O7ZH]RV/9>[9#1W1&C\<^]0[4#W
M7NOFGL3D.J==:YK6WFXN+@I+9VCXV9NU'BZI.3$?&MDD!R@DJ*Y)L((RO_<>
M2H)5Y>^L&-YZW4#.V68USNG3U7XMT+S!30KSKB`_R$+9-.7W;%L.MDBP-%?V
M,'"S0&S\B!!Q(T<W&B@L")96TVASP*K6+Z;-J3G,?*6G#=NTU$SI'J3>&U]N
M0]9BR(JF[2Y^W'T#<>A9'159S,PDLY7#F;(-5&0R7AL1\;@,O#3.6?A;R&'[
M9^OJ]6[>7=EPI6Y=?:7W?]@NM=;4W1VC=SJ=D?\`!QL?!UHWLW8]"=KC4PW<
M+R5%M`2L5*5P[(`4W[LFK8<4A8X3Q=_J,B]#[EYVZ+X1F+W3Y?4=1V!HK;^N
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M`35E""N:`RRJTZ21+QD>#E+"'&E>X-_+>TZ]%V&I42ZEL5>_7(Z6AZU$$,R>
M(NVS%?K;MNF1Z?.D@#1\SEBM"$G88]Z"\#AE9RU_VI'QA)_@/`>`\!X#P'@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>!@ERVAKG7KT6+>+Q5ZL=.IDE0
M,9,S((4O/?IP\R$LF"B''L24RN-!Q\SZ16G5--_U*QC&?7P(ME>M>?8.:Q7Y
MF_*BI5<V-6QV)"I7@1@Z?,-5&BP\8>_6D1\K(O22<C8:&==7^3_M>GR?T^!.
M-:LD+;X")L]=-_80<X$Q(QAGXY0BGQ2$^YM3@AS`IPCV/]%M/-MNMJQE*TI5
MC.,![G@/`>`\!X#P'@1S;]O:PH)00%QO=9@)&2,7'Q\8;*#_`+4X]L%N3<#%
MC&5.GODHC'4DY0EO*L#Y^3./9_5X&`SO5O.];?9%EMJUIHMXK\'\07)\F6P;
M^C59<!&"Q@1A`)BX3&"$M/)0XI*DXPG*E)QD(Q$^Q/B<W;$;H<?HFAKW9,PC
MUBB=2Y<ET;%DH9A@TQPP*GKBTSQ.<1T>Z7\26,OY#3\_L^+.%Y"6!>A=?!Q6
M";!*S/YC`[Y1JXG66UG!/A00$AM0S#E1?-6O#4J-A2/12\JRO.,>UM?L#E=Z
M4TXP?$13]CF6)*>^+]."_0-B,E'_`"LX(Q\##E42YG#;.?<YZXQ\7_O?MSX'
M8#Z*T^>9!1XEI,=-LQLV!`#_`-HW5MR6)KBF$S>`L.UU&'F8[)*/D=Q_M>F<
MYPK.,9]`_@O1NES7V!1+JT^^2>]%#-MP=ESDB5'+G0'XIC/Z;VO2C9E7D6\C
M)SE_W`O8]O\`MJ]`[DQO_45?7AN=N#,0M4B%$-HD8>PAK=EI$!Z5#BV4OQ*%
M/2+T6.LGX$>KJ1T9<4G",>[P,.-[#YAC8Z1EY'=='CXF(,_7RLH=(.AQL<;A
MHA]0QIQ`[8HSK;0CJEX6O'LPVKW>GIGP.E`]L<B6@)4E7NDM,RX",84LP*_5
MYT=*,DB!*=4[@W",,-EG--K<_P"AM:\85G&?7P.FONKBUMKYW>K>>VFL./,N
M*=VY1VO@?&,+CB!BDN325"%CGQ[[*VG,(<0ZRM.4XRG.,!ZIO9_(D;^1B2Z>
MT%'+#:">+:/VU1@GA428N#X[!+),XTZPX>"K#[*%IPMUE27$XRA6,Y#(D=0\
MTND%B(Z%T@HH"03$FCXVM1?F%E%OE"HCGV\SN%-&N%`OM):SZ+4ZPZC&/<VO
M"0[(O2W.1S+)(6_M*%CD$K#8>&VI1GFGC&LQR71&EMSJDK*:5+B84WC^M.2F
ML9Q_N(]0](7?NB3GC1PMU:E,(C6L/R+`NQZ<0\`PKW^CQK34RM8K6?B5Z*<P
MG'].?^6?`]1&X=2.-*?;VEKE;*(XB86\B[UE32(@-&'2Y13B9/*$QPK:L*<?
MSGXD)SZY5C'@>IG8VO4N*95>Z:EY+HS"FLV>$PXE\W+*0V5(R=[L.EJ);PTG
MT]7,N)]OK[L>H=UBYT\K*L#6NM$92,Z8K#$[%O92(Q\?SE*PV4K.!F?F1[U_
M]*?=CUS_`#CP/1Q-PJF\.IEXM32BE@I<P>)EM1S9"@W`\+P[[<E-EHRTIOU]
M^',93G'N_CP.W^8)C_[:&_Z/E_\`;[7_`+:]?;\G_5_T>[^/7_3U\#DP^QGV
MXP\UG*L^U.,.(S[L^F%>B?Y_G/IGU_\`:>!R^N/7T]?Y_P"7_'P'@/`>`\!X
M#P'@/`>`\!X#P'K_`,/^/^OI_P"U]?3_`.#Z>!XL]7(&TQ4K!V*(CYJ(FXF1
M@I>/D16B1I"&EQEAR<82AQ.?D#/%<4AU'_2M.?3/@0Z#2MF:ZG0LT2Q-W/7!
M\Q!#2="O)V6Y37U4AZ5)PBD:OM`X#ATP0?80X@A\*POOIPU^<MDQM;C3/@9$
M+"Z_VR'&71RKD`6*->D68N=EJP95]@5"8Q&2U:/5'ES,6'-1QH@4N6PV\C"A
MW&W<J;RXVK"LA&-AJ>Q-?4R7P+(6"]M1\)+DMV*A05:AMJ+D\TPB"?L$Q2D#
ML:TVU8?:(PZ*(Y&"M+)0TA(JTMH3D*[0]HL=&E[M8:5^!%`2<Y?Y!V\5$B9G
M>>EW>)T]#R2">H-;2C&=@<ZGNR##3J\5UU8*DBM.&OMDGX8("T[]_I]G"AM:
M;V@H.`E[Y^GJD:%)&-26O-HV65H(]LL$7JRQE(!.L,>$TJ0%;2<'%212`7EI
M%^/^<AS1-"V7JZ5B0]=V`>Y:M=DZ5"O:]OTB;^]US3XFO%5J3+H%]4W)2MG^
M-T2)-5&V'\@AW+<@M,G\A###89MKG<%#VBJ:#K$LMNQU@A0MMI,X*]!7FI/9
MD96+&59*G(I9F(L.4*A"L@%K;R'(LLJ=%=>:_K\"3O`>`\!X#P'@/`>`\!X#
MP'@/`>`\!X#P'@/`>`\!X#P'@/`U[6+6FQMCRF_W*K":E?G+5NZB4AW8MCI*
M`+5!:9K;6OBK_4Y)!46I_8@RH7]JQ$*_,&%R_*N>Y.4#X40%K[&='3&V:#3W
M<E+*@X.R;*=;8DA&!D*#<`J,/B0BUKP=(-D.V(MUEUI.6AW0\8=SC+K6%AXF
MIZF'#W7=MM@7FFZM?[G$RH801S1D439(FN`PMPLX"0I,^/'=FY(5`Y:4MC/J
M,CG5/(RK.%J"=?`>`\!X'$\\R,RZ00ZT...TX\^^\XAIEEEI&5NNNNKRE#;3
M:$YRI6<XQC&/7/@58/ZKK$L3$N:NA2]D4TD0.4G]M1TW48/556B2+BU3GE&6
MNTV&$9D)3"\%'"L"-O-&BA+PT]EUT9#P4/.V_=-D'W2"N&S-P[?DH.Z@U^C5
M_D>F2FLZ$</8<U$0&1L^V9[]E%.9A9%V7'<?--$BUCL$$Y1EM+2V`@=<1;-*
M[[,J$50H.KU;9M<UM5=R2.U[1-=1T^BFS4]9"HVQVQ5:JCD13,W<"8;B$R=N
M0,%^.$-AEMN*"R1X%[SM!;EE+`(76MX:(J%CUA+QT/2?U.GG_P`O71=HJP+=
MAII8\#=*16+<R]4Y%MNOI+B&W(X53#RFGB$X>R&J#8W`V;%]AD'<F.AR:YND
M[?%-VO';%CHJ(L.C9?9FO-/RU*2+LZAO!,BS'2XU);C1\UM5ABQWX<P.5%89
M0-@-T-G7^-_L0=O\G3P?L3U0U*#@/6&*@YKA.'6S(PHQD2P:^B1C>@QGC0(Q
MZ99%?]/PR$ON(SCW)]5*"+J6[]H-WV+;Z'2.W^6+5`Z[%<B[ELN3X2L0]?8O
MZ8ZODOTR`3&]DQ[MK*CV9MPHTP-G`$0\RB/(>>,^=ID(ZHFZOLRM![L-)=6\
M<`6IJ:GJT]5H?B^ZVQE<G6J1$[`_+A[9']S1U4D8RV5:<9.C'G#6OE8RA+J!
M2/>Q@..0W?\`:M"127K#NGDZHR)U2G+<&B^<3[GKS7XE4A=@6FPAQB8GK:S.
MS9@$'1&_R,82UEK$R*ZVE[T6WD/1A]R?9B_%DV>R]*\>U2L5J*C)4J4N'$&W
MA5SCZYK<,!)CA?K>Q7_TY#"=4.E.+6G+3,?*,9RKY?>WD.P7T']EU>BI"1M>
MS^(ZK!Q\8F5EYB2Y>Z!9!A8QRS[,BB98L=/1_P#VJ41^G)4U]F0R#EE$L$A>
M</\`O:P&>IW]W8#'WK\FX\"GOTR'O9YL>SJCI*&B#@-;S.PQ)E]5H(O$A5@_
M^ZI$@RH-TE1`3S&7'<>PEKP.,#>?=B++-5$A'!@!PTT.(4W&T#>\F*46>O8R
MX\\PH6W#B?ED`:V-<?8QE\@1QYI#F<X7[_`QL/HSM>TYJ3T?(?7T3/7XG5\S
M#0=@U+T]&6;X-H@C8IDI,BG2JE1DNU&)1^0.0X@X1@1["D8PTC"PA&4Z%ZZ;
MJ=#N,CSMP?,RNYA7)31!M<H=N,F[0DB"DKK"3\0R";L:0$G,[`N([C,<<&,9
MDM^0?RWGVONI#Q;)V_>^;JP/.[WY-:Z'1@VGWZ-E;'K*B:GV1KTZSOC50:,D
MJ]KBE;=UKDR.N\>5E%@<LL:OVO)&6T@AM&'PQ:+^S&F]+B*H^D/KSI\/L(R.
MQ.T&S;2H"KO%4N_3Y[L<#9,T2CZ>F)0RP54CTE)((^0K+^1E#J66TT3\[06<
MUK$[,NKM^@I[CCF+=<U1+&Y*4Z0V?JVL:PO&:?9',1V3IEB@Z]VOJB'.F[I7
MI\G\(*RDS:X9`STD`.\4TRZ'FVG8U<3:'WIKAKZ\K)<1&SX^:D_[ID9]41"Z
MEL\/&%MD6:+Y&L@S1],O,H-^+%ONB/H>;<6SG#@).&0\IRZU:LFRLU(_7I]>
M@[Y(=EG<R\)L4X4RRETG,I1MDLAM.\9L&X,JIBY`3VO^PB1`<:?:9P@C&&P[
M\8]"3O[&-C_K,X)D`Z5:;=!SY,;MKX(.M7`&6N\?9DD3IG'49!1>5%ZME429
MI)(S7RH&^1Q2#&5K#^6AK7M-C2QK']<_`HL2%'IMP1C6\(UZJR<>AV:+,_#M
M)?+8,&8!'OULKU`&>*1B02TU@=+KF%)#\Q]]'6Y"057^LSF>QR5TM+E1JD74
M=YA+3:S]=#NVZPO5*1.YXB@"@->D+R@Z:9>;A&#<H#P>M];+*PXIKH38.NXB
MQ+8^J>.#BZK+&$3K-;ZQU_'65L9*?[@L\R/555^(V!)@11LH42^V@%2'QF%F
M-8<'R.MP/Q#=*[(&`J,@!]63T2!=B9]=9PYW7H8$B:S\HBU2327;:V$2J;2?
MA7R.D8=2ME[W^F&\+6'YA]X[5L@@+T;]0LX7#+B0+G%FC]M:"04AB5!C)X>3
M(:<N@Q+,N:!;V<H^-Q\PAHA3/IG&%-X#RA>J-H7J,K=Q'^JO9;M7S"Q,O"2C
MG;]`JD8Y7U-U*/BI*3AS+=!1[R$-7(+"TG(6_@1Q:LI5[7T-AYNI>M]/W.W2
M8^[M*_V<^\(]LFVU"%NV]Z/=M<7HY_7K&O*5,";<D]::\VP/;-?RS4AF2IDD
M?#D."MK_``U)D&'G0LB!U%]?]P%?<@*CM22%#5,1Q)HKEVJ$2PN8&)+EAB;3
M-WZKUMLM0\@Z0TTX=@A"DY<&3[V<*0%=(O[!:I+.*,#YU#;AAC81,WL("S],
MSNJ]91%N&MXK:MGWFHZ>EZS9T)$K0*3":B]:X2!>,P_+F1S;+;[H6-C^U./Y
M"M5QO8=&V379ZW4A[#B=<NWC842^,T@`"Q,5BX:IGSIP0>/()8PV48/#R'QN
MH5\;;GR(0'BWGL'FA^N1\GK2KR95;B2Y=FW6S9.S=JZVS#B`5R3C666Z=6";
M;O:^7>6L#34='"?V[EU1V5FLD9?996Z']U?M>A"@["ONZH?H^AZNFX"E6O6,
M,3?MN34\(#3*8[&;B3@6CVK-R;5%W.9):+#/$&,.5'X)_%S^'C(X<C$XY2R=
MJVK8^K_L"G*[3KI<#=?R5:WFB+JDQJLO+$K&9"BC>BJA9`UUW\22PZ_/BB23
M.8XKX7G6?ARZ$HHGZ*-8X@7.K/L-"-M&92"BZVC>4\@4X-(29YV5"&"Z5<.:
M1"J@2VFW1GDF>]XK"T.L^U;88RSM_12!GK::'W2$`([&3<B"7T7976`0R)*R
MQ4`])1L5T@6]'0TJ0MYMI&<MMEY`;_(PMT=WT#&8R0T[#'`JC!_L5LDU-Q4G
M$BF$]+J?F)DJN6!XHN3$Q-=$1;\P9$(LKHB<"H>BQ@<^GPH=6VXZ&*;?V0Y0
MZ'"S.JYSMD)V"OF;18IB[7NZ[1%L,3"PEXL#>L!R:K>]@K@9*WVMH(8+)D>H
M+XP\BOY2)\R,A&;VU9)T4"-`WOTM7#8N3ED'(*GNI+#8K/$U"(K^+`+$GG:T
MD*E%61Y>P8]I(TC\?]22GLN)4&T4,'\CM^2<5=-?6V/V=NBI)4J!A(Z9V:C:
M&S%G4@3_`!=+2D`##$:P:LKD]LRN3DN0(Z>S)GDRL0WAP/Y6Q?G#83I+O:I7
M6.&7N&%3IH^5&4=6#I5JX#U6WQ\8@>)L)U=GK=3:@Q*9$NB"0!A0\F%DCX8*
MRVV@A.,!;>;UQ6K!)$7J`>S7;Z;638>&V#`K0^2,Q(`$,Q\B_%/K?K%J3'9*
MP\,B2%,9QE*?;C&/3T"N=]DK/K*RF'V5I^'AK=9]3UUR^8_N&YT#:MCL==E*
M41$WJF1@<E*\[K#FP1<-3\5_[B%OGQF327\H?%2')3=HVF-L%."CY2&FH6Y5
MO5:86D_M!2=<QP,M'3:""=$[X#IT?&[;?5%0!!SL9,/LR2Q`?G8RA!#:%!-L
MS#5#:\1D&0=G==7B7BZC(%_J)R)K&X:P-$SI%EKH!LC`'RR_P&Y>-,]PN738
MHUO);2DOLN/I4&'F[&V9IB)EY7<\.Y?Z5$-["LINS-45*8+DJY6(V?ALTF!L
M>J(HFS7*Q6%RL2I;A\G`,$!^Z(<=4&*E]M"0G^"L,#:(YN7K<S%ST6ZZ0PW(
M1!PT@'D@1Y8Q@V7Q7'6TDADM*:>;SG"VG$Y0K&%8SC`>QX#P'@/`>`\!X#P'
M@/`>`\!X#P'@/`>`\!X#P'@/`>!!](O]3;L^SH`F8DHXT+<.:<,W;K2%(,S%
MG/UG5[^J)HP[\B^<%&,5PE9&(W+;*F5CENMM_!CY,AA_3H5;MD)5]6*)%$V1
MLN7>A]>R(YTE$6RKBM,M@[`V%3IN+K-I_43]"I,X46$X8PW'.R2Q1B'48(QG
MP(OI-VV1R_)5;3FVHD"Q:/K>L=4UZE;[K%>9K`0MM>M)&NBZ7=*RB9."C$--
MFUY46H''O6.^]E2'_@(=9"]`I@AS."`BAS&,K<;P^*^T0SEQE:FG48<:4M'O
M:<3E*L>OJE6,XS_/@=CP'@15N7=&OM#4:3O^QIE,9$`X;9"`'PT3/6.6)<;'
MCZ_6(A3S+\U.R1+J&V6&\X_E7O6I#:5K2&O;8>U0-D[3EA=F/6NS06IQCW7>
M2:50IV5G)JQ3C=BBH`C=0[[%B@KW1)B0C8T2L2L*PH%JV$EC./81'$N>!F'/
M_.<GL"-K>QK=:GH77$L)J.?@^>J/-60#7-"LFO,5J;G(5-?DSI&,#`CMD4>-
M':B16T,",Q3V</KR>^TD/)WC+6S3-AV)5--E1,MIJS!#3'0L/8-?RE\@.;8Z
MZ6)XJ^[3C`0Q',;#&N];)DW)"I/+*3%O)Q,O)3&)(!*#(Z?6*]JB)C-0:O'$
MN_,FT0<REUWK9I"-V840?L#-Q&)CI^P2<#+5;9<#/(AX^*6J6??7'`R30V5*
M'7'L-!TC[01I!<KS_KNS76"T<S.1M<1O,""8L\?RB]8G&#&];/3MI_9#VA$J
M1)-"PL@\U*,TM4L(B4:6$RPC(2;MNQ\@Z,IH^E=XW&IU*#O\;`&OR]AE9!%U
ML4K&3]:KXVV+W;(:+9)KTO'71^"6/<9`L5+,VMA2"&'6FO`KC#[\<NP,)ITC
MH026TB[7)>V`]6UQM\VT[5UO$N3K,/6:W9:K*R@<-LJBD5QE=OLTE'#QTZ`M
M7ZP/#Y!3D8$D1FX^?2H0#2#=_P!<ZCHU09,CZE5Z*W/@QMDK:W'S=;252D!,
M5"4C2JN/&LDSH#8IL>8Z9AA;KP[Z''PUSQNV=_V/L+:?.7,6DZ=NRJ_XT)W?
ML';M2W*#H2@PA6SZE`\_5^.;U[(:]V,PC8+Y6ALS<:/E[,=^J**5A>"&F',A
M:_9(?:,U#VV&:X<2ZY*:H(J)DA2=M\ZSZ;/)V&/L$&8.X/?['KD4T6I#3:WA
M!3AA176U93\V<^]MP,&C8OMV&'/33/KQM3*)6EP<:96-F=DZ:'J$H4L[<MID
MHVTIJ<O>RY#(,[N##66L#D!>^/RIMQS#0;V`J07MS;>P:49`S/UQ_9!K*TR0
MP%?MGLK\-N6L0$M,'=2'VF8@;(5-0;VR119O>`F/D?BFAG1B4MK9;1&+?P&9
MZ(#^T#NJ3ZIGH&Q<Y\C<\QVS+9JBAZ#W=H+95^W#\1M/F)BT/;XJ%:Z#J%&B
M+!+M[=96^L0DS,FTEMYT<5Q@?T`'3OLUUKLHH>PZTVK:(T6T7F3W%<N:M;\U
M5ZGVL\V<OK&E+1SG$[.WK,7?$/=FK^^3L:)N"YER&*!:.$RWEW./`Z&X=6?=
M#H#E.>Z)C]D_72-;-5ZZ'Z.V?J<O3>Z:4T[<:518F;V,U)[*C-_7V(DINOQ=
M5=2V4(,)$2I#*DY:8'=PO`9YS#M3EV7U,W-0&U="=3VHCF>@W2Z5FNS@9CO.
M3<M*3TM%WT:>A(,IG4.F(Z&DI*0D9=;8DN*5!-/`H+66PP,&SPRB!5V+D:5L
M@6-W2#N5%-`MFR+#;78)Z7+F9`.IQB:E7B+';38',.:2"7'8A_U`@Y3R'VB5
M2"LNK"I\=K^OAR*.4-J2]-V1,2FTV:V!U.YB&K%D8G&M95J8D];XS!P<@'KO
MI?-:E6BH2,RMR-L4(@V26\V?AT%T,+INQ=YSUTDN(H/:%=AI02ZSD;L'IMF=
MFV!;1482.JI;]*U]4[!*.MQN]I:2O3(UD<AUBL2"4O2XJ@7SV<"A7L>*ZSJ_
M<>QN:^/^>]8R^GM=ZK`V3L^ZVO9MIT^?)25QVGM:C:_IV'I.F[<9M-HD6-7$
MSATE^$()(M&R*U+:4Z(C(6#DM%]ZNR5ED!^>]9`F6:&EHTVR1W58<U:#";+8
M+C*NF3+4[SQ$5N171!;;\<4[D7Y9)37O-QA;+&<AV<Z9[7#D[?*-\B:[L4E-
MV:3G@928Z[B`E9$F`^DI;]0=`YT1-T<O^W[;O7`K!)D,<W+0_P`KIHB'PPQ7
M`PN3IGV&WRZS=-M_!&OJ;2#JS2&IJX07:+>[1;%`/YOT/+4C$9LG6^MI5,B*
M183\2#H<C'9&JAPXXSA)/_;-A7[;4MVGJZW4K3(/-,L(BFZONVUX6_Q6M[MM
M*_#1-(V03`:KTOSAO#0:[%":PV57*ELJ<&K\;;Z_B%-K[3<6<Y@)XO*`R2+S
MWOO?.UG">4FW8W%CA:_;,ZCQ9M*US>U!+J,18("E6^$[$D=53UXA*5*W*QQT
M\X"+%Q<N:M6%,N"M+CB@KY8._:3RYT11M`]FZWC^,=BT2FQ5@NNW+IMFNVQ>
MR:ONW)7ZUS7I-(A)*OV:.E+7IAX6UBSAL*L%M@;+:S&5NM^!GDI]EW%M1$-V
M'3.P]9[`L54@J6U7ZD#MFGFWNY$4[5^MC`JZU&A&F1X0-ML481'J"B`9F<8G
M7%K862*E3"PP6J_8SS;6E05:V'/ZCUG+S4[%UZU[:F]MF04<J5Q2=0;:B+O7
MJS-T>.@[N,!C6::_8')U<&@6WM$PB</I#-=4$ZTC[)^&H!1UFFOL7Y:I$>+?
MZ7/S5>8W#1#46>.CM><L-L&8K==AU1)\R*=2)P0DIYQYR/+PM`A>`\J_'#\<
M_P#='$MKM,=-4CK_`)P>EFM54UA8I.Y-3ZC4?;Y('0LGL25F'-35L\>4M$M*
M0$R+(+)6.MAP!UH%3HA+I8P?R#^YK6$?"?H:I:]3'*3$=!N0UT@>C]=`*V$S
MH*;HU>L]DG*J]6SAJ-8K/6X@I-'!"1-#3.,8REYEM+ZT!.6MNI>3=K4BK6_9
M&^.,;3#'5+G&2G(W:!6L<QT>W>&:H6?$QYTQOFW?ISGH)\QE8+#98V,.--GN
M/C-80\&)ZXZ;Y<N3`!?/73O-`VO=?ZI72#PM3;@TN,!'S,W+PLC&0$O`SEIA
MLJ*BTP3K0_QK<0-'NK<5A*5LM.!CNSNUM6ZNM^U:_';%IEW:(JYM^N\]K[8V
MA=AS>8_:6P=O:OUP-#0EGM@H=E*@DU:))D&X50!F`)!!LD-[,YQD,FU+NC1V
MQZC;P:?>=!ZZV'5I_P#QG;*@!T'1K0Z>[3">A8.6E$#6*WP4=L2.D)J^N%*R
M0M#!8"5*2I[X17%!&FP_L:YIYJVU`T9VO7?HN?MHP>LX6K<9V^`W9;92X[&-
MZF*A:]-ZYDK"S>,I9K,86=^SA6\"0[+GND2/:H%M\,,J/>\OS)7H2.L'UV]A
MZ:JFS+[K_45UE^GP8W7FAYI%LL)M4I9-WWU;KI;IR$EB)*:`C<_EQ0D!^B==
M!?9<2,,ZH.V5]BFGCETS4&EN:>@MQYM-[V!@:>YWN6@=I=,U&U<]LTYN^@4B
M`C[FV]+ZXK"Y;^W`[0T\/&JC0FVXMB5!?8?\#&]A_8+):JUA.4W=7'?;^C:E
M?9N8#AK#L74%-U;I78,I8*MM^]VW6%YC+#NI@5,:53XQ#1`29YDNS8")%#R"
M_@5;P;$XWH/0$M+2,14-Q:GE[458;$M@C1.PZ=1[2%7JRK631PDC;9.U6C^V
MJ+$0\>P;+1R?@PJ,%P>K*<!_,L.*0V7")OL%FK&T++L?O^?@2;(!<(^8LDC.
MBC<U2LFW.V!,@+!22Y'\K#,P>\6DUH<)'XS:6EK4.&6V<<.PB<[EQ]G_`+TE
MX27H*=F!/R+-L`U\>S.<PS-UJK<6J4:K=>CJW!55V4,4@EHJ"RZZ8VI/O<]P
M>/4-[;2YZ)TW4HIFR;HD-X5B9(A]3V)BWV;;<==ZKJ>N[4DX#_*B1O\`'T.)
M'U<PI@0:QEQ\866D>-%FD$I2P\&PJF;S#-;B(;:$*5K:RS-F#U_"JGQW8VN;
M!N>*ZY*S(]#7)Y:EGHP>0`-"85(#BX+>91@5927QW'@Z5KT[:J\J7L>@+,+4
MITR/I$.G6UJ>D2-&&0M5F3G9,2/K,0W^;KN>L5;EWP52T)A&&W!@'7PS$BY9
M=#"*08)%$5>.G==V96PZ;6C)2EZON#T5=+?7VX6?FZ--6RG[\M$HJ/LH,G#7
M1MAAHR69E6XDM.'F&''W1_`S6A;0MZ(RT6/8;8>*5%C6FP#GYK5BK>S*M%09
MH8K-9NFK66;)(2\K^!\\AB8C'&&#!W&<-1R$J0^\&4Q]:K5CK6+MHJQURIYO
M[1EZ"N-3AXJ;J=T-N</&/L7*>A1"(^.MQ$HP!'D?G_.S(.L-?&@I#;SGN#V)
MRT[*CY!\:%U8BP`-I>^&4_OF#B/R5-OCMM8_!*$=>8_(8<<<_E6?9\?MS_*L
M>!QNVS9R1@76]2H=)?Q+?FB_W]!(_`R(W$*B\?.H/V%?MW#"T_TXQ^/^'ZK]
M</(]`XR[;M%D-+PNHD&%Y0(I07^0(`?VK>Q,_E(_)<"4VK\/(0G\^GHY^;_'
MI\*_4(-M.ZMHQ.SQ*<;)ZGU@Q(U@>4@Z[L6*L\U-6Z4(L<+62%56TUJR1\,?
M%5XRP`?M$8`62(Y)#9<RAC*WO`P>\[SWUJZ.CW;I?>8'/[C473H2R`5R]"5@
M+9L.`?*6&*-87LR4EYHR*BZS*$HKP?LERFVG$-N_*(M!`2S;+=OVJP\Y?2K/
MI!W7<6["2K*HV@[0L-K?K++H>+`*%%P]M<=G+9.Y6X-$BC,)^$I;25I*SE2/
M`JHKKWJEB`@[0_K?41L#;3#VJJ96!MMV)TME,A*30SLDI41$U\2%@=;09Y<]
M+#2AK`DD`XR`Q),NC//!976G15F#K%ALO3`.LM31C->7LBG2\->TS"9K56%0
M[)LW9H)UAU^JSU4/L,>)+LC&RT:@L]I`II*?5>0FB2WCJ6(>0Q)7R"%=61@5
M"%O/*RHA2(YS#6,MLKQE642PV?\`7_1Y.?\`CX'MR.SM>Q-?D+5)7"!$KL5/
MFU4^7=/:P&/98V:>KI\$IS&<Y7*B3H[@KC"<*<2\VI.<>J<^@8Q)]!:2A5-)
ME]GTZ,2^)8CV7CY@<49T&HPPEALIS9;V4"K"A84]@E]W"_C0V\C/KZJQC(=D
M[>^G8QEDB0V-50V'Y..AFG7Y-M",RDO/6>KQH*E9QZ-D&6.F2P*,*]/4J/?;
M_P"MO./`\B/Z7YZECX:+B]UZQD)&Q#MF0((5S@B2I@-ZKP]V9,C6635N&"/4
MZ?#E4.HQEM<>^DC&<M>JL!GS.Q:`1*G0;%WJ+TS&/('D8IJQ1#AX!+AIT<@4
MP5)>7ARLR$62Q\:\87AUA:<X]R<XP'4BMJZOGBL!0>R*%,F9C1)G`D5<*](E
M9AY!O#P$KA@.1>=S&FM9]S+_`*?$XG^4JSCP,P9DXX@XR+8D`GY./9$(/CF2
MV'#@1S\DI!?,$0XH@9DU0;V&E+2E+F6E^W.?:KT#N^`\!X#P'@/`>!!=0KT&
M3?N@HR5IT$)BSSE5D)/+A@\F[>X*1UG!55,[-P3LA(_KV7,PAT(GW,BMF,1N
M<_$KT6ZZ$1)HM^.WS8Y?76V"8FG:<@XF+$TPMV#G*O*V>?UZ2AB$F!7QG)2A
M0\>`F`,`6$ZP;C#AOHK(QRDY#U]7=*5?87PZEWC7(_5FYW:'3)F[ZOM[HS]:
ME47Z>L5&&$J$M,M"CV^+E+;6#`6AG6&C%_*QA3"L$-*<#WHGGHO65HF[1HVY
MFTV,L]AG[C;]63S+UEUS8;#*QDEA&8)DDQN2UFR799)<H=F(5\11.<>]C+:,
M->!Z&EM^*V`3#Z]V)4S]6]`C:FIVU;_JHI14R'6(RV35BK#&(NZL`L5^Q-(G
MZH8A3;+GY8[2F%$,M?,W[@EC8FP:GJJDV385XDG(JK52+(EI<L>/D9@[+#"?
MZ!8N%AA#YF<ESGLI9$"#'?++(6AIEM;BTIR&K^7V?.RFU1=O3VHK38S]L':?
MJ7'F=VPT=3H>A9LL[?V)XL:EBZ_O.R=:7,%->&FI"8D@R<E`2T(R;F*PRL4<
M)!U-J^>KYUMLU7OS\MVA`FMV+<%(NEFA'HZ?B;+7F9F+U85.@T"*_9:NC#Y=
MMV$M$7$B&+,'^`QW"F2@&@]BQ;G%N\Q>S]*V6VZ^EJE4CT]&YFHJ#KM2UL8Q
M)D!E)=,V(?3J\!O@H*LF,1<PMV0AF(M`I\FRZ"_%K>"GM-^P35L!9-AZ1X1T
MO/='V6]WA^HTW:6M=DP5SKMTWFW0:V9=;_T%/I8F5:.J,0$<P:_<3P)(*T%0
MLNR*,_*I%%D`S#4_U`SH<A9KQT'VMOW8]^MIH,@-`:ZA=/:OTMJX-,FFWD4_
M6.L_\96*&#B8Z]E$DC2CK34P4(@1HQQY8V'%A`K.E.*K[9W*'2ONY-*NTY=Y
MRM,4>!W1P+/3)19CS0D7K8*C)U&1E<M#NMD(=2R'B0E"2'%F?,]GW>!G$[]-
M^F-L0^TN?R/L0ZYG8]+&MF]SZQK]_P">6YAARMJB+5HT*^#Q&E<7&OUJNL0:
M)"#B/R`07W'23&T*<)(<<"[5(T-]5==J]"K5,UMPXJOW)RXAZ]2)#:7FGKZ;
MK9Z1E=AXKTN5B1E+M*48@8LB:4V081&Y;=43EOV+S@,NC>.?KCNM8'V=!\Z\
MC66F2<8180]A5_7^K9"L&PB&I!PR9"MD3'N13T/ED@E3S[9&6%)RO*\YQC/H
M'F<LTCZW:=L>X6?CN0YG'V'L6N0L;:A=';&J4TN8K-2>D,Q*6*?5K/(P\:#'
M$.$96\$$Q\B\*RZI>4_P%L2MRZ@!_._-VKK8/]9<V]<27Y5YK`_Z_8;S`Y35
M#.^:41^)<W1C&G$Q;GM.4VZA6&O12<Y#+2;/6@I^+JAEA@Q+3.`R,G"ULF6`
M8GYB-AU"IEY"+AW2$2,@#%J-9P2ZTVMMC+R/?E/N3ZAXC&S=;DW%_78VP:01
ML`9*U$T9BUP+MQ'2V&B1<4_66SU33241[J7\Y4QCT95A>?Z<XSX%.N6[53JA
M9>Y)BS6RJUZ/)[DL<8Y(S)\/6P\3!.D]"B!1+YQCXK)DN0EM*6\+6I]W'HG&
M/XQC`7IB)J&L`+4G`RT9-QKV5)9D(@\62!=RC/HO#18;KP[F49_C/HK/IGP.
M>1CH^7CSHF6!#E(J4#*CI.,D16#8^1CS6%C&`G!DH=&+#+&=4VZTXE2'$*RE
M6,XSG'@:"^E[?J+@[[#X#9%"HVEZW*;/YEI5"Q4OT$!KL,(/.W-F*L-X!-IT
M.B7GI8R2FX81X0H9X<QUD,/!4=DM1K03P_)ZT)AYN!H6Y:A)Z4W0S7@-TVR9
MC*C5[W&R5GGI&-Q#ZBB':N`V_+XL$C\-MB)W+1=(%+9+":_-><1@(VNFPU;B
M5)<DZ@/URSS)6+@[#3=^.N]>7;KRF(B'Y6.TG4(>QRM0LL78K7L*"/B%6&,P
M62RPC)(Q"'?:XZ%5^:=Q]4]#<>4+7&LOK$G-E<^!D*`B-ES/4.L]`7*QW366
MW;&/*6P*0@9$.S'O`/U*,.C;F.VAVXR&722@XS"EIP%TOK<U?U=&].=);FZ5
MYUO&C%732FC:`',W3;>H-H/[&NE+VGTE<+=-@_XPM=H(BXH6(V;#M#*-2#\Z
ML/Y0,UC&$8#=/X#P'@/`>!JBTLZ85]PW?,>6PAF)'Y!X5(9#DS"GW95]^V=0
MH;GH&+^-4:S$-9;?!*>6K!&2Q\83C*/=Z!M13'QZ%)6@$-"T*PI"TC,I4E6,
M^N%)5A&,I5C/\XSC_CX'*^*,2GV$CL$(_G^A]IMU/\^OK_2XE6/Y]?`Q20UU
MKZ6;?9E:)39-HH18!+4A6(0UL@%QE\=P-]!(+B71%L$N(RVK&490XK'IZ*SC
M(45X.U5JUW4NYH9>O:`9#B=E=IQ(L<NEP6(X6+BNGMF#1D.R"_&_"@&$'80,
M.WA/Q-MLIPWC",)\"_@]3JHL=B(%K-?&B<,?BXBQX:.9CL#>W*/Q\!-C)&PQ
M[%9Q[/;[?3/IZ>!AF=%Z2RKW9T[JS*L>[T5G7M2]W]?\K_G]1Z_UY_U_Y^!1
M?1_/?/0G8G:]<`Y_TS'1`=<YNE/PQM95AH(N4N0VX;19I)8CL/\`K5&S,Z<Z
M26ZPC"B'UY6]E3G\^!=6&YRYZKF%8KVA],P6%KRZO$-J^D1>%N*;4RIQ7X,&
MQ[EY95E.<Y_GVYSC_3P/T9SKS[(D.%R&BM-G%N_#\I)FL:220Y^.RT.Q\CST
M(MQ?P,,(0CUSGVH0G&/3&,8\#]5SG?G^GS(%BJ6C-.U:P11"RHN=KFLJ5"3,
M:4XP\*X2!)QD(*:&0X,0XVI;:TJRVXI.<^BLXR$HR<1$S8V`IF+CI</#[!6!
M),(8\;!(KJ7AB,,%-.M8?&>3A;:_3W(5C&<9QGP.@%4ZM&%L'QU:K\><*Q^*
M*:%#1PA8PV6DL9'8(8&;>98RRA*/8G.$^W&,>GICP,?V-J?5FX84>M[;UI0-
MI5T0[]F+`;%IM=NT*-)?A&1O[!B*LL=)@LF_KI$ACY4MX7\+[B/7VK5C(:_N
MT.".$#N1.HT2_(/-@02=![>DR9"!T?0X.="?C:%.2+$G%S-5K05E`E`WPVW&
MG@G4$I6C'LSZ_P`>!6;3U)D!=;<SRY-$K04'F-C*\])SL.5)1$Y`R-)YQ<6L
M&+JX,B1&14@B.E/CS)J=PED<OYG6V5LJ0&>Q6:ME/-YIU(IDE&2\I2XY3Z]6
MP7]F2LY9!^4&(J7B["W6(F\$%N*G2/P$FM$?,EQ[)WRJ`&0P'OZ4388'8_&H
MM"N=(U3%VF-9<V50I,\>2?VS08CE.MRK&NJ0W:2)B\U:]579UICK0^,^)#R$
ME`B/OE*]J4I?#9?L_4]=VE&CLR)T]6K)$"SK=0OU/D&HNY4>0GXEZ(*F:X86
M))1*S6&W$/M,R`9P/Y8[#RQUN,-*0%:`"=H<I1DB'*0\[MS6A5LJT)4IUFX%
MD+UK0QHL1VR6'8S5C#/EXW\9_,BIK,:_*`E.,A#X;B6GO1@+1G!Z]W=1)>&D
MP0[C1;(D^&DP9$(X84_$=(+'=4V@ID$UOX#PL/AF,^WURAHD9W.,M.Y"`[?I
M.PQDZ'9FS938$56_\J3=6FU$H'WOI]%FH68D6M:FL0PX@5^@C36B$(B[0X\M
M)!(;JRGTQXS;0>;$4F\U.V2%\GI2+UO&$6.A6RX[)KDBV+#[-JM:U>=&6EK>
M6MKL\W7=2F!.CLALR5=DI(IY0P+Q#K3+3HK8699O]?&F*[5K/)0M1NMP>M.:
MA3)BQP6;#:H^J$*S(2==!'.<=F&6HAP<]]`^''0QR$_.EM6%8P&<>`\#!-B:
MWJ.TJ^FN7&+1(A#R4=.1KN'2!BXJ<B"$E1DH$2(\P^AQAY/M=:RK+!@RW1B$
M.C//-+"I6M>=-8\U!W6-M$YE5%V%1X&E2T>@1%8UZ6J.$7718,2%<M4[8Y._
M61F3?8CD!I4_B/PS%CJRP%%"CA"U'KF%:9GMR1-JL;G*]KCK79IG0EERG5MA
MB"869G(9)=BN4A<IO%.&ERV4O7059D",PZ$Y(%CL'N3`YH60T#*VWHW4UG-V
MVN$<H]T;LM79H<2`75K7!`$2\HX1'667@;2J7K<Y`Q9X\4..EN+FF,1Z)$I(
M9I:@``KWM&DR^A=>7"GVR:K-IU"====.U"IQ$I8X;845!9NT"IS8+J1V7XQN
M>J%JD639MV4>*KUM2#AV44&]('MD!C0G,%7T1M#55+LONVUKC8Z50EDF+VRV
MFNP.:37H"L4"IQ<4N3#J%7-9,L$J6$_AUHQ^/?5"!#OA`1H887;J>B>6+2EN
M_4:FZWLD?/1*6A9VJG#359DHN3AD!-E@)BI$JNO*.KY*6D%LH^58CF$I<RVK
M'J';F>2^?+`-D26U\@AK(X(GN;L]S#(2''`HC`P6RP;$,6V"U&MI'RPE>&EL
M)PA2<IQZ>!A$OP+R=/'R$G+:M(,*E'G"3_=L/:30I!2HEJ"9*5'L79H!!4=$
MLX9"<2TE8.,JR/EI2UY4'\9X*YB%?=)#JE_!>>3$I=5'[_Z%`2O]&V*U%*RT
M'M-AK"Q$!-^BL)]RE8RI6<J4K.0Q%&LN/(<^!TPD"YD!2MC.C(F67L+>EBK&
M;Q$?ELF4&0VFNXR8,;:15Q[N<0!TFRM12/1#"B<XQD)3-XXY_/A`JX16K9B%
M!,EI!L,;;FX`EDFS4@3)G/RQX5\'DYW&#"UJ';.>(9#3A*1T-)2G&`DK6.EJ
M!I]J4:HHME&3-(!3)KLFP=@7X@M4>])/C$*,OUHLQB#/=+.I<>2XEU]O#2'%
M+0PREL)5\!X#P'@/`>`\"'X-XMO>>Q!BH-H4<G7>LBHBP-G60MV8;%FMCL2D
M<2&2XY4X=,,02RIK`F&SB_RW%$X6VT-E(=#2::=*?Y3O%69+P==-NW)%L).4
MIYPB>UVZ)J-*0R'6$.+B&XJ@#J'0EQ]E&7%_$K"5>Q(>QL_2VO\`;4>Z/:(A
M`\VE$'^IN\*V''7JMD5>V0U[K9=>LRA"#`'(2Y5X*28;S\@^21TY6VO&58R$
M3BF;ST@X.Q8G1=W:VD+W)BMSHW[*+VA0J?-.GD5Q$J*298V]OV`BVS`<.EL)
MNOM!Q;7Y6<+4C+"@YI&(YO[ET^`2E<?<JI<J[2+E#R@S95=OE;87)!7G7TVL
M0\8&U523C;!#,2(PL@,VA1(F4O,.(PXWD*7;AWCM,O;FY8&>'C+YH#3%VUDL
M@"*DK[HZ603-F4K$>V1L-Z`74]FIK%WA95$A%Q4N.\8AY0;PKB6EM.A*E8T?
M5]I2,[LYELC2G<*V"+@%;UWE[:Q5?C\G6,"K1H*9`YL6>YYE"R%A2,$&/!*,
M:&^!S\4P88ED/.LMNF.IKC-:PU49G1?1VG<V6$O>\!E0ILE3FF6H]N.B:/'#
MR#B=RTB[GR0,B<"2IV"AW@<#2?X\^*,PR%0^E-HZ-F``>#:AK"ME=M;S%O\`
MK<OEV-GF8C6^S*M'D-V"];AW)LZ%CFBO[!J=<LI=LCI1EY5MCYTU\4<-Z4P6
M-X&T+D?EL/F/7XD9*V\S96V+)`UG_-.UY"*CH<_:=[@V#VB+@6`*AXB.:PQ(
M8!`!R4^/'Q8@S#6,*2\Z\%L?`_SC;-7M>V;ZN]Y[4+V?]05;8"W#T;M"2UC;
MM3TN!^P\(*N=H;'N3U)UUML&^GRT3?;8F-`B:K[*NAMN.+882E*?8K`?37S/
MU%SMJ'[6OM<9W1L_6>A)6]ZRX"V?6P]P62!UP;8J7`\]2T79INNS]S.A&K96
MJ?).-AFNA_**&7[_`'*PXIQ*0U<\D+@,T?Z&)5!4?-1DCJC[N[97W2HMUE48
MF<BK-,"W&*+D!S2&8W->DE,,E-?ABOC&X<;>2VXEEX-FOUQ;TT1_[HGY\UG!
M;CU');'8^N>2'SKJ-O5/1=,S@>E;!*348NFQTQ_<&)()QDA96,#X?S\;CJ\8
MS[LX#4C;Z']>FM_J'^L'<VB*US71?L;)F?K>/U)8N=HVAPW35OVK8+9JD/;,
M00%K`ENYW)R?UM(6+-B`E''0RE*7DOT(^+P,GZXTWK[KW8'0NC[N\328S9/_
M`*D766N6[M0RRP[WKVSQWU[5V*J=V8L(\%(P@L])V2*&>`;='>1C#F127&W,
MK>P&(6OK'KZ8Z"Z&KFP*I)K^S'Z_?I@[LU;L65AP%5W-_DSMDZ-F].])Z2EJ
M1FQR$G,;)UT^_,MQH+/K%V8)8JL!-O\`O0'!OW7WUP:<^N;G+I?ESD;76Y(L
MC5NO]F;"^P'4_8>JM2=Q::W0JSU&1?DW;W<(N;VQLC8\S<Y\P*5C6\./_CH?
MBUB,M?`AL+G_`&0U`':&FT4J2I.L=P'67_U"FH:HSJO;]G('UIL,V3IU>AO[
M%O%IC*Y:'JS6I2,?RT_C]3-/`AYPQ^.IY/QMA(_U34F0YU^UGI;GYSGK4/(%
M7MG$^MMJTKG?F/I"0WCI!YRJ[216;;N&PUTB+HS5!V/<@[K`1@ONK;#DB!"D
M/I)<2K*WP^G_`,#31VOSGJKHKIW9T5MFIU:>CJG]?SEHK<]8`JL9)4F>A]TS
MTXJ?JQEF9D$56;P-#82B90*K]>K"7??A:$)4&N"7*GW'!KD;8L)<5FUVXJM1
M.UM</R-;A[/_`(ZVPZP]$#U^P?F0E;LT#/84,.<2F=Q@(=M4?^:6V@,CB;<9
M7+A$[+O<Q58LUS;OYD7<)C8M%IUNQ)R-F;U>4VG5]D?K"(J$!!()]AS<B2X4
M^V4Z(EU+C82PD?ZG>JNRG."=!BZ+^O..VOIV)8V+`T_8@G8NFZDNP,0.Y=B0
MLHMNF2%*#(KHL>:"XPP*\K#R$M>Q>,>F%J#:OJ7L38QVSXG4G57,EBY,LE\%
M0YIN=D]DU';FNMH3(BRL3U&9O]&$8@ZAL<`9+!0,)*Y'*G0W7G([\G(1B&0O
MKX#P'@/`^5SM^D;1V?\`9UUK"K:^TS:5.UOS%R??M=T#Z[^IJGHX>A6&QO;_
M``['B[52Y[EULQ-/7TO7X2XXR/CY9[+HA+2\>N&VE!4+ZJM];KVG]CWUZF[0
MVEM*T7Z3Y5ZMU'T-$V.?F\V)5\YO!U\#`U'H-;T>"#<]CZH>O9C4A^0A!`%D
MERBDX3@[/S!=CM[>6YJ9-?<P)`;GW?6AZ)TA]0</JUFM7FT1J=>L;;E]'QFR
M@J>7%23)50JFP(^2*9ET#N,#ON.KRI&''%*4&T+ZV[_=K]L3[0,7&\W.Z"T3
M[*=HZWHXUMG9J5$I5(K^DN?Y,&F5*.E,,BP%9C9RP2#S+`C*&7%$J<][V%)=
M4&LKGSFO>796T_LZVI$?9G]@.F[IH/O?HG3FCJ?KC?,58M!TF,I]/I%EI8]B
MTI=Z_;(VV0L78+6_@F'(+!$(";0,C#6$X=P&L_FCLOHR[\^SVVY;=.Q:K/7?
MZ9?M1ZTN\1IZTE42GL]&K[NM8#FUZS&Q,F7&UN_1/X;S`!>"4/1;+JT#^[.<
MMI"\3'V*;]!H?.'%>^]FV&A]@:N[9^M:*QLVLSUCBC>T^0]XVVMDQVV($=QN
MKNSC,]'/$5G8464^^P#(L+=)5DDP8+P,D,W9M?H75W2/>72/V)=D\2ZIU[V/
MNCEOGO4G+.GXPT6A06N-A3NMJO,[SUP/JK=]UV[?K':XY@V7PZXQ%QXPB@6D
M#X)(]`LMP_V#;+!HKM7L":V55>E-A:^X^U;=R+QK:B7ZD:SVN7JJN],'0%DK
MFL+/#UF[5V1O+->:>FX]P)E8DDZ^*&XH)D96`\C4^BOM?M'*NC^SHC[/UL]%
M;+K^K=]7G1>WM9ZIB^&A:MLH2`F[!JD,:.H.=T4V/J=%F<,`R35C<>*F@OF<
M0Q@Q:V`^B`=YL@=@AIYDEI]EIYL@=25COMNH2M#S"TK<2MEU*L*3G"E8RG./
MYS_KX'-X#P'@/`K;V6MEOD'JIPAH5YAOF_>"WF30%RH;K2-96=2VRHQMQIR0
M'6G&<+82I.74YRG&<>OKX&D;</U8\E!?6M<-^4$?<&HM\B<,1MKIVT:1TGT_
M&.4Z[Q&E("3B)*'J4+M\2N-"2LM7(MF0#9"PR8.*TG+>5-H]`JE3.FNA]E4S
M6]DV!M7G_2]C<+I;8,+1$#VF3$J%JK]<C[1^VOFP[5/568ODOL'4$2,0.P7G
M+0_Y30;SY32B"`O!Q5PB1MKDWC7K'3>\]J::Z+&TG5['6R]JS!?6&I(^^RFO
M6->679N=9;:GCR:_=-AU<-34F=6+!!D?AR)0R'E(<RO(6HYG^RXD[(6ONSZ>
M%I>YD7&3I%#WY!-G#<M]'L@3-C@XV[:RE[00S=:$/-&U0UIV.LHC`[+[2%AR
M,@$9'EE!MH$+%/%&.!)'-"-'9+#,$>;(%+%(;2\.2,0RI;3X[[2\*0M.<I4G
M.,XSG&?`KUM?1Q]H+M=RH5^NU'V59([7D")+MV2PS%5@`J=/6%TD^#H94NFL
M04_/UZZ20)\D,-ATA"`G"6RD@M,J#%@.D%T[8(.H-EUFX#RC\G3:/3KB3'@O
MR^UK%(?L1)^T`U.MB)"3601A`)8XV(<-8B195?[`>,P`7AL);VCJUV^@&F5R
MW3.O+ZF#?A(6YQ;`LX&,([(!2RXRPTJ<_(J]LKT@;'MMFC/M-%.!K>9'+%4Z
MIW`58G:780;RJ/V&EN#@K5>[#&1D:003:]>;FL-IU;+Q@,E5;*XIS87)5_FI
M*2*'(3'OD1"VX]:!5.%R67'`G2B7V,JU;G*WD[8%ULVNH.#S,44N/G+%L4(5
M)9E?(,"F[1'5J6VA&DRT2:H:92A69(<7+C675+3\@3S%3L)._L<0LO&2RH>3
M(A)=$<<,8N)F1&V'BXB30.ZXL"4%:);4X.[A#J$N)SE.,*QZAZO@8S<*;5[_
M`%R2J5RA`;!7I9#*38T]O*F\NBDLF@'"O-J;)CY6*D!FB@S!UM%!ELMOL.-N
MMH6D-=]PYQA^8J)"&5R]V>7TC0PI1Z4UGLL&_;DCK=>YR%JM&KL_<W8AYY@&
MDHCV)0BP8-C"`79V5S9C"6C6"'2`]*,J5FT9J8;<G,-(M=HF+%6AIB>T=)7&
M7M\4&RS7YRPBT"'CW#(D:ORE/DS,1(DH.*;+D--C1A3#HC(KD8$C5.`VN_J_
M9V")"C[!W!<+%6S9VH2N4/Q%*+-K>N19C76QBA+1;F8<A<9\ASZ(9D<4,0A*
MPQWW,),-"O\`KWA:S<^VZD1]!+K]CU;=1J71]RU@:JO,!O`TZ,E)&'N9ITW=
MSK8U+5*=#9>J]A6?.VB&?6-'%/'AMCR42'6UEJDJMW&HRW*-U#&TSJV#B=>6
MC<5QM*+:-/LZO!M`$C5[!"H74QYFDBA,*8+EV"\Y_?%#3`B%*Q,D20;/JU>:
M3<V6R:?<*O:QW6,E-$5N?BIQAT;&6<9(;>C"RFW&,9(;]58SE./D3_/]6/4,
MI\#!=C,FOU210/:)&D@(:()L-MA\Q_[F!K@(19TJ9$_M(J9#2:XT-AG#F6%.
M#I=4\WZN-IQD/Y286@IH<,+KT*%!HDW&XGH-=499BXXT:T*7856,!V-0-G\^
M;+DE2"S4^A#Q3RB%+RZK*\A^Z!,9FX-3S#5@:C(R0E*O'JMD7*1ME.S4)4ZK
MFS4@N67@J3$GBXE181GPM8,$=0^GW)=2K(9QX#P'@/`>`\!X#P(_P#EG:BY)
MT\O"9'7[0(47_<,FX"M4+8GB),_^U,0Z884MO$\(W^PS(*)(0KX<#I0SEQ8=
MZ@Q1\+5@8V2;#;+8*F7%9!1$M-/-%S4@8.4ZU!0\#$-&EL$)=(2P,E.'UK]5
MNJ]SJPS+P'@4&WYI9.HHZP[ZT9;XS2\O4J19&).OAQE<BJ=>Y:9OE8N$4Y>)
MJ0@Y]\6+#D0#8YM"`R?PHZ>.3'I%(<;>0$14V$VON8&C:(V9+;>K<U7H^PWB
M3VT'8:I6;Y#V$"/B1J-;JJW5HD&%8CVB9Y!(04G#/B22V36CQ4(;<CLAV)+:
M5UZ1DP>>M>;!K6MY>$M-R5)=*5*P-+"O\M1#),>P5;0D.-D%C85N!CS1P=ED
M%,LQU8(.+8CORCVV3(\/56,UNF2C-!:VJI^D=D\X1),3_P"0=<+@_P`'6+N7
MCHH.*UBP\=:'-J0M_(I:,VFN2IC'ZT%P=4LO,HD3T"J_%]9H\I]D%CN0='UE
M!35>Y9NE3A3J(,!)P!,0!LW5+/[NAVU@@]RSP<Z:9(RRY%];<CA-BP*0I]Q+
MSJ@WP^`\"NB>/N242@4XCEOG1$W&RK,]'3"=):T3*1\X-^)D>9"D,5G!8LJQ
M^`Q["&UI>3\+?HK'L3Z!UMX<:\D],S5<LG1',VB-X6&HI':K,]M755*O<S"B
M"%%G#QH,G9(:0-:B$&GOO?A^_(JG75KRWE2LY\"1)K2.FK(?3)6P:IUU,R6N
M8.=K&OSY.F5XPNDUFT06*O9*Y5'WX];E?@9^N)2`8&+EH8D1"6G$*0E.,!`%
M6^N3@&C6:(NE(XKY;IMO@<2N(>T5/1>MZY/QR)R#D:U,M#2\-70CD,RM?EB@
MR$>_V.C$+0K&4JSCP/3UI]?W"^F+W&[1U'QYS-K/8\*DM,->J+I+757M</\`
MGLO#&JB9R&KP<C&.%BDN-.+8<;4MEQ2,Y]BLXR$@XY9YPQ-O67&D-9)GR-SL
M=%D2Z:C#I/?WP-!8K`VWGR,#8<=V"/7DX#1**SDI`^/9A>,>!E3FD=/.[97O
MES6-%7NERC.ZR>VIFL1']^D:\?DVIEVE$V?\7]L3652K*2/PW'5,8=Q[L)QG
MP*:.?4)]83NYW>@W>&.<7=NO3Z;6[:W==1#C;EG2:Y)8L2JXM"JIF<S(N9(R
M7^#\ZG\)<RK*DIS@*X['XUW':"MX:XV#QIR'UUH^Z]:6+I[7'^9][VFI2];F
M[+7(B+1)&5-KG6^QL=8ZN7F3;#)$DEJ4(2C/JEWWY\#O<%Z8UGS/U?L/4U>^
MO?F+DB^7+0HVT)O87/\`LZ4V,?:JQ'[&:ID'4K(]-Z:U@6`%DD=TP1I@@MAC
M`WQJ:;_VU*#<YX&G'9(6Y`?MAW%:PFL%<\A_4J/'W>,6U6S[-)['QO?;$G3\
MZRC)MMA93PM?#EF)UMTMJ+>=.ATE(4KX7&@UK6"#FZE+_P!P"TC8L#&&4"G7
ME,9:8.#J,=(2--$TF[6PP8^GRL*9+-!MU-#AS<K^F'KTZ\00$RX=AHQL*\=&
M,6;9^K#G*;K+8D_N>Z2M$U;3+5FM218-<V52=QY<CK\1*#7"WWR[,MR`TU$0
MXCL9,J6[*M`%BL1[9BDA'^C!^INB]%#W7FC:NT#82P5<B-DI#76[NL,,4>,$
ME*SBLZ^L&I*3J>LT[1UDU$339@;]I$2#9]WB2U'EMH_.9RX''U_1.HM:Z1L7
M2FT_M#I=9T/L.3TSM'5,<]OR9V1';0ID/9IJP2]RU+0+K<=;Q(E@B+-G64H*
M>,IN4AR&3DAO`..)<?#?QJG?/3NLMT<5U?>G0%.WW#]9:]OJ9VM4O3M;U0SK
M?80430[U`R$6EBSVRW'UN,BI@^(_",7^2EK""R75*;=]@;BO`>`\#65OOZLM
M0[WWQ>.D!]_]H:*VIL>LT.FW63YQZ2L^J8N>J^M`;"'3H4N#"!D8W\.)=MDD
M4C"4)5@LY]W&<*=<]P:F*)]1G/>Q.M>K>;:?9^DM#%<=5GD#8O,W4&M=XW)K
M?E*V+NFL;B-WI.LW.T*G&+.7ML^MQY-N:.:+$E7&1DK990PPA(;#:K]+FD8;
MF':7/=JWGT5L^Y[UWEK'H+=G3^Q+-4K3O_9=XTY=JI<];!3D_,TV0@6ZM5<4
ML&.%":CT_!'_`#-MN(R\I6`Z%K^FYF0V[NO;VL?L9^R#G@O?NYY[>>P*/I#<
MNN:YKHBY3T%6JRYD&N3NG[*ZP*)`5,(1&5D.O*88;2M:L,L^P(]G_H?I<E;N
M@9NK_85]D&IJ;U#MBX;AW7J34.Y]<T6@6^TWYN.!M_R?A:>?M@C4Y!Q(T>\Z
MW*8)R*RE.',9QZ^!@O-_U.<Y[1T_MN"A;)L#5E:%U/\`89]8\53=>25:S`T?
M2MO["V!.K,K$A+UZ2G,VFL/1+;(C[[K;#S;CF"A'%>W.`NYT+]5^E>DBN#[3
M=+198;:GU^;.UQL'4NTZC$U:*LUAB-?XCFG]=W%),3(,N4ZWL0XCD@R#D/*#
M&,/#_"E2FE!!6Q_IXM4?O/<.\.+/L'ZBX7<Z0GY:U;_UIKJ+UGLG5=NM<^I'
M[^[TJH[)K4D+JS84RC&<O34;E927L_*W[%J<RX'K\&\;:DY_N/8G%8N)K9>G
M*WHKE?64M_D^6%LUDO\`!6BI;L=N+UZ)"'C6""[21/F*(0R,(Q['O:RVA&,8
M\"$XCZ&7&Z+2>7[E]BW8NS/KTI$S7)9CBN[-ZG,B[%%U*T,VJO:RMV[`:0#M
M6P:4CRPQF$UEXG+*11FVT/(PVW\8;_(^/CXB/!B8D$.,BXP,:/C8V/&9"CX^
M/"90,&""&,AH<0,0=I+;33:4H;0G"4XQC&,>!W/`>`\!X%;NR7LC<A]4D8D$
M1.6.<=WO8E7/?\<;EO6=G7@]?QMNK]@GI\F?1*L^B?XQG_3P*E[OEHZ"^G&Y
M2DF1%B-#?7^.D%<VY#MQ*ITC1X0M:%D?[@SB%=%,L3PK*VR?]IW"_9G&?=Z>
M!5>K\-\70TF15[IJV2@K)`Z]H$RI^T16R396I2\H1=8HN$K5)JWK`MT8T^2L
MY@$TA190\F9GXB48AP$#A6WEA72NU-3+^M[5-SU.9SIK[5.(4"Z.-[9UW?;1
MK"#DWF(?5P&X*=*V$%N)V<T(W$ER[4'"SXU0,/<:"3("-.E!=+ICLO6,=`+T
MK`5S7HVWZ5"/RMTY1NP\'9KG#YCP3*+'3-4Q$V-IB'CJ7`@,S4.;&NC+E6#H
M@/Y(PB72I`:Q^7^G>@^'W:W3=8EV/?5!)LMI@Y?E&QV]FYOZ[UW1F'Y0RV:"
MV.Q&0!L$!660#X9^$G(H=^0DALO?BK0Y^V4'T+\N]LZ<[!8KLWJ*WB1RB->,
MW2UZ<OT*[7-Y5IBR2;(E/EY.$3.E`"5_VPTLP0Z,F2%)(RQEDQ&&UH>"V%BK
M$!;`6XVQ1@\H(P:+(C(>^1#H<B$O*Q#P2F%M%`G#Y5GV.LK0XG"LX]?16<9"
MHP&M]N<V1&5:ZM<CL[5\3/`3AM%EZ>JT[?DQ#A"`;4UBZL6.(79Y:5F"69;)
M[X*Y##K3_P`^#E/*5X$_:[V]!7K$7"28)E!V:16WK/-ZBMI,4W?*Y'!3I%:.
M.*"C#Y`21A$38WL'D1'7@RF'QWVU_&0UE00YLS4.PHZK7"OTB=M5RU_<S=AV
M.UU-R]SU>W)6I*P"A34!GGK:G[0<6L8KMOCGB`8:82L-MR2]K4@&"(T`X&&U
MI(<7+%;:M5E*J+#-GH]QL<^!7HW6=Y;K)U`EHMZ!ZY@CEI@I.)JHC@[*IYC"
M/QB1FL8_':CEJP%DH7:P0Y]<J^R$0U#O-MDIX&J0Z)MZ8@[@U#_*:.14[0_$
MPP,J;(5].#LQRD-2#+:'O]I;;"W<A+G@<!(PQHQ`9@[!89;#HQ0I+3;XQ(S[
M:FGQR&'4K:>8>:7E*T*QE*DYSC./3P*23G--PI>RZWL?24E&8!I<*7'U;6UN
ME91F@5^O)BZ[7FM;4JO1C6(FD`9CQSRXV998((BG2B0ECE`$#M`!@\5S+M"$
MO:]M4NYPE:W>=)2-KV3#L5VRQVII67L\:F/5#P:F"Q(R3HTX171R9YEQB0FW
M)!+<JT_'2"W4EA.D%T=#[.V\?JO4\Q`GHI>;$%L>=EHNT*^&:C6AVAP:%\`#
M,/9AX:47\$N606&"E;[;0+YA+1K(H5.K-4O4_O\`MD_SV=%U#E6SL0)VWJE$
M.T]_7UP,/1>!KU:HQ0</-'UK:4R!'0[!T7%OQN%PYC<E(/)D,"BN!BY.HM$1
MDR=L;4VV*/HC6>C:A7[+\M)C(*O3>M9^5JM=QK>)@B):E-PTCIJ7KC9B$NHR
M^W,,2!\2Y^2*V(U$!M(UM8S[?0ZG:)-R"?-GH0.4>)JZYIRN%I+;^5@V#=L,
M9#S+L6:.I+K"GQFU*;7C./<G.%J#-_`@`G0@?][$3\5=;9#4V=M";S<]:A2!
M+<!8;<"D0B'/CC&"ACZG&+G65RLP$![$3\C\>3%J'_('*"?_``'@/`>`\!X#
MP'@/`A+9+4A7[SKS9V#60*G4XZZ0=_4Q`ES\W(PUK:@$0$=$B104C.*5BXQ8
M+R\",K7E+><*]$95ZAZ&AXD>&U)2A0X-ZMB%1Y<V)!E9MWYT:-9)4^PL,2;5
M];9N(LOEJ4PHQB0;:(')4XUEMO",(2$N^`\"AW=UQB*["Z,AY[%#;B+%NV#5
M(E[/N$MK^DCB0\'.O^IEQB)R*5%3+)131,<V2.>&20+\;C;2\MD-!1O5][M&
M[++;3-SK8U=JOIF7B-:V#=^I;3?!XBX2%<URX3&Z,J%GGFJY>]-U*3S89$\"
MWO,1*)\II<8$R+EX`R5"U1D%1NDZ<5S9K:(57>8-&/P5/O6Z"8\FE*DY&C!1
MDAB`YSFX@6O!*<AV1OAL%SCOQ8F/<?<$C5%D8.Q'AA%-2YO68HFF-JE+B:=K
M\8EC3F[AZH=53.J0X-PVM686'L1B(P^A.&$5YDN;BH8YQ&PX`A1H+N(59#2`
MQ?FTF>3]G>W82=BX469K_*<8%9Y.H6-B5I$A)M777\2"+5:XW^P)UW#QCT'(
MX8KYDB3)@H=RX2A#9`CCP;BO`>`\!X#P'@/`>`\!X#P-3_2/096@N_=>%Q//
M^[N@9ZY<MR=3BH/2C%)DIF$2_M7,_('FQM[NM%C&(IP.M9642T6X[C([*<MY
MQZ*P'J/?9G<`R7`S_K"^T!MYI[V+<C]':BF0LL+94^R2R=&[_?'>PM.6TK0G
M/O;<7E*L>J%^@:RMU=U[3OW66ZO[>XAWM0$V7B+5VH1B.G)34O/LW52-D;7W
MZ7+GCP$CLZ4E-L1%C8J0J`PJV9^Y2N+D$LL./98PL/*-T#TO9-CE;;U;K2ZC
M5&P6H.^PUSMT+B'J=NI]FD-42FO:V95*V\U<)6/IR]8`!P;3\`H\<2>?:-P\
M".@!8:_;[:^EZ-OS?Q1<]LVFV6A7"HQZ*S#ZL(KD(U.2W.^AK5.[*`U]8*M=
MJRY$&KA!FI5]M]F;,?"4:V[\RLY="@/U^6WH?Z[+)S1NZB=8=,M<AW;9-DU#
M&\DQ]6;W%4*]M6[:?TS^XM>QX2T[PU%4ZW6K#N??>9<%]Q]/ZYL=A9!CKSCO
M@;]M.T#>-PYL^U'6^=DZFG-1U&_=HHDX[<&B9^W6;44?=HR^&6ZGZ%J55V<U
M&4.F14M$OR0,$^NP%9E2GB,GDI=989"KW#&H^A=']\\;UG>%0N&O)E]V^5V$
MA)*J3,M7[J)!T_6Y-FL-)V)*;)O^+12P@F!GF7U1M?>SEIQ]P(5T=?Q!]H/@
M>3#8G<"D?W"N)6;F4E\BYAFS&Q4PN9,O,`@C!SKKJI1$-\&#%)SAI17R9;2E
M'MQX'K>`\#6)S@-D?[1?LV<6,,RX;JCZ_#&GVWBG"#!,5?H8%"B6G%Y$'P.6
M"\AO#2<+5C.5+SG^CT#9WX#P'@4TX=(^?6>UF_C.1^#U[VA'Y5(..///9#Z@
MVFUE]M;I!"\BN9Q_M8_HPE'IC"$8QZ>!<OP'@4>TF06]W#W.T]DM0@M2Y'9#
M^9[#@J5+J6T224!M?$CX/1;Z5.8]R_<I7K_'KZ>!>'P'@/`>`\!X%4^[9@NO
M\1=ASH&6DG0_+N_9(/+P+,DS@H/5=J(8^:/),CQC&LNHQ[FW'V6U8]<*6E/K
MG`?/GU!JO859Y!X5U:3W=T3L*8ZR/Y4@*_SW>Y3GRJP*]=TV$I&R]L61N5@-
M,U*VN1>KX2"9DTI-E602S$"19BWVY#(Y`<,S]B?4%5I&W!@+=J/<^PMKS5`Y
M^YPN]_JD?FO;1J^P[?;*'KS+-DUQ=Z=6S[>T=)R,K+QJF037V@W5OL1V%,,I
M"1=F\M;H^O!AVMZUZ'![-WUUI<]5TGGO0^VN<JO&KK5WU7>+7L&K[,SL345Y
MUO+T;7.FV;K*G2TY+,3A#0^66<_DM82&H+0R_P!>'`)NG*CS7U=^)>NGA["%
MO0[:EUV/?*%M2V]*[%_9!+V51MO"%BG,QKMM4N*`#`47$PC;X8+D>EPIA@D-
M?NP^0ME\%RFJI/KV'=Z5XPC"69#:F_-14\</<&N)0B\N?KU;?TY694*&V-3I
M0*?#Q;+3!06!XF+A5%MQ0B\OE.AZG<&T:IMV[5^R\[;8B++':7J&M[*_VWJ/
M,"_>+_(4O%2M#D!B3HRF=<;#EH)$H)(DXBPH!#HQ,E%MDA?K34.!='1GVW*U
M.635NS#OS]1A3,;`5[LT"("A:Y&D3MGF8.`@.D:_$_\`N!UQ;UQH(LD43'K6
M,#&EY>D10F@C3?`WR0\Q$6&*CIV`E(Z<@Y@(:2B)F'.&DXJ4CC6D$!GQTB$Z
M^(<$6PXE;3K2U-N(SC*<YQGU\"+[=IN&FYF4N%3E#M;["G%5=B?N]4'!1)V>
M'JKQZ0J_:&"F'&)B,<C)<L3#G^T:,AUMP<AIX89QD(2KN\9G4%H?UUT#.@1%
M4A:G5(.@[-O!XC6Q]OV:"9,$NUMFXBG0;5`2!/`M#RK+<8X,<`D:5</C`06!
M2B`L1;M95VT%2=@%;16[Z=6QJHQL*&#!3:1:^#-HL@D"Z:0P[^QK2II&72(Y
M[W#$(==0I.,.JSX$/DTR`I8=QD+PO7&M:C/[3&D;'(F$BEU[:CUVJ55II\Y,
M#3WZEK6]XL]E<<C&4`EE-*8PG.5/OF*RR&+Q&W[=35'1-<U_>KM3-8Q=O#OE
M2FR")+I0`Z,.,E*S,U.(**<KVU:1.03C#,?D245)K2ZTG*GBVGQL!I[ZSW;U
M%SKVSIWI2];)M]ZTQ9BMF"UK4O.U/V=;8Z%H-&O,#6(_4@3#)P>M;-LW:<1+
MYL.QY.\C0H&OQZJ03&R[2`<CFAN/Y8[0UQT[3M=2&(Z0U9M"]ZRK.U#-(7.4
MK\A=JK7+BN==JZCI.JR4S4Y=RQPE>>F`<`'$./PCC!^4('?;6H.IMG1\]5;7
M9=YZ;E)D.RRP$C_>%%%S%O`6R1FG:!&&3[,S/*(-J4<Q"44+,V'%80[("AY=
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M/6V835XB`$FRYM]^NUNO.9P:L=MJ38$=)1AM:'V&`GOP/XI24)4M:DI0E.5*
M4K.$I2E./52E*SZ8PG&,?SGP*XZ&NESV+*;&LUJ<8$!BK+)4RKQ((LK#!E5Z
M'GIXZ$MRX&7DI0U+MFKDH`IJ0=_!5(LM?.T&T(H9U\+'^`\!X#P'@/`>`\!X
M#P'@:3OM.Y1DNX]K<[Z1@[S5ZY)T:%V)LIN+V)J:J[WU(678(0ZIB_Y/U;:C
MP1R6I:MQTZ-!S`^'RHL]#N$-9P0I2`]WCK4,R;R'I[G^6,M-0Y4U'0&(/9MT
MVF/B!V!NMVHS;HQ=+8$L)!3^N=35X2MN`S1+N,K,CW6@8(@4`5)K@490']@&
M]NDH'F_AGJYW47,^J-5P.Q2YCH:B2<[:YNJ2NY[)5:`%4(ZBS>NIN0HPE#UV
MRU#B2KS'[..R\B7]A#[F%!;([AG[69&O,5F<^PO1MN0*X,;'6.?YFMK<]79F
M'%+;KMAJK:=TGL05GBRR$O)DF7,/X4W_`$XPE2T+#\\4_7;VCS+UM4]\;0WO
MSWMJB.Z!G^>;?6:%K[:>J)P(#-Q-VS&;;+)LVQ]ON;EV]<-B%N#6*5GS@RE@
M/9);>=(^1MP-Y7@/`>!'%ZG=E1$SK0.@T&(N4-8+RF)V;-2MR9JZ]=4--;L$
MD[<(J,7$R;]VE'+$!'QC<6TL17MD%$J>P@=2%A(_@/`C@VR["8VO7ZD'K5L[
M5LC1K'.SFV\7.*&>KEVBYJ`"@*(N@/!?NI5JS0\D::F58(_'$S'*9=;PIYI6
M0D?P'@/`CFH6VYSUQVG7[%K*7I==I5@K\71+L=8*[+1NVX:5IT'/RMDA(J(,
M?F*R/7+')%PCP\HTP0\1'K?:PH=UI>0U\[-S\7VT<XY+D1073>=;@U7X[V26
M#+""!_E!VXK3EEI(+C%=-.@E+4X[EMG)S:5M9=>&<;"SF_NS=(Z"U1T%M0NR
M1.R5<P0P,[N?7NM;CKJ2V-2P3<#EH;G8&P7*MBP<FJ#<<D!PCR1#)$=A2`FR
M2%LLN!J2ANH-&=+]N7+;<GSEOF2T);.=-&<QDWG>?+V[]912[?L[9.^1QX*/
MCMF5ZH9=J,LU9(UF4EQ`Y!;+AHC:<L>Y2G0OBSN'<')K8^G]KAL]`+LUC/$Y
MHGPK"B+M3]<;GT(J6O=_6:Y$ELBV:L5$-^17?#%,!3?X#HKC7[G`_P"V#4;N
M3?+&FMY=TT??W&K?7>SD6ZG$2/1>NJ?7*[78R1L7(>CE0]6#IMA>MD[6Q:N(
M.X0E;\K()6PO#BWLN.*1@,\^K7ZZ=+;\XTTYO4W8.^*#:;@@LB9"UI>0JU7B
MC*0>J@QDB@2=JM@FRRB(6HB9_/*-(+=]J7&76FL,-M!VFXS;>G[!]C_$/)>G
M9KL4_;`DLW*[`O':^C*KL:CG;'YOI$'+)G*+8(N&M']O1MVMI<DJ5!CR!W#Y
M5]C+N'6<,-!G%OV!TI=^V_J1@M_<I3'+KNNMK;I33C#-]ZSW3C9Z_P#Q2OU2
ML\.MC6`S5BA\PL7(HE_R"G$1K^!%X*'5Z-.,!]$'@/`>`\#6-S1%L!?9K]H!
MR&WVWYBD\%$O?(;*E-/(%UWN()HEA@YU^/C4*RRIK+0>6FUJ:4XMK#JU.NAL
MY\!X'BV2"#M%>GJS(/2(P%BA92".(AY(V&EF`Y<%^/)>BYB->'D8J1:9(4I@
MD=QMYAW"5H4E2<9P%(/K=B1*[SM8:J$LQT>G]+=;TYHB5-*D[`4Q5>E-GP(9
M=HE9!Q4I+6<D(!I9Y9:6RBR<J>=3A:\YR%^?`>!JHU'=-*<W]E]K1FQ=U@UQ
MVU1_/,P"9N2Z(%.,=-CMKV,P.-M%F>$#D(R+78_Q0`6G<KC@1FV,(PTVC.0N
M2YV%R>SAK+O2VB6\/-8>9RO:U(3AUE2EHPZW[IO'O;RMM6/7'\>N,_\`+P./
M_P`R.2?_`)IK0O\`\MFC?_#SP*"_9-V5KW_QI4)SYTS4Q;_+;)HP`D[J?:\3
M_<\'F.S,7,+*U5BQ,GO14W*5!B.,#6E\:2%+<$>8>:>6VH-QG@/`UC=Y7;?M
M5WMP74M#;<+UB?O;;>TM.VG$G$5BUT540SI&Z;;$LLQ29F,1,V2QP\EJQ`$=
M@"8BL#,RY3S_`.0AO#7@:_\`IA_[#!F;YSOVSOO3VO\`FO=GIKV#Z`J.E9^<
MU-<*G9HN2<MNMM[S,9*1,OSF1,1P+T40?)O?VY,1TC@<:9'D%Y:2%,MD4+I3
M<35+[N@K$B=TTC6A7+O`VO:]`34+M@C1=5@B)B:Z7J50=C[$HJ:ZGCZ`U)CM
MQT,],1]2Q%):6*E1#S0>WH@S4*M]RO06\*>JL<\_7^V3U/<;FY#%KB;CT[O7
M$B/K>BZYJ?ZP4G$U6B[&47&1J7&2627(%M`[CQI93P;)-/Q&\*;5ME_;3U:J
M(H6S[/33IB(YXVP4\F)YSY?!E196A:NBYN%:E%5+?<M!'R#UA,&`,Q+3<N-&
MNL,X$7ET*;U5B*^S'H"R7+;_`$1>]%;MV16]AB_7IKK5RYN0A]`:OUY(V2)`
MV7MJ;KI@,4YNC>1L;)V(.!?EH:3S"5EPB->0Y&MEBA/L#UOOOE/H'4NF/L5'
ML=?'>VU$1FC^H)VR5%'+VU866H-IU_*Q9FTP:W67=6[3%#E1I3^W;\D95A-$
M?1%'E&$,-.AA?7_UKZ>N+UYW=PW&R?,&YI1)$+:*7C4U'O'+NS[-;GHJU2_^
M1M+#'YD:CLRZ#%1J'IVN8$L<B&\RR@&8R4@8@.QQ-H@J.H.UYGK'C#8,'T&=
M$[`T_8JF;6HW;FLXI*HZ"E(:;UC8`@2J2QKNT5JU1P(F9!YK,0'$N,(%CFW)
M45`=B,UQN/Z[&'-@\JW[=4IS37#EVC=>K.PXJ<A:UKO6$43,SNP+I#;>MT?%
M`F%1^77RGC9B3S-9C\L8R8<T"V"^&SGAK['>=>[M<U2X:WME<C;38XQLY5"S
M;86?*==2R>\<FJ3D<I@*YC1J(HA121VF9&.0WC]B$"M:6\A>R2B(J80(B5C@
MI%($@'+`8-%9)_"E(]WY@)(3YD+R,<&[_4TZCT6C/^F<>O@56N57VIJ.R-6W
M3<#*WNMR,=@F\U,ZZGGSMGLM9H=G"ACB';<[)CPS5D?C(8(R0AT.23TA\+Y(
MA#."7$A*50NE!Z"J%N@)*N)DXUG*Z5L2F6N)%EH19<E`@'3%?R=A)]1N\0TQ
M*Y#(*C2#H_)3+X^7,/,/-H#'[=JN)K-8&<J-4LUO7#;/J=^B*\QL>6@C:DM$
MM$A60^E2<D6[@>)"A%&FD5Q;S<;,-NE!92A!>4>!"BAJSJT7Y=BR:9>-M.'-
M:R5N`:S3]578W=$F797CMU4&GAN1.N=B2/JEIZSN1P`II,^PA3Z%&*&9#5S_
M`.!O17*%FOFT>7(/2(NSMY:K/IM"NV]K.Q8;GP.BOU:6-O$O66ZY`@O],T)X
M$`*(AUAAQE@A(T6N1;HI,!&9&'"?/K9^QZ?V?K*I5O>E2W^>;+;`UY0Z-NRR
MT:M62`DHK<>K:CL_4,'M?9&ID#45_9C\?94`2A0$2`,(\1&IEFHZ1-6/@-G>
M^JGMDV(:NFD)X5F]U<"1RYK^?:#53-LQ*V<O)JLT<XEF1K=A"+1\T#+L$(9!
M-<6DMD@1]Y&`JIJ30VZKO1#*!UM:;"/5M:5N$C*?.0MGL,#9Y29,IZ6K;L:<
MV*_LZ^SD_(1.2G/TY9;T?(UN047_`+LBI@"7R'9UA#C6BZZ_'ZF:HI%LK<3)
M5;4K$RUK"7+V#`D[$=LNL;3*2D<;)2S=G<BM9B%#BA?#!RA@JI%M.#$X`BPG
MOJS8`=,JD$)$2\=%[6.F$2VJ,R-5_NX5=CA716,CEQK0ZI584\J7:AG&8I\>
M;,3)Y9!4IQ2D^!5N7,NZZM$$W6:F9;NZPLRXU'U74]D06L9%-1<VT=L*BB3#
M4:;)5W$!6J-5'&I"0.%3_<(<?,,Y!][Y(;83%JCI?8A,_)Q>U*#9_P`-N-<(
ME3ZW2#W2J'9X&G0AT]`258@)&Y3+M<LTXU)_HB'W?V6"6DAO,.LDQAYP8A:;
M;9NMM6;`34YF7TP+6YJO,G2$Q-U_XYS7<VPAZYP"%U:;O0@,^_'BYP/*'0<O
M'MF)_'#:-966O`=G@]R-L*]DW"(BKM21!WA*"=19(AJ9HY\Y4[3=TE[5`L:V
M22C-F;#C2@U6D/\`-=R`Z(*V\E3O^^X&Q'P'@/`>`\!X#P'@/`>`\"C%^E''
M.XJA$>^2SB'Y0V7;`FFJ\#B+;E5W.(A!I!VX$",D"2HX))3+`6""6LM$NNK:
M8_A;X4MY>C-FS.CN?]@]%1TR/R.N@:WFT:KL@SMYL+.P@0:T'&;1VIEYJ[-Y
MT-^?#HN,0SDZ/76CG/SY/"F,,C1H2/S(IM_[/>O)$=XMP.4Y\U>:&@F>38QD
MCXWQT`(V5$2/R/+8B)=`V#60LK4@')"F6L):2A.`VY>`\!X#P'@/`>!K\[-J
M,QM7:?)^EF=D[NU?5]AV;<+]IL.A-FV75=S2JHZJDIN!P98:Q+!E?HFY3^5H
M>%*8R7D=*LMY6G#H?-#TU9Y07L**U=HK[7?L^K&F(2X:XU]N4Y^_[:F)'6-B
M9O,E"[E"DB[1S/;942PPU6P*2*P6I(0[B\%$O-!N-_*%YB)?Z]UU@`<C[Y?L
M*K\@#``QTK<3NI96$=(ET($4JQ3(%ITPN`@Y::7ZH:#^`8-:WOC''^3"?0/"
MA;U]8[;[HX__`*DKJV9E<.EDAX=^P'41CH>!F0R,I5$M:PR$>/&HCB'7$DL/
M(4A]SY<*0VWAL/6G-V?7S'JA1!/_`%,6_*<[`'NG&-']3<ARQ,M+H><;]9O^
M\^?99U83#"$L9C<>R/RIK+BF,O+=6H.XGK'BV16>#&?^IXV>.;'DQ[3SQ5M^
MO'(JTDH8.Q@%PCD((:5:+!RM"7AG76VW?=C.<K:6C`5([`VU6JEM?CV^Z>^_
M+:.TI^3V;-Z?D+*T?P38S=;4O9<U0J[L"QA!U_GJ)BE8'S%#FOIDAR$Y"BWL
MC+0O&<N!/N\]<?7O6N4M^6^_?:WC>.S3:;O&>VK=G]D<[0]RZ&19HFO@4O6E
MFI%#IH4:\_2-F56'<J#T7&-R,8^<6QC+H<@0TL.3FKH[16W;MM2G[";UAVDG
M6=QUU)4^_P`9-76MU?5DILO_`!Y4='!;<H=QL*HFK1M0L,A8&9&V,LRC;+D0
MA8CGYK[`20V6OCQ^EAB-#;!I\=U79]_UBDTH38-IE'K:*94[7;6FS-4;)V+L
M"1D4/U^FE[&EIG7\0:2([88,(AC\IR=SDF1#0-U;QUM+_P`F=S;$_N*$W%1J
M/O&FZ!V-;-EZXMVR)2[;%)YSYCCX`#:!U?KNP['7ZD1B_N,L%Q@WY"(X!8[A
MK9[S"\ALH^O*7O5F^O;GVGZV^R#CO7M1MNJ`7;]&Q&O7%[9UK.63Y)7:M5@;
M8=TC6':U<:DL\P-LT^O))C3T?D_$I*&_`L)_X&\WZ-:Z:VCHW>O/FO-BWS<E
M`ZMT+,RE)I>8+0<YJ36](I\]#X3KRU578&RZ%LJLP);=G1B2&*D6+&7E:GB"
M7'GPUG2?=?3^X]P_7MM.T]@?33%7PN8F$:ZA9*G]$IM]`DMS:A=;V#8Y&M3>
MWHA"9&GUA;M;7\,HP,DB;;46XTV^GX@WF%VGO9L1O$)U/];<W(-8"_/3(ZAV
MY#"MB--KQ)R2%Q_5,\\E;KJF\MLK2EM&,YQE[/\`&?`\@.S_`&9$!-?)OKZO
MLRR`LO'B!T/?1((Y."6V<I9*5OEHIP+"<._[JV&U?*A*?;_*LI#V6Y#[0G8D
MDL/<'UJ2)^1UJCVDZZZ"8B'2%9:=&_)E&=X'/MCO#J_E2!UYQ[\*QA6,>B@\
M,N>^W-M;2`+)]6AR/C]'7RW^FHQ:WOF=PGX@V967PVVIC",^F7UYPO*L?SC&
M%*#7V=>?L6YXZ0Z5W,_M?Z;I6][@J>F8>WT.U=/[MH1U?=T[7[8W6X^%JDW!
M2KT?)6<.^8<7E]UE)&5CJ_A.?7P+8ZAWS]M6ZM1ZRW%3`_JD*KVT*56[S$M-
M;:Z4D6!(ZRQ4;*CB?N8NCE@R)8*37&2,M)2VEX?*4YS[L^P)=#E/N860$I^M
M_5^\`IUK\_\`$O\`U0DA+:2,H*9"<7KIYEQY+:?1*UX3C#BO3*/1/]09R':/
MM+#CQ<S.H>#I`YALAR4(BM^[XB(Y[XE'J:_":D>?Y%\-#C2AO<IYQS",H=S_
M`#A2/8$0:"J'V;Z1K%IKF=2<.VN/M.S-[;4#(`Z&WM$2`$EN+:-HV;&1\R9+
M:#LF)[]&NU*#**:4/^8D=+C2&,*^-(641??L"4IW"^9^6VTH6E+2\=<[&7\Z
M,M-J4[E..2,99]'5*1[<Y5_"?=Z_SZ8#S)'8_P!BHSB4QW*/*\HWE+>5.N=F
M[#C<H4I:\.)PVOCLO*\-(2E6,^N/=[O3^/3UR$)Z5O.W=9]7;KG.I-&GZL<Z
M.C-+Q5!O%`OK&Y=!/6'753LX:*`7:'ZQ0+[5]BSCLF6MG!M6:ACVQFF63U&+
M:%="/:?]JLY=98H",YS@60Q1$2"3S-M6]DB2CUC2Y7YD)!*YXQ.RC"V0&'&L
MH83@ADQ"V<N>F<9"5-:=[;(V7H;<700/-=8C*CI4.XE6(,O>R")"2S2:&#L6
M63#+&U*H9\=4!*BH:>6I"'25.81[F4(>>#!/LJD9OH/25*T+I*D739.W;T9K
M#:$A2Z88%&1E5U?:,V2"8M6U9Z7)@XMBBGR*"QVQ$%L29SH#SPJ%8"?R@-O?
M@/`U<=PK#:[3^HQ;SHR"W>GM[BBL^H29$EIWCK>#Q"&LFA$X<C&G!672$,N,
M$9>;'4C.<(5CP*-?;YUW/[(LTQP)H^7$"AJU$06P^W+T1*34$`WKQ0<E;JWR
MC5K!6Y*)L6-G;]"KGPR2(Q]!<?`&-86I"#UN,!6[2'971')-;`U_1=26+?FS
M9F'D]5<\<Q.V*3@HZO[(B9^^QEOK5'8-S*R:*9K:K:T@CYD<QYQD1DB2>&.A
MVLNA+#/N+J=%]![HUW8=E;`-DN9-+;8M.\\;;M%>M-)9^PO["S@JQ5=A[IF#
M9,:*KL1I#04Q96:CKNNGL1Y!K@`S0B#Q8W&6PLS.UB+^P+I;8/)FK]@8N7`G
M.&ZH>V]GM&6J"M<)L#=41#@IAN#:9"?V^22+J.AV>J#7'8"BS7E/3DNF'&?;
MP.<(P%CNL:6Y3]PZ!:Y1B-7TS=%:VE?^K=CB6Z"#KFA4T]_5$YI[8^XN@;#6
MH\:T15IEJE*.5VKR`;ZRGI,EPPL4Z-BY##`33`=!<S=6\Y98Z)K>NZ[2]I:V
MOUPMNE-\RE`GHVRZ@H$DANP;-_1R19#-ATU(1^0+!$S)H(+CD)(1YQ`H+KN&
M6PU'\IZ5WY7-1+Z2YIIO^;.(I_;^=E<G<D[,G+4]N?6O-%5:JR-3;(T+;K7.
MU("9$GIFFIM51U[=5/-15.-B@HZ7`)9<#)#:K2.P-:]<Z%W"/17XN#MT@5NC
M3</KZY2+X]Q>M->K4AE^#M^NQP&=H4BWB1I6,RU8DX82>"?:>;99*'R*84%X
M)>GU6WTLZBW"LP=JIL_7G*Y8*E:(@2=KTY`F@_@G0DY"33!84I&F"+4T\.2V
MXAQ&<I6G/KGP-;?0'U(<T;.KNOF=&,F\97S52JRS2K]S3%0-$)>@JC$+K\%4
M+C%1P`K=C@(^#7D00IIX&P1+.5?K9,)2UY4%?]9_8K?>-;A'<_\`V;3=1AZL
MGX*CJGMB&)(:UALN?K84HJVU_8Y<MB-D82ZU<>(6N6/Q&CQX^&U/%*2TXV8^
M&\"-DXV9CPY:'D`96*D1FC(^3C2V#H\\0A&'&"@S!7'1BAGFU84A:%*2K&?7
M&<X\"#+KSQ49V#L</2R)K4A%QG3[)89S4\X;K^:S:9DJ')DK^"J);(K[M\P1
M"L/+,/C3OSTX>'(]6RWU9#&*/T*\!(VV%Z!<HFH9ENYR@>NH21M#S=@L.OF+
MC7=:PMKG1)6.C`6E3M]L`@PQ4>\3'$M2@/\`4R^XX.V&<;4UC9)L"S3NI)VM
MT794Y%BC'R4]4HRS5F]HKX<OBM5G80)#"I!ZL8+E5M$O@.,2:0W%(:=Q[6\)
M"O%\KT9"'VY=DF=C[.WN3"P>]:'J>GGU22L&J9:(@XO6.T+%RA8-J0D*,N,6
MS/N.&Q,A(%-?]YAE(@_[)+#P41ZGX+67+S^S(WHFZ<>M?Y7(V4`_H:/E9/7$
M[)-T2+U9J>8=U)LJ>*T]J7IL<VQ0L0+,(^(&67$LFC,`2"E$BA"7UT]M[[CM
MB\^\J60^NF2$38IS3V]]`;'F=EW7LVI7MK6<IO/9O1\Q)6^X6:2IG.\)LBXQ
M]2KX5D>-<-A,CE`R+^7!QU!O5W]HR-W-7&_QB,1-W@&#':K++,E0HJ04XL20
M53;XW!D@RL]K*PS$2`[+QC3[*W\ALNM.-/LM.)"L]JN02\U?6F_M2VUO8SB:
M1%:XVCK&ON/LE[&3/L2[>OZ)LJX!1#\;/U!H)@QR7.S'Q$X`@IYO*'FBP&0\
M.VG;"H6X:09M/6.J9#:FT9*;K>J-LZH'O$LNL3X=4-!F;#=:C9AC`!EYI,.R
MH610HEB&9>*%+>0!^3(/!?>B4&NT2+;%AA$.%N,?`7/&$R,Q89<1,A)20+4U
M9IZ1FK%.9"<EGLH648]A*G5Y;2VA7LP&OC<6UNEAD76IEQ<7KL=O840W";I'
M3*,:7=JWZ6\2]A1MJZ10B;/%4!BL0K`#DA$.14Y&69K\0HR.!R),%A)''TA6
M=J:.M&I[-KRRQ(4`/FD7<:^6"4GIV_-S8AKYDT]8GUXEY>K6"+(0[$O$$M2'
MZA]EHH")=;5',!>Z/`"B@`8N-%9"CHT,8``(9&&AQ`@V4#BBL-I]$MLCL-I0
ME./XPG&,>!V_`>`\!X#P'@/`>`\!X#P-0'>O0C//F[8":A!#[5.V?3=AJ%AJ
MXMJG<?KX"6-.);EX>DC1LK%'VU]R,^)@U:A6H\3+KIGO86A2`M%S;MS5M!Y$
MT\=,S\(")6-)4N6FH:L?O+B<"TNO@//`B1,<FQ669EE$$X;R*PDLAPE?L;PO
M&4>H4<XUM^JZ[]EF^M;Q$'":VL%UYPC;A4*8J6SA^=B8?IC?)MMEJH@B>E1+
M7!K.MHYOYD5C``C9&!&FAV!FT9#>!X#P'@/`>`\!X%(=ZK>1V=P?C*?8&XCJ
M-I1&72&4JD/\6P;H<?CV,Y%)62&R4_AE;B5YP+EQ"%X:6IL-!G)'-.B.QOM&
M^T;7?26K:GL_7M,Z0WO-4ZMSF;*,Y&V8N!XW#LLZQ(`VIM963$"#8]B&V,!*
M=>2C/Q%Y9;"SOV)_6/P+RYRQ.;FT3S-4-:[0KVY.40:_>JR-8[!,UYJP=7:4
M@9E\<"?F)N)4V=!R!(;N7AG$*:(4WG'HOP-T^WZ,V'2)9&J=":LOUV/CYP>"
M`M434XJGQT\/79B2KA=R4^PS)/UXFS@A!%(CT/'-)+^5*/:VM20U.Q/#&I*@
M'N2W57KO;_,#<9?W[CO/5$QJ;CS:D;7-HV62.3#S%3?W9RWL"Y6`"YCRK`%:
M+#)-*LK6!VL_-*9?80$5Q?UR6:5DQF>@=N72FZAE)12M9SEHYD^M&9COP3W`
MYA8^[8]/%,"UJ.6M\R<RQ&A-FFX=/^05TD8MP9D@.#>?U/T(L*V:AT^Y';+V
M`7"BM7-BOZ"XCTK(UNFRK$<#,141N.JZ!#L&O]D2%9._)@7&!W\,OO-.OJ8%
M6A>`N_R']>GUV+TY"!1>C];[BL-5LEL$MMKW9IO78VZJ[>3I\R>EJC>XEBH0
MC]1EZ@/*C@1X7X[>&8,<#+#A`N1R'0ERY?4U]<-\(_*G^0=1,OJ%<!?56(N1
MHR30'%H>R!)M4B4KS4H"@A&74,DI=:;><<<2G"W7%*"DW6OU2_7?I74)FP=8
M5.?Y?OL#-03U0L^EK!LF0M]PG\!/U:OZV#JZ;%,IFDVA$@/'L_&-[P\LC+RK
M\8;+60QOCKEZK:$HU@H.O:+.\[!TJ)C-F[^C;OW)TY4IQNSCQRZM*[+V088B
MV5PE=AB-;M+#G4%MQ)\;'9)80RVRH1@,&K_!>G)&6C(K2/`O,<Y909"J#C6/
M:>Z.KK-9!Z1!S<=!3=NNMLN>OZW*!N5Y#SA56%?)*DK-#CC/A##QC[9C`>G)
M?71KS8$W+A1]"IVMX>DU39-><L>FK#M^O:?EMB#V4&;!$(?D+5!7J&N=516<
M"O6=]V2K`_[-+`0YQ)!S``>-SCQ!KC;4L;`(OE@U[L*LE6<:QZ&VQ1=LRP+#
M"!7*B;:HETCHZ/E+M3'C8XAAR2_8%MIEW'&?4?VC(2&8;:^J.*I*:?\`M-G6
MD?7DI9DQDY+:KU.-/1.O2YVP+,BY^[5;:UBW];+-53+#/K8*D&SP(^KQ:,/&
M9Q&"I_%#LM?1/3K"%%RT1US8#HJ1BX\L2;C-*:0.?F@W(D=B'E1[*+%J=D6&
MH_#2@'U+?PVSA&6UY],*\"':_P#3<W/;,MU-,Z$-JFQZZZ3,@*M7/.GR9NU4
M`N??K8VQZE>(,;\27CB8-YW!$9E+)\+*.##&H;'>$))#N6/Z&=U333@\=V0)
M`C$/BX,&5JC7]B&+BVABQS(A\:=I1#*F)51?O?7Z?(K"$H]?9CT\";^:?H[H
M=7L-S(ZT1IS?]4+K]7B]=04;K_$#*4J4AY:1.EY3$V.S%-N"RPOZYML5`WJ.
MX'E:7<X<]N`E"5^H/ZQO[S+A97F$2%K3<'!Q>+X-LRVPU>+LH9,RE-.7%Q-I
M&3%2@$86VXX8XV,T8I]@;"G7V4H0'2W-]0GU::NUC;+;9=?&:_:"CSOU5O,V
MQO.4(CK,6&0Q`.QU>B[T\?9I)J27AYF,%'>?-=PK&&UJ5Z^!#_&?U(\26/7E
MBJ&[(4O:.WJQ8Y4:R,IMF[];D1U*E!D@U3X:ZK9.6[=0K:$*3)1DXA#L=(?E
M.,MYPZ&ZTT$T6GZC_JX7=V=;$4^\C6.0AX^87KVJ;UW&.Y!5G\A,1'3SX$3=
M4S,-!DS`>&6U(=PE;B7<I1^*P2ID,*WA]!?'EDH%N=T="W2L[8D(]C^U96V]
M"[X?I:35NAMFNR8H-HF'0LDQR7UCOC"NI&-6V[EAYA*QG`J51?IMY+IHA('0
M5TW?J2V:[I<3*;'V[KGKVV4^N7:RQ[U/;L,I0*#9F9$_^P8ZVS@P^"6<!O(E
M?P@VPE$D>WP(1UA]!FGNJK=T/.!=,=*:WKNKNBS-?UFK6V"UQ>;<V+&ZLU3?
MFI:W3-XJ+EA3:G)W8)JW&W_18J,H:QC"DJ4H.YLG_P!+KBKQX$KH?IJQ6B?1
M("@/05KJ^K-1M`1Q,>7'-64&\4+6,_+.N5,UX<O,/@(=$H&TZ*DP-:D.X"YM
M(^A._46@9U5'_9QU$=K--0E:,+KTF#AXBD`UV6$6"\`/5*=9*M!/#LB/.-)8
M(8?%=:=4V^T\CT3@/81]%ET:M$'>%]^;5F[O5`:T%3KO;*/+35NI>:>>U(U9
MRK2P6X85H-BMR#IQ@`A#!00YTD^KXE#*_$\"+-;4#NO9NQN:*X?V%UQ+ZNW9
M';$F;-LK4E3D`*W3B-6V/8-8F(*Z7X^R72#H_P">7'5M^.;<RR5,ONGCL?*V
MA[X`OZOZ^]@`5B:?Q]KO>(\3!BF-FVHO9.IS"()5=>1F;/FY0W6ST7^8$Q&N
MMFI=99'95EU666\X]$A%=B^O_8FQ-@4S8VL?LLZ4V#L_2]BB+'6G[5-:XF-=
M5:!V+&R=8NF8O`>G[/2)NV'40L@V,8D1954=)#QA2T#CO842%.]O\//:/K^W
MRN=K+M#9`U'L]RV5O>)W))-P.VF+:]B.MNTMZ$74J(BK#M6N[B@(@\>-.ASV
M'(8V>)6.[[!<#Q(0)H33NTMPW.D:OJC\B/O;JK2:&;]MH8T93O`'US%@5P&,
MS38X!$Q&4/J;N2)C8\MV((<:7%!(0K"$)B'<$AM0Z%V;K_F[G35O`M=51N<&
M3(ZM:>M-RK<?%6[6_)G-@XAD)&]!6[\UY47K06[2$+B!I9]K^-K%O,082@D>
M/.5@*E=DP?.'*=]!D].4CH;B'<>O=24,/E7KK1X"KMH;KZO00STJ%SOT+*N_
MW-K62CWKC-*48]LG,9)O,$.3,9-H]2,Y#=KR]H.?UQK^=FMX2E9V/T/O%P:V
M])W&&"D?[*L-G(AVX@:C4>$L!DF]%:@UW7$MP4!'N9QE\$=9IB7)$XY]X*$;
M"Y@YLW]NVF<=:7YQTU`<[<^7RM;NZPMM4UQ3X"&:V-"Y;F=/<ZU(^.B&5&6J
MPO,YF+U@)QMR)JK0,47E3%C4Q@-L.R]E:XT1K2T;-V188FB:VUY`N2L]-%MK
M;`B8H)+8PH@,>`P^8>>8^MH2/CPF'C#BW611677W6VU!0[N+DCFK:U>:Z[G[
M*/SSMW4=2>LU>ZDAH7];;X"MH`00Q'V8-T06>G&Q\+;5&,8PU.1\C\:`5I4X
M\*2&/?6/NOHS9>L*U!;,UW-IK<!#F.G;2N=J<?E2W3@*R=3Z[!1[[4U(VM!`
MAIYSY[TFXT)&NQR<N_E.DQT<&PW86XM5ZF_3YV7?ZK1\3RS\16;),"1:26(E
MALF7D%*(<3@:'AVGVOS#G?C#%4^REUU"GFL+"F=BX7Y!ZEVV/O3=&DQ+_L;2
MFR]E#ZLM]C5)1(\0+?:!7*Y9RJTQ6;*W$VB%EHQU&63Y!A18\D/\C.&G!6'<
M!I_R5]AOU:;4ZLOU#U'3P_K.U1L/6:ZM6NA>Q:RJ-D=.V>,!BK/8]*35K$@Q
M=+.ZWE`6AT0\^46J0_-:&2@\C'['(;_N6.N]"=E:ZSLG0M[B;9&`2)4%:X-L
MV/S:J)90"RP3*[<H40PQR(/P^`ZL9WWN!R(N$%!/$"NM/+"7K]K>G[-BQH>X
MQCLB&$>/)"*%DI2',8)'6E?HB0AS`#?Q2,)PE]C+F67TXQA:5>F/0*LQ,C9N
M182YR^V+QM/;.O18ZE1='6)5J><W&%MR$W6X:IPT15P8J;`FBX5F(8/,E'40
MIAWQO,.BD$D,*"XD>6!9H6,FQ&I`8>9AV#H]T^,/@IT(.9"9(0DB.EQ`YF"D
MDLN(^4<AEDAAU/L=0E:,IP%6I"E!ZT(K6;:;8]B[%VP0K0YNUY#6QMRCIBJ(
M7<K=1QMY5/7F:I3PF(\9PF)18G(X,'!1:677!_V&$*#S-/("K.TCHBE`R,'6
M1W!-,R=!VP/$5FX4F-U!1@S:E*:<GD5R3M&[*':8F;%(,5(665:C7'\K8<$)
M:DP,A;*LVRKW2+Q-U"PPMGB/RS8]4E`R0<J&W(1A+@4E'O/A//-LR$::RMDA
MA>4NL.H4A:4JQG'@?NSPCEA@)6('DR((\T$IF*L0(41(2=:EEL.(C;'$BS\=
M+PKLM!F*02-^4*0Q\S:?>VM/JG(:N%;)L/.6]9%&[*Y8[/(7Z`8KK-[D=@_N
M=824+"6ETN6=BHJ>@9@VC;*LD1:39"*J`I(@L\MUN`CVBOU;1^0\:^;\V]"!
M%1P.Q';1K&P2-3DYVR1L+G_-T=JJRC#14\<%1(2/UQG4QFIW(R87<0L(E;"P
M!#&%!)!D?D&`"T)7,W]\T[4T2)ML>[T"-GPM@S19\8!.#VB1ER7YXRV4>5"D
M'QH5B2BSG8F,'0X2$+$S!9BE&2:13$!%<TF4YFJE>U;.:Y(D=;4NN?XMI>^:
M_6ZY;KB#K,^O_P!PV5^9U;#U=29C"3:Z-%38@B,D',,?NL-NJ4\P,&=</7K<
M%E&V)6[W&OYH=0DQ6=<6"8S,%39P!\C/>^/&L>8,&J6ZMAQP8JV<A$.E5XUT
MJ#(6>W'C2\@%]_`>`\!X#P'@/`>`\!X#P-6?;<I51-L04;9[,Y'L3>M0Q7H1
MS6[-Y''AV]G5=$A;0\2\"=5E2V7"D1&<&DM+#$-=*;RSEO#N0\G5]DAHG6T?
M7:K$WT6M@U&@!`5"C54/84),UA.8HF.@P)RL:U-+M@=>B9)[\<J(RIQP)+9!
M#GMP^ZV%/M)Q/]S_`'!4&:NTA9XZ?UIJOI(K31+VN=1:BKMCTKM=G5KU;UV^
M(Q&Q6]=B6.EO5R1(->D<G0HSP'YH[^%2&1Q0^B/P'@/`>`\!X#P*-;U>>QVU
MP8/A"E#N1O5SSBOPA'D-OL:XJ#;"LG.MJ+"<RV2[A*6E)2\G*O?Z^U/H'SV<
MDW?I[6?V9?;+/<L\ZTCHS8DGU7N!@JAVKH>,T@&+4_U'-*)2PR!LK'7.39.&
M.8$R%@B"*%*:-=2`6&VV4PZ&Q'I!_P"TWK?5\/I>X?7_`$34<8?LC1^P9F\U
M[LNC7;,&7J7>5&V0B)Q`HK=+,F(B1%J'R$%8>PZAE7Q(!>=5C*`VWR3$KJ2Q
M2]N%&&E=;68M$A<QQHU`\U03FPY^2FKFR0&0X39JY+'(%:5$CQSLBP>:^9^0
MX.I3(X0KV>/I6OPM)VY<+!&U+;5,G0R=*3(,&S<;7;+$,M1[5&CM=-DL%;7!
M-PI9346A+K\<:AJ4!4-("CDMA*&MMJ5;>-<M5#VI3H>J[`J[#(6W-,6]P2=%
MCQGA`)<&PQKDO&QX]SUO-B%LO@S+8B1\$(>#(2-)!&B#!`G/6SJA0M@WK6-/
M+>M6B7;9",U';JG;)/#M7RY0%.8K^MU7H^6O9VZ7IA`<J:[;GY`%F'2P)#DL
MJ7D4HD.OV@32-535'V379*.#W#?;G4ZFYJ$-NV-.=4,QSWK6*E:E:Z"E+3!8
MI4T@0QFWO@2$;"@MO`2C3L6>ZU@+@:;V)3-D4@&1I8YT.-`O/U*8ITX"_#VF
MASE;7^K.J-I@3<XD(>4C?QTY;P[C*"A%LE,+=&?9><#PY+GW5,WN""W=::OF
MY[*K485&4VPVIW,Z!K\=1CQ7STF"-4J#I\\\V:L=R4CA&9,L9/QDD.I2GP,(
MZ=U=JVS08M\M=@HFNKI6_A`K&PKT2&)5B_>LLD>D[`C3Y6(A[_23WGGWDP\I
MDL84["9`9E)@[3J0BO7X52NU4!T]-,2E4;>:I5PV;*5[:+1UNVG;!6Z4^P99
M;T$+'26Q];;6CD!Q#<NZZ$79A`WX[\9D)E2,AYFV=V/4ZI%T)W7$94AH4":B
MZ#1`KD3K(^P5Z+KY4.'$Q<B%&Q$U0*S5*C-BGF6"M.'/#DQQ41"LR!B6/R`I
MZ%R]NS:$T]O*R[&BJONF`EKM.1.]VY[]1"Z*#J$?$QK5.MU7:M:YE^C;3BXF
M$ELT`EF%75(Y,H3-RYUA,4Z2&P#E[HI_;`UET_N.+37-^4!@&-V#5Y+,*1!7
M0*4A1C,737Q$7AR&GZ'.I?>]C33I;H6$J8)<6M.59#UC&)WEN3*EXL>4LW-L
MP>@F=AVGED&\UCC1\P\9-UF/646=-Z<)4S&Q[%:APVU57",OC-N@./(!"PML
MK$9L"OC8&E702FLM3M/ML*Z*41!3.0WDPUFBTOI*AY9(N"_E0P6T4`4GT2\T
MZWG*<ABM"OU@)F9"A[.BHBKWL-^1>KR@9<9Z'V75@GDX_NJG#%+8E\NQ@Y(R
M9L!3+F8@DIE.776GQW7`SZVUU-MKDM7%S5BKJ98;`V9NI2SL%8X['RMN_/$R
M["''02<_'[?>G&<^U6<?\?`[4A7X28BGH2;BHZ<B2L,?F@30(LF&>L9UE]EX
MX4QET<MY!`S;N%+3G.'$85CTSC&<!`3.E(2.OFKIJU6K95P30(J3C*0]9;JI
M^NMRGO&2`9<X\B0:/O6Q#69`C\.1>9>:0Q'H4M""VT$/ADFX]0%WY=<N-)L6
M:%N'7Q+Y]#NJ1R#8U]DIM34O2+[!C&`?W=KBTL9]AL>XZAP=]+)P;C!PH[Z`
MA'D1&MX2/V%'2D-)5;H46:2OH%O9YE9DMFRTH0(!B+L#]OBHB"&O&KI01UO$
M!)B,(C,IPZ-[&#6#!F0LO=90NE`0,L"T4Q4(.361<$QC<.V+7:/$U*PO.DIC
M51I,D?'C28H2?Q8U.3_<I/Q?[*76U!W;;3*MLJ#%0<V"7EM8LW5K**'!2QU?
MF1T*?@K96GIJ-FXEN8A274E@$+'?0P2AMY*<K0G.`U<;VJ&S.7=X272?-L)9
MK?L6["5\CH?09A2XG6/5*)`YZETO&MIL:%P%`=0:ZC@1<N3JHMQJ1J@+(EB*
M2VF//##8YH/?NL^EM:0^UM4RTC(5R4?-C38VPP$W3KI4;'%._CSE-O\`1;0#
M%6NBW2`)SALV*E!!C1\J2I3?L6A2@F;P'@:X.;XW81''^B:Q3H-5H*GMDV!R
MU64K84[6@Z16@=T72WR%BR2%F!M]NCVW(UJ-%@V,#(/9*0.8I`/Y&<A:6O8*
MUY&6FH2=4I&KJ)$1$>7$;-A#8"*J$Y;KBK*K4<72)%_!M<D7+S)NO^TTN21)
M9)2MTQ9#CB?`BI_6FS.?Z34<\_V$/8.*]4):NJU#>2:W6HS:-A6#/S=;F*S:
M(T>'C=?SK-@.RLY+0A8!,`U^.V.TX**Y@,N58J7KW6XTCM%12-@3S=7O%QK5
M8AK3<+2F_7=<116Y"MZT:F]JS<3!KLQ;<>,,AXZ%`],X<>RTEUW(4LMZ:']4
M>END]JU35U!L-WVM:;_L>`B*`)`:P"N\[6:O$1FI]>NT8,M\T95<I4<IDM-2
MBSDOLQ1LFD!,C)*'>#/N3-&4#3W*^U=N[$W%KS8FR.E:_8]K]/\`3D_/1]DU
M?/S!\-,#*&$.E94>#C]$ZFC3GXN'AL$C``QC+J,Y;6Z\KP*8_6=SG"7OFNB!
MZZW)';/Y.N`B:9T7PMT35A-K4:BR$)"F0<L'J1BTB1-XTE$6&>BHJRQ]*GH\
MN$&BC/4<((A_!>0V&=,[2F="TK37*?)T/7P]^[>;#U)H2")!*FJKI'7E2KJV
MK/OF]0S7Y!#NM-)U6-;PPP2XRU.V$B*A?R&W)'#J`LEHS25!YNU?$ZWI&#OU
M$0J2F[%:[/()E+?>K;,D.RUQV1L6SO-L$66[V^8>>.E9(CT6^^YG/]+:4(2$
M,[0YWE>AN@=.7R_V>%FN9])QT7M"@ZMB27#!-C]$N2$C_;6P]ELN!.0\W4=.
MP+8DG3Q&2'D+LQW[1Y#;T3&K4&7]=\Q0O7&EY34,U>;QKI3DS"VR!M5%EGP"
MXVVU0A<G529Z)2\Q'W6K`3B6"C(,_.0)+\="'L>F,9P&HT(3O_@S:,J;(T_>
M.^>/M2LT,*0N],OS&W+EM2I7&8B(N>FH?G6338K51I_2T3`Q<7_;M1&C80B.
M7*30Y#3I6(MD+--3.E/L4@]:;'@[I#0DG=M?;1I%1)IVT[-0;-L+5US0Q&[.
MU-9PAX*3&E8^1:K#A,G$.(:M%7("8-;3&EHRZD,MTM(]@L]$356:@`X#7%3>
MV9#W"%:73Y/FUJNQ#E.AN<1M.V&*=3MJM;&73AB56R)/')!"*%(]X@K)L*4X
M%FMXZJGNA]5673>Y-$:'VMK>](DX>[4*]7>QF5F9A@9X@FNE+:QK(EW\TD,`
M$WVIPV[&2"LI:?=^!#[@4,W#]<^Q[/=XCH#FL+6O%/2\)&CHQ<-.76;DZ+;&
M(",E&ZY2]D:QQK.G5N[51R9EOGD&O<!B18"89(]5)'?##WN,_M*C]A$U33'9
M-8$YMZ&FH\?-/EYAX\'3N_`V(R`=58M>VZ:C8N*K=HERYG'_`,2AA1#V7$N)
MBCIEAAXAH-P2DI4G*58PI*L92I*L8RE2<X],XSC/\9QG'@58LVI[93-GSF]:
M18+M:`Q:+9TJT<'-I;%M%S.+P<*4Q(6"79C%Q[N''<M`D9:2`2E*@7QVG212
M`R74/0-2VA$1`4VX'3;Y*)P,_19D@L$XM\@65DQ6H+]V!"E2Y9%<BUGEQS;7
M[2#Q[Q9,<0MA]E`87MW4%J6'%"TT1B7UI6*W"1\-K:K/.T3:-9MXFPZ:8/?M
M=;G:F6R(0"#I3,KF1@7PR/W_`,3(F"&V7B&'P]D*7M,I)-E:YI#^L*E/!5G>
M*K6_68>,<V<=(LE-WW6VRZM.1L-8=;79V+3$K_;F*R7EW*L*3G$>2.\$VU6X
M#SX4(S*#CUFXR5:`LLC1#)R!E9^&%*R@<AQ:H20/$DHP:3]XR3QEN!OK1ZH7
MGUQCP*B=D*N$_B%J<%4ZML6KQ,:);;?K*_9K$'0]A%D6R&C*Y7;1<;-9&F@H
MQ,6'.&K'1!RC3*PVSG<K6(/'R`5*Z3R!467*MIS6,7/ZO!F@;_O"T4*5L'Q&
MSYEMN,[7ZI?W*!K2-*O%*K-DAY&/P.B=D6XE10SL[$%"):CY4)\B>@H?3NHZ
M]<-3ZH=<U#!(Q3;S7?SAZBC76T\7BL1$NF5E)R`%D[*%96;420#/C,J@S\@L
M.?,V/),E-!)SF_JILK0.RMTV2"B;%H-VJ.RL163W:Q%R$O#@DS4/8(?8TG8+
M@JNPII1@C#Q$06B-/A6LY%D$+-^<)D,LY.7M.5H?]T;-@ZU7FIK^*!#UG&8N
M-AM:-EFET>"CJJ(*-'0T'#P9S;(#Q&$S)PB6WCQX]U28L$+5^`\!X#P'@/`>
M`\!X#P'@:?\`OIZ@!;2BC;57-'SRD5JK-$#[/M3^)R4*,ND?"UNLU^GP\@\:
M:[/3TX-EO!3+'YCPB4LM%I:?2D(QU)H:*E:W`PEDK.KR[?@&!:O)`MKL.9RU
M1MH@PI>`S=_PN?K6+."/2<A^4PVX9^`&XXI*'R%#Y6H/>J>J3-7]B<%`9C8N
M,!?SU`C`L9,R,FVV6#J9YA]EE@_36I,MP\4\0X.&XEMY"6%H0E#:5)RH-V'@
M/`>`\!X#P'@:W^N]DTS4O6W!MUV%(XK]3;_\GH)VRO1LE("AS,WKVHIB(I>8
MJ+DBFGY9`A#B?Y;1\0CJU^J6U*0&F+ZG;K;=S=D?97M[FTC7;#EUZSZM5"RN
MR*D7D8BJUZ\:8J*YAF=@D0UQ*&N,O6U/,!%L.,"M1V<84VZO*W0W_-@]ZX;9
M2Y8^2OEQ$Q"R'?[3V\ZWF?6C+<^PTPFVC*Q!L+5\H2\N?DN>W#;N$>N7,!WQ
MQNXGI%D0V8Y:#AG)"+07-@5_:I$N+$_IWL39`=?+LF`"I3^X<MY#:</;9R#A
M7RKP[G&$AS4;EFNTW9%.O9D@#<6Z#"7QNB8LM>#_`+CUU9-F2L>9>7:!-0Q$
M3%0M+LD?'LCN0[L80X,H9#C!:/F*0\&8[RT5";?B,D#O8@+W'QI,5"VD<B9"
M_*@S3`CIFD6K%?E860G*+9L@(;,"4_CXE^TH?+93+3J0D^DT^O4*JPM1JM=@
M:I!PXJFQ8&L`-1L&"^4^Z=)*!$9;:QC!DF4\^XXK'RO.NJ<<RIQ:E9#$_P#"
M^OR-LB;QEH5F=VC$U8JCUNU2J&GBJK4CI:2ES8>N#M-M!QBI!Z2RT64AO\PL
M=EIMYU:48QD,2MFD"G-OU3=>K[!#:YMS\C#0V\<YJ(LT/O354'%V0>$J%B=9
MD(8X"STR:G<&U^=^4AR-;46(L<@8Q:$!)MG#V"1.T9^H355CZR'-GKV1$ST%
M*R$S8:X1!20L<+3YV/G8X:KS$;8GA3''B@I)HL5AP;"1UNX):"#.I>?%;_H=
M>J;MGKM9;J=U!O<-8;)`2-D>A)Z!K<U%U8EH=-LKXDHC,]+)3*,2*B196'?*
M`<:QDC#Z`C)KB:)!T1KNCU':-M?V9JFJDP5*VT[+.Q69N/\`S&)9&MK8%4EQ
M[CVC79:,"&_1!OM%@QP;2!C4%8<*="'F>4>G7Y8VXS\QK6;VC8K3&RMAV@[9
MCRI6+@J^U/2-472J;9M96>B1%_I$[,E1U;D?Q$!P-9EC<X8+FUOR186D!U_L
M.#KD)0:EK2AU;77XA!=G@F[[/RTB;.'V1N<L?K+OQ(IEE1:VB#$%$RCJU$/$
MJ=+9(3[F'0J!<N1^E+Z6]8WDTK6-QJ]<`/TS-:NOP#IVM-COGW(BP2BYFRZ4
MR59&+/''QBK,86PX59Y7Y\*2)'M8:*#9UK5O8+5#JS6UGZX5L1N)8;MA52;+
M:KQ,JC*TK?CFC4I?;PZSA"G4^F&\/97AO&&_;CP(THVK+%J&ZM1.N7(=.@Y]
MN</D*">^H$C5%GRW'D1ZM4L`Q2AG:/:3<'O2D0:^G($B2@@!Q`ZWA$A+]FK(
M5E#::==)!D`GV3(F7`+D(^0CC1BAC6O:7$FQI[L:40$TDX/YT#R`N%#D)6RX
MM&0_M659?U+8]L;#5,`N*`=D@%I0-8$"-MM8L2(Y/O\`T7[EQ*GOP,O$Y$PK
M#?SN^GOR'M$-E.*%R,2V.ELE+A:5C?D9*%PT\E0S:OF:_&<4\M"_D]%^F$93
M[?ZO7`<,K%QTY&2$-+B,R$5+!%1TD"0GWCF`FLK'*%?1ZX]S3[#BDJQ_QQGP
M,-K(U^B[)9H^?*`GZ>687-5.>^5L.>B&3WV'%TR5BQPFA)`6)?=?R#((<0Y^
M%AEA]#CR%DNAC.U=0C7IP&V5HT*H[;K`CHU/OKD<1(M-A/%CG&5.X1`<E#JN
M-`FWAD_F11!"6TN^TH=3!C++[82'43K+(UR*+N,")6K0X-A,W#1TLB=C13VE
M*:?5&2R1PW#HPA2/D'6ZPP_\2TX=:;<PI&`QYYB8IAX#5>@GYRJ2DB$`_"Q3
MD)'+I"'UP,2(1!161(8%RIB,X.DI7+IKI[2\>T1@CY$LMA[=HJ,=:6PU$D2,
M9)1CCCL3.0I?X,Q%+(^)!>`RO8ZE+1P[7POH4A2'&LYQG'KZ9P&D??>@7=:]
M"R>VV:_M][?,W9-$))W9HVQW[6L+L#4A,\33;A*;$KE=;+U79>@*Z+-V!9"'
MXAP-NEAQ.$.9*8$!6$;;#VST-:-?6V/1;=K6#^_-IU:[-)IK.ZX1.IH&.OB6
MY?5@,;9ZE6+3L[694%1&"`IN.EX.7._=F..AAC?K\OAU:=O?M"(A=?;(O+VR
MW)]^KQNMY+EN`V/('VIJ6E:/'W2<V7=]HS=`E==5Z^5VPU@>"B8I4F6"</-$
MNF'#E+]C8=+G'5]NH&Z>?&M,;`V9$2,FS1Y[H.,FMT;QBM=["WJ)K?8TCNG7
M^M]67X&4U414CI>38FYD\4!K`\Q\38#^'&GFA@VMTV'ZX-L.UP=G&UR8BI>Q
M/S%8@`1X8V@-ZTG:^Q`P^NSL3=/"-.L,>9$'&3CS9QC!#A[6<?$PZ@5D,8U)
M7.HH+8NR%WH;5L^R(-3)'5]-A['E>=7PZHYVI.&QD;(U=L*F-6.,AI!I8466
M6.[G"U>YA.4L*"*+Q#;XLVU+M==]ZU&I@.HJ3LE_GC>NL%/(V!58*9,'%MT\
MJ?B?\AUX"=75A4O)A)J"*!DQA&_:U\[A3"0@[9=KI'V##1FER-_0-*N6H2(6
M]D;EUR;-MM"6ZE;/@)%LG6\]$;(IYL%.Q]']T99;`#"GPPY!T@RDIH0;X"@U
MST9N/J70M7T[VS,Q//>CX:PV;:?6E)H\Q6:[J?=>[J=M'5+>G=J]0ZD#.M>K
M](T'>FR1).<C4TMX%F_?"DRT!1;>4,$!M9W3$="D?84S$\;2^J8`K?6M>=+)
MU!NUV#$GYS3VD-(WS89&8UN&S#$U6X[*Z7@[XN&ILA*$&+AP*Y(/Y$4,R.Y@
M+W["Y?#MO1NJNGJEM#8FL+]18C%%OL-6#@#Z+O34;3]BEXW7&R*K/AR(3*:S
M:[,3+1,S$YCY<,EUUI;[XKN6,!2;>?3%PZ+VXCZ\!*EM/DRS[$N5SB+OLK90
M@$+_`)-YEJ40>9.R7)5[I]LD82P[+V^AG(8HRB43E2@!IB6.CF7A@&R0VKT>
ME536M+J.NZ)!`5>D4.LP5-I]:BVU-1M?J]9BQ86!A8]I:EK0'%Q833+>,J4K
M"$8]<YS_`#X&4>!2/=7V'\J:'W&_SU<KW*RF[P=/WO?4OK*BTNVWBQ5W4VO*
MA9KG,W&T.5Z(,AJN#(@5,H6*1(%#/RLBIH89#BW,>!K)U>9SSW%8>A]N?6'<
M-B<D]8Q#=`M^^-;;3U7L'2M;WU&WC6LU_AV:V9K.Q!PUKI<?>:[@@>,V=141
M=G%842O!!N4H9\"U''O6APVYYWF'>FO+#I#H2Q%WS9%XA=PW37@!5[F(INN0
MX]UYH=J\'`0&\]!3<'#O)'DQ5MVR!<C%(LD8,Z2T2Z&U>%FX:R1,;/UV7C)^
M"F`QY&(FH4\64B96/*;2Z*=&R0+KX9P9+2L*;=:6I"TYQG&<X\"MD'UQKJ=W
M07IMJ`V`$E=KG-;UK9QM9SC6%TVO3X61L=[UC`3@IA4J/9:?!19#[ST@"#&&
M*$+9"*)>$>;2$>S_`"IJ[K'G'7E9WQ`AS$^/1'HX"Y52UH<FX)R<%88E'Z[>
M:64`Q(1DM@(=U]IIQ81*FFU*2I;;;B0U=\Z?9ALKGK:N\="].4WH"R:+T)O@
MG00O1VQ=1VZ&M/[Z6$7=X&=;+Q)6EO8VF6J$:@UN6<)78(Z+9:**S(,ECN)#
M?[2[I!WFMP5I@YBN2\/:!7Y2MRE:L0%EA;!!?.K\"9AI@#VBR09H*FG\J:]R
M6LN^S*L^GKD,"VQHZ"VU9-/VF5GK'$'::V`/L"%$B2ATQ<T8W&FQ;@$R*2.\
M\Q_L'*RT;'NA2#:?D&4^Y'ER`1@>56MY&R.U\ZAM&NYNK3^*7*WAV08F(:S0
M\3$A7";K,0NS$1+F'JZQ=HZ(5(PA#S>1RTL&BN+8,"4PX&3;+U[8+H34IJI[
M!F:;)UF806;%9;1/4#8%9-'(`GJ=?:>4ZT/)QL@`8IT4P-X*0"/98<P\X-@@
M,D*G7F3C-;V@JNTZ*N%DVO5W+O>8FTVX!%R$YWTA9"HF-LYE=$A5PT_>ZF2Q
M'N.U^JLN3)HY_P`3)&1`16,,A*.E;70&3W]3N`3%B9V54XS9L!MF<6)::=T]
M$3-4@(VV7(26!^>"CYQ#+(R9"`<8"81'D#/`-.B+<P.'NLZVB]!R.SMKP!6P
M+4S=#ES-KJBIB+=C&S37(D$BZRQ)Z1Y(A%-KD2P)@EI9,DS`B_!AD]0X33(4
M;NE<U!/UI%FCMU;%&T_KF?9KL%KENYTZHU9ZR2!=3EHW6`<K:TC6\DK,(`W8
M("P&9]HL'/OF#G(;6TZ$&?ZAVC3[2'5&=-5Z!MVI82,CZ@;S]5E5Z,JT74HV
MY"UBL;VHG]TQ\"S<=6Q64NORRR1VY5MP5DD9*_B;8+"\^GMV47=T')R]-D6W
M2Z[*X@K3".$@DR%?EG8\*9`0^]&E&QY\7/U^4$E(J0%>>"E(HT<H=Q;3N,^!
M+G@/`>`\!X#P'@/`>`\!X&H+NB_,4K?%;.EB<1H>*!$A1ARZ=&N1/R-WJ-FS
MU6:X2,I%$M##D""*9PV[^`&Q^4XXC!^8X@8(4UQT?!$U^FO2TY4GG8BJ5P38
M!\6+N,<B*FPZV[D!*YQ%^%$A8DEMAU<;)&A(#>*PVXRKY<81@*P\N<#?9CO[
M57)_<LW]IENC]^$:?N]@U[5=E\N:=L%5U?4.EXZJ3)L0RF/:A)B:M(%>KL0T
M])2O[!)3[+SS3(OY3N,A?=7.?W7MC)8&^RKEU;R&VDX-D^%D&$+6DK+K[CZ(
M[<,((OY1<_"A+;36&\XPO/OSZIR';=Y_^ZA#>,L?8?RH2[G,:TI+W%A03:$X
M6*W+F)6WM8Y3BU-8>=''RE./?E#2G<8]7?`Z;.NOO9"&>(QT9]>,X>I;S#,9
M(ZCW!%1K8Y)S9"9']I&ED'?G1@;'P-#Y'4R^E]:G%X6VA60R2&KGWC8>#3-;
M+^LIIAO\U@ET6@=)2KR_4=*0)-]C%AK:#?0C'N<!9<`]N/7T+7[DI;#T8H;[
MNF9=X:>E/K"DH5N'=_'EX2-Z@@3BYYJV$_`X1"R)5E:C8HRC?#[V$&%NL2WR
M*P^Z/[$>!(@37VOJ0\F4<X+:<RRG##L3(;W7A!&%*PM;K1]:Q\C"D9QG"<+2
MK"L9QZYQG^`_1S/VN)^+,2]P<Y[C<J)3+G;T0EN-]4+PT*J/KGN6?ZMY;^1S
M&&_:YE?L]482L*';KU!U-T[U)QUIKN2,U51*@^)TR?%2W,]VD)U^[2<+KBFI
M,5*0^U-9FAP].(Q*/9;#(26;EUIE:G$^W/J%#_I+IVTM)=(]Z:KHT1JJ4VK1
M^H>NR=@5>][&DA8ZI5>U[*TG+5TT:Y5?6\S+S+\K$,^_Y7X:#!,?CWFF$>P?
MT"#Z/U[<WG'&MQ\Q`\WNE+L@$-^%7-Q;'L$S\##8K4^PF$!T<Z^BP8E"<,,"
MN.-M,M*P\\[ZX4UX&+4_>?7%WK<+9Z]RY1'HV:BI"5:=MNZ;KJ\MMQLXY,7%
M-UFX\_XN[:S(]MC*R9.+A\I(4Y[!UC89)?"Y<$5*G0D0;.Q+<#-EQ@),O!LR
M+<PU#R;XS3AT8U+,CBM2;8)*E-)(2TVE["??A*?7TP'J^`\!X'G!S$1(&2T<
M!*QITA`E#@SH`9PQ)D*:9'B2P@DL*RZM^.**BCV"6VWDH6L=YMQ.,H6G.0]'
MP*&=I\K;(Z*$@S:/LU@!FLBM%)U!>(\*2U%;++#27[^N6:=8;B3Y5,_'FCX!
M:4Y^2`R,4LG\51HP3S(9IRCIN^:)I4)%[6W#/6RP66!JD./0)F:J\G3->6""
MBI9^2JFI)6)I&NY2?@,1K7\.2`&9`EJ.R4I+'O=9;"W_`('X2XVO+B4+0M32
M\-NI2K"LMN9;0[A#F,9SE"\M.)5Z9],^U6,_Z9QX'[\!X#P'@/`>`\!X#P'@
M/`>`\"K'6-8Z>M.NW@>8KK4ZG94^KTF+-BD`3L\PP0*^U%UF\9S+1E+>,0VX
MT001#2*U-+]&5C.>CN`RO0<5O"*K;;6XI:MF?(&RN)BQ(J::MT&1DZ1R6):[
M$=LK9$;9UN"9'6TZ,^UAE65MY]Z<(]H>7T(!L.1E-"-ZQ;J"K&#NEJ6,>NZY
MC,(#6A-9;*&GC,!P)84E(266#D,"-X<PT@E]#KN%-MJ3D(L'N_:<OL6^T6%'
MY6PJCQ%,F5/FE;6=R<W;G+E^(`2@5I#L.:IJN,J<<]I;;3;^%(2_GW(2'7BI
MSM9W9MPBVPN6BRHF*UZ8?&+M.SQ65UN4=O24Y$4W$2DC%SCLA'N840_'J#>9
M0C#?O<0][`S<"1[K6-'*E*?R6,8G]@J69`V1N(T9_P!F1_U34<21JL!T7Y\?
M-DAQUI[X<^S"$.?U9\",]L:0W):%;!Q7-+<W'HL$Q"VF+D);<.U(>0)M50P0
M!4[,BOA:HD*W7+"+!L#,F_"Z^--,X_!D,O!(_P!P*IN:[L%IU5L'1=BKW/3>
M['*6-KK4E=HTEJG7T1+LQ]CMHTCN;3LW#P!UZJ>QX1<<]_<E7D$E0HLW`XR.
MZD,M]+@5_G]7;#X4VO%;SY'ILI<(-[215[ZK*:+KU.U5T]NH$?()*=GNFSX1
M7-Q[44V;,5@F(J<C&YD)8:-#`8C$.LJ#8=S[]GW,6U*5)G[;V?IWFW9U4MUL
MI%WU=LO<]0AC`9>H'N!F3=4/NJ-?35OH4DTCY`9G,."R3['<)1Z-96H)UQU!
MQ%<K)4LXZ(Y6M5PC)CX:)G&V]23EECY^>:S!Y:J6<6`J4$EYI@S(?M#]KQ*'
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MK_>NOXJ]0`$S'6:O$O/2$/:*7;(=]!,/<*!=:^9%6^AV^*>1_L2<0:&:A"EM
M_)EMQ:%!K;FK?T7];4W-WG<S%GZHY(356XA6\*?^1$[5T>I%E-.C'-^Z3KX6
M-?3NK8-$VZX;L>HA1TC#@Y(7-P[X([)PP6$DJ-HKH6*M.UN:;3J^@=4[ET,)
M+5/==-.@[N\/!RQ;\4J?BIRJ29=5L7RR$4[`REC@WG)=D5MEO!2?A!0D(\YR
MBMN:'Y,-N-,@FY>IV"Z5^>H^EZE-7C;06G=%(<BX:SYUC)6*53L:[V&UB`&V
M,.**DF!(4N70(RG#`+F"0EVU0-8V;H_7%>JC=<ZBLMA=(G8JQ6NW:_<D(>J;
M`D)<:Z7%*"B9-H^"@XF8*B6@0<$OY0TTS@I)#.#$!I@T]S]]C/UD4<60/V+1
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M*1%'5[:N=SRHKILG([.4B%!D+`?85'$MF&1U7CH2NY$"$+R",PV+\`WX?PJQ
M^2P[G`1R1,]$UQM529%I$]>XB2B0JX;+_P!Q4^C[@UL/,5HNP'A&UU4G':TV
M_$UHF690`L8@*0D!AWD9&CG7$C!,U9G9RORUZA[98*]*4ND1,=,?W_*VR%1:
M0RI)<_.V"'V!7XZ`K\'5(^K5_,<Z`=AU7YH#V5OI0ME3Q`03.ZYU!UQ1+<!5
M#"F*R/.D#4G:L9$?L,1]HCY..599/5I=K8DJW-T5R0KHPKR!A78&1)'(3Z%-
M9SX$&ZJT_+Z<@3[A&:(A(?8FG8Z]_LZVD[9%KA;)?9F*/*!VAIB\W&__`*\:
MD7,6PF%VL-F'=G</$K%<_),!9_)"?N*-@5S96L9*TAV]-DN,A8Y'-YA<P];K
M3%`.!*)AP:15ZU72I)$9KN&1%NXAG7SI$@Y*GR7RG"G2$H"X_@/`>`\!X#P'
M@0ETKN%WGKGK=^^6:F_>U:8U5?-HKI@TY'UHFSL42M2-F*A1I^5:>C8D@\:-
M6VV\\A:$+SCUQG_3P*K;:^Q2GZNUOU#;DZVL]BM/*NK=$[*NE28FH*/C9]6_
M0B3*S`5NS+665AZ)_"=280;%B)]/8II#F%9]H;%$9RI"59Q[<J2G.4^OKZ9S
MC&<X]?3'KZ?^TQX'Z\#27]E3MA!W?K+-`LC=;L\O27&;#))WR+K&536AMAT:
M.BXZ,C3G'@L,+NT[$Y(:>92W,,%.CJ<^))#!(8E?YO\`QMS+;;-=-KFU8.F:
M>>G)C83+]%D(C7-BK]$C#XBPRVJ9E'XKJLG2JVV:ZRHKY%(P&/[,*0IP+0?4
M4;9G>27(:T2EC*<I.W=FZ\@*]9=QPF_B]>T^AR8E6J6O1-LU^)AXZW1]:@HQ
ME*'O8ZZEQQ:''7%ISGP-H/@/`>`\!X#P'@4/WPR\YW5P&ZAI:VV('KQ3[B4Y
MRAI+FO\`7[:,N*QCT1A;BL)QZ_ZYSZ>!J>^L2@P=J^PC[6Q;9`Q%BK<OU!OA
MUV&D_P!3*Q[;T1LW7)P'YR55T66GU&2H"S$CRA\@-!Y:^&/0PR42WX'T.X=U
M]0!RL8<J5/8^-H@W&%Q,)\J&A#GV7ROY'60K`<82M*E^Y66V'<XSZ(7Z!C!V
MXX!J0A8V"KM^NCDZ=.QPY]3IDN;`!%5T<A^01+VB0;BZU%(<6,ID93Q:4E/_
M`-#65Y]?0)93GW)2K*5(RI.,Y2KT]R?7'K[5>W*L>['_`!],YQX'Z\#";S<L
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MZ"X1)P4<1BOR'X4C&%24*0H+!X1\A&RCP[SGS*SEA:FT^U*W,+"`[KL>X7BQ
MGZKT,^,U-P<O#B;0VM(!9(K&L8QXK!$E#UQLZ.*B+[M0R-$>8:C6\N!P3CK9
M,LI'_;!'!(E8J]*T=0R6!R7F8N-:5,VBU6*08*LELG%"B"2%LN5@*_$5/6N;
M_$:P^4]E*G580VC"4);;2&+0*)S;LM"7DUZ:K>L8[\.;HE?;>G("7O[4M7D/
MAVV[!HD8LL2MN!6!QEJJS$8DL<\)!A/L=2TPT$\>!X@L.M$F9*'G.2;RBGEP
MJ7Q0F,5^.*`BQBXH)T5AI\I@HR.42MPA3KOO>RC"L-H0E(1O;IZ?N14UK[6L
MV17I45I0MDV2&%#S(5+?<8QE^&BV3LR03VR!FC@C&PI`)0:`7_F<SE66VG`]
MMG&O-$ZY:;.F1ZG0J:%E+LO;+&>>IA!)BEY=DK!8SSI65E)23,SC&7GWB2B7
ML(3[EJ2G(8E'5Z>VE,15LO\`$S%2K]0M3DYKVF,61P<J9<!:2)&VK9<;%,X8
M68*8V^5%1:)$H)L<EIXUG)S3:!`E&;LHT09%Q#0Y$C.33F,Q\6'AC#^0&#XP
M.7F'G"WQ!6P()F400_C+N'G6TY0PAUW*49#L5T.=!BFF;+-"S\RITEXN0`B?
MT4=_O/K<9&CXM9\L0*&(SE+:,/%DO*]ON4XK.?X#RIB2G#),&&J^!DI:-;<L
MD^]^`>+"-`%P)SU>?B\R@4GB8M$'(/?BOH:=8$PCY7<>JF4.!R6R_46A-1;]
MYN=5IK,Y+`P,*]:;!$U]J7FY,I@&.AXQR5+$2=)GFE-,LL-94ZZZXA"4Y4K&
M,A7+=':NG]"79-$V(%>XR2>!`D@YA590!3CP#%M-$F!W*?DH6MN#0SQ#31SF
M24H'(>:8SG+[S3:PDG:58M%T32K-1'ZO9@H3\R716)^<.BZS:%GIB#*]/"S\
M/$V1#$C`J!4\`\H(L=7Y.<YQZ>F?`I&=4=CGEUS7VZH"`U=%R-@@)6X2=4MC
M,%K?:LTC$H/$5^MVLB?K]HBZM282N-ORE61@>9N8YI25J$CV2D$!C[^UZ$B<
M>_L066VBXEF4:)E-:11]UE=R@1P-P-(I^30(.P0M*TP)!PS"87\>0P9.OM-1
M0RLI=:?.#,*W7=PRHI%B:YBJ?XQ3$K=I[9F^+?BN;`L\JJ/AR<28^F*-6WX:
MIF2"HIIK$83+13@Z!$.%>A+CN5!19&XNI(?J/F71T")J`*Q7&*O&Q*N=#:1=
M8`F8R8H>V%2-H9NR;E9ZMI^8J]FC"(LJNR!4D5:6Y9UT0EMR.(:P%CY3>/6>
MC_RY'J&_ZOTZ_:\AQ\#>:ORS<]H3EHQ'@T>.KM6)3KF_3T5.7E5FL-DRW'8?
M'=<!$07'A+;?)'""R6MR-M['M]SM6K]]:KFG)ND:K/3L=7,-O<J,Y".2MZ7'
MP,9(_P"6X,>;EX'XCD',LS)#T0^?ALL,9[VX>"R@U=Z,8=1\VV=0&C?LQGW4
MO:*MC)7ZA`H;1<>R^-OUMALT@IIYULI3*T-8>2C+*\-^Y8=XF*Z!4?(+$O>G
M6HS]@:[%#$ZHNKYR8IUTE4>%(FM;F''6>$PIE+Q+3"6R5H6I+#&%X2@*G;`K
MF^M>[9I&TI:6J^S$BI)>!U_1:@-1PW))K#8>PYJ/)N-NL;L;)&:RD).2PTB2
M]\@;$L,*5E/I[@_FY-=T/IFC[`W.X.$BL0>MGI#6=@I7H;>;)/PD1*3;9UZJ
MTTM="N0,!(O(&@*]88^1:8)<,(]S7YC>&PJ/]5^B]*;7UOUI);1T]0=HE0?V
M*]CP->L&V-8UBPS3<5'WJ.9,CHM-G@"G(J"AYYLL$9@1:A/C$PIO/IGVI#:/
M&\B\H0TB!+Q',//,5+11HLE%RD;I;6P,C&R`+Z"0CP#1:TT2&:&2TEQIUM25
MMK3A2<XSC&?`C*76_G[$]?MICVG1D\7[=6[*-LJ00"^O=^E,,@%$(A\H?8E4
M-K<90X>G+2@W,ML9^1QS`73\#Y%/NJW/P/5.G;7JP/F^<V!W1L*$H@MOWGM>
M\=D:RY7TM6PZF,;3;;;IK1LLMVZ2U>A,LD!053CL&$GJS\AK!F,H6%ROHEI'
M"%)(Z!%YJZ\V?U5T*6#2BNCR[H!OBF4>K@DV"_'T0/3FKMWLE'5+7;1!LF,$
MMF6FWR$,>]XKVJ:;2'T0^!^5)2M*D+2E:%IRE:%8PI*DJQZ*2I.?7"DJQGTS
MC/\`KX&H?J/FMKE8O_RPY/L4UJ<L>[4F'V#H.O0`5ETQ?L[=VC7:;;K74];N
MDQ0^LMLV)ZV-N2,Y7B0,RGXJ'31C"$)4L)\7O@GFOF/1UZL$,N?K\^WKVAUN
MJ.3%?@K7A=VCX=FC.7#9FT+W4:AB9!8&*5.'EH#Q)&DHRRP,M&6GP]W1B:UN
MF,I_6NFM?ZMJ+^P=:#P4*79*^V?<(:-8MU_E[%#IG:/:Y"G/0LK<)5)JGHGU
M3(.?.\Z25AP;(X19N/K\GF;?G]K;-B*B65L'7]1EHR1JSF0EL@C;0/IP:)5B
MP2X)TL9&!VITUU(>"'GQ07O@80M.$.!2GLSBO>N@-MS/6?#R&]<QNSZG"0/6
M>N-8NV@*`LPT?)PR;/:(NEU<R'EPK18:J$B.#MM?(BIFHY"_/RT8T2<GP+"<
M=?9BULS6UME]]1=VU_>JOK^#O4=4[=J*3JTE/P((%?KLZF/M=5F[IK38%XM&
MSSRHV&`KQ;>)126T!"J?:D!@`OQK/2]"S/KW2=2SA+I:WW;8&U=5DR=CJ)=A
M_--?0ZQ*K-?A[$&)+.`I3^03F'"4N-`<'`_[?(>%:=!L4>3-V=HV-FP[7&S9
M=WSJF'V%(4;7-]FWH.4B)B')AW1)JFP*[BF0028]^MPV]+!C&*4R1\Q*PS/4
M?1VLMTS%AK-2)G0K948R)D+;4K57I*M6.LOR94E'O0LS'2+2%#3D+(Q3C1H^
M%*RTEP<A&7!3!'WPH!L*K[(VD<UJ"D;<M=DTC'7&2J=UVQ_B]Z[%7-YG$-/-
M:"V=LV&N\+:)#5<<W#/B6VUQ@PBGD/#0I$A^0U*)<"[M"Q`:>E;Q6`;#(-46
M+KIVQ8[7DH'=;;=*ZA<E/(EF-<OXDYU$OK'$?7T.0U8A@GS(9;^&4I:8*!!9
M"<1L5*[,P=F!S$SV(<Z4?K\TPD<MZ&EDL2=8F?PWEI6N/E!$/%@%M*PEUES#
MK+J<*2I.`A_0NH9#5"K7^^)CY6RVDS,C-3M6AF*K2Y?(\U8"1)<6F-EE,56Y
MV%,PX?8FP,IBSI=YXYI#3A+R/`L3X#P'@/`>`\!X%?.LM>&;<YAZ!U4!%7*=
M*V3I[85$3!Z\MU8H%YF6[96)*"(B:I=KI'2]2JD[(C'+9'/D17PQG%X6ZA2<
M9QX'R:;@Y"W)IBM['V!TY3_NBAM&;(FM05;HVZP':WU_[O:33J6N'A*/8[GK
M.H:9`NUVI5/R0T*^Q%-JDG$>]'PO8RE2P^TMOT^-OT]V<>Q/IE6,85G'MQZ>
M[&,)QA7_`#QC&/`_?@:O>YS-OQ=XK,CJJ<_MP,*MUXJYG%SR8@4F,<W;J9C/
MZJ-_N6K?O;&!%L&-,I()P"H<]YCV9(<;=9"F>J]I=#W75\#6D5J-L^M9*A1M
M93=*]N&YSI&4["HR&8^6F3I+<5VC;1LJ8BY)N6$@45Q;P2R1Y3+"OE4,.%W/
MIVB*8)];/)=DINIJKIQ6Q=14^^VRMU*F1]$"F[G*P,='3-[/A8["6WY>[-1#
M![QKB4/&I=0\MMK*OA;#9EX#P'@/`>`\!X%'MWM-+[=X5<6U'+<9KG6>67"B
M#VCF<KI.NT+5%L#*P&4ZM&<I=P3C*4-9RI']>,9\#4+]4>8JV=__`&NU8::-
M81$=A],DV`>$L9H5DCRL;4H$E$-E24+,MGQT!/H).0TVXAM9.!WQT8;0!\A(
M?0Q7M3ZWJLY+6F$IT*-:)T@4J8M!(^9.RR#H`[PH/Y-@E5FRZV@!B7&V&_F^
M-E#BL(2G"L^H>=-;PU#`3PU3D-B55RWFP\C8`*;%2C$]<Y"#B"&1)26CJC!Y
MD;&>!'D/I2\ZR*M+><*]<X]JO0))`-'D@0I$13BA)`0<T53PY`CRARF4/LJ=
M$+:8+%<RVYCW-NH0XC/\*3C.,X\#M^!`6_\`\K\/4N!),"+5G?>JUD.2-<,L
M3!00\RZ4='M*"&*<@#3!6%H8DEX2P*][?E6VVI2\!F4"-3M<`,1U<C!(NF'E
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MDNERDW/31Y)II"_E*.-(<><4XZXI2@Z%2/.N,:+9INOSU6P^_)-@5.QH9%E`
MF`I>0`&DI@6.DS8\A4Z"&,>,P]A3P*'4I5[7O>E(9UX#P,`M']WSV8$.CRD5
M&0AY;SUDN0YX9DS$B19(A#`%<@S:[/0,ZY87F'@#'"7Q?UXZENM?*_A"4ACE
MV/U!I;5B?[M,`I&MZ\]!1X3#)DF&X[)D3@6*[!Q#<6_^]G)^P6-QE@<$?YRY
M4I_X?8\IY2%!%]-H-TW19*MN/>L2Y7(2MG#6G3G/TB'`FYHDNN/:Q%;'VB>@
M:3>-W=%,G'##BQLBJ#@6"5);P6=C\Y`3)>;Z1$E9IM,%"L&SY2+49#0))3+8
M$((8Q,#Q=SNB$%L2XU`8GHM(99`#)9:7GFT-LJRKW)#FH.LXBC%62=48=8[K
M=#?S+==IMN+_`'\T.)(S)M<@778B,APT5RD!SCT?$#I82I@/&,NK>(6^^Z'N
M68*?FF\P<26[!!&-*1+V!G&,R"(\L61$?&K)`\F.1#V80E0Y+)CXQ0J$84GX
MUK5ZMAY&Q=CU_5]=_;S>9$XE[*@8.%B8J8GIVQ3/XA#X<8#&P$9+22W"U#92
MI[X,LL^ON<RG'@5GA^<"=[2,AL;K*-_NL*P1&!Z;S?96(23H>EA3@SXZ4<)5
M#&&Q]VV%,1Y#:GY9YQU,6[C*([+7IEY82;$ZWUAM"`J$-8XF,MCNA;?*5B.=
MDD%R[C!T!"%55\&0+L&#9"3&EZW)L+/9((,20[A'SND.-?)X$>\FO[-@[=T[
MJB[#V@FG:LW`,%J"RV52R4S%#N=1A;T/$0TFL4%!T1329Y4:PVRRV-'M-)!:
M]R1OD6%K;53JC>HA^O7>K5RXP!6%X*@[5!QEAB"<.,NCN8?C9<4P)["V'UHS
M[D9]4+5C/\9SCP-=^L-FO0'5'3<SKL^][<T9(4[6@B*52(:>F!-:[VI1\K1K
M+4JI#28<1!0@MMJ>(PTDADQ$2I4;EQ2F5X<<("Y%UN.T@*!<++7J/$Q<O`Q*
MIJ,"L\RF3>D`8XHXF:8S%P*VF4S"JZ&EP!E<BTR\<0EE]YAMM3J@TJAL5Z4^
MR;@!6O\`%7D*E:-%RVSQS:_"E,P`G[$SI2V3>(MD6;N(8,B]8K&5EQ]Z5?3E
MU;N$.NJ5ZJ#>IM"LT2STR3:V,/'9K4`L2YJE9#`[:JI*4PIJR0]SC#B&W,1$
MU4Y&-;.$,3C"QWF,+Q_&,XR&J_C</9MOV=MF,'[#N5N!<JGQ"3L3!\^PTFJ>
MA=C7QB9EI35I]0FSX@\L>Q1\E^W!CP(J?>D73B1_0J/4Z&QMG6&U6U,Y<Z4V
M`^EK",N)<HVETY(<2.TVKY5,ZZ;]K+A"%.92C"%XPO*<+],8S@.^SKW:#,<2
M"K?MJ*??9:0U,E4?6/[4)Y.65NO"H#J@<*K#JFE)]KP3V$MN*Q_UX0M(5-[=
MB-@0VE",26Y5KB3C)<"S!SM7J8&MY"H*UM<&+&UN(4:+D)V4UD^GW.2S,=[7
MU..#I0C+:5MNAE&]-APZ>='+9IB%UW-4VT:3MMA/V+8KDW5^?:CK4.@".?M-
MCFT29&G94"7@6&X^)3#L./,--/Y;+`;:RXH-:'US=3GZ0K72%%QS-U'N:)D^
MY^KIYS9^@==1FP=4P!1>Q4!2U%_82EPKMJ9(UQ)B$Q"F&8PQA`T>W\)1GN^9
M87-NOV@13/.]QW=1>7>QW!!=-V7:%0FK#SO(KJ3C`E+.M,%*3<@';A05UQ26
MFG2'FCFV\B^Y27TX]%X"8Z;-2MFZ]T].SQ$>Q.R?"4O.34;!OM9B%RM@V;JP
MJ0>'04`F9(C1#&5H`6Z_A*&W'/5K"UJ5X%\/`^<;['[1L8#J.Z4_075_VW7+
M:QM0H%LMO+'U]:VYQMU*T34G8B5CZA<+?;]^4<6`J+FT96K2+B(]%E>DY1]M
MUQ(.!6DJP$O_`%&[(GK_`&S<\>5U?V5M78=!D:K5NA.7_L3INJJ#T5S*I^$L
M4I0I>`A].T>#A)B$VXAYLUJ25*2467'"X4SE!F'T8#>F04,(W\Q9#`K7NPGY
M2'6V6_<K_I3[W%)3[E>G\8]?Y\#D;<0ZA#K2T.-N(2XVXVK"T.(7C"D+0M.<
MI4A2<^N,X_C./`I_W@LEKFV;=$:9?)9V=SJ\TP0VMQA[+716JW,LO)0.9Z-.
MI3E*LJ')0G&?5;+R?5M097K'75$VIRSJNB;7HT!LJER^M-?_`+6H;6UI!XBY
MAJ-C(F0AW+)K&>'EX.(/$)#8)P#EKX@"6TX90UAM"$!8"OUZ`J4%#U>JP</6
M:S7HT.&@*[7XP*&@H.'CAT"Q\5#Q$:P-'QD:`*TEMEAEM#33:<)2G&,8QX%*
MI6@[/O?5LD9=-7<VV[6E<@:FT),6PJR3][B*F3)W"4ARJK`2E$?KX-Q=ML1A
MR45F0R'D44!0[F"&7\>!"7??8LQ4P+CHK1HMLL&R`Z59[%L*6U^V&[,T^MQ$
M-'DR<:!-.R@2*8<$S:(DZP6%Y.6ZS7C,+']TT=$,J#01KC:FT--[6J-\CBHI
M,]#V465=@)5NSMZZ$EJP^QK&%CJS1Q8J6=C82+@RIW(J<8D)X9N7?><;5+/X
M<2'UC\[]0ZCZ4I$%:J%:8I<N<$-B?I!<@"U;:I/XB8V5EH"4BFRGU$+C&I1I
M23`UE1IHSC9(A)`KS3RPGN4E(R#C)&:FI$&(AX@$N4EI63+8`C8R-`'<*.D)
M`XIQH8,(,5I3CKKBDH;0G*E9QC&<^!0VP5VR;7M"NAM-QE7AZ9.ZVL$3(2C5
M<DQ[SO2(/KN4TZ5)+IUDI=R-A8]F1]L,'*EBD@?]R^PVPZ\(0T%O=3PH-9U[
M6*M%Z_`U;%U4#^V8NB0^8]<)`QL"\[&`-03D8AD5V$*%&0^*K+;+RF'4_,TV
M[[T)#!Y355B.V7#S1$O'3M$#+G+B!B<,LC.P]=[%<3%!QG]B6&*D!AS-:SD0
MJ19EH`["4>YQ*$N/".*$:#KZH!U.#8;;=]8&A#5W;$N182'*Y.QQVO[E>!B6
MH>WVZ.C@E$,0MT?E&6X^8]%CJ/,&RXZRX4E]U03%6;3#6X`F2@W#EC!S,Y`%
M)DH:9@2V92N2QD)*LYCYZ/C3U,-R(#F&2$MY&+:PEYAQUE:'%!D7@/`>`\!X
M#P'@0YT-'W*6T7MN,UWC82KV?K^T"U%.I;%0JCLY5@?B26XO%"M&TAC-<0%K
MR7E/X)<XTY%L/^U9"<MX5CP/CMV[?;T+L[3G,O8[OW1[UG+]M"AVX[BH/H#Z
MZ=S6"[U.KV<6[P;F]]<<Q1`>T*/J6#D8N,-D#S2P1)I`V66\HR[G+0?;FC.%
M(3E.,I3E*<XPI.4*QC.,9QA2%8PI.<8_UQG'KCP/UX&G;M<7$EU+5ASY84-(
M6IH.4AA1M,7>[2V40FTHBTO2IMJ'V-JZ")KU7N->@98B#BBSS,L!/R<FTS&1
MSSF0C2C[*N!>G(B1<WEF9D\ZEC[D[$&SFJQ;+&FNT,-LAB3<B>S\,/J8+99;
M&2Q`J$8?:4Y^.0^I65ALVXE^3_PSY)R\S\#R^9]$N/,_(MY3;SNKZLXZEQ]Q
MMEQ]W#BL^]Q2$*6OU5G&,Y]/`L]X#P'@/`>`\!X%0-]['YOUGO;FF:W9.,T^
MZO`;N&U5=;!88^LT&#'S7ZDF_!VN3F9N+AVBYL)R/:C<.-O/*?0M+>6\*7[P
MT-?59#3NW^Q/LON.C]ZKH];NW8/5)!%@KE(HMH6168;;QU===H4[.A%OO2,_
M9W<RJY681+A#J%2$""D7"UNA]%J.>:5+1WX&RY*U[H]39`US_*,PW,12_P!@
MN0PH/^SX@."HWX(P<FZ*TC,9E>1?:AQ;F<>[P)'=30->A%2;^*?1XY?^\;(.
MXA:T$KVJPGY2BE_A,*]JW\8]RU?QE?\`[/@9.$:')!B2,<6,?'GC,&@G!/M%
M!FAE-(?%+$*86XP2,2PXE;;B%*0M"L9QG.,^!V?`JSUW%5F?UI!UZ[+*#I-G
MV)5*E;YL78#>MLUV!M^)&K%2[MA>;4V]A+DP@=L/WM**((;2E>%^W"@QS3VB
M>=/K^T?;8N,E7:_K%J?7>+/+W)4*XC,N]'U^N@MAP]6KL#"I(6Q`@#""1T8D
MDLO"<X2\2[E2@R?F_:&W]SKN6R+;3HJ@Z;GLPK6C:[)"RXNU2@(Y^>$M-JV&
MP8I$8`)97TA.0X@S6,LC-N.*>);>9>4&$]T\K:J['U7$:5V58KM67RK?!VFN
MGZU*AD6Y!4*4B'>+-C9F-EQYFC1B[2T[+)6QE`BLCDH<8):&>0%P8,!R$@(>
M++.R<[$0\>`3).X>;R8X`$R.\<Y@HLXAO)"FLN9^1]Y>/7^IQ>?560C&-NT[
M*[&8J-'I+.==PJ)LR\[%-=9C8(B<*>-0/7M>L`?DKM-@9LK9*I]YY`H@"DJ1
M\SQ:UM-A#72O(4=T3M#G':9NU]BZ^>YRO0MZ"@*6^,U&W,@2UT>S_@3KCC3A
MHC)3%-<B25C9PHB&F)`5S"D/_P!(6GK1-D,8D2[)'CPZWIB01$Q#3K)9(4*(
M[^""](2`I1`AA<Q@91_HVEK`K12!E86XRMUP,=N]KG@FR*]KH"OV;8JFXHA,
M',V`>(CZ]"RY9HC=OLZ6?R9K]`RY&$(::#&>)-):^%O"$8>?8",([1-O`ZGG
M>A<[MNA%(G=5!T!>@WLR+M'"L8<J`:B^AK>L3L6-(8!#6QAEF*:>RHEYQ92T
MK^+`9G4+(ZY;E4>B:]!BM5U*,D@I"W(R35XQNRIQ6SX2"UW66:OB%N-;*"F)
M#]C+"R0[$;(Q^0\,D.N/*&#*-CWRIZTJ4I<[D\0F)A672VA(V).L-@ECQQWR
M18BJUJ(%.G++9S\,*0&``P^82[_2TA6?`@CFK4>Y*'8MV7[;FY+9>T[?N[UF
MI>KI@MV0KVC:NW,VD^-JT#(D$NK.-(CIX8<M0S$<`V/&"-(%4^V2::$IS.QH
MJ&V!$T"J5<ZW6V?.9D;J[7D!MQM"@TC1HW]R[#FW,X&BC9".2TB(CW<YD9E`
MSGXK:F!"76`R79L2U/ZVV%!/V9%*9FJ/;(EZY.9&2W4FI&!/#<LSBC7A@\(@
M4/9*SEYQMKT:_J4E/KG`5SXJ@]NUC6<O7MHVB4V%'Q]G.7K[9$^/:(&;M=2(
M;;R,QFCW4VP6^LP5:RTD``F4F#SIQ+3DCE`[!`Z%!.M[KM`%E(G:<U2Z_8-A
M4B)L(.OY4B,CR+>V1,`9(.K-2D'V5GLF63$:EO++&?<[[?YQG&,^!5GL3GJY
M]<Z]UU0H/;L[I&QQQ+]ZMU7JFRMH42=DA)2AV6JACN6?3-[UO=OQ*;<[`,>R
MIQQZ+,*CTH?&RKXU-!,/+M>DJI2[779J6E[#,0NQI^(E;--QD7&&VF1B(R!B
M2[+E,6I?Y:)MX')'SD944I:U)<4O*<+4%E/`>!@A>S]=!3$A77;K6G;)$_B_
MM*T#+AR5DCOSE_&#^;7XYTJ8&_-=Q[6?>QCY5?PGUS_'@1U>-R.QT+9%Q6J=
MB6>+CJ_+2DE-&"@TFJ-PX+J1I4A^:L<E'SOPM1RWBTY`CC2'16%*8;6M325A
MISH#:X;[`?KWKH5?_%B7.<):SPL[5]M6F_"!5B;A>@SFP+*1=*Y2)BWEVZ8G
MVWG2B(U3L,J,4VRV(DUQ*0WWVF%59*S8JZ@Y<8N>@Y:&3(MBBFN`9E`"`<&(
M".;="+4-E_WX:>2IIS*?:K&4YSCP-1G)?$>KQK]L=&S#;?L2X:PK\UJ<J4.>
M:@*I_;EVM1UAQ&1<I"L`7TF=!AZZ%D[$I-')P&8'\2?A0,\L-BG_`(\:?^;\
M]MJWLNN(96@@;<.V6$82$2XZRXREF]H83@<@O./5*?3TRE&?5*4IP&8/ZDI[
MYIQV7+@R[)RQ,T>T)L78(@9)I:6_F3@`:S-!C`Y<:2XD9E#8R'?5:48RI6<A
MKJ^Q#G2G2&NZ196;?8H*1KUI(%CTS[A6RFIY>*X]8P*FX_L&7D6:U$RLA01<
M/N"/`D%$_%Z$H?\`C5D)"DN<Z%H#EC8=BKLM<C=@YU"Q%["V".\Q,W+:']KB
MEX'J5G9AZ],5X:);(+(AF7PXA&*Y&/NY86PVVZYX&J7E;IW:$!I:]:JY^UGM
MRYVO??=O;&T7MI\_U#6.SJ]C23.X)B6V';M67#8]ZJFG+7>TVFQ0M<?<+>($
M%D9DDYD&0:CWVL!>V3Z,UE5^1;!R"_3M]:(V:WPAL\/459Z%I494[)L%C6^G
MTUV9BZQ::3+XUU<=HU]V0&)D8:"D1S<MJ<-%80`GYT!.^LC7BNP-(,-QTP@$
M?Z[/S\3B<.I@I!V4V=K-MN+?2Z!E/[:-9C<OMX22E>&BU^]M6/8I(;%?`T'W
M_37VLZ)[_P"W^@>1-(<I;CU%UK'\Q_C+W5T+?]5V2KR>C-1OT684Q"U#7=J:
M6W.'RJL(>_(0\EL%.?3T<3A(21]?:>BY_O'M?8/7VH](:8Z`F^=N,80FI:/V
MK:]O0Y-$@K1U,B%L\Y89[7--$B#YZ8>-9'CFR'GVA8]+CC7^YAYP*5]0RGUD
M[0^ROKJM?;5T;HI-8TO4N;:YRES]OC>"]8U*FP=QUP]>MJ[%CJJBW5:)M5GO
M%QD&!"#"DE&!A1(S><(8='RH)X^HJ]\E1?6G<7.O`F^(S:W'5%UARMLR@4BG
M;8G-Z:OU)L/8!6[X+9\-KN[S-DLBJK'3[=*ASBZVV44PR<XZ6TMC\AP=(;)?
ML0(?%Y?DG19",BR_\T<JMB&3&'W(]LEWJ;33;+;XPJV2#\OK5AM`R'65$+5A
MO#C?N]^`E;6-LHFI.:=46+8&QZ_7JC&ZXU\DR_;!MK<+#.O3$-%(">-LUV*C
MWL9DS34-C?FN8*<RM"%>YW.?4)ZBI6+G8T&9A)("8B),5DZ-E8HP>0C9`(A&
M'!RP3A''A2Q7VU84AQM2D*3GUQG./`U3_8;W!(<[B7Z@TDTG^][)KR(!BIV#
M"C5R.NI:4)FXY;\:>:DN.EMF32[-".0<2:A(L0&@J>D$KCV4#'AI&TSNC8VC
M=MRVQM=6$QN]&S"TW8`DA-AUS-TO$QLB;C]<F?MI&0,SKB/E7I#)MM68S/2\
MTI<L\Y@G)*)8+?7K2FL^F:=/;LY$J<W$SH4<1-;RX]4696+=6Y*-&V`T=(TB
M%6TL&QP5DL.7HQD=@$V/:($]0PG'&9FKR@4#'DY>KVS-NK-KDJC.U4L`""N\
M+&B1<M7RIZ5K01WJZ21%QDQF&E#)W#*8TN.4\,F2]IB"6),B/#<R;V#KOK@#
M2=+N5AL^J<Q=HUF7O37=@UY,6VK567?NH#-$E=A;#)3`T(FK[*L\-F#@AIB/
M]6)DG)1D>T9&8':#=Q'1P<2&P``UED89M#;>%NO$/+PA.$?(042XZ462YA/J
MMUU:W7%>JEJ4K.<^!#6]-6W+9T'#C4/:5@U;8(B6&(5(Q;DB]&2T0Z8"])@R
M49'RT.MR1'2"A^-+^7.!"V\)>:*">,#)#NZYNQPY`VK-CVJMSFXJ_$!DSKU;
M!/`#L,22J29@[@Y%NCK%K)=H&A27W8S!+Z!26"&V'7V&TO*#$+;SKJG*MMV(
MRMSTO7]F1*);8>K(-:"*U<+C`KCCHV_Q5:PEAP#::VH,4;\X(D3)V6!UDX<>
M89>0&1:6UVFK1N)Z?M,GLO8*XW^QIC:UEK\;5KO;JS4+'8W:V!=8RO1E?K!L
MQ6R)@QC\X*.$',]RB&FTH?SC(3EX#P'@/`>`\!X%0?L#O)VLN&NN]B1D[L2L
M2-(YTV]:`;)J1V-'V=`EPM'F3QYBADS`QL4):8UUC#P;Q++K++R,+6A24YQD
M/GLU]JFP?7_KWM0WFSL'H9F6YA!YZV'O<RQ\^<>7G:W2!^[:_#V:L/6G>UJJ
M$IL>_6P""E7`B"I]YA(KF<(`0T+E"<!]9Z<^J4Y_G^4XS_/^O\X]?Y]/X]?`
M_7@:<NVY5('3,,1+BV%R&A]2PDF)@JY5NKP!)B-O4:8/?K[,S<(!M\F(C*LY
MF;6Z'(./PQ)#(R&\?DN)"'=>V$.R\]0TM-05"GQ3-)2J(8*B;6K%$BB)56M8
M/#&8V/$Z)ETR:((BTF*_#)B4NJ;*&]K2'!AU.!LH^NZSQ5RX&XILT)DK,7*\
MJ:!=%2<S^,<U\.K:N*\.<+\KRA#AB&%MO,J5E;3B5(5Z*QG&`N/X#P'@/`X\
M/,Y=4QAUO+Z6TNJ9PM.74M+4I"'%-^OOPVM2,XQGT],YQG_EX')X#P-*GVMZ
M)N/26X^(=4T$/5,S82GND+*57-QM5HFFS=:A*=11I@8P.Q:NV]@K"R)<5M26
M(C*_C=5ZO-8]/<&L?_T_E(W9KK>G?%`G:_JVN72D]1;XBIA$1;@Y2KF1Y_2/
MQ[)<CJ71H6H,58J%AX$8:MJ,B@F9-*\.(0&,TZ.L/IRB=77XZJ"0NR-WV^R3
M?O`=EYJAQ$)J<0]P-Z-,6T`+#HFK'#!$F`N86AN9<=4,0MA;JT_U9#+8K4^N
MX@H>09JX4A*BA@QX\U8WCK9.M"QT6_"#(3.6@J8E_D5%E.LO.9>^0A+J\NJ6
MI:LY#+R5BU^$(<#CE?A0D4ZL6)B14X5^+&B*4Q'1@+"4HPKXF<-,M(QC'KZ)
MQCP-=_&O9=NZ&VEL6I66EGU2-(@`]H5"/LMDJC-II]8D<PE:`H4G38N%CYUV
M88G8V:+DC7B#1A7,L-,$DCD#.)#8#<*I#7JJV*F6%LMV#M$-(04J@"1.B)#`
M4F*X*^Y'RT60))Q1[2'/>P2.ZT^PZE+C:TK3C.`IT)S/>-N[.B]@=.2D'-T;
M7,J0_I?143(3,]6HM;4,FOBW7:TM(?KAMD7HL8B0=RV2&Y&B(.:0VA3XRRB0
MM'=[\]6B`(&N5R0NUUF,+5&UR.<4(((.@60,Q)VRPY%,`IT*6W$DLBE&)P@P
MU&!F,./*]N`[E&J!U:`418I]ZW7&2P.]9;,MDV,`D9!@(6.^:#JKTQ,1=.`<
M#`9PL0!2&G749?=RZ^MQU8:H/MBV);]G\#=@Q^HX/^XJ!7*";"SMKCA9FT%W
MBV!VJL`F46DU2I&A3MCAHUPQ7[@I#[0QWXS\6VK&%D%#!K/Z>YCZGXSB]N1N
MLK50%;K^S,/4_%VG-#\HUK<O/_.VO7(J<MMDVEO.;MEIN6\T:BV;/ZVGBH,&
M3C$PP.#G&"<LDFY<?2%2]5Y[3E.E>*_K9V5KRL5K>G)-W[0)BZ[OLS<O0'/E
M_P"6]H:FJFTN<F;GMZJ.ZW`VM>:(E^0J+4P4ZDD66@_RW@5O.+;6$,:MA>_K
M?,,Z<YUG;;4NFJ)H'[)F.G=)RB]H:S-I-D/[`T-?K;REQQMV2D+;4(RZ$:UL
M!,7K+8ZWIX6/KT@\X-AEQ/J.%L+3)Z?WY3-<ZYY*O'1//VMMK5/ZM*]2)E5\
MVS"[OU!9Y+K3LNM;:G+.1<$GSQFP:C<PLD6@V1)SF5$#^-U:0"&B6PX+1T9O
MZUVO;UB[RA=XZYYWUSV)S/K[[#7M+6O80%>FZ!7^2[/7=>;/U<WK,MV[R?(.
M^][OP<W8&X/#1>0"&FB<Y9;.SX%P/JIZMUI7Z-WG_A"A$ZBUW#6_4%=YV@!>
MA]L=6Z"M.ZMH5JVUJG4;0P=RUK0[!5"RYR`B2;C7P)&2!!,DLE9?CQ$K>R&L
M?0W4G.6G=C<+[*L%KW)8>IZQLHV>[\O$]U%NX'I'6FR45"UHZ7H>XN:;K0;=
M1MN\T51EB1DAIN#1"A@`C1K,6ZWG'Y!`>B_VWVI6=>=5S^X@^@:,/]CG,^T^
M@*#)V_:Y%AJO/6P*U'3NV=-ZIUM&ZK+F+[I5Z^\D&@C2\$85'R(A%8*FVQ7&
MB5"^!.=DW?T']?O1?6[\OKTWGG;FV^-:Q3>3>;HOHSH#I_5O8?3>V]Y15*KF
M[H/<6SQ:R+2;'I&4N<97RX3.(\X"O2#19!(\:.PZD,,=Z$V[5]:4CB?M+:'8
M>I^2]<;]HUGZ3W;<-G-270$SQ)T?3]BV'G2Q[,Z"UI=MF2$AI:S]#@?V%;I*
M'D(QVO0(L<@U]E,B\,$%8RNLAX(HC5FJNB=Z:9T:S]D_+=7L<];_`+5[QMKG
MQ=<O6C>ASK71*[VMJ.&7M/7--LH=*AY2=&DIN>#A99X-6$CK2^G(?6;]:$%!
M26IYB\XN85\EFK[=(0(J%[[V!]AE:K82QJJ.7'1FWKX.#(Q)DJW""G/0KR27
M(O)"LMO-I+>9P%M@;I.;-O?XNN3(X375)EI.'O=^9R"9)6*V09HB'M=T]@@*
M0%<B(TC!#5@DG/B4P0E`@65O_E.AAZ6E!'V@MCR#S*D(G=Q;"E0BL28\JQ)Q
MZ9)F+!/$(&6XVR,H:,2WAC.?<PIM2,^F<>G@33X'&\TT0TZP\A+C+S:VG6UX
M]4N-.)RAQ"L?\4K2K.,_^QX&$5RDZUU>'(.5:KTRA!R)63)@F'B8>NHDSGWE
M*4;+EC,BJD#7R",YRZ^M;BUKSZYSG/\`(0E>NG-!EKF=<XE9?9;\M#F1]EC]
M:U*P7^%AX*6'7'R!-OM\'%FT.HQC8A*U$/2TB(TRQA;CGHVA:L!JYIU974^_
MN':TV!),P\)HDV,KTE(1%.ER;*!\'1DX);'<Z]FYJ"B1)R/-4\DY1"A\/9RM
M++;K[><!ON\"D_-%9IB;UU.Y7:U1T0E\V$1,WJ4K8<>"JY["-D;C7K<W?JWC
MYY(6WPU7AX6+*?/7ER4!'&(0VV.MIO`30SJSGF-.&%9IFK@I",D/RA`D@5]@
M@&1<.'/RI@/T2H=YV2%:?RG",>Y]M*\XRM.,X#WI6HZ@E#)1R8C*86=+J(_;
M9+>C\D'*+&_&(_*2I_"UY>$!RE7KC^4M9_\`?<^!2_N74?/=JU3&15LH-5MD
M`_=ZW+V&#_:Q<=$&B5T.RV:K$VQMP"?<D((.^AQ[X3;4=(/?O<`NLC$.MH:4
M&#[XU'5-_<V;NVQK2_6[0E6OM4N5@(^:2J<7K#<KC<,*.)M"S-135B,9@;^Q
M!A-BR$>]'''1F5O+'=_8+2X%!.1JGU)?J7]>*-=;E=TCL26U-]C]^(L&U>3:
M2:%4X.7Z>T@D+4'^%:Q<M;B4,:#"E,HBD#R3#XX0>&B!L9Q\+(8[V^YV=9=E
M:<Y)F^]M<6^S7?H#5^MI6PP7UI1@\#IN[7>HVC8%/LT3LJQ;_MHU=WI5*I6G
M;%7V8=3,B&SE!9#K`ZT*4$P=F[P^QCDB.8B8;MW4FX]L.Q].GFJ&#]=DW$5N
M,J]KV3!ZXCI_9&T0NGI"K:R"LDT86'"8.Q\\U*"K9&:RT.8\,&W7KK<DGH/2
MH^SA[-6::+%[6Y]@;99[C#NS%=AZ5>]YZZH=Y*D!19J&<#S_`&O92TLF8(6D
M!]2"%-O(:4VL-`G<OVYS&I>DMFU;6'V@:FUA0H=VJDP5/EOJQZ?ZKAHMMRB0
MDA,M@]"Z0MX%&N41(3!2B7<L-9+BW''A'5^X?"<AGOU+=S:HW!O3K;?6X/L)
MTAN^W3.KN?J5(%"<J;TX8KU1J^N[!O:=B7,-]$S[L/>RS7M@'8?>CEJ)`8$:
M_)SA#K>5!N0GK;]>.TY)R>M5AXVV%,G)?*?E[+):5L\J5B(0#"$/D&R[IIKF
M8UID81:EJ]64(:;SZ8PG'@09]?\`=0[JLJVU"P\-P-&OL;8Y8?4_.^KD4+;L
M6NO6EV(A\["D0=L6,&7<K,<^L>02J`!<;-+3Z8%QE3"@AO[+=Q;U/V74^5Z+
M#ZE$U]>/_&"T$7*Q6J3C]M#;"/Z>;)APM<TY@"4#N(T)&ZP5)%H^)E3;:%H6
M4-EUEU`6.EN']:[LTIK1AJW;#A2F`M<72'S9#"MB41)D0$(7A!W/^XI+8^J!
M@)<(EYO\3(.2(SYL*$?8>:0Y@(?Z=I-;X:Y%JPM+NVY%RM8A2-8TPR(V#8J=
M7(N2)K5LNUFV))Z[UJ55*_(KK<)6Y66#A8X1AITAAD`?`K+BG6PL'R?QY#:Z
MJ\_=MQ1T;>=Q[HK;;&T4V%N,M49'@3S'Y5DJ'Y3HN8^S2%B(=1FUS*6!V;2:
M(PK`HD:'%QH`:M.VOKXL&A!+1M+3SPM@T8\Z:1+U6;20[.:3CIM4DS.OCV@X
MJ5DI/7,L99B<FE8P$_`AH;620AII,]"!K@IVT[7IBW-[$U#9(R%M=<;MT[5R
M8W89;1,[&2PNQ9"4"L,!.PLO#DCS&8>)>+CW!7,9DHY]A`^'OT\<&%NM[;6T
MKONFAVQ%:_QEUTEAT+<$!2Z0;<M07_#5MM53-N<:%`R4J,Y:)"TN/6(&$66Y
M)3XB%9))>CQV;?%!L-U-]5U=7S@U5;39\5?8%I>K%G2J(%@=@5BN"!0(\.94
M+.U80GH[;>;]6_2*O$JZD-=FBDMQK&18H0%AH+=\4!]"5"#V!J3?+,<^UJV9
M@('75A9L'[\VPU5^"0XZ2P49+S%G*J31;&%0[T\O$\PPZY''.GO1V9:0"[W@
M1GM;64;M2J%ULZ0D(IQQ#N1C8\L\5*U*1Z_@2R(LZ*D#X`QYMO\`+&8+$?=0
MC&6B&'4H>0&)Z_F[53I*&UGL`B=L<G*XGGZG:5C,RN78.!**'9!M$C$H4ZR8
MS$#"$_M)%H7!CT@@7*W2VUK>";TABI,=D$L-X-?&'#>)PG_=<%%=)?&84K_B
MVRZ8ZI./^&7,_P#/P.SX#P'@/`>`\!X%7NVM/V7H+C[IS1E-9%(M>W=%[-UU
M7ASI]%4#)EK=4I2$"')LSE;N"*^R^^9A"C/U9_XV,_)AE>4^G@?(-G6+%$F[
M?6_M!ZX^V+@63W3*Z>HEYE-NL<W[AY5Z%E]7I5&Z^HE<W_HO3)K*PQ@X]WX4
MRX=4-D1%?*ZIPK#F&P^YA'IE"?;GW)]J?17_`#QZ8],__/QX'Z\#35W!JFN[
M)Z%4_9VW"VJ[K"L%U6&K%/D_[UG[G.7N.I48`Y=7(^5@1H5#UJ'<]4MCEA,)
M-^=]`+SJV@\1==<US0)`4+2FSJ^;2-4V21+'ECP;=-35*J%`A`RI.2LS^P"(
M@DR+8PM#?L8,D"R6589$]V5>T-2^O:]6>(-P<Z]"?7GQ0'<B:_KWK?5^Z=&1
MO2^>>F0L3^R:Z[HUPJI[-D+C7;C8:U3M=3.)$>)P]^&\@\I]?Y8[OJ&W<3[9
M+H?E]L#E^G'D"0D#-%-"]F:%80AN?CH68'8:?ET12'4,P\Q^7^7_`$QSXS2E
MCD/8]?0,:L/W&6V/B7_[7Y!`OUS?:>>KE%KW:?)P\E:FV<)=R_"'S=VC`3@<
M#>]:B!_G91E&4Y5_.,^!BFION>V]<->_W?L?@E&LIB/#*D;!"I[LXOGPXV$`
M!<*=M3<@3L>O'.5TU\(QH7*@T%.*#<SEG"/C6L)-COM\F#$%D/\`%FVA@HJ/
M5,3!B=L:&<8$B6`OSBS&2R+P%&YPVTZS\>"R`L/84M25>U&,K#6#OSI9CM+I
M.A;)M^EOL/\`K\H%"TQL*&VKTQH/;^BZW=[M7I&2I%JT?5%RM9M]].Q5V29.
M7EF4(CFY!I^5%7[D-+7E(2#HS3Y&W>N8/GS47V7_`&?7G2KNGI?8,]=KITW,
M#;.CY^KV2-9$B(M^4UM!!F5PF1E\().R"=@]A6&6BUC81A`:NY[[*[]KBZ['
MHY/V,;A=&IMNN5+&S)1NY;S,`2]$W!(ZWC`IG$;0SY]Z47K^"3*2Q2AF(HR1
M*40VYG^6\!=7FNZ;BZLU]0NGX'HGH3>U[U5T;MW6M8@JO+7;3H$E5,Z;BI&Q
M@'V"0I,K.:\Q*LFMH9DS"5P<I/`QPZLLL&I)8"P7TUP^Y=1]$],TNQTV0V!M
M:1M=CE-WS<OL2N*S6+W:2*%<+T=-V5S)Q-X=?MDJ<G\J%&?#?,=_I0RA3RV0
M^B,2*W_*3I!$U;];U2J>I7X<-5ZG-6"TY2L\G\/)EIL,Z)")<:B5-8<2W"J3
MDM.585EK^A04XW'LVG<]WJDZJV/;MI;XO&][-&DM04K>).JOURG/7=`<Y;J=
M7:)6(2#_`+<UX-.MKE!V2LR"(P)E:LKRXM3@;,$)PA"4)]WM0E*<>Y2EJ]$X
MQC'N6O*EK5Z8_G.<YSG_`(^!&NO=04#5A]]D:-"9A'MDW`Z]6II)QQ0C]DE$
M)5*%1PIA!#,,)(GJ>.=%%PT,H\PDC",.D.J4$F>!Q/I=6P\AAW##ZVG$LOJ;
MP]AEU2,X;=RSE2,.X;7G&?;G./=Z>GKCP,5J=.!JZ3R\D%2]AG'L%6"Q23Y)
M<A(O?.64T$.LPDQV+KD83($9CHMES\./0\M+*<96M2P\_8]%<V-!#UAZT6&L
MP9,K'$V=%6,7$3%C@@2$EDU7$^.I$G!Q4\ZRAB0="4T8Z`IYAIYA3OS(#VXF
M'C:75V(>)4R'$U^->:CDR).&08X`1#K@HKA&$80'$QK&$M-XPGVL#-I3C'HG
M'@8G2HUJ3G;+=7K\B[_GFC1L;#1AD093]?JAA'`SXVOX`94<J;DG"5.2A)I#
MSZUY2VTV,SCX<A[NPXNY3=+L$/K^Q@T^W2H28Z)M4A&?N6ZY^80R.?-"1:G&
MQS9B-C''G0$$>\7)R&<D-N,X<;4']H-&B-<U.(J$,7.20D5@]Q<M:)N0LECE
MY*8DRYN<F)J;E'GBS9&:FCWRGO3*&4+=]C+;3*6VT!_;'41;6,1#2J4CP#[\
M4Z:+'K82JR!"O/NR-:LHY,>\R56)1.4-%#)7Z&#K=9=]&EK0X&2"1L>`(S'@
M@!!@#B,`#A""L#B,`"LX'%"9&90AEH08?'L;;2G"$(_IQC&/X\"%=?:KEFK#
MG9FV'H*>V6.5:0ZBS!8>75-6TVP.Q3#E5I7Y4?%%E/S(M>%+EY,QC\TL]UYM
MM3026!FPS#8],D[77)>+JQ\-5Y^P(&B3[<3`A3,G'0!#S#4XY%CEMY%(FU1+
M:V@5%X=$'(RVZZR^AK+#@>Q7*+6ZS7@JV(%F0#$PIQ\N><5.2TO(/#Y&.F9R
M4D?G+EIJ2;4K!!+RE..X5E.?Z?1.`PVQZLQ==DUFX667-<K-$".;@*`TU%KK
MD[8))`B\6ZTK<C\RL@17T-J9C8[+_P"`P_C\Y:'24BJ$"42HB*.6\X;&1YCA
M`>8\APH(8A;X&7?GR"\IUM:G0\O?U_$KU1[OY]/7P,+B=954%+ZI")B)=XE*
M6G&G(6.$A6AV23"!6A*X,UB&'>8R<XG)66EF/)SA+KRT(;2@,3M>A:=,5*6I
M=,2WJ&&M5L"M%^QJZ'@JD5?FTX'9G8>QG1<<,?\`%;8X)D*1.%='E5A-X:;*
M:Q_.`\XO4^RW8-%8A]X'TR"9AYN"$33:!50Y:-"/$BPH0B,E)]5E2-*5AD4I
M;#ZF',//%)6\A?PIPH)@JE9CJ;7(>KQ+LD0!"@LA,%34H?.3)OQX]739:9E'
MR9&4DS'E*=?(><6XZZO*LY_GP,A\!X&$,:XI;4D_+OPC<K)ODK+_`#+"9(V5
MX5YS$-[L1O[\R23$L?)7@G,-"X9:P\,AS"?D]59#$KIL_2M/$?J%CV)0JF;-
M"HC18%<[#BS+O]P/@08CP=>%)1*/MNF3@J?D;:]B</(4I24Y]V`U$+1+17VC
M<(1T@:,%F/T%?:X^-,52RL3-@1B(Z7*BG(&PL1%8J,;'PH,,WDH,B/:))P8.
MH3_;9>4L-W=ML@-.JMFM\FV^[&U6OS-DD&A?A_)<!@XTF3+;'_(>''^=;`JL
M(][B$>[T]RL8]<X#5Q]>NXZ%<MJ[NC:3K._:Z5MD-/1=@BK$'6BA<6:<O-LJ
MT[9[-8H!Y;9=LNF`Q06$MN&C9:JQ33;_`+1$N$!L?>TWJ$BP+MA&JM;OVEV1
M3,.65ZCUAVP.2Z7</IE%S*XM4BN12_C"\/Y<^7"\>ON]?`B6Q:TX]HTS6WKS
MJ[G&EV.RES3%:.GZ+KN)>E9/+KDE+`1,[(P839,T>DYTQP5#GY1*<D/80XEM
M]:0I5U[.\)Q]<H:TTC55Y&5=![?,Q>IM;5&TR$[$:=!8VJ%"R5XJY4*WK/,-
M<F*]8AI,D]E(SD<@CV9;0XXV'M[WE^9IOD[J3_%4IK=JFRG.A&R]GZXOD401
MH(2G[:Q/W62EM@U_]%,UVLVB[13THX<VAMPE",H(+#6WAE>0^>BBD:-IFE.)
M=DXMO.U`%V;,_9'8H=KJ;?%QVIHB`4WT5HTL"/TW'\?2%-HVN+@V&R.^.-7A
M8^(""7(MN*+<)%>4%MK*]I@KZJ.?-P6(+E?"J_\`8S-2=:V@\G>T/HZMOYZ#
MV1K%%OCK%.3S&^&H&3U)%,P(1(9C[BHEP5A"<@MJ2@)[[REN"JK]=\[(<V7>
ME!3O6L_IF8U59T6ZR760VN)SWT-1IFWBURS[3L!)8T!2H=Z=P_\`&6,X,R:8
M\&P^6[AIX-Q79[\BSI:MN1+CB%KZ%Y'02IB)F9\142[T_J%,HF1C8-IPTB%7
M'9<P2I7L';8]SCZDM)7G`5?Z*Y(W/LO<MHMNOOMEZ"Y7K4@BOABZ(UG7N7C:
MC47`:^`*0Y'8V5K&UVEHZRFX5)D9>)4E;A2L-H2WE'H$3_7QL3<H78'8O$NW
M^F([O2FZ&UUH'9%6WY,4_3T!?=?6+;3^Q1[5HG<"-:,0\18;,D6LA3L.6Q$,
M8'A2\#%K^5#670W#DT:DF?)^93ZL5\RU.N_DU^)?^5Q24I4XY\HBO>M24XQG
M.?7.<8QX$1S>AP"M_P"HMTP*:O`#:[I>Y:M.1(=6#8FK(3M!_6#T<>U8!%CK
M$&A,4![#X[C3N"U%M*]R,CXPL*6=K:JZ:H>S;YVQSW;N?(IBA\PKBK=#[<UQ
M-6>WN!:ADMH;'*11;4!/18=:S;8.WEQ3RWD_$.OV$.I)0CX/`LAPG=IN\\_5
MB0L$'(5B1`CJ4"_6Y'Y<*@WS=4:ZLI\<&V7,V"29CF9.P/\`PI+-*(]N?7+B
MTY2K(52^Y]7_`."S7&QF7GIUV^WE-7P+%0\V<F;1RMTH]E047+9RZ:]F':+3
MEL-+A:V\J3A/PY>S@-M@:<(#$0GU]J1F$I]?7U]$M)QCU]<YSZ^F/`[&<85C
M*58PI*L9PI.<8SC.,X],XSC/\9QG'@?/=]DO'].U49"['T^:[7U;3LYU<.U(
M#1`+5!@R\K$6AXR\5"/::!RTB/-L)*EUXDE(,D5+.A"J%8DCQRPO+PKP=7-`
M@C[4OD)'/[JLJS+*2PK+D@JD2]B8D1)(XN3(D)1,YLTVK2#,-*2S;GXPH(WZ
MZ,PV$HET\+\VRRDQCH-?@F13;?/#F$PH!SY<>&J/BS(@6?DE2:(F3`23"BS+
M9#0;N6UG93E",I3AQQL(2FYG9MNMEMU7K2//UXY&59AVY=)'U.%P*]=I*&,$
M@1=>U&;8.$O4E$G`CD2[IR,18P"L!L/N%+RH4)=HMNG9PJQU^U5B0K5CJQJ6
MENJ:?)@;+`EF2@D!:X*::'_4JQ/-0[K[\4DAX^'][;9>$_(RX\$B>!Y\C',R
M3*6W%+9>95EX(QK#2GP2\(6ADQA+[;PZW6%*]R4NH<:5G&/<E6/X\##JE8KF
M?8KG7;;2\P0U?*!?JUL`F6IF!NU>E7))(;^,*CXDZ$M43B.]LK'K8<'94^RX
M.20V[G#82#X#P'@/`>`\!X%:>RK,-3.4NA;<?O&3YHC:QJ6ZSTMO^$J3-[F]
M00\5"DFR]]A:@0)(,STS7XUEU\5A0Y&,D)1GXG?3XU!\I?*EFYYZ$W_JJR?7
MC]?-\[8V=;XR4W-)_9!]J^XI^12[6M>[0JE'L=[U13[.9L&>E)&OSDTT[#!!
M1U'P`7[TBM8PP5ED/M*\!X&F#N2-/D.H:P3`3<2&17Z!09J<"`FJ18[`O*]^
MZO3%MS5"M]7LAU=CI2M1]@&`*C5Q[MC(6Y%*>5EQ*<!%`.L[?;]9PLVXR0!A
MRGQ]A)J\ERUSX$6Z_<@_S_U\A$UTVE7"+GR8XK&%1H1/R1BLJ%?2GW-+0&=T
M0J:Q2AGJS*UZ+&&LO0+<&N]7K>L)9H^6EKIL-F<DH^W@1;U/IU9P7%RKD39P
MVC`[1&X!<6R,T4MQL/!JUKV!!%0(L/8*FF9E#.:]?V*3DMW;TK\L^1`Z3ODX
MU%F7XNA30=^<)9(_8OJB1'?A(<4.MPC&,O#!87C6ZQ-6GX]RU72E)KL[SSK8
M37AP]HGW#;7F"OV]7IY494;S5:Y;89\86-<<4*$Y(AD"AK);]$-+>="U6_-R
M:3%T_LS-BO\`18+]E0KC!QIEO-3"B&2LA49Q\&)$?/:'(//+98=6V()\ICR4
M+^)M2L>G@:KA+!<DD*G+;?*S"1>L"K19+Q(G]=P[H<>',:"HBA(L@^X<[P?M
MJKI1Z(]"&TI,%=$4T_C#^$NY#\`3U@)C;YANT529*C;1<YG!-4[<K\VX]96M
M$OGS<Z*[.Z8KS<M8FX&--R^9C(<2(@1YM3`IH[ZD!2>DH[/U?TR5O'GA'&+]
M7N<C>M<5M[=>\;85L5!-[FV)&)M@VD(>!H[IA8;K32EFR%D8C9:&)5)LD8&>
M%(=".^<G/L1T!M`7<\+9.#[S=H.Y;#UWL>HS-_73H1T?>-ZO]U7K\R]L]"[*
M1K`V'M.ITR+?Q4Q]Y(RR7<H(&;]$A)?1?9O=N_*S2IVV\G<H05-9GK36,V'5
MO<(]M+LD+L71EHJ]DN4JV_R);+*'IO7J+-DB>D\"BMQ9L0M!>,?BX?:#*?K=
MWI=-8;&Z>[`VO2HZ<K?2-MV(91'=1[6JFRJY80M:[`-UK.25;_'AJ+"!.QC>
MLOED6(49Y$M\BI845N/:+<%#:?8.S.CY:`>N=8UQ0:)4(P$U=FB3(G9N^MR1
MR9N,BXJH3-5UWK&-KT#>$QUHD_VI0+,XRJ9K*$O13[[N7,-!%-`M6S[;?-"R
M>R.R]AWJ-V=;UQ3E;U;!5[6VK9-#-$LUED'XF_TX,N2L--4U&Q940@&2<+:.
MF"@#)$I82QX\-U:$X0E*,95G"4X3C*U96K.$XQCU4M6<J4K/I_.<_P`YSX'Z
M\!X#P.I(2`$2`=*RIP<9%Q@9,A)24@2R$!'@!,K),..,)6V.(&(.VIQUUQ24
M-H3E2LXQC.?`_01H<D&)(QQ8Q\>>,P:"<$^T4&:&4TA\4L0IA;C!(Q+#B5MN
M(4I"T*QG&<XSX%<.H.8JCT_2Q*U996PQ$E7B#9BH&QMIN\57PK,\`Z&!)VRJ
M5&VU(2^1\6XYAYL(Y[V8<3ZMK:5G*_`C?D[AZF\M2<_:P;A:K;<K,`;#R;SQ
MI<13FXMZ89D&'1*:T<:R3/K8CQ&WI*2*DC6T,J9$<%$7D;P-,<AWIWO(]W]0
MZ\9V%NB+TKSGUMFAQ5?U=]:Q>ZM2675<?JK4FU2:OM#JP#90@VI+&:Q;2P23
MW0'EQ(I0\H\W\+J!F`D'5?:WV!JT5QMW7L#?/*5BTMW5L"BPL7S/$:[(@[+I
MBL]$0D_(ZMC-?;L=O6'-T[/TR^P$NV1LA`Q@\D*#,J:<"P*AW`3+L7OKH:M<
M5<`;RJ-VU-.7/H3E3:>W=A6(^FB%UJS7BE\%W[HB&8J\6'L6#:APU['K"/RQ
MAWS?>$RZSA3&/Z_`C#Z__LZZGZ.["U3SQ:55^^5:?YYM^X]T9L?$^_>&]BZ>
M;#:IP.N)Z`'WCN38`>]JM?+9*242^_7HT<2/<%0^LA*7&V7`V)T;J+:\]KO[
M(;5*LT14GRCN#=]&U-^-`V".CR8+7^B*!M"N9O\`^;/.M3<BF=MKS1A$:2$P
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MT8!KW5,91*AO+2NJ:[,;2A^AJ,-MJ(V2YK`2SR%'Z`;UM*\R0USJ\Q<I6-&@
M9N<!)/E(T,5"ODE1_8&\WP,"VC5+#>=?6RH52[RNM[#88AZ+B[W!#LE356?(
M6VE<O%,$*0PN0&9]WQ>_/MPO.,Y_T\#5OJCZ_P#HNJ[XO%]G>C96!C2"Q<`;
M.I\FW(;3VO%/2T5-GL;!J4A4(?5M0D4OPC#)#P@4RU)(=?4IIES+3B`W"^`\
M#C>2XMEU#+OP.K;6EI[V)<^%Q2<X0[\:LX2Y\:LXS[<_QGT]/`KB-S7$3U7$
MKFZ-@;&WLIB08E'R+A.M5:,,?;BD`/`F5/5PE&JLK".$NED8%D!#OY+RVM;C
M;(Z6@R*8K?/^MJ_FF$1FJ-:1EU"L,#&0;0]9I29_!T:5F>"B`@L114@]D`MQ
MPE(F,NH:4I>?3'\^!J)INQQ]K_8?QI8(NPUBRMQVF;-6I)VC6.,V%!!%5P;H
MU@238O"Y6?CYS!L$RP.<X,<7)"GO.,/N)?:*0D-Z,["1EEA)FN30V#8:?BI"
M$E@\N/,X+C)41X$\;+P[C3[6'Q7UH]R%)6GU]<9QGTSX&L3@;6^GX7;?3)=,
MJ5HK=LU9>I+5LJ-;S=@.S`69>P6*\&."&RY:*!<*O/QLK%DQLE"LO8:0A8I3
MZCV"O`VH>!@.S-9U#;E0D:3=@22X@Y;!+!49)R$%/P<L$OYHRP5FQ0Y(4U7+
M%$$XPX*:(\T^RO\`T5[<J3D-5_V$.ZNHFE:--].6&-E+QKR[0D&U?Z?'V*K6
MB5B-ND3M.K*JS5@E$!6S8%NM41&"/PHYK@N36DFDK"CO>E`21N'G2(U;R+<H
M:C;ZV/2=1OZAD0KKFA0L3=[7:V#:B-`P,GJY^18M4)3R<H8!8#C0HP^N$A*<
M9(#>;>R^V&KCDOH*YZ)MU*LVQM3=#;2K7-9_V#:E%<U)J![8-G>U=N_IG2ML
MT#.LQ]&A*Y%V.L1E'UC*$2UC9&&BFF/QLLO$H]RVPV$=?;JA.I]"<C&\T7QR
M`VAM;H7E7;6K,D5.*M.Q:9K8O;$?`VW<)NK95XP=,!5J@;*N.%R3?ZQ#J/9E
MSY?;C`1+W!L#IW;7'^PN4I3F;H^:W@FYZ>KTWM[6VHZS+:8N=:IO2-(EY'8-
M:4Y=#)4,*Z:PJ3YY<>+'D&UXHU3*/7X6"5AM6Z<V-/:OH=.GZY-@0<C,[^YH
MU\\](1XTBS(PVS=^ZZU_8H)EDI:$LG3D!8R11WT9RZ,\XEU&,J3C'@?+]]J,
M-J&U=+=P;8B_J\XBZ-+Y,M/%-'W3L'H"Z[&J^W]N[!ZE`IM4UPY5"Z5#RD#'
MTS6;=MJK4AF46X06",:.P.G&6G/`VH_416ML\YV_IWAW;G.G$^BI/3,;H_<M
M>FN':W;Z+K;94'OP'8,<27,578LO8+U*6:I6#4Y@!,Z68I!Z5(:2TW^/[G`W
M<^`\"O77(KAW*/3H33P([IG/6Z16B)/TQ&L.$:WLK2'I#U9(Q^"TI>%._P"V
MO_;QG^G/^F0K/R%U!S^SHZFS4[N#6],#L]!U->8./NDL+KR674I?2VOFQ[*2
MU;Y45J;B9&4B#TM2T>E,3G\98J5J($)SX$$_:WN/55FYF$`J]ZH5\)*!V)=$
MP,#<@)I,G3S.:.A8N)L1\76B9"3E:/,3SS`2264_$\^\C(ZUOH;0H-7%=^HC
MJ*'"!S*Z/&9^&!$C',:^Z\F+#+9.7(A$R4B`7LX>.@XT0QOY%)8<%D,LXQGT
M4XKVXR'O2WU6]4/DOMP=*Z6K(#&+,Q&`0?8FDQ(L8::DUD".,%(J#=B;,BH`
ME$4PYAUOY6`\//X42M3S@8C/\D;3YRV3J:P[JAMMC!S5EA8&K&["Z/=WC`,3
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MV72X`AY+"UDCK&+)#PM8WO8E5N7^$MVJ,L5D*5,R&L=O158(#K^TZG$1T+(R
M6;:Q`1?]JZXV+7S)=X)R,60VS-"@_L@4H2X0$$%F?`>`\!X#P'@/`>`\#A('
M','?$+89*%)9<')&(:0^.0P\C+;S#[+J5-NLNMJRE258RE6,^F<>G@:H]N?3
M3QK;MA1^]M$5Z?XKZ1K[3ZZ_N7DF;/TRHTK]HU8A@MD:ZIY,1KS:M1(LH[9<
MG$RP"FY9.7&GW?1S*L!M@1A6$)PM6%KPE.%KPGV84K&,84K"?7/MPK/\^GKG
MT\#]>!JF[$_>IW1)$AR&Z3QP-;ZQD0JGK#4P=F'6_%[TJ,[(2Y$Z!5+=:IU:
MAH9+'XH(RC8U6<.#)<>(:1D*NRNT+R[SA6J]7-4RV=7Q6J($9>;*CJ6GU`BO
MRM$$-FK!7K#&\0YLX\>UFQ$#CR;TO'$/)=^8A0KR7V\AY-1JDM<*R'%/4[H%
M%/<VQTO4[04U)]>U(?*9"S;":I<4+0-?0E1UU5]?21`<<$@*/=9!88=2U*$^
MY9.'0]2!H9+<E"01-=Z2JT!5I75\G`S!U^[\C(P^8I]*M(]QPC+8<TQKV"JY
MQ7ZEQ;"S`FT?`L-10I*&Q`[-2V&]`Z\BKM1V$B=:3=1!3//.U/=N]KIJ76,)
M8_PX^LZY&MVIP9"M1-D5)&*FUO1L0!'#N.%O#_D,LM+#S-;;@W3#I)*W!;[_
M`#M(=N$C.[;I^UZ'<]D4-_40;Y`-@BFE7/7]9D:A(P<-*-2T'+1$K+Q]QB!V
MI',=%/+(B?`PNQ3BZU/W?9%)O^+#`4>?V+:-1/-=(;SCK/9:W8=54K7=0434
M)ND[318Y]XRM-`@L-MRCLO)C_&H2.RMU:P[EFW#DS%LC"+/.%3\'L^_Q#D>]
M>=A.BA1`/.TDU'W0G]SS0"NRD6N^M2,01-#-BLEMJ>B5/JRZXCP/S4V^K-C4
M^R7[4VD*ELVBZPV1?T#3@O94W1;#-V6J;&K]WM!E%K97-]XDM=5>1E*V4R]5
M#).9:=2Y'CM*:!'=$>"G6C?LIY7OU0U=;0MK\PT!HFP::O\`,T(O=,!%7BK'
M$6GI6SBQ\?.W?3%15.6(8*RQYR4R3>60,2<JAUMG#C*&0L7JCJG4>R8J7QI[
M:M,&)U].,0\Q;-1]8:9G;2=)3G/]YJPPNT9"2YUJDM"S40!$2LA".(?(#F#8
M(50Q;B2UYR$N:VG]NW[JGH>O:TTF'LLO69E%EZY-W?:&NX*LRJ+?^WNC=KAY
MR)U18`Z+-ZWL5N-3%2D)&&'S9>,$Y(_&9)'*"QM/I/?>JZZS'T_G_5,E8((=
MR/I<\'N.BU<"+KZ;I)RHU.FJZ#IP=PBK2L;D4R<'C)&-:*D<95%M0Z,K;4'"
MQ$]`"],:DOUFYQU'IBK!;$.MMNC;/T!0;ZZDFV521I-HV!IF,'UXU=J7L&9)
ML`@TI'QCV(BRLCNI(PP:[@PD-Q'@/`_F<X3C*E9PE*<9RI6<XQC&,8]<YSG/
M\8QC'@5QE>HM?!$3[,-6=R7IFLV$2K2LCKS2FS;G$YF2V@7O9%R<+6B`YV.%
M;DF<D'@K(`'QE67'DX;=]@>AJ_?M.VW,V:@&UJY4:^5Z+C9"P:^V;3Y>L2!=
M>L3\Z#&R\$[,!,P]TKYRZ^8TZ1&O%LL.-*:?]B_1.0J7T9$]`\<:DNUUY*FM
M6,:NKS<O<9;76YJ9>KM5].PD;7+[8+"3K[%%OE/GXZ@R=E5"M_I\9=C:H`T6
MZ&T@)7PA!2VO]C_83OR2YOT=&:3X[QNOH?1!G;,5=C;SOR/UAH;G@F"U0)3Z
MK:6(*/B[Y=]V638EYEH1UZ&E(J'S#1_Y[C?^\N.R&(6?[9.XX>D#2*-!<>P&
MSZIUK`\)[*U7=M];*BS)C=TYNFF:J'VQJ>8"UB43-\]N1^T*[)J<.CV)UCYR
M6LL.>P=1(9Y)]/QW!G7.G-3+YMUN#L3L2YU+8'V*;)U!MVRR.M=6[5Z#LLII
M?FFXHK]Y`;N5D1LS9E6172Y1N&AF0(]IL@IOX6AT,A*W!_&O$6Y$+[19Y/H]
M&V2-O_J2&K=4&M>P+3JNC6#6N]-T:%F=@4'3]FDV-4:[N>RHN"*D9DB&KH#K
MA<B[G+CKGN?<#4+<]8T72.PN\=@Z'^O#5N\^2]`3F]>>;#:-R]H;"HEC#&L.
MK`)_J32/'VKF(R]:YU2PN#LQL,S(,D5DJ1(CW8MYYA;3.5A:'_S?HV^.XM"5
M/5NKN'(6Q<_6/4=/Y@M6Z.SIW276CVK>C>:=4;`DF*]H4>AG'[4J,G`;$!!?
MKCLV4-(R,.EY"6SQ1WD!@G5TYH[37:\/*W[C&:A[#O/9ND:SO.3;^RG:VN9#
M:.X>G5PVB+(/H'DNGV)^N=#BZQJ"(Z3E3"PH!YN'(')0.P4V[\(8'P?N*BR&
MW[HSP7R5"6VS0VO-C1^H]>[;^Y'9FQ1X77E1V7$ZRG@=T<VVZ;VY&Z49DZ5Z
M'0;T5$6$6(]4P9Q,>:XXA(3ASA2N8=K_`$QWK8]ZX5FN=>=^4]I='](Z0U-S
M1U%MYR3VJ=I9C8#A>X=?[GJ&==;-5"['M\C8QH-1"?C=BVPRQVLA9#;2%)M7
M:\<W1J^.L5?XZOV\-KZ2U5)[7H>]]0_<WOUBI$\[;U_8V&]03?14&3-VB.V;
M%R>IX))-!.04,J-DV)%#X^5.LI#*;_$U75_.^I^[+GP]OVH2^T]H<J;$IW(^
MJ_L#MVVJ3W7!4+40VZ,]`[YIV!J8));ATYKK6_\`<TE('1[Y=@F*T"F546V\
MZXH/I>U;V1$[;Z8E-&5FFFYJ(W-&LN@H[9)$@YATLW8VR-MT-JEOUL>,)&98
M#&U4\>U+HDG`S4/IPQAQM33S@45:^Q$"E<P;9Z7VHC>S<+1K'UI)TF/KTU3)
M9[8"-";FONH[%7S)1.M:Y3==XK[[`1,8++FK;)C6U%X<-4`?A(2;RGTAU7OX
MS;QP%6_M*S:WK^M#H?7U\V/J'=FA-H1=[%=E6)_7'36@*K"EB6<7^UY>+DPC
M`)(>-(>#+_'<'(;3X&U.L6`2TP,=/!M.#M'M+RZ$0\$\9&FC/.B2,3(9CRC1
M692)D&'1BF<.J4P0TMM?HM*DX#WO`\N<&DS867#A9/$+,EQ9XT3,9$8/Q$R3
MXKK0,ED$I*QC,`E*2[\3F,H<]OM5C.,Y\#59)R';M7I]\KN_Z9L+97]Q5LJL
MQ%FYWV33(ZM.N/3`<.W*3S8FK*5M#5^)J*GGGY.3BG97]8#%9?$;')<RE`5N
MH\AS5;C;I-[?.LT@S4CZ00YIVWQ-R<WIMJ9V/=A5:O7#5ZR34PB@Z)GI5T@4
M:`K)B(2S1SI$O8WV8GW!-A$-[VQ?-1].:0WG(:HL>S`-2QT9K!&KM-PP:Y__
M`"9LI6TH.#T=K>5EHFJT;=LA47K@<;/V2N)C8R/_`%I##C0[>!\$AMUL78&R
M*YKD>_N\%=E2A3T;!'NTN"CN>INW#.S*@L/`+@XGH(V545$?EJ_)2D?.6_B5
M[L)QC.<!B_`F]BNGH6_;_AZ7MZDZGV8BG3NGQMN3<":?/U<Q5LDC;1$5ZN2L
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M:3&&J477HV/O%2XO,KUG8UK`3!E&HC!>Q=+-SN8.&24?\,:%,#9P,0O.'$+P
MLA06.T/JCL+9FF=([2G/L'V<S*W[7.KMA6&&8Y_Y?'AE/6>O0-EGX01IK6:I
M4$$A)KXS*\'./C)4E?R.J1ZJ"=.W1\/ZIURE3;CWP]9\4D8]CJFLH4/UCIUW
M#R\H3GY$-Y3ZJ1GT2O'\9]/`K1T=]+7!75NU]K[GW/3]N2MVW;FA?Y-Q5NC]
M]:[J]J3K"(BXBA)DZ50=@URIF*J^(,,H-QT-QX<T9#[:TK]?4+`\D\`Z&XLL
M.V;/IR2W/+2VYLU!NW%;BWGM#>!8\?0U6=54AH"5VG9;3-Q,1$9N$A[&<%+]
MV7\Y5G.?Y\"[7@/`KQUVVI[D_IYI"$N+=YXW4VAM6'5)<4O6UE2E"DL?[ZDJ
MSGTSA']>?^'\^!&7$!U<MVE434=EB6`(.@04Y,E_[A>!=C-9:]CI.$($(83B
MIE14N,0R7"(RI,>:E[&?:XI:$A6S[>X*+,YPJPJ3A:H4Y<+ZU%V9EO\`!<@C
MP^5ND28HE$D)AM^+:%(;]</8]4,8]5*3[,*S@(X1]F>^4`Q9"-.<HE-E`C.O
MO?\`F_3!VF27B36L(9<54"U&BJ9`6E+W^VI3_JGV>Q&5J#SR_M>VC'(/==TE
MSK+C@@DG.&5OLB"E`<(&`)DFALFXUBD7!TP(RW^"TI2<D/DL#_P^^VWD*L=/
M==7WHFY:7INT-#:\UE&4Z\T6Z`SL-T%4]ES\P5([TYZKE7"`@8^GPUAK_P#[
MFYQ]<DPO#BD+A\-D)92^P\D/IE\!X&(WNB5/9E3F:1=X=N<K4\,D>0!42<`0
MA33K9(9\9+11(,Q!S46:RV2#(`D#G`EM-OCNM/-H6D.C9[C6]8Q=?78G9`*O
M$24#4TV(IQR1#C)&9D(VMUEF?.(*>ELJG9J1'$26I#Z$ON^\EQI&<N>!#U?V
M!(#V?&N]K-YL]9O\Y*DZFV+BO$CP-B:9+?L#=)LPH4-B"J\C7PE"M01Y!JD6
MIME;C/L*:6TX$PW?84/KY5<(L8LNW"6"<$K:["!%FRL7`2\J^P-"JLV8YDE^
M"@Y$EQ32Y0A"(X-S",$O,X=;SD,[2I*DX4G.%)5C"DJ3G&4J3G'KC.,X_C.,
MX\#^^`\!X#P'@/`>!&FYKI;-<ZEV1?:'K2=W+=J=2K%8ZGJ:LR<5"V#8]BB8
MLDR(ID/+SCC4/%GV$YI`S9!*OA9RY[U8SC'ID/E(TQ]C'9'=W66O^:.C^S=9
M_5VMO7H6W;+H+6VKKAKCH(R]!7B-@QN9;EM/L*%KP$[-R\#+(E,DZ\B269$4
M9_(I3C'H]@/L!Q_IC^?7^,?S_KZ_^SZ_\?7P/[X&B'[#=,,;LZIJ80A&C,&U
M6H4)LN(V/*;-9/DR+K?AH*O%V$6AE@ML5YB1;]L>I9(V"2FGQ5)<<)'2H,:M
MG+]>H>GXUO$7L&PRL?IJ4RXFG:PB+O8;++5X&#K,<;)457,D3F2.:@Z\&IN(
M/FHY;S.<XQ@A/P$)#E^OOCC3.X;AV_L&[67>UI$K/:=]U[JJ##ZCWO`5#7-#
M@]4:H(_1TZ%UY?J='QV"Y*T'(D$+P0RI]G"F4LYRYA8;$)KZ[-$2KV'0[SUQ
M6$8#CP<#57N#KN'%PQ$@CQD9Z,IW.]C#@,<PIEM7KZX0\YZ^N5>N`KKT%]8M
MSDH"JSO)76W2>J=L4>S"S(4=N3H_HS=.B-B03[@C,Y3-P:\E=G,SU@@WP6,N
M!KC):),&/2V^MYU*/CR%0:)]9?V[R<S3*WT%]HM=L>HD[@JU[V.5H6H;6Y[W
M/(Z[K41.CFZ8J-OJ.QU5J.I-PF+(\7)9*C'I+#S#;C)B%*PED-E?_NN2A-..
MO@].?8''%.+0\A\?N;H8EIA]M2E-O)BY.Y2$(_Z9SZ*;>%=9<2E*5H4E.$X#
MS6_K<@,)EF".ROL3D`97XF_UTEU]>3A`1LL'#2`0OSB+)(%EFC$X>P6X2IO(
M[>1U,Y4]\H4:Y[Z\YBYFY2V?R?LG>6PI_;]-V!U_JO$W>-:;2N%QV!,,[@VC
M"4XJ3ND)JF.I=YL\E`/1C"W1G%H4XCX%K6IIQ>0I%]=4M])-(XBX_A.EM>\X
M"](1VB-65+;AEUTX7.7*)V1!5L-,\%<[(FK2>*[-5Z3AU-F/EE#(C'DH:<6S
MEUE#@13S]T]Q14.GNH*QS+K:FZE+NW20413[A<;V-HW5NTN?:GSE:*X;>M=W
ML^J&Q@FN=$6)9JSATR/S88L+@4:&DM]O*`M7]5'7Q^X-T]&;TINL[YMB[6O4
M?.SUXHE',JKDHY9L42CUVPR#6P]C%ZLKUY$I<[`FQQ#N25/B>S#;#.$*]F`W
M_.[PO@67&3^7MZ.%#RXD:2J$,TU+QS@A1S(:YV.-7MF/>-B1&GL$NI4PR;@=
M"_:.IU.&E!3G?NIG>A;;0-FN\Z=)1%[JNPM5L`P\G8=,0=0>#J5]K$VNV6U0
M&R)J15"U&,L$L0/D%_!;ZABVTC/9=90^&U+P'@5=ZJDM:(IL-7]QVO\`M754
MR99YG9"OV5JAVYVAZ]U_;=@VF"D9&KQA:\5Q^-KF7Y@8DD%DZ(')'][N7/QW
M0R;F_IGGCJ_7"=G<Q[3IFW=:"3<C3\66BF?E0P4]`-!YD8!Q"F!G`C8T<UC*
MF5-HREMU&<8]JL9\#T]QZ7C=JQX!D=,$4/8]:+;DJ-M"#"9>LM2D4ARD6ZMG
M&7A,2D<5#SIXKP1#F176S'/<C/KG&0CBL79[;]6VSS]N9C-,V5$4X&G[$*@D
M.!5V7C-H4K+0ERH$J<Y)!H".**D1&!2'W2QSHQ]*T+;2A:PUE;=^LRIZBC-'
M6366_=]ZB8YDU`QJRG[XTW+4HC>&B-5ATRHUVWPA%/L5&MM0VKSK=#J0S8)B
MO$Q!9]8LGH=!):!4Z(*%C!/JYTJ_S!KS1M0V]M0W,;U/K+MRR;RO$O$;,VEN
M;=-4V?6]QD6:^2MCC&XSX+U-UD!@IB*%C&F(\=MD9#6,*]P1'MGZ7N0NFY[K
MJ8Z+JI]WZ-Z*L<A:*KTU*5NN/[+TE!1VO:9KS6K6D+2)740-5'U:;7,G1(!F
M"95LQYYXAPAMQ#V0FKF;@KHCEVTQQ\?]@VY]G:BB[;MJ_2?/$]I?FN&K5MG-
MMVBT;%LPSEUB:!'WV)6_L.T$20[K4JUAI3BV<Y_'6I&`QW<_U;$[.NO0\EKC
MLKH[G_5'7!@,IT_S]1%:]L%,O-B7782KVF4KEBN-8GKYJ(_9%,AA(NR8K4H`
MB2!3ZMX8>5\_@97I7G/57U^;#VI+O00;NFMU;$J5AJ&PY`:O,Q?-(E9U-K72
MM3U#,F'XCWZ]K%J.UG"!UR2'<,(>D3%#R7Q?&R8^'1[!^M2?ZSVF];B>M]M4
M35UEQJ%&P]%L5FDVFMS`FFKDJ^QD3K^XR@0M\TY#[&L0<;_>K,(:G-C&BQVU
M*86A+J0JII7ZFP8^:ME;)Z=V='MZHT%UKSKHC7TGK2H"R^B!.V2HNW[#MSVU
MP(2K8Z9"@DXB'($M3`[D<3@H>4,*D%.I&#:5+<FUU?&8'&=#O5XTI6H'2E5T
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M/5NP]#[CVYN>R[AKU3L\E)7FST;9,%&7&X9ABA8Z!>&N\`\IN.(6@I#V0NQ]
M6?`%VY8D-H[WVKC55+V;OFH:KK4[I_G/44=SUI>$&UM'2B<7VR:FK%VO%/=W
ME>)&>(5+R(!*!1(T<,`=&,-/+<#8YJJ*C(:W;W%BZ\S7V2MHARY/P2:#&IN0
ME=:T$DZ?1&M,M-5_\Y_U0X-CW*??:<+7GWDJ\":O`ZQCI#`93XHN32F1GW1@
ML/-CY+(;:4MD7!#WHRQDAS&$>]?]*?7US_&/`A^&W)ZYM";Y0KEK5NI"&2DG
M-33</.U!V%!(D4$RP]KJ$I.QP;(@4?@HAF0P`4P.ZE2FO1+GL#PMQ8TU:]77
M&U62I4G:@-7I5@N0\,8U`%'FM!U]5AP(*7).C+B'9H2#:2M;CPZ%-M8^56&T
M9]`T6;8TUKW2_)O#'>#6FX\?>]3VWQX<Z55!S)?-6UY>-GAPLO&4H>4B]BOT
M"H2M`O:F)9F%!<*<$2SC*EOCI>R%?KU_Z@CI&R;*WG%:MT]IK5&LM/P.KUN/
M[XK.[I*[2LUL6"N)I6"K)&HI&JZ+'Q<K54AM.6`@1:G2\+RRZR.2I`;=?J&L
M#%NY@U#;,@2(^+%R_P`O3-4D3)!)N)[7,O2IF7A)HV/9IM4&J-I*M)TVB5B&
MW#F&7FD$C.)$+'PH-LO@/`>!K*?US)<\35JY9YFBZU4J;N3]IM:JU"$GHN,L
ME"&MNRBC>J;/30[=:3C'"9*1O298`AD)<)"S<JTTH7*7&V7@I-N"?@*QTIR#
M8J#KFW4VE::OO)&C'-4ILM8HMSF$;"M^\-65;&P]43\=%AV.*UG+&+FX&0KT
M^O\`VD3;ZVRF?:*\%X?M`K>SY[3E%D=8:TO]P,HVPC;_`#]]T_;]2U/<FEJ_
M7]<7QH^Z:TSNTI&N9>5FVI%4">/)"2[&8:4,S@!Y[X7&`O/IZ]1.T-2:MV7`
M?M?T6Q-<TB]0O[Y@(:<_4VVLQD_&_N1HU2XX>5_#D$?D('5EA#WNPC.4XQX$
M1=<U&XW;6U)AZ/"&3LN)TERC9CF0B'&%QM6IO2.K[9<;"^A$K$-F!5VK0Q9K
MX[BW6GFF5)4P_P"OQ*"T?@/`>`\#3#V[LZR1^UMOZL$5L.QQD]I24,DM=E6P
M436LS7++0;#4''&1V&F9$:3F9YQ(XD5@M"3Y`-U1#7XQ.'4!5/2&[7J=K\*&
MJLK%2<77Q@\(K^J=QGUVKP='B:-I^"H$I8K%%;6`KD$XF'!'CF87(XIQR))3
MC+#?Z]W)`>#TCMV2Z5TI3H"OW1<+8MAD;#KD<':K],VHJ->N&GMJ4,5QX.H6
M":C8V4`A9MZ2CRP4F9DHS!2'LC'X9]@:XY#E*6.D+4'_`);@H^Q4V?*@+C78
MB<VH&_37BWL"Q0%P4Y:S*W#2+8\U'*;#CGC#G1L-Y<2W)N*"<#TY/B_8-2>@
M86+W2F*N.6\3Y0=YNT_%62$I];<)Q,V,RQYUT5$C.N-P[[TBEI]US(993K0>
M!(UW#H9CJKF[<\7(ZMW+'3U)ME9'K8TB]K^LW@D.W_VKK^ZT&ZW`BNMRFK(>
M,V&5K0NAX@#1(3.27523:4J_&^8QH/L7HUG3=:53[DF/?B4VVKP%F3%$D#%D
M1J9Z)$E$@/E!+=#)>#P5\:G&E*;6I.<ISG&<9\#*?`>!U3@0I0$R,DA!CXZ1
M%(!/`,8;)#-"+96.4(4,\E;)`Q+#BD+0K&4K2K.,XSC/@8E:-;4.YT(_5]GJ
MT3+:_DH4>O$U9X?+48F(#0PF/&$0*IAZ.<BU"LN!O#K:?$>9;=96AQM"DAB*
M"CH@R5H.QHP*:H$T"6!!68YLZ5BSH8QLL4VG[#;DA#@8]8T>\P&T;('O8L"G
MLXSC#^5-9"486'`K\6%"Q3.!HN-9_%C@T^U+``#:E8#C@VT)0A@".']K`[>,
M>C3#:48_C'@>IX#P'@/`>`\!X#P(*WYS%SUU)5!Z3T1IO7VX:T#*1TY%`WFM
MQ\R_!3D24@V,FZY*.M8EZW-!$(]6RP'QR$I4I/O]BUIR$Z8QC&,8Q_IC&,8_
M]IC^,>!_?`TP]O220.CA?RHB1FHS%/H\M[Y^NV.8JE:DX#9M!87)4QFFZJV+
M)2-QL,;9\`2OY.6G@8!#[H6'<**;\"N@^-<,Z6S&0^D>9S_P-54F:#-K0^U8
MN,=PFO5S];=&)]')1<8P'$^D<B-+8LA'PH^)?Y_HXPOP+M_5BPL:![08RD1"
M6.W[P*A(K!(BD*`T=S['DLFA/96-&20I@KC+X0RE,`K;RQZ_(VYC`;3O`>`\
M!X#P("M'*7+EWE3YRZ<VZ#MTW*FO24I,6?3VO)Z5DI$G.<D'GR$K72RS#2,Y
MSE;KBU+7Z_SG/@8^_P`2\9%8823R/S&0D4;\,9+^A=5NX'$P\Z1^*QA=45AH
M?\A]:_8GT3[UJ5Z>N<Y\"H>TM)ZDT)U?SC9]'<FZT6ZUISJ8JQP.H(/4&IYD
ML8-[1J(V1GF)$VC0]GK8!!:V,H?<*4"48T^VUZXRK`:F_I^W:!7-X=W[XL=&
MW/,HV)MS>=A_M&@U*W;MEZD]-]$W^89J<)7-6U60CVA$,(0APP9IA@IYMMQ:
M$*=]<A]%M8ZAH]IPVIBA]$PN%OC#KQ:.9-]US+"B8\^0RX\F3U\QG#`V`/A=
M6GW)02\RWZ^KF/`R\#>E#D9>JPC(>S!S[FEQ4&J4T?NN%CT_$28(I$[,3&O@
M(>INY>!7E*)9\):VU-K3C*'FE+"8?`>!6;HS7E>VX[KO5UQBK?*4N_E[*JEL
M36IPV%C&H:<T]>XPG-GR$^RHD1U)7M!SG"LL2?X[J<?T9\"&9W7M4^OOFO<]
MIT<(\_+3EWK5YFB+@,N;`)M%E)UIJ<N7<KM.'JP0((E9AA7G!XL8?#A+3A*V
MWGG7?E"X6R[D]0JHNQ#QK\N1_<%+@6`!DCY<==MUR@*FASU*.C6$-C*F_E6I
M3V/8A&582O.,(4%5_L*T%KGH3GUVM[+C[;)P\%<JU)!L4MFOF3+!5L67J:3D
MVX^TP%F@2<P]6V/(EM/.AK>CR&6S!UMD#M.)#Q=J<M:?U_1Y2=BXMS#IQ]-I
MLBG-`H5L)E(*TW&M5AF&D0VM?ES,U#11DGB20,I;C*C6DO$I>:2IO(1KM?A7
M0^N:;9+LATT1+B*?$RKH6MM*.^PE=J@H6NVIQ`&I,.`.43)J2!G6<,C1X[*U
MJPAM+BO`C;<WU2:0==UQM@B[7]V;T&>#/5:-';UE68,\YNX4.Q)DYMR)U0?(
MN2,:=205#J'^'Y1V<!.*P-E'PA-MRX8J5/U_;#Z_L/8`+<(%,V=F.AXF@I=+
M2)5GXXV*7AVO"9D52PB7<.$$/X-RI[^@EO*&E-AT+=PA"Q5>V3>!-IVXZP%P
M$A/`EDU[7,<<I$3!2:AZ](R[%;%=>A"1G,"J<4MDUH9;B?RO7*5MA#CGUM%C
M62Q]%L]0;OD&Y+1U=BHW3L@,5):PA7*W$"2K:H76@3[L2/@G]+'MLBC1*I!A
M33[:77D%N#^!FD3P_;6J.+>WNC[R.^7052LL(Y6[A!R#P10#<VN'+;3L*#G!
M$M!D&!O,%-(*]I:\*2TMII+09O7^7;;!ZT5=0=Y79>7JH-?A0OAWK^<%(BP`
MLV#&@0`_1"#VX9@\?Y_[?2OXG2U>U7N5A/H&+:_Y#VY#U&X[+D.V][V5K8F5
M[,C`+L3>R6M55R?A$2$K6*6!$[/JQK1C$,[^`*5*9,=CF6&U,,-%J+(*"1ZC
MRYL&8JE5L<'T/8X?-C@J^=(H"ENA2`"X$Z.:,2,&V1TL"0Q._$0A&)EW"CEI
M3ZNHRK/](8_3]`[PVKJR'L`O2%XHZKI3B7$"R0&VG[55YDV!)AXR99<E>BYR
M.9DH$YL8YEI8[F%$L_,I22'%.8#S^7=";]SJJFSEAZ>V'<"LF78MM-UD[^]-
M89(O\L5"Q$E),[9FQI6,KT>Q@)I9B#3B1<(PLAOTRWX$S@\[MVN3@-D!6P"8
ML`!C1,?<BS+(;.9(CQ;#6G2?VPL\UDPJ(CYN2%BU/?+B*;E)%`^&\&D86%>(
MK7'2W6&@M;7S6W2ENYX?G$6>0?">&M]HG'\.Q<[0`%R,L[<JT4I<`<*U.!)2
MUD$TU"%D,+;6K"PNKHMB0!LN\8B3LN;3(05YI,-(2JZC'58DR3#T=JO]E)R)
M$<PVW9).;+<48Z7E:DL)?0$C"&Q$X\"Q/@>18'&V8";=>DU0K+41)..S"&!R
ME1+:`GE+DTBECEB$J`3C+N&W6G6UY1Z*0K&<XR&JGC"^:%YGJ,I5;KL/?M3D
M))(9+\GU-KJ1U'"FI8(GIPB6A5#Q0VNF)<QN><*FR!RT8=PAM[#;`C;2&PO?
MMK6_/6Q:69:MF5BD6&LPH2;DBW_D`Q1D:P$@6PLSL/?(P^)D893R!6'L%,2`
MZ76_;[EY;5_(:-^S=/[TZPJ_$^QUW&P5[4FW-G\H1DU3GKIL*:AX^;BMX3UG
M;C;-JB7;=@KS2;]69"+->L+YK4Y&EU4/"7B`SG7V`HU+_5]T?$].]JQ-((U9
MLJ1H.I.0R$S43'WO5<D1!Q&J-\A$5NHU"%V1,F@CRTR5\X:$FG"N'@Y82RV-
M\@:@WJ_4=6+W7.9:*NV9@R*M*:4YG+TL_`QB:JY#Z<_PO`9KE'O%(9LLW'Q.
MVJC.N2F+'(!C1P<N06TXVRGX\MM!M6\!X#P*H]*YUWKN1UKT5+5>M2VTZ/9H
MC5>O9"5LU?I\\?$[PMU3K5MH%8F[-Z19,G:<@!&#Q>7!ERLA$BL8(8]?D2%`
MM_:)(Z;M=,)VY<EZ]OE6E*]LBR6O5")JJ6?5DWHXKHA^IB<_9O.N-A36UM@0
MH\S*LR)(P$!^PCV&9B)4E+F!EA$\.7VI#ZPN6L2MA2ZZY2M3[N,E6.F-SZ\5
MO*2U+N.5M$GJ#>?0,N_!HA]7*TQ`"XAGX`Z3%(L@RI4MQ\)R`:"D0LI5N.KY
M0Z_7ZQJ_9W2K=%AX2:BM6P8?<4V<(W#U^K&0E#R?DW3%C&@==SL'&CI%<%)E
MU1!9H2T">_#BQPZTEKS:>P:/#5.B=1="Z]O]\,PW0P);HRH"[%*H5=17/[MN
MR0K'RI=&WVX^0=D1'7TCF!%AMB$C2F"9)EM@(.Y/ZH*Y7V-NK6W5VZ^H-GQZ
MZYJNV4RPWV@['Z&EA#I&OF9NT?&6KG;1(E)9K0TCAG`F'8R+D'<X7@AI9#1&
M4!>*=^TCBVL,LD6.\;6@AR9EZNC/2_*76D>T3.L)<4J)&<*T<TD@]>&5?&TC
M*E.^W/LPK./`]^6^R+D*OM$$6&\;#KHH0AA\B=8><>EH*/B0@!I(LTR9D);4
M`84.,,-$O+6LIQI.,?'_`#ZO,^\/6K/V%\AV^-CYB`VE(DQLJIC$<67JW<$0
MV6T4@ET8QG$Q0`',QI#0BE(*],#*2IO.%^CS7O#5UO:\T'>&];ALCGO;>O)4
MF2%BV#+2%KVAVJTQC]-J-KARJ58XK<4J&-6ZG79*M&R\E.L!QAP[B61&\'-M
MF88"`HK7\50IBGZW<K<U9YO-YL$-K>]WFK+L,[&473FI:@%838ZJ-1@\$7'6
M6".$(7D>73`NDX<98PB2=>'%"9Y.%U\U!P`Q.IJ!`SSDM.W61*PU1+&QK(^H
M5:W,%V6NPM34X)O&1EH1.3/U#+[_`..=())=;;=$PPT$56:%!K-+*M5<J\>"
M10ZGBQ,2@U+U(F<VR8NA%7S7\Q>=5T\+$;J\N.O=HE#V8I,>^F?=6^*MDR0]
M[#@>Y*:P:M=T*AR8[X[,I,O<R4LU2IN_-3_\]@UA6OK'J>;A*7$#7R"A&$Q9
MUE4$PQ7G!!R6TCC_`)I)`=:;T?#IUML.S#RF8"4QKR8G((2]/Z@D`Z)L%R#@
MY`2T6/95:L:9":L]T8-:S`M@L3[C(9[[C$<V4D9.0^BC3C^"M1:K*2LUQ).N
M*.^ER2R;F17AZL1;F%GYDDHD<FJPKU=_(QA[W^OOQA7KX$C^`\!X#P//E8F*
MG8\F)FXR/F(LQ*4&1LJ$-(1Y2$.(>0@D,MMX=]*'6TJQA2<XPI.,_P"N,>!Z
M'@/`>`\!X#P'@/`>`\!X#P-4_5CX@N^94E;=2D)'%(H[<=`6)FZ6Z2D/=L>C
MM.OUJ!-J:=<0$L^$06,VWB565($?!E[`P7YSJ0JQOCH/6W*?-4#M0[0%8NX)
M\'1:V14Z=6="ZJMT.0Q14V!<^*0389.AUV9BVZGA^,!_;&"X>8#8#6^0D5#H
M62^FXJYVSG7;>Y[9IG9>AXSHGIO8.[]:4#;S4$-?VM36JFZUC*'-6`6OE'"-
M&S<77\O.+>>=+(=RI]Y:EN>O@;;?`>`\".]E;8U]I^)@9O8UC:K49:+O3M;P
M!#@$K)*D[M?YP6MU&!8&AP)$K#\Q,F-M8=4A+#*<Y<>6VTE2\!(G@/`>!2'>
M"73.M.?06&5/EC<Z=B2H+;3K2W/R\%\]0[>%1_X2WR6W,2WLPI;Z1L+5A*FG
M'%-+:#Y__HVW?K"EWKI*_6QZ1J57E9VVU^LR`M.E)>$F!C-W[!PI^$_L2-/<
MAZ_4WZP]'23\M&1B1SF\YRZI"\9R'TE!]@\V''-1K.U89HQ\PD$=LZ.L48@E
MX-LUTET9^2AA!R`6T1[G_<H6H;*LH3AS.76L+#FK?7?-=NFHNNU[<%3D)N:7
M`LQ<=\IPCYA-H)2)70V\G!#-I.FGUIP,PI6'G4J2I*<I5C.0L=X#P,-OE41<
M:V5&-Y"9F!'1YNJ24@P66'"7&%=Q(5:<)"!/C")`:*F667GA?G;04RE;*\^Q
MQ6,AKYZ6W/BT<_RNH]M".ZIWK(O4"4LE2A_W,X$NO070VKZA)W?6-P:K)<%:
M!#W;%&'Q@BE,R@B9(=N19$>9)2T&4WSL'G[<=3&J-%M;4C8978.O`H#^ZZ!L
M)FO_`-UUS:^OR,QJR/TH`ZK+'%EBO!"N$-8?(4UGURUAS*0\#;G<7,>Q]=DU
MVN[+/CY,RPU>15FP43<].2&'0-T5B,N3)I^*[7#8B5C)**?"P,\0RI9>4(=;
M<'6I*PR:<[.Y[WS6("MZ@V(9,3-ILVM)B!-*KE\U^-F,C=RZQC9$YB:N=+`C
MTGLO6`;`D<1A"YMQ2A6/=C#ZF0\?9_:W,.WZ@5K"D;=,:N5NME0JD2RB$V!0
MI@*83LROPI.1)JP5>(#CIJ//&(2*P\ZVHXH-QAK#F4KQ@,VLW=7+=HE[1J&K
M;6A)C8XEHEJ`Y`F1$Y$13EMJ]C_16N"&M=JJV*%)2E>-#>2Z.@IY2W4MH1_4
M^QE8>'L3MCDK9];VUI*%V_4R[O*5+:-)<K]N@[]78-Z6BZC:U304C,&U!`KL
M8(-!G9>=%R1\B!7DLX=6GV9#S-K=V\EG4;:FGXK<]*F-H?V/M*C1M#)<N,$_
M9+A7*[9822K44>%`*D2<_NHEX)3T5@I]#N,88PMY325A_+;W)QW#ZZFM-D[^
MUV#LD;5,M7B=<Q.PI+%P@)@6C):<K<A-PD<;9:K80W"6AT/OC-2;1*DY2QDC
MT:\#MRO9/*4+JHC3LCT=K8G9X^LH6B?VH9M(3%UEK?8JZY58:):FYP/,F989
M:?:RRLU\);S+ZOG*91ZY3D,P=ZVY;!UU)Z]E>EM./7J`UO%0T_`F;EIL':T2
M\S5H(2.'+,66P3%3,R59@,-O8%PM#QS2L-8SG"/`]NK=+:$J=#JVN)WH76N-
MG0FL:D(?"V+:E*?O)$P_7X.,$>E%21(239N4EI,;"G716TOOD)6II*5^WP,L
MJ/2O/\9!UFLSN[]7Q%MCH*N1<Q7)_9]`=L\=-9@J\0[%RV(R94`3,)3."9<4
M+[F'E$MJ9RI#C><A^=2]*ZZM6MJ18;IL_6L1;)ZJA6*7B7I3%+(%24"U*97F
MJ7,P6TQ#:(XEIW*"V\+]N?=C.49QGP,'Y/V]IP;1U!@F]CZNC)$2.,*(KP<N
MS5G(MN<MEI5&M*J]I("L<7^6\$0AO!#6,ON,N+:RM'HO(9EI7;&J(G5U8:D-
METZ.)?8E)IP:P;`9<E/BGK+/',%.+N#T5/($.>R[^*DAAM#;:/B:]6VTY\"+
M>&;%5:+QMSK'%E)#)E8L^)BJ^UDHJ9)L)5DM4A)P`,:0TS(/&P[HIN'VDH4@
M9`;N,+4VW[\A:/5=1L]6BK"7=9D68MMQM\Y;IK$25.O5N(P;D>-A(&M#3QIA
M`4?#UF*"8>RT@5DP]!!F!V5DK1@)/\#'[:.:75;,+&!-R<B37YD>/C7B!!&9
M`UZ.);%!=*/#D01FBWU);4X\.^TC"O5;:TXRG(:KJ_LJ4&A1=G=#T=L?>I\3
M.P=4UU9G&+CHW0M0@VZP;;)$RSZ\%G8:Z6LS#(QDG+#`-R\A).LP8+(0J,N*
M"IM4J,3L>TSL=3+!BLQ\H0^Y;;O%W*#K=JZ#V%76[09=PM<T*3NU.US!VC8N
MM9!W$HR^(1`Z_%`&8><E)-+C,6&;=('[[/FZUI*LSUBW;MS4=RK?16K(%;M$
MU9+`3NK-IH+@J7;9*R`3D(/7+MJ<`R*!ER#4E.ES+1YH#(;K+0X1"_2^S=32
M>X>E-;;DV/LO?/04VY2)&NRDIKA'*MX9BXB>GH*.TA:+'58]J"+T55151,?+
MV65IM?MAB9;(SN"7FL+#8!]8.M?\,4FR:>"FW;'7]45;7FMX.7DF("PV-MFD
MRVR:T_`S^UZS5:C'W<J"_6(QD$D94G!OO/-D.NX?;<4&TOP'@/`@'IZDU"\:
M3N;%OK`UJ551Q-BTL-PX6(DX[:&O3&;;K"?K$\6\.U7[?"WF*!?BS?>GX3$H
MSGW)RI"@H+NC=NMIBVUO>MES8(#6L;G60-=M<8;<G)B1VCK<7HB_(BK/2(N)
MDIND4.!G(%Z-+F2:Z>[-$DN#)'PP,V]D/#"Z3U'?)9BDV^Z)G(J`V!`A;*FV
MM=@1<SVG95T_`M(J)`X3E1BJY!PLXZIB8BIP$B-(8CXX)L]\<@S"`S4G==,I
MU1):C*?-'!WBK@5J2UG!;"@8/6L%-QD76Z\QIC1DU:WH&=A`[Q3:<0'"-Q8<
M'3SY%I9"RXX@IPEH&T]A44\*>LDMNY_6$C>+/7Z4U;;94&J=:N:=0A0+<O<Z
M'K^=AOV$E#[#M[4,LAR:EI-,/G\L8YILAH$00T(?U5O/6T*Y&0,GKC6EX@&R
M9*J:S/J,17]?"MT6(O4L9L.[;*I,'8)"L/33M/A![,(N$B4-Y(E&1%-1SIYJ
M`@FZ,7RZN[@JUK8[6/-A4_$C3M<6-DR\:OM9,3#U@*G[(4`:8=876*=)7`9M
M34;,13A3SYKCC#SB<$M!S2LQK>M0X#A5%C-B_K-=3,F*U_:I-!M>Z=G0Q*TY
M#E9./$:UO2-6K><;<:_,*+<?)RE>,*1%/_F!^1YW7%=O5)H6P#ZM=9NPDS>P
M-A&S=1$Q/!!S8,N/KBB:O75"X&.+34A(TF.?.%:-/_4PH^#!U$2:3%AK;D+=
M2;[G8$/L&6O359@YWH>=`EFM7N6>.K1QW0VW('7;,+/5^2+NX3[57<92.](N
M#PL:T9@)PT-!+;#885$%#&V$("%V[!-QYVP&T1\]7;QLN*K]%B(-RMO2$Q;<
M-V6!L8LB+-6IIP@6(CI;)+33CQ,ND5A4D@.Q)N51UBMS4!?P*_&?F9(^%H':
M-*?U]6+/2[`:+*F)B)T\UJPV"IU*:_6-NA'FYS^./DE0Q7\!Y-B@I=JL)*>O
M#9=BN0\/#O)U^Y=:[9+E-PN*2S1R6[)+-N0=TKL9;6669^;%;(02G!.75+'^
M%HX,Q_5V"2M=P=)V)5I8IR'M5@E)V2G=C!U".IE/V16M@NPD5>IJ-F(UVE$!
M'#BO"PR%R/O!(&/(5,.+RR&7ZS@(>5V)J&EF6JF2-&KNQM<4"(C`Q]DD1L[F
MU7VNIV%0;"!<JZW''P\H!K@P4<64<?;:(PID-[&$MM.!])888D<(+'@"C@@`
MC,!A!!L-C"!B#-)9&%%'92AD<<=E"4(0C&$H3C&,8QC'@=GP'@/`>`\!X#P'
M@/`>`\!X'4/'?*"*&%.?C"7QW6F)`5L5X@)Y:,I;)9:.8*#=<95G"L)=;6C/
MIZ9QG'@=K&,XQC&<^[.,8QG/IZ>N?3^<^F/]/7/@?WP'@/`TQ]K7BL4+H`V6
MO%AZ"B*M_;=:>E%U']"?KT>#:)B(ZR/LU\.N3UL-D019EI]1*E!M#940ZV\X
M\..(2$7V4&CZ_P"5[`;9K:LZKPV@[18ZZ7K^,U)-$G,V&E0D%1(05HCG:J2:
MIIF7NQ",,9-88CQ<K=->?<R2MH-C'UX[)*V9QWI`F5US?-3V2@U`#3%TH6QP
M8T"RUZ^:69;UC>`%HBK+;A"8X:U5@ML5_P#/?<>91A2_1><X\"ZG@/`>`\!X
M#P'@4AW@I/\`Y6:32KY\Y_\`%[LA36&FW/C2YB9YMQE9+S3J?1'Q95A*7$J;
MRO.,XSA>$^H:/O\`T^;L'!VCJ2TG*J\"-*V:X@2DXM8L,N3/!V[;\QC1I`B8
MZNGJ$C\NH:<4W^6EI/L1G#",(2'T^XM]25Z>VT5W/NRG"?2;C<^[*O;[<8]"
M?YRKW8]/^?KCP.^/-0YCJ&!):,*><PO+;(YXK[JTM^F',H;:=4M6&\JQ[O3'
M\>O\^!Z?@/`>!Y4S"15@$;`F`T'!MGQDFD=Q;J&LFPTB-*QSKF&G&_F0.>&V
MYEM?N;<]OM6E2<YQD/U*PT;-"?@R0WSC?DQQ>6T/$#*R_%2`TH!G+HKK#V6V
M3@VUY;RKXW,)]J\*1E2<AU[!78>T1KL3-BK*`?(CB76FBS0'%NQ,D++`X45'
M$"%_"@X)M2V_?\;R,*;<2MM:T*#CG:O7[*&U'SD4+(",2<',LM.)4W\<G6YD
M&PP9:'&%-.I<CIF,8?1CW>W*F\85C*<YQD..=J%9LH"HR<A03P5DQ9:F5-Y9
MS^1"RX,]%N8>&4R^G\.8C6'TIPK"<K;QZXSCUQD.>?@`K%$2$.4LD1L]OT_.
MC7$"281*,I4-(QQGQN*$DPG6TN,/IQ[VG$)4G.,XQX'6ME8'ME<GZ\J2F*^Y
M/1$E%8L58*9C+/"*D@'H[,M`2KHQ>(^9"9>]P[^6W/C6E.?;G&/3P/Y)52,D
M(B;BVE%1),]`OU\NPQ#C8EG:&=#+#8+'FELOD?LH_P#-<='=<^3XWU97Z9SG
M/J'BJUM`9J$A4T*(:>E:M(5>1MJ1()=N.3+1;$7*3AQS\,]&G3LE^*T00X^(
MX.^0VE3C*DIPCP//*TYKLVN/UXRJP!V2:2)0")N1@((^=*K@`GXP`9IS\:K!
MC0CF/G0TM/XZ7_ZTMX\#J.:-U84+[I6@4.?L3D.-%'6Z?H5-D)Z7<$%''1(3
M#R(09DM]QX1MY;:4-L>].,(0A.$XP'<=TYK9Q?[)%%HX]K1#*B![DW2*J]80
MT_J50Z'AS#HHQ>4LAJ]B67<N,Y:_VU)4WG*<AT@]%:F0#EF8UUK^Q29L17(F
MQ3TG0*8W(6A%7'AV8IV9:`@Q`%MB.P`CK`S338@JQVL,--I;;2D,8=Y:T3+*
M0?=-<5/8MH=@H>NS-VN]9K4G:[+'03@3T6B?-"AHP(O\,B/9=;0V.RRTXCW(
M0G.<^H>='\C:`P$_BWZYJ^TK/))'39MD;.K56M&R;ID!!8L2JY6_,$%(6','
M$F9`"P_ZX'!2EE.,)]?4/4!Y:T`S-Q5OE]3T"VW^(;RVSLBV4NIRU\?]6DC^
MI-B_2#D?&EAM*$M-X;8;2G'M0G^?`R35^C=8Z@"#&I-7C03`HEN`:G700%3W
MZ$=;60X1,@,&+D>'!:&9;:%92TQA`[?JG*D^[P)<\!X&.7##JJC:4L,RA#ZJ
MY-X98A'@1II]W,85AMF((E/_`'&,2CB_1(ZR/]A+N4Y<_HQGP-1'$.U^3^?*
M#*N*LVQZE7MFNN7(25V]KB.JE<S'5YRQR,\5'6:H1JZA9*WKX!U")*UM.8KZ
M`\!(07\B'4("^#FG^0][1\I)QE2U+:LW3,-:)B<I[<-'6&9(P_'34%-2\K6E
M@SA!C)T$(4UDM>58)`96I/O'3[`U*];7^"X!N#]$TS>MY15[NE5I<I8M@VFT
M:>L<"T#:+EL"P2.!HNPUF;V19-B3-:U=9Y`TQ$00%B.B\#,F,RI(+;@>!`4#
M[(=2\BT7H2LF\F0EDH%2DMB3PT#*66,U_-<YR`,W:3HO&JT:?AZR/N8:BNQ+
M:I]+P[9+D<7[Q6U2+J$!<CZBY8ZSZ3,NDY!GQUYO%1TG;MO6.:@@*O.;0W!8
M]<"3EMVN7&`#L-S8UUC)*-4U/)QAJ2R.ME*4+$<;;#;7X#P'@5I[$I=,V#S)
MN.K7^'C)VLE5-R1?CI>88@`52U>."L59,5*%N(!8*B[-%!E#((PZ.\2RVVZT
M\VI32PJ]L.CRN;UHFI<W&%4.+C;%3:A+'1-"JX96OX"NP'01MDGW(.3NFOC%
MRLJ6\..^AV'/&;8E$ELA2#9CN1PJC"UGIJ:B0ZG+]356L`9E*V5H2P_XBKH5
M%VA8Z^%)4[:ENMZKF96<7I_]PT=8SL2C!3LHET>1BG'G,L8<":#\=<1L#8YV
MG]0#WJ#K.S"ZN],JTGKAN0OQ,@J3&'US4V0Q;.MT2'N,@'%+D9K,&*AMMU[\
MEL-I);H8_7:1L&F:SNT9);T9ODC&FM6Z_6'9.IZA9IF1N^V!'XI&KJ5>)2QQ
MM'V!L`8`C]1&P,C$GPHKLB$(X]G([?H&7V"4Z/E[1;==7B>U*^[,U0,;?EFB
MJQLZPURDU8ND#D1]3-Q7+Q#3]#L-N;*DS!DQS3D6M@3VD2;AA@K6`_,/H+IJ
MK6=R_0-PUQ)7,2C"RVO]>359E8B*KU2BK:0;*URLBRT`10]42D]2%0-6+8S@
MJ3R(`VG,JVD1PM\/0K)'9UT`@!1['K37#-MLVQ:]$4^.U9$XG0*TT.ZN)VI\
M%C&`"73X`Q]HE]8&9)N5(E1_82THA([88'7=%=$<V2T2;3+;I@J"M]A/F+6;
M)Z3V9<4;#W<8[1]?0$T;78JT3=]B2Z]JZH+&391'50[$2%^28WA",*4&NN4B
M"<KVS"V._P!%S;56[H@DJ5!U\^Y!8,IF\MKV:5/L"R#@Y61KT%$T]#K3L1*N
M'"S-F#0P&0VP8D</;BQ:[&V>$E6;C98*`_77,H<D#0]?BY2&F8*I-1%;#K<`
MW66(0FO6$>=2N-#-?%<AGV'W"Y$_\YA+8>D:W52H&SVBS;-A'5*3/JODL9J*
M.&@R8V(8O>:Y)3N"ZT["V&QUB`#CQVADPKX&7TK+;C7<8R,Z'=F92[Z[00(+
MM.@0,##26JS:QZ:KL\?(,5R[A0DA;+?`/%;"J#-7K8.O33SBQVDQ8;,6V.ZJ
M,0M@@58>F&J:B=GS4/$;,AA:;+PDY=T-P\5?*74?[VC]E."DFRG[9R*D;3.E
MN+)F6K*DL59(CJ%?B^QIYY(>SK:YNS>V]'-*V15KQ,3'4M=`O`C8PQ<D_*5;
M8PY,+*"%)LQKP4,2$PXF/D7AW'G$5W`+CR%$LM/!])7@/`>`\!X#P'@/`>`\
M!X#P'@/`>`\!X#P-)_=D-7K+TR-$SD@)C\?3@SC+$5!61JSL-6#8M#JLG&+M
M0^U]3PXJ)^'E7VPLM/&E`/X66I'QLY:>#P;9?&0.=+'`04MLVGOQ>D)44$ZZ
M5'1EHE&F8.GXD+'5Y)T;:R<S,T_4!',/I;$0XRR[@KURI*$^!-'`MQJW&O".
MFV.N[_S7S2!;+#?+3KD.0W[.N4M%,V=;)[:M&K`VPNCS:_?+1<(>J6=#4EB0
M>+-6\.XZIQ2<^B0LY_[L9^O?_P";NXU__&?TE_\`?QX'J`=^<(RK+Y$9VMR3
M)#BO"#DO@='Z<,9'(/>2,"P^Z/<G$,O&D*PVTE6<*<7G"4XSG^/`S<7K'EDY
MYD<+I;0!A!#3CX[`NY-=$//LM)E%.O,M-6-:W6FDP9N5*3C.$X#?]?\`VTY[
M0S=G<FH2'R!A]JZW?)#PQDL=F\UAU\7!+?S#9(:1**<8P0UCW(]V,>]/\X]<
M>!V?\KZM_P#DE4#_`.[&N_\`PQ\#L#[,UN6M;8NP:02MMETAQ`]K@7EH881E
MQ]Y:6SU92RRWC*EJS_"<?SG/@>^-8J^8RV2).PY0[V,Y:(&DPGV7<8SE.<MN
MM/J;7C"DYQ_&<_SCP-?W1NMX_<G9O+%?+M5UK<7'\_==6`*:UQ<3:I)YF6K;
MR[`('-.BLY5,0RXZ9*P^`_E8;SF$?,VOVIQX&IGZ/==5A&Z.\M:SQ@&P:?KC
M=NWJ+28V]1K-FLDI!4+H+9U''M-W,EQR(HZP)_098'(CG#6G1W5Y?=:)PXUX
M'T6GZ.TI*OJ)E-/ZNDB%(BFU$'T"J%O91`LK'@T9=(B7%Y3#,.J0+CU_[="L
MI;]N,^G@=&$YZT'69>.L%;TEJ2OSL1).3,5-0FN:A%2T9+NBN`NR<?(@P[!8
M<@X&\MI3S:TN9;5E.<^F?3P)@\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!
MX#P'@/`H#8M07S6NXK[9:D&7-4+>RM?!W'94K-2FP=G:Q)B+)*"+JM9J\[7+
M"4;K(\&R.K:SB8#CJGA\PI@!2W'75A2V2E.?]K2"9>IVZGIDDR%@KE&L*)6N
M4C9LZW!9MV:W*W=Z`N,#M\@O$Y_>X\9#L#YM-SGCUDR.0H]3F<!B?<=(S>(V
M-H>M-U&678H1DS%5W;95*J&SMR50K4]M#V)9HD?`>L+39C:=&2\IB-E#4@&Q
M`ZW8J.9$5)+=/'"KM_T=WE3].*US1/L9Z^VO6P5S.M9>JQ_$_,UN:)IE+A9%
MEB?B`AZQ*%3#=JGPAZ]D%J<_;#EN_DD#B_&0VR&XSZV=)V?0VD&=>V&[LW<.
MH1&M*162_P"Q!:$?'1%8U=4U2<;*1J*95SGR6[E+2JTJ>*E,(0OT]XCV2`!@
MV)>`\!X%8>KZUJZX4.FP.U\'%0K6Y-46^&AXJR/0DI*6?6EPC]EQ+XL.*:,7
M?6:O_:3DV5!-LGY-$C'%9$(PUEO(:FMS],1<?9_\UUS8-2IF\;A%L3%?HVM<
M';#L>SY+GBG60ZS42';!U1)7/;6MP`=\UN)D0XL&+LT3-2,F\P2*$GTR&2S_
M`%MMO8-X(@MT:7H]8I,/=CZM&;8KVH]W6RQO9UTQ6-[P4Y!)NVJ8Z'C]=;"F
MZ4%$?`2\^:U9F'!_B<<$#64&"\F<X;A[EYSIV[[!]@>YJO=)LQ).QM,Q&N>8
M[/6-,;XISQD<=6;1&VS1C5[Q?M<M.`J1D]^+-24RV5@=D(EL!`3I8_K2[&?R
MIVK_`&=W/)2WHMG!-XYVI1#@T+7DRB*S&"DZ=N^C93\JMXEG5QQ;A3BHU[W.
M"(8<=4O`1',?7O\`9!KZR1DW2>A]`[^IXZU7B>UI8X[<'-!-GV]4KC6[WK6S
M6"XO6CKD:ZLQD_#*=7^SC&'F%C@HPZ^(,@1(?O/'_P!J5OL-;K)=UT%IK5;T
MI82+,Z!T%TYN$:'"F2K?>9-N!U=28KD<64>LFR)81&,D61IJ#A4?@`M8`2L)
MX)"NWU.[*V0_'6*R]`:[BMFQFMRZ'';2@M5[BF+=5Y4NW4NV9NFLK#?^I+;L
M'5&4(IJHQV"A+$/"F@2YWY33KSB7,!E$5]<G0&JJO:JQSOT1KC2\#(;0D=EU
MNO5JD=.BU6I1DQ6:^!8Z-%TBM=N4*JFM3EHA7YC$B7Z*;)D7TK:4M2B%!J[U
MK9;^30JX?7*/$U6_;,UN\5/1,$/:Y*!$W!>"+%?J^NM5J8FKY*HE]R+C$((*
MQ)NU@88Y[*ER.9E0B`SB!!VQ8[=$OBU1ARG5,BU#[4GQ8Z7'>#FID*L.R-*E
M+M>)VER1UKJL##N/8(`+6E!9PWH4&DIWU#R2FWBXX8JT"3\I,L3,P7L68!8O
M@<;1G=?V^S0SJY<R+*8@8>;@]FUQAE8M.&*6+!D/B.FL8?6H@.@=;'1H.:9-
MJ+(?RI@(>JDUB4V3K^]QE/V!J*&NVP(ZRW,J+BK%//RNHYJ5)$4H<^5CW$-F
M.,//O-X\#(BBH;&RQKO#ZPM@<6]83I1:70;:!'F3$ST.F9CIU%P11I:5(J#-
MPAUG!5Y=:*=1'FCCD*6\[D!H,[YMGBC+YRO"U^HV(ZGYW!60P-D)K$]#B2L4
M#+DV`&>KT->78\V'$G@@`QK0>$PDEX[W^N'FRR,#!],_@/`>`\!X#P'@/`>`
M\!X#P'@/`>`\!X#P-0G:9=MB]V'&`7=0D#_8M:.<J_\`:M+.9==C[Y1F)!A=
MCD-KTJVA-E0QY62F!!"?5IYI26"%^T.0"KV[]/;".YK!@N5976/^77Z[5ZM^
M=*Q&MJVAF#,U99XB)$!O=^A[V,)`!SF*P(3\H7SO0\67AG_OOP?Q@XN$];]6
M=2M\GQ?7^D>4`*3]?J-Q<[[&C8*VVG:#]WV%7M64[7%7G(&H776Z*LFJ6.J2
M`TX/(IFSGOA?PCV)RXI"0W-*Y$Y/7EU2^8.>%*?>R0]E6E=;*R\1G*LY?=SF
MM9RX]G*\^JL^JOYS_/\`/@<3W'G)!"&6W^6N<WT#.*>'0]I'6;B&'EH<;6ZR
ME=85AIQ;;JDY4GTSG"LX_P!,Y\#R\\1<7*1AM7(?+ZF\../81G06J<HP\[C"
M77<)S4_;\CB4XPI7^N<8_GP.-SAOBAU"FW>/N6W6U93E2'.?M3+0K*%)6C*D
MJJ6<9RA:<9Q_RSC&?`ZSO!_#K[8[3W&G*;K0BLK%:<YXU$ML92AW1%*80JH9
M2UG(KZV\^W&/Z%Y3_IG./`_`W!G#867%`\9\I@J=;(9=6%SSJ,1;K)C:VC&'
M5#U%M3C!;3BD.H5G*7$*SA6,XSG'@=IOAOB]A"&A^3><1F6L>UI@72^NQAVD
M^GI[6F&*\VRUC_V$IQ_KX$,CZ0U/J#MW0+FI-.ZWUVW)<W=5#2$A3*C'551*
MV[[RX4'$DN0<6.$H(EY3A"TKS\N7&L+2A6,+RD-.OT^UNL[)VAW`7T-BI33K
M?4W2[I!#UUF3:PU:1.S]T.M1]6G"R*TW-5X:?64T)ET%AXA2<I=;POY&\!OA
MD-#\D3IA$D\%5\DE'5B5?7$[,L$2RLZBP<E6*^7^-"W`(1*HZ$-)'=]J,))Q
M_41AU:$J2%=-21]'C>TMPUIEM=;U7J#5FDV]:F2^Q[:Y&3EPE69O-JE(,@V7
M1#V0"-B(:(CC63"),H4\1;CGQX-SA0;(Q+163R&!`+%!&E%(><&&$EX\D@AL
M9W#!"V&62%N.H'>5A"\IQG"%9],^F?`]WP'@/`>`\!X#P'@/`>`\!X#P'@/`
M>`\#BR[Z/(9^-W/O:<=^7"/5E/QK:3\:W/7T2ZOY?5./^.$JS_P\#3CV9+;9
M9ZFU%4H6P;LCH"5W/SO;8*/JA\B=K\B(%ERX^]N6(6$9S*#Q;QT!'`O1SZ7H
M_"I%PI>6L%//,AN3\!X#P'@5HZFI<9-:JLUF!UT-=;_68YMRH%QNMM=[(NT/
MDN6C6I=^KPNQV<0ABDQF77"1LO-N/L-KPU[G_B3D-?7'=W1==E`V%V!@YQ9/
M4FQZI7]CM4>7H<Z34`^7(JQ@E.CJ@8L@A<T>A]LT*48#2&ZG",842PVX0&R;
MF]N91JL=RPM&LS!=[V^<4F09%&*6V7MV\O@/J%!DY@(9!,:MEQ"&B%I]JL9S
M[59RG`3MX#P'@/`U][/5K]'4[>^;1J6W7Z'YVU4[2U[#A$3=KCM=6>]7"OS]
MB*C-8KSF/FI:MU2.%.D+!`C2$]$@J>#RC"'E-+#3WH?JO7NDN]]H7+<.Z'ML
MAME=MT#6S=WV=%/;/U%7];R[-WN+ESHMKLRT00%R7H]B!K1=6P8[-Q[<8J3C
MXCVC),"6)_\`]2/S12+#"4G8'/&_JW>9+6U:V))04=-:*NL=!JV2,<5INID6
MNG;9F*\7:=G9:%%9$9>4]%R!B1CT#JQC*PH1LC[)*U)[TJ?V!Z2HO05#`LA,
M)==@10>*LX-9-,ZFV9%<X[0@K4Q5KVUJ>V0%GF!)L9#%G2]L&I6FJL*&_$B)
MM@@<-QGU]_95LON7H[9<`5K&/U!J*M:^*>@:-8%*L&TQ[7`XU%,F6"QW&$D,
M4AL29C=R)`7#QS4HR(_"_,W*O9?>8:#<WX#P'@/`^0/GJ?W[JG<77NF.GJ9'
M2>P>5;//:TY_#IC<C`Q>R>?-EP85BUW?+SLL!-EB:R>/&9K@V6QRQ'J\\4AK
M`63'LN+"S@FY:E,;E;NLXNU6$>'-VL%*3@S5"C[)#F3HL.=6Y6I5.B3)$/8%
M%M5F:#&G)<8F4,42D4C^E#*%!$]GV]2I:/#8LE;&JLH'<9*SSL5BE5:T!0N6
M9S;!E1!FFW7(V2O%MEYA;\,5&RQ\U&$K"45DE[#(8R`](7:+D4WNUEAVSRP,
MF'0'$1YU=C#(.U_VKH53.:F^--!RV:#"UD)(1TA&QH\2^6`RB`RDO*\CH#^1
M4[6V+XY-8D8(&3EZ].R<_&3(,@Y3*^YG<@B(>JS+(]<DJ<N?K]E`"9>L5?BP
MFCI!65.3;@S^6W0]?43A1VW^78JH6NJW2VU+HFFU>XR=:5&'TBMLT6JR\+1?
M[AL[<#%6N7S8Z4>4F(CH(^7B`\9#3*X8)']C0?4AX#P'@/`>`\!X#P'@/`>`
M\!X#P'@/`>`\#2SW0520=VVR4G;9HVAJ8UWKB,D[A<6'TVR*RO:E'EV%$G8M
M-%BT8&BQ'U0J'3R2L6-Z*>^!L=E2G0[U;A-=R-5`$`V!%X-@:U`GG`7<BQ&6
M6U35>H3TA,-2JHKH%N)N%SAKO^L?E_DC@W8W#I(B4H-+:=:"OGU'PERK_7O6
M2"=P;QV+K>\Z\KFXJ5)[%O$.=2-N$W'<NUZ$]NVE:JBX**-U.T/6M/Q582+)
M+<*.S%/FLJ>$)9<P'T-^`\!X#P'@/`>!2Z^N"X^P#F5I26_SE<M]?.-*RD/Y
M<"(V/R$DA*5*7^PPWEYQK*L(3EG.<8]^<*PWC(:8OI4@XG;NS_L6'N[$E/5^
M`ZPZ`B0!I![]1!"2#/9W3ME2[2S8"2>DII"ENX5*.R9BC0WTH8:3^$_C&0^@
M%'/6E?RG",4F/=*<FC;(M;DI-OKS.F1[<*?+>UV5<PDU^-;0.XO&,9RVE*<_
MZ8]`_(_-FB1R`2<:PJY+D<LAP1,B*]*L(=+>206^X+)OEC$/E$(PMQQQ"UN+
M]<JSG.<^H8GM+G/2)>O+HY&:BUW$3H-6D3J].URJ5^K62#FZ_G-FK$G`V:&C
MPI:"D82TQPQXK[#J,L%,I=Q_./`S#F^<LEDT+J.<M\L]/V>1H5=>G)XK\;\R
M<D4@-,OS!V`HF!"P?**;^=_#`0K.'G%8;;2CTQX'OZ?M%@N>OH>R6D1@";D3
M[.DD`?(64!#@VN;CHT1:H^2EQ%D#1@C*'E)(7E3J595A"LY;2':IB9UNQ;2;
MEG+4]'9NP#]:<L*X1<2W$O4.F?D"4O$9'@R**ZQ.-EY<Q(K*)_9K+]CWX_PM
M-!K1W_L[;8/8-VH-1O+X$,SJK64O%!_#:)&.IIC@6Y9>V2$+5XRW5=_:NWK+
M`5E&8&FQH<S@U<>R><H(01]!H>#'S6[:IM_BRL6"U[EKA$C:YPW9%&3>V-ES
MJ-=/4Z"K&K'^F"D2YXB)>SV]^4S*24$`+$8M:<ACO.`A8)?#:)MF3.AZBP?'
M$O"$)NFM!5$,RK$/[1)'8U5C3VWBB,90\,0$6XVX-C&5F(7EA']3F/`]+9IV
M(S6VP9+)98&(^CVP[)P$HB#/"P)`GO\`Y84VXAQN'+&^/WME*2I(ZTX<SC.$
M^G@=R@FER5%I<C(+2Z>?4ZX::X@]$HEPLJ'#?)6F3;2A$BE;SBLX?2G&'L?U
MXQCU\#)V'L/M(>2AUO#B?=A#S2V74X_Y+:<PE:,_^QG'@1WK:?GY]N\+GC8P
MU,3LFWP$'^NAY&'=$@(DMD<`*5Q($OXDI-ASY/<8PED<AE3>4(]<*6L.A5[A
M.RNW-KTTUZ&7`U"#UE(03(;)C<TR3:A[<Y,YFGGE9$?8=7#,9$^'&/:G#F%^
MJO\`0)*E#<1T;(R&6GG\``EFY9';^8A[`H[C^6F&?<CY7G/9Z)3ZX]RLXQZX
M\#PZ)-DV:D4VQFH^,RP56O39;?P_C?&3*Q`9[Z/Q_F(^#VNOYQ[/D7[?]/=G
MT]<AZ<$Z8]&,NG%"&D+?.5@D)YH@9P?\\G\/#;K+`S:E-A_&E7HC^%XSC.59
MQE60QJF621GI?9(![*&6ZE>DUR-]'&%O/1RZ73K$A]]#'K\*G"I][V87GY,M
M80K/IA6,>!U(^VFE[9M%)4L),9!T*F6(="20%2#LC8)VZ`G*=$00J3:%'%@1
M?:MQE#"E.YPVM:\.);#^V2V&1&P=:59E!&1+>BZ*-<0".0.G^WH<0\9#Y:S6
M"8]:W",Y0I#+Z'/;E"_9G*%>!GQ)+(C7S/Y7AOY1V?5MEY]7R%$-#,X^-AMU
MSVY>>3[E>GM0GU4K.$XSG`83M2SRU*UK?;?`A#24U6*C/ST4`:@AT,P^*C"#
M1ARFQ71R5#NNLXPO"%H5[?7T5C_7P.+9LB6'JJ_2H,ZJL'C4*S'!V1D(N35`
MF-P!KXTPW'Q[)1Y_ZY_"7L-,-N/.>SVHQE6<>!H]U]U)T*97IF7UY,SVWFY/
M:$1S(YJR9A=VQ5BH]O$`UO#3^U3]MD3<T8-&TG<=[?%M4.^C$J15`''HHI3@
M*\%AQ1G4N\G-_P"Q=30F_8F][CUU6,;MD:])TC:E(I%HHMV@M%,0%%<U6->)
M&X:=!.,DK7^DLTZK`(1S+2C$/MI)P@)`YXVY<=U;NU1K_:6T-J4&#Z%Y_L>X
M]4ZYK-LVS!VVCFZRE-=OFTZZ[2F#U@;,N15!VO&'3[T,P-`#2@I`XSYK*F7G
M@V62?,;!T:N.'W[T["HR\@G)T;N$]<BEU"WE.92;+QDHXEAYMW"%,_\`MA*6
MTY0A*_<M0:S"NZ>?)#K+3>M-)[+=Z<3J.'MS1=PJW0L=L]8EPFZWO<,ZO7G7
M],UMLB]3'Z02FK%58(YS!;#ID>T0V\*IUQ03GI/NJO#+-UPW1-*Z[>K][M-1
M+KL?MJ>;5&W>P;"NA0*)FKLZH*N5)"L;$<=(2$G.QD;%"R2"V/REY:SGP-FE
M5.NAPY:[I6Z]6RFR,(!8KUM.MK)0OMSG+Y)!U1J*@WL*_CXTMO8SC^??_P`/
M`RKP'@15O'9*M/ZAV'LQN&?L1-.K$C+`0;#XPF9632C#$6$^<82(+'@OR+[6
M"27'$I&'][N?7V>F0UI2M33P!RO&:GJL7'F#5:R73<#=@U[+UVIO0I3K=DV/
M&'[28NDX8?LZPV[:;/X2BQQADV)#;Q+S(:QG&W@TZ<>4+LOHXR2V]';!YDV[
M/<OQ$S6KHKI?76M8ZK0E]ER(0K;]DU5":YT;+?A-HVKH!0HD[+R#$NX)%H(]
M$,NMHP&V31MCH,5]7VL.M=R\S<Z;<L]XUH!>Y.EZ,UGKS^UFJYT=90F)"OLG
M*J80;PP->NJ/[S(;`3^4Z.?[AR%8]'`UX==]>\O]?<QPNB.+^;]CP6];.)2&
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M&B54\:(5AWX&TM9SD-L7@/`^:'JD2TP7?F_8RNVA=,B[5*U:YU^5F@]=9`FM
MJXY6##*H^MY'+0>Y*;M4:LT)%MA++B4AZ6W)1*P7R'S'7V1PCN9BFX:7CJ`J
M_P#/@D+97KP1;QZZ]):\U1)WH"FQ[UAO>UXJ2N@+.UB9&,FL.Y98BOV:%$AM
M+-<0XIQL.J%5+7^4Y!AOZW&O!D_&G[#K]6DTO[-L>)Q%T;S_`'=$UJZ;*M$"
MF7M=K9*<E)Q\H*+D)=,H^U@9Q/N#-(G1"[+&ELXMNO6\V^,I%E?M]8L<S.Y7
M3]=Q%?L46W4G:%(WO.R&QYM_$%-N#@$D0@CJ3E)'P4A.0_L/17O8?,N16N94
MZ;.JD,1&!W:WV4:"GE;,_M=B,F9]$&5(PUCD=7CBR#<38F1);$HE];.,^W"A
M@S+5FO=@TBYZ%VI;<5V5-T_L`3-A(`&W3=I"%K-Y,EYR^R\JQ;ZE4YNF,Q4+
M/*.BD$COM3+D>^>X02TTVE(;PB^H=-QPB)&3GI6/BU&P$?F5?JEG=C&RK,V(
MJ)P\<'%%#LB.OG,C+*4K`C1KB15.X(5AK(6#\!X#P'@/`>`\!X#P'@/`>`\!
MX#P'@/`T/?9)'U6;WDI=]LL;"P]:UJ.B(C+Q&:\EJP8U9IJOQ5JF(^'MUMK$
MF<"&&Z,.^4,0*D0UQ&/D:ROYL!V*CN'3L)68!,Q,6=P*D:IBVY<Z#=&4($W&
MU4$EU[Y)OI>3L9!\P&!EW+3@RY`O+B5$.*6A24A&'U==$\2B@[EZA<U3?=/;
M.WOM:Q@0%KNO+NW*ML.V:!%171]6N%DQ-+L"&*1)?IG9,9IX]UD9XE;GN2VX
MWE0;?_\`S6YJ_P#Z^D__`)7&TO\`[RO`QR6^P?CV`+0!.;F"ACG&626PY2H;
M"`*6.0ZZP.^@<JI-.J9>?86A"L8]%*0K&/YQGP.T1WUR,&XMD[<0$>ZV*T<M
MN2JM\CE)">;==:+S@ZK#Y_&6VPM6'/\`I]$YSZ^!AY_V@?7S$KD&Y?K;34,Y
M%&!1LDW,V7$0X!(R3I#,9'%(DAQ5,2$DZ*XD9A6,.D93_MI5_'@=EC[-_K[)
M2I;/7VBE)1E"59S>8QO^5LM$)],.+1G/JT^G/\?Z>OI_KC.,!Q%?:!]=X*DI
M.[-YY"4I.%)29LJO"*4E2_C2I*2"FU*2IS'MQG'\95_'^O@<*/M(^N=W*$M=
MJ\XNJ<4E+:6MHUES+BE*]J4MX0:K*U*5GTQC'KG.?X\#7[U1]K')^L^I>9]H
MZZVA0^A`P=4=(4&U4G6FU]6`6&M(M-KYJF0;@>/<;#!_DCLLUMX1@9M]I1#Q
M:?Y]J<J0&N?_`-.15]5]AU[N?8FY],ZZNS5VZLVKL@=NVTFOS``<C:]T[#LJ
MF*Q[@Y6$:#CWT-?D9!)2TMSV>N'_`'*=\#9]]C'+O/VEX#AJR:7U=J?35E!^
MS'@V/;F:I`0=*E)>"$O[T`55_P!K$XBI<\-=;+?6Z&V_E)#0^5D(<:;<\#>A
MX&"[0845K/8@R#'8Y9%%MK"9!D`&5>!4]`2#:3&HR4+`C))T;*O>E@E]EA[*
M?8XXA&<JP&%\UNFD:!T^1(-3[)A&OZV0^W:60AK#[B(YEY*Y42-*.CPBG$+P
MK+#+[S3"<X;2XO"?=D/[SL,X+J6"0Z(2$X].7\Y0YL<U%&8_9;$M<AAXH)AU
MYG!!22L.K<1G"7U+R[A*/?[<!U]0LO-73HQQY#F5$;F#<01F)*C!R64:?U2R
MS^.\^MP>6R(VWAAPIC/QJ<:4A6$NH<3@-<>SZ/3K9]M&J0+Q4(FVQE@U#>WV
M(RXBQ=JK[I.N:O`$QTK'5N8BS`H>1B"-DD(06A>"7LDNX],(0GU!M"@TZL?9
MUIEBM4BCUN/:UEKV>$&C*N175GVF;V-O#$_-1RZ1&A,3Y@T6)EV3S/OYCPB'
MH]YI"RR/7P-G&ZFW7*2(EE4VE>-A:A7Z5X`*1DUH1MBE*=:_'D$.,(CG6L92
M:\G&7APLNN->CJ$9\#WMHFYC=9[%D<-F.Y`HMN,PU'P@]ED',C0$@]AL&N%N
ML"SYB\H]&@G7$-E+SAI2L85G.`[U!8(&HE+&+=)?*'J5<8)?,A!JT8\0U#AM
MO.EUP/&`X`EQQ.<N!-8^(56<M)_I3CP.:E5QRH5.OUAV7.GW(*+%C5S4FD5$
MA)J&1[,F%M@CB!-//>GKE++332?]$(2G&,8"-=%R#DA'[-4X3DK`F\=KQ[:E
M$1;[C+8=G?;P,M,2VT.-@=7JE#;GJ5\6$J(SE]3F?`Y:>7).[RW6&01++C!*
MWJ!V.'*>!7$,/E#WG]@N*::;Q(LOO_`U^3\R\M*REO+24Y^3*PE^24\B./4.
MRV00D(I3`[JUMM/O88<RTRXXVE:T-NKQA.<IQG.,9]<8SX$;Z+5%KTMJ9<&Z
MEZ&7KFFKBE)-D)'"(]5?`4&Q^?*F'R9?XS&4M_(0\X^KV^JU95Z^![NN!HD2
MG1;4(`-&1RWY@IH,1\LD=#YTY)&G.MO&MLDJR4>0ZZK&4I2E2\X3CVXQX'AZ
MX;1BP;D>;CC`4$;1PKY3(LN._9N,:XUV&]("O$L,MRP671LLH*9][6<LJ;]V
M5MKQ@/,B0F%=!WF3:<DFB&]1ZTC3!G(*+&BB49MNSRPCAK&E6)N6-:]SS3@B
M\9$"1[5HSAPAS'@>7L`@!G>G/C1+H#9A3&W&8Y!&74G/K15X@@EN/5A.658P
M.SE;R%*PK*4X4G&<)5Z!F&S`AY!BD#$3K$%A.RZ6:RMXH(9<J1%2*I5J"&_-
ME(O\A^5R#\>6FOR7EM^[VL.>F?0/$Z**<"T+N(MDF,#='UO<'6R9N1EH>':6
MB#,RG,K+P7_N9BH[.?X>)%]7QV\Y<1C.4^G@<F\,.KT1M!IIEMQTG6EH$0RB
M<5!M8497RQ?5NPX4RJ,2U\WJDKW-_'Z87E2/3W8#7O\`3LMM>B>B,C`-QP6>
MZ.J'!&6C+3(I*_(N8A1<QF0M[04J:[/2#[QSKJ1`QG'B%J9;4C.'7`VOX`!2
M<N32$)B2<%;!<D,#,X.<":=<?:#67A'Y"A6WW5+2WE7LPM6<XQZYSX%+=Q.!
MX[IXE:<2G)[FM.PUBKRV5E:16P-#X-2EU!K0;:5N.,9REP=YQ7MQE"VL)7AT
M+LN_^VG/5/NQ\:_Z<X4K"OZ<_P!.4H2I:O7_`)8QG.?^&/`HE];]0K\5QOS?
M,M5F(CY_&KAHU,KB`BXZ;;AG)4Q\:+64.`'(I!2RRQZ-/I:(5\:%$M((PM*0
MP6YZTU-T8+.16KM=0L3==9].76;M%VN$'&6`BCWJ'78@I^Z,UVP&'QUWK^Q,
MA.1R([*U#C-&I.R(DD)EO`9O]?>V@;II2"I,G9];%W2F`LKS4:+L8&\YJ]/D
MQP96#@$-&J%OHT30/V_]M,O6$(66(3%H=+Q\[JO4+Z>!U3C1HT(R1,6IL0`4
M@TIQ#+Q"VQA65OOK0P.VZ0\I+3><X0VE2U9_A.,YSC'@:H_L&/C;#JF&L>RR
MJ]0VJ_?IZV:Z+$LM;%O!6K(K6LJ_8'YZH;)B4@2@VP95QB#E(9L;YP(Z384\
M0R_EU+(5O^P;?\!H/73=-LNM+W=NE-CZ>L?1<GMC5^N:`%3'B-7U27KU78V!
M9K+(%(15J--3,0',DLBH#C8,YV15^(\2A#@1'SUPK]I6F=-2M1UG:.;M>#;C
MU=0(79$+=0=AWZR14E':GB:?-+23(WUW]/=S["1,2D^3^TLC<I.21!C9ZFUM
M--`TSSEW)9N(FM:\_P!OTC'T22W-MVC;&U78M<AR<M"%ZCV58*9/S=*O<Y=3
M:/,0UMV7K3!C40]`-#1T%**%:?<(%20Z'<Y,^JKM/5VU:KM3.[=;Z1)U%!A1
ME$BRM=O[C9N4C(ZL`TW8W[9&QVUZ@!%PC-+JT26PR"0.MZQ9*-<1Z.*2X&XS
MGC06UM<;)W%MW=&V*1M.][:K>I:F05K_`%-*ZBA0(K4SNQWXXDN%DMH[.Q)S
M$BK8SK3A*7AUX'#8;5\B4-X;#Y^>X,[/UKW]U#N_G/67V?<L[$?"U36=@=`\
MF<L5/ICG;J*A5NB4:7_O/:E%W%*P=*!N6L7BI"!CYN`*24F,!(P=Z8]R'`M9
M]`FY>4M[5#JS9?/L]UYN79=WVA5+9TGU=UO1(6E3&][\9#SD-!0FOQJ@>310
M:?J*N0*(YB&B&F!8<8T=.,NX?PK`?0IX#P/E!&VEK?L?I'[!]A:J>JI(=!W3
MKV"KCES@=6L6:<J..?82C;.M<>7;Z#>K^S0ZW<Z66^T)$/H;D''G1S0QEJ7A
MP,PA-7VA6QJBBAFPLNVD/9\G$HK,K$5L^0@KA&:L*+MU-AX>@3XU62L#8V(0
M8-TQ0),HE+PQ+!93BR`YU5>S0Q^JH8&.KM'J4=M[5-;"%E&PX">FIR7+O^OJ
M\T%(DU3,G*0.P3H\6?#&(FF9!UU]LA3#+"QU,!X)NM[R72[&:!K>+F%ZUU+#
M*!@@3ZE*S5+B)Y4@'/V"1UPU5+#$2T]L1,$9#1([J7"5NB$DCF+;4^X\'IO:
M8=F=@62))U1'RQLML8HF7%A(9V/=E*PQ8M.5]NQ_M7*LV$74Z5*:>;6B3@XW
M,:05-X8$;%$,-;(#$AJPV4',[+LVJXTF1CXH]V%BSIF&;N^P!+$UL`L6]HHC
M\'41Y-MJ<M,E%Q`!!`\0R0E`@ZFFDA('#GDPI"0IE;L\11(JN7.+W;J[7L<'
M578F'DZM'L;?UWKVX?K2@I"6,E*=*"Q8TRQ@@(44H.,<20A/M-*4'U<8_P#:
M^O\`[.?^/_L_QZ8\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`UH733-9VMUGT;*
MSP%WR5K[2F@YJK2M<V!:Z(#FS.36S["N%?=B)L4:11F0H<`<\E]I0#:QF,J:
M4O+RG0UP;<@.TI_G+84U`;.E],W%C55@<L]D9E(&\5R0A8#F[9M(D%2.NRNT
M+DPW&+/E8^8BQHZMQ\JU/@L9,%=]Y&4!OBYIDQ)KG+0$R`P^,#+:3U5)AC%/
MFE%#B'T6!*'8)*DA@Y$E]IEW"5N/LM/+5C.5H2K.4X";/`>`\#SI*'B9EL5J
M7BXZ5:!D0)@)N2"&.;#EHHELV+E!4%-.I'D8TQI#H[Z,8=9=3A2%85C&?`[^
M4(S_`*H3G_VJ<9__`#>!YIL'"R2TN2,/%GK0E*$K-CQ"EI0ASY4(2I]ES.$H
M=_JQC'\85_/^O@==JL5IA3:F:]!LJ:6EQI342`VII:5>]*V\H'QE"TK_`)QG
M'IG&?Y\"E=_%!%^Q[F8]L(9LE[D/LO)93`3>326V-H<7X0AUUEK)1.&T(QA"
M/57_`"3CP-)GUV`=6\L7GKN^Z7XDD;W#=$]%;1O%PC[G;;_I:TUJ9E]R;5OU
M+=E*A):VN<3&&/ZIV?7FRQ1A(PAMMII9*5/-NMMA,?6>_NQ>C6=>:^MWU\R\
M>9H_?O/O39E;UYM2Z["O,[`4"]6HZ&B7(&0Y@@J[",[`.HLK%-$%2;;32,X(
M_(9;4T1@)?1]SVVV9R2K<M]6?943/P:&W9NO.(K1=E":_2JLY6!8$)M\V7)&
MK##YV&Q<.X>:'6EM2E^U.0B'5'V8=JPFM[52.L/K<[OWK(729MC0ESU'H&%@
M*^UKJRUF&=!JJH']G'2V"8MR6)'280S\C[*T^]Q9#)"&PB^+["T[5HMJ,S],
MOVMP[,>VTM]!6N;9%&X%DV'(L=#B(;8(K0P!*(5U3#`^&F6'</*:0UEYW+@8
M%T3WEJX_6=D"U7]<7V)4#=D)#0X&K+!M#2^XBJ;^_?F#D3^+./6MLPSQTRU3
M\2C0!9A&4J)(2WEQMM*O4,2UM]H7!=+UWKT?L70W;-/W+:"QM1R)F*?NX?72
M]B2L=3XHK4FO+_<MI+/>@[/+54$X=$S)O*%<?R.\<H9E2L!:S0F[-!_^5^L=
MY:+T;W)2M,TVI[4J^T&[_H'<6R`7+->&6YK6UEJ-FBF-MVT^#E!OVHF?24Q"
M"#YC1166O;\;08A]DN_;.YND/<VG=!=/W.,DM::<I5H1.\I=CP]=_6ZQO^]M
MJOA'C52'U7:$FN3ID(TV8B44V$R<IY`4FI"P70LELCK[ZK-35XX_;6RNFZ6$
M2>S4I'%IU_VG3`YZ<@;,Q/O5MR4+H==KKL]79C6SS[CCA+!T8*(8KYF&5DY4
M$7A=L?5,,`0;%;DZV1$C5R<C!YQRZ;_FZ.5$RE;,K$A&L*E+%(:_OG[D8]3(
M[2T2GY,UZJ'S^S2ZK`?K>?W1%ZZ-IM4X\H>N=FZVJ^MXL>SR&VKHS1;U6[`!
M,(K41!%UF<LU9?6(9"LH(09EQU;CHQ;2T-N-M(?"&8G[VNF6`Q4R'/6HG$C_
M`(3A3Q.TZ"T\J.=`<;PY^:WN\T,TMR66VWDE'L&5EIY"$YSE&4ARTS[O[M3P
M;(L_3FLJZF?V%/SJ!F;E0YA.5W&?7D!TH^%W,V,Z20Z\A13V6FD,Y<QEU7K[
MEY#-X3[B;VQ;YJY1.A:&9,7*+J0$H:'=*.TY.1M:F)J,A1QWR=[/"BXP?8B1
M1U_#_P#9/RY<3E"<9R$@D?=]966GQ+'S&EH8V,E2!U1^V=8%.R@9\VW`U]N'
MR#;+%'2<@Y_NJ6.AQUPIEQDE#;;*EI2&4:V^Y:-'JT3"S.GG:WFKU**PEV9(
MM!!MACXJNI*S*A06IM776*JK<B&(EP1F15%"EK?0Q'Y(RAQ+01[K?O\`T5-V
MNX0]LZ+Z:TC48O$3)PF=?P=]N5)NTG:I:\66WXB2+US4%LBJ'PLN>)^0VIMD
M!;:V&0\_$DE&0E,[MKBQB5L+]2^P/I_7IKF0K$:*]JRW6%!DDN#B*8U/NIO>
MB9X,Y!2ZT._^+_MAY*2^K+.4/K1D(XN/V6\5T62M\M7_`+!]S7W<A5;"&KU2
M9U=)UNV;*FJ9/WXH+5""Y+EPK7=8CY64O`T4.4.$P:E]I"R"'?B]W@<U,^R;
MD:?"U[>=\]@;DU/L:OHOD5_9DMKN7M\O6I.1.=C1;;"6&"Y(BA3P+C40@BV&
M7!1VAP#/8IOYUO\`H&?-_;!]:.#G'Y;[,-D6)@>>#<2N1T[955Z*.!GY0+#L
M;,PG,T<&$U^>,\)DM9CK"1V%>JO3*G,A"&S?MAY0B-4S1E,^R#/5MJEX5^JB
M:IBJO`:S.L\E..P\.=:&9-G2-I<C!:6)@N1<#_5G,/BY2EUMQ?\`ONA[Y7VK
M\<;`UA,.SWVD5>ES,W#XS9=.V+6%8+O-+FYL%J4LNHYE4N$FOR,Y#)4["_E*
MQ^$(5CY?ERC*?<$8\+?;K]<W)FOMQ46][@V`,Q<^K^CMKT65C]$[AND79J%L
MK8!-KJ4K#S%`U42R4&F!E16L8*PIUKVI90ZZRAI7@6.V/_ZCG@2O-U(K5K>X
M-TQ\A8D!WTJ)T_M6@KUU4&B8\:3N>1-D4.N$7QT#)REIAH'!LP^V,^I#'M:5
MG`"?MY^N?<?7?,]QK700\)6];4'HP2V7+:&M]C:<J$$3>A=3C5N'>MNW:'3A
M7)NQ$0!&10@BE*?0$\MU&?B:S@+*=4_<7R%SUKVNWRH['H&]@9J_L4*=;UI>
MLV5RD)*@;3+HL%@`U[6=EVS$<\7651[*F(AYK)I+6'7&F\Y7@**<2?;[I`ZU
M<U:5K&[]!1'.T!SS4HO:)VQX[;=!VC5]TN0NR9P^*B[=LT&D4ZP0,.U6HH(U
M#<:MYPV04ZTZVWE+"`O9H_84=0Z=V%N(V9C+9H2_[YW8JOB4EW)5[MMT_NDB
MM$/ZSFP)`@78H%F@1TLC-QY*#`"X5UD,<AQ3F$`^M;2T;42K#L&+GY>P-IUE
MK_6!5@?C!`*W=%POY-A!L5<;+8"OS1D>#*)!D";.J3EI=*12,EH0C`Z0VS>!
M"4UK4S:GY2-L"YBQ*W=)>1UNUKO8%\KLH-$_J<P4?8K#-5XNJEXM)8IDAE([
M"G!`ACL-^]YY&7_`UT=Z<6T*>A*)8(JSW6);BGMAQ2Z[+R<[?XZRF6:!79_C
ME[AL.?F2Z5`C%5%3F0@2042Y;@["LK^-ME84?^P^K;;O?+@L.HH38&A.;7-Z
MZFNMEI^M8*V;`(,H.NF)"M;XK=BVY_9A%4/H$-"S,382:F=.`YD<D+#CI%D5
M$9X&S!>A=SYBZRS"_:SOX:;V-71G-5C6:D\9J>M)$1`9FV3HN'+YWCIRRY>C
MG6RY=ME>7E"XRKU']<K\#Q/JMK>PM8:[VWI/<^WM@[(W52-F&W/9E:ONN=9T
MIK7=BW4N0V7-CTRQ:JB(ZN;-I%TN<M,3,9,.K5(($*;$*8$>'6Q@-I_@/`^-
MW[;;U,;%ZUN>GM\_9]];D7R;JZQTN)&^OO?^W=W::DYNR&TVBVL<_J*RZH&<
MO6S8I22BY`2*?D6ZP\R<,DMM3K2\9#<]]3'6MBZ2C-TU!_;?UK[.H.DVM75_
M7('UQS=Z*K%-!EQ[P/-Q%[K5RQ^'5AEE5IC%?1%Y4*2(T0YZ^WX_`W">!_%>
M["593C&5>W/MQG/IC*O3^,9S_P`,9SX'RI:OQ9GHJIIIL-*R3D+J>N`0KH9%
M9/HE?N]MH_YEOM%4'N%N7"T7_'5A;+?D[&_#$@$R)2P\8P28XKP/:L<E;P6:
M\\-$$6^;'>VTF>EZPB4DJSNM*(#7-;+V@RM]MV8L\0Q!L1D3@N*,5)CKKY+J
M7)`5)*60Q%T6PK+F8BG1`V)P+;E1F9W91M(=`@-K2<'<)^)?@UV&:G1XRY29
M%FPU*Y:CB3,H&-2U^.ZZQEX4/!L,N0909HD[3L.+3K_K&-_`(DJ_'TI^MK1J
M^M1]EA/Q;'L5B^0[4^;+.Q'YY\6EYA465/LC%/(D5K#T2;@3:RIZ(C&]6!LS
M];M#-@B[1*13OY1L^;JI%GD'9H?8M,#H=_I]G958%5T=4;%9B!OC"-(>3E3(
M>8+LF.G8H*+-BJQ)'%UZUH_!)Q3XJ/M<FW5)V`E6)J2KLL&32Z]I@N?2ZW+S
MV8LF6E4)+B\/,JR(\$D#V#9)#40Z73:-4\KW;0#'K?Z0>W+I3CY^?TU;)"!*
M,CK:MN1B-@0-7&*CI!]D^.`C%K@4$(*6,8R'U-8]?3'K_.?^.?\`3US_`.T_
MGT\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`I&,.I[??;V!G:U)K?T;HH7]6:N2
M2EDY,#O-7X=I<?<Q"-19S!3"L88]I*6%K41GXU#>@:M2K99;+S]*0A5_BZFZ
M]IW;=1D*>S;T`0HN=9:FN;9<NW!P?1$B_`:VV'BE2&`5FQ)#D,PG&9`;'M6C
M`;E>.):5G>3.:)>;IDIKN3.T1JIXFD3<]`VB7K/_`,1,*AB+D;#5UKK\P6R.
ME&5OB>C*\Y]<)3_TX"R/@/`>`\!X#P'@:Q/L0H]P$L_+.[]6[FONE]DQ^Z:#
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M(:A(@PMU+1BLLL#+6K&$X5E(>9"??+6K0?%1%4X5["M$U-,N$1\+`UZHG2I#
M`N8MR5>:#Q8&UD-00$V&6:MGY$#C%LJSG*G$HR$@Z_\`O8Y6S.2L-U73]B<"
MLQK21&9OK.1UK3HF0M;BP"6:0PB`O5CF1+$77)-J6'R2&P(^"V0I#^5C.H2%
M<.^.TN-^W]W_`%:<M<Z]2:9VI;;SVY7-WXL6J&:GOG.N872.H-L6R/L)Y+)T
MO1:C+3\V0/#L#3K#SY0IICK`R\!O^@;(GXBH:!T0SS+:*796X6HAQ&O]#2<7
M'05E8WU.6"+F2X>'$A`JV)30MGRDA'2)<F`=!L5^%_B4'6V&-ET0(.F;9MVG
M[4U!1;%,9G>AW@I:(BI/8E)"A@KK6GK5#V:O1*]CUOUU]9[_`*0KN)999C<6
M@%J&MJ,HRY8UI"/#J7>*8Z'VM8;_`*7T9O.MGQ-WUW`['VQ%VO7VIPX>T4B2
MU7<(3<$10MD-E7Q=ZI]%V/)H$2=7VH^S5M,O$3@KJ'X]KP*G<+WCISLSZV./
M--:FRNHV>;KXFSN@^F]NZ3EWJ#7).J[;+V+7J?0:8N8U]&;'O-_LPH)#YT(4
M[7HB%;)=0ZV60`VT$K\_+^V#<.T>E-G0.[>&ZU;:7<F^:#(VR<S[H/J]MJFF
M[3;+/1-A1Z8OI..L4";;8W;4HDX(EQ]+*PQ%CJRRZMQP+?MUS[EDMH2O<7UE
M.K2A*5N9YOZF1\B\)QA2_8GJCVH]^?Y],?QCP.!Z`^Z%*TX'VQ]8#J/>QA2G
MN?.K6%X0IQ6"E)0CIHC"ELM82IO&58PXK.4YRC&/=D,6LE%^Z2UP-CJTKLWZ
MN4PUDAI*`-=$TCUJR?D"9C28X];2L=#XP,2AHCT;5A:O3U]W\9QC&0C"L<P?
M:G68CER"39_KKDQ.5HN/A*H4[7NFALV6-`U#):D<_?Q[MED\)DB0Y%)K1&"7
M<"O,93EM_+WO8">N9'M]2':N_HSIBO:#BKM$\L\O9"SI"6O4U!62*.V5T[ER
M8,!O\-%%PF(^5$('89;P2K*%Y^0AWT0EL-EOZF*__AD?_P#N0W_UOP*9_825
M$5GC?=TLY"ADM-0U>#6RV!&.+QB8NU8AE/(:.!,%<6.D[Y,8RC"L^ST2MM7M
M<2%IIW6FN+0:#(V77])L4A&(2B-/G:I!2YL>A"3$(0"5(`$/B(2B0(QC#:DX
MQA]S'_O:O4,<&T)HL.0,EA-+ZF%E9#'MD),;7-/8D#D^WV>AAK4.DDG'L_C^
MM2OX_CP*WLZUUD/VFU7P=95H&*'Y:EY,T4&KT\>I2!=CVW'C*7*13+;9KT\T
MU#/?"\L5;*ARB4_+A65(4$^N<T\XNC,A.\_Z3<#'<?>'$<U51%C,.DX822ZR
MPJ!RTTX0D9O"U)QC*\-I]?7VX]`@_I#E_0?_`([[W;K.B=*0UA7IO9C-?E0]
M041XF+FG*5--1)XS#-0E777PSLMK0E`I*U93C"6G,^B,AJE.WW6==\ST/:+'
MTIP^X]&DQ5>K(%HH$MR/8Y<G,?:8?6<$=8:5;,56R?-8;`ZA0^!69%YG&%++
MP+A*E8"*5]0\G$\I2??>/HKJIO/M,:E"3[F.'P>Y8H\.BWU&O9*3!@W;>PR=
M%P]@&)RDADM;?P"J7ZXQ[L)"<9-OB*6V5H[6>O\`ZA^<9/HJQKM*;?J#9<3S
M+KRXZ(-8KRIC.+"[78+9\#:0K54!WCX^1AWS8T@+XE((][^$)";3.1]?3LM(
M/6OZ-N/S,K2>,F7C9[F.47(#&,H">PIN1UC7"6FC`$)2XE6/7'M]OHK'HKP,
M$DN&M2S.$8E/H'XO,PAF/&3EVU\QY4@>+:8'`93E.KD*^,5@9"$I]?3*$^W/
MKC.<>!V."N=6Z%/!='VG5=4TOK/6.R.KZ'K3F+4@IR:+RVTFZ62(O-RL$9&R
M6->6694_KXT&)/IU<AU,@VHUPE1[D@]D<+=\<["Y^I#6[U0ESTO4(6_[VN5[
MR5_>T/7+5>=B65MN2V78+I299V'<K%N&F&,@$CY';.>1'?D')_*6ZK(6[D=?
MZ&NMP$M9T31K!=58`EPY1$@(3+.I@316P)%I(ION?;C3HAMI+OM4E*F<MYSZ
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MS&"WB/Q3M.<N91EA;+#;0.70=-`/_C,NM+<]V%8>5EW.,K],)]`]<72/18RV
MLN=I7\]#3BE*0=IO06/R$9;RVELA4=08[/HE6??ZM?%G*\?^^_T^!I^&IW;W
M9W978>AZ7V50]1:GXPE].T.?OYO&W-^X-Q[CW#L#4%:V.:=,O7RNDT2M5*H5
M2QC!ML"1*))TQ:LX?0+[6,!-O!U4[3@=O=9\P[KWMJ9NYZ"(TC.P6Y-%\UZB
MUH-NS6NWZW;S:S-[#H3#,BFO;'@[)2YQN1P(MN(=_)0H)I"<.^X);OG1$Y2@
MM^3%C[/N.O8+FK<FKM#;-EK5RG5YX95^W,'J([71%::K>$R,S5IU>[((+\]`
MV&&2WG<N*0T.XOP/-VKTGM#58O5(X&_KE?+;Q92]7W3<L$9IC0NO*W/QNU(8
M^PPA-0V!LO8FN*)'"Q<-`FDRN3YA.1&\(:;4\0II#H:4?KZA:W60[9;[)>#%
M5/I:QA['H>O[E_9=-?UGIVQU.<L(^GM]4R9H>(VWSL3-8)*N3U1%>)8F%@O%
MX?:;R2Z%_:Q&T^5VEK$AB[ZW;(KM9N$0VBJ!+EZ7#UG-<U#7XVT:B**CDP-7
MIU0MDO..CNVD=$B=*$2R(Y3;[#2\!&`4DX\#1B[,=3KSKZ-V?KLZF1UXN=4A
M-*B-R9!;6J2=69E;$[%#7>#<;'8BQ9TU2',I0PF-RY^.0@."U5P^7USN#8]^
M-J"<NZWC9!^2A(VGU8D2`D]4B/P&+7590J>R':8':$G(-9*0($).2\H2O.$.
M1J%^!FCE8MT3M*Q,Q4)*'-O31]YK$3!4V7'DJRZ[=J$%/P00$3;HVQ[BJF&R
MD,AS47'Y46XIMPLYAYP=3@>,71JK)8K,P3K4PIVU3=TGJ[?8&]4:T$4*9_L&
MZ0<W&P>NC+]8[!/YLV8]X\H$1J8R^[*B$EX*RRKX@Z-PH9\C'5\^1PR1)"[D
MU='"XH@,YKN$G9>-OU/K&9:)$V1$O2U5_75ID8&+B9AK.)Q![4Z"0$&)^0@/
MIU\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`I0/E\K?G:L6QE]XE_1NCU""LCL`
M(RX5";N&3\<N$T24^>^\VE*LO(4\.C#7L1E&4>X-:M\H%I(Y+W%)/;JV#.RS
MW)LNHBD'WBU2(HY-@T!<K&/4)BJ"[_FPI=1-9`*,'$;A/<L=GYDBO(5[,ANY
MTWG.=0ZJSG_7.MZ-G/\`&<?S_;$7_P`,_P`X_P#G^!)'@/`>`\!X#P'@4C[G
M9$>JO.B33!@6D]N<B/-NE"K+;=+8W-77@0T-MNLY;)/,0AEEW.<I9=<2O*58
M3E.0NYX#P-3'?]C#K/6/UOR$M96JK!-;6O#\U*%#LXCTB-YU^*RU+3);@X-?
MC"3#VQUOO/-X6M]"$X<7Z)\#61]^/2=?E3=*TC7W9NB*;$5BG;?V5;==D/<_
M;"E;G,M5IJFU^N28-\L2"X>'OE4N,]$?U-+CS&7GTK2HC`N4A0[ZTJYN62Z'
MKE(UW]D^@-?#3&CM^T&)CX_4^A2BXF-F]PT\>=J^O"ZO?:U;)>ZR%]E4R+93
MQ3JQ)-.5M-E-*4&.%_MBU'4.L?M)TUJ6M:3=Z!UV[4;I*1^G*7K;55V%L4%%
M\T:PJ_Y]EM.V9JKTB?FV9V(3,O$KEW[.2[EQS++HBR7DA2>Y[VY4V]V'PTQQ
MQQ.?S'8J5VW;-7;=U=9O_$SGR9G[58%WNAS%R$BHV]725?L&EWG[-:8`>-#^
M.;=<<_VRPRU>!O5METN&NIZ]\9,RE0<4P6)=:3N62N$)0H/G:C6DRY/FLP(%
M$C8NTQ>QM<ZVATRT;&NF-G64^<+4WD"LB$+8"R%H#Z!E;)2M+6+8D-7#X.HR
M![&VY;6]8LS?3\E&0Q4>Y5BJB4VS2=<,BS<I$R\V"B1%D9\D#VQ;04<P2Z@,
MKYEJ^U:O%]+A;$L$E8+7);(:G8V5,$K+3<<N?T?K"5>K`3=3$BXN734+"62&
MJ14&$3*J;_(>;RXXIUP-:7TP;>Z!JWU7<70E9Y3N^V0H[4F&Q[Q$;9T=7H:Q
M/NW:UJ.<"C[1>P+!',`X5[/C)$:6EU"FL(PA"7%A;OZQ/W9>.QYR:KMEJ!$O
MUK>LE52QO9EG("=8B()=EB6+=@7(EQ<B9@IP%XL$Z3C&5"8%&(7@=><AM+\!
MX#P'@4PH91CO?/2@JH4)H`7FCE/+5A1A?YYA3]]ZB6_$/Y7%,I_&!:PAYO"#
M'D^Y]6<MMYSZK"Y_@4=^R-$@YQ9NE$2,X7)*:H&`A64...OD9VE2/C;0AI;;
MBE*S_P`,*QGP+Q>`\"EX;XZ_L0L0J72L%C<7TM]UC\>-0"H<W>-];8=R6A'[
M@@I#H#F,-NJ_&90KU:Q[W7O`NAX$&=/^O_C9T!E(&)56-+;/4B-R-+FX.6FE
M32D"Y#K^<3Q7S*QA/QA9P6OU]&?]S*?`^?*7VP]M[ZEJSS-%\J=V;.LD_'5-
MW!>D=7[/J$/.!P&ZHS9),_1=\HD*XVF)*AXU;H$@)(I?D5>UI"L_-[O`IAJ"
ML=8+B-;ZFZ(U-]TP_,[[LE!7:@P>O:;=8-,/0ZI`-5:"+J2*K=[$57YZX8=?
MD6GTNB2.7\N,'EX$7GP-O+.Z=8;4^U#EJP5+5NQ=;S%FU]LULZ3VIHRV:)MU
M_D:W3-@Q;[T=_?M0J<]L(2KUUL'\M6"#T1H)06$-,96OU#>MX#P-,^M]@['9
MTKOVG8>B0J3(=&]6,7'8](7,;"V!08.Q=K[RKDT#*:UI9\-8H.+F:'&Y'!MP
MTHE%<,2<:8,E$2O#P>OQ5L[FV>B;56I+6C,2T\FGVV&Q-Z_K%BK*X2]LF@P0
MD'.UTNWFS9Q#\80[)$E)PA!;SB?R'D8PO(;`1)+G),J,P-!4028_)3#B>^A,
MQYGS/2D>(D49U^OCK^!V9E!D84E7Q*(>1_/NSCP/%Q<>1Y(DTQ1FDR2SU'S,
MF43&5;\@M<5*O!RDK(OD@I<=5'3(RT$/NYSEE]/JM6,_SX&O_O/:/-2J91&J
M*U`6.55:C;S+`:PU]K^SE3T/3XUI+L#.2DJ.T55CI*=GXQT0D#'[UK\9T@/V
MY$<<0%9>[N@++,<\6VE[!U:7)[KZ,U/MRWUX6J%U`VDR&@Y36]WHU3C!K!:M
ME1M@@VX!J_@25H)B8U3X:%%$K&4E8_RAX=)^NE-<[AYWD-V\K<]4+6=MB=[5
M$JMT;H3:'1,5L&99H\%9(F?M,=M;G_6AE=G!!-<QRL8189/).8YEW\1Q\<D_
MP-Y^H.4N;-`S,O8]*Z/UKK*P3T=B'F)RGU6,B)>0B<&(D,QA$B.S@M0#A[2'
MEL^_#;CK:%JQE2$YP%@?`>!IVZ!^ICZL=_;WVGNS;\`^SN^_'UJ2VQ+5[J+;
M^M)"3*CH&NTBHKL-;I>U*W&!)&B`0A`<*$:PI3W]/N6]GW!ZWU[<X\\\A=1=
MN<]<[:T>IU<B*3R1L68M4SL_<>SK;<Y"_![Z`'"FY#:UKM(@@%6'IN?P,Q"V
MVW$'N)(]SC2,("EW;O$?VO[&L/8U!YFKW!KN@>E^D>?>CHJR[6V_T+";JB+%
MH\/G.47&'1-;UG,T>/BI^Q<]L#)0*4XXR)(..>[+GIAL+6<G:HZ3U+L/[!.J
M?LRA.6*;`;M@N;"W(S3=\V7M;6@D+HFFW&`FC9:-VO4:\6":6=+`+$#"C%J*
M(]$I^9_#>5!K+IS&O-F3VT39`&<F'9G:=[N*@$ZZJU(V$+4)ZYVPD&L+'W`]
M5S(RP22)!(IY!,>27%Y:6P0RDE;2FPS\76M;-O@K\A%W:)K=Y9L"AH5$93IF
M)ARDD:A`KE4CZ]%2S%-,AJ\I4_..%,R$6L:'E&QVQ'6)`=PD,HGJ376K=/OV
M2J;+-;C78IV&J`=8U1%RPH,6#$@1\A+TL*U#$VVSUP\DS\)X0>=8BQ<-MMO1
M9++;[`8#)U&K4F(D)&PT_>,7!474HTG,C$4:CA24B\<R&=&RSUDB]@9,B;%1
MFYUD>1=FY.*-:<=(?!%8D1$Y6'4LL5!$S%X>D)^<S-QM^GMAQ@SE!C[#%56A
M$7&*EKY6I-(%T",$M-7"IQ39$>Z''-`J6^L_VN84TV'ZNL;5A:Y9X:%;V;<+
MN;#E3-'.CX".)G:\DVJ6L-P*>;E+L'=*85"GS1V9M0<6=@4>2BRB3$EM@IR&
M*V,Z*EFZ=B4O#SP&QY>G'2TD4+-&?DSY%6JQ=-539*R7^/47'0\@?^OC76X-
MRSS:Q2F#",ML/EN!X%/H3$967YVWVRTAR'Z.2&.Q2JU=;CKZ+*A+V:59#TK'
M(US:YH5E(D3%_,(LI,9B8&(;&>3+NJ>#V(>+/"D[G43MFG0@510&$U#STY:7
M&9!N1@WYB,;O!L>9(MA3,L"9E365&H(;EA%)2^D!EQ3`2Y3X.I3]BE&2=F7X
M)@?-<V?3+'$W>3?LUA?E["\=88F!I6+^;3QJ2F/;9@S3S`9EH5YTE([:$*6^
MP&_[E$8T'G#3@,A*3\V6!2(H!<S:<M?W%*H!PX*/(3*1Y>?$;/,'90XM#!Q@
MZ,J]K3SC>$KR%@_`>`\!X#P'@/`>`\!X#P'@/`I1#",JZ'[:=,:D3@RM.Z$%
M?$,.41%NCLUW=&2`HX5J7)7'8>05G+Z,#!*<6Y\F,N^["\!I@W-I?8.^^4!Z
M&;MZ]:_B;5KVA$NGP,ESM+AU*&NL):*DILRH1U^'MY0R'MKIE&6ULD%@'A!L
M"L/_`(V7'0N;J[7G<7(6]^"]1;)[[F.GM-WE%_U!>X:Y:'T-K^:+L%!T);;I
M3#QK97B!+P42<15_D6RW^Q+6T+E9+RTN..9#=3X'Q6=F?:?UQJ+H7[&I:)^T
MJ(T-!<G;BL]6U#RQ9_K;F]VPNQ(Z!U+0[I&Q,SO2F@MHK$%,VJT/1Q4@8?@R
M.#;_`&*\)96TWD-XW$/9V[.B.U-DZ^N<S6VM;L?7MPET;&T6NN4B=B*MM??*
M=GO;(_M:^UTPV3N=3SFMBC,O_DR$=AP;*V'\8=QA84UJG>W85OWWJW53N[*R
MU'6#[P^O^3YM^M:WK9&'.8]"Z%FMM535AIQE>>#&L"9*/88D)ADA$DXVZM.'
ME.-.(;#9_P#5AO\`VSU']=W/V]]P6R!M.VKY6[Z[9K9`UT6$A#96O;*O53`*
M:KP+$2`TH,"!';(0.AEA]]I:V\X0M*O`THZ=Z?\`O%@>$P?M0L_17*/16F(;
M5-@WI<^4".=S-8W.1U=4YB1>O+%7VO6;1E$?>:]2X$T^/R4(4`2^W\#S:O<E
MW`25V+]K/65.!^Q>Y<T256(CM-Z2^I[97+=/V!0XX1QV7[1VNU#7.+V`4:2$
M5ARSUXH>/2V^8SF%=<6ZCT6CY,!V]]?:\WT-3?K!L5"JZ]?1>Q^U;I1>QJ'=
M()XW;'+^V./]<3VXMA:\4*4C,6U;J9+U1PMM)0!&9J(^!P=`ZB4K;#'-.]L?
M=I;N.]:=?9G/KK9KEY@8NYZ6T9T"!9=/](=2ZEA'F3'K4];87;:-+:NVON*D
M89F8J$#C9*(AW90=DM]",9S@/I`K^UX,C2D3NZZN1=!KW^,Q=F73)UDA)J(H
ML<Q64V2TLR-MAB7Z[)!U-ILAL@\9Y0CB1E.(5E&<9\#1MP3TC5?MT+V7KK[#
MN0]/+F(2(B>G^2*1L2B-3*[?PGT<_8JOJZZVBK74J=97>G2*"]B>PVRR#A1$
M06.RC*AGLAL`&^H+ZP0&'A8WA?G"*&()(,?'A]=1$0R^24)'@D.O-1J!4.Y<
M$BQT>BL9QC#?\8QG*LY#Y[=]<5<DU_L?["0HKE>C[2K?-U+YYV-K7GB,@+[(
MUMVXAT2@GF0P-'JA#9NQ9:YZ^/L$H8!'LEOP;-6%+><8%,=0X$<;0V1J[G/9
M%[N'$_USO`T1M&O[;6UZJ'[1UC>*-KD,B#_PMU!"0</%UF`D83=\A9'X%V.K
M@;YX`L42-/,D`_EI6&33=_Z$^PBY#5?<O'4K>]AZ<W-K^EZ:O6_"MFU*)UGL
M_=AVY1J9M""!5K(36-FUYJ&.HP$K8WH,<2UD-E1S0DK^0.R^Z&^/ZN.?T1/#
MY^L-P6U[=EC>Z+ZL(G]@6K"2K9:":MT]M:ET^VS"BRY:0#E!X*F"-AM/&&9!
M#';"0ZH=E+20SG8&RY/0ML7IBZ259V:_.`UFT:""N4!2:36J&S31ZY%2E^MU
MTA(ABNU=VH3S)\\^M^-!/D2"0PJR.<^T<@0*F](<K73',UTLDUNK9\G?=^[8
MY2U5:]H0-HNU0M-E9O\`TISSIVQ;)R#KVU59K63DAK8#,6F*JAXD`L)6#LL?
MDD%)=#;]SOH#6/+.E=>\^:8B#J_JS5D'_;5'@I*;EK(7#P2#2S1XY<W/%GS,
M@V(LQ2&UDONNX;PE.59]/7P)H\!X#P*C=X=7`<.<D;KZLDZ41L8+3=?BIUVC
MAV6+J!ME7*VF!J[$8#8)D<N/#.=(G4990IIQPEU*6&DJ=<1C(4NH'V=[S%W/
M%Z+ZGX&MW+=QO6D]W[FU(^;T5IK;D7=Q]"P\%-W"OSN*`I<OKO+X5B8R+)28
MGZYQ:5M?)\^$M+"MT=]D<-4H'9GV1KU+*8A]H<-_5I<!=+YN40B>=E>F=Y[M
MK51BFK@Y&MPK\G#QVP1%.^H[33V1G$>YOUPK`6XS]I4?G;!6K6=(FONB?9G'
M?6VY,-;,KRL_NSM")W^O;GZC$+DO$&)7E9"7$^_\O\Q.<?-C&/3P,%^\#KX7
MESF;5E-:U)<=QVWK3I73O-VN*U2K57:;*-;`F;&Q>*X\N>LQ(4='I.(I&0V'
M\O-88,(96M:&DK<0'E?^[I*W3Z3U&UT-R+T1S-T1R]S%;.MY'G;:1&O"S-JZ
M:JCQ$>=8]2;0H]IM5#L[(<ZTV!()6ZP_'D/H][2TX7E(2]%?;-I-GMW4O#>P
MZ5>M87;>V@-:;FU/?+`T)):_M-MV.'8Y4?1:YN"P>'$[)#@ZG(F,8(=2')-@
M/I'<RYAI+P5-VK]K.H-+=;;<MUBUWLFU6R'B2..-.Z5UC#L7?<'1>]*INFZ*
MS`:SA19,6-5'/1^6RC'S%"(A&?D6:[Z*82L+N<R_8?-[AW:CFS?G'G2/&>[9
MNDRFR]=PFW0*?<*)LVCU[%?:MA-3VUJBQ7"B8M-+-LP34M"&$C'BI+86E+J7
M%>P/UTK]B<CH/IB,Y=IO'G3/3EX-T/CH0TG0J=/E,0M)Q=Y6@NI.!V-M/7I[
MYR)Z/:0EL9+ZW?R4_&E7M7Z!<+0&UY[=NJZ[LFRZ8VIS_+3SLNAW5NZ`JQ';
M&@&HR7-BQR)T"H6:W0HB9AD/!8R$'..?C/(RM*%9RG`3-X'7=$%?>%(?&'>(
M!<<="?=9;<>$=>9<&><%=6G*QW'1W5-JRC.,J0K*<_QG./`['@1QN*=DJOJ/
M:=FAI!N)F*[KB\3L3*NCH+:C)*(K,I(`R#@CF,ME-AE#H<RVK'HO"?3/^O@:
MIOJ\L<9KWBK7EX)$F-OC;L"V5M?86VY+%9IMMDMPW"Q%W>XZGV56[TO68(]N
M?W%>;'6*_F(!1"&-1[#[WXGYOR.!EO$UMT_1&[S86-*3M>V"J3CJ'8"]7:?V
M#L1,9!Q,9'385?,VG2JX94[]5Q3YA94)(QXX;1<84R3AI>7EOK"]@/3-'D,@
MI9I70+2Y`1DUE)W-.^X_XFGU,(2V:L[7@[<>6A1"?>R^IMUO&%94G"4*S@/5
MD^@Z3$D20Q5;W4Z[%S@M=>S'<\[UEF"9$PB589=C2HO7A@LE#8Q#N..23"UQ
MS#;K&7'T?.SA8:^N^K5IS9E<H))6O;?,7L:WSFL]>GW;16UA5BV'8E;+C`\U
M^!NL#4(&RQJ[$+'E2)>"$+BH^.?DFGFTAJ7D*4?;/9]G3&A7]`VS5%>T/1(;
M6TU5ZOLDN7K,I5YS:$6'4FZG6-*>[7UJO^`I*&>(9"2V;2Y)Y\%Z/?);;>&)
M=#8R6GIIWK#C]O?X?/\`^&))]`EP$AJ,F_.R;A7^)W@T,F1UW8::CV,!%NY=
M='>)<6O*$?[2/?\`*&S7P'@/`^.K[#ZGRLWW5T^;L_<?_IT&9:U2U$_=4[M:
MC6MGJ2O8#H&M%N1^TK/5-LUAR;<-S`,FQC;XB5,!$"+1G"6_C6&UWZ6]9TFJ
M4[==]U\]]8]@K&Q"=7A"WWZT96^G5>S%4B(M4?(!;4$NETN[($W$&RRWXAL8
ME+@P$@L-_P"7`;)#P;N/`P'9VL=?[CI4MKW:%8CKC29EV**EJ_*_D?@EOP,N
M!8(<AS(KX[Z7HR:BQRF5)6E2'F4*Q_*<>!\@7*&O>DI1SI6Q7N8-HM%VKNR<
MV3H>&I4M/7J*TCRA+SKEWJU3S3["_&DS=ALDF^F2>@QGG<&R)S9SF%/.CY0&
MPB%U3/6)$5L6,M$!!5^'F8$ZHC?C2]:&36ZD(L"3I!\>Y:Y",E9URV2!F2')
MYF<+>;992R4@5N/0('D#05E0Q&C#&6<'4PUANM?FRINQVT:SFWJ3N0+FOS:B
M-<KFUN5<<NP14<DIT.P-UTE1;I6&_@96MP/*L49LJ)*MT!>))E4,:U6D[`FA
M[5MEF:A#)QF<'UF,^%'3-AV5'R,O(%!M6`Z'<"),SCY[,TYGV,^!TIR$N4'8
MW)M<1`&V.UL6&8JTXR!LVU5@P2,,E17YRRTZAY>@K96K,W+0DS^9-FGY>DB3
MGTM_(WESP._-;W/_`%\3B>P1"#L['TV+!CD439,%-/1S5K.AY6^3&T!+-.VG
M<@^RP8T!]BM/C1[CZ)5&"?E>]A&0\^T[+NQC%'*F8"Q3(NMKK%$R4)`Z^O-+
M(NIK&L(T6/DJ&$=L6;>J4#6R3,BM0+`,P`J>0PE4BS&KR0T'<QL:S@2I<:W_
M`'B9B:KXH\A%,5[9T5K(.29N7^0SYAJKNB765E"I&/%4SBWM/9:CY8K`B'?5
M!>5!U,;ECG!(3*Y5@(_8*1\BUZFZ_M=<GXC`XC-.8'VI&VR.M5GOC")JT/G/
MHK'ZHLV-;,*;2U@EC.`Y;]LNCF6.WUBO#BQ\)(Z<K^O3B:52'Y&(@0I!HJL&
M13\8%46MHVD**24`\3-23[SP3N2A!2,8<*S@-Z_()\?)\S:9-B7(AR+=I82(
M[-?AIBOP"`AWR1Q68.(GQQ9<.&'9:2V+\S3>5L)2M*<(4G'@60\!X#P'@/`>
M`\!X#P'@/`>`\"HK56S#;0[&V!\,C#LV'76LX3)C0:Z*@XBET>\R#UBCMC$X
M4P86V/;&0E');4U#JCD8RI2DK0V%*#UV7&IJ$3"-V"0C"(S7$X++$W-PA;A$
MBEL6T6$FZ3>O8VNS$B5(3:L_D?E#-RSV<.1^$L$^O@5^IVLXFH_<&%M>5U7(
MTJ,V/NO>58I\Q=]46=%DF+^/S-#KEKC2]VR#`=6?UAL>"IDBN/K(;4B4@Z.+
M-5(BMJ5%^!]"7@:1[_\`5[UFJ>[<;T+]AT7J'7'<VQ+ML78=-LG(E.VQ9*J=
M>-75O5,G&U._3VTXO'Z]NN5,1MA!D20T-C*\MMXSZ>!X!_U)[NYVL^H-E_6U
MUM$Z-O\`K_D?5_&-]C>A=0";UI>Y-::8.++U?<)UN"LFNY2M;)IK4L<.@D'W
M!%B/I96.A+>5.![NK?J-N>LW.,I@SII>PKUHCKSH_L[HN^V36X$5)]+;;Z&U
MS?:$;*)B82<1&T+^VA[@PR(AK):$1H#8Z?:K"7$AQ\C\)?9MR%K73>@:?W)R
M_9]$:J*"CW(BP\?7C-_F*<783;/:8E-RSTJ6.S-&E2A(@AKH3R6!UI<6RM:/
M;D*^0OU#_85*\CU'Z\+Y]@&DX'C(6%S0=A`ZAY;L,%ON[:C?L3UAEZ`QLRU[
MKLM>@W+,.ZN+/D68/Y%@$._[6<JRA03-U']26Q=R2_;9&MMDZBJ,!TW"_71`
MZ_K=FI%KD4T&+X1V.S?7HNP2L78AR)F&NX["0&!AFV%")3AU;BU8]/`AS["/
MJWHCGV*\>?8)7[XNKTN;Z1UI3>B^<W8F3+H^ZME;'AS]`4[;+"(Z7CHNO7D>
MD6]V*G"R!WL3,>`$RY[E(RET(AV'])G<<YH2&X?_`,O_`%^="<K:RBKA0N:]
MG=@<QW?8W5?-NK+J%B,<BJ:="V\'7,[<J?"98`B9E]D1]+42$M6$>GQ-AM`W
MI]>-^M'UJZD^M72VZ&ZA1H6C:+YWW%LVR`R+5VN/,M$C8.N;;@JPBL/#"PMZ
MVQ481<8MYQ>0QQ)$I&?52D+2%>JO](&I^3>J.<.L/KM*5IFWZ]/G-=[VJVU]
MH;PVO6=K<PVN,2R9JRL)NMNNZJ`32K"&'+P#<>T,`V2-AIU.&O3VAOA\#75M
MKZK.,-U=$R_6%XHMRQT'+Q#<#G9M8VYM&F3\5#8I!.MR8J`<JMLB682,DZ-(
M&1Q@HZ$#&,G$*>;6XZI?@5^V=]8_-'-&F]S[NT)(]`ZYW!K'DZ\T>B7R(ZDW
MVY,0M$US5IRWT'7_`+IO81\612*O:1$FB@$LN#-O..95C*7%XR&T31LM*3^E
M-/3LX:1)3<UJW7TM,2):\.%'RDC4X@R0-)<QC&%D%%O+<7G_`(J5G/@?.OSY
ML^+U1U_V)/:\@*]'[)M45U$_4MD[!UFQH[4-(`=[(L@`QFQMDQ`KP72`MXM[
MI),',-/BEQ;T,;"N#,N%/'O!:&_<W].1<%6>DHF4*$EKC+,6WH37^W/W=^F%
MC)9,FJA([#'JAD8H*MZ>L[XKC$536EETP4!XBNE.(-D&G@I/<0:!<]\\[2`-
M7CZOJRG6'C+7<UKT+6^T(NI:WA++VA_=FO-/'CUF6<H51WE6I>4K4B:>MS]4
M97#G%"MR3!H,@*'U8^`\!X#P->OVMZ'V9T[]>G4&A-.U&.OFRMG4B+KU6J,M
M8(VK1LV3_>=8/-&-GIEUF*!';B@GW58(5AEW#?QJ_A?@:9-1?6SN6V=U:PW+
MK3Z^\_610X?2W1>M^DME3_4E4Z%ENAJSM+74G2=>:K#U94KW=H4N(I-ZDQ;8
MHF84&RK$0T,G*<X;0L*L:TYL^RK8Q$=]65GY:@=6`:TTQ];6G=S]<#[BI,]J
M,GFSD#<>R-C5.^U6AC@&[`L.S=Z`UYJ'9CE(!3#2,>4EYYH)"'E!>+97)/<U
M,NE^VW2.7"]XV6#^]ISN6DU8/:FDZ$;;N:$\BLZ01+QEEM-M:`KTNU/MI'3&
MFI8.+:&0ZZVA*\K0$,_:G>>[NL-5\L;,*^N#;7/YW%GV$<O]`V6.V-NKF^03
M<J2"NU1Q3^N+1$W::K[5I$L\A#Q33<B*M.2YE'M9>2V[E`>]UGI#OK[#8'N+
MI6Y\:7_GAFE_7-T7QAR5S79+OJNY;NW+L3H,JI3=^V3.MU,^1J=3K@3-1C8R
M-$38'B"<LO/IQG"E,NA9V_?6C)]D;'Z8UIO:HWW5M9+Y(^N-&A]^0+M21,Z^
MZ5T`7OV==M^N9,0-4D)<M7S-G#8D$/86&4!(*:86C#JOC#4WK[G3[)XCI;47
M55WYQI>P^_>*+QT3T#LG1$3,5VGUKIC6/16Q;5HR]6G1\W*$2<#$V24@:.-;
M:O\`G/1.,NY)'4VI]]IG`;(>+7^]-_?93$]`#:O^RKEWD0%K<-JW?JCNW;=#
M_P`=3]LN%/:KNM*1SOI"ICR\_#Q%5M!)<L^6;*NQS(X[>$9^9;2,A;CH'C&P
M=,_:6W:+E_Y'T+1L#P!$U8#:^C=U[.T0R?MI/1TG8%4J0LFK[36).?)$IY*B
M_P`(S!0:&W\N)2E[&,X#:CIK545I+6M9U?"6G8MTB:JW),`6/;-[G]F[`.'D
M9F1F4LV"]6HHZQV)4=F1R*,Z8^\^@-EIM2U>S&<A)_@/`>`\#4MQ^7!4:I[C
MMNSX*BPG/^J^J.LK5JJ]OH(=D:+=9OK+HFH[0<M[2)64CXT,=,VVN/DF!618
MZ(-)P8^TI+J6@]OFK;NQ*R#N6-J'+.U+4U7-OSE4Q"5VY\[P,8P%!D1,=$6:
MK5N:VG!R5:I]ZK17]Q!CR>&#G$N.*2.VR^(E87=K^V;Q+28H,ISEN*L"&S;4
M6B7E)72A@0,>Z\2TJQ2[,)MZ4D!HMAMA#BVQV2C/:\G"6%*PM*0[=PVQ8:I+
M.QPNB-S7(1"9%3<]3V=7EQ)&8^/_`&"4--3.T(.;0J0PE;(_RAMX60CV9RG*
MV_>%!>T-RW&TZKK"6><=QUW,C<8RNM_WN%K<)UDK8-?LM'=/,S5]TJM434]=
M*GVI^U'1^%.YKX!30JW5K7A(41^\O76QJWI#2^Q@:SMB(H&N-9W#0]Q;YLVW
M38E!\SO>\Z)UOK75-EIVV`QC;KJ*[ST:.W*IAVU65Q;`@B5?CN$.+#;MNZ>A
M_P#RMXA;19(@;Y)GH7*F<EQ*U2:6].F_^X]M;[WSM+0K'Y6<L?[F4B*QG_;^
M3P+GCF!E^[\4H8GV8QE7X[[3WMPKU],J^-2O3&?3/IZ^!V?`>!I%ZI[)#U1O
M#8U4Q]*'8W4)=>L=>6)O/5_/>CKE2]C2+52B91%BAK/8[F!:'L5A,DW%)**#
M0O!([[3*LI8SZAD?U:ZRVL_MOL[K"Z\D.<&4KI66T?&4/FF31KQ-T,=T[1)&
MM63=&Q1=?K/C*[8KD=+HB@XUDAMO$5!L%NL?DEN/.!N7\".=M[7UEH[7-LVM
MN.]5G6NM:9%KD[7=;A+#PE?A`5.MB-N&2!+C:$NE%D-L,-H]SS[[B&FDJ<6E
M.0^8'E>R5JVZ9I&YI)J!UYA4%2&)L&PJN&O]G5)W0T)-U;84E:9&6A9)]BLB
M:^UV1*Y((R5DEH]Y!3+3RGVQ@MEK_G+;.T[D):HO6E]?=-SK3Y;[>9QZB&!U
M"RTVOER]N"NEJUW,3U[L48JJ1C;P9;,J0.Y^,.\E60T.BA<.$X2VMBT5VU&;
M/@:A*Q7[*-,G:S^78[VY73;83*C@BW&5KE=%3B/@)0L88=45@)M]6<O-E,OO
MM9"8K!PO"6^(J85CV]L5,O3CQY&#L-?#IP!,0\.U#/8;A8RP5ZV0@'RV"NAR
M^271R9!J1;4I@EEG*&6PQJ:^NVGN9LAE1VOL*I2ENBWHNR^\.JS\18&I(M^0
ML+DFR?#-64-%BD2/R"!XJ7BPVW6&/A9:0U[%!BEUX,N4@6[,0NPJM-3:9N)E
MF#IFE0$0X;%PGQN@U.:&D8'8E=4*LY\IY4K&QL9*H0IAM*_>RHAT*W6_3&UJ
M;5*W#R_-X\*!7+K%BDW>-11-@!5R#<C3Q)6XP:&(:YR[\<E!$F_(ER4'#O*2
M<'\N%KP6G`07#3?/P3R$KC`"*B5552"Z3$U*M;)9FFTV%UK!C=]NL+,[#:@3
MPI%EU3!I@[<HT(ZT,E7\OX#^6,K2UI"D8E"*F$!<H61E;).7?70<6#>P!JS*
MFPXM&_0,18NJV99JN&NMD_\`N6;`&]Y+C:U)PO(1G*W77\A?[@)682S32AJ7
MK06L;1CCJ.)C6^QT6&6E/VM_?L#5<AY&CV>^XI[&!`&F![0^8A2S&LK83D-^
MG&20L<M:/S&K;<CG:)'/QZF"(4H3`)+I!`:`7ZX%&P2HYH=Q*1L"C#LH8PA*
M6F\8]B0LWX#P'@/`>`\!X#P'@/`>`\!X%&Z!)R@LW]AEAFK1,26(;9:@(4*7
M$CY46FU>`Y?U+,B14-"",H?(B7IF9D9+X"G%O%O&N9QA+;C?J&N:L5+>$K3J
M9=Y&MZS;`9$U]<")B;T=*PCY)-DE)&LS;H[&>>XHR'=8@"'%NN-R;SJE.`K6
M2R,9DMT+V=SZ4ZSV)>>3=I\F6#58%EY[V7>;G9ZQMTN4$J]VB;5K6;H3,/EV
M*JUG,"=PW/$X48-^(<*TZKX'?ZW$*"JVS^SOLRTI:Y&B37-W/FZ;E'C:PFOT
MVF6>GFP7J;:8^T9V-=4V(C6-M"<B=92-:7G`@[9$O,?,T**)^6[A*0\:=[9^
MSV"T`+UD]HKA\O1S#ELG;&"'MW>(U]C*!!7A=7KL]#8L^L:M`SV;G$LJDVW7
MU1C80KC2\H(]V4X#>GX'&XZTU[/E<;;^1Q+3?R+2CWNK_A#:/=G'N<7G_3&/
MYSX')X$)[HZ2T!SD%`R>^]R:XT[&6<_,9`R6Q[9#U&.DS4EQ@"V6#IHH03&$
M'S83"EK6E"7BV49SA3J,*"#&_LR^N5V0_5)[TXY_892`M`J^E=.MK>3**>3'
M_CJ<N"$$Y+4PKV8;RK.?XS_IG'J%8^Q.Z^-)VC\^S56ZRY]L44/V;S>Y(2=0
MW!K2TH`!KNTF5S[YXT=8S2D1PZHA\4AYEIQ8ZU>[^E*5.(#;:+)QQT:-,!'A
MEQ!@+,F)*#DLO1Y,<0PDI@]@QM:AW0WAEX<2ZE64*1G"L9]/Y\#S6;;52!`C
MQ[-7WP9)T-B.-9F8YT0]Z10*['LA$H)4R4Z<V<PIE*,JRZEY&4^N%I]0R#P'
M@/`KSUTC#G*'3K:L(RE?/.Z4*PXMUMO.%:WLJ<X6MC.'T(SC/\Y1G"\8_P!/
MY\"D?/\`UIT[<N/ZA>*%P'MB&E(W30KE'B;OL34;";6N(U_#2%'EHB)_R"W:
MY&O6]MYM*$&XCI)+B5-J1ZYP]X')]9NBMT.:*C]A=LZFJU*WO+[LW=MJ-ULY
M#4J87J0V][=W190GH.\0+ITI8A)6J[1<0*F3=R9'"NJ9<0E]3ZE!M>\#2[]C
M7-\KJRA.]+\[ZRM>QK-0]C\\66<T-K6JG62R6ZOT_J31MV(`UW7H/V8CXVHQ
M<99)Y^/&%^<DL\I;)(S;YC189E7OMK"F8,N?/^NK[4H((60LS6/S>,K*XZ]#
MP4F8-'3J`T6!,I\-@BAT&-#_`(_Y+&7,LNHPXC^H+T\L=+4GKG2=5WQKNN[$
MJM2N#DLF*AMJ5`BC71IB*DR8Y!DA6R23'0Q)5L=)0F5.94X*\VI:4+RIM(6'
M\!X#P'@43JMAJU>^PGH&.FI:IUZ9M/-W*+<$,?9(4.P6Y8]^ZB&_[*$,>'ER
MD@/*^%&6$O,J4KT_I<SZ9"]6%)SC.<*3G&/]<XSC.,>F/7^<_P##^/`HW]D;
MS+'&VTW"11RP4SFG<2:2\E8$&B5;OUNF5D2L`D"'+'BHY3I*TLN(=6EK.$Y]
M<X\"\W@/`HM&95_[LPNN/R%*1CA;5^?Q?][V-*5O[;W_`''\X^#W$83[?XS[
M_1O^?X]O@7I\!X#P'@/`>`\#4+H_;4S,ZSV3JRE42TVD2[]%?8$FRW1;3*X6
M`@@]_;Y:CX-']NN8-S9MB2T,_&0B5_AML`H7(/D_-@0:0#&/K[D^E=?15BH<
MK1C+$W3-::=`8UW_`&@!JB.J=C7$@QA\.1L"=K<4JV(AJ?'"DAN,M82[DIP?
M`@[#`Y#P;66K9>,O"M$:JF4)?--8?('M--?'""9/*8!.>^68$)=R:`TT0III
MI:F5._'ZJRC*LA^YFU7<)!6(?5TM-O-.$(%];14(P8I+1*F67E/$RKCX[90Z
M?E3ZLJ6G&<)4E*O7&`UI]VWCH`F3UU#P%)GZ='G-7<JO'PVL:_NRUHLD74E,
MG/@2`=K"AJ8=)UBPRH0XJVY`B32RY^/\3OL\"JW>T/0MJ:CD)7<0-WB+/LY.
M@E[/U#NV`)A]3[`K56FP=H5.T5JK/R\P+"NZALB/GD8IBQ(R$XIT><0>^H=3
MH;1;W]='$6PAX9J6YLUE!&5VP(L\'/:ZA?\`%EIC)E-4.HSKP]HUN[5I_(A=
M0DWX]\19"Q'V'/\`<;4M*%)#(]"\2<\<UW*?OVJ:S9`+78JT/3S92R[%V!>E
M"UIB1:EUQ$0Q=++.CPXQDHPT^1^,EM3[C*/?G.$8Q@+9>`\#X=?M(@/[TZB[
MI?W'S3]F^U-I`]4<G0/.EXT'JWJRQ:/=XFB*ASK)]#:K@S-7SD=K<EJVM'7O
M$FC(*C#I!Y#>2_D3CX`W0?2]7M,0FR>[#N7N?NF.8>9;%/\`.TG0M0=#ZHVY
MIH*+NXU`M4-LV=UI3-JX4X/"V!V,BW)%T)Q7S2#:EO83A3/J&Z[96S:/J"GR
M5\V).M5^LQ;H`KI61)"4..DY<\:)A(*"@X820G;'8Y^7,9#CXT`8DX\MYMEA
MIQU:4Y#2?*V/87V9;AITC!ZDHU_Y'K+S<=+4K;<]$2E'13MRZ*@[G4.@YB$J
M%NS-E=$T6:EGH:+JF6U"1D-,F&.R<;.,#?`&S[27'VK-/"EGGC8V3>YH&`$L
M5UN49%._.BNPZH2,#KE7&&37*A$A@O/-H;$9R6\AU63"BW<J=4%EY^P0-5AY
M"PV>:BJ[`1(ZRY2:FY`2*BHX5'IA9!L@<ZP**RG.<8]RUIQZY]/`@_9G36OM
M70B[++1&Q)ZN#-2CLK/U*@6&:AH3($<`<&W+2:AA`QE6!^6$$CU)6M#Y+^,9
M4AMM]QH,3M?4[-=CH-QC74H=.VJ9KL'7ZR[<J'^Y23:<-$11MCC*_.V>;@8<
M>+=R:>2@(O`(J%NN8^-*EX#QP^K9<38V=:VG7U/8DV*D_9Y:5IF^=>66(K)*
M)(,`*NVA%H1KR9B9:<9+R1'^@CK93+#V<9QAI><!G]5Z7J5DL\]2S*;M&M6>
MKD@B6,&1I14\#"N2$.1-#N2M@H9-PKT4.X*&\E"BRAU.K;_H2K"V\K">HN7C
MID5DR-*00R^,&8E.4N,$ML'C-F"9*"(0T8$X^*\E>&WFT.8QG^<8\"NV].2=
M.;\2\?:('$3;G08V(Q=X##8D_F$CI%F01$'-.H>AYX%&6\Y':DA3&A'_`&/M
M(2ZTVI(:E.J^3#]6$W;95WMMAD->#)D_[OG94D4N%V%K^>B9)!P$_6JL)6V6
M+Y$FG.P0,6IJ/@I0>1'=7)LFED9&""-@:T,"O)D41;FZ?+VG7,'<H<&;]VHF
MGP2Y9V%E:RSKZ%L,NDVUXG8L<LJ.>P3&(9:&<>-<>4MED-]_(ASLES/I8]W]
MYE)5'C'1566M#4^=<CE*>_5NR5;$-DV(M]V.PTKVX)(RXG.',NN*7E:@L=X#
MP'@/`>!'.S[N70H`"7"B4S#QUE@8!0ZU3"$,LS)N!7C<N0T).OI<&;]5-I<;
M9:==]K>7D+6CU#76QL.*GZ%792NQO[AJ+3S[^%96=U[A'+MT5'W#7)U3;`BI
MJIO;"F<RK]J+9+PFOH+EWTDQ[CF7RUIP$@R/1,3-!")LL#<Z8P!E4*NH04_N
M]^=:G<U&"6.%+KU'5IQ>`8R*V"(&E8AS[!L^[[&4%G!#N-!!&J>EZQ48><(/
MC+Y5Z5BO-5E4#9=C=/W"6UF:=7YJ^S+MNL\G&V.4>DI2*0R1B8:=7(0:S`@%
M+84^WA81K<[]5KK0+/:[J7M:M6V!I>TW'V;EO/ITW&N+/"PAFXA7C-.5.K5;
M$Z4Q""LY4D=U3S$:M8#/Y`F%L^!^"SZL/73/Q=;[*KY$9:V=D[-'([;ZD9;%
MJ!HFT_W;K<S\<8JJ`AC4T%Y,=$CI2.[)!"J8:=4ZXD/V-L2O!VP*UNU3<D%1
MK/KYMFL`F=L]##Q,['4*3V"JTG*=GGU%AER$+1G?41]@5PT90Y;SZ%O.K&#)
MZUM9J8I%V<`"VVE$)-[(2);)?KWJP2"K,U#UFRVW%7?G"8:L0UG?JD%4B2R(
MT4Q2!A&\?U90Z@AX*/[3<*@]ES\IG7.N9MFW7*8L3<).3T3MS%C,C:E79N8L
M*=FV"V"SEGBI)D=V3)A)UIQZOJ:0(.-D58BWP]>J7LVT['C:4^^//R]K+JEH
M<=9N$/2$D4ZNR>,"QE%;;,L-?BQ*_;QVVRFF1HZ.<(86P0XT04AI(;2XCI+9
MPD?><!SDOM0Z*HE3FH/^W:!'4T&,-?H57M,J=8$7(]=H`58S+&W@`=09RV/F
M2R\EO+>77`ZS?1&\6+7L&')GQLHK=LND='5/%+#.V69##`;_`"ZJW#P3+$/`
M'3<@53(9T,=<H[DF):0I]3))6?<$-=1$/=7:\Z(YDW<NJR^FK3,2-?LM)M"Y
MNER4S4J4UTA?1(X*4I!X4WD:9D-(P+Y#V)%"G8<8W/M;R[EM04[F^$>(*1SW
M1I*M:WV*Y:@Q#02JI9^K.T@9M&OX&J;MQ3ID:-JF]XV/M5CM8^K598(6T$W)
M1V'EX9%4I+6`_6S?K<XPNQ]HQ;'>MJI%:L5LC9U"$K'5G51&3;?K^[W("GS8
M69GHRR3EOD#8N"=<CL1(04DXI@I22&G5_P!02//\-\^JMD;68RF]'SPDU:[K
M!*#@.VNV]?3L.-&V9Z/A)`FWVKI.<KRQ8R*CG5.BI9:/E5O?*SC\<8A*@R#2
M'U]<^Z]Z6T9OF)+WKG:E-T7(0"M<;DZ4ON_XFJ-76OZ]L=PC*^-O%N?#L-Y)
M/*20>?"E83@X852&$MH4PR$VZ_;+9MK&'J[`2-B_QMI^2E&=GP5&L]S$ARA^
M3XZZ"QCE,C)6+EORHVPRBR'5,,O/V(I:V&TBK9<R$:@PM9V1KN;HMA$B89%D
MJEIIDO+E!C:BV[69"P#<8A*MXTG&U[(=1V!1G]B&%#8C6\C#2;@K+2?5;R4A
M6>(X4#U1K@O40W4GV-UVCT6CS%18U],=DW<2)`KGKJ&GU:M4ER-C86+F*\&N
M]G1;[K[B&P#6D(?3\#7QK#SV?K^H0D+#4L>UGJ6,%J:J6>?HG/>O:?)"ZKTK
MK:P;ZU0/J$ZK6%ZQ:MZ"'12!@YB_P[\RB>E)7*,A?&`$Q'!E]LYCNI-<EHN2
M[I^R2O-VPF;I4G`5;J1$X#8(6>@K\6K$3>MU:_L$96CF*M#MJ>.'3%C@2?SC
M8)^7\=8P9G7-&[-J[4;'R?<'V4%1AMCV/6X!V>Z&T_8['97->3VYJ9FF5Y5+
MT,)%4\EB,U2!8GY:U-9PZU*KC1R'9-AQ/@2,W3-RQ5RK-=;[,[4K\#/2>P&$
MG6G86B;N7;5Z\EMUQ&8>IS,;H]0%0D)FNZB'G<DS36`QAC'QUH<.0I*`P+HK
MG+8&X-;1NH=F]J_8+7ZET+M!GG6?I$/>>;*A:O[8MT=M)9,U(V(CGY$K+Q4[
M!ZV4:*+$Y@B"XX]2</E)5[%!MBY]N^M-6\X\BTZQWP6!79M6:MUYKA&Q28:J
M6Z[R<'K0!X8-<,C\$#-I*A859)0P*/QD/>J&/<A37O"V7@/`>!Y4XJ01"3"X
M@8<R63%2"HP,M:VQ2I!(CV0AB5MJ2X@=\G"4KRG.%83G/IGU\#5%R5PGTEHW
M3RZ/#]M;'JL+(3\Y+Q]07H#1P:ZHW(!*B)$1DF2S?94S!DL'B6#*S(M*RA['
MS#)<6ZE(5C,^HSIQZH0]>C.JS*]^,+K2CK!%W%V#,M5Z`ILK6)>>WG"RT[N\
ML2P[RL$A%FN)@92'S0VQ7A1%!J^!\DL+)=&Z5^TV*@JHUI#OME\\R[-&6`\G
MB'4ET*#AX@=RP1<"Z*/M_6Z0ZY9I2(1#R12&S2TCR&5(6)[<D("8JSH+[(T1
M`B;I]AVL#+!^0I1[U2XBKD-!K$^<C*&@09O=MCD62<BY:QEQPIU&'$KS\>4J
M2E`9`O1OV`(^'(_>^O'<LX;4O!_&-><24MO#V<H?R%NH'*&2%O8PO#7L7A#2
M,(4G.5J6&OH7ZT-A[:^QASH3[`1=&]EP\5K"H:TTR^_R\Y2ZCJ.KU@O:5ND;
M`%)R.U[^AW8ECLMI'%.9('R&^.O"F4M_"UC`6#VG]1.E;AT%K[8NO*UI35.I
MHNK1$1LS74-IQDJ;M\K4]CQ-YKIU:E!+1"TZNYEHS]E#3+\E!3K[T:4E`V!W
M$X>2$N[(^I?Z_P#8FL[;K)SF+54+&6NM%UETR.A)$0L8,@W$FWC\J'FX68<9
M9D4I<]K9K"\I3A&%I3C'H$26WZ:>.HOG63UCI'1>JJ)M"(H\C#ZZV`IW947B
M*M+S8+K,M*SD;>9#87X\B;%L?F$)E2)#"?5:'<KQCP,YU9]3_+$+2GA-SZ]K
M^VMCV*5L-@MUN5*[(`#',LAQ!B:W3<2M_GK1%U2IA/-@1>2Y,N1^%C#SQ"GU
MJS@(<IGT2\'5W;NT=HS6IX*<SL]$XP<.!9=Y5N=CPBIZ#DJU$Q\Y'[M=!BHJ
MK14)@9*(Z/!=*?)((<=QA];'@3[_`.ZAOKP]SJO_`!\7ZO+(6O\`^.WO/VX4
M2Z&ZYAI/^3?:PA*@48;2C"4M)4XE&$I==PL**_81]/7(@/,5FG-*4^Q:CV32
M5Q<Y1]GM;2ZJOKU$L4&S+JI4T338/8-JEKK"!W.2#<DHA,:>J3']4_'\R&'6
M0S^U;*^V_9]%W%JG7-JY+%WMJJFZ<OY4MK*I;4K)]VC;<>1;(N!UW8]Q2$IK
MN&M%\KU(D(PM$T`0!".2;67<K1Z.X#)#:#]R>=C:F7';8H3->_R!,[`EO[C>
MU]8==0>M!]:G0@7/NZPZAK'6FS;A>2[T>/,"7"J%C1>5BNB$`-M(:>."KW:A
MO8/0DC5-+[NWESC2M-:PV_KU_?XG*=C[%U1O6;M5N*D:MKG6E5V54Y)]ZLA2
M[\TL\YXIM0;[8>6W,LH3@C`7RAOIEXWB1X=DBR=ESSL5\62#)S[`>UGRIU3;
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MHKYI&$+>;83EL45#C[V?D=Q_"4YSC'\_\/`Z%+NE>V!`-V:KEN'0[DK8X5+[
MPI(3N)*IV.6JDZ.L8QIDAM0<Y"$L_P!2<>[V>['KC.,^!3?[`A;(5K.A.5BZ
M677AD1LX"Q%6R(BZ[-5QJ-A*K:R9*M[#B['%2+95,O$>IV'(P(Z!()6:A0Y3
M#F,+P%!/MYTON:8U'G&K3)6V;IFK)R_!ZUV#8823+%'(J?4E(V-.4-=>UTU1
MJZ>JS"5UEO(,D>#_`'"@A<>@EI7LSX$PZFZZ^T_9$-)I%^O_`)[8F:G^MBIC
M^_NP+AJ:?L)^)"4@)*P"Z^9YAV<W48PN2@"RV0G[!(K:$4A""B7,*SD._M[L
M'[,])4VQ7R[<&\JIK=<CY^0>.B^\]B',D-P%?797LOD(X=P+7`2H\,W&)"76
M!&C.!+P20SAX;+X0-ICIW[9>E=F3-*CU<P\OH;J,9>JD+LGEGH+9+5H@2Y-T
M*P#KMHF^->0,:?3OE!91[DJ_>NE.$"H;%:]?`MU(5[[=H".7*/;LX<MV1F@V
MR(.L<K[D8FB<DM1@1IT;^\Z]BHU[,44@@[`[A#2B&'<LI5\K3>'PHI&;S^WQ
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M[LH91C_3&/`C&1Z#K4_))J-&.EQY>0V<YJ>/N,E1K$;2B;1`I>E+W&0LMAL4
M21-A(2(DA6C_`/=B&IL?\=Q;V6GF?`PHC3^Y)W9J;N]:=;R5?RJH+@#MA:P_
M9[#IH,76;6'9V(L:)G(:M*GK+89,!>#EM,Y"CT%,):=RZTMD(X30N1*.F?H<
M[=;EM1N,D)B::UI_<MPO,/01XER+N9T/&4+7`HU;KD8(>,P[\DD+DA;IV!'"
M5(+2.L,]F=N::JK0Q-1TH'-W1B";S$UV.#TY3I42&CXL1\=DN>M=LKT/`Q`3
M5@:&QA96$MK*]J$92OUR'C']%ZM.GB8W:ND$QLR0ZA,*Z\?I'9Y%A)0*\ZS'
M--5.ZS\R%.8C0DNH8*':0XPMO#+KBO>AL,HD3.><1DG85R\US]([$+R#BRM%
M2.IIN977G&IET^.2<E$*^,8V^YG):AUI.;^925+]F5I#%FN7;7199QG5RM=(
M&);OUAC=G3P$V#N*K;5N`<9\ERFRH`D*N[1K\_-8/-G(EU$(A[+Z&Q\H;0E*
M`D+4.S+2$+)0.R[E$VURFUF&>GIXZK25&VRF<.F30UOVW4<5&2$3'P4@"\(X
M%(QA2QW,)<4MEM&4N>!8UIZN7*OI=8=A+75;+%YRAUI8,Y7Y^%DQ\IS[5HR5
M'2L7(".YQ_&7&G6U?\<9\#2_TGR2GG]K96P:[8[;)Z1N-9B*O/58M@K8E@J(
M:+(98I7]-)V&D7.#US68*M1^(N'GY#&1H1@QY!CZ,?AE"AM,YNDP)G1FM92,
M`&BP3:ZV^P")8Q[>,QA196%_#9A6V69E#KF%+P_A*<J]W]6/=C/@3?X#P'@/
M`>!3?MQQ?^,*JPTU=2GE;/JAS(&OB'V+5)/0S,I+"QT8D,"3/<>*-$:PG+33
M>&E8PXX0(VA1+8:-)W;U=T_!4;%]MUW%E=7Q^K+%;0XBVKC;%MA-3/YVV#"Y
M-B&460H>LQ%:JR!XD:3/",B9,AM#BWP""3L!F$#J_O(&GZEU=K#1>PL5VG(B
MWYB#MEHC:T"W.T/8E7MX,_5+'-U*M0D8$B6UX^J)$>?99=_;Y?<CL)6EUX,T
MC^*_L(AIQ%$`V7J.39IM.G@JI&2<Q`$GJH=SE9H205ATV%/M$;8<0<,'$(D\
MQS<9DT\QQ*%,MML,A$1E9Z#TQ3+E`;QU7L[65$'I[M.DY37L%6-ATRHERK-N
M``)&M5GKN#MCPA,C>,..N+E8#XGT8"&PO+V'6PX]3MP<E29Z<U_)6*MRQ(,'
M>'JZR[,RVR8Z7,MG2$M*3,Y697GEV,M%]L]9D&HG$9F7/B9<O)T<(8.W%1A"
M0G4:O0D7=9^]46?M\M!W"K6]KXX*#_O7+T958/J8V6CIB@BZ'I]J$$"Q:289
M+KDK,O&2;:H-IT7XWSF@S8ZM#`S#YK@+R[FS$64)]<9I+8UYG8JFO5S8)7]R
MR50CM%`X)#S84EH1/`99'GVG%1S+K+I*/:$:2&KQ)FRG@8BR*1.`Q]%;:V+(
M4R\:NME;:.M$I;5V874L)ID><N[LY,DE)#8+=Q!NRKRV\!)D(MUXL*67,4H.
M5`KDPVU1+',2^T;'7Y._5VPP<9,F%:Z+30K)6XC\'7LA1@B0+*QF%&E<%.IE
M7!'<N+0R4EL+OYTQ_D9FKV*8YD[ZL;,;6[(&S*!]AWEJ(GJ_:9*)ET1<>7#-
MP&9^HV"$;92TY'M#Y9"'2*AO*$,9\#LA:*NTN$56YSEGMXL6QO,3%A?O';TU
M+M*(47-&!`STIB`EC)!\HN;*#*2TDI[(>6UG*]%KSX&3?XTN$7$FQRN5^]9A
MJ5L!+3UDQTQ`_LGRI`0V'D;'D10T65+CV1K9DZ>7B;CE,MDM+0Z@=+[C*0[B
M#-X.:TM6J<<K]+J<EY6^O.![$B!+H4=,7B?VNZ$?!;^I=[6-#R*@=B1"ED.U
M)`41%!FM.'F&X2TT&4VF4LQF;Q'`<]=GI)GL;6F8N7_QR/8H'$Q?[W<CG[55
M(ZQGER=7N#,2U%JCWWR(DF,`-P'CX<H(^,#<M-A;*KEAB-']969JOW/=UP%;
MONB+P%7QC[9;"2(4ZK8A9"1>B)5NJRK[,;@P4-M\4XU9+@YBW!B`P>*"N;>Y
M8*WVWG[I]-6BXS7EL<&@=;3;^O:_+P&EX.GN8FZLW0I7;.P+K(;"`!>R\*:,
MI@"&&>6D5ULA!(9)2I*ZT3X7$:BZ`UZX1KO4@!\EKG2VUK4";+4ECF.L6P&;
MG;E'Q-Q@R`PM;SD>E+2WV2:V#^RP\Y(/,L.A"[%QW-#:XU0JLT_HF/'@9>;K
M4]6H/0X89`F"-:Z1(U<`+:-P5^S2=JA('9E%R\9)/9_?'I"?=<:RPD-3H9/5
M=JR#5'JSMICKM0[/)529(O:\Z5V;=WSMKP4CS`Q?F6A:Q2IB$A1ZG-U>5#>%
MBSB1G0652BE>U"\8"00]W:>G$LK@+?<9P:M1!Q3YZT[$M`T&'(<X637L+8G*
M[,5!A4V$],J6AH-^3::*49^\+?::_P!`C#>.V:@8%%_V2_O2US6-[4F0)K$;
MJ2T`Q-BB8B#V9"I:=US=K#7A8:KPUGML#,/ME2H3<I(#`'"J;:,7D8.S4]T4
M:4TT4?:P*["7F;H?Y6PJN]I[>XE<,VF7MS=5QO=9Q!5^C3`'YT?<=B!2LMB'
M+>_&(?R\EU\93"UAU;%N#2#MP#L5=V&BDC6#_P`B*ZU)P>J[<#`R$%-;(ZV_
M21$D]L\(*IRD;9;Y<H8MU^++&7(/J9>6^+$NM/X#-X'8.M#YW0E8UG*2DK,%
M=IP=CM&0&9L*@RD<]8]^@2-@BS%1C%T$E6YJ?'PK]FMX!V0=80-E4:E#Z`F^
M3XF"Z6TAI6^4V[,04A:^?].:NDXJUN1>T*'6]6QPH$M(3&N5$UX&>8V8*0T.
M^%(Y.&%?)&2I]E"W'EJ#:W4*TS3JQ!5=B7L4^U!1HT:B;MLT78K+*_CHPE1T
MW-FYR3(R)*O53CF?;CUSZ)2E.,)P&1^`\!X#P'@1?:+]-5_86MZ@!2S[+"7<
MR>CIZRPSQI"]>O1E=DI^*E;1'M0ST>+69QV,S'(*>D!WL2)([;3#Z5NK9"C-
MG[7V1$]40.JP*$+BJ$7UG3ANM9"(LA.YYZ3F156`#?M<,KXDQ6(W2]8@`'UR
MF)'#6<BO-OI+;)^./>"_5#M-ELS=G9M5"EZ')UJUR5=:;.D(V8B+5%C,!'15
MQJ<M'.8697YD(]"?86.$<*6R^.\PG+6%N!$-XZ?J5*N4_`NQ1Q]0UY%,R&W]
MF(*'8JM`E)E\&/I]$'PE!)MJV19Y*6$RF(%2WD4-]#KKOS.BC$A%7:_7$MS9
M%0$76`J1&VFV0]CL<3=-QRDA`:E!"I"`Y2<KA9D-[YV2NUCCG,BQ83:1VL//
MI=<>5E"!2`L!IS<9>S(.N$VRB3>I+E:JPF\Q^L[48'(W&*ISRHX<:0MF(1!,
M+7I=TX_XE1V2WGV_9GW9]Z7FV0FU6582K*4^Y6$YRE/KA/N5C'\)]V?XQZY_
MX^!4O:W41&J^>AMRV/5URK=HEI<6E!:[L[07Y$#?):<-JL3BX3<`9+Q05#7.
MBI>7-BN$L.1CS1+:5?(E'@8#S/VXQOZNFF9U^<\?1K\SJ':%CUO),[)ULQL=
MZ59B6%4"S5MH_-JJF&7FI"4(=P*]70C1LF)5A:W$!?3P*_\`5#I#//6U7!3K
M+'.IK"_<53SH&-LV&%&AI*8AS;*I,.P48+E;/JYZN92YG#.%/9;QD($Y66:]
MOSHC+Y\V8S':KY"A/8;*C20+1@^L[%+E.DY#>?C<VDQ,ZA9KX*UB/CX&5A:L
M_P"@7-%OM,.N<IKL.RQ)-WA84*Q2M89*0N5!A9$E\,20?'Q_TM.$,93G'KE:
M/<C*\)PXWE0:W]RYG0)WK$@XZ3_1YM/,)K.*W37JO.@C)V1"-'-"SC)V!]BL
MN,X:4IA[`_SJ62._ZCN-9\#8U<MC4/7G]M?WS;8&J9N-HB:354SDB.`JP6R=
M<4U$0$4AY:5&21RT9]C:,9SZ8SG/IC&<^!`'1XY9.P>7VAXM,DPK<8BY!::2
MBWO@"A#LRS1N35(<730V)"-86Y*I2K++J6D9]F',O-!S\8ENFZ2?><*68E&Y
M.D!F'7S7I4Q`PG0FS1F1S9EX@G,R0*AKX_R4Y0EQM*?1MOT]F`Q?E"8C6G=O
MY+EXG+CET@$)*.CX"&M!^&J%6U)>M<E!X;A+1+-CJ0A!H;CS&!4-->[WMKQX
M$Z[CV'5Z5J;8UZD9^3'AZ/3IVZ31E+EZD/91(2J`NSLN3%$VP\*LLO,QX#F5
M9->:']GNPI2?7&?`BKC+:%6V9S;K79T//NDU_:[%KVW47K#(U+$P_1=F7>S7
MRED$#U6<G80-C^TYX3XF&BWECLX2V_G#Z'4X#">V646*IZ[1!EQ9AP]QG'F'
MA9=EV7#RO6=ZRHJ%@O>N/L9'X[;B7&"O1EH?*WD^KK;>,A('7;62*#KII:34
M`KZ*YW7)F@BO*(C0F=LU<C!>)$4P.1K_`+C&FF?RQ\.N^KV&<M^QY:D!R:79
M`9W1O]U`"H^2*;J#AF#7IU$PZ&U<=QI`?,C3H2&A08LE3CS\<^+\[QHSOO=>
M>;0.\L,EW)<ZA9N9MQVZN6J+GZB3J?:&$6NI2L).1WP1]?L$7,%Q\IC]I`/N
MPQ8CZ'<O8=89>'6EY/HA:?`BO3LK+F[,HI0TY8IZBV#3,/+TDMF5076I2NNT
MG5:\6$B55*X!OAZI3#F<G@!#8%_8LY4TI)2GDA;R-L4!-%ST?#S45+'U:41"
M64*-D!#2Z_,NQ4;.M1,T.,\X]%R3L+,"%I8>PAS(Q33N,>QQ"LAJSIQ)&&.(
MDGRMFK:9/<V]#X.(#M=%CFXFBM7R58I5`(KK3(\G(P(L.J(#R`@9^8AFVG&)
M%UDI#CB0V&WB<EY&S5W6=;*LL(?8(Z9L$[=(*&@)0*J5^$7'B8!++FYD?,-8
MK2=+IQ$NHBYIO*02LO,(0G#F`ECP("OVS8BSZL_+U/,,7@W9DE(ZSHLO2+3&
M#,(L9)TM69Z<8L[+S[08VMEQ,E(2;@B"CAVX@A(X[Y*4,+#QP;8WH36^K*YM
M.RS6TMMBZ[AH24+@F,.V#8)U-CH-B^WAJ+E)./C!8X`PW$@>:8^S\#+N/<XI
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MV$W\1AW"VA5DK6TE*\^[P*WHT?M;44U4)K75YE;15*V%=C;<#/3<\B:L#_\`
M9S@U73+4R$B)6M7\@ZSK(D94H)B!L!1ZFGDD$K64V0'<JVQ]>]#"BP$ZFPZR
MVS-U"Y5>G;`@,-UF=DFA\,`W^0TY9B<R9P,A5I^-PJ0KLZ,-8(8H/"92)0E'
MN6'GZ:M;>E;GLO7^Z[Q7:F<:X';J<`[%C4'5\C`#I9#GIG5[TC/$@D9;?F(I
MNRALL1OX]C(=)2+\4BRZZ%S"AH*UP98);,78JY/QQ0!HKR192'F(F08<$-$(
M;5\PAP)@SJVW$9]R%H5G&<9QG/@5IU!#6+2%]DM)&.8?TP?&BRO/\H<?'9/A
MS'"[7*7#3.$EV.3MDZQ3(H-B0C#'A!Q!X=Y`+:UY#SX%K?`>`\!X#P*0]X0&
MU+;JZKU+2?[9C95HV'6H>"FHF&A)-52921F7D+>>79:G;*W'0\0U$I0?B2:_
M"+`(?'RR6^X.,X&/\C\*Z/T97:[<?TP]WV<:A5A.O=B3/&X!E)1U,CZU"&N"
MR)2I@`.NN_AI?]\HP@I]+Q+BGG<J#,87=FFM(U:YGIV41<J+(&W39>O71(Z#
M'K;PQS%NL,SJ_7.PL8@J;L*POV>DV(P01<B])L-D);?<_&0R]D,``ZHK'^2;
M'L/^R)$*"SSW6;-*R\HT3"249&14_;I9F,F9.4'8K7SY3,9;9!9*R<T?\S3C
M:E+:Q@,SJO8>D]M7X:AJ?*KC-?*;./E[9/5`&!_O=BRK@Z=1\D1,]8867G9\
MD$Z0"&R4V_A<:VII"W\*PP$$=V\>:@L=.M-YJ`Q%.VY81?QH>H4*+CT';UGH
MR'E%L:^S$18XMF9=MD<G\2<DX0D,UJN,E9+<5'H+3D-4A>T+L?;WM.[THT7L
MK9>K*;M2CXI7ZRL4U\V(S"[XKUNV4^BF:L-C'8^,UG*1HY.2DJJN?^W+8R1E
M:W``]\F.0X%*DDTF='I,?L#9DY9H_P#34:0@9.4EH[:F98IVY6+2!E>G8>!I
MP<8`U#1KP+X\8,0I\?)`;Y[P9">&;&_W`S"ZK#B,Q16OS;C/"1@SUOS-6,HR
M(L9T5AC7T[4'INQ4PU$>7\H8Z&S'B1\88*]I+(3KK-"S,;GC->Q\Y1&&H+7$
MR>.-3XMO:%N;E)753CD!6*O9H6/J$C23(.7!R391UF'JEB)(-G+K@B<X#?@.
M..&.P((PR***RT.,,.TA@<<=A"6F6&&6DI;999;3A*4IQA*4XQC&/3P.;P'@
M/`>`\!X#P'@/`>`\!X'6>##(5[GQ!GE?U?U/,-.*_K3A"_Y6E6?ZD)QC/_/&
M/3P(5WF(^-5ZJ=&R35>%B-I:VD99X6,2<6=&JML>([!QP++#KQ$A83C61$);
M3[U9>S_P]?`BW7'2^C:!S[SE.[+W33:XU>]74AV`E[M8ZW"GV-(M<@QY6<,8
M#D28X%@$PME,H0AW,?&E$H9=>1E;?N"XF,X5C"DYQG&<8SC.,^N,XS_.,XSC
M^,XSCP/[X&(7R_4W6%4E;O?K#&U:JPB&%2,S*/9:':664R""*TA"5OEGR)Y+
M0XP[*%OD/NH;;0I:DIR'4UQLRA[=J4?>];6>-MU4DWCQA9>,6[\>#(HY^,E(
M\H8EI@V/DHV0%<8('?;:?9=1E*TXSCP,Z\"L]_VX]/W(G4>A=KZ6QOBG.QUB
MMNL=@$'F.G4B1&)CC'\CU\UBP`D094B)(Y<&:)1EQED$K\1,@V6R&9:8*JAT
M;9WH6W%W^RQMPLM:OENEX1$-,NV2)G)*1*J^$_IH=:ZU2G)]8,,UC):!H_#:
M/R27<ND.AA6WW];:XE+9N+:<+$UVH?V77:M.[FB9&TB72N1/]T+>7#23E8A\
MR%6H@I!>#Y.<:EA6$M>U!C*614D>!-%]K\O=:)9JY5[Q-Z[FK%`F`0E^K`L)
M(3=8,,'S@2;BQ+%'2T,4\.I6%82\PK"DYS[5-K]KB0J[I_65?@[K#TR^MUJ)
MG-9QI\KI/4\7/2\X('3(V2G::9O&9E)H,62NNR;\F7;7-?F$R^:_DD1&7E&%
MNGGA('1-;V=(C5>Q:OJ>F[=)0)$@S*IV^)8C/[2C#_PG';U1A:Y7K.7,V:MI
M"4[^FPP(Y-I]C")`-2<*<#O<O0^M0]21%CUC?R=N1E^+*N%@VV?))DY39-P=
M0/`S]BDOA;&`AB1WX%,?B(#&"#A&PD@,C#H&PTD%VL<U'V,5G:-EI>K]4D6E
MJM09V;`PN0V=*S@(F("MS9<_$L0M7C9?+\F"]'HRL\X\<)09R,O9&4&<;DU]
M*;3UQ8M?15Q,HG]TM"14K8(Z&BIR036GCQO[GB0!9I#H(9L_7\$`M'>Q;L>X
M1@EI.76D8\#PJ!'Z;@S?\+TA58CUZ9AJR*%JX%G\3^SX`@84BI3J8.04X\:A
MQR/>0)-M84VX0T2S\N262?0(8,&L/(TG)V`!<W;.5I4XV7LL!A$G8K9SI*RL
MD.^?9*NAML^9LND3##BC9>/6IPJI)PL@+#D5A8L>&:=3+KEUY:V,0.FI7.JV
M:H19X2I&5<=IUCAI*1AS`3,2\'DI9<6>*ZAX=T7+GSX4CX\JPK&?`HY4>G"=
M&['V7<MG4D6(;N.NN;1!JZWLRD/6(\Z*IUJ,4%KB(08P#L`1RONDGJ=;>2<A
MX0EAQQT=`"LA4#771'/^NMR1>SIV$N<L(+=KA<]?0;]JHD:=5KO;`Y6&GWY.
MV1%A_N/<!LQ69%Z.@PIO\8`)II6$M9RM,@L/5V#V'J:=<Z"DQZ5.U]K99^L;
MF8R%;!#CU-:]NM+DUO7R,8NC6(L:RQDF(RLF!+5',#.!*4^EPGY,!CW9.\>>
MND;B!>&K5+0N:NFKZ?V%7MFQ%$N6OHFF["LU5FY^1J01,H^?4[C.P<<J._:,
M%Q&'W7$M-'M+:=9+"WLAO+7]Z:Y-;ULY/V@/3]HJPT%7"MA59>U;\RMZO4FJ
M$E5-N/G9@V,L0V52[<I)EP<.0`SDW\E:<M.LA,W(>Y+1`ZRK%.>TCN288E+E
MO^1!N(<<^=5&0XS=EQ:2&>_-_J9JI'E8+SD>)(#0,S\3C(#Y0C3#[@8MI&;A
MQ?[G`/YID]D_$Z7)Q)<#'4RZU*HLP=%@"RZ7`%'N$FU]V2<)4H9A]W.9H\A\
MD?'QO8\#S^L]?4?H[FO?//#_`"KL>E0.S-.S49/6*"K<'KA>8,T&.G)JL-V>
M-C#9)AR3COF$.$%9424C!`C64/K0K`8/];^O==::XSYIUA2^9;Q=8"$U/KMN
MH7&YB4*WDRM,V9'REJA$B7Y\05!U<BXPQ:7AW77TQ#+S0N7R&<COOA)/4*:T
M7$UB)#Y[G*G`B2EU9N<ZS7Z12:`FI@T.XC#QMWV)EA,I5X23LZ8]Z,S'M$I(
ME&1$OH2POWX#.^EMKDVNFZW!FM9[,HCK70//-BC6K`[08PBQ%5[=VO26*@'E
MZS2;"I&WY=?$;"6A!)0XIJ/]C&6'W`@&Z6>,L=.Z/B42FQM/5W:KX,-$2^LI
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M0#)18DB"IF.%M,F9*#8$8*<]KHJ"G$MN?#E/@1:R;7=`?N#;SL@P\*\VH.+U
MK0Q(,04*J5^(B&V`*3K>D5@0F9EQX&%"*F)L[."GTL-DEO9&`%0T.$;:/UC5
M-E1ERVA>JW>I]6T[&^>7%[OAJ@0/8X&`.*3KN6AZHBN1DE6:9"P)S@L+&R(L
M<:Z,M9LF$N2*>*<"YW@/`C6W;FU#0),:%O.T=>T^9-9))$B++<:_"2A`H8ZR
MS"VH^1D!S%B"#-J<==PCXVT8]59QCP//@=^:-M,S'URM[BU?.V*5^;$97XJ^
M5@Z=/4.(](/H$AQY-<B0MJ/'<(4E+><X80IST]F,JP$LXSC.,9QG&<9QC.,X
MSZXSC/\`.,XSC^,XSCP.N8PZ2,\PR80`ZZC*$&")%62.K.<?[C*31C!,KQ_^
MT:6G_P!CP(0O_/\`J2V`VV1FZS)ID9>5@;NY,5J5L(MEA;E1L$%URWT+$<=E
M58N0CKB_>_%M,/2GR*9,P4VXMM01;KNX";YU@U6'=GT*P[CKK$I-5^<9KTC'
M2L;+U.P2E8A;)L35,IF`EJY:(.VPJA;76T.LM!R;#PGO82MM"0Q;GS9%SKUR
M.U_:])@:JJ$E8)^.*G(*1L\U%2N_9$E-GL[,5`N@E-:^I-OBB7)H'\MUD1P@
MQ"6'RGR7?8%H=Q:BJF[:.?1[:VZT,^2!(QLR"!73INNR\86R8'+P.;3"6*'%
MD4?$IK*W1'DK8=<;5C*5J\#5;5]/Q;Q>U9E5,D;,=4[W28H"D2=9UF8[=8BP
MFRY\G5+091]?1KU25$RCI<<-,NK`C@OC1*/D/#K4M0;(^?=-0&IZ\8;!KF!5
MWL>OV&9@9)=)*9A99$2VRX,+)TRL5X>5RP,ML53ZE/M.H%0MKV^Y>5A8'P'@
M/`\B7L$#7TB+GIN)A4'F#QX*Y:1#CD&'EOM"B!"K,>92^644^VVVVG.5N.+2
ME.,J5C&0UD=0;%M<CM(C7.N8:+&G'(Z6O8D#<XLZGQ-IM&NL1X8.P[&;,W'7
MV=D0D3(QD?"P=9')%C[*LQTTLMV-B74H#73MHRCU*EQ+%,EFBIC-+<JE2@H2
M^/$3,-MJY3-DK>P*5;[[#U&DI5J,$2U(;I2JQ+TNF.-PJ8R,R@(M9+08&/O]
MIJK0%#I5:##D"H-VOK&?'=.+`$K&VF+U88*2IEG`"'$N$I6Z^\#^U.M/XC!@
M34BA]B/6EU@,CU'L>DKA*_'J-M^+G.T",NUZL9H#=DMDOM^QR>M[)J:KASQ-
MW=*D=2ZR)H<?'6"Q7UE<:2RTAM,H$6:M18;&^1"AZMN2QL[)D+CL:USDA(QM
M8V)/M2L[2M?R4S,V67<JFJ)&:O\`L6>@=8;"!5E01)[K13$W'&P4@0T6R'#`
MA$OVIZCJ-]"A-U:]MIA>PZO+L:0O<?7)4BVP(L%/C62-)&ME7.3-ZLILG"QM
MLEFC)2PC"_-''.QJEO.$"L>!6=B0UU=7)HXZ`LD169L"UGQ)+_/U2L:H4Z[5
MO?5+CY4_6J]-V"%CUL1;CAHDP6.(:6&[@)>,Q:W?F"7!IB+JQEI8BHBL62N(
M%8E9JTL:OI4<S#K@-?D3T\PY02=1L?W+)!U:H"_ER3@323Y&4Q!"O.%#?%@.
M2M6^CP<ML@]BH1K*ELT0:!E&N<9^3I5!V#&VO0]>8>G:BC7-3BHN6A8>4A5M
MSY9@0@@S32GF6&PWEO!OT\!X#P'@/`>`\!X#P'@/`>`\!X&'[`HT#LRE6>@V
M=,A^BM<.9#2#T/*'0<T$@MK*6I*#G(M\:3@YR,?]A`9HSC9`I+:'6U)6C&<!
MJ0Z)Y!MMPVMM2W6DK:;.NO[0I\",Y4FX&^/7;5KP-C>V#JT5ABB66R5M*+*!
M%E`B#03&`WCS2?VQ0Q3H,<&9:G^P<C$!6*=5>1MRBAT8*K5NW4N/5=;Y>M>Q
MWN7')AWD15#GHJ;MU=A0TF%PY\X!-*&4A2&G5.L8>"30^_+>D49R=XVZ0B7W
MXM$D5\=6D70*\\N)"+3"V<N7A:^3'369$]+7L8&+'P,.41E['XZFE!7W=74T
M3T_0B]?RF@^B]2V**N5<E-:;%7'4%Q^-V1#'V(>*D:8<;(6"O&B&IBWPR#C6
M,1S4-,Y4ZMH[&0FP[7-.ZZ[SQ4SJM4>?=I72VW-:;C=-E2MHU9&V+<VU3`VR
M+I-33!%PRW!C0QRW!TJ?>5Z#MMI&P9CW/*"S3/?U<<9((=T;N\9ED26F4+<A
MZLO\FL0Q:`C)]A#-I<<RK+KF%-1F<8F7FLX<;$4WG"O`H73CM1UKH:&VBEOH
M63J%2G9S:M`U,1/:BBH6I;7W3)W=VVV^7NB-BQ]@NV;XF5)*1`2))&:XX>X.
M2T&(X.".%D-L[(KTS=A.@M15ZT4;>M)JK!9<<=<=1053WW`,U2>/C-.;>+`M
M%GD4Q$(]8?S0#F4,N`2?PK2X\RA;?@6\_P#)&JS$>_'3^O+&E1L<5AV"D)C4
M)V)5YI`RWH5H3&RB&WBWPRL/X;>PA&&?^M25Y2G(5^U'?I/0<\FA1!5MO^A)
M'(P&MZ_8IC6Q>P=4$CQI1DA60[:;MMENWZBK`T>B.#8=!Q+PC_L:R1(!J0Z,
M$A[INND=S5`9HJS3M3FJP;&6^@[2KTM!Q,UK:S*40FN7!IQVRA-F0JWQ_4N,
MD4.Q4R'A0Y3#S2LIP&3T;J.)'K(C.U2ZR+:P'&0)"8JMCJ*JS96&VLLJN4;%
M%W`J:J48=(#O,NQLBMPD`MM;*7BV4MEO!!]EVM"ZUOCFQM!%1A\?=KF$3O#3
MTO:*9%QMA>-)CXZ7V#KHJ0M;4?6=J"1HF2"(OY0HJRJ?403EN1SD@@)WO>S=
M&;EI,U2[5#'VJLSR,A>P`Z`0<@QDE;#<W5IF,M+,G"V*KF-X+&D@7F#HPAI#
M[#C;S:58#\4_H6!@F"H2=L1MY:"<FR(VRLKJ;,J0&W,RQS<3*!BSC(6<URO$
M`C,EI==(D&V%DDX:<5GWA'>X[IKK8;L3>*%<DZRW31&)5O7VTBU5N2@6A)(,
MEB0KE]@A;K&8O.LIAS&5$1SSJ<CFL-&B*8,%:>2$CUSK_7A$&.]>TB5"S,M2
M^+#7HNS5R\"1)$5/KKR&1Y:`.RY)*F7\M.AL?BM&J:=]'!VUMNI0%#MO;,KU
M!KMVH7/4K+W>C;E:'>C-+B+#`,U->Y<O,F]-:TMDZHZIP=`6Y"*7.4YW+#T$
M\_DV*RU^0V"Z&343?L1#=0VV]6*KWI6KQM914'1Y2-AH@@)N4@:[2$VEE=:Q
M*&VVPEQCD<^H6?`&'C\BOY$3@AQ:%^!=)?7VD#<.M%XLSC3*(DI*"*><4LIB
M7")+8.BX]I),A,A!H'<;+)#8?8#7E.'EH2XA2@\EOL7F0E+)I94]'Y('>$0]
M.ZAV!$D)BB&\#9=+3)U$<@"$DE"8&:<(PTP4XVEM'OS[,9#B<ZMYP+#D)#$+
M99!#<;\I33>G[03(%`M2$<SF._`57\G/S#+LC^3^E4C]OAAEY_`GL1E60J'N
MO:>D;9OS0>QJL-;(JJ:KF[-.WVU06J+0*&\7$'0Y'X,I%/4C,Y:,QS%/.943
M&8<>BEX]B\*04G*`F/FSJ7450U?"56T!;#IDP?=+J\P,[J?=$E%NXV!>[;<:
MO)-V155FHP9FSUZ49DATNEMMMLD)0EMGTPP@-.1KO2&MK^BQ:_ZAW+"4J1Z0
M3,3%HWUT7(TFC4BKC[/HT?0KYLY.T]15^1VO0I?5C<G59*MC3.<.2ZPRVOR`
MT(D(X/(N.V/L*KYMUN=&^S#GG-*M.]=B[/J^K=MV;7AD>)IJ@[(V#8]8\T`;
M&M=,;P;/=>:NV#7&V9!X9+%2B*^A[#9ZC,J2&%#7+[0=6.D4RW=LZI+CV0:_
M4!X[_/>KZ#:;3=+E7*+-&ZZUPY,UQ^`H.Q.?MA5*Q&SP"TR`$U4)%,-$/1KN
M0VLAB6Q+Y]F^T8N4O<=T-4^MJ?2"AT0=0YHO.OSB6;A(SNUC1F]HQ$9KR[TB
MY5JD:_MN:G(QT2TF8L3^8"=6$TX$4P@/H9ZEVUKK8E/HL+5SI2QS-<Z#TE/R
M`L?1K5+AUQ=5M,;<7YFU^^MY>C*S"A`_D&EM_&MIM&4YSG_<:4'@5G<G.Q>X
MKZO9L>5(KN#P-6I\S=]);`$C)E^N;%V9(F1D2!)4<JM1L:+\T20Q+()Q_<N<
MC'J5E7P)0$J-[9X:?CY^<7%ZZ8%)BXNPV9V1TO*1QID?924.@F3(,C1!I(MT
MLP[W/(>:4\RZI>7DH4E?H'I?Y]XL)G5.NR>OOWMH<C\%R1FNI%A^5<E6@A0E
M3$T74FVLY=:2PTI13V/CPA*%Y3[/3`="7WCQ>)`V*+:.I##/YK\`9&PVNY1)
MSTXSDTAAL$&/J#Q190Q]96MDEEEUMHH-&<*^1",>!7_3565.T_CFA0<>\(!7
M;5LN=O6%W>O2<E4HL6=DKA&0,S"66@@6X@;9/XR1U1#;$2F*C77FGL.K'&=;
M#:LM:&D+==6AMMM"EN.+5A"$(1C*EK6M6<)2A*<>N<Y_C&/`K/2;!2-GV%MR
M)N9<J;-_H=QR57/&B&)2+JPA)%=UM'R59G:@'88.M2<G"%2PRW_C/_<`/+8)
MRSA2<A@Z9FX[-Z+='8K&RXK7E<"*KP%E6U*P5/(16IF5Q=IL"9B+Y"/MS\]<
M08^&";5'OG)C8H]Q3?ZV2PXX%TO`_*U>U*E>U2O:G*O:C'JI7IC.?:G&<XQE
M6?\`A_[/@5N.JFQ]YPQ`=]>F]/ZZL$!8H66UY79C(>TS2V;RPJ`GS-GU6;RU
M6HB<I,)C+\/'MY,PB:=9(,2MC+?@=2M7+GF%GYD+55*C;#*Y@W#+)/:EUO\`
MNXPJ-;$B\YCY*]P45B"GYA\507_N-0>5)+;RTM3'QXPO`?S9^Q]$16?;NC7A
MXT*[(L_/9+IIJ6L=/'DEUXI."Y6Q#5Z?AXMH>ON$C.GEN-",-?(PMY.,Y1D,
MNK-/CZX).VS2TZF<AK(\9-!TIVWLE:S*F&@`H7&*W*MP]I-ID8G]*AO(42I$
M6R1EUS\3Y%.>X,TU]<RK=`QB[)!MT;8"(.'D[KK,FR5^R3E&.ED$I;!D3JZ:
M6$8$^2`1@(U'L:-::RM"4YPM"`SWP*@]*7>Q:ID]>62K5`:10;,RK#T\S$.2
M:X%P89^TV2&S$P=7DK')%;5@(DF-%_%+2YB=;CW/QR?13:PPS?.KJWM(FGWN
M#VUL?7U?W5&UJKY)I$U'U*+GY=Z$GK)J6U3_`._DX:TA2\3-N!+C\0;+4UDM
MH9HKU!00A`6TU=;3+UKZI6N3B$5^5F(AAV8@F[)7K>B&F1U+#EXM-GJAAU>G
M/P)(9UK\@5SV.93ZY2VKW-I"JU[J=5HU[V\?$QW]IDWN3TE>YZ9I5<<%FWE1
MEEF!;):9.9^$J/E#T#1>,J8P(X\E#>??DK)J1L!=.$=0]#1#S2GEMNQ@#K:R
M!E!/K0X(TM"G@UB`+$>4G/JIK+#.6\^J<MH]/;@/3\!X#P(HWK6W[?IG:=;!
MK=;M\O*T*TL5^M6X44RMR]F1#E/5D:79-;='P)_<#0RLKRGW-*3A:<X4G&<!
MH\^.9JRM@0MNTX/9ZB[#4=;MHM='I^\-;W2NZ2K<CI6A5[+ER.$DM<&W-C6\
M_(BRCXK4##_W',._$8:]DIT->@;#TH45/#.6NQK+9&A'#8*1)#D+["/Y/E%4
MXT:%:@W+Y7V28)IH*)``P<D7#<0$R,T,M*`X`(8XB0@J^^&U&VR%I-CFYB0#
M@HRR%1D01KROU!R2&(BVIJT3C\!69<8XEU*(8E)0KR,+*,0@CP,KADR+LJ:Y
M64#2V&1CI^.DLU"=AZP<"+!1(#<9:8:/DHDJ2TZ9(5L>NSLDVR^R5"RK1)``
MJ,XR@-DNP1PI>PUD&TZNE[W;+=5$1,O?+7IC4='T\[*1]PM!QH)R8&="N,U/
M2F_BZ[/`#C)GWUR@*$@^KD@6IP-L<5K#6L]SUG75:H8VO=>72@F9:I,57FJ6
M]`-7,!Z9-:>@(E0?ZB>;DI5QXIM*L.8-RO*U95E2LA\R^E]?U"WUYB/LE,$M
M:ZC_`'[\\]9KO8HN$MLO.1.T)KVT^VR^M;.#/.-<^-1T=@<:2=E:^,CX4M`Q
MPQ#HH2(9IB%*V/..YK566R4%KJ+LI8UFO]L=(<:FK?\`*W^_3H,;7]:LMV#%
M'S+/RC?YB""$.F^]GXOE">M)PUNJ4KLN$K.NZ<V'-ZSU?);&,KVQRZ-=QB47
MZKA-R=4V)8-/5JE'KD60D(D8^5RB>EATAXP\D9J.R4'T1^`\!X#P'@/`>`\!
MX#P'@/`>`\!X#P*<<KDDE7CKE3D0;$#M](V%@;!%*#J0DGD>NUX9Z8CY$2Q3
MR[JV>IG&7)1Y`+RW4Y9R.VEI./`N/X$`\RXD?\2CKE7W2#G=@;G<=4[8$VC+
M3>=RW[`HK4TF.B,$#!");9:;4*PX.VA+3B<N(6I03]X%`^P^Z">6ME:#TW4N
M>-G=)[5Z(A]VSU(HNKK'K*N2^8[0U8@+;</>1M*X4J&*-,BI]"0!F2E/$D(R
MWA./=C/@5ZV7]NM>T?79\[>/+F\]6W:H\;;H[5MNJ9F7U;,7>O:]TONRL:4.
MKA2ZS=IBL%6FY'6X.6AOQY%T)Z.4K#S[#Z<L^!D$)]K5=@]J06L>EN2>I>/0
M[95]N6NJ[(WI&Z?<U[/C:/H\ELS80@1NM]M7R>4?&T6%+DFD8C\J?:85Z8QG
M'@1CK7[HZELO_'RP>'NT(9C?.MK=L;E61DJKJ`R%Z>=J4(';WZ/K>PP.WI>`
M@;W*4-PF:$!M!4!ET2.*:]V"VOQ\A)?+?VF+ZCWU8-"0_"?9FM9#7MN+U[N:
M][&K>G6:!IF]-Z_8V;'UB]2=2V_:I!)<W5Y.,6,X$*6S^1*#M.*0O*_:%N^Q
M.M]7\4:<SN?:4+=K1'R%[U[JZJ4O6E=%M&P+[L;:=KCJ91:;5(4V3A(\N6FI
MR40E/Y!@S*&TK5E?\8QD*:1/VXTF;9V/&@</?841LG4-OIM=V9IAOGJMXV93
M:SL6JV.VT/:<J.]LQBGN:UL@M4/%2:-,$/"G#K:)8:_A60P,'[NM025+U+?1
M.(_L8<@M^V:NU712/_':EXEMQ2=FH=NV=&OZ]B<[@_.L$6BB4>0DGRT(2.PP
MAO*U8RZC&0S97W)\^B4_8$K*<^=G5_9VM=J:.T]8^:Y[0#</T&];>D$3[^FW
M("I&6]NMV&'N0U8.<:(#F7<LX8REU"'/Z/`]0G[9*="TFX7>Z\,?8YK=FLSV
MKZE`UV^\Q1T!9MJ7';VPPM95.GZH"_R(2!;;)_<$@TZ4-DD?+("L$8RM&4^H
M>UG[.*Z[4K%<YC@3[*H@.E.UTHN.GN/9,>=5^\$L[I$E!@_W0^F1&JK$"XF6
M)'<RV'@X;^M:'_7`2=Q5UKH7N>J2.QM2Z"W%2*._%UZVUB\;HY_>UA7=I0U]
M7+2"+%KB9D4E,6X?!44IR06E2'6W'V'%I5AY*\A<I6MM=K>')70:6L@0L@\1
M]56@U/"G%B?@%&CNY!RMDLD'_9<<3G"UM?T9SE/\>!T'=1:G?5A;^L->/*P*
MX#A3M*K;BL!.H8;=#QE<9G.!7$#-I4W_`-&<-IQG']./0.'_``UI_P"?)7^*
M=;?E9$R!DG^QJO\`/D'*O=D++WZOY,B95_/Q^OL]?^'@<2-)Z9;=+?;U'K%#
MQ[8+1SR*%54NFM1B<IC6RW,1.%D-QZ59PQA><X:QG^GT\#KR6A]'3/QXE],Z
MIE?A-_9,_LM=U`[XI'\7`7Y[?Y4.[[#?PL89^7'HY\6/9Z^W^/`QU?+',3F1
M,N<YZ(7D!?R`Y5J+7^<A+RXZ[E0N?[?]1U9=?6K/L]/52U9_XY\#]N<O<UO-
M?`[S]I5QCY)=[X%ZOI66<O3S[I4R[EK,+\:G9,AY:WE9Q[EJ7G.<_P`Y\"OW
M1WUR\V;_`*.)6`:'2=3V"(G0K!!W6BZUU]^>,2+#SE==CY:)DJ\1%6"%(@K(
M8VVP^C"PC/QSA'!S0Q7V@I#'?0'RD*-+,2FV>C+/_<"*^=,,6*V4LV%Q;*'J
M^1TQK*T0M89H0U;ADT?5\EF#S$X%=A9J-''8E!#$-9PL,/G/_3VZ(-7=FX?I
MCI,4';4[>K7M5JQFZ]M1Q-RV1,Q]XNEVU1(YI<.O3=ELNSZ]%3)J`$%0[C86
M1&P&FUI<:"\O(GUIZ=YBTG%:5M9$9T$%77UMUVU[$H=9&M$?"/5.O5,N&*DP
M\%&RK9XL!A3RGGO9['?@0VVPVVW@+1N\L\YO(::<TOKWX60S(YH=%<!:'1'R
M#H3QL>D=I"&<`$.1S/JS[?B]$>F$XQG.,AV1>:=%`,NC@:V@0&7UCK=:`5(!
M(<_$-<D14*P*<UZLCFO+<0W_`-"5+5Z8_J5ZAZ>=!ZC_``51N*:,V"L[,BX,
MS)SK*'2\Y97E3N6I1"W6?D'0OXE9RU[\95[?=G.<AZG^'M=_(X]F"?RX\<B2
M=5F>L>?E-;-7)((<Q^W]JU)DW%%8QG'M_)5EWT^3.5>!W&-7TH7.%#1TB/G"
M)!&?@LMH:PO]K(ORL@MU*)E*7GBCR%N*<7ZK_GVXSA.,8P$1P-.JX73Q94.9
M9!#Z7HL5DJ$=D9X^N'L[0NZD#R[[DC.&!+GXI&F\L-?]KA]`YKN?ESAU2<A)
MVZ$3#NI]A#0"9A<P=59:-`Q7@W3YU+TF,N/RY#BL-NNN2339.5,YPE7L<QA7
MIG&/3P(GH1T6Q2MY6BC`2<4-"GV.A5,(Z!&CV6&--UINBQK%<_5DCD3D`]8X
MDM8:\/M.>]Y;"<,K1E*0Z_*==!&KUELZ+9-W`]X^.UBL^9E+#(.1P.DQ7J(1
M%.?O+!-)=FUW(>:/EBDMADO21SS)2%O#?(H+7>!$6;/(V?;)E)B"*N15:'!`
M2FP$./3V+@+=)PL&4U_'1B1,"0@\0W"QIIDCE]TAU[YPVT-);R\K(<$5;8C:
M\_L>I-1(LE1J+)?V;.6-%APC]E>$1PIUCK0L?$K^9(5<C9AE@YX@AA6#EK82
MRKXEN)#`("[V>9@&Z_S%K.ABZWK@L%!TB^3\\'7M32L`W#Q[[9.L*]00)Z3L
M58A!B4!,*RF%"(('=0.]EEM#RP]DBU]`:_KTW8KU3JEM<6)"C"_UFD1IR(NI
M&$OQ8U@_54RYRDH%/?B"J-D&669IHUY+;83(Y#ZL.K#]1H,#K^*(NVDPJQ(Z
M^L=KD[3?XF'G!68GYY`T>+LUHJ14G:8JB4QN%D4&3-D:0UA<@^.4KX\R+RU.
M!Z-Z!+;G]>;DHTRTY'"OA1EX8A(2*L+&P=86)A[`#S4C$UV:MQCU5FSAI6+S
M'E)%4RLM+C:T$9=:"=_`P/:$5F9U];1&PX<\QB&)EX@6PDS8<"N?@/;.UY<T
M56T.S[$4Q.1P[A"@VW2,-)5[&W%>B%!2BJT6P;`Y#N%,NY)U:35)==VU7?;)
M'NI.CJLQ^CW/KN<6V7)J.!>IH<UFNE^_(3B&HUYM;#;:E-Y"4N/IG4;5=O>N
M-'R]/1K+65GBHJEZZJ\-*P)6IJ[-5.$F44Z:CI)]0["<V!V2)CD!L#"-QCK"
M$)<]N7W0_'6<J96VM?R0<ZU!-VR;)UN>4587(849N9%S80I-;3;1CJ&`GJTM
MLV09%-<BHT@@I0ZVFG%MA:BL+RY6J\XHP:14Y!Q*U2`<@F6$.RH`=63!91`@
M")(8K.?>@C##.'DJPO#:/7VX#W/`>`\"#NA=3U;;FK[5#3]$IE^EH^OS<E3(
MJ]1;LK`HMP@63Z\LY@539V0LS@`JGTLJ2XMM'IC^?3P-(.T=,8D]/,6D?7HR
MKO896$NS>.2M33$>G7YD>!:K#'#7/:%TL;=>DZ)32]A-LRTBAH.50X+EYN/8
M4U_M!22`!G2P:N5#K1881V.J4A&'U6?U<XB4DWW762X*@RM<F+!$8"*N\K)Q
M<9EQTI#DFT(T,1G#F'6PQ`8H"SQ\R^&$K*E5R/IH\A&5LZ$:$BXW6AL''C+9
MKTTP4)57@*P049^>H,MUX!M#26F%/H(#DEYDE()$C@0J\FD0[H<3"4"VP<D?
M*2EA(@=;TUI<=7[2^9#K+,M8"9AAE2A1@QVRB"W$^];07.1!Z:B*=`_XQB:/
M,;&_QF<:+IO9UYO$=L9=1A7K-T,[4*UC7]XOIU**TJ*FHR[!BU3"CV+&RN2=
MR4:PO`;E&N2]"5>@)L-NK\K&2L#1"2[;,QVUMLUX(9QB%0?:"V7(6X1J(L#)
MHSQ/J.PSAE2E.-H0M2O4-#>B+96:UK@K]3.P`HY$3L`4TN>JFRK0*/,VBLS4
M;,U]YB`AXFEQ=;E!%GIQ+E$-R,B*$G#[*02"W,A)TGM&.DBV3X6'B;=#3"*]
M#66:"H&T#J[2:^_.S1^S"+5KZOL7(BOUVA0$Q'OGE$#1QC`9,:$44..VA:`E
MC4NRJW,YVX`?8*0Y7Q*[J()4J!KJ\Q-")V2_L>I(DM;R-%MP>;)+WN/BFQCF
MXU"W"XA@D9PL5I(["E!]"/@/`>`\!X#P'@/`>`\!X#P'@/`>`\"E7)K+36P>
MR'$,@#.$]+3;SP@=O8LCHZD5>NC(<-BFENN5!^4;'P?D%Y:G59+R[C#;2VVF
MPNKX$"<UE"$ZP>0(9$&?A;,W@`2J$`<BP1S!MTW[#XBH]U:W!S!LJPDCUS_N
M/>YS'IA>/`GOP-3GV"_7#7>^^C^(I;<--JU_YJT8)TZ]MJJR]SN%5L9DYM/7
MU6K6N9"J(IZH@YUV(E8<E11&)8-QAIW&$MO86OVA33M/ZA=B6J"MFI>+ZSJR
MC:6_]U<;^XEHT;L#8]^.EHRZ[KZ1T_MQW)1DE&6VQF5X.!H<JO\`8%2[[[4A
M)-)0.III25!DUA^H&S\\=1:TZ0^OHBO5=VP:3VSH+;M?W_?+KN<C4']]U[)-
M5WYS=-;CSM]^N[!@;:&*%.0*FTUZR0/N:?:2M&4D!6S@[ZR^W]']DZ'V?(<T
M<I\?5/51EJ=Z3V)S'U%NR<H78XMQUE8H@P6`Y#>K%5U+JUG_`">>'85X_!C$
MQ1;*FP&WV/3P-N?$',VU-(='_91MFZF5DN@=9=+4K<NFU5VQKFG?[6B]'T/7
M<J].@9C!&(:6*F:FI>,-$%MOBY:5[DY3E/@>K]H.A]Y]'<N':ST50><MQ'F7
MJDRFP=']0`S3>NMQZPB9;!=HI,9=J[EV:U3?E+0.=!V8<8MR,-#3E+:5J2ZV
M%+?JKY/ZIT49U7;+-IF=Y'TGLZG4V*T5QU?.KYCL.YTW9=<;OF;ULZ8VS/&6
M>/JD-?WYN+8"K\?+R00[(.2G&QB'W6E!W+A]<^\-CZ*^F?3EO><C1>/)^IS/
M3QVN=UVG6=@C507*E]U(MW6EVH@==N\@:U?+8UZ.Q\G"^^,P0EQ#R7L-H"A.
MVOIOZAJL=T)I?7VM*QTOJS9O=_,W9D3NJ_\`5&PM?].7K76KK%)RUFYTVSNB
M6;MNPL3^MTO-L4&RQKZ%L@&DK)=:.92LH))L7UR[L?YMVIH>@\&WJJA7>]\J
M[%LE?V!]L&W]TQ>PX?4&^8Z7M>O*5L^[%FW[G>S@T!Y^3'L5?$&=)<0D;U6X
MPTAP+N\-\U;8T/5.E=9YY6W#IJ'V/K<TJME[#^P:;[=IQMKB8(VNPM3JF-M/
M+MVOW9,6?RX0MP1465@/VOJSAH?#@6Y^K[4&SN?_`*\.-]([GK::?M756@->
MT6^U=$E$3"(.R5V&9CI".;E:_+SD&>VPXSZ)=$)6,M/IEM+2?1I`7P\!X#P'
M@/`>`\!X#P'@/`>`\!X#P'@8I'!59BX6@R.80W;3XJL?W,ZG\["R(P14ZW6E
M.8=S^O\`]M3AR<*9QAS.,>CF<X2CT"(.HFS']8Q8P3%)>=+V]H4=S-_RZJ"&
M&<W50\DECC-L/I,GQF4Y5&MN?&S^=AM3BTH3GP,9FD_C\W[0]^;:A9EAV\HW
M"H*J6*TP;DOM2SY.5$0?[26K4W_;BBUN1J7WUK?8896^TA_*QTA(/.TX%:-6
M1EE$GJK97YNQ7PF:F*3.JL57>LHMZL4791(N2R\\U[XJ<CWQ"F6\-ML&,/-X
M;1E.4X";_`@72)=?EI;>D]$2$^5*G[NL<7:09Q<HEF%EZ;7ZM20@*^!*LLNQ
MT`77:\$>WAG*Q"R#7BV5901CT"-P#G:SR2?(N"B7=R1#L+MI:OK;M29GV[K?
M)%N]OV`"5<0H,MP:<.<R`W[&R'TI&%0AMQE"0MC$1$57XF,@8*-!AH2%CPXF
M'B(L1@",BXN.';$`CH\$5#0P800K*&VFFTI0VA.$IQC&,8\#T?`B^CU"O5>4
MV-#0:ZXS!2]B3/D4R&JT5!#04E9(H<JQD22P4H382[E*Y>D7R'V\+4X0M&<K
M],Y\#Q=?V5^/T@-829&J2KM8KEE1DNMX!'J?LII,Q'-"#,5;$H''C1S,0D=\
M<-#JA7&EM);]Z/CP&?T.>)M5&IEH,5$*+LE4KL\4JOFNR4`HF8B`Y!]4)(D,
M#/GQ&72,_C/K;;6ZS[592G.<XP&5Y_TS_P#2]?\`Z'_'P*AZ1IDVQ6=X`S4(
M7@"TE1`L2&465`HG@_\`#5,B#B6J"IQT_5?YT@ET=P%3C;RUM9)PPSAQ*G`Y
M^.I*^EZHKL9?-72.M7JS3=?5V$>/NP%R5<HB+JXXK%A?6*P.8'*(PS@8EPM/
MSE?$A?\`2G&&T!FO0NO!]C0E&C&S3(*?CMC04K5[8##0\ZNKRK`,NA\HZ-FI
MB'8,A)F+6_%G,(_*R4,<IAP=QAQW*0E6FQ=FAH4>-M,Y`SYHC0PPYE=JCU.!
M2*,&,/AO,0[8[*VAQ3[2UX^)UII"%I;2WCV>Y097X#P'@8Y9*K$VQ@,2:_.>
M!$+46Y'C21P`4BK\4@9MB69"?8Q(B,+?P^VTYG*$$M-N8Q[D)SX&JKH^D5S6
M<R3KS7%TL,#*OQKEIJ6M:!-WR`JU'K`,R7=YC8'0MJ43<(,RLLV8RQYAX&43
M#Q]I$?S7@T*<80ZR&N>V<O1,P3&V#4LV<='LS;,*)?9FU:FAVK71+>W4+"/9
MC8:;LM;@QE:]L,X0U(PTDIG80A$C7&U"DNMDGRP8/*Z'VM-6N((+AHBCNS5)
MKU@G9>5$ASZY7("W4!FH1TB*]#0G]OPI@ECK1L/#LCK8;6-/ME)SEV/94L),
MIU$7#3]:N,G6J,]+5^Y$+1L2<'9O>)JE5RFV,V7U'6D1IAU*VQL6.%4_BHBP
M#%MM#+*W%*:#$=;E$AL-Y_TUM^Z6G6IHEUO\;SI#5"LS5B8MFUGK?=Y6WU^R
MW5K.O@KEKZP!1-PA[>+B&EK2:2J2A4@!1L-$N&C9+>%#,.\YF2T[K>2"A.@Y
M*C0NRA`Z</KJ;:K;P<;70!X"-LYU$GX]5>VC`8%J8;^2G!CY!UATE1`Z@G<8
M?2%!'HK5ZJZ;5+#)UFTQL6/LQF6FK'-Z?627=PM4[IJ]R0JR%Q`\2PS+BDX?
M1#)6HZ$PWDE4@E+?MP'(J-UZ[(7H0F/B3QI=4]4ZRZ/6-'SDE#J$KEO&GLW7
M?T;#)AZ4)%-5:)?.C%CX&K1*_P!D<<:R6SA`>MK:$I[AVS#*O0![`6]'ZG?K
M)=,JVILSM9N,?;Z"6N>D-UT*L5VEUTAQBIH?>!)$--+?(;>1(K;E0D+#Z(/`
M>`\!X#P'@/`>`\!X#P([M.U*34B"(\^7;,FA6DODP43[)"6$94E#B'I%EMQ+
M$.RZTKWM+-<'2]A.<-Y6KT3D,-5OZ`][*&*7LN0R_P#.IK]35FY?WM,J+2V\
MC$9)EJ=0;@3W#X1A2WFW6EI3E#B59#I)Z,KZQLEM:UWX\QB,7+^K.D-@N._A
MM$I#?9_&3#Y*Q,,$JRE49E&)/T2I6!\H2I6`]/.^8#`Q).:%O#VBKCFG&L:1
MV7DE;LH^2P,D8?%<RZ6AO(N5$.M86R&VM"GUM87CP.O*=%4:%&E#Y2O;@%C(
M,>1*F)+_``;MXD6-'BHU^7->)0'3""\--QH^74*2TK#ON0AO*G%H0H*E<^],
MZXB<[@V',25Q(USM/>"YRG7H725RAJC&QEC3%TJNAV&0B:VXH)^1F(5M&9.5
M;&60\>S\RDY7C/@3N)VYH4I^$!R[MD>5L<2'/PD*]SUOI<O)0)_]K_BS8P`N
MN"7EQ>572*2Z]Z82*LU*'_B6AU+80OS7VIHHW7A<8G-^8F86\[0=L$)7]/;C
MNOZ!,UN?9J8I<T?4M4MQT3*23$:LLN+>3B1AOF2P?ZO8^9X+"'=>Z-C")@0T
M_93+\":='2J<:!W\^D<N._'R4VV\/K%UDQ'H6C+;C"G&WTYSEI2\)5G`=A?6
M^B4?'ZV&VJ4[+/P:&VM1;B>=Q)#*%20VXRS0ENM#L?FMY40O"1TI]RLK]J%Y
M2']QUMH7(8YW]USV&"V"B1TKUGM-!3C(?Y7S9_`72DG)7G`+V6T9;PMU+2\H
MPK"<Y\#E9ZRT&]'_`+3-U-$"]Z$*<DZ/L*)<1EQPEI"G!I2J!E-MJ<#<Q[U(
MPG^,?SZ93ZAZB^G-$-LRI"]C1.&H5]0TBO`<TKXW4);6K#"4QF5'(QAW'];&
M'49SZX]?7&<8#O`]!Z,='<P%LBI-,`X6RL?\O`BAUC?AI4$D-UIEY)2,'-82
M.E'RY]<^B<^Q?M#(`]R:H/RW@?8M.][Y#(K#9$_'!/$%/A!2#8X[)C[#I#^!
M9%G*DHPI2%+]BL87A2<!R-;@U2ZRR1C8]);:(7(('419H@3)'ZHI0<@L=)1;
M*WF1B$^F7$XRC.%)5C.4J3G(<:]SZ@;:4\YM/72&4.C,+=7=*XEM+QJTMAM*
M6J1PG#I3BL);3_JO.<8QZ^!_'-SZ?93A;VU-=-(4XEI*W+I7$)4ZI7M2UA2I
M'&,N*5GTPG_7.?`(W/I]QQ;+>U-=./-.Y8<:1=:XIQM],>W+*96A,EE2'<13
MJ2<ISCU_'5AS_HSC/@<HFX-3'X2H'9VOC$K2\I"A;C7B,+2/Z_.I.6I%>%)9
M],^_./\`I]/Y\!C<&ILI6O&SM?90V"B3<7BXU[*41SB?>V>M6)'T2$M'\X=S
M_1G'\XSX!6X=2(RO"MI:Z3EMG)"\*NU:3[1TMY>4_GUD\>C*6DY5E?\`TX3C
M.<Y]/`X/\UZ;PKV9VUK+W_D8$]O]^57W?E9QC.!O;^U]?R,X5C/L_P"K^?\`
M3P.PQM_4I2VFQMHZZ(<?P]EAMB[5IY;V!QFS2,M);DU*<PP&ZEY?IZ^UI6%9
M]$YQGP/X)N+49Z4J!VGKDQ*E+2E0EWK)"5*:)9#<2G+,FO&5-ED-M*Q_P<6E
M.?ZE8QD.1G;FJ25+0/L[7KZVQ'#W$LW2MNJ0"RXEIXU:422LI$:=5A*G,_T)
M5G&,Y]?`[CFR]<-8<R[L"DM89RQAW+EK@D8:R2O#8V',J/Q[,D.9]J/7T]^?
MXQZ^!SIV%05N+:1>*@MUM]0JVTV6%4X@E"L(6.M&#<J2^A>?3*,X]V,_QZ>!
MW![A4B__`+%M-<)_J0C_`+>;C'OZG6,DMI_VRE?U.#8^1./]<H_JQ_'\^!R-
MVRK/-I=:LM?=:4A#B7&YF.6VIMQ:VVUI6DG*<H<<;4E.?7TRI.<8_G'@>TT^
MP^TAYEYIYEU"7&W6G$.-.-KQZI6AQ&<H6A6/],XSZ9\#^9('P\D?+[.'U-K>
M2QEU&'E--J0AQU+>5>_+:%NIQE7IZ8RK&/\`CCP/Z@AAQ;K3;S*W&%I0^VAQ
M"ELK6VEU"'4)5E3:UM+PK&,^F<ISC/\`IGP.7U__`"_]I_K_`/`\!X#P'@1?
M&"3P6X;:\Y*#/5:;H5-*`AW/:J1"L<3,VT*;-87DCWXBC8HJ-3\>&?1!#2U^
M_P!7/;@,5Z;0E.D[=*.3IU:'JQ52O!LU'BR9KH<91+K7;C+)("AGF9(N+,BX
M1Y@UIK*\K#==QE#B<Y;4$:C1<#8](]/:U;ICJX:#LNYXQ=?KY8RCKDF\QG^7
M7RHY.*]&A1\A9CMA.-)0E@O"'_52WGW<N*\#/^<)BK2%5M@=9!Q$9$V3=9J5
MAU20$D\,5L.57LX0[Y(V.C`VQ)N+N3!;&&D/->QWT027C&270L+X$+UMYNL;
MBOE;DK=$DO[&"C]C5"IJ9<:L`8E<C8.EW8I1/X:&#XILM,2IKU(<=942M'QH
M;PE2@Q6N4W7H,5;.9+&"2;7)EFVS,!!V%V&88LE'LLJB;L(%;1`1T`XW&4:>
MM&`,(^-908Z@UK)=<<RM(9V1LANCQ+1&W/UE4?(FY6-C387%BL$$9%,S0D77
MY*0D&X%+=</FF9,7*@RG%X:?6MML@A+:G,!_#]QT]UDD2DF,['M:X*S2T)5*
M@6,:_+FUH$8IV#+GE+Q6JI('OGCL,9ERPD+<=S[<JPVY[0PC%ML.MZ()*WE&
MOPMZ;9G!V(:E!S5C&KLIL&6"$C:]3!99B+MTY(AU.#`&&E9T6':&<'`?E'0@
MF5.(:#/I:O&5W54K7:M7V)*47"2`Z8:.4.(R?+V!YYV>-2M$O26TY*D),DQW
M+)D:XM2E?$IIS*,8"2AF&11AQAF6QAQV&F!QV6TLLL,LMI;:9::1_0TVTA.$
MI3C^$XQZ8\#S+)8(FIUV?M,\6@"#K4+*V"9.<]_QA1,,"_(R);GQI4OV#AC+
M7GVXSGTQ_&/`TW]`7SHBH:!K&XN<`;U+V2%Z#JFTMUT&#%?F2;+K'5'-O]P[
M2T/;;E?!)289;NSU-8K(5C+>_)#GRQ,_(MA.49"EG(VPOL[TYM+3\KT]%]"V
M&D0\O8(3?-3H6IXG9T2!7'W^OW=80\,BD4.-LB*M5XK.O&63T94;\`K;I&%-
MG+<?#O;TZB[[_P`0\UU'\3?=/V/_`)LWN'T)/6[GJ_U1,FR=-;%M'/<11+MK
MK2VW$Q$`!"PR01YJ(AI%G/XHK<EA*S4*6'KU^U_:O1L2<2A6VPV]IVS=UZU=
M.E:Y5<I>G8E.OM/Z[KNI-G5\^FR/X8%)U2Z;.0-B<1%!2M5G2W'V,%Q#KZ`[
M-W[P^P2*@M$[.H.H.GY]FAP>BXGH+1=DYL;K=PVQLK7^L=SSG6E.KLI)5=;X
M2I$B5J+D-.Q"&:Z?.`M@QI3Z2"VVPW-\,6W?%WY7U58>GFL,]`.,W"(VNAFK
MN4Z-_NZLW^UUDY==@WPHTA-0=;AT*ABW1V'9**R.8M"5OJ3@+:>!33M>6Z0K
M%#I%TYGC):S6JG7YV7L=&BQ`3&;S72Z!>8$&"FFWUIDFX4>YS$4<ZZ"E\AAP
M1#JF76$.I\#.],SE0W/1[<NR:EGJM.3*S*1MRK;8UXQ`S-N0,(2`DF9&,#<C
M;?3K-"'K?`RA;XJ`C%#+;'=0^*T$:WGE:RR5X*N&N;-K2AQT74Z_5*O4$ZQE
M,BRC$.[7#77MBV6MWVK6"Q_$12X<2/2RH=(,6$L96'T%.^@0)*<+7H6%(J5'
MC=35V)11Y%JN661FR9:WU.]?W$-;@A!BVM0!*FJ-:9E]\.SX4\$9)UX$(#&,
M.Y6:R$YT?E\>N6\9S9,E5KH/::4_62(R$U7(I'9+:$E<3P9&Q;C9-G7R(K)\
M8<*D$%$M$"L$1+2F\NO$+;\"4-U;DU[R?KF'D\4.X2T:*S`TNG4'4=$EI]0@
M(*Q(:'#9C($)4)3JC7F3FL/EOY&$##3_`![_`&);\#01M\;IS?FUKKN+^V;O
M'PT]H78!,:'FV6!`T/KV\:VW[$5]R4IL&\3+53^T<T=E14,F#DBK80486@=@
MMX>'P'I7V!Z--E)[6\O5=Z80I&P[Z,4-L>]V60E:QL+7_0T)^$754%LSE3F@
MXV50YAK`RVK,-'2(@D@&ZEMQT.":K70H-/OKH&F>HG8UV1N=5M]K'V#L(U0\
M9/4N+B)B1O-.36W;!;X^(4%\\N."^TA8BG&15.%XR^2$NTX38^O`MRS.QM9V
M.NU,B'T_<;S';'_NTV/P!-;*UF/.6^N4Z#B7;K:;-6E4X?Y'BL1D9"QS0C"<
MNK$/;6&Z!OJGGMT9LQ.U*Y@1UDE]!+G[%ECXPUI0_P"YUX%"$.8PK"TH5G"W
M&L_(C"F_ZO`]'_R2T@K&,M;!BR<9C@I9/X8DP9[X^38R7&D-_BQKWR?L1,9>
M'0GU6\SC*T84C'KX'Y+Z5T4"E*B=DP*,+)4&UA*9!Y3QC4H-"$AL(8"<6^6!
M+FLCDM(QEP5UYM+N$96GU#MXZ'TJIYH=.Q(%3K\FU#LI2HM6')-]\,5H)*\"
MY;^9PHYMK'\^GR94GU]R%X2'3,Z5T;'E_A%[#BF2,HD'$X_$F'&G&XMHE^0<
M:(:C5C.H%9#=4K*5YQZ(SZ?\/4.B5U5SP%F+P5MBK,?NAE&Q:G'3$H-$2H]&
M2FE_B>S\?*XLC&%YSA*LLJ],Y]/`\!KM+EEX)<BG==/2$@,J040ZY(L(_##=
M6P0^GYP&U+2AUM6,8QC.5>G].,^!VW>QN71R5!E[QH`1"2PP/8?,8`QDV00E
MT(5+AC3#2R"D+QE",*RI7KCT\#T7>L>:!UR:"MYZR"_3+=:E'#[9%`L!/,39
M=;=8>),?8'P0FP`/!?'A65Y*;RWC&5_QX'-']5\SR@PI8>_-1+&-=2R&Z]?Z
MT)@IU9)`F&Q\%R+"GE_.([C.$XS[<-+5GT2G.<!X-PZ@TZ157T:YVYK6XV^P
MDHK5.B:KLR@NR\A.R%@#J&2(M19,P$XJ#EI%*U^\4I"EMX:PTZM:&UAKFTS>
M>(-HE7+9W0_26H]H$7?:T-6Z-1[I/YI</#P%8::B]<A;/UW(_P!J0NP]AW5^
M'Q.&S$W"Y!-=P`V"WAF/%=4%GA3OJJ"<.K\<'Q(`Y9GK#2Y0")@-0!*DW`8A
MF^V.`D<QT<SGVM13S<FZVZK"<^Y+F/5?IX'*EOZJ,%2T9Z<),O1"':M-!N*T
M:,**F(9K,\]"GMNY;"6J+;FXLG+:_=EE1#>?X5G/@<C41]6=J,;D@BN*)(R=
M>CYE*XJQZ@:7+E,ME$1DHX+&RC*3S&L&..M/+0IS"\)<QGW-H4D,(WAKS@?.
MB=U[#U]7.6)"9I>NKC=T6&OR-0^.(D6:LP>S9"Y>GFYD(^05&)%^"0PK#Z!W
MF\)7\+N4K"V]>Y;YG8_MRPQ6B=:1I8`4.3#*:I\*PN,2&RR_&_$.P/\`B-/@
MXPG"5)3G*?;C&,^F,>![T#S7HJK$"F5K6E=@#06GF`#H9!D:<`P1'BQ#S(!H
MA;1033D2`P)E+2T8_%8;9]/C0E.`HGV>+"\U1&OE:4U!2Z&BU#2%6L^])6K6
M4_7FK*72(VSVF)J$RC7I^;G`2FP;):#68PL:/)%?---2^MLLQE_`9IS/*SM>
MJ.M(G=M3VI7Z_L$;\K6UIV):;/FXUR5_.#B(O6&X"2-ASTBJSS+4AAZJEJ^5
MT^%%RU,9'F&%+/"=]_<W2U_I[3^H-B6O56UZI)-6FB6'^[;S)5(^=C<%D"5S
M8=719F![)19L@C+1P_\`#J&5>K6?Z<MK").8KQK;=9-RUKL&J3.MNF]..`PV
MZ]5YV;?2Q1I.7AHB;?N>NSW;4@RU:JG"I[*(R36RRZA2<M+0CT:6Z'9VIJ>S
MZ<O#&V*9%[-V[J`^%9KNU=.B7C8-KOM>:<+:AH2Y:'!*MX/R+'Q8"";7&&%N
MJ?B8]IZ)2@T?`IP6O)UC0K,QF5'3*K<-$PV+(BVNV(2S\;/X[+B!$S:!<.C*
M1_4A;?\`*TYPYC.?=CP*]T`)$%9@]3;_``/Q]ARDF45KW958L-VAJANEL`*3
MD'#(Z.18'?[#V7#1$>Z1+5[YW1,M^AL8\^QE\>/#J[XYRO3%2!L/.UMMJ;K3
MGBI-[75WVOL<NF[@C"1_@FJM8+$9.2]CJEA/&QE<9-@N)<#/2A3B5-J6I(>'
MS2WH7I"@F6FN.[LKUEB#2:?M+65QW;N\:\:GO@3$?F9I5FC#[PR9%R<3EA&!
MGT-M8='7E:/;EQU&`CW85?<YLOTI/[CN.Z+%S'<),>2%VA';9VK&N<V'1R6S
MGP]MR8-X#99T<ZS%?+_<167%1Q1#@\AZAO?,R%JIKGBNV*IRS%,VMNNKGV*/
M$(@[M"[NV38%QV4_A&19\8/,VV3ASHQU`C>%LX3\1(SCB?=CY<K\"']+K&L4
MP]J+=4EM6@]#5ILF:E8,/=FUFZ;M"%C&(V'*VGI<QZ\&.S&M)%XYA1$20O$E
M7)`C\>082M0Y984/H.RMSS?7*=&R+V^V@RY6[TN?TL9MG9J=E:LUG$,5-V$Z
M2/VDJ:C];6)BPOV7!KK8LM+H;:(:BHL91@9*G0V([+YY9JFL]B6.%W#TP9,U
MW7=WDH)@KH.^,M_LPJ>7B-6X3^Q1A3[!P+9#;Q&7<((RI2_<A2T*#QM<<QR%
MIU?KN;L/07385CF]=50^<4#M`7*1[%+Q#,I/'QZ9"J$?KUEEGJ96PTAH/+#*
M$_CIS[\K#.E<DQ?ZYZ.1N[?7L>E!Y)))EAH<X6,EB,5&KCQ7+'KF8;8!-RZX
M01Z(^=\EU2EN93G",!Z3_+<4^0`3_EC;#3T>>86EQI.J,.$BFXRR["DNKU4M
MW]-B/]@>&FU-J4(TAM2U83X%+;?KYZL5_;*(78UL"/U_NS6NK*BK`VB"7;"'
M;8_6ZI.&DPX/4$7^NDI!VUG.C^LCF1P:XV1CX%?$%X$"]*?W1IC:<)K^L.S\
MI7:\%7`)2M;>K6K3I_J("8FJ,!'06C\U7G6Y1UHFZ]DPD)8,LJ-=*GB!4%N`
M@82^<$VV3440[L^TQDRY<!:Y_P"+W_D98V;GK7F1VZ)N,7/DCU^J%A_XAL8E
MI_M*'%?'/&0VH:')P)[2#52.,CA%/1(<11-,:P.I,9JFJRF[:!7K^1<MXZ.T
M_%Z6@%UNI8OA$?9<Q.J!);%WMLD..VD0A;#Z"'_>&C\A.&4!*>:U4;-'<R;`
MD-61,69T;L,R"L0=ZY9U#?)6N114;81Q5A3\-6($VK4JROH47#S$R(<MZ.DQ
MTFCBNON,("7^>>;M6[+H0U[LFN=`LV1FX;<K;#]8T1HHM`(%;VM88.'0N6:H
MSR'YI@6M#.GJ'RV,[(X6KXTY0C"0F<CC#4Y"I'TAJ2(P?#1L*V(#I+1(XX+4
M8^Z4*:*E>MWE+.%)?6L;Y<N,"J6K+;6,JSGP.,CB?2YA+YQM+U49(%?"LR0)
MY]T*\:8^$RVU&$DD+UYEQYV,6C*V?7/HG*O3T]N,8P%5+9IBJUB;Z`Q+UO5S
MT-5Y34+P"K#S]H:)3++N[(]2EK&1(T^DREI(!CPDX9#D21@G6B8UYGWX"9RZ
MD/6U3R1*7JEP6P8ZY<TN!VV.DI<8:N<FT9=>=_:V:4E`EH-(EQ#),:-&_%5E
M:V&73I)IXHC*D.I8:"0U<9[#$8?9B+KH@7YQ&675+YT!2ZZF)GAB:P$HIFZ8
M);#A*^+\&/C4AK\MU;S3#",)9P!_E[:->J]C-)M7/;I#,85,DL-ZHFZC`RTC
M%Q1\@PB=EW]A33D+7W)P<%9BDH>Q^,.Z\K"B%X<0$/4G9,U.UFBS<F.*&F7Z
M9A=*CL:GL8VWZM'PY`<(S'%G6*%(JHU>?AC)A(YJ'X]2!V&,^C;V<I)6%R8W
M2KE!VYK"]@/YL;(L)L"A6"=EC&`YV.`M[E=GH=L=D.N'DS\<Y.U-#*QW3P6!
M%/X(QAU7N3X%BK?5("^5.T4>UQH\S5KG79NJ66'+3E0LK`6*-)B)F-)2G*5*
M'.CC'&EXQG&<I7GP*SZA4FF6JNU:<L,A9Y&U4K&OIZ58H-_BJS)[&TDTN(D"
M"9.VV"P,PTC:::1AX4-6/9*,Q)1C1IJ<I]@>;K.6JNE-DV^@6RY68J9NVP`X
MFGIM+\:Y&C15C;M=KUM7X9],H7(I!>`:F(&);<0W[FZFZWAII+;:G@N9X$?[
M)J4Q;:ZEFLV(ZK6V#D!K'4I<<P]F,38(M#WX8%JC@7V4V&GR[;[@DF"[C/RB
M/+6RIDIM@AH,(ME5K&Z*\G6NP))41L"M)K-I6;1IPZLV:IVUB/PX%L#6\@ZM
M,Z/$LR;QH8ACS+@I:6BPB4/(_*84'>49O>O3#S'Z*B[%JKG[9\:4:LAM*NP6
M5/3)<5&$P;U<E*M--I9P$(HM$A&JQE2W5,*]G]8>)(VWHV:KZGZ7INDU*P&Q
MLO\``UMG9V,)A)7"!&H%R1C=95R[BS8V2'WGBV6)8;.&1TH;?][_`+F0]\2G
MU*HRD+LK9$K#SNRV84.E#WJ5%8CDB*E\!N3$!0(9P@W-:`M4V'^2Z(.Z0<6E
MIAHD@E`8WQ!V:;B3N\Y_D>7!V#40P&Y:O5.E6&0:B02XQ1JL/7R4J\05AU9E
MH&8'_"%GL.'Q`[.<I8"?++:4$N>!6SIC86N:U2)*I7:U)BBK+!R,U_;D:/'2
M=JL]1JLA"NVR.@8F0D8QA9$UB2%A6'W'/C;D)89/M6I>$9#!MOV#6.K]>:LT
MKM>6H=9@]M6&0JME=CU1NL**F"B8*S;-OS[\?,N6>.A*M8QJ^[&F"O%)0]F7
MRPV6R\ZRKP*U;LJN]+3]9>RXGF8K9<7NS;:TKUE.#W*4_O$"%O6XXJ/@+/BW
M4N6&E8"M":D?9+<)AGVSPH5*EM?(:G.7`U4;,KOV=:/KU1JU[L%RWQ$<GZ\N
M](O^*G?+$99^@I_KS^_)>DEZX;W2ITGHF5Y>'B*\$P?)S\#.-@@SV<Q!6'Q/
MD#QH?4_W6ZK5+:TC+IN"S,5ZDW&\RTQ6[K=KI2MBZ8?TOHJ.D-?Z'VOM;%HO
M.M.P-A;!KMK?AD6023BZ1(>]4<PL249?\#=W$=+WC1^T=?UK?L1.Q'.G0<51
MF-#;=N0;,-8=0[,E8"&`1S;TR\9,GNBW>W26<.UVP...M2<PZ7$%.X,2`LX-
MBW@/`>`\!X#P'@/`_F,83CT3C&,>N<^F,8QCU5G*E9_C_BI6<YS_`,\^!I$F
M.^^W>GNBNA=-?6AHOG*PT+DJ_?X6WCT!UI?K_5ZK-[M"BL6.>U[J:JZG@+%.
MV`6FQ[HX4I(GD!I8D91K*!W&65J>"%]I?:_WWIWE&OW':7!5<U/UHWWQJ#AZ
M8U_L2ZV@7G_9'^9R/PZ=N72>W86!DSIS7AI4K'M$$N!E?KR&S!UX=?9PWX$J
M5C[`OL#U9UAR1H+N?DCF#554ZYN5YU54;AI/IB?VO:P[E5];679`))]0L&L*
M4IBH'#U5\-Q[!#ZT%%,8SZ?S[@QFJ_8%W_UZ1L.]?6WQ1S'>^5M?[1M>J:CN
M'HSH&9UU*;W.U987*IL.6UC1Z1K>TIK]-=FQB`8:4EC,?/F/=>4+E#C;:0QG
M7_W(3VWU<.5H#DB+J6UMU]M7[@KKC6.R+&.U.\Q;?U'0F=@WIJN+`A"<;"@7
M*TVZ7%E.ICFWQ71U+2E2_;D-B&^>E(S4'6_-_,H^FJ/9HK=NF>L=S$V<F2%C
MI:N2N@([6LFU$AU_%8/%>8O#EVRDB264A;"Q4_[+O\YP%"^`_N"TOV7Q#T9T
MN=S;'ZFWQS5K6^[BV'S"8,.38YJ@Q].L%WU+L"GS152AS[-0MM5&+2.'--QN
M6$GM%LHPZTTVMX$I]D?2%DV+I#4?*GUKZOZ,N.R^"-*]O69(?36N]3PNOF=V
M3<C#IK+1MSUREJR@`RT6][3!5-D%H6EU3#6,9PH+2\"=S1/5MUWCS=O'DR:Y
M$[#YR"I!F[]$VC%7O=7)JUU!*51K[KC:U5!14]A4>=0*2TPI&&R!%MK:6WZ8
M]Z@C_IWNS?M(Z]MW(_-WUHC]L3>O]-ZNW79IZ)Z(TCIA=5AMAV"]5J`CSH7<
M<.$R:4S)40M;3T<:3A+3J/>AE7_6&5:E[%O-EW3S#H7I/Z[U\P[)Z1'Z4.Q$
M6/:.F-IHJ(7.D-K.T`2K,GKT`^'M\;?![LRD=0Y(Y,67&.8=96C"'<!/?:?1
M^A>,J+3)ZR:+L6Y]@;0V$)0M)Z)TGK""N>U]L;*+!+L;P-5B2\Q4.`B%@X`B
M5DY60,##`#"4ZX][\-H6%/J;]C];C>@]"\_]A_7%MOC&1Z3LA52YVV7LQK0=
M\U79+E(ULJ>K>M9ZV:]MLRN@[;M$$.2+^B6P2E,AC`2"GU.X5X&'/?9G4+%M
MO:$'P_\`5UO?LNK<^[1MU`VGT+IN'T!1]=@WNFQ#!%TA-1V#8=UK,AM2Z0$W
M+#QY8,>D7W+6\XT^]\:4.AE\Q]VNE)C1G..W],<R=+;]N/2.Z]D\V@\\5*J4
M>O;TUYN/3%;M%IV?K_8]>OUSK<+%2E,!J1BWDLR!#:F_8XWG*5X\"2N?OM$B
M]K])Z\Y1W?P[U=QSM'<U5V!<M-YZ"J^K7*KLH/4`L/,7T&&G-=;%O&!)JK@3
M(A2F2F6L>QQ&4KPI2,*"0^Z^ZZ;QC<=`:VSR9O;J2[=*+VNJHTSG:D4>V6!E
M&F*[!VZR/RD9;+/4T%*S#S:GQFQEOD+P*]E*/5./4*:2GW8<DTG7W3-KW9QQ
MU#SS<N9*#JW9]DTSNO0M/J&RKQJK;VUHO2=4N]#%39Y"OR<"QL*;0$<DH\5U
MA/O4A#N$N82&\1-`H)#'HNC5#+9(;8KK2ZU"K2L/T4M(;J<A90X,C+JO1&?5
M'KG/\?SX%(M%_9MS3T%VET!PAKO^]U[<YRB9"3L\])0$:%K.THK<I5:[=HW7
M=G9G"2;-*:]L]O%BYME(;6(\Y+C3F<*2GW![_/?V,<X=)=3=8<:T:4GH[?G'
MDW$QVR:E9@`8W,]#2X8+S5QH;P\H:Y/5D`^19"-=<;&=$*?8PXWA+[*UAGO&
M/8VK.Z]-E[NU'#W6'J(.R=C:P>`V#$P\/8$6?5-K,J5E6J/AIZR"MA-SL:ZD
M=:B,..)1[_9A.4Y4%F[%7H.VP,S5[-%A3E=L46="SD/(LI(`DXJ2&<$.!+87
M_2Z.2,ZI"L?\L^!W8\$>+`!C`\.I$C@Q@1</D/EO8'$90.QAXHIQXDEW#3>/
M<XXM;B\_RK.<YSGP.3(@JB6S5##J,99>&:+RRWDEH<A;#A##;^4_*AE]P9M2
MT8SA*LMISG&<IQZ!SYQA6,I5C"DJQG"DYQC.,XSCTSC.,_QG&<>!U00`8P5L
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M9`P<C)P\V?#11LS7E'K@)8N/$(DX14J+^#)YB3GFEE1V9$+_`&G_`(5(^9O^
ME?KC^/`]+#36'5/X;;P\MM#2WL(3AU33:EK;;4YZ>]3:%NJSC&<^F,JSG'^N
M?`\FR5^)MM=GJK/#?FP=FA92OS(>7'&ORXF9!?CI$;Y6E(=;^<,E:/<G.%8]
M?7&<9\"#H3E+1M<7$N05<LD2J"A%5R(_!VAM49$?"+?P5D`9IJ[):;:P1ZJQ
MG"?<GW*QC.,*5C(9>SI&C#.H(&*V".^V&R`EQ&W-K.8RRPTEE"UM/W-X=TM3
M:,>]]:%/+S_4I659SGP.4?3=7$'>#&F]DMB$$#%O,*VML9_*BA\9QEY)1-F>
M.9P3G/J\VVZEEU6/52/7P,:FN9M0V0">B;!$V29BK7.C6:U1DAL&_O1UCL`6
M(3\"6E0?[F2*\3'N5J/<'PA"$,NAM+0G"D^O@>DYH6DOJBG"I38AI$'*8FHD
MN0VA?I$R/DDMO-8?&*/L!+[25-/92IO"OB7A*<*2KVX]`\8[F+5,F5,R,BQ<
MSY6QT@W6T],G;(OITS*4.1(>+,J[TH787SAXP@HIUQ6&%LN96YE65>J492'K
M.Z`H3M;S3W"[T_5\1D)#LPI^Q+I,"#`5QU#L,@9<U-R1+)02FF\X*PY^6I33
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M45X0(,#<^Q@XX!M]C`Z\A1(U@:BALH:QCXTI8PAE6/<VE*LYSD/V1SY$NJ"P
M-M+?H`XBVE/BC[EN1"))IMMQM0YQ,H;(R*4/X>7E:QWV'LJSA6%XRAO*`Q64
MY>*D$,M#=*]2PS30S0RT1^RH,G\E+.'DI=)7.TJ9=<>6E[T<5[L?+[4Y7A6<
M>O@8SCB#7C(L7'Q^QMVQ,="SS=RC`8Z[QS;8^P$,L97?5$OUHB1)L+\F*T>X
MT\\Y&**1Z?B?`I;*PSA7.DJ5B$:F>C>A9\.%M58M:@9&7U:.U+/5:2AI<:'E
M"874\1)_I)*2A$+,0,^,^ZA]]E+J!W<M>!9;P*^;`T+BZR-HF0[W.P4C)2FM
M[G41W(>LSD'1-GZT*D%B7N,!/BFY8UVWPS@4/.AKD&VR(@'#8:P7WWR5AE^R
M-8O[&#BV,;`OE'+CA)H1TVAR[$0F1Q,1J6&GRPI`27%P7`S@@<I&E-X0:(2)
MAM+^1B#&"`SVO@2,5`0D7,39-FEHV(C0)2R&AQ\>98)$,)D<Z;+`B1Q(L$F6
M);4^XR,TT.TMS*6T)1C&,!Z_@8'==8T788I0UMK[![AD017W90,J0@K$W!&'
M`21\,):(`N+L8$5(F1C"B1V"FVB<-X2ZE:,Y3D.DW5[_`!WX[43LE)8;$:$!
M[+?3XV:+<?$&(;=E'#*X?24J-/(6TMU/Q8'PEO*6VV\J]V`Z4Q6-LRL84`/M
M:&K9+^5X9FJ[K87,H$A2V/;^.U:+3:89QU#&'L84Z&XG+BFU93[4*;=#)$46
M`?EHFQS@C5DLL&[DN&FIIADQ^`D2(0>`E3JPRZA;%97,@LJP2D+#27,NN>O\
M+5ZAF7@/`C$'7Y.+O.W.2G3)!F=_`8<JLJU%341%"5Y6<0*:V4N(CCH9EXM.
M)0IE>27,R3F<I?RVTUC`8S:](1]TOY-WLLH+8!68^C@5FJV"OART)37JS/R\
MU/6&`QDH9YBY6EB4;&1**SDB*P&RX+[5X<]X3BTTAEIMEI/L;:;0TVC&<YPE
M#:<)0G&<YSG/M3CT_GP*G_X6V'*2>WY21)HE;D-P&4@:Q2]=(L$J>[68!%EK
M$D$&U*QX34+.#T$H!`1S+CF<RJRG<H::2RCP+3QXF0``05$D&J##&$R85\&"
MB\CLH9R23@9D8;!#^4>Y?QMMH]V<^U*<>F,!B&S]:T;<6O;AJ[9=1@;Y0[S!
M'5ZSU"SB),@IV,-;]JPSVLH6M"<.I2MMYOT>'=0EUI27$)5@-0WUQ3OV6:DZ
M-WWS?]@\$7<Z#-Q-7N/'V[=<'3FSM4Q-$J(Q]1G=1[$VC,5JLW16X7(Z/CYM
MV0LH`Z[`ZZ8\V]AW*!O`W:>`\!X#P(@W=OC57.U#G=B[:M\35H&$A+#-M#%&
M"8GK'BLPAMADHBH0;C[4A:+!F,CW5M!")<?7[?7TPGUS@*R\F_8=I[K"8DJO
M%1$QK6XCB"R4-5KI:=6S9MICWCK7%&H@C=:7Z]1#D[`25(DT2,2\0U)BCLMF
M98R$0.0X%^?`>!\PUVT_WIQUL;O_`$+`<<[<[,X3[QW%L#?]6V+RUOO7.F>C
M-&W#<=<B/\N48X>YV"K2N`9.RP^'(J9C#&'8]EUQ:'<NK;88"C%I^NGNR\\2
M%:TV3S;O\&M;F^W+BS:\#H+:75LWV!L[3W*U>@ZM$;3E+WM<&>:GAH5FQ@2,
M@8-'2()L6@_U03ZM?*X%W;3]<)GUA?8;ROU[R/S[MKK31US@Y3G[?%6MT]8^
MD=W\O1:HTXJN;MT)<]L34]>*O6"/RS!K/#@R.<R33RFF&\K?9:0'I\E6KMGZ
M==;[%XQEOK@Z/[#U97]P;BMO)6\^6IC4]F`O%-V7=9R]1-5WO!V2ZUFQZAFZ
MQ)V%`)$RZ)("F#Y4ZTSG\97S!7^?X4[[UCHS47?M[YT'W)V/5?M;V#]E>X^/
M]67BMOEUW5M]UF;J,G6=&G<DJK>S]D4"D5:OEQKR<$FJ)R^.)AQQ2_E"XT?M
M_H;NKN/6/0T-P=TESISQQ]S+V-49Z^=35>'U_?MB;1WQ2M7$Q-(IND@)2Q7:
M?KT-&TUAU4H/\XII!KHJ$H?&RET-;-U^O_HX7Z<.2.QN1M;3L!V_JGZ\;'S5
MT1HF5H<S!6_I#G:^TJ4IE\U1<*I(M0UD<V!IDDM^P59G(JY-PH/(0^',/LLK
M"U-*WYC@KL;G#9>U.?>O;C3I;Z3./](X_P`"\F;8VR]7ME5.]VFPS-1NSM0@
M"\0=AC(IQ"OQ"<C."_+EMUO&<ISX%SOK;I?0N_NYNOOLVWKS5L'D:L;<U'IG
MFSG_`$]MZ0@/\O2VO]8RUFM-CV1L2KPP;CE)(L4[-#-Q\:^8Z0TVT_[\O-?B
MO>!BVV..(#KC[C-^XVACI?6]1I7!_-H%)V/HW;^\.?0[E+'[=WD?:X$^Z:KD
M:M#71ZM()CW,@'G%$@9?2XTREMUS.`P/KB9HOUT]J_5K:9NN]8[ATUHWG_MF
MESFPXS5^X>O=F1K^Q3],)KCMZO->A[3;4$/+'.S@HS.7G(\);2?DQC./`QKK
MGK`[J0GCK[%^/N>MY=`:Z^N_HN^R70>E+QSQ>=7[9F=>;0TT9`D;2TM6=P5:
M%F;E.ZO_`"A)5IF"$)DGVWE);4UE+B5!U-T=2D_<!TKPII/D;GS>2-.<Z]7:
ML[!Z)ZJWKHK8ND:YK6*TUF:E*[KG6"MEPE8L$KL_9$@3^%D@%A?X02U*S[V%
MD.,!C?#O8%>^F[6.UN%>U-,]5BV;66^=_P!_U!N'7//^U.@JEU#J;:^Q;1L^
MGWEG8NM:_8HU.T2$SRH^>!F51KPIR&LNJQA;F6@J'#\?]!;AL_'=\W3%="\C
M*[X^W[J[L"#A='75K7VYN8-5;(XQN$;K9$M?Z9!6N(H]ZO**RP_8QR!1EEG2
MSXA2FC'WW/`MMI;GRW<%_<YKC_RXL/2':E7W]0[7KOZ\NQ-Q[!L^QIOF^;1%
M-%;5Y\NU-AT+J<;+WFN,L/M7YX&+?DFF717,+^1_+(6M^U#5^Z=I_8+]2,/S
M]OB<YJVD*UWP16MOBZ<K^ZZQ7WUZ.HZ"P;74K=+P]9+9GHG!(HS;KF"<N+4\
M.I"F%9\"@OVS?7!,Z#^M/[$>H-N[OVOVQV;NV@<V:ZN^V)FEPM6`AM=4GJ;4
M-KB:!IO2.LP/UE'I$=+8?DRF?R94QUQKY777/5WW!?;;'_J&?KOCM$[TM.F-
MM72U[3U[I2^W:B5"=YVZ"H>;;<(2$4U5JW%2&S]94NLRDO*60P1"0<'8?=8^
M5Q*<MM.*2&H^>YJ^P;ZR.<N._L#VF7S)<&>--M6???14SJ"O;&CM_;9UMW=?
MA9?L2$V?*763'I!4?62KB.<(Z*$IW!5;!?:8%]BTI"=(KF2X;>LWV)=^\12F
M4=M\A_:UMRW:[57I--?&Z0T8SH?DZ2VSR9L(W$:0Y-4W:$1&/NPV3&"4@6`<
M5\;+;;KJU!>?_P!,S90[K]6==NR((ZK2]UZ6ZXM]FJ\DY).GUR:LV_;K-,PA
M2I$</_?CH$T%M66666UJQE:D)=4[CP/H$\!X#P'@/`>`\!X#P'@/`>`\!X#P
M'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>
M`\!X#P'@:\?L(Y`M'3E,KEIUE9BH+<&H(39^*%%KGK36(2X,[&K04)9*M)6&
MCVRC6>!D)42(9:CS?V+D4.0O.9$"0$RMCP-2'!_UE[:O*Z58-IE=*<X:VUU9
MX.PGT6XRHVO]H7NYU&K;)I]68BXW5>VK/K.*I]2A;D"^3,D0:9(R5&5&U_$3
M5HZ,'6&Y?'`FM,&CR*=O=5I,#E6),-2>D=DI$90/(.2R(LF*Q*8AYJ*S(DO+
M4W(#EK4T[^-E?XK0[#(<B."]<MX(RWM_J7#Y1(93Q3G0U^*=6MA\APUG#)9I
M`+0<T,Z@<IEME#>4,H<;PV1ZO9#R9KZ_JK-%A&?^2/845F/+,*&%A=['1H6?
MGA\Q`@Y30\(EXT>,]?R4?*XI9!6/<4HA'JC(<H'`]>CG\$C])=<Y>00`ZA9&
MYOR\99$:BT$A/#%5UZ/<`E'(U2WF,,I83^0ZEI#:,X3@,?3]=L6PV[D#K;M4
M(M\-0[Q2MU"23:R&W)!P(QN.EJB?%A?C*.0MQ@9E@8IX1AQYM:\.Y>#^M?7=
M%L*!P-UKVR*&#^I3F)3OHZ1CCDQDH3)O9D7;%#3DV^]+)*R(4I!K>%A(0TE*
M/9A7@=D?Z_D#_&A77O:9#&`E`OI<W>0P8\WEJ)9R1B8`A0IEJ3<3%>]PW\A1
MRW2'LX>2EQ:,AYW_`+KR(60PZ7VIW6<VQF/82V[T9;0U9CP4-9RG*H=R,97,
M/D(6I1ZVU/+;<RVO"\83G`=:*^O2=CU%K+[@[<EE/.&*&29OR[I:%:+5)9P-
M[69E#BFQ6BV$-.-K9)2D5.<NY4X\I8=5?UWVE2I;&.\NY$LR8\`.,W_G*Q^^
M#3%,1[4I^H?P6E[*K,Z,0Z2X7DLAE9B\#.,-M#(9#RB_KDV`6N4__P"BO=XK
M!_NR.,%M@8?]<EQ3[>0!COU*Y94:((4O`V5$9D$D(:=>+?\`:M#H9E,<-;.D
M&YAL#OGKV%Q,R;1SSHMJK9!`@JD1N3XJ+67`.M1`9C\>KV*$0PZ,R0XEI27,
M_+X'\B>)]W0^7D#_`&%=3DC%89^1N51KJ9?#6(P0&(J),E:H8\/C\0G.2$E?
MFI*)0AY>/<G"?`Y)3C/H(ML8>-^Q7IF'&"%88$RU7=.G'?DX;4HV8//.HKRY
M63.+><5\1"5Q8[64-LAM_&A?@>L1RCT@XEQD?[!-XB,+CW(YM2=?:<?-'2Z3
M'/*D&BB:FZAR70.$ZPAYYIUI*"G%?%ES#2VPZN.4^K!`E(COL;W4N2<'6T05
M,Z>YYDQ'7$L/-#/,!)UZ)^O<:46ZI>6UYPZI+&5)SEG/R!_#N8.P<NAMP_V*
M['`$PZZR<29HG0TI+)BF159CAX]154S#8E%2*O<8:0&^MX?&&VTLJQES(=5S
MFON5A<B2%]C-B*>?,8<``EN:M"_JPQ6YD0]U*U1U>$D75O1C+H>4_+A.$N^_
M&?<G&?`_`W//?HC*_3[#!I$KUB`VU2W+.HE"?@-EM&STFIF*7%/_`-Q%)PL,
M/_=R`P+GW.#O/^CB0]W_``IWM^S()_\`..C8CG1F<#Q__BG5\X%,01-*<<^;
M_("2'Q71R@4J0IS"_P#M5^U:<O>Y`<)&D>ZY`AD*5[!U1(US$D*02V5RI"O3
M!,:RX)@J/4HC8C\*AP\-LAM3V!/<VLGWIQ[6\,K#BD=,=[G54>!/ZKT/9BC!
MW0[*]8N5_P#W&',/?D-^\.(8VF^%[F,.MO9:)0^T]\.&<X1[U/\`@=MO7/?L
M5&)3"[EY?1*.'(+EOBTG:H0>><5'(`?,**%N4E^(=CWIRA7XK^?9'#(4K*''
MDX#SJY0?L>B/8,3N'C[$4U79!3($-I#8D4[_`':;(&N-8*(1L583\8(*H9W\
MID05;SN"6UB9^9D@8.X[7/LU0TVH;:_%3I;A&5OX+TWN=$>,*V[!KP..,/MW
M!I+Q3;,DCY5DMX'P0/\`[;V67,O!["X#[%\%,-IV1R$X!\Z\/E8UEMD8]`R)
MJ4PTXD56P3127GJTL+Y$8<'PB0:?RE>67FT,!US8G[($FCM1ETX\>C\LR&2"
M9.B[<9,8)P%(KCL):"N3K,B.[)Y$;6C'X:F1DNN_(\XI+"0[80'V&X;+=E+)
MRDIW&&%!!Q-8V8I&$*=3DED@P^Q,Y>):90K"'4M,MKRYC.6T>S.%A^4#?8JK
MU:7)\B,*4IE"#\@;8-;90WAX@AUZ&2_&K)<*5\8J?9(,I8Q[R/1W.4L)#L'*
M^PMD=#T:/R6>6H1>7XX^3VI'#(D/UK#++8DN-"'NI`Q.?*0XIP-QU0.4LI2A
MY&770Z[;GV,-L$9>'X[)-^)YH=+).X!8W)CC@"PS5*<').3%CCI):)'SA1#C
MJFWFGL(PIC(=>3(^Q]*WFX0/CMQ))#Z`GYAG;J4Q0V'$J:>E&P)KWRCF$94E
M*1\,?+C"5JRSGU;\#QLR_P!G[8#2<4[B4N4?RQA;N+1N@".CDY>(64XMG,7(
M%2;C8RV4-M)6,E;K;BE.(2M.$A_?V7V?H0&TNM<1O.K+QD\P:9W5AE@'.,)]
M@H!#;3I1:,XRO*EOM(SC*483Z^J\!QMV#[/<L,.N:[XRP^R=AHP1-VVWG!H/
MX:6,%`%9AO:&M<JPM]:74.Y9#?;;3AYYM>5AZ;%D^R9IAU16K.0#ROS)Y+`[
M&T=JQ(^(_"E9K#[ICE$FG5&K;=0DYK`^&TJ9<RTYG"T8P'._<?L7:4-[='\K
MO>Z(<++2'N[81"&Y9N!.=S$L$':NAW'$JLGXC+#ZF4H?$4^MW\5;;27P_A%Z
M^Q-H%]\;GGF$TQ`Q/Q`.]"WF.RX6S8%!CX:)3IJ39>8,KF4F?[GXZFW_`',9
M]?X7D.C*[>^PV/8<=$XNTG.N8=AVVAHCKUUMY:)!;V)%]Q4[HF#'::@$);4]
MC#BUOY6K#"7/8G+@=]O;_>:C`5YXUULB-)5*-E,.]012)&.P$(80`6\ZSKHH
M,C]R4A@=MAK"\L_(MUUU*480H/1;VYV_A(^2^/-;CIRPZ:<ZSU&.<@-A`964
MQH[`^GOS)*84>TWC/L;0/\#ON2XIU/Q9#F%W)V<XAMPKBVNCX_32)CK*>GJ>
MZ3B8"PEX:(:PFD?C*3+L9RV._EW#:2L>U_+#/_<>!U7=_P#6H^,Y>X0L*U?B
MN$(:"Z#U"8MU:13'_P`9+F'&A6B&W6&FUX=<;2K+^,LJ>RA6/`_"NB>J&FV'
MG^$KG[7B`V%,B[MU,44.T89""I/?;26VQ@-A,@6MY*7%%,H!RI3/M=2I(<`'
M3/2IN!G'N$-H1B22:\PE@_:.JLF-,3H$@60<2D"7-`&&KCX:&)!*B/R$..X^
M%IY.4*6'3;ZFZ84VC/\`[KYW4Z\]*S`+33&T-%M(;$CR2\`2!;\M=XI+"):.
M';(3C&%H;60ACWJ=2[AL.9'4?2>0&25_7UO!HTD,`EB,5L[0"W4$EN+41#G%
ML;$=`"DH\).'77%.*CLK5\2"U.XRGP.[GJ3>R5FMKX1WVVL5V1:1A5LTR\@G
M(KA.`7&7@K\6PMF5'&PXA25K^+Y4(=]B\Y3@.`OK'<@3F!GN&^AWBD'AQQ'Z
M\[7)X+;\A\*Q7&)%JU89+";:)1^24G&!17,.)=<3AM2O`YU=4[F]YH[?$F^<
MDB24L(TIR4H:(^0#BQ_5,B">W.O8]AYB%ML(>0S\K>$N(4K"\)P';1U!N!;9
M!*N,]VL!I40H)YZ2J"B3ATS<=$BN?JA)$J5`?<8-=*=:)9:^-@-Y2%/)RPIX
M/#)[`VT*Z6RKACI@E4=)HB#E`-T(AIQ]1$J(J2AG7+4.B;K[;T:A:BV<XS^.
M2TY\><JPC(?MOKS;R4,OF\+=+"C/M,JPIE>MY,IAPAYAIIHL&-N1)#7K@I&5
MY1AS+&4O?+AM+659#F5U[M$8UD"0X9ZF:=?FGX5#X`>LI<!.&G`Q4S3YP.P5
M,#P*BCDKR\KT>R&T\ZVTXXU\"@[TCUW=XU1"E<6]8R0[2)1QAZ&K&OC'#T1;
MY:<_CB$[%!*&7)"Q[SH;9:177LK'0I*%$)]H<1?8-X#:4]GB?KD]#;49\N(N
MLZS?=2:;&DR)P#8YFT(\@K,)D7+!!#*7!5D*0VRZZI6,>!U\]G6Y#IPSO$79
MC3["<HCE)HNN"PI@U4B/'###G`;4+:!8)P\HG\HS`XS0C2UNK0KV-K#\C]J6
M$@@$;_PG[896>[&-I>(UC1V@QDR"?<ZX<0K9_J'B-^-SY_>G'I[4X3[LN-X4
M'*#VG-E-N*(XP[5CG6V<O)9+U945_D?[K[:!QG@]CE,9*6AI*_:ZII*<.)QE
M6,X7A(&NVGOP@RC.2>RA"37U)1#(TZ"=-M1Z!H\EV:>"!MK[:8]C]N*TXA+B
MC$$+6WECU8?^,/RYW1#CEM@%\P]GB'.A-'(%<Y]EG580^H!MIMT@28)"'6LD
MU37N<=2UAP=W&5XQA&5ACQ?V(5`'WNE<Q]P("00V#B18YCMQXKDDLXV.=CFT
M1Q19BG1BX]U*WOAP+ZIS[75>U7M#B)^R'50H[A&=(]AO8:D1XIQICE_9:W4&
MN@NGD(]%1Z&U,1K;>$/O85EC#CB,(6O"L*\#LQ'V+ZMEWP&$Z2[#C\F_ENN.
M2G+>TA&H\`$AP8F2,5^I<RL1"AGLX2/A\ASXO1#:ENL)>#(6.]M8+&R25JCJ
MJ,2EL)U;4AS%MQ!+;<O^6FNK>&&KA+S*;(^+\0F5X3CY'&\/?%A7KX'=_P#/
M;1:(TZ4+A=]1S,=E""FC^;=YL/MO?`>64QG']AK:2J,"BR'BUJ7AH5MK_<6E
M2D)4'"_]@O-K`DV9F0V?EJ"C9R5?2YHS<83A8L##S4\3@%$E2`OD*+BX`AX9
ME>6W7F<8>PG#.?D\#3GL#[4M\S'5>F0Z"=,0E4NE=U+;XK0XK>O3(&4K6T"T
M9AS-CV&3HTMN"3_.@H>R*E"Z<,L6LDM192$2\:+-%LA]`?/VXHGH'3&NMRPD
M67"1VP*Z/.-Q!KR"GXPCY7PSP4G--,,28PT@*ZA@MI"62V<(>;Q['$^!,7@/
M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!
MX#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@
M/`>`\!X#P'@/`>!_%>WVJ]_M]GMS[O=Z>WV^G]7N]?X]OI_KX'SO[(U/]<UB
MV[M&\4OJNN:]U+%;!8>Z5TC4M4@6:N6VV0]BT6?=1:A?6:N]:*S!VL1FH@SO
M]IOE!-1[DDMAP3&95UD-\&J/\8?XTHO^%?[._P`2_P!K0W^.O\>_JO[(_M#\
?%G]'_:_Z3_W$_IOP?9\'P?[?L_T\"0?`>`\!X'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g275067g17q90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g275067g17q90.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0JV4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````I````4P````&`&<`,0`W
M`'$`.0`P`````0`````````````````````````!``````````````%,````
MI``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"!H````!````<````#<`
M``%0``!(,```!_X`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``W`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#7=A9NX_J]O)_,=X_!-]BS?^X]O^8[^Y:YZG@->^M]FQU3O3>'`B'2
M6?P_S$W[6Z:0"V\.W"6AH))\&M;'TW_X-%#D_8LW_N/;_F._N2^Q9O\`W'M_
MS'?W+7KZI@VE@8\_I'!C"1RX]HW;_9/O?M]+^6K22G`&%F['?J]O+?S'?RO)
M*O#R@]ILQ;G,!]S0QP)'@#"Z`"0?B/XJE;UCIM4AUI<6N#'-:UQ(<7-K:/=M
M_.=_T+?]&DIH?9![?U3+&GO@=_Y'L_ZI3?BU!I%6%EN<)VEX(:=?SPUN_P"C
M^ZKS^J]-9<:'9#?5:[86"2=VX5[>/WW)G]5Z>RJVXV%S*#MMVL<XM=#CL+8^
ME[$E.3]BS?\`N/;_`)CO[E*S#S?9^KVZ,:/H._N6OCY^-D6>G5OW:Z.;MX&\
MQ[O<W^5^^B9.9C8Q8+W^GN:"">(G;_U7M_ML24X;,/+#VE^-<Y@(W-V.$C\X
M2`K+L2C4LP\N3.C@8&GMC:P.^EM_L;U>'4^GE[6"X;GN#&:'W./YK=/Y20ZE
M@$`^L!.FH//[O'T_Y*2G+OPK-P^S8V3LC7U&$F9_DM'YJ']BS?\`N/;_`)CO
M[EL5]3P;:A:RPEI;OC:[=MEM<[`-WTWM^BHT=6PKWM97ZDO+=I<R`=YVM_._
MU8DI_]#N_1N_</X)>C=^X?'MR@ORNJ&]S,:O%N8U[FO_`$L/;!=LK>W?_.O;
ML_J*S1=:XN;D^C6XZU-8\$EHT>7;G'Z#_8BIAZ-W.PR=)TX2]"[]P_A_>K.B
M=)5-7T;H/L/;P\TO2OB-ICPT5BSU!38:0TVAI],.^B70=@?_`"=RI')ZNQWZ
M3%QVL_>]:)/,^YS?HM_-24D]"S=O]/W1&Z!,<[=R?T;N=A_!`QL[.LM(NKQF
M4!A.]EP)W`.=[AZGMK=[7_R&?^!IV;U$4M+::'WAE1MJ%@,6/.RW;M?_`#3M
MS?1>Y)2?T;OW...$YINT]AX'@ANNZQZ9+,2@/@$`V;ASKJTM_,]ZO/V@Z'VC
M@G31)34]&[LP_@F^SV2#Z>K9VF!I/TMO]9%MO'IG[.^I]QC8USP&DEP;[MO^
MN]`9E9[WEK:*=2=GZ4:@?N[=WJ;/STE,O0MW!_I^X"`[28YVS^ZG]&[]SO/;
ME3HMO>`Z]E=8>`&;'[I<9]F[Z+O[",TM<`6D.!X(,A)3_]'NK,'I=M@MLKK-
M@+CND@DO.Y^[:?=[CN3?LWI`?O%56\`C=N=,.U>WZ7T7JH_J6&Q[V/<\.K)#
M@*WN^B=NFQK_`,X>Q,[JF"S1UC@=1'IOGV@.<8V?1][?>BIU6NI8T-:YH:T0
MT`\`)_4J_?;]ZS#G8XM?3[R^J=VULC0.<=KI]W\V[^W[$=)#<]2J/IM^]"R&
MX-[15DFJQL[FL>1S&S<T?]<VH/8_+^*I9U#[G!PQ69!H`-9?8:]26N=]$C=]
M#_K7_7$E.A]EZ:\/]M;Q8'-MAT[@X>F\60?I;';/Y">O%Z<QCV5-K96\AUC&
M.AI(VM:YS&NV;OT3&?\`6UE68.]C@["K>X.W4CU2UI+Q^E<Z'_F>G5_Z+0[\
M'8YS:NEU/KK$8SO5(!<&N:-[6^VFK:VOZ7T-_P"^DEWF''K8UE98RMH`8UL!
MH'8-C\U/8:'LV/+7,<!+3P1RLS"9=76^NS&;BM#B6-8_?,GW.=I[7:*T[M_5
M"2&;,;I["TL:QI9&T@G2#ZD<_1W^_:I4TX5!F@,K/\DD3_6_?Y_.0$Q>T&"3
M/P)_($E-CTL+V:,'IO%C(,0]NC'Z?2VM_>4JABU"*RQLF3!U)\7._.59..4E
M6__2[GW>?DE[_-?.*2*'Z-]WFF7SFDDI^C1Q\Q_%9>38'Y#?MF'6V`X4FR]H
M)VO;Z;MH^CZGJ/\`[=:\&224^XXW[/-X->)C5Y#7$U1DM>\O#ZS5_-G\^UW_
M`&[5_+K4*WX(L;Z6!B;9.X_:V'W=MH_._/7B*2"GW_ISF[-E%%55!<[>:K1;
M%@`W!Y;^?^^K[NW]4+YQ214_1B?5?.222GZ,3CE?.222G__9.$))300A````
M``!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````
M$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X
M0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("
M`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`*0!3`,!
M$0`"$0$#$0'_W0`$`"K_Q`"J``$``P`"`P$!````````````!08'!`@#"0H"
M`0$!`0$!`0````````````````$"`P00``$$`@$!!0,(!`L%"`,```4"`P0&
M`0<`"!$2$Q06%=475$5EE5>7UQ@A(L2%,4$CPR2$)74VEK8R=#6U"32TQ29V
MAC='84.W$0$``@$"!00"`@("`@,``````1$A`A+P,4%1@:'A4A-A<<$BD?&Q
MT3)"8G(#_]H`#`,!``(1`Q$`/P#NQ9/\1'O[Z*?]^?Y[HY0\J%Y0X#@.`X#@
M.`X#@.`X#@73_P"N_P#WI_X'R=?`I?*'`<"]!]:W8\W0W!(7S:-F6V91:0KV
MB)8]MVJ!(KD26+[),]G(WPI%M'I\>7Y>,KS':ES.&W<HEQ%_A:G"I/CIT=QY
MIV*]A3$UP<[E*,N-XG-*RE<5+S7?:<>QE.>Q*59SG'Z<=N.5'X5"FHR^E<24
MA49&').%1W4YCMY6EO#C^,HQEI&7%83VJ[,=N<8_AX'\1#F.>6\.+)7YQ2D0
M^XPZKS2T+PVM$;NISXZDKSA.<)[<XS^C@30RH68P.L98:$GRQU2#PK!8Y2&N
MZV+#$28T/!(/X<RA:V94\M'2CP\+5E"\N=GAH6M,N,%/`9K9D"1)BR$5M4@1
M+EPISXV;`-BTO0'FH\I44V%DD`Q",T](;QXT>0ZRKQ$]BLX4GM78F+1KZVTV
M*-F6(5Y!DHTVXQV3(4IUG+R%NL,SF8DA]V!(?81E:$/80I6$KQC]=MU*$3$\
MEF*4OE0X#@;/L3_XSZ?_`/T9=/\`^KW?F8YZEGEI_3&.:0X#@.!J0[2VSRT/
M79$?5)+X_;#AYG7\[,\0S#L#]8GS!IV.F2^0:9&R1\R`ZG+<Q4=:TXPM&%(4
MA2L[HSGDM3C'-FR(<QWR^6XLES$QQ;,3*&'5^:=;RA+C4?NISX[B,N)QE*>W
M.,JQV_PXYI%D"46UV(+:+"&$+FB::'C6"Q2,2H+#T,)*,Q:^@G'@RI3,\I$9
M+S6F7UQ&G\1\J[SO<1C*L2XBH6IS)8J);*HL2V>#/0G#=5#W:`VV_$G.9JY]
MG,D.5F-CY$M8M$Z+C#J6I6&7\-+0M2,)<1E2)B>14PKK@^>TEY;L*6TB.EA4
MA3D9Y"6$RL=L53RE(QAI,G&.UO*NSO\`\7;RHXG`<!P'`<#_T.[%D_Q$>_OH
MI_WY_GNCE#RH7E#@.`X#@.`X#@.`X#@.!=/_`*[_`/>G_@?)U\"E\H<!P.W^
MI.HD5K@+H(-F`.E,4;=1Z\7QTIKZC6T@U5R4_5[L;T28M`LD6KY[$6KD,K<'
M/#7L.XC+\;*VVU,\]6F]WYAJ-55^U^"]2>OANL@-=2F4P\.;6.,55\%8R+!4
MDO<Z]B-WF))9V$+ID,G&`J::1)?"RRS4F*F*AS,)S"F9.B;GCHNZ*B'`C=20
M@W)VC*+['V75)1[:-DN,`F(AH-%;=0"`2SB`^MB#9$DH:/@B<EL>6BR42!C#
M4Z3E*4K0C"[MJJB.1NC/[:CKWJ%UX;L73S7(TZ,)AC+IH#$L0='GHHZA/:[!
M9`6<W%L9;84FFC&#\]UQ_*QX.(Y.8DK<(.8D,I6]F=,UJ\KNC^OAG)WJ)JL[
M6=MH*MD[!L5@-ZE.@E;"-!Y4$B;)S=JUZ\BZ.3C,6$E,2)8K<(B.4^Y(=BL*
M*R66TKB_I=L:9N)J*M-T55]$Q8^K.HS[$84*F7.-4;'<>K,Y8PF8S;$0Z.W!
MK@;6];MEAK9540@X+L,9QZ0AWO)B)SAQO+BOT81HFOSCT-W\NC5CO-KMK$"/
M8C#Q-L:TTS&RZS$:=4EB.B*PN9(CQV7R+[+".ZAR0IUQ/>7G"NUQ>5=(B(Y,
MW:I\J'`<#9]B?_&?3_\`^C+I_P#U>[\S'/4L\M/Z8QS2'`<!P/9;H[?82IU/
M35/M,489I58I]CE$([ETU_"*U?9#E]V+9ZM::Y!)7"%)QF37K<@:3:?1%<6R
M^K"DJS';PKCJTW.J8YNFF:KLL=4W74Z\&THTN5650Z7/TCDU5F[77)<D%,UQ
M(7FW6H#-F[LQ2HLVS*4_(3Y((S+F>T'VY3B%(2ZXG3,[N>;XY$3R9S7[93*B
M=U#7$FX=JUN`U=LK4.T)/JS68$@?KVP[E?#S\H(,<OY+'>%>I(4V-AYU"_-0
MD9SA&<8SBS<[IZW?5.5=J:3K'=E2#;0V%L2RE6A4(YLFHS`]6';%K,P2YJRJ
M#BE?"@E#0NW*J-FG1`/$.+W#."(ORBGLHC+>PC')JTS41';M[+$Q<RQG;5^`
M&^G"H:PC6.3*/Z\:J[\TYFSZX((V`SCVZVY79T,+995FR,U?DREBO*=\YA<1
MR5E34;M;2BZ8_O,US_:3/]8B\NB7.K!P'`<!P/_1]\I+HFHQ`C/G_&JUL^>F
MRIGA?!P.YX7F7W'O#\3XRH[_`'._V=O=QV]G\&.>K[)^/K[//4=YX\N'^1JC
M?;=:_N9#_C/Q]D_'U]BH[SQY/R-4;[;K7]S(?\9^/LGX^OL5'>>/)^1JC?;=
M:_N9#_C/Q]D_'U]BH[SQY/R-4;[;K7]S(?\`&?C[)^/K[%1WGCR?D:HWVW6O
M[F0_XS\?9/Q]?8J.\\>3\C5&^VZU_<R'_&?C[)^/K[%1WGCR?D:HWVW6O[F0
M_P",_'V3\?7V*CO/'D_(U1OMNM?W,A_QGX^R?CZ^Q4=YX\GY&J-]MUK^YD/^
M,_'V3\?7V*CO/'D_(U1OMNM?W,A_QGX^R?CZ^Q4=YX\GY&J-]MUK^YD/^,_'
MV3\?7V*CO/'D_(U1OMNM?W,A_P`9^/LGX^OL5'>>/*Q?DII7I+V9\9[3X7J+
MSWF?@^)\3Q/9OE_`\O\`&'N]SN_K=_Q.WM_1W?X^3?-WM]?8J.\\>5=_(U1O
MMNM?W,A_QGY?LGX^OL5'>>/)^1JC?;=:_N9#_C/Q]D_'U]BH[SQY/R-4;[;K
M7]S(?\9^/LGX^OL5'>>/)^1JC?;=:_N9#_C/Q]D_'U]BH[SQY/R-4;[;K7]S
M(?\`&?C[)^/K[%1WGCR?D:HWVW6O[F0_XS\?9/Q]?8J.\\>3\C5&^VZU_<R'
M_&?C[)^/K[%1WGCR?D:HWVW6O[F0_P",_'V3\?7V*CO/'D_(U1OMNM?W,A_Q
MGX^R?CZ^Q4=YX\GY&J-]MUK^YD/^,_'V3\?7V*CO/'D_(U1OMNM?W,A_QGX^
MR?CZ^Q4=YX\GY&J-]MUK^YD/^,_'V3\?7V*CO/'D_(U1OMNM?W,A_P`9^/LG
MX^OL5'>>/+0[;T;TTG3=5BG=P6:,U7*[8H,:4WJ85(<(MSKS9##C[\96VXR1
MZV'IZF<(2[(PM+>'.\G*LMID:YO5_7U]EF(J,L\_(U1OMNM?W,A_QGY?LGX^
MOLE1WGCR?D:HWVW6O[F0_P",_'V3\?7V*CO/'D_(U1OMNM?W,A_QGX^R?CZ^
MQ4=YX\GY&J-]MUK^YD/^,_'V3\?7V*CO/'D_(U1OMNM?W,A_QGX^R?CZ^Q4=
MYX\GY&J-]MUK^YD/^,_'V3\?7V*CO/'D_(U1OMNM?W,A_P`9^/LGX^OL5'>>
M/)^1JC?;=:_N9#_C/Q]D_'U]BH[SQY/R-4;[;K7]S(?\9^/LGX^OL5'>>/)^
M1JC?;=:_N9#_`(S\?9/Q]?8J.\\>3\C5&^VZU_<R'_&?C[)^/K[%1WGCR?D:
MHWVW6O[F0_XS\?9/Q]?8J.\\>3\C5&^VZU_<R'_&?C[)^/K[%1WGCRY'Y$:5
MY3SGQPM/A>8\MW?@T)\3Q/#\7M[/C-W>YW?_`,]O;_%Q]D_'U]BH[SQY?__2
M^ISG=YC@.`X#@.`X#@.`X#@.`X$M\Q?O;]CX$3P'`<!P'`<!P'`<!P'`<!P+
M8=_P_2?[J+?ZD+\D=5GEI_2I\J'`<!P'`<!P'`<!P'`<!P);YB_>W['P/__3
M^ISG=YC@.`X#@.`X'&C3(DS#^8DJ-*Q&DO0Y.8S[3^(\N.KNR(K^6E*\*2PK
M/8M"NQ2<_P`.,<#D\!P'`<!P);YB_>W['P(G@.`X#@.`X#@.`X#@.`X#@6P[
M_A^D_P!U%O\`4A?DCJL\M/Z5/E0X#@.`X#@.`X#@.`X#@.!+?,7[V_8^!__4
M]O74G'O5,ZH*IOZDTBU727K#1DT0Z"KHPG+<ND*]76767J8R]%CO1_%BV0@#
M/R<9_E&8@9;F>ZCO9YTF]U_ARTU.F8F><NOU&;V_H77!>@/W#:E.C!)O5O8:
MQ::M0$V8QM_>D;;LI^K0BT<W1[DJ2FY-3'B8P:SB+FP^>D9:6ZB)CPIF(K]M
M36J;J.G^'!S>>JRCC3T41#<UBY/M?4?>1J9T:SI$6;<1O==B?$UA<()H;=9R
M[`XX_+*X8>"\$E'H1-YV)+<<CMOQ']BM,^G'1MI7;6[8<><;FW39T"[A]PCO
MB?JV%K*,5HU`TX!ZRM6A))P?;6J./+M0IG33DI+0\J1/=L8V;/)1VV/((\K;
MGC]I4?BJ_C_ME%CV#U!S]E[0V/2X%O4/DK12Z]=RE7.5M@!IV;O:K+E%PTF3
MK*Y/IAHJLF0ZP24`+^5@2%$\MNQX_?Q,W,K6FHB>)2.R16Q^H70MBKVQ!SM]
MC5BI6Y<1X5$LI%VWCMA;@&4FBEHLB=K35$XX4$ZYJ=JA2"4$%%B3Q\]F>SE3
M4I#SB;F"*TZL*Y:*=U`WBZ13+@38Z;/K[IPWYTT#R;,(J-GVV?15:H7;MCU(
MHIP3'%EMY.39,<))\=A2W0K3S+G8A2L,^A$Z8CS;7KB0&"SBR?1'0F*^\2TK
M9M3EW*SKNP:YJ$+9FP+OJNJZ(>MT!BK"Y."FH695G,D5>2D2ZR#9G-RT1USH
MJ';_`/5(CYSU_P!NQW2,`MVK1EYT+:JI!JPW71J)8-9-`;`9N=9SK+8F216$
M$@W(Q3*(X4)56ZCCL1V'B`TH<-R.3G'ANLJ5=.,4SJJ:F)=P>:8.`X#@2WS%
M^]OV/@1/`]1Q6T=6\4-8K3#OVX7"$6@=1VP!]830:8\*5:-8=0,.IZIIS,=6
MMG#CH6R:[ENO/1/-JGEVTXDM/I;1CLQEU_KRJ.G_``T07C<S'4BWU-RZ-';U
MU8]E%.GMQS!VTKOD32GGX5%J!B?K5[7S(]D)\?`3MFCF,&U8C5>ROOJ80WEY
MS+-W28V[;S5LE_Z?-3FU"3TUMQ:L*'RF^DF'5=E1*?H"[:5>JUI;%:BGX5O"
MS6*45![8V"@F`E0($EE0J8R\Z6D(B/,2GLPFGI^EUS>[/7NE=D[UZGH&QKBW
MK==[G1TV#?-2E`BM5BR'*B*IM:M<NG6,'2HVJGX<=^<[5VY]5F$+<5?N:9F<
M*$H9D1F(:9U="-.FHM6R>]-P.6?:U/I6S-YV*O";X9@TJSV*D0*20\<;I#3-
MFA4N>;5H&TFW2Y"TWJ?,`"6ZAF59<15X7.1"C+\\N<U*[8Q,Q%\?E9-9G>I&
M\6TN_-GWO5K5XAG+[:R5+UO5@3IBU1.BGH0(!,3I]EH9_P`V_#V$6L<)AR1E
MZ8OV:X*4ZN-`\JTBYX_23MB._P#N68;6VAU+WO6NX:R??O9*=L7I+N[K=-IE
M7(UDC2K+-Z0$W9V.<J!G5JYTFOE]F1YHZ'81-M?E/FRJ0:Q[68F5LR9FI_7\
M-1&F)B?S_+OKM41=[%LSI*+ZJL0YUN&.V;*5?[73B^P0+H@GKT4B`0,QJY:=
M>)3,L:>ZIA_ST=I3JL]UI?;W<:GGIISBJUW#H5'UZ8:VH(D[;!:ZF-M%NM=4
MJP;)Z5+WMRA3BY[J5J943+K=,@W)N;4W[`'9>EP)#Y:?AV`AQ*%NX5XF,UW_
M`#T;O&/QU_"U;0T<:N4GJ(MM3UIJRPUN)J_2(42\KIXG1]A1*E#UU('60UTR
M33-H'HHUKHXO*Y@`$N)-4V4C1HZI"'.[G*N>")K;$S//O_R[$5*/KVT]6(HO
M3A5BKL^KD2IBR;&L5:O:;ANHP6U0X"@Z_9L)>OMPXVE:8!G(*.QY<UAEZVC8
MV(D1+D=]^1KJS-QIR]A_-.;P;AHP79NHD:[L6'O8=WH=PJY-R*O#<V-%-%3T
M!<T>_G"LQ24#+^'HSR?UV7VT+3G"DXSS//=#5UMGCF]4!>[;G(X#;4M4"[4>
MV03-;Z9YDZ.%77Q##U7I]FM>Z;BU;BM`OA*EZ]VGN6$'$0#,.O$W#":P.:A-
MMI)-S$3/-NHY1RYO!0-T=3IFJ)*6XSLH-M\;6JZWJ_5R=3LO@MP.-`SD>Q$[
M\J30J\0#$7K7#\$Q)CR@;5?1$B/X@1T$?*343/DF-/2,(/85ZW,X&$V/6-SV
MQLRPA=;[%+L6:TZ)"1C=&V3-U:V[-``"3>NP2TS?43*?-ATP6UCY;BA[JW48
MQ#B2;Z+$1F)B(RMNTK]U.42]V6A1KK<<:NK]LL,EG<-H8'UTRZ\YJ34)ZKU5
M5CJ73=M4(3'3KI:;+*BM(K3'F9PEL5F;E&6ALFS?A(C3,1-9X_+6-Y%]C-U#
MH=V'9L6&!=`>P4V/8HO78,O.AKMQ+H^Z@&DAH]:.P`QN7$-[/EP08^`0P-D2
M'RC41?EY;S:FK/\`ZRFFKUQ'+WAU^U[L'J?V+LFAT+&PMKB:`<N&HIYK9(</
M63)G+!?1_6;8MA"7CYK0%3HP6"FZ:THC1`?$'%(H(F1\FP2\26W&8D7,_C_:
MS&F(F:B_]>Z%LF]>IV)8P`H!;=ER[U8-1[$.[5IQJA-`Z;K$J,ZF>F.ED+#K
M6P1M,'I1X?2]37FP+C3&8]KCH')BF7XTW+RO-RY7;I[=?XE#'BVY[/:J'8K*
M2(6[+@HS5:*N$*GW2OVX"'ZL.F`B_*(^J=*ZVAV4^&KB2TADO$!QFGAH2.4C
MONK:=F*9P8J:XQ+6,WSJJKX75I"5:MJ%(NQZG=R>TI4C7U>FE=80:MU0=/E)
MB3:*'%Z\3*Q97=+[$L\AF%/9+2B/LQ$QB/)=B+9D6YJ$K3G'%2L$D_>=J=$W
M5_#0=O.QR<6S[TI-`G6JG+&W`C7PSL>'6X+]7%UVI39JHV5*0WGR3$F6C&%J
MSWUY5QF=.HQ&O1X4+JRH6WB5I-.WU=0V"-=K?2NVHC7-"79^E0Q0;KLTW8;3
M'MU*<V5?IEZ'#*U!DD24"//'K=$L/85W$YR\F3$WQW-,Q6/SU_"0):@%WZQZ
M.`4&H].9:(,M>WS!M2^C6V4_3T61)UN&B@\6G79N\-NR[#*E17&V#6"F$H1E
M#28JUM9\168_Z+J-4S,_Y4\A6*CG4]!U=::19*OM>60W6*GV!VBW1ZA]*^3&
MT)!>X6'18VN!K`,@'Q+TMAC5\N!EM[V3'9DO2H[#<F.]>D8RN;N)Q_SQU>[/
MYB_>W['S;B__U?J<YW>8X#@.`X#@.`X#@.`X#@.!+?,7[V_8^!$\!P'`<"*.
M@@UG#%:Y8Q0\Z`.CY8DR&+1&)XPJ,GL+C38$^%)0Y'E1)4=Q2'&UIRE2<YQG
M'"\LPA*50*=KH9+$TP#$!PR)-XT44RJ1)G&#,B+#@O&#92<]**&BKD`='CYD
MRGGGO+QVF^]W&T)3"9F>:X<J'`<!P'`<!P+8=_P_2?[J+?ZD+\D=5GEI_2I\
MJ'`<!P'`<#.JGJ36M%.F++4:8$`G3J9#1`E!C9P_Y682>,S8$##BW&PXN<9D
M+F/Q8:6(S\Q>7UH4[GO\E0LS,\Y:+RHK]IJM=NP*;6K6(AG09!4-V2/G-Y6U
MF2-GQBHN<PXA2'XA$25A,2XDEE2)$64PV\TM#K:%8+$UF'BJ-.J]#!1JU3PD
M"O@XK\^8W`'M9;0Y.+3Y)0L2E.K4N1.*%RDQZ5+E/+<D2I+JW75K<6I683,S
MF5EY4.`X$M\Q?O;]CX'_UOJ<YW>8X#@.`X#@.`X#@.`X#@.!+?,7[V_8^!$\
M!P'`<!P'`<!P'`<!P'`<"V'?\/TG^ZBW^I"_)'59Y:?TJ?*AP'`<!P'`<!P'
M`<!P'`<"6^8OWM^Q\#__U_L)]!5;Z?\`K0=[BYURX[8/056^G_K0=[BXR;8/
M056^G_K0=[BXR;8/056^G_K0=[BXR;8/056^G_K0=[BXR;8/056^G_K0=[BX
MR;8/056^G_K0=[BXR;8/056^G_K0=[BXR;8/056^G_K0=[BXR;8/056^G_K0
M=[BXR;8/056^G_K0=[BXR;8/056^G_K0=[BXR;8/056^G_K0=[BXR;8<_P!#
M5GV7X7]N]SS_`(G_`!,?W^_Y?N_[7L/L[O9_%V=O;_'QDVPX'H*K?3_UH.]Q
M<9-L'H*K?3_UH.]Q<9-L'H*K?3_UH.]Q<9-L'H*K?3_UH.]Q<9-L'H*K?3_U
MH.]Q<9-L'H*K?3_UH.]Q<9-L'H*K?3_UH.]Q<9-L'H*K?3_UH.]Q<9-L'H*K
M?3_UH.]Q<9-L'H*K?3_UH.]Q<9-L'H*K?3_UH.]Q<9-L'H*K?3_UH.]Q<9-L
M'H*K?3_UH.]Q<9-L)TI2:VZ)K3*_;?AQH$]MGN$H"5]QPR0>7XJLA5)6KQ',
M]F<83C">S'9G/Z<HO*S$807H*K?3_P!:#O<7&4VP>@JM]/\`UH.]Q<9-L'H*
MK?3_`-:#O<7&3;!Z"JWT_P#6@[W%QDVP>@JM]/\`UH.]Q<9-L'H*K?3_`-:#
MO<7&3;!Z"JWT_P#6@[W%QDVP>@JM]/\`UH.]Q<9-L'H*K?3_`-:#O<7&3;!Z
M"JWT_P#6@[W%QDVP>@JM]/\`UH.]Q<9-L'H*K?3_`-:#O<7&3;!Z"JWT_P#6
M@[W%QDVPY_H:L^R_"_MWN>?\3_B8_O\`?\OW?]KV'V=WL_B[.WM_CXR;8?_0
M^S?G5R.`X#@.`X#@.`X#@.`X#@<SYO\`ZY_,\#A\!P'`<!P'`<!P'`<!P'`<
M"8(?\-`_[G,_YK-XCJO9#\(<!P'`<!P'`<!P'`<!P'`YGS?_`%S^9X'_T?H:
MW_J0WM;JQ&06-::AOPJ+TSSVF9F[`)8U6ZR;F;)RRV4K:1HJ4ZFSLQE86I,>
M8,EJ83CN26L]BT])S+,36GGU=?L[/WU1]A5+I[KVVMDWQFJDH>@+9[6J^OX%
MB>!".EPGF+N9L#`J-XV9[2L>UPL>9$MAH\*KI$E-6+BBIF4-OO3,8M<5,UQ;
M&-3;LWA4-:TB,&ODL'12\'3D:V[UG(U979D.0!Z-].2FZH2V):=4W>B8(D-A
M2R<%V68$3IN7P2@Z)#,UQ&.2)GPLQ%SCBV^@=L]7]NKABVG[E:QDZ7MW3NGL
M:]J&L18FK^GMD]%>G+]<;P"]:ZRC[A@DA6X;\3DC<$)36!LB+@?/BO\`A.,)
MMS25I]/Y=].C::LATF]-LIZRRK=,7I+6K9([.E#9D^07C5,7&,0Y\@5%A1%3
MPY1EZ$^E3>)"'8ZDR,J?PXK.HY0SJYR[*<,G`<!P'`<!P'`YGS?_`%S^9X'J
MLZI;M;]2=6E/W:(8N1ZL:QZ?9[=MHM<?*/L7,;L"^3:8-%Q0C&5C9IYC8DNL
MS,/K;4_&@1)'=SA"EXS)Q-MQ$3IKK;JA7-U]0G3IKD?09UZ<'SQUPZQ#Q79U
MRG4K$#8^UZENW(X!2DO[/(MRIU9*N%9<UROUY#=F)PGX[85^.F'(PK-S'5:B
M9_PFB_5%M#7#6X0R=PV\5L,EM;J4M\2HE&M/OR*Z6`5W49C6^KXI/9[`TD]6
M%Q;1(S%JP<(9NAZ'X3D%^`VRXY)7/=:B:QBH<7=/5CN2V5+?U9D['F5Z2;T#
M9[4$%ZDQ5/.:QCBM24K8DN;;QMB#!]PZW?>3/GM>H5KM-3,PYL=N')%S>[A2
M9G*1IC&.J?VSU9[.LDG;-)UYM>RV$6;I_5S1&9`B'J045JSVK]+[(L5!O5-@
M4MTYM$4=LA>C(=BG#^1@NRQB&9U?$LP<P)J[,SW(TQBX[)>D=1-S#-V,4_OL
M3K:@._$*P5C?)FLU6YL;,NE+T?TDOT.JN1X8W`JV>LLW<Z5E"JW$AGK+B'E@
M$]$S$D8S+GN5_P#'/^VJ?]42Q$\Z]U=7(I"*`BR,[%V.7.6"?BM!;#%I]"=J
MZM6U&.82B([U(VK.S\G=919LB-Y&SU1,_*G5#_+/W5/)-'.>./RV#9.[C6V>
MD?79+5(&TIN/5#Z<UO7*\V8BB[U6(EBB%)NV//'7WQD*M;"UWK*L61Y2GG6$
MP[$/1'4O"^S/+,W"1%:IOHZG63>NS:EI\QH^^7R=T^2]5:WZE*00MMN54[`;
MN5IIH+79KICH:;63EDQEB+7G2.QDS2.!3J+`>-!I[8Z<P\/(=LN:J9:J+NKX
MRJ6LNJW8NL];WALO;Q5<93I7J:FZ[</P!N9MGWUKZOZ05KNN"G"K3TVUW:4Q
M8I[B`C7CR2>.^OR[O@JRE=6LZ8O$=G8*Y=2^]JC&V$+.FY86)J^#`N%BO\2@
M5>>[.J6]3FJP^D&H4>RF:70A<>NSK;=H4\N3)P!HA5$:(G'$C7I"WERS$1-,
MYJ'4OU(;&E'*V"V5/$#*-2>LZVQ;O&J^K;D=OCNE1W2"?U/#,FPE9SK.=#(N
M;X,QYDBNCXK)@=#1F&ZT]_3DKGNM1'I_+M;T.W:QWE_J3+7"XEC-BF;FK)]5
M,+3!KF->A;AT_:7M(L4$&MP8IL56)$@I*;@)F./)=;B96A2GLR77;'7]LZHJ
ML/820_X:!_W.9_S6;RQU3LA^$.`X&?;6O2-::WN=[5#=)/5H!.GCQ;#+LA\N
M8RWY<&'998REUQTL8?8C)PG.,]KO\./X>6,R3AZWM?7S=VAJ?L&@7EBWUVR3
MU:KV-%N^PUUBYJK@BYV>I43J`M4?%2LUH#2:]1SLE\P.AO/-NQX<OQ93"6&E
M>)K$TF7[@;-O(AB\G*I;'+N3;)=8YVH6A(AJ6D[,IVI]>D*?/!C4(D#9D!\K
M^NVB(WF#.4K*V4>$XE/(7AI9[J;OL*+<=I5&<UL+66O[%K-HF%K8>&0S9*W>
MM9,XGR`):!#=ERY@;91.&XYEEQ2&FL2&7.SP\I2KN7V>&3O+<56VAJ;7A^V,
M3[(N1I<+L^OR*]5A,&7+V'B7FS&*^B-YNSF((B;(:B(FL)&C(+K*&7LRI#N4
M\5&2^3/K-MC>1/5,J58]AS1K5CU6!V#),#*V)K#].?%;TK-3*1VR++.$^S9E
M2GN/3\R^U/8TM>/"CJ6UQCLGE[31CJ'QH]YJ>DJV]!B.ME$^7[I)#C#:T3T^
M40W%[LQ.?$QX24M_K?JXQCLY&G.Y`X#@<SYO_KG\SP/_TOJ*V]U%6'7VSFM:
MUNIZY*.Q]5D-LF3VR]RKU*+CAA]@6!=&BGOAU=X<\EWFU/*7+D#8C3?Z5O)3
MVJQTF:8B,6@P77ETXDJ%`V$9LMEJ`5W6<C9Y9X_K?9*1P.$)U0[NJUU%VSP:
ME,JAG9-.UW"F$"-:&SIAUEJ!)[(F<L.82N*LVRU6K=2>F[B8KU>#68FU8K2>
MDUH+7;!1[]4+`^6C4LGL/"982VU<(4$CIU,#R9\.=,:8A3VFLIC/.KRE&;<)
M4LJJG7%I:U/6B3$D6.6!@6"KAJ1.J](V+>['L6+8]25K;KID1KNHTDI?!T`*
M%L/ARU/P<H8RTE3JVLO-MYD3$KMEPHO71I\AL)JH0IJ&ZR[+I+L;9A5NRCZ0
M>K=YZ;]I]30^R5*P-5*=6C$2%0=8O/R/,$8##<=;R\OXD,,PY:X-LU:ZJZR-
M`(]GL+L%W09+$XH@14%Z3W@G8)>7.K9FWCW16N%:YQ?"8PC6JX1EQIK`YR%(
M:'RO#=4J.]A"X-LM^J%MK=^JM<N]/+Q3U5MH4;8JZ:A>)Y4H&+Q&IP^:TEYM
MI]K#\9Y*LH<0AQ&<Y2M*58SC%3EA8^$.`X#@.`X',^;_`.N?S/`X?`<#(=Q;
MDK>E1U*,6OPF!%PV15==+*2R<`0.`OVG,Y+!HK.).-1FQT-4+.',94G.<KQV
M9XE8B^3KN>ZWZSF\O4+7=?!W^=\5F=50;%\2JX#I,TA\"T[UFD_4[40Y&9:A
MB.^.\'"%N+G)[.U*<_HE]%V]^R<.=4EH#VFN49.M*@_:"NMRNS2WFMW5T55Q
MH:!<9=3CPQ-IFUQ,6P$926$25X\**U'PO*%+SW,KRLK%WA^A?6#`,!M1WF+J
M78L75NUH.B<QKV62!@8''NHHR/KU``#@*2DF?</9)0O"S8)PU;T$;#G-2F7)
MD=$M<5?(V\XO*?VWU6U#3NP/0MF$2&V6H^BY<ZSR"XP6$'1-Y;:L&IA\J<^0
M4VF-'K<ZOKFRUK6E*XZ\)3G"L9SQ,U-$1:#G=8M0(W4UK?6@J#LRY8NM.U_3
ML!+B#Q5;*?M.O+5L\E,)V8>@WFN5NF5.F3GB<E$6?(PYAIEB,\^^RTM9MGG+
M:`FPKH_0+=8[+J.RB[K3,GXS^O@!418EW*>''-$X&=:V8DNJC;"(M#<EIF!+
M(M!E(DY<:F-15LNX34\L&U;NW2.M=7[6LA$:O6(^C;DLH;9?G;=*V5@OLNSK
MJUH-DPMV<)&2-Y9[]^A1)&4JQD-)BR!>68Z!OA-RXRLQ,S#N;$EQ)\9F9!E1
MYL20C#C$J(\W)C/MYSG&%LOLJ6TXC.<?PISG'*RY/`<"8(?\-`_[G,_YK-XC
MJO9#\(ZMB^JNDF`U`)P(?FIEZ#WPPL'&-B9)6NMT.NF+#*9,1F75NM+(M!U-
M-9RE.$K7C.?T=O+7,MP(75"J1K(OM&11H:1,$-3R\$:-V+5#967FYEQ(H;#)
MQX'>S7G6<ETK=S)QC"?#6G_:3GBLTEIX3U`&2LBX@(VJ3D^ZU&;1F'0(&S5@
M\+D0;[@SD>8EVF++;&AX`E%>EK(8?1XS#>&5)0YA]OM4M_A.P]]`B&L=?[0B
M@RV!M^N-'I488^\/Q-&D;G?(.OO,/R(DB8/FP1A66IWQ8[KC<J.C"VE9PM/%
M%LV&;HT_:;?J*_RH7_G*Q2=HT`<F5<%ROA\(JHRZ6:S&)]5;*+$0EG(^NL-K
MG(A(G*9=9:6]EE/<X[I<8:AK;;%IOTP'(FZI/UJGW"IXN=1M[QH258=%OJ'N
MCAUK&Q,-2:M8BHTFW*8BI7.;\-+B%/)=;6C"OROA+;GV\'TM3G;<7"V*P)\T
MQ#CC:X+E3W<K=5VNRR4UMI0\$)ALXRMV7,<::[W=:1E;SC32T18MJ[Y4&[DU
MKY9V&FX/!'K$V$SA_P`90AB=&&NO^9\+R*7\3)C:<1\NXD*2KOX;RC&58#*-
MJ=0$#5^QM7ZZD58J<G;-DY9@RH4AMIQ"4V&N5Z2D1`\O(</30^+&@D1:[\5,
M,1&?D]]S*,-91%EKYLR^$Z`'C$Q=)-71QUP@Y-;&30X@>#%B0Y`V1,'C9V9"
M'#(28X[++/>5G+TIYM'ZJ<J<0'&JNY*#;5T:%",>2.["H$390"NDV'HQ7%9D
MM5IQ2I^4I=@0B<==M@HS$6_YAS+JE-)6AMQ:5#4N0<SYO_KG\SP/_]/ZQ[#H
M*AV[<<#<5K%![.0%Z[^'XP'8:\&-#QR?5.+3[?@/$HTE^(5\=.&>UO"?U,=O
M;V\ZUESN:IU$ZE>AVR[)U3O:FTZ]HEB+,.ZD=CZSUM-"PQ,AK?>[M.;1U^I1
M[9'M-SQ]?I/[/(%(\+V6S,B$'T+<GO0V$0^2=/-J-53#5YO2E:I]Q$[?E;AB
MO;S"VX:8A7->MXJ:BJL"->7O64&K2J#'ML=YZ4@)L@J240P71G)YY+N&,#FT
MBL*S?5+Z5AE]?_Z=T"FU\97*QN2QOBH\H!DR'N5<BV"M6>(`U13=4P9I^KA#
M=0"FK*)B4ULB-=GMS0L6=+?R\*E-^$AN;:7=^'";_P"FC1WJQ5-=EMBGBFN*
MYK2FZXEB/8<*)9C<:J=(>Z>C-Z:]9F2*H$-DQKC<;L]3#8O*V3$'"TO9CO>7
M:NWH;Y[9][;77>E(A\:ZQU"[&VB_=]GUK``2B6(IL&F5^?4JC2-RU"LB)`1!
MD^ZR53-WL?+3YK<E+4J:^E#$6)%;;80K-]4O%1&&\:8UE!TQJF@:I&$Y9H?0
M*P,K$,M/99CS"#`QG#*)4EB/G+#3KN,=N<)_1CEB*BDF;F9:=PAP'`<!P'`Y
MGS?_`%S^9X'#X#@9'MS4HW;D:@0RLY$2)1MH5'9:HKPQ@K&-KJF2&4!)3$EY
MIIF/.S._6=[',H[F/U%=OZ'-8FK=:K[T20+%L&9L2KV'7XV6_MN'M:/4;[IU
MG86OFWV-`M:&D"9E9'WJB.35KAH459E)E,J9F92G+;B4]Y4VYM8U5_A87^C.
MDW4HV3W0-U?=HV-0F=1)K%0U1C7]2$02MQDVINQ4Z!.N=Y,4VPP\/X0F3"()
MD(EHQ+9=8<PE*%=S=/1Y`O3CMV'?M37"T;RJFRH6IZY7Z\&@WW3YJ:9:F169
MPBX["$E`.Y:]78&U[Y59OLYXW,"$TC6\.X@QF&)I&/,5R+BIPG]K]+`C:^SF
M-C$[.Y$0VWH!E^NN`8I.#+:T1N*P[<CM/O2)[6%MVA^P*@.IRTK$9MK#N/%R
MKN83%S9$TA[)TFMN;!-[7UW<AE"O>;U1+_3E/4.*=J8$G5-:7+4QL58*Z/L-
M5FVD!<*??"&'VHY`3(C3$QI#;^5QTXRHW8J8PUH)KS9L2@7P.7W42D[-O$HV
M4B[%"5$5!"T`I-"C@8)G7VN;7/O8L;6J\R(8D>SR$TIF;.=E2'WU.2E93?*7
M%QC#&171;1#-2V96]Q,TR\_%*U@K:5@TW7D77-*KA,"&K@GSE)J,ZP7Z57R]
MA<KJ9!B=DD^^16[W%=UI"$8E<UW3BG<`2($@1T0.#&#@H@>SB/`%B848<.A,
M8SE6&(D&&TS&C,X4K.<)0E..W/\`!RHD>$.!,$/^&@?]SF?\UF\1U7LA^$=4
M172C5PX/78N"4BQB%$#;!#RCT6L#HI*SIOM;-5UQ\D\S*2^E0M)C+R$J<>\5
M3>$YRGM[<6RG#@=,$[&M)^JC5NITNMRPE,"8D`]2P*X7E-TPX!*QG;!,3:R;
M5@\_%#+8>0XVWC*Y*G>W]&4*64_IGI7\J$VA4]6WY[5M,VH9"'"U7$UM$F`&
MDL-.Q[C!K3X\[7IH4)L",U%1-BL.(Q'PV_Y936)*L(M\BFHD=1J,:^H%&G&1
MD/T);M:6B-(KE8;!!W8^LKB&M(D&/KOM><V&@/1`C,+]62]X2>U:4Y_0CD*4
M8)TM4X1'UJTI^%)DT*Q['.$R+=>@P25PB;&`;!`3`Y.?'D><CQX$>^J4A?B/
M97Y1&.ZGO=J%I2TZQU5>:)*KD0UM=^ST^D4S%(J56A51JM^-!:R*9A&KP2]O
M&\6NS#1H=N,P_&CBHZ$./+S'RMU2N+_"^5XVG0F=GZ_LU"?).!V;)":AK),Q
MDS'(F&IL:9XB(RWHZ7LJS&[O9E:?X>W@<!W3>M7MD-;9=J(1=Y9$N"4&5"QV
M7L]^5%E)*K7F)E]1UA,-#+<S*_';C=K6,]S/9Q<\A@>_.DC.[;1/L<;8":?(
M*"ZP/649JBRMTKBZLJT)CYH-O8M`)56''8MLE-%8CL2>B8G/>2IE?ZV+$TDQ
M;3]NZ>L6TZ+6:,B^1J\/'RQ$FXL)JKY,1?H@F*E&:Z6&)M0R7&JI*<G#TJ'B
M8[F2VA+#KBV<NI=D32TG(ND:`Y<JWLPY6JR5V.!K"*^[9(U;&C6)LOMKCBCK
M8Y29[T0G!<K+#8YS,EYX=$4N.V[E"LYROH-@Y!S/F_\`KG\SP/_4^S?G5R.`
MX#@.`X#@.`X#@.`X#@<SYO\`ZY_,\#A\!P'`<!P'`<!P'`<!P'`<"8(?\-`_
M[G,_YK-XCJO9#\(<!P'`<!P'`<!P'`<!P'`YGS?_`%S^9X'_U?K5^(]N^6#?
M\M5CW/SM4.&Z3XCV[Y8-_P`M5CW/Q4&Z3XCV[Y8-_P`M5CW/Q4&Z3XCV[Y8-
M_P`M5CW/Q4&Z3XCV[Y8-_P`M5CW/Q4&Z3XCV[Y8-_P`M5CW/Q4&Z3XCV[Y8-
M_P`M5CW/Q4&Z3XCV[Y8-_P`M5CW/Q4&Z3XCV[Y8-_P`M5CW/Q4&Z3XCV[Y8-
M_P`M5CW/Q4&Z3XCV[Y8-_P`M5CW/Q4&Z3XCV[Y8-_P`M5CW/Q4&Z3XCV[Y8-
M_P`M5CW/Q4&Z7/7?[2L/AY4R#AS!/P^U`&OMX[GE>]V90V+2C.>]_'G';Q4&
MZ45Z_M7RZ']1@?=G%0ER>O[5\NA_48'W9Q4%RZS9ZXDXVU<M7XKUO4,UYYN-
M>=H-U6ANT*JE8-*'[!E0C;;<U5S@0&:T5C*R36(P+S*D-L8D96M/;,735:JB
M;774/5.6W%&+RQ5>M-7CBFP\AIVV5O77A%(IMF8]%S$?JI6U1QY6'B"I,\02
M7!."U+:\Y"8P^SEQ%23<=5/TOUM2MT_#]42F7RAM;6U-C=FN7KT`U"I%JU^G
MT/F41831+;>71$R"G9`;+D4DF$^K$S^32YEI_#:*GI),3%YC$M*>ZHZI'S(0
M_M"CM.1!=I-267$U1+[`FD6INC7`@ZQF!XR(M;N3J1<Q64]C$]6&5=CGZO&$
M_LK<_K4U,+A6,D0WQJ:+`J$N'!LTQTO0\1PDJ>7=K\)L@[AG*6<2;!'='H5_
ML9G,N1^WQFUH2_KW6M?:6>6+_J)ZOJNK+OMHW=AL('3<;@5#"O1M;LV>^MZ5
MDDX=C?U\/D$&81^,:EP&F13KDF,W)?(0V7<L.R6T97IJUK7<0V=[JCJD?,A#
M^T*.TY$%VDU)9<35$OL":1:FZ-<"#K&8'C(BUNY.I%S%93V,3U895V.?J\89
M_LS(GUY40/7M>&"%O#MF=FEM2":U1(CVJ"]T<SN;8U?UG52*X88T1#31,<R>
M5+DOP9TQ*QHZ>]$Q*S%<;XQA:U9:[5>HX'>2M@!TS8](M)BJ25Q+&,`9IY6:
M%?;G3Q3B)\>'$><8PT6%2XBE9QW4RXC[&<X=9=0EA)W1S7KU_:OET/ZC`^[.
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MUOJ<YW>8X#@.`X#@.`X#@.`X#@.!+?,7[V_8^!$\!P.@.T.D&U[9W>7M]BM5
M3@T<Q7S=<E'*Y79(#;<FDV"GFJL0U07-"YL438ZQY\Z^0;FD&Y*VF>[&3%Q(
M0V11F8N?PZ1KB(JLM6Z=M`&=/$"98U.HR'GM9ZGU1#$:XJ\FJ5^6.U-FYJBW
M,I!D3IG<L=D]9*:5%;[[8Z-#::3)E=[O(1%)JU6S3IAZ/">@9.K'%3]3C$:T
MU%$U<8F:MUK*I5AW#(ABJV,BV?:1ARQS8YB1`?`/3FVUQ'I'GR#KB932/&:E
M(BJ-6K=?/,OZ=Z*<%MR/[1C7SV:/=VI3K;BLLA7,HQKX,7*[.MVOER\$T(5Z
M\W[/;L<Z5X6&W(K&(;C+G;E[C;FUWXJNG'H@A/1=<>_H*"?V#6G0G3*$HE)U
M[[*KI9)2VU6H[/T]?Y):]KG&WF&[;+':4%P6LQ_&9;ER)LWO=DG$5EMY9Y&_
M_P`L<WAOO1;=R]9WN"I]_J,=_J&K.^J':Y5MK1LG%K%9W#=KM<Q96KP1IZ$E
MVR5WUS+B2</+;9GK3%D=YO$+RTEMYYYD:XQ<<J6,[T4X+;D?VC&OGLT>[M2G
M6W%99"N91C7P8N5V=;M?+EX)H0KUYOV>W8YTKPL-N16,0W&7.W+W&W-F_%5T
MX]%<KW1;=ZC5Z;0@U_J,VLQ[ATM7J\$C5:-OV)9?IEO%"L[$"DI8/)'"A5U'
MT&*PK$C#N1KZY;N$RLS?Z*V]+-\3<UG/JT#INZ4I^B[$$GD;+BRPJ)K&?JJG
MDY5MW"=-%`Q<W6#!(J7`W38MAH%0EOXI8Y+T<(,;0_*P\^T[$8<Q!2B*35JN
M/+NKS3!P+8=_P_2?[J+?ZD+\D=5GEI_2I\J'`<!P'`<!P'`<!P'`<!P);YB_
M>W['P/_7^E.Z[EU!K6=#%[&VKK:@$R$%TG`'76\UBJSIPUA[R[Q"'$.E($B3
M!9D?R:G4)4VE?ZN<]OZ.=KB.<O/$3/*%^@3X)6#"*"YL0D,)1(T\<1@269D&
M?!F,HD1)L*7'6Y'E1)4=Q+C;C:E(6A6%)SG&<9Y4<O@.`X#@5(C?Z&'M(:C%
M[M41=VL<9V97J<1L@:#:3T1CS'C2@U>DS6BQ2,SY5WO+89<2GPU]N?U<]DM:
MFKK#]@+U2+5,L(^KW&JV2?49ZA=K@@+"(,3*P32N2VH=88PZ9(>"STN0WDY9
MDI:<PII>.SM2KL%3V>1FZTV2'K-BCVVLR*_=<ADTTXR>%.A[;FQQ<3J]BLDT
M2U0CV3T)6'H7E5N^::SWVN\G]/!4YPLW*AP'`<"6^8OWM^Q\")X&#]2E@,5W
M4L_(.9-&3+1==0ZT?-#'51R5=#;;V_1-76*SCY2'&50IM8K]PE$&I&%HRPY&
MPYWL=WMY)Y-:<RR*\[:W#1#.T'0]:-6C3U)JEW.F[DJ@.5,WK;%7I9<XW`H[
M9LXO\PTUR?"89@1H`(</3A3B9!E]]&&%RYSV6(B:[\?X=2=<W.\9MM-U7L39
M9V-33-IU')V"?J/4/:KR#RFR:`WE8H3,7?6"0.YU*7?-BZ\B2YP`?(@P1R&!
MS<25)B'O">D=IEN8BKB,_K\]D\[;-S#];:BW.5V"><CV;4[4=1.`;(3[C,I]
M7H6XRMKO+5!8$1J$0E$*9+$71HVZ\P_,L(L<'RPEB:QE#-1*5%S%.V=CWDX"
MZ?X%OHP]NKNPMC4[2:I^PI#-G#TA3VW@NF3EPL!,3:O`M8BNI?>F(=07;\VX
MA")3\969&6;>&8C^U2PW7NP=C;3ZK]2C#=['DZKKVL]8,-YVF0BX.G;1,:WL
M_3%5Q5R3"C7(G#7."M[>FB7D/.$(D<@-)89;;Q,2F',S,+,1&F<9Q_*Y6_J9
MVF)ZD"FN0]7$.4JM;+TUK65%)R]=BB5DB[1#UTN:N@XK9=T5FX^'6VK0OR,,
M73S39!RNDXR7UON]HRW-TD:8VW>:=/\`IVZJ]HPM/5Z.:V+6*P\YK6GVDCN'
M=A"WWH>4L=4Z">A79;-2F9L>R`[42R[%/;;.&)/D'XR),4(1DXBK)RY9%>8F
M:Y\5#>K3%SCBY?JG=3NVK%M8=9I&UZ5K1"]1[8NI:!>)5O,:YL1:'TJ_]+S;
MS42%4"NSPHH+-%E]DG5L>S5,MPPT@J\W'Q/G3R+JYOGQ@G3%577^96R+U=;M
M&$+8@0*>&2;+:=C;&EHV)+J<V#01M+T?TP'V]7-8V3NC2X4`*9,;)GS"JXI!
MZ1#9BR'&82LOORXEN3;IQQUE[:*:;F66H56QD1601"P5L&;GA%3H9-0:85&1
M9\H5DD/<>@$,CWWU,^.PM;+O<[R,Y3G&>:<IQ,PLG*BV'?\`#])_NHM_J0OR
M1U6>6G]*GRH<!P'`<!P'`<!P'`<!P'`EOF+][?L?`__0]Z.VM3[DMF]9MQUA
M?36K7HW3R0K(.W11%$L->G7=5X46&@K4(M=;LA1T0AC"7G5#O(O]S.>QY6<8
M;SUF)NX[.,3$::F.KJO7]4=0<&Q:J%B@VPM:U`"#Z=ZM2Z@PR>O$"GU6IY'0
M]U5VVV<1O^@T5*3*&2;)(D2K96>5$/PGQ7?(1X\:'*G#5Z<YSGVZ/+8=5=5_
M@5YVS%KK*JU/(.:K),B';=:SMWIVK:R1':TVT6!ZUW5J*SNE=C62TE99/$8K
MA]J7%#R)47*(B7(:M1$Z>G-R8&D^JI^JV`X4.[/G[<D;*U>#%&9U\F5T8_K9
M[H^U54;^4GT4+L.R:]$OS-PJ..%<QE37,F8^)<5YU$>#(2K5Y+TW^/=X[!7N
MJ2XY@$AP+:=1ID+7W2-5+_`L6"90R=DZ^8ZI)NWWP-0I6WJ1;3.,W*ST=!AV
M(8'R;`,A.X9P4AI;8E,G]8[7<_PDJI3.IX/?-$%RCFUKBU#34AY,;9F3E8!C
M:7(V[?WR$]XL"Z@+?["M5*U*<%>VH-Q:MTRXI&P&6YK4]N7X#-P7IK5RX\.P
M^U`!>V[SK5;^$UFBZ^9LFHKU=MF5\-7Y<R_VW7EJS9-:UN66>L0\K7:5K&PQ
M(Q<G)\M*?G=]4*.TAE4Q3]GGRPS&(YY9QT_Z,.3&M=T[:6O'V*]K'I:`:"VA
MBRCA*0>WKZ+M%9)R#,%N#/E.6BJK<JDXHZY+1Y66FTJ9<PN1DDPTB.5QT75/
M.8GG+]5;I]L36@?^GG"-4%M>T=$#NFP5:<2W!LDG08-<U^+%;$9C2<S783>6
M"8YIB6N$MQR2EI*4J<;QCDK&GN;HW?\`Z9Q-O8KS;F<!P'`EOF+][?L?`B>!
M6[A4P5[JQ^FV6)F:!LHJ8')QT/.QG_+3&5-9>AS(ZVY4`A%5G#L:2RI#\9]"
M'6U)6A*L3FL34W"AC=]Z1F/6D9'W%KV5.U\U9L7CS-OKL9^M>A"#H:[2+)C,
MF)'$^E"<?+97*TM-CU.-Y>PTEUKO+CNNV>S&[IU']+M*J<6$SZ/M58MH_;MC
M:!U=FAHKQ*?I^L8V#>X9YVREZU4`AQ,5+"^^8DPV4/O-/2GH[&%2$2X6-.J9
M_+9RFX]'BC]B#F-BZY@V6@@R<JSP9UA!,E:I7T,@R!S)-#LC$@6/CQI8N1.0
MKNI::?AN/82EQA2K<=TJ>V%)C=073GB50]=UZS4HR&V(]?:T$C5=VOSZ9#]#
M5J':;:+.>4D)&BXV*\<C2,-*;RE^--:>[OEW4NY7'(VZLRO->V5I-RB%[S5;
M?K[X>:W$%TFK""(A45VD`@HF)82[4Y^"I,:OC(@!J,06A6&FU0<L2,8RRII>
M5Q7X*FZGFB!&X>G2Z6JG+";"U-9KF9'2WJ)(@G:P5L,T9+<-1)6*W+;?>G^`
M256R2,(85CS21TKNX6F.]W%QW*U1$XFF8["LO2MLJH+GS-WUD%5@9!FO$BM`
MVF.KD.5FS#&HT6O3U!I^8TS)H/74.#9#3>)\=D?Y@;)8\%;F)B>JQNB>66@5
MRRZ*)%H6M1<&CN,U@15"%,2Y*I)D:5#MU<0;"$JJF*8+%DLAJX*@.HD2V(BG
M([#+T93[+6'47')*U<TR"V)H/;9!VK`+3K'8!-AD;<WJ]&FUX_-;2J(+EP+$
MH4O,A[$F)$+05J?[GBQ4RXW?RCQFN\N)*U1ELW*R<"V'?\/TG^ZBW^I"_)'5
M9Y:?TJ?*AP'`<!P*):Q^S9DZ(Y1[=1*Z-1`G-SHEKUS8+E.DDW&74C9D0@(V
ME1&(4"(_EM3\9<:0Y(0E24/LY5A:)E8KK"K*!]066I>$[.TWAY<0<B"XK15V
M4U&G-)C8+29;..HI"YL2:M#V8[*%QUQ<.(PMV1X:LN,]U_KVG_/LO%6AWJ)[
M6];6.IV#QIZG`?I:EF*=[.&9[W=AEO:U^O/MF?CM3VR6?(-Y[,_R&.W]!)KI
M"V<J'`<!P'`EOF+][?L?`__1^ISG=YC@.`X#@.`X#@.`X#@.`X$M\Q?O;]CX
M$3P'`]9@?I:W1<ZK8!QRP5376`.]>KJ_ZW0S7'"E@()VOU#;--!'[F_DO+"N
M`S5`.9EQ7XK."$9TG"D>&Q,$8\YBI==T1_B/^'`LO09>[!5MIBE;("Y+;=(;
MQ45DEY%^M>:T*W/TLTGIT;:8L-QL=CMEQ(5!^A19^')LJ(W.9D+8;1`;:9;P
MV_E(UQ%8Y?\`=IB\]!12XR+^,S>&,`;-9=Y7P$3+6'<9:<(L^[HES@3!R]=Y
MV9&U"T.K<38!)AJ:T)S(E0TQFLL,2&G)SS;S(UU6.S5;ATL'#NX++LZ%8ZM+
M@V\Y8UE*W9@$LA`C@+/H&N::F-/QV9J6;$XQ.K3<Q<-S,-F7$D.,*>:4G#BK
M6;2-6*KBT97NE*Z,].741HT]L%A/QJH-LHE9;3.NMV#:UCV/5GPZ4_`+[!L)
M:[F1;D_*B+8QV<B*+CY1`AY2TUXKBL3!NC=IU5R>#9/1L[?]GW*R/6I]-.V1
M=-=WFR0,W'<`6?7"&M:Y408F!6:M4=A@-;'$2Y=&@3691<8^L?)<E>(U/:=9
M:C)TW)&NHCNB2?27LPU`UC++W2DK/Z9%U2L5-BGM[)U5BS@ZO2+S2UD;'>Z!
M=!M^"SYZ;JJ3"'QWYPX,VF9&3YKVH^^TKDNZ,XYN$QT'JC4LI68&P&0924WK
M6.(.AQMH><K<8+0+-JO9C(=ZQWFP6?LME!OIR**7*+RGQ#[\9YQR5F-C"YM_
M)OSR734G2,YJ[:`^RM'&"%1K%JW'<JI'7:=O/$8Q#<!\X9D"$4J9L-_48&!7
M8UFFQER8@9;Q7*8[^6X;[;JY%B*E)U7'Y=WN:8.!;#O^'Z3_`'46_P!2%^2.
MJSRT_I4^5#@.`X#@.`X#@.`X#@.`X$M\Q?O;]CX'_]+ZG.=WF.`X#@.`X#@.
M`X#@.`X#@2WS%^]OV/@1/`]6^.M_8R+0V(9B:\,AKO4"EMH=DCU>T`*_61#7
M4;I'1<2T'9M@O#5DOE&%C=S+,$2B@=-CJ17Y:8BWVG%/1<;G79%<=I44+U+[
MCI>Z=BA#MEJUX5`WF'HDF6UFX1J@(K]DWST*:?/M!*NN^$1P)ZOUW;IR6G$E
MZ<Z-,X7WGEQLRH\A<W/'8VQ,1^O^V[3>K+8Z+!91`P31"<([M'8NB=2%8<$Q
M,CHVM6[G0Z_7(5N\M:\K.0':[:BYHBS`3`<8A5(CG+S/>1X:YRFV,?IEY3KB
MVTBS!*\`C:P,,;,379^NCKE-N8T$+#G.K[IUZ;VY\A1/8$&V;$%R0F]WIC1'
MV)4(JR(9:8R9K#CF6&Z5V15\<IG^&N:UW#N"Y=3=%I-BL57:#5VI=8X"[#*Y
M6#`H-=#.JMD=+PFJ6J!!)70_*K<^(+V7EM#3L@FEK&9Z>\OSC"H%B9F?\I,1
M&F9_7\LI?ZE.H&DWG:T1):DV^K5*=UN[=("2E(M$RV/Z]Z:YW3S&KVK:5.&;
M"B#QQLY$VG,:]IOCYK2)#;;F(*_UVW)<Y\KMTS$=\>MK2,ZL]S.,,U8O$UY#
MO94SKO``C"I)8SDT+NFO]HW2>-`ZKKFYK"2G/BF]:8E1CIJT5<&0#D%R&\XD
MP<PYBY3;'CC\,VH_5EON\W2NG01C7D(?LO6_2`+C5PO6C5@J]9LFSMH=7%2M
MEV"9!;(B9G^=:U0R]F+B<\U*C)A1TS$^6=F3)NG'C^5G3IB/\_PGX_6IO$=6
MPTDT"UR;.W\#19%0<K51LT`?5RI_><K2Y9^QP3&S7\6F-+PVU.&0VB`%2Y[S
M8M<M674SL7=)LC+FYZQM[Y@[0)K"ZN@1M'ZU<O=OA2P9&>3NT@+MG9%'+BA/
MIW;9H?K681!4A&5Q)SYZ4!+^.P^F:A.,I7.39IQ^5_U9L/9K=]I,ZU7"7:F;
MIU<=6FAD!X<2>-#B*/6QFSKW42)`<\;+QI!*HR](>RHDYM,;&(9_+#B%N8\9
MVQ,X_<I,14U'2'L+YIS6P[_A^D_W46_U(7Y(ZK/+3^E3Y4.`X#@.`X#@.`X#
M@.`X#@2WS%^]OV/@?__3^ISG=YC@.`X#@.`X#@.`X#@.`X$M\Q?O;]CX$3P,
M5"?ET\:\>F_@KYCOVKXE>Q/0WC=_PHWK?UQY#]?O^!X/M7S_`.GN=SS'Z.[R
M8RU_;'-B`3\I_P`2R7LOT3Z;_+^5\EY#X9?E]^&/J>O?$'R_L'^S_/\`F?37
MM3VS_1?9_D?(_J>=Y,7X6=U>?+LW7?A=[(K/I+T#[!\[%]&^G?3WLCVAZ;>\
MCZ9]F_T/SOI#Q/"\K^O[-[W=_D>WE9SU5,!^73VJ<]+?!7VYZJQZD]@>AO:O
MK?V^![/;GL[^E^JO5/LS_M']+]H>5_\`W>%QA?[=;6A_X4>J*UYGX>>M?;=J
M]'^/Z;]4>I/8V?6WIKQ/[6]M^G^WVKY7^7\G_P!H_D^,>4SX`GPH];V7TY\/
M?B1WW_6'L3TWZW[_`)"K>9]2^0_M[O\`LSV)XGFOT^!Y'M_4\#C'DS47=,U3
M^4?T(5[OY<OAEZY3[<[OPS]"?$KQF.[[5[/_`"_ZY\?P^SQOZ?W^[_'V<8_%
M+_:^MKLCX'>K0?A_"GUU[)D^F^YZ0]6^PO4N?.>P^[_;'LGUCV^+Y?\`D?:?
M^U_+\8\G]OS3G$?A#[")>U_AOZ:]-3_:_M'TQ["]'^?>]J>TO,_T#TU[3\3S
M'B_T7Q^]W_U^WC"9<:O_``5]*L>E?A=Z)](0O*^G_2?I7T%YDA[.\#V=_9/I
M#SGFO![O]"\7Q>[^MW^,+_:\W:H1/@E\:Q_L?V#\0/"V!XOI_P!@^S?6/DZ'
MZP]4^R?Z5\5/27LOP?:/].]A^8\#^0\SQBS^VW\.P'*RMAW_``_2?[J+?ZD+
B\D=5GEI_2I\J'`<!P'`<!P'`<!P'`<!P);YB_>W['P/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g275067g33o37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g275067g33o37.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1.44&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````R0```,4````&`&<`,P`S
M`&\`,P`W`````0`````````````````````````!``````````````#%````
MR0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````$/@````!````;@```'``
M``%,``"10```$-P`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`&X#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))#OM;139<X$MJ:7D#DAHW:3"2D3.I8#[WX[;V>K6X-<V8]Q.S:
MV?INW^SV?X3V+.SZJNK6XE^!U04>EJWTG![;0Y^/;]$6-KN9Z55C*_I_I+?4
M_,LJN#;TC&R;F7NP+I;8Z[TQ>S83:VP7U[/5<VJK(?=Z^1Z'I?:+F?I?48G;
MT3!:[>.DV;P6D/\`7&X&LAU6Q_K[F>GL;]!)2`86=?<YE77QZ]5?+6AVUMCJ
M;=VPV['M?6WVV/\`TGZ?]';Z'Z%%.,S)ZAEWX/5C5D67M:ZO\UK6,^S>BQA+
M/6?]KP[K=_Z2KU*,G#V?I,_U6KZ#AT^D*.FVU"FYF0`+F.W.KW.8'>K:_:SU
M'^J[TMF__BT0]'Q76NM?TRU[W/-AW7@B7/=DO8!ZW\T_)L?>ZK^;W_\`%UI*
M1VX&0QK<G*ZV!53#GV:-FMUKK*B[])Z3[/\``46/KV?Z*K>FK9DN=DXUO6FW
MY##CN`=7Z;664%N3E?S;V[J<A];_`%-MGZO59]GL]1)OU=Z<QNUO2;1[6LD7
MB=K`ZMK-WK[MGI6>EL_T7Z/_``;$7)Z1C93K79'3+;?6+R6NO!:/4&R[TV>M
MMK]7Z3]G^$_XM)2]N#U,VDNZT*3ZKGV5M8PCTX-EE+?4=^B=54^K99_P++WU
M_K&1Z@\G"R<5^1FCJ09NOI<Y^W<YWLKH9@N],.<W[3:ZNW]%]#U/T./^DL]1
MG_5[IUFX/Z18X.<^QP=>""^QOIVO=NO][W,_?_?>B5]&PJ]^WI+SZEC+7E]K
M7DN86N9N=9<YSO?6U[_])^>DI;&P.J`4.?UJ7L+1<P!KFF/4J=4WU';M_KV>
MGZMG^C_F_P";].%%'4'W&@==%EF**69#16)#V-=O/T]N^[<U]M?^D_[93W=`
MZ=<\66]'<YXB#ZK>SWY'^F_.MNLW_O\`\VB9'2L?(R'9-_3KG6V%I<?M$#V_
M1;#;Q[/^#^@DIT<*ZBG%QJ'Y3<BSTX]8N!-AK&VZWEWYZ,,S$+G,%S"Y@:YW
MN&@<YU3/\ZVM]?\`77/OP.B-KBSIX#+&[9=DL`+<=M;"UI.1]&BO$K]79_PG
MJ_SER)57TVA][J<-^_+N8_(<W):X^HP.ZA4^QWVC]%[&^I_Q?I_X))3_`/_0
M]!Z=EYUW5NI47S]FH=6,;]$Y@]S2;-MSO9;_`*O_`,)L0<GH6'CX;GUOM`Q<
M2RBIH=MAD>I].H,M^DS_`$GIV?X7U/2JV+H;:J^H=1I^U4Y.2U[#>*J74O:2
M#M]9_JV57O?MW/?4RO\`2^I_Q==W,R\6[`O%-U=ALQ[+*PQP=N8!M]1FT^ZO
M<[Z:2D&?A8F;B@9-+;O387U@@DAVS\P-;9[O^M6_\6JK>B="]K7=/;NT!/I6
M1)(;]+:UOTG?^C%IM^BW^J/R)TE.77T;ZOV.V-P&!VW=#Z[&:0T_X3;_`*3_
M`#_^+>B?\WNA_P#<&G[C_P"25F_U*[69#2W:`*WM=()#WCW,L#MGTW,_P/\`
MUQ6"#*2G._YO=#_[@T_<?_))?\W^A_\`<&G[C_Y):$%))3G_`/-[H?\`W!I^
MX_\`DDO^;_0_^X-/W'_R2T$DE.?_`,W^A_\`<&G[C_Y)%Q>E=,P[AD8N+73:
M`6A[09@_2;SY*VDDIRG_`%;Z>^JFD.L95C^KZ+&>FT,]8^H[:WT?HU6>^IGT
M/\%9ZE/Z-"L^KW3:@R@"QU>38QCP7"0*Z<IU>PM8W_"OLN_2>I]/TOZ-Z="V
MD#)_G,3_`(__`-$Y"2G_T>YZ26OZYUECGMLDU`M%OJ$"+&['5PWTO]:O5_1_
MHBY/1.G8^#8ZNLS1C6U5RYQ]K@;';M?>[?N][_\`26_Z15N@9F/D]5ZI<RR3
M9Z;B/48^&L]2H$LJ;OH]S;/9E?K/[_\`-^G7?RNI8&1A6LIO8]U^-;;4T'5S
M&C8]_P#9>[:DI,-6M_JC\B=,WZ+?ZH_(G24LYH<(,Q(.A+=6D/;JTM_.;_;0
MQC4@`#?H`!^EL/`:W_2?\&S_`%MM14DE(CC4D$'?!D?SM@Y#FG_"?\([_6NM
M0;953D6,>\MW[',#R\@E[MK_`$S9^C_G[ZV?H7?H_P!&SV?HU82DI*85VU6M
MW5.#VB-1Q[FBQG^=6]KU-"+;FY#[6M:\6-8TR=KAL]3\[:_?_.)P[()`]-@F
M)_2'22S=_@OS6NN_[:9_IOT24D24*7NLJ:]S=CB/<R9@@[7#=#=S=P]K]JFD
MI2!D_P`YB?\`'_\`HG(1?4J`!+V@&2#N$$#Z4:_F_G(.0YALQH<TAM_N((,?
MH,A_N_L'>DI__]+N^FV9M_6NH,?D^IAT'8<9S*A[G[7,<W8UN2QM;197^L^M
M]I_G:D;+Z1TVG!N->.V:L>RMFZ7`-C?MVOW?GMW_`/G:K]&#:^I]6<6"IK'5
M@AK1L`#7.]MPI;ZG/OK^UV^C_P!Q,/?^L'RNL8%_37N986MR,:ZRMSVN:V&1
M2\/>\!M;_5MK9Z=G\Y_@TE-H?1;_`%1^1.F&C6CR'Y$#.S:L''^TVQZ?JU5.
M<2&AHNL9C^JYSO;MJ]7>DIL)+*'UDZ<;Q0&W%QL=4'-9N$LGZ+6.=;9NV_S-
M=;\KZ%UV/51=19;#_G3TW>&%EX<6[_H-/Z,![WVNBWV[*:_7]/\`G_3?7LJ]
M3]&DIV$E5Z9U"KJ6&S+K8ZL.):ZM_P!)KFZ/;_5_T;]K/5K_`$W\W8Q6DE*2
M!@RDDDI`,7:S8RZQC?=`;L$;O5,M#:]OTK]W_6*/^%]67HN]9MAOMVMWS5N:
M&.WG\Z&>I^B_P.RQ%224Y57U=Q*\.K$%KRS';<VAY95N8Z]AI?<S]'LWL8^W
M9[/3_2O];U$-W0.GT70T$TYF0SU*"VO8&54Y`9CM;Z?\UM_1_P#%_P##?IEL
MH&3_`#F)_P`?_P"B<A)3_]/N.@Y3,CJO4S2Y_H%S7,8XR`_=;5D.;7MK]#=;
M7LL8_?\`I:[/TOJUWTT:&7C8]'3\@45,J#:'M`8T-@;3[1M5?IV7DOZEU.O(
ML>^JAS#2TM`#6D.)8UK&>INT_/LM]7V6,V(-WU@P<K!<UC;&G*Q+;F2V8#9J
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M^FEQ/VS'/A^F9_Y-(=1Z<YP:W+H+G$``6L)))AH'O4*NN^O6YU.'D.<&N<WV
M@,=#;'M'JEVUNYU7H_\`'(-W5CET9-#J'TED[2_\YK74C=M(:YN[UO;_`,78
MDIT4D[_I'XE,DI22222E(&3_`#F)_P`?_P"B<A'0,G^<Q/\`C_\`T3D)*?_4
M[CHC*J^M=5KK!&PL)+M\N#W6O]GJ!K6U5_S+-OJ?S?Z+]'^B6IU!K1@9)``/
MHV?]2?[E5Z7A9V)9EVY998;7!S#4^PS`]WZM<[[/1;8[](_[/LW^I_P7J*O;
MUBW(P"'8=M9R,2ZQPB2QS?;Z3M[:_IUN]7])Z7_@B2FSBG(%F3Z#6.=N9(>X
MM'\PW9]%EG^%]/\`ZW_F([AU,UY&TTML<U_V4G<0UWN;3ZNC-[/H6V_VZO\`
MA$!@RZ+;'TMJL9<&.][W,(+6-KCV57;OHHGVGJ7^AQ_^W7_^\R2FMM^LVS96
M['`V_P`Y=+[)(/TO09CT;VO_`':=G_&[_4KE_P!DA<W=]FAK7N.W<"7;'^C7
M[M_M];9ZO\W_`-76C_:>I?Z''_[=?_[S)?:>I?Z''_[=?_[S)*:^WZQ.HC?0
MQY<-I:"'AI-7OLW^K3OK9]H]6EC/UC]'Z61B>IZE37-Z@W"RFYC@]L-+'^V9
M=8]SJ_8UFZNFK[/7O<S?99ZJL_:>I?Z''_[=?_[S(>2>H9-+J'5T,:^)<+'N
M(`()AGV=F[_/24V7_2/Q*9(F23XE))2DDDDE*0,G^<Q/^/\`_1.0CJOD_P`[
MB?\`'_\`HG(24__5]54+:V6U/J>)98TM<.-"-IX4TDE./9]GJZG1T\Y63NLK
M<=NXD;C[J-UL[FN]/%S-K=O[_J_X#U+O[.;_`-R,C_MUR.:*77-O=6TW,:6,
MM(&X-=!>QK_I-:_8S<B)*<FUM5?4\?".3D@W5V.'N.PN!86#UW.;^EV,OVX]
M6][Z_5N?_,*W^SF_]R,C_MUR.<>AU[<AU;#>QI8RTM&\-.KF-?\`2:UT(/4[
MLNCI^1=A,%F34POJK<USPXM]WI[*RU_O^A[4E.9DY.-C]0;BOOS)W5U.$G:7
M9!_06MM>YNZJOTK*[?3W_P`[_P`%^CTOV<W_`+D9'_;KEE7]1O%SGW]%?DOH
M<\MO;7J78_J^A94Q[7N]_J?JS_5_PUWI_P#"GNZWG,>P5=.LM<^FFUU<D/8;
MO4#F6^U_\TZMG_@O[GZ1*1Y.3C8_4!BOOS(::J[-7;`[)+OLUSLA[F-957]E
MOJ?^8^ZZNG^D[*UI?LYO_<C(_P"W7+)OZI;>?7_85EMM<OK=<R'!U7]%_P`%
M8_U&OR+/YGU?2_2_9[+W^K6B?\X,]E;/7Z=;6]SB-\.],_S#JF#<UCV6Y3+W
MU5>I]#+J]!)2V3E8^/U)F&^W,$EE>CI:XW%K:;?5]3=6RIS+*O3>SU+/5]3]
M)53ZBT_V<W_N1D?]NN4ST_`-SKSC5&Y[VVNMV-WE[&^E5:Y\;O4JK_1UO_,8
MK"2G"R,G'HSQC/MS`&NKJ<0Z6;KY]&Y]V_\`05U^A;3^F]/U;+:O2]7U*-^@
M[I=3BTNNO)8=S#ZKM##F3_F/>BNZ?@.M=>[&J-SGMM=86-+C96/3JM<_;N]6
MJOV5V?F*PDI__]DX0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D
M;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`R0#%`P$1``(1`0,1`?_=``0`&?_$`)\``0`"`@,!
M`0$````````````'"`$&!0D*!`(#`0$!`0$``````````````````0(#$```
M!@$"`00+"PL#`P4````"`P0%!@<!``@1$A,4"?`A,4$5U187&#A846%QD997
ME[=XF!F!H;'!T?$BU%;6V.$C)#*T=D0E=3:V$0$``@$#!0$``P``````````
M`1$A,5$"06&!$C)Q\-$B_]H`#`,!``(1`Q$`/P#W\:!H&@:!H&@\Z_6-S_?#
M`KZW72:CGJYG:G&W;SM.@;I"H*LEI2R'R>VK#O/DWG59K4XHQH'Z&/4#:&65
MEM.,J#H_)>F*\"`V)^3&XJHW3#--]V]MCD%Q(V&I&IX%&'BZ&MRC`=OMTJ%F
MV^(P+<5`JPK>W)C*4DKRS;AVNRZ5D;O/@,L9*:5AR-I$%&:,E.L,P2HQE`L#
MWM[Y8")E0,T;=[C8K#W1;CS@V/+Z6OE4WS5I:[D@,?A=95W%QR9WE]'QMVKU
M_=7QFZ4GD*=.F2`$F)-0(W$X):A:/>?6&[*[-YF8!M_G<QKQN0[3HC(6:=YW
M';@:@@596$;=\N2J9T15E7,3W7&XB7`CJ,E.?&Y8-`WGH<%\Z?S><!T2*B,N
M!E6^/>NWOE[H&*N(F8NAZ/<GT:*/5$7ZD*H]/55RQB#47))G8D>/E[9<27<=
M73LLD"(IA:493>$H*H9F6Q`YJ"Q485^LO=?O*G-;9L%@\OZ?E22G=O+U*9*"
ML[%\'IR2.L3,JNR71DK-HMV:UR[QTRG4@GDV1M6!.4EBP1JTYZ!N6I$[>6(B
M^R>J<W.[T$THIZLT5;GOC#>UR;@LL<K>6NRI$H@$2H/=YN2S<:27S"PIN_FH
M`612;5"T=?\`351#:A<78T+>E&T)4R)$28C,VFK8QNHW/[E:KOQVOBNRJYD,
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MC`I0&UL,:W"?;I>;4YNT='2>)\ZQB*P23R9%$W&8Q2S!',9299.FP;^!/AE(
M.32;"@HE:^L7JE6QM^V\J+VWN"BD8IX3_&XM%&IXK8Q+M^MAW-AZ!2YT0GD,
MJN%&;+8G+A*(3&[`DCWAL8FUT:Y:6S#0-;VF5MB[I1*BHREK;UN8W?7'>=3P
M%V3Q!CJTV,[E)>_6FJHFP(Z5></J&V:2A-;2"%,4EGJ194I]D,-CN9X!KS'L
MI<%G,7H"!(5!'-"8BN[MJU630-!__]#W\:!H&@CBXK.8:3J.T[EE12LZ,5)7
M$XLZ1DH``,7&L,"C+I*G@I$`P0"QJS&]J,P7@6<8R/...<8T(SA0#'6(2.I'
MZ*QW=O2Z>NW*TX%"+'J=+1LJ?[]7N94XM2MJ<#6TA9RZ_A#SBQ(_-;@C90AM
M2=R;G0MP,RD'RDP@&2VO7:7'S?K4JW;']O987!)<YMBFLG.=O$PE[/(XJWPB
M31O=%'MK,MJJ;1H,><)4R32-SI8X)UG+)YHA60D`'G4ZSI1*SU[MV8>M2VJO
MSXW,98;C;/"C]%V5,^/%+3U%%`II?=2_;HR291*<-1S&EBJF[D0([A88>'`U
M:@LPL(TH3CR5GK+6;`ZTJHVFPF^I8`P21[LE-<$:KJ6QB=L$EKI6VQJ0M]K!
M#.&DEW9C5BI.3(ZN.1A2+24"H92@"G!?,&$F&K/64A;=>L-JJ[XYM^1.36_1
MBX+PC%*.N:X2-BUU(:5]P;92]SP'5O?3"41;I7#)%4K@@,?1%DEY=T(T0B@J
M<A+S4F*O9HKKOPLJ.VW8J1ZJ>O0;?JXWFUALK?9P"S7]+9J28VY$Z4=XK.<0
M<^NS8HLB!,GO%K;%A>9`G5$$A-5\!`*R6.+6.]-C<.M3VA-4(/GSI))DR,AZ
M*M7Z*^5,%>X0*P(1<+@_M=9V/"U\X!&V!=`):MBR\LAR5+4990RB@GX*&M0!
M5+/66U/?65;0(Q8`JXDUD+HX])H%BP7=:^0^5MC-'6_-/N.X#P!(52II+4M4
MQ#2[0ID(VPPGI!20K!0^2K-)3F5*EK$.W]%SZ'[W)LQU7*6)LVGP-KFS"U6&
MV2"!RF<%N=%CN0@E[CSXR%+8NF4\`)R#B^F8,3F!-S@)F!DA%52.XQUAL^9Y
M97U?7K6-<0B4VBW;89M!W&"6!-I]'7F`;C)9(X68B7%JZLC+PPV!#GN/@QT8
M12EK7DKBAA6E9+.`&+6M2W1-ULFS%53K3>1$SDQ\&D4L41&-C00YT>79_6H(
M098[NK0-['X3P23'H6G-5.B528G=&I27X/6)"',PE$:L]9NFQSSK.]H];2AS
MC$MEDL;NAU@\VXTR$4`E6(O,H:P0)MLUT<84[&MY7E$B(A3N0LPX%%X9Q9YT
MG"SGTRHHFVGK+^RGK-=H[>&F\NLW=FT5W\#XKD<<7N"%N:3K%)J1NDK^^,F7
M2.DQ-\L924W-[HC6+4*XL0UQ!HVU.J6D+/6<H6W.[V8/([1BVUV+-VVJZJLN
MJJ92XR]]GD\E4@@SX%)/&>N'NLP(JIK>V$+DXJ,/F1J"W$:),7@`BS1ASG'&
M+$=>J2)+UJNTB%L'E3,72QXO'C9O;$);WAXK*4%(7OS#29SB5U2]B/3IE(7B
M"UB]-N"71R(Y80FJ"2"0'*1"(!;3UE-U-;V]N=^VU/:5JZ;&R";UZ5*%#@#P
M.YI&5^1068@KR=N$0>U"<""1MT-G)Q+6M/)%S65"@H1`CB1X-T)B84_BO6DD
MH+4LZ%WO5">G&>#9E&"F97(9@.YD);/=<-IN).+M7DRK"`,$UC%C@G"!\3OD
M#?I<SM"4X"=8HR(TE09+7UTI/DDZQBA(_)Y%#4;%<4RDL5!N#4/K5!*Q>)0H
M0-^V)\C4=MEU491'8+(;&UUEJ`E&<9D`5YIX"BN)QA11E2I:G*.LWH%BEY*=
M`O<'RN&F(65*I?.VYBD"H@I%7S+MAE+F\Q429N,:7V)Q:+[FFU7(UQBI-EMZ
M,>`H"@:98$A9ZRW&9=8YMI@.6!5*%E@H(Y)+9F---TWQ74E/@PY9!;03TP_G
M%RDI,)L<&HFRSAMH,HQJE0L)SE62`HRA*-"I<+Z;[K^'IZ;_`)NV_P`*^17E
M9YN_*-3X/YSRU\D^A>4?@?I/(YO_`'^7T/CROX>3P_BT*S3_T??QH&@:"$KD
MMK;K"&XR$7[:=.0ANL%@?F[,8M>>PV)%S"-'$`:)(G(;)4[MHGEIYAU`G5\V
M$PL.%`0#SCEXQD9=4,[HSJNY!%&B.P_>C5<5<6R;[=UY,NDF\E99<KC]2;?;
MBB]M-=(5E(Y)?!,CJ>-N!\=$F2+F1:0K;%)I*W.%1J-.`,:N=DEN%>=42XML
M;:SMP](`)CC-(F0U2'>4B.<Y83+;@9[]DCA8+JLM%4XSQ\>;B9@2`]<Z&JE0
MEYIHN7R1\G`N7(D1'JDT[<F:BMP6WP*)(AB#<07G=9%!""D@NY$W=C&R\F9G
M^1B$CNXT3D,6<YR<G_X@^4F_VM5,M38J<ZG2-R5DE;1?M&$.D<=Q/3$%3O%;
M')`U*,/<TD*9.B0.=F+$Q"%(Z6"[C"4'&,&=*XFY,$`O()A;Y.1J%FZOJH=Q
M,>O!FWC;3A,M5[6*ZVAT1"$5JP%*Z0BK8'E.?A5-YR\7!)#K-E@SR1IFY?X.
M9QM;4H4)A85&J5*HX3,S%4W(Q%U6:FVWJXW'=#33J^R"TFN[W2)N6\AK4U0J
MM]CB;!"&.QE%3^<P$`62EFCD7;RDAZA`=A.<D)4`#A022:`7.S5VRO.J)98L
M\P]HW%TZA:'9IA\82B]-]6N71B"5^?(%4+K"(+72X5YL<J>/*)4XC*BR?DL)
MO2N!R0T)1&"A<OVRUOU-L<<TRYDMO;0W-Y-8(:@4Q(G=H@%!'N%ME9FTRW%R
MB%G6N9')8_I*J.\!!=G).J<Q(BR>4>(U.G-*8+Y-Q@&>J\K>&W5!6#=+3SDR
M;@H\GBMIJ9MO/26)(Y`Q(X(.M$*`$LG5I2&3-Y3?"A!0I^95`Y@HL'(Y.0!X
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MP/!-J(29TSG6$E+=BVYR`H;TYO.$$D@2'J$QTPM\EB&*V.K:BUFI;;B^X/:A
M&9DC@3S6I!D>O2JF1EQ%I!*6N9NY(HZV2I,RC<5TA9TYPUF2,J<X#D/+Y.<X
MS4RA.217JDI9$X3#7G<#0F&JO9E<$WBRQEW@-T5D2)POV=O%D7`T'2>*6BRO
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M1MK>E`D2Y*3AP7B86^3772JNIY=H]6$8,OB@D3145=M%7Q`EIW>,S4(438IB
MU6$VE2(2&RB0RARQ.FD#JH5+\'G+UAIHU0C\#Y.&"^64Q9E_5B!V[@VE"W,;
M<,4V;'C6(N+9W/03#J8R$/Q+^>$#[F<^'QX)>5!8AFX.XAYP(,YX"QC-3.K_
MTO?QH(UN.T&>E:MGEL/[-*I$SP&-N,D7,4(8%DGE;N4@*Y86]D9D>,"/5JC<
MA#SIPR$:4&1'JCB$Q9IP!&4`W!O5KZF:YJ"RGV*31Z:[<9,2\EN80QOPE$8(
MWPPJ=2Z8R'#U(6=(I0Q%D4DA/2MYJQQ5'G@`F(-#@P8"Q%M%<+.K6PMY"!N@
M-A0:<.$,H*?LLP0Q"6,$E611YQ:<$(RTR5*RN"T]B<\'H#P<PJ"4;RR3,<GB
M`7!&J<OGRV*\;T9*&86>0/D$N">D/3OEG);Z;J^46F](CL(U"WICJU15(K5M
MK7D"?(,*#<8+R:((./$6-:B+<U9?Q&:_]G#?1]S^X?$NM>O>`_$9K_V<-]'W
M/[A\2Z>L[P'XC-?^SAOH^Y_</B73UG>`_$9K_P!G#?3]SZX?$NIZ]X#\1FO_
M`&<-]'W/[A\2ZOKW@/Q&:_\`9PWT?<_N'Q+IZ]X#\1FO_9PWT?<^N'Q+IZ]X
M#\1FO_9PWT?<^N'Q+IZ]X#\1FO\`V<-]'W/[A\2Z>O>`_$9K_P!G#?1]S^X?
M$NGK.\!^(S7_`+.&^C[GUP^)=3U[P'XC-?\`LX;Z?N?7#XEU?7O`?B,U_P"S
MAOH^Y]</B73U[P'XC-?^SAOH^Y_</B73UG>`_$9K_P!G#?3]SZX?$NGKW@<F
MR=8)`GU\8F$J@=YK08^OC,R`=9)M3MQE86T3PYI6["YU=#F$T"5&ERIY8\X"
M(8N3R0AR+.,9GK.\"2=R^X2548];>&N/UHKF#5<U[0*IY/,%#NTM<?KMLE[^
MU,A:I6C-<`25XDKP-T%EL3)41J,($:HQ8H3Y`F*5Y6(N\]$67WO,?J?W)P*F
M6R#L3Y%%`]N@;*?W%^<T$C0@W67=*MOU7#AC8E9EC6N\GYK$CE;SA:H*R8@.
M`$CDF!$+*UCC<3*J,5ZTBRYQ%6P,?J&O4\_M)52$DI1,Z3249B>*WOJL]QEM
M1;SBJD\3P[)9FSQO:\_I%@$!8T1BU>C&`02P&8'+7T[I_D^Y]A\"4CO0\G%_
MDQ^&ENEW/^2/3@>$_`/1-GEK>3GA+H?-]/\`!_\`Q>?Z/R><_CYOA_#J]TK7
MCW?_T_1!O^LNW8QODH^.0K<V.M8:O:*3%)F,J1W8TLM:`6W4Y%KI%,(S`*KE
M=76#YW,I$#8E2RF0,V438S.AAH2V8UT6DQJ*J<.[R3QQIF$:D,2?B!JF.4L;
MM''E,6><F,4-+V@4-CB06I3C+/3C-1JAAP,`@C!G/'&<9QC595YF6SJC+!8(
MK%Y@T2IZC\)5L9L8:3+"G"-&V-;+"45?'1,);<_(^D0B2QE"`#TS&Y&W.ZC.
M5*DDQ1P,P6Y:Q8'K>0O[-\^^LZN=(U9Y?/E*^JPA&(^3<?L.[G90UPZ+G.TJ
MKPASD1$^\*NLJ<UT3CS"P>5$<6`3IH(["/4)VUM1EC'ET+R2>'B8?@.K.D"3
MQ2R+!$:`4ECX1$/Y$4.#EY;L")E"DH@Y-&S<94\HM_4$JBA@1YX*!A,#G`,X
M%CB&0RJ,#/3I@21@&I5O2V.)4X7AN$<ID3:G4*G%A3E849&<]($J,TPY*'&3
MRBRAB$'&`BS@.>[.SO:@S_KV_P#30.UW>S'Y^WW/@T&/S\>'QYX?KT&??X>]
MWOR]WN:#'[M`[_N_M_+CMZ#/O?KQ^WMZ!\7:QC\N?R9SH'<_;W<][X-!C/Y_
MWZ#/[._V^'?_`#Z!P^#O]W/;T&ASRM(39A,53S=E\-DPF=16RXP#PD[-O@R;
M0E?X4C#URFA>@$M\&+OX^C*,FI#O^DTHP/:T+I%9VTJA%4LKZ<KX@[NLJK`X
MT^).SU8EF/0N<\IW::-F92D=IBL06`"*2Q\5.#`%_*<PQQ6;SC7A&((.26YS
M#3P[#-JI<1DD(35JX(6&42=IERT;99=L-<A:'5@3O")@20J8MTY33"NHNPMT
MC<TB%DCZYL94:-T7)R4H"%BDLU1[3J_M)X)#//\`4C67DPR^;WT1]TL$\C.@
M)_)WR,\M-GD?\F/!?(Z+X%\"?\3H_)YOF/X.'#M:'2?U_]3T@W!%VC<=OAB$
M[B=`T3N698XPF-D3<9G?UP4'+HE)-JFXBR*GO=7(*_:*9DT+O*-U_:#Z0F9D
M4D.,1EN)2E4V"RF7"5:C48C5W;ZK)H*;6!ZWD+^S?/OK.KG2-4Y?/E*_9^?5
M8:>HKZ!+%+XM5PJ)JE<G>8M(I(J41UI.42!_@Q[4JA;X]'&)!&.CO$5+"A,;
M%)^1G(1HR!$B!DH&0T?S%6]>C,4'#@L/$:KF:2QE1HHTSB&IL%`0C2H9RH'E
M'D1TO1IFX@LIR%Q6%@(`$)F,`#C"Y'&O-95^<W*S":ZB2]>G=I-,FXDII:FM
M6*;R1G=&I[D2%X*2`4,\ID2!V4I%+J6(*L12HSEF9"(6,KG<</0<8%#*?@<7
M,@1U7"9V<:44!43I799T8SE<L.Z`9.UQJA7),CYWG>?&,6<<YR.X'&DYF<B7
MNS/YN][VH,]SN=KC^OW^/:T&/]/<[WO=O0/A_3V=_.@S^SW/R8[F=!C/9P_1
M[F@SW^.>Y^7W./#08_+^GXM`[.YH'P]G?_)W=!GW^W[GYO=T&.Y[_P";X,Z!
MH&@:"N4G];>D?LY[I?K,V>:+TG]?_]7TUV/2'5Y4CN6;CY;>VXNL+JFTF>[!
M01R*;E]UC+#FD>X&\\R9]1JVF#R?-<UY!K2NI8:N4M2W+<U.1Z92J,*&2C4G
M$QJYF-,.XW59-!3:P/6\A?V;Y]]9U<Z1JG+Y\I7QJL,\/AX=_/#]^@QW>SO=
M_P"'.@^5<B2.:%8VKR"U2%P2J$2Q,;C.2U"164-.I3F8QG&>;.),$'/?X9T%
M9V6!,%"3"MHM6DLB<'@<N-30M)3\ND*T#<0V0Z.3B1%)-O\`&@+$@$LR<G)S
MZ<_B/RN"H:T'+P`L1.!ZU=W>J+1:RI\?[_VXT#O^]^KW^'#MZ#/:S[O'M]OC
MQX_HT#/9^G.,?'H,=OL[/<T&?@[WYL>_G'N:#'9[V@=G9WNWH,\<_GSW]!CW
M^'?_`$\>YC0-`T#0-!7*3^MO2/V<]TOUF;/-%Z3^O__6]"'6&P.8R3>M2T@:
MMN+?+6F,IJ2D;A83I);.0Q6<L4<LJ8-2ZM9;%XI;\#@DJ=FJ56$T+VU0^-#L
M3$F8M\=5:=V1'8;BI+<:3EVJ;MZPDEP4:[P>+-C9(%ID\I*5NT0>CTB9IL&%
M5S>%<V-8E8N1KD`UIRCL^`11SCQ@%H<H#`N60*<<P(S59C$NNRT]ENY2>[<-
MI-/(D\;2SVA(W$(.LF[S*4TCC+`J50&#D+K0BK`>0V.89M4<@9#VZ.2#!X7=
M(06H.(0F@=3.B1;BYE:5P9IXU;R4!LRG#9+T3C04_41A&WPTN*F1MK\Z<$%A
ML6*RWYYS(#L%&D@Z1D"7/$K.>1_'P#8U9Y?/E9#5<S09]_AGCWN[W>/'X>YH
M,?H_;VOCX:"/Y6S2URE=;.#!F$A8&-]>5LSS)&)6ZR3+8HC+H@;`0)P(6I2(
M^\">U)'2U!P#PF-^#B@@Y1F!!O21KC,7N`PDA>']940UP8;+0V%EH;)<6D.L
M(0VCR&.AX%;P<:FAY185WA0I9DY89G)',&%\!\I@?@@O<'X.#A0LJ'+KYH5!
M8Q$M<PP@\^__`*98``WC*CS4XX?[B;(O"V>\?C3`PZE[A,M4IPR+:?"]BKR,
MAA@G1LF`VPJU0^%O+!1)2TKR4J4P(W&4/@XE,(IP+S@_GC1\H')8'(R(%W9.
MF7DHJJ\M.+R!\W_A]OE)YQ.`NP<V?Y79;W5.!3D]CXX8^AX)YE5VU7.@_ATP
M-GASM+'@J1#EL8:XL:WS"1M$?*;)0"4A?(DW+LD1Z3KC0-#/AB='U%CGCVO.
M%&4`_P#;RH._ZM)Z#</<[W<]WX_AU!CL[/<[F@S^?'?^/_3OZ!^W/?X][WL<
M.WPT&.S]OQZ#/Y?]>WQT#CGO9]_M_E^'&@QH&@:"N4G];>D?LY[I?K,V>:+T
MG]?_U^\[K*XQMJ<=]%:O-@'OH+.;V;:N(<F<*AJ>SF:NXF=<MLLS,DB!L_L.
M+S5K?)BY/BYV$I8&MU3M1\2`;DEP6J@-"R2W%T]%6JP:"FU@>MY"_LWS[ZSJ
MYTC5.7SY2OJL,_I[ON=S\G:T&/>^/X^[^[0/=_7\?:T&<]W]?=_/PXZ#';]W
MCQX9[7N_MT#L[/=[>@SVN.?<SGN=_AQ[V@QH*U020(J\<+*CRFD'BOSU+Y<-
MP"-@K,?*V2?-Z62I<'2]4[,:$I&7:5EB7!7`CX\F.9F`F?\`7R,YUJ<UD;HM
MNAG0L[P\CA5K'DLU7-=K'(DE;R12ZK6MU*7FE11J;BDN5+E8Z4+<+"EB+QE>
M0(TK`P8R8'4J1+:8\*I,G5!`<4%204>$I04(A07@XO!@2SR!XP82<#`N`@"Q
MC(1=K.@_MV=K4&>[VNUV?DT#MY[V._WO>[WQZ#'[_@[WPZ#.>[^W]/?[N@QH
M&@:"N4G];>D?LY[I?K,V>:+TG]?_T.]G?9:,3EN]ZDES+N6V8QP%</$%5P4$
M^E%,%7&RVA"KOG=0SV(QTR7U7+YHV,)S\I<#I"6V/*10ZJX06QH_!:PU4M4Q
MN(Q.'H?U6#04VL#UO(7]F^??6=7.D:IR^?*5\=G'A^O589X]_O\`N]W08[>.
M'P<?W:!V?NT#]6@>]\.@:!\7>Q_KH'<[F?=T#0<3("<J&%[380JW/)[0Y$X;
MD"[+6O<.=1G`PA0N>%2++<K5\KFRS^>)R2,6!\L/#E8L")Z+7QYHJNMX^6VK
MH&K"A5QQ)`IA9*.R9BS/+`)=X;BKG,_*F7&RZ1L70C^FC"XKC2N:'@P>.;%R
M4ZB4DLHC2X+>-%(F-8%VPY9:AI7=`H"YA93,E.^6\1*@>%N&DX.0J<E\KF!8
MX#Y.<:#^)4OB:@M*>1*(Z<2N8U,H1'%/3:84LC2/*;"R0I3`*<@4,:7*PGG%
M8,Y3@YT'*'CE!XAS216E7I4RY`J3K42P@E4D6)#BE*56E4%X-(4I5)(ADGIS
MRAX$`8!9",.<9QG.-0?1GM=GZ-`[/BT#0-`T%<I/ZV](_9SW2_69L\T7I/Z_
M_]'T"RY!N_S8-@R1)5/63K+U1;G)R?7$RC-U56AV68I1KW`.":LVU;32K<8@
M1NT+==O:!#X:-70@V0C<U:LPDT!F"#2XWBNE.W[<=:KS357"E\<:&]ZD3K8M
M(U;'TSP8J+9$3[>=V5[23._OW0<A7&1^+.-A%.:\L@0#C4:0P`!@$+`\5F,J
M1VGUADNAFW3:K=T;JUB=GB^8:DL*71=RD+F6FA\7;HLQNTK<TJ]"TFGEPU&^
MR-$D,E"THI`T)5:=6L3Y`=D!<6LS"3W"PF"<;R$"%E;YRB/BE!3]I=!R^L;*
MKU&J58M."$\[&G&?1.--\S;.6B'GIK.:N1\@18N=Y)I61V-6>7SY60QV?L_+
MJN;/=XYX?%V=K08[79VOR\.&=`_3V?JT&?CX9[WZ.WVM!C]'N=OAH''/<[WN
M?L]S0/=[O9GO]S09[/AX?%GAGCH,:!H--2UU7Z)6V.".$1)*O99')IBSK$\=
M:2535+9KETS,9,W*"T@343_*O#:WPBL+R%0MZ6=SHA\X/C;D?AMK:O&4MA*9
MX+$&HJ+AD08T6WQQG1@CX9>>)5*PLH4Z,O#6&2J3!&+\$\CI8Q9$;RLYXZ7(
M^9+5-7H4S8C15W"$B-EA3A6[,F3Q5D((:Z\=LMV76"MQ)2():*(.0FA)S[<7
M@*0WHQ7*+SS8>"YW&I[?SD0JW2I&UZDCVU,\@ET?:1R>`I*T5-36P25S:6Z-
MML40,$:2$1J,I$@$+6H`EP%8A(*/P,WE\L5G435[W9\&LC.?>[G'/ZM!72\-
MTM1;>7B$,=DN3ZF73GIRU)X"C#U(R(]%VF1PJ(/4\F*AH2J2HS"&2560P(%2
M]1G`"CG4H7)R4`\PDL1,W3Z[-W)5_4EAUO6LO:+*\,6O(HW$H:],-7SB20E5
M)I2L>D[>Q.$U9&5;&VAS2HX\L<%I2A06)"U$#6GX`FQDS`B+B90DLZQ"@D"6
M3],9;P0O\6FT.KE3"76B;,8ILZ3><0R460T1UB8']@:SG-P2US#E[\N"$0<(
MFH!1YN0A4IL'+7UE]LGNBM/.92.XCRF)\SWH0[I;H\L>A.7,>;3R@V>3CRF\
M&]#\,<SY+_\`*YCH_2>3_#S?+_AT*G,=;?_2])^_2R=X4-W'L\3J:[[;K.'3
MR'T^EJ]JKYDV0.4/5RSSDRA!>CA9#_N0CB^PHF-OKTUI-9O!Q#JC5J^4$@M0
MJY3?F-15:.RZK(W+[%VWUS'-UT.B$AGTFK&($W?"W9FCT@B2V7G,K>HD[6Y,
MF,.\47`)>@CYXE.)2W!4`ST<9A."QYJ=<.86[=MOSB6UDN%%4XO*8W2//C*4
MMK&$JBV=[B+`V16)O#6`]D&%O=(Q%V5&VMR@K`#42!(2G)$`DH``BYW0S8'K
M>0O[-\^^LZN=(U9Y?/E*^JP=G9\&@:!H&@:!H,\>WQ[.S.@QH&@:!H&@:")&
M6J3V@V-FFVG;;V*.SB4S887J3MQY4@!*&Y\;@0V2$HV!"2O@T:\-X/:D(`DC
M3*4288C3.;%@=OL/[,M7&,RF$*165:KOY%.4\<1D/4I3+4\QQ.E;BK`@G!8&
M<C+VVPKPAS3"6#*?*`H@D(A'<C.1/`C66[:5DHC=<QTC<3N/C8Z[;26T;\R3
M>.#?)V,AVC[L4\V$>\0MU1O\A3'1\.$ZLLA-S6%)^,@$$S(=+UP(\W5[+T^Y
MF30M_!8/D42@@DMIZQT9T5,E!\ZJ"<S^G['D+$Q+BY5&BX-,L/U+MY:1Z$0Z
MD$)%RP!B`XP28U-*:CE24P4E+'RU:5M2Q;$:)2MIJ,W4WI&-D@9\5:W>7VD[
M1-'')P7TF:R8QI60&M&9TC^$^.D>$1OZI7SJ;`0)=$O$Q"L5O=7H;:]/N5<+
MK7:1O4AW+6SN*F+G*:Q4RB"SH=C><-DCD,EU?(K(B[HY):I@DK9D+&L+D!`B
MW.*-[B,G.0]&`I8Y9TZ-MD]+&^4=([=O.!+.>]`'=+2WG3Y23RZYWIVSR#><
M#E\WT#RLY?\`[CQY',],[W)[6A>LUU?_T^_S<K$[2L7K`DCY":289'*"H?6[
M#)XK+(;U?=N2R/P&MKFN$J+V6S$6KNDC-PPUAG#$\&OB<]L8!B+2J$Y1@/"Z
M-6B2QJ*K5W^:K)H*;6!ZWD+^S?/OK.KG2-4Y?/E*^JP:!H&@:!H&@:!H&@:!
MH&@:!H&@:!H&@:"N4G];>D?LY[I?K,V>:+TG]?_4]`N[LQFM#?/4$/O"L8Q(
MG.)*V*15!7<JW45M124*YFM::HH[8T*=A4RTVQ9TJ>HTT-STJC35-S4*$)XF
MU4W"SA2H5QJ,1-.\V8S.)U[&G:93F1LT2BK&26>[R!_<$S8U(`'J2424)ZM4
M865@Y8N4E)R"\9R8>H-`46$1@PAS66B2;</0,*C$.FLSO"H8?#K$;T3K`)7*
MK)AL<CDW;'%(WKV]PB3T\O*)ND2-:A=DIQ1B0PX!A2DH6,YP8#.14[(7L#UO
M(7]F^??6=7.D:IR^?*5]5@T$(WQ="6C8W")$J8#Y&":7=1=+E)4[@6VB;U5W
M6M%*M2OYAIB19A01'CY2%88GP$`E("<EX,+R+`\%B+?%/]SM'U?8#'6$XFHV
M:9/Q,44EHRHO,7EH8DD\E"F$01;.98Q1YSB-<()Q,D9S2S'R!<V$NKB4-,E$
M:<'(,"(F<PUZL-Y&V^XY,ZQ*OK%RZ.[3'4TO$<[0Z>P]@>(BND*^*-TLB$MF
M<6C\4G,8=I"U*4R-P95J]&L$0,1)A@`Y%H3$PT=RZPK:<T,CQ)W&>3!-%8_)
MYG$7R6YHN_C8DT.==28R&3U>XRDFKS&!)$H=*B^@.3\-3AC1J1`":K#RP<I:
M^LM3M'K(MN<%C5P+HT].<VF-.I;)-=8>KB\_@*!]6TU93)5%LM<9G\PA*.%2
M1;7LOD"4IR`UJG`9!2@A1D/1E!)XED<9FEOJNM2!W1#6^PZS?,R>%.ZIU2LL
MD+:GIK;7T#.YJVA2Z,)CVVM@WR.JEB(P2%T2!.;G)/R5"0\\@P!HB3%8E(6B
M&@:!H&@:!H&@:!H&@:"N4G];>D?LY[I?K,V>:+TG]?_5]%V\FQ:M8M]<;C5_
MQBHK@B(XK1KI4M>V?OAJBHVR%S[,VG1+Y+UFUBT+?96.S'4\S#,:R/(HRI7X
M4)%"5*:,00X#&HTP[7-PU3N5T5F*',D@11B0-=A4M:<:=W-K5/+.&447<\`N
MZ,MSZV(71D7*X^^/U>IT*_!"H@\*-2:(L7+P'&:D803%=I4D:J@VWT1))\PR
M&NJ'EU.OKVG315Q;5EF-E0P)2M:6YY3K9,^(4`<;B4+-*4Q>,'E)FMI+;Q\\
M?_SM"]7`N$$2PW>2@6IY+.7\4GH*?NAZ>82]XDZ-G'FTX(;T.-)70\XI@;.*
MO(>CI\!+Y!9>.'``=(U3E\^5D-5S-!"]\T=&]P4&10:2OTMBQ33.:]L=CD<&
M7M+=)F.85=,F:>PYV;E#XR2)I%EODC`F-$6>C/*-"#(1!X9SHL32#'+8A6<E
M?T$FG5@W-/G<Y-7Z"P#)%*X^C17,U5)83S:-4-%JM$3B$9:'Q!7LO?U1B/",
MAO,5HS1(W`:U'D1&5+[2I]!]F-.;3\S"R-YT\I.8T6S0V'4Q4L'G$16O4"AT
M8CED2Z>0A(WQVR76>FIG2.8?2T[8C2C<52%.B/4C7&EX"%)*W7VF<<;MM6Y+
M:!L%#1T(0WG;KA%*>7K;^+B;^YS>&K&5_5;K);(+OFKNPJGR)R)H0.;.I/6N
M33(F8E$Y-4>3J0*%YC68O"<P1/*\1G^F_P`OV7[.;'ECI1+Y-Y`Y3IYB&YVT
MW.#)98Q&OA\#WA7E#;#M&3*6_,<4$ACBFR8.D1,XAAYLM-T@D72<\3"[4)'+
ME&>B[M,TY$:(A7F[@(W8B%I)%*7R.1]R5IU:*&H94_+I$;#XJ$E&D&WPQC7N
M1P&M$8([*!((*8L?,%%%EDF;RE;1#0-`T#0-`T#0-`T#0-!7*3^MO2/V<]TO
MUF;/-%Z3^O_6[N=UFY9RN7<'X.;S+6;ZEK"UB6NW(:QO6UEB+#"*-W9Q.BFR
MQFZ122B;"O)),;!W"IG5*RQ9))HXJ7Q^)FN2%8G.7)R38W$8>C_58-!3:P/6
M\A?V;Y]]9U<Z1JG+Y\I7U6#0-!T\V#M:NNUM^UE3UG:F^'P9E>]I$B;KB>Y!
M,4$@3Q^$(YHJM*OZMB:>-N<(F:*SFXTM@D^5SBVA0(U`!Y*7&9*+)G5NX]8\
MOT_=64^P)E87FC)C#Y-.HM9K%8"./S^)U_3,.D"='6=R56O:'R34A3RM^P66
MUW*H<2,'MCD7E6VE$X"0$\P\"CVW<M:>Q^^I!0M&TO#WNJG`W;O5KI0$4>9?
M+9FV$3ROIWL[5;=I?8<P1-==R`3%.XK,WE0Y-K*F$X(GAK38*.<VT]8(2-1'
M*+F6R[<]AEK4+O!>K]<KKC5EPE_J"0UTNR\PI:SVE@KRCA0Z]BISF0]N;$LB
ML%B$,3)259?1!F'%F"$@R>M5+<J)Y1,53M)U6#0-`T#0-`T#0-`T#0-`T%<I
M/ZV](_9SW2_69L\T7I/Z_]?UD6_.*6A>Y916<8V(,]PV&M5T_?-CV:U(]I\%
M(:9.ZOD\B%8S]S<;AL2`S>P9U#RXH\F$KVI$Z+&DD8"R#L'J,%:C4:7;LPU6
M304VL#UO(7]F^??6=7.D:IR^?*,-O.VG;C9#;;LML2@*3GLJ7[B[R)72::55
M!)3(%A*&=N2-$4J>7QA7.*@I&D)`44$9F<%EAP$/`.,8T6YJ,]%@?0NV=>R=
MMH^@FK?[5T6YW/0NV=>R=MH^@FK?[5T+G<]"[9U[)VVCZ":M_M70N=ST+MG7
MLG;:/H)JW^U="YW/0NV=>R=MH^@FK?[5T+G<]"[9U[)VVCZ":M_M70N=ST+M
MG7LG;:/H)JW^U="YW/0NV=>R=MH^@FK?[5T+G<]"[9U[)VVCZ":M_M70N=T*
M[0T2-MVT4VW-R1,@;T$.2(D"!$04E1HD:52J(2I$B4@!9"9,F(+"`LL`0@``
M.,8QC&-6-&.7U*Q^C)H&@:!H&@:!H&@KE)_6WI'[.>Z7ZS-GFB])_7__T/0!
MOQBT;F6]VK)("O:@G+RVHJ9;JSD*^O-CDVCBV2L=U3%HNABW(S2\4RO<!%(_
M"8XA)\FBX0>D4)WC*_!(CW,L*4$;C1VR;MY_+:RHUWEL,=O)M>">4C''Z9=$
M:5OF]KJ<WA7,'MFSN:D"%SCI7FQJZ1O$@Y]R2J6U-X-YY64:G`8`59C5UX6Q
MO5O]FVM[59XQC\'6-)(XPOFX$;%'VDR3D2G%%AM".5DPP.21M_1!G]WJ59!C
M%%S1M+B[*QDL:5S;%:TM<GBU%RM"X2.6ON\E`GDU>.<'2M%!3]&Q+W"0QA\+
MEB#SIP0&'=&1'G)>H:B<ED%CYI:$D_@=C')XA%C%C5GE\^7\ZTL":5C1%TS&
MOZCDUXRAOW,W.0BKF(.S$QOKN2OM5:C6*DSC)%*1I)+:4IPU)N#!X$,LO(0\
M19QC5C,FWXK=+KGZSC<19U10BHJ/FNQ:$B'.C[8M6T6:G;L1'%%L*59"4;:P
M)7W*I(:)X0*$QHP"#RNF@$+C@O6HCC$3>4GLOAM*1;D#Z%1MN[AX1/-P&2&Q
M&UV>XXA00_PC$RY>^M\)<R$42-3DQ]Q7Q`M(HSA,=SZ<PSCSO.8Y6L\JO&A#
MJT3K.M.JJI9P\M,:L"?VM!WMGVLUJC>GTN8M\_@-%0VY'UFW3/K8ZK')&;)-
MR4R>XRV.K@J28<3RVW`%2QF*,$O)SET_S*RJZW.L!-;)VI/KZ3,:LNR$Z-21
M':=B4F(A%3#ET_2QB1U.>YV\@=;>F4FA;?&%<@;%[824P*'1=@!_.)`I,$J'
M$>6G6)(K%?E#+$'))#`SJ/OZEM?X@2[F21I7/^S2-/C$A&;94O0P5N116562
MO$E95ZM&0L9<FE''\@TU<,/RR6WUA*_;/OPD=RP%IKV:PRJIHZ46I@B=W4R1
M'+$[%:!C^DCB)9'$14B30]M:XZMCJE.)YPZKUAQ8U9V0\P0*BXIL<?>>L%D;
M_(&2%K8X"!./G:-K.2RD26/IVV)P2Y&6/5"I5V2LAEZ+YFX6K4#R>[#5+&0P
MQ8%`4;@X@W*@Q34PXR^X'O4PY/#DRS6V'M:^[,'^(.C16LH1)X7#;B#:E+E*
M9?$3&*.51()1.38:KDJ_!I8&9T5MJ$2!F&RJC\J!Q8IN&R%PO9MG)$#M=WGK
MDK:-L<$?)NV3R1/,B4QR7.E[7^1!%R8Q]<W]W;72;5JE`-8A<G-T?4+>TM1#
MJM6K0&+E0FF_[4/5UJ;_`,7!_P!\MUJ-'+E]2L+HAH&@:!H&@:!H&@KE)_6W
MI'[.>Z7ZS-GFB])_7__1[M=X,"A4(WF3C$SN!@(1."G;%-(G5^=O^SQKLA:F
MN;<9.V60Q^@Y?.(XHLR?2D$P.7/3JH9T0'$Q2XA`:L5N2CE@C<::/2'JL&@I
MM8'K>0O[-\^^LZN=(U3E\^7#4'8\&JVL;)DMA2=KB3"LW86O%$SJ[G"(1FR*
M8W`HC48:<&!`/@J>7UR(2D\>`<FFAXYQCMZL1,S4+TC\2C)MU-0M9!#=&9.V
MS6=/\XLRHH%"&I0:F5S*ZJK9GQUDU7%O*M*%EC[PC-83DYRIP.3H2#.'*-[F
M,O6?"6DZL[)8[.8%+JTC"2YL3LIB<U8^<RH.B,[9TR,<GB"M:`HM$XJX^L68
M(,4I1&I#LXY11@@YQG28I5(:TWQR=XAE86'.H3#7!)N-CE:2B@ZAJJ;(E^X`
M0K/32=\;8K8$7L4^"P9I&P1:-FFN+X;(&Y"!W2K6LM.(].28JRU6R/I7UM-6
M`@%A3&MJ@N"9BBT(72.,+G0BO8Q$Y=(4M!4ON.-B8%JFP5,J:E;57%Z-*A:>
MH9RTG/HEQ"8Y08%)A6L]=TJOG6/5E&DTM6OE0WL@0P8.X9SDRP2"HU!2&%;4
MI#'8MN!L$HM)<*A2OC=>/DM;2!)DY9KZZ]+P)L;UH"CQ%6T]9E]I^]@]JI>K
M;->8>GRZ63?EW5.6T-:DX\A''Z$/W&S*8O*?*LU)A0]KJ@VTO!R(@T\A.)Z4
MD%C,P3QQD4XQNZR2LW)H0.1=0W2B6*9B5"G*/O*_;ZQ/4?<%U5TG=+&M<,O%
M^(F=R;G^N[]8%A/@I6Y*4Q@CTZPE*H+"68*:`JWK;B#62S#XM6-(31ZB-^07
M;_%#V>P9Z7")K8\X?BHZ\U^PRL4`4J7MQIA6K)-E[XG0@;$@"G$@)(5C2M3!
MBU&Z]5-6L;9PK8;G!L):GVIKHF]4O)"0PT]"H*:BVB51!S3'G<!C.=:YF#*H
M6!X<DEQ,4$AXA+QG-95PVH>KK4W_`(N#_OENK&C'+ZE871#0-`T#0-`T#0-!
M7*3^MO2/V<]TOUF;/-%Z3^O_TO2)O0A]^V1O5B8JGN-(WDU!'MOSJ16*>P8A
M5JUD063,;J0SF=.3E**Y>7Z2MSL5"F=$I(8'LE8<SE+R""4R\"<Q=&HJLP[M
M-5DT%-K`];R%_9OGWUG5SI&J<OGRYW:+_P#3;2^T??GUB.VB[+6:!H(3,VT[
M<3D<T;SJ`I,U!8[HWOEAH3*J@@T<]>VEQ4.[4\31,)AR3*'1M=E9JI.H7!/.
M)4&C,`+`Q9%DMSNY)10=%*T;@W*Z6J54WNR=:D=4*BN8<<C<TKE!8]5SBF<$
MIC,(A:G7UG$FJ.G@,"()K$V)$`L92IB2@"YW?A=M^H9S;61F<J2J)P9XS)%\
MRCC2NK:&JVV/R]U4F+725,B$]E,2M4D<EAHC5"X@!:HXT61#'D6<YT2YW?J3
M475,JCT=BBZ%,"*/16:F6`R,S.TMC6U)I*X*GXZ3J3&E.CPUJB9RDESTD?"S
M21X<TSRMP;G)AXC-"VZQJ%PZ%@="X=$XS$RWQ:W.+T"-,+6Q`>'!HB\>A#2O
M=`M:5*%P6M<+B+2T)S3>6,AK;$B4&0D)B2P!H4/V[;?J\YOR`HNG(-S,D)F1
M/D?6,)C/-2],C?&Y/*B_`K(BY$D(;Y0YD`78X*@DN*D&!X">;@9;G=MD$KV,
MUTBD**-)E!6)5-YE83^J6J3%J]RDTX?UC^[*5"LW_=,3I!*@(D16>(4C:E3I
M@?[9(,8(I_M0]76IO_%P?]\MU8T8Y?4K"Z(:!H&@:!H&@:!H*Y2?UMZ1^SGN
ME^LS9YHO2?U__]/T1F5E?LHW2$RO<1U8+'N088S+]Q4=8[ODK7U>LBD1T9<=
MUSM,=JLSCS[-K"17$R1:IMORWH&6T1:1P"L,YP2(]9C)V)X;Q6.3N1M2SXQ3
MT*6SN6^$3&M,\1&-(D#,BRXO3[*K`F##7\%BS(AYP@"I[EDVE#>V(P#,*+RI
M5@Y8P`Y0\5C5$C]O!HZ/UU15H*'YU6QO<BXQIHJ).UL#DND$C<95#W:<MR,U
M@`4%R:E"9B9%&%8%("Q)%>`I3,!4&`+$6IRU6P/6\A?V;Y]]9U<Z1JSR^?+0
M*NL&QZ6!8T46;9+KG9#I<5GS5HE,%D6VX,==&.9RA8_-0TY,ZW`P>4)U)257
M@!Y:EM(R`T(L!R,/`>1<8RE'TGIS[&NYOY1;0/\`*_0N-STGIS[&NYOY1;0/
M\K]"XW/2>G/L:[F_E%M`_P`K]"XW/2>G/L:[F_E%M`_ROT+C<])Z<^QKN;^4
M6T#_`"OT+C<])Z<^QKN;^46T#_*_0N-STGIS[&NYOY1;0/\`*_0N-STGIS[&
MNYOY1;0/\K]"XW/2>G/L:[F_E%M`_P`K]"XW:WMTC,BAM'UI&98TFL,D:8RE
M)>610K:UZAI7&FGJ36]0M9%[HSJ5"3GL`,&E4J",CQGD&##P%FLS-S,IIT0T
M#0-`T#0-`T#05RD_K;TC]G/=+]9FSS1>D_K_U/?QH(ON.IV*ZX&J@4@=7YA3
MBDE?S1HD,7,9RY#&YC5M@1>T8#)6?RA9I''SET=G$-;EH"5[>M1'Y(YL\@TH
M0@9$85ID^P>LY;2L4V^.M@VKFJX?&4D':V$L55F*AP8=:%UC)HP>]K:K6/)7
MELWB4N*]W3'IY$E=%IXVQP;TV2DI1;S:.IRTT!0N\%F>TS;3U+G6#1%A.4C=
MR$<*KHV;R`%H016:O>W`LMG')7D`W`\T1IXSC\9/,%G/\8LY=4FYX^4M^D%0
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M*(B2)U:ZQ]I!Z%*>IP[Y)*4K"6Y0,H`A8$8$@S(<9P`7`M34X?_5]_&@:!H.
M$=XU''\1`WV/LCT-,$84PG=J0.0DX3<AR:$@2P@[)03,@#D6`\./#''N:"D-
MBR':G$=WU+Q"3F,K992NMYA"&F()*G6N<4&9>THBSS!5TRG+>Q'Q6&/,B5[9
MG]#'4KB<48\&DK2R!8,*``\N:7&\W->_T'#/DNR?R.A<[GFYKW^@X9\EV3^1
MT+G=\ZN!UH@2J5RV%0A*C1)SE:M2?&F(LE.F3EB.//.,$AP$!1)0,B%G/:QC
M&A<[JO;/2]NEDU,IDE4,+G*X9()_9=BLTIL/;A8E,9?&RZ[`DUUM)L107!7\
M.<9=#4#58)*1O>6T"EM6$)PY`8$7**+$VM3YN:]_H.&?)=D_D="YW/-S7O\`
M0<,^2[)_(Z%SNI#<]B;+3)^_0I_EM?,4IVAMS-N@N)I9X0E?_)R$$,\J8D;/
M)#&=N/"E>W4IY"L*:2\*'8PG*4P*00%:<8XL6L=3[W0=Z0DF>U]$&%0S9>Y-
M%W%#(*VS$9-'97#']PBTMBTHBDG86J01V0QV0-2A*J2JTY1@!E\K'*`((A5)
MN.J4/-S7O]!PSY+LG\CH7.[79<T4G`(P^S6<,M9Q*(1=L5/,BDLA:(TTLC*U
M(B\FJE[DXK4Q*5(F)+QQR(8L8[W=SC&A<J55G;NS1"Z1R81XMTG?IWKFW<%4
M3)$]L5I3I8VP)MKB@Z</>9"G@5;RTRN864X)&E6I=9.%B0IU+T8`8L8(.,Q%
MROOYN:]_H.&?)=D_D=5+G<\W->_T'#/DNR?R.A<[J7;GY?M,P&3;39OT2#S&
M\H$37265--)2*0QB#KMP)TDJ:L#Y+.V>*#@D4?IA,"%25C1N;L@.7K$V`!R#
M!I0QB+U2?M^MO:KN?:I"]4XSQY_01E6R%+A.U6KH@H5M4J844JA<M94<LC+,
MK?(1.8NX$N#,\)0&H'%,+.2C,B`8$`FX6"\W->_T'#/DNR?R.A<[N+?(G5$:
M9'B1OL0A#:R,#6X/;PXGQ9GR2@:FI(<N<%IV"FXPW)25(0,8L!"(7`/:QG.A
M<[NO5IW&;&%<K4WV3Y2BR^%P7;LAJ@O:-=KA9ZF7NT<F6X*)+FNH6>IW*UG,
MF850)4\IU9#"-%AK0&C,4`-)/))BYT=B3=!ZV=6]`YIH!&2DSBB2KTY3C!DC
M.X%D+"`*"@+VAW9T+JU+0%F8P:F5$DJ"!\0&``,(@XJ7.[[/-S7O]!PSY+LG
M\CH7.[__UO?QH&@:!H.O^V-D2NR=U4<OY+8+<S0\Y=MSD%BP51%%SA(7V4;4
M9+=$LJ1;%I>5*D*".MS@[72>%\3J&I=D].TIPD#)$></!;Q3L`T0T&ORQBQ*
M(M)8UD\E+B11]Y8LJ5+>E=TZ?#NW*6_)Y[4NQE$YDD](Y0TYV.:.#C(!_P`.
M<Z"H.Q[:,X;2(C/F)?)($M%/)4R20$.IRME-/TQ#!L4&C,'4*(77*J8SHQH>
MYV?&\ODA4A7\A:[+3!8*QD`CCRS-KO:(:#K\W%;%4=^S.]9)B9H8@DN;:HBV
M^A)1Q?IRMEE[38KW8C18[@(IW:RY"G3+UJ,HYO$).:I*29!E4`(\<@L32=]L
M='NM%0:4M4FDK5+9O8MM6E=,]>X^QKHU&ARVTY<ODRYNC+"YODE<FUA8TB@A
M"GPH7J3S@I\G&"P,S(0B5C-$?,L1(W!.)*O2)ER48R3!IEA!2E.(Q,>6I3F"
M).`,L0R%)(#`9SCB$8<"QPSC&=!U"%=5T\AKS9-`,V;6@%>U2NJN@:ZSATH-
M7<R-16,TADT\I*&L<N>-RZI'"9E10YD="U2=\($U.9W)#QYXI5*:]LR[A-5D
MT%"-P^UJW+UW%TK/5MCU\JV^5,%,Z&45*8E-%8W6P%KF>G>+1R^1JP8TV+YC
M&X::)'$@NB!>WL#BH/<>CGJ<D"3EB8B.[^NQO9H[;1F.0(9)8K98[PL@U$T^
MQ.C-$5D,2I:KVUUYBMZQ+>&Y9*97T^:N#:>I6/"T@U,D.4J,`(3%%E8R,3-K
MY:(XE_+?#F)Z)C*ML020UI<2X^N>D2ES9D3X-&<%I5NS<C6MJQP;$R_)8SR"
ME*<PTK`@A,`+.!8#IN.ZL"UY/0SG6]GV=MSLZT9%:TFM69V]9.WF4V*NFDMF
MM:O]:N$^6-KU<B!5%+$@+>[),PTU@5MC3'T+40A)1!QR5)4IKVB^SM^@T9'"
MX5#X<8^/,G,B<6C\9,DLC4X62&0C86E(UB?'Y8$(`JWEV$EZ0J,QC&##S!"X
M8XZK+:=!_]?W\:!H&@:!H&@:!H&@:#JVW+TNH=M\FWV;-"*WU+(KH;=1,YH"
M.63=;=79]F58LVS8HD+_`!R,3!!"DRX)+B_X3-XDQ13X'*O*@E5DL>01J-)4
MNK2_.LG/BU$,;&2.$L3G$-I-;NK?*MN<VF3Y%EDZZOF17A9L\7R603)"\+7"
M(W3"4T:"6[94A1N3L(AQ,5JLE$:+47*=MN^[K?Q9FXS;Y&+&I5/":PGU*TK,
MITC45+:S624;.ML*2S+$EB6PSFIWBD/?H-N"4CA^(P^+T2PM$E'@PLQ8K1&B
M),1$2T6U;TWI,MF[E1TPN<")`W7]N"CJQM<:U=K4:HM7M%[%J]N*BXRT,:-T
M;$S`.X)R]&J\K.4,]P/D`TQ03#2B`%#&+<:^;O\`K%6`B0LKU%5!);.\.3FW
M6?$]H5M3LI\D3QM6V_7565)`K*+R%]=T<>DUOV3*8FHD8EHA)_)PIO-5)G0_
M*C1:A]-@;A.LJ?B[00HHXNA!4@D][4_'X=&*=>7B5U\O:.K:;-QL5G<>M!*[
M";Y'A+N3*.AK6IPW=#5+%!Q&#U"OHI:5DKBU/;?9^^.(6,*4X?+`L6OK)N.@
MJX?62SZ4LX;D6A4]5=$[!?;80KESBD?(RSM]_5\2TN"!,VE$JWQT<0*#AN2L
MGF!,17\W;[MVW,;L+#FFT)1<T:E\>LIRW-3JI)6W#ALG@4&G5(/FSR7VS-),
MSH9;'X$]N2:`7-`V$&#G:,,SDR*C<L`C%JL2M4H$Q&:T=ZVJP:!H&@:!H&@_
M_]#W\:!H&@:!H&@:!H&@:!H&@:"I]4>M;NX_^&VZ?_DYGHLZ0MAHAH&@J'8/
<KQ[7/LZ[Q_\`]QLZT7I/ZMYHAH&@:!H&@:#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g275067g35o58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g275067g35o58.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0KN4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````[0```?D````&`&<`,P`U
M`&\`-0`X`````0`````````````````````````!``````````````'Y````
M[0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"%(````!````<````#4`
M``%0``!%D```"#8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``U`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TRW'R'6E]>2ZMCHW5[0X::>PN]S$QQ<DB#DNVAT@;0#`(]FYL.54=
M1:(WYU6T'0EA:XC^7+MOT?STCU*MW.=4TQM_1L)_2!QW.VO-GM:QNU[4E-I^
M'<ZOTVY5C=20X1N@AS2R3_6]BIONR07N;=DLW_I0ST/4V@C^9:=I][=GT%)O
M4F6FLU9M327%I8^LC<20U@^FUV[_`*M)_42''=F45C8'AIK=NVF7;];?]&WV
M_P"K$E.?UKJ/UMQ<[TND8->5B^FQSK;&R[U#N#VZ9./^8VO\Q4/VU_C#_P#*
MFG_,/_O:M+K75OK+B9_I=*Z8,S&=6UYN)CWDN:YGTF?18RM4/^</UY_\HF_?
M_P"I$E,!UK_&&``.E4Q_4/\`[VI?MK_&'_Y4T_YA_P#>U3'U@^O```Z$W[S_
M`.E$O^</UX_\HF_?_P"I$E,/VU_C#_\`*JG_`##_`.]J;]M?XPMQ/[*IF!/L
M/_O:B?\`.'Z\_P#E$W[_`/U(K&)UOZV6!YR.D"EP+0T`%TB#K_.)*:G[:_QA
M_P#E53_F'_WM5NOJWUN]-N_``?M&X"HP#'NC];1_VO\`63_RN_Z+O_2BW,5]
MC\:I]S?3M<QIL9^ZXB7-_LN24X6-U+ZRV95%>1A!E#K&BU_IEL-GZ6[[39_U
M"Z)1LX'Q'Y0I)*?_T/3K699>33:QK2![7LW1'=I:ZO\`Z28UYIT]9@`<#(9[
MM@^DTRYS=SOWMBG<^Y@!JK]77W#<&D#^3N]KE!MV43#L<M!U!WM,:3[_`.U[
M?9O24Q=1G;(9D@.$^YU8,SQQL^BJCNH["\C-I`=^E8VRMTMK(EOT+&;O:U[O
M](KK;<R!NQVB6S`LF'1.QWL^CN]F],[(RV_]I2X]]KV1_9W%B2G%ZS]8NJ=,
MSOLV)TJS/K=6RQU[!8!N=N8YGZ.FYOM;6W\]4?\`GIU[_P"=^_\`\&_]Y5>Z
MYUSK_3^H&CI_2G9M#JVO-P%A`>=S75_HVO9[6L8L_P#YU_6[_P`H'_=;_P"D
MTE+CZZ=>``'U?NB-/Y[_`-Y4_P#STZ]_\[]W_@W_`+RJ(^M?UNC_`)`?]UO_
M`*32_P"=?UN_\H'_`'6_^DTE,O\`GIU[_P"=^_\`\%_]Y4P^NG7=Q/\`S?NG
M2?Y[_P!Y4O\`G7];O_*!_P!UO_I-;7U<ZIU7J+,A_4\$X#ZW-;6UVX;FENXO
M_2M;^=[4E.,?KKU^/_$_?_X-_P"\JZK!N?D86/?96:7W5,>^HS+"YH<ZL[@U
MWL^BH'J6$,BS%-S!D4M%EE1<T.:PDM;:YI/\V[;])$KR*WM.P^IL^EM<TQ\8
M<DI)9P/ZP_*I*#S+01P2T_B%-)3_`/_1]50,G[;I]E]+M/J[N/SOH(Z22FG=
M?EU.:UQHE\!FYSFD[6A]L-VOW?1M4/M]I:';\4<S-I[';_HQMV_1_P",5UU=
M;BUSFAQ;.TD21.AVJ)Q\<\U,,Q,M';5J2GGNL_7+'Z+FC#NQK+['5,N-E1:&
M>[<R&[W;O\$J7_CEX7_<"_\`SJ__`":[#TV?NC[O!+8S]T?<DIXX?XRL(`#[
M!?I_*K_\DBT?XQ<*^YM0PKF;I]SG5@:#=^\NL]-G&T?<D:ZSRT?<$E//?\],
M3_N.[_MRO_R2T>C=9JZKZ[ZZS7Z):TRYKID%WYBO^E5^XW[@G:QC22T`3S&G
M"2G++;/VID/F\5NK8T0V@52'/+MEEOZP^SW?I*[/T7^B1V6O%CB3;L(U#C3M
MDCZ6YA]3VJ^F&@A)3`_S;/[/Y0B)B`>?C]R=)3__TO54E\JI)*?JI)?*J22G
MZAN&<<@&AS15LU:]L@NG]YKVV-=M_D;%`#J>PR^LZ&/:=W/_`!GI_17S"DDI
M^H\H91#?LQVF3ND`Z1_*<Q3Q_6]%OK&;/SM`._\`)EJ^64DE/T]CMZF`SUGU
MELG?+(?$GC98ZK^JIWC,.*P5.VW^W>X-:>WN]CWL9]+^6OEY))3]0M&>'M]0
ML+=S9],08AV_=ZCG>W=M^@E>,XWS0YHKV</;+=T_O->VSZ/]A?+R22GZDI&2
M''UBTC8WZ(ANZ7[]LN<_Z/IH3QU#[1;L<!26M]*6@P[\\_3:Y_\`T%\P))*?
M_]DX0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O
M`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``
M-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1`````
M`?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M_\``$0@`[0'Y`P$1``(1`0,1`?_=``0`0/_$`,4``0`"`@,!`0$!````````
M```&!P4(!`D*`@,!"P$!`0$!`0````````````````$"`P00```%`P$%`P<&
M"@0("`@/``(#!`4&``$'"!$2$Q05%A<9U-97EQA8"2$BTU65EC$C)%24)=56
MUQHF=C<*05$S-+4V)YAA,D*T-;<X>(%24V-SLW0HD:&QP6)R1$5&MF=WAZ?'
M$0$``0($!0,$`P`#`0```````1$"(3%1$D%A@9%2<=$3\*'A,B)"8K'!`_'_
MV@`,`P$``A$#$0`_`/?Q04C"-0>-LA3S+^*8VX+1Y4P:I92,A8X<DI;1*4*:
M4,94@B3VW$N*E.W/$9E2$P0$+F0I&@&H).)&:682:$):93P6+")<VS^'1B<,
MI#@G99>QMLD90.J<"-P,9GE*4X-*I2C"<>-&-<WGEG6),N$\H)E@&@+-L,L)
M&<<5@F]`M7!1K7$2-,<ILA;BRSEZO@%B,NG1$FG$%G*3;!V`!<8=X5[6V[;T
M%`1+5%C.>8.A>H6'IYB_XZG[K'F>,B2Q1P)DJE;*9H1CUE`MBR[E'IIN;,%1
M2,\"HHDU$(=QJ0$EEFC`6F-&QE$*#7[(^IC%^,&J[X]J'UU9[95A.$.H19F.
MD!(\K9"D[1"HS#$X$AME"QP.EL@0MJHTD!B1`M47)4FE&$*@D%H_"0ZE(K%V
M1:[N\!SB)6B?VR/!BS)AB>RR8.![LT+WM,Z-,=B30^K7*.%(FM2$]Q*WD:=2
M2).88$_=+N*<V!(U>XP6XTC>4&J.9F>V^5R2919JAS%A/);SE,#CCV2/,0FR
MATQ@VQU3-65GC,F8S42M:K1DI2E!R8%Q[52?B"B_628L;\[OD=3'C2R:-$M"
MM^CB\`4[PVMTA`N''G<:>PS"U+,^6:U8$RL@9J<:E$J37'94D5$DD0+.>?,:
MZ;X<FR-F!W413'=Y)&(N]3DU$:IC,.6S&0-D5CSC,UR>XQQR-JW]X3IS70\%
MD",1H1*3207"*Y8BKGSK,$<QZI6$/C9(5!"''\PR<>X-2-`M17B$!NRVEJPD
M0G,A0>K:K2)"*R8)=SU(5%KD!-W#-PB%8@U58;S:]MT6A[P]HI8]XOC>;&",
M2Z*R&).TDQ'+3$Z=CR#&K/;>F0R&/&+%9*=6)$>><V*%!!2TM.-00$PLQ1')
M3K.PK"'_`#`QRX<W94F`5#$#,DJ[!R-YB&/D$GCB>7L4@D+Y&T;R6EC"B,K"
MERIQL`21H2B&8Y#1@)47*%&UA9A9Q99Q)@#2C0!,*-+$$99A8PV$`PL8;W",
M`PWM>U[7O:]KT1]T'R(00!$,8@@``-Q"$*]@A"$-MHA"%?98(0VMMO>_X*#B
M-KB@>&Y`[M2U,XM;HB2N+:X(CBU*->@7$%J4:U(H*$(I0F5)S0C+&&]PC`*U
M[7V7H*+/_P"U2U_]WY^_ZQHY6_Z=6?[=&P-8:*!0*!0*!007&W^J*/\`Z+_Z
M4D__`$/_`-'_`.M#S_D__/\`_E__`#^_5G,3JH%`H%`H%!!YWO\`*QO<3MRB
M_;B(;UG)RNV`*!UE/OJ$@[.C5SCB1;YQ";>.LH,M8'`.V[E[''T24XJ*4"@4
M"@4"@K5AL9WIY%N)(T%E7C6..&L3/`E3RJ%8Z;\0IU9+O2L+2D2_-Y0ZR!'S
M=S#K7,4<'819RA.,K*J*4"@4"@4&,>MO1W;8`DR_3%^P"@[ER!WY4W8`]18]
M-<@D5_D$/B%[H=M]X.S;8(UC+?MC;'UC$[<D,M!XGQ$K0Y7>6E,/H*#>3M;N
M)T>Q.K<2+YI"FZU9<\JP1\<W>X@K.<I&4)Q44H%`H%`H*UF-C.VV(]Q(T'@M
M)9+Q5"]X$WN*(/8"4;IK&VV>FZS\K-,V%G$W2N'!2C,/X9?#XY5C*Y)SA951
M2@4"@4"@_]#W\4'6=F'3_/YE.LIY_P`!$=CM4^(,I%.^)WJ6M#Y'89F?'BW#
MF&V:;X+G+H>A2%/V,<@/<*4$$KB!*11]]1)71->UP"LHC5>$Y*7M`,TNTXT\
M1G(4?U01",7TT:1S\7KL(`AIS1C3.V,GR1.^9HGEU_D,9E"O&@WIG7,2%P<R
MN3;9+&TS@T"L<H`!*L&&*;X4;LRLV9L+Q=YA69DC=`M0WQ&"II('!ID9<$!C
M+(N9\CSG3.C!(EB@+1*(B5C:1,Y;,!)=8C8KIKMXN44D<M83Q69@O!&2\9ZE
M<MP8QI+(TLLV07K55AQQ+5&`$DRAGY&^M4_Q@E1W&:G''HC-^V4M/3V+(+3J
M9FTW)$/EQ@+J3.'-KO`6W(!^7LAN\[PWJ)+QW,L*ZL8_D.,MS'D,F4O<[:\_
M-+KC9%WD)GAD*ETQ5X_=%0(7(&;IZ)H:%:=N0.)A;2I4)8NE);=Z&HYDG'T.
MFV+LQMLL<\CX_DK6PK<OO/554<S7$4D384N/I3%URUGCR).MCT33IF*0)D[<
MWA421M7NER17<[GG5)UAI(KQ[D-\T!Z?\>'LDW>\FP#77B>0YG##V)Y=):T+
ML9Z\DV2<U9`NE9D3HO*-.942Z3H3;%#/=$JI.>C+/NI(`9&N,^CL*CLL?HGC
M_/+U`(SFO(KBP-B^80@O*S))V=ZG4W,A]TZ+'\99Y,S1R5%,2=PCZ``E9R,A
M)8]U-W#;A(.,#66O&=-,>-'+%N'\(JH#DR0YWQEB1R2:=-1T)CLI2.&/,P(V
MYG)-F!V58V*Z#'SY(9:U)'UUL_C*:'XH@PA2%?<0D9L6)G&>#.9785[MJGD:
MI[9YE.(+&_AYY*C.<6+&%GQKETS>YQDJ)+,;L</.C+ZQR!++%K'")V%M)1+T
MBQ.)P#<L\%S0#H<.K9_4.P-LMQ:AA[I%5\P99'/<-)'V,G1ESF"=RB:'*\'>
M)>FDK<2A=P'-`8FW++K><M<HXL(BQ7&(=@BJ0T,8\`YYPN',V$A)G/(^G6&Z
M6\ZQS2I*BC'623]G:<GF0-(W:<)6FW5[L\G8M4P\),<=1",&MCBU,G.%<YM4
M&CBUB:3Q7UHMTR-$$A>!\R3>\\<,ZLVDG%>G\\B>%H6D>,(DRMD<>97CF/QE
MHCL83I"5$Y9"C5BY<6O<UUF]+82TU.0GM:I,\.#2C45A7(4YEGQ0FIJBNHDU
MSSFR8K9\*,L'C2])`,P/D9P2T19;'9H]25G(Q^'':Z8H+-$AL\.;8E<&(]46
M4<(!F_46."=S'$NHUQ(U83AOCN1`9N:\:Z?3,?ML`F$[C4/5NJ;'Z%KU'Q3`
M`I.\(X*C='AOZFV,"A47<I$Y&I%5KEC`(VA6,(X*_P`NP*>'8*=8]BN#:OW]
MLR/$-7DNQZ#)D2-3NN,LF.6,<?%8YBT;Q-C1@QL9AEP6S&SZNA#TZW2)(LZI
MG,1._P!8:"RA$XK#R?#,\9)G;DG;(-,9RQ9'QJ[1:1M&0H=+\?R#&ZMTTD2%
M(@EL$RTD=4<-D..9+/7@EF>L>OR8AV12U:<\E7+`F,`$8.QS3`RJ(YITPE'U
MD7>X6O9,90]J<HO(R[$O;0Z(&5(E=$[@2%<Y<$TQP*,,L"YPA!`.UKV!>UP!
MJ3G+K#^)IKUDVA/*^.9_#<:1[*#C)(,[P5P9Y)+'.'I6Y.>^)I&%Q(7-D<DI
MBI1OM8"^%<H`=TRXM_:&P;](MF;.K']NCK?_`)CW-GNB8L]=\M_A34V7<FL#
M^8]S9[HF+/7?+?X4TV7<C`_F/<V>Z)BSUWRW^%--EW(P/YCW-GNB8L]=\M_A
M339=R,#^8]S9[HF+/7?+?X4TV7<C`_F/<V>Z)BSUWRW^%--EW(P/YCW-GNB8
ML]=\M_A339=R,&$CW]XDS2P-1+67I&Q*,!2ER46$FS)+$1.UQ<ECB*P4P<7'
MV"*PE=["%O7X@MHMEM[99-ETZ&#-_P`Q[FSW1,6>N^6_PIILNY&!_,>YL]T3
M%GKOEO\`"FFR[D8'\Q[FSW1,6>N^6_PIILNY&!_,>YL]T3%GKOEO\*:;+N1@
M?S'N;/=$Q9Z[Y;_"FFR[D8'\Q[FSW1,6>N^6_P`*:;+N1@PCY_>(LR/A3<4I
MT@XE&%N>VE[)LHS;.!V"I:5A:P@97)XX;Q!/`87:X+F7-)L+_CE&!VANBRZ-
M#!F_YCW-GNB8L]=\M_A339=R,#^8]S9[HF+/7?+?X4TV7<C`_F/<V>Z)BSUW
MRW^%--EW(P/YCW-GNB8L]=\M_A339=R,#^8]S9[HF+/7?+?X4TV7<C`_F/<V
M>Z)BSUWRW^%--EW(P/YCW-GNB8L]=\M_A339=R,$<0_WAK,*&3R&4%:0,1A6
MR%MCK:K-+S9/+*S"8Z-Z&D"I,.QZH;AE%W>S.%8A(F,#O"XHSMI=BFRZD1@8
M5JD?\Q[FSW1,6>N^6_PIILNY&!_,>YL]T3%GKOEO\*:;+N1@?S'N;/=$Q9Z[
MY;_"FFR[D8'\Q[FSW1,6>N^6_P`*:;+N1@?S'N;/=$Q9Z[Y;_"FFR[D8'\Q[
MFSW1,6>N^6_PIILNY&#A.7]XYS0<W+R3M(6*QE&HE11H19NF%PB+,(,`,(K%
M8N(,O:X;WM?=,`+_`!"M?Y:;+HT,&QF,?C`ZDCL:X].9],.`430;!XF:UH^^
M[)9?*-QC"WB0IN&KQ2\J@<!-<(-ABQ49;9L$<;?:,6_BNNQK&+&^VW#'#ZU3
MGQ?-4GNUX"]>.1/X+T^&[6#Y+>9XOFJ3W:\!>O'(G\%Z?#=K!\EO,\7S5)[M
M>`O7CD3^"]/ANU@^2WF>+YJD]VO`7KQR)_!>GPW:P?);S/%\U2>[7@+UXY$_
M@O3X;M8/DMYGB^:I/=KP%Z\<B?P7I\-VL'R6\TWP?\2_*>9-4&GK&N5<%XEB
M+/)7^?@:Y5%,F3V6/;,[M^*9HY%<LTKH7#6H9;D0E&E,&I$K"`LZ]P%!,L$T
M$N_\[K8SS6+K;LN#OB"*PK6%;\%[;;?^&N33^T"@4"@4'__1]_%`H%`H%`H%
M!P4[8W)%K@XI4*1,O=A)1.BPA.44H<1HB.52&+30!"-4:F2VL4`0[B$$L(0V
MONAM:P<Z@4'!1-C<VC7&-Z%(B,=%QCFYF)DY1)C@XFDD)AKEQA80C5*[I4A1
M7$'<0K%%`!:^Z`-K!SJ!00+*&3X-AF!23)N27TJ-PN*)"5;PZC2+W$ZPEBU*
MUMC>W-32E7.[T]O3NN3HD"!&0>L7K5!2<@HPXP`!#-&8UF&SU,V2"/>-,FP)
MYDD4E$Q8U,N;(P<R+6N).L3:G-&<]PZ6RUN:)">*9I%"5L7C2KU*4I4:`J]D
MBCAA<=`H%`H/*;_>#/\`67%/_IU7_,#J[6?K/JY_WGT>;.M-E`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H.*N_S)9_[*H_\`5#I.4CN%PS_8_BG_
M`/;:"_\`Y7:ZZV_K;Z.%W[7>JR:TR4"@4"@4$XT^?]M'2%_7_('_`%,Y`KE_
MZ_K#I9_;T>OTC_(E?_4#_P#)7E=8RA^M%*!0*!0?_]+W\4"@4"@4"@4"@4"@
M4"@4&F6NK#4_S/AJ,)\8$`>9IBK/>GO4"U0=2XHVA!DTO!F78ID=PQTM<G-8
M@:$8Y*W,1H41BTXI$%R+37/,)*L(XLL9OUSQ-Y5D/3[D$,"PSE!]<SXV26XQ
M=X1/..Y048H<FU,^LK8WC6,SI-E;8R*52A4D:%Y;<^I"36]*YB,5!H=6B&-,
M`S%WGT'9<J82G2C#T>S9K`>W9A>(VG1P4>-\HPMG<X8S),=QV0OB2T57R=8N
M$C9;E*P(%1@;&7NH*&:"*Y^(L:YNNV::(KJ2P7F#)YQVCK1K&F.7,TL3-+K@
MO5%A1P=E.=%4ZE94T:I%#5$J>CV-:IE3)U"\C:6A6AL%8&R9,O$\:2@4BP'G
M>4XQU5HI/`-1:[4,*%:AH&6_)W+%Z#$>6P3G+2>7X<D$&=X\2@R+)W9J8D:4
M3`<^+"S,>HNI-?'2$J"B50T=V\%A\4@D7;HU"6<+#&TYKFY(FNUG`(RE,B=E
MTC=CSPNHS'(*M>\.RA0=8^_$L::*U[6O\EJRZF=?6BF.:Q\VQ.&2UM/<T++`
M7&:(24TQF4.&4H(>FV/B,&NA;JSKE(=QP';@FF#)^7>W=X(;VZVS&R:US<YK
M%V&;2[P%<0?NDZ>O7//GK2MG/O\`DW7ZQVCV/`5Q!^Z3IZ]<\^>M*V<^_P"3
M=?K':/8\!7$'[I.GKUSSYZTK9S[_`)-U^L=H]CP%<0?NDZ>O7//GK2MG/O\`
MDW7ZQVCV/`5Q!^Z3IZ]<\^>M*V<^_P"3=?K':/8\!7$'[I.GKUSSYZTK9S[_
M`)-U^L=H]CP%<0?NDZ>O7//GK2MG/O\`DW7ZQVCV8*-_`GQ*[-!*X^,G*##%
M3F3<UNSWG8])<*-T6HP!`87.3`W,++3V"9;;\TVPK7V7MLI6S2>\^YNOUCM'
MLSO@*X@_=)T]>N>?/6E;.??\FZ_6.T>QX"N(/W2=/7KGGSUI6SGW_)NOUCM'
ML>`KB#]TG3UZYY\]:5LY]_R;K]8[1['@*X@_=)T]>N>?/6E;.??\FZ_6.T>Q
MX"N(/W2=/7KGGSUI6SGW_)NOUCM'L>`KB#]TG3UZYY\]:5LY]_R;K]8[1[,"
M_P#P*,4-9388GB1U[K7YF:S>>S_G!*'EW!:6F/NF$JR"C"<ML`?XHH%S#3![
M+`+'?YM*V<^\^YNOUCM'LSW@*X@_=)T]>N>?/6E;.??\FZ_6.T>QX"N(/W2=
M/7KGGSUI6SGW_)NOUCM'L>`KB#]TG3UZYY\]:5LY]_R;K]8[1['@*X@_=)T]
M>N>?/6E;.??\FZ_6.T>QX"N(/W2=/7KGGSUI6SGW_)NOUCM'L>`KB#]TG3UZ
MYY\]:5LY]_R;K]8[1['@*X@_=)T]>N>?/6E;.??\FZ_6.T>R+M_P+\5JY9)6
M(R(BY-G:XRM2W(U!YM-=+FO(WX*JSB@*R*<N1)K6:R^7&<F(`=?B<,9NX/AV
MMG/[^YNOUCM'LE'@*X@_=)T]>N>?/6I6SGW_`";K]8[1['@*X@_=)T]>N>?/
M6E;.??\`)NOUCM'L>`KB#]TG3UZYY\]:5LY]_P`FZ_6.T>QX"N(/W2=/7KGG
MSUI6SGW_`";K]8[1['@*X@_=)T]>N>?/6E;.??\`)NOUCM'L>`KB#]TG3UZY
MY\]:5LY]_P`FZ_6.T>SB.'P&<0D(%IP8BN%<E(I-L%1G?.P"!7+)&.P3QFSD
MHH!-[V^=<0@AL';MO:WRTK9I/?\`)NOUCM'LSD)^#4S*H9$5)*J;-Y2B,,!Y
M2!@U2:BC&)"6:U)#`)&4QKR<M;!M*8(K`373G&D7)"&Y8Q`V"O=UL8?R[S[I
M6Z<<.T>R3^#&U?6V3/\`>BU,?Q%IOM_UWGW/Y<NT>QX,;5];9,_WHM3'\1:;
M[?\`7>?<_ER[1['@QM7UMDS_`'HM3'\1:;[?]=Y]S^7+M'L>#&U?6V3/]Z+4
MQ_$6F^W_`%WGW/Y<NT>QX,;5];9,_P!Z+4Q_$6F^W_7>?<_ER[1['@QM7UMD
MS_>BU,?Q%IOM_P!=Y]S^7+M'LG>&/AB(,%Z@<+9"1]6<5[6_R0"13,<]9<F9
MK791"9"4J4QZ-3^>N+8XN:A((9!ER42L\E*::9L+"$1H$W6S$Y_=8W98=H=]
MY8;@+`&_X0AM;_X+5Q='W0*!0*!0?__3]_%`H%`H%`H%`H%`H%`H%`H%`H%`
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MA-G]83C*S:BE`H%`H%!C'NV\S.X>&2;M;%]N$I-X"<S:D-MPU!_&3<$D?X!C
MXA>Z';?>#^&R!&,7E\+&>.RN4;$'#@L1+Y%D<.K,R+<8&\/*-#KU-ZZFV)]F
MXG4<XKXQ5@CXQNW?%9SGU2,H3JHI0*!0*!05E,RM^<X?,Y%E4\&3R<?-N+KR
M+FV[^/I27QX^W]9;NMK3]_@G%<LX<)(8:=PR^'QR[&5R3G"S:BE`H%`H%!__
MU/;C!-3./9]EC,N"4*.1LF8<(@9W&1P"1)V1$[2&+21E;GF.S:$+D;\XL$@B
MSKU,M(,VZPA0W+MA+@2DN81<TM,IX+8Q_,DF1(-$9ZWMCLS-TSCC1*&UM?;-
M@7A*VOB$ER;PN(&9S>6PM28C4`&()2HZP=[9<6]:]K$9M\<5#0SN;JE9G20J
M6Y"I6$,3'TWK#N8G*$:%O;.LN3.U77*KAW"K*%2<JX[VWAAM\M!KO!-5$,R9
M@S#^?(-$9]((UFQQBC=$XTG)A9$X0WE3L<U<>0-*V;)FQ#>,62GJ7M*2N4N#
M4F2J+G)[#3*"RBT;.40H-8,CZKX%CM"T.0(Y-YRWON<&+3LTK82GB9R-=E=]
M?#XO=@3JI1+XLG,3LDJ3&M;DKL*Z9$XD')QCXB=0$HM&4D&?GR/1]4["TXZA
M'E\3S4,.*@T=:,7O$F6)[Q)!+#9JG7)\K=B"H4G"X!;AJ#W@E5=U`).%,+YH
MQ"G-"$^LJ+.4(Q5*6#$^8Y%)\P&S0V+8B;$>,B,GE,>/GPV/RN5KT;SE!JAZ
MB-MR\Q$()S>\KC3TSFF/++&3QQD"G-LBSSEC>)3)(0$2A!+(LA97ES8G`)!:
MP<>D9KJF8)(BNF4*DZMD=5S`X)BS0CWP*4)Q9@`"#:UR,VROK3(D9R]F6`7(
MT[L_L1QY8#BP@=HN^N,:?D=PGEE#N-N?&E0G$*UK@$(J]P7$&]A7#5URUDX]
M:8%JUR,MB&1P1W1>ZS!IS!8""'&+SSX)BJ+YIDIL/3!FUP/:=%CV8H%8;G#2
M#.,-$0`(C@"!8M,N;9V-/9<ECS)(B4*YL(?6I"[$('/D>H)2'!,6J(*66;5K
MD@LH"4;;>L4>:"U_DL*]$9N@4&&D<B8XA'GZ62=T1,<:C#,Z2*0O;B<%.WL[
M&RH3W)V=%Z@?S"$3>@3&'&CO\@0`O>_X*#CDOBTZ5N<;%%I"G;F^/,;X3-3K
ML'91V6O#E(4"F+-@2GXV47D,?(8RE:ZY[80@LF<TG`5'G74%)PQ4SR/!L>`9
M!363-D>O)'8MB8"5I@[JGAW,),/"A;D9!9RI4=8HJ]Q;@+V#\FV]KB#M"8D'
MDJ225*8XI0G4%%GD'D&`-)/)-!8PHXDTNX@&%&`%801!O>U[7VVH*#/_`.U2
MU_\`=^?O^L:.5O\`IU9_MT;`UAHH%`H%`H%!"<>6V11);<9P?K*2?-83.*V6
MVR5WOM*'Q3MJ@7X5%MZ^Q1<RVRVS9:SFD)M44H%`H%`H(+/2^(DC-N4;%>[.
MH<9NNCATXLC<>DXN;1#ZFU\TYIMF\G3[QW',M8/!-V[E[''T24ZJ*4"@4"@4
M"@K)@*W<K9).Y%E)XL8QJ#J"5UYE]6\(Z=?B'AGZRJZ6B0\3:C-Y%'S5S3K<
M11PMA-G]83C*S:BE`H%`H%!C'NV\S.X>&2;M;%]N$I-X"<S:D-MPU!_&3<$D
M?X!CXA>Z';?>#^&R!&,7E\+&>.RN4;$'#@L1+Y%D<.K,R+<8&\/*-#KU-ZZF
MV)]FXG4<XKXQ5@CXQNW?%9SGU2,H3JHI0*!0*!05E,RM^<X?,Y%E4\&3R<?-
MN+KR+FV[^/I27QX^W]9;NMK3]_@G%<LX<)(8:=PR^'QR[&5R3G"S:BE`H%`H
M%!__U?7!F73)D#)[]DW*F."!XCU(8QR\1D#3+E)]4,JV.RYK-PUB>'2['LY0
M1=^<WQ;AO)ZR%J6QY;UY*-:F,*2.J4GFD:85%KV4(HT_9Q=L@:?T&2L9Y/>H
M:'3=I,:&!7C*5860H].^H+"3_))#/+S202]09/6-C>KO34(Y\@9QBEZ0LBAK
M5I58+H2E$6L8ICA3$>:HCF;"[<YX6E;1%\6ZAOB,/CS/0O>,PQ(6-M0.9LCY
M/PE>/I4L\,EBUA)BLV:DAB&S648V+B3"`D7+3&&%C"BX]/\`ITR%BG4#F-L<
M`-(M-#5/)'G?3N@*5#-7,>0]0B8\68&#IY=TY#,WP25I9.O;`A+,*-29'.)#
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M)46EPRGD_%Q>7\BQ[)$D?Y_)V(DLA_4/!&1\D*RL?QM[5)`\-T>;N)92)820
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MGID:<X((S'9^BF&CO$6'8LJ=H^PYF:X*E`?D.(KREH9,G3F&MP"^.$TC<*#-
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M[UW8;ETL?10IN:,V2J;OKLDT]1=R5&/[BN=BH7-T=GAD='`@@J)E);IR!I;J
M!D!+6D]6X&I#3ID[(CKFQ5`--+JV,&0-*^FN"1IB1OF#XZ<@F4`SO-I@_1<T
M"#)B5&TNL2@S\DL%8F.$WVN7<E$L.N6#:2)Y\5[8@THLUYCJ.1RW%2K&D"3:
MLVC-.G)+'7&&,[2B:%>FW3_%Y2]1IC@[X[E10Y?FR)2AT.+4I6];=R56="MB
M@^YUJE<G8,B1I6Y&D;T)`$R)`F(1HTQ=KV+3I4I0"$Y!=KWO>P"B@6#;_@M1
M'G4^.AG/,F!I-A"1X6R7+<8/SPQ/3(ZN\0<0MRYP:+N!ZZ[<I-$2=OI;K$A1
MN[LM\\NU_P#!76V(FR:ZL_VZ.@;Q&]>WO=9O^])?D--EK59/$;U[>]UF_P"]
M)?D--EI63Q&]>WO=9O\`O27Y#39:5D\1O7M[W6;_`+TE^0TV6E9/$;U[>]UF
M_P"])?D--EI63Q&]>WO=9O\`O27Y#39:5D\1O7M[W6;_`+TE^0TV6E9<!M^(
M1KG9T8$#9JOS4B1EFJCP)R90"Q835JHY:J':UT5[[QZM0,P7_P!(5ZNR$JY_
MB-Z]O>ZS?]Z2_(:FRU:R>(WKV][K-_WI+\AILM*R>(WKV][K-_WI+\AILM*R
M>(WKV][K-_WI+\AILM*R>(WKV][K-_WI+\AILM*R>(WKV][K-_WI+\AILM*R
MX"_XA&N=T`F+<-5^:E8$:]&YI0FR@%[$+V\X*E$J!L16V&ISP6$&_P#CM5V0
ME7/\1O7M[W6;_O27Y#4V6K63Q&]>WO=9O^])?D--EI63Q&]>WO=9O^])?D--
MEI63Q&]>WO=9O^])?D--EI63Q&]>WO=9O^])?D--EI63Q&]>WO=9O^])?D--
MEI63Q&]>WO=9O^])?D--EI66PNF#5OJNR`XY;D,UU4YTBZMI<,/HFW*KY*E-
ML-67*>WQ:+&^=W*/`3RV!Q>9#-N4VRE-NI6=QL'F1F6,`@79F(K3@5RFF/W;
MMO&;=2!:W(K>NU!ZL8>!"THG29QQ/-E,MS/I>4F;A2:>M<61$#8]36EU\5I1
M[SRREA>T!=E)8S!'A."TRD8INFD9>_M+()<X:ESW^,VMGK-;Z[/</-6`QY"L
MZ*E<8SE$2R1K.^[1?E=T,NTRJ4M3:>%:YP.3&J%%DNY<H\HHL"QU4CZ_Z3=/
MUP]?=A$.=]1EV:'K$6K7+3V5VI/8H=D"09'E\/QAFATXPFQ7@O.I8TXY=I2U
M*M:^UD::YQ1C*L=K6#R(C3^CI5(7=-<OK_N'\<<Z:A4J*?"/U3ZFXLQLKR@6
M/DAE,F<%60]*;\=NK2H;J;QDT+B4TPT^R(LDWD<@Q-6F"4@"88:JN0G->*4C
M$W36,O?TY\F<.S5J6O(')`LS?J:3N:V&E.$FQ9$,NJ)+.8^R`+"G*U#:290I
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M*!0*!0*"M9BE,.FV(SP-K0L`CDLE--6KW,2-Q:0FP"4)PJ6-#9X;[.ZM28;9
M.<5=,OX24TPWAE[G'+L97).<+*J*4"@4"@4'_];W0H,TX^7N*Q&![3DI"LB7
MQ&TO!YA06V59.1E.9L@A<5$`P:E\=(H-H5$N8B2[D)%2):2,=C4"T*<+'4.S
M4D3JE:IR;TR5""YBU2H6)B4Z,L)QR81BHXPP):<`5"<PN]QWM:PRQ!_"&]K!
M^PEJ(!B<D:M*`U8`9B0H2@H)BHL`B0C,3@N.PCP`$I+M>X;7M:Y@?_&MM#$1
M261N<QUJEL0>4,BC+XG$K9GUK-YAL=45CC"0+FY4&UBUB$\15Q$GEW$4<7L&
M6(0!!%<)#0<$ET;%(5@T[BA4`;U9B!>,E6G-"A7%6*N:B6"`8*R9658X&\6/
M=&'?#MM\MJ#CIU+$)=8]*>TB<G4DTNQR<U'=<Y)V)0,@\NQA8N.L)9E2\0!V
MVB"G,.O:^[<=]H5AF+-L:PW"5,Y<6YVEC>@G&.H$ZH(B?'U+DS.N2IW&,?-"
MQT)=WQF*(;VUWEJ0Y:``S5H4EQ#)3G"M8%RQ%4HDF2(Q%3HB-W6!*99G)$T-
M;9.2:F/CZ66.JH+=&V)T7%GWY%1*7G:VH#!!X)KJ(E%<=E2I*4<1JFLUR8VB
MX,Z.CEB7+;!!M/N;D&',R9$Z=BD46CLK?H]C.6"EAS<TY25SAWB9;7EQE,6+
MD[.<J(XIPS2+%ISC`EHWANK2V,,*NI3V-*"8(TNYQ=C"PD@3FFB,!O;P`E%J
MBA"O>UMT)@+W^05MI'&$\-`2&U4)T;@I7@U*0T*1+DUB'4Y<2)0B);3KF\-<
M:L(!<902KBN8"U[AVVMMH,/+9O$8''I/*YC(VF.QV%QQPETK=7-840G88RUH
M7)R7O;C;;<TAO(0LRLS?W=@@IC-W;<`K6",YDR_",#XXD64LAKU*&,QWI281
M;<B.<WEZ?)&]-T8B<6CS4G_'NTFETJ>4;8VI0;+J%RLH&\&PKBL&$8LI/;K+
MF>$3'#\W@P)/$9;*$;\_.&/WJ*$E1MQBR`V&/ZZ-3![,13IS02@:TM$42J;C
M4;:M&4N.X`K4$XB[=CV%Q9&DA:"&Q.%$`6K4":+I61BBQ)8^:<W%6C):0)6D
ML`^&<H.,!:UK[HS!7^05Z"4G+4:=0D2J%:8A4X#-+0)CCRBE"TQ.0-2>6D)&
M,)BD9*8L1@[`L*X0!N*_R6O>@^;KT-C%A5UJ2QK>46>O+NI)XB$DX!AA1RP&
M_O)BC2RA""(=@V$$-[V^2UZ#D%F%FAN(HP!@;#,+N(L01AL828(DXN]PWO:P
MRC0""*WX0BM>U_EM0>7G^\4[_.:?MPI0=?EGG:%.F/4BM;BN'RB`G+,$$/\`
MPWMLKK9,19-=6:?RZ/,3L._,G/[*<O):NZW5:3H;#OS)S^RG+R6FZW4I.AL.
M_,G/[*<O):;K=2DZ&P[\R<_LIR\EINMU*3H;#OS)S^RG+R6FZW4I.AL._,G/
M[*<O):;K=2DZ&P[\R<_LIR\EINMU*3H^`#&8'?+2.)@;W%:P@-CB(-[A%<(K
M;0I;VVA%:]K_`.*]J;K=2DZ/O8=^9.?V4Y>2TW6ZE)T-AWYDY_93EY+3=;J4
MG0V'?F3G]E.7DM-UNI2=#8=^9.?V4Y>2TW6ZE)T-AWYDY_93EY+3=;J4G0V'
M?F3G]E.7DM-UNI2='P,8R]VXTCB"PA!`&XVQQ#O#'?=``.U+;:(5_DM;\-[T
MW6ZE)T?>P[\R<_LIR\EINMU*3H;#OS)S^RG+R6FZW4I.AL._,G/[*<O):;K=
M2DZ&P[\R<_LIR\EINMU*3H;#OS)S^RG+R6FZW4I.AL._,G/[*<O):;K=2DZ&
MP[\R<_LIR\EINMU*3HVVT5SF.P&99,4/;^NQJ\2HO'\889XO3J)/!5`5B:<$
MN$&SGA-3=*=/,+2X"D*=>ZH]U;'5-RS@*$19IJD.)F-TXK,3,1@W=[Z\0M;.
M285)%4::\6.IA*",P^3V?LG:;7=Q;R["FVCG)RMOLW9OP`^)B@V<\=NQ-U9!
M!-D_3[6+3,MU8U^N3.V:Y?GUY\W+,RKC#^D<75OV-'T)AJ;(4H@["[.4*PUF
M)6%S$J39FP!(CCP/>D35>U+U5EBUE4JD[>Y+3!B">(8C7A&K'U]824G/'ZUU
MA^P<VXQ=UJ19;*45>%^4(\%F*GF0XD<4PY@CJ%N5INY7X@&&T36$+=*6UN3F
M-[9DIE1W(&$)0A!LFW&]U5C7ZYFV?'ZY>SB%9VQ<D(CDD29)D,3M#5BB&QJ0
MV7E3G/>FE8>-*)3%BW(=E37K(T?OBJY(Q(S#%3PWDA`98)BHD(V56-?K_N#;
M-)P_/M+X%EC$Z!"Z,)[A$TB.!O!$K=<7XXEQ[5'61X5'KPD9WT`Y67<O?&,I
M%<9YKMC5X/3)#"SS4I5P$&#/>E8^O^BDZ?6D^[GFY>QFYK7QN43K&$L5Y-92
MY"^F2-K<(MA/5&T(T9"BR3/4)):QN^E[5<SI$Y%D\O0(^27K$B<P99@BR&IO
M5C4I.&$X?;WA@7W.V-E3.EDB#++XB<'6,O6.XSD60M9<DS+!DW*K4YF#-6,+
M3''MFIO!:M6<:6TS%M5K%K:8HNHNIM<Q2\&JQJ;9TP^WK&CUR:,0#+T>Z4"S
M`"+,+TUX*`,`PW",`PXOBP1`&$5K""((K;+VO\MKUAJ<Y;*4"@4"@4"@KB7I
MN--,3G=*;%W*2.2&<^M=^07,O$@<F(YIG;NJ(NN*E7%Y8TG@+."G-&=N`X?&
M+L97).<+'J*4"@4"@4'_U_3Q"-/$N<,2:?X8\P!IR!/-,.OC,^0,BL[^"-IW
M1WB,\GNHQW9\@LZB373M*XB7-.78]+#[`4<8183R[6.=$=TEXU7&?1R(AI7D
MN/\`&##TS2RPGS1]USY^GN0C6$S#Y,];L#3;.^J3)N(Y(T6<INT8ZF]H:TY6
M9$H8[(5JQ$Q@6N2U&V*W!$C+4"O/@@.)-+VHY@9='3:Y8H6)%F+\3Z;,59=C
M>2U^"L@8@<8GC_(LR#+.E`:98?/,>9(QS$%9CDP.,8`L9I,6YH6EX1A)27NV
MB9C%PX_I&S)CW&.`X\U:<&QX=XIH@UF:2)VVQ=_P^W)U$WRH]:<W[',^>53S
M)V!,Z8Z?UN&GBXS2>=?4(W-*8>V`$:KLF%>?%8##IOG3UEO`4FR%I(2'LF`H
M=@U3&UY;K@FSA,=02"(Q:&NV5\FR@F:.$L*B.GB-(N#'FU"C<SEKJ0<O+)&8
MC9Q"%<\5$L&DC4"YPN=L#WIA<&!+,,+_``TFH,05RC!*V/LV0M,&IK*,RS`S
MLZDC*\H?WQ&W8SD+2%ID,C<W61/B5,`#@O&L!P"A6-6P<:TDRB(9B:9W$]/C
M+%`,GQ!W/+;(_,'=*SN#%I\?M+[KC1\*:#&N3$N+6R.^27]>J5L::P#%-URE
M6-,,P\W?%>?!0:#2=J.?HS/TSQIL518<QP7I-:9-"+3/##C&':;8`U9RC+<]
MA$;>.\A]E,V1/D)?#+L#[-EP5KL-4<)U/:331I0"L+TG&F=TB^&,P8TQE`TV
M)`:D-9FG"?X<P\P$QPE/B=MA$GTVO&3)U=IB"QU@\1&V'X@D4T/3M2TU$,=D
MXP""\.)J>XKBK?*6D3/$U;M<K5'\5SQLR-F_5BP9ITZ9"<,R1A#A.&G1G$^G
MB,Q+(F4\9(LFO:&3CB4ZQ.X.'35<*?CUP"V\%[%WL$U`*QAI18&1-(>3%:;6
MW/8AAR,*LLSC5+A#+&/7,E3CN)2/+V'(3CW1DCS/C>.S*SB_J,9&Y=E>`9#<
M2=W$2@7'JD)CIQ"#5%R17)7&;]*65WO$AT0Q#I<FS*FD>)-1#S'$3[DW#3_D
M3'.6<BY+@61T\2E%I#E=9BN&HY=(V$]Y+6PH3V:@="22B'5H(`<-P%<<TIU*
MZ3L^YM7ZL&Z*XY2V8M06"]040&WYI/Q$_((YDB5Z?VR#XRD^(<A1A]<LGQI,
MZRE@9$SY'W]&O8D)[8-T:U"4PE,4H$3$4;A:H\!RW.&GG'+/C&/M&.)]B3+6
MGW4'C[&[ZK:VJ,]<P1DJ,Y'0XODJR&V?&1J2/"!D-;;GMUUJ)"N&4<`2@@K:
M94B:2SF=%V7LJ:?L@LL>TXO8W]UC:<L>-\E3/'Z%=)KG.K7=>P-:C'67C8\N
M5DM059W`<I,Q-J\XDE">I`E6*%*0=6D&-=),[-R="U^3]-1DAQW&,YZNYV:C
MG0M.+Y=7#\VQ)A6QQ*=%8U*;10M6[S$I6-<C3I"4A;F,:D5K@%94.+7F_;3]
MIPSK$$.`H5GS3G?+R)#ICT01!-/560\><SITS3IA)+',POZF\U23!UC;Q,$"
M:2MKE$^LJGI3Q$#LG3)MPRPF8QI*!R'1IF668MU/Q668)E;_`)N7P[47!8CF
M`W*^-1P+-C'E[+R/(<,7,4;#,FJ1,$A:K-J%:O-E2-$*++T1I+">M*7G'%EK
M&#NOA,.B$"C#;%X)#(]CZ,(A+UJ*(19C9(VRM*M\<EC\]7(9XZ44RIU;@^.:
ME4K&185E"L\TX0AC,$,5852?_P!JEK_[OS]_UC1RM_TZL_VZ-@:PT4"@4"@4
M"@@N-@[L11AX361^M)/?ALZCFF^VV4O-]XL[FEF\<9MWCK<2^X?<8=@=F[:S
MFD9)U44H%`H%`H(3."..ECENGH'#AS:)'[B]QZ:!+PG@@?4$P^?;^;7HMF^2
MFVF\<=K`X1FW=O8X^B2FU12@4"@4"@4%<,2;<R?D)5TIL3\Q',>%]73N_,NS
MGRYTUORKDS=44=*2M?&VICN43<W=0;;?.X.PJ\(3C*QZBE`H%`H%!C7D.^T.
MH.$4?OMJX/`/.Y<D[>2FVX1Q_%(X!1FW8(>^#=M?;O6V;:".8U)Y;',`3\@@
M:N7A45)Z6UN/6&QMX3$@!R#<[<^Z]40(]WADJ>:4\<L-A\4S>W[V<Y2,H36H
MI0*!0*!05Q+TW&FF)SNE-B[E)')#.?6N_(+F7B0.3$<TSMW5$77%2KB\L:3P
M%G!3FC.W`</C%V,KDG.%CU%*!0*!0*#_T/?G8@D)QBD))05!I1)!I]BP6.,)
M3C/,(),-M;?&40-28(`;WO8-S!7MLWK[0_6@4"@4"@4"@_*Y!(CBU(B2A*"B
MCB"C[E@N<62H&08>26;>V^`H\:8L0PVO:PKEAO?;NVV!^M`H%`H%`H%`H%`H
M-38RVSANU4F=M)8Q2GF<'2`YDZ)#U$2Z4V7R-'MQ`NYB52?JZH.VVU0'E;7V
M7_%6V_)N:;,(XLX[L=&V58:*!0*!0*!007&P=V(HP\)K(_6DGOPV=1S3?;;*
M7F^\6=S2S>.,V[QUN)?</N,.P.S=M9S2,DZJ*4"@4"@4$)G!''2QRW3T#APY
MM$C]Q>X]-`EX3P0/J"8?/M_-KT6S?)3;3>..U@<(S;NWL<?1)3:HI0*!0*!0
M*"N&)-N9/R$JZ4V)^8CF/"^KIW?F79SY<Z:WY5R9NJ*.E)6OC;4QW*)N;NH-
MMOG<'85>$)QE8]12@4"@4"@QKR'?:'4'"*/WVU<'@'G<N2=O)3;<(X_BD<`H
MS;L$/?!NVOMWK;-M!',:D\MCF`)^00-7+PJ*D]+:W'K#8V\)B0`Y!N=N?=>J
M($>[PR5/-*>.6&P^*9O;][.<I&4)K44H%`H%`H*XEZ;C33$YW2FQ=RDCDAG/
MK7?D%S+Q(')B.:9V[JB+KBI5Q>6-)X"S@IS1G;@.'QB[&5R3G"QZBE`H%`H%
M!__1]_%!UG:CGC.N(=04@U!8E73_`")!,7XGQFX9UTTH7A[D:>=XZE4JR^GD
MD^Q!%'1V-:6/,^-$T(2KDB-L*1VE+=SC>?8Y6)N,(C48Q1B87K$2EXWQXKT^
MMCMJ7D.H([5WF#%"A9/94O:)%CO#^:4[&B;D#X]D2AS90+4N0X\UH4MR"$[4
M1<X\TK:C$E.%-5H#UHO@5DA0.&'`M0V#4+I?P2X)%F106=TR;4Q%L5/Y4C4E
M-</7MQ3W!5>40I%+8G7*$RRZ$9I+D"Q@0AJ447%WF50/(VJ;0W)Y[E=YE.5L
MC,&1=.DW>LIY)4S9)@C/J)P'.D<,G:V2GR!@<=,;OCR9&H"$CDG"%`%D*N$)
MJS\9%TEL6\:G7N%Z@X)I]209L<F*29.4X*8Y"JR"[O\`("7MOTG2G4XSR>6N
M"=DE*9E)<D4"<F$UJ?'$J7'BL2^A3*6Q60:=4IA5*-+>I*5Z@CLF-THQK&\:
M/^')B\8MR*PMF4KY!7-F3F!Z=@+D39PX)$RW*!.D,$S/#4]FW2*E8W,]$<VI
M3F\ZY@F*-)]6F:)W+=)GQ7LE1V8S*!N>G5OR;B/$*Z#RN2PEYC:S'>&8#.WF
M=`<XXX-+D&6.V0I>K*+/">,DMG:T`2@EC-6W4358C&UN6PXM2SE5/HF^M>J+
M$C*]1N)I-]XU0S8^0R9(ED:QV>1Q![AV:9V^X]4-O)ID*YR9'9G=E*1UX0QA
M"%*8&HU?;L,YLD6F2:$:<9E*I$W3[4',)@U,6;-6>K;KCQA&$740.,17'.I1
M+.Y9GC':3*3I`6Z8)W%"ZW1EE/:I/<@U"J&346L5Q6BR9K-B;?\`#WE4003I
MLA&IQ63A5Z@63IE*9[+F)T7Z><CYKA+U(Y?*7:72%\F,4<L-*V)S>!N"L3NF
M>3%2H:\2="<GJ4S1C44;JKB>0=/^<\8%.RW(T3PODF4Z@-)T5R#(YOC'-4<9
M7C"*.4P[&Q<F31-G298A8I2X+8?(B6=E5O*DFS<Y%\HNN%/%BF,*W=)*]:IX
M<W9*TA:A)S&726ZG6]ZP[+%TVR.XP?\`4FD!-DE1C#(V-'60],-@;O/V54UR
M5A4(@J&DX]8-,6E<DY1I0RPF&PFD34.CU'9,RVXN**7P')F+X'B6!YJP1(I.
M^J"\/Y?M),SAE:`N/=2%%'!ODS.UM+@SR%$FX;ZPF(U)9EM\98*DQ1HOJ,F>
M7V28?%6=((LU(N;UAYIQ%)\62>+9VD#;CC`:U9I^9);()HYXT<\HIR)1$XTO
M$HD;I&VV*OMGQ.E-1$I##U``5-5C@W">-=[\TWRG)FF`PJ9X>Q5%L'O161$.
M1)`S/V1S-0L9:U>+5<9@YN,G)*S-[S*7Y"F<++7:UVMM/YPL2TT(T0!1]Y*U
MJ9=QABZ9S.3:?T#%(H6FSJ_DL<@G@T_;F)X;A$>GS6Z1:/,,=D>1TW;END`D
MBH\]E,1190W*3EQIJ8QN,7BG-E<JZWW*&RJ0PAEAT>9Y'?%[_D/&X,J/4GBB
M+**5IPF^Y54*,?NS9$'B*3-7&W=M`UO,>3NY$C1I2E+H).!O"G/45*-M<#R>
M53;">)9C."FPF72K'4.D4@LSK!KFXUQ>6%"X'*DYXV9@W><YBQHR@I"BR#!B
M*!<8`!,$2<U*Y)RUBS$FI=@><J9)@6-&APP:^M2!UGTO8(>W+G04]8EEFY&M
MD#@WIE*ZZ1.8;P@"$9PP"%LV!O>VOZ=6?[=$F]M?1M[V.FSUXXR\YJRUTD]M
M?1M[V.FSUXXR\YJ'23VU]&WO8Z;/7CC+SFH=)/;7T;>]CIL]>.,O.:ATD]M?
M1M[V.FSUXXR\YJ'23VU]&WO8Z;/7CC+SFH=)/;7T;>]CIL]>.,O.:ATE#,?Z
MR](""+)4JS5'I?;E`7&1&"2(,Z8V&E`!1(W922:`1LN5#N8I(-":9\^]K&#%
M:U@VV!M9SS2*Z2F?MKZ-O>QTV>O'&7G-47I)[:^C;WL=-GKQQEYS4.DGMKZ-
MO>QTV>O'&7G-0Z2>VOHV]['39Z\<9><U#I)[:^C;WL=-GKQQEYS4.DGMKZ-O
M>QTV>O'&7G-0Z2ATSUBZ07-,P`2:G-,[L)',8LYGEFY\QFDLB2-[J0H4NH!6
MF*3CFMQ0+FA*VCXE[;NX/\%6..*371,?;7T;>]CIL]>.,O.:HO23VU]&WO8Z
M;/7CC+SFH=)/;7T;>]CIL]>.,O.:ATD]M?1M[V.FSUXXR\YJ'23VU]&WO8Z;
M/7CC+SFH=)/;7T;>]CIL]>.,O.:ATD]M?1M[V.FSUXXR\YJ'25?LNK_2*ER1
M/'L[4MIE2-[O'X$C1/X,_P"-#CWH]H-F`ER$YO[:&V1`9;.15P&<N3Q^:%\X
MSA_,O",4QK."P/;7T;>]CIL]>.,O.:HO23VU]&WO8Z;/7CC+SFH=)/;7T;>]
MCIL]>.,O.:ATD]M?1M[V.FSUXXR\YJ'23VU]&WO8Z;/7CC+SFH=)/;7T;>]C
MIL]>.,O.:ATECW;6CHZ4M3FG*U5::E1I[>M)+3"SKC,H*@PU,8`!`C>U17#"
M:(6[<6\'9MV[;?AH=)75B4Y(=BS&PT%FH"2\"A_+EL;N0_LQ)/9UNX134^)5
MSFF>6TLO98A46I4`4%6"8$TRPK"O9SE(RB%A5%*!0*!0*"LIF1Q9SA\WIR)7
MRTGDYG.J7'E%+5Q,?2DGF&]%SR;JIRGB<`9?"4<,HT1NZ'<X@;&5R3G"S:BE
M`H%`H%!__]+W\4$63PR/I9BYST@AP!)WEC:(VY*KOK\-O4LS"J=ES.DO'S',
M4>*&@5ORTP!P$H3]Y49M'?>O04=(M'6G*2Q^&1H['@X\W8ZGD[R5`U6/9E/L
M62&(R_*+]))-DA7'Y;C24Q.5MC3.WB7N(W9J*6A:5Y2FY!R89`"RP%K+D2#2
M+I^DTL%-7.%.);X-^QC*A@99_DB-1\<IPT8WWQG*!P^-R]IB`I)%4S4E2%+[
MH>;/;TQ2,\PU*6`FPJMM?C:".F0XUEAPB[4KR/#HK+(1&9<:2*[LSQ6<N44=
MY4S)3+#L5R[LXPEL,$(0!&%<N()0@!./":3DJ5TTDX&>,BWRLJB\C3S?O(29
M@*7-&4<KL#.ER>DQ@XX7%-T,08INW0Y!(''%[J>SKSB$!=W),.PE=CC0`,"6
MLI=",`XFQS*BIM#(PH9),7C6(8A,<@2:6K0K<?0!0Z*H8R.R!R?5C:\J(X>^
M+;IEZLDYR!SA]N8O8XRPB50N1Z6L:S"^?(W*FOKV*]37*.^7X`:Y/;0F>Y:F
MA\;QPXNA#C'W%K<RFR70")-2)S1!/`G$:U@/"&YJM6(9:Y+(C>((7%7E;(6X
M<U7/2YB.C=W&4Y2RA.%"%F4JBERQ(QBFDQ?PQT:Y6F),4'(+)CU`DQ'$&+@$
M[A*L0XX!QDOC.-(<2BET=CF($+:U0%N@V4,HX\Z6S-+"5&4#&YK(),HXOE;"
M4RIRRA(7<U>D-$4`T98C0!'85?UYPTP2&>XOE3B4E2,>$D4@%C&)LQ%FQO9I
M-)8JJ@2B5[Z*R82-2P8_=G1D:DJ7AITZ5X6&#XA@DO)AF8OB&"PXZ$*&)(_@
M.QU!AXXB)CI.9U(A((@:!B`>WK;R*2.O7UBKLR@$<O<>;<3AI"Q#/$*VV@X#
M=@K%+,K`M8HH".G`R6_9BN&-O$@CJ4[)4I:5;))96K0,CL@0K%K^W."D*PHT
ML:908J/-&6(TXT8PE+9CR$LT[EN36J-MC?/9XP0R+S*3I2A%.,C8L>JI<LA:
M%UN$=B5/9XZ=NO`-N#C<-7<L0Q`+*"6%-2;2!I^F3WDU^DT0?'91FD;5?+;6
M=DS*A42R0F968N.MS5,X,FFQ,+D#`7'B@H#&U2@,0'HOQ!I(RKW#<M921UTU
M8.?4666MZQ^VNS-G&-M<0RBPN2]\6QZ31MC9#8XRM(8^H=#&9B3M+,;<A-=M
M(1C(M8(@"L,(16%95^Y:']-SU&F&*O45FKRWQZ-9'A:9R=\X9V<Y>[P[+K3'
MV+(\3F4^79*/G,_C,I:8BT$G('UQ<4I=F=!<HLL2)+<H5E+2]*N"N>1+UD/<
M7SIYJ=4D;)3.\ARV.`<D^,S<.A?#(K)Y6[QE3)#L:'FM)[F:D&X*"#C!&G#-
M,&8(5E;D'A4;QQ$([!(>B4-L6BC6F96%O5.KP^'HFQ&#AI4HG5_7NCPM"07L
M"$2A0:.P;6MMV6M:Q'E[_O!YIADBQ(`8Q"`2:K"4&]_D`$2(\=[!_P`5KBOM
MKM9^D^K']^CS7UIHH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!Q5
MW^9+/_95'_JATG*1_H8?#H5*%6B;3"-0:,T0,#8>+"(=]M[`!CB-!"&W_`&U
MODKA)$UF[U;L5%*!0*!0*"LIF1Q9SA\WIR)7RTGDYG.J7'E%+5Q,?2DGF&]%
MSR;JIRGB<`9?"4<,HT1NZ'<X@;&5R3G"S:BE`H%`H%!__]/W\4"@4"@4"@4"
M@4"@4"@4&CWQ!,JS7%>"8]V$>UT-<\J:@-.&!'C)3<408KQ9#\W9IAF.IE/D
M@U0;I$;HU1M]4DMRDVX0)'-2F.VWN78`BPF4]B3'I]:E^:X>X210="H%+F,^
M"S7-\B10.8J)(ZQ-WM)Y6\9+EKDQHIBQGQ7>O(5`%3H-N5N!-[*3#R@A"BXS
MK4RO.7V'0*(8=A!LUD^3=1^+#UTOGTZA,?;W3!;.B?&A\-95V(%\Q3H9<UO"
M4Q2C4IB%38I"8F#=47<*RT6D:X)%C+6?+,[QR`R##6)6=V4NVGK2AJ3GL8E>
M128TZQ^&ZJ!/RQO8XZXFQLYG>7B"1>(/#HK5*S&]$O&D(1)[V-4*#4%28H@<
MB^(!/46-LH9JBVG59),11""YCE,7F2^<`C:5\></Y"[&=EG$"J-K#2G&?,J9
MP=FVZ,"HM$-H4(G`:88R5`HM.;L4ABJ:K(ZC49#9(M'):8I=[+V>&2EVFD=2
MHRWA>6Q#1R1\A\"<G!2KCX$IRL(VI,!.L,-)+N<66`\VLO.=\;;!.7<ZSS'#
M!B2)E2IY:T"M]7I%#LF9P$M(0!;A*P'J2S0'7LM5E@W+6V_.V_X*[6?K/JYY
M7XZ.BKPZ-;?H9;_OPT^25:SI]VMUNL]CPZ-;?H9;_OPT^24K.GW-UNL]CPZ-
M;?H9;_OPT^24K.GW-UNL]CPZ-;?H9;_OPT^24K.GW-UNL]CPZ-;?H9;_`+\-
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MPT^24K.GW-UNL]CPZ-;?H9;_`+\-/DE*SI]S=;K/8\.C6WZ&6_[\-/DE*SI]
MS=;K/8\.C6WZ&6_[\-/DE*SI]S=;K/8\.C6WZ&6_[\-/DE*SI]S=;K/9PBOA
M[ZTCERQN+PZVW5(24:A07:>L8A@*7W563B$4`H1Y=AW2#V7&`(1;+[MQ;!;&
M.GW-UNOV<WPZ-;?H9;_OPT^24K.GW-UNL]CPZ-;?H9;_`+\-/DE*SI]S=;K/
M8\.C6WZ&6_[\-/DE*SI]S=;K/8\.C6WZ&6_[\-/DE*SI]S=;K/8\.C6WZ&6_
M[\-/DE*SI]S=;K/8\.C6WZ&6_P"_#3Y)2LZ?<W6ZSV<=7\.;6T)(J"+#;<"U
MTY]KC%.6@(0VN4+:(5Q)@AM8-OE^6]K4QG"GW-UNL]GMWT%1AXAFD?3_`!1_
M3EIGF.X@QFQN9)*@E60!>TP=A0++)U:89B=6190G%N&EB$`P.P0;WM>UZXW8
M21QGA+<"HT4"@4"@4%93,CBSG#YO3D2OEI/)S.=4N/**6KB8^E)/,-Z+GDW5
M3E/$X`R^$HX91HC=T.YQ`V,KDG.%FU%*!0*!0*#_U/?Q0*!0*!0*!0*!0*!0
M*!01:;0B(9)B;]!)]&F:80Z3MYK7((U($"=S:'9`;<(A$*T:D`RA[AH`F%BV
M6&4:`(P7",(16"K'?3+A^105WQQ)FJ8RR+O+<D:S[2[+6797(T!#>YMKV@4Q
MR<2*=.<WB3PA>V5$M)7M3BC7%+$*8\)UC4Y(P"K#QK2-@:(R$B6,,:E*:2I7
M^8RI.]JLL9>=G`J29`9$D=F;X%0[SM>+J<B:T)5E!W_'N?:ZBU[*!"-$6K&-
M^BO36T.&)G1GQ^X,RS"4`8\40`3-D/)S20#%L87)W.,8UF:-NF:9'E*`1IP3
M`/;F:4EO+<@-WA$$EW&/>%9?SV*=-=BLMHRX$Z$-&<39(?D>-)LDY32Q!P4S
M1Y3R*<JHY#4\V*BN/E<]?TA2U_-CR-J,?%9835XE`PV%85G!M&02!.2207<T
M0""BR0"//.4G"`6"P`W.4J3#5"@V]@_.&8(0QW^45[WO>]$:ZN38WK]4S66L
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M)-]'0I!V7COU*V?H2;Z.A2$'G<5CXTL;W8RQK-V<1`=PJ>60!("%Y3W$L)%Q
MDG,J4MOG%D;1\85MW<'MV58XXI,0G'9>._4K9^A)OHZBT@[+QWZE;/T)-]'0
MI!V7COU*V?H2;Z.A2#LO'?J5L_0DWT="D'9>._4K9^A)OHZ%(.R\=^I6S]"3
M?1T*0=EX[]2MGZ$F^CH4A6K#$V`.4\C&WBS`2`R,XX"!Q*-3GK5URSIQOD*V
MOF3NG$H=^UR3.7)YGC#^<9P_F:X0E(K."RNR\=^I6S]"3?1UE:0=EX[]2MGZ
M$F^CH4@[+QWZE;/T)-]'0I!V7COU*V?H2;Z.A2#LO'?J5L_0DWT="D'9>._4
MK9^A)OHZ%(8UZB\>NSNUK,+2;>[8OM8HQ,F(+,O=*;L+&=L*X(!_@N+>#NVO
MMVV_#5*0X.*DA2'&..TI3<B:0DP:)%]-;E87!"@N!@;PW1I'`*E;9>F2[-PL
M_C'<4`;"WQ[=ZZ<Y(RA/JBE`H%`H%!64S(XLYP^;TY$KY:3R<SG5+CRBEJXF
M/I23S#>BYY-U4Y3Q.`,OA*.&4:(W=#N<0-C*Y)SA9M12@4"@4"@__]7W\4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4&IL9@46@VJDSLR@5(>O8.D#JZ<R\O;OQUP\
MC1[>-*ZTXN')@OOW_%D<,JW_`(M;F9FS'5FD1=T;95AHH%`H%`H%!"<>`X<4
M2!Y=G2['*27X+"LY]L#O25W%OE*N><MY0;MWU`>-?AJ!&`W0;NX&SFD)M44H
M%`H%`H(+/2>,DC-N22KN'.H<=NJEO(A3\)Z3BYTD7-).95)-F^61M'Q16W=P
M>W=JQQ]$G@G512@4"@4"@4%9,!&YE;)"CIR(CCQC&I?4RG'CKG#@'3J_+K&S
MGCNGDM_%VDF<N3S'&'\XSA_,LY0G&5FU%*!0*!0*#&/8=]F=P\,!V\V+P\$T
MS@EF[4IMN&8=OE<(`]NRXMX.[:^W;;\-!&,7D\OC/'9'))6W@P6(D].1+>I(
MD'#8&\'))''FEW/I4N[N%G\<[B@#86^/;O7LYSZI&4)U44H%`H%`H*RF9'%G
M.'S>G(E?+2>3F<ZI<>44M7$Q]*2>8;T7/)NJG*>)P!E\)1PRC1&[H=SB!L97
M).<+-J*4"@4"@4'_UO?Q0*#5C57J/=M,,7AT^[L'/)4*73(#+D2\6=UEIO"H
M8EC,EELER!'H8GC#L&?I87'8LK<7%N`O;E@F].<-)94I"4D.+$539BS>Q/\`
M(7H](NA-\2M^)\<9:;,M!G)5VMX8LD+IPG;%($QS&G8TK&4CA0E(7#K!@3BU
M1>PH.R][BC,M>><)/1"-0VY<QNH"O;)@\I2KS2/$+#&K'C@0T9!7B0*7`E:2
MF@;LI+2/8AEALTJAA*5<(R]@T2DJI#J9-OJ;QEA.T8C"S&6;<(2C+F'LZ,V1
M>M()Z[0UPB(GZ#M<:11`3.,T42FB1^0.!,@4%N+66>823>Q!MP%IA5G674C$
MFV*F3',;WC?$C*[2F;HX&L69'"YI)5`(E)K1M)DA8L>8Q#D[(S/%CTJT9A=U
MS8B1.2(PQP%S(;6%%BWS3AP,L<H$++.,[3EF?(W&'B&7G<6M+&J2S)M<GF(1
MYRCMW7K"%\E30RK%;:D-)`H7)DAQI(!@*&()*3H_&590;F'(F/\`$[<G`[SS
M(#9+)8E:QJN23M./<?*8NAFTR<E-B%(N6;WB<,C8F(+`,]2O=B/FA3E*CTX:
M\81U.Y1S,F=G<K$.-XZQLVI?,^G10`_.[PKD[D;A'*LVQM)Y5'V-5A%F;'4X
MYN@BY\+:Q.9!UD!)@>,(PO8,LQ1\M^H_.4;R:X1K-^#\60#'B#$64LTK)=!,
M_P`RRS.([$<<N,91I4TQQQ;3;"&9N?I0FD1AB=.UR5Z!<QJ7%IS%=B;&#%(I
MA+`XFUL7G&`GW4S*V?#J+$D=D84C\ZXES9(LJN,-BB96B02E\R0WR?"F'C(7
M*<:F+@JY%'P\^:E:B3U"=2J-`G2JQ3&C=9IE\4?WJ51MDDC&[R&"N#:U31C;
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MZTX3.$P/(+5EZ$)HQDP1%H4L=Y`U-ASO9:_MT7;A#2J%=CFT3B_O;>B*`JL2
M;9:Y)$I@0*CRR;EI.C+,FIS!3^IRLE0Y)C%AX7GH<:3[CNR`L3=,!1=LE=FM
M,G"H,6+C1(7`T@-BR[C-6-ZTDL(A)3=@I*XV%_8I4QL\FB[TTR2-R%L0O3!(
M&%Q1O#&^,SFF+6-KLSNS><H0.;8X(S@&D'DF#*-+'8017#>UZ(\^'QE-6>?]
M+V0<92C`$\*@$C<F-QB;LYF16)RNRYB/4`?!HN3EK.](D]^HHB1\4LL!OS-W
M>W;WM?K;;$V9\6*_RZ.EGQD_B7^\HE]3.$_,*FSFUT/&3^)?[RB7U,X3\PJ;
M.9T/&3^)?[RB7U,X3\PJ;.9T/&3^)?[RB7U,X3\PJ;.9T/&3^)?[RB7U,X3\
MPJ;.9T/&3^)?[RB7U,X3\PJ;.9T/&3^)?[RB7U,X3\PJ;.9T8YJ^+[\1]D1%
MMS7J*1(T11JL\"<&&\+C"$U<K/7JQV$;!3![3E:DP=_EV6N+Y-EMEJ;.9AHR
M/C)_$O\`>42^IG"?F%39S.AXR?Q+_>42^IG"?F%39S.AXR?Q+_>42^IG"?F%
M39S.AXR?Q+_>42^IG"?F%39S.AXR?Q+_`'E$OJ9PGYA4V<SH>,G\2_WE$OJ9
MPGYA4V<SHQ3M\7GXC[V6A*<=1R<X#<ZMSTDL'#V%RN&X-2D"M"=>Y<$#<82C
MP6O<-]H1?@O:]J;.9AHROC)_$O\`>42^IG"?F%39S.AXR?Q+_>42^IG"?F%3
M9S.AXR?Q+_>42^IG"?F%39S.AXR?Q+_>42^IG"?F%39S.AXR?Q+_`'E$OJ9P
MGYA4V<SH>,G\2_WE$OJ9PGYA4V<SH>,G\2_WE$OJ9PGYA4V<SH[MO@AZO-0.
MJ>7:HW//\Y(GKVQI\+H6AS*BL4B@DK>81DLXQ(-+$V=F1'VXUMZPQEB,^6]M
M[96+HIA4PPPQ>A6LJ4"@4"@4&,>P[[,[AX8#MYL7AX)IG!+-VI3;<,P[?*X0
M![=EQ;P=VU]NVWX:",8O)Y?&>.R.22MO!@L1)Z<B6]21(.&P-X.22./-+N?2
MI=W<+/XYW%`&PM\>W>O9SGU2,H3JHI0*!0*!05E,R.+.</F].1*^6D\G,YU2
MX\HI:N)CZ4D\PWHN>3=5.4\3@#+X2CAE&B-W0[G$#8RN2<X6;44H%`H%`H/_
MU_?Q0*"K\A1>1R"0XD=&-.PJ4<)R`OD\A*>G5<VFG-*[&V0(((EI*1L#V4N7
M`/FH3[EGB2E"+($'B6N.UPAUY._PZ)+%HUJIA&$<CMD?Q[E%;IYR)I_QI*R7
M93$,-9%PWFN69VE^.RKLMD[HW:?LE3-0A'=L0FC.:"W9X+2%`(LD(J-5R2\S
M2QF%(XXQGL.@NGB`RQ(S:CV3(\`9)[/EL00J\]Q_&K=>:-&0C\3(I'DR1-CG
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M^]LVL+%.>DY*APBB[!F2\`20LH9@^SDDD<]QE/L>O9R<`!\%A>AQ5X:UZJUA
MF$KCFL.Y<HPXPD<%&8!TI9&PZZ21T68STUKY;)M56?,Z@S$GD#ZKR#%XCG?,
M,\F[HR-:13A9`>[29HQ]/%3"2(][(0W-'QQ`$2#EC!,U;3V@^1F:8Z@,I,P8
M:]S>5Q^&1##[,^/CZSQD$6Q]&G1Y8FZ=N+=&W=<PK7++.0).)8J;T;J.S,)`
M+=,-+NF*&C6;..`I?*]/FKN,DQN,,6:M<,%58G=XW!7=SD\)C#C*L:APNJGS
MI)W.,09?(;16..9KH[O![0V''MC:B;B4IZHA/SHKC&D-X(@@E#2KD32[(8\3
M%VU0P(H$Z-[RYN<H?&9+$V-*Z+9XE6L;8A;GXF1)U1)'**EY:AO+(-&,HT0R
M`$:KZ:=*A>)WG+\ZG\'PZ^Y,ENH3-^88#-6E(%XDT=CV6'M4ZIHP;+WJ#-,@
M8SDJ92),JNBN>08`T>RU[7N$19GLKC&.DW,^*H_H><F=VQVZ2_2WCG)F*9M#
M3I-)FB!SECR>@AH5DJ99,3`7-V02J./,`1*$H%#((!Z9>O3B.*N:$^HM8Q0[
M$>A#*&&)#@HZ$3*/QY)C=-#VV?R%FF$M`VY*AZ62S2:2;&TAP4ZQ-V@#DV19
M\F2I/!9"2Z-D@C:(ZQ=C#$Y`49PF8E`)!H5U.'89@N&&QRP0YM,)PBT8K2/@
MI=.H*]J'J$9399;'GY]<6/%4B>I9&97&&GAG1U0N3-,>=#3#^$^F73J48KBL
MW(^C[/#A(I'-8>KP_)5R35\AU11R!366Y!B,5G+7)M-"?3QD''LQDT6ADD>H
M(Z1X)JEUCK^@0OP5!E@%*VXHH9P!")_X=@^*(0CQQCB'P=`Q1:+I8ZS)T14:
MA"8U)$&"XA#4&,T:*/(2J!LS::>(D@TTHDT\L%C!EEB'<`:S+S#_`-X56)$<
MBQ.8L5)TH!*50`C4GE$`$/IY]]T(C1!M<6RU[[/P[+5VL_6?5SC]Y]'FFZZR
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M%"P":9<GT$A4[1L&.&])-8E&Y:E0*9#)C5")/(V=&\$)%!I4;L48<F*66`,0
M?FW$&][?)6IB(F8Q2)F8B:);Q\R_5>,OMZ5>;E3^/,Q./F7ZKQE]O2KS<I_'
MF8N.K#F!:D4HSFK&0B5:<Y,:'K\LMM*/+$49;:"/`%;:$=_P7M?_`(:8<S%C
MXZUY7C,?8XVV-&,BFV/L[8R-Y7:"7CX:)J1$($@-]0PJ#Q[A"<-MHS!CO_A%
M>^V][-)QQ(K$49CCYE^J\9?;TJ\W*G\>9B<?,OU7C+[>E7FY3^/,Q8A_?<PL
M#$]/IS+C504RM+D[&D%R"4!,/+;49RP9)8A1S=",P)-PVO?Y+7O5_CS,5D1E
MW%((W'GX9`4HWMC:7<28)ES0IQ.2!.M$0$VX07,"3<[=L*X;;=FW9:I,4F85
MG*@4%<2])QYIB=1T@A?R4DDAO43'/DS6+BP.3)N<3H>8)ZN-9QN5$5N&\(!U
MS=EMS>M8RE)SA8]12@4"@4"@_]#W\4"@4"@4"@4"@4"@4"@4"@4"@4"@4&AF
M:=/>-<YZD6-CR+&F>3-J7#3Q($R1Z;DCD00Y$3-B:@*2BE9)P"SK)%`P;UK6
MOL%>W^&ND32SJQ,5NZ./X;>E7T30/[JLOD-3?)MGRD\-O2KZ)H']U67R&F^3
M;/E)X;>E7T30/[JLOD--\FV?*3PV]*OHF@?W59?(:;Y-L^4GAMZ5?1-`_NJR
M^0TWR;9\I/#;TJ^B:!_=5E\AIODVSY2>&WI5]$T#^ZK+Y#3?)MGRE$(+\.72
M\MC250KQ%C4H\2]_`(#:S,;LCL`B0.A!-P+@C=K&&B)+#<T''%P3;B+W2]WA
M@3=,?_$VSY)?X;>E7T30/[JLOD--\KMGRD\-O2KZ)H']U67R&F^3;/E)X;>E
M7T30/[JLOD--\FV?*3PV]*OHF@?W59?(:;Y-L^4GAMZ5?1-`_NJR^0TWR;9\
MI/#;TJ^B:!_=5E\AIODVSY2BLK^'#I>)(9+I<-0)8(R4QTDX(F-E0<!*:Y%!
M4*[#Y<CF1)B[W%8C:+C7MN[HMNRD7&V=4J\-O2KZ)H']U67R&F^3;/E)X;>E
M7T30/[JLOD--\FV?*3PV]*OHF@?W59?(:;Y-L^4GAMZ5?1-`_NJR^0TWR;9\
MI/#;TJ^B:!_=5E\AIODVSY2>&WI5]$T#^ZK+Y#3?)MGRD\-O2KZ)H']U67R&
MF^3;/E*Q=/\`IUQO@>?9)2X[@C!$6]S98$<>O8[(DEWM26.8!&2K9T8@61W:
M@"#N'"*!=1S`K6$+A_-DS6(6(F,VVU9:*!0>6SXQV3IEC/19\.I5$\F3#&@'
M:.-29T6Q&=R"!C<PIL.1(Y&E<%K`[M!JTHDP8QEE&#$&PMHK6V_+6YI\EU<J
MREOZQ3DR?]W.RU.\GR?6T3+<K3C)S<P,.EHUFM+\AR2?)V-:\.&I@#S=J'('
MIY"UG.9#2BYFQ-R[G!3D[]K[@-DNI7#)KA%7;%&'/+I&FJ*9!D#)DL[5Z4F;
M9#+&]VA65'F*1S*DV5EPA^A1D9CZN.-TVP=BYQF9IB!,V''MPTC(3)+A4*R3
M%H\+QI7!R"\PZR)4R3^4Q>#M<43-#(MM`HC-L,Y%M)9/-)A/<RPS'$>=3#)4
MQF,C)%F,N!/TJ>2D:Y$E(/=``N$C8I0BD,]+<HZLF]3D^-QR+M+O)8*^,D9B
MSKW49%01;(]\E)(_:/2MH4W5/+`CBV.)!D-"A>E0)`K5)$T0?%BQN"G<$IK0
M*0G^"I?FB=SU6Z9!!)H]%DF-"'ME8E6-W6"-#RNGN6LI'L13VGE#:K?6J>8_
MQ)$XN4YMQ;L<`I:]J;FE!N$N]5)HVYHB&9'_`+/)Y_4R4?Z#758SA)RE_,;_
M`-G<"_J7%O\`0:&EW[3ZD90FE12@KB7I./-,3J.D$+^2DDD-ZB8Y\F:Q<6!R
M9-SB=#S!/5QK.-RHBMPWA`.N;LMN;UK&4I.<+'J*4"@4"@4'_]'W\4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4&IL9A3?#=5)G(/$P=NM8.D#DH[6S.33#DS19&CV
MU.T=HW-RZ,WVW_D3IN$3;9;8'Y+5N9K9U9I2[HVRK#10*!0*!0*""XV+X411
M@Y1L1;'23WY9G<.J(`[\I>1\0M;U-XWSS][B'`Y@7"/$,O=+W>&"W9I"=5%*
M!0*!0*"$SA/S*6.!Z:4Y\*;1)1N&KN0LDX#P09U(`^,1S)J#9Q`D;1<:]MW=
M%MV58X^B2FU12@4"@4"@4%<,23AY/R&LZ00FYJ-X[*ZT!SY@]VY4Z:WY,YJY
M@?3@-/,;0&\(OF>9%\H^%\V\(3C*QZBE`H-`#]0^FS3SI<TR/.I)_;&%C>\3
MXW2L!SG!)1.RQ+2(5$DJ@?*1>+R@]L+NH=DB>QYQ9)0SU)15A7,,`&^K_P!K
MO5+?UCT6IIJU,Z6=0*_(+5IQD+4[NF/Q,8,AMJ/'<NQXO:!NKO-H^S`<4<NB
M$34+1!?H&_(16+"==*L;E))O#,#<-\K1;;+F?&LC7K&QBD8G5P;<E.F('1&B
M99`<H:,C,L<O+W.-/!86K:TFIHQ<*_F5/"1C3&%C`:*QA>\6DK.$((`B&,00
M``&XA"%>P0A"&VT0A"OLM8-K6VWO>B())<GP6(I&=:]/Y5D\@0N3JRW:43G(
MS7)H9FJ[VZO25-'43JI,9&]KN`TU9N<J#C%!N/?.*",)4SO+5(&Y.[LB],YM
MJOC6(6)#0FE",3'FI%1`]GSBE*-6082>4.P3"3BQ%C"$81!L&3H(9D?^SR>?
MU,E'^@UU6,X2<I?S&_\`9W`OZEQ;_0:&EW[3ZD90FE12@KB7I./-,3J.D$+^
M2DDD-ZB8Y\F:Q<6!R9-SB=#S!/5QK.-RHBMPWA`.N;LMN;UK&4I.<+'J*4"@
M4"@4'__2]_%`H%`H%`H-:\QYX?<;94P1B6/09IE;[GQPG[7'G!ZFJR(M+*LQ
MW"UT[=NLF(85,5ETJQE;QEIQD$F#NJN$`P`+O<VQ4`OJ?R0/+,$PF1@]FM/I
MMAW+F:BDZO+I);*&+XAR9`\;K2&EZ;X"Z$.RV9BR6T.C&(X*$@U`<9SHT)Q=
MBQBF%:HVW:Y$\V0:6%^+,8*Y%?585D\F+()A+4\)7Q=\Q''G]_F##(A-K!-F
MP]0`<96(4JE&J4(E*L(!!.LD,LJH4SQ7KISU*XWU,XQ@^2X0H5LUIRW2Y<EA
M,J-:$4X:S<>S9PQM/$ZYH;G1U3JT\5G36:W'KD)ZMN,,N4,H\PL\D0Q,40I;
MJ+G"[.&;,(PK%\6>G/!V.L49,?7J3Y45PY&],F8%&5DD;0,Y96-I(G(=D2C$
M#E9;SJE*C)`>E$%0.PSN`*81*\$F6L<FNK-%W"<0MGG+RH+;"8&OE\=!+@2"
MS(ED2R-A8^HV<5+VW,ZL"DT@LH1@4PK';O#%85R(!(M1<09<^XUT_(#&=_E$
M\3S8YWNVRME-=(,.'Q=+*BB9#%R!J7HB[X@6E73B."F!<!EAAN.U]E%IA59*
M3*N+UZ4Y:AR1`EJ)/(6R(J%:281Y0E(E;T<G3LT8.4$N(RBI"[*%90$J(5[*
M3QF@"``KBM:Y'$CN9,02]Q8V>)Y5QO*':3-+F_1MKCLYC#TXR%B97$]H>'IC
M1-KHI4NS2TNR8Q*I4IPF$D*"Q%C$$8;AL$?F>HO!./FE<^2[+>/6=L:IY#L8
MNZD^7,(@LT\GKZW1V+QAX"6O$-J=EZ]S+'<D^Q8RDH3%`[!)*,&$4E\RS.D"
M:6QWO%YIB^42AG-2<S&5F58E&Q$(PR&-L;ZL<7!0<X],LQ@DZ80@F$?C5*A,
MFV@,5%7N$V4SZ*"?7B$L\EBCQD=J9%3W?'A<I9B)5=*20C-(/6M','.C8W*#
M'1&&ZLU/P2[*RA7VV&#>",8`RRCSW@C"F=&YF4QUOS1B3&^64$?6JBERQB1Y
M&AS-,$K,K6D%$$+%+80\!(,-```#!@N*P;6OLH3A,PC)_P#VJ6O_`+OS]_UC
M1RM_TZL_VZ-@:PT4"@4"@4"@@N-B^%$48.4;$6QTD]^69W#JB`._*7D?$+6]
M3>-\\_>XAP.8%PCQ#+W2]WA@MV:0G512@4"@4"@@\[*L<EC=KMH7/<G$0-L`
M:L:3D[E/*<5G((@&%7/$@O;B6*OM"9>V[>U_P58XX\"4XJ!0*!0*!0*"M6$@
M(,IY&469P)1'QK'`!/=EQAQCO8@Z<7"C&WB.$4B"T<6]PC"`%S^9OMN+<MLO
M",4XRLJHI0*#H7UMZ9=0&HO2_H%%@7':;(JJ$P1FO,D`I3"XLXMD=F&)(DP'
MN+4;/7ENB[N99-90!0V.*1V:GI$(YL7I.47&GDZN_>[UDM_6/1F_@^:0-3.F
M.4ZG93J`QPA@)V281IRC<32]K83*#G19BEQU"%NA2A\B4CF#ZK:&QCF[&G;C
MGT]4Z(6WA-7,N);6!<IRLTI$-W7W2A.U9\DF$9R(DB4TFT"8TLRCR$"@^(.6
M4DTU4/LQGC4^&-X'EB>)]`']XAMW,"$U6RLRI,),2;R@2!Q:L/-]&KS*DDF;
M4!N/6=GEF(<DXM>VI0E>WD2I=D5>!S-GJ1<K)+3,\I8>WD[1(;DHA)T:%Z"2
ME+3)3CD90JN[,F#WC)AT00-BB,QQN@;A")%CR3-0'%CF6+I;''5<FD#C%[-I
M)K>[,$LQ^O&Q*652,AO/0F'IU8525283:I$T:G2G3!D_'^+E29"L;I@XI\1-
M,6B[+$6=WN7&-0,N7Y!13G+:=E0-!HW%AD4CR<0^OAQ@R0\A'K)C&Y:(22Z.
M+6*KO@FE9UAD[B;TB71UNAK-+#I>NBZ14].Q"9.'&\;QVTPIF3O"2X+`9C\4
MPI\M(KG)W-2Z(WD(T]D[R:654JVIR/\`V>3S^IDH_P!!KJL9PS.4OYC?^SN!
M?U+BW^@T-+OVGU(RA-*BE!6LQ(";-L1FW9P.%TTEDHPN0EQB83#<R`2@FZPM
M*`XL#B)8$SE;@&$RQ=CKF6M:X;"M8RNQ2<X6544H%`H%`H/_T_?Q0*!0*!0*
M#2O4;@)US'J!TAR]9"HQ,\:X:DF6GC(;?*@L;@0>5/<8.L'C@VJ//)2E,\*&
MA]6%*U7%L3P4H+C(N>?:Q-RQ.$JKROI25N&HC#4M9,&0#)N$,2:1<L:=T$&E
MSZS(;HW:93'!+O#E3"4\-+]=.WL,6Q2M;U"VXB%Q%UQ=R`FAN9>T6)PSQJJ_
M'^B'-,;0:#8ED%Z+F;'IUDFHE9.5D3R+*V8V)P7*\?F<;Q9C"`2T2F*9!F#)
MB9D?&YF.7KKM:I<SM_$X(QCY&PK&+L6B./(_C=^A<2QWAS'41QI$\;OD?8I#
M&K-3`Y0V_:"-*$>.F"'H(N6`N)R(D![DK5%.9)8%K:2$Q(<,X)Y59:<S#33(
MGO51J3S#)L"0#,$-RCA?3YC:"%R21QUMD3$^8F<\]N<I<"5:]E=U<7;W\64F
MH*56A-NML-O,&82"Y9&_&JX1BC;UIDS0\SC(TZ60J%ER.<:KM%V<3W5D>6U/
M:\:P1%<3M&34B4]:$+L4H4N$,>@,B4XP0521Q*YDY,(Y2$H5A5`]%VJ)Y;6W
M&BQ1$&%1%1_$':4.IM%,#`R]W2:P02M;!\@M\731Y0]))Y%5TG3">DBA:0E&
ML:"S$JHXH1?"%89Z?Z.\QY1/@LQ>(#$8Z\QF(Z$\;S#'*.0L3C$9DFTQZP8%
MJ(GS^B.,3A3JXH@A<0<V:$E+RDC@I,DRLEQ1MA`AF7%86*R:6\HMF2H5*4<8
M9&`AM^(!GG4H^OS2[1\MWMC7*>F3-N%68PL'"%=PEJ>9Y/;7-6B.L--9(W&F
M6../"00:*_\`"I,=Z)\X-F!8Y$GC'F/VG-F)W'1+&BY\X:@<JS)GSM$-&^J+
M&N<DJE(@?VB0$8;CTA98<YFMK=9$XGH7J0J2+A(1I^8<!6*K7E^E#($AQMK/
M0D8_A161,[Y^9\A05V$Y,@S01%.R8(;EJ5WDMT!;FWG!<,5+SK)PE&!,`<D%
M\@QG`3BN3DLV#=0B353'<NKL?Q,F'1'*6H.0$%L,U9&HIRB>58''D+&Z)8Z3
M'@N"N<N*J.IR'\QW=%!8G<D-T)B=L%OEBL4;7Z/L:RK"^D[3-AJ<D(2)EB#`
M>(L52FS4N"Y-)[_CF!,,-=5S0OL60-6SN*QE&H2#,*).NG,!Q2BC-XL-2<Y=
M0/QA-8^=-)>0\7RW`,@8(W)76-ND/>U4BBB"6)5#*H7`?[D$(W`XDM.?SR`D
M7%#?>W0W#^"]=+;:V9\6*QOZ.F_QP?B2>E'&/J6C?EU/CYM5C0\<'XDGI1QC
MZEHWY=3X^96-#QP?B2>E'&/J6C?EU/CYE8T/'!^))Z4<8^I:-^74^/F5C0\<
M'XDGI1QCZEHWY=3X^96-#QP?B2>E'&/J6C?EU/CYE8T/'!^))Z4<8^I:-^74
M^/F5C1BV?XU'Q$F!`6UM.2,8I$)1RU061W.,1^Z<X+5#BL'Q5+F<=?C+%9@]
MEQ7L'>V!M8-K6LV<RL:,IXX/Q)/2CC'U+1ORZGQ\RL:'C@_$D]*.,?4M&_+J
M?'S*QH>.#\23THXQ]2T;\NI\?,K&AXX/Q)/2CC'U+1ORZGQ\RL:'C@_$D]*.
M,?4M&_+J?'S*QH>.#\23THXQ]2T;\NI\?,K&CZ0_&2^(=.I-!HT\Y4QR2D6S
MF,F!4I<,QL)Z54F<`J$J@(;K[`.L4<7:]P"V!%;Y+U8LQC%)F*3-&_OM^:_O
M>"AMO_X(AG_SN%ZW\,>3G\O^7\]OS7][P4.]1$+\OI\$>1\O^3V_-?WO!0[U
M$0OR^GP1Y'R_Y/;\U_>\%#O41"_+Z?!'D?+_`)/;\U_>\%#O41"_+Z?!'D?+
M_D]OS7][P4.]1$+\OI\$>1\O^3V_-?WO!0[U$0OR^GP1Y'R_Y;\_"ZU%YIS9
MEG4^CS;+FB:O3(P8'$SNS3#VR'`*0+@Y9N>D/0M1YR<\0#DP1!,O?>V"O;_!
M7.^W;_&N#=LQ.-,7='7-HH%!U,9>UB3+2=IPT6@A./HQ/'').+8VB4!E,H=8
MPB:4L7QG$%]S23&F/R`]8H5F.5@;H@%A"$-[[;WOLKIMF_\`]+HC66:Q;9$R
MGF@O7-.-6LXSG!YQC.*0%5B**86E:%=%)<[RA.^I\M.^:F@Q(K+=XU'C&\YD
M,Q%OA$#C!/"MV7W+E_.S=;-DTE8F+HK"[8EJTBBI]=&29C"VJ77*<V@V.4D?
M890\JW9@AV=([IL,DLG&G0J4T>*6YE?KMQ1A@@I!HB`KN+8H[<+RU1ELFYZE
MT4S`7C"$011/CVW'$>GDE1-K9(E#FF.F>1[0>%-%G1N1+&!A3R)`PRA?S[H)
M.D2]G!`,%PU(U",4<YLU>8->&>S^@?)'T49)[DG<G"!S9D2KHTC<8\U+IHU#
M?6%MN\PU`XRMO(-<4ECT]E)XB+7NH(4%$BDN.OUC8'0*#$O7)4YJ3"HZI9D\
M=QKD24J94CE;MDACCJJ)I8W&'54_A>W/#\F"A*(!=0O3M-U24LY(J0GJA24@
M!J?Q`>L/0HWMQ<#R'M-&@\@Q.JHI3(C>W`5,?3&E)KEFOS<=CAY)-1;;*S%*
M2Q!!9QQQ!9HHS+KD"-3W'N7!1E2I6DQINR1%')68B4IT=WR+'2B)R!$D4F@"
M4K&UR"/*TQNY>]PB*M>]MT8+BL9PDY)KC?\`L[@7]2XM_H-#2[]I]4C*$TJ*
M4%8S-+QISA\_I?.\G)Y.;SW.\MT?BX]E2?FN5WK=0YKB\ON;+[G%XG_)VU8R
MN2<X6=44H%`H%`H/_]3W\4"@4"@4"@4"@4"@4&ONHS/S1IZC$.?G9*RFBG.1
MX_C1J72R4A@T(9760-[XZ$.DTF8F:17CC)R\?-3E&A0*AJ'%0E3!!:Y]AA+$
M53C%.36?*D,8)*C*"ROJV/1ITEL#7+T:B68W?G]C1/*F%39N3CYEDD[$)6).
MJ3*"R30&E"V@MLHC6B^K]^?L?Y>S?C7$J>>8,PY(<DL;C)03M4TSR?D81=G=
MBS"[XH@A<#=V*4H6%_CCHV,_.2)J$^N+8>`-DR<292H+3AQ;"1;/N$IG';2J
M-Y7Q\XL@(I#)NM56EK&08S13(C:E>(,^2!*I7%*X^AE;<M*-0C6@(LI".VYO
M7H4EREF=,)-QTL3.&8L6(%$"*"=.B%F0HDE.A9(W,]D`;+"CW<`XX4-Y2FI+
M"66)M=46(K_*!N&Q*(XTZ@<<2&26+CN1\)/\!*QY*9VNE[1F6-.+NC*B$PM#
MG]6*,(4JEO%!6)R3+4KF_B=P%-SLDNA-3\2XAEEHRBS4/@!O8VV4+\YX=0QI
MY.D:9GD*S)L*3,;LHAYJLB6D-KL<]@0+CHL>@/`XA*,&)",DRQU@7`+8*3HL
M]E>F:2,S3(HZ[-C_`!]_;$#TQ/K*O2NK,],SJE*7-CLTN:$T]$XMCBB/`<0>
M2,91Q0PC`*X;VO1'E@_O!G^LN*?_`$ZK_F!U=K/UGU<_[SZ/-G6FR@4"@4"@
M4"@4"@4"@4"@E6/_`.TC'']>8_\`\ZO2,[?5)RGT=S5=HRAYRJ%`H%`H%!V5
M_!W_`+=]5_\`573]_P#Z_7F_]OVZ.UGZV^LO0?7%T*!0=061,&X*U7Z=])K-
M)M3R7#S_`(HQM%C"SHI)L4'NHU+SCR,M#RS/C9/&Z0ITPTAK8':$))1Y9H+A
M%?\`#:ND[[;[IMB<Y8B;9MB)F$XT;Z=-.FCZ09>D[=JU3Y4><PL&,XR[JIM,
M<0,W16C%RW)S@R$LH($WQ8(#EBK*S@(\TWB&_BR=P0-V^V7;[IK,358FV(I$
MQ1?49A>BN'J8>M8)9CY,M@A+$GC"Q7G!R>%:0F-K<AN;2!<J>9XX'OVXYY4>
MU1]W`2JZQ4H(.47-,0H!)L[;O&6M\>4+":)#IJ8IE.L@-F3H*5+<D(HVW2YT
M/S&%>6K01!(Y(XXB:VQ?+U31%TS86\*QA`UD(@F*%)IYEAG&",NVW>,INC6$
M3"TZ0$Z2(I4$MQ0D+@40BD&B1%\G(U#<AC4"7H'>"M;LUCEH4<J31%Z:TZQ#
MU,*HQ.I`(P`PC,&(3;=XRNZ/*$"Q+"-/F-7U3('3/N/9@KM+AY)9DY\PCC6C
M8LH/3/D%BG\]3F"EKJZKUT[;,CKBC&]6J/9VDOYK6D16&.UVV[QDF^)XPE[?
M%M&[6A8FE).89T6,2<F81]@59]?'"/-#\CFC'D-J-11]PR$J9BFZ/S*.(US6
M@X'(-0RK@1DD%&&`&VW>,F^/*'-N]Z;\=8OR+'X'D.`D6?6)_<5]UF5R)8_/
M[[:%(HPG7N;W)92^2%[=CF=@0IKFGJ#3C;$!WKB'>][V+;JQ_&4FZ)B<8;!8
MW_L[@7]2XM_H-#4N_:?4C*$TJ*4%8S-+QISA\_I?.\G)Y.;SW.\MT?BX]E2?
MFN5WK=0YKB\ON;+[G%XG_)VU8RN2<X6=44H%`H%`H/_5]_%`H%`H%`H%`H%`
MH%!UK:Q=+F:-1&1%C>GO$9!A=XPDGCD.`X9!D4"F.GO4@Q3Y1-&#47$$C=")
M>SRM]1E(60#>>;=.O9%#*84GO=*\..PL3$>J\M(4-U"0.$/;!J(9\3]M!/[@
M\/.0\92A_?#\RREW<%Y[YDB0,#S!H@5CWJ#<6W)D3&2J>@-B=/R92JR1*EL,
M33@I:-Z9LU8CP+F;2GB<O'ZN`3Z0YU58KR1)9"[)W#%T<U%2V83R6(I;"$\:
M6&3)QQO)LAN@F("9U*+D"0I,G7'M0K&*ABN-4D8]%8,=9"TX7Q>_$MF(,;8+
MQ]@;+,9=^84ON0(SIO5-4CTLK4RQ+RZ9,[0.6C=QN!Q@167(70U-N6`*^P5S
MU:E3G0]JFG23*"`UCP&WF3K`VK#"1!@,C2-BB!-\Q9VC&388]-T#C>#3&R--
M2EH;%`G0BW4',]>H--6+EYNZ>;%K#:C4SIYS9D.=FSK&3/AHY.DTUS7%Z=CF
M[H<INIF<HR]AS(XQ(V9UQ;*X;RQ+5CE<6A<W(E86E>5"12>UJ2"CBA5(F.*O
M<8:3\]1K(V.Y<^L^*@M$)U9Y[U!*"E&69O+)"H9<MX1E&/&I(E<'3$B<2V1M
M\ADUQJC3SR`72@,$6*][@)O%JW"TE8NE^$M->%\0STR-G2S&\"8X>[GQ!U='
MJ-GG,J>R,LYH<'F/Q9R-2#(+#NA-0D7+_P"+:U[6M>]2<9:EZJ-*,,U-:@H]
M&9LR1R0($&+'25)$LD8&R0)4RQ/)V=DXZ=,ZIU!)"BY*L0>(&UA;HKVV[+WK
MK;,19-8KBY3$[L)4_P"#W@+T;XK]6D/_`&94W6^$%+_*3P>\!>C?%?JTA_[,
MINM\(*7^4G@]X"]&^*_5I#_V93=;X04O\I/![P%Z-\5^K2'_`+,INM\(*7^4
MG@]X"]&^*_5I#_V93=;X04O\I/![P%Z-\5^K2'_LRFZWP@I?Y2>#W@+T;XK]
M6D/_`&93=;X04O\`*4:B'PA,&+&%.>MQEB$A0):\@$6C@D.=$]BR7IP(($%:
M$MRL,8R"PB&#C"X0[W+W0;NX%-UOC!2_RE)?![P%Z-\5^K2'_LRFZWP@I?Y2
M>#W@+T;XK]6D/_9E-UOA!2_RD\'O`7HWQ7ZM(?\`LRFZWP@I?Y2>#W@+T;XK
M]6D/_9E-UOA!2_RD\'O`7HWQ7ZM(?^S*;K?""E_E)X/>`O1OBOU:0_\`9E-U
MOA!2_P`I0^8_!TP2(,<.18RQJ<,,G9"5I:6#1A#NH5"X)*A2:$EE$$XI*4/?
M$7<5[&6MLO;_``5J+[:?K!2_RE.#_@]Z>OF6(QKBL-K6O87^SF)F[;_)L^4;
M,3L_^.L[[?""E_E+C^#W@+T;XK]6D/\`V93=;X04O\I/![P%Z-\5^K2'_LRF
MZWP@I?Y2>#W@+T;XK]6D/_9E-UOA!2_RD\'O`7HWQ7ZM(?\`LRFZWP@I?Y2>
M#W@+T;XK]6D/_9E-UOA!2_RD\'O`7HWQ7ZM(?^S*;K?""E_E+9W1_I'B&E^;
M9010R&QZ+-CVTP-2:OC;.UL21]5D#EY8RSFYJ3IRK'M)9@;<45KB'91:VWYM
M2Z8F(I"VQ=7&9=@%8;*!087LW'?J%E^RT/T%6LZAV;COU"R_9:'Z"E9U#LW'
M?J%E^RT/T%*SJ,8]1J/"9W8-HZS'7$V+[6*LWH2KFWNE-M8NQMB;7*N._P`F
M]_R=NVE9U$:QE%V`K&V/2C(JT-YA<'B99B`:9$X#0C`PH`B1C7B*&)<),*VY
M<Z][W-N'>VWVTF9K.*1E"<=FX[]0LOV6A^@I6=5.S<=^H67[+0_04K.H=FX[
M]0LOV6A^@I6=1F`A"`(0`"$``!L$(0VL$(0AML"$(;;+!"&UMEK6_!4'U0*"
ML9FEXTYP^?TOG>3D\G-Y[G>6Z/Q<>RI/S7*[UNH<UQ>7W-E]SB\3_D[:L97)
M.<+.J*4"@4"@4'__UO?Q0*!0*!0*!0*!0*!0*!0*!0*!0*!05D9"'`>9$>2+
M*T=FI/C)RA`D-[G]0$X+94U/Q:L-N%RW)@3(!`OM'O[XK;`[-MZM?XTYI3&O
M)9M12@4"@4"@4$=BK-=@9"&NZ9`DN4L=U'`;3EYZ,/47A>XV&`US-.67-.LK
MWS;"%<`31"L"UB[!M:S-2$BJ!0*!0*!01:5LIKVG9"BDQ"J[=*8X]#"H5G)+
M$E-3D2K,4E")*-N>>G"#>`4+=`:*VZ(5K7VU8F@E-0*!0*!0*!00AICIZ&>S
M.3#1I2D\@9(6W$K2UR@Y6K''S)2,XE2WC)`F1%)+/(.$86,8C^(+>L'AAWK7
M"(3C*;U%*!0*!0*#@N:82QM<$@0!,$J0JTP2QF"*`8(\@PJP!F@"(9817%LN
M*UKWM;Y;6H,)!F8V.0F'QX],0C/88M'V8Y&E5G+TR0UK:4B$Q,F7*"B3UI!`
MR+A`:,`!F!M80@VO>]JLXS,I&$0E-12@4"@4"@A$DCI[M*,=O):-*H*BKV^.
M*A2<N4)CT`'&(OK$`Y&D*),)<C3CG()0BS1%A++&(RU[B!8-[$X2D\$WJ*4"
M@4"@4'__U_?Q0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#_]#W\4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@__1]_%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H/_TO?Q0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#_]/W\4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4'%6I"EZ12B/&J+)5$F$&C1+5C:K"`T-P"$F
M7MQZ5>C.M:_S3"3`&`O\H16O\M!Y_M-NIW4_#]/&G?50,O*N8<0HM!KGEO5F
M9D]X.;F^5YK$5CQP@!F%7R9H3W\$F=&U7(SG8MJ!V'LC+3`M<A=NU&YB*S#L
MK?=8$BCDT)QNLP)-GN>LA..'W)<8@(I#D11#87EK)LZ@$-?4+M$8(YQMR<T#
M)!3Y(^('5:P61LXA60GN:HOEQUFB#9>U)3N>:;=0DWQU"I)&(![/.J.4XTSU
M&IPRA=V>4X7)=X^V&OD:$0B=8PHF3JB.<XV<WGO0C&]O/ZF!I4\),8*8P_!^
MU5'XD?<G*EL+G4Z>XAAC0(^*D`LBHRV"0H]2V6\NX?:G.,L#LELW1B5-TJC:
MPQZ/-.MUE*6AL(PJR8(JBT9Y=JI"ZO./4DSAL@A;S%M8TAT_R\B)Y.,/BB)\
M:L`S+)S>\O:VT<85<_@;G"'0A6)M.0H[I7H!!@M^Z(`S*E/^$Q9=5TK=\;$9
M>,P@K;\:2N"X=R+C:;+LEPU%'UT<S#*F]B3WR8I<@MZK&ZN!1UZ1R60"2$R%
M&0QB.Y-0M<";(#13FK"(ZBWS,^5M'LI93)#"6.6R[6KC6?0`M\/6Q]PD^G=_
ME.+G-28,;8QJ'QN(FD'6JFM0K1(U'*&%#,2ICA&%!%*5=D%$*#2#7%*)/%&C
M30;%I-(XR;*-9.G/'LB,CKZZL@WF&3:9!:Y1'UXFQ6EN>B=4(>&*]_QA=MMR
MQ`%>]Z+'%K([YUR9IPR#EY@S)+'Q]TOYBGDU@^$\L+'IT+D&G;-"1H`!DQ'/
MI8:X6>#(!E56$!D/?35-SD$BN8RJA;BUK%>+2)I3-/(^5))SK#;L7N.2\MMD
M0]@K&.3TR&/Y0FK5=+D=WR=*8TKF8K`>34[HYC:&PDL1"\M6WG"!O')C!"%>
MXX=5P:#,PY#RSC'*#5E!]*FLLP7J5SUIU,R:2W-#/WIM&)9LI9F&<+6B/I$,
M?;)"H:#R4+R2@))16>D"NY)1)=PDEU);O40H%!THRF9:FWC4)JZB>G^399>L
MDXVUG:5HMC]E7.#N\82BN"Y9@W3+D+4`BR**7"50=(PB:IM)W)+9(9VO+<E"
M4IIMP"[$AC6%(JM73EJUGD8@3='<APJ79$4*F'7=.H/+`SEH>9U/`:8=0#\P
MF0-6U/Q;.ULZAPC$B;$3$O6/?"-$@.`L`A+"2:>)A:)VOZ*-<(G<MDK)%H^D
MQUJ':-/LGF9T_<E6"VH^1X4A>>(WDEWS`1CRPF#&CY%<@-#80\+V5,W=H%Z=
M-=19(>4O'4HF<3UB@FN2VJ!QK$DWD#41,6#'.0YC&43]*&+'DQD.&HWF5.K6
MR%ABB['3K`FU%+$#*N<P2(EP(>%15PMAB"XEP!1(-0TBE4>S;H/3,$K?F=EG
M&IF=P6;QM`H3$LDOCMM%NK7(:)(_%72"6JPM4OQVU+4P`G@)"<GL,0!B"`0!
M&4MM:(4&J6NZ3R.#:)M7D]ASZ[1B98_TRYVGL.D;&O5-KHPRV&8OE,EC3PE4
M)32[C&VO380=PC;#3G6!N&@,+$(%RQG#KKE$YU51:4,LAB+QF`>G)7D#X?S9
M#@9#>53/+ICF&=YD,CN=XK'768W+R,MPR\PAT:`+.TES$=W0\T;/<U($00Q<
M,=6T$Y^(-W?88D>69#B,!)V.P:IS,EL9>2&[D41^DB77CT\C^/'4V,%/F199
M+F-,L?H\F$S-*,;4UK1NBMJ$2$)M2F.:?91UT8]Q'/\`,$+EJ%&AMA2!O61Y
M$VK)(!FR1*(8R8ROD53,L80!^9FM'DF%"<!@C`G!J>#S$LFL:E5)TX"^,,1%
M:+RPIEU^RH&<DR+%\OQNLALF3,R-3(&:8MS!-FAQ86M]12.'K9Q"L>R!<F2&
M.!K:XE'M*>Z1T0G@+$I373JU`F%-XRA60HCJDD)3=F/)N2,>FXE=5N9FC("\
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M38E9$4Q;DN<G)&$`U"-&,\HN]2F"%#^(4P.<<9%V-X,FSC)I'%LFSV.L6"Y2
M_94;))$L2F8V02A,U.T6QNM?&>>+9%DHEF0M,C9X^F"[H5)#BO;@V+-,%&WF
M3FH^?XK7V1JLM,93BR`>SFG&;FC@F5G1)=M,6!BK6\/*ME4Q)^5'&%A$,M>U
MJB3R^%=44&YFTBK=#D\<<D:4<,RA[ELJFTD!'G&*R]]GC*5'YV";0"2O<"FT
M?G+80G2$@FD/ED:6-#L<`HH*IP0G'V"'B;+%G.6U]$*#\5)`%2<]*:(X):DD
MT@P292H1J`@.`(L8B%:0TA6E.L$7S3"A@,`+8((K7M:]!T.Z6M0V628W\..2
M2V59B9R=0DRF\'RY/<N2<F9XDRQ:\1RH.$1.(C3269ON.,OO,S:&DUBN)-%&
MYP0-CF0H$H5F(4RB-3&;L#T&R>2RO'F<'B82J22A:RZR-96/VI9)Y`Z/8FB$
M8KU(Y*@$%CZ$;HK462H6")1]*FW[?C5'"XIXS31"'>I/#T5+,M5LEC.N+&#:
M.3%7TZRF0RC24ZL-T"H($N?%[<S3B&Y4N^\L!$<PK9*R.>,^3N*YA,C$'YU[
M'A#:+3#F[/ZK+__4]_%`H%`H%`H%`H%`H%`H%`H%`H%`H%!C'KC](<N6ZGS'
M)*.#T7IW5]_ABW>F]6_5O._^3X_XO>V;:#KJCWLD^&8T]"[QO8D[CFWH>[U3
MMCW$=/2].Y?B_P!-N3Z)N[.-^O.!MV_C-E3@UCNYLSEKV</:QQ[VB[]^_;NG
MC/>/W6]X/8WN:[8R#NZ]JGNZ_H;V,[Q.O]+YK\1N=;YC]1=3JI%:*@C_`+%?
M935]T#VA.Y?D]27;OB]Z'<1P^;?/:I]F[K/]#^I]5Z[SG0?ROB=6[/\`XKG*
MBXX)'D?V5>L3WMKWT]3[H]"/;7E.6_L^[])U['&YR'_WAW[]I>8Y3\HXO'ZO
M^K.5H8I'_P"[+V^_*.]CM-[=/X_F>3Z=[6/L_P#XWC[GXCLSW`[=[9_1[<V[
M/UG0Q^RB(-[#OLZ*NPWM5=SO;_"OL^\SWN_Y/O\`8GW&>R'VS_5G=;WL]$Y7
M@?D71^E<_P#J?I5#&O-<F"/93[6X=[M^_'JW?]KB[N>VW:S@]Y_>;,_:LZAV
MU_6/1NVW5>!S/S.8XW+_`);S%":XNSNJR4&IFK/NAZ;A+OA[;<K[0^*.[#L9
MP>)W[=?+[INI[W_V;K^]N\Y^I=NWJ'XK<HL<49R3[,GL[ZI?:'W_`&>N:GW?
MQWM]*Z%_FZ;M)TKH_P"7;_,<KTKD_P`LZER_3ORO<H8UBF:K)?[.7M``W?:4
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M3V^_V7=F?9IY#K'&_5/4^G<E^4]&H8]']TX^PSWU,GLR=\G0>[3`7-=C.^;V
M6.;[EHC[//>%U+^B_>][/_9SDNK_`(WDNA<_^MNC4)K3%N3G#NS[RM*/;SM;
MVK[\7SN-[/;G3.];N(S'UGM%M^;R7<+VX_SG\DX/'W/UCTVJD<6R-$*#7K5G
MW8>S)GSOP[0=R'=#D3OI[,<7J_=%V2=^\K@\E^N.!V,YWC=-_6?"WN4_'\.B
MQG""99[I.Z/`_;WO"[*=ZN`.[GI_(]H.\3MA'^Y'M%R?Y/RW;#IO%XOY'O;O
M4/Q'&H:M`\Q>P7V<RQVU]I7HO83XC_?'V/[5?V=]IHO[:?:#LW\SLYWG=*Y#
MEOQ7.?YI^IN:J+CAT7CE_P!B[M*]>TYWD=C>GY`X/?GUSN]ZO[%!G?#T+G/]
MH7->R+U7K_$_H[S_`%/_`/$>_0QX-E]'/8#NJ2]AO:'W-QLXOM2]XW>[T+IY
M?8_C]Y?ZW[+=$V<ERWXGFN;YO]<=4JI+7[2#[/?>2Z]U_MN]0YW)O']H'VG.
MZGMMVM.[Q.0[T/\`9]WE]=ZAO;GZPX//\+YG&J+/1V:U62@U+R!W0^U]I\[2
M]MN_7NPSIW.]/X/9/N[ZIA_OVZCL_(M_J78WB\[^6;>%T[Y.=HO"5*9Q]F;M
MMJ$[PN]7K>_H][VN@[O3]WO:<O99Z%POQVYWK\WQ^2^=MV]6_(N'46*X*1-]
MC/MY+.6]K#K/._$+Z;V9[U.C<QUU![97=IV8_&<;O=XG3^!^4]I-_IWY%RM#
M%\2;V)NWD>W?:4]IKONROVS[D^W??[VA[L\%=^W>1W!?J'NW[K^[3J_1?Q7/
M=%Y+^D>]0QZ.Q[*.YV3Q_P!D>]C@]K(QV=[B^S'-\ETASY+M%VO_`*(=W73_
M`/.>>_)^+RV[^,X=5$@PQW;]W;1W3_ZG=3EO^7ZOUCM;VQ?^\?M=VB_I+V_[
MQ>J]HNJ?K7KO-\[^5<:B+2H%!PG+C].7\KSO,\DJY?IO3NH\?@#X7(=7_5/.
M\39PN:_)]_9Q/F;U!U)8(]@KL]I*Z%WR]WW;-;['??%WH]V'>MR,WY/L]V@_
MH;WF<GUSL]VG_+=_C=(_&U&IKBG&'?9TY22=VWM2=E/:JR;VRW>U?8OVD^_A
MZ[S>N<#\BZ-W[\WSN[_1/B;VW]7;:$UY)-ECV8O8B3=YO>]W"]OX1Q-[KW?+
MWB=_K/V+YCIG^TGM_P"T%T_;P?Z1=7V<S\O,T(K7!MM^N_\`]9O_`.OJK+__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g275067g36l13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g275067g36l13.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`40#$`P$1``(1`0,1`?_$`'T```$$`@,!`0``````
M```````("0H+!0<"!`8#`0$!`````````````````````!````<``0,#`@4#
M`0,-`````0(#!`4&!P@`$0D2$PHA%#$B%18703(8(R09&O!187&Q0G*R,[,T
M=#41`0````````````````````#_V@`,`P$``A$#$0`_`)_'0'0'0'0'0'0'
M0'0'0'0'0-*^=/D9.<5_%!S.UZI6R>H]Y:9@6H4&U5A=9G8(2Z:'8(6CP,C$
MOVYB+1KMDZGO=*Y*8IT`()RCZ@+T$.GXG/(SF[RS\DEQ?[1RAWK6,SR#CI>;
M),UF_P"HW"T5M>;L\]5*E73N(F7DW;!=TB=\X71]1?44R(G*/<H]!9`=`=`=
M`=`=`=`=`=`=`=`=`=`=`=!Q.<B8>I0Y2%^OYCF`H?0!,/U$0#Z%`1_Z@Z#]
M*8IR@8ABF*8.Y3%$#%$!_J`AW`0Z#]Z`Z#IR$C'Q+15_*OV48Q0]/OO9!T@S
M:(^LY4R>ZY<G313]:AP*'<P=Q$`_'H.K$3T'8$%7,#-1,VV07.U7<1$BSDD$
M7*7;W&RJK-99--=/N'J((@8/ZAT&6Z"*O\J;R><E?'=QQX\07$_3VV5ZAOFB
M7.,G+,UB(28M;*@4VKM59(]:"=9232(<*SUD8`=Z1$5TO2!2&*)Q'H->?$+D
MMZV+BQRMY;\B=1T'7[KMO(5C4HVX:+>YZYS"L-EM/9K.FZ*4U(/"0S8DY>7(
M`FB5(ARE*`!Z2%``Z/S-]H/1O&SE&1-'KAL[W'DE6TGK9`X$*^KV<UFPVE\D
M[#UE.=HE.+1A_3V$!5*01[=@[@E7X1F'M(O$.:W(QU'B64N.F4#((B141$.\
M-1JV\MLNBV<>L0,FM)W=O[I0*'8R!1[C^`!-B?:UE47/)U:3TS/HZSJN3,TJ
MX^N=<:3RCPA"J':IQ#B23D#N2IG`PD!,3``@/;Z]!L'H#H,%8[36:?%KSEML
M<%5H5J`&=3%CEX^$BVP"8I`%>0DW#5HB`G.`!ZCA]1`/Z]!AZAI6<Z"1PI0K
M_2KN1H(@Z/4+5!64C82F*4P.#0S]Z"(E,8`'U=NPB'0>UZ`[A^'?_E^/_9T&
MNK#L&25&>:U:UZEG58L[Y1JBRKEAN]9A9YXJ^$2LDFL1)2;:0<*/#`()%(F(
MJ"'Y>_0;%Z#!V"S5NIQR\Q:K#!UF(:I*+NI2P2S"&CFR"(`999=](N&S9%)(
MH@)C&,`%`?KT&M8GD;QZGY,86"W?&9J9*K[!HF)U"D2,F"_K,E[(L&<XLZ!7
MW"B7T^COZ@$/QZ#;WW;3[;[W[IO]G[?O?=^\G]M[/;O[OO\`J]KV^W_>[]N@
MQEFLM>IE=G;?;IN*K-6J\1(V"QV*=?-HN%@H.(:*OY27EI)XHBT81T>R0.JL
MLH8I$TR"8P@`=!7T^43Y7?(#:=4?<5?$'6Y!I'24Z:E16]-J>I<]:U*=,Y<,
M@#%:*Y92+:!A'RGI^S=O8]W*.BE]TB34HAW!*J/@@^2US61;:UR`VZPUB;GX
MP7+:*WGE/9VEG:-9`ZBAH]S4*0-F95;L1XIZV:A&QDB]TS)`'8O0,^4ZR^2[
MB9SC1X2QW*[<\[V."W6N<=)M'+=\N$O622-@N,%`S$97%QFQ;/B.I.626'_1
M*(*IF*<A#`8H!<,7VSMLJR2YW.6D73IGF^<V*SR<L\`KAZX;4^LO)5[(N@*!
M2+NE4HXRIP```QQ'_GZ"HY\9WF$T3B7S"OW+_:=-V?78^G9AM<KE^*VC4;O)
MU.[ZUH"2-<I4-+LY&;=1$3!0AK*ZE'BJ:)_808"5J3W12[`YU'>.'Y"_GUAP
MY2[AKC#-,>M,8K,Y)7-2M]DRS/Y:%>@A+1:6<8W2X>8>M:PNX!,$)F9;$7>$
M3*L"[D``W0-(76$\KWQ_>5\)#S%[NN`Z.*+&_P`,U@KH\MF);)62O'#,RKYF
M@X5J>AP+A5F=K((O4`>,E#`"Q$51*8`L?U.6FK^3/P:WK?\`B#3G;KD1O_&F
MX4^O9[`VN/A):J[%()N:!<8EG97<A&(P[JN2!G;]F=5=!?[<J`^HJAP'H*J?
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M-2K$4P:N3`[:IN5""9TY%,4T.@\;SU\'GE+X"9HVY0<I,W!2EO[`P:6/1:GI
MT/I<G4K%+K%3BEKR\AY)W+1)Y-[Z44GYA5;&<F(D*P*G(4P2E?B#>5O>MPL^
MJ^/WD->[5JK*EYV&LX/<+A)NK!8ZQ!0,O$URX9V^GY%9>5?P(%GF+V*(NHK]
MG[3E(A@3.F0H/0^>KSLT'Q-9:SH.<M831>9VJP;QSFM%?*E<P&<0)_=9EU32
MVK=9)TI$I/2'3BHLIDE99TD?N=-NBJ?H()6*<)O./\@V8L&WR5LO.ET!.3>1
MIM3WC0GM%Q)H]0=D7<UK.Z\DW7CW:$2X](*(0$.LW:J$`JQR*%Z!+G*O@]Y.
M_!%MF9VFYS<]AEOL+J4E\FV+$-(-(5FTK51=@$L@UDXE1FN8[0LFW%S&3#)$
M5FZX>M`Z1AZ":SIWEAN7,OXK_('EK:)%Q4MX&E'X\:'-5(SFO@XU(FATVFO+
M/`C&*M5(5*W5Z>0D!2;J>VU5=J)%_(3T@$(_@UY@.3_`^H<H7N87R]3&V[QG
M$#E-'T2W6N6M#+'H-6P#-7>X5R'G7[YN?0GK1@T9Q3LR8IL/6JN(&.1,H@OC
MQC^'GR?<H.;/#?EER&XZ;Q.89;N0V:Z?H>V:L^)^JS%3A+`VN[FU3#:WS9;N
M_@Y@(LI$W)VADG(+E!,3%.`]!)&\ZGRE$N(M^M_$+Q_-JA?-OJ_W4%JF\3R1
M+#2<IM":R9'=3I4$`_IETNL,0ITW[ET=2,CG0^P*3E9-8B01=L5\:OG9\W"S
MOD!,+ZG?J1<E7#EOL7)'3WU)S>:0.L7W4J/"2:JBK^`2.`%2+!0QXT@%])!#
MT"!01#Y+_$]RC\2MURBH<DY_*G=EU:O3EOJ7\3W25LBK"-K<LVB7+F5-(5VM
M.XQ15ZY+]L<A#E4]"G8P&3,'0.H?Q?O/_"V_Y&_RQJ7M_P"\=_7/M?WU=?9_
MC']F_P`-_8>C]7^U_0_Y$_U?MO3]M]S_`*O;W?KT#U7S%O*#;\]B,_\`&AD4
M_P#I*6FU5GJO)9_&/%T)9W33S#EKG^8N!(D":</8G\.XE9,GK$RZ+5HD8/:4
M5*<%]?&'\-E&XA\;Z9SBV:HM)3ECR0IS*SU=2=CT55\/QNR(@_J]<K#=RT3/
M#6BZP:R#^:=I]EA1619E$B::X+!*MG)AE7H68GY-9-O&P<7(3$@X54(DD@RC
M6BSUVLHJH)4TDTD$3&$QA`I0#N/TZ"I9\/$:;G;\@S%]&GVH3*-EY1;1RJF$
M$7B[]*.6K4W=M=8*OSJ-%`6:IRJ#`B:@']!P]`^HHB)>@L</-GLY,#\47.S0
M_<;%=FX_W"CQ:;F1)%@XE-120S5D@B[.4_I<BK:_4F0`]2AB^D.PCW`*X3XS
MOC1K_D2\@;20UZ")8>//%^O-M9TZOOBG/$W2=4D"QF;9[)%3`J2\7.3Z:L@^
M0$?2ZCXI=`P"581Z"V^:M6S)LW9,FZ#1FT02:M&C5)-NV:MFZ94D&[=!(I$D
M4$4B`4A"@!2E`````.@A!?-RK]0/QOX-6U\R:#<V.Z:+78R0*5$DJ%3EJ`WD
M;$U16$IE3,BS$/%J&+V$I5`+]2B;Z@LCX=#F97\5-L(^<+N8='E;JX5Y9<A"
MB=NM7,_7DC$,'=8Y32BB@B)Q$?4(]OI].@A&?(&V!_RK\T_+0\&^1FFT-JE<
MX_4PS8H@B*><Q,%GAFJ8F`!4]=J:/3";\#&4$0_+VZ"W+XZY>QQ+`,1QR-;-
M6;++,FSS/D&[)(J+4@5"IQ,"<44RB(%*HHQ$WXB(B/<1$?KT%35\G7:3[9YG
MN5!&X*G8Y2>@8E%)B!A-WHM+ARRY4R>L_P"52TRK\Q0+V]7J[]NXCT%ACX"/
M%W0O&OP5S9HXKD8;D=MU7@--Y`7A1HD>>6F[)'H3$1G;>0.@1TWK.>QKM-DF
MU*()*/RN'(@)UA$`R?R-+A"TSPN<['<VV2=I3N;5ZGQS=9,JI!FK7HU-AHER
M4IC%[*QKMT5TF8.XD.@!NWTZ"$%\05)G4N>?)3D%8G)F5%X]<)M6O%T=%,<!
M3BC6"G**^DO<B"BA6$6Y4*4Y@[BEW#\.X`S9J?(J!\F7D^?;KS*UIUE.4;MO
M+5YH%YDDIFP!DN%-I;VX^MP,=&-I.0/^UJ"Q2C(Y)!$Q/NO0<Q0`QS=!8PP'
MR/?`IQ'QK.\GQO<7+G/,[I[.J4;/\EQ?27AXB'KL:@1C'*$?UB!CD)"1,;N=
MPY<$^X>'4574`QCG$(5?GY\WA/,GIF.YYBN26&F8;B\Q839NVLC=!_J^CW*_
M)P$2]DI6(@74JPB43%AT6T;&-%G:QS*F.HH8YRI)@N/GMQWT;QB_&7XU<7]@
M82L)L_,[EVVW*^4V0>D27SJ,85):P1]0>L$54U/U-I%P,`K(MU`5*TDUUDS^
ME1-/H-5_%`\55)YO<HKKRCWBL-+9AO$AQ6W,%4IEHB\K]ZW*=,O(U1G.,G(&
M0E(.CQ<<I+.6IRF35>'8E5`R1CD.$TWY$/D<E?&UXY;O;LXDRP^Z;7)I87B3
MMLHFB[K4S9(J1=6.],4S(+IBM2*DP<KM?R@4L@HU[_E[]!!2^,]XE8/R;<NK
M3K_(:)>6CC/QI6A[=?XN4.NNSUS4;"\<O*AGTX]5$RSZ'6^P<RLX7U^XX;H)
MMSB!78FZ"UYB8F*@8N.@X.,CX:%AV+6,B(B)9MHZ+BXU@@1JQCXZ/9IHM&+%
MFV2*FDBD0J:9"@4H```'057WS!-P4TWRQFS9O)IOHCC[@F9T<C9),H!'3UK_
M`%;2IQ`RI55/>4,VMC+U=P()#`)1#\O<0E$?X1M/^$E_Q_\`T,_Z_P#X+?Y#
M?:?;#]S^^_O?\E_N_:_O]S[_`/)ZO[O:_IW^G00R?)O,/N:GR'=;J-OD4WL3
M=.<>?\>FXN2N6S1E1ZU<*GD;-@";TI%4DTH>,,)_RE(HL<YRAV,'06^,9&L(
M6-CX>*:HL8R)8M(V-8MB`FW9L&+=-JS:H)E[%31;MTBD*4/H!0`.@92^0US5
MA^$OBNY)60DRA'Z-M-5D./.3L2NVZ,H]M&K1[ROS$G'(*+I.%@JE+6DI-0Z9
M3^V9L0![>LO<(=/PL\8;V_R`<@]J<)$40QOC4YA&(J^@YVT_JEY@V+99`1)Z
M@.%?J<BF8X>D0*J(?@;H'0OEX>3WCI(<?A\:V;7!:]\AG.IY]?-8B*HJ@^K.
M=P%1+(R;&HWV035%%>W34N]8.D8='W'#;[=-5R"0F1(H"V/B1<(MAXJ<%]4T
MW>\NF\OO_)O58:Y5N/M4<VA[1(X[6*-#1U!D9"%$B4M!M7TI*S#ALV>D17,B
ML5?VP*J4Q@E;]!6/?,0YWUWD'S.S#A_G4V6;KG$*MS0Z`HP4368+;;IAH9W,
M022R"JOW;FHU"*CFJP`!3(/W;I`WYDQ``F7^$[C)_NX?#UA]9T,%X2RQV6VG
MDAKZ<@D!5:_/WEB\TB;BG**?J,!ZG7S-F"H"(F,=F8?IW](!60^.*JR'./S-
M\:4K&=U++;1S2C=4MRZB:9EG4<WOCW6+0NY1.4$@2-'1:XJ$[`7T=R@'X!T%
MT)(/VL7'OI-ZI[+*.9N7[M7L)O::LT3N'"GI*`F-Z$DQ'L'U'MT%+%0$G_D(
M\R];4`'DB7E'S]0ESE7`7+O]L7/:32ZR:H.3D$P,:J<Q1]9@`I$_K]`Z"ZF2
M3(BFFBD4"))$(FF0OT*0A"@4A0_Z"E#MT$0WYFNVJ4+QK99CS43E<[QR0K+9
MZ)%/1W@,UKL];WI5"`J0RJ0SAHSN'I,4#=A'L/;H(]W@LRV0K'A7\^_)F/<.
MXV7E^/SK&8.1;`*:I&<'G]LLUF(W7[B)0<)W%HFH`%^I?Z_3H&9_#3XXZSY3
M^:<5Q.M.P2&*-)7.+W>6ELBJLUN$@\>TMO'O/T)K$/9F";^IXS<K+&5%<13(
MW-V(;H)E]0^$9Q*CW3=6\\T^0EH:IKH*.&E;I&=TT7#<BA3+MP</PN1T3+)@
M)0.`")._?L/;H'U.!_@*\9/CTL<?H.,89^[=;BS$4B]<V>85TF[0;DA>PO*P
M61;MJS4GP_T<1D<U<E[?13ZCW")W\W3:3RN^<*>/C5VT4:TO*;_K$NT3,4[M
M&1O]J:5:*^X`!]2!/L*"N8@#_>"G?^@=P?\`/B7X:VR/P]9I<#QR329W_4=5
MUF3=E3.1:09H6'^.H`ZQC@'K*C$T0@$[?E[&'M^/0,%?-YU.8>;QP=Q1.2<A
M7Z_DNCZ@YB"G[,U)JW7!C56<BHGV_,Y;L*8LF0W?Z$5,']>@?:^(ODE8S[Q`
M4R[1#=']P;7LNN7BW/BD("[AW!SY<\AVBIR_F,DPAJ@D)`-]0,L<?P$`Z"1]
MJVH4?$LRO^P:7/,JOGV95"P7FY6"0630:15=K,8YEI1V<ZIR%.H5JU,":8#Z
MU5!*0H"8P`(4GG*[>K%Y)O(II>URB`P<AREY"L6\)'D1]X]>KMEL,73J1%&2
M2`#.G$'5TV*"@A^991(1_$W074?\.UW^`O\`'_VT_P!I_P`/_P`.^U[)?9_;
MO[+_`&5[?V_?T>W^F_3T=^W;Z=!5!>?OCUK'CZ\T.N:VQB92+A]`UF$Y;8%=
M%V+@L),.).8C[BZ19O!'[=\XJ.B,7D>]1!0%2E2(H8I2+)"8)EN1_+W\6MEX
M[L](U:5U//-MBZLQ7M6"LLWGK%+25S!D`/XNAVUB4U,E(-W)IF^U=R#^-.F@
M8IG*:1NX=!%N\@6N<R_/?F_*CR5Z+597`/'WP2SV688%4U%'$BTLVB6JXU*L
MLJ\S=J(-&EPO,PI*H.[3+H)@SAF;=NQ1_,)1.'U\(6H<D^-7B+\T/(CB)5K?
M-[ZA(<8,SKLU3H9Q-SM&K5F>WMK=-!@XYDQ>O74Q28.8.[3.0IBLE#)NCE]*
M8CT#`F1W_DSB4Y-\JZQ6I<EF:V@$$.0^D48US7J.BR#U>57DX"<OK.3KSS47
MGMJ+&751?2B!!472!-0!6*$DOP/?(NVC'N5MX;>3OFQI=RXSW#+YHZ#W46]P
MU1]`ZE'3D">JGJWZ'&S$Q7&LA$NY,CTI4P8J$33]8`<B0@#O'D\^8!QVK&4V
MO./&TPMVE[-9FLA`1FX72HNJCFN>HN&Q$%;57(>Q"WL=RL307!OLDG+%FQ1<
M)^ZL*R9025!IWX['@GVGFKR&K?D-YQ52U,N.M;M8ZW5$-*;O@LO*?45)I::8
MSKA"8$LG(YRSL)324E)KE%.;<D(V1]Y)1RHF%A5SJ@[99.$O+RN4!H]>W6<X
MQ[I#5*/BR]Y%[/R.8V9G$L8X@%-ZGKMVL1-$H!W%0P`'UZ"G>\1G-:F^.CR%
M8'RRTRCSUZIN6R=N:VBM5W[!*T)LK92;'2EY&$2F%F;!66@U)T')4%ED`5]H
MR?N$$P&`+(2(\^'&GG#XU?)KR1P"I:W2H7BSB%FB7K[4XRO5MU+V_0Z+:65-
M2K_[<M5B_P!4LTF@F/N+(J^\LF!`^H#T$*'XGV,AK/F1R&R/8\TA&XEG.MZT
M\640!P@TD$:LM2()RL=0#%27)-79(Z1O[@4(`A]0Z"VGZ"N*^;?LA9KDMPRP
M9J]5.G0,;O&E2K'W`^W2?Z1;FL#'+>V501]\6.?*=Q,4/RF#L/X]`]]\<;A3
M6KA\?5[DUR8E:,^;K;DC)6IRX:")OTJ^#)Y'!R!2`<BCI)G`51JY1_,7N<1[
M=@^O00"*7.<M/!3Y,H>?G:>I`[CQ9T=\F]K5A(_8U?3Z.^1>P[\K9^U$#R-%
MTVF2"AFCYL90")N2*E_U4A*`3HZ7\T;QP2E$:S-ZQ'E/4K\#5(TA2(6LT&V1
MA7WJ3(NE&6Y2^5])VT#N8Q%%V;4XD#ZI@8>W0>2XC?+(8\XO)%QDXG9GQN3R
M?"=?N<O3IR^Z39_UW2926=5.PKTYI%0M<21K571?6EJS35%5S*'4(IZ`%+ZG
M$(L?RFMB:[!YG.0[&-4:N6F1US+L:2.R%P?UOJU3F$S,(K^Z'I,]:SUG<H*`
MD'H`4@+]3`81"SG\8&+I<>?'9PIQLK(T>YI'&S)F<LT42*@LG89*I1L[9C.4
MB@`$=KV&4<J*]_K[AC=^X]^@B+?-2X4Z);([C'SHI5=E[#3LYK]@P_8W<6R7
M>HTR/DY\EHSNRR_L$.+"%D)>5E&"KI3LB1THU3,8#+$`P-T_'Y^21E?C0X^6
M'B-ROS;1;7EL?<IV^93>LH9P4S8*XM:@2<V>H6.N3\Y7$GL6XF4!>LGC=V*B
M2CE9-1(2>V<H'D<\U7,3Y!FET7QT\`<5NF?XQH-ICTYBJJ/4G]ZU(&$D@LWL
MFOSD,12#H>3TX"%DGC0JZS5,Z8+.W*XIH)E!CSAC@*]'\Q_'#C89VWT%YG?/
MG/LQ>R,0@HV8V5YGVT,(B4DHY!5115..<.(-59,#F]7L@`F[#W#H+J_H$(<_
M_&WQ*\F63,,@Y89ZK;(>ORBL[2[1!2B];OE"FW":2#R1J-G:$4<1XR+=NFF[
M;J$79O$TR%714]!/2#">9?#4\75,M1)^[W[E!K4.@]2=H4RQ7VIUR"622745
M^QDGE+H\%8G;15,2)G]IZV4$"B(&#U?0']-?\<7$?8>%LAX^WV9-J%Q7?0\'
M!)9SE;D:,G%1M>L;&VL"14A'I*NFSE6PQY'3IP83N'BIE#+'.9503`WLURCQ
MI_&9X><@]QI+._5VAW6<K;]S2YR^R%YM^IZG'Q<O&TFDT0M@4(5K*S"#A?[@
M_<$&[1!1TM^1`W<*\CE3S]7\M7(IOJ_.;7'7&SB3G4])NZ+Q^PZJL[9/UZNS
M\LFXE:]C%&(6LUVT:79$$1<3=NL;M@S*KW./K*#=@<)%_`GP:_'V\P676?3N
M&VB<T<L>YY+1=;T?-[5=J:-SITG*5PQX1]*1D[5+FT>1%C<-EW;=ZRD5FR[E
MLY0*"!4Q13!Z;C%\4KQ,<=K)"6^S4G3N2L]77"3N';;_`'LDW4&;E!87"2AZ
M-4(>FUN52*OZ3"A((O&YQ*'J3$!,!@DD,6+*,9-(V-:-8^.CVK=BP8,6Z31D
MR9-$B(-6C1J@1-!LU;()E(FF0I2$(4````.@[0@`@("'<!^@@/U`0'\0$.@B
MH\O_`(BGCGY/[3:]IIEWVGC6[O,BYG;/0\K=4^0SU2R2+Q=[,3,##6VN2SZM
MA++KB=1FV=?8I*=Q112*/HZ!77''XZO"/CUP:WO@0E=-]O&5<F;A3[IL5AD[
MQ#UNZ3;ZCN89Y!Q$6_J-8B&D36P<0B8KM#(N!7`ZA3G$INP!O#QV^#7@7XOM
M1N>P\6J_IK*\7JCFSR9?7W17UQ:(UI6<C;"X0CF"K%@W;.G,C#MO6L8%#@1+
MTE]/J/Z@>$Z!DCG?\?SQ[>1S?GW)/DW&;--Z2\J=;I*9JOJS^L5^.KM51<IQ
M;*,A6\8X3:A[[Y=PJ/K-[CA=0XA^;MT#I'&SCSF/$[!\LXWXS%OH;+L=J,?2
MJ5'2<DXF9-"'CO<.0\C*NO\`:)%^Y76.JLL?L*BAS#V#OVZ!'?D,\0_!3R?1
MD`3E7E"LS<*BT&-J.J4N:=TW3:[$*//OW$&UL;$JR,C!.'1C'%G(-GC=,ZAS
MI$34.8X@PXR^%;XXT9\\@\Y!\NWL"+I19.O!8LK:G(W,X65(S/,)Y@=R<J:!
MR)>L"%./H$PCW-]`>TX+>$;QL>.Z5:6_CMQXA@U%DBJ@WV+2)![H^G-"+E*1
MP,-/6,Z[2J'<%`04&':QXJ$,)#=R=B@"3]P^,;XLN1'('1^2^IU;;9S3-6T:
M8U"Y*([+-,8)]99R5-,/TV\4@P[LX@7)O2FV(KV31[$*(%`.P2!V#%I%L6<;
M'MTVC".:-V+%JB7THMFC1$C=LW2+]?2FBBF4I0_H`=!Y71\YH>OT*WY=J%2@
MKWG=^K\G5KG3K-'H2D#8Z],-CM)&*DV+@IDEVSE!00_H8H]C%$#``@$6;3OA
MN^+&\7E6TT^X<G,BKKIT+ESGM0T&L35<0*=1111M$R-ZI%HM#!L/K`"E5?.1
M(4O8!#^@/7^/CQ.\'?&+6YF'XH9&C7+':FK=E=-1M,DXMVIW%FU6!RA'S%OD
M@!=K"I.P!8L<P391P+`"GL>L`,`)0S[XZOC&S+E?"\TZMG^I)[W`;,XWJ/L$
MCLMVDXK^1G=C<VMQ(N8)V].Q=L59IVHH+90#)B4WI_M^G0/G=`=`=`=`QIY[
MO%7$>5#BA5J>[WZ(XYR^"7IWL,7?+DV!YFQ6"-9E86Q-[V7]1BE(N/0BW8N$
MI(BPF9&2-W(<BAP`*P#5,%Q:3TFA\9>$%PU/FWR%G;BK3F.DT6BJTG.[#)-'
MJK..@,&S\',OH5C823CU*NK%8#Q3<&J(JH,DT#F7*%FM\?#Q!/O$UQ.FXC3)
M9C.\E.0,K`7K;C1"C=U`4TT)&.F=3S*`DD2]YAO44)5X=X^`PI.Y%VL*(>P1
M$Q@>_P!#TG.\CJ,M?]5O=.S6BP*:2LW<K[98:HU>)(NL1NW&1GI]XPBV8N'*
MI4TP45**BA@*7N80`01/B'DNXT:ID,OO-ST/-\2R-]R/U3CWD=^T74Z5&57:
MSYO:Y*I,;K1YYZ^CHMW%W1W"O5V+=-590K5N*ICB0?4`:RVKR>05.Y86WBEC
M55SG7K5BG'N:Y)\AU9?>:3FLG4ZF$=*JTVE4>+L#=PPM-\LCIJT<O3R+Z%AH
M*(?MG3MYW<HIF!9"7+7CY%RU&I&A['D.9[!>$J6S;8U:M8H"5_;6R\0#:?AZ
M<VB$YW[B;EG2"XE:F9D52?@7UMQ.4Q1$/:J\@,+0V!#CVOL>8H[LY@`M+;'%
MKS6T],<5TR:RP3+>DGDBV)9@+=NHK[A6XA[)!4_L`3=`EVU>0S#O\O<1X69C
M9J/L6J:3-ZPPU6(I6BUV0F,$KV6Y\\M4C-7J#C59"00=25A5CX5-FH+59)P\
M,8P@*(IF!4MWWC$,OMM#SS0M<S>CWO39)O"9O2;3=("%MMZDG#@K%NSJ==D9
M!&9GU#O#E1[MD5`]TQ2"/J,`"'F(_E?QBEM?E>/\5R"QR3W""82LG-9/'Z+5
M'M_B&4$W^[G%9*KMI1269&A68@L[342*HV1,!U"E(("(9',N37'+:9>=K^/[
MUCNI3M7A8FQV2&S[2:A<)2`@)TASP\U,,8"7?N8Z+D2IF]I=4I$S"`AW[_3H
M/!H\Z>&SFBZ/I[3D[B+W.,CG6-8TB]L=#KCVI5.Q2C@&D9"2-@:OEHL\I)/#
M>PW1155467[ID`QP$O09N3YB\489+'UI+D;B[8G(,\>GA8#HU654V`TI)Q<,
MQ#-D4))16Y`M*S35`18%7!-18H']/U[!Y_0.<'%[+N3>4\/+SK-=@>0NT5:;
MN-#H#I?TO7\%"O6T<5=XX^C:.<3CY95.,15,"K\63H4BB#=00#3/`GR4X#SL
MJ+IW4[SF$3J#!]I4A*XS#:=7[?>J]GU*U&RYW!W6R1C(K)[$(V-M"-GZJ)T?
M]@"0134.(F*8P;HIO./B#>*;JFB5KE#@M@H6+318G4[I%:16?VOG2CIT1E&?
MO&<6E?TV*0D71A3;/%%",W9P$$3G])NP8JX^0?@[G]:S>XW7E;A5:K.P,TI/
M+YB5T2O-FMZAEI`T2E8*WW>"K(UH\F7V`DB%^P]TQ2^[W,7N&?FN;W#^N[3'
M<<YODKC$;N\K8V%09Y*XO]?"]A:9:&9V"&K[ROE>F?1LO.0TB@NQ0<E24>E5
M*"`*&'MT'AE^<^749AR/NF_S6<8?D&$;2QQ:(U*5V&E6R.O<ZXK=9E'K1U!5
MHZ\U1;C&SM@/'J5Q^126]"'W0IE1/^4-FNN8?%EI,8E7S[]E:\WR1:M7^#QD
M?<(F4>:K&/@1^SEZ<C&N'9I2&='<$33>%[-3K'!(%/<'T]`I'H#H#H#H(.OS
M0^5?)?.L@XY\7L]966M\>-S-:[/M%XB&3Y-A<9JDOXD:GD\E8&QOMVT6B5=:
M:>1ZOH&0.BU.`G3;*EZ"-+XF^/OF!UB!G*UXVL#G\F;7'LSNW+V)K4;F5L4A
MS>Z<M8B>3E]07?U2K*#[1GL34/:=21$NSKW@,``%L5@D/IM>P['8#:9*'FM@
M@\OH</J,Q7UG3F#EM!C*O%LK?)Q+AZBV=KQ[^?0752.HFF<Q#@(E*(]@!NOR
M(8YR(N_(;A=J68\=X#EAF6.)\@'=@QJU:'4:-5X3;;93J]$8;L]I8W5!>(LT
M'0TD+`Q,"*+R0BU9HKUFV4<)$$H-$'\0/*1C6."-"TG/KGJF5PO#[1<2Y!Y7
MA6Z9#D<7GFQ\B-JE-?Y&S,G):)5K*XG<NNT+8CP7NTY6/L2+>((W17!!V(`"
MX-F\:NMV7/\`R'U>BYOGT<MRUV3A]C=)(TF85FZAN$.+0&%T2ZNI2:>J??K3
M`52'M?:+65.N]*5NF('$X#T'6TCQAZGJ-NY#:#8LYS0][Y`>43BIITG;EY>'
M>V"N\&N)<AE[VAM(&379BZAI=17/72H03,Z*A59A<3''N/0:LQKQD<B6_*/E
M+H.N5729715=<Y9;_P`8N3;W=<N-BL'I>QU"P9[BMGC<?KM00VYG;\ZSF80@
MS(SLG(P<.FP%6.0_U4P*&W?&SPDY*YYMG&K0]SXW9GQMI'%K@E+<>ZU!5/4:
M]J%ST'D!H=[J$KM^MVZ9KL4R1-'WEO0D))L9RY?/EG,DNH[.FN)DP#:L+QZY
M54[FASJL:6#5J[&Y0QQ9+"N<LIHE)5><?8*MX>A6<\QUUFLN@;1(Z-J&MLW$
MH0T`!F;TTNH]6'[A,X""#..7CYY_4NI+BZXWY!CLUC/BWW7C3C#1OM%:NEKT
MOF_KTE6%-)Y%W:Z1,,U&,;:RO#B[;O'2KJ3;I>\5^)%%"$Z#;5R\0.K05.TK
M/..$1G6/1$+XB*'PBRJ6@)D*TYN>I/\`3E]`VME<)&!8EGHV.N4?5V4>I/']
MYR8]@>."![A#^H,_RJXF<PN1F,<&9FI<5'/'8G%K6[4^L7$##.4N34N=<0*N
M4JT++]!I&S*9[,9I%+YO+23XQ(M6/%Z#%T9=LX2>D2`H*@XM^..,QGE5EFEC
MD=$J6)<=>#E-Q#CI5W]K<:?<\ZUV_P"J6S4.1TT:P3D>15S+RCO](0-84A2<
MRAC.1`B29S)]!GMVXZ<CYCG9K?(*C9S2K56Y7QIW3!\1N[BT5Z$L-#Y`'N]K
MN'Z/-QLJQ/*J1%^4=P)&TLU5,A&%C'!5R`"Q1,")3^(3:H?':IDF6.J%E#NB
M>&;0.&U:N\&_;L917E;MT[3936[)*KPL2E+K1$Z2BE%>;,LLL9>56721]TIA
M.&&S_P`4NA6/BI7LEM/'1MG5LT;D'PLA>4X:MR;9\A'^@<2>+LQ%W-2EPLG"
M4ZLUB&IC&:CE(N,JK9DD5Q'O%UG*GN*>@H=K;O'5S3N7)CD/'U;+\*>XGR!Y
M7\,=%G=TE+ZW8VF&X7<='65+O^']1RM.IF<P!&MGJLG,*G2D$H21:/7"8IF=
M.``@:>XH<<=WYR636KRXPRFYAQUV7RRW/E_=>3%DLS1WKNO9MQ.U5E5L&RRB
MYZG#I6BFIC8\@:H.):2?(MTH8CLS-!07X``>YU#Q9\P9.K<;;ZBU=VS0*URO
MYY\@MTS#(.2R_&V8D+'RRN,JSSW1*OMB5&M:IG^<Y6DG$OVOV:+T[65<@S7(
MJB4#@K&(X1;/D_,#B/9N*6&0'';'N-F!1V*7RS([HSN%+V/#4Z_8;8AQR3RF
M5J[BU-+75MRDF\@QO;AVT6!`SM94CD7'VI0<Q_>W*?\`Q;_?7\&9[_EC^Q_U
M7^!/Y=-_'?[[]_M^U/YB_:G_`.9]K^;]0_2?3[GY?1Z?S]`IKH#H#H,!9*G5
MKE&FAK?6H"UQ!U/=-%62&CIV-,K[2J'N&8RC9TU%3V%SD[B7OZ#F#\!'H,HP
MCV$4R:QL6Q9QL<R1(W9L&#9%FR:-TP]*:#5JW(F@@BF'T*4A0*`?@'0=OH#H
M#H#H#H#H#H#H#H#H#H#H./H#U^YW-ZA*!.WJ-Z>P"(]_1W]`&[C^/;N(=!RZ
M`Z`Z#YHHHMTRHH))()%$PE213*FF43F$YA*0@%*`F.81'Z?41[]!].@.@.@.
M@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@ZK[_P"$\_\`JN/_`&C]!]T_
3_33_`/`7_P`H=!SZ`Z`Z`Z#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g275067g72o39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g275067g72o39.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1#T4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````R````-D````&`&<`-P`R
M`&\`,P`Y`````0`````````````````````````!``````````````#9````
MR``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#E<````!````<````&<`
M``%0``"',```#CL`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!G`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U50MMKIJ?;:X,KK:7/<>``)<Y4\/J3LO.S<,U>D,-S6MMWM=OW-W3
ML;_-[/Y7_F"JY=/6&8;S?D5OK9A[+])+[A_.7-#&4>GZC=WY_IL_[CI*;.7G
MX=^+=0S(-3[6.8VP-=+2X%H?^;]!8XIRZ1771UDFIA:TE];]Y#766NOML]_K
MY5F]GJ[6X^/;_HO2_0+7S1U(O+L/);4&@_HG5"PN=/YMC[:FL_=55MG5"2T]
M3J:X/+(^S`ZAYI_-O_.>DIK45WU%L];>65N:6,%)^BT-K<QYL=9ZF]C?SO\`
M"?I4)F';7?=8SKE@;<]SBPU.<`QSK[?2;ZCW_P"%RG^YO^#]*K_`T>GH5NZI
M;I5U2EY@.@8PG:X![';?M&[:YKVJ.4/K%3CV78^55E6U#>W&-'I^IM.Y]+;1
M<_T[+6>RI_\`I$E-<5V''R*[^KNO=:PLKW5.8UNYV\ES:2Q[_9LJ^G_I/3^F
MH>CD-;MIZTZII#AM%+G!NXU.:*W6.<_]'Z5E5>_?^BL5P_6'"KN93F&WIQM:
MYU3LP"ECMI8',9:YY;ZGZ5GL6B7/&A)'S24X3V9SFN`ZZYI=ZFHH.F]U;Z]N
MO^#].QO_`%[]&BV5M=9;<SJUC+[=OZ3TI@-J?4T-;]'^D/KR;&_S=GI>GZ?T
M[%L;G?O'[TMSO$_>DIQ#58_"RL:_J[[G7BH5/-;F>GZ<>I_,['/]:/=_X)ZO
MZ3U)1DDASNMN!81MVTD#:7,]3>TES7N=3ZU5?^B?8R__``2V=SO$_>EN=XG[
MTE.%;1>^HTCK;PQQ<-:72&.K?7Z>YKFN_GK76[_I[/0J_P`%ZMFT>K=/:"YU
MP`:"22'``#5Q/M4]SOWC]Z!G.=]AR=3_`#-G?^0Y)3__T._Z-38S+ZA;=0:+
MK;&EYW5/:Z![7-=2/M+/^*ROH5^GZ7^%5SJG_)N5_P`4_P#(5F=*I;^VNM0'
M5NL-0+FL#/S7C<RSU+7.L_.]U=/^#L]-2R.D/Q<)]AR[7^AAG'V]G!I]3>\/
M]3W?X/\`?]+\])3I.^D?B4MSO$I.^D?B4R2D=U(M]P)9:T$5VB9;)#NSF[V>
MWW5N2<S(]Q;:)U+1Z8\7EK?I?RJF?]:_X5$224UK+JG5OQ<ZL-KNKBP/AU=C
M2&5W,.S=^?=LV*KC=*H9OKP,[*HIW&ST*7,V,+RYI%?KT6/:SU*[/T?J>Q:8
M)'!A"MQJ+7[[&;GENS=)!VD/;M]KF_Z6Q)34KQ>OTM+!G8][`YQ99D8[S;M)
M+F,M?1?12]U;#Z>]E-:EZ?7_`/N3@_\`L/=_[V(YH<RX6TD"8:]ADR'/#[7;
MW.]OL_D*6_*VSZ#=T3'JCG;.WZ'^D_1_^")*:WI]?_[DX/\`[#W?^]B7I]?_
M`.Y."?\`T'N'_NVK/VE@<YE@-;VNV@0YP()_1O:]K=OO;_VVHNSL5C=[GNV^
MT:5V'Z7I;=&L_P"[%/\`K5:DIHY&+U]QR?0RF,%EK'XQ)'L8T^]KF^ENV[?3
M_1;_`-*_'_G/UGTU`X_6JZ\I^;D,NI]#+EK#`.]QLQ-M)K;Z?V?'WT_SS_[:
M+?\`6'!H=D![+/U6ZNA\;-3:XU[VR_VMK=79OW^_T_TO\U8A?M["SZ\C%I:]
MKW8M]H+ML0PNHV.`=O;8[^=V?N)*?__1[GHGINZOU6]H:!<ZLLAFS<UOJ5FU
MKB?TS7/;_.L_1O5[J-]-G3L@5V->7T.L;M(,L(_G&Q^9_+5'IC2_JO4:648C
M,1LUVNIK-=KG$[F-ML^C=]/(]7Z'Z7Z"GE]%Z?C85MU3#ZE.*:&.+B3L:?7:
MTZ^[]+[TE.@[Z1^)3)W?2/Q*9)2DDDDE*22224I))))2@2."EN=XE)))2VUD
MR6M))DD@3(VZ_P#08@9K6C"R2&@'T;=0`#JU[G?YSO<K"!G?T')_XFS_`*AR
M2G__TN[Z2ZIG5>L;BUCF/K=8PQN:W:]S;++=V[99]-C?\$C9W4L*_I]K:[)-
M^,ZVLEKF@M_F_I/:UK;/4>UGHN_3?\&J_1+ZK^I]4%-A?CES2*W;MH?-M>1M
M:]K&LW6LVV,_TC/I_N7,[$Q:.EY#::F5M;06-#6@`-:"6-;_`"6N24G=](_$
MH-V150^AEAC[38:F'0`.#++_`'S_`"*7*5N1C5V.;9=6QP.K7/:TZ_R7%"MR
M<!S#OMHLV^]K7/8[W-U9W=[MR2FM7]8>CV06WD`M<\.<QP$-&Z)+?IN8W?6Q
M#M^L_1JJ[7NLL)H#C8STW!PVL;<6ND;6NVO;_P!<_1J@<GJ%M-><RC`HS36*
MX+J_5:U[S;;6YEEOI5U/=M]=GJ>KL]7_``_Z)6*\S/\`VHTG[*W`=<382ZC<
M*]GZ,R+'/=[_`$]_^$];U/\``>FDIV:K:[JF75'=7:T/8[B6N&YCO\U301EX
M0``OI`'`%C`/^J4F9&/8[;7;78Z)VM>UQ@?R6E)21))))2DDDDE*0,[^@Y/_
M`!-G_4.1T#._H.3_`,39_P!0Y)3_`/_3]`P,V]V?U.N^QUE>,YIK;L`VM(<[
M8`P;W.T_/_G/IH.3US$S,&RNMMC3?AG(82T$;7$T[":G6>]K_I_X'_A4_1VA
MG5NIL#'M:'-(L>+(?O=:_P#1.M]FRIQ]+]'_`.>]E:T.J?\`)N5_Q3_R)*:G
M[0Z;@/RWY^13C!U[G-]9S6[@VJC?LWGW[?Y*3>O](?4RUN_8^T8XWTOJ/J%C
M<AK#7DLIL]V._P!;?L]/TT7'-GKY0;4+!ZYEQ(&WV8_C_)W._L)[K>K"JIS*
M*W6&S]*T$&&$;MHWOI_._0ON_2?Z;[*_^:K2D+?K#T)];;*[VO:X!P(8[@[/
M=JS\WU6)V]?Z,]ECZ[-XJ<&6@5OW-<6NNVNK<P/W>G6_V?3_`+:BW)ZV75?Y
M-J8TN&^;FR&[2USO:WV_F_Z1(Y/6',K<_IS"]UA(J+P=K6M86O-K=[&V;_5V
M^W_@_P#A4E+OZ_TIK=[0][-07^DYHEIJ$;KFU[OZ2QWM_P#/B:O/Q,]^+;C`
M[6V/G<(.M=[1_G>D_P#E_OI79'7VEKQBTFL?3K;-C@`;3O8_?3ZGMKQOT7V?
M_"?H_71\@?IL1Y8*['N<;`-?=Z-G+A]+:DI*DDDDI22222E(&=_0<G_B;/\`
MJ'(Z!G?T')_XFS_J')*?_]3T3I^#DX3\RZUU5[KW>HWTJS4XD`Z6_I'UOL=_
MI-M2JY'4<Z_!>RW!?4VW#=98^3[+)V.J<+64_18?5_TW_`+;4+JJ[ZGTVC=7
M8TM>)(D$0=6^Y)33]/,JNO=1;6&76;]KZW$@[65QN;:S_1J6[J7^EH_[:?\`
M^EE6`Q#UAW3]V1O]`7?SUFR-VV?YWU=VOT_YG_KBN_L_'_>N_P"WK?\`TJDI
M%NZE_I:/^VG_`/I9/NZE_I:/^VG_`/I95J6XEG5<C!W9`=376^#=9M.XNW/K
MVVFS\YC;/5_ZW^>KO[/Q_P!Z[_MZW_TJDI'NZE_I:/\`MI__`*64#7EV7567
MV5EM1<0UE;FDES75_2=8_P#?_=5+&RL*[J;L&,H/<;``^YT-]$^F7-V7N?Z=
MT>IO_,_1>KZ=ENQ:G[/Q_P!Z[_MZW_TJDI:"E!6;T^_$R\Q^,6Y5;G-?8T67
MN]HJM=A6U-]*^S_"5>M[O]/_`,9Z6D>GXX!,W&/^'M_]*I*5!2@K*Z1F8/4<
MAU+/M$NK%[''(<YFP[6?HGTW.WTNGU*+_H7_`*3T_P"96G;AXM53[7.MAC2X
MS?8-`)^D^UK6_P!I)3*"@9P_4<G_`(FS_J'*IT;(P^I"P-^T`M:RX%][R"R[
M=95Z9IN=^B:UNVM[OIK1?TS%>QS'^JYK@6N:;K8((AP_G$E/_]7U5)?*J22G
MZI]N[MNCYPG7RJDDI^J!LW&(W0-WC&NV4G@N8YK7%A((#A!(/[WNEJ^5TDE/
MT95?]:*Q6UV-3<YM=9>Y[V-<]Y8'Y5;?2=LJ;7>/2W>G;]/?^D]-%=E?6,TT
M%N)4W)<QYMK)W,#@[V_I`YNUWI[?;ZG^%_[KKYN224_1_P!J^LA+@S"H%@&I
MW@^+>UF[^<_3>[_PO^E_I*B<OZT,H_28E;R?4.]NT$>USL9CJ1;;_A6MIMV6
M?0M_X/U%\Y))*?J>OT8_1;8C\V.)/[O\K<I&(.[CO/$+Y6224_4]?I1^CVQI
M]&/EPIKY5224_P#_V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`
M#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!
M`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#_\``$0@`R`#9`P$1``(1`0,1`?_=``0`'/_$`*<``0`!
M!`,!`0$````````````(!@<)"@$%"P0#`@$!`0$!`0````````````````$"
M!`,0```&`P```0@%!P<)!@<```(#!`4&!P`!"!$A$A,4EA=8"?`5UQC8,4%A
M@19XN%%QD:'!-AG1X2(CU%8XF%FQ,B0E-[?$E2=7*(@:$0$!``$$`@("`00#
M`````````1$A,5$280)!@7%BD?"AP2+1X5+_V@`,`P$``A$#$0`_`-_C`8#`
M8#`QQ_,GL'H*OX1S8/F-2SAMF8]<5K`V=IE4C=XQ!)$2_P`)L\?U58B]B3+'
M95!4S@A3.#@D3E#/5EH=%E>!H@"T68^6+UC^:!/Z3JJ@65HF)EB7.\/SJ?UM
M#>BFX]UL5NN%->\4K&[JOAKD3<=7L]8(:V^M')<SM$7B4W+;HZ0WKES6@;E0
MW4^9:ZYMX=G>WS+.AI)`.]80PR>K$CE6T(^9"U,9E*MTWC5U<[!Y3M,==U%8
M]FR1PL"3M1Y5P-QYA:`:5K8O!W:SC$9BDOUI*VLD]9F+@SKYL]V,MD=?1&&M
M5-2)MIVL[]EE<:>X8_L#O'I=1/1E2T@IB5H($5\OTN?/V@:+0"[_`/C8[7:X
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MFM3\HNEGL`>=%"Y>A>X4^IYC*E;H_@;"M-!FCENUR;:40]%DTFFCLX1\R*[H
MM.N;(,XM4'60FVKZO6!R$Y0FE=@VH[#0]_W90;8GA[?+[X8)E]312$QI`O5G
MQYHL338$9@3VI@9$J<W&3K-5%QKYO_03Y!IH_P`CB52UFN',:UC#&Y/L7CC^
MDI>7S5VM(EWI"]XY]\N)E-M@L;/`T@P.DG?JNVH6K1(PLFU9K4G=&3K%QX7\
MUF]'Z=\>HGBLH-IBZ%Y[K"PWFOH6Q.,HMEWL::1*=O$A;HJ@=;;BDO884POD
M43)-K6^%3UM;?6Q!?'=G,"3Z=DZS75>#A/YC%Z=')5@IUSRZS=*KE%0LVYAS
M][H2XY4RJRFIQ6S2,7,S/O5$XDC<KHI6B)`]JB@I9$J+6!T.*-JLDU'LEDGR
MC7S?;W5]?\CUAT&-8N?+!O*VN=J2C$WO7H*X.@(&\)[VZ@8ZG>Y8KH8+E72"
MNW6+-+H48C`VO9^S?`18AA+V,(RXF522'YIO4T0G'541/I6#35;0,=N%-J/1
M]J;F&7Q9RJZ6PJ'QNXYQ&%/1<GGJZF+;;GQQE:`I3'(H6@84I(2'MW`)2X)F
M4ZS35)J/]36[=GRYK^N9?+6.I9Q'2;6C,2O.JXH@LF(N3+'%925DN:+PFK[,
MZ,"0P#1JQA7`;9-*1-NT2I:G4*2BRO%\&-9$'J,^8Y/*BB*M-(9G#IE`]6S<
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M\TE)Z^%RI_OQ5(')DKU];FID5'$P1[8%JX9Y)K^VN)I#6`8F+4[OEPS66V/P
M5R'/9[(WB7S27T!6L@E$HD"X]S>W][<XVB4N#JZN"D0U"Q<L4#V,PP>]B$+?
MCO+$]M+4U<(8'__0W^,!@,"R=V78FI=-7O\`]/9]9KU9L^'7<9C-=CK\AWV[
MD5_/K*5KUZNRI]7,<2,Z2.5RO\\?KXU`E`R0`)'H8A`"VGWGIS\&O3?M%R!^
M*_"9G)]YZ<_!KTW[1<@?BOP9G)]YZ<_!KTW[1<@?BOP9G*B(':XZQ;7QH@G"
M_2<=;I)-YU8[VE32KDY2!?-K+E;M.)R_F#7]<*S"U$@E3XK6&%@$$@L9VPE`
M`7H(-%S.5;_>>G/P:]-^T7('XK\)F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?
MM%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?
MM%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?
MM%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?
MM%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?
MM%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?M%R!^*_!F<GWGIS\&O3?
MM%R!^*_!F<GWGIS\&O3?M%R!^*_!F<L8?_\`1#R1_P#83KWV6Y^_$ADRWU\O
M_]'??<Y''F14TH7E^9FA<_*3D3$C<W1"@5/2Q.G&K/2-*=6>4<XJ2$I8C1ED
MZ&,)8=BWK6M>.!\\M<7]HC+\YQ6-ZF$E0M:Q2PQ<;RDCI;\[%DB$A:SGY>4H
M2,Z=6H\T)BD91WH0;V+19F]:`((*I.L+2?..>;[K:HW7K3;?0SA3D8+3O)LB
M653!I#9JXHIQ='8:94W29QCC424<4E!H]*>J5FIP"&7H8O`N)GPMXLZ49>@R
M/EP24,3G\3DU@RJ)70YM3Q6MF(88R$V-P3?TQ_9ULMAVAS=6DJ>6?]L2DYJ1
MO=5"T)A"C0R0B2J@DI\)[3$]D@KGLUYJ:'@E3%4=G74M&[HFO<-J5%%U\J`2
MK*5FF/`R)=*8@TZ:D.TV@'"TKV;H1P/-+%K8MAU)EYHI??CLK_IW]S^S-$_;
MSFNO[1?L^_)9/_3O[G]F:(^WK'7]H?9]^.RO^G?W/[,T1]O6.O[0^S[\=E?]
M._N?V9HC[>L=?VA]GWX[*_Z=_<_LS1'V]8Z_M#[/OR63_P!._N?V9HC[>L=?
MVA]KG<R]@1/I=]M6'IJ]LBHI_3CVUL<RK^VB(8W2T@;NUIW=,X)&^)3*8%'-
M04ZLD(SA&@"$PT(?+O>2S")<YD->7`8#`8#`8#`8#>O#`8#`8#`8'G-YET/_
MTLX/S=HY4KQTY`G*62FQ6,UDI$PVY'F-5%7%BZK>E3*\[46Z?*XE$PM*`RVN
M+)FD7:IZ8)8P-<G_`/'Q-@5*DI2AO;`*Y6_79L;Y6%H7/GRA'J.*H<\TA4+M
M$5L68X,MBSG6L,7QQ7"HPZJWZ-P]4QJF4UL41://B\]:A;QE;2)%9QAQ18#!
MB%L9O*SG2*)&VRWBIN;DB9`WH.D7M$@0(B"DJ-$C2\=]6$)4B1*0`LA,F3$%
MA`66`(0``'6M:UK6"[5<_*\U(2"$,TED,'DKB>^%.-?NSH\L13:_N[4VJ%CO
M'W*-JP2!J0*T[=)$(&]U-&20N+.*)4Z`>`(32P#U<BR,`5/T#:9:5':/L\G3
MUTJ]H5::4V.UR=Q<8_,I,@,D-VM2AZF+\6Q5NWZ<#U"*/)S4ZI.@1Z`2@),,
MT5ENOS\"MG6Q["0HIXH14=+'=1%IU&(Q&42:20T@ZP(T]GQ@MYGS*8J=RR6I
MFBI;VM&H2KMDKC]-1NB2Q[,)\Z8G(Y>;E1Q.:EQ.9Q23QY!()I%8)7,I(;E$
MD:9Z^R..JWY7L),9(=%D/;&`UO-2*5CT%"E$>'7F&;",/BQF9%Y_[/+^77Z_
M#>0/[/YOT>']7YL#'-;'#T^<NFG#J7FJ]HES;/916@ZXL/9G/<>M$R>%"D+<
M_!?W=:X3B):^MB@,B%*$P9)QH2$^@Z,\W?FZUVTQ9D\+-W$H^8]S*NJ.P#KM
M>^P(,IMJ-,EK593W'$89)R36YR9S7R%]:5C=8,@-T<3]7EI@!%I*#TBD._3@
MWK6A6=;G3!HE70G<E;WM-I_7)\`N2CIO6[3&7Q^C?0D39*V=E#7+A..F94U(
M=2MZ5JRC=-A@A"&$H.@[#YNQ>._"7UL\B9I!Q"DDI2G.)4)SRPFDGDF!-).+
M&'0@#*-!L0#`#"+QUL.]ZWK\F9'Z_3P_E_J\->3>!Q]/Y\!]/IY,!@/I^;]&
M`^GC^?`Y_H\OZ/T_FP./I]/+@,!@,!@><WF70__3V5[WKH'5_6D.E59R/D>0
M2&+1&QHY!Z_ZYY-GMW.$3FO(-['Q*YK/K*51NUZV:8B'4INF)(#2#S1*7/:-
M(K3@,TD&)+&II/EFARLF!$CI[^_/&O[S<B_A`ZOPEVJXN5@_G_7@<^/]'Z/I
M_+@<?E_7^K]?].!3,TA\?L&)R*#RM(I7QJ5LZYA?42-U=V-4J:W).-,L(3O#
M`N:WIL-,)'O03DJ@D\O?E`,.]:WEV%M&YOFT-L>:E-3).)C#)!"$\F:G!\GD
M5%&8Q+XR4BCK;5D-C1R-))VL,I;PC=%3HM/6(]*0BT(P`A:!ETN.1W,=F5FN
MA]>%OM-K8R3)H0L?YTH-G41=M5G,""6H:2`JBFX\8Y8H7&K%(-.3=YZ$OU/>
MQ;\#2_&:<CX(U85DN2VL$$FI%\B1LR8Y,YSA2.8Q!^;:M<V7T'U/'G)8T+3-
MR9=)]'"V2:WEC3D!+%Z4>M^&ML3747FT+6_*$6M^7>M[#O6_+KR;UY/SZ_/D
M$,.C."N:>D#)K*IK542<K9DD)6Q1KLAR)=C'5G4%-"U!&E^RT#HA`>7'E2D)
MY8/#6Q>9X>/ES4]K,<&O*.U:\W?,NJJO856<7ZWYL'&X#&&6(L0W7FZ3KW,3
M4P-Y#:AVX+O>F3ZVLVF3A](9YH?/%X[\-9;?6ZZKIPI2_P#_`!8Z2I^;6HQ7
M70]P.L/1(%Z2M8/R_,#Y9*_67EM;%")D*1V*\*1JDR9<-1O04QO^K)%XZUK_
M`$M)UNAHN@D^9W#?54WKO*/?7KGJY/K6R>2YSZ+UGT8?3^C\5'CZ/TOCX?G\
M,G7RGW'T?XG4$\?^%'O[]/\`^)<YU_7ZSCK3[A_B=P3Q\?NH]_>/[I<X_P!H
MQUI]S^3?S.X)\*/?W_*7.=?_`!/ACK>3[A_B=P3X4N_O^4N<?R?I48ZWD^Y_
M)_B=P3X4>_O^4N<?[1^?'6\GW/Y<?XG<$^%+O[?_`.I<Y_VC'6GW%1W9TK+I
M'47*4CJ%Z=*5UU+<$-@RV;3Z!D'/]6QA[J:S;4.<%$6F6D;%IT7+Z_2,H35H
M3D?_`)GL1/GF;)%D]IBX7UUSE8">=@W[(>.>+[FC#@7`9/>,#C\OMYP@T,8)
M],F%Q=>?)19K`5!ZOF#@,2Z)2F7,8#EZCS5A[7&M&J=F$D`/<TF>&L3/M.%M
MV#YF5B3Z]N/H$-9%J5B]@T(7+;M=9Q#WH]KU;TWY@#=;6E9SG0QF*)K"HEJQ
M%MU6!>$8UZM2<C&I3A;E1HV5ZR2U-[ABV[7L`B_83<DY:+#E%06PSQUAEC:Q
MQ5E4R:OY35-?3J,R]6&O'%[KL;7,%T@<'!B*0+CUZ:.'("W70'+2C0K&?:28
MPTCLR]G_U-E7I6FOE7U#>OUI=1MUP^V[!)L.R'EW@-[]U,\?B+'/!RBR+`E$
MC.J"SD<!J*+3Q;2[JY&DB"UIG8^,'G%DFZ;31IYHU+[8T9H\K+XOK)N]0"Z^
MOHOJL:8M:!R]:(]0&C-+":4K"L])ZN),84+0@F:%YFP[UO6_#`BKT]_?GC7]
MYN1?P@=7X2[5<7*PYWY?ZO\`/_7@<>3^;^O\W]N\#G\GY-_V8#\F]?H\O]N!
MQ]-?3\N`^GY_R_Y<"CI)`(C+7R$R.0M`'%ZKI[62.&K1*ER?;,\N#*OCZM:`
ME*I((5B.:',\GS#PF@UH?G:#H6@BU<V9%DGJIW>M'Z&R>CFM]5H16"\*)Q61
M4]*CT)<TEN2](YV1:;V6]('I8]2&&@.5.#<W)SDP#QC&07H&A!\VYSN*M<YC
M>B=//S&RFF-Q4LL_BS)`"#;,;D89Q7[DHC@)5.'`X;,;J*N$;3KW(934;H\U
M=M``(3`>L!\V:::CNF2Q5JBT+$@$C21%@21MLC#_``U25/V5RE4LC;HB**?I
M`[P8`"'B(M#+*A";25!^SB5HP^>`0=[\S&-(+GC5I"]GZ,5)B]IBM'J=#/*!
MM.3L(A!-/\X6MDE;T'?@(7AK?AOR^3`_0*@@1OH0G%"/T4$_9(3`;,]`+?FA
M-]'H7G^B$+6]>=^3>\@_3Z?U8#]>`_-_D_[-_P!&!SX?E_+Y-[\?[?S_`,FL
M!_1^O]7]'A@<>'T_/^G`I"=5]`K0C2Z%V9"(A8D.<QI3'*)SF-,TNC+B8A4E
M+41BYB?T3@UJQHUA`#2MF%"V68`(@^`M:W@VV4A)>?:%FB5<AF-(U%+$3F=$
ME#DCDM;0Q]2N"B`)UB."'KD[HRJBE9T*2."@IH$9H0FTL\P*?981BULN;RKE
MSAD/>E\?=7F*1MV=(GIT#%G)S8FM>OC07MJ-8WH,?6*DIJAFT[LAXT:K281?
MK"48BC/.+WL.$=77U85K4C"9%JJKR#5E&#G-:]'1ROHDP0QA->7/98G)V,:(
MXWMK>-S<!$@V>?LO9INPZ\X6_#6"VW>O/4S+H?_5V`?FK5;:UBW]`AU[RBYV
MP6RUU&'XR=)=7J.*3Y,Q:Z))?:#LM-5-JU_$'1L?G"0L4:1)Y*D<B"&BSY"N
MT6>VHGA(HE;]=MV8#J.MI+<G-U\5/#5K>@E=D5)/X5'CW=4H0,YCM)(RY-2-
M"\N"-$Y+&YF<SE6DRM02F4G$)C1F`*-$'0!5F:6,=LCY&N%XY,2TP"D:ZV<U
MWO+;]CE2&S:$J:D8V6?7?:\G34NZ1E\K%_ALQ:8)!YBD6"1'-Z)G*>AA&W*M
MB:THU,7.N<JW45);U.I?ENP2?VTTSUMKV30^M5J!-$#4S@NFT)X'OV-2&:&S
MA8]F.+TFD#NQN"L)![<G,T%P!H0O.)_UEGPS[66>VB<&5YN?R;_E_M_EP.,#
MG?\`3K\WE\?T?H_DP./#?Z?Z_P!&`^G]O]&`P.?Y_#RZ_P`F_P!/EW@/T>3R
M_K_/X?FP'CO^7?\`3]/+Y<"T<UH6FK'52E?.:YB\F7S:)M<%E2YT;PG+7N'L
MCX*2M<;5JPB`HTTI'X?K>B@""$1X0B%X["'PLMGR/V?Z.J64*+'5R"!,+JIM
MV(H('91RH@T0YC#FQ*XHD$?>=A.#Z5O2I792``0^9O03A>7\G@S1;A?$7^)W
M',;`A='Q%Q&30)4:9YY^VVFV52A[C+R8OBE4;9EI7U4PQ4H*I0>)S,-\AXPZ
M$'8=>.KO)F_(NS%;*BD@9Z^4FRB'B=[$9=N,?0,\E;'5-(%+>V`<)$")JR%&
M]2-$S:\\0SD_GAT4'SQ>&LF+KH/K;K-KIX(CBEIG41<D\P=G5AB9Z&0M2HF2
MO;&6Y&O32Q&$*A@=')I+9U8E))&QF$A3&['K7F"\&+/@?H59%>GE)3R9O%#B
M%\N40!$<6_M8RE<X1J%257$$PPJ1!.DR54B.+,1!\5`!E##L'B'>,45ID#`?
MYO+_`";_`%?HP&`P&`P/.;S+H?_6S9?./A]72R^&O]K97+-/3914?5.)@JR>
M[!KB@(2@C_9DK>[5?DZ2X*]3JW.8QN(OKTF0)FE^-5NM2M1+@6%I/5$J)6_7
M\-D;*P8$2.GO[\\:_O-R+^$#J_"7:KBY6#`>/E_D^GAOR?IP'T_F\OYO+O`>
M/^;]'^3`?3\V`^GY/#`?3^;].L!]/I^3\V`P'C^K^;]>`\?T?T_YO#`XWK0M
M;T+6A!%K>A:WK6];UO7AO6];UX;\=8%(MU>P!HU%`M$'A[6&!IUR2#Z;HRR(
MM0U*Z)MHW--%-)D16H\G<48ME'@2>A"<5OS!^(?)ES>1^#=6E<M!,=3-,`A3
M6GB#JZ/L3(;HJQ(B8N^/A;B4]/,=*3("@,CJ\%.ZL*I0FT4<H"J.T8(6C!^<
MS>13TMIR'/\`#W>+L#:S0!<K=7>6,,JB\1A9KS#;%=_7#3+.CJ1_CSRP`GA2
MYP.4Z7J$9YAAQ@A&^D\\6MLT=&N0=%IV67)&-]J96[E2N(%UXXR)KE0@&0!-
M^SA<V%/"VI2E`?-UY93J-`-N`2@+,,3>D+\T)FMW_73<?O)$_1`TMLZB+E3Q
M*TX,=]QPI"VS`Y,@&!.3J6>]`+>N+,7A.5>DV@^J]E>8#S?2^._''^N@Z"UT
M74JMBM<NH9!4#.['0QF#4"B21R1O2])-"RG;<K%)ROKUI9C$BSQ1A9C->>4E
M/\\Q82I*UZ(4T/RC[V_`IA,ZGYZ33F!++TB$6O&%2/I^N*TAZMW26+!4M9V6
MS*26BLW)^=75^CJ"X'F-NX6L:U>H3DH0GC&=ZL,>Y6O6ZWE`_H6HN@YSP=R#
M1TQK>R9C9M.1^J2KU7N=;CNUEVYN_*UM11*I,@XWQJ07H^PZR5;2E5+TKD(^
M,R(:-_V8H"E&(4^(U+)[>U^'5-E(]8E]`HY3(:5DK_)WJC(K$FE:J='0EYK*
M"'<&KHK,8\T]8-\F"W@FR;JM$>@^I%C,M3KS7S<D]'Z9.E6(1F8QG3/^?^$N
M?E,U99=1U%9\>G\!=(&A<9[#'J.I%T#!3[>H7$T75$8L`IAI\M[D)<71I+"C
M+B)6[A5"!+G8]8\`UYBH(QHGO9;,5IZ9'J__U\]GS4/VKF7059AA=7<NSH5?
MQ%DFD,L.T"*7?WINGD5?KH3/M72$,ZLB+NS9%9!8K?`FTX>D*U.WM"Z5.)>P
MN#4229*WZ[;UL&96#`B1T]_?GC7]YN1?P@=7X2[5<7*P8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`\YO,NA__]#+GU'8L'62CJ6S9;*(F1<M,3R[FZG^5'+Y
M=D(M6$VBUUR_R!PC,=EUO/?.LJGJQ;?D@`L<3')HF#4G;UL@V?O0M@.T;&Y\
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M#[R[YN7EVX/=]!6?GT+8?3,8GT127,[6XU3>[+#>YM/8VOJ*AFR`PV1M,\G3
M4UQAN.&U"4)5H3WQ#YVM)U`E">-29B9M-RAK[*Y1;G*UH0W)6.YH=-8;.XDV
M/+\='WMF,<Y'`7I?%Y`-'%93J*S1O0#<F9;Z)"X`;UJ<W6RSM:%JI=*_/?&5
M);K\FM/-LH,=2NA4H1K"KDM0B7(;!_;^26<OM-OG*>7%3!!9K[-):O4.#T2M
M`K6)CO4C!;0@`F",W=;FXZQKZL7KA"+P"'L,59(?=NX'&TK6@)+.:X=%.*>G
M&&.QXM>9HQQ/;FEG9DJ<H!IIF]%IR_'>]AUO"6Z5(#*\S`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8'G-YET/_]+/'\Q7JACC'32!K#TDA9Z_25$U-J.&1#YA
MT9XY=F6SH_;%P1:RG%]9=Q&1N\V"HVPMS4$X\\HAL6,BHDHO9IBD6HW)ILV%
M<K!@1(Z>_OSQK^\W(OX0.K\)=JN+E8,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@><WF70__3V&N\>BW-HZ;AA%/]E,'*2IFAK>BFD\F,QE]B0EZ)CMGV;%Y%
M#"^/5%4R&%R5_:W%F7$*)4"4Q)R'LU.2$]84WE`!&IMK&=[*R8$2.GO[\\:_
MO-R+^$#J_"7:KBY6#`8%-1&8Q6?,"250J0-,IC:\]S2HGMC6DN#8J4,KJM8W
M8DA6G$,HPQN>&U0F.UK?B`XD8=^4.\"I<!@,"FB9C%5$P<:_(D#2;-VB-,LQ
M=(J6M)$^H(K(W1^9&&0*F[0O6"6EW=XLY)DYPM:`:<B."'>]EB\!Y5+@,!@,
M!@,!@,!@,!@,!@,!@><WF70__]39.[@D\H5]EQB'U]V57_"<DBU'UE.)-:UB
MW*I5)9[$I#9=R-*:$Q[E2P]M-"3M6R&Q%?Z[)E+CIZ;@OJ8&R?1DI/21J;;9
M9,NHS[/2\W7PII0+F*VB*DGYM=Z8TQ*R0ZEH(RY"9AQE&I*/2*Y2!7H(FPH\
MLQ.8OT2$T`R]B#NI-]4%4[S=#]Q)8,<9U74I=LH)#9+E03HZ1:XHG:KG`I'?
M<[A/-QEHR&20DB0[TWQO;8NDK>X!)EB")D%+WLI.>:-09%TRN):+1:T.GO$,
M`DH6B70*(W(-G;;C?K*>'NX["D[;Q9TBD<G6=0`-5,,49#79=MQ/-5HI*N\X
M11.PI"@J!@25F[5*S*\S`8&(F%TCUZBX^E_*R:!H*]?FY?+'UBLULNE,@23U
MH=NDO>6^UR0HB3<.9P`ZQJK>G-D$[E^<-M-.V/7@+8!!FN,-V^O;ME!SKNGN
MGJZJ%IC#FT6M*4TQ@W<#?3%+5I-.E)S[C9W8;=7YO.B%1:M<0V0%3610U"VO
MC4U-,B/;FDD4D/1H51C6D5*2#4LMT\,F$TY>Z`G\EYP#8EE$6%7\+N64SN5Q
M=&2OJ@^*08WG^U8U"80[N\)EY[I:NFBT7QA$J4#-3!6%)C#321%[&#=8S-<3
M5#2H^%>QBB'IFM-1]51:7VOQC.9-&(QT-8;ZV`!6DLMO72REE?G9T*L).FG;
M&Z1\1>ESLYN[XC)+^L5HE0#2"9BM7V]?AV%><*=?1*^>?;>?GTN41.I896$#
MF]:N%CJUGO&9(ST/UN\L:MRD"E4%R=EM$5S<49?6)"XJ#6QT7(1I#PZ4)DJ@
MEBE]O7%C/)E>9@,!@,!@,!@,!@,!@,!@,#SF\RZ'_]78I^:+$)G+;,9S:X)L
M\$N7P./UI#9$UV3\M:*4LCM=U>Y<\1R*3UNZICDDZ$5OAJ-Y2+EA$93K"36=
M00-N1*%VE0#96_79G/RL&!$CI[^_/&O[S<B_A`ZOPEVJXN5@P&!$?M?H*0\T
M4NWV/&A0).O7V]2%<J7:SU3DA@D<9K2M2*P%[E4D7-*Q"L1-L9:W\U<8=H>P
M%!(V(81!UL.U:]9FX1"B?9G55EQR!RN!0".NT?=%L[CCW)X715C6]`9:NK^[
M[+J[<]KV<M%T0<I)!IU'88B>FQ.K0K#TZ9<$S:I6284/<S5Z^NNJF>5>IYHX
M]/V`TVW>!!C`87U`EM2"R][A#3&^?YQ#>W&B@^3H6W["WM+A&%MQ5>][V@(7
M*SS94K+)5)]&F'!V,63&D_K"&S]V/T265./-OF0G*W23LJ:ZX^;(H##F[GI_
M,[Z>Z19Z\-L`R**]<\,<FH]$;ZP[NZ=R-]`T!<20;4KMJC#6)II_WHS;<,V+
M*;9Y$Y_L*</:V2S&25TTGR>0KT+8A.?'Q"-0UN3J3MET!F=&]>J0B-2.20LA
M*[)1%K2B22U`2@6;//VF/:Q*["&`P&`P&`P&`P&`P&`P&`P/.;S+H?_6V3+B
M^4BNM>>WW*5MI5TK:;5!:Z.!))+2^WF1U>?TK(8*??-D*I'^W!/[97#'85!$
MS!6[OI.U@B2`)`#2UOJP-BF&I[8PS6963`B1T]_?GC7]YN1?P@=7X2[513B^
MW3+KGF%7U:KJ]C006L*KGKJZ3]DEC\K=%=GRNYH\0@;R8[(X^2A3,Y-2;,$(
MSTPCA+?#7F:+_P!*I)+,U4?N_P"N_P#?3G#V`L[[1\F5ZSR>[_KO_?3G#V`L
M[[1\9.L\J#L+G+H.U6ID9)\\<W/[7')S`[)9D@HA<;:%)-*REK1.H0\B,:+5
M;SE0664L255M,<(Q&J]%Z)04:2(98A))RK@FN>MDY)2=/+^:R"""P$D$$UY9
M91)))0=`+**+!8H0%EE@#K00ZUK6M:\-8R=9Y?*;5?5!^U&SI'S"=M8<C4*]
MFUI8QFU2AO&48@/4;'8>]GG(1D`$2(7B(K8`[#O7AK!B>7(ZMZJ,`X`,DO,1
M@'8.PNH!UK8P@.81)0(1!<`BL/>EH=HBPD[T9YW^J#H'_=UK6#$\OL#7O7(`
MA`"9\W!`$.@A"&O[-"$(0Z\`A"'5C:UH.M:\FL9.L\N?=_UW_OISA[`6=]H^
M,G6>3W?]=_[Z<X>P%G?:/C)UGE0EB*^GJE9X_+Y0\T-(8ZIM&E((]-;#$K!:
M'H3=:]Q02K%2YK<'";NJ$E:T%3+:LO1J<PLP1'F;UK0O.TR=9JDEE8,!@,!@
M,!@,!@,!@,#SF\RZ'__7V`OF<1F)*^I(T_S)PH^5LGN&AC>XQ6YZKZWLV/TH
MVH[&M$U7<LI?.>G5N@M-06='NY#4L>Y0-.6L,CH?`\"=O/$"-39G0FDQC%=P
M^53^:O"6/0Z$1QZELJ?ENCA)&:.QUN4N[TZ*0IRCE`R4#<D,-$$L`S!:#X!"
M(6]:W65H3>IJ1)IHF^S)*_ZKI0^&Q0GS:UL\<^',4TT4UVM@_N=!#17`&>-T
MW1'MJICVQ:=DBE.<$Y.#11FPEQ\+;]!/;7)7[AV1LBH*YE?^AG)[:%P2SB0K
M&MUXUZI7(%025)9*@H*A(>`>@F``,/CX"UK?CK"7:OVJ3_BWZ!_=SY._]S.S
M<5/7;[2^5*TB$D2A:J3HTX=AT(]4<6G)#L6_`.A&FB`#6Q;\FO+Y<*Z97+(T
MB:7A\.>VX;7'VU6[O*M(I`OT@;4*8Y8J5'%(=J3]A+3IQB\`A$(7F[T'6]^3
M!OLIF(V]64]=D['"YLPR=T55W"K93I657I=LRMK'.?$\"F6CB0B(TR2\V,N&
MF\S8];4Z1';!K>BQ;T,+CX'3-T@:'5R?V=`K].XQ=:B;WU/ZNJ*]16.#4A>T
M9/ICB2R%/IFMQ)-\XD1@0^?YHMZ'H0=!W.!3D4ET:G#*7(XB\HG]B.<'ML3N
MS<,1R%2LCCXXQQX`E4;"$"HE*\M*@G1Q?G$G>C\\L0RQ!'L.NF=C02N]1?<Y
MEK#%13:8L%?0\IZ<4Z(^43>4J=I6"+,*<T>CW5[<C`#$`@D(QZ)*,-%H)19@
MPA9QR[)Y79V><2!SONLT;-6TO+@4Z<#9*C]!&Y:8>[IM-"_S1"'YY9T=<]&&
MEZ&G*^JE^QC#I"KV27%X47T_,HM,Z6`=%GQO?"V+J+D&//`D!WI?JYX3]9<_
M.(D*D.]!$`9S6Z)59(O#S%"-42>4(9)I8Q$Y_"[.5YF`P&`P&`P&`P&`P&!Y
MS>9=#__0S/?,,NR!OO1=AQ-[G5(-\PKVM4,8M>MMV1VY!G^ZZV5S6VGVO:7F
M\*J""*(K<#<Y1LT9OU3YYAAJN1+$Q)IC<Y:THC<V;!%WU4T7G3UG4X_.#@SM
M-FP>2PI6]-.B!.C)^T#4I;R'QM+5EG(CG!F4G`5$EJ"S4YAA6@F@&7L0!5C9
M#^1\%F3"D%M/RVRX[*3U]GKKY6/<EIYI?8^XW5(K=E]H3!U>:^<I8H8'>MW9
MMEHF!+&SC/2HT*<*@;BI6BV?HN=72SSGV%TU)^"0-+E,I-)HU9C;5BV9S"9R
M9]=90TPKAOHB-)7I\:5+J**ZDSL1$TJA:M3($YQZD1H]B\3C?/);F5634SS*
M07]U4R5Y,2J]G#GRSRRCB\W/CZ"5$QAX-LGLW21X,CCH(#<\@2#\NTYV]%C_
M`";RZ9UV2;(WW%\O+KKI.+(*SZ)[N;;'J4R6Q.2RF$(>;H-"C9*FB[RF=OJ@
M<DBSTWO;<0O"0(H8B3=;T$?CX;\,U/;UFTN37PDWRQ\OJD./K5O&P*50G1>-
MW*T5VRAK8A0XKHY&$\$0NX#U:-4^N3P[+%\B<WU2>HV,X)(0>8`)>O`0A2^U
MN,B&SY\H%:LI2<4XW73%ER"46\0[,IMATRRV`SQ;GF`UC,:WYXHQ"R+'QM\P
M='J95I[1O*8](N-<0':2C;_6`F$8P].VNRLG;Y84L>=V:I=;0J23.L^;ZP4.
M#W.J/>I=);#40)[H=_75;?\`(3;7;=6WSVXG4NL1IX\8C1&IT4H5!$>/1:H#
MJPG9\DI^4\AF[4]M,OFE?O:)?%9$VM#5JKU9$7C4J7\G0?G6,22.QQTF4A$T
MIX')(:"0,R?:M0H;=!3%D*0J$I:O&#LD%RCPV]\WWK>-S/-M);"';XW484VX
M6I8)3_YU,U\VU^W4NU+G,JP?V-VY"9(X-4WE*&AB)"G+.T`PPO!;F2(V0'Y6
M(7.-56JLQSCJ*;UW6'.M('/8XPPRJ2FPZ@(Q=M63MR:'YU&\M/JW1L7L<EQ7
M)EB$THPOQ3NR13O8TY3!VQG"_<2^63256PJ&Q*K$\?:E41Z*JZ^TDD<JHI-@
M>$(X/+H*_22/,7N;K.ID#=^V;5`TJ-0K,(/4"\POTHC222B05,\K*R3Y5\I>
MVYY$1?+"FD+/(8T54;B;7$N*0Q6"1A'V>W-">7%,=R,3[)K!:DW<4D/(>&YQ
M8R!+F-J.$D\W1Y8IAKM.%S9Y5<RKR!7C(9>N7*@V5V_P@[QP;BXH%[H[L,#L
M+BFG-361Z:M!;B)/.7BN5:\X)>@""@$B+,+*-+&6"LW;Z32RO(P&`P&`P&`P
M&`P&`P/.;S+H?__1V)?F;7J]4_=*F,-'0D5KA;<W/D*AC*6?.;\CDRH!\8[5
MG,O2]!,\(I"E+4(MXV4&M1+>D8WIQCA2L$87(`''M[F\:)E:]?PSIY63`B1T
M]_?GC7]YN1?P@=7X2[50+'(WJ(]!]32:.PM\L9\8^7.6'%J@L95L:%_E2Q/9
M/9HB69H625S9F%,N6"_T0#5JDY&M_P#>'K67Y)LO?++>M)G9IVNC?-U@2IUB
MZ&OU4;9PR>O&G<_/EVD@Y*@95JF3'%-JFN`GF:<MKM$%J!D[TC$HUO0ML3_T
M?3M(&HN=E.D<;G"/<X.`@>Y='+&*31>(1TXYXD#P./U*='4,B>I(!VA[&6D+
M5/1B4")<$S1@-Z-](2!<?!/+%Y6/5-\1.L0R]PF=T65/7YIHLB]$-W\SR..5
M7R9:$V3S(VS2V@BMZ^A-@2:+1%T9TS2ICVCGL32`YL<%#X6G7*59N6[)P[]/
MVQVQ*DXS&^A8S!BI(2Z0./-SI%+-=IS'[&<>#9_U-&)FM:EI+.0OA15BP8F.
M[:E:)N=SAO:=*HTB<$QJ=2,1U5?=N]=:I9EG,QC5=&MJJ?UO50+(.I^^%B1K
M+/YE;;DDUHS^&0X3O*=MDXL)U1Q%G);D25$B<U'G'J3#C$S>:,3*Y;5T5T.[
M\H=.6E+&B4T_/CK5KB.1ABDS<V*'F@(S:E<\S)Y6(LU0V(6J1'4J_63(5XU2
MHLY,:N;30F^)(-E!'S'5H>L>[I`3+6Z&\_Q63/QB>6O5>-D<CAJIT3Q^#=$V
M)32Y/+RKAOR@(DZ.K]%8XV/I!B:3(3"`'&;`E7EFEB*&)RZ*R9IWML4\FD8F
M=KQ2<5_Q#-+BE_/(ZVY\<H""Z)2WS2%TS&X0",12\;"<'MM<*]?Y,Y-R2QY:
M6H<2&I&`H21:-$8-/[KJ\@7?;$IG5/P^:2"8RMNFE'].2%R=)JC:DSBH)HOI
M>$0.H+$0B0U]5:Y0SW37UI+#D:I5'VHQ>@C:<[S%!GI5RH61)?L7_P!&V;]X
MCCG^+VC,K/*L\KS,!@,!@,!@,!@,!@,#SF\RZ'__TMDGL6O@W_T&^HH_SG]Y
MB"R>GF6$+7BI^K(W1%AE2ND+$ON`W77\E:7>R&<R70UFB?09L;<QIFH@;85,
MW1`H6';<R2T4:EQ-V:_*R8$2.GO[\\:_O-R+^$#J_"7:O@J3_BWZ!_=SY._]
MS.S<4]=OM,;"F`P&`P.L>F5FDC,[1V1-+8_Q]_;%[*^L3T@2NK,],SJE-0N;
M2[-BXH]$XMCBB/&2>0<`91Q0Q`&'8=[U@=B$(0!"``0@``.@A"'6@A"$.O`(
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M#1*E.;ZF6;YAI8O`>JDWB$CKV3;:?C*2V7$G^@Y=>3!>#K3K))G=RB,/J681
MQDZO=*'W:J./S7H"O4"K;Q#8^X'H&DN<)"W65)MH$JH!8O`N+C7P+K\57?\`
MX=C^.)381$NG+'8H[-4P=N@M=RE=*.%^AWE:1&F$5EV0^L1QBM^-V6@,<'=.
MG`E-`6[.!8"EBJQGVF)5\I%4+VX6*\6;"[NM:IGZ1PJ&P21)(,W4N[M#RT0%
M]G\@C*E01:=062L1N2199;H$8TBA,4<4,O0R]B+T+*Q+C3#CW<7)\971'LCR
M%^%?&%[>#W<7)\971'LCR%^%?&#MX/=Q<GQE=$>R/(7X5\8.W@]W%R?&5T1[
M(\A?A7Q@[>#W<7)\971'LCR%^%?&#MX/=Q<GQE=$>R/(7X5\8.W@]W%R?&5T
M1[(\A?A7Q@[>#W<7)\971'LCR%^%?&#MX/=Q<GQE=$>R/(7X5\8.WAT3_1LW
MF)3&W3?J:_)?'6:<5U/3HPY,/,36UO;I6$_C5DQQ`ZK8ISA'9&6TFR.*)/6@
MHEZ-0:GT,`3B]B\[3!V\)$X9,!@,!@,!@,!@,!@,#SF\RZ'_U-_C`_@PLLXL
MPDXL!I1H!%FE&!",LPL8=A&68`6MA&`8=[UO6];UO6\"E/V`@?U6)D_8F(_4
MHV1%&AM'[-LWU6..-IQRENCXD'J7J@F1`H4&&$)-@]`4,8A!#K8M[V$<^J&N
M5$J^9Y-#Z]E4_1UQ?2^225C@J=B->&R,K^<.A*_3.9")[>X^C.1IY+-&Q,,!
M9VS`!4:%H&P!%L(QF6+92?HMQAK:F=Y-SKT6U-RR0Q&*)E1T6@AP#9!.Y6RP
M>)-N@);'/,T:\RJ1(D8!;#HL`S]",$`O0AA93I>8J'WP3+X8^D/9NO/M-RY3
MI>8>^"9?#'TA[-UY]IN,G2\P]\$R^&/I#V;KS[3<9.EYBGE/1;BCE;+!U/.O
M194JD4>D\K9F?<6@FSET?AKE$6B3.19P;'$D+*:G&=M)0PC,"8/:T.P!%H)F
MP3*]+S%0^^"9?#'TA[-UY]IN7*=+S#WP3+X8^D/9NO/M-QDZ7F'O@F7PQ](>
MS=>?:;C)TO,4\U]%N+T]2>.M?.O1:MZABML0R9`"+00!C2K>6A*^MA)QAMCE
MD'"5M*XH[6RA#UH(]:%O0O'6IE>EYBH??!,OACZ0]FZ\^TW+E.EYA[X)E\,?
M2'LW7GVFXR=+S#WP3+X8^D/9NO/M-QDZ7F*>BW1;C-64B11?G7HMW95*MV0D
M+R8M!"2S%;&[KF)U)T6JL<@_0D;LVGDBWL.M"$7O8=[#O6]S*]+S%0^^"9?#
M'TA[-UY]IN7*=+S#WP3+X8^D/9NO/M-QDZ7F*>EG1;C!XX[RV5\Z]%L\=84@
MESLYG1:"'%(D@1@`(X922QU"D8=#'K7@``M^7\F3*]+S%0^^"9?#'TA[-UY]
MIN7*=+S#WP3+X8^D/9NO/M-QDZ7F'O@F7PQ](>S=>?:;C)TO,4\]=%N,=<HB
MT//.O1:%QG<A4Q2))3(M!#!O,@1Q23SA2VD#)L<TL@TJ*PUS6;$<(LO8$@@Z
M%LP0`"F5Z7F*A]\$R^&/I#V;KS[3<N4Z7F'O@F7PQ](>S=>?:;C)TO,/?!,O
MACZ0]FZ\^TW&3I>8T^_\,#YA_P`(UE?_`#VK?M"S+VS.7__5W^,!@,!@0:[A
MOY+3L>K>-)JA17;+)Q*7B:QV'/$\45FQ)">9XTOZ1<90JER6,R\\+RQJJV1?
M4S?ZB(AR=SDY2LY*B]:4E%D2QK>=LMHUW`K-C8588[8L+BT[80KR=)UP667,
M:&0-85J<(S`D*](7`OT@-"%H(_'7COP\<(K3`8&/.P.K(I'N\Z_H,RNF,V2I
M*]8FA/<,JG$CBB1#[^'V0N[G6$-:D]?/T2E4O5I^>FIT,1KWMI6*"QD`0Z-\
MQ5K"XTRR&80P*1GDMU!(=(9?^S4NF0F!N-7%12!L@I%,9"H"(!:9ICS/H](4
MJ<5IY@0!V<>G3%:WLP\XDD`S`AB/C7S+X\D9JWMQKYN-:!W77U;7?T::HM,)
MCQ6D-E=UL?*D$4QY*3#5S9:DG0O(!J%Z$HV.)D[0VG&%*E:L:=.IC6/C+,]E
M9,")O8?4@^3JU;9^35,TM8YTF,/BHD4;$2TQ^-))/+H]%E,GG$Q6IUB&-L[>
M*0%^KE`3JUKDM$6F((\T1QZ<LF5I:8ZLB:CJ6Q^-X=7+'#(U6,@DZ!KDKS.)
M&C>I[(-1*$6Q.U,!B#G7PV21-C)(+6&C<=D2HU<C.3FG#1%IAD;%%LTRR&96
M3`@'U%T0N@%D0"F;(H9ODM"7:_Q^M3YX=;#>CF#W('UHF,H?PPVEV)B=9/)H
MA5\=A>G&5.:IV8C4*-4`Q$F<0E*/1ED\ZNPXL[3/ZV*D`':K!U6Y)JMH*_(H
M@#-B9T%^I+IQBE[]4;Z\K"(S&"HU.#D\$<RGEC*TY)VTXLOT3BL`;H819A.S
M"&!B'OGO=UJ^PY>R6QRGH^24@4GMRDD[#<A<TE+B7+KD0\>0Z13^,0&"/XZR
M5VA'[D='EA0D&2U4HCB5S&H3HW%"8E*C6--V1>@;8)O*GX1:R<F,IBYBWK%O
MJL0E:F:L*,Q&[N#2>B3R)=&8:X*5J,YO$4L(4M:%2A6@-2G%!-)'E97AP&`P
M/__6W^,!@,!@1QZ.Y?KSIUDC;3-G6<QAPB+A(5D=EE<2<R)RQM23*&O]>3=D
M+<])'`@UFE\(DZUO6%C($87Z0M2F&G6ITRDDLN%\HQ&F*&1J/0^+MQ+/&HFQ
MM,:CK0F$:).UL3$@3M;2W$"/,-/$2A0)2R@[&,0]A#KQWO?EPCO,!@1HG7*\
M!L>X(K;\LD]I.0HB\PV6-]8F6`[&5";.:[V_"@LY%"E.E&FQ_C9LB/.T6W*4
M+<O4@(4+DJM0G(-`7.F$E\(8%IK`ORBJF<D3+:ETU-6;PY(=.C<TV!8T/ACD
MO;=J#DFG%$AD;RVJE2':I.87Z8`!%^D`(/CXAWK00WC'`G(\MC]3H(?+Y3)X
MU1S>U5^L)BUGM[BTSYAC-CL-]1J!W!J/IMI'I%&;`)0O:=.1]6JA$J!$'C.0
M+#TYY<UDAPCKEKPT-JMH0.+HW(%T@7'-;"C6KDR56]N29K<'M0W-"<\TLYR7
M$,K2K6#))T,P*5*:;O6BRQBT%NKMIR)7[6SU5<Y,>"8R_.,2=%QC"L(;W32F
M&3%@G#1HA6H1KR2RA/4;3Z.ULH6QD;&'6P[WH6ALM\@Y7@*:^0=!N,GM*429
ML6R9WAD4EU@.TCK^N)#-HVSQ"8OL"87'1JYE.?XVREI/4AK#VEO+.4[;TB02
MD\1A<Z87T=YA$H^>!*_2F.,BDQ;&6XM.[O;8VGF.$U>#H[#D`"EBHDP2V6R!
M,8A;"M:\]>L+$21H9@=AT14>!#1VY6K:U>B(AV,VV[8;D_-4(30:.-<<?*UD
M%4+*_-=-NL@86Q.Y0&1.25NG:\L/UXI;'9*K<BB"21GZ)3D%E%SIA4W,_(%3
M<I)I"FK13-W/;\R0*&)U4[EBN6+(U6=3MKJSU35<9/4DIQ(8+7+<_KRVPHW2
MA;OUPT2E2H'O0@BVU*7"&!`=A^7W"HW);UEK/?/33>^]!3(BQ9FY-<^B+"ZH
M)TU2"//L4?&601VO&B2JFR%)8V4T-D?=UKK%@,9ZA"<V'D'##A<I34O3T,H6
MMV&K8"2Y@CC$JD;IM2]N:AY?'F0S.4/4WF<G?713X#7/DLF4C7N:PP(2RMJ5
M8_1EEE^:6$FZZ6`P&!__U]_C`8#`8#`8#`8#`8#`A9V!2#[;[URBX1N$M,KW
M6_6%<3^=J5PHV0:T5HR1.R$#VM&)^5)#71$G=7Y'K:%+ZPI-$;YX"!:`,02R
MXRQF77RW\Q"2S3JAU@+]>T>9_P!F^QI;S4C@G4`J]95UL.B_DX7,216P,MK,
M*';"!)&)OI.W/J<MC1EZ4%+RRBUQ9:J:M2^NCYKGYF^9PB?9I%J9GUX#JAMN
MFY#J;<U%\.$RL5D;Y35O+ZBJ+'E+[*NHZE?9?5\)L]!9?I8Y(W21%DF*BRA1
M)S;3$&T+4S$J>](==[_8<.3U\<\*IK(^$?F"U=0SG$G;]BES-VK+J_K!VJQX
M9)2J>&=-"I(Y0>(RX#,YG.).FP):H6SR="$=A)C^ZRZ?EGO>$V&X/56V/>VR
MD-^-B.%+K7Z@D]HP5%2\L^7T[HIX_P`L@\TLR3%25"W=U&(C"$RAO5/#4$K8
MV,A,S",$-JN?5UE?\T]VR,=41R:NW4D%J8=ZT<X6PR/W8BYRMP30P<V=*L?1
M,S3VM7US.,G*IJR;OD$$-8HNVNY2U`:B$O*:&<H.DZ(F9JL:U<+=GS%="G6Y
MX1;;W84]K3Y0H;<LE%T3'$X8])^6NDUS[TN0Y?5ERHEP;+98*O0O[(_1]L7:
M&<F=S$#D4[N:@ET+F?'E>D^B/F5-"ODDQG<[@D/NUM"UVV8-4EZ'4'QU169/
M8<A=:V>K=DK-T%$I7-5:KE$AN3$+'=KMY0=O>DJUC0.8U+H%J9]=60[@9`[I
M:=G[B<G4HH7*>H.K)E4+>K2GHC$]42J_9Z\Q=:C1*0A/2,$G/5*GEG*WX!`S
7.*30`$EZ`056:FYA#`8#`8#`8#`__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 17 - us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>17.&#160;&#160;&#160;&#160;Employee Benefit Plan </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company sponsors a 401(k) retirement savings plan (the &#8220;Plan&#8221;). Participation in the Plan is available to
   full-time employees who meet eligibility requirements. Eligible employees may defer a portion of their salary as defined by Internal Revenue Service regulations. The Company may make matching contributions on behalf of all participants in the 401(k)
   Plan in an amount determined by the Company&#8217;s board of directors. The Company may also make additional discretionary profit sharing contributions in amounts as determined by the board of directors, subject to statutory limitations. Matching and
   profit-sharing contributions, if any, are subject to a vesting schedule; all other contributions are at all times fully vested. The Company intends the 401(k) Plan, and the accompanying trust, to qualify under Sections&#160;401(k) and 501 of the
   Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that the Company will be able to deduct its
   contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, invests the assets of the 401(k) Plan in any of a number of investment options. To date, the Company has not made any matching contributions.
   </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 87<br><br> -Paragraph 264<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 158<br><br> -Paragraph 7, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS106-2<br><br> -Paragraph 20, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Implementation Guide (Q and A)<br><br> -Number FAS88<br><br> -Paragraph 63<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 30<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 03-2<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 8<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph q<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 106<br><br> -Paragraph 518<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Nature of Business<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations-->
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2">
   <b></b></font>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>1.&#160;&#160;&#160;&#160;Nature of Business </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Galena Biopharma Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;)
   is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. Galena is pursuing the development of novel cancer therapeutics using
   peptide-based immunotherapy products, including our main product candidate, NeuVax (E75), for the treatment of various cancers. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company was incorporated as Argonaut Pharmaceuticals, Inc., in Delaware, on April&#160;3, 2006. The Company changed its name to RXi
   Pharmaceuticals Corporation on November&#160;28, 2006. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We acquired Apthera and our NeuVax product candidate in April 2011.
   Prior to that time, we were engaged primarily in conducting discovery research and preclinical development activities based on RNAi. Our acquisition of Apthera followed from the determination by our board of directors to broaden our strategic
   direction by giving us access to a late-stage clinical candidate, NeuVax. In connection with our acquisition of Apthera, we reduced the scope of our RNAi activities to focus primarily on RXI-109, our lead RNAi-product, while maintaining our key
   development alliances and core RNAi discovery and development capability. Following the Apthera acquisition, our board of directors undertook to explore strategic alternatives for our RNAi platform that would enable us to commit more resources to
   our later-stage oncology drug programs. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On September&#160;26, 2011, the Company changed its name from RXi Pharmaceuticals
   Corporation to Galena Biopharma, Inc. in connection with the Company&#8217;s planned separation into two companies: (i)&#160;Galena, which will operate as a late-stage oncology drug development company; and (ii)&#160;RXi Pharmaceuticals Corporation,
   or RXi, which will continue to develop novel RNAi-based therapies utilizing our historical RNAi assets. RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in the
   Company&#8217;s name to Galena. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As the Company has not generated any revenue from inception through December&#160;31, 2011, the
   Company is considered a development-stage company for accounting purposes. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font style="font-family:times new roman" size="2">The Company had cash and cash
   equivalents of approximately $11.4 million as of December&#160;31, 2011. On February&#160;17, 2012, the Company entered into a Controlled Equity Offering</font><font style="font-family:times new roman" size="1"><sup>
   SM</sup></font><font style="font-family:times new roman" size="2"> sales agreement with Cantor Fitzgerald&#160;&#038; Co. (&#8220;Cantor&#8221;), pursuant to which the Company may offer
   and sell from time to time through Cantor, acting as agent, shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to $10 million. The offer and sale of our shares through Cantor will be registered pursuant
   to the Company&#8217;s Registration Statement on Form S-3 (File No.&#160;333-167025) declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May&#160;21, 2010. The offering pursuant to the sales agreement will terminate
   upon the sale of all shares subject to the sales agreement or the earlier termination of the sales agreement as permitted therein. There is no assurance that additional funding will be available to the Company on acceptable terms, or at all.
   </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company believes that its existing cash and cash equivalents should be sufficient to fund its operations through at least
   the first quarter of 2013. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has not generated revenue to date and may not generate product revenue in the
   foreseeable future, if ever. The Company expects to incur significant operating losses as it advances its product candidates through the drug development and regulatory process. The Company expects to continue to devote a substantial portion of its
   resources to research and development programs. As a result of the costs expected to be incurred in connection with our recently commenced clinical trials of NeuVax and FBP, the Company expects that their research and development expense will
   increase significantly from historic levels for the foreseeable future. The Company will need to generate significant revenue to achieve profitability and might never do so. In the absence of product revenue, our potential sources of operational
   funding are expected to be the proceeds from equity financings, funded research and development payments and payments received under partnership and collaborative agreements. There is no guarantee that additional funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, it
   would be forced to scale back or terminate operations or to seek to merge with or to be acquired by another company. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>30
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T
M,6(Q,&1B9F,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?17AP/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4W1O/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?4W1O,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O
M;&ED871E9%]3=&%T96UE;G1S7V]F7T-A<S$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#@N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y.871U<F5?;V9?0G5S:6YE<W,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"87-I<U]O9E]0<F5S
M96YT871I;VY?86YD7U-U;6T\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y296-E;G1?06-C;W5N=&EN9U]0<F]N;W5N8V5M96X\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!<'1H97)A7T%C
M<75I<VET:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4EAI7U-P:6Y/=70\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y&86ER7U9A;'5E7TUE87-U<F5M96YT<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-A<&ET86Q?3&5A<V5?3V)L:6=A
M=&EO;G,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!
M8V-R=65D7T5X<&5N<V5S7V%N9%]/=&AE<E]#=7(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN
M9V5N8VEE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-T;V-K:&]L9&5R<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y$979E;&]P;65N=%]3=&%G95]3=7!P;&5M96YT86P\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]"
M87-E9%]#;VUP96YS871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y.971?3&]S<U]097)?4VAA<F4\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C$N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,:6-E;G-E7T%G<F5E;65N
M=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y296QA
M=&5D7U!A<G1Y7U1R86YS86-T:6]N<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D5M<&QO>65E7T)E;F5F:71?4&QA;CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E
M;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E
M="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I
M=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T
M=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17
M:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O
M<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y
M/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R
M;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#-A-F4P,35?-C!A.%\T,&5C7SDP
M,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8R]7;W)K<VAE
M971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$564D%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#(V+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/D=A;&5N82!":6]P:&%R;6$L($EN8RX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT
M<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,#`P,3,Y,#0W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,3`M2SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y$96,@,S$L#0H)"3(P,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C(P,3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!0
M97)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D99
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!3
M96%S;VYE9"!)<W-U97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@5F]L=6YT87)Y($9I;&5R<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3
M=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#Y3;6%L;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4'5B;&EC
M($9L;V%T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q+#`P
M,"PP-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L-#DS+#,Y-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#-A-F4P
M,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q
M8C$P9&)F8R]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5134%'
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E
M(%-H965T<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD
M(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3$L-#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V+#@Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!C87-H/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$L.#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPP-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5Q=6EP;65N="!A;F0@9G5R;FES:&EN9W,L(&YE
M="!O9B!A8V-U;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO
M;B!O9B`D-C4W(&%N9"`D-#DQ(&EN(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I
M=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;BUP<F]C97-S(')E<V5A<F-H("9A;7`[(&1E=F5L;W!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPX-C0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';V]D=VEL;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX.3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!O<VET<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PY-C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#0W
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$U-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M<G5E9"!E>'!E;G-E(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$V.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3$S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV
M97)T:6)L92!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT(&UA='5R:71I97,@;V8@
M8V%P:71A;"!L96%S92!O8FQI9V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!W87)R86YT<R!P;W1E
M;G1I86QL>2!S971T;&5A8FQE(&EN(&-A<V@\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPQ,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@8V]N=&EN9V5N="!P
M=7)C:&%S92!P<FEC92!C;VYS:61E<F%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PR,#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`R
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%P:71A;"!L96%S92!O8FQI9V%T:6]N<RP@;F5T(&]F(&-U<G)E;G0@
M;6%T=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F97)R960@=&%X(&QI86)I;&ET>2P@;F]N+6-U<G)E;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#4S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N="!P
M=7)C:&%S92!P<FEC92!C;VYS:61E<F%T:6]N+"!N970@;V8@8W5R<F5N="!P
M;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#4V.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C`L.#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PP-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!C;VYT:6YG96YC
M:65S("A.;W1E(#DI/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S
M)R!E<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@)#`N,#`P,2!P87(@=F%L=64[(#4L
M,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9#L@;F\@<VAA<F5S(&ES<W5E9"!A
M;F0@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP
M,#`Q('!A<B!V86QU93L@,3(U+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960@
M86YD(#0W+#@Q,2PT-3,@<VAA<F5S(&ES<W5E9"!A;F0@-#<L,3,V+#0U,R!S
M:&%R97,@;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3$[(&%N9"`U
M,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&%N9"`Q.2PP-#<L-S4Y('-H
M87)E<R!I<W-U960@86YD(#$X+#,W,BPW-3D@;W5T<W1A;F1I;F<@870@1&5C
M96UB97(@,S$L(#(P,3`L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,2PQ.#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BPP,C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E9FEC:70@86-C=6UU;&%T960@9'5R:6YG('1H92!D979E;&]P;65N=&%L
M('-T86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-RPR,C@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-34L-S0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5S<R!T<F5A<W5R>2!S:&%R97,@870@8V]S="P@-C<U+#`P
M,"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L.#0Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,L.#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ,3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0S,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI
M86)I;&ET:65S(&%N9"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,"PY-C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<L-#<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T,V$V93`Q-5\V,&$X
M7S0P96-?.3`P-U\Y9&$T,6(Q,&1B9F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO-#-A-F4P,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C
M+U=O<FMS:&5E=',O4VAE970P,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P155#044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S
M("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC
M97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&]F(&5Q
M=6EP;65N="!A;F0@9G5R;FES:&EN9W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`T.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H
M87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W
M+#@Q,2PT-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.2PP-#<L-S4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O=71S
M=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L,3,V
M+#0U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$X+#,W,BPW-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<U+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W-2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0S839E,#$U7S8P
M83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8PT*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B
M9F,O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0D]!1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O
M9B!%>'!E;G-E<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H
M87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3`X($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY%>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L-S0R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V
M+#`T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,S<L-#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@96UP;&]Y
M964@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@V-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#@T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-S,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H
M(&%N9"!D979E;&]P;65N="!N;VXM96UP;&]Y964@<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L.3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!I
M<W-U960@:6X@97AC:&%N9V4@9F]R(&QI8V5N<VEN9R!R:6=H=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.34T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q+#4S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<L.#<S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L-C0U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A
M9&UI;FES=')A=&EV92!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#@V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L-#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C<L.3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&-O;6UO
M;B!S=&]C:R!W87)R86YT<R!I<W-U960@9F]R(&=E;F5R86P@86YD(&%D;6EN
M:7-T<F%T:79E(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!I
M<W-U960@:6X@97AC:&%N9V4@9F]R(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T
M:79E(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@96UP;&]Y964@<W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,C`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU-#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#4Y,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&=E;F5R
M86P@86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDL,C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^."PW-3(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PS,3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@
M;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`L-S@W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V
M+#8R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Y,"PY-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&EN8V]M92\H97AP96YS92DZ
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=&5R97-T(&EN8V]M92P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO<W,@;VX@=V%R<F%N="!E>&-H86YG93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DP,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&EN8V]M
M92P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ-S(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#8R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S+#DS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&]T:&5R(&EN8V]M92P@;F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#,P,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-C,R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-CDU/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S
M(&]N('=A<G)A;G0@97AC:&%N9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#DP,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Y,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!I;F-O;64L(&YE=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3<R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV,C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPY,S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S
M(&)E9F]R92!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3$L-#@U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#DY,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-RPR-CDI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3$L-#@U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3$L.3DS*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-S<L
M,C8Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY.970@;&]S<R!P97(@8V]M;6]N('-H87)E.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A
M;F0@9&EL=71E9"!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@P+C,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,"XV-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A
M9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9SH@8F%S:6,@86YD(&1I;'5T
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#,S-"PT,3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-RPX.#,L,S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B9F,-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#-A-F4P,35?-C!A.%\T,&5C
M7SDP,#=?.61A-#%B,3!D8F9C+U=O<FMS:&5E=',O4VAE970P-2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14PT2DT^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L:61A
M=&5D(%-T871E;65N=',@;V8@4W1O8VMH;VQD97)S)R!%<75I='D@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T86P\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4')E9&5C97-S;W(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4W5C8V5S<V]R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB<CY0<F5D96-E
M<W-O<CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@
M4W1O8VL\8G(^4W5C8V5S<V]R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D%D9&ET:6]N86P@4&%I9"U);B!#87!I=&%L/&)R/E!R961E8V5S
M<V]R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N
M86P@4&%I9"U);B!#87!I=&%L/&)R/E-U8V-E<W-O<CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$969I8VET($%C8W5M=6QA=&5D($1U<FEN
M9R!$979E;&]P;65N="!3=&%G93QB<CY3=6-C97-S;W(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^5')E87-U<GD@4W1O8VL\8G(^4W5C8V5S
M<V]R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E!A<F5N="!#
M;VUP86YY)W,@3F5T($1E9FEC:70\8G(^4')E9&5C97-S;W(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!B86QA;F-E
M(&%T($1E8RX@,S$L(#(P,#,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@X.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!B86QA;F-E+"!S:&%R
M97,@870@1&5C+B`S,2P@,C`P,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,L,C<R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,L,C<R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T('1R86YS86-T:6]N<R!W:71H(%!A<F5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS.3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,Y,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YD:6YG(&)A;&%N8V4@870@1&5C+B`S,2P@,C`P-#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.38X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.38X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG(&)A;&%N8V4L
M('-H87)E<R!A="!$96,N(#,Q+"`R,#`T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,BPR,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPR,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@=')A;G-A8W1I;VYS('=I=&@@
M4&%R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<R-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;F1I;F<@8F%L86YC92!A="!$96,N(#,Q+"`R,#`U/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-3`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-3`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L
M86YC92P@<VAA<F5S(&%T($1E8RX@,S$L(#(P,#4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R+#0P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R+#0P-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!T<F%N<V%C=&EO;G,@
M=VET:"!087)E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M-3@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPU.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E(&%T($1E8RX@,S$L(#(P,#8\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I
M;F<@8F%L86YC92P@<VAA<F5S(&%T($1E8RX@,S$L(#(P,#8\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!B86QA;F-E(&%T
M($%P<BX@,#,L(#(P,#8\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC92P@<VAA<F5S(&%T($%P<BX@,#,L
M(#(P,#8\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:RP@9F]R(&-A<V@@*&YE="!O9B!O9F9E<FEN
M9R!C;W-T<R!O9B`D-SDV+"`D-C,V+"`D.38U(&%N9"`D,2PX.3`@9F]R('1H
M92!P97)I;V0@96YD:6YG(#(P,#@@=&\@,C`Q,2!R97-P96-T:79E;'DI('-H
M87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,C0L,C<X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&9O<B!C87-H("AN970@;V8@
M;V9F97)I;F<@8V]S=',@;V8@)#<Y-BP@)#8S-BP@)#DV-2!A;F0@)#$L.#DP
M(&9O<B!T:&4@<&5R:6]D(&5N9&EN9R`R,#`X('1O(#(P,3$@<F5S<&5C=&EV
M96QY*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!B86QA;F-E(&%T($1E8RX@,S$L(#(P,#8\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E+"!S:&%R97,@
M870@1&5C+B`S,2P@,C`P-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-C(T+#(W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!T;R!#>712>"!F
M;W(@8V]N=')I8G5T:6]N(&]F(%)8:2!A;F0@;W1H97(@87-S971S+"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,#0P+#,Q.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K(&ES<W5E9"!T;R!#>712>"!F;W(@8V]N=')I8G5T:6]N
M(&]F(%)8:2!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!F
M;W(@8V%S:"`H;F5T(&]F(&]F9F5R:6YG(&-O<W1S(&]F("0W.38L("0V,S8L
M("0Y-C4@86YD("0Q+#@Y,"!F;W(@=&AE('!E<FEO9"!E;F1I;F<@,C`P."!T
M;R`R,#$Q(')E<W!E8W1I=F5L>2D@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#(W,RPR.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:RP@9F]R(&-A<V@@*&YE="!O9B!O9F9E<FEN9R!C;W-T<R!O9B`D-SDV
M+"`D-C,V+"`D.38U(&%N9"`D,2PX.3`@9F]R('1H92!P97)I;V0@96YD:6YG
M(#(P,#@@=&\@,C`Q,2!R97-P96-T:79E;'DI/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-2PS-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PS-#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U
M960@=&\@0WET4G@@9F]R(')E:6UB=7)S96UE;G0@;V8@97AP96YS97,L('-H
M87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@X+#,X-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K(&ES<W5E9"!T;R!#>712>"!F;W(@<F5I;6)U<G-E;65N
M="!O9B!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>'!E;G-E<R!I;F-U<G)E9"!B>2!#>712>"!F;W(@4EAI/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,S$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:R!I<W-U960@=&\@54U-4R!F;W(@861D:71I;VYA;"!I;G1E;&QE8W1U
M86P@<')O<&5R=&EE<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-C(L,3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D('1O(%5-35,@
M9F]R(&%D9&ET:6]N86P@:6YT96QL96-T=6%L('!R;W!E<G1I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S$Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS,3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:R!I<W-U960@=&\@9&ER96-T;W)S+"!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E
M9"!T;R!D:7)E8W1O<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!U<&]N(&5X97)C:7-E(&]F
M('-T;V-K(&]P=&EO;G,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C8L,#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D('5P;VX@97AE
M<F-I<V4@;V8@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B87-E9"!C;VUP96YS871I;VX@97AP
M96YS92!F;W(@9&ER96-T;W)S(&%N9"!E;7!L;WEE97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O
M;7!E;G-A=&EO;B!E>'!E;G-E(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S8V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L.3DP*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#DY,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!B
M86QA;F-E(&%T($1E8RX@,S$L(#(P,#<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#@R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,2PX,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PY.3`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG(&)A;&%N
M8V4L('-H87)E<R!A="!$96,N(#,Q+"`R,#`W/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,BPV.#0L-#,R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VLL(&9O<B!C87-H("AN970@;V8@;V9F97)I;F<@8V]S=',@;V8@)#<Y
M-BP@)#8S-BP@)#DV-2!A;F0@)#$L.#DP(&9O<B!T:&4@<&5R:6]D(&5N9&EN
M9R`R,#`X('1O(#(P,3$@<F5S<&5C=&EV96QY*2!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#<S+#(Y.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M;6]N('-T;V-K+"!F;W(@8V%S:"`H;F5T(&]F(&]F9F5R:6YG(&-O<W1S
M(&]F("0W.38L("0V,S8L("0Y-C4@86YD("0Q+#@Y,"!F;W(@=&AE('!E<FEO
M9"!E;F1I;F<@,C`P."!T;R`R,#$Q(')E<W!E8W1I=F5L>2D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.3$X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPY,3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!I<W-U960@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS+"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VL@:7-S=65D('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R(&1I<F5C=&]R<R!A;F0@
M96UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(Q
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,C$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:R!B87-E9"!C;VUP96YS871I;VX@97AP96YS92!F;W(@
M<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C$S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PV,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E9A;'5E(&]F(&-O;6UO;B!S=&]C:R!W87)R86YT<R!I<W-U960@
M*&5X<&5N<V4I(&EN(&5X8VAA;F=E(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L,S<S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T+#,W,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!B86QA;F-E(&%T($1E8RX@,S$L(#(P,#@\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@L.38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,T+#,S,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U+#,V,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L
M86YC92P@<VAA<F5S(&%T($1E8RX@,S$L(#(P,#@\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S+#<V,RPR,S$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:RP@9F]R(&-A<V@@*&YE="!O9B!O9F9E<FEN9R!C;W-T<R!O9B`D
M-SDV+"`D-C,V+"`D.38U(&%N9"`D,2PX.3`@9F]R('1H92!P97)I;V0@96YD
M:6YG(#(P,#@@=&\@,C`Q,2!R97-P96-T:79E;'DI('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS.#4L-S$U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!C;VUM;VX@<W1O8VLL(&9O<B!C87-H("AN970@;V8@;V9F97)I;F<@8V]S
M=',@;V8@)#<Y-BP@)#8S-BP@)#DV-2!A;F0@)#$L.#DP(&9O<B!T:&4@<&5R
M:6]D(&5N9&EN9R`R,#`X('1O(#(P,3$@<F5S<&5C=&EV96QY*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW,30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW,3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:R!W87)R86YT<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H('1H92`R
M,#`Y+"`R,#$P(&%N9"`R,#$Q(&]F9F5R:6YG<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPX-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,BPX-C,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S
M=65D('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@<VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!I<W-U960@87,@8V]M;6ET;65N="!F964@:6X@8V]N;F5C=&EO;B!W:71H
M(%-%1$$L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3@L,SDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&%S(&-O;6UI=&UE;G0@9F5E
M(&EN(&-O;FYE8W1I;VX@=VET:"!3141!/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E(&9O<B!D:7)E8W1O<G,@86YD(&5M<&QO>65E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY,#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DP-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R('-E<G9I8V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,CDV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y686QU92!O9B!C;VUM
M;VX@<W1O8VL@=V%R<F%N=',@:7-S=65D("AE>'!E;G-E*2!I;B!E>&-H86YG
M92!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$X+#,X-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q."PS.#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L86YC92!A="!$96,N(#,Q
M+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L
M-#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-#,L-S4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E+"!S:&%R97,@870@1&5C+B`S
M,2P@,C`P.3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,C`W
M+#8R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!F;W(@8V%S:"`H;F5T
M(&]F(&]F9F5R:6YG(&-O<W1S(&]F("0W.38L("0V,S8L("0Y-C4@86YD("0Q
M+#@Y,"!F;W(@=&AE('!E<FEO9"!E;F1I;F<@,C`P."!T;R`R,#$Q(')E<W!E
M8W1I=F5L>2D@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:RP@9F]R(&-A
M<V@@*&YE="!O9B!O9F9E<FEN9R!C;W-T<R!O9B`D-SDV+"`D-C,V+"`D.38U
M(&%N9"`D,2PX.3`@9F]R('1H92!P97)I;V0@96YD:6YG(#(P,#@@=&\@,C`Q
M,2!R97-P96-T:79E;'DI/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-2PR,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-2PR,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F(#8W-2PP,#`@<VAA<F5S(&]F
M('1R96%S=7)Y('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#@T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@S+#@T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!W87)R86YT<R!I<W-U960@
M:6X@8V]N;F5C=&EO;B!W:71H('1H92`R,#`Y+"`R,#$P(&%N9"`R,#$Q(&]F
M9F5R:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPT-C8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,BPT-C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER('9A;'5E(&]F('-H87)E<R!M86YD871O<FEL>2!R961E
M96UA8FQE(&9O<B!C87-H('5P;VX@97AE<F-I<V4@;V8@=V%R<F%N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<X-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W.#4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VL@:7-S=65D('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@
M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPU,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:R!I<W-U960@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O
M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(')E<W1R:6-T960@<W1O8VL@=6YI=',L('-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8L-C,T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC
M92!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E(&9O<B!D:7)E8W1O<G,@86YD(&5M<&QO>65E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV,C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8R-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S
M960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R('-E<G9I8V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5E(&]F(&-O;6UO
M;B!S=&]C:R!W87)R86YT<R!I<W-U960@*&5X<&5N<V4I(&EN(&5X8VAA;F=E
M(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3$L.3DS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$Q+#DY,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,2PY.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L86YC92!A="!$
M96,N(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#0S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L-#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8R+#`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#4U+#<T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#@T.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E
M+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3DL,#0W+#<U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K+"!F;W(@8V%S:"`H;F5T(&]F(&]F9F5R:6YG(&-O<W1S(&]F("0W.38L
M("0V,S8L("0Y-C4@86YD("0Q+#@Y,"!F;W(@=&AE('!E<FEO9"!E;F1I;F<@
M,C`P."!T;R`R,#$Q(')E<W!E8W1I=F5L>2D@<VAA<F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ."PV-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VLL(&9O<B!C87-H("AN970@;V8@;V9F97)I;F<@8V]S=',@
M;V8@)#<Y-BP@)#8S-BP@)#DV-2!A;F0@)#$L.#DP(&9O<B!T:&4@<&5R:6]D
M(&5N9&EN9R`R,#`X('1O(#(P,3$@<F5S<&5C=&EV96QY*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L-C$U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#8Q,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K('=A<G)A;G1S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE(#(P
M,#DL(#(P,3`@86YD(#(P,3$@;V9F97)I;F=S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,BPW,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-S`Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@<W1O
M8VL@:6X@;&EE=2!O9B!C87-H(&)O;G5S+"!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$T-RPP-#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F('-T;V-K
M(&EN(&QI974@;V8@8V%S:"!B;VYU<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!R97-T<FEC=&5D('-T;V-K
M('5N:71S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(R,"PW,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F(')E<W1R:6-T960@<W1O8VL@=6YI=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!S97)V:6-E<RP@<VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPU-3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:R!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U
M<&]N(&5X97)C:7-E(&]F('=A<G)A;G0L('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N
M('-T;V-K('5P;VX@97AE<F-I<V4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N
M('-T;V-K(&EN(&-A<VAL97-S(&5X8VAA;F=E(&]F(&]U='-T86YD:6YG('=A
M<G)A;G1S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,34Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&EN(&-A<VAL
M97-S(&5X8VAA;F=E(&]F(&]U='-T86YD:6YG('=A<G)A;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$R,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3(P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!C;VUM;VX@<W1O8VL@<F5L871E9"!T;R!A8W%U:7-I=&EO;B!O9B!!<'1H
M97)A($EN8RXL('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-"PY-S0L,#DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@<F5L871E
M9"!T;R!A8W%U:7-I=&EO;B!O9B!!<'1H97)A($EN8RX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L,S8W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,S8V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL@<W5B:F5C="!T;R!E;7!L;WEE92!T97)M:6YA=&EO;B!A
M9W)E96UE;G1S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,Y."PT-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!S=6)J96-T
M('1O(&5M<&QO>65E('1E<FUI;F%T:6]N(&%G<F5E;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M
M;6]N('-T;V-K('-U8FIE8W0@=&\@16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@
M4&QA;BP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M."PX,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!S=6)J96-T('1O($5M
M<&QO>65E(%-T;V-K(%!U<F-H87-E(%!L86X\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E(&9O<B!D:7)E8W1O<G,@86YD(&5M<&QO>65E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW-S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<W-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R('-E<G9I8V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64@;V8@8V]M;6]N
M('-T;V-K('=A<G)A;G1S(&ES<W5E9"`H97AP96YS92D@:6X@97AC:&%N9V4@
M9F]R('-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,2PT.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3$L-#@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$Q+#0X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E(&%T($1E
M8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`L,3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,"PQ,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#@Q+#$X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-C<L,C(X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RPX-#DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;F1I;F<@8F%L86YC92P@<VAA<F5S(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W+#@Q,2PT-3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0S839E,#$U7S8P83A?
M-#!E8U\Y,#`W7SED830Q8C$P9&)F8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B9F,O
M5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,E1!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!3
M=&]C:VAO;&1E<G,G($5Q=6ET>2`H4&%R96YT:&5T:6-A;"D@*%-U8V-E<W-O
M<BP@55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#@\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5A;F-E(&-O<W0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PX.3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DV-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`W.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K+"!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8W-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U86YC92!C
M;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@Y,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M061D:71I;VYA;"!086ED+4EN($-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=6%N8V4@8V]S=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#@Y,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.38U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V,S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<Y-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5')E87-U<GD@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5')E87-U<GD@<W1O8VLL('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-#-A-F4P,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B
M,3!D8F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0S839E,#$U
M7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8R]7;W)K<VAE971S+U-H965T
M,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$591T))/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A<V@@1FQO=W,@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3`X($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@;W!E<F%T:6YG(&%C
M=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#$Q+#0X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$Q+#DY,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#<W+#(V.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T
M;65N="!T;R!R96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@=7-E9"!I
M;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ
M871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;W-S(&]N(&1I<W!O<V%L(&]F(&5Q=6EP;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!R96YT
M(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-R971I;VX@86YD(')E8V5I<'0@;V8@8F]N9"!D:7-C;W5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H('-H87)E(&)A
M<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#,V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X+#@U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!E>&-H86YG92!O9B!E<75I
M='D@:6YS=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!O9B!S:&%R97,@;6%N9&%T;W)I;'D@<F5D
M965M86)L92!F;W(@8V%S:"!U<&]N(&5X97)C:7-E(&]F('=A<G)A;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W.#4I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S@U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V
M86QU92!O9B!C;VUM;VX@<W1O8VL@=V%R<F%N=',@:7-S=65D(&EN(&5X8VAA
M;F=E(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPT,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@8V]M;6]N('-T;V-K(&ES
M<W5E9"!I;B!E>&-H86YG92!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O
M9B!C;VUM;VX@<W1O8VL@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#DL.#@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,L,#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#`W,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@
M8V]M;6]N('-T;V-K(&ES<W5E9"!I;B!E>&-H86YG92!F;W(@;&EC96YS:6YG
M(')I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY-30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-H86YG92!I;B!F86ER('9A;'5E(&]F(&-O;G1I;F=E;G0@8V]N<VED97)A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B
M:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-#DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT
M<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$=64@=&\@9F]R;65R('!A<F5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N
M<V5S(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C4X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@
M=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,30L-C8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#(U-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U."PW-S@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-A<V@@9FQO=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN
M(')E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3`Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$P,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<V@@<F5C96EV960@:6X@86-Q=6ES:71I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@
M;V8@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-2PY.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S<L-3,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%T=7)I=&EE<R!O9B!S:&]R
M="UT97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU+#DY,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,W+#0Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!P86ED(&9O<B!P=7)C:&%S92!O9B!E
M<75I<&UE;G0@86YD(&9U<FYI<VAI;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-S,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&ES<&]S86P@;V8@97%U:7!M96YT
M(&%N9"!F=7)N:7-H:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@<F5F=6YD960@*'!A:60I(&9O<B!L96%S92!D97!O<VET
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S
M:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<U,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M<')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#8Q-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#(S-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T+#DX,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!P86ED(&9O<B!R97!U<F-H87-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPX-#DI/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPX-#DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M<')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!C;VUM;VX@<W1O8VL@;W!T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M<')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!C;VUM;VX@<W1O8VL@=V%R<F%N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@15-04#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('!R;V-E961S
M(&9R;VT@:7-S=6%N8V4@;V8@8V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!A>6UE
M;G1S(&]F(&-A<&ET86P@;&5A<V4@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@861V86YC97,@
M9G)O;2!F;W)M97(@<&%R96YT(&-O;7!A;GDL(&YE=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^."PW-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B
M>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3DL,3DV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3$L-3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L.38T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8W)E87-E(&EN
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L-30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PR,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PT,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',@870@=&AE(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#DQ/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV.#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD
M(&-A<V@@97%U:79A;&5N=',@870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-#,S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPX.3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PT,S,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W5P<&QE;65N=&%L(&1I<V-L;W-U<F4@;V8@8V%S:"!F;&]W(&EN9F]R
M;6%T:6]N.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H(')E8V5I=F5D(&1U<FEN9R!T:&4@<&5R:6]D<R!F;W(@:6YT
M97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@<&%I9"!D=7)I;F<@=&AE('!E<FEO9',@9F]R(&EN=&5R97-T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE
M;65N=&%L(&1I<V-L;W-U<F4@;V8@;F]N+6-A<V@@:6YV97-T:6YG(&%N9"!F
M:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V5T=&QE;65N="!O9B!C;W)P;W)A=&4@9F]R
M;6%T:6]N(&5X<&5N<V5S(&EN(&5X8VAA;F=E(&9O<B!C;VUM;VX@<W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU
M92!O9B!W87)R86YT<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(&-O;6UO
M;B!S=&]C:R!R96-O<F1E9"!A<R!C;W-T(&]F(&5Q=6ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-S`Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT-C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PP,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:R!I;B!E>&-H86YG92!O9B!O=71S=&%N9&EN
M9R!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#$R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!O9B!S:&%R97,@;6%N9&%T;W)I;'D@<F5D
M965M86)L92!F;W(@8V%S:"!U<&]N(&5X97)C:7-E(&]F('=A<G)A;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%L;&]C871I
M;VX@;V8@;6%N86=E;65N="!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%<75I<&UE;G0@86YD(&9U<FYI<VAI;F=S(&5X
M8VAA;F=E9"!F;W(@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17%U:7!M96YT(&%N9"!F=7)N:7-H:6YG<R!A8W%U
M:7)E9"!T:')O=6=H(&-A<&ET86P@;&5A<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H(&QE87-E(&1E<&]S:70\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y686QU92!O9B!R
M97-T<FEC=&5D('-T;V-K('5N:71S(&%N9"!C;VUM;VX@<W1O8VL@:7-S=65D
M(&EN(&QI974@;V8@8V%S:"!B;VYU<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07!T:&5R82!!8W%U:7-I
M=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!V86QU92!O9B!S:&%R97,@:7-S=65D('1O(&%C<75I<F4@07!T
M:&5R83PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPS-C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#,V
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!V86QU92!O9B!C;VYT:6YG96YT('!U<F-H87-E('!R:6-E(&-O
M;G-I9&5R871I;VX@:6X@8V]N;F5C=&EO;B!W:71H($%P=&AE<F$@86-Q=6ES
M:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-#8P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPT
M-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!A<W-E=',@86-Q=6ER960@97AC;'5D:6YG(&-A<V@@;V8@)#$V
M.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPX,C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R
M+#@R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-#-A-F4P,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W
M7SED830Q8C$P9&)F8R]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5713X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A
M=&5M96YT<R!O9B!#87-H($9L;W=S("A087)E;G1H971I8V%L*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!E>&-L=61I;F<@9G)O;2!N970@87-S971S(&%C<75I<F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#-A-F4P,35?-C!A.%\T,&5C
M7SDP,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8R]7;W)K
M<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY.871U<F4@;V8@0G5S:6YE<W,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F%T=7)E(&]F($)U
M<VEN97-S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F%T=7)E(&]F($)U<VEN97-S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@
M,2`M('5S+6=A87`Z3F%T=7)E3V9/<&5R871I;VYS+2T^#0H@("`\(2TM('AB
M<FPL;G,@+2T^#0H@("`\(2TM('AB<FPL;G@@+2T^#0H@("`\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB
M/CPO8CX\+V9O;G0^#0H@("`\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CPO8CX\+V9O;G0^#0H@("`\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/@T*("`@/&(^/"]B/CPO9F]N=#X-"B`@(#QP('-T>6QE/3-$;6%R
M9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^,2XF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M.871U<F4@;V8@0G5S:6YE<W,@/"]B
M/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM
M87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1V%L
M96YA($)I;W!H87)M82!);F,N("@F(S@R,C`[=V4L)B,X,C(Q.R`F(S@R,C`[
M=7,L)B,X,C(Q.R`F(S@R,C`[;W5R+"8C.#(R,3L@)B,X,C(P.T=A;&5N828C
M.#(R,3L@;W(@=&AE("8C.#(R,#M#;VUP86YY)B,X,C(Q.RD-"B`@(&ES(&$@
M8FEO=&5C:&YO;&]G>2!C;VUP86YY(&9O8W5S960@;VX@9&ES8V]V97)I;F<L
M(&1E=F5L;W!I;F<@86YD(&-O;6UE<F-I86QI>FEN9R!I;FYO=F%T:79E('1H
M97)A<&EE<R!A9&1R97-S:6YG(&UA:F]R('5N;65T(&UE9&EC86P@;F5E9',@
M=7-I;F<@=&%R9V5T960@8FEO=&AE<F%P975T:6-S+B!'86QE;F$@:7,@<'5R
M<W5I;F<@=&AE(&1E=F5L;W!M96YT(&]F(&YO=F5L(&-A;F-E<B!T:&5R87!E
M=71I8W,@=7-I;F<-"B`@('!E<'1I9&4M8F%S960@:6UM=6YO=&AE<F%P>2!P
M<F]D=6-T<RP@:6YC;'5D:6YG(&]U<B!M86EN('!R;V1U8W0@8V%N9&ED871E
M+"!.975687@@*$4W-2DL(&9O<B!T:&4@=')E871M96YT(&]F('9A<FEO=7,@
M8V%N8V5R<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY4:&4@0V]M<&%N>2!W87,@:6YC;W)P;W)A=&5D(&%S($%R9V]N875T
M(%!H87)M86-E=71I8V%L<RP@26YC+BP@:6X@1&5L87=A<F4L(&]N($%P<FEL
M)B,Q-C`[,RP@,C`P-BX@5&AE($-O;7!A;GD@8VAA;F=E9"!I=',@;F%M92!T
M;R!26&D-"B`@(%!H87)M86-E=71I8V%L<R!#;W)P;W)A=&EO;B!O;B!.;W9E
M;6)E<B8C,38P.S(X+"`R,#`V+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD
M96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/E=E(&%C<75I<F5D($%P=&AE<F$@86YD(&]U<B!.
M975687@@<')O9'5C="!C86YD:61A=&4@:6X@07!R:6P@,C`Q,2X-"B`@(%!R
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M:70@;6]R92!R97-O=7)C97,@=&\-"B`@(&]U<B!L871E<BUS=&%G92!O;F-O
M;&]G>2!D<G5G('!R;V=R86US+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD
M96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/D]N(%-E<'1E;6)E<B8C,38P.S(V+"`R,#$Q+"!T
M:&4@0V]M<&%N>2!C:&%N9V5D(&ET<R!N86UE(&9R;VT@4EAI(%!H87)M86-E
M=71I8V%L<PT*("`@0V]R<&]R871I;VX@=&\@1V%L96YA($)I;W!H87)M82P@
M26YC+B!I;B!C;VYN96-T:6]N('=I=&@@=&AE($-O;7!A;GDF(S@R,3<[<R!P
M;&%N;F5D('-E<&%R871I;VX@:6YT;R!T=V\@8V]M<&%N:65S.B`H:2DF(S$V
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M;F=E(&EN('1H90T*("`@0V]M<&%N>28C.#(Q-SMS(&YA;64@=&\@1V%L96YA
M+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[
M;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D%S
M('1H92!#;VUP86YY(&AA<R!N;W0@9V5N97)A=&5D(&%N>2!R979E;G5E(&9R
M;VT@:6YC97!T:6]N('1H<F]U9V@@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@
M=&AE#0H@("!#;VUP86YY(&ES(&-O;G-I9&5R960@82!D979E;&]P;65N="US
M=&%G92!C;VUP86YY(&9O<B!A8V-O=6YT:6YG('!U<G!O<V5S+B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O
M='1O;3HP<'@[('1E>'0M:6YD96YT.C0E.W!A9&1I;F<M8F]T=&]M.C!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^5&AE($-O;7!A;GD@:&%D(&-A<V@@86YD(&-A<V@-"B`@(&5Q
M=6EV86QE;G1S(&]F(&%P<')O>&EM871E;'D@)#$Q+C0@;6EL;&EO;B!A<R!O
M9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+B!/;B!&96)R=6%R>28C,38P.S$W
M+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!#;VYT<F]L;&5D
M($5Q=6ET>2!/9F9E<FEN9SPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQS=7`^#0H@("!333PO
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M=&]C:RP@)#`N,#`P,2!P87(@=F%L=64@<&5R('-H87)E+"!H879I;F<@86X@
M86=G<F5G871E(&]F9F5R:6YG('!R:6-E(&]F('5P('1O("0Q,"!M:6QL:6]N
M+B!4:&4@;V9F97(@86YD('-A;&4@;V8@;W5R('-H87)E<R!T:')O=6=H($-A
M;G1O<B!W:6QL(&)E(')E9VES=&5R960@<'5R<W5A;G0-"B`@('1O('1H92!#
M;VUP86YY)B,X,C$W.W,@4F5G:7-T<F%T:6]N(%-T871E;65N="!O;B!&;W)M
M(%,M,R`H1FEL92!.;RXF(S$V,#LS,S,M,38W,#(U*2!D96-L87)E9"!E9F9E
M8W1I=F4@8GD@=&AE(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O;6UI<W-I
M;VX@*'1H92`F(S@R,C`[4T5#)B,X,C(Q.RD@;VX@36%Y)B,Q-C`[,C$L(#(P
M,3`N(%1H92!O9F9E<FEN9R!P=7)S=6%N="!T;R!T:&4@<V%L97,@86=R965M
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M0V]M<&%N>2!O;B!A8V-E<'1A8FQE('1E<FUS+"!O<B!A="!A;&PN#0H@("`\
M+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R
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M<75A<G1E<B!O9B`R,#$S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
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M92!T;R!D979O=&4@82!S=6)S=&%N=&EA;"!P;W)T:6]N(&]F(&ET<PT*("`@
M<F5S;W5R8V5S('1O(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!P<F]G<F%M
M<RX@07,@82!R97-U;'0@;V8@=&AE(&-O<W1S(&5X<&5C=&5D('1O(&)E(&EN
M8W5R<F5D(&EN(&-O;FYE8W1I;VX@=VET:"!O=7(@<F5C96YT;'D@8V]M;65N
M8V5D(&-L:6YI8V%L('1R:6%L<R!O9B!.975687@@86YD($9"4"P@=&AE($-O
M;7!A;GD@97AP96-T<R!T:&%T('1H96ER(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!E>'!E;G-E('=I;&P-"B`@(&EN8W)E87-E('-I9VYI9FEC86YT;'D@
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M<&%R=&YE<G-H:7`@86YD(&-O;&QA8F]R871I=F4@86=R965M96YT<RX@5&AE
M<F4@:7,@;F\@9W5A<F%N=&5E('1H870@861D:71I;VYA;"!F=6YD:6YG('=I
M;&P@8F4@879A:6QA8FQE('1O('1H92!#;VUP86YY(&]N(&%C8V5P=&%B;&4@
M=&5R;7,L(&]R(&%T(&%L;"X@268@=&AE($-O;7!A;GD@9F%I;',@=&\@;V)T
M86EN(&%D9&ET:6]N86P@9G5N9&EN9R!W:&5N(&YE961E9"P@:70-"B`@('=O
M=6QD(&)E(&9O<F-E9"!T;R!S8V%L92!B86-K(&]R('1E<FUI;F%T92!O<&5R
M871I;VYS(&]R('1O('-E96L@=&\@;65R9V4@=VET:"!O<B!T;R!B92!A8W%U
M:7)E9"!B>2!A;F]T:&5R(&-O;7!A;GDN(#PO9F]N=#X\+W`^#0H\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0S839E,#$U7S8P
M83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8PT*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B
M9F,O5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0F%S:7,@;V8@4')E<V5N=&%T:6]N(&%N9"!3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0F%S:7,@;V8@4')E<V5N=&%T:6]N(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S
M96YT871I;VX@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M
M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4
M<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ
M+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E
M9VEN($)L;V-K(%1A9V=E9"!.;W1E(#(@+2!U<RUG86%P.D)A<VES3V90<F5S
M96YT871I;VY!;F13:6=N:69I8V%N=$%C8V]U;G1I;F=0;VQI8VEE<U1E>'1"
M;&]C:RTM/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C$R<'@[;6%R9VEN
M+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXR+B8C,38P.R8C,38P.R8C,38P.R8C
M,38P.T)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(#PO8CX\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP
M<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/E5S97,@;V8@97-T:6UA
M=&5S(&EN('!R97!A<F%T:6]N(&]F(&9I;F%N8VEA;"!S=&%T96UE;G1S(#PO
M:3XF(S@R,3([(%1H92!P<F5P87)A=&EO;B!O9B!F:6YA;F-I86P@<W1A=&5M
M96YT<R!I;@T*("`@86-C;W)D86YC92!W:71H(&%C8V]U;G1I;F<@<')I;F-I
M<&QE<R!G96YE<F%L;'D@86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@
M;V8@06UE<FEC82!W:&EC:"!R97%U:7)E<R!M86YA9V5M96YT('1O(&UA:V4@
M97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<R!T:&%T(&%F9F5C="!T:&4@<F5P
M;W)T960@86UO=6YT<R!O9B!A<W-E=',@86YD(&QI86)I;&ET:65S(&%N9"!D
M:7-C;&]S=7)E(&]F(&-O;G1I;F=E;G0@87-S971S(&%N9`T*("`@;&EA8FEL
M:71I97,@870@=&AE(&1A=&4@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&%N9"!T:&4@<F5P;W)T960@86UO=6YT<R!O9B!R979E;G5E<R!A;F0@97AP
M96YS97,@9'5R:6YG('1H92!R97!O<G1I;F<@<&5R:6]D+B!!8W1U86P@<F5S
M=6QT<R!C;W5L9"!D:69F97(@;6%T97)I86QL>2!F<F]M('1H;W-E(&5S=&EM
M871E<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
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M=VYE9`T*("`@<W5B<VED:6%R:65S+B!!;&P@;6%T97)I86P@:6YT97)C;VUP
M86YY(&%C8V]U;G1S(&AA=F4@8F5E;B!E;&EM:6YA=&5D(&EN(&-O;G-O;&ED
M871I;VXN/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
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M)B,Q-C`[9&%Y<R!O<B!L97-S('1O(&)E(&-A<V@@97%U:79A;&5N=',N($-A
M<V@@97%U:79A;&5N=',@8V]N<VES="!P<FEM87)I;'D@;V8@86UO=6YT<R!I
M;G9E<W1E9"!I;B!M;VYE>2!M87)K970@86-C;W5N=',N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M
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M/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB
M;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y&86ER(%9A
M;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<R`\+VD^)B,X,C$R.R!4:&4@
M8V%R<GEI;F<@86UO=6YT<R!R97!O<G1E9`T*("`@:6X@=&AE(&)A;&%N8V4@
M<VAE970@9F]R(&-A<V@@97%U:79A;&5N=',L(&%C8V]U;G1S('!A>6%B;&4L
M(&-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4@86YD(&-A<&ET86P@;&5A<V5S
M(&%P<')O>&EM871E('1H96ER(&9A:7(@=F%L=65S(&1U92!T;R!T:&5I<B!S
M:&]R="UT97)M(&YA='5R92!A;F0@;6%R:V5T(')A=&5S(&]F(&EN=&5R97-T
M+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[
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M9`T*("`@;VX@=&AE(&5S=&EM871E9"!U<V5F=6P@;&EV97,@*&=E;F5R86QL
M>2!T:')E92!T;R!F:79E('EE87)S(&9O<B!E<75I<&UE;G0@86YD(&9U<FYI
M='5R92D@;V8@=&AE(')E;&%T960@87-S971S+B`\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[
M('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/D=O;V1W:6QL#0H@("!A;F0@
M26YT86YG:6)L92!!<W-E=',@/"]I/B8C.#(Q,CL@1V]O9'=I;&P@:&%S(&%N
M(&EN9&5F:6YI=&4@=7-E9G5L(&QI9F4@86YD(&ES(&YO="!A;6]R=&EZ960@
M8G5T(&ES(&5V86QU871E9"!F;W(@:6UP86ER;65N="!A;FYU86QL>2!O<B!W
M:&5N979E<B!E=F5N=',@;W(@8VAA;F=E<R!I;B!C:7)C=6US=&%N8V5S(&EN
M9&EC871E('1H870@=&AE(&-A<G)Y:6YG('9A;'5E(&UA>2!N;W0@8F4@<F5C
M;W9E<F%B;&4N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^5&AE($EN+5!R;V-E<W,@4F5S96%R8V@F(S$V,#LF(S`S.#L@1&5V
M96QO<&UE;G0@*"8C.#(R,#M)4%(F(S`S.#M$)B,X,C(Q.RD@87-S970@:7,@
M8V]N<VED97)E9"!A;B!I;F1E9FEN:71E+6QI=F5D(&EN=&%N9VEB;&4@87-S
M970@86YD(&ES(&YO=`T*("`@<W5B:F5C="!T;R!A;6]R=&EZ871I;VXN($E0
M4B8C,#,X.T0@;75S="!B92!T97-T960@9F]R(&EM<&%I<FUE;G0@86YN=6%L
M;'D@;W(@;6]R92!F<F5Q=65N=&QY(&EF(&5V96YT<R!O<B!C:&%N9V5S(&EN
M(&-I<F-U;7-T86YC97,@:6YD:6-A=&4@=&AA="!T:&4@87-S970@;6EG:'0@
M8F4@:6UP86ER960N(%1H92!I;7!A:7)M96YT('1E<W0@8V]N<VES=',@;V8@
M82!C;VUP87)I<V]N(&]F('1H92!F86ER('9A;'5E(&]F('1H90T*("`@25!2
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M8V%R<GEI;F<@86UO=6YT(&]F('1H90T*("`@25!2)B,P,S@[1"!W:6QL(&)E
M(&ET<R!N97<@86-C;W5N=&EN9R!B87-I<RX@4W5B<V5Q=65N="!R979E<G-A
M;"!O9B!A('!R979I;W5S;'D@<F5C;V=N:7IE9"!I;7!A:7)M96YT(&QO<W,@
M:7,@<')O:&EB:71E9"X@5&AE(&EN:71I86P@9&5T97)M:6YA=&EO;B!A;F0@
M<W5B<V5Q=65N="!E=F%L=6%T:6]N(&9O<B!I;7!A:7)M96YT+"!O9B!T:&4@
M25!2)B,P,S@[1"!A<W-E="!R97%U:7)E<R!M86YA9V5M96YT('1O(&UA:V4-
M"B`@('-I9VYI9FEC86YT(&IU9&=M96YT<R!A;F0@97-T:6UA=&5S+B!4:&4@
M0V]M<&%N>2!B96QI979E<R!N;R!I;7!A:7)M96YT(&]F(&ET<R!)4%(F(S`S
M.#M$(&5X:7-T<R!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2X@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4-"B`@($-O;7!A
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M=&AE<F5O9BX@1V]O9'=I;&P-"B`@(&ES('1E<W1E9"!F;W(@:6UP86ER;65N
M="!A;FYU86QL>2!U=&EL:7II;F<@=&AE("8C.#(R,#MF86ER('9A;'5E)B,X
M,C(Q.R!M971H;V1O;&]G>2X@5&AE(&%N;G5A;"!M96%S=7)E;65N="!D871E
M(&ES($1E8V5M8F5R)B,Q-C`[,S$N($9A8W1O<G,@=&AE($-O;7!A;GD@8V]N
M<VED97)S(&EM<&]R=&%N="!T:&%T(&-O=6QD('1R:6=G97(@86X@:6YT97)I
M;2!R979I97<@9F]R(&EM<&%I<FUE;G0@:6YC;'5D92P@8G5T(&%R92!N;W0-
M"B`@(&QI;6ET960@=&\L('1H92!F;VQL;W=I;F<Z(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R
M9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@
M8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I
M9'1H/3-$,3`P)3X@#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-"4^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('=I9'1H
M/3-$,24@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(R
M-CL\+V9O;G0^/"]T9#X@#0H@("`\=&0@=VED=&@],T0Q)2!V86QI9VX],T1T
M;W`^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^#0H@("`\<"!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CYS:6=N:69I8V%N="!C:&%N9V5S(&EN('1H92!M86YN97(@
M;V8@:71S('5S92!O9B!A8W%U:7)E9"!A<W-E=',@;W(@=&AE('-T<F%T96=Y
M(&9O<B!I=',@;W9E<F%L;"!B=7-I;F5S<SL@/"]F;VYT/CPO<#X-"B`@(#PO
M=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$9F]N
M="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF
M(S$V,#L\+W`^#0H@("`\=&%B;&4@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E
M.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!B;W)D97(],T0P(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E/B`-"B`@
M(#QT<CX@#0H@("`\=&0@=VED=&@],T0T)3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=VED=&@],T0Q)2!V86QI9VX],T1T
M;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C(V.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1'1O<#X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1'1O<#X-"B`@(#QP(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/G-I9VYI
M9FEC86YT(&YE9V%T:79E(&EN9'5S=')Y(&]R(&5C;VYO;6EC('1R96YD<SL@
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X-
M"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM
M87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@<W1Y;&4]
M,T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T
M)R!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M=VED=&@],T0Q,#`E/B`-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0T)3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=VED
M=&@],T0Q)2!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X
M,C(V.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS
M1'1O<#X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<#X-"B`@(#QP(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/G-I9VYI9FEC86YT(&1E8VQI;F4@:6X@<W1O8VL@<')I
M8V4@9F]R(&$@<W5S=&%I;F5D('!E<FEO9#L@86YD(#PO9F]N=#X\+W`^#0H@
M("`\+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL93TS
M1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP
M<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@8F]R9&5R/3-$,"!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X@
M#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-"4^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('=I9'1H/3-$,24@=F%L:6=N
M/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(R-CL\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=VED=&@],T0Q)2!V86QI9VX],T1T;W`^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1T;W`^#0H@("`\<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CYS
M:6=N:69I8V%N="!D96-L:6YE(&EN(&UA<FME="!C87!I=&%L:7IA=&EO;B!R
M96QA=&EV92!T;R!N970@8F]O:R!V86QU92X@/"]F;VYT/CPO<#X-"B`@(#PO
M=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X@#0H@("`\<"!S='EL93TS1&9O
M;G0M<VEZ93HQ<'@[;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^
M)B,Q-C`[/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'@[;6%R
M9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D=O;V1W
M:6QL(&ES#0H@("!E=F%L=6%T960@9F]R(&EM<&%I<FUE;G0@=7-I;F<@82!T
M=V\M<W1E<"!P<F]C97-S+B!4:&4@9FER<W0@<W1E<"!I<R!T;R!C;VUP87)E
M('1H92!F86ER('9A;'5E('1O('1H92!C87)R>6EN9R!A;6]U;G0@*'1H92`F
M(S@R,C`[1FER<W0@4W1E<"8C.#(R,3LI+B!)9B!T:&4@8V%R<GEI;F<@86UO
M=6YT(&5X8V5E9',@=&AE(&9A:7(@=F%L=64L(&$@<V5C;VYD('-T97`@;75S
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M=&AE($-O;7!A;GD@9&5T97)M:6YE<PT*("`@9F%I<B!V86QU92!U<VEN9R!T
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M"B`@(')E<&]R=&EN9R!U;FET(&]V97(@82!M=6QT:2UY96%R('!E<FEO9"P@
M87,@=V5L;"!A<R!D971E<FUI;F4@=&AE('=E:6=H=&5D(&%V97)A9V4@8V]S
M="!O9B!C87!I=&%L('1O(&)E('5S960@87,@82!D:7-C;W5N="!R871E+B!4
M:&4@,C`Q,2!A;F%L>7-I<R!C;VYF:7)M960@=&AA="!F86ER('9A;'5E<R!E
M>&-E961E9"!C87)R>6EN9R!V86QU97,@86YD+"!T:&5R969O<F4L(&YO(&EM
M<&%I<FUE;G0@97AI<W1E9"X\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/CQI/D-O;G1I;F=E;G0@0V]N<VED97)A=&EO;B`\+VD^
M)B,X,C$R.R!#;VYT:6YG96YT(&-O;G-I9&5R871I;VX@:7,@<F5C;W)D960@
M870@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&%S(&]F('1H92!A8W%U:7-I
M=&EO;B!D871E+B!4:&4-"B`@(&9A:7(@=F%L=64@;V8@=&AE(&-O;G1I;F=E
M;G0@8V]N<VED97)A=&EO;B!I<R!R96UE87-U<F5D(&%T(&5A8V@@<F5P;W)T
M:6YG('!E<FEO9"!W:71H(&%N>2!A9&IU<W1M96YT<R!I;B!F86ER('9A;'5E
M(&EN8VQU9&5D(&EN(&]U<B!C;VYS;VQI9&%T960@<W1A=&5M96YT(&]F(&5X
M<&5N<V5S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/@T*("`@/&D^4&%T96YT<R!A;F0@4&%T96YT($%P<&QI8V%T:6]N($-O
M<W1S(#PO:3XF(S@R,3([($%L=&AO=6=H('1H92!#;VUP86YY(&)E;&EE=F5S
M('1H870@:71S('!A=&5N=',@86YD('5N9&5R;'EI;F<@=&5C:&YO;&]G>2!H
M879E(&-O;G1I;G5I;F<@=F%L=64L('1H92!A;6]U;G0@;V8@9G5T=7)E(&)E
M;F5F:71S('1O(&)E(&1E<FEV960@9G)O;2!T:&4-"B`@('!A=&5N=',@:7,@
M=6YC97)T86EN+B!0871E;G0@8V]S=',@87)E+"!T:&5R969O<F4L(&5X<&5N
M<V5D(&%S(&EN8W5R<F5D+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/CQI/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B`\+VD^
M)B,X,C$R.R!4:&4@0V]M<&%N>0T*("`@9F]L;&]W<R!T:&4@<')O=FES:6]N
M<R!O9B!T:&4@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D
M("@F(S@R,C`[1D%30B8C.#(R,3LI($%C8V]U;G1I;F<@4W1A;F1A<F1S($-O
M9&EF:6-A=&EO;B`H)B,X,C(P.T%30R8C.#(R,3LI(%1O<&EC(#<Q."P@)B,X
M,C(P.SQI/D-O;7!E;G-A=&EO;B8C,38P.R8C.#(Q,CL@4W1O8VL@0V]M<&5N
M<V%T:6]N)B,X,C(Q.R`\+VD^*"8C.#(R,#M!4T,@-S$X)B,X,C(Q.RDL('=H
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M;G-E(&)A<V5D(&]N('1H92!G<F%N="!D871E(&9A:7(@=F%L=64-"B`@(&5S
M=&EM871E9"!I;B!A8V-O<F1A;F-E('=I=&@@=&AE('!R;W9I<VEO;G,@;V8@
M05-#)B,Q-C`[-S$X(&ES(')E8V]G;FEZ960@87,@86X@97AP96YS92!O=F5R
M('1H92!R97%U:7-I=&4@<V5R=FEC92!P97)I;V0N(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P
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M(')E<75I<F5M96YT<R!O9B!&05-"($%30R!4;W!I8R`U,#4M-3`@*"8C.#(R
M,#M!4T,@-3`U+34P)B,X,C(Q.RDL("8C.#(R,#L@/&D^17%U:71Y($)A<V5D
M(%!A>6UE;G1S('1O($YO;BT-"B`@($5M<&QO>65E<SPO:3X@+B8C.#(R,3L@
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M;V8-"B`@('1H97-E(&]P=&EO;G,L(&%S(&-A;&-U;&%T960@=7-I;F<@=&AE
M($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96PL('=I;&P@8F4@
M<F4M;65A<W5R960@=7-I;F<@=&AE(&9A:7(@=F%L=64@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@86YD('1H92!N;VXM8V%S:"!C;VUP
M96YS871I;VX@<F5C;V=N:7IE9"!D=7)I;F<@=&AE('!E<FEO9"!W:6QL(&)E
M(&%D:G5S=&5D(&%C8V]R9&EN9VQY+B!3:6YC92!T:&4-"B`@(&9A:7(@;6%R
M:V5T('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!N;VXM96UP;&]Y965S
M(&ES('-U8FIE8W0@=&\@8VAA;F=E(&EN('1H92!F=71U<F4L('1H92!A;6]U
M;G0@;V8@=&AE(&9U='5R92!C;VUP96YS871I;VX@97AP96YS92!W:6QL(&EN
M8VQU9&4@9F%I<B!V86QU92!R92UM96%S=7)E;65N=',@=6YT:6P@=&AE('-T
M;V-K(&]P=&EO;G,@87)E(&9U;&QY('9E<W1E9"X@/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!R96-O9VYI
M>F5D("@D-S`L,#`P*2!A;F0@)#<T,RPP,#`@;V8@<W1O8VL@8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!N;VXM96UP;&]Y964@<W1O
M8VL@;W!T:6]N<R!F;W(@=&AE('EE87)S#0H@("!E;F1E9"!$96-E;6)E<B8C
M,38P.S,Q+"`R,#$Q(&%N9"`R,#$P+"!R97-P96-T:79E;'DN(#PO9F]N=#X\
M+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T
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M("!S<&5C=6QA=&EV92!P=7)P;W-E<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!R96-O9VYI>F5S(&%L
M;"!D97)I=F%T:79E<R!A<R!A<W-E=',@;W(@;&EA8FEL:71I97,@;65A<W5R
M960@870@9F%I<B!V86QU92!W:71H(&-H86YG97,@:6X-"B`@(&9A:7(@=F%L
M=64@;V8@9&5R:79A=&EV97,@<F5F;&5C=&5D(&%S(&-U<G)E;G0@<&5R:6]D
M(&EN8V]M92!O<B!L;W-S('5N;&5S<R!T:&4@9&5R:79A=&EV97,@<75A;&EF
M>2!F;W(@:&5D9V4@86-C;W5N=&EN9R!A;F0@87)E(&%C8V]U;G1E9"!F;W(@
M87,@<W5C:"X@26X@86-C;W)D86YC92!W:71H($9!4T(@05-#(%1O<&EC(#@Q
M-2TT,"P@)B,X,C(P.SQI/D1E<FEV871I=F5S(&%N9"!(961G:6YG)B,Q-C`[
M)B,X,C$R.R!#;VYT<F%C=',-"B`@(&EN($5N=&ET>28C.#(Q-SMS($]W;B!3
M=&]C:RPF(S@R,C$[(#PO:3YT:&4@=F%L=64@;V8@=&AE<V4@=V%R<F%N=',@
M:7,@<F5Q=6ER960@=&\@8F4@<F5C;W)D960@87,@82!L:6%B:6QI='DL(&%S
M('1H92!H;VQD97)S(&AA=F4@86X@;W!T:6]N('1O('!U="!T:&4@=V%R<F%N
M=',@8F%C:R!T;R!T:&4@0V]M<&%N>2!U<&]N('1H92!O8V-U<G)E;F-E(&]F
M(&-E<G1A:6X@979E;G1S('-E="!F;W)T:"!I;B!T:&4@=V%R<F%N=`T*("`@
M86=R965M96YT+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CQI/D]B;&EG871I;VYS('1O(%)E<'5R8VAA<V4@4VAA<F5S(&]F
M('1H92!#;VUP86YY)B,X,C$W.W,@17%U:71Y(%-E8W5R:71I97,@/"]I/B8C
M.#(Q,CL@26X@86-C;W)D86YC92!W:71H($9!4T(@05-##0H@("!4;W!I8R`T
M.#`M,3`L(#QI/B8C.#(R,#M$:7-T:6YG=6ES:&EN9R!,:6%B:6QI=&EE<R!F
M<F]M($5Q=6ET>2PF(S@R,C$[/"]I/B!T:&4@0V]M<&%N>2!R96-O9VYI>F5S
M(&%L;"!O8FQI9V%T:6]N<R!T;R!R97!U<F-H87-E('-H87)E<R!O9B!I=',@
M97%U:71Y('-E8W5R:71I97,@=&AA="!R97%U:7)E(&]R(&UA>2!R97%U:7)E
M('1H92!#;VUP86YY('1O('-E='1L92!T:&4@;V)L:6=A=&EO;B!B>2!T<F%N
M<V9E<G)I;F<@87-S971S+"!A<PT*("`@;&EA8FEL:71I97,@;W(@87-S971S
M(&EN('-O;64@8VER8W5M<W1A;F-E<R!M96%S=7)E9"!A="!F86ER('9A;'5E
M('=I=&@@8VAA;F=E<R!I;B!F86ER('9A;'5E(')E9FQE8W1E9"!A<R!C=7)R
M96YT('!E<FEO9"!I;F-O;64@;W(@;&]S<R!A;F0@87)E(&%C8V]U;G1E9"!F
M;W(@87,@<W5C:"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US
M:7IE.C%P>#MM87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V
M,#L\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&D^4F5S96%R
M8V@@86YD#0H@("!$979E;&]P;65N="!%>'!E;G-E<R`\+VD^)B,X,C$R.R!2
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E(&5X<&5N<V5D(&%S
M(&EN8W5R<F5D+B!);F-L=61E9"!I;B!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@8V]S=',@87)E('=A9V5S+"!B96YE9FET<R!A;F0@;W1H97(@;W!E<F%T
M:6YG(&-O<W1S+"!C;&EN:6-A;"!T<FEA;"!R96QA=&5D(&5X<&5N<V5S+"!F
M86-I;&ET:65S+"!S=7!P;&EE<RP@97AT97)N86P-"B`@('-E<G9I8V5S(&%N
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M;6%Y(&AA=F4@8F5E;B!A8VAI979E9"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@(#QI/DEN8V]M92!487AE<R`\+VD^
M)B,X,C$R.R!4:&4@0V]M<&%N>2!R96-O9VYI>F5S(&QI86)I;&ET:65S(&]R
M(&%S<V5T<R!F;W(@=&AE(&1E9F5R<F5D('1A>"!C;VYS97%U96YC97,@;V8@
M=&5M<&]R87)Y(&1I9F9E<F5N8V5S(&)E='=E96X@=&AE('1A>"!B87-I<R!O
M9B!A<W-E=',@;W(@;&EA8FEL:71I97,@86YD('1H96ER(')E<&]R=&5D(&%M
M;W5N=',-"B`@(&EN('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!I;B!A8V-O
M<F1A;F-E('=I=&@@1D%30B!!4T,F(S$V,#LW-#`M,3`L("8C.#(R,#L\:3Y!
M8V-O=6YT:6YG(&9O<B!);F-O;64@5&%X97,F(S@R,C$[("@F(S@R,C`[05-#
M(#<T,"TQ,"8C.#(R,3LI+CPO:3X@5&AE<V4@=&5M<&]R87)Y(&1I9F9E<F5N
M8V5S('=I;&P@<F5S=6QT(&EN('1A>&%B;&4@;W(@9&5D=6-T:6)L92!A;6]U
M;G1S(&EN(&9U='5R92!Y96%R<R!W:&5N('1H92!R97!O<G1E9`T*("`@86UO
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M<W-E="!W:6QL(&YO="!B90T*("`@<F5A;&EZ960N(%1H92!#;VUP86YY(&5V
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M9W,@8GD-"B`@('1A>&EN9R!A=71H;W)I=&EE<RX@1&EF9F5R96YC97,@8F5T
M=V5E;B!A8W1U86P@<F5S=6QT<R!A;F0@=&AE($-O;7!A;GDF(S@R,3<[<R!A
M<W-U;7!T:6]N<R!O<B!C:&%N9V5S(&EN('1H92!#;VUP86YY)B,X,C$W.W,@
M87-S=6UP=&EO;G,@:6X@9G5T=7)E('!E<FEO9',@87)E(')E8V]R9&5D(&EN
M('1H92!P97)I;V0@=&AE>2!B96-O;64@:VYO=VX@/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y#;VYC96YT<F%T:6]N<R!O
M9B!#<F5D:70@4FES:R`\+VD^)B,X,C$R.R!&:6YA;F-I86P@:6YS=')U;65N
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M<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&-A<V@-"B`@(&5Q=6EV86QE;G1S('=E<F4@:6YV97-T960@:6X@;6]N
M97D@;6%R:V5T(&UU='5A;"!F=6YD<RX@5&AE($-O;7!A;GDF(S@R,3<[<R!I
M;G9E<W1M96YT('!O;&EC>2!D:7-A;&QO=W,@:6YV97-T;65N="!I;B!A;GD@
M9&5B="!S96-U<FET:65S(')A=&5D(&QE<W,@=&AA;B`F(S@R,C`[:6YV97-T
M;65N="!G<F%D928C.#(R,3L@8GD@;F%T:6]N86P@<F%T:6YG<R!S97)V:6-E
M<RX@5&AE($-O;7!A;GD@:&%S(&YO="!E>'!E<FEE;F-E9"!A;GD-"B`@(&QO
M<W-E<R!O;B!I=',@9&5P;W-I=',@;V8@8V%S:"!A;F0@8V%S:"!E<75I=F%L
M96YT<RX@06QL(&]F('1H92!N;VXM:6YT97)E<W0@8F5A<FEN9R!C87-H(&)A
M;&%N8V5S('=E<F4@9G5L;'D@:6YS=7)E9"!A="!$96-E;6)E<B8C,38P.S,Q
M+"`R,#$Q(&1U92!T;R!T96UP;W)A<GD@9F5D97)A;"!P<F]G<F%M(&EN(&5F
M9F5C="!F<F]M($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3`@=&AR;W5G:"!$96-E
M;6)E<B8C,38P.S,Q+"`R,#$R+@T*("`@56YD97(@=&AE('!R;V=R86TL('1H
M97)E(&ES(&YO(&QI;6ET('1O('1H92!A;6]U;G0@;V8@:6YS=7)A;F-E(&9O
M<B!E;&EG:6)L92!A8V-O=6YT<RX@0F5G:6YN:6YG(&EN(#(P,3,L(&EN<W5R
M86YC92!C;W9E<F%G92!W:6QL(')E=F5R="!T;R`D,C4P+#`P,"!P97(@9&5P
M;W-I=&]R(&%T(&5A8V@@9FEN86YC:6%L(&EN<W1I='5T:6]N+"!A;F0@=&AE
M(&YO;BUI;G1E<F5S="!B96%R:6YG(&-A<V@@8F%L86YC97,@;6%Y(&%G86EN
M#0H@("!E>&-E960@9F5D97)A;&QY(&EN<W5R960@;&EM:71S+B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O
M='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/D-O;7!R96AE
M;G-I=F4@3&]S<R`\+VD^)B,X,C$R.R!4:&4@0V]M<&%N>28C.#(Q-SMS(&-O
M;7!R96AE;G-I=F4@;&]S<R!I<R!E<75A;"!T;R!I=',@;F5T#0H@("!L;W-S
M(&9O<B!A;&P@<&5R:6]D<R!P<F5S96YT960N(#PO9F]N=#X\+W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@
M=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&D^4&%R96YT($-O;7!A;GDF(S@R
M,3<[<R!.970@1&5F:6-I="`\+VD^)B,X,C$R.R!4:&4@4&%R96YT($-O;7!A
M;GDF(S@R,3<[<R!.970@1&5F:6-I="!O9B!T:&4-"B`@(%!R961E8V5S<V]R
M(&-O;G-I<W1S(&]F($-Y=%)X)B,X,C$W.W,@:6YI=&EA;"!I;G9E<W1M96YT
M(&EN(%)8:2!A;F0@<W5B<V5Q=65N="!C:&%N9V5S(&EN(%)8:28C.#(Q-SMS
M(&YE="!I;G9E<W1M96YT(')E<W5L=&EN9R!F<F]M(%)8:2!B96EN9R!A;B!I
M;G1E9W)A=&5D('!A<G0@;V8@0WET4G@N($%L;"!D:7-B=7)S96UE;G1S(&9O
M<B!T:&4@4')E9&5C97-S;W(@=V5R92!M861E(&)Y($-Y=%)X+B`\+V9O;G0^
M/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B9F,-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#-A-F4P,35?-C!A.%\T,&5C7SDP
M,#=?.61A-#%B,3!D8F9C+U=O<FMS:&5E=',O4VAE970Q,2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E8V5N="!!8V-O=6YT
M:6YG(%!R;VYO=6YC96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO
M=6YC96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-4
M65!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I
M=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O
M>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!"
M;&]C:R!486=G960@3F]T92`S("T@=7,M9V%A<#I!8V-O=6YT:6YG0VAA;F=E
M<T%N9$5R<F]R0V]R<F5C=&EO;G-497AT0FQO8VLM+3X-"B`@(#QP('-T>6QE
M/3-$;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M/&(^,RXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M296-E;G0@06-C;W5N=&EN
M9R!0<F]N;W5N8V5M96YT<R`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\
M:3Y296-E;G1L>2!!9&]P=&5D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',@
M/"]I/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M#0H@("!);B!$96-E;6)E<B`R,#$P+"!T:&4@1D%30B!I<W-U960@05-#(%5P
M9&%T92`R,#$P+3(Y+"!"=7-I;F5S<R!#;VUB:6YA=&EO;G,@*%1O<&EC(#@P
M-2D@)B,X,C$R.SQI/B!$:7-C;&]S=7)E(&]F(%-U<'!L96UE;G1A<GD@4')O
M($9O<FUA($EN9F]R;6%T:6]N(&9O<B!"=7-I;F5S<R!#;VUB:6YA=&EO;G,\
M+VD^("A5<&1A=&4@3F\N)B,Q-C`[,C`Q,"TR.2DN#0H@("!4:&ES(%5P9&%T
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M('!R:6]R(&%N;G5A;"!R97!O<G1I;F<-"B`@('!E<FEO9"X@5&AI<R!5<&1A
M=&4@869F96-T<R!A;GD@<'5B;&EC(&5N=&ET>2!T:&%T(&5N=&5R<R!I;G1O
M(&)U<VEN97-S(&-O;6)I;F%T:6]N<R!T:&%T(&%R92!M871E<FEA;"!O;B!A
M;B!I;F1I=FED=6%L(&]R(&%G9W)E9V%T92!B87-I<R!A;F0@:7,@969F96-T
M:79E('!R;W-P96-T:79E;'D@9F]R(&)U<VEN97-S(&-O;6)I;F%T:6]N<R!F
M;W(@=VAI8V@@=&AE(&%C<75I<VET:6]N(&1A=&4@:7,@;VX@;W(@869T97(@
M=&AE(&)E9VEN;FEN9R!O9B!T:&4@9FER<W0-"B`@(&%N;G5A;"!R97!O<G1I
M;F<@<&5R:6]D(&)E9VEN;FEN9R!O;B!O<B!A9G1E<B!$96-E;6)E<B8C,38P
M.S$U+"`R,#$P+B!!;&P@9&ES8VQO<W5R97,@87)E('!R97-E;G1E9"!I;B!A
M8V-O<F1A;F-E('=I=&@@=&AE(&%C<75I<VET:6]N(&]F($%P=&AE<F$L($EN
M8RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X
M.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("`\:3Y296-E;G1L>2!)
M<W-U960@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<R`\+VD^/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!-87DF(S$V,#LR
M,#$Q+"!T:&4@1D%30@T*("`@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S
M(%5P9&%T960@*"8C.#(R,#M!4U4F(S@R,C$[*2`R,#$Q+3`T/&D^+"!&86ER
M(%9A;'5E($UE87-U<F5M96YT/"]I/B`H5&]P:6,@.#(P*3H@/&D^06UE;F1M
M96YT<R!T;R!!8VAI979E($-O;6UO;B!&86ER(%9A;'5E($UE87-U<F5M96YT
M(&%N9"!$:7-C;&]S=7)E(%)E<75I<F5M96YT<R!I;B!5+E,N/"]I/B`\:3Y'
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M('5N;V)S97)V86)L92`H3&5V96P@,RD@:6YP=71S+B!4:&ES(&YE=R!S=&%N
M9&%R9"!I<R!E9F9E8W1I=F4@;VX-"B`@(&$@<')O<W!E8W1I=F4@8F%S:7,@
M9F]R(&%N;G5A;"!A;F0@:6YT97)I;2!R97!O<G1I;F<@<&5R:6]D<R!B96=I
M;FYI;F<@;VX@;W(@869T97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q,2X@5&AE
M($-O;7!A;GD@9&]E<R!N;W0@97AP96-T('1H870@861O<'1I;VX@;V8@=&AI
M<R!N97<@<W1A;F1A<F0@=VEL;"!H879E(&$@;6%T97)I86P@:6UP86-T(&]N
M(&ET<R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N#0H@("`\
M+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R
M9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DEN($IU
M;F4F(S$V,#LR,#$Q+"!T:&4@1D%30B!I<W-U960@05-5(#(P,3$M,#4L(#QI
M/D-O;7!R96AE;G-I=F4@26YC;VUE/"]I/B`H5&]P:6,@,C(P*3H@/&D^4')E
M<V5N=&%T:6]N(&]F($-O;7!R96AE;G-I=F4-"B`@($EN8V]M93PO:3XL(&$@
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M96YT(&]F(&YE=`T*("`@:6YC;VUE(&%N9"!O=&AE<B!C;VUP<F5H96YS:79E
M(&EN8V]M92!A;F0@<F5Q=6ER97,@86X@96YT:71Y('1O('!R97-E;G0@<F5C
M;&%S<VEF:6-A=&EO;B!A9&IU<W1M96YT<R!O;B!T:&4@9F%C92!O9B!T:&4@
M9FEN86YC:6%L('-T871E;65N=',@9G)O;2!O=&AE<B!C;VUP<F5H96YS:79E
M(&EN8V]M92!T;R!N970@:6YC;VUE+B!4:&4@86UE;F1M96YT<R!I;B!T:&ES
M(&YE=R!S=&%N9&%R9"!D;R!N;W0@8VAA;F=E('1H92!I=&5M<PT*("`@=&AA
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M<F0@:7,@<F5Q=6ER960@=&\@8F4-"B`@(&%P<&QI960@<F5T<F]S<&5C=&EV
M96QY(&%N9"!I<R!E9F9E8W1I=F4@9F]R(&9I<V-A;"!Y96%R<R!A;F0@:6YT
M97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!Y96%R<R!B96=I;FYI;F<@869T
M97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q,2X@07,@=&AI<R!N97<@<W1A;F1A
M<F0@;VYL>2!R97%U:7)E<R!E;FAA;F-E9"!D:7-C;&]S=7)E+"!T:&4@861O
M<'1I;VX@;V8@=&AI<R!S=&%N9&%R9"!W:6QL(&YO="!I;7!A8W0@=&AE#0H@
M("!#;VUP86YY)B,X,C$W.W,@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/DEN(%-E<'1E;6)E<B8C,38P.S(P,3$L('1H92!&05-"(&ES<W5E9"!!
M4U4@,C`Q,2TP."P@/&D^26YT86YG:6)L97,@)B,X,C$R.PT*("`@1V]O9'=I
M;&P@86YD($]T:&5R/"]I/B`H5&]P:6,@,S4P*3H@/&D^5&5S=&EN9R!';V]D
M=VEL;"!F;W(@26UP86ER;65N=#PO:3XL(&$@;F5W(&%C8V]U;G1I;F<@<W1A
M;F1A<F0@=&\@<VEM<&QI9GD@:&]W(&5N=&ET:65S('1E<W0@9V]O9'=I;&P@
M9F]R(&EM<&%I<FUE;G0N(%1H92!A;65N9&UE;G1S(&EN('1H92!5<&1A=&4@
M<&5R;6ET(&%N(&5N=&ET>2!T;R!F:7)S="!A<W-E<W,@<75A;&ET871I=F4@
M9F%C=&]R<R!T;PT*("`@9&5T97)M:6YE('=H971H97(@:70@:7,@;6]R92!L
M:6ME;'D@=&AA;B!N;W0@=&AA="!T:&4@9F%I<B!V86QU92!O9B!A(')E<&]R
M=&EN9R!U;FET(&ES(&QE<W,@=&AA;B!I=',@8V%R<GEI;F<@86UO=6YT(&%S
M(&$@8F%S:7,@9F]R(&1E=&5R;6EN:6YG('=H971H97(@:70@:7,@;F5C97-S
M87)Y('1O('!E<F9O<FT@=&AE('1W;RUS=&5P(&=O;V1W:6QL(&EM<&%I<FUE
M;G0@=&5S="!D97-C<FEB960@:6X@5&]P:6,@,S4P+B!4:&4-"B`@(&UO<F4M
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M=64@;V8@82!R97!O<G1I;F<-"B`@('5N:70@=VET:"!I=',@8V%R<GEI;F<@
M86UO=6YT+"!I;F-L=61I;F<@9V]O9'=I;&P@*'-T97`@;VYE*2X@268@=&AE
M(&9A:7(@=F%L=64@;V8@82!R97!O<G1I;F<@=6YI="!I<R!L97-S('1H86X@
M:71S(&-A<G)Y:6YG(&%M;W5N="P@=&AE;B!T:&4@<V5C;VYD('-T97`@;V8@
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M(&YE=R!S=&%N9&%R9"!I<R!E9F9E8W1I=F4-"B`@(&9O<B!F:7-C86P@>65A
M<G,@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R)B,Q-C`[,34L(#(P,3$[(&AO
M=V5V97(L(&5A<FQY(&%D;W!T:6]N(&ES('!E<FUI='1E9"X@5&AE($-O;7!A
M;GD@861O<'1E9"!T:&ES('-T86YD87)D(&9O<B!T:&4@9FES8V%L('EE87(@
M96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2X@5&AE(&%D;W!T:6]N(&]F
M('1H:7,@<W1A;F1A<F0@:&%D(&YO(&UA=&5R:6%L(&EM<&%C="!O;B!T:&4-
M"B`@($-O;7!A;GDF(S@R,3<[<R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T
M871E;65N=',N(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S0S839E,#$U7S8P83A?-#!E8U\Y,#`W7SED
M830Q8C$P9&)F8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T,V$V
M93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B9F,O5V]R:W-H965T<R]3
M:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^07!T:&5R82!!8W%U:7-I=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<'1H97)A($%C<75I<VET:6]N
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^07!T:&5R82!!8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S
M0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W
M=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T
M9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#0@+2!U
M<RUG86%P.D)U<VEN97-S0V]M8FEN871I;VY$:7-C;&]S=7)E5&5X=$)L;V-K
M+2T^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T
M=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/CQB/C0N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M07!T:&5R82!!8W%U:7-I=&EO;B`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY/;B!!<')I;"8C,38P.S$S+"`R,#$Q+"!T
M:&4@0V]M<&%N>2!C;VUP;&5T960@:71S(&%C<75I<VET:6]N(&]F($%P=&AE
M<F$L($EN8RXL(&$@1&5L87=A<F4@8V]R<&]R871I;VX-"B`@("@F(S@R,C`[
M07!T:&5R828C.#(R,3LI+"!U;F1E<B!A;B!!9W)E96UE;G0@86YD(%!L86X@
M;V8@365R9V5R("@F(S@R,C`[365R9V5R($%G<F5E;65N="8C.#(R,3LI(&5N
M=&5R960@:6YT;R!O;B!-87)C:"8C,38P.S,Q+"`R,#$Q+B!3=6)J96-T('1O
M('1H92!T97)M<R!A;F0@8V]N9&ET:6]N<R!O9B!T:&4@365R9V5R($%G<F5E
M;65N="P@=&AE($-O;7!A;GDF(S@R,3<[<R!W:&]L;'D@;W=N960@<W5B<VED
M:6%R>2!F;W)M960@9F]R('1H:7,-"B`@('!U<G!O<V4@=V%S(&UE<F=E9"!W
M:71H(&%N9"!I;G1O($%P=&AE<F$L('=I=&@@07!T:&5R82!S=7)V:79I;F<@
M87,@82!W:&]L;'DM;W=N960@<W5B<VED:6%R>2!O9B!T:&4@0V]M<&%N>2X@
M56YD97(@=&AE($UE<F=E<B!!9W)E96UE;G0L('1H92!#;VUP86YY(&ES<W5E
M9"!T;R!!<'1H97)A)B,X,C$W.W,@<W1O8VMH;VQD97)S(&%P<')O>&EM871E
M;'D@-2XP)B,Q-C`[;6EL;&EO;B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]F
M('1H90T*("`@0V]M<&%N>2`H=&AE("8C.#(R,#M!9V=R96=A=&4@4W1O8VL@
M0V]N<VED97)A=&EO;B8C.#(R,3LI(&%N9"!A9W)E960@=&\@;6%K92!F=71U
M<F4@8V]N=&EN9V5N="!P87EM96YT<R!O9B!U<"!T;R`D,S(F(S$V,#MM:6QL
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M=&@@4G5L92`U-C,U*&$I(&]F('1H92!.05-$05$@36%R:V5T<&QA8V4@4G5L
M97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M26X@8V]N;F5C=&EO;@T*("`@=VET:"!T:&4@365R9V5R($%G<F5E;65N="P@
M=&AE($-O;7!A;GD@9&5P;W-I=&5D('=I=&@@82!T:&ER9"UP87)T>2!E<V-R
M;W<@86=E;G0@8V5R=&EF:6-A=&5S(')E<')E<V5N=&EN9R`Q,"4@;V8@=&AE
M($%G9W)E9V%T92!3=&]C:R!#;VYS:61E<F%T:6]N+"!W:&EC:"!S:&%R97,@
M=VEL;"!B92!A=F%I;&%B;&4@=&\@8V]M<&5N<V%T92!T:&4@0V]M<&%N>2!A
M;F0@<F5L871E9"!P87)T:65S(&9O<B!C97)T86EN#0H@("!I;F1E;6YI9FEA
M8FQE(&QO<W-E<R!A<R!D97-C<FEB960@:6X@=&AE(&UE<F=E<B!A9W)E96UE
M;G0N($]N($]C=&]B97(F(S$V,#LQ,RP@,C`Q,2P@=&AE(&5S8W)O=R!A9V5N
M="!R96QE87-E9"!F<F]M('1H92!E<V-R;W<@-24@;V8@=&AE($%G9W)E9V%T
M92!3=&]C:R!#;VYS:61E<F%T:6]N+"!O<B`R-#@L-S`U('-H87)E<RX@5&AE
M(')E;6%I;FEN9R!!9V=R96=A=&4@4W1O8VL@0V]N<VED97)A=&EO;B!H96QD
M('=I=&@@=&AE#0H@("!E<V-R;W<@86=E;G0@:7,@97AP96-T960@=&\@8F4@
M<F5L96%S960@:6X@07!R:6P@,C`Q,BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>28C.#(Q-SMS(&%C<75I
M<VET:6]N(&]F($%P=&AE<F$@=V%S(&EN(&-O;F-E<G0@=VET:"!T:&4-"B`@
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M<V5S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV
M<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E1H92!P=7)C:&%S92!P<FEC92!C;VYS:61E<F%T:6]N(&%N9"!A;&QO8V%T
M:6]N(&]F('!U<F-H87-E('!R:6-E(&]F($%P=&AE<F$@=V5R92!A<R!F;VQL
M;W=S.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z-G!X
M.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-
M"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.3(E(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E
M.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-
M"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\
M=&0@=VED=&@],T0X.24^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED
M(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#$^/&(^*&EN(#`P,"8C.#(Q-SMS*3PO8CX\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CY#86QC=6QA=&EO;B!O9B!A
M;&QO8V%B;&4@<'5R8VAA<V4@<')I8V4Z/"]B/CPO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/D9A:7(@=F%L=64@;V8@<VAA<F5S(&ES<W5E9"!A="!C
M;&]S:6YG(&EN8VQU9&EN9R!E<V-R;W=E9"!S:&%R97,@97AP96-T960@=&\@
M8F4@<F5L96%S960\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-BPS-C<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BAI*28C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%<W1I
M;6%T960@=F%L=64@;V8@96%R;BUO=70\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV+#0V,#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M5&]T86P@86QL;V-A8FQE('!U<F-H87-E('!R:6-E/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$R+#@R-SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL
M93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CY!;&QO8V%T:6]N(&]F('!U<F-H
M87-E('!R:6-E.CPO8CX\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#
M87-H/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$V
M.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E!R97!A:60@97AP96YS97,@
M86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,30\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%<75I<&UE;G0@
M86YD(&9U<FYI<VAI;F=S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,3$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY'
M;V]D=VEL;#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C4L.#DX/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^26XM<')O8V5S<R!R97-E87)C:"!A;F0@
M9&5V96QO<&UE;G0\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXQ,BPX-C0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!
M8V-O=6YT<R!P87EA8FQE/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^*#DS,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!8V-R=65D(&5X<&5N<V5S
M(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*#$T,SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@
M8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY.;W1E<R!P87EA8FQE/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*#$\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1&5F
M97)R960@=&%X(&QI86)I;&ET>2P@;F]N+6-U<G)E;G0\+V9O;G0^/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH-2PP-3,\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,BPX,C<\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T
M86)L93X-"B`@(#QP('-T>6QE/3-$)VQI;F4M:&5I9VAT.CAP>#MM87)G:6XM
M=&]P.C!P>#MM87)G:6XM8F]T=&]M.C)P>#MB;W)D97(M8F]T=&]M.C`N-7!T
M('-O;&ED(",P,#`P,#`[=VED=&@Z,3,E)SXF(S$V,#L\+W`^#0H@("`\=&%B
M;&4@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L
M:6=N.B!L969T)R!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@=VED=&@],T0Q,#`E/B`-"B`@(#QT<CX@#0H@("`\=&0@=VED
M=&@],T0S)2!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*&DI
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T
M;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CY4:&4@=F%L=64@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C
M;VUM;VX@<W1O8VL@=V%S(&)A<V5D('5P;VX@82!P97(@<VAA<F4@=F%L=64@
M;V8@)#$N,C@L('1H92!C;&]S:6YG('!R:6-E(&]F('1H92!#;VUP86YY)B,X
M,C$W.W,@8V]M;6]N('-T;V-K(&%S(&]F('1H92!C;&]S92!O9B!B=7-I;F5S
M<PT*("`@;VX@07!R:6PF(S$V,#LQ,RP@,C`Q,2X@/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O
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M92!T:&4-"B`@(&-O;G1I;F=E;G0@;&EA8FEL:71Y(&%S(&]F('1H92!R97!O
M<G1I;F<@9&%T92X@5&AE(&1E8W)E87-E(&EN('1H92!F86ER('9A;'5E(&]F
M('1H92!C;VYT:6YG96YT(&QI86)I;&ET>2!F<F]M(&1A=&4@;V8@:7-S=6%N
M8V4@=&\@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!I<R`D,3`Y+#`P,"P@=VAI
M8V@@=V%S(&EN8VQU9&5D(&EN(&]T:&5R(&EN8V]M92!A;F0@97AP96YS92!I
M;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9`T*("`@<W1A=&5M96YT
M<R!O9B!E>'!E;G-E<R!F;W(@=&AE('1W96QV92!M;VYT:',@96YD960@1&5C
M96UB97(F(S$V,#LS,2P@,C`Q,2X@5&AE(&9A:7(@=F%L=64@;V8@=&AE(&-O
M;G1I;F=E;G0@;&EA8FEL:71Y(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@
M=V%S("0V+#,U,2PP,#`N($]F('1H:7,@86UO=6YT("0Q+#<X,BPP,#`@=V%S
M(')E8V]R9&5D(&%S(&$@8W5R<F5N="!L:6%B:6QI='DN($]N($IA;G5A<GDF
M(S$V,#LQ.2P@,C`Q,BP-"B`@('1H92!F:7)S="!M:6QE<W1O;F4@;V8@)#$L
M,#`P+#`P,"!O9B!T:&ES(&-O;G1I;F=E;G0@;&EA8FEL:71Y('=A<R!T<FEG
M9V5R960@=VET:"!T:&4@9FER<W0@<&%T:65N="!E;G)O;&QE9"!I;B!O=7(@
M4&AA<V4@,R!P<F5S96YT(&-L:6YI8V%L('1R:6%L(&9O<B!B<F5A<W0@8V%N
M8V5R+B!/;B!-87)C:"8C,38P.S@L(#(P,3(L('1H92!#;VUP86YY(&ES<W5E
M9"`Q+#,Q-2PW.#D@<F5S=')I8W1E9"!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(&EN('!A>6UE;G0@;V8@=&AE(&9I<G-T(&UI;&5S=&]N92X@5&AE(&-E<G1I
M9FEC871E<R!E=FED96YC:6YG('1H92!M:6QE<W1O;F4@<VAA<F5S(&AA=F4@
M8F5E;@T*("`@9&5P;W-I=&5D('=I=&@@82!T:&ER9"!P87)T>2!E<V-R;W<@
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M,C`Q,B!A;FYU86P@<W1O8VMH;VQD97)S(&UE971I;F<N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^268@<W1O8VMH;VQD97(@
M87!P<F]V86P@:7,@;V)T86EN960L('1H92!N=6UB97(@;V8@;6EL97-T;VYE
M('-H87)E<R!W:6QL(&)E('-U8FIE8W0-"B`@('1O(&EN8W)E87-E('1O('1H
M92!E>'1E;G0@=&AA="`D,"XW-B`H/&D^:2YE/"]I/BXL('1H92!C;&]S:6YG
M('!R:6-E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%S
M(')E<&]R=&5D(&]N(%1H92!.05-$05$@0V%P:71A;"!-87)K970@;VX@2F%N
M=6%R>28C,38P.S$X+"`R,#$R+"!T:&4@9&%Y('!R:6]R('1O(&%C:&EE=F5M
M96YT(&]F(&ET<R!F:7)S="!M:6QE<W1O;F4L('5S960@9F]R('!U<G!O<V5S
M(&]F#0H@("!D971E<FUI;FEN9R!T:&4@;G5M8F5R(&]F(&UI;&5S=&]N92!S
M:&%R97,@:6XI(&ES(&=R96%T97(@=&AA;B!T:&4@8VQO<VEN9R!P<FEC92!O
M9B!C;VUM;VX@<W1O8VL@87,@;V8@=&AE(&UO<W0@<F5C96YT('1R861I;F<@
M9&%Y('!R:6]R('1O('1H92!R96-E:7!T(&]F('-T;V-K:&]L9&5R(&%P<')O
M=F%L+B!7:&5T:&5R(&]R(&YO="!S=&]C:VAO;&1E<B!A<'!R;W9A;"!I<R!O
M8G1A:6YE9"P@:6X@861D:71I;VX@=&\@=&AE#0H@("!R96QE87-E(&9R;VT@
M97-C<F]W(&]F('1H92!M:6QE<W1O;F4@<VAA<F5S(&]R('1H92!P87EM96YT
M(&EN(&-A<V@@;V8@=&AE(&9I;F%L(&UI;&5S=&]N92!A<R!T:&4@8V%S92!M
M87D@8F4L('1H92!#;VUP86YY('=I;&P@<&%Y(&-O;F-U<G)E;G1L>2!T;R!T
M:&4@9F]R;65R($%P=&AE<F$@<VAA<F5H;VQD97)S(&EN(&-A<V@@86X@:6YT
M97)E<W0@9F%C=&]R(&]F('1E;B!P97)C96YT("@Q,"4I)B,Q-C`[<&5R(&%N
M;G5M(&]N('1H90T*("`@86UO=6YT(&]F('1H92!F:6YA;"!M:6QE<W1O;F4@
M9G)O;2!&96)R=6%R>28C,38P.S$P+"`R,#$R('1H<F]U9V@@=&AE(&1A>2!I
M;6UE9&EA=&5L>2!P<FEO<B!T;R!T:&4@<F5L96%S92!O9B!T:&4@;6EL97-T
M;VYE('-H87)E<R!F<F]M(&5S8W)O=R!O<B!T:&4@8V%S:"!P87EM96YT+"!A
M<R!T:&4@8V%S92!M87D@8F4L(&QE<W,@8V5R=&%I;B!L96=A;"!F965S(&]F
M('1H92!S=&]C:VAO;&1E<B!R97!R97-E;G1A=&EV92!T;R!B90T*("`@<&%I
M9"!O<B!R96EM8G5R<V5D(&)Y('1H92!#;VUP86YY+B`\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP
M<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D1U<FEN9R!T:&4@9F]U<G1H
M('%U87)T97(@;V8@,C`Q,2P@=&AE($-O;7!A;GD@9FEN86QI>F5D(&ET<R!P
M=7)C:&%S92!P<FEC92!A;&QO8V%T:6]N#0H@("!W:&EC:"!R97-U;'1E9"!I
M;B!A;B!I;F-R96%S92!I;B!G;V]D=VEL;"!A;F0@9&5F97)R960@=&%X(&QI
M86)I;&ET>2!O9B`D-2PP-3,L,#`P+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M
M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@<')E<V5N=',@=&AE
M('!R;R!F;W)M82!N970-"B`@(&QO<W,@86YD('!R;R!F;W)M82!N970@;&]S
M<R!P97(@8V]M;6]N('-H87)E(&]F('1H92!#;VUP86YY(&%N9"!T=V5L=F4@
M;6]N=&AS(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@86YD(#(P,3`@
M87,@:68@=&AE($-O;7!A;GDF(S@R,3<[<R!A8W%U:7-I=&EO;B!O9B!!<'1H
M97)A(&]C8W5R<F5D(&%S(&]F($IA;G5A<GDF(S$V,#LQ+"`R,#$P.B`\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I;BUT
M;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E
M(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@
M0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@]
M,T0W,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1F]R('1H92!4=V5L
M=F4@36]N=&AS($5N9&5D/&)R("\^1&5C96UB97(F(S$V,#LS,2P\+V(^/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q
M,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/C(P,3`\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^*'5N875D:71E9"D\+V(^/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N
M9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM
M/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^4')O(&9O<FUA(&YE="!L;W-S
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@Q,BPW
M-S@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^*#$T+#(R.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ
M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^4')O(&9O<FUA(&YE="!L;W-S('!E<B!C;VUM;VX@
M<VAA<F4\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*#`N,S0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^*#`N-C(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US
M:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E=E:6=H=&5D(&%V
M97)A9V4@<VAA<F5S(&]U='-T86YD:6YG/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,S<L-S(T+#0S,SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^,C(L.#4W+#0W,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-
M"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/B`-"CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#-A-F4P
M,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q
M8C$P9&)F8R]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY26&D@4W!I;BU/=70\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4EAI(%-P
M:6XM3W5T(&%N9"!296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)8:2!3<&EN+4]U=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N
M,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT
M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM
M($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#4@+2!R>&EI.E!A<G1N97)#;VUP
M86YY5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3)P
M>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/C4N)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[4EAI(%-P:6XM3W5T(#PO8CX\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[
M(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI/D-O;G1R:6)U=&EO;B!!
M9W)E96UE;G0@/"]I/CPO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/@T*("`@3VX@4V5P=&5M8F5R)B,Q-C`[,C0L(#(P,3$L
M('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A($-O;G1R:6)U=&EO;B!!9W)E
M96UE;G0@*"8C.#(R,#M#;VYT<FEB=71I;VX@06=R965M96YT)B,X,C(Q.RD@
M=VET:"!26&D@<'5R<W5A;G0@=&\@=VAI8V@@=V4@87-S:6=N960@86YD(&-O
M;G1R:6)U=&5D('1O(%)8:2!S=6)S=&%N=&EA;&QY(&%L;"!O9B!T:&4-"B`@
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M;&%B;W)A=&]R>2!F86-I;&ET>2P@9FEX960-"B`@(&%S<V5T<R!A;F0@;W1H
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M=&AE#0H@("!C87!I=&%L(&]F(%)8:2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY0=7)S=6%N="!T;R!T:&4@0V]N=')I8G5T
M:6]N($%G<F5E;65N="P@4EAI(&AA<R!A9W)E960@=&\@87-S=6UE(&-E<G1A
M:6X@<F5C96YT(&%C8W)U960@97AP96YS97,@;V8@;W5R#0H@("!26$DM,3`Y
M(&1E=F5L;W!M96YT('!R;V=R86T@86YD(&%L;"!F=71U<F4@;V)L:6=A=&EO
M;G,@=6YD97(@=&AE(&-O;G1R:6)U=&5D(&QI8V5N<V5S+"!E;7!L;WEM96YT
M(&%R<F%N9V5M96YT<R!A;F0@;W1H97(@86=R965M96YT<RX@4EAI(&AA<R!A
M;'-O(&%G<F5E9"!T;R!M86ME(&9U='5R92!M:6QE<W1O;F4@<&%Y;65N=',@
M=&\@=7,@;V8@=7`@=&\@)#0U)B,Q-C`[;6EL;&EO;BP@8V]N<VES=&EN9R!O
M9B!T=V\@;VYE+71I;64-"B`@('!A>6UE;G1S(&]F("0Q-28C,38P.VUI;&QI
M;VX@86YD("0S,"8C,38P.VUI;&QI;VXL(')E<W!E8W1I=F5L>2P@:68@4EAI
M(&%C:&EE=F5S(&%N;G5A;"!N970@<V%L97,@97%U86P@=&\@;W(@9W)E871E
M<B!T:&%N("0U,#`@;6EL;&EO;B!A;F0@)#$F(S$V,#MB:6QL:6]N+"!R97-P
M96-T:79E;'DL(&]F(&%N>2!C;W9E<F5D('!R;V1U8W1S('1H870@;6%Y(&)E
M(&1E=F5L;W!E9"!W:71H('1H92!C;VYT<FEB=71E9"!23D%I#0H@("!T96-H
M;F]L;V=I97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^26X@=&AE($-O;G1R:6)U=&EO;B!!9W)E96UE;G0L('1H92!#;VUP
M86YY(&UA9&4@8W5S=&]M87)Y(')E<')E<V5N=&%T:6]N<R!A;F0@=V%R<F%N
M=&EE<R!T;R!26&D@<F5G87)D:6YG('1H90T*("`@8V]N=')I8G5T960@87-S
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M:6]N<RP-"B`@('=A<G)A;G1I97,@86YD(&-O=F5N86YT<R!S970@9F]R=&@@
M:6X@=&AE($-O;G1R:6)U=&EO;B!!9W)E96UE;G0N(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP
M<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI/E-E8W5R:71I97,@
M4'5R8VAA<V4@06=R965M96YT(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/;B!397!T96UB97(F(S$V,#LR-"P@
M,C`Q,2P@=&AE($-O;7!A;GD@86QS;R!E;G1E<F5D(&EN=&\@82!396-U<FET
M:65S(%!U<F-H87-E($%G<F5E;65N="`H)B,X,C(P.U-E8W5R:71I97,@4'5R
M8VAA<V4@06=R965M96YT)B,X,C(Q.RD@=VET:`T*("`@4EAI(&%N9"!T=V\@
M:6YS=&ET=71I;VYA;"!);G9E<W1O<G,@*'1H92`F(S@R,C`[26YV97-T;W)S
M)B,X,C(Q.RDL('!U<G-U86YT('1O('=H:6-H('1H92!);G9E<W1O<G,@86=R
M965D('1O('!U<F-H87-E(&$@=&]T86P@;V8@)#DL-3`P+#`P,"!O9B!397)I
M97,F(S$V,#M!(%!R969E<G)E9"!3=&]C:R!O9B!26&D@*"8C.#(R,#M26&D@
M4')E9F5R<F5D(%-T;V-K)B,X,C(Q.RD@870@=&AE(&-L;W-I;F<@;V8@=&AE
M('-P:6XM;V9F(&]F#0H@("!26&DL(&%N9"!T;R!L96YD('5P('1O("0Q+#4P
M,"PP,#`@=&\@4EAI('1O(&9U;F0@:71S(&]P97)A=&EO;G,@8F5T=V5E;B!S
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M<F5S96YT(&$@<&]R=&EO;B!O9B!T:&4@)#DL-3`P+#`P,"!T;W1A;"!I;G9E
M<W1M96YT+"!W:&EC:"!I<R!R969E<G)E9"!T;R!H97)E:6X@87,@=&AE("8C
M.#(R,#M26&D@9FEN86YC:6YG+B8C.#(R,3L@5&AE(%)8:2!F:6YA;F-I;F<@
M86YD('1H92!S<&EN+6]F9B!O9B!26&D@87)E#0H@("!S=6)J96-T('1O(&-U
M<W1O;6%R>2!C;&]S:6YG(&-O;F1I=&EO;G,L(&EN8VQU9&EN9R!T:&4@<F5G
M:7-T<F%T:6]N('5N9&5R('1H92!396-U<FET:65S($%C="!O9B`Q.3,S+"!A
M<R!A;65N9&5D("AT:&4@)B,X,C(P.U-E8W5R:71I97,@06-T)B,X,C(Q.RDL
M(&]F('1H92!D:7-T<FEB=71I;VX@8GD@=7,@;V8@=&AE('-P:6XM;V9F('-H
M87)E<RX@5&AE<F4@:7,@;F\@87-S=7)A;F-E('1H870@=&AE(%)8:2!F:6YA
M;F-I;F<@86YD('1H90T*("`@<W!I;BUO9F8@;V8@4EAI('=I;&P@8F4@8V]M
M<&QE=&5D+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M+"!T:&4@<VAA<F5S(&]F('1H92!0<F5F97)R960-"B`@(%-T;V-K('1O(&)E
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M9RP@87-S=6UI;F<-"B`@('1H92!C;VYV97)S:6]N(&EN(&9U;&P@;V8@=&AE
M(%!R969E<G)E9"!3=&]C:RP@=VAI8V@@=V4@<F5F97(@=&\@87,@=&AE("8C
M.#(R,#MA<RUC;VYV97)T960@8V]M;6]N('-T;V-K+B8C.#(R,3L@5&AE($-O
M;7!A;GD@=VEL;"!O=VX@87!P<F]X:6UA=&5L>2`Q,B4@;V8@=&AE(&%S+6-O
M;G9E<G1E9"!C;VUM;VX@<W1O8VL@:6UM961I871E;'D@<')I;W(@=&\@=&AE
M('-P:6XM;V9F(&]F(%)8:2P@86YD($%D=FER;F$L($Q,0RP@82!K97D-"B`@
M(&QI8V5N<V]R(&]F(%)8:2P@=VEL;"!B92!I<W-U960@=&AE(')E;6%I;FEN
M9R`U)2!O9B!T:&4@87,M8V]N=F5R=&5D(&-O;6UO;B!S=&]C:R!P=7)S=6%N
M="!T;R!T:&4@86=R965M96YT('=I=&@@061V:7)N82P@3$Q#(&%S(&1E<V-R
M:6)E9"!B96QO=RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^#0H@("`\:3Y3<&EN+4]F9B`\+VD^/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!H87,@86=R
M965D(&EN('1H92!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="!T;PT*
M("`@=6YD97)T86ME('1O(&1I<W1R:6)U=&4@=&\@;W5R('-T;V-K:&]L9&5R
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M:"!S:&%R92!O9B!'86QE;F$@=&AA="!I<R!I<W-U960-"B`@(&%N9"!O=71S
M=&%N9&EN9R!A<R!O9B!T:&4@<F5C;W)D(&1A=&4@9F]R('1H92!D:7-T<FEB
M=71I;VXN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^3VX@1F5B<G5A<GDF(S$V,#LR-RP@,C`Q,BP@=&AE($-O;7!A;GD@86YN
M;W5N8V5D+"!A<R!R97%U:7)E9"!B>0T*("`@3D%31$%1($QI<W1I;F<@4G5L
M92`U,C4P*&4I*#8I+"!T:&%T(&ET<R!B;V%R9"!O9B!D:7)E8W1O<G,@:&%D
M(&1E8VQA<F5D(&$@8V]N9&ET:6]N86P@9&EV:61E;F0@;VX@1V%L96YA(&-O
M;6UO;B!S=&]C:R!O9B!O;F4@<VAA<F4@;V8@8V]M;6]N('-T;V-K(&]F(%)8
M:2!F;W(@96%C:"!O=71S=&%N9&EN9R!S:&%R92!O9B!'86QE;F$@8V]M;6]N
M('-T;V-K+B!4:&4@<W!I;BUO9F8@<VAA<F5S('=I;&P@8F4@<&%Y86)L92P-
M"B`@('-U8FIE8W0@=&\@8V5R=&%I;B!C;VYD:71I;VYS(&1E<V-R:6)E9"!B
M96QO=RP@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!S=&]C:VAO;&1E<G,@87,@
M;V8@8VQO<V4@;V8@8G5S:6YE<W,@*$5A<W1E<FX@=&EM92D@;VX@36%R8V@F
M(S$V,#LX+"`R,#$R+"!T:&4@<F5C;W)D(&1A=&4@9F]R('1H92!D:7-T<FEB
M=71I;VXL(&EN('1H92!R871I;R!O9B!O;F4@4EAI('-H87)E(&9O<B!E86-H
M('-H87)E(&]F($=A;&5N82!C;VUM;VX@<W1O8VL-"B`@(&AE;&0@87,@;V8@
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M('1R861I;F<-"B`@("8C.#(R,#ME>"UD:79I9&5N9"XF(S@R,C$[(%1H92!D
M:7-T<FEB=71I;VX@;V8@=&AE('-P:6XM;V9F('-H87)E<R!W:6QL(&)E('1A
M>&%B;&4@=&\@1V%L96YA('-T;V-K:&]L9&5R<R!W:&\@<F5C96EV92!26&D@
M<VAA<F5S(&EN('1H92!D:7-T<FEB=71I;VXN(#PO9F]N=#X\+W`^#0H@("`\
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M;VX-"B`@($9E8G)U87)Y)B,Q-C`[,30L(#(P,3(N($)E8V%U<V4@=&AE(%)8
M:2!R96=I<W1R871I;VX@<W1A=&5M96YT('=I;&P@9V\@)B,X,C(P.W-T86QE
M)B,X,C(Q.R!O;B!!<')I;"8C,38P.S,P+"`R,#$R+"!T:&4@0V]M<&%N>2!M
M=7-T(&-O;7!L971E('1H92!D:7-T<FEB=71I;VX@;V8@=&AE('-P:6XM;V9F
M('-H87)E<R!B>2!T:&%T(&1A=&4L('5N;&5S<R!T:&4@0V]M<&%N>2!W97)E
M('1O(&-A=7-E(%)8:2!T;R!A;65N9"!T:&4-"B`@(')E9VES=')A=&EO;B!S
M=&%T96UE;G0N($ET(&ES(&QI:V5L>2!T:&%T('1H92!#;VUP86YY('=O=6QD
M(&%B86YD;VX@=&AE('!A<G1I86P@<W!I;BUO9F8@;V8@4EAI(&EF('1H92!D
M:7-T<FEB=71I;VX@;V8@=&AE('-P:6XM;V9F('-H87)E<R!H87,@;F]T(&)E
M96X@;6%D92!B>2!!<')I;"8C,38P.S,P+"`R,#$R+"!A;'1H;W5G:"!T:&4@
M0V]M<&%N>28C.#(Q-SMS#0H@("!B;V%R9"!O9B!D:7)E8W1O<G,@:&%S(&YO
M="!M861E(&%N>2!D96-I<VEO;B!I;B!T:&ES(')E9V%R9"X@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
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M;F5D(`T*("`@=7!O;B!T:&4@8VQO<VEN9R!O9B!T:&4@4EAI(&9I;F%N8VEN
M9RP@=VAI8V@@:7,@<W5B:F5C="!T;R!C97)T86EN(&-L;W-I;F<@8V]N9&ET
M:6]N<R!T:&%T(&UA>2!O<B!M87D@;F]T(&)E('-A=&ES9FEE9"X@26X@861D
M:71I;VXL('1H92!S96-U<FET:65S('!U<F-H87-E(&%G<F5E;65N="!A;6]N
M9R!'86QE;F$L(%)8:2!A;F0@=&AE($EN=F5S=&]R<R!P<F]V:61E<R!T:&%T
M('1H92!A9W)E96UE;G0@;6%Y(&)E('5N:6QA=&5R86QL>0T*("`@=&5R;6EN
M871E9"!B>2!T:&4@0V]M<&%N>2!O<B!B>2!T:&4@26YV97-T;W)S(&EF('1H
M92!C;&]S:6YG(&]F('1H92!T<F%N<V%C=&EO;G,@:&%S(&YO="!O8V-U<G)E
M9"!B>2!-87)C:"8C,38P.S,Q+"`R,#$R+"!A;F0@:70@:7,@;F]T('!O<W-I
M8FQE(&9O<B!T:&4@8VQO<VEN9R!T;R!O8V-U<B!B>2!T:&ES(&1A=&4N($%C
M8V]R9&EN9VQY+"!U;FQE<W,@=&AI<R!D871E(&ES(&5X=&5N9&5D(&)Y(&UU
M='5A;"!A9W)E96UE;G0@;V8-"B`@('1H92!);G9E<W1O<G,@86YD('1H92!#
M;VUP86YY+"!E:71H97(@=&AE($-O;7!A;GD@;W(@=&AE($EN=F5S=&]R<R!G
M96YE<F%L;'D@;6%Y('1E<FUI;F%T92!T:&4@<V5C=7)I=&EE<R!P=7)C:&%S
M92!A9W)E96UE;G0@870@86YY('1I;64@869T97(@36%R8V@F(S$V,#LS,2P@
M,C`Q,BP@=6YL97-S('1H92!F86EL=7)E(&]F('1H92!C;&]S:6YG('1O(&]C
M8W5R('=A<R!D=64@=&\@=&AE(&9A=6QT(&]F('1H92!P87)T>2!S965K:6YG
M#0H@("!T;R!T97)M:6YA=&4@=&AE('-E8W5R:71I97,@<'5R8VAA<V4@86=R
M965M96YT+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/D%L=&AO=6=H('1H92!#;VUP86YY(&AA<R!N;R!P<F5S96YT(&EN=&5N
M=&EO;B!T;R!T97)M:6YA=&4@=&AE('-E8W5R:71I97,-"B`@('!U<F-H87-E
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M;W(@86QL(&]F('1H92!F;W)E9V]I;F<-"B`@(')E87-O;G,L('1H97)E(&ES
M(&YO(&%S<W5R86YC92!T:&%T('1H92!P87EM96YT(&%N9"!D:7-T<FEB=71I
M;VX@;V8@=&AE('-P:6XM;V9F('-H87)E<R!W:6QL(&)E(&-O;7!L971E9"X@
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM
M87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&D^
M4'5R8VAA<V4-"B`@($%G<F5E;65N="!497)M<R!A;F0@0V]N9&ET:6]N<R`\
M+VD^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X
M.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY)
M;B!T:&4@4V5C=7)I=&EE<R!0=7)C:&%S92!!9W)E96UE;G0L('1H92!P87)T
M:65S(&AA=F4@;6%D92!C=7-T;VUA<GD@<F5P<F5S96YT871I;VYS(&%N9`T*
M("`@=V%R<F%N=&EE<R!T;R!T:&4@;W1H97(@<&%R=&EE<R!A;F0@:&%V92!A
M9W)E960@=&\@8W5S=&]M87)Y(&-O=F5N86YT<R!R96=A<F1I;F<@=&AE('!A
M<G1I97,F(S@R,3<[(&%C=&EO;G,@:6X@8V]N;F5C=&EO;B!W:71H('1H92!S
M<&EN+6]F9B!O9B!26&D@86YD(&]T:&5R(&UA='1E<G,L(&EN8VQU9&EN9R!T
M:&4@9FEL:6YG(&]F(&$@<F5S86QE(')E9VES=')A=&EO;B!S=&%T96UE;G0@
M<F5G:7-T97)I;F<@82!P;W)T:6]N(&]F('1H90T*("`@8V]M;6]N('-T;V-K
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M:71I97,-"B`@(%!U<F-H87-E($%G<F5E;65N="X@4EAI(&AA<R!A9W)E960L
M('5P;VX@8V]M<&QE=&EO;B!O9B!T:&4@<W!I;BUO9F8@;V8@4EAI+"!T;R!R
M96EM8G5R<V4@=&AE($-O;7!A;GD@86YD('1H92!);G9E<W1O<G,@9F]R('5P
M('1O(&$@=&]T86P@;V8@)#,P,"PP,#`@86YD("0Q,#`L,#`P+"!R97-P96-T
M:79E;'DL(&]F('1R86YS86-T:6]N(&-O<W1S(')E;&%T:6YG('1O('1H92!#
M;VYT<FEB=71I;VX@06=R965M96YT+"!T:&4-"B`@(%-E8W5R:71I97,@4'5R
M8VAA<V4@06=R965M96YT(&%N9"!T:&4@=')A;G-A8W1I;VYS(&-O;G1E;7!L
M871E9"!B>2!T:&4@86=R965M96YT<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
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M<F5D(&)Y($UA<F-H)B,Q-C`[,S$L(#(P,3(N($EF('1H92!396-U<FET:65S
M(%!U<F-H87-E($%G<F5E;65N="!I<R!T97)M:6YA=&5D('=I=&AO=70@8V%U
M<V4@9'5E('1O('1H92!F86-T('1H870@=&AE('-P:6XM;V9F(&AA<R!N;W0-
M"B`@(&]C8W5R<F5D(&)Y('-U8V@@9&%T92P@=&AE;B!A('!O<G1I;VX@;V8@
M=&AE($)R:61G92!,;V%N('=I;&P@8F4@8V]N=F5R=&5D(&EN=&\@8V]M;6]N
M('-T;V-K(&]F(%)8:2P@87,@9&5S8W)I8F5D(&)E;&]W+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y"<FED9V4@3&]A
M;B`\+VD^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX-"B`@(%!U<G-U86YT('1O('1H92!396-U<FET:65S(%!U<F-H87-E($%G
M<F5E;65N="P@=&AE($EN=F5S=&]R<R!A9W)E960@=&\@<')O=FED92!T:&4@
M0G)I9&=E($QO86X@8GD@<'5R8VAA<VEN9R`D-3`P+#`P,"!O9B!S96-U<F5D
M(&-O;G9E<G1I8FQE('!R;VUI<W-O<GD@;F]T97,@;V8@4EAI("@F(S@R,C`[
M4EAI(&-O;G9E<G1I8FQE(&YO=&5S)B,X,C(Q.RD@86YD#0H@("!A9W)E96EN
M9R!T;R!P=7)C:&%S92!U<"!T;R!A;B!A9&1I=&EO;F%L("0Q+#`P,"PP,#`@
M;V8@4EAI(&-O;G9E<G1I8FQE(&YO=&5S('!R:6]R('1O('1H92!C;&]S:6YG
M(&]F('1H92!S<&EN+6]F9B!O9B!26&DN(%1H92!26&D@8V]N=F5R=&EB;&4@
M;F]T97,@=VEL;"P@97AC97!T(&%S(&1E<V-R:6)E9"!B96QO=RP@8F4@8V]N
M=F5R=&EB;&4@:6YT;R!S:&%R97,@;V8@4EAI(%!R969E<G)E9"!3=&]C:R!A
M="!A(&-O;G9E<G-I;VX-"B`@('!R:6-E(&]F("0Q+#`P,"!P97(@<VAA<F4N
M(%1H92!P<F]C965D<R!F<F]M('1H92!"<FED9V4@3&]A;B!W:6QL(&)E('5S
M960@8GD@4EAI(&EN(&%C8V]R9&%N8V4@=VET:"!A;B!O<&5R871I;F<@8G5D
M9V5T(&%P<')O=F5D(&)Y('1H92!);G9E<W1O<G,@=&\@9G5N9"!26&DF(S@R
M,3<[<R!B=7-I;F5S<R!A;F0@;W!E<F%T:6]N<R!P96YD:6YG(&-O;7!L971I
M;VX@;V8@=&AE('-P:6XM;V9F(&]F(%)8:2X@/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@4EAI(&-O;G9E<G1I8FQE(&YO
M=&5S(&%C8W)U92!I;G1E<F5S="!A="!A(')A=&4@;V8@-R4F(S$V,#MP97(@
M86YN=6T@*&]R(#$X)28C,38P.W!E<B!A;FYU;2!I;B!T:&4@8V%S92!O9B!A
M;B!E=F5N="!O9B!D969A=6QT*2!A;F0-"B`@(&UA='5R92!O;B!-87)C:"8C
M,38P.S,Q+"`R,#$R+"!O<B!E87)L:65R(&EN('1H92!C87-E(&]F(&%N(&5V
M96YT(&]F(&1E9F%U;'0N(%1H92!O8FQI9V%T:6]N<R!D=64@=6YD97(@=&AE
M(%)8:2!C;VYV97)T:6)L92!N;W1E<R!A<F4@<V5C=7)E9"!B>2!A(&9I<G-T
M+7!R:6]R:71Y(&)L86YK970@;&EE;B!O;B!T:&4@87-S971S(&]F(%)8:2!A
M;F0@87)E(&=U87)A;G1E960@8GD@1V%L96YA+B!!9&1I=&EO;F%L;'DL($=A
M;&5N80T*("`@:&%S('!L961G960@86QL(&]F('1H92!S:&%R97,@;V8@4EAI
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M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ<'@[;6%R9VEN
M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E
M>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/DEF('1H92!C;&]S:6YG#0H@("!U;F1E
M<B!T:&4@4V5C=7)I=&EE<R!0=7)C:&%S92!!9W)E96UE;G0@:&%S(&YO="!O
M8V-U<G)E9"!B>2!T:&4@36%R8V@F(S$V,#LS,2P@,C`Q,B!M871U<FET>2!D
M871E(&]F('1H92!26&D@8V]N=F5R=&EB;&4@;F]T97,L('1H96X@-3`E(&]F
M('1H92!O=71S=&%N9&EN9R!"<FED9V4@3&]A;B!B86QA;F-E('=I;&P@8F4@
M8V]N=F5R=&5D(&EN=&\@82!N=6UB97(@;V8@<VAA<F5S(&]F(%)8:2!C;VUM
M;VX@<W1O8VL@97%U86P@=&\-"B`@(#4Q)2!O9B!T:&4@<&]S="UC;VYV97)S
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M97,-"B`@('1O('1H92!E>'1E;G0@=&AE>2!A<F4@;F]T(&-O;G9E<G1E9"X@
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M(&5V96YT+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M97-T;W)S('1O(&5X=&5N9"!T:&4@8W5R<F5N="!-87)C:"8C,38P.S,Q+"`R
M,#$R(&UA='5R:71Y(&1A=&4@;V8@=&AE(%)8:0T*("`@8V]N=F5R=&EB;&4@
M;F]T97,L(&)U="!T:&5R92!I<R!N;R!A<W-U<F%N8V4@=&AA="!T:&4@;6%T
M=7)I='D@9&%T92!W:6QL(&)E(&5X=&5N9&5D+B`\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[
M('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!26&D@8V]N=F5R=&EB;&4@
M;F]T97,@=VEL;"!B90T*("`@:7-S=65D+"!A;F0@=&AE($)R:61G92!,;V%N
M('=I;&P@8F4@9G5N9&5D+"!I;B!T:')E92!T<F%N8VAE<R!O9B`D-3`P+#`P
M,"!E86-H+B!4:&4@9FER<W0@86YD('-E8V]N9"!T<F%N8VAE<R!W97)E(&ES
M<W5E9"!A;F0@9G5N9&5D(&]N(%-E<'1E;6)E<B8C,38P.S(T+"`R,#$Q(&%N
M9"!&96)R=6%R>28C,38P.S(T+"`R,#$R+"!R97-P96-T:79E;'DL(&%N9"!T
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M(&]F('-U8V@@9G5N9',N($%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L('1H
M92!F:7)S="!T<F%N8VAE(&]F#0H@("`D-3`P+#`P,"!H860@8F5E;B!R96-E
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M8F4-"B`@(')E979A;'5A=&5D(&EN('1H92!F=71U<F4N($EN('1H92!E=F5N
M="!T:&%T('1H92!F86-T<R!A;F0@8VER8W5M<W1A;F-E<R!I;F1I8V%T92!T
M:&%T(&$@8V]N=&EN9V5N8WD@:7,@<F5M;W9E9"P@870@=&AA="!P;VEN="!T
M:&4@8F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U<F4L(&EF(&%N>2P@=VEL
M;"!B92!R96-O<F1E9"X@3VX@1F5B<G5A<GDF(S$V,#LR-"P@,C`Q,BP@=&AE
M('-E8V]N9"!T<F%N8VAE(&]F("0U,#`L,#`P('=A<PT*("`@<F5C96EV960@
M86YD(')E8V]R9&5D('1O(&-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4N(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R
M9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI
M/D%D=FER;F$@06=R965M96YT(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!<R!P87)T(&]F('1H92!T<F%N<V%C
M=&EO;G,@8V]N=&5M<&QA=&5D(&)Y('1H92!#;VYT<FEB=71I;VX@06=R965M
M96YT(&%N9"!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="P@4EAI(&AA
M<R!E;G1E<F5D(&EN=&\@86X-"B`@(&%G<F5E;65N="!W:71H($%D=FER;F$L
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M8FQI9V%T:6]N<R!R96UA:6X@=&\@;6%K92!A;B!A;FYU86P@)#$P,"PP,#`@
M;6%I;G1E;F%N8V4@9F5E(&%N9"!A(&]N92UT:6UE#0H@("!M:6QE<W1O;F4@
M<&%Y;65N="!O9B`D,S4P+#`P,"!T;R!!9'9I<FYA('5P;VX@=&AE(&ES<W5A
M;F-E(&]F(&$@<&%T96YT('=I=&@@=F%L:60@8VQA:6US(&-O=F5R:6YG('1H
M92!A<W-I9VYE9"!T96-H;F]L;V=Y+B!!9&1I=&EO;F%L;'DL(%)8:2!W:6QL
M(&)E(')E<75I<F5D('1O('!A>2!A(#$E(')O>6%L='D@=&\@061V:7)N82!F
M;W(@86YY(&QI8V5N<VEN9R!R979E;G5E(')E8V5I=F5D(&)Y(%)8:2!O;B!T
M:&4@;&EC96YS92!O9@T*("`@=&AE(&%S<VEG;F5D($%D=FER;F$@=&5C:&YO
M;&]G>2X@26X@97AC:&%N9V4L(%)8:2!H87,@86=R965D('1O(&ES<W5E('1O
M($%D=FER;F$@=7!O;B!T:&4@96%R;&EE<B!O9B!T:&4@8VQO<VEN9R!U;F1E
M<B!T:&4@4V5C=7)I=&EE<R!0=7)C:&%S92!!9W)E96UE;G0@;W(@=&AE('!A
M<G1I86P@8V]N=F5R<VEO;B!O9B!T:&4@4EAI(&-O;G9E<G1I8FQE(&YO=&5S
M+"!A(&YU;6)E<B!O9B!S:&%R97,@;V8@4EAI(&-O;6UO;B!S=&]C:PT*("`@
M97%U86P@=&\@-24@;V8@=&AE(&%S+6-O;G9E<G1E9"!C;VUM;VX@<W1O8VL@
M;V8@4EAI+B`\+V9O;G0^/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T
M,6(Q,&1B9F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#-A-F4P
M,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C+U=O<FMS:&5E=',O4VAE
M970Q-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D9A:7(@5F%L=64@365A<W5R96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R
M96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!-96%S=7)E;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"
M3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@
M(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS
M:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@
M3F]T92`V("T@=7,M9V%A<#I&:6YA;F-I86Q);G-T<G5M96YT<T1I<V-L;W-U
M<F5497AT0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X
M.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^-BXF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#M&86ER(%9A;'5E($UE87-U<F5M96YT<R`\+V(^/"]F;VYT
M/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB
M;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N
M>2!F;VQL;W=S($%30R8C,38P.S@R,"P@)B,X,C(P.T9A:7(@5F%L=64@365A
M<W5R96UE;G1S(&%N9"!$:7-C;&]S=7)E<RPF(S@R,C$[("@F(S@R,C`[05-#
M(#@R,"8C.#(R,3LI(&9O<B!T:&4-"B`@($-O;7!A;GDF(S@R,3<[<R!F:6YA
M;F-I86P@87-S971S(&%N9"!L:6%B:6QI=&EE<R!T:&%T(&%R92!R92UM96%S
M=7)E9"!A;F0@<F5P;W)T960@870@9F%I<B!V86QU92!A="!E86-H(')E<&]R
M=&EN9R!P97)I;V0L(&%N9"!A<F4@<F4M;65A<W5R960@86YD(')E<&]R=&5D
M(&%T(&9A:7(@=F%L=64@870@;&5A<W0@86YN=6%L;'D@=7-I;F<@82!F86ER
M('9A;'5E(&AI97)A<F-H>2!T:&%T(&ES(&)R;VME;B!D;W=N(&EN=&\@=&AR
M964-"B`@(&QE=F5L<RX@3&5V96P@:6YP=71S(&%R92!A<R!D969I;F5D(&%S
M(&9O;&QO=W,Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z."4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^3&5V96PF(S$V,#LQ)B,Q-C`[)B,X,C$R.R!Q=6]T960@<')I8V5S
M(&EN(&%C=&EV92!M87)K971S(&9O<B!I9&5N=&EC86P@87-S971S#0H@("!O
M<B!L:6%B:6QI=&EE<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M87)G:6XM;&5F=#HX
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CY,979E;"8C,38P.S(F(S$V,#LF(S@R,3([(&]T:&5R('-I
M9VYI9FEC86YT(&]B<V5R=F%B;&4@:6YP=71S(&9O<B!T:&4@87-S971S(&]R
M(&QI86)I;&ET:65S('1H<F]U9V@-"B`@(&-O<G)O8F]R871I;VX@=VET:"!M
M87)K970@9&%T82!A="!T:&4@;65A<W5R96UE;G0@9&%T92X@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
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M<F5M96YT(&1A=&4N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M
M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N
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M92!#;VUP86YY(&-A=&5G;W)I>F5D(&ET<R!W87)R86YT<PT*("`@<&]T96YT
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M<VEN9R!T:&4-"B`@($)L86-K+5-C:&]L97,@;65T:&]D+"!U<VEN9R!A<W-U
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M(&)A<V5D(&]N(&$-"B`@(&-O<G!O<F%T92!D96)T(&EN=&5R97-T(')A=&4@
M:6YD97@@<'5B;&EC;'D@:7-S=65D+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P('-T>6QE
M/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F
M="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@
M+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-#(E/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$P)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^#0H@("`\<"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W=I9'1H.C,Y<'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1&5S
M8W)I<'1I;VX\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB97(F(S$V,#LS,2P\8G(@+SXR,#$Q
M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#$^/&(^475O=&5D)B,Q-C`[4')I8V5S)B,Q-C`[26X\8G(@
M+SY!8W1I=F4@36%R:V5T<SQB<B`O/BA,979E;"`Q*3PO8CX\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/E-I9VYI9FEC86YT)B,Q-C`[3W1H97(\8G(@+SY/8G-E<G9A8FQE)B,Q-C`[
M26YP=71S/&)R("\^*$QE=F5L(#(I/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^56YO8G-E<G9A
M8FQE)B,Q-C`[26YP=71S/&)R("\^*$QE=F5L(#,I/"]B/CPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@
M2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT
M<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/D%S<V5T<SH\+V9O;G0^/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#87-H(&5Q=6EV86QE;G1S/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$Q+#0S,SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C$Q+#0S,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C(N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY4;W1A;"!A<W-E=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,3$L-#,S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3$L-#,S/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z
M,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^3&EA8FEL:71I97,Z/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5V%R<F%N
M=',@<&]T96YT:6%L;'D@<V5T=&QE86)L92!I;B!C87-H/"]F;VYT/CPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,L-S0V/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C,L-S0V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O
M;G1I;F=E;G0@<'5R8VAA<V4@<')I8V4@8V]N<VED97)A=&EO;CPO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8L,S4Q/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXV+#,U,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G
M8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM;&5F=#HR+C`P96T[('1E>'0M:6YD96YT.BTQ
M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^5&]T86P@;&EA8FEL:71I97,\+V9O;G0^/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3`L,#DW/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C,L-S0V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-BPS-3$\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y
M;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*
M("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C9P>#MM87)G
M:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#$P,"4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L
M;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@
M/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W
M:61T:#TS1#0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$P)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MW:61T
M:#HS.7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0Q/CQB/D1E<V-R:7!T:6]N/"]B/CPO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/D1E8V5M
M8F5R)B,Q-C`[,S$L/&)R("\^,C`Q,#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E%U;W1E9"8C
M,38P.U!R:6-E<R8C,38P.VEN/&)R("\^06-T:79E($UA<FME=',\8G(@+SXH
M3&5V96P@,2D\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L
M:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY3:6=N:69I8V%N="8C,38P.T]T:&5R
M/&)R("\^3V)S97)V86)L928C,38P.TEN<'5T<SQB<B`O/BA,979E;"`R*3PO
M8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0Q/CQB/E5N;V)S97)V86)L928C,38P.TEN<'5T<SQB<B`O/BA,
M979E;"`S*3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN
M(%1A8FQE($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!<W-E
M=',Z/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^0V%S:"!E<75I=F%L96YT<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXV+#@Y,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8L.#DQ/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L(&%S<V5T<SPO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV+#@Y,3PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8L
M.#DQ/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@
M<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3&EA8FEL:71I97,Z/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L
M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^5V%R<F%N=',@<&]T96YT:6%L;'D@<V5T=&QE86)L92!I
M;B!C87-H/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^,RPQ,S@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPQ,S@\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C(N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4;W1A
M;"!L:6%B:6QI=&EE<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXS+#$S.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS+#$S.#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!H87,@8VQA<W-I
M9FEE9"!I=',@;&EA8FEL:71I97,@9F]R(&-O;G1I;F=E;G0@96%R;BUO=70@
M8V]N<VED97)A=&EO;B!R96QA=&EN9R!T;R!I=',-"B`@(&%C<75I<VET:6]N
M<R!O9B!!<'1H97)A('=I=&AI;B!,979E;"`S(&]F('1H92!F86ER('9A;'5E
M(&AI97)A<F-H>2!B96-A=7-E('1H92!F86ER('9A;'5E<R!A<F4@9&5T97)M
M:6YE9"!U<VEN9R!S:6=N:69I8V%N="!U;F]B<V5R=F%B;&4@:6YP=71S+"!W
M:&EC:"!I;F-L=61E9"!P<F]B86)I;&ET>2!W96EG:'1E9"!C87-H(&9L;W=S
M+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA
M<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!H87,@;F]T
M#0H@("!T<F%N<V9E<G)E9"!A;GD@9FEN86YC:6%L(&EN<W1R=6UE;G1S(&EN
M=&\@;W(@;W5T(&]F($QE=F5L(#,@8VQA<W-I9FEC871I;VX@9'5R:6YG(#(P
M,3`@;W(@,C`Q,2X@02!R96-O;F-I;&EA=&EO;B!O9B!T:&4@8F5G:6YN:6YG
M(&%N9"!E;F1I;F<@3&5V96P@,R!L:6%B:6QI=&EE<R!F;W(@=&AE('EE87(@
M96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!I<R!A<R!F;VQL;W=S.B`\
M+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I
M;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT
M86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M.3(E(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA
M+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED
M=&@],T0X,R4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/D9A:7(@5F%L=64\8G(@+SY-96%S=7)E;65N=',\
M8G(@+SY5<VEN9R8C,38P.U-I9VYI9FEC86YT/&)R("\^56YO8G-E<G9A8FQE
M/&)R("\^26YP=71S/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/@T*("`@/&(^
M*$QE=F5L(#,I/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/BA);B!4:&]U<V%N9',I/"]B/CPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@
M2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT
M<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/D)A;&%N8V4@870@2F%N=6%R>28C,38P.S$L
M(#(P,3$\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,X,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/DEN:71I86P@9F%I<B!V86QU92!O9B!C;VYT:6YG
M96YT(&5A<FYO=70@8V]N<VED97)A=&EO;B!R96QA=&5D('1O($UE<FED:6%N
M($%C<75I<VET:6]N/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^-BPT-C`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#
M:&%N9V4@:6X@9F%I<B!V86QU92!O9B!E87)N;W5T(&-O;G-I9&5R871I;VX\
M+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH
M,3`Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXI/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ
M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^0F%L86YC92!A="!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$Q/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8L
M,S4Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@
M(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B9F,-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#-A-F4P,35?-C!A.%\T
M,&5C7SDP,#=?.61A-#%B,3!D8F9C+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-A<&ET86P@
M3&5A<V4@3V)L:6=A=&EO;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%P:71A;"!,96%S92!/8FQI9V%T:6]N
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<&ET86P@3&5A<V4@3V)L:6=A=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#
M("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT
M='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I
M;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T
M92`W("T@=7,M9V%A<#I#87!I=&%L3&5A<V5S26Y&:6YA;F-I86Q3=&%T96UE
M;G1S3V9,97-S965$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL
M93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/CQB/C<N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[0V%P:71A;"!,96%S92!/
M8FQI9V%T:6]N<R`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!A8W%U:7)E9"!E<75I<&UE;G0@=6YD
M97(@8V%P:71A;"!L96%S97,@=&AA="!I<R!I;F-L=61E9"!I;B!E<75I<&UE
M;G0@86YD(&9U<FYI<VAI;F=S(&EN('1H92!A8V-O;7!A;GEI;F<-"B`@(&-O
M;G-O;&ED871E9"!B86QA;F-E('-H965T+B!4:&4@8V]S="!A;F0@86-C=6UU
M;&%T960@86UO<G1I>F%T:6]N(&]F(&-A<&ET86QI>F5D(&QE87-E9"!E<75I
M<&UE;G0@=V%S(&%P<')O>&EM871E;'D@)#(W,BPP,#`@86YD("0Y-2PP,#`@
M870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@<F5S<&5C=&EV96QY+"!A;F0@
M)#$Y-BPP,#`@86YD("0U-BPP,#`@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q
M,"P@<F5S<&5C=&EV96QY+@T*("`@06UO<G1I>F%T:6]N(&5X<&5N<V4@9F]R
M(&-A<&ET86QI>F5D(&QE87-E9"!E<75I<&UE;G0@=V%S(&%P<')O>&EM871E
M;'D@)#4T+#`P,"!I;B`R,#$Q(&%N9"`D,SDL,#`P(&EN(#(P,3`N($9U='5R
M92!M:6YI;75M(&QE87-E('!A>6UE;G1S('5N9&5R('1H92!C87!I=&%L(&QE
M87-E<R!I;F-L=61I;F<@:6YT97)E<W0@87)E(&%P<')O>&EM871E;'D@)#,X
M+#`P,"P@)#(U+#`P,"!A;F0@)#$T+#`P,"!F;W(@=&AE('EE87)S#0H@("!E
M;F1I;F<@1&5C96UB97(F(S$V,#LS,2P@,C`Q,BP@,C`Q,R!A;F0@,C`Q-"P@
M<F5S<&5C=&EV96QY+B!);G1E<F5S="!E>'!E;G-E(')E;&%T960@=&\@=&AE
M(&-A<&ET86P@;&5A<V5S('=A<R`D-BPP,#`@9F]R(&5A8V@@;V8@=&AE('EE
M87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@86YD(#(P,3`N(#PO
M9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S0S839E,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T,V$V93`Q-5\V,&$X7S0P
M96-?.3`P-U\Y9&$T,6(Q,&1B9F,O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C<G5E9"!%
M>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!,:6%B:6QI=&EE<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-R
M=65D($5X<&5N<V5S(&%N9"!/=&AE<B!#=7)R96YT($QI86)I;&ET:65S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C<G5E9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!,:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/
M0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N
M<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T14
M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN
M($)L;V-K(%1A9V=E9"!.;W1E(#@@+2!U<RUG86%P.D%C8V]U;G1S4&%Y86)L
M94%C8W)U961,:6%B:6QI=&EE<T%N9$]T:&5R3&EA8FEL:71I97-$:7-C;&]S
M=7)E0W5R<F5N=%1E>'1";&]C:RTM/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM
M=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXX+B8C,38P
M.R8C,38P.R8C,38P.R8C,38P.T%C8W)U960@17AP96YS97,@86YD($]T:&5R
M($-U<G)E;G0@3&EA8FEL:71I97,@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^06-C<G5E9"!E>'!E;G-E<R!A;F0@;W1H
M97(@8W5R<F5N="!L:6%B:6QI=&EE<R!C;VYS:7-T(&]F('1H92!F;VQL;W=I
M;F<@*&EN('1H;W5S86YD<RDZ(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP
M<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&%L
M:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*
M("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#@R)3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,3X\8CY&;W(@=&AE(%EE87)S/&)R("\^16YD960\8G(@+SY$96-E
M;6)E<B8C,38P.S,Q+#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,#PO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@
M16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@
M+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY0<F]F97-S:6]N86P@9F5E
M<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU,C`\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXS,3,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M8V]S=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXW-34\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C8P/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C
M8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^4&%Y<F]L;"!R96QA=&5D(&-O<W1S/"]F;VYT/CPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^.#8X/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW
M-#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E
M;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CY/=&AE<CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C(U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E
M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^5&]T86P@86-C<G5E9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!L
M:6%B:6QI=&EE<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXR+#$V.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C$L,3$S/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N
M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO
M=&%B;&4^(`T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT
M;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0S839E,#$U7S8P
M83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8PT*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B
M9F,O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I
M97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S
M0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W
M=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T
M9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#D@+2!U
M<RUG86%P.D-O;6UI=&UE;G1S06YD0V]N=&EN9V5N8VEE<T1I<V-L;W-U<F54
M97AT0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R
M9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXY+B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.T-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S(#PO8CX\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN
M+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!#;VUP
M86YY(&%C<75I<F5S(&%S<V5T<R!S=&EL;"!I;B!D979E;&]P;65N="!A;F0@
M96YT97)S(&EN=&\@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&%R<F%N9V5M
M96YT<R!W:71H('1H:7)D#0H@("!P87)T:65S('1H870@;V9T96X@<F5Q=6ER
M92!M:6QE<W1O;F4@86YD(')O>6%L='D@<&%Y;65N=',@8F%S960@;VX@=&AE
M('!R;V=R97-S(&]F('1H92!A<W-E="!T:')O=6=H(&1E=F5L;W!M96YT('-T
M86=E<RX@36EL97-T;VYE('!A>6UE;G1S(&UA>2!B92!R97%U:7)E9"P@9F]R
M(&5X86UP;&4L('5P;VX@87!P<F]V86P@;V8@=&AE('!R;V1U8W0@9F]R(&UA
M<FME=&EN9R!B>2!A(')E9W5L871O<GD@86=E;F-Y+B!);B!C97)T86EN#0H@
M("!A9W)E96UE;G1S+"!T:&4@0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!M86ME
M(')O>6%L='D@<&%Y;65N=',@8F%S960@=7!O;B!A('!E<F-E;G1A9V4@;V8@
M=&AE('-A;&5S+B!"96-A=7-E(&]F('1H92!C;VYT:6YG96YT(&YA='5R92!O
M9B!T:&5S92!P87EM96YT<RP@=&AE>2!A<F4@;F]T(&EN8VQU9&5D(&EN('1H
M92!T86)L92!O9B!C;VYT<F%C='5A;"!O8FQI9V%T:6]N<R!S:&]W;B!B96QO
M=R`H<V5E(&%L<V\@3F]T928C,38P.S$U*2X-"B`@(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P
M>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE<V4@87)R86YG96UE;G1S
M(&UA>2!B92!M871E<FEA;"!I;F1I=FED=6%L;'DL(&%N9"!I;B!T:&4@=6YL
M:6ME;'D@979E;G0@=&AA="!M:6QE<W1O;F5S(&9O<B!M=6QT:7!L92!P<F]D
M=6-T<R!C;W9E<F5D(&)Y#0H@("!T:&5S92!A<G)A;F=E;65N=',@=V5R92!R
M96%C:&5D(&EN('1H92!S86UE('!E<FEO9"P@=&AE(&%G9W)E9V%T92!C:&%R
M9V4@=&\@97AP96YS92!C;W5L9"!B92!M871E<FEA;"!T;R!T:&4@<F5S=6QT
M<R!O9B!O<&5R871I;VYS+B!);B!A9&1I=&EO;BP@=&AE<V4@87)R86YG96UE
M;G1S(&]F=&5N(&=I=F4@=&AE($-O;7!A;GD@=&AE(&1I<V-R971I;VX@=&\@
M=6YI;&%T97)A;&QY('1E<FUI;F%T92!D979E;&]P;65N="!O9B!T:&4-"B`@
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M=')A8W1U86P@;V)L:6=A=&EO;G,@=&AA=`T*("`@=VEL;"!R97%U:7)E(&9U
M='5R92!C87-H('!A>6UE;G1S(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3$@87)E(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[
M;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E
M<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT
M+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G:6X@
M5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0T.24^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/D]P97)A=&EN9SQB<B`O/DQE87-E<R@Q*3PO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@
M<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY.;VXM0V%N8V5L86)L93QB<B`O
M/D5M<&QO>6UE;G0\8G(@+SY!9W)E96UE;G1S*#(I/"]B/CPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0Q/CQB/E-U8G1O=&%L/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/D-A;F-E;&%B;&4\8G(@+SY,:6-E;G-E/&)R("\^06=R965M
M96YT<R@S*3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY4;W1A;#PO
M8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA
M+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O
M9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR,#$R/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$S.3PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L
M-S<T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,2PY,30\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU-S@\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+#0Y,CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C(P,3,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXR-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PP,#8\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$L,#,Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXT-3,\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L-#@T/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,C`Q-#PO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0Q
M,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^-#$U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT-C,\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C@W.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C(P,34\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXS/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS,#`\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C,P,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-3,X/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXX-#$\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR,#$V/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,3`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXQ,#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CDX.#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^,2PP.3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXR,#$W(&%N9"!4:&5R96%F=&5R/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^-RPQ-S,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<L,3<S/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L
M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,3<R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPU.3,\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS+#<V-3PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C$P+#$Y,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C$S+#DU.#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T1F
M;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P
M>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@<W1Y;&4],T0G8F]R9&5R+6-O;&QA
M<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!B;W)D97(],T0P(&-E
M;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^*#$I/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/<&5R871I;F<@;&5A
M<V5S(&%R92!P<FEM87)I;'D@9F%C:6QI='D@86YD(&5Q=6EP;65N="!R96QA
M=&5D(&]B;&EG871I;VYS('=I=&@@=&AI<F0@<&%R='D@=F5N9&]R<RX@3W!E
M<F%T:6YG(&QE87-E(&5X<&5N<V5S(&1U<FEN9R!T:&4@>65A<G,@96YD960@
M1&5C96UB97(F(S$V,#LS,2P-"B`@(#(P,3$@86YD(#(P,3`@=V5R92!A<'!R
M;WAI;6%T96QY("0R,S,L,#`P(&%N9"`D,C<T+#`P,"P@<F5S<&5C=&EV96QY
M+B`\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@
M<W1Y;&4],T1F;VYT+7-I>F4Z,W!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB
M;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!S='EL93TS1"=B;W)D
M97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&)O<F1E
M<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS
M1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#,E('9A;&EG;CTS
M1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,BD\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
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M("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE
M.C-P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\
M+W`^#0H@("`\=&%B;&4@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!T97AT+6%L:6=N.B!L969T)R!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^*#,I/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
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M86UO=6YT<R!W:6QL(&)E(&1U92X@/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*
M("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA
M<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@
M0V]M<&%N>2!A<'!L:65S('1H92!D:7-C;&]S=7)E('!R;W9I<VEO;G,@1D%3
M0B!!4T,@5&]P:6,@-#8P("@F(S@R,C`[05-#(#0V,"8C.#(R,3LI+"`F(S@R
M,C`[(#QI/D=U87)A;G1O<B8C.#(Q-SMS($%C8V]U;G1I;F<@86YD#0H@("!$
M:7-C;&]S=7)E(%)E<75I<F5M96YT<R!F;W(@1W5A<F%N=&5E<RP@26YC;'5D
M:6YG($EN9&ER96-T($=U87)A;G1E97,@;V8@26YD96)T961N97-S(&]F($]T
M:&5R/"]I/CQI/G,\+VD^)B,X,C(Q.RP@=&\@:71S(&%G<F5E;65N=',@=&AA
M="!C;VYT86EN(&=U87)A;G1E92!O<B!I;F1E;6YI9FEC871I;VX@8VQA=7-E
M<RX@5&AE($-O;7!A;GD@<')O=FED97,@*&DI)B,Q-C`[:6YD96UN:69I8V%T
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M;V8@=F%R>6EN9R!S8V]P92!A;F0@<VEZ92!T;R!O9F9I8V5R<R!A;F0-"B`@
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M9B!T:&5S92!O8FQI9V%T:6]N<R!A;F0-"B`@(&1O97,@;F]T(&5X<&5C="!T
M;R!I;F-U<B!M871E<FEA;"!C;W-T<R!I;B!T:&4@9G5T=7)E+B!!8V-O<F1I
M;F=L>2P@=&AE($-O;7!A;GD@:&%S(&YO="!A8V-R=65D(&%N>2!L:6%B:6QI
M=&EE<R!I;B!I=',@9FEN86YC:6%L('-T871E;65N=',@<F5L871E9"!T;R!T
M:&5S92!I;F1E;6YI9FEC871I;VYS+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,'!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY/;@T*("`@3F]V96UB97(F(S$V,#LR,2P@,C`Q,2P@2'5D<V]N($)A>2!-
M87-T97(@1G5N9"P@3'1D+B`H)B,X,C(P.TAU9'-O;B!"87DF(S@R,C$[*2!F
M:6QE9"!A($-O;7!L86EN="!A9V%I;G-T('1H92!#;VUP86YY(&EN('1H92!5
M;FET960@4W1A=&5S($1I<W1R:6-T($-O=7)T(&9O<B!T:&4@4V]U=&AE<FX@
M1&ES=')I8W0@;V8@3F5W(%EO<FL@*'1H92`F(S@R,C`[0V]U<G0F(S@R,C$[
M*2P@8V%P=&EO;F5D(#QU/DAU9'-O;B!"87D@36%S=&5R#0H@("!&=6YD+"!,
M=&0N('8N($=A;&5N82!":6]P:&%R;6$L($EN8RXL(#$Q($-I=BX@.#0S,B`H
M2E!/*3PO=3XL(&%L;&5G:6YG('1H870@=&AE($-O;7!A;GDF(S@R,3<[<R!P
M;&%N('1O('!A<G1I86QL>2!S<&EN(&]F9B!26&D@86YD(')E;&%T960@86-T
M:6]N<R!T86ME;B!I;B!P<F5P87)A=&EO;B!F;W(@=&AE('-P:6XM;V9F(&=I
M=F5S($AU9'-O;B!"87D@=&AE(')I9VAT('1O(')E<75I<F4@=7,@=&\@<F5P
M=7)C:&%S92!T:&4-"B`@('=A<G)A;G1S(&%C<75I<F5D(&)Y($AU9'-O;B!"
M87D@:6X@;W5R($%P<FEL(#(P,3$@=6YD97)W<FET=&5N('!U8FQI8R!O9F9E
M<FEN9RX@2'5D<V]N($)A>2!A;'-O('-E96MS(')E;&%T960@9&5C;&%R871O
M<GD@86YD(&EN:G5N8W1I=F4@<F5L:65F+B!/;B!*86YU87)Y)B,Q-C`[,3(L
M(#(P,3(L('1H<F5E(&]T:&5R('=A<G)A;G0@:&]L9&5R<R!A9F9I;&EA=&5D
M('=I=&@@96%C:"!O=&AE<B!F:6QE9"!A($-O;7!L86EN="!I;@T*("`@=&AE
M($-O=7)T+"!C87!T:6]N960@/'4^5&5N;W(@3W!P;W)T=6YI='D@1G5N9"P@
M3'1D+BP@07)I82!/<'!O<G1U;FET>2!&=6YD+"!,=&0N+"!A;F0@/"]U/CQU
M/E!A<G-O;VX@3W!P;W)T=6YI='D@1G5N9"P@3'1D+B!V+B!'86QE;F$@0FEO
M<&AA<FUA+"!);F,N+"`Q,B!#258@,#(V,#PO=3XL(&%N9"!O;B!*86YU87)Y
M)B,Q-C`[,C`L(#(P,3(@86YD($9E8G)U87)Y)B,Q-C`[,BP@,C`Q,BP@<F5S
M<&5C=&EV96QY+"!T=V\@;W1H97(-"B`@('=A<G)A;G0@:&]L9&5R<R!F:6QE
M9"!T:&5I<B!O=VX@0V]M<&QA:6YT<R!I;B!T:&4@0V]U<G0L(&-A<'1I;VYE
M9"`\=3Y#<F%N<VAI<F4@0V%P:71A;"!-87-T97(@1G5N9"P@3'1D+B!V+B!'
M86QE;F$@0FEO<&AA<FUA+"!);F,N+"`Q,B8C,38P.T-)5B`P-#DS/"]U/B!A
M;F0@/'4^27)O<75O:7,@36%S=&5R($9U;F0L($QT9"X@=BX@1V%L96YA($)I
M;W!H87)M82P@26YC+BP@,3(@0TE6(#`X,SD\+W4^+"!R97-P96-T:79E;'DN
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M('1O(')E<75I<F4@=&AE($-O;7!A;GD@=&\-"B`@(')E<'5R8VAA<V4@=&AE
M($-O;7!A;GDF(S@R,3<[<R!O=71S=&%N9&EN9R!W87)R86YT<R!H96QD(&)Y
M('1H96TN($%C8V]R9&EN9R!T;R!T:&4@86QL96=A=&EO;G,@:6X@=&AE($-O
M;7!L86EN=',L('1H92!R97!U<F-H87-E('!R:6-E(&]F('1H92!P;&%I;G1I
M9F9S)B,X,C$W.R!W87)R86YT<R!W;W5L9"!A;6]U;G0@=&\@87!P<F]X:6UA
M=&5L>2`D-2XR(&UI;&QI;VX@:6X@=&AE(&%G9W)E9V%T92X@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/;B!-87)C:"8C,38P
M.S(Q+"`R,#$R+"!T:&4@0V]M<&%N>2!R96-E:79E9"!L971T97)S(&9R;VT@
M96%C:"!O9B!T:&4@<&QA:6YT:69F+7=A<G)A;G0@:&]L9&5R<R!W:71H9')A
M=VEN9R!T:&5I<B!R97!U<F-H87-E(&1E;6%N9',@=VET:`T*("`@<F5S<&5C
M="!T;R!T:&5I<B!W87)R86YT<R!C;W9E<FEN9R!A;B!A9V=R96=A=&4@;V8@
M-BPS-3`L,#`P('-H87)E<R!O=70@;V8@82!T;W1A;"!O9B`V+#@U,"PP,#`@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!P=7)C:&%S86)L92!U;F1E<B!T:&5I
M<B!W87)R86YT<R`H=&AE("8C.#(R,#M7:71H9')A=V%L($YO=&EC93QB/G,\
M+V(^)B,X,C(Q.RDN($%F=&5R(&=I=FEN9R!E9F9E8W0@=&\@=&AE(%=I=&AD
M<F%W86P@3F]T:6-E<RP@=&AE#0H@("!P;&%I;G1I9F8M=V%R<F%N="!H;VQD
M97)S(&-O;G1I;G5E9"!T;R!D96UA;F0@=&AA="!T:&4@0V]M<&%N>2!R97!U
M<F-H87-E('1H96ER('=A<G)A;G1S(&-O=F5R:6YG('1H92!B86QA;F-E(&]F
M(#4P,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I;B!T:&4@86=G<F5G
M871E+B!"87-E9"!O;B!T:&4@<&QA:6YT:69F+7=A<G)A;G0@:&]L9&5R<R8C
M.#(Q-SL@8VQA:6US(&EN('1H96ER($-O;7!L86EN=',L('1H92!#;VUP86YY
M#0H@("!B96QI979E<R!T:&%T('1H92!R97!U<F-H87-E('!R:6-E(&9O<B!T
M:&5S92!W87)R86YT<R!I<R`D,"XW,2!P97(@=6YD97)L>6EN9R!S:&%R92P@
M;W(@86X@86=G<F5G871E(&]F("0S-34L,#`P+B!/;B!-87)C:"`R-RP@,C`Q
M,BP@=&AE($-O;7!A;GD@=&5N9&5R960@=&\@=&AE('!L86EN=&EF9BUW87)R
M86YT(&AO;&1E<G,@86X@86=G<F5G871E(&]F("0S-34L,#`P(&%S('!A>6UE
M;G0@:6X@9G5L;"!O9B!T:&4@<F5P=7)C:&%S90T*("`@<')I8V4@9F]R('1H
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M(%=I=&AD<F%W86P-"B`@($YO=&EC97,@<'5R<&]R="!T;R!R97-E<G9E(&%L
M;"!R:6=H=',@;V8@=&AE('!L86EN=&EF9BUW87)R86YT(&AO;&1E<G,@=6YD
M97(@=&AE($-O;7!L86EN=',N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^268@=&AE($-O;7!A;GD@=V5R92!T;R!B96-O;64-
M"B`@(&QI86)L92!T;R!R97!U<F-H87-E('1H92!P;&%I;G1I9F9S)B,X,C$W
M.R!W87)R86YT<RP@=&AE($-O;7!A;GD@;6%Y(&YO="!H879E(&]N(&AA;F0@
M<W5F9FEC:65N="!F=6YD<R!T;R!S871I<V9Y('1H92!L:6%B:6QI='D@86YD
M('1O(&UE970@:71S(&]T:&5R(&]B;&EG871I;VYS(&%S('1H97D@8V]M92!D
M=64L('=H:6-H(&-O=6QD(')A:7-E(&1O=6)T<R!A<R!T;R!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&%B:6QI='D@=&\@8V]N=&EN=64-"B`@(&%S(&$@9V]I;F<@
M8V]N8V5R;BX@/"]F;VYT/CPO<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-#-A-F4P,35?-C!A.%\T,&5C7SDP,#=?.61A
M-#%B,3!D8F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0S839E
M,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8R]7;W)K<VAE971S+U-H
M965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET
M>2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O
M5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O
M=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN
M9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@,3`@
M+2!U<RUG86%P.E-T;V-K:&]L9&5R<T5Q=6ET>4YO=&5$:7-C;&]S=7)E5&5X
M=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/CQB/C$P+B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.U-T;V-K:&]L9&5R<R8C.#(Q-SL@17%U:71Y(#PO8CX\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O
M='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/E!R969E<G)E
M9"!3=&]C:R`\+VD^)B,X,C$R.R!4:&4@0V]M<&%N>2!H87,@875T:&]R:7IE
M9"!U<"!T;R`U+#`P,"PP,#`F(S$V,#MS:&%R97,@;V8@<')E9F5R<F5D('-T
M;V-K+`T*("`@)#`N,#`P,28C,38P.W!A<B!V86QU92!P97(@<VAA<F4L(&9O
M<B!I<W-U86YC92X@5&AE('!R969E<G)E9"!S=&]C:R!W:6QL(&AA=F4@<W5C
M:"!R:6=H=',L('!R969E<F5N8V5S+"!P<FEV:6QE9V5S(&%N9"!R97-T<FEC
M=&EO;G,L(&EN8VQU9&EN9R!V;W1I;F<@<FEG:'1S+"!D:79I9&5N9"!R:6=H
M=',L(&-O;G9E<G-I;VX@<FEG:'1S+"!R961E;7!T:6]N('!R:79I;&5G97,@
M86YD(&QI<75I9&%T:6]N('!R969E<F5N8V5S+"!A<PT*("`@<VAA;&P@8F4@
M9&5T97)M:6YE9"!B>2!T:&4@0V]M<&%N>28C.#(Q-SMS(&)O87)D(&]F(&1I
M<F5C=&]R<R!U<&]N(&ET<R!I<W-U86YC92X@070@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,2P@=&AE<F4@=V5R92!N;R!S:&%R97,@;V8@<')E9F5R<F5D('-T
M;V-K(&]U='-T86YD:6YG+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/@T*("`@/&D^0V]M;6]N(%-T;V-K(#PO:3XF(S@R,3([
M(%1H92!#;VUP86YY(&AA<R!A=71H;W)I>F5D('5P('1O(#$R-2PP,#`L,#`P
M)B,Q-C`[<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@)#`N,#`P,28C,38P.W!A
M<B!V86QU92!P97(@<VAA<F4L(&9O<B!I<W-U86YC92X@4VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!A<F4@<F5S97)V960@87,@9F]L;&]W<SH-"B`@(#PO9F]N
M=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O
M<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@
M8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[
M('1E>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"
M96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS
M1#@V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,3X\8CY!<R!O9CQB<B`O/D1E8V5M8F5R)B,Q-C`[,S$L/&)R("\^
M,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-
M"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A
M8FQE($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY787)R86YT
M<R!O=71S=&%N9&EN9SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C$T+#$R,"PV-#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY3=&]C:R!O<'1I;VYS
M(&]U='-T86YD:6YG/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^-BPQ-C,L,3,W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E
M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^3W!T:6]N<R!R97-E<G9E9"!F;W(@9G5T=7)E(&ES<W5A;F-E('5N9&5R
M('1H92!#;VUP86YY)B,X,C$W.W,@,C`P-R!);F-E;G1I=F4@4&QA;CPO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L,CDY
M+#<Q-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&]T86P@<F5S97)V960@9F]R(&9U='5R
M92!I<W-U86YC93PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C(Q+#4X,RPT.38\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!4
M86)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$9F]N
M="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD
M96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/CQI/D-O;6UO;B!3=&]C:R!787)R86YT<R`\+VD^
M)B,X,C$R.R!/;B!!=6=U<W0F(S$V,#LW+"`R,#`X+"!T:&4@0V]M<&%N>2!I
M<W-U960@,3DP+#`P,`T*("`@=V%R<F%N=',@=&\@86X@:6YV97-T;65N="!B
M86YK(&%S(&-O;G-I9&5R871I;VX@9F]R(&EN=F5S=&UE;G0@86YD(&)U<VEN
M97-S(&%D=FES;W)Y('-E<G9I8V5S+B!4:&4@=V%R<F%N=',@:&%V92!A;B!E
M>&5R8VES92!P<FEC92!O9B`D-RXP,S8@<&5R('-H87)E(&%N9"!E>'!I<F4@
M-28C,38P.WEE87)S(&9R;VT@=&AE(&1A=&4@;V8@:7-S=6%N8V4L(&]N($%U
M9W5S="8C,38P.S<L(#(P,3,N(%1H92!W87)R86YT<R!V97-T960@87,-"B`@
M('1O(#DT+#`P,"8C,38P.W-H87)E<R!U<&]N(&ES<W5A;F-E+"!A;F0@=F5S
M=&5D(&%T(&$@<F%T92!O9B`S,BPP,#`F(S$V,#MS:&%R97,F(S$V,#MP97(@
M;6]N=&@@<W1A<G1I;F<@;VX@=&AE(#DP)B,Q-C`[9&%Y(&%N;FEV97)S87)Y
M(&]F(&ES<W5A;F-E+"!A;F0@87)E(&5X97)C:7-A8FQE(&9O<B!A('!E<FEO
M9"!O9B!F:79E('EE87)S+B!!;&P@<VAA<F5S('=E<F4@=F5S=&5D(&%N9"!C
M;VUP96YS871I;VX@8V]S="!W87,-"B`@(&9U;&QY(')E8V]R9&5D(&%T($1E
M8V5M8F5R)B,Q-C`[,S$L(#(P,#DN(%1H92!#;VUP86YY(&%L<V\@86=R965D
M('1O(&=I=F4@=&AE(&AO;&1E<B!O9B!T:&4@=V%R<F%N=',@=6YL:6UI=&5D
M("8C.#(R,#MP:6=G>2!B86-K)B,X,C(Q.R!R96=I<W1R871I;VX@<FEG:'1S
M('=I=&@@<F5S<&5C="!T;R!T:&4@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X
M,C$W.W,@8V]M;6]N('-T;V-K('5N9&5R;'EI;F<@=&AE('=A<G)A;G1S(&EN
M(&%N>0T*("`@<F5G:7-T<F%T:6]N('-T871E;65N="!T:&4@0V]M<&%N>2!F
M:6QE<R!I;B!C;VYN96-T:6]N('=I=&@@86X@=6YD97)W<FET=&5N(&]F9F5R
M:6YG(&]F(&ET<R!C;VUM;VX@<W1O8VLN(#PO9F]N=#X\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3VX@3V-T;V)E<B8C,38P.S,L#0H@("`R
M,#`X+"!T:&4@0V]M<&%N>2!A8W%U:7)E9"!T:&4@<FEG:'1S('1O(&QI8V5N
M<V4@97AC;'5S:79E('=O<FQD=VED92!T96-H;F]L;V=Y(&9O<B!T:&4@;W)A
M;"!D96QI=F5R>2!O9B!23D%I('1H97)A<&5U=&EC<RX@07,@8V]N<VED97)A
M=&EO;B!F;W(@=&AI<R!L:6-E;G-E+"!T:&4@0V]M<&%N>2!A9W)E960@=&\@
M<&%Y(&$@=&]T86P@;&EC96YS92!F964@;V8@)#(L-3`P+#`P,"!O=F5R(&$@
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M;&4-"B`@('5P;VX@8V]N=F5R<VEO;B!O9B!T:&4@=V%R<F%N="!H879E(&)E
M96X@<F5G:7-T97)E9"!F;W(@<F5S86QE('5N9&5R('1H92!396-U<FET:65S
M($%C="!O9B`Q.3,S+B!.;R!W87)R86YT<R!H879E(&)E96X@:7-S=65D('5N
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M9&5D#0H@("!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&%N9"`R,#$P+B`\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN
M+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]N($IA;G5A
M<GDF(S$V,#LR.2P@,C`P.2P@=&AE($-O;7!A;GD@:7-S=65D(#$T,BPU,#`@
M=V%R<F%N=',@=&\@86X@:6YV97-T;65N="!B86YK(&%S#0H@("!C;VYS:61E
M<F%T:6]N(&9O<B!I;G9E<W1M96YT(&%N9"!B=7-I;F5S<R!A9'9I<V]R>2!S
M97)V:6-E<RX@5&AE('=A<G)A;G1S(&AA=F4@86X@97AE<F-I<V4@<')I8V4@
M;V8@)#0N,C<S('!E<B!S:&%R92!A;F0@97AP:7)E(&9I=F4@>65A<G,@9G)O
M;2!T:&4@9&%T92!O9B!I<W-U86YC92!O;B!*86YU87)Y)B,Q-C`[,CDL(#(P
M,30N(%1H92!W87)R86YT<R!V97-T960@87,@=&\@-S$L,C4P)B,Q-C`[<VAA
M<F5S('5P;VX-"B`@(&ES<W5A;F-E+"!A;F0@=F5S=&5D(&%T(&$@<F%T92!O
M9B`R,RPW-3`F(S$V,#MS:&%R97,F(S$V,#MP97(@;6]N=&@@<W1A<G1I;F<@
M;VX@=&AE(#DP)B,Q-C`[9&%Y(&%N;FEV97)S87)Y(&]F(&ES<W5A;F-E+"!A
M;F0@87)E(&5X97)C:7-A8FQE(&9O<B!A('!E<FEO9"!O9B!F:79E('EE87)S
M+B!!;&P@<VAA<F5S('=E<F4@=F5S=&5D(&%N9"!C;VUP96YS871I;VX@97AP
M96YS92!W87,@9G5L;'D@<F5C;W)D960@870-"B`@($1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,#DN(%1H92!#;VUP86YY(&AA<R!A;'-O(&%G<F5E9"!T;R!G:79E
M('1H92!H;VQD97(@;V8@=&AE('=A<G)A;G1S('5N;&EM:71E9"`F(S@R,C`[
M<&EG9WD@8F%C:R8C.#(R,3L@<F5G:7-T<F%T:6]N(')I9VAT<R!W:71H(')E
M<W!E8W0@=&\@=&AE('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=6YD97)L>6EN
M9R!T:&4@=V%R<F%N=',@:6X@86YY(')E9VES=')A=&EO;B!S=&%T96UE;G0@
M=&AE($-O;7!A;GD-"B`@(&9I;&5S(&EN(&-O;FYE8W1I;VX@=VET:"!A;B!U
M;F1E<G=R:71T96X@;V9F97)I;F<@;V8@=&AE(&-O;6UO;B!S=&]C:RX@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I
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M92!H96%D:6YG("8C.#(R,#LR,#`Y(%)E9VES=&5R960@1&ER96-T($]F9F5R
M:6YG)B,X,C(Q.R!B96QO=RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N
M=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY);B!C;VYN96-T:6]N('=I=&@@=&AE(#(P,3`@3V9F
M97)I;F<L('1H92!#;VUP86YY(&ES<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S
M92`U-#`L,#`P)B,Q-C`[<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@
M8V]M;6]N('-T;V-K+@T*("`@1&5T86EL<R!O9B!T:&4@=')A;G-A8W1I;VX@
M8V%N(&)E(&9O=6YD('5N9&5R('1H92!H96%D:6YG("8C.#(R,#LR,#$P(%)E
M9VES=&5R960@1&ER96-T($]F9F5R:6YG)B,X,C(Q.R!B96QO=RX@/"]F;VYT
M/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB
M;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!C;VYN96-T
M:6]N#0H@("!W:71H('1H92!-87)C:"`R,#$Q($]F9F5R:6YG+"!T:&4@0V]M
M<&%N>2!I<W-U960@=V%R<F%N=',@=&\@<'5R8VAA<V4@-BPP,#`L,#`P)B,Q
M-C`[<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K
M+B!$971A:6QS(&]F('1H92!T<F%N<V%C=&EO;B!C86X@8F4@9F]U;F0@=6YD
M97(@=&AE(&AE861I;F<@)B,X,C(P.TUA<F-H(#(P,3$@4F5G:7-T97)E9"!$
M:7)E8W0@3V9F97)I;F<F(S@R,C$[(&)E;&]W+@T*("`@/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!C;VYN96-T:6]N('=I
M=&@@=&AE($%P<FEL(#(P,3$@3V9F97)I;F<L('1H92!#;VUP86YY(&ES<W5E
M9"!W87)R86YT<R!T;R!P=7)C:&%S92`Q,2PY-3`L,#`P)B,Q-C`[<VAA<F5S
M(&]F('1H90T*("`@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@1&5T
M86EL<R!O9B!T:&4@=')A;G-A8W1I;VX@8V%N(&)E(&9O=6YD('5N9&5R('1H
M92!H96%D:6YG("8C.#(R,#M!<')I;"`R,#$Q(%)E9VES=&5R960@1&ER96-T
M($]F9F5R:6YG)B,X,C(Q.R!B96QO=RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@($1U<FEN9R`R,#$Q+"!T:&4@0V]M
M<&%N>2!I<W-U960@,34P+#`P,"!W87)R86YT<R!I;B!E>&-H86YG92!F;W(@
M8G5S:6YE<W,@861V:7-O<GD@<V5R=FEC97,N(%1H92!#;VUP86YY(')E8V]G
M;FEZ97,@=&AE('1O=&%L(&9A:7(@=F%L=64@;V8@=&AE<V4@=V%R<F%N=',@
M87,@<W1O8VL@8V]M<&5N<V%T:6]N(&5X<&5N<V4L(&]V97(@=&AE(')E<75I
M<VET90T*("`@<V5R=FEC92!P97)I;V0N(%1H92!#;VUP86YY('5S960@=&AE
M($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96P@=&\@8V]M<'5T
M92!T:&4@97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@=&AE<V4@=V%R<F%N="!G
M<F%N=',@;VX@=&AE(&1A=&4@;V8@=&AE(&%W87)D+B!4;W1A;"!E>'!E;G-E
M(')E;&%T960@=&\@=&AE<V4@=V%R<F%N=',@=V%S("0Q,#@L,#`P(&EN(#(P
M,3$N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M/&D^4')I=F%T92!);G9E<W1M96YT(&EN(%!U8FQI8R!%<75I='D@/"]I/B8C
M.#(Q,CL@3VX@2G5N928C,38P.S(T+"`R,#`X+"!T:&4@0V]M<&%N>2!E;G1E
M<F5D(&EN=&\@82!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="!P=7)S
M=6%N=`T*("`@=&\@=VAI8V@@4EAI(&ES<W5E9"!A;F0@<V]L9"!T;R!C97)T
M86EN(&EN=F5S=&]R<R!A;B!A9V=R96=A=&4@;V8@,2PP-S,L,CDY)B,Q-C`[
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I;B!A('!R:79A=&4@<&QA8V5M96YT
M(&%T(&$@<')I8V4@;V8@)#@N,3(@<&5R('-H87)E+B!.970@<')O8V5E9',@
M=&\@=&AE($-O;7!A;GD@=V5R92!A<'!R;WAI;6%T96QY("0W+CDF(S$V,#MM
M:6QL:6]N+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z
M,7!X.VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3XR,#`Y(%)E9VES
M=&5R960-"B`@($1I<F5C="!/9F9E<FEN9R`\+VD^)B,X,C$R.R!/;B!-87)C
M:"8C,38P.S$W+"`R,#`Y+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!P
M;&%C96UE;G0@86=E;F-Y(&%G<F5E;65N="P@=VAI8V@@=V%S('-U8G-E<75E
M;G1L>2!A;65N9&5D(&]N($UA>28C,38P.S(V+"`R,#`Y(&%N9"!*=6QY)B,Q
M-C`[,C(L(#(P,#DL('=I=&@@4F]D;6%N)B,Q-C`[)B,P,S@[(%)E;G-H87<L
M($Q,0R`H)B,X,C(P.U)O9&UA;B8C.#(R,3LI(&%S('1H90T*("`@97AC;'5S
M:79E('!L86-E;65N="!A9V5N="P@<F5L871I;F<@=&\@82!P<F]P;W-E9"!O
M9F9E<FEN9R!B>2!T:&4@0V]M<&%N>2!O9B!N97<@<V5C=7)I=&EE<R!T;R!P
M;W1E;G1I86P@:6YV97-T;W)S+B!/;B!*=6QY)B,Q-C`[,S`L(#(P,#DL('1H
M92!#;VUP86YY(&5N=&5R960@:6YT;R!D969I;FET:79E(&%G<F5E;65N=',@
M9F]R('1H92!S86QE(&%N9"!I<W-U86YC92!B>2!T:&4@0V]M<&%N>2!T;R!C
M97)T86EN(&EN=F5S=&]R<PT*("`@;V8@,BPS.#4L-S$U)B,Q-C`[=6YI=',L
M('=I=&@@96%C:"!U;FET(&-O;G-I<W1I;F<@;V8@;VYE('-H87)E(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%N9"!A('=A<G)A;G0@
M=&\@<'5R8VAA<V4@,"XT,"!O9B!A('-H87)E(&]F(&-O;6UO;B!S=&]C:RP@
M870@82!P=7)C:&%S92!P<FEC92!O9B`D,RXU,"!P97(@=6YI="`H=&AE("8C
M.#(R,#LR,#`Y($]F9F5R:6YG)B,X,C(Q.RDN(%1H92`R,#`Y($]F9F5R:6YG
M#0H@("!C;&]S960@;VX@075G=7-T)B,Q-C`[-"P@,C`P.2X@5&AE('=A<G)A
M;G1S(&AA=F4@86X@97AE<F-I<V4@<')I8V4@;V8@)#0N-3`@<&5R('-H87)E
M(&%N9"!A<F4@97AE<F-I<V%B;&4@9F]R(&$@<&5R:6]D(&)E9VEN;FEN9R!O
M;B!&96)R=6%R>28C,38P.S,L(#(P,3`@=6YT:6P@=&AE:7(@97AP:7)A=&EO
M;B!O;B!!=6=U<W0F(S$V,#LS+"`R,#$T+B!4:&4@0V]M<&%N>2!R86ES960@
M9W)O<W,@<')O8V5E9',@;V8-"B`@(&%P<')O>&EM871E;'D@)#@L,S4P+#`P
M,"!I;B!T:&4@,C`P.2!/9F9E<FEN9R!A;F0@;F5T(&-A<V@@<')O8V5E9',L
M(&%F=&5R(&1E9'5C=&EN9R!T:&4@<&QA8V5M96YT(&%G96YT<R8C.#(Q-SL@
M9F5E<R!A;F0@;W1H97(@;V9F97)I;F<@97AP96YS97,@<&%Y86)L92!B>2!T
M:&4@0V]M<&%N>2P@;V8@87!P<F]X:6UA=&5L>2`D-RXW)B,Q-C`[;6EL;&EO
M;BX@5&]T86P@=V%R<F%N=',@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!T
M:&4-"B`@('1R86YS86-T:6]N('=E<F4@.34T+#(X-2X@/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!<R!P87)T(&]F('1H92!P
M;&%C96UE;G0@86=E;F-Y(&%G<F5E;65N="P@=&AE($-O;7!A;GD@:7-S=65D
M(&$@=V%R<F%N="!T;R!P=7)C:&%S90T*("`@,C,L.#4W)B,Q-C`[<VAA<F5S
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K('1O(%)O9&UA
M;BX@5&AE('=A<G)A;G0@:&%S(&%N(&5X97)C:7-E('!R:6-E(&]F("0T+C,X
M('!E<B!S:&%R92X@5&AE('=A<G)A;G0@:7,@:6UM961I871E;'D@=F5S=&5D
M(&%N9"!I<R!E>&5R8VES86)L92!U;G1I;"!I=',@97AP:7)A=&EO;B!O;B!!
M=6=U<W0F(S$V,#LS+"`R,#$T+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD
M96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/D-E<G1A:6X@=V%R<F%N=',@:7-S=65D(&EN(&-O
M;FYE8W1I;VX@=VET:"!T:&4@<W1O8VL@;V9F97)I;F<@;VX@075G=7-T)B,Q
M-C`[-"P@,C`P.2!W97)E(&1E=&5R;6EN960@;F]T('1O(&)E(&EN9&5X960@
M=&\@=&AE#0H@("!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%S('1H
M97D@87)E('!O=&5N=&EA;&QY('-E='1L96%B;&4@:6X@8V%S:"X@5&AE(&9A
M:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&%T('1H92!D871E<R!O9B!I<W-U
M86YC92!T;W1A;&EN9R`D,BPX-C,L,#`P('=A<R!R96-O<F1E9"!A<R!A(&QI
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M92!P=6)L:6-L>0T*("`@=')A9&5D+B!4:&4@0V]M<&%N>2!U<V5D(&$@=V5I
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M,2P@,C`Q,2!A;F0@,C`Q,"!W87,-"B`@("0Q+#@W.2PP,#`@86YD("0Q+#<W
M."PP,#`L(')E<W!E8W1I=F5L>2X@5&AE<V4@86UO=6YT<R!H879E(&)E96X@
M:6YC;'5D960@:6X@;W1H97(@:6YC;VUE(&%N9"!E>'!E;G-E(&EN('1H92!A
M8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D('-T871E;65N=',@;V8@97AP96YS
M97,N(%1H92!F86ER('9A;'5E(&]F('1H92!W87)R86YT<R!A="!$96-E;6)E
M<B8C,38P.S,Q+"`R,#$Q(&]F("0V-"PP,#`@:7,@:6YC;'5D960@87,@80T*
M("`@8W5R<F5N="!L:6%B:6QI='D@:6X@=&AE(&%C8V]M<&%N>6EN9R!B86QA
M;F-E('-H965T(&%S(&]F('1H870@9&%T92!A;F0@=V%S(&1E=&5R;6EN960@
M8GD@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96PN(%1H
M92!F;VQL;W=I;F<@87-S=6UP=&EO;G,@=V5R92!U<V5D('1O(&1E=&5R;6EN
M92!T:&4@9F%I<B!V86QU92!A<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q
M.B!W96EG:'1E9"!A=F5R86=E(&5X<&5C=&5D#0H@("!S=&]C:R!V;VQA=&EL
M:71Y(&]F(#DX+CDQ)3L@86X@97AP96-T960@;&EF92!O9B`R+C8@>65A<G,@
M86YD(&$@9&EV:61E;F0@>6EE;&0@;V8@>F5R;R!A;F0@82!R:7-K(&9R964@
M<F%T92!O9B`P+C,Q)2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CX\:3XR,#$P#0H@("!296=I<W1E<F5D($1I<F5C="!/9F9E
M<FEN9SPO:3XF(S$V,#LF(S@R,3([($]N($UA<F-H)B,Q-C`[,C(L(#(P,3`L
M('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A('!L86-E;65N="!A9V5N8WD@
M86=R965M96YT(')E;&%T:6YG('1O(&$@<')O<&]S960@;V9F97)I;F<@8GD@
M=&AE($-O;7!A;GD@;V8@;F5W('-E8W5R:71I97,@=&\@<&]T96YT:6%L(&EN
M=F5S=&]R<RX@3VX@36%R8V@F(S$V,#LR,RP@,C`Q,"P@=&AE($-O;7!A;GD-
M"B`@(&5N=&5R960@:6YT;R!D969I;FET:79E(&%G<F5E;65N=',@9F]R('1H
M92!S86QE(&%N9"!I<W-U86YC92!B>2!T:&4@0V]M<&%N>2!T;R!C97)T86EN
M(&EN=F5S=&]R<R!O9B`R+#<P,"PP,#`F(S$V,#MU;FET<RP@=VET:"!E86-H
M('5N:70@8V]N<VES=&EN9R!O9B!O;F4@<VAA<F4@;V8@=&AE($-O;7!A;GDF
M(S@R,3<[<R!C;VUM;VX@<W1O8VL@86YD(&$@=V%R<F%N="!T;R!P=7)C:&%S
M92`P+C(P(&]F(&$@<VAA<F4@;V8@=&AE#0H@("!#;VUP86YY)B,X,C$W.W,@
M8V]M;6]N('-T;V-K+"!A="!A('!U<F-H87-E('!R:6-E(&]F("0V+C`P('!E
M<B!U;FET("AT:&4@)B,X,C(P.S(P,3`@3V9F97)I;F<F(S@R,C$[*2X@5&AE
M(#(P,3`@3V9F97)I;F<@8VQO<V5D(&]N($UA<F-H)B,Q-C`[,C8L(#(P,3`N
M(%1H92!#;VUP86YY(&ES<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S92`U-#`L
M,#`P)B,Q-C`[<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N
M('-T;V-K(&%T(&%N#0H@("!E>&5R8VES92!P<FEC92!O9B`D-BXP,"!P97(@
M<VAA<F4@86YD('1H870@87)E(&5X97)C:7-A8FQE(&)E9VEN;FEN9R!O;B!3
M97!T96UB97(F(S$V,#LR-BP@,C`Q,"!U;G1I;"!T:&5I<B!E>'!I<F%T:6]N
M(&]N($UA<F-H)B,Q-C`[,C8L(#(P,38N(%1H92!#;VUP86YY(')A:7-E9"!G
M<F]S<R!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0Q-BXR)B,Q-C`[;6EL
M;&EO;B!I;B!T:&4@,C`Q,"!/9F9E<FEN9R!A;F0@;F5T(&-A<V@-"B`@('!R
M;V-E961S+"!A9G1E<B!D961U8W1I;F<@=&AE('!L86-E;65N="!A9V5N="!F
M965S(&%N9"!O=&AE<B!O9F9E<FEN9R!E>'!E;G-E<R!P87EA8FQE(&)Y('1H
M92!#;VUP86YY+"!O9B!A<'!R;WAI;6%T96QY("0Q-2XR)B,Q-C`[;6EL;&EO
M;BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X
M.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-
M"B`@($%S('!A<G0@;V8@=&AE(#(P,3`@3V9F97)I;F<L('1H92!#;VUP86YY
M(&5N=&5R960@:6X@82!S=&]C:R!R961E;7!T:6]N(&%G<F5E;65N="!W:&5R
M96)Y('1H92!#;VUP86YY('=A<R!R97%U:7)E9"!T;R!U<V4@,C4E(&]F('1H
M92!N970@<')O8V5E9',@9G)O;2!T:&4@,C`Q,"!/9F9E<FEN9R!T;R!R97!U
M<F-H87-E(&9R;VT@0WET4G@-"B`@($-O<G!O<F%T:6]N("@F(S@R,C`[0WET
M4G@F(S@R,C$[*2`V-S4L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&-O;6UO;B!S=&]C:R!H96QD(&)Y($-Y=%)X("@F(S@R,C`[0WET4G@@
M<VAA<F5S)B,X,C(Q.RDN(%1H92!#;VUP86YY(')E<'5R8VAA<V5D('-U8V@@
M<VAA<F5S(&]N($UA<F-H)B,Q-C`[,CDL(#(P,3`N(%1H92!V86QU97,@;V8@
M=&AE('-H87)E<R!A="!T:&4@9&%T92!O9B!R97!U<F-H87-E('1O=&%L:6YG
M#0H@("`D,RPX-#DL,#`P('=E<F4@<F5C;W)D960@870@8V]S="!A;F0@:&%V
M92!B965N(&EN8VQU9&5D(&EN('1R96%S=7)Y('-T;V-K(&EN('1H92!A8V-O
M;7!A;GEI;F<@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970@870@1&5C96UB
M97(F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q,"X@/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C9P>#MM87)G:6XM
M8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^4VAA<F5S(&]F(&-O;6UO;@T*("`@<W1O8VL@=&AA="!A<F4@;6%N
M9&%T;W)I;'D@<F5D965M86)L92!U;F1E<B!T:&4@<W1O8VL@<F5D96UP=&EO
M;B!A9W)E96UE;G0@=7!O;B!T:&4@97AE<F-I<V4@;V8@=V%R<F%N=',@:7-S
M=65D(&EN('1H92`R,#$P($]F9F5R:6YG+"!W97)E(&1E=&5R;6EN960@=&\@
M96UB;V1Y(&%N(&]B;&EG871I;VX@=&AA="!M87D@<F5Q=6ER92!T:&4@0V]M
M<&%N>2!T;R!S971T;&4@=&AE(&]B;&EG871I;VX@8GD@=')A;G-F97)R:6YG
M#0H@("!A<W-E=',L(&%N9"!A<R!S=6-H+"!S:&%L;"!B92!C;&%S<VEF:65D
M(&%S(&$@;&EA8FEL:71Y+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@8V]M;6]N
M('-T;V-K('!O=&5N=&EA;&QY(')E9&5E;6%B;&4@=6YD97(@=&AE('-T;V-K
M(')E9&5M<'1I;VX@86=R965M96YT('1O=&%L:6YG("0W.#4L,#`P('=A<R!R
M96-O<F1E9"!A<R!A(&QI86)I;&ET>2!A;F0@82!C;W-T(&]F(&5Q=6ET>2!A
M;F0@=V%S(&1E=&5R;6EN960@=7-I;F<@=&AE#0H@("!F:7AE9"!M;VYE=&%R
M>2!A;6]U;G0@;V8@96%C:"!W87)R86YT(&UU;'1I<&QI960@8GD@87-S=6UP
M=&EO;G,@<F5G87)D:6YG('1H92!N=6UB97(@86YD('1I;6EN9R!O9B!W87)R
M86YT<R!T;R!B92!E>&5R8VES960N($]N($1E8V5M8F5R)B,Q-C`[,CDL(#(P
M,3`L($-Y=%)X('-O;&0@86QL(&]F('1H96ER('-H87)E<R!H96QD(&EN($=A
M;&5N82P@=&AU<R!R961U8VEN9R!T:&4@<&]T96YT:6%L(')E9&5M<'1I;VX@
M;&EA8FEL:71Y#0H@("!T;R!Z97)O(&%S($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3`N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M0V5R=&%I;B!W87)R86YT<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H('1H
M92`R,#$P($]F9F5R:6YG('=E<F4@9&5T97)M:6YE9"!N;W0@=&\@8F4-"B`@
M(&EN9&5X960@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@
M87,@=&AE>2!A<F4@<&]T96YT:6%L;'D@<V5T=&QE86)L92!I;B!C87-H+B!4
M:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',@870@=&AE(&1A=&5S(&]F
M(&ES<W5A;F-E('1O=&%L:6YG("0R+#0V-BPP,#`@=V%S(')E8V]R9&5D(&%S
M(&$@;&EA8FEL:71Y(&%N9"!A(&-O<W0@;V8@97%U:71Y(&%N9"!W87,@9&5T
M97)M:6YE9"!B>2!T:&4-"B`@($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I
M;F<@;6]D96PN($1U92!T;R!T:&4@9F%C="!T:&%T('1H92!#;VUP86YY(&AA
M<R!L:6UI=&5D('1R861I;F<@:&ES=&]R>2P@=&AE($-O;7!A;GDF(S@R,3<[
M<R!E>'!E8W1E9"!S=&]C:R!V;VQA=&EL:71Y(&%S<W5M<'1I;VX@:7,@8F%S
M960@;VX@82!C;VUB:6YA=&EO;B!O9B!I;7!L:65D('9O;&%T:6QI=&EE<R!O
M9B!S:6UI;&%R(&5N=&ET:65S('=H;W-E('-H87)E(&]R(&]P=&EO;@T*("`@
M<')I8V5S(&%R92!P=6)L:6-A;&QY('1R861E9"X@5&AE($-O;7!A;GD@=7-E
M9"!A('=E:6=H=&5D(&%V97)A9V4@97AP96-T960@<W1O8VL@=F]L871I;&ET
M>2!O9B`Q,3DN-#DE+B!4:&4@97AP96-T960@;&EF92!A<W-U;7!T:6]N(&ES
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M:&4@=V%R<F%N=',@9'5R:6YG('1H92!Y96%R<R!E;F1E9`T*("`@1&5C96UB
M97(F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q,"!W87,@)#$L,#<Y+#`P,"!A;F0@
M)#$L,C<Q+#`P,"P@<F5S<&5C=&EV96QY+B!4:&5S92!A;6]U;G1S(&AA=F4@
M8F5E;B!I;F-L=61E9"!I;B!O=&AE<B!I;F-O;64@86YD(&5X<&5N<V4@:6X@
M=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!E
M>'!E;G-E<RX@5&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&%T($1E
M8V5M8F5R)B,Q-C`[,S$L#0H@("`R,#$Q(&]F("0Q,38L,#`P(&ES(&EN8VQU
M9&5D(&%S(&$@8W5R<F5N="!L:6%B:6QI='D@:6X@=&AE(&%C8V]M<&%N>6EN
M9R!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E=',@86YD('=A<R!D971E<FUI
M;F5D(&)Y('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L
M+B!);B!T:&4@;6]D96PL('1H92!#;VUP86YY('5S960@82!W96EG:'1E9"!A
M=F5R86=E(&5X<&5C=&5D('-T;V-K('9O;&%T:6QI='D@;V8@.3@N.3$E+@T*
M("`@5&AE(&5X<&5C=&5D(&QI9F4@87-S=6UP=&EO;B!I<R!B87-E9"!O;B!T
M:&4@<F5M86EN:6YG(&-O;G1R86-T('1E<FT@;V8@-"XX)B,Q-C`[>65A<G,N
M(%1H92!D:79I9&5N9"!Y:65L9"!O9B!Z97)O(&ES(&)A<V5D(&]N('1H92!F
M86-T('1H870@=&AE($-O;7!A;GD@:&%S(&YO('!R97-E;G0@:6YT96YT:6]N
M('1O('!A>2!C87-H(&1I=FED96YD<RX@5&AE(')I<VL@9G)E92!R871E(&]F
M(#`N.#,E('5S960@9F]R('1H92!W87)R86YT#0H@("!I<R!E<75A;"!T;R!T
M:&4@>F5R;R!C;W5P;VX@<F%T92!I;B!E9F9E8W0@;VX@=&AE(&1A=&4@;V8@
M=&AE(')E+6UE87-U<F5M96YT+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD
M96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/CQI/DUA<F-H(#(P,3$@4F5G:7-T97)E9"!$:7)E
M8W0-"B`@($]F9F5R:6YG/"]I/B8C,38P.R8C.#(Q,CL@3VX@36%R8V@F(S$V
M,#LT+"`R,#$Q+"!T:&4@0V]M<&%N>2!C;&]S960@86X@=6YD97)W<FET=&5N
M('!U8FQI8R!O9F9E<FEN9R!O9B`V+#`P,"PP,#`@=6YI=',@870@82!P<FEC
M92!T;R!T:&4@<'5B;&EC(&]F("0Q+C,U('!E<B!U;FET(&9O<B!G<F]S<R!P
M<F]C965D<R!O9B`D."XQ)B,Q-C`[;6EL;&EO;B`H=&AE("8C.#(R,#M-87)C
M:"8C,38P.S(P,3$@3V9F97)I;F<F(S@R,C$[*2X@5&AE#0H@("!O9F9E<FEN
M9R!P<F]V:61E9"!A<'!R;WAI;6%T96QY("0W+C,F(S$V,#MM:6QL:6]N('1O
M('1H92!#;VUP86YY(&%F=&5R(&1E9'5C=&EN9R!T:&4@=6YD97)W<FET:6YG
M(&1I<V-O=6YT<R!A;F0@8V]M;6ES<VEO;G,@86YD(&]F9F5R:6YG(&5X<&5N
M<V5S+B!%86-H('5N:70@8V]N<VES=',@;V8@*&DI)B,Q-C`[;VYE('-H87)E
M(&]F(&-O;6UO;B!S=&]C:RP@*&EI*28C,38P.V$@=&AI<G1E96XM;6]N=&@@
M=V%R<F%N="!T;PT*("`@<'5R8VAA<V4@,"XU,"!O9B!A('-H87)E(&]F(&-O
M;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D,2XW,"!P97(@
M<VAA<F4@*'-U8FIE8W0@=&\@86YT:2UD:6QU=&EO;B!A9&IU<W1M96YT*2!A
M;F0@*&EI:2DF(S$V,#MA(&9I=F4M>65A<B!W87)R86YT('1O('!U<F-H87-E
M(#`N-3`@;V8@82!S:&%R92!O9B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I
M<V4@<')I8V4@;V8@)#$N.#<@<&5R('-H87)E("AS=6)J96-T('1O#0H@("!A
M;G1I+61I;'5T:6]N(&%D:G5S=&UE;G0I+B!/;B!!<')I;"8C,38P.S$U+"`R
M,#$Q+"!T:&4@:&]L9&5R<R!O9B!O=71S=&%N9&EN9R!W87)R86YT<R!I<W-U
M960@:6X@=&AE($UA<F-H)B,Q-C`[,C`Q,2!/9F9E<FEN9R!T;R!P=7)C:&%S
M92!A;B!A9V=R96=A=&4@;V8@,RPT-3`L,#`P('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@86=R965D('1O(&5X8VAA;F=E('-U8V@@=V%R<F%N=',@9F]R('=A
M<G)A;G1S(&5X97)C:7-A8FQE(&9O<@T*("`@=&AE('-A;64@;G5M8F5R(&]F
M('-H87)E<R!A<R!T:&]S92!B96EN9R!E>&-H86YG960L(&)U="!O=&AE<G=I
M<V4@;VX@=&AE('-A;64@=&5R;7,@;V8@=&AE('=A<G)A;G1S('-O;&0@:6X@
M=&AE($-O;7!A;GDF(S@R,3<[<R!!<')I;"8C,38P.S(P,3$@9FEN86YC:6YG
M+B!0<FEO<B!T;R!T:&4@97AC:&%N9V4L('1H92!#;VUP86YY(')E8V]R9&5D
M(&$@9&5C<F5A<V4@:6X@9F%I<B!V86QU92!O9B`D,2PP,#`L,#`P(')E;&%T
M960@=&\-"B`@('1H92!E>&-H86YG960@=V%R<F%N=',N(%5P;VX@=&AE(&5X
M8VAA;F=E+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!A(&QO<W,@;V8@)#DP,"PP
M,#`L('=H:6-H(')E<')E<V5N=&5D('1H92!D:69F97)E;F-E(&)E='=E96X@
M=&AE(&%D:G5S=&5D(&9A:7(@=F%L=64@;V8@=&AE($UA<F-H)B,Q-C`[,C`Q
M,2!W87)R86YT<R!A<R!C;VUP87)E9"!T;R!T:&4@9F%I<B!V86QU92!O9B!T
M:&4@07!R:6PF(S$V,#LR,#$Q('=A<G)A;G1S#0H@("!R96-E:79E9"!I;B!T
M:&4@97AC:&%N9V4N($%S(&$@<F5S=6QT(&]F(&$@<W5B<V5Q=65N="!O9F9E
M<FEN9R!T:&%T('=A<R!C;VUP;&5T960@;VX@07!R:6PF(S$V,#LQ-2P@,C`Q
M,2P@=&AE(&5X97)C:7-E('!R:6-E(&]F('1H92!R96UA:6YI;F<@,BPU-3`L
M,#`P(&]U='-T86YD:6YG('=A<G)A;G1S('-O;&0@:6X@=&AE($UA<F-H)B,Q
M-C`[,C`Q,2!/9F9E<FEN9R!W87,@<F5D=6-E9"!T;R`D,2XP,"!P97(@<VAA
M<F4@87,@80T*("`@<F5S=6QT(&]F('1H92!A;G1I+61I;'5T:6]N(&%D:G5S
M=&UE;G0N($%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L(#$U,"PP,#`@=V%R
M<F%N=',@9G)O;2!T:&4@36%R8V@F(S$V,#LR,#$Q($]F9F5R:6YG(&AA9"!B
M965N(&5X97)C:7-E9"!W:71H(&$@<F5M86EN:6YG(&]U='-T86YD:6YG(&)A
M;&%N8V4@;V8@-2PX-3`L,#`P+B!!<R!A(')E<W5L="!O9B!T:&4@<W5B<V5Q
M=65N="!O9F9E<FEN9R!O;B!397!T96UB97(F(S$V,#LR-BP-"B`@(#(P,3$L
M('1H92!E>&5R8VES92!P<FEC92!O9B!T:&4@<F5M86EN:6YG(#4L.#4P+#`P
M,"!W87)R86YT<R!S;VQD(&EN('1H92!-87)C:"8C,38P.S0L(#(P,3$@3V9F
M97)I;F<@=V5R92!R961U8V5D('1O("0P+C8U('!E<B!S:&%R92!A<R!A(')E
M<W5L="!O9B!T:&4@86YT:2UD:6QU=&EO;B!A9&IU<W1M96YT+CPO9F]N=#X\
M+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T
M=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("!4:&4@=&AI
M<G1E96XM;6]N=&@@86YD(&9I=F4M>65A<B!W87)R86YT<R!I<W-U960@:6X@
M8V]N;F5C=&EO;B!W:71H('1H92!-87)C:"`R,#$Q($]F9F5R:6YG('=E<F4@
M9&5T97)M:6YE9"!N;W0@=&\@8F4@:6YD97AE9"!T;R!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:R!A<R!T:&5Y(&%R92!P;W1E;G1I86QL>2!S
M971T;&5A8FQE(&EN(&-A<V@N#0H@("!4:&4@9F%I<B!V86QU92!O9B!T:&4@
M,BPU-3`L,#`P('=A<G)A;G1S(&%T('1H92!D871E(&]F(&ES<W5A;F-E('1O
M=&%L:6YG("0Q+#<Y,"PP,#`@=V%S(')E8V]R9&5D(&%S(&$@;&EA8FEL:71Y
M(&%N9"!A(&-O<W0@;V8@97%U:71Y(&%N9"!W87,@9&5T97)M:6YE9"!U<VEN
M9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"X@1'5E
M('1O('1H92!F86-T('1H870@=&AE($-O;7!A;GD-"B`@(&AA<R!L:6UI=&5D
M('1R861I;F<@:&ES=&]R>2P@=&AE($-O;7!A;GD@97AP96-T960@<W1O8VL@
M=F]L871I;&ET>2!A<W-U;7!T:6]N(&ES(&)A<V5D(&]N(&$@8V]M8FEN871I
M;VX@;V8@:6UP;&EE9"!V;VQA=&EL:71I97,@;V8@<VEM:6QA<B!E;G1I=&EE
M<R!W:&]S92!S:&%R97,@;W(@;W!T:6]N<R!A<F4@<'5B;&EC;'D@=')A9&5D
M+@T*("`@5&AE($-O;7!A;GD@=7-E9"!A('=E:6=H=&5D(&%V97)A9V4@97AP
M96-T960@<W1O8VL@=F]L871I;&ET>2!O9B`Q,3,N,C4E+B!4:&4@97AP96-T
M960@;&EF92!A<W-U;7!T:6]N(&ES(&)A<V5D(&]N('1H92!C;VYT<F%C="!T
M97)M(&]F(#$N,#@@>65A<G,@=7-E9"!F;W(@=&AE('1H:7)T965N+6UO;G1H
M('=A<G)A;G1S(&%N9"`U('EE87)S('5S960@9F]R('1H92!F:79E+7EE87(@
M=V%R<F%N=',N(%1H92!D:79I9&5N9"!Y:65L9`T*("`@;V8@>F5R;R!I<R!B
M87-E9"!O;B!T:&4@9F%C="!T:&%T('=E(&AA=F4@;F\@<')E<V5N="!I;G1E
M;G1I;VX@=&\@<&%Y(&-A<V@@9&EV:61E;F1S+B!4:&4@<FES:R!F<F5E(')A
M=&4@;V8@,"XR-B4@=7-E9"!F;W(@=&AE('1H:7)T965N+6UO;G1H('=A<G)A
M;G1S(&%N9"`R+C$W)2!U<V5D(&9O<B!T:&4@9FEV92UY96%R('=A<G)A;G1S
M(&ES(&5Q=6%L('1O('1H92!Z97)O(&-O=7!O;B!R871E(&EN(&5F9F5C="!A
M="!T:&4@=&EM90T*("`@;V8@=&AE(&=R86YT+B!);B!*=6QY(#(P,3$L(#<U
M+#`P,"!O9B!T:&4@=&AI<G1E96XM;6]N=&@@=V%R<F%N=',@=V5R92!E>&5R
M8VES960@870@)#$N,#`@<&5R(&-O;6UO;B!S:&%R92!W:&EC:"!R97-U;'1E
M9"!I;B!A("0S-"PP,#`@<F5D=6-T:6]N(&]F('1H92!W87)R86YT(&QI86)I
M;&ET>2X@26X@2G5L>2`R,#$Q+"`W-2PP,#`@;V8@=&AE(&9I=F4M>65A<B!W
M87)R86YT<R!W97)E(&5X97)C:7-E9"!A="`D,2XP,"!P97(-"B`@(&-O;6UO
M;B!S:&%R92!W:&EC:"!R97-U;'1E9"!I;B!A("0V."PP,#`@<F5D=6-T:6]N
M(&]F('1H92!W87)R86YT(&QI86)I;&ET>2X@5&AE(&1E8W)E87-E(&EN('1H
M92!F86ER('9A;'5E(&]F('1H92!W87)R86YT<R!F<F]M('1H92!D871E(&]F
M(&ES<W5A;F-E('1O($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@;V8@)#$L,S<X
M+#`P,"!H87,@8F5E;B!I;F-L=61E9"!I;B!O=&AE<B!I;F-O;64@86YD(&5X
M<&5N<V4@:6X@=&AE#0H@("!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D('-T
M871E;65N=',@;V8@97AP96YS97,@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M
M8F5R)B,Q-C`[,S$L(#(P,3$N(%1H92!F86ER('9A;'5E(&]F('1H92!W87)R
M86YT<R!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&]F("0T,3(L,#`P(&ES
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M:65S(&]F('-I;6EL87(@96YT:71I97,-"B`@('=H;W-E('-H87)E<R!O<B!O
M<'1I;VYS(&%R92!P=6)L:6-L>2!T<F%D960N(%1H92!#;VUP86YY('5S960@
M82!W96EG:'1E9"!A=F5R86=E(&5X<&5C=&5D('-T;V-K('9O;&%T:6QI='D@
M;V8@.3@N.3$E+B!4:&4@97AP96-T960@;&EF92!A<W-U;7!T:6]N(&ES(&)A
M<V5D(&]N('1H92!R96UA:6YI;F<@8V]N=')A8W0@=&5R;2!O9B`P+C,@>65A
M<G,@=7-E9"!F;W(@=&AE('1H:7)T965N+6UO;G1H('=A<G)A;G1S(&%N9"`T
M+C(-"B`@('EE87)S('5S960@9F]R('1H92!F:79E+2!Y96%R('=A<G)A;G1S
M+B!4:&4@9&EV:61E;F0@>6EE;&0@;V8@>F5R;R!I<R!B87-E9"!O;B!T:&4@
M9F%C="!T:&%T('1H92!#;VUP86YY(&AA<R!N;R!P<F5S96YT(&EN=&5N=&EO
M;B!T;R!P87D@8V%S:"!D:79I9&5N9',N(%1H92!R:7-K(&9R964@<F%T92!O
M9B`P+C`R)2!U<V5D(&9O<B!T:&4@=&AI<G1E96XM;6]N=&@@=V%R<F%N=',@
M86YD(#`N-C`E('5S960@9F]R('1H90T*("`@9FEV92UY96%R('=A<G)A;G1S
M(&ES(&5Q=6%L('1O('1H92!Z97)O(&-O=7!O;B!R871E(&EN(&5F9F5C="!O
M;B!T:&4@9&%T92!O9B!T:&4@<F4M;65A<W5R96UE;G0N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&D^07!R:6P@,C`Q,2!2
M96=I<W1E<F5D#0H@("!$:7)E8W0@3V9F97)I;F<\+VD^)B,Q-C`[)B,X,C$R
M.R!/;B!!<')I;"8C,38P.S(P+"`R,#$Q+"!T:&4@0V]M<&%N>2!C;VUP;&5T
M960@86X@=6YD97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9R!O9B`Q,2PY-3`L
M,#`P('5N:71S(&%T(&$@<')I8V4@=&\@=&AE('!U8FQI8R!O9B`D,2XP,"!P
M97(@=6YI="!F;W(@9W)O<W,@<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`D
M,3(F(S$V,#MM:6QL:6]N("AT:&4-"B`@("8C.#(R,#M!<')I;"8C,38P.S(P
M,3$@3V9F97)I;F<F(S@R,C$[*2X@16%C:"!U;FET(&-O;G-I<W1E9"!O9B!O
M;F4@<VAA<F4@;V8@8V]M;6]N('-T;V-K(&%N9"!A('=A<G)A;G0@=&\@<'5R
M8VAA<V4@;VYE('-H87)E(&]F(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES
M92!P<FEC92!O9B`D,2XP,"!P97(@<VAA<F4@*'-U8FIE8W0@=&\@86YT:2UD
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M96YS97,L('=E<F4@87!P<F]X:6UA=&5L>2`D,3`N.28C,38P.VUI;&QI;VXN
M($%S(&$@<F5S=6QT(&]F('1H92!S=6)S97%U96YT(&]F9F5R:6YG('1H870@
M=V%S(&-O;7!L971E9"!O;B!397!T96UB97(F(S$V,#LR-BP@,C`Q,2P@=&AE
M(&5X97)C:7-E('!R:6-E(&]F('1H92`Q,2PY-3`L,#`P(&]U='-T86YD:6YG
M#0H@("!W87)R86YT<R!S;VQD(&EN('1H92!!<')I;"8C,38P.S(P,3$@3V9F
M97)I;F<@=V%S(')E9'5C960@=&\@)#`N-C4@<&5R('-H87)E(&%S(&$@<F5S
M=6QT(&]F('1H92!A;G1I+61I;'5T:6]N(&%D:G5S=&UE;G0N)B,Q-C`[3VX@
M1&5C96UB97(F(S$V,#LV+"`R,#$Q+"!T:&4@0V]M<&%N>2!E9F9E8W1E9"!A
M('=A<G)A;G0@97AC:&%N9V4@=VET:"!A(')A=&EO(&]F(#$N-#(X-3<@=V%R
M<F%N=',@:6X@97AC:&%N9V4@9F]R(&]N90T*("`@<VAA<F4@;V8@8V]M;6]N
M('-T;V-K('=I=&@@<V5V97)A;"!O9B!T:&4@07!R:6P@,C`Q,2!W87)R86YT
M(&AO;&1E<G,N($EN('1O=&%L+"`U+#DS,"PP,#`@=V%R<F%N=',@=V5R92!E
M>&-H86YG960@9F]R(#0L,34Q+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(&EN('1H:7,@=')A;G-A8W1I;VXN($%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3$L(#8L,#(P+#`P,"!W87)R86YT<R!S;VQD(&EN('1H92!!<')I;"8C,38P
M.S(P+"`R,#$Q#0H@("!/9F9E<FEN9R!R96UA:6YE9"!O=71S=&%N9&EN9RX@
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA
M<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@
M=V%R<F%N=',@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@07!R:6P@
M,C`Q,2!/9F9E<FEN9RP@:6YC;'5D:6YG('1H92!W87)R86YT<R!I<W-U960-
M"B`@(&EN(&5X8VAA;F=E(&9O<B!T:&4@,RPT-3`L,#`P)B,Q-C`[36%R8V@@
M,C`Q,2!W87)R86YT<RP@=V5R92!D971E<FUI;F5D(&YO="!T;R!B92!I;F1E
M>&5D('1O('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%S('1H
M97D@87)E('!O=&5N=&EA;&QY('-E='1L96%B;&4@:6X@8V%S:"X@5&AE(&9A
M:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&%T('1H92!D871E<R!O9B!I<W-U
M86YC92!T;W1A;&EN9R`D,3$L,#$U+#`P,"!W87,-"B`@(')E8V]R9&5D(&%S
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M('1H92!C;VYT<F%C="!T97)M(&]F(#8N,"!Y96%R<RX-"B`@(%1H92!D:79I
M9&5N9"!Y:65L9"!O9B!Z97)O(&ES(&)A<V5D(&]N('1H92!F86-T('1H870@
M=V4@:&%V92!N;R!P<F5S96YT(&EN=&5N=&EO;B!T;R!P87D@8V%S:"!D:79I
M9&5N9',N(%1H92!R:7-K(&9R964@<F%T92!O9B`R+C@Q)2!U<V5D(&9O<B!T
M:&4@=V%R<F%N=',@:7,@97%U86P@=&\@=&AE('IE<F\@8V]U<&]N(')A=&4@
M:6X@969F96-T(&%T('1H92!T:6UE(&]F('1H92!G<F%N="X@26X@1&5C96UB
M97(@,C`Q,2P@=&AE#0H@("!#;VUP86YY(&5X8VAA;F=E9"`T+#$U,2PP,#`@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I;B!E>&-H86YG92!F;W(@-2PY,S`L
M,#`P(&]F('1H97-E($%P<FEL('=A<G)A;G1S(&%T(&$@<F%T:6\@;V8@,"XW
M(&-O;6UO;B!S:&%R97,@9F]R(&5A8V@@=V%R<F%N="!W:&EC:"!R97-U;'1E
M9"!I;B!A(')E9'5C=&EO;B!T;R!W87)R86YT(&QI86)I;&ET>2!O9B`D,RPQ
M,C`L,#`P+B!4:&4@9&5C<F5A<V4@:6X@=&AE(&9A:7(@=F%L=64@;V8-"B`@
M('1H92!W87)R86YT<R!F<F]M(&1A=&4@;V8@:7-S=6%N8V4@=&\@1&5C96UB
M97(F(S$V,#LS,2P@,C`Q,2!I<R`D-2PQ-C@L,#`P+"!O9B!W:&EC:"!A;&P@
M:&%S(&)E96X@:6YC;'5D960@:6X@;W1H97(@:6YC;VUE(&%N9"!E>'!E;G-E
M(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D('-T871E;65N=',@
M;V8@97AP96YS97,@9F]R('1H92!T=V5L=F4@;6]N=&AS(&5N9&5D($1E8V5M
M8F5R)B,Q-C`[,S$L(#(P,3$N(%1H92!F86ER('9A;'5E(&]F('1H92!W87)R
M86YT<R!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&]F("0S+#$U-"PP,#`@
M:7,@:6YC;'5D960@87,@80T*("`@8W5R<F5N="!L:6%B:6QI='D@:6X@=&AE
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M9B`Y."XY,24N(%1H92!E>'!E8W1E9"!L:69E(&%S<W5M<'1I;VX@:7,@8F%S
M960@;VX@=&AE(')E;6%I;FEN9R!C;VYT<F%C=`T*("`@=&5R;2!O9B`U+C,@
M>65A<G,N(%1H92!D:79I9&5N9"!Y:65L9"!O9B!Z97)O(&ES(&)A<V5D(&]N
M('1H92!F86-T('1H870@=&AE($-O;7!A;GD@:&%S(&YO('!R97-E;G0@:6YT
M96YT:6]N('1O('!A>2!C87-H(&1I=FED96YD<RX@5&AE(')I<VL@9G)E92!R
M871E(&]F(#`N.#,E('5S960@9F]R('1H92!W87)R86YT<R!I<R!E<75A;"!T
M;R!T:&4@>F5R;R!C;W5P;VX@<F%T92!I;B!E9F9E8W0@;VX@=&AE(&1A=&4@
M;V8@=&AE#0H@("!R92UM96%S=7)E;65N="X@/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y397!T96UB97(@,C`Q,2!296=I
M<W1E<F5D($1I<F5C="!/9F9E<FEN9SPO:3XF(S$V,#LF(S@R,3([($]N(%-E
M<'1E;6)E<B8C,38P.S(V+"`R,#$Q+"!T:&4@0V]M<&%N>2!C;VUP;&5T960-
M"B`@(&$@9&ER96-T(&]F9F5R:6YG(&]F(#<P,"PP,#`@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!F;W(@9W)O<W,@<')O8V5E9',@;V8@)#0U-2PP,#`N(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R
M9VEN+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI
M/E-T;V-K($]P=&EO;G,@36]D:69I960-"B`@(#PO:3X\+V(^/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/;B!!<')I;"8C,38P
M.S$T+"`R,#$Q+"!A;&P@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!D:7)E8W1O
M<G,@86YD(&-E<G1A:6X@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!E>&5C=71I
M=F4@;V9F:6-E<G,-"B`@(&5X96-U=&5D(&%G<F5E;65N=',@=VET:"!T:&4@
M0V]M<&%N>2!U;F1E<B!W:&EC:"!T:&5Y(&%G<F5E9"!T:&%T(&YO;F4@;V8@
M=&AE:7(@;W5T<W1A;F1I;F<@<W1O8VL@;W!T:6]N<R!W:6QL(&)E(&5X97)C
M:7-A8FQE('5N;&5S<R!A;F0@=6YT:6P@=&AE($-O;7!A;GD@:6YC<F5A<V5S
M('1H92!N=6UB97(@;V8@875T:&]R:7IE9"!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K('1O(&$@;G5M8F5R('1H870@:7,@<W5F9FEC:65N="!T;PT*("`@<&5R
M;6ET('1H92!E>&5R8VES92!O<B!C;VYV97)S:6]N(&EN(&9U;&P@;V8@86QL
M('1H96X@;W5T<W1A;F1I;F<@;W!T:6]N<R!O9B!T:&4@0V]M<&%N>2`H:6YC
M;'5D:6YG('1H96ER('-T;V-K(&]P=&EO;G,I+"!W87)R86YT<R!A;F0@;W1H
M97(@<V5C=7)I=&EE<R!O9B!T:&4@0V]M<&%N>2!T:&%T(&%R92!C;VYV97)T
M:6)L92!I;G1O('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN($%N(&%G9W)E9V%T
M92!O9B`S+#0Y."PR-38@;W!T:6]N#0H@("!S:&%R97,@87)E(&-O=F5R960@
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M:&5I<@T*("`@;W!T:6]N<R!R97-U;'1I;F<@:6X@=&AE(')E8VQA<W-I9FEC
M871I;VX@;V8@=&AE(&]P=&EO;G,@9G)O;2!E<75I='D@=&\@82!L:6%B:6QI
M='DN($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@;6]D:69I8V%T:6]N+"!T:&4@
M0V]M<&%N>2!W:6QL(')E8V]G;FEZ92!C;VUP96YS871I;VX@8V]S="!E<75A
M;"!T;R!T:&4@9W)E871E<B!O9B`H82DF(S$V,#MT:&4@9W)A;G0@9&%T92!F
M86ER('9A;'5E(&]F('1H92!O<FEG:6YA;"!E<75I='D-"B`@(&%W87)D('!L
M=7,@86X@:6YC<F5M96YT86P@8V]S="!A<W-O8VEA=&5D('=I=&@@=&AE(&UO
M9&EF:6-A=&EO;B!O<B`H8BDF(S$V,#MT:&4@9F%I<B!V86QU92!O9B!T:&4@
M;6]D:69I960@87=A<F0@=VAE;B!I="!I<R!S971T;&5D+B!/;B!*=6QY)B,Q
M-C`[,34L(#(P,3$L('1H92!";V%R9"!O9B!$:7)E8W1O<G,@;V8@=&AE($-O
M;7!A;GD@861O<'1E9"!A;B!A;65N9&UE;G0@=&\@:6YC<F5A<V4@=&AE(&%U
M=&AO<FEZ960@<VAA<F5S#0H@("!O9B!C;VUM;VX@<W1O8VL@=&\@,3(U+#`P
M,"PP,#`L('=H:6-H('=A<R!P<F5S96YT960@=&\@86YD(&%P<')O=F5D(&)Y
M('1H92!S=&]C:VAO;&1E<G,@;V8@=&AE($-O;7!A;GD@870@=&AE(#(P,3$@
M06YN=6%L($UE971I;F<@;V8@4W1O8VMH;VQD97)S+B!4:&ES(&EN8W)E87-E
M(&EN('1H92!A=71H;W)I>F5D('-H87)E<R!W87,@<W5F9FEC:65N="!T;R!P
M97)M:70@=&AE(&5X97)C:7-E(&]R(&-O;G9E<G-I;VX@:6X@9G5L;"!O9@T*
M("`@86QL('1H96X@;W5T<W1A;F1I;F<@;W!T:6]N<R!O9B!T:&4@0V]M<&%N
M>2`H:6YC;'5D:6YG('1H96ER('-T;V-K(&]P=&EO;G,I+"!W87)R86YT<R!A
M;F0@;W1H97(@<V5C=7)I=&EE<R!O9B!T:&4@0V]M<&%N>2!T:&%T(&%R92!C
M;VYV97)T:6)L92!I;G1O('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL(&%S(&$@
M<F5S=6QT+"!T:&4@;&EA8FEL:71Y('=A<R!M87)K960@=&\@;6%R:V5T('1H
M<F]U9V@@2G5L>28C,38P.S$U+"`R,#$Q#0H@("!A;F0L('5P;VX@<V5T=&QE
M;65N="P@=&AE('9A;'5E(&]F("0Q+#`S-BPP,#`@=V%S(')E8VQA<W-I9FEE
M9"!T;R!A9&1I=&EO;F%L('!A:60@:6X@8V%P:71A;"X@07,@82!R97-U;'0@
M;V8@=&AE(&UO9&EF:6-A=&EO;BP@=&AE($-O;7!A;GD@<F5C;W)D960@861D
M:71I;VYA;"!S=&]C:R!C;VUP96YS871I;VX@97AP96YS92!O9B`D,S4L,#`P
M(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q
M+@T*("`@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^/&(^/&D^3W1H97(@17%U:71Y(%1R86YS86-T:6]N<R`\+VD^/"]B/CPO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("!/
M;B!-87)C:"8C,38P.S,P+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN
M=&\@82!S979E<F%N8V4@86=R965M96YT('=I=&@@:71S(&9O<FUE<B!0<F5S
M:61E;G0@86YD($-H:65F($5X96-U=&EV92!/9F9I8V5R('=H97)E8GDL(&%M
M;VYG(&]T:&5R('1H:6YG<RP@:70@86=R965D('1O(&ES<W5E('-H87)E<R!T
M;R!T:&4@9F]R;65R(&]F9FEC97(-"B`@('-U8V@@=&AA="!T:&4@;G5M8F5R
M(&]F('-H87)E<R!I<W-U960@=&EM97,@=&AE(&UA<FME="!P<FEC92!O9B!T
M:&4@<VAA<F5S(&]N('1H92!D87D@:6UM961I871E;'D@9F]L;&]W:6YG('1H
M92!S97!A<F%T:6]N(&1A=&4@97%U86P@82!V86QU92!O9B`D,S`P+#`P,"X@
M07,@;V8@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2P@86QL('!A>6UE;G1S(&%N
M9"!S:&%R97,@9'5E('5N9&5R('1H:7,@<V5V97)A;F-E(&%G<F5E;65N="!H
M879E#0H@("!B965N(&ES<W5E9"!A;F0@<F5C;W)D960@=&\@<W1O8VL@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@[;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X/B8C,38P.SPO<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-#-A-F4P,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B,3!D
M8F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0S839E,#$U7S8P
M83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8R]7;W)K<VAE971S+U-H965T,3DN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$979E
M;&]P;65N="!3=&%G92!3=7!P;&5M96YT86P@17%U:71Y($1I<V-L;W-U<F4\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1&5V96QO<&UE;G0@4W1A9V4@4W5P<&QE;65N=&%L($5Q=6ET>2!$:7-C
M;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5V96QO<&UE;G0@4W1A9V4@4W5P<&QE;65N=&%L
M($5Q=6ET>2!$:7-C;&]S=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A4
M34P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]4
M4B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@
M(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@,3$@+2!U<RUG86%P.D1E
M=F5L;W!M96YT4W1A9V5%;G1E<G!R:7-E1V5N97)A;$1I<V-L;W-U<F5S5&5X
M=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,'!X.VUA<F=I
M;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^,3$N)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[1&5V96QO<&UE;G0@4W1A9V4@4W5P<&QE;65N=&%L($5Q=6ET>2!$
M:7-C;&]S=7)E(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
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M,C$W.W,@:6YC97!T:6]N('1H<F]U9V@@1&5C96UB97(F(S$V,#LS,2P@,C`Q
M,2`H:6X@=&AO=7-A;F1S(&5X8V5P="!P97(@<VAA<F4@9&%T82DN(#PO9F]N
M=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O
M<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@
M0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@]
M,T0R-R4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MW
M:61T:#HT.7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0Q/CQB/E1Y<&4@;V8@4V5C=7)I='D\+V(^/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1&%T928C,38P
M.V]F)B,Q-C`[27-S=6%N8V4\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^4VAA<F5S(&]F/&)R("\^0V]M;6]N/&)R("\^
M4W1O8VL\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@
M(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,3X\8CY$;VQL87(\8G(@+SY!;6]U;G0@;V8\8G(@
M+SY#;VYS:61E<F%T:6]N/&)R("\^*"0I/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^4')I8V4F
M(S$V,#MP97(\8G(@+SY3:&%R92!O<CQB<B`O/D5X97)C:7-E/&)R("\^4')I
M8V4@<&5R/&)R("\^4VAA<F4\8G(@+SXH)"D\+V(^/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY#;W5N=&5R/"]B/CPO9F]N
M=#X\8G(@+SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0Q/CQB/E!A<G1Y('1O/"]B/CPO9F]N=#X\8G(@+SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/@T*("`@/&(^5')A;G-A8W1I;VX\+V(^/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#$^/&(^3F%T=7)E(&]F/&)R("\^3F]N+4-A<V@\8G(@+SY#
M;VYS:61E<F%T:6]N/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/D)A<VES(&]F/&)R("\^07-S:6=N:6YG($-O<W0\+V(^/"]F;VYT/CPO=&0^
M#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA
M+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C
M965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/D-O;6UO;B!3=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D%P<FEL(#,L
M(#(P,#8\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#8R-"PR-S@\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C`N,#`R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY&;W5N9&5R<SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/DY!/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V%S:#PO9F]N
M=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUM;VX@4W1O8VL\+V9O;G0^
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY*86YU87)Y(#@L(#(P,#<\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXW+C`T,"PS,3@\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0X/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH
M02DF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXP+C`P-SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0WET4G@\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY#;VYT<FEB=71E9#QB<B`O/D%S<V5T<SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E!R961E8V5S
M<V]R/&)R("\^0V]S=#PO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@
M8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY#;VUM;VX@4W1O8VL\+V9O;G0^/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY!<')I;"`S,"P@,C`P-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C,L,C<S+#(Y,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^,34L,S0X/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH0BDF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+C$Y/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#>712>#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DY!/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^0V%S:#PO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#
M;VUM;VX@4W1O8VL\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!<')I;"`S,"P@,C`P
M-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0V,BPQ,3(\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(L
M,S$Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXU+C`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY5
M34U3/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^26YT96QL96-T=6%L/&)R("\^4')O<&5R=&EE<SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/DEN9&5P96YD96YT/&)R("\^5&AI<F0@4&%R='D\8G(@+SY6
M86QU871I;VX\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L
M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^0V]M;6]N(%-T;V-K/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M075G=7-T(#$X+"`R,#`W/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,S`L,#`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXQ-3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C4N,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/D1I<F5C=&]R<SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY#87-H/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O;6UO
M;B!3=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E-E<'1E;6)E<B`R."P@,C`P
M-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$X."PS.#<\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CDW
M.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-2XQ.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0WET
M4G@\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY.03PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DEN9&5P96YD96YT/&)R("\^
M5&AI<F0@4&%R='D\8G(@+SY686QU871I;VX\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V]M;6]N(%-T;V-K/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^3F]V96UB97(@,C$L(#(P,#<\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXV-BPP-#4\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,S,3PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-2XP,#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^17AE<F-I<V4@;V8@4W1O
M8VL\8G(@+SY/<'1I;VYS/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3D$\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#87-H
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M
M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O;6UO;B!3=&]C:SPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/DIU;F4@,C8L(#(P,#@\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXQ+#`W,RPR.3D\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<L.3$X/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXX+C$R
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY025!%/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^3D$\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY.970@0V%S:#PO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUM;VX@4W1O8VL\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY/8W1O8F5R)B,Q-C`[-BPF(S$V,#LR,#`X)B,Q
M-C`[86YD/&)R("\^3F]V96UB97(@,38L(#(P,#@\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXU+#4P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,C8\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C4N,#`\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/D5X97)C:7-E(&]F(%-T;V-K/&)R("\^
M3W!T:6]N<SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/DY!/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V%S:#PO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUM;VX@4W1O8VL\+V9O;G0^/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CY*86YU87)Y(#,P+"`R,#`Y/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^-3@L,SDX/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.03PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3D$\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/DY!/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^36%R:V5T(%9A
M;'5E/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$
M(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/D-O;6UO;B!3=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DUA>2`Q
M+"`R,#`Y/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,C@Q/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.
M03PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-"XQ.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^17AE
M<F-I<V4@;V8@4W1O8VL\8G(@+SY/<'1I;VYS/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3D$\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY#87-H/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O
M;6UO;B!3=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D%U9W5S="`S+"`R,#`Y
M(&%N9#QB<B`O/D%U9W5S="`T+"`R,#`Y/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,BPS.#4L-S$U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW+#<Q-#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RXU,#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^4F5G:7-T97)E9"8C,38P.T1I<F5C
M=#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/DY!/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3F5T($-A<V@\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V]M;6]N
M(%-T;V-K/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^36%R8V@@,C(L(#(P,3`\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+#<P,"PP,#`\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$U+#(S
M-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-BXP,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^4F5G
M:7-T97)E9"!$:7)E8W0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.03PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DYE="!#
M87-H/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O;6UO;B!3=&]C
M:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E9A<FEO=7,F(S$V,#LF(S@R,3([(#(P
M,3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU,RPU,#`\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(U
M-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-"XW-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^17AE
M<F-I<V4@;V8@4W1O8VL\8G(@+SY/<'1I;VYS/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3D$\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY#87-H/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B
M9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/D-O;6UO;B!3=&]C:SPO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/DIA;G5A<GDF(S$V,#LR+"8C,38P.S(P,3`F(S$V,#MA;F0\8G(@+SY&
M96)R=6%R>2`Y+"`R,#$P/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M.#8L-C,T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXR,#<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/DY!/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY297-T<FEC=&5D(%-T;V-K/&)R("\^56YI=',\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY.03PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/DUA<FME="!686QU93PO9F]N=#X\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY#;VUM;VX@4W1O8VL\+V9O;G0^/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY-87)C:"`T+"`R,#$Q/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M-BPP,#`L,#`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXW+#,P-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2XS-3PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^4F5G:7-T97)E9"!$:7)E8W0\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.
M03PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/DYE="!#87-H/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O;6UO;B!3=&]C:SPO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/DUA<F-H(#$U+"`R,#$Q/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,C(P+#<R.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,C4V/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+C$V/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY297-T<FEC=&5D(%-T;V-K/&)R("\^
M56YI=',\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY.03PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DUA<FME="!686QU93PO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUM;VX@4W1O8VL\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY!<')I;"`Q,RP@,C`Q,3PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C0L.3<T+#`Y,#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-BPS-C<\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DY!/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T
M;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY!8W%U:7)E9"!#;VUP86YY
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^3D$\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY-87)K970@5F%L=64\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V]M
M;6]N(%-T;V-K/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^07!R:6P@,C`L(#(P,3$\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,2PY-3`L,#`P/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ
M,"PX-3,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C$N,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E)E9VES=&5R960@1&ER96-T/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3D$\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.
M970@0V%S:#PO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUM;VX@
M4W1O8VL\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY*=6QY(#$L(#(P,3$\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ."PX,C0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$U/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXP+C@S
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%4U!0/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^3D$\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY#87-H/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O;6UO;B!3=&]C:SPO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/DIU;'D@,C<L(#(P,3$\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXQ-3`L,#`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ-3`\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$N,#`\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/D5X97)C:7-E(&]F/&)R("\^5V%R<F%N
M=',\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY.03PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-A<V@\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT
M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^0V]M;6]N(%-T;V-K/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^4V5P=&5M8F5R(#(V+"`R,#$Q/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^-S`P+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^-#4U/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXP+C8U/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY296=I<W1E<F5D($1I<F5C=#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/DY!/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^0V%S:#PO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUM;VX@4W1O8VL\+V9O;G0^
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY$96-E;6)E<B`V+"`R,#$Q/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^-"PQ-3$L,#`P/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS+#$R,#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3D$\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1'1O
M<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D5X8VAA;F=E('=I=&@\8G(@
M+SY787)R86YT($AO;&1E<G,\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.03PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DUA
M<FME="8C,38P.U9A;'5E/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/D-O;6UO;B!3=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E9A<FEO=7,@)B,X
M,C$R.R`R,#$Q/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-3DY+#`U
M,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-3DT/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY.03PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^4W1O8VLF(S$V,#M#;VUP96YS871I;VX\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.03PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/DUA<FME="8C,38P.U9A;'5E/"]F;VYT/CPO=&0^#0H@("`\+W1R
M/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@
M("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA
M<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G
M(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#,E('9A
M;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH02D\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E1R86YS86-T:6]N<R!B971W965N(')E;&%T960@<&%R=&EE<R!A<F4@86-C
M;W5N=&5D(&9O<B!A="!T:&4@:&ES=&]R:6-A;"!C;W-T(&]F($-Y=%)X+"!W
M:71H('1H92!I;G1E;&QE8W1U86P@<')O<&5R='D@=VAI8V@@=V%S('!R979I
M;W5S;'D@97AP96YS960@;VX@0WET4G@F(S@R,3<[<PT*("`@8F]O:W,@8F5I
M;F<@<F5C;W)D960@870@>F5R;R!C;W-T(&%N9"!E<75I<&UE;G0@86YD(&9U
M<FYI<VAI;F=S(&)E:6YG(')E8V]R9&5D(&%T("0T."PP,#`N(#PO9F]N=#X\
M+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL93TS1&9O
M;G0M<VEZ93HS<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^
M)B,Q-C`[/"]P/@T*("`@/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S
M93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@8F]R9&5R/3-$,"!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X@#0H@
M("`\='(^(`T*("`@/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/BA"*3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$=&]P/@T*("`@/'`@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^5&AE($-O;7!A;GD@<F5C96EV960@9W)O<W,@<')O8V5E9',@;V8@
M)#$W+C`F(S$V,#MM:6QL:6]N(&9O<B!T:&4@:7-S=6%N8V4@;V8@=&AE(#,L
M,C<S+#(Y,B8C,38P.W-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=VAI8V@@97%U
M86QS("0U+C$Y('!E<B!S:&%R92X-"B`@(%1H92!G<F]S<R!P<F]C965D<R!W
M97)E(')E9'5C960@8GD@82!R96EM8G5R<V5M96YT('1O($-Y=%)X(&]F("@Q
M*28C,38P.R0Q+C,F(S$V,#MM:6QL:6]N(&9O<B!26&DF(S@R,3<[<R!P<F\@
M<F%T82!S:&%R92!O9B!O9F9E<FEN9R!C;W-T<R!R96QA=&5D('1O('1H92!!
M<')I;"8C,38P.S$W+"`R,#`W('!R:79A=&4@<&QA8V5M96YT#0H@("!C;VYD
M=6-T960@8GD@0WET4G@@=&\@9G5N9"!I=',@8V%P:71A;"!C;VYT<FEB=71I
M;VX@=&\@=&AE($-O;7!A;GD@86YD("@R*28C,38P.R0S-C,L,#`P(&]F(&5X
M<&5N<V5S(&EN8W5R<F5D(&]N(&)E:&%L9B!O9B!26&D@9F]R('1H92!Y96%R
M(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,#8N($YE="!P<F]C965D<R!T
M;R!26&D@869T97(-"B`@('1H97-E(&-H87)G97,@=V5R92`D,34N,R8C,38P
M.VUI;&QI;VX@;W(@)#0N-CD@82!S:&%R92X@/"]F;VYT/CPO<#X-"B`@(#PO
M=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X-"CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#-A-F4P,35?-C!A.%\T,&5C7SDP
M,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8R]7;W)K<VAE
M971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY3=&]C:R!"87-E9"!#;VUP96YS871I;VX\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VL@0F%S
M960@0V]M<&5N<V%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@0F%S960@0V]M<&5N<V%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E0
M12!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I
M;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH
M=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO
M8VL@5&%G9V5D($YO=&4@,3(@+2!U<RUG86%P.D1I<V-L;W-U<F5/9D-O;7!E
M;G-A=&EO;E)E;&%T961#;W-T<U-H87)E0F%S961087EM96YT<U1E>'1";&]C
M:RTM/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O
M='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CX\8CXQ,BXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#M3=&]C:R!"87-E9"!#;VUP96YS871I;VX@/"]B/CPO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P
M>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&D^3W!T:6]N<R!T;R!0=7)C
M:&%S92!3:&%R97,@;V8@0V]M;6]N(%-T;V-K(#PO:3XF(S@R,3([(%1H92!#
M;VUP86YY(&9O;&QO=W,@=&AE('!R;W9I<VEO;G,@05-#)B,Q-C`[-S$X('=H
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M;G-E(&)A<V5D(&]N('1H92!G<F%N="!D871E(&9A:7(@=F%L=64-"B`@(&5S
M=&EM871E9"!I;B!A8V-O<F1A;F-E('=I=&@@=&AE('!R;W9I<VEO;G,@;V8@
M05-#)B,Q-C`[-S$X(&ES(')E8V]G;FEZ960@87,@86X@97AP96YS92!O=F5R
M('1H92!R97%U:7-I=&4@<V5R=FEC92!P97)I;V0N(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P
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M(')E<75I<F5M96YT<R!O9B!!4T,@5&]P:6,@-3`U+34P+"!.;VXM96UP;&]Y
M964@;W!T:6]N(&=R86YT<R!T:&%T(&1O(&YO="!V97-T(&EM;65D:6%T96QY
M('5P;VX@9W)A;G0-"B`@(&%R92!R96-O<F1E9"!A<R!A;B!E>'!E;G-E(&]V
M97(@=&AE('9E<W1I;F<@<&5R:6]D(&]F('1H92!U;F1E<FQY:6YG('-T;V-K
M(&]P=&EO;G,N($%T('1H92!E;F0@;V8@96%C:"!F:6YA;F-I86P@<F5P;W)T
M:6YG('!E<FEO9"!P<FEO<B!T;R!V97-T:6YG+"!T:&4@=F%L=64@;V8@=&AE
M<V4@;W!T:6]N<RP@87,@8V%L8W5L871E9"!U<VEN9R!T:&4@0FQA8VLM4V-H
M;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"P@:7,@8F5I;F<-"B`@(')E+6UE
M87-U<F5D('5S:6YG('1H92!F86ER('9A;'5E(&]F('1H92!#;VUP86YY)B,X
M,C$W.W,@8V]M;6]N('-T;V-K(&%N9"!T:&4@;F]N+6-A<V@@8V]M<&5N<V%T
M:6]N(')E8V]G;FEZ960@9'5R:6YG('1H92!P97)I;V0@=VEL;"!B92!A9&IU
M<W1E9"!A8V-O<F1I;F=L>2X@4VEN8V4@=&AE(&9A:7(@;6%R:V5T('9A;'5E
M(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!N;VXM96UP;&]Y965S(&ES('-U8FIE
M8W0@=&\@8VAA;F=E(&EN('1H90T*("`@9G5T=7)E+"!T:&4@86UO=6YT(&]F
M('1H92!F=71U<F4@8V]M<&5N<V%T:6]N(&5X<&5N<V4@=VEL;"!I;F-L=61E
M(&9A:7(@=F%L=64@<F4M;65A<W5R96UE;G1S('5N=&EL('1H92!S=&]C:R!O
M<'1I;VYS(&%R92!F=6QL>2!V97-T960N(#PO9F]N=#X\+W`^#0H@("`\<"!S
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M=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q
M,"P-"B`@('1H92!F;VQL;W=I;F<@87-S=6UP=&EO;G,@=V5R92!U<V5D.B`\
M+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I
M;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT
M86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M.3(E(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA
M+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED
M=&@],T0U."4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L
M:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$P/"]B/CPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY796EG:'1E9"!A=F5R86=E(')I<VL@9G)E92!I;G1E<F5S="!R871E/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,"XY,B4F(S$V
M,#LM)B,Q-C`[,RXQ-B4\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ
M+C@X)28C,38P.RTF(S$V,#LS+C(X)3PO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY796EG:'1E9"!A=F5R86=E('9O;&%T:6QI='D\+V9O;G0^/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXY."XV,24F(S$V,#LM)B,Q
M-C`[,3$S+C@W)3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$Q."XS
M)28C,38P.RTF(S$V,#LQ,S,N-C(E/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D5X<&5C=&5D(&QI=F5S("AY96%R
M<RD\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+C<Q
M("T@.2XR-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8@+2`Q,#PO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%>'!E8W1E9"!D:79I9&5N
M9"!Y:65L9#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C`E/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,"4\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@
M/"]T86)L93X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I
M;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@=V5I
M9VAT960@879E<F%G92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"!D
M=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@
M86YD(#(P,3`-"B`@('=A<R`D,"XX.2!A;F0@)#0N,S$@<&5R('-H87)E+"!R
M97-P96-T:79E;'DN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^5&AE($-O;7!A;GDF(S@R,3<[<R!E>'!E8W1E9"!C;VUM;VX@
M<W1O8VL@<')I8V4@=F]L871I;&ET>2!A<W-U;7!T:6]N(&ES(&)A<V5D#0H@
M("!U<&]N('1H92!V;VQA=&EL:71Y(&]F(&$@8F%S:V5T(&]F(&-O;7!A<F%B
M;&4@8V]M<&%N:65S+B!4:&4@97AP96-T960@;&EF92!A<W-U;7!T:6]N<R!F
M;W(@96UP;&]Y964@9W)A;G1S('=E<F4@8F%S960@=7!O;B!T:&4@<VEM<&QI
M9FEE9"!M971H;V0@<')O=FED960@9F]R('5N9&5R($%30R8C,38P.S<Q."TQ
M,"P@=VAI8V@@879E<F%G97,@=&AE(&-O;G1R86-T=6%L('1E<FT@;V8@=&AE
M($-O;7!A;GDF(S@R,3<[<R!O<'1I;VYS(&]F#0H@("!T96X@>65A<G,@=VET
M:"!T:&4@879E<F%G92!V97-T:6YG('1E<FT@;V8@9F]U<B!Y96%R<R!F;W(@
M86X@879E<F%G92!O9B!S:7@@>65A<G,N(%1H92!E>'!E8W1E9"!L:69E(&%S
M<W5M<'1I;VYS(&9O<B!N;VXM96UP;&]Y965S('=E<F4@8F%S960@=7!O;B!T
M:&4@8V]N=')A8W1U86P@=&5R;2!O9B!T:&4@;W!T:6]N+B!4:&4@9&EV:61E
M;F0@>6EE;&0@87-S=6UP=&EO;B!O9B!Z97)O(&ES(&)A<V5D('5P;VX@=&AE
M(&9A8W0@=&AA=`T*("`@1V%L96YA(&AA<R!N979E<B!P86ED(&-A<V@@9&EV
M:61E;F1S(&%N9"!P<F5S96YT;'D@:&%S(&YO(&EN=&5N=&EO;B!O9B!P87EI
M;F<@8V%S:"!D:79I9&5N9',@:6X@=&AE(&9U='5R92X@5&AE(')I<VLM9G)E
M92!I;G1E<F5S="!R871E('5S960@9F]R(&5A8V@@9W)A;G0@=V%S(&%L<V\@
M8F%S960@=7!O;B!P<F5V86EL:6YG('-H;W)T+71E<FT@:6YT97)E<W0@<F%T
M97,N(%1H92!#;VUP86YY(&AA<R!E<W1I;6%T960@86X-"B`@(&%N;G5A;&EZ
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M=V5R('1H86X-"B`@(&5S=&EM871E9"!A;F0@=VEL;"!R96-O<F0@82!R96-O
M=F5R>2!O9B!P<FEO<B!E>'!E;G-E(&EF('1H92!A8W1U86P@9F]R9F5I='5R
M92!R871E<R!A<F4@:&EG:&5R('1H86X@97-T:6UA=&5D+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY#0H@
M("!R96-O<F1E9"!A<'!R;WAI;6%T96QY("0S+#`P,2PP,#`@86YD("0T+#,V
M."PP,#`@;V8@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&9O<B!T:&4@>65A
M<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q,"P@<F5S
M<&5C=&EV96QY+B!!<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!T:&5R
M92!W87,@)#$L,#$R+#`P,"!O9B!U;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N
M(&-O<W0@<F5L871E9"!T;PT*("`@;W5T<W1A;F1I;F<@;W!T:6]N<R!T:&%T
M(&ES(&5X<&5C=&5D('1O(&)E(')E8V]G;FEZ960@87,@82!C;VUP;VYE;G0@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!O<&5R871I;F<@97AP96YS97,@;W9E
M<B!A('=E:6=H=&5D(&%V97)A9V4@<&5R:6]D(&]F(#,N,R!Y96%R<RX@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM
M=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3VX@3F]V96UB97(F(S$V,#LT+`T*("`@
M,C`P.2P@87,@<&%R="!O9B!A('!L86X@<W5C8V5S<VEO;B!I;B!L96%D97)S
M:&EP+"!4;V0@5V]O;&8L)B,Q-C`[4&@N1"XL(')E<VEG;F5D(&%S(&]U<B!0
M<F5S:61E;G0L($-H:65F($5X96-U=&EV92!/9F9I8V5R(&%N9"!A(&UE;6)E
M<B!O9B!O=7(@0F]A<F0@;V8@1&ER96-T;W)S+B!!8V-O<F1I;F<@=&\@=&AE
M(%-E<&%R871I;VX@06=R965M96YT(&)E='=E96X@1'(N)B,Q-C`[5V]O;&8@
M86YD('1H92!#;VUP86YY+`T*("`@1'(N)B,Q-C`[5V]O;&8@<F5C96EV960@
M:6X@;VYE(&QU;7`@<W5M('!A>6UE;G0@:&ES(&9U;&P@<V5V97)A;F-E(&5Q
M=6EV86QE;G0@=&\@82!S:7@@*#8I)B,Q-C`[;6]N=&@@<V%L87)Y("@D,3@W
M+#4P,"DL('-I>"`H-BDF(S$V,#MM;VYT:',@86-C96QE<F%T:6]N(&]F('9E
M<W1I;F<@;V8@86QL(&]F(&AI<R!O=71S=&%N9&EN9R!U;G9E<W1E9"!3=&]C
M:R!/<'1I;VYS(&%S(&]F($YO=F5M8F5R)B,Q-C`[-"P@,C`P.2P@86YD(&%N
M#0H@("!O9F9E<B!T;R!J;VEN('1H92!#;VUP86YY)B,X,C$W.W,@4V-I96YT
M:69I8R!!9'9I<V]R>2!";V%R9"`H4T%"*2!F;W(@,R8C,38P.WEE87)S("AT
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M('1H92!L871E<B!O9CH@*&DI)B,Q-C`[82!P97)I;V0@;V8@='=O("@R*28C
M,38P.WEE87)S(&9R;VT@:&ES(')E<VEG;F%T:6]N("AU;G1I;"!.;W9E;6)E
M<B8C,38P.S0L(#(P,3$I+"!O<B`H:6DI)B,Q-C`[;FEN971Y("@Y,"DF(S$V
M,#MD87ES(&9O;&QO=VEN9R!T:&4@96YD(&]F('1H92!T97)M(&]F('1H92!3
M04(F(S$V,#M!9W)E96UE;G0-"B`@("A&96)R=6%R>28C,38P.S0L(#(P,3,I
M)B,Q-C`[;W(@<W5C:"!E87)L:65R(&1A=&4@87,@=&AE(%-!0B8C,38P.T%G
M<F5E;65N="!M87D@8F4@=&5R;6EN871E9"!P=7)S=6%N="!T;R!T:&4@=&5R
M;7,@;V8@=&AE(%-!0B8C,38P.T%G<F5E;65N="!P<F]V:61E9"!$<BXF(S$V
M,#M7;V]L9B!H87,@;F]T('9I;VQA=&5D('1H92!N;VXM8V]M<&5T:71I;VX@
M<')O=FES:6]N<R!O9B!T:&4@4T%")B,Q-C`[06=R965M96YT('!R:6]R('1O
M#0H@("!T:&4@9&%T92!O9B!E>&5R8VES92`H=VAE=&AE<B!O<B!N;W0@=&AE
M(%-!0B8C,38P.T%G<F5E;65N="!I<R!S=&EL;"!I;B!E9F9E8W0@870@=&AA
M="!T:6UE*2X@3F]T=VET:'-T86YD:6YG(&%N>2!P<F]V:7-I;VX@;V8@=&AE
M($-O;7!A;GDF(S@R,3<[<R`R,#`W($EN8V5N=&EV92!0;&%N+"!T:&4@0V]M
M<&%N>2!A;'-O(&%G<F5E9"!T:&%T($1R+B8C,38P.U=O;VQF)B,X,C$W.W,@
M<')E=FEO=7-L>2!A=V%R9&5D(%-T;V-K#0H@("!/<'1I;VYS('-H86QL(&-O
M;G1I;G5E('1O('9E<W0@9'5R:6YG(&AI<R!C;VYT:6YU:6YG(')O;&4@:6X@
M=&AE($-O;7!A;GD@:6X@=&AE($YE=R!0;W-I=&EO;BX@5&AE('1O=&%L(&5X
M<&5N<V4@9F]R(#(P,3$@86YD(#(P,3`@=V%S("0V-2PP,#`@86YD("0Q.3,L
M,#`P+"!R97-P96-T:79E;'DN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^#0H@("!$=7)I;F<@=&AE(&9I<V-A;"!Y96%R(&5N
M9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L('=E(&=R86YT960@=&\@;W5R
M(%!R97-I9&5N="!A;F0@0VAI968@17AE8W5T:79E($]F9FEC97(@,S`P+#`P
M,"!S=&]C:R!O<'1I;VYS('-U8FIE8W0@=&\@<&5R9F]R;6%N8V4M8F%S960@
M=F5S=&EN9RX@5&AE(&%G9W)E9V%T92!F86ER(&UA<FME="!V86QU92!O9@T*
M("`@=&AE('-T;V-K(&]P=&EO;B!G<F%N="!W87,@=F%L=65D('5S:6YG('1H
M92!L871T:6-E(&UO9&5L(&%N9"!I<R!B96EN9R!A;6]R=&EZ960@=&\@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@;W9E<B!T:&4@=F5S=&EN9R!P97)I;V0N($-O
M;7!E;G-A=&EO;B!E>'!E;G-E(')E8V]G;FEZ960@<F5L871E9"!T;R!T:&ES
M(&=R86YT('=A<R!A<'!R;WAI;6%T96QY("0R,RPP,#`@9F]R('1H92!Y96%R
M(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L#0H@("`R,#$Q+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D%S(&]F($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,3$L(&%N(&%G9W)E9V%T92!O9B`X+#<U,"PP,#`F(S$V
M,#MS:&%R97,@;V8@8V]M;6]N('-T;V-K('=E<F4@<F5S97)V960@9F]R(&ES
M<W5A;F-E('5N9&5R('1H90T*("`@0V]M<&%N>28C.#(Q-SMS(#(P,#<@26YC
M96YT:79E(%!L86XL(&EN8VQU9&EN9R`V+#$V,RPQ,S<F(S$V,#MS:&%R97,@
M<W5B:F5C="!T;R!O=71S=&%N9&EN9R!C;VUM;VX@<W1O8VL@;W!T:6]N<R!G
M<F%N=&5D('5N9&5R('1H:7,@<&QA;B!A;F0@,2PR.3DL-S$W)B,Q-C`[<VAA
M<F5S(&%V86EL86)L92!F;W(@9G5T=7)E(&=R86YT<RX@5&AE(&%D;6EN:7-T
M<F%T;W(@;V8@=&AE('!L86X@9&5T97)M:6YE<R!T:&4@=&EM97,@=VAE;B!A
M;@T*("`@;W!T:6]N(&UA>2!B96-O;64@97AE<F-I<V%B;&4N(%9E<W1I;F<@
M<&5R:6]D<R!O9B!O<'1I;VYS(&=R86YT960@=&\@9&%T92!I;F-L=61E('9E
M<W1I;F<@=7!O;B!G<F%N="!T;R!V97-T:6YG(&%T('1H92!E;F0@;V8@82!F
M;W5R('EE87(@<&5R:6]D+B!4:&4@;W!T:6]N<R!W:6QL(&5X<&ER92P@=6YL
M97-S('!R979I;W5S;'D@97AE<F-I<V5D+"!N;R!L871E<B!T:&%N('1E;B!Y
M96%R<R!F<F]M('1H92!G<F%N="!D871E+B!4:&4-"B`@($-O;7!A;GD@:7,@
M=7-I;F<@=6YI<W-U960@<VAA<F5S(&9O<B!A;&P@<VAA<F5S(&ES<W5E9"!F
M;W(@;W!T:6]N<RP@<F5S=')I8W1E9"!S:&%R92!A=V%R9',@86YD($534%`@
M:7-S=6%N8V5S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E1H92!F;VQL;W=I;F<-"B`@('1A8FQE('-U;6UA<FEZ97,@=&AE
M(&]P=&EO;G,F(S@R,3<[(&%C=&EV:71Y(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@<W1O8VL@;W!T:6]N('!L86XZ(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O
M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G
M(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM
M/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#<S)3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
M,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,3X\8CY3=&]C:SQB<B`O/D]P=&EO;G,\+V(^/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\
M8CY796EG:'1E9#QB<B`O/D%V97)A9V4\8G(@+SY%>&5R8VES928C,38P.U!R
M:6-E/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*
M("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B
M;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]U='-T86YD
M:6YG)B,Q-C`[)B,X,C$R.R!*86YU87)Y)B,Q-C`[,2P@,C`Q,#PO9F]N=#X\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,L-3@R+#,S
M.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C4N,38\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY'<F%N=&5D/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^.3(V+#<V.#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-"XX,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D5X97)C:7-E
M9#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B@U,RPU,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+C<U/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1F]R9F5I=&5D
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*#$R,BPT-S$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+C@U/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$
M9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3W5T<W1A;F1I;F<F(S$V
M,#LF(S@R,3([($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3`\+V9O;G0^/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+#,S,RPQ,S8\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C4N,3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY'<F%N=&5D/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPS,C(L-3`P/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXQ+C(Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^17AE<F-I
M<V5D/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,X,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D9O<F9E
M:71E9#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B@Q+#0Y,BPT.3D\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT+CDY/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T
M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3W5T<W1A;F1I
M;F<F(S$V,#LF(S@R,3([($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$\+V9O;G0^
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV+#$V,RPQ
M,S<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C,N,#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/D5X97)C:7-A8FQE)B,Q-C`[)B,X,C$R.R!$96-E;6)E<B8C,38P
M.S,Q+"`R,#$P/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,RPQ-34L.3`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+C(R/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%>&5R
M8VES86)L928C,38P.R8C.#(Q,CL@1&5C96UB97(F(S$V,#LS,2P@,C`Q,3PO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0L
M-C<S+#<V.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RXT,#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O
M;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@=V5I9VAT960@879E
M<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF92!O9B!O<'1I;VYS(&]U
M='-T86YD:6YG(&%N9"!E>&5R8VES86)L92!A=`T*("`@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,2!W87,@-RXX-R!Y96%R<R!A;F0@-RXU-B!Y96%R<RP@<F5S
M<&5C=&EV96QY+B!4:&4@=V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N
M=')A8W1U86P@;&EF92!O9B!O<'1I;VYS(&]U='-T86YD:6YG(&%N9"!E>&5R
M8VES86)L92!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$P('=A<R`W+C,U('EE
M87)S(&%N9"`W+C`Y('EE87)S+"!R97-P96-T:79E;'DN(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE(&%G9W)E9V%T92!I
M;G1R:6YS:6,@=F%L=64@;V8@;W5T<W1A;F1I;F<@;W!T:6]N<R!A<R!O9B!$
M96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&%N9"`R,#$P(&ES("0P(&%N9"`D,3,W
M+#`P,"P@<F5S<&5C=&EV96QY+B!4:&4@86=G<F5G871E#0H@("!I;G1R:6YS
M:6,@=F%L=64@;V8@97AE<F-I<V%B;&4@;W!T:6]N<R!A<R!O9B!$96-E;6)E
M<B8C,38P.S,Q+"`R,#$Q(&%N9"`R,#$P(&ES("0P(&%N9"`D,S0L,#`P+"!R
M97-P96-T:79E;'DN(%1H92!A9V=R96=A=&4@:6YT<FEN<VEC('9A;'5E(&ES
M(&-A;&-U;&%T960@8F%S960@;VX@=&AE('!O<VET:79E(&1I9F9E<F5N8V4@
M8F5T=V5E;B!T:&4@8VQO<VEN9R!F86ER(&UA<FME="!V86QU92!O9B!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A;F0@=&AE(&5X97)C:7-E
M('!R:6-E#0H@("!O9B!T:&4@=6YD97)L>6EN9R!O<'1I;VYS+B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O
M='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!A9V=R96=A
M=&4@:6YT<FEN<VEC('9A;'5E(&]F(&]P=&EO;G,@97AE<F-I<V5D(&1U<FEN
M9R`R,#$P('=A<R!A<'!R;WAI;6%T96QY("0Q-C0L,#`P+B!4:&5R90T*("`@
M=V5R92!N;R!O<'1I;VYS(&5X97)C:7-E9"!D=7)I;F<@,C`Q,2X@/"]F;VYT
M/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB
M;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y%;7!L;WEE
M92!3=&]C:R!0=7)C:&%S92!0;&%N/"]I/B`F(S@R,3([)B,Q-C`[5&AE($-O
M;7!A;GD@86QS;R!H87,@86X@96UP;&]Y964@<W1O8VL-"B`@('!U<F-H87-E
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M<')I8V4@:7,@97%U86P@=&\-"B`@(#@U)2!O9B!T:&4@;6%R:V5T('9A;'5E
M('!E<B!S:&%R92!O;B!E:71H97(@=&AE(&9I<G-T(&]R(&QA<W0@9&%Y(&]F
M('1H92!S96UI+6%N;G5A;"!P97)I;V0L('=H:6-H979E<B!I<R!L;W=E<BX@
M3W5R($534%`@:7,@;F]N+6-O;7!E;G-A=&]R>2!P=7)S=6%N="!T;R!T:&4@
M<')O=FES:6]N<R!O9B!G96YE<F%L;'D@86-C97!T960@86-C;W5N=&EN9R!P
M<FEN8VEP;&5S(&9O<B!S:&%R92UB87-E9"!C;VUP96YS871I;VX-"B`@(&5X
M<&5N<V4N(%1H92!%4U!0(&-O;G1A:6YS(&%N("8C.#(R,#ME=F5R9W)E96X@
M<')O=FES:6]N)B,X,C(Q.R!W:71H(&%N;G5A;"!I;F-R96%S97,@:6X@=&AE
M(&YU;6)E<B!O9B!S:&%R97,@879A:6QA8FQE(&9O<B!I<W-U86YC92!O;B!T
M:&4@9FER<W0@9&%Y(&]F(&5A8V@@>65A<B!T:')O=6=H($IA;G5A<GDF(S$V
M,#LQ+"`R,#$U(&5Q=6%L('1O('1H92!L97-S97(@;V8Z("AA*28C,38P.S(U
M,"PP,#`@<VAA<F5S(&EN8W)E87-E9`T*("`@;VX@96%C:"!A;FYI=F5R<V%R
M>2!O9B!T:&4@861O<'1I;VX@;V8@=&AE(%!L86X@8GD@;VYE('!E<F-E;G0@
M*#$E*28C,38P.V]F('1H92!T;W1A;"!S:&%R97,@;V8@<W1O8VL@=&AE;B!O
M=71S=&%N9&EN9R!A;F0@*&(I)B,Q-C`[,2PP,#`L,#`P('-H87)E<RXF(S$V
M,#M!<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!A;B!A9V=R96=A=&4@
M;V8@,C,Q+#$W-B!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=E<F4@875T:&]R
M:7IE9`T*("`@86YD(&%V86EL86)L92!F;W(@:7-S=6%N8V4@=6YD97(@=&AE
M($534%`N(%5N9&5R('1H92!E=F5R9W)E96X@<')O=FES:6]N+"!O;B!*86YU
M87)Y)B,Q-C`[,2P@,C`Q,BP@86X@861D:71I;VYA;"`R-3`L,#`P('-H87)E
M<R!W97)E(&%U=&AO<FEZ960@=6YD97(@;W5R($534%`N(%1H92!#;VUP86YY
M(&AA<R!I<W-U960@,3@L.#(T('-H87)E<R!U;F1E<B!T:&4@15-04"!T:')O
M=6=H($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$N#0H@("`\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP
M<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/E)E<W1R:6-T960@4W1O
M8VL@56YI=',@/"]I/B8C.#(Q,CL@26X@861D:71I;VX@=&\@;W!T:6]N<R!T
M;R!P=7)C:&%S92!S:&%R97,@;V8@8V]M;6]N('-T;V-K+"!T:&4@0V]M<&%N
M>2!M87D@9W)A;G0-"B`@(')E<W1R:6-T960@<W1O8VL@=6YI=',@*"8C.#(R
M,#M24U4F(S@R,C$[*2!A<R!P87)T(&]F(&ET<R!C;VUP96YS871I;VX@<&%C
M:V%G92X@16%C:"!24U4@:7,@9W)A;G1E9"!A="!T:&4@9F%I<B!M87)K970@
M=F%L=64@8F%S960@;VX@=&AE(&1A=&4@;V8@9W)A;G0N(%9E<W1I;F<@:7,@
M9&5T97)M:6YE9"!O;B!A(&=R86YT(&)Y(&=R86YT(&)A<VES+B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O
M='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DEN(#(P,3$@86YD
M(#(P,3`L('1H92!#;VUP86YY(&=R86YT960@82!T;W1A;"!O9B`R,C`L-S(X
M(&%N9"`T,RPU-#$@4E-5<RP@<F5S<&5C=&EV96QY+B!4:&4@4E-5<R!G<F%N
M=&5D(&EN(#(P,3$@86YD(#(P,3`@:&%D(&%N(&%G9W)E9V%T90T*("`@:6YT
M<FEN<VEC('9A;'5E(&]F("0R-38L,#`P(&%N9"`D,3$R+#`P,"X@07,@;V8@
M1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q,"P@86QL(&]F('1H92!2
M4U5S(&AA9"!V97-T960@:6X@9G5L;"X@/"]F;VYT/CPO<#X-"CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#-A-F4P,35?-C!A
M.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F
M8R]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY.970@3&]S<R!097(@4VAA<F4\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F5T($QO
M<W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@4&5R(%-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!5
M0DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB
M(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N
M<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D
M($YO=&4@,3,@+2!U<RUG86%P.D5A<FYI;F=S4&5R4VAA<F5497AT0FQO8VLM
M+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^/&(^,3,N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M3F5T($QO<W,@4&5R(%-H87)E(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M
M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&%C8V]U;G1S(&9O<B!A
M;F0@9&ES8VQO<V5S(&YE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@:6X@86-C
M;W)D86YC92!W:71H($9!4T(@05-#(%1O<&EC(#(V,"`F(S@R,C`[#0H@("`\
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M("`@4&]T96YT:6%L(&-O;6UO;B!S:&%R97,@8V]N<VES="!O9B!S:&%R97,@
M:7-S=6%B;&4@=7!O;B!T:&4@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<R!A
M;F0@=V%R<F%N=',N($)E8V%U<V4@=&AE(&EN8VQU<VEO;B!O9B!P;W1E;G1I
M86P@8V]M;6]N('-H87)E<R!W;W5L9"!B92!A;G1I+61I;'5T:79E(&9O<B!A
M;&P@<&5R:6]D<R!P<F5S96YT960L(&1I;'5T960@;F5T(&QO<W,@<&5R(&-O
M;6UO;B!S:&%R92!I<R!T:&4@<V%M92!A<PT*("`@8F%S:6,@;F5T(&QO<W,@
M<&5R(&-O;6UO;B!S:&%R92X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N
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M=F4Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[
M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*
M("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z
M8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*
M("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT
M9"!W:61T:#TS1#<U)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY$96-E
M;6)E<B8C,38P.S,Q+#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,#PO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@
M16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@
M+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/<'1I;VYS('1O('!U<F-H
M87-E(&-O;6UO;B!S=&]C:SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C8L,38S+#$S-SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"PS,S,L
M,3,V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^5V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,30L,3(P+#8T,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BPQ,#`L-C0R/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T
M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&]T
M86P\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXR,"PR.#,L-S<Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV+#0S,RPW-S@\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@
M<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y
M("TM/@T*("`@/"]T86)L93X@#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@[;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO
M<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-#-A-F4P,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W
M7SED830Q8C$P9&)F8R]7;W)K<VAE971S+U-H965T,C(N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M26YC;VUE(%1A>&5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE(%1A>&5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@
M,30@+2!U<RUG86%P.DEN8V]M951A>$1I<V-L;W-U<F5497AT0FQO8VLM+3X-
M"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP
M<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CX\8CXQ-"XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M);F-O
M;64@5&%X97,@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^5&AE(&-O;7!O;F5N=',@;V8@9F5D97)A;"!A;F0@<W1A=&4@
M:6YC;VUE('1A>"!E>'!E;G-E(&%R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N
M9',I.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z-G!X
M.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-
M"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.3(E(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E
M.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-
M"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\
M=&0@=VED=&@],T0W.24^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^07,@
M;V8@1&5C96UB97(F(S$V,#LS,2P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O
M;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P
M,3`\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@
M("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L
M92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0W5R<F5N=#PO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HR+C`P96T[('1E>'0M:6YD96YT
M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^1F5D97)A;#PO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E-T871E/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,X,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/E1O=&%L(&-U<G)E;G0\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1&5F97)R960\+V9O;G0^/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/D9E9&5R86P\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXW+#4S,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-"PX-3,\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C(N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY3=&%T93PO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(L.#,Q/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXQ+#(X,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O
M=&%L(&1E9F5R<F5D/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,3`L,S8R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV+#$S-CPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E9A;'5A=&EO;B!A;&QO=V%N8V4\+V9O;G0^
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,3`L,S8R
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXI/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^*#8L,3,V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI/"]F;VYT/CPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,BXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E1O=&%L(&EN8V]M92!T87@@97AP96YS93PO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A
M8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/E1H92!C;VUP;VYE;G1S(&]F(&YE="!D969E<G)E9"!T87@@
M87-S971S(&%R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I;BUT;W`Z
M,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&)O
M<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T
M97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G
M:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0W
M-R4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^07,@;V8@1&5C96UB97(F
M(S$V,#LS,2P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3`\+V(^/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!4
M86)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3F5T(&]P97)A=&EN9R!L;W-S(&-A
M<G)Y9F]R=V%R9',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^,3@L-S@V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3,L,S(X/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&%X(&-R961I
M="!C87)R>69O<G=A<F1S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,RPQ-C`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L,#8Q/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@
M/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^4W1O8VL@8F%S960@8V]M<&5N<V%T:6]N
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M-BPX.#4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C4L.#8T/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V
M86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P
M96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3W1H97(\+V9O;G0^
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ.3,\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/C$P-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DQI8V5N
M<VEN9R!D961U8W1I;VX@9&5F97)R86P\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW+#0U.#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPR
M-C0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY'<F]S<R!D
M969E<G)E9"!T87@@87-S971S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^,S8L-#@R/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR,RPV,C$\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY686QU871I;VX@86QL;W=A;F-E
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*#,V+#0X,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B@R,RPV,C$\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE
M/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3F5T(&1E9F5R<F5D('1A>"!A<W-E=#PO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O
M;'-P86X],T0T/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P86X],T0T/B8C
M,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!C;VUP;VYE;G1S(&]F
M(&YE="!D969E<G)E9"!T87@@;&EA8FEL:71I97,@87)E(&%S(&9O;&QO=W,@
M*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P86X],T0X/B8C,38P.SPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0Q/CQB/D%S)B,Q-C`[;V8F(S$V,#M$96-E;6)E<B8C
M,38P.S,Q+#PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,3X\8CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LR,#$Q)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[,C`Q,"8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@
M8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY);BUP<F]C97-S(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!N;W0@<W5B:F5C="!T;R!F=71U<F4@86UO<G1I>F%T:6]N(&9O
M<B!T87@@<'5R<&]S97,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^-2PP-3,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S@R,3([/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P
M>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^1W)O<W,@9&5F97)R960@=&%X(&QI86)I;&ET>3PO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+#`U,SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M.#(Q,CL\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM
M($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X@#0H@("`\<"!S='EL
M93TS1&9O;G0M<VEZ93HQ<'@[;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O
M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP
M<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E1H92!P<F]V:7-I;VX@9F]R#0H@("!I;F-O;64@=&%X97,@9&EF9F5R<R!F
M<F]M('1H92!P<F]V:7-I;VX@8V]M<'5T960@8GD@87!P;'EI;F<@=&AE(&9E
M9&5R86P@<W1A='5T;W)Y(')A=&4@=&\@;F5T(&QO<W,@8F5F;W)E(&EN8V]M
M92!T87AE<R!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I;BUT;W`Z,'!X
M.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&)O<F1E
M<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT
M+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G:6X@
M5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0W.24^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X
M('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^07,@;V8@1&5C96UB97(F(S$V
M,#LS,2P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3`\+V(^/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L
M92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@
M/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^17AP96-T960@9F5D97)A;"!I;F-O;64@
M=&%X(&)E;F5F:70\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^*#,L.3`U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B@T+#`W.#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*28C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.;VXM<75A
M;&EF:65D('-T;V-K(&-O;7!E;G-A=&EO;CPO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@S+#$X.3PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^*28C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B@Q+#(S-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%9F9E8W0@;V8@
M8VAA;F=E(&EN('9A;'5A=&EO;B!A;&QO=V%N8V4\+V9O;G0^/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXX+#4U,3PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^-BPQ,S8\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY);F-O;64@=&%X(&-R961I=',\+V9O;G0^/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,C8P/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^*#(S,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*
M("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY3=&%T
M92!I;F-O;64@=&%X97,@869T97(@8W)E9&ET<SPO9F]N=#X\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@Q+#$Y-SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B@Y.30\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT
M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^3W1H97(\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT
M,#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO
M<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A
M8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/E1H92!#;VUP86YY(&AA<R!I;F-U<G)E9"!N970@;W!E<F%T
M:6YG(&QO<W-E<R!F<F]M(&EN8V5P=&EO;BX@070@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,2P@=&AE($-O;7!A;GD@:&%D#0H@("!D;VUE<W1I8R!F961E<F%L
M(&%N9"!S=&%T92!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!O
M9B!A<'!R;WAI;6%T96QY("0T,2XV)B,Q-C`[;6EL;&EO;B!A=F%I;&%B;&4@
M=&\@<F5D=6-E(&9U='5R92!T87AA8FQE(&EN8V]M92P@=VAI8V@@97AP:7)E
M(&%T('9A<FEO=7,@9&%T97,@8F5G:6YN:6YG(&EN(#(P,3,@=&AR;W5G:"`R
M,#,Q+B!4:&4@0V]M<&%N>2!A;'-O(&AA9"!F961E<F%L(&%N9"!S=&%T92!R
M97-E87)C:`T*("`@86YD(&1E=F5L;W!M96YT('1A>"!C<F5D:70@8V%R<GEF
M;W)W87)D<R!O9B!A<'!R;WAI;6%T96QY("0R+#`P,"PP,#`@86YD("0Q+#@P
M,"PP,#`L(')E<W!E8W1I=F5L>2P@879A:6QA8FQE('1O(')E9'5C92!F=71U
M<F4@=&%X(&QI86)I;&ET:65S(&%N9"!W:&EC:"!E>'!I<F4@870@=F%R:6]U
M<R!D871E<R!B96=I;FYI;F<@:6X@,C`R,R!T:')O=6=H(#(P,S$N(#PO9F]N
M=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM
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M92X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X
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M9WD@8V]M<&%N:65S+"!T:&4@0V]M<&%N>2!H87,-"B`@(&-O;F-L=61E9"!T
M:&%T(&ET(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1H870@=&AE<V4@;F5T
M(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@86YD(&-R961I=',@=VEL
M;"!N;W0@8F4@<F5A;&EZ960@86YD+"!A<R!A(')E<W5L="P@82`Q,#`E(&1E
M9F5R<F5D(&EN8V]M92!T87@@=F%L=6%T:6]N(&%L;&]W86YC92!H87,@8F5E
M;B!R96-O<F1E9"!A9V%I;G-T('1H97-E(&%S<V5T<RX@/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!A9&]P
M=&5D(&-E<G1A:6X@<')O=FES:6]N<R!O9B!T:&4@/&D^05-#(#<T,"P\+VD^
M(&5F9F5C=&EV92!*86YU87)Y)B,Q-C`[,2P@,C`P-R!W:&EC:"!C;&%R:69I
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M:6]N#0H@("!O9B`\:3Y!4T,@-S0P+3$P/"]I/B!D:60@;F]T(&AA=F4@86YY
M(&5F9F5C="!O;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA;"!P;W-I
M=&EO;B!O<B!R97-U;'1S(&]F(&]P97)A=&EO;G,N(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P
M>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD-"B`@(&9I
M;&5S(&EN8V]M92!T87@@<F5T=7)N<R!I;B!T:&4@52Y3+B8C,38P.V9E9&5R
M86PL($UA<W-A8VAU<V5T=',@86YD($]R96=O;B!J=7)I<V1I8W1I;VYS+B!4
M:&4@0V]M<&%N>2!I<R!S=6)J96-T('1O('1A>"!E>&%M:6YA=&EO;G,@9F]R
M('1H92`R,#`W('1A>"!Y96%R(&%N9"!B97EO;F0N(%1H92!#;VUP86YY(&1O
M97,@;F]T(&)E;&EE=F4@=&AE<F4@=VEL;"!B92!A;GD@;6%T97)I86P@8VAA
M;F=E<R!I;B!I=',-"B`@('5N<F5C;V=N:7IE9"!T87@@<&]S:71I;VYS(&]V
M97(@=&AE(&YE>'0@,3(F(S$V,#MM;VYT:',N(%1H92!#;VUP86YY(&AA<R!N
M;W0@:6YC=7)R960@86YY(&EN=&5R97-T(&]R('!E;F%L=&EE<RX@26X@=&AE
M(&5V96YT('1H870@=&AE($-O;7!A;GD@:7,@87-S97-S960@:6YT97)E<W0@
M;W(@<&5N86QT:65S(&%T('-O;64@<&]I;G0@:6X@=&AE(&9U='5R92P@=&AE
M>2!W:6QL(&)E(&-L87-S:69I960@:6X@=&AE(&9I;F%N8VEA;`T*("`@<W1A
M=&5M96YT<R!A<R!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E>'!E;G-E
M+B`\+V9O;G0^/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B
M9F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#-A-F4P,35?-C!A
M.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C+U=O<FMS:&5E=',O4VAE970R,RYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQI8V5N
M<V4@06=R965M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%G<F5E;65N=',@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6-E;G-E($%G<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-
M3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12
M+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@
M/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`Q-2`M('5S+6=A87`Z26YT
M86YG:6)L94%S<V5T<T1I<V-L;W-U<F5497AT0FQO8VLM+3X-"B`@(#QP('-T
M>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^/&(^,34N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[3&EC96YS92!!9W)E
M96UE;G1S(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/D%S('!A<G0@;V8@:71S(&)U<VEN97-S+"!T:&4@0V]M<&%N>2!E
M;G1E<G,@:6YT;R!L:6-E;G-I;F<@86=R965M96YT<R!W:71H('1H:7)D('!A
M<G1I97,@=&AA="!O9G1E;B!R97%U:7)E(&UI;&5S=&]N90T*("`@86YD(')O
M>6%L='D@<&%Y;65N=',@8F%S960@;VX@=&AE('!R;V=R97-S(&]F('1H92!A
M<W-E="!T:')O=6=H(&1E=F5L;W!M96YT('-T86=E<RX@36EL97-T;VYE('!A
M>6UE;G1S(&UA>2!B92!R97%U:7)E9"P@9F]R(&5X86UP;&4L('5P;VX@87!P
M<F]V86P@;V8@=&AE('!R;V1U8W0@9F]R(&UA<FME=&EN9R!B>2!A(')E9W5L
M871O<GD@86=E;F-Y+B!);B!C97)T86EN(&%G<F5E;65N=',L('1H92!#;VUP
M86YY(&ES(')E<75I<F5D('1O#0H@("!M86ME(')O>6%L='D@<&%Y;65N=',@
M8F%S960@=7!O;B!A('!E<F-E;G1A9V4@;V8@;F5T('-A;&5S+B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O
M='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!E>'!E;F1I
M='5R97,@<F5Q=6ER960@=6YD97(@=&AE<V4@87)R86YG96UE;G1S(&UA>2!B
M92!M871E<FEA;`T*("`@:6YD:79I9'5A;&QY(&EN('1H92!E=F5N="!T:&%T
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M;V)J96-T:79E<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY$=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS
M,2P@,C`P-RP-"B`@('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&QI8V5N
M<V4@86=R965M96YT('=I=&@@0V]L9"!3<')I;F<@2&%R8F]R($QA8F]R871O
M<GD@*"8C.#(R,#M#4TA,)B,X,C(Q.RD@9F]R('-M86QL(&AA:7)P:6X@4DY!
M+"!O<B`F(S@R,C`[<VA23D$F(S@R,C$[+"!F;W(@=VAI8V@@=&AE($-O;7!A
M;GD@<&%I9"`D-3`L,#`P(&%N9"!A9W)E960@=&\@;6%K92!F=71U<F4@;6EL
M97-T;VYE(&%N9"!R;WEA;'1Y('!A>6UE;G1S('5P;VX-"B`@('-U8V-E<W-F
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M9F]R('=H:6-H('1H90T*("`@0V]M<&%N>2!P86ED(&-A<V@@;V8@)#0U,RPP
M,#`@86YD(&ES<W5E9"`T-C(L,3$R('-H87)E<R!O9B!I=',@8V]M;6]N('-T
M;V-K('9A;'5E9"!A="`D,BXS(&UI;&QI;VXL(&]R("0U+C`P('!E<B!S:&%R
M92X@1F]R(&5A8V@@4DY!:2!P<F]D=6-T(&1E=F5L;W!E9"!I;B!C;VYN96-T
M:6]N('=I=&@@=&AE(&QI8V5N<V4@9W)A;G1E9"!B>2!#4TA,+"!T:&4@<&]S
M<VEB;&4@86=G<F5G871E(&UI;&5S=&]N92!P87EM96YT<R!E<75A;`T*("`@
M)#(L-C4P+#`P,"X@5&AE(&EN=F5N=&EO;B!D:7-C;&]S=7)E(&%G<F5E;65N
M="!H87,@86X@:6YI=&EA;"!T97)M(&]F('1H<F5E('EE87)S(&%N9"!P<F]V
M:61E<R!T:&4@;W!T:6]N('1O(&YE9V]T:6%T92!L:6-E;G-E<R!T;R!C97)T
M86EN(%).06D@=&5C:&YO;&]G:65S(&1I<V-O=F5R960@870@54U-4RX@1'5R
M:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L('1H
M92!#;VUP86YY(&-A;F-E;&QE9`T*("`@<V5V97)A;"!O9B!I=',@;&EC96YS
M97,@=VET:"!534U3+B!5<&]N('1H92!S:6=N:6YG(&]F('1H92!#;VYT<FEB
M=71I;VX@06=R965M96YT(&]N(%-E<'1E;6)E<B8C,38P.S(T+"`R,#$Q+"!O
M;F4@;V8@=&AE(')E;6%I;FEN9R!534U3(&QI8V5N<V5S('=A<R!T<F%N<V9E
M<G)E9"!T;R!26&D@86YD('1H92!#4TA,(&QI8V5N<V4@86=R965M96YT('=A
M<R!R971A:6YE9"!B>2!T:&4@0V]M<&%N>2!A;F0@;F]T('1R86YS9F5R<F5D
M('1O#0H@("!26&DN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^26X@3V-T;V)E<B`R,#`W+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@82!L:6-E;G-E(&%G<F5E;65N="!W:71H($1H87)M86-O;BP@26YC
M+B`H;F]W('!A<G0@;V8@5&AE<FUO($9I<VAE<B!38VEE;G1I9FEC#0H@("!)
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M;R!L:6-E;G-E(&%D9&ET:6]N86P-"B`@(%).06D@<V5Q=65N8V5S+"!U;F1E
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M+`T*("`@=&AE($-O;7!A;GD@<&%I9"!A;B!U<"UF<F]N="!F964@;V8@)#$U
M,"PP,#`@86YD(&%G<F5E9"!T;R!P87D@9G5T=7)E(&-L:6YI8V%L(&UI;&5S
M=&]N92!P87EM96YT<R!A;F0@<F]Y86QT>2!P87EM96YT<R!B87-E9"!O;B!S
M86QE<R!O9B!S:5).02!C;VUP;W-I=&EO;G,@9&5V96QO<&5D(&EN(&-O;FYE
M8W1I;VX@=VET:"!T:&4@;&EC96YS960@=&5C:&YO;&]G>2X@26X@861D:71I
M;VXL('1H92!#;VUP86YY(&AA<R!A9W)E960@=&\-"B`@('!A>2!F=71U<F4@
M8VQI;FEC86P@;6EL97-T;VYE('!A>6UE;G1S(&EN(&%N(&%G9W)E9V%T92!A
M;6]U;G0@;V8@=7`@=&\@)#(L,#`P+#`P,"!A;F0@<F]Y86QT>2!P87EM96YT
M<R!O9B!E:71H97(@,"XR-24@;W(@,"XU)2!B87-E9"!O;B!T:&4@;&5V96P@
M;V8@86YY(&9U='5R92!S86QE<R!O9B!S:5).02!C;VUP;W-I=&EO;G,@9&5V
M96QO<&5D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@;&EC96YS960@=&5C:&YO
M;&]G>2X@3F\-"B`@(&%M;W5N=',@=V5R92!E>'!E;G-E9"!I;B`R,#$P(&%N
M9"`R,#$Q(')E;&%T960@=&\@=&AI<R!L:6-E;G-E+B`\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP
M<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DEN(%-E<'1E;6)E<BP@,C`P
M.2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@4&%T96YT(&%N9`T*("`@
M5&5C:&YO;&]G>2!!<W-I9VYM96YT($%G<F5E;65N="!W:71H($%D=FER;F$L
M($Q,0R`H)B,X,C(P.T%D=FER;F$F(S@R,C$[*2P@82!#;VQO<F%D;R!L:6UI
M=&5D(&QI86)I;&ET>2!C;VUP86YY(&-O+69O=6YD960@8GD@=&AE($-O;7!A
M;GDF(S@R,3<[<R!F;W)M97(@0VAI968@4V-I96YT:69I8R!/9F9I8V5R+B!0
M=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@=&AE(&%G<F5E;65N="P@061V:7)N
M82!A<W-I9VYE9"!T;R!T:&4@0V]M<&%N>0T*("`@8V5R=&%I;B!P871E;G0@
M86YD('1E8VAN;VQO9WD@<FEG:'1S(')E;&%T960@=&\@8VAE;6EC86QL>2!M
M;V1I9FEE9"!P;VQY;G5C;&5O=&ED97,@*'1H92`F(S@R,C`[4FEG:'1S)B,X
M,C(Q.RD@86YD('1H92!#;VUP86YY(&=R86YT960@=&\@061V:7)N82!A(&9U
M;&QY('!A:60M=7`@;&EC96YS92!T;R!T:&4@4FEG:'1S(&EN(&$@<W!E8VEF
M:65D(&9I96QD+B!$=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,2P-"B`@('1H92!#;VUP86YY('!A:60@86YD(&5X<&5N<V5D
M("0Q,#`L,#`P(&9O<B!T:&4@86YN=6%L(&UA:6YT96YA;F-E(&9E97,@=6YD
M97(@=&AI<R!A9W)E96UE;G0N(%1H97)E('=A<R!N;R!E>'!E;G-E(')E8V]R
M9&5D(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$P
M+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[
M;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*
M("`@07,@<&%R="!O9B!T:&4@=')A;G-A8W1I;VYS(&-O;G1E;7!L871E9"!B
M>2!T:&4@0V]N=')I8G5T:6]N($%G<F5E;65N="!A;F0@4V5C=7)I=&EE<R!0
M=7)C:&%S92!!9W)E96UE;G0L(&]N(%-E<'1E;6)E<B8C,38P.S(T+"`R,#$Q
M+"!26&D@96YT97)E9"!I;G1O(&%N(&%G<F5E;65N="!W:71H($%D=FER;F$@
M<'5R<W5A;G0@=&\@=VAI8V@Z#0H@("`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z-G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!S='EL93TS1"=B;W)D97(M
M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&)O<F1E<CTS
M1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P
M,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#0E/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!W:61T:#TS1#$E('9A
M;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,C8[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$=&]P/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$=&]P/@T*("`@/'`@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^061V:7)N82!A<W-I9VYE9"!T;R!26&D@:71S(&5X:7-T:6YG('!A=&5N
M="!A;F0@=&5C:&YO;&]G>2!R:6=H=',@<F5L871E9"!T;R!S9"UR>%).02!T
M96-H;F]L;V=Y(&EN(&5X8VAA;F=E(&9O<B!26&DF(S@R,3<[<R!A9W)E96UE
M;G0@=&\@<&%Y($%D=FER;F$@86X-"B`@(&%N;G5A;"`D,3`P+#`P,"!M86EN
M=&5N86YC92!F964@86YD(&$@;VYE+71I;64@)#,U,"PP,#`@;6EL97-T;VYE
M('!A>6UE;G0@=7!O;B!T:&4@9G5T=7)E(&ES<W5A;F-E(&]F('1H92!F:7)S
M="!P871E;G0@=VET:"!V86QI9"!C;&%I;7,@8V]V97)I;F<@=&AE(&%S<VEG
M;F5D('!A=&5N="!A;F0@=&5C:&YO;&]G>2!R:6=H=',[(#PO9F]N=#X\+W`^
M#0H@("`\+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL
M93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O
M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@8F]R9&5R/3-$
M,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P
M)3X@#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-"4^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('=I9'1H/3-$,24@=F%L
M:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(R-CL\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=VED=&@],T0Q)2!V86QI9VX],T1T;W`^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1T;W`^#0H@("`\<"!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY26&D@=VEL;"!B92!R97%U:7)E9"!T;R!P87D@82`Q)2!R;WEA;'1Y('1O
M($%D=FER;F$@9F]R(&%N>2!L:6-E;G-I;F<@<F5V96YU92!R96-E:79E9"!B
M>2!26&D@=VET:"!R97-P96-T('1O(&9U='5R92!L:6-E;G-I;F<@;V8@=&AE
M(&%S<VEG;F5D($%D=FER;F$-"B`@('!A=&5N="!A;F0@=&5C:&YO;&]G>2!R
M:6=H=',[(#PO9F]N=#X\+W`^#0H@("`\+W1D/@T*("`@/"]T<CX-"B`@(#PO
M=&%B;&4^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O
M<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE
M('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG
M;CH@;&5F="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('=I9'1H/3-$,3`P)3X@#0H@("`\='(^(`T*("`@/'1D('=I9'1H
M/3-$-"4^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C.#(R-CL\+V9O;G0^/"]T9#X@#0H@("`\=&0@=VED=&@],T0Q)2!V
M86QI9VX],T1T;W`^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^#0H@("`\<"!A
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M<SL@86YD(#PO9F]N=#X\+W`^#0H@("`\+W1D/@T*("`@/"]T<CX-"B`@(#PO
M=&%B;&4^(`T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L
M92!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI
M9VXZ(&QE9G0G(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(`T*("`@/'1R/B`-"B`@(#QT9"!W:61T
M:#TS1#0E/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!W:61T:#TS1#$E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S@R,C8[/"]F;VYT/CPO=&0^(`T*("`@/'1D('=I9'1H/3-$,24@
M=F%L:6=N/3-$=&]P/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/@T*("`@/'`@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^4EAI(&AA<R!A9W)E960@=&\@:7-S=64@
M=&\@061V:7)N82P@=7!O;B!T:&4@8V]M<&QE=&EO;B!O9B!T:&4@<W!I;BUO
M9F8@=')A;G-A8W1I;VXL('-H87)E<R!O9B!26&DF(S@R,3<[<R!C;VUM;VX@
M<W1O8VL@97%U86P@=&\@87!P<F]X:6UA=&5L>2`U)2!O9B!T:&4-"B`@(&9U
M;&QY(&1I;'5T960@<VAA<F5S(&]F(%)8:2!C;VUM;VX@<W1O8VL@87-S=6UI
M;F<@=&AE(&-O;G9E<G-I;VX@:6X@9G5L;"!O9B!A;&P@;W5T<W1A;F1I;F<@
M4V5R:65S($$@4')E9F5R<F5D(%-T;V-K+B`\+V9O;G0^/"]P/@T*("`@/"]T
M9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/@T*("`@26X@8V]N:G5N8W1I;VX@=VET:"!T:&4@86-Q=6ES
M:71I;VX@;V8@07!T:&5R82P@=&AE($-O;7!A;GD@87-S=6UE9"!T:&4@<FEG
M:'1S(&%N9"!O8FQI9V%T:6]N<R!O9B!A(&-E<G1A:6X@;&EC96YS92!A9W)E
M96UE;G0L(&%S(&%M96YD960L(&9R;VT@5&AE(%5N:79E<G-I='D@;V8@5&5X
M87,@32X@1"X@06YD97)S;VX@0V%N8V5R($-E;G1E<@T*("`@*"8C.#(R,#M-
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M9VX@<&%T96YT<R!A;F0-"B`@('!A=&5N="!A<'!L:6-A=&EO;G,@8V]V97)I
M;F<@;65T:&]D<R!O9B!U<VEN9R!T:&4@<&5P=&ED92!A<R!A('9A8V-I;F4N
M(%5N9&5R('1H92!T97)M<R!O9B!T:&ES(&QI8V5N<V4L('=E(&%R92!R97%U
M:7)E9"!T;R!M86ME(&9U='5R92!A;FYU86P@;6%I;G1E;F%N8V4@9F5E('!A
M>6UE;G1S+"!A<R!W96QL(&%S(&-L:6YI8V%L(&UI;&5S=&]N92!P87EM96YT
M<R!A;F0@<F]Y86QT>2!P87EM96YT<R!B87-E9"!O;B!S86QE<R!O9@T*("`@
M=&AE<F%P975T:6,@<')O9'5C=',@9&5V96QO<&5D(&9R;VT@=&AE(&QI8V5N
M<V5D('1E8VAN;VQO9VEE<RX@07,@<&%R="!O9B!T:&4@97AP96-T960@<&%Y
M;65N=',@=6YD97(@=&AE('1E<FUS(&]F('1H92!L:6-E;G-E+"!T:&4@0V]M
M<&%N>2!M=7-T('!A>2!A;B!A;FYU86P@;6%I;G1E;F%N8V4@9F5E(&]F("0R
M,#`L,#`P+B!);B!A9&1I=&EO;BP@=7!O;B!C;VUM96YC:6YG('1H92!0:&%S
M92`S('1R:6%L+"!W92!W:6QL('!A>2!A#0H@("!M:6QE<W1O;F4@<&%Y;65N
M="!O9B`D,C`P+#`P,"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT
M)3MP861D:6YG+6)O='1O;3HP<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DEN($IU;'D@,C`Q,2P@
M=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<W5B<V5Q=65N="!N;VXM97AC
M;'5S:79E(&QI8V5N<V4-"B`@(&%G<F5E;65N="!W:71H($A*1B!W:&EC:"!H
M87,@<VEN8V4@8F5E;B!M861E(&5X8VQU<VEV92P@9W)A;G1I;F<@<&%T96YT
M(')I9VAT<R!T;R!T:&4@=7-E(&]F('1H92!%-S4@<&5P=&ED92!I;B!C;VUB
M:6YA=&EO;B!W:71H($AE<F-E<'1I;CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/'-U<#X-"B`@("9R96<[
M/"]S=7`^/"]F;VYT/BX@07,@<&%R="!O9B!T:&4@97AP96-T960@<&%Y;65N
M=',@=6YD97(@=&AE('1E<FUS(&]F('1H92!L:6-E;G-E+"!T:&4@0V]M<&%N
M>2!P86ED(&%N(&ES<W5E(')O>6%L='D@9F5E(&]F("0Q,#`L,#`P+B!);B!A
M9&1I=&EO;BP@=&AE($-O;7!A;GD@;75S="!P87D@86X@86YN=6%L#0H@("!M
M86EN=&5N86YC92!F964@;V8@)#4P+#`P,"`H)#(U+#`P,"!F;W(@96%C:"!P
M871E;G0I(&%N9"!R;WEA;'1I97,@8F%S960@;VX@;F5T('-A;&5S('5P;VX@
M8V]M;65R8VEA;&EZ871I;VXN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^26X@4V5P=&5M8F5R#0H@("`R,#$Q+"!T:&4@0V]M
M<&%N>2!L:6-E;G-E9"!W;W)L9'=I9&4@<FEG:'1S('1O(&1E=F5L;W`@86YD
M(&-O;6UE<F-I86QI>F4@82!&;VQA=&4@0FEN9&EN9R!0<F]T96EN+44S.2`H
M1D)0*2!T87)G971E9"!V86-C:6YE('1O('!R979E;G0@<F5C=7)R96YC92!I
M;B!G>6YE8V]L;V=I8V%L(&-A;F-E<G,@<W5C:"!A<R!O=F%R:6%N(&%N9"!E
M;F1O;65T<FEA;"!A9&5N;V-A<F-O;FEM87,N(%1H92!&0E`@=F%C8VEN92!W
M87,@;&EC96YS960-"B`@(&9R;VT@5&AE(%5N:79E<G-I='D@;V8@5&5X87,@
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M(%!H87-E(#$@=')I86QS(&)Y('1H92!E;F0@;V8@,C`Q,2X@07,@<&%R="!O
M9B!T:&4@97AP96-T960@<&%Y;65N=',@=6YD97(@=&AE('1E<FUS(&]F('1H
M92!L:6-E;G-E+"!T:&4@0V]M<&%N>2!P86ED(&%N(&ES<W5E(')O>6%L='D@
M9F5E(&]F("0Q,#`L,#`P+@T*("`@061D:71I;VYA;&QY+"!T:&4@0V]M<&%N
M>2!S:&%L;"!P87D@=&AE($A*1B!A(&YO;BUC<F5D:71A8FQE+"!N;VYR969U
M;F1A8FQE($QI8V5N<V4@:7-S=64@<F]Y86QT>2!I;B!T:&4@<W5M(&]F("0Q
M-2PP,#`@9F]R(&5A8V@@861D:71I;VYA;"!I=&5M(&]F(&9O;&QO=RUO;B!I
M;G1E;&QE8W1U86P@<')O<&5R='DN($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N
M>2!M=7-T('!A>2!A;B!A;FYU86P@;6%I;G1E;F%N8V4@9F5E(&]F#0H@("`D
M,C4L,#`P(&EN(#(P,3(@86YD("0U,"PP,#`@:6X@,C`Q,RX@/"]F;VYT/CPO
M<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-#-A-F4P,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B,3!D8F9C#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0S839E,#$U7S8P83A?-#!E8U\Y,#`W
M7SED830Q8C$P9&)F8R]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R
M86YS86-T:6]N<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY26&D@4W!I;BU/=70@86YD(%)E;&%T960@4&%R='D@
M5')A;G-A8W1I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5L871E9"!087)T>2!4<F%N<V%C=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%
M(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO
M;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT
M;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C
M:R!486=G960@3F]T92`Q-B`M('5S+6=A87`Z4F5L871E9%!A<G1Y5')A;G-A
M8W1I;VYS1&ES8VQO<W5R951E>'1";&]C:RTM/@T*("`@/'`@<W1Y;&4],T1M
M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXQ
M-BXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M296QA=&5D(%!A<G1Y(%1R86YS
M86-T:6]N<R`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY26&D@86YD($%D=FER;F$L($Q,0RP@=VAI8V@@:7,@-3`E+6]W
M;F5D(&)Y('1H92!#;VUP86YY)B,X,C$W.W,@9F]R;65R($-H:65F(%-C:65N
M=&EF:6,@3V9F:6-E<BP@;W(@0U-/+"!A<F4@<&%R=&EE<R!T;PT*("`@86X@
M;W!T:6]N(&%G<F5E;65N="!W:&5R96)Y('1H92!#;VUP86YY('!A:60@)#4L
M,#`P(&EN(#(P,#@@9F]R(&-O;G-I9&5R871I;VX@=&\@8F4@9W)A;G1E9"!T
M:&4@97AC;'5S:79E('=O<FQD=VED92!R:6=H=',@=&\@;&EC96YS92!C97)T
M86EN('1E8VAN;VQO9WD@86YD("0W-2PP,#`@9F]R('1H92!I;FET:6%L(&UA
M:6YT96YA;F-E(&EN(#(P,#D@=6YD97(@82!0871E;G0@86YD(%1E8VAN;VQO
M9WD@07-S:6=N;65N=`T*("`@06=R965M96YT('=I=&@@061V:7)N82!E;G1E
M<F5D(&EN=&\@:6X@4V5P=&5M8F5R(#(P,#D@*'-E92!A;'-O($YO=&4F(S$V
M,#LQ-2DN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^3VX@1F5B<G5A<GDF(S$V,#LR-BP@,C`P-RP@=&AE($-O;7!A;GD@96YT
M97)E9`T*("`@:6YT;R!38VEE;G1I9FEC($%D=FES;W)Y($)O87)D($%G<F5E
M;65N=',@*'1H92`F(S@R,C`[4T%")B,Q-C`[06=R965M96YT<R8C.#(R,3LI
M+"!W:71H(&9O=7(@;V8@:71S(&9O=6YD97)S+B!!="!T:&4@=&EM92!O9B!T
M:&4@97AE8W5T:6]N(&]F('1H92!304(F(S$V,#M!9W)E96UE;G1S+"!E86-H
M(&]F('1H92!F;W5N9&5R<R!W97)E(&)E;F5F:6-I86P@;W=N97)S(&]F(&UO
M<F4@=&AA;B!F:79E('!E<F-E;G0@;V8@=&AE#0H@("!#;VUP86YY)B,X,C$W
M.W,@;W5T<W1A;F1I;F<@<W1O8VLN(%!U<G-U86YT('1O('1H92!304(F(S$V
M,#M!9W)E96UE;G1S+"!O;B!-87DF(S$V,#LR,RP@,C`P-RP@=&AE($-O;7!A
M;GD@9W)A;G1E9"!T;R!E86-H(&]F('1H92!F;W5N9&5R<R!A('-T;V-K(&]P
M=&EO;B!U;F1E<B!T:&4@,C`P-R!0;&%N('1O('!U<F-H87-E(#4R+#@S,B8C
M,38P.W-H87)E<R!O9B!I=',@8V]M;6]N('-T;V-K+B!);B!A9&1I=&EO;BP@
M=6YD97(@=&AE#0H@("!304(F(S$V,#M!9W)E96UE;G1S+"!T:&4@0V]M<&%N
M>2!W:6QL(&=R86YT(&5A8V@@;V8@=&AE(&9O=6YD97)S(&$@<W1O8VL@;W!T
M:6]N('5N9&5R('1H92`R,#`W(%!L86X@=&\@<'5R8VAA<V4@-3(L.#,R)B,Q
M-C`[<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@;VX@1F5B<G5A<GDF(S$V
M,#LR-BP@,C`P."P@2G5N928C,38P.S4L(#(P,#D@86YD($IU;F4F(S$V,#LT
M+"`R,#$P('=I=&@@82!P97(@<VAA<F4@97AE<F-I<V4@<')I8V4-"B`@(&5Q
M=6%L('1O('1H92!C;&]S:6YG('!R:6-E(&]F('-U8V@@<W1O8VL@;VX@=&AE
M('!U8FQI8R!M87)K970@;VX@=&AE(&1A=&4@;V8@9W)A;G0@=6YL97-S(&$@
M9F]U;F1E<B!T97)M:6YA=&5S(&$@4T%")B,Q-C`[06=R965M96YT('=I=&AO
M=70@9V]O9"!R96%S;VX@*&%S(&1E9FEN960I(&]R('1H92!#;VUP86YY('1E
M<FUI;F%T97,@82!304(F(S$V,#M!9W)E96UE;G0@=VET:"!C875S92`H87,@
M9&5F:6YE9"!T:&5R96EN*2!I;@T*("`@=VAI8V@@8V%S92!N;R!F=7)T:&5R
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M9`T*("`@8F]A<F0@;65E=&EN9R!A9G1E<B!S=6-H(&1A=&4@86YD('1H92!P
M97(@<VAA<F4@97AE<F-I<V4@<')I8V4@;V8@=&AE(&]P=&EO;G,@=VEL;"!B
M92!D971E<FUI;F5D(&EN(&=O;V0@9F%I=&@@8GD@=&AE($-O;7!A;GDF(S@R
M,3<[<R!B;V%R9"!O9B!D:7)E8W1O<G,N($%L;"!O<'1I;VYS(&=R86YT960@
M<'5R<W5A;G0@=&\@=&AE(%-!0B8C,38P.T%G<F5E;65N=',@87)E(&9U;&QY
M('9E<W1E9"!O;B!T:&4@9&%T92!O9B!G<F%N=`T*("`@86YD(&AA=F4@82!T
M97)M(&]F('1E;B!Y96%R<RX@5&AE(&9A:7(@=F%L=64@;V8@<W1O8VL@;W!T
M:6]N<R!G<F%N=&5D(&1U<FEN9R`R,#$Q(&%N9"`R,#$P('5N9&5R('1H92!3
M04(F(S$V,#M!9W)E96UE;G0@9F]R(&5A8V@@9F]U;F1E<B!I<R!A<'!R;WAI
M;6%T96QY("0P(&%N9"`D,30R+#`P,"!W:&EC:"!W87,@97-T:6UA=&5D('5S
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M960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,"!I<R!A<'!R;WAI;6%T96QY("0U
M-C8L,#`P(&]F(&5X<&5N<V4@<F5L871E9"!T;R!T:&4-"B`@(&=R86YT:6YG
M(&]F('1H97-E('-T;V-K(&]P=&EO;G,N($YO(&]P=&EO;G,@=6YD97(@=&AE
M(%-!0B!A9W)E96UE;G1S('=E<F4@:7-S=65D(&1U<FEN9R!T:&4@>65A<B!E
M;F1E9"!$96-E;6)E<B`F(S$V,#LS,2P@,C`Q,3PO9F]N=#X\+W`^#0H@("`\
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M+"`R,#`W+"!T:&4@)B,X,C(P.U-!0B8C,38P.TQE='1E<G,F(S@R,C$[+"!I
M;B!F=7)T:&5R(&-O;G-I9&5R871I;VX@;V8@=&AE('-E<G9I8V5S('1O(&)E
M(')E;F1E<F5D(&)Y('1H92!F;W5N9&5R<R!U;F1E<B!T:&4@4T%")B,Q-C`[
M06=R965M96YT<RP@=&AE($-O;7!A;GD@9W)A;G1E9"!A9&1I=&EO;F%L('-T
M;V-K(&]P=&EO;G,@;VX@36%Y)B,Q-C`[,C,L(#(P,#<@=6YD97(@=&AE(#(P
M,#<@4&QA;B!T;PT*("`@96%C:"!O9B!T:&4@9F]U;F1E<G,@=&\@<'5R8VAA
M<V4@,C8L-#$V)B,Q-C`[<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VLN(%5N
M;&5S<R!A(&9O=6YD97(@=&5R;6EN871E<R!A(%-!0B8C,38P.T%G<F5E;65N
M="!W:71H;W5T(&=O;V0@<F5A<V]N("AA<R!D969I;F5D*2!O<B!T:&4@0V]M
M<&%N>2!T97)M:6YA=&5S(&$@4T%")B,Q-C`[06=R965M96YT('=I=&@@8V%U
M<V4@*&%S(&1E9FEN960@=&AE<F5I;BDL('1H92!O<'1I;VYS#0H@("!G<F%N
M=&5D('!U<G-U86YT('1O('1H92!304(F(S$V,#M,971T97)S('=I;&P@9G5L
M;'D@=F5S="!F<F]M(&%N9"!A9G1E<B!!<')I;"8C,38P.S(Y+"`R,#$R(&%N
M9"!W:6QL(&AA=F4@82!T97)M(&]F('1E;B!Y96%R<R!F<F]M('1H92!D871E
M(&]F(&=R86YT+B!!="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&%N9"`R,#$P
M('1H92!F86ER(&UA<FME="!V86QU92!O9B!S=&]C:R!O<'1I;VYS('5N9&5R
M('1H92!304(F(S$V,#M!9W)E96UE;G0@9F]R#0H@("!E86-H(&9O=6YD97(@
M:7,@87!P<F]X:6UA=&5L>2`D-2PP,#`@86YD("0U.2PP,#`L(')E<W!E8W1I
M=F5L>2P@=VAI8V@@=V%S(&5S=&EM871E9"!U<VEN9R!T:&4@0FQA8VLM4V-H
M;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"!A<R!M;W)E(&9U;&QY(&1I<V-U
M<W-E9"!A8F]V92!U;F1E<B!T:&4@<W5M;6%R>2!O9B!S:6=N:69I8V%N="!A
M8V-O=6YT:6YG('!O;&EC:65S(&%N9"!T:&4@<W1O8VL@8F%S960@8V]M<&5N
M<V%T:6]N(&9O;W1N;W1E+B!);F-L=61E9"!I;B!T:&4-"B`@(&%C8V]M<&%N
M>6EN9R!F:6YA;F-I86P@<W1A=&5M96YT<R!F;W(@=&AE('EE87)S(&5N9&5D
M($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@86YD(#(P,3`@:7,@87!P<F]X:6UA
M=&5L>2`D,34Y+#`P,"!A;F0@)#8P+#`P,"!O9B!I;F-O;64L(')E<W!E8W1I
M=F5L>2P@<F5L871E9"!T;R!T:&5S92!S=&]C:R!O<'1I;VYS+B`\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O
M='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D1U<FEN9R`R,#$R
M+"!T:&4@0V]M<&%N>2!R971A:6YE9"!4<F]Y1V]U;&0@4$,@=&\@8F4@:71S
M(&]U='-I9&4@8V]R<&]R871E(&-O=6YS96PN(%-A;F9O<F0@2BX@2&EL;'-B
M97)G+"!T:&4@0VAA:7)M86X@;V8@=&AE($-O;7!A;GDL(&ES#0H@("!A('-E
M;FEO<B!L87=Y97(@=VET:"!4<F]Y1V]U;&0@4$,N(#PO9F]N=#X\+W`^#0H\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0S839E
M,#$U7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8PT*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T
M,6(Q,&1B9F,O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^16UP;&]Y964@0F5N969I="!0;&%N
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D5M<&QO>65E($)E;F5F:70@4&QA;B!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E($)E
M;F5F:70@4&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M
M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4
M<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ
M+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E
M9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$W("T@=7,M9V%A<#I096YS:6]N06YD
M3W1H97)0;W-T<F5T:7)E;65N=$)E;F5F:71S1&ES8VQO<W5R951E>'1";&]C
M:RTM/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O
M='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CX\8CXQ-RXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#M%;7!L;WEE92!"96YE9FET(%!L86X@/"]B/CPO9F]N=#X\+W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@
M=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@<W!O;G-O<G,@
M82`T,#$H:RD@<F5T:7)E;65N="!S879I;F=S('!L86X@*'1H92`F(S@R,C`[
M4&QA;B8C.#(R,3LI+B!087)T:6-I<&%T:6]N(&EN('1H92!0;&%N(&ES(&%V
M86EL86)L92!T;PT*("`@9G5L;"UT:6UE(&5M<&QO>65E<R!W:&\@;65E="!E
M;&EG:6)I;&ET>2!R97%U:7)E;65N=',N($5L:6=I8FQE(&5M<&QO>65E<R!M
M87D@9&5F97(@82!P;W)T:6]N(&]F('1H96ER('-A;&%R>2!A<R!D969I;F5D
M(&)Y($EN=&5R;F%L(%)E=F5N=64@4V5R=FEC92!R96=U;&%T:6]N<RX@5&AE
M($-O;7!A;GD@;6%Y(&UA:V4@;6%T8VAI;F<@8V]N=')I8G5T:6]N<R!O;B!B
M96AA;&8@;V8@86QL('!A<G1I8VEP86YT<R!I;B!T:&4@-#`Q*&LI#0H@("!0
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M<75A;&EF>2!U;F1E<B!396-T:6]N<R8C,38P.S0P,2AK*2!A;F0@-3`Q(&]F
M('1H90T*("`@26YT97)N86P@4F5V96YU92!#;V1E('-O('1H870@8V]N=')I
M8G5T:6]N<R!B>2!E;7!L;WEE97,@=&\@=&AE(#0P,2AK*2!0;&%N+"!A;F0@
M:6YC;VUE(&5A<FYE9"`H:68@86YY*2!O;B!P;&%N(&-O;G1R:6)U=&EO;G,L
M(&%R92!N;W0@=&%X86)L92!T;R!E;7!L;WEE97,@=6YT:6P@=VET:&1R87=N
M(&9R;VT@=&AE(#0P,2AK*2!0;&%N+"!A;F0@<V\@=&AA="!T:&4@0V]M<&%N
M>2!W:6QL(&)E(&%B;&4@=&\@9&5D=6-T(&ET<PT*("`@8V]N=')I8G5T:6]N
M<RP@:68@86YY+"!W:&5N(&UA9&4N(%1H92!T<G5S=&5E('5N9&5R('1H92`T
M,#$H:RD@4&QA;BP@870@=&AE(&1I<F5C=&EO;B!O9B!E86-H('!A<G1I8VEP
M86YT+"!I;G9E<W1S('1H92!A<W-E=',@;V8@=&AE(#0P,2AK*2!0;&%N(&EN
M(&%N>2!O9B!A(&YU;6)E<B!O9B!I;G9E<W1M96YT(&]P=&EO;G,N(%1O(&1A
M=&4L('1H92!#;VUP86YY(&AA<R!N;W0@;6%D92!A;GD@;6%T8VAI;F<@8V]N
M=')I8G5T:6]N<RX-"B`@(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0S839E,#$U7S8P83A?-#!E8U\Y
M,#`W7SED830Q8C$P9&)F8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\T,V$V93`Q-5\V,&$X7S0P96-?.3`P-U\Y9&$T,6(Q,&1B9F,O5V]R:W-H
M965T<R]3:&5E=#(V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N
M=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S
M0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W
M=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T
M9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$X("T@
M=7,M9V%A<#I3=6)S97%U96YT179E;G1S5&5X=$)L;V-K+2T^#0H@("`\<"!S
M='EL93TS1&UA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/CQB/C$X+B8C,38P.R8C,38P.R8C,38P.R8C,38P.U-U8G-E<75E;G0@
M179E;G1S(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E1H92!#;VUP86YY(&5V86QU871E9"!A;&P@979E;G1S(&]R('1R
M86YS86-T:6]N<R!T:&%T(&]C8W5R<F5D(&%F=&5R($1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,3$@=7`@=&AR;W5G:"!T:&4@9&%T92!T:&5S90T*("`@9FEN86YC
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M=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3VX@2F%N=6%R
M>28C,38P.S$R+"`R,#$R+"!T:&4@0V]M<&%N>2!G<F%N=&5D(&%N(&]P=&EO
M;B!T;R!P=7)C:&%S92`U,"PP,#`F(S$V,#MS:&%R97,@;V8@8V]M;6]N('-T
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M871E<B!T:&%N(#$P('EE87)S#0H@("!F<F]M('1H92!G<F%N="!D871E+B`\
M+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R
M9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]N($IA
M;G5A<GDF(S$V,#LQ,BP@,C`Q,BP@=&AE($-O;7!A;GD@9W)A;G1E9"!O<'1I
M;VYS('1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`X,C4L,#`P)B,Q-C`[
M<VAA<F5S(&]F#0H@("!C;VUM;VX@<W1O8VL@=&\@8V5R=&%I;B!E;7!L;WEE
M97,@870@82!P<FEC92!O9B`D,"XW,B!P97(@<VAA<F4L('=H:6-H(')E<')E
M<V5N=&5D('1H92!#;VUP86YY)B,X,C$W.W,@8VQO<VEN9R!S=&]C:R!P<FEC
M92!O;B!T:&%T(&1A=&4N(%1H92!O<'1I;VYS('9E<W0@<75A<G1E<FQY(&]V
M97(@9F]U<B!Y96%R<R!B96=I;FYI;F<@=&AR964@;6]N=&AS(&9R;VT@=&AE
M(&1A=&4@;V8@9W)A;G0@86YD(&5X<&ER92!N;W0@;&%T97(@=&AA;B`Q,"!Y
M96%R<R!F<F]M('1H92!D871E(&]F(&=R86YT+B`\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[
M('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]N($9E8G)U87)Y)B,Q-C`[-"P@
M,C`Q,BP@=&AE($-O;7!A;GD@9W)A;G1E9"!W87)R86YT<R!T;R!P=7)C:&%S
M92`T,#`L,#`P)B,Q-C`[<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A="!A;B!E
M>&5R8VES92!P<FEC92!O9B`D,"XV-B!P97(-"B`@('-H87)E(&EN(&5X8VAA
M;F=E(&9O<B!B=7-I;F5S<R!A9'9I<V]R>2!S97)V:6-E<R!T;R!T:&4@0V]M
M<&%N>2!F;W(@82!P97)I;V0@;V8@=7`@=&\@='=E;'9E(&UO;G1H<RX@5&AE
M('=A<G)A;G1S('9E<W1E9"!A<R!T;R`Q,#`L,#`P)B,Q-C`[<VAA<F5S('5P
M;VX@:7-S=6%N8V4L(&%N9"!T:&5N('=I;&P@=F5S="!A="!A(')A=&4@;V8@
M,3`P+#`P,"8C,38P.W-H87)E<R8C,38P.W!E<B!Q=6%R=&5R('-T87)T:6YG
M(&]N('1H90T*("`@.3`F(S$V,#MD87D@86YN:79E<G-A<GD@;V8@:7-S=6%N
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M+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[
M;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]N
M($IA;G5A<GDF(S$V,#LR,"P@,C`Q,BP@=&AE($-O;7!A;GD@<V]L9"`U-SDL
M-S$P('-H87)E<R!O9B!O=7(@8V]M;6]N#0H@("!S=&]C:R!F;W(@)#0P,"PP
M,#`@=&\@2W=A;F<@1&]N9R!0:&%R;6%C975T:6-A;"!#;VUP86YY(&%S('!A
M<G0@;V8@82!E>&ES=&EN9R!L:6-E;G-E(&%G<F5E;65N="!F;W(@3F5U5F%X
M(&-O=F5R:6YG('1E<G)I=&]R:6%L(')I9VAT<R!F;W(@=&AE(&-O;7!O=6YD
M(&EN(%-O=71H($MO<F5A('1H870@=&AE($-O;7!A;GD@86-Q=6ER960@:6X@
M:71S(&UE<F=E<B!A8W%U:7-I=&EO;B!O9B!!<'1H97)A+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]N($9E8G)U87)Y)B,Q
M-C`[,RP@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#$P,"PP,#`@<VAA<F5S
M(&]F(&]U<B!C;VUM;VX@<W1O8VL@:6X@<&%Y;65N="!O9B`D,3,U+#`P,"!O
M9B!A8V-R=65D(&QE9V%L(&9E97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI
M;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^3VX@36%R8V@F(S$V,#LX+"`R,#$R+"!T:&4@
M0V]M<&%N>2!I<W-U960@,2PS,34L-S@Y(')E<W1R:6-T960@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!I;B!P87EM96YT(&]F('1H92!F:7)S="!M:6QE<W1O
M;F4@=6YD97(@=&AE#0H@("!C;VYT:6YG96YT('9A;'5E(')I9VAT<R!A9W)E
M96UE;G0@96YT97)E9"!I;G1O(&EN(&-O;FYE8W1I;VX@=VET:"!O=7(@;65R
M9V5R(&%C<75I<VET:6]N(&]F($%P=&AE<F$@:6X@07!R:6P@,C`Q,2X@5&AE
M(&-E<G1I9FEC871E<R!E=FED96YC:6YG('1H92!M:6QE<W1O;F4@<VAA<F5S
M(&AA=F4@8F5E;B!D97!O<VET960@=VET:"!A('1H:7)D+7!A<G1Y(&5S8W)O
M=R!A9V5N="X@5&AE(&UI;&5S=&]N92!S:&%R97,@=VEL;"!B90T*("`@<F5L
M96%S960@=&\@=&AE(&9O<FUE<B!!<'1H97)A('-H87)E:&]L9&5R<R!F<F]M
M(&5S8W)O=R!I9B!T:&4@:7-S=6%N8V4@;V8@=&AE(&UI;&5S=&]N92!S:&%R
M97,@:7,@87!P<F]V960@8GD@=&AE('-T;V-K:&]L9&5R<R!O9B!T:&4@0V]M
M<&%N>2!A="!T:&4@0V]M<&%N>28C.#(Q-SMS(#(P,3(@86YN=6%L('-T;V-K
M:&]L9&5R<R!M965T:6YG+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/D9R;VT@2F%N=6%R>2`R,RP@,C`Q,B!T:')O=6=H($UA
M<F-H(#(S+"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@,2PS-CDL.30T('-H
M87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!S=6)J
M96-T('1O('1H90T*("`@97AE<F-I<V4@;V8@;W5T<W1A;F1I;F<@=V%R<F%N
M=',@9G)O;2!V87)I;W5S('=A<G)A;G0@:&]L9&5R<RX@5&AE($-O;7!A;GD@
M<F5C96EV960@)#$L,C(S+#0V-"!I;B!T;W1A;"!P87EM96YT<R!A="!E>&5R
M8VES92!P<FEC97,@<F%N9VEN9R!F<F]M("0P+C8U('1O("0R+C4P('!E<B!S
M:&%R92X@/"]F;VYT/CPO<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-#-A-F4P,35?-C!A.%\T,&5C7SDP,#=?.61A-#%B
M,3!D8F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0S839E,#$U
M7S8P83A?-#!E8U\Y,#`W7SED830Q8C$P9&)F8R]7;W)K<VAE971S+V9I;&5L
M:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$
M(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C8N:'1M
M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S0S839E,#$U7S8P83A?
:-#!E8U\Y,#`W7SED830Q8C$P9&)F8RTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Consolidated Statements of Cash Flows [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CashExcludingFromNetAssetsAcquired', window );">Cash excluding from net assets acquired</a></td>
        <td class="nump">$ 168<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CashExcludingFromNetAssetsAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash excluding from net assets acquired</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CashExcludingFromNetAssetsAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfCashFlowsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQMAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 11,433<span></span></td>
        <td class="nump">$ 6,891<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump">101<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">276<span></span></td>
        <td class="nump">150<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">11,810<span></span></td>
        <td class="nump">7,041<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and furnishings, net of accumulated depreciation and amortization of $657 and $491 in 2011 and 2010, respectively</a></td>
        <td class="nump">393<span></span></td>
        <td class="nump">419<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_InProcessResearchDevelopment', window );">In-process research &amp; development</a></td>
        <td class="nump">12,864<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">5,898<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">16<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">30,968<span></span></td>
        <td class="nump">7,476<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,155<span></span></td>
        <td class="nump">724<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expense and other current liabilities</a></td>
        <td class="nump">2,168<span></span></td>
        <td class="nump">1,113<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
        <td class="nump">500<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">816<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current maturities of capital lease obligations</a></td>
        <td class="nump">35<span></span></td>
        <td class="nump">51<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfWarrantsPotentiallySettleableInCash', window );">Fair value of warrants potentially settleable in cash</a></td>
        <td class="nump">3,746<span></span></td>
        <td class="nump">3,138<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CurrentContingentPurchasePriceConsideration', window );">Current contingent purchase price consideration</a></td>
        <td class="nump">1,782<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">11,202<span></span></td>
        <td class="nump">5,026<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, net of current maturities</a></td>
        <td class="nump">32<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax liability, non-current</a></td>
        <td class="nump">5,053<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent purchase price consideration, net of current portion</a></td>
        <td class="nump">4,569<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">20,856<span></span></td>
        <td class="nump">5,046<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 125,000,000 shares authorized and 47,811,453 shares issued and 47,136,453 shares outstanding at December 31, 2011; and 50,000,000 shares authorized and 19,047,759 shares issued and 18,372,759 outstanding at December 31, 2010, respectively</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">81,184<span></span></td>
        <td class="nump">62,020<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_DeficitAccumulatedDuringDevelopmentalStage', window );">Deficit accumulated during the developmental stage</a></td>
        <td class="num">(67,228)<span></span></td>
        <td class="num">(55,743)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury shares at cost, 675,000 shares</a></td>
        <td class="num">(3,849)<span></span></td>
        <td class="num">(3,849)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">10,112<span></span></td>
        <td class="nump">2,430<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 30,968<span></span></td>
        <td class="nump">$ 7,476<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent purchase price consideration, net of current portion</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CurrentContingentPurchasePriceConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Current contingent purchase price consideration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CurrentContingentPurchasePriceConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_DeficitAccumulatedDuringDevelopmentalStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deficit accumulated during the developmental stage</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_DeficitAccumulatedDuringDevelopmentalStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfWarrantsPotentiallySettleableInCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants potentially settleable in cash (Note 8)</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfWarrantsPotentiallySettleableInCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_InProcessResearchDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In-process research &amp; development</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_InProcessResearchDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 7, 10, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 7, 10, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For entities that net deferred tax assets and tax liabilities, represents the net amount of deferred tax assets (after reduction for valuation allowance) and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities that are classified as noncurrent in the financial statements, or that are expected to reverse after the next twelve months (or beyond the normal operating cycle, if longer). A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 109<br><br><br><br> -Paragraph 41, 42, 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Audit and Accounting Guide (AAG)<br><br><br><br> -Number AAG-BRD<br><br><br><br> -Chapter 4<br><br><br><br> -Paragraph 80<br><br><br><br> -Subparagraph Exhibit 4-8, 3<br><br><br><br> -IssueDate 2006-05-01<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-6<br><br><br><br> -Paragraph 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2TAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) (Successor, USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2008</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance cost</a></td>
        <td class="nump">$ 1,890<span></span></td>
        <td class="nump">$ 965<span></span></td>
        <td class="nump">$ 636<span></span></td>
        <td class="nump">$ 796<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">675,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance cost</a></td>
        <td class="nump">1,890<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Additional Paid-In Capital</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance cost</a></td>
        <td class="nump">$ 1,890<span></span></td>
        <td class="nump">$ 965<span></span></td>
        <td class="nump">$ 636<span></span></td>
        <td class="nump">$ 796<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Treasury Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">675,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares that have been repurchased during the period and are being held in treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockSharesAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>34
<FILENAME>0001193125-12-137599-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-12-137599-xbrl.zip
M4$L#!!0````(`(F)?$"JQ`701,T``()D"``1`!P`<GAI:2TR,#$Q,3(S,2YX
M;6Q55`D``[%^<T^Q?G-/=7@+``$$)0X```0Y`0``[%UI<^NVDOT^5?,?^#PU
MJ;RJ*XN[)-_EE;S=^,5;V4YN\LE%BY"$%XK4</&27S\-+A))B2)!@K0LL2J5
M:W%!GVX<-!I``_SRK]>9P3TCV\&6^?5`..0/.&2.+!V;DZ\'GM/1G!'&!__Z
M]M__]>4?G0[WQ_'=)?<=F<C67*1S+]B=^M>N-/LO[L2:O]EX,G6YGT_^R3V]
M<7=WW*EEFL@PT!O7Z42%'&L.O&N906GBH1#>>WVR#0[PF,[7@ZGKSH^ZW9>7
MET-R^="R)UV1YZ4N-AU7,T?H('CRR,#F7QL>)[>?0%[T^.O*\R^2_[0P&`RZ
M_MWH4?L5X\63\&,^U>R9=CBR9E"T(`BB)$2/8L>21:&W"7;P1/0"6':B:?/%
M"V/->?(?#F_X$CJ\T%G*(.5A"L.0N_KRA?C#:C>X&3VJH]1S#AH=3JSG+MQ8
MA\3!ZRP(!0O=/ZXN[T=3--,Z"SQ0M1SWA5CVR/%OW:$QYUOZR'V;HZ\'#I[-
M#8+;OS:UT?CK`3%^)S+SX:NC'W#=H"#"H!/+=-&KR]VCD0O$#?@#]T;A=:Q_
M/7AX0<8SNH(K4^?,U)'^*`FG:`1E\H\/-M(<SWY[O'>MT5^/5VCVA.S'>V\T
M0HYCV>&%`#D4BTP7NV_A+_B-=7)EC)'-^1JAA#DBXYU<_'KPC0>C2`->[O6_
M=)>O+8MRT&0&5Q<7X%)0-T?H=6[@$78#+)R.X;F@E88<.;IWH1&2M\_^SP-\
M)]9L;IGPTQF^8N?@6_18I*RO:U#:E^Y:(=50W(^0J=G82DI?&+68Y"_=I$6^
M=!/&_S)'($&/V<_5;/<4$'PC%4MXR@M0QN+JXD%DZLO'!!'H3(K68P]]Z<8*
M_](-N;1*K&MLKJ,5KSX.=1T3/FK&XZV&]<<+\_%$FV,7?N\VQ9:*$[TOS%#K
M728;KW9X&?[+(1L\5A/9/BR5]J7J-G5`T)!FEKD7W4^@:MOYL.E\,DG%]UM2
M[1RI^'XA4L%C-74R+:5VCE+-='['FD$&?T/G9KSH]H1VW+4SE`I&]^XW?W8@
M9$ITC053VJ'4;@^EZN9/FAV/IVA,8#\.1R-OYAED^O+QU+.Q.8%;S\BPY@0]
M."9M@CX:HYC4($,ND\F[H]#@,7L'YHY9VS?V;O!KO[BR7;71SN?N9+_`U\&4
M-J[8F[BB%OZT<44;5S3)K_WBRE;5!C]8;>UK`XW]JJ/MB&C*,X4?U,&4-J[8
ME[BB'OZT<44;5S3)K_WBRG;51K^=K]C%?J%?!U/:N&)OXHI:^-/&%6U<T22_
M]HLKVU4;O3:NV,5^H5<'4]JX8F_BBEKXT\85;5S1)+_VBRO;51MJ&U?L8K^@
MUL&46QOI*-DSW"%7PR9T!V>:;8*#<CX:7=975$S3=ULXBTP;6?9C<J:-1?<F
M%FW*Y^12ZL,P:'N=3R7V;AN'VO%,.YYIDE_[Q95MJXW5'N.#UP=U?[`=-<)+
MP[G=CC!W-]HC6TTEMDQI1PM[-%JH@3]MI-=&>DWR:[^XLAVU$45Z2CL?N=OS
MD0K[T<%:SK3S2;L[G]00A_:-(=M5(W+;$^QV3R`WQ)FV)]C=GJ`A#NT;0[:K
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M9>=]A%*,8DJ3%-LW)GWH"FQ/`MEY'R$7HYC<),7VC4D?N0(%H9V6WZ-I^?>>
M+UF3T/9AR+3WE<</6E^Q1[[BO2?LVT^Y?^3*:[_GO5>^XKV3G=K/,W_<RA/X
MUE?LD:]X[[3Q-;L8/@R9]J7RXGOG1/5*LZ%(L?9:HCA72>SP4D=4F>P-Y/_M
MF638MDWZ01VK'8EG>@;==NG'_O2T;=*OXKE?_];,CM#QYVM`.2BHLQ45^`ZS
M(0M+\#%+O']5OX-/CBS!2UO+"?#)37!B[:EX[VZ(:N>Y_:/3^<W$+G>/1B0>
M[72"RQZY1G3^[?[T[/9^H:2.GP'@4CAY[MJ;(5MSK42`.O.__X:^8<>21:%W
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M0:D25JHIT/P.S2W;Q>:$C#"\8G+^),3/*RDMST=Q`J:=6'8Q4MS/-`/>X18%
M<V0,K9EO<>&)8I<RH];Q\#8OQ@KH&W\-RHV_NBQP")=T<OG<T":%2AQKAH."
M(A,OKX*\]7TR#8?C/5AF2:N"`IH'#YW#M6+5??YG4LA**5F"2'LJ+H;\?YV@
M12EI1MUZ3S"X/3<LS4T(6#^TXG0TPL`HY^L!?\`1-^L_[+MG60`'Q*MRG%BQ
MTE>:SC(+.N@C;CR7]+(ZX6@6DN4@-H;DXOH\AB7J<!1>'DC20$TTL@TRE_W%
MA=_;CU#4<3@<]`W<\?!R>'UR]GC_R]G9P_VB$UDD=6O.=&CJY!\R5?5,_+_K
M#-T3S;;?H/C?-<-#V19>#.Z21HUIV9&@?0FR)(&1H8>C$5L'TG3UIY"J_8%0
M%>@=@OX1CURD-V-</HF84GR]V'/,S0KVK8WF&M;/7N?(=!"\?.-.D3UT'.0Z
M80]5U<QB3TV8N8!(]AASS"DH?#6,3"TF"'TAB8>9Y!P[]'A9*"KXUK9@6`0N
M'Z2X8")".7]G]C6J;`%I(*7J(UL60U0YUI&%04E4\8WL:&Y#J?[(`_XV$/D#
M7A[.2+CVMW\]L^"J=E657K)Z&>%Z)VWSZBO5);'5UC^HX((\1181P`M#Q#6:
MQDXHJ.P&Q+XJ^PKDBF*%*+_7*0@E,OEWR])?L&%4M872'_03=1D57%)<\>YU
MO2#@C.5@Z%Q]_WAMF2,VKC_I]K*D,,*2URFJ)<`$=ZN;8:#VUW1$I63E]7ER
M*D!9*VHTLCP(IFZU-^W)0*Q"(T%1TAYJC1@F4/*L(,IED-@>TB^Q]H0-[&+$
M+&04TK6?)8D5H+RF(`A2&4`GEOD,70@&"UY;+F),'S]HC0^Y-DICBJRX_Z0!
M=8K&""[K=]"=F!XK,_57'-DZ*4R0%#=+$1!A4LLETAQT\V3@B1^6L&IDDI(:
MKV\2QA18CI64]$1"/C`_*CG7L.T/<6_&/V#$JQ'O!8PS7:P9QML]<ET#$>J1
M;"%G6ME\/5E=!F=TLNL#G6-:29#Z#$"'MH>F32:8R0RJ!T$@U,^MC4<(+CM8
M)TM29/&E:A#<ZXM+Q!2":X);,$*F!AJQG7UG*@@B+R9:5%ZOQ;[_5'A1I8*0
MT>@9!MIB$2>3%>56AY=C,)&O`B_J7!ZTUR"8C9G[&KGLK-A1>"4]9"DHNB[$
M]%UP0:A!NR[0H.'=FW'(ZELRG5#="\J*.HAYP7(@&E"CJ'>LHL`:%U)YO,'W
ME4S_5%YJKE.4"PHERUC8]9>FR/Q^9+T1`9&4\.K@(Q,;7P]<&)X<%+%+MR%1
M_(JH6SML@/[Z7,DEG10*!B)6:HU&Q*UFW]A^VK'N2[M%MK_P2*L8R1E*K7A^
MXP])PD=BD:*`Y%K0\N^!-EC!'7KNU++QWTBGLFFX2IQ&&0RA^2R8:9%,X?'O
M`,]/FREG.9IF0"5LG1WHA17))F"K'HU$>AUCJ0M,5KM3H_U4Z15E%XAF2\AN
MTID6$,L>9PDW6@5G'0Y4$%=\U`:)[*`5=YY,D%7PFRE4<J\O"+(B;4`5"&.#
MJ("=!))"VE,&51%5]<`KAA(D=;.A5K*YF&`K8K*^U!,WFRP36\;6Q5@!U2>\
MA7YJ-2=7)G.,>?EBP:14"8Q%/Q"@&?XG`BI/<:@]48Q-FA:77`_<'+MV%*4G
M2^7A1K7Q8/L)]F_L`A"I+R?39U9%5(:0-_U="4+0KEFX-K6G9,,(WJF.HX`;
MH\;AWYA:AHYL)]B@S2`)4TB&AZLR*F/("T_]!D,!(391,S1U]D9937_(D\@8
M'VW*1#%XV;G6]P]7UP^/%]<G-U=G*YG649(1E!SS6F%NYMGKR/!()SL<@208
MH"URDTXL)SE;G)%"GT//GIRD9P4T-:N5W&FYN?=-3SUNK5:I79-Y2[*BPE8M
MOP_-*&4V-ZPWA'RV'VL.TLE&&RC8G[X.950F8%^-K3)7`%*G.A3$$_B^O.WZ
M4%%.[$G-Z',-CS;"N$Z/S].H*)::E:+@72(FWF:E:,BG#`9U:!5+"XD-OB[@
MR=%4,R?HW+(O\8B<M6).[O!DZJ[?J4:C24<:*#&_0(^`HA.J'A,(BM0OWLU4
MAD9#\WY/:@X9%5=Y5:;HFV-T_(Y,9&L&2<[79]CT]U"[^!F%3Q;:)IFS=4V-
M-:,\<961452G(@\:1$93G6)OT"L';7W;CO+/@HE&:-\Y)3(([-<GPE7`U)"2
M-.Y`^*!*4E%1YL7&M0P*2O1(M?NI>(-CAJHQ3:FBZ@+!0"55,Q_=&"I5KD%1
MY)4"3G,CB)JTH/`JHA)N$MTZ+6@X-E`&/!LM%CO%:NZR!F)J]KJ0$ZN$CH(5
M_9XB-HN.IK9E7A(J&.]F[F<EFA-FSESD(59/`%J140H"S5R,JJ:FRYA`H&J$
M_$"5BT`(MYVZR$:.>V&.K&+',N7NM5SN:(T732F3)J)G(Y+&QJK2+R#TTG*<
M&S.,DZ).M;K+XF,V7BNB%`0ZBA6#L"`@.>GAVC*MB(B!J=B-.X1>TD]N%E@=
M'`4[957L-8F-IAX%:2"5!U=?A<((/5F?]2"BJD6I`41T=:<.E#*0@ENDU9[;
MUBS(1O?@E;"7L$SG&(TM&P7//6BOR+G"IF5C]RWR=-#!)TL)5B2OD#NUX,XS
M/!*L0U:>-Q<$N9_4LD'X6V8W"KJ"W0:IXU[VUFY4<^:]GJ@.MLEN4&#8BH\A
MN![C,BNZFY.BKY&[1%='BTT(H)9=C?659%=DS@;9T5<9H_1B&`7C$9FTQX;G
MIC)0B]1"*LM9!#S\H20NL>0(9(!N0SVM1:?V&D2WJ297T?&4R/PP^`<BBV9(
M'SZ#7YB@:X]\Y^!F[+\5RUNM5-.K*6<\#+E429)E00K#\7(X:E(DBQ1K%1%Z
M_;XD]04&BN1E19T,[W]Y/+^\^;$\@]*7F6BR\%>0R^('Q2P]8YZL*HC*^<L:
M$97THL40+?<=YY\]5GV<J:X<)94KE!5,FCFHU&"X09A4<RBI62IZF-\U;`:S
M#Z?8\0_2@D=NQFN.L"J=LQ.;V]PDK"HNJC:2GG3-!Q:T)<L_<N2.80*"&&^J
M*\6OGB,55&FL/F_&@#DX%`MJ^M9&,^S-'*81O;1R&E@)&*ELZ3`28+R2!<XE
M>4K/>CGEL=#,=TBI9&G&6*AF.OI]I3B8V)QD-!EY,PX&7"0BL#TV,Q-KID`W
MB*L,K>+L;#%HL57A($"[@A"+?*@"&V]W2$=H1DXN.K=LTM!_FY,\-V2/L!,[
MZXA!ME4L1&(`J`'U:.JF&?5NM>"@)/\;!9L7^.^1_8Q'#!;?LI)_2F"I62D&
MR3Y;IQ23Y)[26BVFK.!!,N0"/I/WH"^->!I[Y<8^,30\8Y:[4THX:]QE,G$J
M``]._/$KX\(LDIYU89Y8IAE\N^<'=J>_DR\W>N%.HG-L@GPRS5&]6^SW8WDL
M-2!\#_TI'(;$RX-=TY\J5A/YGMB4`0IGL;%.K2^469\+(Z\JT^=YG60>JEBN
MO\XCZD;Y[,%3T8P%^-A""]FCBT"Z_R_9LN9_JB(ZS&[M)RNJN\J5=:82*.K3
MA,KI;;,F=*%1$Y62.@>\,I/29U;G2F0"D((@N52O`1]=KY4ZJ;TRPE,//5@^
M)>Z0?T($Q-999[^6FM:"?C8'<0Z$7`V2AVE7WW2;.C$\5R(+@#0F90YP]3S[
MZIVVE-HE5T0J*YPTZ>SR2O))4S"IW+VJ5#7G-7+)[,RM;9%/N.K';[\Y).I;
MI-P.(9Y]9E/Y'4%64[.RQ:6S14VUR,B+J2\DO1-J*O^J]'L]-K9>Y53RZW(L
MTE]S2)P4R``>7:Q>!EX0V?L+2B.$GXFE_2,E@N4M!FU)C<WL9<HIC85N08\"
M2V1%B$/\Z?L'*SQIXWYJV>X#LF<L\PB5P2`96A82RPHIW3DE2BI#MPQ4<E0)
MTOT<O7O-0%>:ZY%$/O_49L,(YB:<FW&])J8'48\6E,?$#'J,U4C77[%OVI4:
M0$F;F5/P&WU5$5.=^:)N`V2JI2]IP`9RBE@WX_HP=X2-G-X@>J7G&'NF3L9@
MF&R5O@PZ0#];HSI(64EW'YG""@5409-D&[P*<I%@:HUDMHCI`E=U&S#3Y<\I
M*_G/I3#'F;Y<G\HZJ[04(?JJH&2VKK4RF4"D<;***+T#1*HD.GG0%RM!#+TP
M^(D[-`\GR]F:<>6$T'R93#!2Q2^5,<:[!G+[9NX'.%'*!GW6_)HC`K([HW42
M60"DXJ*P(9#-!A@E^L8?7R:ZK%DNK.YZE%B"%(UDEH"IAM`,`*]9FDRNMYXY
M\SD;TRZ^2%1`(A.$U+8LB3!E^KA[7?M!SNK3%-'23BGQK)'33:!51QXY$G#`
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M-^>8Q@8`4%&6#1Y\Z)]4'VV4J=XWB[UXKB([9`VJ2Y7XH6[^@OO6:TNW,XW/
M^?9[=777SN%=Q'9TQ?;",YLAD00Q-GHK`Z$.#:@F]%AJ4'VCUK;MBZM?N7?<
M%1=3;F@8UBC<XPOE:!,4.Q"].LL4);;;9;.L&*C%(B%$6.>>;6)G2G8V1&PD
M:W8LY[;EF(NB$YWLR6,5$^0Y1]]XJ3[IDAP(9@JJA(<F)T.J'P_=R?"],H`R
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MOQU?7IQP!YUN]X=TTNV>/IQR?_SR<'7)"8<\]P!QNA-^FKC;/;L^X`ZFKCL_
MZG9?7EX.7Z1#RYYT'^ZZKZ0L@;P<_MEQ8V\>ZJY^`$K\-'$_$SVX$$BFO@+7
MX;)U75/0ZY-M?`(K9-YZ3=\:@[TXQWTST-<#\G=GK,U@Y'+DXAET?B9ZX:"J
M-/.`<_#?B!PW2-XF+SY%?W27?Y$"MKWTQ=N%1,RC\F>:#774<:WYD2#.7S^'
MOY\LU[5F1_S\=0&]FL["X4_:;/[Y?P25_[SYKX`0G#7FCCT'F\AQN`QM_!_S
M7+W4=6I]YDASZF!3!P]])/]O-36_DXEYC3O&UAPZZIG&0;1]R/T<*-471?[S
M"_JT^"5\YF)W/"?KCN796;<"@?&;ELVY4Q1_)CQ!)/;0/WT[88?3N"<,#7$T
M-2W#FI`9./]1;FR-/)*#!!VC3H[B>D;D@]J?P/_Y7S$CGYC73.)`9S,RV-<,
M_#>YADW3>O8_,4$PV#```5-IN@XA"]EGS\VT_P`\SYPAEYLA'8\T`RR)=(?S
M_/LNU`XBIU<25'X!R'/QR#GD0L,"Y+EG.Y[_,&BI+[^J1H@"TI'!C<C4DLW%
M"PC*][6>H[D+'6_GB9Q7Q>'9S#-#66_<W+9T;^0ZGT"3T)-S8'S`#>XKO$F*
MU[&NN>@3=XV\W[57[N>SGO+/3_YYE@24:R/-C2`]!\<FA*!`DRUE[@,`#XG"
MO6@.,8!ESRV;+*ES\'MH3\#%>RYWZQ-[Y-L5>L)//L6)P;A39&@O$)Y^(K09
MSFUL+!NS](F#;E\]Y.)RPDD.#D8'G*G-P'(6=_<']DV1$@/O!&A(K`;_74--
MDP-(EQ+$?B1B2RW\`W%:%'D,YS[E_$9$"!82:85BQ*R^)3G2L_]_>V_:W#:2
M+(K^%3Q?]PL[`J2XD[)G)D*6[6G/;=MZEGIZSJ<.D"R*:(,`!XMDG5__<JD-
M($A1$BDNQHT[IRT)0%5E9N6^U!DR0%`Q@BJ=>JF#2[K.K8#_#\Q2A-<>0A1>
M@=/`EO`#H#+@5Y&8U66^<V(YFI"V@)T>`S^D^VA?*<^$ZOFZ`.2_?3GSZ\Y7
MV+1GJ<]`Z>I,DR@(HEMX>`)`D+<T%?',#QE[PSLZ\C#RXC&^-P:(C-(H3O!,
MPSCR`-KT!(VK`<UA1,?FQ^0'KF%;<!RX5]X(IQGCJYZ#^1^U)/5PI(8ZSL)M
MK0/!(DBDNNW<@KY-RY4?AV`+*,M&<"(\#`!P3E()WT%@V%"";1#KM!"`(/O/
MIUJS<>K2*X'PQO1>36(;5ICZ@2`FD\+_%-/Y+N[XX#9"@L!'1I)(]@LHIRT8
MO.+O[3=&WIQ+9>_JSD?"C.*=F@;-N=UEF,'ZA3B-HN]X0O%C'N#*&C^P+4!P
M2(R?V_IJV,P!)_"+&1/K;90%8R!22FG+"%PH0GR0!OA!H$EX<41PI*,3O&"-
M6&(U`J9$<FH<9]=X6ZYC;[:_//5KZ%R"M"DRJIY+M]DE+"SEA71[@!L6.2$=
MRN:&`,2BVL%,6=[]'*%;2RI]H-E_FR">X,&QDXBY)[\+U`@\YC:22@&0]QOG
ME?_:'(17)?(%/G+K!X'#`R\$"HS<=<PC+D>?O)FW1+BO?/O[)8>W#^XRB<0(
MI-PF1F1Q9R1.Y%)2,Z!KQYS,Z"?P::F^(+E-_01C&\@Z^'*3"5<G3+!<A)L"
MU_!N04)^^W)^*0&/9X$7LYGD&830>XXCL?57%A;0)8<$P9_A)XG]100J^<E(
MV=LK<9;DJ'X*<`/UR[FF264$R!!E$[>0H"L`8!9S)O1I'&774]`S1H4KU6Y:
M5\H&$2J,(^EIP8_;I*<DA59Y40105Q&D!5`SYU$BMLE<WLY!-8:U[$<VI\1-
M0<R,T`%#D@+^01L6)GL(.;PW!R;Z`T15*H"B7X**T7%@F0#![=$3RX$-2D#H
M?!3#.//B._/G9I_^W,JS-T$)*6-F*IZ#3K$8RT['CHS]?YU,R,98@/8#`='4
M$$PR@Z?+S_1=^:NGKL'`=A*`(_"YZUA09)%O[+D')XR=CW[ZO]<X?&]<-&T;
M[<%;.'_>*N2W;`O-94,'P[D`,>9N-D!G'J@6"#,Z'^(X$<#[6.?RF1?P?^6M
MX25<TE;0?,.=PZY=)R&7LM)H1N2C!V!$H^^N\[)1;S0:30>$`E@RF-D&#)[?
M<('";M@0A"\!$*Z1\4<2C:@`C4A-RN:XE9?-AB(LM@'H0=XW@%&M+O>2WS-S
M]2'J!]?`G8F.%'#H]*0+E\NU;_2*Y+"7*6R1#3.@7-1*+FMMY]5'U+Z^1)9C
MHMUNUYJ]?J/5?8TNO\##)07L>$2V+2B@N-ZE&&$)M2^U,3W.#<,</AB\L,BK
M@BE^^>'<1C+NX[-G79X6WZV&!2/)C#0ID`ZZ0'D`(*5C,P/,YL0QA08OR"P%
MWB0;_@5'6?8U:<:">1#X:$=;NCM\I^P-(*8Y/I6F4K(*G]$,2IV/')ZD84SC
M'T@11,;'/D,':V/QC`K)WHWG!Z0@YM&*L$)E?Y[R'V$],#Z1:9-:7-?\>`^E
MGLV7AP*@>D-$#CM'=4_\\*GX,\^N<ZPZF9+F#.!)LLG$'_F"B0&!1]^(C(=8
M71[X.M@:B;PBL(.)'R>I\U]@UP`\1"506GMO-86KE6J"4A%0Q2.%$^"`+-%^
M2IO3ZF%+A<(148D01$J3#!V-KN-/''@PSOLHP-B!JT*FBH^1<]CC=>@#"O`Z
MZOEN3A`E&$Q%!1&I^X:--,3,@DUO,$2V<5$AQI,`H\L"S+$AEQ0:N$LW55!V
MT:ONX07']"E45)TY]M7GJPO;H</;=E;>$6!OQ)A79ZC-PW-9D"H.,(H2HES<
M!][Y"&G35YD,)88'<G>P)N'#P1W[#4.TJ+6=GL8^*L3P>>D+P>U\?'=14"/4
MP<GU,15^O'S_0DY50,;"_DZ9V&VC$#9#(E.I_7!EX`N)]N4MTDD>$\2UT(6)
M(-"$9].(1:G>:(I7'R$[\5-IEC/I8@=2^`Z0GS..G"0B+P5NP!LF""D$3(&<
MV5B?`\89T0JG*$H5-_#XY(K'>N@BRN,,UYC+1&D&A6"%;*);O+H.]R]802JR
M5HB=2>J'6"5VD_<`=8@4X)-,_;GT7@3`YR,>26R$29(7'-?`K@",8GN"P_DT
MR3T^@<_0S8B&Z(XI77(J0L*Z&`/;8`Y[JS@TD,R(P9N,4/8.O=%WDJE*/MO,
MFCUY0&'D69F)^%K(^Q)+!&F?X1!))9)S?6BK*WBW51&S$%<S<<@/@(;E4<B'
M1"IQ[%."_3>`1,+4D[-B+LT].-.FU444H`!+KD!8\(>/*J;9LF*:3X%*8<EG
M#]2UU@[4T2F1[=CGI"M^F<U@>VBH.-:A'7-J1QU[_T-[^**/__@]82:+'3MF
M),\I.&0<9_`WR3R1*RN;0QZ1/J%-E-9;DB;KO.V';.F-,$&=-&GB$[;+`FR%
MD3]'U9PE$7JIF/.Q3$8NA[E8\!.90G2,,V`Z@!9I8L:"N$T"RI3*F"7&Y'T7
MUH&U?VNN5$[DI60?T2)P'-`ZT.$RHRZM9']P2V!\-;!Z1I(H\9,1*%`RVCO2
M"3/6.W3VW'N\TIB-3JG?EH`-O[]L2U*0\D-")2&/LUBYR/DE@BV5AH$J-$HS
M6("5(?0M(=,?^V3,(FQB]@W*T$>46%#;6TU;4_:%(2"`#F8HP>T<,UF6$J_A
M`5>D$ZH7,/A33L,8566E0Q(N+27]UYXT9FZG$0(QN@T%(Q[U67_L>[&/8#P#
M>:]@C0XE$2L?GO[FU$,S78"4!FN+I:[22LV9ZON.CW-E#](_K,*_<FS0OG/Q
M5>GY3,CXGX*.&=S5`A^^@^K;$*Q/:\P1<Q/@/[$/A_,(Q-0A#A%TVC"H'GMW
MI+<$,NX&.DK17JWSCFT+EO:2I'9@;*+OHD_]CQA%LR@4Z-Z*OXM4(W3_[XY)
M>>6SES-[ZZF13(Y#J-`E&&'C!920DC&/93\RN'Q3)(*5\1MSW1"G?IH18V:)
MD;"JG:)$(,/&)WS(V(4#1M$8VYYY\?@`X(R9E0X7V0*,/NICVQ.[E@O:D:R7
MU92GQ((T$`F^0R[8=9*I`!)$@!7IVS6<9LX=,EQ$I6J=@5X(H?\D/3J4C$\>
M&10XQN\NS=@)GHM<K"B!E`WCHTL4-EA#X\$).2.*?1UT/V)%++XL^-Q_!)IN
M@&3AFZ(7@S7'1EO^^8EYGJQ9$BYCU`;0(R$-4SFX$BW/1(ER=`*CD0W\+Q1@
M:.&L;TYJX#`BHUX):WQ33#+`%X6T7QE]*IW&@K`S0:OU#NQA=A:(Q6TBLEXK
MY23F[A0ZGKCO:/IG%(VUYP2/]`D4^_":R%M.=RB_9NI%<MIY&-8<BPE&386!
MZ82)V&>OGL>C']'$S5+\I<![P%H$<BO@=GXL01MFA`4,"H`-3OX25.)2DDCL
M?R=]?.3'HVS&$X?Q%V/BJ]IO9!@!1S64ZY""#)1)@3=W;[&$K.Q36+M@WR!*
M%?++E(::WEM^&COD].GBFWGJ?2XJ031:#)W:F*P%Y-?Q#4GP*P:I2FU3<0;/
M&N]9=_)K.[,L(="GK`2L0#JEB4S02&%'(KML'XY^WBY[W=!Q2:N),?OVK+5Q
M1SDA[;'O)?83$PTQK%O^A@Y?."-);Q*\>1&DW4^%WZN/%SXC?K"G#K]DUG4)
M/6;;Z(W64$6"!MO[?UF]PF@=+P!`1+^KS"/##Z.;^6R24EQNX7-^8GV)O;+>
M^*\L85VF;._E8&!G':6Y`'%;YNL0W0AUYQ)T?<8OV6=Q`ILDP`-7O\%4RN`N
M=Z3%;8)HG?I#-',E/CEEHY"&1J%'LY;D.?B7//VY2S#!)+3"7N8K8+D]_LK&
MU\8HM>S"TO!0&-EG8^_](C407>8C]8X)T.\O^\HE:<14=)\L\!.R\JV$'!+Q
M49PC?.``VD.J(U^AG=16MT67IP<3E5@CZCN<[$NL=:G+FY0ZG3/II1Y?(Q1Z
M9'>:4!7%0Z-)W<F)5*#3>]B=R4LJ!)'-\>V\;U9I*,N**8H_!+_WT+-"W^:4
MTJ0TJ:/N?/1D&F:I"0E;!!9.0>@IJ5OH^0!CYOI:\@O40/T97EH?T%XXE;3\
M71+QJ+@I&8'F.4<C7!EPD3F*;]:G7B(\)#";>)&6&\O]HT94+GZ8`P7RXT/L
M!Q'7R(2:)^*-^H>\$EX`-_P-Z/63](7#S_[]1>,%6'-!(/-[],_)W!NIGV_]
M<3K]^XMFH\&7R3&KQX6?Q^KAA7MG9[SD#Y0#6SI>]L7F+R^0DN`(?W\!`'OA
MR'_3<9ZF2"K2[#UI0YLZKWVNA04LBMK8^6W&;RDF2.(S3+6,%4L'I3C'?"2'
MDO%'F6-[I^UVTDU1ALJ:F+?W7A,)#NOGN/`SDGMULZJ;=7@W*\2L,S3$03,!
M530F(P&TB3":^2,LQ`G'U0VI;LA/?$/&5-E#N4^4TRD3,RG;&>R?!%,<,)^2
MXEN<A5]=E^JZ5-=%N=BEYU[ZKMB/2P6N$7PO!3J*OK,Q=K^YO?[%<5;=G&;^
MYI0:[/??G#+;O_02;KA"6KF'?8Y.+?7ULNO>PPJD&MC)\WPF).>RTN]]54<V
M1[NRX)"3J6!%!U4Q+_LC?>X2/F<[0I?ZYI07+K^8BQP5E8\Q;TPYX'1!)&[3
M"T:8VBE,XAZ[`\S!%W+&^9.+FZ-ALK=^PEZ0PL'M+1:VSX;VM4$$N;XM7Z_,
MYI1.4>E>(LNEX$N@+$6?PFAD]$>3,N>Z_*U:,)_1J9QR@LG!.H&)W7P*`;M8
ML`@DX(VFKO8$)W,QHIO+D1GAO,<Z2#BBBL)^!,`[G\DS@G0#1S5N/AD#6N+!
M@Z7(=ZUR1%PKV5>EBKC.;11_Y\QM#N_Y>GJ:JW\'FY39ERJS>P*[TBFF,B-7
M)9I@OQ$R\H"89EF0^C6,,4GY["(N;K'.`_ZK(4<GOQ7HS$9LH8%X+:2S;**W
MP4BEJGZJSAM+4%$,D2\5.@UAEUYPE[#S?X(D.6:'CQV@9.*R';_R#W!$EQU>
MF#CK%IR8Y*X4X_W/NS`92+DV/4LB7M;CH]SCTF6._415OI(),%J4;BZ878,\
M5G@I7@R=@KUJ67E5:6'A4697/I=))7S<23>^RM"Q5Y)>._*(<G&0E>&3F&J:
MB;X2>^MSUNMSII.7:D<\_QNY2^!SOTCGG++;R[%]%@#;4-G[RXLZYM8*E/\<
MT#VQ>FU0CI),W]=72`96=!B%<\[A^Z&8^*G*MX'/40!.5=AS8PNYHH_EVIA,
MXF$1CCP=Y^M3V99U/276B".HY/V]Q:!&'O5`DV6\B``XPJKK:4579.E'0/Q7
M9K[?^`EG8O.M,ADE5I;J)?:BQ?P8YQW5QMMQU(]GE^]RT=/2]\ZC,>?V4%68
M]?K99;XB["J:^R.GWQRXM@Y@L29SWF*XEX_+34H7GY.M8S2("IO`)?/UA_F$
M4%U%9.L`7*M"L3B5NSJR$:)*,,C:Q/HSVAMC3I8).-@R9(S2=TS:FIC-@^A.
MH'`-H["F?C2]"%Q9/!!B!J87YINUZ,=YI8CS4^N.ZMQ:LC?=V()T%.J?2V$2
MPP993]6,VP\7DG`724FC%=$#H,V'3QU.C5!;(''/22+,_F'_(KY!.UWEG>[I
MG?P8<?UI#MP,13YE7C(A'<B3(3A"5C>'=SE4)WD%44,M*<??$G1(NIVI2F>\
MIH@5><&ZC6ZMVRC>1/GK_#VP'C$"1%8MOR/B4</ID'Z_P$D()!_4<<R5<^KV
M5?QBDS>#CB$GI<@X(KT<%4IL4R3&/E=I4V4G$ZH7"TO#**<I.5E227W)YBR1
M5+@J9U)1">E94AU,<N&"$C%7S6CD,HP[I:<HII&H`R:DP6HCR$[0>A=XH^^U
MR]$THOQC>KR&SBIJ'!6-!1@.IA"XIO4;\X5%%:DL4](N<-;9X4A_,B'3(C'K
MPEI)X5I]DF5'*@F"J1">"NZ`X?A<ZVHI;]*?H#=8O"WH4+"O`;(,*X,FUP9"
MURSFM07SE_*[PO:>3,*VP&7@R72,XBN0\2?[8B.]33(TMCA?=V_YTE49`P&Y
M_;+?<!N-QFM"_,M^IXT_(>1LR50*.I6_5\!2`4"J;)#R`EEN4.7<\BX*M!,L
M^78QUV#.%>;!JM*N/='"WJ,.RJZPAV3AOC<7*8SB&65U9''"]P00H>*:[F(K
M@[Q<\+$'+EC#:D(!M=)2]2C(C\(Q)C,LR""T[45,/8F4**H[GU)*`?2").(/
M6]]-J'*1<Y`H:UYF>]HUDOD<GG$DV*="72]DSPOR=6B0H=X?>UC*.E$B%'"?
M2=_B,S0?V<+]XC(#<TB"G0EGV]4[MG5J\2&2WB9:7F+XVE\'*R;@4E9$,AHO
M6(K*W-EGEQ$NBUEA6<C5"E.1^P)FP/D3#JY/Q?A:V/EH5.04ZU])#Z6'3'DT
M)<]74>\HZ!B#9K?6:93K\>]M*,%"O\+JV/VD5*4_5\2BLM0_P`[3O%C[>ANR
MENN6J_NV6)8B69,XZ:8JARI2.8-:J="8NR/IC5\"(4U)063#8M'(7-^MC/4'
M_7$J?RU4Y.KF%-&(\<8%SM)H52F="6??8]YD:'^34Y)5O?#>WA&-:WM.(W8X
MU/.+G4O=>F69MB+U3*O52#E;74&-7!9$%-D9-&HH:?36+-)\STTH,LZN=WZS
M;BMQ8MZ)35V68KM$84=^$.5/'YO3F\8SU`6#3YJ8DY(6+`F37+[>G?[17I`*
MJ-,TX-^:]:A/"Y;R3D0<<\\;Y$5(Q`OEA'2SB5-AH!191SZ%>#V&E=>IUN9.
M]W":M>G[2$)$FCJ_6<F7M"D[EUT/C2F_$-^6)6YJ3]@2[]<GR^>Y-/O3?.36
MNT:+53OH2`VA(GT3+Z"GW4*O"ZU1FFC"Q!M)>G0!]>B/Q'\!9+&Y(L>)M/5,
MZX"--\5VDNP<H<1HK:4NXRA+SS3&&F3I!K;"#'Q4ZEXAKYYQ80:P%?;Z_F'E
MF9M26JD.)ZI?B/:U>-075W!QX<23CAW+CZ-+C>=RDB=<9FE-^O&8-#)Y;9>=
MTW(G\.4E3)BK:G7M9#<61K#8#\L=>X%081M1J#@1LA]35RI[>>RO"91W>,L0
MVI7W8^F-6:+3E7-)9>B,!3)7I#CO!RG:E$XOVY"D`G.&L0$`5TCS'X8BO44(
MXNOXUE"U#RA7%:6)3IU>\B7<=LW>DG+CI4+1<LYUI$PLT=(L5RX>V`:BK64M
MN%+ID[E@K24KK^A"E,.&#'39:0=/YOV@_!98>RRHAR_EL.NJ667L<QD:=26Q
M:]U943+U[KKR91'(L2Y\P@L:2X$JJ9MA80YFSJ*#I]P!P(JN>NAD)[@/*>H%
MYP#-`CY.N[1BK28`K((GJ(]2>#?POPL*[(*&B>84+X(Z!49'K<9&GJ%#+LO@
MMCQ4T"7CJYC!H0I"=#<AF7N02*A1EH?LRB.U$DSQT-^68AN)UNIF4')F8J"A
MP'0%P+"K6W$1ZPM59KXL>-$6L:E\HU:\>9T*N9,L^P'0C#Q9CR2W5-8[E*00
M1X:PCIB:[,!V=<JD0+Y*=:X@^2+9V68I(%8`@3I/J5@TUF.4DH%E9-2=,ROD
M*&55V3O*7\5MF^@6R'\OX_IF=WQRY93'EZ6,9AJPPQ944&N%-=`-H>3Y&A(5
M0<$@1AU77XFRTA\RH'1TCGGJ),4V!1@:9[Q)-Q`G&-TZ@7>+L1#X%U58S&.1
MJMY!$],ZCI\B098%5!VKY*7W@U3?+)U&K%<#Q95P8R_?V$(Y1LO.:W?^R)?=
MK?.&X5JL#"=Y+[;\BE24X9\87"6<?@^CVW!?I:V=.X!-SF*#HW.NK__F)]^7
M2-Z/N>)]Y3\C;J>SA(`/:F=PP?:Q*PV*JQ-<9(5_C#NP*I^PUP<75DZ6MQ[,
M<TS5HSSAYV2E/!M-@BH33&4\AV)N(W@J_)ZH>*)L6<]81UN?Z@Y)#11C66,-
MWR=;BVJ#N/_<RDZT[E+"*^U[2YWRE[:<F&5T$;#55_[P!3ZC$GT`1:`&HQA/
M/`XL6W^C@LL[=AM:EBT7ADF7%`@$2W^P7KZ.O7&NQ`L#9;*MF\.F16+Y,&T\
MJ8:)J(F#GDVM]E3\6[8JC$+)UXEU)?<0`?9<D1H$NK]5NP&XFUZL6U=J<B`(
M<Z!`X1+POL()KCH>:*5($H-J0DB4POV%R!FQ]%,-Y]XNT2UN%?H[-:63D5M<
M0V9&R+YS1'N*ZYL("QV'9!,5_0>^+"O4?4JH+5C(PU"HP:9KO<.5Y=="Z7G8
M,(*ZX[:Z%)>@[KH2(]R@KA!_LYI[N+G@U3T((>?VM2==JIR^M>+"[3^3G8$<
M!$4R047FMRA9PZ8I!@&M#ZC"85T1+34_?5UT`H,267/N=+;'YI^5ZA1S(MLB
M%+X(O)383C9=`;\U/V#5?%\`+9'R&\6YXOGSN_3;CP(;Y=+L/,O$3OF%\FQ+
MR8"_YKZ!*KKU/FLP9+*I"0I#(?M4XRVY9N:K8CJT)^9OP,&'&(IB\:LL7/LP
MQ-<H4P58L7QS*?Y-"\:GM`'<1K-&L]PY@Q5V\P%L@/@\BN60E6/MSMBVNC,^
M"`R[;L?87KL=XS?JLIMKLAA'8816AQ68W6RKQ8TY?&6#X+-Q1$T+[SF$O]%#
M;,'_]BDT;1DXR$\YANB$HC#SF,*%O\\IXPP?J+5.73/O#GCN4/:K2)Q7,JK8
MZ+ZV&R1IX%'RNVFC>(D.9`(6ZE,`/>IXCQ/I,/9M\K%*%[-</*_D[G(-\N56
M7]=ESSD0GO(Q;?YZSCP;`C/#(#CZ$=!+P!LDC<NA70!'SN]&A?]10INCDRDD
M8X7:1%0QE<4FC2BU3$])TW;0+*N:,E,C#B\.2976>=6X,CKF>>-*$"RLQQX&
M-E0I+JK3@HMIW%I_6.=X5JH1I?[C(`]V.>LM#K62J;QZ[%%:!,6GB:R,89]/
M>8O,6!B%QE4J\6I(Z730I=#B55$YYARQA=0QT]/>.':W`D6%N+6AN;#W(G@M
MS-=SU,\]4!,R^@KD3TUV4$M/."%DQ2$\TC)D@TMV&6(+HQM_C+O`_>AY&^P\
MEWV7S(0*P)_))5IQL2;42$O-%ED`N$]F(BY(78%*@4656+)+6"D1VJ]8'UNT
MSYI=-?Q":F/Z`N<H=%G&Y[+Y;321Z3%"8AOR/!^5T?+NDQ0&ARON/A4GF6B_
M#$H[V?*F>$B3'\_W9UP(I?R>2XW'3]8:'0T]U[&:07XV_EM;>$F9V6J\?F.%
M,N"IL78^G\FN_#R=?LDWZ8I9`O:;G5X,!/E[_=*.\>BE_GEV=L'M\SY^N[3%
M*A8+YAM@R41JA@@S`IP\`R:"#%!X5H6*G2VC?,!6\H'MS;[.?+XILLLQ_$=F
M0EDW;))KJ^3DLD$U3[*[(U+FL.5YS,)HB+XHXIJO?L.XLM-^#:"99^Q$])ET
M]`%S_"J2S:UMQB5YV\3P7V)SNLU0GLLD#V4SS64Y>S_8^\[3!F1B$_&ZX@ED
MET.,JUC]B.%SHU1YU^YMB;S78VO@3O\K"\6R2VU4V-_EW>Q:J45Y'PV'3A=O
M9BM_,W,=Y*D'M?41J5'G/[1XCPIW2#>`9J*W,M5X+2WQHU#5"I@A"^8`,K!D
M98-R>K15`V?Y*"@K6";)6<X*F>3DVG%3[ILM1ID4W'D`+"RBW%)J/SK=I'R[
MH57@BM4!6A=7I\?)KUZ2F.(DNQI09NE-O-'J)NOD:5FQ#5DKSS_)[F2&!Y,^
M7[Q<LOI!9KWCRCZLILJ0,!U#MS>4RB/6*"[?@NP82KH4?.@>-%N]$R5T9.JW
M/@5F+^,FT_Q99!/\:71KM&4],HU::IK:!_B`Y4<LY9#YM$SFD907A&A-<TK>
M@@Y(+-W'&20R/\!FGXIIHO9$\$>SC!\S?/1^#DKC'(O[CL+@SE"="*<>Q1^,
MN%'=(PO,-<]8$?N2F:8KYE[>SV'WF+N638>]A\4.7#NI1_4U3&R/`!U,]UE`
MK%.G@$7FV^[FF.^5K!32KU+.BR[?7I/G8D!R-J>T:KH%R'%(@\'HQ+7]:5,9
M7LX2A+*J>+9<GG]Q`PC,0$AD'G<J35S5Q9!'")O,!+C^=.'O2S!9+"7RBO7Y
M\+X)WI4T=>6T::._J$W(V4'6-G22B%V70)E1JNV%Z=-0:$L[%LDH]H?,^31"
M3<4XGK#&)ZSA1FM\0KB3*)AP<6KGRV:WFN7((/&G$9>*$93HE%T*3HT(61>R
M$ZM1+7G"D]Z$X5LYG*TB`1H:K_-D"DDR+OK;9>/=TF(OKV";$Y:6M=RU$PWU
M;EX1L$$',%T_GD@$=(OE#$:K*XB4HP0+)68DXIG/2]V[I+2KT.N6FY_B&"@=
MRY097PNBE2^2:Z%#=OVP!8SI3;+&Z:V*"OG%AR9RY5L8WPO.^VP(6=M=D'GK
M"[.WR*XP(NO2Y,L[(Y]\:[IEWFCPI)LZ+[[T[#BSD7O+P"0'7"H2T6T51F5F
MQK:$HPE?/2A.LI7A8M)W97FHC2E^I(&JCCU&;*WS[SI"U5D[0B5=<\Z9Y;';
M0E!JL^K:U]`YF\=^8'&.=DGZ$8FI0)!!@O;`"J<DJE'O18`-$(2>Q^)+5TC.
M$<9OY<O26>0"KSPS8WBQFTG@T4J?<91@G/N,_)5^/N=<$_:`;AI+G!LH8/C4
M97YX,(U35"T9QK[.>L._%1=<GJ=E3WPRTY[(<ST3BJ/*CF&R.-*Y]1(>F*A;
MV<C=:R#3KQ6QP5VY\5G)0>6,5ZPMK)BOQ;)$Z^K3*$7=+)\[G^T/*`Q=[]:M
MV4IJ]KHIC<J5JULY%FK=8K>P,QT:4(U`K.+7',:IZ@@/,]83WG3MN.XLI(=Y
MFDG>[=;B?G---&1IA':+2#_E0O=T'`(;DT"R2BVXOQXJ><L3;GE"K/Q59R`M
MGH5!NRQ35[5)TL-[5'>F0(ZLS5.!2^EG/KL+,*\*O8MF*F@YLEQ3NJ+-"I-&
MR>-&N-08?R._@:XCV%V"1HS*;><N[.5GD%J8'$&*67]L%_'H4M2_D=9N>(0"
M\J,<(98$4KYE@7"ZO7;WE:='UWPYNWQ_]O\A1_@NTGF`SB!\;*\M:S-^F#:C
M@T2K+[%,O=,<Q:%JHQIZ_.X<-+?`H/48#?:PKEA(/P[2;;/QBP+<RKNH$F(E
MYDNGV.I.!/F"1_;J!3J/R9<.?'G3I']P+&;HG:=OF?'4.:L1/SICB%CUM"#I
MOH(-G=>2<[(N!PK8B:#KK[I1J3]WUP4$;+W5&;C]1E="0Z7H8[HQPG3E^\Y4
M!&8ZFFS68^W/7YA3K7?L2YG.::'[2L[+DAC+=0N2BUP/@O20!\Q8C+@<8GBW
ME+MRBRM,N%8MESAW`V>QH%>'LX87YX1S/FJDTO4]ATQ)L#6P&:&>E)$KHI0R
M=E4<A@8X,^_2MKIJ@J8KHD@_P"J,0^B;H.N?N1-SGJ&34`Y`G=<1@,+C-J(Q
M&Q%9/C<TV_G`C&+?Y&)?9=DW^+3U2Z[]\B.:-\O6OR-26E\LL:FN:%._8GUL
MP31:WK9Y</I+V6E+NA2KQL0,)GVX_IKO/\-#Q3;#*]M6%XZ3)_+']W)^GL_B
M?$L@O!!O68$V"M0EB;HY_^&08\3Y/PWZ?X^]U<V\"?P*R`Z^9K/3UZL,VZU"
M;&F;:>6<67Y!BI?H732^6[Q$SO`:`!_!+?X_HY$0DTFQ.[HY34G[[CS_Q7O]
MIEEO-,0LSW%K_,L-^2C.I8M3Z=;$:2G/*\=EWZSOC=@=U3^*3VWVI4>QF!W3
MPL><7UO976R]4\I-E'#UCNE%@,HD>@GXV27*Y)X3RF/!]?)1#%G^&&-/ZJ>M
MWW/;O?Y:>PBCV]B;__T%__?%1J'PRG_]<(;K'"2O_*"3O/0EP4R&6I2E1TKB
M3U0^-DGKG5YCY[3^1$(OZT6TG-AW(LL6;Y94#RE&4JX;KC)_]F?9HY+45Q'.
M+5BFHQTI,]JUO&VVW$%K]P+W)V=";>`&XRA#JG]6+K2A=1_%A@Y'1=+FY-D*
M3UUE0QZO#8FSA?8<J0<K?WJ#0Q<^!\/'+F(Q]WS3@=*N)I`UD]SBZTAI?6\,
MOV;GP&E^7RD<FQ:;C)-)%H?<WKBBZ&U3=//`*?IPN+@JUZA(>KLDW74'IX>N
MF^PK#7_"43\TWG5I?^J*O+?O^.D=NAYR.%S[3+7)E#FH%7EOE[Q?G;9WKY(\
M,8BXQ[0<9V*E'6DU&Z\H?<N4WNRT#YW2#X>/8[%6Q<2?C;0/G;#WE8S?VW,\
MK'E?-!B3>7A%W%LF[J[;Z!X^YS[TT.O/E__Q"&'[.%SMV<W?>:BK2K78@_O^
MLZ1:Z)_SZ?]EJ?TG5,]3?H+`#T5M*I#ZWPSN*Q["=@/YRHM&O3M/\XSN+97.
MO&FV2TMGR@J-'E$Q9-4;%<N2BF5+LI*GV6C\4J3CI75#L/<<CU1<@A9_FE;@
MOUZ+0]@++K+KQZY^59@:>_]$=:P^Y&IP&O+J6=W/](=>-NNM`5>2JG1[7=RV
MUB*F=R_WD[;F1A-,HJ6]&LHJ`^^Y+ZMNP_-7#XK%]&PJN94IVH5R0@1VK]YU
M5)U^!&++#VGFAYJX1(<R6),U_+K(81Y'0VL4F%W;GQM%O\U*_\72?C7[)*1V
M>-PEB!K,4;NDF'H=6<,F57,-P9-X]+`4_!6='Q'T0W9L#E0S!U?M3`-##:Z2
M31&X<M74@V"C2=T7V9Q4M]2V`9ED(PIWT!@9'/*BG]=S77+G273C/[Q*F6R7
M^]_,B^$LL&7NR$H+1W`RY7>S^ZOG>TO1N:W&`MKHLVZ7Z?ED^BGH$6P*_;EZ
MFC3?<<%\E(K#"758S0OPI9X#L*454X'\!%A%XQ0GXZAJ>2YN-A-:V<MH=;N4
M/DBU.^QO0&3%<UA-.R0ZOM7"DH:IY<>6.NFM"&X0H&$Z3=9LX;0F.%:/0\)3
MONRY[6X3SUYWOLIV4+(=V,NFVQ^T:&`0/ID?UEWTN-Y10?^_O!!(Q>K/W#SE
M84@N`4(W\K;(D!@UP1X74AVI2D^#NTB!M5Q3"QG=;(&_.`?JP\=%&(.`EFC+
M8N>"<B7;NA-I83PN-2V/J1O<"&DEIG,4VM(,Y"'*6K$TW7:S"X`ZQ9`B?)/N
MZ)+&*K`E>:ES;<T--&0O$;OK@YR?J*^=!IQ<0\^*)0B7MY9P%EM+\$H+7U/]
M(73O`LF;='L;?$PU]J#+)C_*U>'$(:U>(-1.3MW"(L=2:\HF`;F>(<7.**9[
MO`8_<%=J,8UCN<5W.KUL]X:X4HW]<E^="8%4M;=U^Y\F]GX-)+%!OFRUPC08
M9C3K`ULG+L.@'./']RXRXRVUL$FY*S'`[&6CWN\YKW#;U'C3KUN=C^M/U*!T
MXUSXY95I\W+NS7VLN^!V+_C'1=Z1NW9C[TZ.2:`AT;G>/]3C+W^37!!5LJ63
M:M>@YDG8;3+O`:8?OD;@7P/H>#*!%Y9#8XG>2$(RYDDY:>R-6<99!V'Q-Q+^
MG`Y2AOVZ\X?LY0FO8,N*^TD$.^[(QD%R$3JXO-2Y>[OL4DK9I-@5=OJ@ED2F
M/7-@ZQ*RQ31^';L.#46>5Q)1PK>H70A+CN!.G9^Z;\7E+$:M*Z=JD3K%K5=Y
M\G.HVH4ZKYJ-7RRGXEQP/_>9W;PPW^>R>`@"RT<QC`MDV&`R=-3(/T6-/JB;
M8Y_;:Q40RG!>!ML<_&,%N:D"MEL*3NK`I%3?0%RC[!)"4YI-%+I1$+>J-4V=
M*0V7AJ3X,YI!-BYT:-E;SOC>S%F9@%0'T29U4CS_8G<\0BU.8B;64.AM8AJ?
ML%%"HH7GN<FQ'Z%AE_#CM=WC>%P:P2`MAASKK$GM*11)<]2"6A))HNP&.8HG
M-Y$0CYS[$_]ZSAW-9ZJ'7$$@L&WQ(+667J')FJAZ+Q<O2[H1Z8$\S'L790G/
M?*F:URC7W..;U_2;3VQ>LV[SFV=^:-EV!_NSW4>%?`^\UTYOM[UV/DH!?<7<
M[#-SLP_(S>B9V#DA^53&V.BL0WWJYX/LST@G.^[)A#)L9_C^R0'?J"[:+AGR
M9O#X*@N];(RNJZJ7V1YD:ETL*/WW:<[[PN(.+#WC5;/E]ON[K_A9(R&K0NV#
M4Z3=5NOT$%!;Y=X<8.Y-!<F?N6_5HH1><,M5(GL[?+U1;^^^A+$2V-M`;*]U
M"(BMQ/4!"ID*DGM:9K`C`?X'I3=CS.I&Q#B^0H7>LY0&\OGA]9$*\+TIAFKW
MW7ZKXW;:NR^(.CYIOC=8;K7<0;?O=OJ[K^NL1/M1"J0*DGM53^38<V77&VNZ
MR8&R\0_??W/AQ6DH8IG#<J3C8[M.S5EUVET/B^VN/2SVVW]\YW(.>_B:I4Q-
M2P)0CT[DLG7*UA,3N?0!\1^4IGL.K\;^,*/$*#.KE;;LZ\UO^DR;3$ZC];^&
MSJ68IX5<"E#12I+\<K-D/6<)!.S1M.6/Z`=P7"F/IP1BF&<QYJW3!%I9%()Y
MK@EP2QHX3Y-H^6N<)H\OX8174-U3GVJ?X/^4S%+-I;-]^W+FU]20Q52,IB'8
M+M>^;&[#;5'-@%&U&O^>B["P]"'V`3=^0&F(6/,01C<BH&_3]+LHPT1Y_&#@
MC[CVQ*Z*PC?H67M]2D*]%9CUR`F".J45'_\CBD<B27&*^6?8C#>:9K`CV%+@
M#;$"*L*ANMY(=G>8^#]D)8S<N&G<(W3G3,K)Y.$X7.\SDB4L^"PL*6;S(.)D
M9"^.<4`X5]00PE1>;#+"&A"LG7"M:BP"Y1@SOI,TYIS8N8@3G-T9X(1>54-!
MU3V\CLRL!9P61K$'291#Q<MFO6L(51?`33BCUTJ^'LF$=_75/;V%%Q;9\V4K
MNS(N43L.@C6C?0&WV4QH5,BL=Z_8M(DIB([Y[3^?:LW&:=F81S6A4)?]#4%-
M\7CL<Z9G)=N(4*3M+J440W5Z"BG<+7T0Q&SYH&*3P*WG%,,3F3VMN+-(!*ZZ
MGZI:[Q8G7HL:@I^.;P\]?MDLH2+<\,OVXMQF%[.5L1H0*#G`L<%$4JHH(E&E
M+Q@62+P`:XC^BS_C58_SM0PONXV&DUNN:58;EJ^FAP7?$/>519,)EY)PMKK"
MJ%VE9>,*N0V!P.8X>WLE/H4K;T)^XO(83IH!L<QPRK>=B(^4BQ"^)9JD8;I2
M:.#,V7@LT]N95RSR>D.\,R\%_"&#E@6<:C8O<3%#P68;B*K00TK++46CU+'>
ME5E23BZI.F=@E*%^/D']*)I,<IQ1K4[WI[`%-1WXCFM/U>4#]I"D>EAP[%,I
M#15%>%2+-U)U)GYLT5X1FEQ2:(&39;(Z*D`-PV-`??XJ_#V.ZLJ5UFWK>)=B
ME,74W,ZY4"4-!ZGJ/43+([HJJ'JK`6%K?"N?7%#\I%3R9?T"$C"P[S23$]@_
MA3<H!^+$>84[M);1?[$_Z9;HD/B>^8RY*;I$Q8.?I)KP\M3MFK+82Q%C5T,-
MK3/G(E:U*#RNFF]E[OCX<^&QW*&ELJ7*V50MD;GG"B*N&KL<`#]00J^I]R<Y
M&?QG`M*9BFZ`^\>2[0U%>BL$:&>@.U.%*%Y4N601DN]B?WPMG-\B+[1WRKS&
M\HRCTAN._+G'93E*S3!%8FI*N/5!*D,#_>#'"(A/JA%*71GY\2B;X==!L;7&
MEP]!CMTRJQD2QP2IERI*+`'O_2#5!$8U19JI80\+K()G[1'?L?#/-.$3X;#4
M87+RD:6K@B1@OW!VK%]BC;U`!U@3177$=0NP!-;<7[586=ARS,))%I861(P\
M+HH4G]FS-=N2B^*NI?H-)S0JG'5!SU@4-4_;;;(^O!D7#15))/]*_L9)T(UQ
M*<7KAW=25\N=RAH!'V.1,AA-I,+&W#%@*O%8"AN&0P$^JO`6+:Y``(WLK4*C
M<%XD77,"HG*:>0[`\QQ5;,ISTO';3/^FS!T^)S474P>K;UI)R3'^++]Z&V4!
MZ#:WH3.+J&<$7-33^NGIZ2\:9_8R^5);FR/8]9C>!'7<:_^&1JM.)I)@DPPN
M#1\/Y]/7G3^`ZV,_$U:,>*?<?D`^`G;%S&>-PRUL!G_2(*33,QAY8.M4!+JZ
MTG!\ZE8C*<2ZZNO=P#+\+.(A#R#-7W1I_@]J[`(P&K37@3"ABW$TS'%@ERT^
M^!>K\E-A@PW8T"33_H\BJ;G&I4)_8/NQR+6\I&88KKVI!0Z6JS-&4LJ?M-G2
M)UWZS>7EO`4TL"@\&]_X<>BYSF^_G<-OG._BCL#`9BB7)]/#"FFR702SPIG'
MY>?=-?8U+UCDVGAEV\K>",*P(+KV5[_5&V#=EGRO`.2"&KN?W%/1F^4!D5;&
M:M4TC6CW)/Y2]#``3K6L$LH9E^^$@9V%Z'[6P)RI<;GMT$O\I'B=UZ`E1926
M#%^0S64BE#L)316?N$]\VYVYM4)0IZ.?29Y1RN"(\TKI6=)``.Z,]*S&@I2V
MSOU'-F:R-B@(7^Y:"'.IX0*U&$'&$B-4YI'Q@Z[@F]AYPB.'SYWPV-\%&K$?
MC:T*[$5!4&IBKZ8I;`#ACT5B!*O^B.(]RVD(2"'B%W5_@J*T,?0I6_^,?6I)
M0QT]R%C7K_W3`_/`X^_Y:MPY.W[)BVMDM=W\"=L*<<\FU1')IKV]U:+`B%UL
M%M'JE[4*\L(PRD"M'+O<$>6_F1]3[P4Z@^R(\IMT%7[+0*QW6]W&*_'Z5>^U
M*\$))M4P0AT%X#:&UT>D3TP];$DP"CRJ?3>W#:P%&TT2,45>D,-Y":,P;<-L
MW!71G9/,1+`%)5N3DNQ?[B[8$<H(T\QBP0);U;XMQR^9LA8:]CFO/G@8L`A)
M?7V-0%G5Y.D^JM3L@YBF@B6%@`@Z&G"K@$5@(#VQ]#K406\$?>)ZJCN6V.@-
M/=4/3_L`L=U145=9!K-26DJXOXP@8U1V?ED!`KS4+`HD"<<9>IO+B,WG3]\)
MW0>'KZ]1]L2/FJ+8!?6N*(M*##E-8ZGW@S($@%[D1G+D@>$>:KAS8Z$K4=@\
M",9#ZR^`9<EYET#+3Z290A[KHHJ9TP=T]SJP4`+N&,/B03KV+>F$!/'A!PBH
M\)JH;@820$46-)=B:PSA+QNPE+3<84]@J^Z\$R,O2X0VDI;LC)!_'=GT!'\,
MA$U(B]TZVXTR9CW+L!><5$-*5:$R@)*EY_%U<>%64+N>G`:#;@;D=70>Z2TC
M%X?5GZGL<,`&2)H&_G=4\[24UQ\FV\P;`I!E5\TES$"U55GG.(H78&,YIA$X
MX%+P>0%:T=?39=R&W6?+.0XM@&<!(O&5^4B&.-OE>WL5\1:"90\,QT^FJAO9
M&KPSYT@JM`3,/>>C),08##Y`S@-\Q+0`U9>)9!R%YKB#IYP7S5>6[NK'3U^^
MG9&O&;N?I266/C&$:V#/QISY>G4N6[0!7X^C;&[I_LG=;!@%>3?CIT\+S'O5
M\<BYS_X6%FRP,EM(ZJ@%/VK.46)Y0<N4B067I`E11C']ARG<20!6R<1'C]TG
MTSE-NGL,=S,^>JU[>P"]:\EW71,YR+E\%O5S\[X,EV:ACQD@,=HV,BZ*#>HH
M'R+?H`MWON!4\B=EH*+$+F_$)U<W3?=)@H\4]!_9B:G%<MU/E<P&>R<A5Y,B
M9+4.6JOX.=X04BHI+3ARC&*,&"S6C%#^&3]*?L`Q[V&6I1B:-A"1(8="G"1O
MPKF.\,FX+``F_](UW`F"*$%90W0=K%I^3G8D+@65Q>@GGA]8&MD"E+![Z3C3
M#1@G7A:DMOIV1WTLM3LM>LB6]Y9!GI5(!DF,NB,K=?+4O0J7')HYY2*N9#_(
M^Z6?6R`/)(K1-(JX)>883/RH)-4'GT*A-#9/Y=W@DV66F>HRJ2X^7RC)5H<8
MHE*QJF*WT[J#38=,\AA>/'$=*<K`OG047TE71RX4WR7EZP$*]!/C%\\5&O=E
MMA(1!+N6-%%<`>29:YP;YK_WCL5/:SFD-(FKC(_[<TZ*B1*2`[&#3N=O`+0>
MG$$B7[9T/4=)'#;G0T$_&FNA+!!:R&O)QPU!@Y%"S<-D$!"URXP`_K6(N4U[
M/IBZ$)QB/89[NA="%^4ABUUGNSP@T^4RSS47J<C*>I/.T"5QJ44>&IGFH047
M5U'O076!$P7LG(:VC&ASLAG_4))A9BDOL*TD+>OCOS0=BV-Q*YVF:KLY)8E2
M\P$$MMYEIPKN*=^XWT7,:F91L\0;6I;]8-_`!5TSRFM=?GEZPP/43="Y)VM$
M3M!A8;9^*\.V;$SGM*J1%6'6VY+[(0C8>Z*@!IOL*8UY*.9@%+-'2I)`2@,L
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MKL1,ACP60C?&'J>P2QSX-*WEOB_+I$*KM``EB7%P+3E_+/3UI^PHFCQ0HRN&
M!2O#P`MQI`%L(E1SCF02MZ7SXE>N,P\U.L$?8B]2W3G35QMU(?XM1XK@Q@$U
MC;'ZSK(.[\O=`<,3@P&2B&/22N7*=\J;*"BF7O#4<;?\M8!"-0@H\!^>(%F:
M2U!NUSW@LN0JI-_>=W7N+V$MNX6EC<`W/A#$@I7)'5E#82I3P?"M)5>'+Q?2
MKYJ>M`+9I"MU&SK[PHX.Y^2G%TB.6ZHY>=;HC154K*I7Z/C=IEYU#G9!S;+;
M%MMGU$TB`^=<J<O.8I\H7@:\5$:6VK):8W66L4&&=6QVH,I@7+Y&2M_X!4FR
M</M*0:]=@U,KG5+<$3?)73_R9)/7E9B>XB,+J6L*-:&8^"/.K<'TN4[G%WJT
M^TN9;5;`^'+4,20T#D9@P=Y1,@JFD=#[-2^@NJK8OT&RDU.T#%SIP`O9]>AG
MH!J9**@[7RQGL)'8(4@">6:=!8.XSRM\-"LBDQ4ND=(5#-SV5CR?Z6DV%%.Q
MKJSQE^!/9UP*]HV&\"#H/T;QS`JT-FK_%Q_5Q0D)&=9Z?)GSD6,M\(E+,\0,
MJ<TC5T@A28NFIM%`N8P"OXGQ^^1T*8X`,&N3<\0>RI94G521-0VS]#[':/Z3
MBCI45&)O4;Y:+5?VO9HIJ!P<9:HQ4KS.@`/61%Z0T93OL+9RT#,EA\W1:"7\
M(N@]$7Y8/7_+@*;,5OP[?QGI;$5]#SU9DCK544I<GN-H5PU-,I-+FP0&LSJ=
M7^X`A1_P7&,"E%I`Z\I2.IK.VB/=2,U=*IH**C'(IUS!42PXE%A:8D=&AXJJ
M9:RFDD<"#Y&`)KAJ>I\K;SNB1@%%L@2-0LP.HPB^S'AA).E!?N2\6#`5.4=K
MZ92_*[I<Q`*,#3H1I)HGMO!"\6S,'2Y?<LZ0O>@5%PH0Y"@>/:LOTE,`C8BR
M7;5J7=<:<@1(P\&(RL5%4*(Z7BD3A;0#-#]`GY'TJ>:*@.#>T@P^?M(SNQG=
M<>'-#(U%EQ5:#P.E/LOCU9LE79F'VNEA>XP0&CVXZF+(D)AU!7,W%OBOA,!#
ML;W?SJE\%:147PZS\O$L(;E9&J,O<S\O:6J!B+W'UZ7<L/G2R=#XELI+",I&
M+=(M362-AN7,4N_9&1^>UN&\":HBVET+JH@'-ROQ/>?_3F\BY)ZN<S&MOZ\O
M3U*4D^$N18C,^]_H%0*6@8.')0S.I[X`WJ*[/CA?85$:XBFONF<`HNC&:.1*
MF^8L+(SCBA\R"7?NI3I,H&K4[V3[#\9`'H0RGTM@M1!%K]%`UZ-&\T-WX^C.
M"T#]L)L)J,T9B:2JW_1";W.>"FG/J$X%Z!)D54\%51S\>XHA(H#:1,@N&/D.
M!`N-#3A$T]5%G7I;*AW''N;I*2@1!+"1%)9U>OXLX>8`6E:JIBD&DD4OAYUO
MKM.C44_WT,$")I^"F;4G2K`'.N.*&UPL1L:>"</_I.R7>Y<=(FS%66]-?=3>
M(I"0D,F,9?TN2/$H!9+R0!4R0=;5-O3H1<YC6(Q,+K'*US.GZ>RZ(<0Z!4CW
M>BK_=K*J!]0F.VNIGE[:+/D4)FF<T34J:>IU7,VV>D[->2``=MU_J[=V_ZV/
M.-#ZWS30^C-/#V?>N/<2W4X98AL!M-S+<ZNNH-5P;:FY[*3(GPT*DYQ4M4-(
M\'$'OID+&DDC8FF;J8DVXZUV(DJI]U6*$BKUL:C)Z>U*?93C>[W4'CH./U'F
M@AG=SL5-KG9NK_^A@*9OL_C2(^8]^R&0\C'Z!V3V,RC?PSCZ#G;-&)U5I-F0
M(<L5F-A[!JRGW_"_\,=YIEP6&+":^"&;AQ)7#Y@(^;`6;X,GTA5MW_+4%"\-
M8+;UUOEO%J74A,=GBX72;R@IB'-VD3!(72(]A)'/4?#8QO]&G1Y;A$*K'`J<
M:D/M)7!L.LK082+B&X^#D$0!RLY6H9BX0/\TVU=ZE>(XHC9F.G.)P8D.(T_%
M+V;F[LK$U\,`8;L<A#;PLG`1?'3QP!`(U$QQ6,>[SK518:\&NL7A?U25RJY%
MRKDF^)%*@^YT:MQ&=0L9YU]RR'<Y?IX.=!,16G^>JP;YF@V5]R)F9`LD=%]<
M1[&>A$Q-Z5"_OD'7>$K5<D5&8[@M>__8F:)B\WB-%MZ@U&:5[SK&RE)V`GJV
MW),T0)XS3_EZ6;PQRW\,+ZN3))4V$6NRB::A<41!$6E08,C!(O*Q0(4;W_DK
M&U]S>'$5Z&3ZG4Q$CBAEF>05-CX$$<9W14XK1]]9D745X:H^2++)B$I]65CT
M$11CM!=B#D]1X;>4L4-*$*'G9=,Z>I,DLYR/7:-^/;#7P$2*5(:OWORX9$>T
M_%BB1ND6[P(/E,K+T33"0K^92*<H\J7$QLKNN79E8.<[;1QBK;1=E@)0S^E(
M_>;`=+F4'K_"U&[ZY%AF6%#-B(4@`W"G;6D+5,B0Y(!+5KYD3V-;QU@*:)]1
M[HW_RA*IORP!,*=X+X.N?;3R$TF0Z^O#43YTA2-Z=<V/MMHY$FL>@8LUM`:2
M)]EHA+DINA8U[X8@I_.<PSSHJL9@/^5Q)-8%5@)1=M(<BZ')6^>D#^1:/P!9
M0T!N<"?=\5OFRZLB]0^:L]UL-/9WT'9'^4X?VCS<G&Y_1E=7^ZWVN^Z8@WO/
M4YC04,Y8[AD__):`\J9].G_T=(G"!-OWE`U)$G!]K\4^3/3=\03GI;/3U7#U
M:K;VCC#S_Y%&;@YS0:JY^?E3:*/IC-5U62YL_^45JV;-W4UV_IFQ>&FL'G.B
MK^@RL7'T59O\-G[1]B_!9*O"Y"XP^;OEF%D#2^UJDOH>C'D[(V?$F_U5!!ZE
M4S[S2]6IJU,?]*D?9>_LF'.=%[S%>\["'GO,74\=;C:K`9058BO$'@YBK<!I
MA=T*N]6\V&U-.5UB2*^*_^S/LA4<*SCNT[(5'+<,QY6L>-/^JM:VK+XKZM7$
M*325Q5<9!A5B*\3^](@]+)N@PNXQ8_>H+;XVJ&CC*,/`W[.JAAM:MX)D!<D*
MDC\=)`\QNO>;*:^IDA.J@'5UZI_WU,_JN-H:0_M#E2^MKL[:<UYWJ#94V^UW
M>@=@/55X/6;;N,)N=6LKO![:K3U$\PD[LZU1J7RDVL;3EMX@H??<=K=Y`"1>
M(?BGX&05FBLT5V@^?'9]U#&VX\R^JN!8P;&"X_'!\5F=TUO.JK1:VAVI8;AK
MQT>SX39.^P>@852(K0R$"KN5'_JX\5K9>WN@%QYKUE4%R0J2%22/%9)%EJQ_
MSK>0*FL/=4)-8,M/8+AXU6]68E[UF^U5_6:K_1[I?E<I>/>>I^HWNXDHTKYT
M45RGWVQC%43WQ!0\/LS<UV_6K_K-'@`6JWZSQX+)JM_L]B)-5;_9JLQGWUZJ
M3GTTIWZ4O;/KE.JJW^SSQ&0&IX<0DZGP6N&UPJLZ>I7Y4&%W]]@]ZCCY<>9/
M5G"LX%C!\?C@N)(5'UA>=-5MMK(+*KQ6>*WP>G`6087=8\;N4=M[QYHY64&R
M@F0%R6.%Y"%&]JI>LU6PNCIU=>K[-,J#2;+ZN7O-/C&]<7/&5-MMM@<'8$8=
M&H(K([G";G5K*[P>\ZT]:M?6<88\*SA6<*S@>'QPW*)+JVKH=N!*1:4L'B=>
M#TM9K+!;W=H*KX=V:X_:Q#O6^&8%R0J2%22/%9)%EJQ_?EI7-ZN/6Z^LCUO>
M`.S\\D3;;RJ<\V@V]\([9^HESBCPDL2?^&+L^&EB&X7.)(IQ()0:%26\.*Q%
M69H?$N7$(O#P$2>-\`MT/F_TW\Q/?/Q[XD03YVR.+50\Y]9/IW[HR)8;^!?X
MO3/Q_!B1G0EGZL-C\6AZYPS%R,L247@@<;Q8.&.1BGCFA[#G+,&E$U^W;7$R
MJ_&'XU._#]>YG?JC*?PT"K(QO#6/HR&?\\ZY%:A:P"\QZ.E,@N@VJ3OW&<0E
M+?F:^99\I:B\GQ[+J**TN]]VJ2*,4MI2&GMA,A%Q#/#!OTW\T`M'OA<`+),T
MSF98ZP[_!MP#L2!Q`$X5>A5IC9A0QEF,N,(.5?@P_+=9=\Z`?H">1H`+?DK2
MQ!"[FH3XO`<72X38C5!_N$BD^,(=D"<^!QLM;9)%ZSD^$!"^$R":WSP&S3OH
MO'C:VM_&BX/V4QLOKON!9WCH4;Z\Y[2XCJ]-TT=D[?]&UDZ_DDV9/@LOR6(Q
M4YTTU.]_1VYO3FYWZ[*?LEL_6;\WS9].AAI6-N#4@X\^EH8X?7__6DO]E`2]
M&4)]]0D8Y#3*$I!'R?Y@=(D.^C,T"WOG!:"+",=+G7]Y8>;%=P9\4M[?)]\K
M3]I/[DG;5]K^%/J8F&F;1J`8%XRQ);88:,"@CG\6L3_VO=`Y,[;8D5Z'O4GI
M[+F=7N/`;\3A\/_SJ0=W`=.5\[>D]&I4I+]=TG_5;)SNG/)?/XK@#SV84N75
M[`M'LC32Y3ZH(^5$N]9)JVE=>\"*JLC/BL@/K/2WDRRI77O>_,U'Y4C_9/SH
M[_UD%$3H^+H"SO0NB$;?_X'?^9M:A7X%:UU?@X[_)4H%+&:>8-M^^3-JZ7-O
M[J=>\)OP$I%\"O5.+E.P'6@C7R>_B201HF1#9(/`#]_$Y.\OP.RN-6O(U/X$
M?E=K\[]?_$-"YOW7\ZO_N?C@3--9X%S\_NZW3^?.B]K)R1_M\Y.3]U?OG?_\
M>O7Y-P<XKW.%<0:R4;S@Y.3#EQ?.BVF:SM^<G-S>WM9OV_4HOCZY^G;R`[_5
MQ)?E/VNI]69]G(Y?+'=[+(*F[]2<C8"EL&99%*?96AXJ>#2[":1WJE^WZ';E
MO^0Q'3JG\W4(%\WC.!U1ZQ*?UOU!JF<.75*$$:-2V'-YCNAQ,E@E=D;R?`'A
MT4FG((S]Q(3^@`[,*QA;FF1QZ"=3L*OQ*8HE>:,1+P._I$.C*8&J#AG70RGE
MDZD0:=W!78VBA#\&;V:SC(UP;Q;%J?^_.JPE=P8'&O/N[,W?>HGCS>=Q],.?
MP=O!G?.RU6^YP,GHNR]/N_SO59J%"_9_,A<T6B2X<_G%YFG/?*7;N_<KC?Q7
MZG3^,_LHXL=<A$`[%!Y^X)FZ'=H`P)G"<;2I]JGUNT;=^9BE<+6<F1_ZLVS&
MGW7FWAW'&AG+B*4"IAG#&";TT>TK$"/PF<(&V@-<S`7H=@U8FKPK.Y3(<6P9
M=UP*K!;]WS9]!?[1*<#.^:1VHF!F.6A*CH``>]G3>Q'>:*KBH;2G^^.;<B.-
M%1%L(X.>Q/&V(9G.X-YEL.R%=X="$WZ,,S&V&C"<A6,:QF+]RFSM/(MCV/21
MBJJ!):HV"Z==RZ[!VK)+'M3YP+<I(7*G@SKR4(YUXOT7:.H\PCY/1.<9R?/8
MJ0[DT$I2G39#60S(GUZ1W%*QJ2JM(7^7'I76T'IB6D-G?[(:#FR[/V/,NK?C
M)`RI^/P/*AGT6YD(\0'U#?L72^</[D4P_&<@E1WGZV@/YB[P_9,#?G>#/:NL
M$ZVS7<31!&PB4N*=B:AJ9[?DS^^V#B&27F'U@;65S?8!8/408X_?1"*P<H)L
MR#$FGD;LA4/?Y+$RJ;U)?^AWNP=`UQ5Z'QM</@19=!Q971?>71P%@?:45^SK
M&>A[T*L:'APQ>ON=0^=?^\JM*/A0<:?MDF^KTJV.&+O'4TQR\.E[QYE)7,%Q
M^QG9AV-?R*&-#XJ\'ZF`W[4SL.4V*[OC"/':=)L'[^8]>%E^K*GX%23WK:BA
M>(3<E7F[9A9AZ:%,JNIF,QZW4E41S69^2EFSL)?S2%9JCW(;.=+<U%.[C.)!
M<%@C]W1%*N*C14,@DRI.UR^;,,<B73%W,+X30RU>5JB*^U,ZD<C)Y?`M/\!^
M7KFH(7?=2D4LNWO%R\*+-$SJFM/%J;^;DT[]>$P'GGLQ):Y2$48T205V**#%
M'=BR2-(H%/3!.+KS@O3.9/D/J90@XG*,>1Q=P_J)2GRE?<._XBB[GN8VDZ3>
MM4CJSF?]=?W%F8<]Y=3Z8Y<S['\`@@/A.MD<UJ)2`>#2:AWX:9R-4GH2\/-=
M4)N[(4`0/G.-51Y1##\@$5"NOS,2<>KY(9W=@RTS5%SZF(*^G^@]8!7`S/LN
MEAV?-^7,18P91[".VECB!7C*=[)%GORMU1TB]*B$@O]@54_05NZH+B*,TEQ1
M#'Z!TW=EHXG8&Z49`L,J$4JFT6T(8`RB6^=5(@`501(1#S`WI=E]73>"8B^O
M`D`D1[:2-K!&).;>=F/_QA]G.!F-RV@D@+(P\+]C'0G07)@R76M*YEYTLRQ(
M?:`I13V8MGTC$-O#.SIZNKC^+?P=J,(;30TN$F\F$/5^-&8"`GX+5`=;=$93
M@)!`ZE%E)2`<@W'N"++`!*X-[(=N3C27K1`2HE7,Q\:?W+(-\5V]]F]$CG;Q
MWV-@XK&@0B!8(PM]#-/%-$..FS+B#NT[R43(_(!!HMHQWM*N/<QBSR\3.=Y-
MY(_Q<E!CR3QQ*V)^ZP`UPD+QP@73:((OC:A\R-Z0KZ[+;`XZQ=A)LM$(N,LD
MPS,`#GQX%OMB^J$_0D@"=G$7T?`O+NQ)N.9+KJ?=E_VWR=)[@X1"$+CU*;3)
M/'#"A4[4=U)??8^0M:K$!XN:=`_#`\W];S8:^YO\WSE]8O)_;W^RZ:OM5ML]
MU.T^*B!\^%GF1:?8+K/.O[+2$%[3;V01"!>,OFKNK@MBA2*#HB]16#O'@O2@
MV._T`]@V$:D5]F_/M&'RJE5A<!\P>)D-4XQ*5<C8`V247Z7?_!$:6DONT0X[
M_%:H,ZB[VNDE6M.=_C/42&%GC$4P53'S3<16V[MOL[B77.FPL>KV^YT*KT>(
MU]-FA=?CPVNW7^4M'1]66V[GM$1OV3N\/LHOMGN5L"0E["A4PKW)I*_J)(X9
MNTVWT>A5"#YJ!+</H8-UA>!';J33/82LZ`J]C[Z_G<$A&'NKU,>#\C&6`+M2
M*#?:K><`J+E"[F.ET4'4Z%3H?31Z*VOPF-';JV[O$:-W<!`.Y@-U1)8PQDIO
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MY)Z=:.\@611N^N>'#$%;/($E#UL;G*Z1A\]:4S*L&1O%61S%61WV;(ZBH%]`
MI'RX_8M11]`7I!0D6OQ)BHGJ+W^?<F0ON."6>O3JNO$]@-&C`;$QCO3Q`77P
MKC,!J`5^>L=SLOZ;^3Q:)A8X#6><F_UB9F+1/*P[YT:$XRA.ZDYA#3.,=IS%
M:N[-G?#BQ($WX*NE0V$(%#P8!K8"_VCP."$:9O7#QX%`L-^7K7;;A<M##[UL
M]3OX@XOC@>8\U":XJSOK*H`/O`'MZ@(\[@*T=GD!S/``,\HL1]=R>)@#;WH\
M-TJ//TI<G%!T"]#%_R8C'_[H3_R1XXUO_`2'I@TC#^[#C,B9)C$!X=-WK;EI
M=>><YZGE9JGQZ*BI=R.<H1`\:RT6\%FX(!,XAX.GHO%7\%\71T[=^+!+&LWE
MA_XLF^'X-`_V$.!,*-SJ^*\LP5OKA2&-_'*\M#CJ2HY8.[=WRB,!4R%RI[47
M&D9AEJCY=\1`>'QE==7V[:JU=WG5Y'`!B\R=:Q'*H6HL4M0\M[*A8PO"!J>3
MO:,+!F3[35SSQ?D]!#8?)RBTX-=7XH?'DRQ_%2%<AG]YH^\)$/5''(G&](V4
M'&7POQ"#0==Z>EWLS7&H([[[^^?/ESB.,1KY)/=H^6]?SGS\*X]8E$/.>))=
M@B)GCK,DPU3?$KYV>@@B?G=6G-]H'])5MS'E4>XSG`P+,E/DYK+)B7'R0B=P
M#?DFYL=)^@#K@,$_!H(>34,Z*FW"?I;.+I]?.@I33.#`/,+-5[I`@IA;M0K.
M'C2#\PB`893"PPKE_")`$GD(3L<#4J()?OA'-8<0)_C)%5A5T9\$-(21!%+"
M\^>&@J&U42:TPWFF\WG@2]R.]8A9YOP)W8J/9Y?OG+/+<^<JFH,4ZO0:SBMU
MA5J-M_@7^)W^3?/M:]>Q_DX']7'9?V9>[(5I%.<NH!Q.C"H;8)1`8T;=P@6D
M:7]\K_%&R(\(`93\B80HOODI',-3H]3Z,Q(<_%H,`8NA)%@:<DRX\!4`Z1^)
M]3MS#E=1G\5:2!CAY4#)>JT6<V!CB)M9B(*:&<`HP/&B^7&'2J#BX,'71HH4
M7J6MWH"0Q9,EHVC.\Q^1WA&+/)>19;L?WN!5CYFA1'@\/3<6H:6>`V@B;2?9
M9$+3-&F_(QSLC),U"?EZ$T*IVO`>G#1$%1?.0Y<+=N5'&8#A;B[D1%E0S6O\
M/)S8G_%.7OD/.E_N;-$$'A1\)#HXHY8.>0V'2=*<0:!6C8%<X7NLQ>`(4!'?
MP'<2'MJJ-!F<NLDX240190G/[(0/`4)#'H"Y_%K`&8#TS2'A#L!W(P?XO\C/
MU)P"2Y,#8QGBHRAA1N?)$:-FUJPMCO3Y(\$?0!,':!RI$C]EYI7R!^7L4Y89
M=;I8,=X.',-:MA^/YX`37PS,Y&_\#E+]!#A@.,+/)RDLQ/2O;#0&30D,RQCC
MO3,T"Z/.2UG@_9K7VO.O-\M-O[(:_26Z*=B7+3ETU'5^S<:H'KP#:?79`VTY
M=CYF*.)_2\?U'#,U#]K\%%`1()X(@T#N9%6HFV#-;F7\@ZJ"&+I,28`"+TUC
M'ZCF'+01GL:,#UU&&3*+T/P=2/`+'/!_HOB[\PH?L;9%[^8Y_,B;([YA(01<
MAH!8."7!Q3KI3=WYIQ>(T'/>^=%\ZL4SCYAXW77``C_WX>^#3KOEO/K7Q5=6
M*>F[+DZYQ0$_U\Q^EZER`!H:JTL,D#279.ZC]0%ZW']\'I4MR=<;R=&RWG>!
M7!0NMH#7C.I&'`3>KN';R!82&XDT'!B#6`X-]^:!M%G"/\TS4&_0(Z$&]][2
M=&"\\2,YNAI8KO4UW"/<YK-Y[`?LC`"0B?@V1OL(MI8!3QCA,00Z-NKVJS1!
M.A'BN[F98P$<,9;3M6GX\E]92%X*?,07D[KS-02-%92[^,X0:[-%Q-I"5A&C
M1"-9(K?N3*-@3"P9>'-@::LX=5D^NDBC<I8WHPL(J)1HKD0(X/XZGX/REX6H
M7QN"<9TS8&]+_XBG,U2BOWCAQ4D$\"E_;241MISS3_]V&JU>(T=](0U37P!9
MJ\$@HP<^BF%<^+,"J.TG`O#>1@PQFS8T@!F*\&<?3(?;T$!3L_?EH#R'+R53
M),5S,#)0NU]D-BM/;_9.8.C(R#E]7$.;?OH41__-(C]YZ`H,WX$<PR3AF_>C
M?=)4@UHY\K#4@H)R8:"6GF1#D$RAO.L^,G.>.1U)ZT/<D+)BP9#!FX<D_E/I
M-0OTCO>+-`S#>I#-(-PU>XB6\Q<U!'Q6SC+R<[NE-\;F'^4F:Y;BN4GQU;QE
M*@*ERLTLV:^`01Q4^Y[TIQ50>=JY7ADXT4@H0Y$?\B>3Q-J%65C.(6<[$H>/
MYUVGW7H+#=(`&:M<6,]B?X"N\+P&$C#(SVBD+LCR5EZ3`KU4`(;'3B"`5>/U
M1>V3F6(!>+4B:2'_',?>K?15PWVW$``Z%4XDIX<D621*]^.'-?Q'H'?$;#U9
M4^YA^9[;[C;(;9W`+11$-_A[3YK^],B@\,@$_8DSP!58%:/OCMP0N;1(*!57
M+VH*?\A3P?>_D"&..!@:&VM8L+%>`ZUB!2_>%#R$`"FGC^DL?(U)E2"R'++2
M=\%:*D-R07$HW+-2@.+C0R_`D98(F&YC):@6B?N=AQZ+*%Q-"/:EDK8,?PKV
M5+RB<O-T_B$*\QOE'RV]P%*1@9_UX8!EOVS4^TUT*3%&`S;#\%`NVH5%,GK9
M[G;QW*0VT*UP6OVRRY!BG"76ML$*!"U;`DTBY;("&$RR(%#WR)R-D6^=+[+.
ME[>V%T&T2%#:657&:?E(N`>U+=@AF.^CV!\BEQ]&I%710[,HXC5FWE]1+!V%
M$J'W,H-2C'L!'"Z[GA9V+JT-WCU`!;4<%BIH\A*K9TFSQKKZ3EL+[RU7_C3)
MT1L%ZN#<0P'WD,D"K=A`+*KA]\BP/!VC3Q'-8XJ2P.V=DG,B0Z\$AF*`+)$S
MPQH8R4@F=]+/R/:S='Y&SDR(E,QHUHYS=KWT2>"VT9>H=)H12=+80_\#1NW9
M1[#"=ZV61(>0Y'GL*4+/PG6$]QI^/P(S;P5._W:2);5KSYN_X9`,V?EGX?B<
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M,]A/SJ,=Q1>Q`"L\)O<*8G'1;]QLO<W)('2V>1DP\AB^-W:R.=Y6DG;X/P,B
MHU7,]1JD6'".`@AM>+QIGI][,<;0,@H.*?&-`M%/D@Q5%A:%A8]Q"(,X6Y(!
MRV$YX<K'X*X+^@%T,3`7I'"$;9&'B*-'OO:YWT3DM%>?&/OH8,7GY2_@BE+(
M#%BH^A7L0\S(;BTN$OA`"C)TEMN,Q]$C.*",O0@.SAC'=1EG'*H`GO$=9_.(
M_9H&0&=I>5:(]-HAXQ8L9L+(68H@VQ[;6]FIUR=B/6?%]4DTW&RMI&);-W8?
M1;Z7Y7HV6OY2U1ESRD`01+?)&Q-G>YCON;?!J'\Q3E^,X\M0_&GKEURX_Q')
M`C)Z+B?%+Y$TRV>F+T\3&/1^>5P2I/I`9\WWG^&A5;GW:R6"!ELNNMC89^&*
M(.&%>-T+M%&@+DG42^IC'\Y>FGFEX`PO+/T4.R?XBU(&:S^`O':5`K!5F*Z9
MP%IVA8K7K"S)]9"*@?]0+@)+G-W'3@^T>.F)=VV#54P=M]EJN+W.(=0*/XJ;
M[IBH6<.)YC+MH*+LYZ+LGMOLM=UFNW_@A'TX_/NK)'*M&UOY@TJI+OC[BE93
MJ]'H8Z@.`VE@(5X$7EC=DVTWBFV=GKK]YL'?DT,O9?WY^M3L*R.CKC0KV5C%
ME+;+E%I-MSMHNYW3D@D=%5=Z3JY4%8X^LG!T?:_>0YG`7N2<XHN+GEQMPM-&
M%URZ7T/G++O.DM0<CP+YC4$^`(IL%AAO\Y2<N_D41DSP46GG%!`?>N%W=,..
M0/?TQ\)*H;0>0@__,$M\RL/796PJ0YLC%2:3":,3L(CX(>*1;V<CO>S7&^V>
M\1AS_>B/.:92=<VAN.I3)X*/99:!DAXN!G5+`=%L%[:"!R`O,Z>D1<YII]3?
MS;$%_7W<EGHUQ21ON8-VJ^QMRRE.:01A.L6,ZYBB*S)[Y-1Z:XQYGR'7(V$E
M7NYHN#1"1@*/;A$BPY,U1/CT!)5[`E+=.0L"%=F@0(?:=CC.%Q9BACG`A0&!
MB1F4_(0,@\ZX+(S2.,UG9%`^'9534)!<I<?)?`25KZ#AGX6!/Z-L9BO%:.Y?
M7]\!W8V^6WE$L)MKS&3FW<KT!TI1S6=.66&<9590+MI@I<CD=H9UE3(1)[>R
M3I7/W2A,.TS*ZBF`S'.YOBK)5U5+V7O9V]@2\)6OHS3*HU^55A>9B\Z!U@F1
MQ%1D^170[2@`1@%D<1O%P?B6:C9,S9=*S8YB4!''(L!+0#>`RN:XO$YDJ3]"
MTBYC2NG4U]5DA8UIJISC!9-)<FI?$\$<J.6J-##,$H/'[*Q9OKM\T?C\,K$#
MT#S$:CR?<D]'7C+%0"J5OF.>$'X',#W$DC.?;WPLHHFNOY7I:YZ#E,P5.C+?
M4I*QO<L9\#5<;>:-A5JM[EQP_E*B?RW7QF07JG71;\"R,EF*:H%A!8H4RP0H
MMW")\BEPR(:`X]#1B2=:,>#\W38UR/+^4.888@@^[-G9ALZE&&4Q5Z:<<9U"
M\[0-G/I+5)`9]#4IO-3KOE6]A9GM64XDT-]C@1E4CRQ_M,L9N5AGZR6-OY66
M-"Y4^ZBB190&0T&YE=PA8>Q:>7;\=\1\G>>I()/'<+=\>.'2Z"MH]5;@HKVE
MD73=6V&?.=AB=O\I"[!RW:A#C.!^O8A.]BRZ4:?>ZK?+=2,C\)=K1>45#@2#
M9F>96H3'[C?=5K=<):+#WZ\6M=IN?_$+!Z$6J5N"EV9!*UIY+8J:$>58[)%V
ME#,L5FM!:VA`K#8^1@O"CQR$%O1I\5RX=\2T\U4>:#&+6_(3FX_HQ-73_L`%
M1E.67;..[EH'VDL]/]`O4(XB5Z8HE62"#0LL63L5'N5V601%!_AF9/1[+K16
M1[*I;`B2[_;P$-1LE"-H)7*ZG:6I3VLA1S*'C2`(#G!T"&+U62%)UAV@,O%P
M5/56Y:D]XTVR#O$0=#TLL6TO[I15ROIP=#6;[FEW%;[HT,^$,^LDQW#%F.MP
M@S2=Y+J@W,J:,%O,@UT^]<)KUIKN4U>M\KCH.H3EV79BBWKB^2KU4W<],!72
MB30ER[0LEVUN+@<"\S4!W8>3@WEUJ<OE]Y`ETM?P+@"=J'8Y`F4**4EG(6.R
M)JB78Q%P'<5LGJ6L=H'.1V6,XU5[=JYEUE18L"Q!`X='<#=T;*4I+C10,(64
M</B7S<:`8`\@1_SL+2%I!_1%[-_@F3\9BP;V?L$UZW9^?YD[^E]9*"QKHU/F
MC:8L1BK:11O+]@9<*(YQIBU\8"*H\J?*7\O^%ZS.E;1-M3R@3B]KHI(O3&NZ
MC7X;(_3W93B3)DPY[?CF'$B-]T-VCK'1!O5FRYAH=>>+2-&C,`*%OUCH4]J'
ML%^W=B*K:G^^AAN:]@JJ*3.W/&M>3GN%`M]FO\S<+Q"?A5@LC+HSOB55PX67
M&.O2@3_!;]%[-./VDQ&N:)O6/5Z/*/)?66#_J:6VPAW!HC&`H%A6TV@/WL+9
M0Z"D6]?Y[;?S7!\1^QW90X2KS@A&QLF:/U#J,GN2=>-(N=$\HB)6!<Y\S042
M-2(I,9<2)7F4"JK*-S>+>T[D3MENW`OPL9CXH4^Y2%8+)MV>`]V$U.%"N3`*
MFRN[XG1^]#FX[4'7[3>ML!%VBDA<JZ\%_H)]-TDJK5%LJL;NE74#".1YT,+"
MUG,:]4Z#Z['U%_-%$\P\%FKR7[;KW8:LWX4-%BNP<P:G30$L%W-_9N]4$,DZ
MY6)0K&,[*M;S0<F=&1?42J_+$/.G0^G06>R@T7;9.L/V8($LD"67%JL%)3MN
MV_XJK89XU-_R.HY`9='L-IIPK62>PPYTT;RLY\[!BTX4`M-&I[K^%&"*2MCA
MFF>C5#E)"E<K5_<V$<+NV*5OE^YA*UM=%BB:>O<MB(1^B4A@G<.J^B;A5^)Z
M42S!UHY)\IQV.VYKT-U;!>0LH3X_5HGS4LY<HN*6WDB.6+7=0;>_Q/*X_[K#
MYYCWYBX->_>67)GVP%8)[+=\P-QL)L8^X]IR0L)?[$O%%P2C"FM>CSU%JFI9
MNQ[AJO([[2U<RL&8I*W20:SOIM)QZE_V0^OC:YF6NH";FM(J88?MID2:!H(P
MH@-OB,\%\\$R>%)M-B0Y=SP92WBJERUWT&M+@RRQ_,M8Y)TO._<X3`^?D=$]
M_.4MM2PH%DV664-T^)Q%!$9TIN-.$P_]Q,4^&DC9R@T-3(3LYZF/LC;?=2X'
M36YDIPLH;R)4.O@8<'Y9(0HT/E0=-/+Q4833#-M6CLVK/L,O@:T$7HQZ!/_N
MEOI#2`D;VW:?:DM.IDIPI]@@P+;$@@2&(=!MCO\$(Q28S(I#H.70:M5[I[_P
ME_23@3\1RX[(CFYN`4T!P&),`K^DBVSO?.SW`T_\KXBCA>\85*'IP_W^'-4Y
M%E0KA$X4JE@W$BK'+N77%UH)7E&L/OGN3+`UF(K;-.O]UB\,'J6369P+2-#T
M8J)=CB**"=/KZ%+@5B^%8#/^FTQJ7E5Z'=1^EE^DAW1]+W9\EV&ZETUWT#\U
MC=Z;;K\_*&OU?D6&NPJP6K%G;NI-_(HE._P&FSS(6!PY`%2?F-&(Z4MV::`D
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M53YG$E^*>5IL*MN[UR@N!T1O/:.X:%_">ZT%`],8QS8J;.-8ZI(/,)`W:10W
MNR6;WEMF2^L7[-D546G#>/!2$N59?54,E[S%=*X"HV$+0F5@8B]L6*K[BUHU
MM/W1.E4HC^5\<RUZZ/PN_?9#L@1L1\:4:/LCZ8F<.[+7[Q:ZZ:UUQU2;2_K@
MXA*.G3MD,XW%MG]CSFM4ZR]>FU.;?Y".H;<I7[*,-_R+W7-,6F^L5[;=08?U
M2E)E[,1I,MB0Z,NUR#067I)A@"W78W"I[EA0T%:JA(_(RCN2`$*QLXRE_VF>
MC%TCL8FR3SE=8[A3^2:8JVX>F3D4051R`)8J\6F47/2BHP)N&^`/RV!`!S5-
MY'B?F"I:WDI6NB+HM]9;R`W0T8?MBQ1U8GHK=1L,R1S`2^&:=DNC`/XN4XYS
M#H=E]DB^?:CE''DH$(T#I#_H;LS]D252_,B,-'3]P'Y%BBF#)JF:-"NE#LVR
M(/79W3"\RUDF&"F4;7:1>V8TD(E$NS^3NIBM:0P-18Q)V5R\G8KKN)+#4:S2
MTWTP_5CQ'F*$0$/<:QDE1(;[`0&KY:O6<"WX:HBI""D;*<ER1K&_6;L/]!;F
MQ=A2CR"GY>6\@OOG$>ST>AOV"-*QU['3C],CJ'V?.:\@X7!S/L'F:;WS=)]@
MKUZL=7ND;[!HT:[C)S0^PF5>P7:]M>]>P77K%61*CMO(>P5;_>;!>P5E=9;T
M##:;O5+7X)INP>4J:/)$IZ`<U$4_Y:V@1]U`]N=Q1N6#+F$,FHL?RK/FKV.G
M/MCX==S056S4!^WRJRASS]>^CB79;;&HS<@X(:K<6R5!>S)79=_2)A_OS^Q8
M'4--"1D[IHJU#85I+L3057XRN<,2.VE,M5)7+\%5K;>[QG6&:%UTX6">V:+/
MINAF*]J[=K;N@@$M\V;DIG5=XD(R0GMQW4)>6YDK2$,(?X'CMF3I&I?;S$`%
M4@.Q%MU"=>=#T0U*0,A-6,MY1/,^RORH,L_!V6(I\.T:EQP9GRBK",8OVEV5
MO</.P#)'8+/>MQV!KY)L^)>LP,%9)K6Q'V1L"M%D5;Q<K]5,M?Q.,3A80XZS
MQ''[Z`T.^N4;9'MQV2;)HJ%\:2NKKFM?#=5U'EW493-,\I;Q*OK,G;28M=EV
M.ZNG6I@2*YW63+X@O1&\5OJ'0O82&T[DU9]IFP_U3.D30DL`%4Q5<\D+C%UG
MB.,W4/[?\H`Y\Q$4)<F"Z";3SYK54E29"Z`F^,B9;=B(^"+VD>='TA'!VU@8
M7R(M!YP:%=,8;9R[D%,G7C8U>S*YRQH(^GS6"(;?C?OCGE5Q+"&M<<HKJ"Q*
M/>94YFZ/_8GL"`U@36]1JR(E1,T>7E2`RHC'SC(G[<4:5K'XA3+PJB_(NG\Y
M_,7/GY8JS^W)?IZ5$6KX%\G\6[F50*0R!6_5_5F\K'G=I.5V)>&77B^;H%9>
M+K8J@4$S?%XV"[$+%33.#2]<RACN[;.]4&^@/<\K=SGUQJQ@:Y^*K":T(&+#
MP1[EHN;>+."*[F0)MI8&8[0BO1Z*],IKH44J%@6OA8V:1KW7+:!F7;3LJ<*F
ME?."($81N"#Q[O/YE-2-K9T+ME&OCS[5(J,QM[;,![3$!=1T^Z>-S7M%-^(!
MTLZ$=;Q`._+\),;UDT\#4^X>C;`GNGS:]5;WR2X?8,`#Z<#(67/ENBHKRMVR
M%Q8O4)FQJI+D[S%8;P5[.39AJ+9ZOZQ_M%:]V?_EOH,]TMNDSFYYG#YQZ8+D
M\C)NJ:H*EVR3F(P13+"`D:**AQ#'5@H/LFP5U'W9[DA]BXRDQ>8I5A1FU>9*
M@+)B7[)5Q7U[ZPW6WAM1EJ58WN.L6]Z;`C!X3VY;TVUSKAXQGH?ZW=BP>:#O
M+=<)Y=YTPPWD[W6:K2UZZ62?MRW*A7V/#,B.3>O+B*?+!^F0W)@SLE%O/U1.
M=.HM.O@R:>'<*RYVY-ML%,,,JTX)>G(C_[@,`#]%;!R!5[2TOKVLD'(-K^B"
MQ5SJ%M76[AJ>4=,*8#W7J)U56.X:+2:*E>2VO5+$46P#L):O=,$928FISE('
MY(K4RQ7O+/?=-1[L7.0;MLQ5I@6#K4#854D)#4X?R@Q7')3%D]2%1!F_0%9:
MH9!P5>JCE*H\>ANOV-VJAIY6KROE5_-_D,V8ZP=5]G*^"%MF*G(#NP<XI=/2
MC$6WM(B[V2BMXE[3$5'N-EJ>*+K2+V'=+\M3DD>X[9Y8=0T6O$9/<4WH)4J3
M9'IEC(5YLK`OD_;N*K\0J@1L3W5:@VY_>8<+H#E."BN]?O2Y1*"`UP-J+49:
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MEE9BCBQMW:/)M`]WWCS><9/>BN!&<&_1^PM&-^#!`6!WGUR$N;ULJYVR5H+`
M,SOY]\:!PS=+,MJN<N+LD;-E62+9$_TE4G\X+)^)-K;N[0MXO\_D7L-MP6_"
MOFHYV#KG+9&UHLMDT))<L4ZWR^S_,6`O'S#_UK$'1;4V`/=A'@%T'C7P[G,T
MI@(5TR?3UR?8YZ'R)=E2.I'05'R4LE0SU9R\$;(.8L4+8%",,BI/!H+QX85$
MU:G"KY'7F:)E;11IODC5.BRCV="0Z5/(:T+TSNC:%#O=(LF-WJ2Y\\.\OR<+
M`VHB23TX93&K*=0-61'AUI$FS<J:0[Z$SJDH7+Y`>_2QJ@F/[0LKD0_E8YKW
MC42Q/;``,Z$RQ@.B`YX,<P?44T5S8'=>Y>Q&+-BQ`?':S?NE6;>Q2M,+7]/U
M:+RQU&=S+HV6G+[NG"UFPYT.W%:W9U<ZJ&0U^O`-\2[6$Q*[@+WN?,1N72/R
M?%'>9Q9CJ7TB)PSH6BT)H@=3[")9DES"PF#49%-03W(PUM2CY:^D.XD*<HD(
M+U6VZ(Q8PT@K$?0T1WC-M$RL[H*S^4HVJY*WW&OZ!=)XI2U+E):/Q99Y%^Q=
MY)DZW0K=);5DXDY.LE[3T>@6O/*L3%!MM+!D7=10X;X`(\,FI+1OEB#8G!1`
MG24\N&#$TA<>XI+4)(E&/D&R]!QX5UX-"YM87'DF>;-<[A;OD,\WDKP3XY+&
M@/F<MW<1O@B?>Z\IJ'!%O#'@AN,)U&Q15@]J#L*T6F0;*LY?9!W-5E?E.]H]
M':U\1-G3`YVZ-T:_I@]8":ZY'3*?(6WA+,2Q(LYG4->EV+ZTWD0%C$V#G!6V
MR/2XSZ3%U![$T)@"#H:IN;;SF,G"F$@("9#4WQDU]"^:]!)EU],EE"7SF,<N
M5^HR*9I><;G4UW:NT,Y4PR(9C,<^GA_0:4;[S'VX0Z7>_.5LP#C0S!>7MT%F
M2Y)=<(7ZIOMMV$<W$]^-IO>5*$FV$;XRWN[DD!0]]J$O5(VT2^.CA2XX'&5`
M"]]J[(`,V><T]1F`YP+H#.TW;B1P/O7%Q/F@)>M7EJRJ'82+%6IXT0FRZ13(
M!\2YGUI)\>3A5E=1^0-X*2FF68?(2"&4S&TA$5YZW!DR1/]\-7,!*--]@0W#
MNUQHT;2#HF<YKH@W@>0<RT;/NJ[MADGJC5;U@F(%VXQ`"C5?'6?"GAU5!GYT
M8+*SPIHWA9_0UQ@9V=+KNXEV"^67<46_A;^=9$GMVO/F;VQIP_?J2Y2*]WZ"
M]4I@@E\!X;\+X)E_X'[^]O_(>9ST*^<*-$LX'[[AU&KFB7<8N5WQC%K\O1F.
M=9EZU^(#$CL01"+^*4*,IIE])'HCY"2!'[Z)R=]?_,L+:\T:XO!/0&^MS?]^
M\0\\+.SD_=?SJ_^Y^.!,TUG@7/S^[K=/Y\Z+VLG)'^WSDY/W5^^=__QZ]?DW
MS*=D;B*Y[<G)AR\OG!?3-)V_.3FYO;VMW[;K47Q]<O7MY`=^JXDORW_64NO-
M^C@=ORB.*%T%$E`!:LZ3X%%8;.T>&AOBS2!$BMZ,9?^RCN?0^9S+;#X/E*(I
MV;HYH[/WK/PRF\$*I(C1H`?28I8:W7R^5POI'KE?*!W*#N8"X_')D;ZBTQ8^
M,)>]0%C96>%\?D6*9)0E'G9W%#_P52LV#_S4>_THQK3^G-U5?6!HI"]8A4&0
MS#WT2/_]1>,%_3Q'E4C^?.N/T^G?7S0;C5]>.#RLF'Z?'U\\`J'AS1/Q1OU#
M4@!-0'[CH**B9V6/2-J^6')Y>0;QK\(;%R]XR?!TN;E6_Y?'C8+6IUOS_?U9
MY!BW^]2=[,])]F>[A[V(,9P6Q\S?NXDPNHV]^=]?\']7CU^7?!,T/H?"?&H`
M^ULZR9O.Z3Q]K`QKYB7YU=V<]&8Y4N5N?>F[YHAYL\4U9ZNO@<\\YUX3=AL"
MV'LP.ZR:\HGY]R<9^EX%PMW!#"0AR-40E9B=PD_W7:/?Q,X)_O*<E"'[-V2B
M["4DCQU![U%EBFU<G*F6:'F46?-L[3^\>OFZPML.\':!/A5S%E#L<_=)MKJR
M?_=!NHCMW]%7G+*7?V8<[Q*OYWCY&!]+X*VPL@$:\F(*:6US,0UGUC^,P;N7
M%+53U'_Q</1"@?%^B<+:N9=,5S+C"HXV'-]YB5]4.<Z2!#:$?N7S*$GOAUE1
M]\_Y"M`[NMQ34/0FO,-6K@O>!&=X#:(DBO_^XO^,1D),)B^6PC2-EMD/=B0&
MZX#$+._[JO$OG]ASTQH+OH=6@H+.H\_'6;C4]+_1VX<[].03/6%==7%I8/S3
M=M%T>ZV.V^H/UMI$P5[>.3`JW*[:1:O"Z='AM`&RHL+K)O'Z,:*X<G(4A_ER
M=A3'4+KT.DK?6@[?2CO;*K[^Y84X(=89D'[6/PH:W`]^WZ\W.@VWW:STL^/#
M;6?'2'UU]KK"ZY9TM/5X8'5?UY2?-*;J*$X"#\;^$(M[\!N6YTNDQZ&"7N!4
MFY%(DGQ@0WOT'JC252ZX?4&L=,$U*AUOP_*B[;;Z\+_3RJX_/MPVNVY[YWK>
MNTK/VP9NN_7F:75E*S6O\L,5E;9*1:M4M*-B]9U>RVTV*P7M^##;<MO-9H77
MH\-K%\1%A=8-HO7WSY\OC^(@G\)4!($8I9D7X$=,FFTTQZ8'XCC\<)]`;YH+
M4I[L4UY-_7CL4%*I_>M_>T%F,A4K']V!(OTLN\Z2U&E6@=B-.^FX>7`E479^
MG(U[Z"JL'A]6*_5OPVC5;;Z.XC3_K^GV>13GJ1QUAX4OJU5MI:IM7*(/!FY[
M4&7@'!]F3ZLZE2/$:A5'W;0V4,51]^L8E2_N)]3QOD0W4L5K5BK>AD5&K^<V
M.MU*:!P=8MOM*AA[?%BMO'$;1NL'W4E^8@2HTA_D`):C..B1*("5?^ZP\/6O
M+!0.#WQJK.=RV/<3[8<@:+H-*G6H[/WCPVW?/:W*E(\0KX-ZE?BZV0K)3Q<?
MCN(@1Z*<?1&I\U@%K7*W[0L6OX[2*#=DH>>:?Y,:IW_RPESQM7;4-2N%;^.6
MO]NM3/\CQ&MKO2:,%5(/":F5FV[#:*W<=(=UC,I-=UCX4GWG9,7K>EZE?3_4
MGLB"@=L^K=PYQX?8-5EUA=0*J0>/U/SK!TA=1Z)7?>81PYC8)AZC7U5>MOW!
MY)W3K)2M37M3!E76T_%AM1+*1XC43E6L4/G(?F9=KO*1'1:^9$L0'IUUZA1B
MG_*OG4JEVWQ?L4'7[3>K(H7CPVT?\-JI\'IT>&W7JUXP&T7K-W'M)ZF(Q=CL
M@!N)',7QCD2CJ_+?CD'/^^S%HZG3:J$FUUR/C>W[D?9#*K3<?J-J_G:<N&UV
MW5:[4M&/#[&]*I5M6ZJ<4VEP>W>,)VAPE;ZV&YS]VXO]*$NLY4U/PDJ%VW`R
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MM8J?;E:VC/Z;^>A[`R$Z]\*[HSA4I:\%E0-NGS#)&ERK46EPFS;HF^YIMPJA
M'BER&^Z@VZX0>WR(K>I8JQCJ3Z/&576LAX>S?V6!;`E<J6N;9/P#=]"J:A6.
M$+%53M3Q(;51'U3:]T8K5B\O+H[B($>BF569;4>AI[7ZE:*V<7E>.=6.%K,5
M5H\/JY5';<.JFFDN@M]0.6U_>''LA55:VSX=H_*M'1:^+L4\Y='TK5ZEN&VZ
M[+`J*#U2S':ZE8_M^+#:J/<JM%:AT$I5JQQN!X'!]V+$NENENFV^&J'9;5;*
MVU'BMNTV6Q5>CP^O537"AKUNHZD77@OGUD])42CXW9Q?HV`LXLK]MD?'X"H%
MLWI57GI@")0S&QQ>7X]JJ%2[S8F)[NFIV^BN!]%*5AP69JMTQN/#:J76;3;B
M0Z)3+XZEIB),/)S0<!3GJS0YZ^?_IU9S/H1CY\H;!L)Y%XWOG%JM\`;^J5RC
MH\WBIMXT6_,?;Z6"!T=[TS`_,@#Q-V7PRFMDM);Z^C"*P7RHC:(@\.:)>*/^
M(;5&`N0;!]7)%PX_^_<7C1?.2`3!W!N/_?!:_YS,O9'Z^=8?IU/`7J/Q2]$Q
MN:C5RH?;O[PHY5ZT^)/0^.KL]5IT8R^X.2*Z`CLM\48T?<49BO16B-")1>!A
MCZ"Y%Z<^O.O%PO%&HR@+\;>3*':\U$FGPIGZ21K%_L@+G%&4I#C:Y?PN_?;#
M)8N0'O'AG2`0HS2#A^9Q-!=Q>N?<3OW1U+GU$OB5N$%]-KASQ`_D,[`"J._T
M&:WB]M\F!(IA%'W';0(F89,C1/D8]_*_(HYX!QZ0LOAOYL]G8%#03Y,L#OUD
M"J^4O?FR,T`?7MUY\,59[UJTJUOQN%OQ;@.WPD+,QC9V!30MFR\@(0G_!@CI
M.HX2).5H),0XP6OPLMFO6_-5X+L!7#&Z.W0KDB3SPA$-0\*?VVZK#_\[;9E7
MDBE<._K6B"W:!,6RO#E`XEZ0."^[]>:I`U?*H:?K=&#<86%#MP)N<"S&V0@V
M.[QS//C!GPVS.!%T3]*(+QRN]JKYVFSB9;/>+C_%M__X]O7$M9S82SW>"7XH
MFDQ$C/<-+V:BF0JLA2>F&GOSZ28E!3?Z\!W_!IYSYH$WHLW1F491")M/>?>\
M5?C.)(/[[<.W1][<3XD)A6GL#S-D9VHAA2SD!:]:]MG:O3;>?=RK9#T)L*M1
M%L?,@X9BZ@5X#CRL1MV=\&)'A,@_5'3%?+--16B-7MW!,D(-?]@*?L*;I"*F
M\\"'$N&,`%370J+G9;-;!FM8]66GWCMU)&3+.%6I4V,MQO6WDRRI77O>_,U[
M<2."B-CF9>I=BP_`MV-`1B+^*4(1>\%[/QD%49(!45X!GWD7`#7^`S_Z-Z5"
MT*]`D;B^!MA\B0")M9IYXIT`KK?B&;T1O<[7B:UZ?F/Z.4=BND1(O/-`5EQX
M=[AELR6B`?CAFYC\_<6_O+#6K*%WY$_`5:W-_W[Q#ZGXO/]Z?O4_%Q^<:3H+
MG(O?W_WVZ=QY43LY^:-]?G+R_NJ]\Y]?KS[_YC3K#8?DI(_[\(*3DP]?7C@O
MIFDZ?W-R<GM[6[]MUZ/X^N3JV\D/_%837Y;_K*76F_5Q.GY1U*]6`:?9<FK.
MAB!36+;HE4/Q9"MQ1?GT:.,(7ASB/YJMNB7D5OZ++!"'CN'8)V7Z'6K"7W$+
MRH[7*SM=W@79^>7II_7Q'W*B'5[]BRR&FP[W_5*S=-M)R8?RC1+`/CU;T$Q`
MQ$>W"?$?8"HW?D+?/KL\-S#K-P=2.,2"F@0EBM,X,^$AU6B5"!6@ZY!H4LH7
M`V')"5G+"P)F.K4AH6+.).5XMUX,7&WFC06>3\SF070G1.*"B1W6U(_.F!(Z
MHAA^CZO"Q4RR(,5\7!?Y;)"A+J+?EO(M8KC5)6Q*]\:[019/H@XC#6.4&1//
MCU$)R`0=722`*I(Y<+=0?XW')'.U;FJ!$L"P`$T_49#Z7U0600\V6XAN!(L#
M`C;<;]B_B&]\^#R(8S\:W\^G=T2A'R,603EP,Q3YE(@G'[1&ACG2@3P9@@/V
M$+,4ME$-"$WS>A%#+2G'WQ)T2+HEKB41XEQ%<W_D=!O=6K?A`D^TR(NWSCO'
MJP':_#B";:7.#6#>\6<S,?8!_6!99'/U(!W=(VU(&0'E>,5O('DR-I6>EN'Y
M@SO\0X%<S]@B`@"1/N'!/9SX(1S0![TD%O,HMC\'@A75B4@MP_`CTI5+)>J`
M>'M0PPE&&2M068(?PN??@8[TO78YFD8!LA5ZO`:?1IW>F45C$;A(Q&3UT,'A
M)DM>8'_&7!MU3-5=S%;P<EHHWF=\$(E@Y"73/)ZM6S/.8K6,//HM*#:P)<<;
M_Y4E1')$"O!4<`>WWD>2T+N:<4\MO;DBN:91G@[QN$DV_`OX#OY-AB=]XA0$
M@4F6PND9W-X,+5IU9OY+.<'2GIEEY<!EX,E$"Y_S`_I:_G8AP4VR`"@1\2WV
MESEH`T)=98`G*<1ABM?H`92'X!\+T"%G?BA*R`QE"ZKNN5M<=X`[Y9&<D*TD
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M.(S^`QAK%"((?+"RG%=H*"0E4:1C)/I.O=]T:LYIO;5>>=KAG;`'QVLNS<D_
M1$ZMZ77LW_AC=!S=^2(8_QP$VSA6+KS\8%M*P7E>!Q'ZAFZ+*D;>LU/TT5DN
M0&+)ZSMOZ+"8)/*R41^<TJ]?=NKMIHEXNP[H[WB-@.6C^_"^R[-#J)7Y5(5B
M`3GG*OK1;+W-<EB1.Q>C'W0B<FN3X]@\BZXU?`3=IC*VX\7L8*(-^"*IDX=/
M&'$Y$3F?&'K:M)==.N'(3\9Q%[UJXL-#_L2'W\U$.B6W=H2LC)UUY"M?B*K4
MF@U7QJDD^7!8BT+W'J<)H==PE2M:45@T8>^>""5EZ5""5GZE%U]]<1)EL7R6
M`ERA?A+^F/@_^&_K`"CO=BX#S[(3\>YYC3SKMQ$-#U-6DT*X^>[$0^?VU.-8
MQC^]0(2>,_60^#!X,?=\H"?TR:N/)W1SYG!3V(U+ST9D_89JK;E'08W">WYH
MN<9YQV@]UQ:M9_*A,N5@Z(.#<GAUO2")[!-@OI<'I(H1E&D4IS4"3>Y;$O[*
M!8W;-:$\+^003A@"7"G$`(M.A$_.>]H)G*;9_87V4A(N0)^S%;8:+'T0@(4Q
M&KC+0!XZ=`IP*ZZG'-,ZW)G?/L4..-KDH#N7,P%,+(R)0M*)^38'#8+HEN)1
M\M0V&,;Y+],_`/_$`3B\=-\2#&Q:9PH<72YD%CD$=BK#6BJ6-P<.](-V#W3^
M$M-[J$17B@ZWW1NHC!]BM3*NG8OYV'&&!\BJHB0ZHQ#F\A<I!`60)_$&FVRV
MU,ZRT(J?Y;9&&8XFCXK.'F5IDL(F\$(I*J98J&^)%R#GH2@&L^G;42A,"*R<
MUU(D&`/U*D>*8J3>HAI@0J7M>EMQTK5)R$HESD=52@GJ_JA*&6V6!F@V2YM?
M0^<+`"B/]`Z'H5J-QBE%<S&QEB7U/(`;EV1@6B<)R??0"82'19-3?^XZ5P#/
M/Z(HF+CF8Q?3^OLZD1LHK8Q+E&H7^`L\@NN<3WTQ<3[\$*,,R='Y.IF`1A$3
MK7H@JZDC`&IJ\-J[R(L)9^\-^SI3$5F50W<I4(D@&CR[!MY/[%!E"[^/K;P>
MVJP.#TN"XM.7/*<3*.'80(E.`-(/H#'3F293H&(,G`(W1B+#V#`F"=R@T*,(
MKT=2^U7/RNL#10JT@,0+/&"&KUXV!WVWVVB\=I<\F6``6@0JWP$@H90&&:6$
M_^`V[(N6A1S'E4DJ*M?'HSM?AGZ%^E`+,,J.Q!/\%4DI6W;[+D<^RFA`GW,V
MOO&3"([$&'MU>?;N-3$K*VF0>=8K_)KZ3*OQ]@M0ZD7$.6CZU\VWK^O.IU"+
M)+DY0YO+\)Y/]?#PU\1@X`X)B7:ANO%)CJ!RB9#*%HA@(<G[<:"5E(J\$6G[
MC?/*MS#MV7D<MU$^$53J@W"9"=%\L?C4KSBBOV3=9A.H"L[VRK?7"OU0@"+^
MZK1A_7+LW256"-I*%<%_VNHAX-6\IJ%.D'GU40SC#,BZN(^VM1+FZV28(NS%
M@0^PH,PH+UGQ;=!Q[E`^<+">,_^S&!.44P56_%.R>H=&^2^YZ*QRILZ-'TGI
MI9)'4+ZEG(J63\=:N1)GS^C8_ECJ?9KP7MU.!<I7AS3U=-7',&,DY?P.1\"E
M!.7:8_W:048/M^1+E*)AH6\_TKW>ZRK920G-GT)T*R`;O@!>7[@]J!RK*X0K
MKKX>=K$$Y>"I:T*`4%<%#..`4Z'],!,JR4B9X4CA\F]4"Q$%*C_&Y'SPCS;;
M8)4VC5)+<\5;G5.!6)?I=8W&U3RE#.L#L=)92AEOQ<1/L+)EK803L&F%;3WD
M)#(!8YE0;G,+P$+&D)7$!)P+0#U#X2?U52F@&"G>-=#/M4Y_+&1,Z2MB?]XR
MS^@Y.QD,KF>*[@=.XL&-JPPRS)>*4U(?,;6J+$]J2?9</9_$JYZV]-%<<8"?
MV/9C7J5O<<K^NLE`4NUJ-O>6Z.ZW$]!)H7$,SP[<OFSW?6^M")=]8/JF-,YU
MW0D[9U16W-K,RZ3M]MQFK^TVV_V%75BD:^M,N9T5[6VU'4`]:<1(=TVW=7KJ
M]IN+*WCH02"?%IY))NZI##*Z$V,09'Z2@NX2Q8I#TX=U2AH+1$8-"(M0ZV5\
M0U@DPIZU-H/KU9U_YP@[69*32/)(Y0NJNV"24*W$3U5))Y4!SWBH]-VYTCZC
MA$U^N#\^NCZS,!!)H8*.Y=\8,[&E+D0VO7&1D9J3SYNF)6PZP"O/'"$+9?:=
MA'PN*SR7FJ>35=&-$_MD=G(ID,P61Y3B1`U-@P\Q#I_?OZ!U->:@7("7S6!E
MRFLVCKS$NC7H8_%OI!MVF5:0X\1(E%7JH8J"/#[UL+]N5M^RK,#^)E,/-_?0
MLNWV]F>[/U$Z))`VW),0^<1.DP!U<R/5<$OJ_G2.?4N7/'9DJ(PK&Q]G[!*U
M?Z5&%%B./(SS[0QE58JH\=D:-;58C<BU>/_RPKS;A97SDG24?<G5>!(\-I--
ML9$^G-U!RVVW3]?:Q[+^/KL'R3XB^>6.<=NM-WL'@-9#S"S[)UNB%7?:+@6?
MMGINOS<X`"*N4/SHO-K!T]I`[IY)'8X:IC3DBG%MF:I?==L8$M\Y8;^N.-<6
M.5?_:9-J=L^Y]I5/?>0,NHI/;9U/-5LMM]/?O02N&-565:Q#9U2E*8S+U2Q[
MPP_U_S_ZI45>*;VCU/>KW#6Z*G*T/\L^+QQW_-)Q:/KW.ER7YD-4+M=MLV.W
MW<:\CD/PS55(?KSO=??6WW$:!Y7O]9DB0VVP#?;!B5&QJ:TAN5EO[=[VJ[RO
M%>O:*%5;>NX!$'>%YI\"S8>H:E5^V&?SP[J=TQ;\;_=Y.)4G=IN>V#U`<.6)
MK3RQ!_'2<6C]C_?$EEAFE=3=)#LV%7;[SY,K)#_6CU5OM`\`OT<M<]L@_,91
MAI4,SRIT-[3N'LC"_9"Z^RIC/Y@"XBK:N6?LUVUVN^YI%48X9B1WZZW6`>"W
MDK&5C-V+EX[#LGV\U*TLVZWG&/7Z[:ITZKB1W*YW#D&KJJ1N)77WXJ4B(>J?
M#WX\0"QFGA]R#S#3$IVZJEOML^Q>8=@KRFJ[Y<A>YRO:,&.KN'Y]T)==KO`#
M_7JWQS\6^P]N;9<K+'FYPW8WM\/&:?D.[]-`=HA>TXO.!S#Y8>*/D,;E[(>2
M;M3>/1WN3/]('R<]R,Z1[7Y9Y\C<!@@:)9NP<?*D3;0[]^YA87T_-ZLW-ZEZ
M3LTT;[!3/#;_%=B'3S51IH$!041-UTHGWSYH+*]IP(LM9@A.BP.,]>CB@R4V
MB5O=]4[U.-7WK=`\LMDCA!(*8P8+M4@,HY7?VM_FD?@B#8[_H,9U<-=D/7$>
MNS;2=NDIQS)_S!6X*C:DG<J1V+G!['34N?HN]5)\I3[7:KS%SG[ZQ^;;UVK$
M!\^M-X,RJ',HHG*8X="(.?X"IS4P>0+=TP0*8(G(B8$MVL.<19P"AX:;`1C-
M9HDKV]K3Y`GLDZHV9[IA8B_%?-_)D.=3)&+FUWB&A'E/]T*TSDFC6+"5_G]I
MC`>W'![H#>>OJ1Y+0^OXZ51V0YWX<9)B*^+`PT:\GFX/F-L&M7N4LU%HD@<L
M2_,?ZLY7.(?LG6BZ)F,[5>P'7NS5G&^C?"U"D&\X>AK;G,_5P&WL:XUM+('&
M1_X\D*T=:?,E0Q'HU+)M*T.(=H.8!(P0M5BT@)O'GL961V>+-'A(BSPTK!X+
M#X<*R*;#8:::TY?V^M3]2]4L%(*LA"AAEEIGIM,XRJZGR_HV=34ZN>6M2!+5
M--RS$HQ:7=F95S:[E'OEV3N*DN`@P-+CQ(LU5KUQI&>XX,]X"9WA'76X!RQC
MDS+G5?,7NV>W;`-._94-^3+-IMB=M*AWO!J^MD_5:-A;M7I(/[R];`O^U.SW
MG%4]9;TLG4;8")-A09WCR_&D^\P2Q=2=W_7/)53B(E27X*S%.S4#5`K8*>Q+
M+AS)B[,X44:V+FT.W$&KHSZ2WZTFH^7@JQL=?(^EPS?3DI7EP^\ACL$Q@L%V
MBUDS`:B%KYHI4LI@;=+(MS;'!KK48I:@8#>%I1UDM`-;@GR[_#TG0*Q1!/AH
MKM_TW!M]!YV][GS`*PAO.K[IORL[ZBYJ43EE3+6,I[=,7U_XCFX13,]ZLE'N
M\$[]PTO\_56:`'N%L30V4C2()*O!Z]YJN/W6@%[HM-UNIXGP+#69\/?Z$WYA
M(;A4XQPO6::=OVQU>U:'>)Y[<_^\'.M$<I1$JK:$*\NA$;`K'!>R`CU_.\F2
MVK7GS=^\]Q/4N+-8?)W8_<F_<2_R\RA)DTND]'=(-Q<\D22Y`F2]"X"$_X$'
M_)LRSNE78*)?7\,NOD1`6[6:>8*;)2Y_1FWI@]1[+D1,*^O%2-3"#]_$Y.\O
M@$/6FC4$RI\`KUJ;__WB'])9\/[K^=7_7'QPINDL<"Y^?_?;IW/G1>WDY(_V
M^<G)^ZOWSG]^O?K\F].L-YPK0&8B&>K)R8<O+YP7TS2=OSDYN;V]K=^VZU%\
M?7+U[>0'?JN)+\M_UE+KS?HX';]8WB-R\=C-ME-S[CUSX8-E%ZK96M[V^"E<
M<XC_:+8M.;KZ7U^`Q_P6)8D#AW#H%$R`0TU]^\<I<FH_:X1J*!Z.)*6[06^G
MH(5BFW%A=&DZ(:#6HT%!).A)J_MX=OD.)_XY5]$<[GRKU[#U0GUB-EDDWNG#
M!+.ZQ?\MHP6N'WQKQ3Y8.&1D;]_Q]#IDY?H-+V5[@[03'EV@A=8T"G#8$KZ8
MEGF%C#YJKYGS`]6=]WY`JZ^[1P+$\^R3IHK<1EDP!C9Y@_Z&@C)I3>>4(W)H
M"*'ZG5&XBU]6K>#G$8T1!&DR1C"@?V,YJ.CD%_J-_(/`XT"TII;R3ZLC-/3P
M0^W9T.JQ]O#@1#POEE,`WHF1!X8AGP$;\:M9+?,EBS.,P)R$]_V:/HH^I>SW
M+Z<H8H?]\3I8)RO/F^$$'CK[<#4Q[ZU>D6N)K]KA"^88<N;F,LB*'S0'86Q&
M#R@'&:.$CK8<B$.#25#H#"[+$5;UTL\+WT?UTN\^L9?^NKWXG_FA`]CNH](;
MGS,:O87V[;W=MF\O-3E6:6];!=G/2``[[M^O,WYV@>^?'/"-O;EH2\+M/\7X
M@Q(7GVU[W*=1[<L-.=1,J:K0ZR=`\B'U57N4$K)C)O:'-/TK+K:K9DT=M]EJ
MN+W.(=1:5%A^Y$9:;K-Q*$@^ZM3>JE'$/AUHW^"XDO0/QC"YPB!U);>WS-$;
M;FO0=OO]0^C]4V'YT39FIXU(/H22JZ.6VU5)SIZ=:.\@N:9G<G4AD+-XA-R5
M>;MF%DWIH4P.U=+DG6UD1WT*P9X75]X/D[EUK`E2'2M!:M6QU\B16A'-?C0+
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M:'Y6@V-K?.R]F`C@8?L^UK'R]U7^OLK?MS><NN]VVX<P+;Q"\*,KZ`;=@Y^5
M5GG]*I*VJZD&%<\Z9@0WL;;B`!!<>?H.SD-5P?%G]_2-#\-./GPFWG#;O4,H
M>*XP_/@.+`??F.-P_'O_]H*,FS_2>`AL+UJQL.T2^*L]X6&O*]:U:<SN!^]:
MBMC*LC@XC;B"X]Y;%EMS^[%EL5C:>*0"NLIG/6;[HL)NY0,\\F81%23WJNW&
M4JF]L[X%.%A!.0I)H'L)S6VH6A5LNU5!_XFM"GK[4_N_SG;7'1KQ#`\]2O$^
M\%+IJE5!U:H@W(>*^:I50=6JH%QU^AE:%>`DP&@N8H^FB=)$JY$7QW>3*+[U
MXG%RGUZU+S?DP"SMYL#M#W;O!=]+'G78B&V[[=:A-RW=5V9U!>;@".Q"/_TI
MF-3>Q.S:+FSB`&BZ0O"CTSX;O4/(ZSV.?!*>:<_3W>TQ\14;VW;6U&#0/0`J
MKQ#\R(UTW4&O<P`(/D3=ZVLZ%7'%H;8LAT\/H?BB0N^C$[,/G3L=CI+UFS\"
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MX]H[ZQ@K_T7%D6L^NS/ZJ1"Y%B(;>X_(XPC\?`IK\S@:B21Q8I$(+QY-'5#0
M0*N[$4$TG\%"8/#"=[/A7V*4.FGD3+(T0]5N%L6I_[\<-9I$,>E_\RR>1XDX
MU@#XKET57;=Q$",:*KP^&J(/^E?EM-H#5\MQ!D4J./Z\P:62O#;EV+FK)'LE
MV2N\5L&EPY/3QQH2J2"Y+5FM?WY(BTIG\0BY*_/VOHZ5]Y^IK/EE:3O(S3>_
MG,?1C9](DY\V9'I9PYMC?P)*0^),X'4GS3V/D:,L!75B>.=X\WEPA[5N^,B$
MYW?"=KPT2Z/XSHF]5*"G`<-+U.)I*&`UD5^J:JZYS>::IU5SS1UM]V<,,.P\
M\E0UU]P',MA]C\>JN6;57+-<Z?L9FFM^^#$7(U31E$IFS2D9BE!,_"K#>%O%
M0.YI8_>]GHZP%FCGF.VXC?[NFTL\L0)H7SG6ERBL_3>#O4Q\8%L)-:JK6M0]
M*]]J#DX/@;HK%#\6Q4VWM1<#$'^2C)P/DPDFVH!!.IIZX35ZO7!K57GV\Y+]
MP.UV=U^X6_&UK2%X/^:Z'J=:]LG8C=S__%@3`O>&FE^U]J#C>:6&;;65Q.[%
MT4^CA%VF&(+,QQLGJ8@K=O9L1D?SM'\(]%ZA^+$H/CW=?4O.(W6+5<W/J]2^
MBD]M!LV=QB'DY:Y4NPX]<_,X*P,J.&Z_PN(1%L?C<+5GW'/74<]*-E;8W1?L
M'K5H/-94_`J2>U74L-2.75K%L/G2@_-H-O?".V?J)>B9RZ@V,5R8!RUD]0$\
M(N88,ZT[9VEY<J^#&9\N%2&8CX_IK.,(=I/Z(YT*ATT1$O(*+BZ9G^Z*H5MO
M/H^C'_X,G@_NG)>=9KUG5H;C!A3+O?'\@("?1DZ,4W^$:JZ0>C_H#^R!=)W;
MJ3^:.N+'W,?."RD06>Q'6>*,80$LCP#8A[@;/\0SM>%(<91=3^&'=K/NV-#S
M@B3"4Y8<3#6`(``4FT"D2V;9EIRVY0(1X__H(R^;[H!_='$%S##TX;-W[CWG
MS_<2@P\]"`:M(@P6I</]-37/0-B_PV?B?*4,@11_\PE3<4-`T3?`0Y@A#L=`
M"R,1IQX<,LF&@+<P]>$)3A7`>V%3LY;3_;?PT=M0Q,G4GSLS[PXQD04I/N\!
MH&=^2ND%!(V(O^'-HBQ,59>WE02/V%G:/:24:!B7HR@+QH`Y)TL!T?\+U]D+
MP\P+@(B`(J+))(&52V\$K<)^^;EWAW_86PR_H[FI>-U#:M*;)`06O#9!8-T!
M<>/#>B,Z89!AL9#K##/NOD(8PDKL:"EZU2,&45,_H6HJP+&?`LJB6!`LAEGB
MA]CP!6$8>*/ON!>@O@D0`==XNTX62BJCVR?I$0`_$_$(Z>U&E8/CW_#KJ1A-
M0["TKN^8G_JP0\YBN8YN@(KIS+&XS@*9QQ)B2S8O2*<C[!,88X$7\FRX[A[R
MA\2E1R)T9#JQGWP'^,(31!L`Q0AV@:>]]=.I,_0CLSRE_WFACU_(,_:$3C^*
M"+P(S"DP$:!,/W%F6%T6^-^1?<&O0P(Z_1T^D:S!\G&O,C0$>P*\X@>&>"Y/
M$?;8Q9(U3]X\^,%I-AJ_F"I[*]>Z)-V'I-Y0B!#>'Z'R`)^\!OPD:HL\>&9O
M;T%.!(VC.2)/,;)%SH?+^/C:V>6YT^\TN`R'?N,(RH\"$G'^Y0&SB.^,8"6)
MWN@K[A*`@)@@_1([&XV0GR'^5.6B(7*^)':T#Z%\'1+JX$\3/P0D^+)(4<RH
M_R5SO?]F((Z2`LU[W`PI2GS"(EQ;H@7[DU3Y6/99?\*4I]]>1I^PSE#@>9(L
MP5-P:25^%Q;'WWM9.HUBN*2L`1#8-9.?+`"Y)HLP&,QC?TRK3+T;Y+9W$NY*
M.I2Q(',<O?<HEO1.J)57"!!]"'1*6YGX`8E5?3=C`>(HU)+V]_IEW1"@U*E<
MYS-<1V\TS>!.2DKY"LP/`/)7!LQL[(\D%.QK`7BVNFSA6N('[#ADB'&++7B<
M*!S_>@?RECX]%'=1.,Y_;!SA&8D)!3Y(8WP5:(AXTY`1BNI:7%`>@'_)JV%1
MJTW+@,<;J;"$`':GV;+T6@#RM'`H9%NX#:VPTTE1L0'U&LEC+D##02E3!WV'
MOHO*CN&^-GA8?-+]*?D`ZH0)HFD>P=_U'2/U@63!G3X^L(8DX9SQXE6DX]NW
M/'&N1:@U96\,&`'!&I.40FU4A,DJY>-O)UE2N_:\^1M.BKKR?KSWDQ'($-C6
M%8#P71"-OO\#E_V;LLCH5V"775_#!K^`<`/#S#S!%4?+GS'K@79X[8-N<4:R
MH619E(9X>[Z)R=]?`#NM-6MH$OT)UE*MS?]^\0]I*[[_>G[U/Q<?G&DZ"YR+
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MUVD/H-\ABT:>/0^`X61SU-_0,@9U3JT#/^%P7WH2P/]=D$*"'1&4<HP:.ZP8
MCNZ((2H=R4#$+7)%M3Y(#3K]S/LNEAV?-P4\,\9"3UA'V7>)%XC]ELK$:D'!
MSF)AG3E3]C.JP'&,@BR''"7DZ`2P&Q^L++8P_9721I)`HC$V`J+RV=4P0A%H
MM"T41D$`8CM#S2=&)0<`S\2L=XC?3#(TC\TFV<21^\A"J=]9&])4S=)_!GJ4
M#[2E]E3<21$$MX(L*]!#C)Q+/!20`))HS(0$_!,H#]T_H`;$U^2+D5+-V.=:
M59`&J-'I6)FT]#J@66QU@3^Y99OB>WOMLTIBX`WL&50KJ2UG(1C%*0I=5'A%
M3%J0R-W+_(52'K);VC%93;G/PS>]FPA46K@<JN\(RC[X-WY,W9*WSC2ZA47B
MA4NFT0-?&@FX2^PEM#;D:R-Y#H;&&+&-;54G&9FLHREJ88"Q`-2'$4(2W8NP
MDX@T/K1X]_;VO0>=5<*,=$ZXAD!0RSRJC;Y+&U[@\JRW1>1P8FFFF1IS^?,(
M<'<YI\5^]>(AD/QO'OQ?9HJOE*W1:KP]O_SU-_UC\^UKNAX)>@=`X?3C.1#[
MMR]G+JJ'UEO)%'YIO<8,FPG'WNW<`T)YV34N3-HG>5^(MTJ/E+Z=Y?(&62TK
MDYH0<O1"+@/M45&-=-D50[>[Q&^;@^,DRE#<C`(0K#=B$:AL=WAHV")+H8'R
M6@DJPIYLF1"^$R?2JY,W83Z+,9'MY6@:14$.&;]__GRY@`P-50)!#K(C+YGB
M`B\[W;8&L9\D&1RLTVNYS6;+28`7L>.)75<SL"UD>2<Z1]".2)V7K7K;D<YT
MPO7+;AT^!\R(WZ\['U$@PR&0&GS-RB46F"D"%P@%F6,&$`J4U\"W9,<BI#AF
M"F`)):A66IQSMJ@;"*Q*I;._;+D]IB5&Z#W80(.)<.:38Q>9'_,Z>("N'Z.5
M?"9CZ7A@NYX[)EU'Z$'39TB88;$205#0KC*?^C4E2H8`0!&3=>=AU[T80!FA
MMPK$(8=1$F2FK/X@(O6F"-2\W.]SJ9,E_C7Y[R5G/P?V%/O#C(ZF]5Y4X"[%
M/"WLI=51>T$LR"_$8@:GQD_B2M;B`&(R-%1_R\CY]A^?7<JX,*"ZC$5YJ';D
M'2WZ<H;L+,E_E2``7]Y;Q@ZR^NLHC0"2S+<?P;/?PT6;>2.\@&#?UIU7(4A>
MI?8#N<>SR/GH)^C%O1SY2/@3?T3GQL=?N]@Q/,F\D'P>BZPX&DJ`PY589'5%
MTD[@UJ$+G8C><\(,B82H`36;E`QYXT@IT2;*O%KQ#_BV%NO`E3]F,3I3%MS+
M9K-$?)AFX6BK1FBM2+*%_(9=H\BRBH;W'GXK6013W#)P,N2EFY^49"#Y.3`!
ME#+S.6Q`NI"TQ]@&!WGBB;9'`H!+H)8,A>T9ACI*!?R9/?*)ST`))_YUIG6_
M,V358,&-I3HH0>WKB[^H&9!$@!6S>6T2(PU/!-W?E\U2^0O\58E?K4F5<-_5
M!B#9.KB(.L7,>+?6E0UC*^*QJ/3FR$+OG@Z_Y@E\CA=I$6.B<=D<`5$(LBX<
M%AX4/J&J46]U?T'IV*C#?W-6<("')7]UJ#>U>>!\X8/S":15(BV,L0Q8\R&0
M@0,9!IX.=1G*V6<>JN41J;^G*]GHA;R6(<O'*Q.W.DM0`!(W.LOSV+/QC1^'
MGNO\]MMY3O.2?["5+XPKG6/&HS>.=$Q0-V^6P3'\;VV"[&Q!E.4=^E$,ZJES
M#K;+Q.8W7R?P?T5<=RXLYDV!!^1:VJ>B3N&J$Z";!<ZX$,CDP)R*!FD(653$
M[#2QJ0.LVAG>'K"N9M&8G;GS*+@+LU$@0`E"Y>@5!9,,P+[15W+*JI;Z$C)*
MYX,5]*X=-N*05]7@^EGB!]_DCW(H'=,;>"OP?X+Q(Y2I91QR;.[,RZ:\^4J2
M<=3<06T'8$?A0F"CB98I?F*004HH1@+(,:]-?1U55-]<9[>-O;V5M+[E@"3B
M1.7,X\@+.[YG<Z8F?05*-4Z$_:48`2+)^P@T/P*V;OEBW7N54E0O\XP@+"I2
MBM@6]*$W)AUK'3B;3,9-MC1]1&]2J[-IL0%JL4&J;,*)\?!B[N72#J4+%/+X
MU%RU_"\O<LG@*F&6CK.1?-E6[TD;VM1Y[7.MJEC;V/G+V#]>"=17Q0^?'6'K
M\OUD7&.5W'K*)^N`VZ4@`X./YP29N6M2A]0["F7`@!BH9JP%3LI**)J6-3RG
M\[(ME=,%Q8T=[";N2'X-^HQD0A,_3E)U5KKXB(`Q1B3]F73H*H&AP;4*-&_O
M90WWY8&NRO*LN$G%3?:-FR#G4(%\*_9%]]ISFK]H8\A2X9`IH#)E0HRQS*G4
M9B\H`?QEN),R3]6:=F9>-!%#OIQR"6G<51>UNJC51347%1T@VHV.N:8YNTI9
M4L;Y=8_,PWM,EA59F1F\&F4I.IRD<%5_F6:P&\IY\N8"%/I1HDWNL>]=AQ'F
M]L.5Q,]O[EH^P^B'ZEY6]W)3]]*X52GZ9EU-U^BQZ#$*A(I-DG]Z#C0;32:V
M0>U:$;NB\IV+WE%<C-SSN9H1]%!.=+B0W2UC/Z!Y(;DOY[\&W"*;6?%\"E]B
MRFQ(WU!)]L@C4H_]XI>@7\/7SIR+6&5>7^*W[G=E/$4\[\#[\8E<M']E8<%'
MZXU`95+IN1/G;$Y<,N^T)+C:@0QVJ4=#($$92Z`L9^6S6P@.<:[[C/Q'+M=C
M72U$F*_$#WCJ<]UY7W?.4`(DL*5SM)9BYYS<)700V^/Y^?W9^?F"_PX__:L(
MXSO\V+]`RN"'/J)_TPY#"*1N_+J*^'Q&GZB';V%PVP^%BF%9"_[ZKX^YY3A$
M11(ML2)2MU$<C&]1#DEPD;,7DX.5(,M9=A_Z76>.U6E8ST,%6#).2F_@+W#>
M#5QW^;:17F5A'?WIF4BGD1*-:BVY#A<?W'@C/&C=,75'EL_6"M0XMYBWDU>P
M[>2'<I>CCC\0_F\%%K@D&XC4**>HDN8F`\J$)/3(H<4@!&47%[R!0O6Z-PD;
M92`1!B+V!9EE9,7?D2.O'!08Q&HU9.`_%R`BWDJI'^%(8>F"7(IMX*D^YH_?
MRE1M6H*S^A9<#;D%MN:'?2LU!?N1)T=,_I4!?U_,'2C$2K#`C0*D6`05UA;B
MO^RZR;M1X;[*.XH2+L$B4"Z;F7EC82ZLRU?8\CN9>TO9>(GVV%AWE<->LZ',
MR9<K8BXE_#E\!$#,'(PDL_"%#"<6UXQ'^9<<@C=,S2H(RVJ`NHXZ$EM*Q*MO
M@TQ$7;P1TG'VZF6KJT,8E*'#:'AM,004TYH3Z!Q5Z_;8B5-[&XFPXX.TET6R
MUPRK3(I(!K>0+@8L&$0<>D6==SZK-A=QE`HXRH?VJ?/JX[N+US+0+\:*[Y.;
M).8,TUA01097'#K7=Z$8$:]$1DU)/'$B,U:QYL,#OL15>R#3(Q`TE`X*=RJ,
M1EX,B@9H<C)C#5;6ZV&421V/5;N5JH#S?HDB0"MO4,3C'G5%G;)//X'^"'8A
M:SAPNB^`T?=Q=FVRN&6@B*3TQRCBN!P]<F;5A7`J%N];R3Z68`@TRI&%9=),
M+O--W/BPTKO(B\=F*5+0,>=/%?W)Y`Q,;45DHRZ,FCM73"H!TI1KJ)T*U-HF
M1',[X1D<A].9+\%=_B.@VDLAA[]%WNT1J^=22E2G7?P9-'5$-%J^JA`BOZQ*
M;LYF,G<DSUM,ZHWCPTW$9WAT8(ULA9+T[0<QNQ)&)S/_>!^<X]#B:GC)`&6A
M_IJ%0_>6LFRC?N@;QUPN@&3NKJS8Z?'7$?6L.J('0&'G]42]M>N)Y*D<.I9C
MGVO_ZXI4KJ:=%J/R_\&"Z39^J6&O@Z=DME`V\?GE5Y=L(%UW)!.9='Z<I7MB
M3D4A*52FD9OKWA@02\JGR'%ML,XZF8I[K$IE:BO3VW*.$G_I=W.I(2J/V&91
MO)E359EBY225YR,Q$R]/5\BI[+ZEZ_`2KQ*,GJ(8PYME56IW7^^MQO85%`LQ
MC/.EY:V>NSQ'5A87`00L4D(()5BXP(+=JMPK9B5=GKTS"YGG\FE=!'5*^9>Y
MU)R_%2?4WH9D-H:FM6P'[<YVVBU9PV4!J8+3\I.<H\<3WZB>FWN'X&-4B4XE
MZ!.D4%E(9COO2GN/6`ZXA+UMQ=2QI1N$,WSV;$RTRS!AI6V5GLB3'D-Y<XVF
M0^74%X%'-W&N<GNZ+7?0MDJ;E]<C%&U[]6&"Q=)#V5LG0Y_V_\Q;1]`NI?2!
M"U9Z:%W9+F<W$IO(_X73G!I,HIZIOT`J!&LEP2HMX%H$$>W_)8\M"%`RP?'/
ME'.*]H;>&WFOLB%P/%DKJ7Z)97C46H2`EH4!=3-1$#,%8_C+<A307H$JG6O4
MXF/AH3GQRD-_T@13N%\[DG_J`K(UOPFF$_H.K$^1WPK,LM?`(0@$LCL%XBK$
M^#)EDROL2L^BBF^3UT)"2QX/"&YYLGH.O3Z7WC,(L0A-]YJQX)A8.8O>,$+7
M"-(),RV<BNN#[9%&<6+3*2G;%E$FA3U2+;Y)=TFP`C%3-2%#^O1,<.TKM]4G
MQ!-:53[F,BI2UT,MK"`U%HPBSBDFM$X\Z@ZS7`L8JD..U2&!F6*\0'Y;,97Y
M>KR*E`6.7:`A:?*L<_2J*Y2YLX:I\`$SC^I[V(J&S<=<ZT07(P=LM:\Q)Y=2
MWK1,H&Y8_&$)F6JS2-T73`_-=_!2G;LZE&6N:BN!IM$^GI'F:!S,[["'4`T+
MP\A92WNL(:[()1V-!3F!27"HP$XRRJB/`Q&<W#&5_X"\T2`R#5OF$1"P:@-F
M:(^=0_:X/SA2E`+-"^3*LLV/M`WQ<T0!U`&FK/&*G?F:W)OZ6@*U;J]'X,+<
M>YU6:V6S,P?4CD<FY*1PDS!?7B,ZA\M<5;R0N66&"I8D[3J+.<9[JG?EW03V
MG?.<0*3D!=)$/!3I+3I&<E$K]$[9A#TFV'LZ@G`&5!E8\&C8FL0RA>PW6MK6
MQER.+S+?SFOS*D0JXAM?UB%1EA)NQU@DFDO>=U>3<B7'\F?D&<,R76F)TL`2
MN4SGL!4*4`@ZS=YZNM#O!R*+75N&F&MY'Z^7M,!"QW!Z]FI2DBA)LP*=M4Y=
MXP"B5Y>Q?A/$RHF,>SI8&MZ?*L$A]:4E\F,=$6%H8[F8Z)HFC]W3L@Z/SR(X
MI.=OAFY>JEO2<F3#,D2+I0W*$0MYB_!M,E09PKV&$BZJ*6@>UGE1LRA6]I3K
MO]<Z3"O/['2M[54<W?V3^CI<G$N&BHQ')7Z-HGB./0*H707(W*#N7'HA(`',
ME+KS*URW!`!_+3^.[0$P-2Q?\`D<G;D`V%HB]`&!@7=[![1%;,3>P%H.VP?X
M#+?AN+W`3-4H/`O'-`?F(DI2;*T1$WV^XSGN/X$7MV]Y<1\+DIV[=/MKNW0_
MS.9!=">`K?)Q6,COO3?WR@X'S>&21.3RZ#2:K[Z_=@R2G,2[`4:1.',\5M&%
MAF>U_65U\FP#PY\S3Y=&`($$^:S5>5AGG'%MAY!@Q!ZU$5FIC@C\:U\64,I\
M&.+T=><#_26PW\*^0]33$STA46QIA2"6$R]`*64I)*`1+K3YO63MT6J76N@%
M@FM0,@X(BM$4V>?(*ETC-7`HIEXP40EP<P4,65J,L&`(T^D9+%QQS'7&EC7]
M0/NYN$]R_M)F+:W5=/M!<'#O6;+V%\_BA[IRF,!6W-?B'ER[C2+*Y8SZQY@N
MQ]C-2P%.YU71'FJE>W"QMP])"33PK8][I/V14U-Z.-YROJ&R#*QS>-RT&O_,
M]\%V%!0:0:*G?IQ86"(,N5IUR>D@:9PEJ8O;0=>:/[F3:M$E%V<GEI^.OX5?
MZ3::ML^VM-.TDZ`FX:6%@P#<#;5+)7EAE[)A)FA`B*I7#+_72)AT?0O@1=A0
M^PS9XQF=N'H)U-\"$L3CV+L-C8J\L*C:[X)S%1M>RN^.!;6`47TNE^#Y=BHS
MAA@Q!&)AZYOYM7E))D!YWV5.B[YV+O5]2=)$9;F+5,?7K8_Q+;SC[$K3OX+?
MY:0&I<]=160D+/8;0$B2WU`V^2SA$/75-:5&DWFLW-R&6G.IT\$^8`)+<JQZ
MR\#26Y:>>>>*R6!MQ<2<P>%#')92(K@;-^?><'>^A#P2=M"<6U*.5(];\@*L
ML/FPAX?L-:F-?3+:6!DILRHMCU_=H<O(8;A;ZF*>V)UB1!#=4@1;!(F@R+22
M^6C6:J:-GBN<RD5G*ULSSUH6&D+KIH"J53"'%F*K>3`7JQC\,_3VUA;]&I;T
M%&^Y)<:I]L2%5O,M$X(C4[W,8Y:+SQ1CE1A0I417*?LXB9)H2,N*Q;@,B:C$
M!$1PM@=U2RI&35XVZOV6B:LH[TPLYCB[0:<?E(:59*".]RV_&#+5(_VPF%0[
M()<8*",QT`>H.-0PFJNGR3_-W2=52PM?RG[J]\@DW6RP[\0D#.*^./+$JQT-
M_5CA,TT]N;X_@+<!IY&5D)-48?(DI1)#C`:%:N>>D`$E,+!CS`QLX=YVW#U\
MB0=T#6I9ZCO=7V)9#+YW5A'++3523?/4TFFLQVR0")9PA5X/R8'@P1'78CL%
M,S%$Y;38`0Y[JU1GK6ZX;E:5WHK@1F&8B42?149*/?I4<\EA*.=;M5+0=E#(
MVCW1&=%X+!&_Y#/F9Z1^29DH[V*.QQDG[ZGU[IA2/3E;6;J8U4X66]V3M6OJ
MZJC-K>6FF/O7UW=4!VLY*]#.-YG#,M.K6(9.'NMRS))5$MPIK[J&K#0E<E_7
MPIT&&V@C>J0M3ZNM%R<K4$Z'S#JYC?T48Q719,(%1]9@&!,#VM_[ML"<6XVR
M^Y9@']IN_]3M`V\Q0$?6Q2?EJT+`1X)_*>\@XNG_WL*M<=Y'F([/K1&I8`FT
M)%-;I[.P/=/]9+&](G[YB\C^C7.W=.V8B`$%$6M=3"@JVJ#[#F,27I0!UOYO
M%`MOT2*F^C].V2,_^DS$URB@2\L"]QF;B]RS789-&257K5W*\*GR9<)<;56S
MW541%V\TBO$C`0CE@'IK[3-@/N,<+@.5P2JHN.UFU^T/3I'7I"`3\@6W*\!C
MLGM,95H^^<WJK\UQ2%5)JDF\F#Q:;"F(&%I)GO@2!5MEA0.R8]1_*/Z'IHX<
MJJ5XH]FJ/",9,U1A,1;4YU",51H;S1RHS2E!6B2C.+JEOOS<0&WQ2]+11">/
M12`HKJBSHBC;6&V:WI@"DQ%*:Y'?ERW$BSV#%M92D<(;P\$)1>J;^>"6DV<`
M.8U.AJ6IBB'W"9F>M;=D_A'!)OFYTY(77QO5=`/TKY=1?N_4/>UT+')?*ZO.
MGM$C*5UK5<153*JK%L6$9#6O4/[6D:#.*Q&ZT.=ETVW!`3J]#AGO4>H%5M5L
M6M#D$@=;[%-(&I="I:[+;4+KW5Q'[#5\?DM]3NLZ]>(?OO_F;/Q7QB[+Y"HR
MJ3T7GC_^%)Y[<Q\.=$F0OXK>B6]BC#QA_#&*/\B#?9W\H<!G^_>N2)?\3*KD
M!XRM_]ENOA<CC*#_><F=UJ/XS\]D-;_`00+\VN^7[U_`'1_Y,U#1_OZBUG[Q
MC_Z@"^S];R>;WNZ.@6"6^1/7^?-3^*=<24+E,,$D7_O`B76?P@_20(%O7RIC
M9"T0-08/!0">_R$`6&.K.SS\QNGCF,!S^L###UJ]8SK\IFGCF,#S</G2'!S3
MX3?.-XX)/,T''K[9.*K#;YHVM@R>+R*UT_+^`(/O`G26,%V347;^O`"S53S@
M0*WV:=N<:.GZ6][CG]]D3N6?'[P87>_)GFZ^^W``]UO]W>_QL0!^]LWW'@[@
M[F`/]OA8`#]X\]03[A.Y"CA#^8)B&L!/O@E_-LSBA%Q87R>2Y21L]:QYM/Z?
MY^12^).668-'\M?M8WWZ\A'XY&#0'O3EL1ZYY?L/S<^=>\GT711FZTN%#9VQ
MTV]T&JO/6-CAND=2*;-7LJ`$,YU,C=7S'K-].NATV^L<<^6NUSTZ4(41I9^L
M%B@7W`'%?W9:[O1:S69K'0"LL?=UP6`TA0=[6C:%^$ZSVS2\Z<&[7?>D#];I
M-G.Z;KO;':QSMA(U;?7S^$?<HT^JX4<AJ*7A)?I>AW<?_IOYZ=U[#'S*G$=3
MW+2N,;PA``S@9J\%@,<>:%V(746FEOMYKW:[L2:!6UM<]U3J'B@'X_BYQ5-W
MW<,M[/3^(_X;XV8/%[P/-+;Z]_.?_$:VMO&-VY';.MIF-(>''::]!J7=O[EG
M/>"F\?FL(-BDBO2P8[;:S37I=B.JT,9/NVFT[P@>2\RF+2']M#]8^XQ+=O9\
M1]LTAI_O\$_2^!_(K9JM-=G5XQ3[IY]GX_SY.4Z\9==\O[W>"=8W6!ZWZXW'
M6[9TKJW;80^4%8,U1<46[:UG`LS&Q>R^@.XQENH##8-U%<D'6:2/WOS&[9[M
M'>_Q]O:6CO!8L_KQ!]D9MI8<527NK9V<]0Z34\^MGC=?HI#K,-A3\4UPLJV2
M!;R%;US41RFX6[J5C0ZK@<]_HKV'Y.9#[!6L-Y,?V&I)Z[2"Y-:3#2M8;TQ/
M/FWT*D@^DV)=P7I#.97M7JM;0?)Y$C0K6&_*EFGU^YT*DL]C3!T!K,D$_,I=
M%'9EBO5[FY)8#SK-?H-PXR[9"LA/-;Z:O6:[@N&VS:X*RD\WN)JMT^JV;]W4
MJJ"\@<*U3G79MU_^5@'YJ695K=FJ8+AU@^J`H&Q"9Y]D"Y7S*%DW'>;!)M*@
M_0A7])(M[N"P&Z_UWBDX9&B4O[4E#:[6&O0>?A5R.WNN@VV<"1S(T1^LZ]1:
MG4<8X3LYV.9Q>B!'?X1>T&^<'L;)MB"M-WSV+R+]1-W\?XN2=:7+PPOD:^U6
MOY7;=F[=[6SID=7$6]_KP\O?:ZU6`>O/L*7'@F_;>WUX<3NPPD;WN;?T:/!M
M>:\/U8-KS<;I:>-Y=_3G>QI-G?YY-AIELXS&;?W)^7+PIQL11'-D>']>IMZU
MV)-3/-2U76MVVOWV\^YH&W#=]BD>K,8WL6G"\^YH&W#=\BD>KDHWFZ>GV\1T
MR8ZV`==MG^+AZFRS,]@FQR_9T5;@^H!37,A.IU\GVD7P4`_'@]L\%@('J[:P
MA<UNW+^\R^,\E"7WVCO=[*9AO^/C/+"QP9X=X,%RY[37W>5F-UX*N\OC/+A*
M9U#0F9]YMQL/'^_X/$^_ND\X@6PRM.C`>N<%^,H9?$.SF7:915NR_?L[J%A[
MM7?PA+V5^GKV9&^ECI0=[ZW1/IO'Y*783$^<S4.MU'^R)QC=%-2:O5:GU1]L
M?'\;:S;8Z@TZG79KXQL<;&J#[7ZOW6HW-[[!3?4"`PPW^KU6=],;!"UD0QL\
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M0]-1!L]@NC]+_E^KV^YMG4]L/G^FW6FWM\X4'ASYV,7M&AS`[7IHPE&_LW6P
M/4L2:*?=W[XO;?,)4IU.9_L^\TTD0FU=OI902>EMV^'E>G!"5JNS=<[Y/*G`
MW6ZQ2G\K)]EX^F&KT7H&!.S_[8)-;D)TU=J#SK:YU2,F"#>WKOT_3V)XK]]J
M;5O5W4*JX*#9''2VO^VGW[+N]C>YPUNV;-K:V8C[2V"OB6VE7RY+4CGM=QJG
MQ8.LL]$'G$]-N**'+K)X-/42<0'(>?;YK(-!J[/F69=O^@$G_R)NZ4_Y@W[Q
MPR65E]O*SEMKCT\^US-,9VSUVZW3UAZ=;&,)@0T\V>D>G6Q3F82M]J#;;W;W
MYV0;2T&D2>@+4F"7)]L<H^R5V>J;/)IBJ5\G9TDB'M`,:#,GQ$'=[>:Z/+*X
MV0><\YO`X4(C;,V+CYW=>O'XBTB_3CY&\43X:;;V*/:-T>V@UVNO*P;7V?YN
MH+$I6F^U&OW6NHQWP^"@/\HN8P\<[K.QF]#K-3KK<N?2_3[3>3<E:;O=M?G:
M+H^[,?$[:.[_:3?&VKKMY\`N3;AZE-7VX-K6_CI2>&$_6S[%%HJ0>_MXSJU$
MO#9ZK*56ZK:*:$L\-`_=VG.>;BOS[Y[M_`]U'SS9I7W?/K:W]6=(CMOVX38Y
M\K/=*7$S[_(`F[](>W;$A_=@:>[9_C??EF6_3OC@Q(E^LR3HL<O];QQ#_69)
MS'>7)WQ.C6G[!WIP.D&SVVJOKR$\RP$VS[CW[(@/[P/3>X`6]RP'V'QKF.(0
MG)T?<2L9&)L[T*.]T0],)EM?H#[*Y?RTLVP\=6Y]Y\4.3ON<HNKQQ]MH^."A
M%VY]_&W,+[[Y0V_>LCP"L#QX+&AW?0?='A]ZX[2P,[`\+7+TP/J"]OJ<[HE.
M]:<=:^.%%8=Q\(>Z+EKK$^U.3[7QVWH(YWZXF.ZN[^78Z;$VSWPW>G"5&$J/
M6OF.\68PMRSZWL_;HBMVL?GM/C@7=JN',&&P&&>Q)>EGD4ZC;5V;A13>=?:R
MQ=UO(B_YL6?ZV\F/81S`/_Y_4$L#!!0````(`(F)?$"!9B2:_`X``"*M```5
M`!P`<GAI:2TR,#$Q,3(S,5]C86PN>&UL550)``.Q?G-/L7YS3W5X"P`!!"4.
M```$.0$``.5=W7/;-A)_OYG['W#NP[4/LJRD7\DDU_%'TO&,'6GDI.U;AR8A
M"U.*4$'2MNZOOP5(2/P`2)`B33#W9%G"@KO[6P"+Q6+Y[I?GC8\>,0L)#=Z?
MS$[/3A`.7.J1X.']21Q.G-`EY.27__SS'^_^-9F@/RZ6-^A7'&#F1-A#3R1:
MB^]N'?87NJ3;'2,/ZPA]>_D=NM^AY1)=T2#`OH]W:#*1G5PX(=#2(.GMU>DL
M_<TGP5_W\!L"GH+P_<DZBK9OI].GIZ?3YWOFGU+V,'UU=O9Z*AN>)"W?/H<D
MU_KIM6P[F_YQ>W/GKO'&F9`@C)S`/5#Q;E1TLS=OWDS%K]`T)&]#07]#72<2
M6JKE"VE;\/\FLMF$?S69O9J\GIT^A]X)Z`"A=XSZ>(E72##P-MIM\?N3D&RV
M/F=<?+=F>/7^A#T3`CW,9K-7"?TW5]2--SB(S@/O0Q"1:'<=K"C;"*Y/$._W
MR_)ZSS[0;]<._'SJTLV4_SJM[F!Z+']W$1@-[S^<K^XBZOZUIKX'IO?A[QB>
M9<1A71=]\7@\BYUQ>$-<'(3X_('AY#%&7"FH4DY<QW=C7V!\`\_-<82?(QQX
MV),\\:[:&U#:,XEX)V=G:()D^^Q')_!00HRJS,]`Y@O'Y^/];HTQE[=:K<K&
M>5R.Y&#A,)!OC2,"*F_$CI+R6-ZR=GH-4_ZFT=C(4W3)RZ43KC_Z]*D6L4JB
M7CAJA*!Y#TI>U<.R;@"JK3@=<;,9'W-[ON#S)0U"ZA-/+.8I+5(-@?U$()@#
M]GSJYAKX?'6D+*^4E$^Q!*Z<\%ZL@^!4/#C.=LJ5-<5^%,IOA/HF9[-T.?PF
M_?K/\S`$?BYCQE4G'^`[]]@7CRW^/AV`18XOS'G\#Y_G'QV?XWX>73J,[<"5
M^LWQ8ZQ@W9!N+U+&*,Y97CJ'N?(!\#%G)V4W)&TQ#>--,KU."-B$I%\QNE&J
M-GT>;<0\9;#Z@6MY@N(0>*);_CQN_$^8^XKBER$P6S"\=8CWX7DK%L;`F\.X
M9'7&9D1E)UY&K*=HO;(-K81-[>@?7.=%9:O5^MHVM2X8W6(6[18P]0NO#0;R
MEB\.G[#:^JN:6P9!-;,I(M]WATC9!>#?_'D=`",N#L,E#C%(M+["C]BG@I."
MB@W:6Z1C`VY3)?]@F]G_2JGW1'Q?8>*'GRQ2=9ZQ5*L_VJ;5*[RE(0$70/#_
MB0:N=AG5-[5,ZWI&4Q1^L@V%&^+<$Y]$!%>X,:I&@RSKKDOC@.]P=\Z]CRN<
M?$W#P<Q%K^:]"Z!A.36<GVTS'."7Q=@SLI^*MG8CHN,Z!>6-;:#`#OT1G!@"
M!O2)1KA^H-016`Q/'>MR)WEF&TA7>(6!1V\)OD\05X"C:V@Q*#J6)1C6[>LO
MG2V)'/\&.R&>W_OD0<A?,9?5$5@,3AWK$J0.M_.:7<Y'AS`1\)FO?G<8<_BZ
M!V,XB(CC^[L['$4^YH/Y.N#Q(M6^IVD/EL+22A:)4X?Q`0U.*<<PU48D>(!/
MBQ@V;6`^"T9<S./!Q..'NYD#FRQ(C<AM1JB1(!*>#H,%G?OZU4Z^'6`4IZ\*
M1VQF7<Q`,]=6;G,-:&S$Q8!M"5.'00C=C&4P1#_A:+Y*36A!F7;V:MN5;2`=
M)XW$SN;0Q7G@J?([JN8X#8D-V%5*HY@-#QA9%R4P0J42AY<]XTMV+X(AW2FL
MLM5@9E-O*$I^I<%8&,'8;&A0"4"YB<7:+S,KSTRMBTN<>QY)6%DXQ..;#;&N
M9R10A?8,B"R&QX1]"5B'L0N-\W*%5\0ET;GKQANN)^Q=Q0P6[<PIF>/?1<Y#
M<5@TIK84DL9R2&RLRT#XS,`=CMFN<B93-;(4&1V[$@!]+&(R&Y%7I6HA1;1N
M/[_$800^/`R0MAEEC7NP,U>IL1@II&>GUL4-9`#]L_.<B)RQ8-B>U1R3&]/:
M,"!U9P<&[,O3]`K\#M/.NVDA._:8E-F*K&:9-_NJ,F_VT`&B*Y2FUUF4/PN:
M3N2ZH:$J3%CXO:.DIP@S&,-YA>;3G/(MAAB:(@$2K)#GB3D\EI(PDT*H4%4=
M02>ZXS#,@_3<X,.SNW8"M7NH:3B$)A,]P#A/57&!`_#Y5%.:MN5@$YAR?,@I
M3,ON/HA6,V-M&:$,O([!UI^#;!]!Y"1H&(/ISK=IC#"\P"O*\%Y2'-Z20/`L
MQRBLO_E>$D?J%D=K"K\\0I/T3I$&[A=Z^A#J;3)]F,P<+VW]`YB''%L5ZC`*
MJ0P^M.:2^^*BGUTRRFT&VEF(]%S`*K/KUIMJ3?O!S%6K\LS.H8IQ:5C6A4DK
M^8;%W8_YG>QS%X86>-3[M.M+&JI6V:-Z&PQ<(R,U`KI.1&D&'>X6-=Z<ALW-
MUJ<[C$5T0MR'OZ0;SKE0CWI8'M^=_<`>+Z-$MO^#:36;L*AU#*YYCZ/&UUQ,
M"7&'Y]?U66V9`X3K0&ZV/E*67*R'F6;)'UWT`%KW,A(HVX@FX=,?;4^&NA8D
M"IOX(/JYMR$!"2/N:SQ6>/2U%/8Z2K6LRSN+_5^1JV%%.:CJ:093O:$9[0=1
MO2@2B@Y/F!O->#*)]3H,8^S!H&XV4CKM>32P=B6P!+__TVK-;"XXS<WI;09L
MAYV/W`1:R2RMH/]4?BTOE=Y9HSFZIJ?1X-M60`FF6;[__U%(4.&UU-_ZTH?9
M+3Q*>"&URDNFIS]5AC@L45M=##U3;B!_:GA$G-A>(37G>K)BQ2@&@HFP)B>J
MLM9!4X![2Q$H5QJ360+?-\@2X+T@1<&R@?,$.%L+1A\)L'"Q^Q)R+V4_)9^[
ML+3I[AHU(>[$2\E-M?`I"?<*<U*Y(I7-AUPO&JI\/TE4"E0_50Q7(H1AEPB=
MP&<?"U6#^[3AEU/^J_(DDT0B$[*1P6@NF(33NKO6OSHD2%:K*Q**0BG`UWRE
M+=95TWZ$`-9())'3[]J:QSIU$R(5EXF7VF-=;:N1J5TKAU2V=576>-V19&1G
MAO5\!1:35(B!`;]@>$/B35B=3=.VHY$A?(RHT@CT4>NA3A?NP*O$=7$3D;*N
M:3A"%'6B2)3Z/W]/)F>YBYJODAWS=1!&+%8-,U.BD8%A*I8$IO_C\TQL5%A)
M>.L$'J<F_FZ)/8PWO$+&1\JXM%^V_/P7,Y>$F9H:-6'F]MV.$=Q.!)?PZX_6
M._-7,OPF5;'Y#.$$N^I`^1UFC\2M/6%HU>/(46\ELP3<NGOFG&M>CCQ]B0(L
M]])*,_S/V:7OD(TR\;@9_<BP;R&A1+K#S$==Q0YA9M>!R0'H=7#)WQ#C<EY^
M)]'Z-X<1&J<W]3Z2``0$)2B'>R^/&9D=]*<(6;JW.MK\LL?.[7.M#/H:(_+M
MI97P]I]4H+3.8N6:^L)C+7H9(Z)MY)18=AEDZNSN$;]ACJ]P\O<Z*!3%52W<
M]30C`]90*@FC=;?2R[Q?Q?@S%6<-2RSJ.8#O65TPN$4?7P7*M5)*U*V[MZZ0
M)5\*U@SE(LW7@6I1*HFB=37YE?-.H0BVZ21<(OLJL%0))N&TKD*>NAK&`H,3
M[Q5%4\#:C'PP>-M(N;]4VL`T),S6!3\T0B0''2U3,93$W7CXXB#.Q>21/T?<
MN$O.096.O+ZQ;=-)A;H/_KI>'&E=^H#+4&XYN)PBW/^9IM<C[]:419\QVU0?
M/QK2C0S'!I+59Z,-!BF_W8H]D11Z!_/EK1/%/"6.3Z/4]Y.`CZAP4PEPFU[&
M"'<;.27XUF7AE(Q7^^8SDS%=03Q&I!N()P&V+XY2M-?YJA'$3:C'B'$3^23(
M+_"J!>$:K&*>S\MKD?(P;.*YBCPQO7-403(R=,R$DI"8!;Z^@LV(4FM2"]8%
M@C1"[`^+VFQ&E,1#SZR'`]7J"LD&-+:-TPJP5+.H1BIIHM9%N>0J#U/+$F_3
M4Y):&`V(QHBC@5@2R"[3?'KP=#BS<\%:*).5O#K_1DTS1ASKI9(P=AB_TM^V
MR?)S2!U3)!HHT\X;T8\,K1822N3Z3\8I\)6=V95O6S1`SZ"/KP!!`REET6+[
MPD$P\Z?+P'QU0X,''LG2O-5),:$VHAX9U(WEDR#KPSXVK)69T^7=%;ZO"P.4
MFX\0QFJ!)&YF!3.^@EVE4F-2"];=B2H?Q"X8#$OBR;/U]%H7*$FD3VCO%+;M
MR#:#;W5X;29J?96$SG(Y%6F(^833#^%VJPQ]F1':AIJ)8V$HFE%1F,%K'I=M
M,/^N#J,16B2Q#56#H'.]4/M2P\>\TX)+L<2KG"9"LMD>''7=</S$S[3`>[V(
M0Q)@7HZ&]_5E>5U5Z:),-*TJG%$H6I%^6U=.H_R0M+>TD@:(@2:(W_3T:0@M
MX9^$A%?.*''67D-WW#C8;KZZ(P\!61&7'Q8D69D`_8+ZQ!7`&^C-M*L>M&GZ
MZ**.7Q5U?.&$1!0G@44EY*_DXNPA)_!0^@C^6^8AZ/`45)*P/2H\FR(G`:,!
M?'1Q>@QK@$9=%SV@4/?(HO9?%[6?=)#3J9KK8^S]/B0>`21S>2I&YJVD[,6:
ME4\JJN_[HOK.M]SA<9"*OR,TMB7!/([,="3;]J$5V7=1#S^4S.@/@GCK29:5
M]@K87T.X%2^*:S`&-90]*$?SI**J?BRJBM,A08B4/+;7FC:68*"WFCA+IYJK
MB0@==/=347<I)1*D2,5G>^VE";FR`J#<S*09\[D\70-]-NBM!PTW>'I1YS^7
MIKBDK_T;QL32++I#:7]()<X19@S[%I)D/XG$J/0:DK%35$G?ASE7/:^HWC<E
MDSY0"\VJ^3UB+5&\B-)D6=&^2KO;%4;_(DVILME94659HG^C`G?M-96I.R]>
M"GL7;X$J>4ML\I`#%T8Z;-9A#]IMQD!1[Z7=4*8[)/I#V0Y3()!"IB.M5U'(
MQ=2"M>5LNK=B;8F=@T9+>Q]!B`0E4G)YQ#X<1[SNR@(S49;#;!M>I.EC%UY\
M1E%)I2T*4"!.@H`&Y1EKKYY,M5LCU>3:]Z"67/]%E92V'4EKE&?GF+WOX13C
M,W/`"%USSU%/W,M^5_>PHLY*?G=*B@0M4G+:7H.R\G;ZGD:>`&JD/"5=#WI3
M/J>HLI*[+:E02H9R_!T7$<!_Q[R(WJ/QSJY,U%,<(/^0HI)*_O&!!/7)6*86
M<+W3-'O=H"API3OU`C+H1)@=)P+Z-JE,M,81`2F^ZT6DI,`%/G]@6!,`F)5B
M)2D-RA)QUMY-.>4].`/PS_\`4$L#!!0````(`(F)?$#+W2-870D``&N5```5
M`!P`<GAI:2TR,#$Q,3(S,5]D968N>&UL550)``.Q?G-/L7YS3W5X"P`!!"4.
M```$.0$``.U=WW/;N!%^[TS_!U3WT.1!IF4W=XU[[HUC^Z:><1*/XO3N[08B
M5Q(:BE`!,I;^^P(@(8D22?&72+#F>,9CD\!RO\7NX@.Y)'[^9;5PT7=@G%#O
M>C`Z.Q\@\&SJ$&]V/0CX$'.;D,$O__SSGW[^RW#X^X?Q(W*H'2S`\Y'-`/O@
MH,D:C<?HCGH>N"ZLT3.>S8!IJ6AT?B9_1C_]^`]T2Y=K1F9S'[VY?1OK-1Q&
MU_B`N9`I^JF+79R-PC,N\;Y=R5\3<1X)K3U^M9HPU_&O!W/?7UY9EOSWC+*9
M=7%^_LX*3PYT4TXV[5Y>7LY>+G7+D?7[Q\<O]AP6>$@\[F//AJA7K,>N]$M+
M:Z+ER_\+-%\=M(\4&KU__]Y29T533JZX4NR1VMA7(W3T"BBUA?QOJ)L-Y:'A
MZ&)X.3I;<6<@3(Q0:&1&71C#%"DMKOSU$JX'G"R6KM1>'9LSF%X/V(H0(68T
M&EV$0G[XX@M_D*[!/T^_^-3^-J>N([S@_K\!\=<#)"5_'3]L4`@)RSEF"WQF
MTX4ESUK'1%BG5+2ZGDEJ8F;GU31E[+0SRT%[IP#,A0AF!Q,8.D1H(>-L@*(+
M[6J^D4(\WQ)-K:B-E2C@U%IO+C5TZ`*3@BH?]FY07YCBP/5+*ZR[GUQC99GA
M`A838`6UC7<]M:;8=8OIISI$6HEI`OU+>S"Z@RGQB,R/Z,TC\0`]B-#DR*?;
M-F_5)*+Q.)L.HOFW&"98^>`YX&A4\M)5\E4DF_A2S/GH\AP-T::/^/N6>IRZ
MQ%$3Z588HE.T*^ZO*!*H4&@<+K5CRKMRFJ`L<4247:>83Y1QQ<P^PWAIR:QH
M@>MS?43ER>'Y*)H7?H@._[%1[1E/MF/NX@FXBB<D-K):US:TVBU=+*DG[7JS
M(OR8\LE]XEBV'G3#XJB$N^H+1)Y;,AF',J:,+M(-'%V8YD9!F?`FP?,VD60E
M!,0VQNY43D`?54[@J`\BP]VR02Q[ZMQ%4W(BAI2VK>DN-%E03[G&QVBZ2]0[
MH5UK.M\XC@HV[#YAXCQXMWA)?.QFZG^D3PDLAU1:'OE#SL`V\6]LL3(,7!F&
M=P$32\@[^`XN74KW%7X\@T1M2TEH;1R>Q:*7!VQ]W'L26[:F]QA\$73@W&/F
M";OR3-73&I]R$CRD]YDS8%8*W9T04W+/_D1X(DQQ3IT$*#./[@))2$;=`W$D
M(T6`+LP'5"II1?`NS8>7F<,B&'_K#HRT?!8A>9>3#O=+SG[)>53;+S9XF!&:
MA]/'VW9MB1G7?C]W]TO+3KM?D[I':GSU^!)L,B5B'LU:3F:T;PW#$P,';."<
MLDQFG="N/;L'=@Z-#UH9M`A(<O98JDKW%&.X\U'OWP64X#[=!'+@506GCV0J
M=N.Z/>UZG;1+LG!%PH]IO-/PE`&C'E=E)J\#C1-)5F3@[=(Q?)!V9;N4@W,]
M\%D`VX/4\X5?W[NJZ_6`PTS^D3.F'KPY,*(*(-"4,K1=V%PA%"EV=:A^'W#&
MN'"C6J>-R('6:54<;6@M?`SX`^?!U@_W]8TU:=>^H1;A3:4G$9O4";5["I@]
MQQP^3V\X!S_=80K),`WKO[$;0#6H*2),0QJ.R"=X4:=*#>=.9]/0J4$H"6Z_
M;WW/K%(N^"ME8R"+2<"XRK6?I_>KI5B3``_MG/3PJK2HDZ-1YDO7HP"8HY):
M?#+ZGX#[:FY_IBD/&'9`R=^2XMQ2GII-JHD\^:B&[B,&8ZO:@R!^K@NV'P@U
M&16+(Y\4&M\",AOSVAKAY1?9T.@]TSO"Q-4I*SY*L;YF/`E7]KVQ!;]CX,@X
M^`C^G*9QK'Q=C<XHOV'&L.=G4LD2<IJ)K7+.=]BU/FUS9=S(^3_`&!P0$Y"<
M8>]7P&PBR5UDR41$M8HWC5^%BJN3GY<2&-=:IZYQ2@@R#;7RQAI`9\EI:"Y0
M)V5]!U$N^BO`5T\LE\5ZWW,FZW#1?$>XS\@D4/>G9@P@O+%3<.:H<*5F,E,3
MIJAZH8:\XA;S^0?J!<7YP4[/9D:MC*K['4W++Z$IQR!=P/;!4<UN7C!S/H%8
M^(BY80K$#PZ7A#7*-<TF:LSJ-TD!L4UE9&#?B5UB`;7MV%"^+*[H7K^&+*KI
M4]HL74I",S:NHGJ:@(:L_N#=K^PY]F9'^'$)(<W8OB*`#!FFY=;0UFH=S-7R
MI-2\$N]O&L;M4K\4Q(3N#<71_6+ITC7`,[`%\7",$!8/J"/2FHFLNB#E$6::
M'\:'0372#XF>7%PN\K*DF88_-F8'"I<(R@Q91M_%4T.GOC@AJ\C!X\IU/U'O
MNV"CL.'J8<;1I"G$/0:;SL)2ARI/$6I2H(-6WKWGTKR)"UZ]V3N=$4N)'JYM
M^8M8"F41_MI$M^9-8L'WX-ET`8^4IV7AO3;UC8P0_"QLP[&MO.(WXL^?A.LD
MWUO*:-QV'6;.`K/#LAQS2DGS08A5ZACS[E@!^^>OS3'FU;%*Z%+*<8QYH:R&
MH=NI5=E_NZR;L/8K<")4/QJ.JEIA3@3RIPZ#/%JP$V'\N^$8ZZG)B<"^-QQL
M314Z>B(_[S#<_!4[&JWIO*5@88^&U15&DZ^H1Z/J"I,I4<.C(9K.9XK5^FA4
MIM.9^NM]-'+3*4^5ZAZ-T73&4Z&81T,TG?"<M(I'&Z'+1*AJ_8Z^4]!E=G10
MZ*-!=9D$[9<$:4Q=84`U5/QHR%VA1]4K>C3B+K.E_=H?C:D37"E?F9"&9#H)
M*E5'I,&9SG[*5!II;-VG/<EU/!I?YQE-)KQ+T\E*B>HD#<UTRE*\*DDC,YVX
M5"Y5TD!-IRM5"Y@T3M-)2N5*)0W4=.92L2A)PS2=S;112J1M8SH9:KP&2!NF
M$TRJMEH@C=IT?I52'J1K"TSG3\>*BC2.W%LWZ"_IR0^DR<UG^F]L]MLWG'#[
MAI-]!U)OG9094C5_#;Z/K=9BJ_]^K2DQ5?WCJM4^YOEHQG?5TR)M5"W2T)MP
M9I^#3VSLOFT_\KKUO<]^9Z\.[^SU:F*J9XK]1E^%7Z@R8:,O`S?+ZK>;ZK>;
M*@CB_V:[J<PPV7\WJ&?;'6`&W6+;_:9&/:LV)W;Z>T3M8.CW"S*`_-2RS4[>
MVP3&;+/S:G);MWC!8[_KSNO8=>?5Q%]UCVY0ZR>\WAVJ/%L;9'<QXT[13K$H
M2_V<<V:/MN?H7-DF>RC,(1S%W_[='XZBRZC6GZ^_FG37/Z`P[;'[:RME>36A
MUM^U,"7$&JALB8[+7Q/,01SY'U!+`P04````"`")B7Q`E`M1==P[``!@5P,`
M%0`<`')X:6DM,C`Q,3$R,S%?;&%B+GAM;%54"0`#L7YS3[%^<T]U>`L``00E
M#@``!#D!``#E?>ESY+BQY_>-V/\!.V_BN3NB--V:\?1,CX\7I:.]"JM;6DGC
M\8N)#0>+A9)HL\@RR5)W^:]?'#S`(DY>"7D_V*.6D(G\@9F)1`)(_/Z_OFQC
M](RS/$J3/WQU^LW;KQ!.PG0=)8]_^&J?GP1Y&$5?_=<?_^?_^/W_.CE!?SV[
MNT9_P@G.@@*OT>>H>&*_^QAD_T#GZ>Z018]/!7IU_AJM#NCN#EVD28+C&!_0
MR4G%Y"S("6V:<&[??G-:_BV.DG^LR-\0D2G)__#54U'L?GKSYO/GS]]\667Q
M-VGV^.;;MV^_>U,U_(JW_.E+'K5:?_ZN:GOZYJ\?K^_#)[P-3J(D+X(D;*@H
M&QG=Z?OW[]^POY*F>?13SNBOTS`HV"@9Y4+*%O1?)U6S$_JKD]-O3[X[_>9+
MOOZ*C`%"O\_2&-_A#6("_%0<=O@/7^71=A=3P=GOGC*\D4L19]D;2O\FP8_T
M`]$>WM,>3M_1'OZC_/5UL,+Q5XBV_/GN2@GH?8M72?1F-BD?TB*(>XDJ4I;R
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M-<T"<2K4D!'E(H2`BG6$XR+=!E&B`*]H"Z-(6L%%!9(VG%UQ-%)T%.982]"O
MO#F@FBSS'!,E/YH/CC`>-X)1#+FHHD:T6TRB"B0X7Z4YOM9HA$R*CBHL[^\O
M'^Z/O_ODVFHG&VODQ?3(13G?9QF-&6RTM-,64ED5@G=U]J@AK.I*A>EH2=D*
M!8SF)R!5MI.5MUV@2F8?5/L\R)](%$S_0^>%YR!FX49Q'F39@2SX_Q+$^^,0
MVI$61O6=@(FF8$4(91H.PG5-A1"Q14A(?\`-^>Q&,PH*]H-`OD!!@2H.B+&`
M,ZO;#.^":'WY98>3'!.L-\43SEK.0C$V5I0P)N4`2C0H"S(H<[(6K:.&)27"
MG'1^&QHN>DG*C(D1HZ,)RI.`RV;F]2+`,@967@14"JU@^5$4ML(IV&C*+HI:
M(";Y)*(60LYXTH&=<V)*=S@K#K=$1I;^)!/HCF://F'UC*0C@9J*S##:<Y"Z
M/=SD8Y))FKK9U<GDS3Y+HOR)A#O$'!)<H'2#@C#<;_<QVXE;XUV&PXBGF2E!
ML$VS(OH7_P5I_/6[[W]@?_CZM^]/490@JC3L%^2'MPM$@.]P6$3/.#X`3'#.
MPU.1+!`CXAGWBFR!""'@E-9\F`OANY"?8\RV'9+U4O@\2O0J3S0:>Z")=.3A
M:<W!(_$&F[Y'E;\[H;JX#*SR0//'"O.-BLA_@>H>V!"(?1"_T_9`B[8+ZN-]
M%!N^5Q10B//\#N>8V-G3!29>.I6Y"(OV`!O#-@#J#6%=X]GV6BPEZ6C258)*
M&E01(8%J$L/1>)7^,$YV)8RL@O&?P7;W.^(TI@6S+G?0F8U!HIDO6OA3FJX_
M1['*]S5_AIFMC\439]OJ;U"S9;O_SH>O_CS[?-53KOETCLQK:1X5.5_4?B):
MH,V_J)O#Z*1)?%%'56VA=%8O3T=7JN:SZW!/.>O$8D,!G5O4)G1@LXGJ-")L
M_E";WP)-&!HRA>`)PAXC-Y\]7$?!*HJC(L(Y61;=%VGXCZ<T7N,LYP>%#.<=
M[,EA;,H5GFAUMK10=NDF7T?_KJ^69U?75P]7E_=H^>D"W3_<G/_Y?]]<7US>
MW?\&7?Z?GZ\>_GMVBQZ*J2&OU][%P8NC%H)H=D>)=`3@QF1QJ$C=V@.#<3M>
M%#>$\Y\Q<I9:(/#KM-$R#--]4N2WP2%8Q=BPP:MH#):@UHA^E&Z6M`1,'BNE
MD24]66.TXZTADKH]I"U;^W!P(0RS/5YW+5:-5]4>3,WU`(XT7=X84-EU`LDT
MB+:O3O&PB"%E1V'"KN.',(9>:&3N'_"$:9J0+U=$Q$`_I06V\_TF(J`SI590
M6H=)M11@IT@MI.J&0@T12B@5V"0Q6'Q&Y=&L<8$WF(BPOL//.-D;3$/5&"KK
MJA.]G7.5M83+N*JED>0Q>6.4\=8`>=<^TI:M/5#P\V`7T4P9#G)\LXJC1[:5
M9XB-3$10]PILH+0O%.@HX&X2F*52+H>W0;'/>)(EW:"0LT(QY872AAG`Q8(^
MH$KQ&142R`89CN+<QH<@RMC=A)O-+T&6!72M0V:CI(B".#[<XZ(@HTAFI:N$
MWF^0;7:[<@`XV]$/9'W:PXU\WO,??63K:!QEPF^H4/.I^""!$6HXT7.9E!?(
M.9'QX#Y7<#]7<'<"W+P%-YP*KO$D"1Q>](I&I>C'UR,ZF])]D="WB))'\M,M
M&;`GXN5NLRC$Y-=YM*95>Q2#X40.X&9ZP*M]C`/MO`[&63#E)-VP0!4/Q)B@
M%A<0OS(>RK!!N:M0[AC*<'*41G<"#A-R=\MZ-\.?W2R[72Q_=J^LKAQ!IC"M
M19;E+$%/;HP_V.#+;>.1/@LZKQ;=^D-^1B+/EM[&XW3GJG5V??LK[*S/?5F"
M6X.3K,*'G1I4Q<86<_(G7-QL2NN_I=<\%+-\7U80,?,PV$W\W(_/S+'T$"%E
M.P@V\32]9DAML8K<2J8P8?94`Z"+03O>:#?A")A#<)^'`"0\-P<\'@3DADC<
M@Q!<&PYZ$G/;!-M^Q-A]1W/.<PS;;5107T,/IM:.(%1;E)8"Z@2#$43[^(*R
M.=S9!8-($I]=4_#R5R)-F79]WTF[SG"*82B0%@UD\6#'*P/^71)PNQ;@WT4`
MYV/R(L%OV*7^XC#_P>:!8I=G^Y=%D46K?<%V4XH4W0;>G'>^S<JS&$QP72U%
M:4NP,F\JH8_*NATW`RSC)A=%5ONL/!R3TZ8+]/7;;]Z^?7N*=D&Y9?<[]/V"
M_(;^#^5/1)6(K]T73VD6_0NO?X>2M/IME.?TL"4[,KHOZ#,2]($,B#IPSMCO
M.7;6>(&N&!!?C(18[TW&:IJOF7RW.+NG`VX%7TWL@RF9H*FM2T7IA\'II3/;
M8&U[P,;3&T=I3X0>I1GB',KS'80'8DQ\L2\F3+ZL79K5R'2)?+`G%12U'1U3
M^&$_<JG,=M.9GH#MQQE':3><#BV5.&!MA<^/#B-0$?AC(VT()OO@K7VR#5$B
M:[N(I'$-B$U8RM^V![_B,B[431/I.L!O4?EC%1(P)M,02'RRCXY8UD;BS]+%
M'4G;7&[42.9-$J>)<;7?;0:7#I:)>YP#%MM`)GZ[<DB3I&FB6=Z??JM9X+/E
M_&]_6/QX>KKX[???2=;ZY(^GW[T3_RB8$'V"X`*'>+LB8?]WIPM64/=WC.[[
MMX9>3]\OWA+F/WS_7M+KZ8^+[W[XEOW1T!UTV5ZWS^17)D*0W3$-844);N,N
M"0@+,@\\@>.2O>T<X/(.@Q'XG7$0X%FF&[04X'9CDVC0-/?`3BR7YFW[@,\O
M]$;@7V:A`T6;5E"V]L06U`D%15-O;$"[%)?J/U`>H9?D+;WW*J"RS1_H23Q1
M?T/F0-?>&T,PK[2EU@"9,.B/X<@NO,@5+-?KB!X*#>+;(%K3&Z7L!+P`4C$,
M-H1`U:.L(;7*2!FIP.I)64K6+<54$R+ZUMH)N^3+:.>O(C4"!DK)[Z$SV@42
MS6K$2QD7>!.%42$^[;'/B)$*]?R#F*QV'H_7X<[4`%<OW,'5MRWL2>>]8.$J
MEZQ6#66`6J^M,!:HQ0,Q)B!W*$;#V'J:BV,LGK#XW@3!F4^&TWA3P@.@\TV^
M#QD.\GUV,*;J90UA)E>UR.)DVFTUKDMXS[4IP8_T^^HF3Y4DW>L(]!66HFQ=
M9QWHG?>\6*!W/WPO9,WG=@$3@:$Y_;?"7SN;!JR%;[E]ZT&H&K;R^YX8.U\#
MV""L6GI@[FVAE?;.FT%%RTI1U/K!UI93FK:U.MO)VUI'^G3E0@%1UM"7*Q8R
M;>ZVFD29=SB+TO5EHIV_5+)T7V7EF[&K@/PVG"9XXP*3X"LK1A'Y##]&23*U
MU#KCLQ;5X<X'Z&5&:T#\3F,NN8$#%=Q,(+H_[]<H,)O)P.]`:^&XO%/CP6UI
MC5SF2[\L&)[-8'1>JR<B^:LTOMR]GN?;S.<1;G:L#$/R>,G+^N>&^ZB:]C`^
MP`A`-'YE8RBK-PC4#9_*9O/?/W65M&Z/*@(O;IG>E0_8$CL6<G6EB)=?PGA/
MX]-E2,PRP^OZL=SS-%=9Q"".,#8SPB"(5C6`'93=#1:YH^\51^;CA?1M]5[*
M[`8[,42!9V7AZ%7-%E5\Z4Y8]:(W93UFR5X%PNTN3@\8LVGZ+,CQ^CS=4OE8
M,K\459;3'\0.8(]L!/CUIMD`7O/NH@T6U$&K2Z8\D8486R3RK?0>9*MMXH%H
M>;!J(%CH>K)B`Q&*`S&ECS/NQ;V$D1C=RWTB&,9U=/8<O?%UKH-@<'>V['SP
M>&ZRVCN]3]2MO4#'-^9XB!:?I,G)B_1_7@[(.(_!",>QK@B,\(D(CC^DV744
MDDY)]'D7/3YUGJWOS07V41A'L+*'82Q9@#T.XR2?X8$8\;`=77M4[-`FS5#-
M$'&.T,_$C`"\?CHE%`X@5[<A(VJ(`OZXQI]-A]_EW9A_KP$P'_?Q';\G>;@^
M&0TO<VG.V3(O\V':[8WL1>6]>F:V0'>?YOLV`\*S/^$$9T%,9%RNMU$2T40_
M/7E7)?]ECM!,`Q!ZV0*I`RT3P;QAE9TT'7TIR9BBM`GK[1N08&D$.$$;#NA2
M;60X_8KD.RVPJI?]^.U($IH8(-@'/.Z<O5F(]1T4P^+,E:T/"[9^,KLLXNHG
M/WD7+(XUNRN/EG9C#I$\VJ^?S8R:(7KTU`6^[#$:/X'%I&DM_OJ$4B,R]\;+
M#A@:4Q;,G;,/OK:WV"[N]JK.'+129[X&B+.,E%..Q>Q4_,J[O:RAFF*)JMTF
M<0KC#9Q\6LY:@38O<K5L/%GZ6LCHM"`V;8_ZM5(>BO[8,/W>#)UE&"C(UC"@
M[C#`I=;=5NC65##I=8>5M24)5(J]WXJ&)W*!%G.Z-'L_..8P$C35/N\W`KSE
MH<`O:>?)K0Z9H7<:35F]X<&D.PII-!<CXC0'J]%@*RW7[;26>=(EC,[?N`]O
MU5#A40:L)*Z2`A-\Q55"9GQIRONX!4#D+Q>RCNC;?YXW4I?UW?F052/$6X$$
MU6Z"1JP5>\\8)OCM(RYZ59ITKYL9(TU/Q1/./J5)[68X`'W`:B("FKBLH+1F
M,2T%V,5$"ZFZOI<236X&VEFBO]@B5>ESZ(4FN6W,$XY.A6;\&?&:A#(W2;F+
M4Z4292Y*T1!@?M2*7$^3TE;SSI8:$;J7YTE;E";5IFF=PP<YZ-A'\'*;KLX3
M@TS[W@INC`"FD'R^.(#[*2K7!V*G_,GN/7%@94R?)OD9WJ09YNT>@B\X_Q@E
M:185ARJJ(4OW-A=>H>$C+IY2\I=GTH0]"J[PN+-*`!.A``RR&.[,V/UL;AH,
MFR2XYS,]I7Z-Z(='C1BHD0.MF"!5B2C.'@G\%U70P*1<D(FDR((T6T=)D!W0
M58&WY)<DR"`*5Y!QB7F8P3'`!$OP@\\<:CFPNRQ]CG*Z4T`W.LNE5D$[A<KX
MO-3QF7OZ(<C+./D,)W@3J>I^*%M#NG6E\%T7W&D*M=34BB-YTG!6PS*[>UO!
M&W_:U,LH*49>7MJ7'9YJZ.>SV4^X:%R2`N51&QC[E`HJ6F6K`90M2H3HJ`%I
M,]W6A<[>;(5K!T'R\I<P,<J0X9W/IBZ#C)8[S:OG]0PEX=3-82S-)+YH=*JV
MLR\=]()(E82%4_4+AIKJ:G,YCQX8J*(C$H#6QP4I7:>X'9SJGP5Y%-*+=U&\
M+Y0OT!FI_#`$!1B=/1R10$U+5F)U"S?35OSN(V_7J%LN>_1S=B.W@U%1-;:^
M0`VTDG;$7/XOF-X-Q^LE^3#!(_ZTI\\JW&Q8S\)C8'K3&,0)8#=@&.AZNZ`?
MFWGW$X;(V%'.BADJN2'.CIX`Y].2P-&LM;-D]Z?!'Y3XQ8FL]0+@3_20:-L?
MP>P1^(M_SD<AR-*8CM(#718HW/5Q(ZC'(&2BMA^"$%O,'KK*NI>\3%`V0K^R
M9H`E@&M1KJ,$LTRV"9C0$%@'.B)+]:!N!:<+1R+H]($VY3L*H$I1WX7B+[G=
MLE=$V'VI3_@S^XM:3ZQH`=^2L076>5[&1`BU('`0KIN()7^DS[@<WU);L+1F
M&.1/Z%5"UJ;DS^EF@]F;?/1%LIS^YNL?WK];H*_??4?___V[[]ET]O7IXL?W
M;QDY?;R//T"#,`]Z"*X?:=Z)O526"4^237.H2&^=_4>M=3NT?':2DY=/EBT0
M8<$;C'EK3[BUR%^2^DA&G%)'\>$.KS'>TNGD0YJ=DP_W\X[6-<19&.6D?76I
M7!8$C<(6]JKTT.&079+NRQ/L>O0P@0T7HSES)'!'#7MF[K0#1'M`51>4KNH$
MNKS<%(-37_`M(_RM,#A9>W"8*]WOV)7`9G`^3S(X[M?%__\;')<;XB]J=&;=
M;J38V4[H&J_/#C_G]/)\?>ED2>=V_E"0?M.D#R.PC<N>D(]V-QVY`&Z!]I*T
MH_-L;MC$Z>><'\1JSF,'-8OYW_$9#1[=OF$0*U9H=4"O*#<4):]1<P^KX3CP
M!2!%A-C:5"4_\1=(V#%XF9/3-@>(Z"S$KR,U3=MY(S"C(+J->;9Q61,A1@42
M#?1#,=G9!^/\/)Z\\\V8R_7?]^6QP(?T#E-KB&+<0O*0CC.G3M,5S*P[Y;")
M\_(4_4#-W--AZ=A5TQ5-[6157_3.&]]D)K^E/_,XEL^)G@0`(*/$!J3N#'5/
M:9$_SQM,C./=+O".?/R(>6SR<XSI#[1\Q#;-BNA?,D_N1@KC?5Q@B=[$A@[*
M.]C+UM%CD937]Q!HP"JPC`1H@6IB7I9%(`<L8A1$";_,=A'ENS2/J#@WFV6>
M8^7E+0,-4`$C&R"M\D4Z`K#B16:AE/<+UXR"5A'9L.>.60GZ^>L5]4!`::H)
MB@`1""D63@IU='_R+S)D19XF=#*_4[[HH6P%L?Y6"MLLNSM-9EYM*_KO+O?(
MQV5AU)WP>`7,TMI!Y!,6)6=3/QIB7EZ/*O.,2^PPS/CD+TS=-QOB%\)T3V)O
M$A/<9G@;[;>Y^09T7V9`R^1!T%L+X5Z<P):Z`Z3M+M,J9BS^(X$ACG;L^,,J
M96?U.,_Y%ZK38'PELGM-8=8<&?Z*YT*\#@TURWOPG6<\@U6>B=<68#8U!CIE
MI16]=:Q*VA+L')5&&O6TQ_9O+6K>3G^@R45\UK@L6*PKUSRX#%)5=^5FP^_'
M7R5YD>UEDZXM$5AY)`LH1Z62-!0099.,XB@72?7S!\1!EF4R!&+`ND3](6$!
M$N:0HHDA658LF@O3.`<1^15BZD."Y*!_2^$>9\]1:'RTI1='V..'`P9!=O*P
M!SNP0X>]936<-^1\4<G8ZEV6BC_T:;J1A\3N#:?C]T3R*0?#Y?2<UZ,Q8T&=
M\J3]S8:A)XN5ZIB@`/PF.X^#2'D)QY$'4/&=/D!;)7E<&(`5ZG$7<H1'@B8U
M:MWB8@RXXET3[L?ITKM^TE#TX(@>)V>\1@Q:SMDX7B4VK^Y=)>=IDM#;*6GR
M2U0\_27(HG2?\X#L0Y00'/0:NLSU3=(-0'@SX7#5,<\$?<P;"$T&H'N"EGL!
MXA$<W@<EK9L^T6?2*2I[K99Q3;\@%S0@QF]C#B-`(DA/QT*8B\(C77HN=:E<
M:VXFTB7;H//?>`#G>&OUFLR\24YZOZ-E#(8]K=KAY?-+J@K@[@^G'C'R])U4
MJ90C/(M:\T6<,?0R?+11<`K1XWH4LNE&8;SW3:&&8>PXGE;P?20C<DN&\BG(
M,?E-'JW+:K[6DX6!BR]1N!58?9"M9>%!#&TAGT.(7'%#%3O4XN=/Z#L,]G$P
M4L,.IT,[)+B=".VN^LC3P^X7DX+BGK6&>(:)/!>8_U>X-G$>[*(BB`V7F%P8
M@%4:=X1X5'S<DAJP'KF3A`JUS8^N_+"#N2S]%T?!*HJ!KO\,1E<Q0*\J%J\I
MTN:*3LG&B_LY7;3+D)^<N@T.FM)O%G2^&)\"D-[FCHC\,36I8+*3;/S`WHXW
M\\"*[`17&$^-YU:.!])@+O;X(65WC.]P3*.[VR"CKNM\G]%-3NL!,O+QQ:`L
M`>L-S,#$'X.S$K1[@6S/:NF35>\69\0*)RNI[V:$_<`HC++$R-]3+/FADN$"
ME2R]LE2\P42H]1U^QLG>?FKKT'ECB7)`!LMK$T$\`F8CD;46EL2HI`9\/JH7
MK%K^3"X_<"R8[?'ZNHG'7:;[#JDO9J.&90P*C^C\F:94LDDO.=#D;/50/5MQ
MI<R'A]QEB^LO#^8L:V3JV)$!OE:C\K$^FF)\7!CX7@]-9G7VU/[7/]/4'#+6
M/?&X[MEX]<[`'ID"^(#@/H;??QNA!J.6D5<^QP*RA>_1</',!QDE-=9@C"H.
M/M9@=(=G\$DUP\EK,/)[\R&.GBF09?C/?<0K4DCWA]2-(7:;3:(WF\JJEC/O
M'>O%D-M`1<`CQIH$9E^T#X!,`!!,#,"\P^DM`MN-^`D!S!<)W`:'LHX=0Y#A
M^Z<T*QYPMC77N;"DA9GOG8")4[P5(=2L[B!<]^WA:I^?E0\G9"<%H2OG\^FN
MK^IF\4%P2EJ:8"ZIT7T#RX/*$_-^K!E]1I:&&*_9\_7W08P_!L6>OG&_3-;G
M:1SSD\KYS<;"@_3A!.1/^H-N>1=W-F"^IJ^H'64N*6GH[)'O&0U>Q8FOCRBO
M!:JXL=QIPX_BUW@FP'F?@-CAK#C<$F@%&8/+JJB=K7/3,/`D`C!"U(8!2FIO
M8@&#A/*(=!=$:W;T>B?,.'5%0Z:^FWV61/G39#=TG"($5Y"R,*'BL4",RX*A
MK!EY$RX`?$^X(.)FX^R!7#CX$318@-0%"QIR7X($HXC=W6U9)55XOS,85S<J
M8/5)G%S/X'3B9I^LZ1&>:$TO[?!=4U;I5IW1T)"`I1:-,(X2C,KV$&E&@S"J
M9",G0[>5/V>4J"0%3#KV@I-5<%[1^>DUO^O%`*TG!&29A)P'D8^[>X,W5_S?
MS1NVB^?_[IUI`WHG;FOMJVTMV2:>QWMXX^W=>76>8-;/"1/:-Q6`A`O%%C&7
M@@X^C-<"4@7O4B(?0G:-8%(=W+6"VDCQ##AHM.X"J1VCBY6FQ,H%\%DZ$I?<
MX6I!;V5*%H2P63DS)%DV3DT%G84S26;(UF18S-?`&E-?1'6JC0*Z:P'2F=/<
M^;79OA10,HV*<K-CNQ?5X])KFRR'G`Y^QM4"4J;+9$0^S+@:P2QF7/$I[U8]
ME91SA,V3.4`[RHXQ#"4IJFG'?>%8%+5Y=5U2ZDN6*7"CAWD#V1F@^"BR-?'L
MKR0[2B:UHK:Z70I6)"V$"/64\AA0+1W&I#4+;9YA]@#K>/Y$7'20M7A61*L8
M?TH+K"B2T),'O%^Q!JKR+48&H/[%4CH+']->3-:\$&.F*E(`X6>&0-:E`QK(
M"8,\99T)5W_SHC%;GD_V"_)\:R&RMBL7>C>;ZS1YI.<MRWHZ;&_G9A5'CTQ1
M5-L?3AQ@UD<]0(HK)0=RJ#63LX@=S6TX,$TM2RKQ/;JTH9Y]R30V,LJ#'Z>L
MRD;QK>*;J3#:IUS`/B),ZD6HF'*XP"N;@TM=$OB$BPJ&*M=RW-Z'-(M<)GEJ
M+U@_T_FLG-Y:!7G8VWQ!<EB@!,]?G:<'H'80*I;<.2!*YMVIA+IH>M]3"5(&
M7IU*T$"T.)4@H?;L5()20KMM[+I\O8=G$=R@:<XBU(Q\/8LPPT><S]=0@/0>
M!_D//5OY',0T@KC%692NC\O'*(;)C06,O^D#4_0X+O10/L==1JG"1E7E'_J<
M!IOTDS7_`3=<9_<Z(X`[K\"P'P0N"\3Y($G1(QC/\^(_Y8Z)>E^0:,H=YY*X
MW2P[$!?)"GJ;/N<Q(!04J'C":(4?HR2ACI:LA[A`$V*]3+3KN\F08EIQ3(5O
MQN?4][M=C%EF,:;R?HC3SU<)72&P9:>A.(XU-="#ZV[@6B^PVY&"/<GN(E[W
MD7.!&JVC/(S3?)_Q=&=5"X?XGIK=_,5O1L3'K)#2(X&!%W7'6\GKI,!D$(NJ
MWH;%>KE+`I]84<%0'AL]:N]#8D4NDZ':R7J?T1F+SE_<I?,S8E')"_:\J!V@
MH]V]DJ@N"C1-1(4SOS[,G)5FN03T5HX"?+L)5.78KICM"K'-W^$JP1[+H#GA
MZ)NE6@A?VR)M`V.'4P[QO%D3&@I\(GI/?FQNIR1K27;HHHZ,#&'P<+9PV94Q
MAN,XXS*$)V069KC<+J%VDB8G+-P6[C;1.^&2/./\`?A$PU$'XPM4<A;NL%'T
MLBPR:MA[$;<+3T:>JM8OK29`JU^)F*TEKO!WL'5L1X:N!>&BX!;$C^-DNS0+
M"O:89KF6JZNX'[^U"7K)Q`::\&KL-`\;Z]]V%HZBDI@ZS=9XO<S/T[RXV?#W
MGF6GKL;D#OOX\4B#(WL.>2!KL`>21Y';\&1RU8?P7/+YT?/?K2/K55=HF2/:
M&>7!NX-^2'G"T:J?L;1X++UU$CRK1BO(R1_X:.'I1LOEP>67/5SC..3[IX`,
M\T<2ZE#J*#[<X37&6WJ@]$.:T?#HYUV:-+<%RC$SC&QOKK`.>.!@R!QO3Y9@
M#G>0O`9'RWDC@3EJN+,`B87CM(/6A:&R#VCO.L'0U&XBYT.S%88F:P\-?]MB
MQ\++9FA@[Q2]T,$9X#F7,6M-QN-F0\`&CVPA<%D&_+(Q,E$`>#P[$+4WTS>?
MUU/9R-)]7:LFHEK1D*&*#L2SC`!EVT#!4T(Q.H)YL`RPV[K>'\T7-44.+\O5
M.2U#IB[QT8L#@%WW`UG;N1OYO';?1[:.PEVV:ET*;%#-AT<ADY7.L'0-$Z`5
M*GO6.:GU/$DIH_?P!NY\*5LA<EKF.2[RL@"Q:N=5TQXFF6L$(&9VE8VATKP&
M@1R4*R@)4?&4I?O'I_:%J=F3O*[`V@LT3E(5[08\!:BXL7:5L-=0549BI(+:
MU;0"T]ZTU)+`[4E:B-4]05SM*TY??E:_@]A'>.4%3U01CABEEI9[A_,BB\("
MK]F$]W,2$3NF;V34<V"5L;R.\/YF0U?79VFR5ZQ`Q^`*$,V.-QAUA#N<Y;Q1
M[UCR=K2Z]O@-ZW)S@S$OGU`1]CR:K1':!:NP02VZ[`4D2)Y^<+)F<'AR?E\/
M3BMGWZ3VXW)PF+M;33@XQICZI8[.F+L:'%K]N(=5!K-#X\..A`*(>K_AB`!X
M-T$JC=U>0>EWFI=D_-@$<$!TG,6.:D3ET@$M=\43S@)/4OAS0!O'R,_3A![3
M(NBJI_MNB3_"Y-=YM&9O?Z?)\::NX9'?,;G#.HZ1!D?F8@:R!G-&H\AM<%M-
M'ZA^3Y+U@EK=R,Z80#]P/,](U3XC;$:JKNZ[8R,5'H_4\8&)TJO`OZC\;S5D
MPTHSMK--EU_">+\FLM)X4C9R)@J8LHL6(,0BBYKFLY=4-,HBO=A]E/!#-1U;
MWD'52NR')>!8ZH0LKK&P]0:QGZ]/W_T(5@QQ3E`#'S&KA:.7W#JBR_#94`$]
M968'IO6:F9YD_@?-;.21WVQH[)G=H928/-BS9OU!X3:HI&LF<$^;S8EJQD)B
M]&EE$N3<[,H00UDP3-(0J#"84N16`;!.*[!"7PI)NK,":T@]_]D^CQ*<`U3N
M<I>U:8I^?<!?"G1&U/4?@'>F;K+'((G^Q62B07H:1VM>RB%9WY(!JPS]9E/>
M``OB>_(;=D`I-UR_'(DWC.&,.C"BK8W">+;)=P*I+4S9B^N$RS!,]VRE>4O0
MAA$VZ;N.`$:)S1!$S52WGEW=3*)T=.@LR*.</W/<*"/;A+G?;[=!=F#)].@Q
MB391&"0D_JM[0%47GFG=.3NM1;>I+K.,'OW*,I[*R.G,P28.X^A9\8#630>@
M<G6U8``5S_004E*).L1'&INE"?DYY.YU]L!G#%`"FI()?Y"<LD$"'T_B)!O(
MUM.##0M_C=)N"C'3`TXJML(YFZ(74T@519VGVQ4)QBBNIE*#:>ZP)8;13S=H
MHF;:44)-$R[2=5UIN:DQ]<Z9SK8&`:C#?H&Z55S$BRE``M'D\O4DWIB0UJ7K
MVL_NPLW"V%B'%UZZ7B=?)406EE+-[=VT-370M0@W<*U+$G:D8%<F7,33G9+X
MB`-*`1/!#T1142.!W#^'S2M8\0Q4'-]0-R#^2N^Z;8FAJC^Z0&O7A;2AG-VQ
MNXAE:U5>N'GQND5>/W8A9D=O-M=D1L/8WOD/Y`E__:?W0*@N!SDS].'J4$^A
M[>_F@-XMF@0=JR773#\-7_8<'>/LWSS$)3?,-\>-8(Q4+JIH=>T6L\\3LNX=
M+JOY,".4R:/J]5/RSVR/U]=1L(IB5E=SF:S9!"C\JM'I<WK9+BDLMP!&ZP0T
M'3GR4$D2EB/U`+S+,"H*6<:><JVKQ;!\/>.*2@Y(8`^U*3'Y&+!.JF>T%Z@:
M%8'K0A@9X=?"Q+2H1\R/&:I$0X>(X0EBTW2EI0!Z[\(,HO7<A;KY[+.:49:!
MQNC%O$<O6T;E>HY>O2P/\8<M.S0N?1R9`*UU>D%M+6Z<.("M9GI(V8W6&B;E
MA6N!S?Q+F,DA^;=`L<)L>FO!C8?'=JE]1<&%P>S32`_I'%77AWF$7==_2N,U
MSG)>@?A36CADSQSH`1\(<`'8>3W`AACT:0%[`>7%^4OZWTQ9<%QG:5.`0)2%
M?Y,#%\[@_8\;P1B.7%31.MHM9G?0LN[M=,,'Q]NH)KWGNZ4+#Y96N\-Q4.`U
MK0F?L^()9T&.UV1-PV81DSL>S!5&UT8:#%$Y![*$<NBCB*UX@X61()'K[*Y^
M&GB"FV?E$AJ^J&3,WM3(%[P"S,F*#43%W9.IP7IH5N+0&*:2H4P]=P?:H>CE
M#:0<9Y_:QA#7V@EX,1U>!AE]#9T^(\^`F28Z37N@<,D$H!4YJ1I#33L&@:1E
M!*[3/$>$@#O5V:<25Y&K]HW(GCC^JR1,M_@A^&*_ZM:30)VB,L-HGYU2MX=[
M8]<DD^396DJ""`U`?G60O/ZMCB5PC`<+-13>V('^"*&R.<"Y08,L6NWW(HXH
M(Z3;("L.#UE`0AQ^%<G>MSIQ@%&Q'B!%E7,@AW+$SB)*+I?QA1]C@40>LWOI
M*<'XY\15:`V>W$SFEZWI?+J)9G;';B=05^W^&J'[792<W.SY(Q4:/?3!^=^2
M)2VOHL$.;]R297*&BXB?8#_#"=Y$+M>"^K,#.K,S$'[K0$]/7E`3QC!YNXO%
M[2Y.#QBCDA3=DC_//G&,#*ID)YQN:G.LP'HXJ8CY*C(<=[7,+D<J[#F`':AP
M!7ETG,*6'.(PA9ML=A;IQ:QSOU_E^)][^C;AL\T>G:8]T!$)$X#6D0A58[`C
M$'J!NFGPNCWB!/.?=Q@JL2=.^1B'P0.KF_NA]CK?JFH[NR/5"V*C.CT]9BG'
M&D=_6Q+'O:;.^T,</*H5*\?A-X_I\QM"PG6*_'"L2A)V\RJ#$@_]^IT_.G]N
MU:C)/Y>SCORQ9HHHU]Y?M#SE_H%,QD'\WSC(+I/U!5GI#?^X:L[S?V<3RNJ3
MJ]H-^?IZGL,5H;JGP#M`M`=$ND"TC]YJ<5%6)[[%692N1],)!=OY%4*+K](&
M::,AJJ!A.%P/*N:(<Q]/!QY(N_$^/><&]\5%-,<?FOYMC._;\!GQLU*FO;_E
M95)$Q>&<\,EHL9(U_O)G?!C^415LY_^Z6GS59Y8V&O*]-0R'?WC.')7<$6./
M"/^A.M"\U<=?Z+K9%WD1)+16_&@*H>T#3#LLD!^IBH9B!+TQ<A]/B83'-Q?5
M8WA"=T-UBH<@=WB79O26"ZTGL<]'TR8%=S`]TJ(]TB!IVQ%T1\-W/*TI(\NZ
M%\2[&:@M'Z(89^<D,GE,L]'FH".F4+HAQ=96B5:3X9H@83>:`C#>J&(^\+/?
MX<>(YA^2XE.P'2&@E'.%^O!R=.TOWVXS_-/+^(WV[1OFB'(?^/'_DL;[I`@R
MKJZC30T=ME"?7X&O_?V/&@U7`"G#T32@YL[]P%"W_PN.XS\GZ>?D'@=YFN`U
M>QI6DYYV4P4E>RB5,.!MJX:B\7`5T3(>355H+R?_H-V@JA_^UG(V4&EN]ZLX
M"C_$:5",I2@MEE#*(<'55@BAP7`EZ#`;[<-SSHBQ'IQHXAE,GK[Z0'XWPC2A
M80V7@E+B/,Y'=1J.D9Q2,!TQ4U5FHLL\).MC)-V@R>U)-$-@#*T7'8QRK:B;
MC:<31RS'UPBV-]%#'\8M>U'6NA2>V+I->4%STS:V%2E4L0M[6.TZ%V:Z^;>Z
MK862U%VI'E4C(<A90/X68G3_A+$G=8SYM8D:H-4E%TEKR`LN2N&[EULZ38$N
MMBCDT&M/NRIN72'.!RT2#*1;0L7>B^EHP=V8&9C"CZD)(1V922K)I>V2ECVY
MYVLQ$P$A?7>8+`0^&T^#:4G`]4X)0Z%NG?:06J80QL71L>>C&0\_%(QM5K%D
MPO%;\?(F0`HD$9,J#"'1RC=8,7;569)KB89T>^^>KF8;@&C%0Z4%REGS24[&
M<E&)MF5%3V'/\&.4)'/)*[,Y"R'YGQ<\`=;KF77Z_CNSA]-O2VM@+\)_PH5X
M\>J7J'BZ#>@.W9&,IL;S6HB=Z-16]"UG<ZLV8DC+8K1NQ5$*Q$DF4<YUN;9F
M%RO&0E"("#XW"+Z9!(+FB/_H"&"KPI;'/#[B[0H?9[DT[>"JNTH%KN8SHZ23
M>5Z9:++*J]59%_0K;]:)7Z;6WS["`CZEL5ZSW$H0WP;1^BHI'_[0JJN!!NBA
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MH$T>S,#&"P=F):.+_^(O+&N]F$_NJQ_^_M[+*Z\UY.-+G=8S^_C:`9C!9W&7
M^Y!>1!D."2\7+R6A]<<O*8&9/%&'T`O?HY#*Q=N4E_V([=5,?/(NM@@5_F1=
MD7D9\[A]/JF_R.O/5T.=*Z;IYQZZI/YX!Q4LJS#%-]\@%\H]$/'5,UCB,SD&
MKQR"TS?3Q`^#W<%8^T9_W^?\D<.'5+$#((P$_7]Z:(,]8J+<5AK"$FK7:?@P
M-)M2X^&?<,]J$.#N7E#-CFKVT=80:G:X%DCT9OR$#3O@S3A/8ND%SG2;7J..
M0V/V#%1(FL%LY8V*JL[,14E("PJLT>H@K`/O_AH!OX&JBMMNR;@^!3F^V2SS
M'"L]EB,/P+=078'6YQ>'()Q:6UV1.2<JR.@66;3:LP>SR#*=ED:G=9135D<Y
M8'QACB$.1*Z.#*L2,0M4L:'`.2/OC)7%5,-L5<'"*U/5PC18JA4^($-5X9K$
M3GVP3UO`.O-D/%Z$=7)'POYXLV.G,B^_X"R,<O5I_AZ,O+)4"\A6,ZL55IC9
M105.>A2^?'2U]?#D,LM(.Y[Z)N&@Y'%6M/P<9$35RUX6J.J'!I*E(4!$QZ.,
MB\R9[7?D-[@DHA;-_YI6^.41!KB!,U<T@GWK^'AEWF;`-K/Q/,8]8$J>3I6]
MF82MO9AY)N9-2EZUJ^IU^6>L"OUAB/,\S;0G_CJMH.KQ2X6M[4@OY72ZTQ&K
M6V2_;`%ZN,]!3L`7NC*\QA8J*6D']*:62N!*+8V23J:8,M$ZAY&;-J#*Z2BK
MWYL9OP0T;BVTMY%[\/%WVT(*V&6O0HO4ATSV,4)M?/.9-\ZK0(>L1,A`)YC=
M-^37#8LGC(B`[Q?D_T_?L@P$53@2!6TPC1SF#7_&&`&'[9F2U8"KSR-7I;@/
M<1*02&WY)5+G!*5M@>M0R`1OUA46$D\84<M%5-8O(=%QV1+]2MM"%I,H!?DY
MR7<XC#81616DVR`ZWL.W:`^D'R8`M8[82CZ=GFA$[>A*V7:!A-;H5]X>M+J-
M)MGS"7]F?^JU,2@0>Y7=4$"S2E@J,8'FY$0LG4?LJ[WV=$,F\F:B7_`=!5H)
MYU6"V>G<:OYFV_*L4,[7/[Q_MT!?O_N._O_[=]^SN?[KT\6/[]\R<AH)E*=V
M,"^R0@#]2*=0%A`0T78T<'C&\>&U=_N'NE&SV3@D]+Q%KXREXK2B0S13GCJX
M2BZ_A$\TU?PAS>YQ]AR%\BL9H[$&..TX\K#4IR%'XCOO:<E1A>X?"]>A<-D)
M_5/5#?,.54<@1RZG'21^KO3(I7;63J_*^PZOZ=!@<6CR*8?&>'1S5@4*&@7:
ME0H4E@I4CE=U+40Y2H#G/UNWBME77X;_W$<97M/#8!]Q\92JLB1VI!Y</C?`
MDMY&M\0SV<QN"4!__;O>VZAH%^R8)>+DX]KF>XXGP8^T(*$JS.L)2SPE\>Z'
M[Q=OW[ZMKE60WQ05Z!RV!H\V&KO#>9%%(1D;UHQMC7_"M#QRFFUP5.R[E^5'
MY.OA`L5E0*S6+GU&`B8RMX3>)VAO6)<;FN49C$]\"21T,,U9ZY3,>[W6>%Z,
MR0(]I)+Z1>`+X)Z#(ZZ-LV80>#"W3R+UJ5=PI\GFAO%]I@-;KURF\W#8'&!Y
M"0[3!7B/0Q\OT%UZ,R+^.<LA0V/VE7/=Z6=_I'N6$5MD?L#XYV2-LWOZT.OJ
MP`O'7]"'_<J3TLO'#+-=&ME2>*J>_+D1/-*@V547Z-V-%_>-1\'0HW(!;]%T
MB4B?B'6*REZK]Q#$?E'=L4]WFJ<90]D1S"!GV;=RR#88R\XJW%]>+#TNG#"-
MKNG*+/`A/!JX/=.UO-0US'5M+>I:H-*UB2HSS.'DAW;DCX\?9\BL:D2\;`\_
M!@3W^A/_3OY]DA$<Y-Z]<NL3*IBF6,8+<>KTW9VS--E+MZ<M"3USNAU(5DZT
MIO+'*1Z)Y.[DV*-*C(-W[LJ$35S;ECXH07&$]VR'E^):389KD*.Q^V@:QZ$&
M-]7JO8\/Z%#ZXP04H.Q6RWZY`:E,/5:S?CH".W26GL#C%>4`EU"N$.?T"3Q<
MTAQ:LZ/SQQ](`=DMK$#.DME+U&/9`WG^:P`PU9%9#TYN#?Y<ND6$`MED>7QW
MLS\F],?NY9`LD^8^6;Y,I#XI;0]MWPJ:E?%[//_W]P)5@G@V-\"\5GG.5%E3
MHP\#?]R"'J)57-"A]L)-Z$1SCQ0J1NJR$N`Q@RU6I?_H5`RI3HM[Y41Z?%=-
M2%$?B,=#RH7T"2Z&N!4E!W_\B@&D7=SAIV?1RM8C$O';M[BA=78N'@<J(SB9
M,F(9Q\O,<,:=G>7/V6V87F?9V_1>'<!4`[0ZFZY#-HD'<I2HU[EJD85'IP"M
M\"D]389C>H&%W>QJ6+#RG#M:AC1`5TGXC=_GIOO;H83<*S-4PK,Y[^R3$<J`
M]#BMZZD)VJ`;:(%S!=J7VUV<'C!^P-DV2H+6<0;WU)Z!FV\!N!5XNV!<R\JC
MP-Q"SAY!>L45"6R;\T\>9A'[#(/2HO/]ZN\X+*A%XVH@"F$@ZG,Z/B<>^RN&
M+K8WC,=,2<JQG)P-,W]\G#UTJT2F_Q[.5DSW!.<+\F^]!V$$]^:56QNH#9JT
MZ`1.;8;L1344K%%5<>"6(.^5R]!Q\VI)90O>*L]ACQHFZZ&%V2<'4CL^WK@N
M5,%X>K0BZP'?QM_IX/N=(U$.18^$B8:75Z9N!]PFE6*-&"2OHH/8(\FB4W*/
M3-P9^E`#GRL%TQ3GNME4NRK.RS<Y$W\6(V:H=GD6&0<O%A\F\7ID5<2"?$2'
M?YGRP,&@;(H#:J51LKIR^5.,\[RI(D>KFNX+=@>*#D^U4^AQ&L59`739$[&@
MGN;$R<3U2JLWXL_P'5[3-<[Z0YI5V[YZES4J>T_KECH.CU/M4DO>_M4O=1)\
M0`W3TE.21BN,JJ[86<]+X33%-)[37!)PIN'Z$$19F9J@]U[XD&R)SZ1N((H/
M*&-,@U6,FZK1GIUGFUVI-'5-<U&I,E&I;,8+J+BI<"P@4[[\HJ7PH)2I'(2T
M@JE>^LG697IQ3?5*6T=+LOF/L@U`D',$_7,>B@CD`F^B,"J6(7$0>[8SSH.J
M"_R,XW3'GO$H@D<L?9*K%P>`.*(?R#I4<".?-QKH(UM'RTHF2.!2+8D$/H@Q
M`GLK#`8NS'0\.\S9#KR0D*$)+ZZ2`L<Q#HL]"36RE*R^BJC'C38KGK[E8AP&
MPBXU8\'0HTR-M;0]$C>$M[AH$;FCAKU_>9S^8R*K`$3BYY\_?KQG@;,0;4?B
M:.QJQA[G=(:JBB[%8S<X,YV3&=<WVK/TQS6Z#H/5R9F7XAC=A'4_1?/RW.+`
M$1GN%;WRAJ/HA^9<S72^<+[W=]F,<1;D],6/+7T6APWRIS1YQCFMV5S6N^?G
MOJN:#WQX[W"8/B:1Y*-`".#OB[_C#K'+4\'3C.W4"9]9QU1N]"O*F>[WU:SK
M1Z.HT:^CC)AYFN7L@<+J>)U_[Q!/-DH.#QBS3D[X@(I2+%`MA_`R2"E*5<^C
MFH\%:5ZB.V5*=;-C5V_F]Z6.O;\T1]IK<(=[T4&CZJ%7<!W&25P"][ZE%/W\
M@=\SU-!1MIJ>AI34&<=5W@8'-CHWFSHTIX=HZ*-RJM/;>A(8IV0#H_(D+O)/
M9OX&@3OO^)7-Z?9PLQIFQYT8"81M.4)H%FE,;/J4]$S)IX''(#4\/$LO#3D$
MJ63@3P)IG".0/&/T`DY`NF(>Y0"D?VFA<<X]/E=??>)CC_?[51ZMHR`["+?X
MEZN\R()0_@2)G@#"P]A`:-R)KO7,OL,L2E=E:AJQ)`2JJ&#\00\<584'@>(G
M(%L>]A6$RA5C[MS?!EF1X(Q&^$%R>,!?BC-"_@\9`&53`%LTB%U;H:+=O/:G
M%4(2TK+6J&R.:'O$"$",SDWXN[]&Z'X7)2<W^VE\A-',^@UVR)OWLJQQ%IS'
MYWPNDP)GNRS*<:Z8)ITH89:?#J"HR3J0S6;!SC))#F4=GZ>[W^]V,;NZ'L3"
M0U9AG.;[#*-?*X:S'[CS"JP/MO<G3+Q#$#?RYJHI<B`OW^S3`KB=Q6H8>63#
M1BDM%+WAADIV@I[GZ-=F(O?0KL<8`+VEPYGWG])T_3F*XV6ROB*R)8_1*L;+
M/,=%WHAGF&0=><"8<R^@HAD[,9C=?'M(U]':ZRADNPQ-31H/IMO9@<UG>VH\
MIHG4BA+&SAQ`B=9E03:[35G+U$VKUI2(D[:B.@\FN_[0NK8$9T!G01[E-YM;
M,DC5LI>XB?OH,8DV41@D],9(ND\*FAQ.XRB,S"'J,)8P)C?&,%0;G6/BGVPC
M="#@8Y5F[&AN7V3(#G\)+%'#$U5,04UYWH'8;[<TTTJWDO5C`N<-[C!]C3@L
M\)H^6TC&@?Z'AMK/04S]U+(X#[+L0(1E>T0*!^#,!<;F>X*MS'P@RLDLVQU6
M)\M:<^!OAU+M93\(7!;H?)]EDJ>JY[#942'2/5HXB_N4)O0<?$`=P%42IEM\
MR0\J*6Q+TQ[&BHP`*GNQEGRP]A1I$<0JW=')V[DK3QFAE&[QH8BU7:`$3Z/R
M*G-VD5=LBWAC]*IL_AK"4"<8[#G7EB&ME8`O,/_O54+F=%I:Y`)O,/%]ZQ(+
M\3\W5&J^#%"N%OHQ@UJ!#H%>6?PXF">SK-X@NTM5S@"]JEB]ID=>2FZH9,.F
M4<:H7-#.7;QH5,P5N/)8+;_HP8TWF`"=C6>'_IX+Q%P8A)^%^ZQS[J)Q*`_!
M%R[^=12LHCBB5P@_X8),-2&/2)6;$];T4+MEC@#;.V26Q`"[8DZ2R8J.,'I$
M&%2IP%<"C]<+1-BPVU+A%$L2LV,='6E!D,8E[8%$06ER,@DTEYV]V:$-.'7&
MKVD+IUNODO,T27!(DS&_1,739;[;R4[W6!("G$AS@E2?3[.BFO>TFH-(JNOW
MK5/F5PEJZ!%E@"@'F--A(X!KU1:@1\@;<)\K<)US9%.[@=G`W=_>CN@'JJ/Y
M-QM1=N%@^TUS%%]W0Z4?'P`O,01P[33Z,)G7A_27T.GVAI^7-CP!#^.#/`$/
MF"_&!4UVWV;I<[3&Z[/#SSEUQ!^BA&`A(BZ)-WUF89GAQ%$?1D`9YMZ0Z]3S
M8*S3I7?[@.OD?7'!-V@J-FAU0*\H)Z+,KU'-##7<`(\EC0:;0=[$Z><<48U!
MFQIG4)-W;N-XL+5CLDPSG6=;/4J[<T4R_RZ*SJITNRG0]M,#SXVPM?+F59GA
M>PUH(-VL97MCUWHKY9C,ETT3.1SU]H@>QXP;(1W!+5/D1R<'_-CA,((YY[$>
MD3_3'PN`V,,8Z5-(-B?*GZ^)".3?Y%_D!UHXA?SC_P%02P,$%`````@`B8E\
M0+V1V0:8(```UOH!`!4`'`!R>&EI+3(P,3$Q,C,Q7W!R92YX;6Q55`D``[%^
M<T^Q?G-/=7@+``$$)0X```0Y`0``[5U9<^,XDG[?B/T/7,_#=C_XD.SRT5&]
M$SX['..R%+:K>_:I@R8A"=,4J>;ALN;7#T`2/`$0/&0`['HJEX2$,O%EXD@D
M,C___7WM&&_`#Z#G_KPW.3C:,X!K>39TES_O1<&^&5@0[OW]__[[OS[_S_Z^
M\<^KIP?C%^`"WPR!;7R#X2K^[(OI_V%<>YNM#Y>KT/CA^D?C=6L\/1DWGNL"
MQP%;8W^?=')E!HC6<Y/>I@>3]#L'NG^\HN\,Q),;_/0>P)_W5F&X^>GP\-NW
M;P??C@\\?WDX/3J:'/[SR\.SM0)K<Q^Z06BZ%M@S4/N?@OC#!\\RPUB@`OG[
MJ^^0#HX/L]]BML#_VR?-]O%'^Y/I_O'DX#VP]Q(6!?K?(\+@#VCB3"XN+@[C
M;_?0&!C&9]]SP!-8&/C?KT_W&8W_#C<KTU^;!Y:W/L3?'MYX5K0&;GCIVK=N
M",/MO;OP4`LL._IAW.E/X78#?MX+X'KC`/+9R@>+G_=0AQ#)-9E,IHE4?^/W
M=UCFKWWWCV88^6"VN(H"Z((@V!.1L4[4FX_G:+TV_>UL\0R7+EQ`RT0B6Y87
M(9G=Y=QSH`6!&'>B7?7F^0E8H-2U[[GH3PM@O,1X;>IB@'%]#:`-T7A<6G]&
M,(")W@@-(Y6R/T<;Z,ZB4(P'TK;WK]Z9T/_5="+P!9@!4EYQB!B4O3FZ-C<P
M-)T'U"N8O3IP&9NT&$],VMY<(57T(V#?OF^`&X``S3JS<`7\Z\CWD=P/T'R%
M#M($05-LT5O_\?36:QC&Z*#?N?9B>T+KIBBO7/K^6A]ZUA\KS['1LGZ+S"G<
MBAD`A:PW+S?@#3C>!HOZ')I+\!QM$!7^K^DD/W(#`\OQL+8+<=FNPV'&,MZP
M(,RP9IGBDQJ#M/\Z"L('+PCFP']&/RDV;#6:WES<HVWB&KR8[X(Z7VH_P'KH
MX!WHW/3#[8MOHL&UQ*<T-G%OOFY1(V\+P!7:(R]@.'=,,66AT@VR(H,_(V0<
MMV_"BU"=:``K0N,=3W=HI]1U=N)WL2L>^[,X&(</T,)+V^72!RWV%!2JE).-
M#P(\;V+=?T`_G/X\INI]ZH`A[N3HR-@W2/OBGZ9K&PFQP3RS@/<0N#:PDW,1
MXM?QK%(#!Q_S/+]IV/`GO_.8OGP-0A]-`:0CQWP%3M*3(-UA*Q;3H8T/C`&P
M#I;>VZ$-X"'F&O\1L[]_-$D/FW]#'V5\O*!N*WS6O\[8*2)\Z9=9,WV+=(3^
M+(%>/\ZF+0XW)MY,[5LKZ-B$>N%[ZU:CE7+AT5CW?&0Q/^]].C@ZWC.B`/'D
M;3"UZ7S$*%\B1FS,S)UC+BG#7/E>JW&N\)X/]"<)`TT$0/L1Z"$9[!LT=7+T
MNM).JX%GR)`#<"(!@(3[)["$F&DW?#37M/&G-]-J^.DBY*,_D3;ZUT@2WW3N
MT2+W_@^P90Y_K9V&XU^3(0=@*@&`U"MPAXZ*IO/_P/394Q"[J58PL,7(D3B7
M9@J_`<?YA^M]<Y^!&7@NL.^#(`(^TR28[;7"I$&6')@+:<#\ZCD1&D5_>P<=
M=-IB`E)KIR$0-1DR`"9'\A:)Q&Z?P,;SL9<0'S(C-@ZLYAK"P1(E1T7>TAUK
MR#6:/I>>SUZX*ZTTQ*`B03[T,A;M5"V\]=IS8_]*[,H,9E&(KX#QE37;++A$
M&@+#%RC'2=[98AZ].M"Z<SRSZEAAM-$0A1+_^:#+<%T0(9(-7G+6O$.?T98*
M3ENM0.#(D>^=SJ2#@7?;8E`46FH,1$&*'(93!@R?#ZMNZ+YN\BO3P0%!SRL`
M!%WD%8K>COI2?_-XN%<@A!:6NBT[%?)!KSF2*[G6=QN$;%!>KLU@A2;2;X)W
M5'3*W7#4'D&1;OB7,)4K$,&KF8HBE^]B)A-\&Y.QAOZ^]MS`<Z`=Q_*EM$9*
MW'F.7)C!:SSI1,'^TC0WR40)G#`@GU1GS/3CWS/69HL[Z")F()K4O208B'%'
M@[@1).L^Z7<7Z#((T%!R6*\VD#'IBP]A/N?3>$^G^LE!;:)'PBP`.LO9#XGD
M3&9C3M^`_^H%(&Z+::'GHT4(=2P3P_0LV@AEK9TL1.FJ5\:NQFP*X?2@?K#6
M&D,\!>,X*_0/OHQ_,QT\-5^&UZ;O;]&!*0ZYHV`J2"<78X9J$J@%94BA/SZH
M>[I*\/71`QG0SWVP,2&)"B1!@:61HP`O1*4T[$(2I*"?C`WT)GAU`I(.V:=A
M(0L]'.$KTTJ]#?##+0Y[BP^>:*:*0SP?`=T\><W57'+Y/*>PGJICB8PXJGL7
M"6*!('A"8XO&956(QZ7%3_';JP>5`-,I5F?J8#6,$?[B>?8WZ#@4@\N_4@^Q
M,G\I..=C`^<&;/!Y+$C&X=%S+>;JQFZJ)GAL?E,P+\8&9B(I<V.B*E"$.W+2
M/QK7)J3P1`BMS_48<\[A7YQ4)P^/N%1$(R9C\QP4AJ#9!<1K+`OWMDI-P9[E
M)II,#^I1`%JCG;Z-#>;FUGQU`.<`R6BH`,I-QTD&YP33T3F`TF>A]1&BP\IJ
MJP6R+.8)N*-S]%Q[+F(BA$B3'[T0-!MN$X'Z,#=)0+`>V$,D'^N;E-TG=!9W
M(P[&K(;J8\OBG&"JD'MHJ(L9:FX!COTV$*B/<9,$!&N%W$L,5V"6K&*V^,WT
M\=.:8(YF)#=$1PMG^PS"T`%X:KIW\>43S3G8M@>UT>TD$H%;(8<5`^Y4\BQ9
M13B/?&N%M'CN0PO@4!)HX[10A7>\1:Q;D6L`="MY",JC\V0);:OUW$]S-M+3
MD7F^&&L2U\LL0*,`QJU\'@(B$068J&/(K.E:8&)Z!.%LD2KW'#^R84S=7;O2
M20'Z24KT8JJ.7@P^P?-G=KW0KC%/`!S8_R5]9N<E&J-X1QK3DND#+U<8`O<)
M]<)"8WMM=6VEXD555[@%KJ>F=)^8QA<6<\)\+#TKC)7:2MY%I"BB5+8)E.-S
MA>4/.IGAR+4FZH-8YYD@J)"#:Z";)MN&B2!S$]K8P1,?)PHC0+MR$B!2'V41
M*0CNZGNZ;L`"6A!G2H[649PI\B;RT>:A$`5H.G'R4=IIJ0VUVLBV%H=`/#HW
MUXL?YV/><J=G6B.U`69Q31Z##.7FNDAP=,$2ZX]2NV.A7?$8=L,YJ@/[KF0?
M<9N&J$.XGGYX-TM$T!_80R4;_2>`!@1::%KI^LBO=0]*/Q=J+4WV\*^>!E3K
MHS&)I7@QWY.!*YC((P@;(NB%:76;*%J(EM]U=%8-ZL)/40U6$I#=)4>H)&-(
M^\TR)4S$,R48/Y3Z^O%[YH1AHC:SXP9`6H`XPTRAOQT0<^?:EVM\^?+O^'/F
MXSIZD.=`7>L4RS^<U-E3Q9%YSLON1F33,S\>:#M>*//"&0WN53:A3NHB*E/N
MCAVU-B0I]BZC<(4D^G>^Y#"UH$Z@+_IU67+4:0]`1H9ZG(U7%''26'>TB1PY
MTO6<AJ-#FIU(E#5,TK.(#HDY+8,H`KZ>051KX`MW$BW6>"$JG11`2*#\JFYD
MJWLM>RYW:>>VUA1T]J)^-K9%O28U<T5GMM0:Y.I:?C:VM;Q%1G#J`&F[B@LE
M`4=XCVP)+UU9)H(W7<>25CJA2Q4@OYK=^9+\(4Y96E[ABC-VRDU;FW=@>`N#
M5/^5X81-V,_XX?A=F2UE6--L$P>VN\NL<C*;<4Y;69;5,.K$F#B<9XEK1Y:[
MA"0ONW3M0K!.*O_MN^5$>)V("ZXC";.<9]=>0(.^5V^RE*-1MPO7IMVER]+F
M*A/UQ`AL8TB9EAZFUZM.QX`6Z=:K.Z55HK]XZN73;:43CTB48=5"O$==-4-<
M0O7R[C8_\2^<->Z1)-;*=)?@SO.3\M)HU)[@<E5+:M>Y%_65H(M4`V?O52:N
MDKM\MMU,*`Z^`/^[R>;;/=2.8=V_`!?)Z^"K?WL-W;@^;@C?0':(HMAR,XW2
MX`G*H%Z*WU83-,D\DGC^T$34(+'XI-V^9_7582A)U4L]W&Y5CP4MK5]=)H@!
M.]=5=3H)JUZNX[:K!G?OVVHM:>A)?;WH*MF.,BO+=]FW6X#P8.N]L`A)D&=-
M5F2?.`S6CR!,G+(/7D"[F*E\K[CCN,+MCO*UR<;LUO1=I-(!B?W@W`&PFRJ.
M))OQ/#W;R*X`JB*C)0=:^-`*G2BDAD`T4L@"N4E#62C7!-A1#K<=[+1^`]AM
M!.Q+U+>Y!(_1^A7XLT4L5N&FGP]JKYX4MNA><BF8QFW(.^@7\SW=9%RA/<@"
MLN^@*2T5QIS+=YXX=^?/U21?T(M<S&NP/Z;PG.^(!\+PI;"OD@YDOH^\0Z.5
M9"2+D/SI0'AN<`46G@\R%0?!%^C&/-^[(4`PXJ=8Y5Z2UYY?0+CRT#=OJ$D<
M"\,T^`_Z=2TFD0\:BWQBFIR?]7UE'0ZCT(P=!Y9EYJ:N3^*^HFTH&`T5AIW'
M=J'XR?'IV70ZM@4$EWY]]%R/3+C)<+%]+TT$"L,LPGZA1,;T=')VVAUO-4]]
M3-$YIWH!&L51%Y`@OWX_.[\XZCT7#P8[L]9JLM24XV*+TW"UA2R(A#6N4&*U
MS'EV*O\`3)0?'/XR==)YC%HL3RJ/48LY_G1D"5_;K.(*+N"M86Y&^+POP@T[
MZ@]_!8$3-MTYWK?L#)<]A#AI\1`"]V(DW<C-1Y.)(Y:'AM)<TAT6YF3N>V\0
MX7BU_1K@&_W,97%IA?`MR;[$V5-UZ$2!!TI,Q`I78JWERAY9*#,A,S9=I?L^
M]%<2^1\O-[0=&+>YM&FVL_9F6Q"N7.H]>!@J@_._HM1M\^(]`<MS+>B`TE"\
M>/WGA=W\C)[*MKOQR%Y@C.Q.5R1]%T7IQ,BDY;;<H>7EJ0]%1D"]MQD#16"9
MT$W.E3<PV*1/CV>+)`DD+?Z*WW[,BM(@NGJ/.%A;&2\N,OG$?(K!;#56=)D"
M[^;%AGRKQT7!DWFN,,G-%DBODS+P:/J;^V`-HW7`OSWLVM%8-:G/F`S\ND29
M5V`DWHH;^1T?-AD-QZPL+)FU>362K(C$&SU;)/?=]RX2-Z+-&J)$8P5=5'YM
M'GX4'KLDV6B^F*Z-J:&S?0(V`&M<V/K.\_&@?=W@]\[`MV!0*(5-4Y%!NAVU
M$@TR0MG3$E76G&8M2_*JX^G2=+?\]U7/P'^#5N.+M$X]_E5TJ]/@[.@-B_R=
M,Y8:9_E'-H<'`>WEB"T5Y)_YUXX)U]1PNW;T8U6R#D-!5$HA]S*KQG9L#_>N
MR`OB>_?:<UU@84E^@^'J5Q.)$J75.M*<<.Z2.H'MY&?&JG"[&[%"E*`^:RA_
M'N^>O$6@KU%K6/=A(6JDD(>YS?26EM$.YY&/9`P`CD%`@^@S7WEWZ674JM-E
M0`HAJZK,/8.]B<!I3L$-2/XM#&5:1):?1U.8>*PJU78<B";1*[9H?"]:'X1+
M*_'#SLTM/B`+*5"-1F+4<TO#8&M#3:@=O6)7X-16D_TF`B]>'+?R!.+R5^B8
MBVWIFEG]KT,?8U"21B'S5_+C5YI4@"?P!EQJU5`!FE$H154H!5_/[W#Y\-%N
MOE`@4W0%J9&-015H<HWV';UX4%NON%^=H_;:2$GT9&3%IQE#D%SV]XP2YW:B
M<90X5RZB)PH%;;)\(W$$D07@&Q8J3@R?Q(E172#LQHK9OX#JYGX,ME0$QZ%\
M7,JX*]`)*CW*I[4`GE>>'[X`?\T/GQ*DTU,;6@A(%&-T?JRX(`2PXTP0SZ8#
MOIAAA(6Y=.UKSW&2ZX6XQ@U73;KTHK'2=!$WKTPYLCUGS83:5#5O0ZRQPK20
M,B]_-O*I9K9HI2AMJ#76E#9B$E51R!W*W78N(ORX>&Y"G)?\(3FFQ^\4V)M/
M#HF>((O)1I`=G<]2?/!Z'3EUU8ZV4N9E%4?EH,#RX\T4^@=/=V]H(L370`!)
M9%<]?!0]:4>N@U.BG419PI6_@E9<(FOQ_2TRC#@H05@=:G3ZZD%-%*(``_NW
M-[&^(7[]<*QJ\+O$9$*#*P(6AJC"P"[L1!5N7:GOMJ+-QHD'S'3(@-V["\]?
M)XAQ$K>(4NJ@"L+"$%50R$L]_,F2)&@C'MZ&HV2]N33(VVDS[<!8%X9`/G#0
M)OH9R9?>B:#X[$2]W"Y^K1F@9>8)@$,YGA4!D(S'H^=:Z,_\;./:6>AZ?L[!
M+Y,=+XBX]3WZ=ZF9HO07F"C7Z&(J"T'M$]KR7_I:%NQ#V4"V#RA)1;#5JA8D
M_X5+X<$"#DA&`MJ7<2ES\CZYX1U([]['H"F##PI1-/6=T/W?(S<H6.=>QZA8
MG0>#*)1"OF^&0ETZ<>LX>PH2U%R"0CEEZJNT)HK1*$*3H"09E4(1F`R0L_LV
M/!:1[\)@A=]5DJ=R^.ZF,$O20&_;PVB4H*W@1"D4>D$]S'ZT,"TFV=C2,`#:
MX973=@R*T2`B48&A'BLKHP)IW'I\S3M[=>`RJ==S[UKXG0I-$1HIQJ(.C8(2
MI5#_Z7&JU4]H0'QHA<".9[:O+HRSJE%>7#]`$"4^WBO/C1B[AB%Z'8.R##88
M1*$&]JKM0*&>H]<`VM#TMX5`98873(1@-&K0("?)5:B0:TOT5)KH;18J*'3F
MK-'(P%E<8=GGQ9H@'UE@9R`8ZUD1YFBF*J=&J#I:&EYB#-F[?JK16^3>%8@^
MKHA#>4.,CDI)!0,\?](4HXE"$[";Q!AI6:3Z:]6Y#S8FM,G[95)FR+7C%^[,
MK.==.QK#`U\Q24FZ4E5*9+)JYV4YYXH[V4(FUD)Y<%YVTF[]C&9WV$W\_"I#
MF1*+.XVZIHRM>-0UE5AMX=J_9N9VHD-P6!>Y\L>.PYZ=I(>&T2:%IO@P.HUB
MKPL$=)T:+T873KDCU[#O%.\\_PELTH-$HRX($&FL#`+2?63U5EFO$;&DLUBN
M@%Q(-P6.,F@TUH5FX90[A;&/T45I\A@#2C)=QJ&Z!;V>D'<0=*C*M3O/<5*_
M`RC[AFZ#S8:&NR"AQH`+2I@575`=ZHH"%S<TZ`SIA_#5`8]>"!BY-#OVH;$"
MM!<V2VL_L@T`VO"DNY_9XL%SESCG"^,FFK(5:$6MI[ZT%C/+$#XR32D:3"''
MZ/8&O#9EJJ@WUU<7^')E^9F563(DN\[:=_#[5&?U:#-0F;+T];,6GZ1+5Y7Z
MU40>I$*YOZ/?9E1)%%.(%GDLFF7+MA:[7B\^'Q9'[P%QF7Q<_;0TJ.`]!#A!
M"Y&K-*QH,[59F?[:/+"\=<)%YI8-"G[9I#C5"H30PG*E_<,0=W4T.9D8^T9&
MA_[&5]J>`VTL3OY%8'@+`W=IQ'T:/Y1Z_7%/R@NK9A]TZ<45K_E@*8:R6V.\
M1M7NE*E'/@$JU?W\PH*0L+<+JF-_T+"W#[&X1YQW#YU=KJ(`NB`(JO:%E`39
M5'Y=B/Z3D&![RH@D6,_,7YIN6G@W-WD8EW6?%T9HMDB73]/))P..F0W4KY1]
M5HIE&@=`/W71&LFRSD$QS#91%`')*KG[6-6/62:C]=KTM[/%,URZ<(%6,#=,
M"WV@F6N.AM$J;*9S4YY63?G*#&"\,A9'VS!=M'`F/X&_*_R(D?^*D?V,G-KF
M%6$Y%LUK+,-,XT''20D+MN;:7"A?D(9<.?3KM7[=2:N-U(@@L>=^\GW81>R'
M&#[.2E(2V/=<]*<%2EF%<X,_KAI\TD')C,M=2#7FI#P:?H-PZ_OX81N")TD$
M+&3>(N0R#%Z$0YZ%MZ27;]+B.!(C;RGBZ-9S2J!OW9I/JM9\N<'AF:91I)*Q
MH*7'@&MO_8KV:4T&RV\N946N<Y2/,W?M%22499(BR&3KK*`L8[.]#71G45BW
MMD^UM?.?T,"M]W%S*;=M^87!BV^Z@=FX-C:3#.(WPOV[P$_KQ[,,AM]4EHF(
MCFKF)6)*,*ZM9O9VZ`LPL0$P=IBG52O!=$9,:)0HI5PF9+4C+ATG?LI0_(A7
M7%:,4$H>!.()N7<1&U',D=AB)4PI[T5+&[RR3`BB8HULX6H(M,A-]*QJHBFE
M$9,:15H)^APSP3/&:@/9F2>"[$*VZ(V<+1[0W@D`,5/LV9\L`Z5C1<M!T4&H
MD9EG6C.3I&LB;^G2DKJ4RJ*YP9[7SGE)7P;I+/;0QMT9:7]&L4,Y#P-PJ!L6
M,V;6='@FS6TMT4-#(O;J]4X)?(6/<H12#`1<.(/]@*P90`#GBDMG,)%'-C_@
M,&*8[FQPSI7T>3[]XN:BMH3GU/%D4*:7L4*RQ1%+/=R.7LHF0(1%[JK?L@-I
M3XF[8)GM`EH*.3*SCM\%K#P'"164,^IFUCPYJEISD>A_C91,@H8GO\RQTFH#
M:8FI2R.,@^W%++`%K2SCHV-02E`M)L#(#.L&O`''BU-AH@/%$A0SOB<CD8]"
MW>1J04R%[HRX/Z/886J#!1(9YE@5^1:7-4#8\<_+0E0R#)?-V"_`!;[IY*/-
MO0[MV(\L@VZ!(K'RCA*.RP$=3W579@!P0D)\[C6IMZ*36E!33&C$E$:)5(;.
M9XS%#T(S7M);!YP&/HBSMKUB=LE;<IYU]^Q0BN&+\GQ5Y)D[!?3M4=ID,(@^
M9/-$WV$8V1[A$80/7H!K.L92U^>*6CP4HC`PB8%HC(1(QK[;]%V<U9LPSMN!
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MXF5NN/<P[+;R*LCRQSTO%<YD?6P65(C;:K[6G!P?B2=B4.7"LY`>H"ZA6"X&
M'IV<Z]&4M1=*LK82[R]R,[&U&OO\_K/,//O*0^K8)T+@9=QSX\GD'=+>XC>T
MEXY,285J$-"95@N1"H\WWMJ$U>HP^:U[K9UT!'B*E'DGZ;RK!40A:^87L'X%
M/@4$2ANY41@,O2F&.E7XW<T5K)206-N&">]S$^(<ITET-Q.\AO9*`]G`^VY*
M'\D`]<6/GV1M^79(;:4T@%2.=Y-J6^J^`NWIP3WZD[N9*#22OG[Q=Q`%3MDV
M)G7`GRW@FNCLUK2!*[=3?-C+S*8C?ZS(R*>\?76##;#@`@*;N6GCM)6.`$UQ
M,B#8?*NU:9NC*1)8(`@\G[E84-I(&_PFW<G3\-9X'L_&[3FR&B"KM5`>L!K'
MX]F2L3UKW+AU!::XVF:$':2>KS)GO>O";0#2&/O6M66"5BBT2X.K]+7"0)7X
MS"$ZN;@X/QD%3GF5CIO(QPG38J82N>=9L29F3="6]`HCW4X0H@JG!^=GP]9Q
M5$@+XB0EW96`0:Z=#C#DR&>#B5P=8.0<8D@3EV&#Z]?(#]++!?)H/M'U"K[]
MNE(3ZWXRY;@?GQQK!'RLQFSQ6N#>V)-^L#>*5%C[IUK9>Z*V+]X-Q&DB/;\-
MT!1:_:"E"%$`\_3H0CLC[@9FG50_+.LR%*`\/SHY'<-N[-+^5Y2F]'KQ&#<O
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M';3(IT([]>3$DM<VC9M=?C-]&ZVQLP6:(1<`XK)NK2_IQ/I45TT&$*ZXI)P?
M=RX4J\R$P3O<#*M"+;K43H-:R%92H$\*GC6:_2!Y5M([`+ZZ2!XT<*[]NLU2
M!Z)Q>(UBT)8^B$>T]4U"CU]24WUV*G)1J\Y.!M[(#']`:G2I[%C%^OZ0?AK6
M5^+2M'5TH;%^X<+45YX;M;X/*Q!JBG]!@A*>4UTGC&3>[()HC5(_2&LBE#"=
MG`SLR/S@58#C`Q.CTP_0B@`E.$]/-44SW=JTA[-*J!^>50G*@!YI;9^I(XUY
M"]BE`_T09DE20OILJOR%!5>!^T#-[$$_K)FBE,UZ\!`QZ1<-W/$H5$MN[4XL
MTZJI$2V%*!O^I\EX0X5R+WMK]"FDVH%/D:&,_>DGN7%B769ZDH_Q!?CKM&IU
MY@)HOW5KZ$U-R'N+5=:"L^GYT'/`Q^[SAE()D<[TTP@1J2H*<3I\`*G:.P0R
M/'$C\C0*)WIMO5_@]:2F[O02J:(XY].CX['O)YC#T7)SP>E'.T5I$JBB)A>3
MHXF&6X\\@FNV(&>LUCL.>B=J(MY5FHIK09W#9H]82/+LZ@H\`1LOG/AI)3EA
M\_5AT.X5UI1!Y2P^A/ITW%F#U`F$8F>0H#7Y_5A5J%G<DF3(?3.T)&DD$`]^
M*!&N)Q":2'J;5`)BYM9A-50Z?1Z+Z13#,YE9=AAS]`U80`N&EY85K:.XB$6R
M&E5+)U*!ZM2#L@AVDH8D4-)MTX66AWPIN7=#X#C`"B.TK/@>FBI"V.'"3JA/
M-6??@80K/A<]/SM6?'_6D.1@0/T0[U(_]1"7K:@=%Q?*[-X_\#EZ5D.S6)GE
MT7/?0(!C9]-@[,2S3L(ADE%^`I:W=.-..SYF&>K'U=30CQZ%TONJHX$C5/32
MW^)#X(]5WI:_/$;-;3D$);6=R/6I=EB5>[K*.'VHJ1L=A2D[RD;V^).[2WT$
MW^*O6E^P%`C55(4V$N3X3V7?Q>_^XJ0#Y%4Z[1"O"E!(MC>2[$Z-Z8S9#7^?
MJHHHG^<4Q&'RY18=G90I6V;A-U;=MTF_NF_&#TG2C!4(H64Z/WZO`S>L2-_K
MP'VO`_>]#MSW.G!J`/&]#IQF&[KO=>"^UX'3QA+_*G7@_CIER50I"/>]+)DZ
M>XCO%:[TG+5JOA7:E%5H)-U:VE:OI"PQTE?WPI,_GYI0D=M:.@1,#RN7[=T8
MC_0KE+FY+;KEFE+C\YNK"RV?;W:]TOX3XX>X5Q^@A1/`UM^D$9?J=/+)V#=N
M8&`Y'E)Q@/Z3TA@%(@GZ]XOGV=^@XURZZ'`4FNX2HODQ*1B5<\MQE[:DEV%B
M;+Y>$,Y7Z)?_H`@F1"7+X#JA1FQ12++=>#M$KS\^'V*.7\T`H/_\!U!+`P04
M````"`")B7Q`7IRK$N0+``#`<0``$0`<`')X:6DM,C`Q,3$R,S$N>'-D550)
M``.Q?G-/L7YS3W5X"P`!!"4.```$.0$``.U=VV[C.!)]7V#_@>N7G0'6<9S,
MS&X'R0R<V\!`.C:<]'2_#6B)MKDC46J22N*_WR(I6=3%NCA)MXSU2V"+54>L
M.F2Q>'/.?WOQ/?1$N*`!N^@-CXY[B#`G<"E;7O0BT<?"H;3WVZ]__]OY/_I]
M].5R=H=^)XQP+(F+GJE<Z6<?,?\+707AFM/E2J(?KGY$\S6:S=!UP!CQ/+)&
M_7X"<HD%Z`;,H)T<#>,RX:R(CQ'4B(F+WDK*\&PP>'Y^/GH^/0KX<G!R?#P<
M?/EX]Z#E>D;P[&7./9H15T\2A=,!94)BYI!$WJ/LKPIQ53R'"F[@"_)Q;88?
M/GP8Z-(>DI@OB;S'/A$A=LA&G+_0<(6YCX^<P`?\X7!X<CI,H*&4UHH2C_B$
MR=N`^]=D@2-/7O2^1MBC"TK<'L)2<CJ/),D(1,P22=WDRLWK;*-_'IC"1!1H
ME^N0B*RP(,[1,G@:)*6ZCOWC83\UB`'9D5_N7%?R@=(;@%`?I`BGSD:O7BE6
M@&:"T#EF+)!80I/5W]63,*1L$<1?X8'BY8P''GD$=:0^?)J-MSA;E0[NJ$.8
M(*,E)]KAHH>H>]$K/MZ\(WF+2Q:445V;XY/ASZB/KJEPO$!$G,"7&`&E$.>#
MO%X>,H(.,F&_ZL\A)P*TM+EW\"#6CD6J-!WL.9&W@V):L^UZ\=/$Q:_P_`/8
M9APS63S(P/EK%7@NX3=?(RK7AH5JD4I&AJ<07M`&`#Y?!4P$'G5U!$N14;!`
M%K;X)S+PZ(<IYB"P(I*"1W\\L->$/=&`/M&,O^/7\7?@*\/7=>!$RE\CYMXP
M"?X90]P$"?5^PU:E1"57BJE$V_Z(F8L,%+*POA4Q3?R[,Z%O1\PE]E2:\K`B
M)!E\LH^JN\FPLIO$2,A`'3R_W?.98%]"0[:\AI/*H2?+R?<:9O:$(WL(&<,$
MQ2?%H25^7LW)28OAY.8E5*G;H;]LY^(*B]6M%SR+(AUI434C/[5@1&$B#7K@
MI)Z3DEC60*Z&K1;I=,K6(;I5LG>/)4P6)XO+2%!&1-R9"D^KIY['P_S4TP`H
M)A*(@]^SO2;R?<S7,"NA2T87T#0A[76<(()DE2VGT*P=2I+0UDRVAJ.3/$>7
M6%#=6::6LW7&'+]0SVO25Z+TG2AYZ8'5#*LSXI`,-SQ@\-&QUW5J9&I8/,VS
M:.`RW&0`#PSE^MU<4)="ZQXY,$D7-)U]EA?5\/%3GH]1"$,-Q\C".%"0I2"D
M;!+)V.GQEQHW%]8V9U\H4KI]4#[X-^/?6TSY']B+R$>"E;>LV%->5./[7_*^
M5RA(PR`;YT!#AH8K'%*)O3OP$)G,/;K4;XZ)V%980\6_\U3$.$@#(0OI0$:&
M#!@>>43<9%H]8NY$A>FKB*NYP1W%<^J!%4G&U5R\AK#_%(8'@[R9X.M\2X.C
M&!U9\`<6LUTJ\'TJ=;`!2F#ZI_(=PM),N4J@AJD/A:Z58FF2,F@'8G)K`-NV
M7]IMN9SHM>0,#=]S8V5/O']-GH@7A*JI/DB\)`]1&)J]>^P9AZ4>C3=:VFC4
M,%:8^UO@2*,C&S[9VTQ5#FP6^Y(^J`(12`T2U@;9EK(:A@HS?PT3'X:Q@0Y,
M9-?&B+P+A)@2_@`E<=?)/ZSQ?6&^#OI(`2!`0!KBX/6,U\U>RB-^209U^T&-
MMPNS<:.+M/+!S[FU*D\MG$\QE^M'CB$$.-8$96MI#0.%R6(,A#02LJ$.?&3X
MN/%#+U@3<DD85%A./1P'_;*"&A8*\\0$`\4@2*$<""@L#9*O$=AX\Y0NF12>
MUKB^,.-+`9!!^#]PN_JCCK+.R`+I@ZIGZBSE14]0:(?J@*M^MN)D<=%39U'[
MR:G3/\'<HQ??2T04?L616<U;WD/QBQ,(S)T"2N$@+8`$(>%JSCU(*I\`2"J5
M>F:71+U'_`MA#VHZ>#/CP?-MC<^1]4ZV7Z5O>2?3/3QO:SJH$.\=C;Y3^.]D
M+O3-MN9FN_,[V7R]>4FIX><#^[@S?,L>ASX'NP,N$2L<1Z\Z'&\.W]\%C@:J
M4%'?^HE>7SWJ#T_ZI\.C%^$F=6Q3A=0'[:J0Z+VN"H43YHUJD==2=?B@ZC#\
MY55UL(_&MZM'P.YWK,H"B[D&*SW8OZ46N@:VYA+C4"L.B"?%!JN?8K6OS0;S
M]9513UK7)7/MP26T<5WR.NK#MK>K"S'Q'0]A[L'`P_B!KE/U@=S17$@.J;Q)
MDU1X^[.9N(F1^O+,&3RC;#F6Q%=9!-@&R1(H1DKC=QY$82)(001BE?X,,8P&
M[J.&<2,>KX_@^`47/<DC@&+4@Q%"!37S?5!FX)A->>`0(68PN$,075F+5Y9A
MU6*V07[`B,1\W=BD?#6+)IJ()Y.BN3F\"::3.95;[-IL]$T6GS&'29<4TT!"
M.85XOGX@$J*]>NN8J9-2EJ5M%;^3[0XG[E;CXXV4S8*]G$9`&03L*40IHDZ-
M49=P:UE-6]Y*JY-F-ZCY/9&316SI%&)/S@6[(G31'2J5<:@Z:!/YD5Z#N(Y4
ML+&Z+O;T^K0=P5HH=='H)#Y!!+:JG,S^RY>/XZU(RPNO0GEGMZ0!OT4X+#?H
M'FK])IYI#M1%YU@A7^UY!DS;,(9*0PB`:'`;<'.3$/K!3%VR%>7C16/E[^6$
MRIYCKA9[0.S(]6$.I)()29](LE%OV5PONC\T)X/\6(B(N,!6C7&UU+<'W!]G
M&9LRC;M%LWE#S"ZZ;&NM*R-CDVY5`]!%9XR9))P(:5\8BF<2V8).QD*U/SEA
M<4].&J9EQ);R+A+QF:A!A[BC)VA;2W(?^7/")PN]\3J)I$JQU"].J+/PCAK4
MJ1=)]=,%&UMW!<C,<I6P>!=7U$4O74_Q$2J)9<"IMYX1EQ!?P4.D47.X3Z'*
M3PAWJ+`F?>5Q:W>T3K9SF,N8?J@:-'SR(D6E/HUGV5\IU4V[`CT[GZFDO3!L
MEQ5VL>>:()-$E\G"G!L:PZR(1]:19BL@5<IVT42K9YE+:FI@PVQ=G1X\$/X$
M*?66+KH34!>=<Z6K.69-TLPQNU*_]J//%7RF<O4'AI='\9'#6\K@;=!E;8^]
M"WHG@T'CM+/U)*\!Q-XTK/S"U]95PAV4.]DLS!C@$$BP@</"92AC[':9#MNT
MB)BK3BY1-?O4%R.N21@(*@N654AVL>%"(J*W(8@K;GG@IVE62>3*YB\MU/;`
M<!5XE)+N>D]J0QM>>1]((J9XK5Z_W?@&JIULV27;,N5CD\4I]-R`0_L>B:M`
MR"0IJM[KV1FTB\WF]1.7-YT%=;1IC3POWDJ>+,`FF./ZZ=3`CB-U@EUL`JIY
MAO&6]&W$&14KE:HE*8N*^U;CMHQMJ]A%X^/F.B-JE]V1Q-5U_<1H?#NJD,G=
M41*9'^>X#%B49?\MP#K9_@L=VQCP&.A\AY.J&%`0[;J%379X\]&_/#=\2]!.
M>@TRAY$0!)JW(=>%OF^6?G)')NH$.VF=JMJFGBHS*EB1RY;KA#MFI<V.?>E`
MM3VS1-)+>=XFT%6;K#AKCB=,-2J,23-"_7G$A5:`["P>G$VT2BS>6?W[K&G7
MF:VCT/;*UUA=J[UGC<!P]1A<0[=T(#VML[]$OL,T-[>K*/[-B-QFV,C];R3,
MC7)(&5Q7CW[84^L/ZCB=_B6'S:::;GY;EFOCQ/VMX/:RA>O"]([^+2&?&"0;
M#VH_;K[>7&(VOU&NSI\F/X+=J#^\`KW#O>>]?/9:\#UK@-K<S<2FB6\LX3VS
MU72'IL86I+O<&7+AM)GL7M+7T-2\<(?)2]8KDT4VMPF+)4K=6K9IQF9;V[=J
M=9-?4]WDT-<CX3YE.#-@-&O'-0C=-%ZWT]?8W@1@+V/8V#K>D>Y6-6@'Y8K?
MF?XFN7LR,[LD9G]!+SJ7G:UJ/AUH#-G1N-C@>H:^G/&1J%-ZB6?::AGCS;\4
M.G,#'U/6A=A@R`/"4G+5:5+/@PEN!$1O+O<VZA:-<#H<)%_OA^8P>Q8PM6$[
MQ,L*O<YZH.PW>].KIK&YU4+YBZ.91M_N?NI;-'KU0SF,\/@$WR-YD9>>WF(T
MQFPMSD0MF3S_IE4OV07,[OK<B#!,#&DHW-&1R#Y(4G+M:;*PSH;GN]]NNEWH
M@N<#<_D</OX/4$L!`AX#%`````@`B8E\0*K$!=!$S0``@F0(`!$`&```````
M`0```*2!`````')X:6DM,C`Q,3$R,S$N>&UL550%``.Q?G-/=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`B8E\0(%F))K\#@``(JT``!4`&````````0``
M`*2!C\T``')X:6DM,C`Q,3$R,S%?8V%L+GAM;%54!0`#L7YS3W5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`(F)?$#+W2-870D``&N5```5`!@```````$`
M``"D@=K<``!R>&EI+3(P,3$Q,C,Q7V1E9BYX;6Q55`4``[%^<T]U>`L``00E
M#@``!#D!``!02P$"'@,4````"`")B7Q`E`M1==P[``!@5P,`%0`8```````!
M````I(&&Y@``<GAI:2TR,#$Q,3(S,5]L86(N>&UL550%``.Q?G-/=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`B8E\0+V1V0:8(```UOH!`!4`&```````
M`0```*2!L2(!`')X:6DM,C`Q,3$R,S%?<')E+GAM;%54!0`#L7YS3W5X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`(F)?$!>G*L2Y`L``,!Q```1`!@`````
M``$```"D@9A#`0!R>&EI+3(P,3$Q,C,Q+GAS9%54!0`#L7YS3W5X"P`!!"4.
=```$.0$``%!+!08`````!@`&`!H"``#'3P$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 14 - us-gaap:IncomeTaxDisclosureTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>14.&#160;&#160;&#160;&#160;Income Taxes </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The components of federal and state income tax expense are as follows (in thousands): </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="79%">&#160;</td>
   <td valign="bottom" width="9%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="8%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>As of December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2010</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Current</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Federal</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">State</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total current</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Deferred</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Federal</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,531</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,853</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">State</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,831</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,283</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total deferred</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,362</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,136</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Valuation allowance</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(10,362</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(6,136</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total income tax expense</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The components of net deferred tax assets are as follows (in thousands): </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="77%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>As of December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2010</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net operating loss carryforwards</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,786</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,328</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Tax credit carryforwards</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,160</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,061</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock based compensation</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,885</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,864</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">193</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">104</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Licensing deduction deferral</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,458</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,264</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Gross deferred tax assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">36,482</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">23,621</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Valuation allowance</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(36,482</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(23,621</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net deferred tax asset</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">The components of net deferred tax liabilities are as follows (in thousands):</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="8">&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>As&#160;of&#160;December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>&#160;&#160;&#160;&#160;2011&#160;&#160;&#160;&#160;</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>&#160;&#160;&#160;&#160;2010&#160;&#160;&#160;&#160;</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">In-process research and development not subject to future amortization for tax purposes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,053</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#160;&#160;&#160;&#160;&#160;&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Gross deferred tax liability</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,053</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The provision for
   income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows (in thousands): </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="79%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>As of December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2010</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected federal income tax benefit</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(3,905</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(4,078</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Non-qualified stock compensation</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(3,189</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1,236</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Effect of change in valuation allowance</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,551</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,136</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Income tax credits</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(260</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(231</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">State income taxes after credits</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1,197</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(994</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">403</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has incurred net operating losses from inception. At December&#160;31, 2011, the Company had
   domestic federal and state net operating loss carryforwards of approximately $41.6&#160;million available to reduce future taxable income, which expire at various dates beginning in 2013 through 2031. The Company also had federal and state research
   and development tax credit carryforwards of approximately $2,000,000 and $1,800,000, respectively, available to reduce future tax liabilities and which expire at various dates beginning in 2023 through 2031. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership may result in a limitation
   on the amount of net operating loss carryforwards and research and development credit carryforwards which could be utilized annually to offset future taxable income and taxes payable. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Based on an assessment of all available evidence including, but not limited to the Company&#8217;s limited operating history in its core
   business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has
   concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a 100% deferred income tax valuation allowance has been recorded against these assets. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company adopted certain provisions of the <i>ASC 740,</i> effective January&#160;1, 2007 which clarifies the accounting for
   uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. The adoption
   of <i>ASC 740-10</i> did not have any effect on the Company&#8217;s financial position or results of operations. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company
   files income tax returns in the U.S.&#160;federal, Massachusetts and Oregon jurisdictions. The Company is subject to tax examinations for the 2007 tax year and beyond. The Company does not believe there will be any material changes in its
   unrecognized tax positions over the next 12&#160;months. The Company has not incurred any interest or penalties. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial
   statements as general and administrative expense. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RXi Spin-Out and Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 16 - us-gaap:RelatedPartyTransactionsDisclosureTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>16.&#160;&#160;&#160;&#160;Related Party Transactions </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">RXi and Advirna, LLC, which is 50%-owned by the Company&#8217;s former Chief Scientific Officer, or CSO, are parties to
   an option agreement whereby the Company paid $5,000 in 2008 for consideration to be granted the exclusive worldwide rights to license certain technology and $75,000 for the initial maintenance in 2009 under a Patent and Technology Assignment
   Agreement with Advirna entered into in September 2009 (see also Note&#160;15). </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On February&#160;26, 2007, the Company entered
   into Scientific Advisory Board Agreements (the &#8220;SAB&#160;Agreements&#8221;), with four of its founders. At the time of the execution of the SAB&#160;Agreements, each of the founders were beneficial owners of more than five percent of the
   Company&#8217;s outstanding stock. Pursuant to the SAB&#160;Agreements, on May&#160;23, 2007, the Company granted to each of the founders a stock option under the 2007 Plan to purchase 52,832&#160;shares of its common stock. In addition, under the
   SAB&#160;Agreements, the Company will grant each of the founders a stock option under the 2007 Plan to purchase 52,832&#160;shares of its common stock on February&#160;26, 2008, June&#160;5, 2009 and June&#160;4, 2010 with a per share exercise price
   equal to the closing price of such stock on the public market on the date of grant unless a founder terminates a SAB&#160;Agreement without good reason (as defined) or the Company terminates a SAB&#160;Agreement with cause (as defined therein) in
   which case no further option grants will be made to the founder. If the Company&#8217;s common stock is not publicly available on the dates specified above, its Board of Directors will grant the stock options to the founders at the first scheduled
   board meeting after such date and the per share exercise price of the options will be determined in good faith by the Company&#8217;s board of directors. All options granted pursuant to the SAB&#160;Agreements are fully vested on the date of grant
   and have a term of ten years. The fair value of stock options granted during 2011 and 2010 under the SAB&#160;Agreement for each founder is approximately $0 and $142,000 which was estimated using the Black-Scholes option-pricing model as more fully discussed above under significant
   accounting policies and the stock based compensation footnote. Included in the accompanying financial statements for the years ended December&#160;31, 2010 is approximately $566,000 of expense related to the
   granting of these stock options. No options under the SAB agreements were issued during the year ended December &#160;31, 2011</font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Additionally, pursuant to a letter agreement between the Company and each founder dated as of
   April&#160;30, 2007, the &#8220;SAB&#160;Letters&#8221;, in further consideration of the services to be rendered by the founders under the SAB&#160;Agreements, the Company granted additional stock options on May&#160;23, 2007 under the 2007 Plan to
   each of the founders to purchase 26,416&#160;shares of its common stock. Unless a founder terminates a SAB&#160;Agreement without good reason (as defined) or the Company terminates a SAB&#160;Agreement with cause (as defined therein), the options
   granted pursuant to the SAB&#160;Letters will fully vest from and after April&#160;29, 2012 and will have a term of ten years from the date of grant. At December&#160;31, 2011 and 2010 the fair market value of stock options under the SAB&#160;Agreement for
   each founder is approximately $5,000 and $59,000, respectively, which was estimated using the Black-Scholes option-pricing model as more fully discussed above under the summary of significant accounting policies and the stock based compensation footnote. Included in the
   accompanying financial statements for the years ended December&#160;31, 2011 and 2010 is approximately $159,000 and $60,000 of income, respectively, related to these stock options. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During 2012, the Company retained TroyGould PC to be its outside corporate counsel. Sanford J. Hillsberg, the Chairman of the Company, is
   a senior lawyer with TroyGould PC. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 04<br><br> -Paragraph b<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EYGBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">108 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetIncomeLossIncludingOther', window );">Net loss</a></td>
        <td class="num">$ (11,485)<span></span></td>
        <td class="num">$ (11,993)<span></span></td>
        <td class="num">$ (77,269)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump">163<span></span></td>
        <td class="nump">172<span></span></td>
        <td class="nump">664<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of equipment</a></td>
        <td class="nump">7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NonCashRentExpense', window );">Non-cash rent expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and receipt of bond discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">35<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash share based compensation</a></td>
        <td class="nump">3,001<span></span></td>
        <td class="nump">4,368<span></span></td>
        <td class="nump">18,858<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_LossOnExchangeOfEquityInstruments', window );">Loss on exchange of equity instruments</a></td>
        <td class="nump">900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants', window );">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(785)<span></span></td>
        <td class="num">(785)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices', window );">Fair value of common stock warrants issued in exchange for services</a></td>
        <td class="nump">108<span></span></td>
        <td class="nump">718<span></span></td>
        <td class="nump">2,402<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Fair value of common stock issued in exchange for services</a></td>
        <td class="nump">73<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">354<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
        <td class="num">(9,881)<span></span></td>
        <td class="num">(3,049)<span></span></td>
        <td class="num">(12,072)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights', window );">Fair value of common stock issued in exchange for licensing rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,954<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
        <td class="num">(109)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(109)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(99)<span></span></td>
        <td class="num">(30)<span></span></td>
        <td class="num">(249)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">500<span></span></td>
        <td class="nump">99<span></span></td>
        <td class="nump">1,224<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent', window );">Due to former parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(207)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump">816<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">816<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
        <td class="nump">1,338<span></span></td>
        <td class="nump">243<span></span></td>
        <td class="nump">2,658<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(14,668)<span></span></td>
        <td class="num">(10,257)<span></span></td>
        <td class="num">(58,778)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
        <td class="num">(101)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(101)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CashReceivedInAcquisition', window );">Cash received in acquisition</a></td>
        <td class="nump">168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">168<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(5,990)<span></span></td>
        <td class="num">(37,532)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of short-term investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,990<span></span></td>
        <td class="nump">37,497<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of equipment and furnishings</a></td>
        <td class="num">(53)<span></span></td>
        <td class="num">(106)<span></span></td>
        <td class="num">(739)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Disposal of equipment and furnishings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CashRefundedPaidForLeaseDeposit', window );">Cash refunded (paid) for lease deposit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(45)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
        <td class="nump">14<span></span></td>
        <td class="num">(106)<span></span></td>
        <td class="num">(753)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
        <td class="nump">18,615<span></span></td>
        <td class="nump">15,235<span></span></td>
        <td class="nump">64,982<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Cash paid for repurchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,849)<span></span></td>
        <td class="num">(3,849)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from exercise of common stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">254<span></span></td>
        <td class="nump">610<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetProceedsFromExerciseOfCommonStockWarrants', window );">Net proceeds from exercise of common stock warrants</a></td>
        <td class="nump">150<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CommonStockIssuedInConnectionWithEspp', window );">Common stock issued in connection with ESPP</a></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable', window );">Net proceeds from issuance of convertible notes payable</a></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Repayments of capital lease obligations</a></td>
        <td class="num">(84)<span></span></td>
        <td class="num">(70)<span></span></td>
        <td class="num">(210)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Cash advances from former parent company, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,766<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">19,196<span></span></td>
        <td class="nump">11,570<span></span></td>
        <td class="nump">70,964<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
        <td class="nump">4,542<span></span></td>
        <td class="nump">1,207<span></span></td>
        <td class="nump">11,433<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of period</a></td>
        <td class="nump">6,891<span></span></td>
        <td class="nump">5,684<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">11,433<span></span></td>
        <td class="nump">6,891<span></span></td>
        <td class="nump">11,433<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the periods for interest</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">726<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the periods for interest</a></td>
        <td class="nump">6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Settlement of corporate formation expenses in exchange for common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">978<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity', window );">Fair value of warrants issued in connection with common stock recorded as cost of equity</a></td>
        <td class="nump">12,709<span></span></td>
        <td class="nump">2,466<span></span></td>
        <td class="nump">18,038<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants', window );">Issuance of common stock in exchange of outstanding warrants</a></td>
        <td class="nump">3,120<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,120<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant', window );">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">785<span></span></td>
        <td class="nump">785<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_AllocationOfManagementExpenses', window );">Allocation of management expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">551<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_EquipmentAndFurnishingsExchangedForCommonStock', window );">Equipment and furnishings exchanged for common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">48<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Equipment and furnishings acquired through capital lease</a></td>
        <td class="nump">80<span></span></td>
        <td class="nump">53<span></span></td>
        <td class="nump">277<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Non-cash lease deposit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses', window );">Value of restricted stock units and common stock issued in lieu of cash bonuses</a></td>
        <td class="nump">427<span></span></td>
        <td class="nump">207<span></span></td>
        <td class="nump">634<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_SubsidiaryAcquisitionAbstract', window );"><strong>Apthera Acquisition:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfSharesIssuedToAcquire', window );">Fair value of shares issued to acquire Apthera</a></td>
        <td class="nump">6,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,367<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition', window );">Fair value of contingent purchase price consideration in connection with Apthera acquisition</a></td>
        <td class="nump">6,460<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,460<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetAssetsAcquiredExcludingCash', window );">Net assets acquired excluding cash of $168</a></td>
        <td class="nump">$ 12,827<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12,827<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_AllocationOfManagementExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation of management expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_AllocationOfManagementExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CashReceivedInAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received in acquisition</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CashReceivedInAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CashRefundedPaidForLeaseDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash refunded (paid) for lease deposit</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CashRefundedPaidForLeaseDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of common stock warrants issued in connection with various equity financings</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ChangeInFairValueOfContingentPurchaseConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of contingent purchase consideration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ChangeInFairValueOfContingentPurchaseConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CommonStockIssuedInConnectionWithEspp">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock issued in connection with Espp.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CommonStockIssuedInConnectionWithEspp</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_EquipmentAndFurnishingsExchangedForCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equipment and furnishings exchanged for common stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_EquipmentAndFurnishingsExchangedForCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock issued in exchange for licensing rights</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of contingent purchase price consideration in connection with Apthera acquisition</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfContingentPurchasePriceConsiderationInConnectionWithAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock warrants issued in exchange for services</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfSharesIssuedToAcquire">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of shares issued to acquire Apthera</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfSharesIssuedToAcquire</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of shares mandatorily redeemable for cash upon exercise of warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of shares mandatorily redeemable for cash upon exercise of warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued in connection with common stock recorded as cost of equity</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock in exchange of outstanding warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_LossOnExchangeOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loss on exchange of equity instruments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_LossOnExchangeOfEquityInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NetAssetsAcquiredExcludingCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net assets acquired excluding cash of $168</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NetAssetsAcquiredExcludingCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NetIncomeLossIncludingOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net loss</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NetIncomeLossIncludingOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NetProceedsFromExerciseOfCommonStockWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net proceeds from exercise of common stock warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NetProceedsFromExerciseOfCommonStockWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net proceeds from issuance of convertible notes payable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NonCashRentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-cash rent expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NonCashRentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_SubsidiaryAcquisitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_SubsidiaryAcquisitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of restricted stock units and common stock issued in lieu of cash bonuses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase during the period in capital lease obligations due to entering into new capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsIncurred</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of assets acquired in noncash investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfAssetsAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gains (losses) included in earnings resulting from the sale or disposal of tangible assets. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in current obligations (due within one year or one operating cycle) to be paid to other entities that could exert significant influence over the reporting entity, not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Section Appendix C<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest received on loans and other debt instruments during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromInterestReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRelatedPartyDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of stock issued in noncash financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization of equipment and furnishings</a></td>
        <td class="nump">$ 657<span></span></td>
        <td class="nump">$ 491<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="nump">50,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">47,811,453<span></span></td>
        <td class="nump">19,047,759<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">47,136,453<span></span></td>
        <td class="nump">18,372,759<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock shares</a></td>
        <td class="nump">675,000<span></span></td>
        <td class="nump">675,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 9 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>9.&#160;&#160;&#160;&#160;Commitments and Contingencies </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company acquires assets still in development and enters into research and development arrangements with third
   parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain
   agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below (see also Note&#160;15).
   </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by
   these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the
   product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&#8217;s contractual obligations that
   will require future cash payments as of December&#160;31, 2011 are as follows (in thousands): </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="49%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Operating<br />Leases(1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Non-Cancelable<br />Employment<br />Agreements(2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Subtotal</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Cancelable<br />License<br />Agreements(3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Total</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2012</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">139</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,774</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,914</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">578</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,492</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2013</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">25</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,006</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,031</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">453</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,484</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2014</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">413</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">415</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">463</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">878</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2015</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">300</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">303</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">538</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">841</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2016</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">100</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">102</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">988</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,090</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2017 and Thereafter</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,173</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,173</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">172</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,593</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,765</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,193</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,958</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="3%" valign="top" align="left"><font style="font-family:times new roman" size="2">(1)</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December&#160;31,
   2011 and 2010 were approximately $233,000 and $274,000, respectively. </font></td>
   </tr>
   </table>
   <p style="font-size:3px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="3%" valign="top" align="left"><font style="font-family:times new roman" size="2">(2)</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been
   revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable. </font></td>
   </tr>
   </table>
   <p style="font-size:3px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="3%" valign="top" align="left"><font style="font-family:times new roman" size="2">(3)</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">License agreements generally relate to the Company&#8217;s obligations with The Board of Regents, University of Texas and Henry Jackson Foundation for our oncology
   therapies and UMMS associated with RNAi and, for future periods, represent minimum annual royalty and milestone payment obligations, of the total amount due. The Company continually assesses the progress of its licensed technology and the progress
   of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, no amounts will be due. </font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company applies the disclosure provisions FASB ASC Topic 460 (&#8220;ASC 460&#8221;), &#8220; <i>Guarantor&#8217;s Accounting and
   Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Other</i><i>s</i>&#8221;, to its agreements that contain guarantee or indemnification clauses. The Company provides (i)&#160;indemnifications of varying scope
   and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&#160;indemnifications of varying scope and size to officers and
   directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&#160;460. To date, the Company has not incurred costs as a result of these obligations and
   does not expect to incur material costs in the future. Accordingly, the Company has not accrued any liabilities in its financial statements related to these indemnifications. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On
   November&#160;21, 2011, Hudson Bay Master Fund, Ltd. (&#8220;Hudson Bay&#8221;) filed a Complaint against the Company in the United States District Court for the Southern District of New York (the &#8220;Court&#8221;), captioned <u>Hudson Bay Master
   Fund, Ltd. v. Galena Biopharma, Inc., 11 Civ. 8432 (JPO)</u>, alleging that the Company&#8217;s plan to partially spin off RXi and related actions taken in preparation for the spin-off gives Hudson Bay the right to require us to repurchase the
   warrants acquired by Hudson Bay in our April 2011 underwritten public offering. Hudson Bay also seeks related declaratory and injunctive relief. On January&#160;12, 2012, three other warrant holders affiliated with each other filed a Complaint in
   the Court, captioned <u>Tenor Opportunity Fund, Ltd., Aria Opportunity Fund, Ltd., and </u><u>Parsoon Opportunity Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0260</u>, and on January&#160;20, 2012 and February&#160;2, 2012, respectively, two other
   warrant holders filed their own Complaints in the Court, captioned <u>Cranshire Capital Master Fund, Ltd. v. Galena Biopharma, Inc., 12&#160;CIV 0493</u> and <u>Iroquois Master Fund, Ltd. v. Galena Biopharma, Inc., 12 CIV 0839</u>, respectively. In
   these latest Complaints, which are substantially identical to the previous Complaints filed in the Court, the various warrant holders also claim that the planned spin-off of RXi and related actions give them the right to require the Company to
   repurchase the Company&#8217;s outstanding warrants held by them. According to the allegations in the Complaints, the repurchase price of the plaintiffs&#8217; warrants would amount to approximately $5.2 million in the aggregate. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On March&#160;21, 2012, the Company received letters from each of the plaintiff-warrant holders withdrawing their repurchase demands with
   respect to their warrants covering an aggregate of 6,350,000 shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the &#8220;Withdrawal Notice<b>s</b>&#8221;). After giving effect to the Withdrawal Notices, the
   plaintiff-warrant holders continued to demand that the Company repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based on the plaintiff-warrant holders&#8217; claims in their Complaints, the Company
   believes that the repurchase price for these warrants is $0.71 per underlying share, or an aggregate of $355,000. On March 27, 2012, the Company tendered to the plaintiff-warrant holders an aggregate of $355,000 as payment in full of the repurchase
   price for those warrants. The Company believes that the Withdrawal Notices and the Company&#8217;s tender of payment as described above render moot the majority of claims of the plaintiff-warrant holders in their Complaints, although the Withdrawal
   Notices purport to reserve all rights of the plaintiff-warrant holders under the Complaints. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">If the Company were to become
   liable to repurchase the plaintiffs&#8217; warrants, the Company may not have on hand sufficient funds to satisfy the liability and to meet its other obligations as they come due, which could raise doubts as to the Company&#8217;s ability to continue
   as a going concern. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 26, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Galena Biopharma, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001390478<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 41,000,064<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,493,396<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 10 - us-gaap:StockholdersEquityNoteDisclosureTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>10.&#160;&#160;&#160;&#160;Stockholders&#8217; Equity </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Preferred Stock </i>&#8212; The Company has authorized up to 5,000,000&#160;shares of preferred stock,
   $0.0001&#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as
   shall be determined by the Company&#8217;s board of directors upon its issuance. At December&#160;31, 2011, there were no shares of preferred stock outstanding. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   <i>Common Stock </i>&#8212; The Company has authorized up to 125,000,000&#160;shares of common stock, $0.0001&#160;par value per share, for issuance. Shares of common stock are reserved as follows:
   </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="86%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>As of<br />December&#160;31,<br />2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,120,642</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,163,137</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,299,717</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total reserved for future issuance</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">21,583,496</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px"><font size="1">&#160;</font></p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Common Stock Warrants </i>&#8212; On August&#160;7, 2008, the Company issued 190,000
   warrants to an investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $7.036 per share and expire 5&#160;years from the date of issuance, on August&#160;7, 2013. The warrants vested as
   to 94,000&#160;shares upon issuance, and vested at a rate of 32,000&#160;shares&#160;per month starting on the 90&#160;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation cost was
   fully recorded at December&#160;31, 2009. The Company also agreed to give the holder of the warrants unlimited &#8220;piggy back&#8221; registration rights with respect to the shares of the Company&#8217;s common stock underlying the warrants in any
   registration statement the Company files in connection with an underwritten offering of its common stock. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On October&#160;3,
   2008, the Company acquired the rights to license exclusive worldwide technology for the oral delivery of RNAi therapeutics. As consideration for this license, the Company agreed to pay a total license fee of $2,500,000 over a 12&#160;month period,
   which can be paid in cash, in equity or a combination thereof, provided that a specified amount of the license fee must be made in cash. Payments made in equity may only be made if, at the time of such payment, the shares of common stock issuable
   upon conversion of the warrant have been registered for resale under the Securities Act of 1933. No warrants have been issued under this agreement thru the date of this report. The Company continually assesses the progress of its research and
   development efforts as it relates to its licensed technology and may terminate with notice to the Licensor at any time. Accordingly, the amounts are being expensed, as payments are made. There was no expense for this license for the years ended
   December&#160;31, 2011 and 2010. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On January&#160;29, 2009, the Company issued 142,500 warrants to an investment bank as
   consideration for investment and business advisory services. The warrants have an exercise price of $4.273 per share and expire five years from the date of issuance on January&#160;29, 2014. The warrants vested as to 71,250&#160;shares upon
   issuance, and vested at a rate of 23,750&#160;shares&#160;per month starting on the 90&#160;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation expense was fully recorded at
   December&#160;31, 2009. The Company has also agreed to give the holder of the warrants unlimited &#8220;piggy back&#8221; registration rights with respect to the shares of Common Stock underlying the warrants in any registration statement the Company
   files in connection with an underwritten offering of the common stock. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In connection with the 2009 Offering, the Company
   issued warrants to purchase 978,142&#160;shares of the Company&#8217;s common stock. Details of the transaction can be found under the heading &#8220;2009 Registered Direct Offering&#8221; below. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In connection with the 2010 Offering, the Company issued warrants to purchase 540,000&#160;shares of the Company&#8217;s common stock.
   Details of the transaction can be found under the heading &#8220;2010 Registered Direct Offering&#8221; below. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In connection
   with the March 2011 Offering, the Company issued warrants to purchase 6,000,000&#160;shares of the Company&#8217;s common stock. Details of the transaction can be found under the heading &#8220;March 2011 Registered Direct Offering&#8221; below.
   </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In connection with the April 2011 Offering, the Company issued warrants to purchase 11,950,000&#160;shares of the
   Company&#8217;s common stock. Details of the transaction can be found under the heading &#8220;April 2011 Registered Direct Offering&#8221; below. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   During 2011, the Company issued 150,000 warrants in exchange for business advisory services. The Company recognizes the total fair value of these warrants as stock compensation expense, over the requisite
   service period. The Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants on the date of the award. Total expense related to these warrants was $108,000 in 2011. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Private Investment in Public Equity </i>&#8212; On June&#160;24, 2008, the Company entered into a Securities Purchase Agreement pursuant
   to which RXi issued and sold to certain investors an aggregate of 1,073,299&#160;shares of common stock in a private placement at a price of $8.12 per share. Net proceeds to the Company were approximately $7.9&#160;million. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>2009 Registered
   Direct Offering </i>&#8212; On March&#160;17, 2009, the Company entered into a placement agency agreement, which was subsequently amended on May&#160;26, 2009 and July&#160;22, 2009, with Rodman&#160;&#038; Renshaw, LLC (&#8220;Rodman&#8221;) as the
   exclusive placement agent, relating to a proposed offering by the Company of new securities to potential investors. On July&#160;30, 2009, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors
   of 2,385,715&#160;units, with each unit consisting of one share of the Company&#8217;s common stock and a warrant to purchase 0.40 of a share of common stock, at a purchase price of $3.50 per unit (the &#8220;2009 Offering&#8221;). The 2009 Offering
   closed on August&#160;4, 2009. The warrants have an exercise price of $4.50 per share and are exercisable for a period beginning on February&#160;3, 2010 until their expiration on August&#160;3, 2014. The Company raised gross proceeds of
   approximately $8,350,000 in the 2009 Offering and net cash proceeds, after deducting the placement agents&#8217; fees and other offering expenses payable by the Company, of approximately $7.7&#160;million. Total warrants issued in connection with the
   transaction were 954,285. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As part of the placement agency agreement, the Company issued a warrant to purchase
   23,857&#160;shares of the Company&#8217;s common stock to Rodman. The warrant has an exercise price of $4.38 per share. The warrant is immediately vested and is exercisable until its expiration on August&#160;3, 2014. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Certain warrants issued in connection with the stock offering on August&#160;4, 2009 were determined not to be indexed to the
   Company&#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,863,000 was recorded as a liability and a cost of equity and was determined by the Black-Scholes option
   pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publicly
   traded. The Company used a weighted average expected stock volatility of 122.69%. The expected life assumption is based on the contract term of five years. The dividend yield of zero is based on the fact that RXi has no present intention to pay cash
   dividends in the future. The risk free rate of 1.72% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. The change in the fair value of the warrants during the years ended December&#160;31, 2011 and 2010 was
   $1,879,000 and $1,778,000, respectively. These amounts have been included in other income and expense in the accompanying consolidated statements of expenses. The fair value of the warrants at December&#160;31, 2011 of $64,000 is included as a
   current liability in the accompanying balance sheet as of that date and was determined by the Black-Scholes option pricing model. The following assumptions were used to determine the fair value as of December&#160;31, 2011: weighted average expected
   stock volatility of 98.91%; an expected life of 2.6 years and a dividend yield of zero and a risk free rate of 0.31%. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>2010
   Registered Direct Offering</i>&#160;&#8212; On March&#160;22, 2010, the Company entered into a placement agency agreement relating to a proposed offering by the Company of new securities to potential investors. On March&#160;23, 2010, the Company
   entered into definitive agreements for the sale and issuance by the Company to certain investors of 2,700,000&#160;units, with each unit consisting of one share of the Company&#8217;s common stock and a warrant to purchase 0.20 of a share of the
   Company&#8217;s common stock, at a purchase price of $6.00 per unit (the &#8220;2010 Offering&#8221;). The 2010 Offering closed on March&#160;26, 2010. The Company issued warrants to purchase 540,000&#160;shares of the Company&#8217;s common stock at an
   exercise price of $6.00 per share and that are exercisable beginning on September&#160;26, 2010 until their expiration on March&#160;26, 2016. The Company raised gross proceeds of approximately $16.2&#160;million in the 2010 Offering and net cash
   proceeds, after deducting the placement agent fees and other offering expenses payable by the Company, of approximately $15.2&#160;million. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   As part of the 2010 Offering, the Company entered in a stock redemption agreement whereby the Company was required to use 25% of the net proceeds from the 2010 Offering to repurchase from CytRx
   Corporation (&#8220;CytRx&#8221;) 675,000 shares of the Company&#8217;s common stock held by CytRx (&#8220;CytRx shares&#8221;). The Company repurchased such shares on March&#160;29, 2010. The values of the shares at the date of repurchase totaling
   $3,849,000 were recorded at cost and have been included in treasury stock in the accompanying consolidated balance sheet at December&#160;31, 2011 and 2010. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Shares of common
   stock that are mandatorily redeemable under the stock redemption agreement upon the exercise of warrants issued in the 2010 Offering, were determined to embody an obligation that may require the Company to settle the obligation by transferring
   assets, and as such, shall be classified as a liability. The fair value of the common stock potentially redeemable under the stock redemption agreement totaling $785,000 was recorded as a liability and a cost of equity and was determined using the
   fixed monetary amount of each warrant multiplied by assumptions regarding the number and timing of warrants to be exercised. On December&#160;29, 2010, CytRx sold all of their shares held in Galena, thus reducing the potential redemption liability
   to zero as December&#160;31, 2010. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Certain warrants issued in connection with the 2010 Offering were determined not to be
   indexed to the Company&#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,466,000 was recorded as a liability and a cost of equity and was determined by the
   Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option
   prices are publically traded. The Company used a weighted average expected stock volatility of 119.49%. The expected life assumption is based on the contract term of 6.5&#160;years. The dividend yield of zero is based on the fact that the Company
   has no present intention to pay cash dividends. The risk free rate of 3.22% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. The change in the fair value of the warrants during the years ended
   December&#160;31, 2011 and 2010 was $1,079,000 and $1,271,000, respectively. These amounts have been included in other income and expense in the accompanying consolidated statements of expenses. The fair value of the warrants at December&#160;31,
   2011 of $116,000 is included as a current liability in the accompanying consolidated balance sheets and was determined by the Black-Scholes option pricing model. In the model, the Company used a weighted average expected stock volatility of 98.91%.
   The expected life assumption is based on the remaining contract term of 4.8&#160;years. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.83% used for the warrant
   is equal to the zero coupon rate in effect on the date of the re-measurement. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>March 2011 Registered Direct
   Offering</i>&#160;&#8212; On March&#160;4, 2011, the Company closed an underwritten public offering of 6,000,000 units at a price to the public of $1.35 per unit for gross proceeds of $8.1&#160;million (the &#8220;March&#160;2011 Offering&#8221;). The
   offering provided approximately $7.3&#160;million to the Company after deducting the underwriting discounts and commissions and offering expenses. Each unit consists of (i)&#160;one share of common stock, (ii)&#160;a thirteen-month warrant to
   purchase 0.50 of a share of common stock at an exercise price of $1.70 per share (subject to anti-dilution adjustment) and (iii)&#160;a five-year warrant to purchase 0.50 of a share of common stock at an exercise price of $1.87 per share (subject to
   anti-dilution adjustment). On April&#160;15, 2011, the holders of outstanding warrants issued in the March&#160;2011 Offering to purchase an aggregate of 3,450,000 shares of common stock agreed to exchange such warrants for warrants exercisable for
   the same number of shares as those being exchanged, but otherwise on the same terms of the warrants sold in the Company&#8217;s April&#160;2011 financing. Prior to the exchange, the Company recorded a decrease in fair value of $1,000,000 related to
   the exchanged warrants. Upon the exchange, the Company recorded a loss of $900,000, which represented the difference between the adjusted fair value of the March&#160;2011 warrants as compared to the fair value of the April&#160;2011 warrants
   received in the exchange. As a result of a subsequent offering that was completed on April&#160;15, 2011, the exercise price of the remaining 2,550,000 outstanding warrants sold in the March&#160;2011 Offering was reduced to $1.00 per share as a
   result of the anti-dilution adjustment. At December&#160;31, 2011, 150,000 warrants from the March&#160;2011 Offering had been exercised with a remaining outstanding balance of 5,850,000. As a result of the subsequent offering on September&#160;26,
   2011, the exercise price of the remaining 5,850,000 warrants sold in the March&#160;4, 2011 Offering were reduced to $0.65 per share as a result of the anti-dilution adjustment.</font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   The thirteen-month and five-year warrants issued in connection with the March 2011 Offering were determined not to be indexed to the Company&#8217;s common stock as they are potentially settleable in cash.
   The fair value of the 2,550,000 warrants at the date of issuance totaling $1,790,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes option pricing model. Due to the fact that the Company
   has limited trading history, the Company expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose shares or options are publicly traded.
   The Company used a weighted average expected stock volatility of 113.25%. The expected life assumption is based on the contract term of 1.08 years used for the thirteen-month warrants and 5 years used for the five-year warrants. The dividend yield
   of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.26% used for the thirteen-month warrants and 2.17% used for the five-year warrants is equal to the zero coupon rate in effect at the time
   of the grant. In July 2011, 75,000 of the thirteen-month warrants were exercised at $1.00 per common share which resulted in a $34,000 reduction of the warrant liability. In July 2011, 75,000 of the five-year warrants were exercised at $1.00 per
   common share which resulted in a $68,000 reduction of the warrant liability. The decrease in the fair value of the warrants from the date of issuance to December&#160;31, 2011 of $1,378,000 has been included in other income and expense in the
   accompanying consolidated statements of expenses for the year ended December&#160;31, 2011. The fair value of the warrants at December&#160;31, 2011 of $412,000 is included as a current liability in the accompanying consolidated balance sheets and
   was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities
   whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 98.91%. The expected life assumption is based on the remaining contract term of 0.3 years used for the thirteen-month warrants and 4.2
   years used for the five- year warrants. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.02% used for the thirteen-month warrants and 0.60% used for the
   five-year warrants is equal to the zero coupon rate in effect on the date of the re-measurement. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>April 2011 Registered
   Direct Offering</i>&#160;&#8212; On April&#160;20, 2011, the Company completed an underwritten public offering of 11,950,000 units at a price to the public of $1.00 per unit for gross proceeds of approximately $12&#160;million (the
   &#8220;April&#160;2011 Offering&#8221;). Each unit consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $1.00 per share (subject to anti-dilution adjustment). The shares of common stock and
   warrants were immediately separable and no separate units were issued. The warrants are exercisable beginning one year and one day from the date of issuance, and expire on the sixth anniversary of the date of issuance. Net proceeds, after
   underwriting discounts and commissions and other offering expenses, were approximately $10.9&#160;million. As a result of the subsequent offering that was completed on September&#160;26, 2011, the exercise price of the 11,950,000 outstanding
   warrants sold in the April&#160;2011 Offering was reduced to $0.65 per share as a result of the anti-dilution adjustment.&#160;On December&#160;6, 2011, the Company effected a warrant exchange with a ratio of 1.42857 warrants in exchange for one
   share of common stock with several of the April 2011 warrant holders. In total, 5,930,000 warrants were exchanged for 4,151,000 shares of common stock in this transaction. At December&#160;31, 2011, 6,020,000 warrants sold in the April&#160;20, 2011
   Offering remained outstanding. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The warrants issued in connection with the April 2011 Offering, including the warrants issued
   in exchange for the 3,450,000&#160;March 2011 warrants, were determined not to be indexed to the Company&#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $11,015,000 was
   recorded as a liability and a cost of equity and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a
   combination of implied volatilities of similar entities whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 99.04%. The expected life assumption is based on the contract term of 6.0 years.
   The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 2.81% used for the warrants is equal to the zero coupon rate in effect at the time of the grant. In December 2011, the
   Company exchanged 4,151,000 shares of common stock in exchange for 5,930,000 of these April warrants at a ratio of 0.7 common shares for each warrant which resulted in a reduction to warrant liability of $3,120,000. The decrease in the fair value of
   the warrants from date of issuance to December&#160;31, 2011 is $5,168,000, of which all has been included in other income and expense in the accompanying consolidated statements of expenses for the twelve months ended December&#160;31, 2011. The fair value of the warrants at December&#160;31, 2011 of $3,154,000 is included as a
   current liability in the accompanying consolidated balance sheets and was determined by the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is
   based on a combination of implied volatilities of similar entities whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 98.91%. The expected life assumption is based on the remaining contract
   term of 5.3 years. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends. The risk free rate of 0.83% used for the warrants is equal to the zero coupon rate in effect on the date of the
   re-measurement. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>September 2011 Registered Direct Offering</i>&#160;&#8212; On September&#160;26, 2011, the Company completed
   a direct offering of 700,000 shares of common stock for gross proceeds of $455,000. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Stock Options Modified
   </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On April&#160;14, 2011, all of the Company&#8217;s directors and certain of the Company&#8217;s executive officers
   executed agreements with the Company under which they agreed that none of their outstanding stock options will be exercisable unless and until the Company increases the number of authorized shares of common stock to a number that is sufficient to
   permit the exercise or conversion in full of all then outstanding options of the Company (including their stock options), warrants and other securities of the Company that are convertible into shares of common stock. An aggregate of 3,498,256 option
   shares are covered by these agreements. For accounting purposes, the agreement of all of the Company&#8217;s directors and certain executive officers to place restrictions of the exercisability of their options is treated as a modification of their
   options resulting in the reclassification of the options from equity to a liability. In connection with the modification, the Company will recognize compensation cost equal to the greater of (a)&#160;the grant date fair value of the original equity
   award plus an incremental cost associated with the modification or (b)&#160;the fair value of the modified award when it is settled. On July&#160;15, 2011, the Board of Directors of the Company adopted an amendment to increase the authorized shares
   of common stock to 125,000,000, which was presented to and approved by the stockholders of the Company at the 2011 Annual Meeting of Stockholders. This increase in the authorized shares was sufficient to permit the exercise or conversion in full of
   all then outstanding options of the Company (including their stock options), warrants and other securities of the Company that are convertible into shares of common stock, as a result, the liability was marked to market through July&#160;15, 2011
   and, upon settlement, the value of $1,036,000 was reclassified to additional paid in capital. As a result of the modification, the Company recorded additional stock compensation expense of $35,000 during the year ended December&#160;31, 2011.
   </font></p>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Other Equity Transactions </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   On March&#160;30, 2011, the Company entered into a severance agreement with its former President and Chief Executive Officer whereby, among other things, it agreed to issue shares to the former officer
   such that the number of shares issued times the market price of the shares on the day immediately following the separation date equal a value of $300,000. As of December&#160;31, 2011, all payments and shares due under this severance agreement have
   been issued and recorded to stock compensation expense. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Expenses (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">108 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
        <td class="nump">$ 10,742<span></span></td>
        <td class="nump">$ 6,046<span></span></td>
        <td class="nump">$ 37,425<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense', window );">Research and development employee stock-based compensation expense</a></td>
        <td class="nump">866<span></span></td>
        <td class="nump">1,084<span></span></td>
        <td class="nump">3,273<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense', window );">Research and development non-employee stock-based compensation expense</a></td>
        <td class="num">(70)<span></span></td>
        <td class="nump">743<span></span></td>
        <td class="nump">5,993<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfCommonStockInExchangeForLicensingRights', window );">Fair value of common stock issued in exchange for licensing rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,954<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
        <td class="nump">11,538<span></span></td>
        <td class="nump">7,873<span></span></td>
        <td class="nump">50,645<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_GeneralAndAdministrativeExpenses', window );">General and administrative expense</a></td>
        <td class="nump">6,863<span></span></td>
        <td class="nump">5,493<span></span></td>
        <td class="nump">27,973<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense', window );">Fair value of common stock warrants issued for general and administrative expense</a></td>
        <td class="nump">108<span></span></td>
        <td class="nump">718<span></span></td>
        <td class="nump">2,402<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses', window );">Fair value of common stock issued in exchange for general and administrative expenses</a></td>
        <td class="nump">73<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">354<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation', window );">General and administrative employee stock-based compensation expense</a></td>
        <td class="nump">2,205<span></span></td>
        <td class="nump">2,541<span></span></td>
        <td class="nump">9,590<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expense</a></td>
        <td class="nump">9,249<span></span></td>
        <td class="nump">8,752<span></span></td>
        <td class="nump">40,319<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating loss</a></td>
        <td class="num">(20,787)<span></span></td>
        <td class="num">(16,625)<span></span></td>
        <td class="num">(90,964)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income/(expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_InterestIncome', window );">Interest income, net</a></td>
        <td class="nump">30<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="nump">658<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_LossOnWarrantExchange', window );">Loss on warrant exchange</a></td>
        <td class="num">(900)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(900)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
        <td class="nump">10,172<span></span></td>
        <td class="nump">4,627<span></span></td>
        <td class="nump">13,937<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
        <td class="nump">9,302<span></span></td>
        <td class="nump">4,632<span></span></td>
        <td class="nump">13,695<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_LossOnWarrantExchange', window );">Loss on warrant exchange</a></td>
        <td class="num">(900)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(900)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
        <td class="nump">10,172<span></span></td>
        <td class="nump">4,627<span></span></td>
        <td class="nump">13,937<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes</a></td>
        <td class="num">(11,485)<span></span></td>
        <td class="num">(11,993)<span></span></td>
        <td class="num">(77,269)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (11,485)<span></span></td>
        <td class="num">$ (11,993)<span></span></td>
        <td class="num">$ (77,269)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
        <td class="num">$ (0.32)<span></span></td>
        <td class="num">$ (0.67)<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding: basic and diluted</a></td>
        <td class="nump">36,334,413<span></span></td>
        <td class="nump">17,883,381<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfCommonStockInExchangeForLicensingRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock issued in exchange for licensing rights</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfCommonStockInExchangeForLicensingRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock issued in exchange for general and administrative expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock warrants issued for general and administrative expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>General and administration employee stock based compensation</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_GeneralAndAdministrativeExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>General and administration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_GeneralAndAdministrativeExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_InterestIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest income (expense)</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_InterestIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_LossOnWarrantExchange">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loss on warrant exchange</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_LossOnWarrantExchange</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development employee stock-based compensation expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development non-employee stock-based compensation expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average common shares outstanding: basic and diluted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1(i)<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Apthera Acquisition<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Apthera Acquisition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Apthera Acquisition</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - us-gaap:BusinessCombinationDisclosureTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>4.&#160;&#160;&#160;&#160;Apthera Acquisition </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On April&#160;13, 2011, the Company completed its acquisition of Apthera, Inc., a Delaware corporation
   (&#8220;Apthera&#8221;), under an Agreement and Plan of Merger (&#8220;Merger Agreement&#8221;) entered into on March&#160;31, 2011. Subject to the terms and conditions of the Merger Agreement, the Company&#8217;s wholly owned subsidiary formed for this
   purpose was merged with and into Apthera, with Apthera surviving as a wholly-owned subsidiary of the Company. Under the Merger Agreement, the Company issued to Apthera&#8217;s stockholders approximately 5.0&#160;million shares of common stock of the
   Company (the &#8220;Aggregate Stock Consideration&#8221;) and agreed to make future contingent payments of up to $32&#160;million based on the achievement of certain development and commercial milestones relating to the Company&#8217;s NeuVax&#8482;
   product candidate. The contingent consideration is payable, at the election of the Company, in either cash or additional shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it
   has first obtained approval of its stockholders in accordance with Rule 5635(a) of the NASDAQ Marketplace Rules. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In connection
   with the Merger Agreement, the Company deposited with a third-party escrow agent certificates representing 10% of the Aggregate Stock Consideration, which shares will be available to compensate the Company and related parties for certain
   indemnifiable losses as described in the merger agreement. On October&#160;13, 2011, the escrow agent released from the escrow 5% of the Aggregate Stock Consideration, or 248,705 shares. The remaining Aggregate Stock Consideration held with the
   escrow agent is expected to be released in April 2012. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company&#8217;s acquisition of Apthera was in concert with the
   decision by the Company&#8217;s Board of Directors to diversify its development programs and to become a late stage clinical development company. The Company does not expect any of its goodwill to be deductible for tax purposes. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The purchase price consideration and allocation of purchase price of Apthera were as follows: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="89%">&#160;</td>
   <td valign="bottom" width="7%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>(in 000&#8217;s)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Calculation of allocable purchase price:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Fair value of shares issued at closing including escrowed shares expected to be released</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,367</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">(i)&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Estimated value of earn-out</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,460</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total allocable purchase price</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,827</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Allocation of purchase price:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Prepaid expenses and other current assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Equipment and furnishings</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Goodwill</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,898</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">In-process research and development</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,864</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accounts payable</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(931</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued expenses and other current liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(143</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Notes payable</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Deferred tax liability, non-current</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(5,053</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,827</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:13%">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="3%" valign="top" align="left"><font style="font-family:times new roman" size="2">(i)</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">The value of the Company&#8217;s common stock was based upon a per share value of $1.28, the closing price of the Company&#8217;s common stock as of the close of business
   on April&#160;13, 2011. </font></td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The estimated value of the earn-out consideration of $6.5 million originally recorded
   was based on the expected probability of achievement in the future of certain development and commercial milestones relating to the Company&#8217;s NeuVax product candidate and then applying a discount rate, based on a corporate debt interest rate
   index publicly issued, to the expected future payments. The expected timing of the milestones, the probability of success for each milestone and the discount rates applied are updated quarterly using the most current information to measure the
   contingent liability as of the reporting date. The decrease in the fair value of the contingent liability from date of issuance to December&#160;31, 2011 is $109,000, which was included in other income and expense in the accompanying consolidated
   statements of expenses for the twelve months ended December&#160;31, 2011. The fair value of the contingent liability at December&#160;31, 2011 was $6,351,000. Of this amount $1,782,000 was recorded as a current liability. On January&#160;19, 2012,
   the first milestone of $1,000,000 of this contingent liability was triggered with the first patient enrolled in our Phase 3 present clinical trial for breast cancer. On March&#160;8, 2012, the Company issued 1,315,789 restricted shares of common stock in payment of the first milestone. The certificates evidencing the milestone shares have been
   deposited with a third party escrow agent. The milestone shares will be released to the Apthera shareholders from escrow following approval of the issuance of the milestone shares by the stockholders of the Company, which the Company intends to seek
   at its 2012 annual stockholders meeting. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">If stockholder approval is obtained, the number of milestone shares will be subject
   to increase to the extent that $0.76 (<i>i.e</i>., the closing price of the Company&#8217;s common stock as reported on The NASDAQ Capital Market on January&#160;18, 2012, the day prior to achievement of its first milestone, used for purposes of
   determining the number of milestone shares in) is greater than the closing price of common stock as of the most recent trading day prior to the receipt of stockholder approval. Whether or not stockholder approval is obtained, in addition to the
   release from escrow of the milestone shares or the payment in cash of the final milestone as the case may be, the Company will pay concurrently to the former Apthera shareholders in cash an interest factor of ten percent (10%)&#160;per annum on the
   amount of the final milestone from February&#160;10, 2012 through the day immediately prior to the release of the milestone shares from escrow or the cash payment, as the case may be, less certain legal fees of the stockholder representative to be
   paid or reimbursed by the Company. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During the fourth quarter of 2011, the Company finalized its purchase price allocation
   which resulted in an increase in goodwill and deferred tax liability of $5,053,000. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following presents the pro forma net
   loss and pro forma net loss per common share of the Company and twelve months ended December&#160;31, 2011 and 2010 as if the Company&#8217;s acquisition of Apthera occurred as of January&#160;1, 2010: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="71%">&#160;</td>
   <td valign="bottom" width="9%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="8%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>For the Twelve Months Ended<br />December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2010</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center"><font style="font-family:times new roman" size="1"><b>(unaudited)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Pro forma net loss</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(12,778</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(14,229</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Pro forma net loss per common share</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.34</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.62</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average shares outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">37,724,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">22,857,471</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51, 52<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1500-128463<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7000-128479<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6927-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7008-128479<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1490-128463<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6996-128479<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Appendix F<br><br> -Paragraph F4<br><br> -Subparagraph e<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1383-128463<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1392-128463<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1497-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 67-73<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1524-128463<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 88-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1486-128463<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - us-gaap:AccountingChangesAndErrorCorrectionsTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>3.&#160;&#160;&#160;&#160;Recent Accounting Pronouncements </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Recently Adopted Accounting Pronouncements </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   In December 2010, the FASB issued ASC Update 2010-29, Business Combinations (Topic 805) &#8212;<i> Disclosure of Supplementary Pro Forma Information for Business Combinations</i> (Update No.&#160;2010-29).
   This Update requires a public entity to disclose pro forma information for business combinations that occurred in the current reporting period. The disclosures include pro forma revenue and earnings of the combined entity for the current reporting
   period as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. If comparative financial statements are presented, the pro forma revenue and earnings of
   the combined entity for the comparable prior reporting period should be reported as though the acquisition date for all business combinations that occurred during the current year had been as of the beginning of the comparable prior annual reporting
   period. This Update affects any public entity that enters into business combinations that are material on an individual or aggregate basis and is effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first
   annual reporting period beginning on or after December&#160;15, 2010. All disclosures are presented in accordance with the acquisition of Apthera, Inc. </font></p>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2">
   <i>Recently Issued Accounting Pronouncements </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In May&#160;2011, the FASB
   issued Accounting Standards Updated (&#8220;ASU&#8221;) 2011-04<i>, Fair Value Measurement</i> (Topic 820): <i>Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.</i> <i>GAAP and IFRSs</i> , a new accounting
   standard that clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on
   a prospective basis for annual and interim reporting periods beginning on or after December&#160;15, 2011. The Company does not expect that adoption of this new standard will have a material impact on its consolidated financial statements.
   </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In June&#160;2011, the FASB issued ASU 2011-05, <i>Comprehensive Income</i> (Topic 220): <i>Presentation of Comprehensive
   Income</i>, a new accounting standard that eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders&#8217; equity, requires the consecutive presentation of the statement of net
   income and other comprehensive income and requires an entity to present reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this new standard do not change the items
   that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This new standard is required to be
   applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December&#160;15, 2011. As this new standard only requires enhanced disclosure, the adoption of this standard will not impact the
   Company&#8217;s consolidated financial statements. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In September&#160;2011, the FASB issued ASU 2011-08, <i>Intangibles &#8212;
   Goodwill and Other</i> (Topic 350): <i>Testing Goodwill for Impairment</i>, a new accounting standard to simplify how entities test goodwill for impairment. The amendments in the Update permit an entity to first assess qualitative factors to
   determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in Topic 350. The
   more-likely-than-not threshold is defined as having a likelihood of more than 50 percent. Previous guidance under Topic 350 required an entity to test goodwill for impairment, on at least an annual basis, by comparing the fair value of a reporting
   unit with its carrying amount, including goodwill (step one). If the fair value of a reporting unit is less than its carrying amount, then the second step of the test must be performed to measure the amount of the impairment loss, if any. Under the
   amendments in this Update, an entity is not required to calculate the fair value of a reporting unit unless the entity determines that it is more likely than not that its fair value is less than its carrying amount. This new standard is effective
   for fiscal years beginning after December&#160;15, 2011; however, early adoption is permitted. The Company adopted this standard for the fiscal year ended December&#160;31, 2011. The adoption of this standard had no material impact on the
   Company&#8217;s consolidated financial statements. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingChangesAndErrorCorrectionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 1.N.Q3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6369664&amp;loc=d3e30840-122693<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6368906&amp;loc=d3e21914-107793<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 154<br><br> -Paragraph 17, 22, 25, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22499-107794<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 1<br><br> -Section N<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22595-107794<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22644-107794<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">License Agreements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 15 - us-gaap:IntangibleAssetsDisclosureTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>15.&#160;&#160;&#160;&#160;License Agreements </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As part of its business, the Company enters into licensing agreements with third parties that often require milestone
   and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to
   make royalty payments based upon a percentage of net sales. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The expenditures required under these arrangements may be material
   individually in the event that the Company develops product candidates covered by the intellectual property licensed under any such arrangement, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of
   operations. In addition, these arrangements often give the Company discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease
   development if the compound successfully achieves clinical testing objectives. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During the year ended December&#160;31, 2007,
   the Company entered into a license agreement with Cold Spring Harbor Laboratory (&#8220;CSHL&#8221;) for small hairpin RNA, or &#8220;shRNA&#8221;, for which the Company paid $50,000 and agreed to make future milestone and royalty payments upon
   successful development and commercialization of products. The Company also entered into four exclusive license agreements and an invention disclosure agreement with the University of Massachusetts Medical School (&#8220;UMMS&#8221;) for which the
   Company paid cash of $453,000 and issued 462,112 shares of its common stock valued at $2.3 million, or $5.00 per share. For each RNAi product developed in connection with the license granted by CSHL, the possible aggregate milestone payments equal
   $2,650,000. The invention disclosure agreement has an initial term of three years and provides the option to negotiate licenses to certain RNAi technologies discovered at UMMS. During the year ended December&#160;31, 2011, the Company cancelled
   several of its licenses with UMMS. Upon the signing of the Contribution Agreement on September&#160;24, 2011, one of the remaining UMMS licenses was transferred to RXi and the CSHL license agreement was retained by the Company and not transferred to
   RXi. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In October 2007, the Company entered into a license agreement with Dharmacon, Inc. (now part of Thermo Fisher Scientific
   Inc.), pursuant to which the Company obtained an exclusive license to certain RNAi sequences to a number of target genes for the development of the Company&#8217;s rxRNA compounds. Further, the Company has obtained the right to license additional
   RNAi sequences, under the same terms, disclosed by Thermo Fisher Scientific Inc. in its pending patent applications against target genes and has received an option for exclusivity for other siRNA configurations. As consideration for this license,
   the Company paid an up-front fee of $150,000 and agreed to pay future clinical milestone payments and royalty payments based on sales of siRNA compositions developed in connection with the licensed technology. In addition, the Company has agreed to
   pay future clinical milestone payments in an aggregate amount of up to $2,000,000 and royalty payments of either 0.25% or 0.5% based on the level of any future sales of siRNA compositions developed in connection with the licensed technology. No
   amounts were expensed in 2010 and 2011 related to this license. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In September, 2009, the Company entered into a Patent and
   Technology Assignment Agreement with Advirna, LLC (&#8220;Advirna&#8221;), a Colorado limited liability company co-founded by the Company&#8217;s former Chief Scientific Officer. Pursuant to the terms of the agreement, Advirna assigned to the Company
   certain patent and technology rights related to chemically modified polynucleotides (the &#8220;Rights&#8221;) and the Company granted to Advirna a fully paid-up license to the Rights in a specified field. During the year ended December&#160;31, 2011,
   the Company paid and expensed $100,000 for the annual maintenance fees under this agreement. There was no expense recorded for the year ended December&#160;31, 2010. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   As part of the transactions contemplated by the Contribution Agreement and Securities Purchase Agreement, on September&#160;24, 2011, RXi entered into an agreement with Advirna pursuant to which:
   </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="1%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">Advirna assigned to RXi its existing patent and technology rights related to sd-rxRNA technology in exchange for RXi&#8217;s agreement to pay Advirna an
   annual $100,000 maintenance fee and a one-time $350,000 milestone payment upon the future issuance of the first patent with valid claims covering the assigned patent and technology rights; </font></p>
   </td>
   </tr>
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="1%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi with respect to future licensing of the assigned Advirna
   patent and technology rights; </font></p>
   </td>
   </tr>
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="1%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">RXi has granted back to Advirna a license under the assigned patent and technology for fields of use outside the fields of human therapeutics and
   diagnostics; and </font></p>
   </td>
   </tr>
   </table>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="1%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">RXi has agreed to issue to Advirna, upon the completion of the spin-off transaction, shares of RXi&#8217;s common stock equal to approximately 5% of the
   fully diluted shares of RXi common stock assuming the conversion in full of all outstanding Series A Preferred Stock. </font></p>
   </td>
   </tr>
   </table>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   In conjunction with the acquisition of Apthera, the Company assumed the rights and obligations of a certain license agreement, as amended, from The University of Texas M. D. Anderson Cancer Center
   (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a U.S. patent covering the E75 peptide, and several U.S. and foreign patents and
   patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to make future annual maintenance fee payments, as well as clinical milestone payments and royalty payments based on sales of
   therapeutic products developed from the licensed technologies. As part of the expected payments under the terms of the license, the Company must pay an annual maintenance fee of $200,000. In addition, upon commencing the Phase 3 trial, we will pay a
   milestone payment of $200,000. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font style="font-family:times new roman" size="2">In July 2011, the Company entered into a subsequent non-exclusive license
   agreement with HJF which has since been made exclusive, granting patent rights to the use of the E75 peptide in combination with Herceptin<font style="font-family:times new roman" size="1"><sup>
   &reg;</sup></font>. As part of the expected payments under the terms of the license, the Company paid an issue royalty fee of $100,000. In addition, the Company must pay an annual
   maintenance fee of $50,000 ($25,000 for each patent) and royalties based on net sales upon commercialization. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In September
   2011, the Company licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39 (FBP) targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarconimas. The FBP vaccine was licensed
   from The University of Texas M D Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. FBP has been granted Investigational New Drug approval by the U.S. Food and Drug Administration to enter clinical
   trials. Institutional Review Board approval has also been received allowing RXi to initiate Phase 1 trials by the end of 2011. As part of the expected payments under the terms of the license, the Company paid an issue royalty fee of $100,000.
   Additionally, the Company shall pay the HJF a non-creditable, nonrefundable License issue royalty in the sum of $15,000 for each additional item of follow-on intellectual property. In addition, the Company must pay an annual maintenance fee of
   $25,000 in 2012 and $50,000 in 2013. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 44, 45, 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Development Stage Supplemental Equity Disclosure<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterprisesAbstract', window );"><strong>Development Stage Supplemental Equity Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock', window );">Development Stage Supplemental Equity Disclosure</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 11 - us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>11.&#160;&#160;&#160;&#160;Development Stage Supplemental Equity Disclosure </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Summarized below are the Company&#8217;s equity (common stock and common stock options) transactions since the
   Company&#8217;s inception through December&#160;31, 2011 (in thousands except per share data). </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="27%">&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap">
   <p style="border-bottom:1px solid #000000;width:49pt"><font style="font-family:times new roman" size="1"><b>Type of Security</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Date&#160;of&#160;Issuance</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Shares of<br />Common<br />Stock</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Dollar<br />Amount of<br />Consideration<br />($)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Price&#160;per<br />Share or<br />Exercise<br />Price per<br />Share<br />($)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Counter</b></font><br /><font style="font-family:times new roman" size="1"><b>Party to</b></font><br /><font style="font-family:times new roman" size="1">
   <b>Transaction</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nature of<br />Non-Cash<br />Consideration</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Basis of<br />Assigning Cost</b></font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">April 3, 2006</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">1,624,278</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">2</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">0.002</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Founders</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">January 8, 2007</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">7.040,318</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">48</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">(A)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">0.007</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">CytRx</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Contributed<br />Assets</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Predecessor<br />Cost</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">April 30, 2007</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">3,273,292</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">15,348</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">(B)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">5.19</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">CytRx</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">April 30, 2007</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">462,112</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">2,311</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">5.00</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">UMMS</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Intellectual<br />Properties</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Independent<br />Third Party<br />Valuation</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">August 18, 2007</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">30,000</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">150</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">5.00</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Directors</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">September 28, 2007</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">188,387</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">978</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">5.19</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">CytRx</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Independent<br />Third Party<br />Valuation</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">November 21, 2007</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">66,045</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">331</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">5.00</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Exercise of Stock<br />Options</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">June 26, 2008</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">1,073,299</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">7,918</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">8.12</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">PIPE</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Net Cash</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">October&#160;6,&#160;2008&#160;and<br />November 16, 2008</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">5,500</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">26</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">5.00</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Exercise of Stock<br />Options</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">January 30, 2009</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">58,398</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">NA</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">NA</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Market Value</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">May 1, 2009</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">281</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">NA</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">4.19</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Exercise of Stock<br />Options</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">August 3, 2009 and<br />August 4, 2009</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">2,385,715</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">7,714</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">3.50</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Registered&#160;Direct</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Net Cash</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">March 22, 2010</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">2,700,000</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">15,235</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">6.00</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Registered Direct</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Net Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Various&#160;&#8212; 2010</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">53,500</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">254</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">4.75</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Exercise of Stock<br />Options</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">January&#160;2,&#160;2010&#160;and<br />February 9, 2010</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">86,634</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">207</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">NA</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Restricted Stock<br />Units</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Market Value</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">March 4, 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">6,000,000</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">7,307</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">1.35</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Registered Direct</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Net Cash</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">March 15, 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">220,729</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">256</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">1.16</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Restricted Stock<br />Units</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Market Value</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">April 13, 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">4,974,090</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">6,367</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">NA</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Acquired Company</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Market Value</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">April 20, 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">11,950,000</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">10,853</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">1.00</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Registered Direct</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Net Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">July 1, 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">18,824</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">15</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">0.83</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">ESPP</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">July 27, 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">150,000</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">150</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">1.00</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Exercise of<br />Warrants</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">September 26, 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">700,000</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">455</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">0.65</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Registered Direct</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Cash</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">December 6, 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">4,151,000</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">3,120</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">NA</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Exchange with<br />Warrant Holders</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Market&#160;Value</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common Stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Various &#8212; 2011</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">599,051</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">594</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="top" align="right"><font style="font-family:times new roman" size="2">NA</font></td>
   <td nowrap="nowrap" valign="top"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Stock&#160;Compensation</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">NA</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="top"><font style="font-family:times new roman" size="2">Market&#160;Value</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="3%" valign="top" align="left"><font style="font-family:times new roman" size="2">(A)</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">Transactions between related parties are accounted for at the historical cost of CytRx, with the intellectual property which was previously expensed on CytRx&#8217;s
   books being recorded at zero cost and equipment and furnishings being recorded at $48,000. </font></td>
   </tr>
   </table>
   <p style="font-size:3px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="3%" valign="top" align="left"><font style="font-family:times new roman" size="2">(B)</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">The Company received gross proceeds of $17.0&#160;million for the issuance of the 3,273,292&#160;shares of common stock which equals $5.19 per share.
   The gross proceeds were reduced by a reimbursement to CytRx of (1)&#160;$1.3&#160;million for RXi&#8217;s pro rata share of offering costs related to the April&#160;17, 2007 private placement
   conducted by CytRx to fund its capital contribution to the Company and (2)&#160;$363,000 of expenses incurred on behalf of RXi for the year ended December&#160;31, 2006. Net proceeds to RXi after
   these charges were $15.3&#160;million or $4.69 a share. </font></p>
   </td>
   </tr>
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the detailed information required for development stage enterprises. The information may also be disclosed on an element-by-element basis. Information may include an identification of the current or prior year financial statements of the entity, its development stage subsidiaries, or its investees as those of one or more development stage enterprises; a description of the nature of the development stage activities in which each enterprise is engaged; and in the first fiscal year in which each enterprise is no longer considered a development stage enterprise, a statement that in prior years the enterprise had been in the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472436&amp;loc=d3e38614-110930<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 210<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 7<br><br> -Paragraph 11, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38942-110933<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472471&amp;loc=d3e38015-110924<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38313-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterprisesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterprisesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Capital Lease Obligations<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Capital Lease Obligations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock', window );">Capital Lease Obligations</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 7 - us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>7.&#160;&#160;&#160;&#160;Capital Lease Obligations </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company acquired equipment under capital leases that is included in equipment and furnishings in the accompanying
   consolidated balance sheet. The cost and accumulated amortization of capitalized leased equipment was approximately $272,000 and $95,000 at December&#160;31, 2011, respectively, and $196,000 and $56,000 at December&#160;31, 2010, respectively.
   Amortization expense for capitalized leased equipment was approximately $54,000 in 2011 and $39,000 in 2010. Future minimum lease payments under the capital leases including interest are approximately $38,000, $25,000 and $14,000 for the years
   ending December&#160;31, 2012, 2013 and 2014, respectively. Interest expense related to the capital leases was $6,000 for each of the years ended December&#160;31, 2011 and 2010. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for capital leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeasesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RXi Spin-Out<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RXi Spin-Out and Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_PartnerCompanyTextBlock', window );">RXi Spin-Out</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - rxii:PartnerCompanyTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>5.&#160;&#160;&#160;&#160;RXi Spin-Out </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Contribution Agreement </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   On September&#160;24, 2011, the Company entered into a Contribution Agreement (&#8220;Contribution Agreement&#8221;) with RXi pursuant to which we assigned and contributed to RXi substantially all of the
   Company&#8217;s RNAi-related technologies and assets. The contributed assets consist primarily of our novel RNAi compounds and licenses relating to our RNAi technologies, as well as the lease of our Worcester, Massachusetts laboratory facility, fixed
   assets and other equipment located at the facility and our employment arrangements with certain scientific, corporate and administrative personnel who have become employees of RXi. The Company also contributed $1.5&#160;million of cash to the
   capital of RXi. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Pursuant to the Contribution Agreement, RXi has agreed to assume certain recent accrued expenses of our
   RXI-109 development program and all future obligations under the contributed licenses, employment arrangements and other agreements. RXi has also agreed to make future milestone payments to us of up to $45&#160;million, consisting of two one-time
   payments of $15&#160;million and $30&#160;million, respectively, if RXi achieves annual net sales equal to or greater than $500 million and $1&#160;billion, respectively, of any covered products that may be developed with the contributed RNAi
   technologies. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In the Contribution Agreement, the Company made customary representations and warranties to RXi regarding the
   contributed assets and other matters, and the parties have agreed to customary covenants regarding the conduct of RXi&#8217;s business pending the spin-off of RXi. The parties also have agreed to indemnify each other against losses arising from a breach of their respective representations,
   warranties and covenants set forth in the Contribution Agreement. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Securities Purchase Agreement </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On September&#160;24, 2011, the Company also entered into a Securities Purchase Agreement (&#8220;Securities Purchase Agreement&#8221;) with
   RXi and two institutional Investors (the &#8220;Investors&#8221;), pursuant to which the Investors agreed to purchase a total of $9,500,000 of Series&#160;A Preferred Stock of RXi (&#8220;RXi Preferred Stock&#8221;) at the closing of the spin-off of
   RXi, and to lend up to $1,500,000 to RXi to fund its operations between signing and closing (the &#8220;Bridge Loan&#8221;). The outstanding principal and accrued interest from the Bridge Loan will, except under certain circumstances described below,
   be converted into RXi Preferred Stock at the closing of the spin-off of RXi and will represent a portion of the $9,500,000 total investment, which is referred to herein as the &#8220;RXi financing.&#8221; The RXi financing and the spin-off of RXi are
   subject to customary closing conditions, including the registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), of the distribution by us of the spin-off shares. There is no assurance that the RXi financing and the
   spin-off of RXi will be completed. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The RXi Preferred Stock will be convertible by a holder at any time into shares of RXi
   common stock, except to the extent that the holder would own more than 9.999% of the shares of RXi common stock outstanding immediately after giving effect to such conversion. Without regard to this conversion limitation, the shares of the Preferred
   Stock to be held by the Investors upon completion of the RXi financing and the spin-off of RXi will be convertible into shares of RXi common stock representing approximately 83% of the shares of RXi common stock that would be outstanding, assuming
   the conversion in full of the Preferred Stock, which we refer to as the &#8220;as-converted common stock.&#8221; The Company will own approximately 12% of the as-converted common stock immediately prior to the spin-off of RXi, and Advirna, LLC, a key
   licensor of RXi, will be issued the remaining 5% of the as-converted common stock pursuant to the agreement with Advirna, LLC as described below. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2">
   <i>Spin-Off </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has agreed in the Securities Purchase Agreement to
   undertake to distribute to our stockholders on a share-for-share basis approximately 8% of the as-converted common stock of RXi, subject to the registration of the distribution of such shares under the Securities Act of 1933 and other conditions.
   Assuming the spin-off of RXi is completed, the Company will initially retain 4% of the as-converted common stock, and the Company agreed, in the Securities Purchase Agreement, not to sell or dispose of our shares of RXi common stock for a one-year
   period following completion of the spin-off of RXi. The Securities Purchase Agreement provides that the spin-off will be on a share-for-share basis, so that one share of RXi will be distributed as a dividend on each share of Galena that is issued
   and outstanding as of the record date for the distribution. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On February&#160;27, 2012, the Company announced, as required by
   NASDAQ Listing Rule 5250(e)(6), that its board of directors had declared a conditional dividend on Galena common stock of one share of common stock of RXi for each outstanding share of Galena common stock. The spin-off shares will be payable,
   subject to certain conditions described below, to the Company&#8217;s stockholders as of close of business (Eastern time) on March&#160;8, 2012, the record date for the distribution, in the ratio of one RXi share for each share of Galena common stock
   held as of the record date. In light of the conditional nature of the partial spin-off of RXi, the Company&#8217;s board of directors has not set a payment date for the distribution, and under NASDAQ rules Galena common stock is not yet trading
   &#8220;ex-dividend.&#8221; The distribution of the spin-off shares will be taxable to Galena stockholders who receive RXi shares in the distribution. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   The distribution to Galena stockholders of the spin-off shares is to be made pursuant to the registration statement filed by RXi with the Securities and Exchange Commission and declared effective on
   February&#160;14, 2012. Because the RXi registration statement will go &#8220;stale&#8221; on April&#160;30, 2012, the Company must complete the distribution of the spin-off shares by that date, unless the Company were to cause RXi to amend the
   registration statement. It is likely that the Company would abandon the partial spin-off of RXi if the distribution of the spin-off shares has not been made by April&#160;30, 2012, although the Company&#8217;s
   board of directors has not made any decision in this regard. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The establishment of a payment date for the distribution and the
   payment of the distribution is dependent upon the timing of effectiveness of an application filed with FINRA to permit RXi common stock to be graded in the OTC Markets Group under the symbol &#8220;RXII.&#8221; The payment of the distribution also is conditioned
   upon the closing of the RXi financing, which is subject to certain closing conditions that may or may not be satisfied. In addition, the securities purchase agreement among Galena, RXi and the Investors provides that the agreement may be unilaterally
   terminated by the Company or by the Investors if the closing of the transactions has not occurred by March&#160;31, 2012, and it is not possible for the closing to occur by this date. Accordingly, unless this date is extended by mutual agreement of
   the Investors and the Company, either the Company or the Investors generally may terminate the securities purchase agreement at any time after March&#160;31, 2012, unless the failure of the closing to occur was due to the fault of the party seeking
   to terminate the securities purchase agreement. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Although the Company has no present intention to terminate the securities
   purchase agreement or to abandon the partial spin-off of RXi, the Investors may choose to do so. The Company also may decide to do so at any time if its board of directors determines that it is in the best interests of the Company. For all of the foregoing
   reasons, there is no assurance that the payment and distribution of the spin-off shares will be completed. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Purchase
   Agreement Terms and Conditions </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In the Securities Purchase Agreement, the parties have made customary representations and
   warranties to the other parties and have agreed to customary covenants regarding the parties&#8217; actions in connection with the spin-off of RXi and other matters, including the filing of a resale registration statement registering a portion of the
   common stock underlying the conversion of the Preferred Stock. The parties also have agreed to indemnify each other against losses arising from a breach of their respective representations, warranties and covenants set forth in the Securities
   Purchase Agreement. RXi has agreed, upon completion of the spin-off of RXi, to reimburse the Company and the Investors for up to a total of $300,000 and $100,000, respectively, of transaction costs relating to the Contribution Agreement, the
   Securities Purchase Agreement and the transactions contemplated by the agreements. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Securities Purchase Agreement may be
   terminated in certain circumstances, including by the Investors or the Company if the spin-off of RXi has not occurred by March&#160;31, 2012. If the Securities Purchase Agreement is terminated without cause due to the fact that the spin-off has not
   occurred by such date, then a portion of the Bridge Loan will be converted into common stock of RXi, as described below. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Bridge Loan </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   Pursuant to the Securities Purchase Agreement, the Investors agreed to provide the Bridge Loan by purchasing $500,000 of secured convertible promissory notes of RXi (&#8220;RXi convertible notes&#8221;) and
   agreeing to purchase up to an additional $1,000,000 of RXi convertible notes prior to the closing of the spin-off of RXi. The RXi convertible notes will, except as described below, be convertible into shares of RXi Preferred Stock at a conversion
   price of $1,000 per share. The proceeds from the Bridge Loan will be used by RXi in accordance with an operating budget approved by the Investors to fund RXi&#8217;s business and operations pending completion of the spin-off of RXi. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The RXi convertible notes accrue interest at a rate of 7%&#160;per annum (or 18%&#160;per annum in the case of an event of default) and
   mature on March&#160;31, 2012, or earlier in the case of an event of default. The obligations due under the RXi convertible notes are secured by a first-priority blanket lien on the assets of RXi and are guaranteed by Galena. Additionally, Galena
   has pledged all of the shares of RXi common stock that it holds to further guaranty the timely repayment of the amounts due under the RXi convertible notes, if not converted into RXi Preferred Stock at the closing under the Securities Purchase
   Agreement. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">If the closing
   under the Securities Purchase Agreement has not occurred by the March&#160;31, 2012 maturity date of the RXi convertible notes, then 50% of the outstanding Bridge Loan balance will be converted into a number of shares of RXi common stock equal to
   51% of the post-conversion shares outstanding. RXi will remain obligated to repay the remaining balance of the principal and accrued interest under the Bridge Loan, and Galena has agreed to guarantee RXi&#8217;s repayment of the RXi convertible notes
   to the extent they are not converted. In this event, Galena and Advirna, LLC will beneficially own 44% and 5%, respectively, of the outstanding shares of RXi common stock, and RXi will carry on as a stand-alone private company under the
   Investors&#8217; control. Neither the Investors nor Galena will be obliged to provide any funding to RXi in this event. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of
   the date of the filing of the Annual Report on Form&#160;10-K of which these Consolidated Financial Statements are a part, the Company was in discussions with the Investors to extend the current March&#160;31, 2012 maturity date of the RXi
   convertible notes, but there is no assurance that the maturity date will be extended. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The RXi convertible notes will be
   issued, and the Bridge Loan will be funded, in three tranches of $500,000 each. The first and second tranches were issued and funded on September&#160;24, 2011 and February&#160;24, 2012, respectively, and the third tranche is to be issued and
   funded as needed by RXi prior to the closing under the Securities Purchase Agreement and following the approval by the Investors, in their discretion, of RXi&#8217;s budget for the use of such funds. At December&#160;31, 2011, the first tranche of
   $500,000 had been received and recorded to convertible notes payable as a current liability. There are additional features of the RXi post spin-off Series A Convertible Preferred Stock which represent contingent beneficial conversion features, to be
   reevaluated in the future. In the event that the facts and circumstances indicate that a contingency is removed, at that point the beneficial conversion feature, if any, will be recorded. On February&#160;24, 2012, the second tranche of $500,000 was
   received and recorded to convertible notes payable. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Advirna Agreement </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As part of the transactions contemplated by the Contribution Agreement and Securities Purchase Agreement, RXi has entered into an
   agreement with Advirna, LLC, which the Company refers to as &#8220;Advirna,&#8221; a company affiliated with Anastasia Khvorova, Ph.D., the Company&#8217;s former Senior Vice President and Chief Scientific Officer. In the agreement, Advirna has agreed
   to amend its existing patent and technology assignment agreement with RXi to eliminate all clinical milestone and royalty payments to Advirna under the amended agreement; obligations remain to make an annual $100,000 maintenance fee and a one-time
   milestone payment of $350,000 to Advirna upon the issuance of a patent with valid claims covering the assigned technology. Additionally, RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi on the license of
   the assigned Advirna technology. In exchange, RXi has agreed to issue to Advirna upon the earlier of the closing under the Securities Purchase Agreement or the partial conversion of the RXi convertible notes, a number of shares of RXi common stock
   equal to 5% of the as-converted common stock of RXi. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_PartnerCompanyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Partner company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_PartnerCompanyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 6 - us-gaap:FinancialInstrumentsDisclosureTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>6.&#160;&#160;&#160;&#160;Fair Value Measurements </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the
   Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three
   levels. Level inputs are as defined as follows: </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:8%"><font style="font-family:times new roman" size="2">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets
   or liabilities. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:8%"><font style="font-family:times new roman" size="2">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through
   corroboration with market data at the measurement date. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:8%"><font style="font-family:times new roman" size="2">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect
   management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date. </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px"><font size="1">&#160;</font></p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company categorized its cash equivalents as Level&#160;1 hierarchy. The valuation
   for Level&#160;1 was determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuations of these assets do not require a significant degree of judgment. The Company categorized its warrants
   potentially settleable in cash as a Level&#160;2 hierarchy. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using the
   Black-Scholes method, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as a Level 3 hierarchy and is measured at its estimated fair value on a recurring basis and is
   adjusted at each quarter-end until it is completely settled. The contingent price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and the updated discount rates based on a
   corporate debt interest rate index publicly issued. </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="42%">&#160;</td>
   <td valign="bottom" width="10%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="10%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="10%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="10%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap">
   <p style="border-bottom:1px solid #000000;width:39pt"><font style="font-family:times new roman" size="1"><b>Description</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,<br />2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Quoted&#160;Prices&#160;In<br />Active Markets<br />(Level 1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Significant&#160;Other<br />Observable&#160;Inputs<br />(Level 2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unobservable&#160;Inputs<br />(Level 3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Assets:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Liabilities:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants potentially settleable in cash</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,746</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,746</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Contingent purchase price consideration</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,351</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,351</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,097</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,746</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,351</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="46%">&#160;</td>
   <td valign="bottom" width="10%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="10%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="10%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="10%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap">
   <p style="border-bottom:1px solid #000000;width:39pt"><font style="font-family:times new roman" size="1"><b>Description</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,<br />2010</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Quoted&#160;Prices&#160;in<br />Active Markets<br />(Level 1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Significant&#160;Other<br />Observable&#160;Inputs<br />(Level 2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unobservable&#160;Inputs<br />(Level 3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Assets:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,891</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,891</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,891</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,891</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Liabilities:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants potentially settleable in cash</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,138</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,138</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,138</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,138</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has classified its liabilities for contingent earn-out consideration relating to its
   acquisitions of Apthera within Level 3 of the fair value hierarchy because the fair values are determined using significant unobservable inputs, which included probability weighted cash flows. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has not
   transferred any financial instruments into or out of Level 3 classification during 2010 or 2011. A reconciliation of the beginning and ending Level 3 liabilities for the year ended December&#160;31, 2011 is as follows: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="83%">&#160;</td>
   <td valign="bottom" width="13%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair Value<br />Measurements<br />Using&#160;Significant<br />Unobservable<br />Inputs</b></font><br /><font style="font-family:times new roman" size="1">
   <b>(Level 3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center"><font style="font-family:times new roman" size="1"><b>(In Thousands)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at January&#160;1, 2011</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Initial fair value of contingent earnout consideration related to Meridian Acquisition</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,460</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Change in fair value of earnout consideration</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(109</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Balance at December&#160;31, 2011</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,351</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancialInstrumentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsAllOtherInvestmentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 8 - us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>8.&#160;&#160;&#160;&#160;Accrued Expenses and Other Current Liabilities </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Accrued expenses and other current liabilities consist of the following (in thousands): </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="82%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>For the Years<br />Ended<br />December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2010</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Professional fees</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">520</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">313</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Research and development costs</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">755</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">60</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Payroll related costs</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">868</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">740</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">25</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total accrued expenses and other current liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,113</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 13 - us-gaap:EarningsPerShareTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>13.&#160;&#160;&#160;&#160;Net Loss Per Share </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;
   <i>Earnings per Share.&#8221;</i> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by
   dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding.
   Potential common shares consist of shares issuable upon the exercise of stock options and warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as
   basic net loss per common share. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following table sets forth the potential common shares excluded from the calculation of
   net loss per common share because their inclusion would be anti-dilutive: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="75%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2010</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options to purchase common stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,163,137</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,333,136</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants to purchase common stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,120,642</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,100,642</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">20,283,779</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,433,778</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 18 - us-gaap:SubsequentEventsTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>18.&#160;&#160;&#160;&#160;Subsequent Events </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company evaluated all events or transactions that occurred after December&#160;31, 2011 up through the date these
   financial statements were issued. Other than what is disclosed below, or elsewhere in the notes to the consolidated financial statements, the Company did not have any material recognizable or unrecognizable subsequent events. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On January&#160;12, 2012, the Company granted an option to purchase 50,000&#160;shares of common stock to each of the five non-employee
   members of the Board of Directors. These options had an exercise price of $0.72 per share, which represented the Company&#8217;s closing stock price on that date. The options vest quarterly over a one-year period and expire not later than 10 years
   from the grant date. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On January&#160;12, 2012, the Company granted options to purchase an aggregate of 825,000&#160;shares of
   common stock to certain employees at a price of $0.72 per share, which represented the Company&#8217;s closing stock price on that date. The options vest quarterly over four years beginning three months from the date of grant and expire not later than 10 years from the date of grant. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On February&#160;4, 2012, the Company granted warrants to purchase 400,000&#160;shares of common stock at an exercise price of $0.66 per
   share in exchange for business advisory services to the Company for a period of up to twelve months. The warrants vested as to 100,000&#160;shares upon issuance, and then will vest at a rate of 100,000&#160;shares&#160;per quarter starting on the
   90&#160;day anniversary of issuance. The Company has also agreed to give &#8220;piggy back&#8221; registration rights with respect to the shares of common stock underlying the warrants in any registration statement filed by the company in connection
   with an underwritten offering of the common stock. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On January&#160;20, 2012, the Company sold 579,710 shares of our common
   stock for $400,000 to Kwang Dong Pharmaceutical Company as part of a existing license agreement for NeuVax covering territorial rights for the compound in South Korea that the Company acquired in its merger acquisition of Apthera. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On February&#160;3, 2012, the Company issued 100,000 shares of our common stock in payment of $135,000 of accrued legal fees. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On March&#160;8, 2012, the Company issued 1,315,789 restricted shares of common stock in payment of the first milestone under the
   contingent value rights agreement entered into in connection with our merger acquisition of Apthera in April 2011. The certificates evidencing the milestone shares have been deposited with a third-party escrow agent. The milestone shares will be
   released to the former Apthera shareholders from escrow if the issuance of the milestone shares is approved by the stockholders of the Company at the Company&#8217;s 2012 annual stockholders meeting. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">From January 23, 2012 through March 23, 2012, the Company issued 1,369,944 shares of the Company&#8217;s common stock subject to the
   exercise of outstanding warrants from various warrant holders. The Company received $1,223,464 in total payments at exercise prices ranging from $0.65 to $2.50 per share. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EL4JM">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Predecessor</div>
        </th>
        <th class="th">
          <div>Successor</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Predecessor</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Successor</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital

</div>
          <div>Predecessor</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital

</div>
          <div>Successor</div>
        </th>
        <th class="th">
          <div>Deficit Accumulated During Development Stage

</div>
          <div>Successor</div>
        </th>
        <th class="th">
          <div>Treasury Stock

</div>
          <div>Successor</div>
        </th>
        <th class="th">
          <div>Parent Company's Net Deficit

</div>
          <div>Predecessor</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2003</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (89)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (89)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2003</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,272)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,272)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetTransactionsWithParent', window );">Net transactions with Parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,393<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,393<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2004</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(968)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(968)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2004</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,209)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,209)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetTransactionsWithParent', window );">Net transactions with Parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,727<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,727<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2005</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(450)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(450)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2005</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,405)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,405)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetTransactionsWithParent', window );">Net transactions with Parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,587<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,587<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2006</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(268)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(268)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2006</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Apr. 03, 2006</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Apr. 03, 2006</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,624,278<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2006</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2006</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,624,278<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Common stock issued to CytRx for contribution of RXi and other assets, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,040,318<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Common stock issued to CytRx for contribution of RXi and other assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">48<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,273,292<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,348<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,348<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares', window );">Common stock issued to CytRx for reimbursement of expenses, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">188,387<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses', window );">Common stock issued to CytRx for reimbursement of expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">978<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">978<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Expenses incurred by CytRx for RXi</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">831<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">831<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties', window );">Common stock issued to UMMS for additional intellectual properties, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">462,112<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties', window );">Common stock issued to UMMS for additional intellectual properties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,311<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,311<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodSharesToDirectors', window );">Common stock issued to directors, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueToDirectors', window );">Common stock issued to directors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">66,045<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">331<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">331<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition', window );">Stock based compensation expense for directors and employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,048<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,048<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">766<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">766<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(10,990)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(10,990)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2007</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,823<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,812<span></span></td>
        <td class="num">(10,990)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2007</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,684,432<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,073,299<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,918<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,918<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition', window );">Stock based compensation expense for directors and employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,211<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,211<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,613<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,613<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices', window );">Value of common stock warrants issued (expense) in exchange for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(14,373)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(14,373)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2008</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,968<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34,330<span></span></td>
        <td class="num">(25,363)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2008</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,763,231<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,385,715<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,714<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,713<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock warrants issued in connection with the 2009, 2010 and 2011 offerings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,863)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,863)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement', window );">Common stock issued as commitment fee in connection with SEDA, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58,398<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement', window );">Common stock issued as commitment fee in connection with SEDA</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition', window );">Stock based compensation expense for directors and employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,906<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,906<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,296<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,296<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices', window );">Value of common stock warrants issued (expense) in exchange for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">826<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">826<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(18,387)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(18,387)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2009</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">741<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44,489<span></span></td>
        <td class="num">(43,750)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2009</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,207,625<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,235<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,235<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of 675,000 shares of treasury stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,849)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,849)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock warrants issued in connection with the 2009, 2010 and 2011 offerings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,466)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,466)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants', window );">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(785)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(785)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">53,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">254<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">254<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">86,634<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">207<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">207<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition', window );">Stock based compensation expense for directors and employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,625<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,625<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">743<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">743<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices', window );">Value of common stock warrants issued (expense) in exchange for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">718<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">718<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(11,993)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(11,993)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(11,993)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2010</a></td>
        <td class="nump">2,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">62,020<span></span></td>
        <td class="num">(55,743)<span></span></td>
        <td class="num">(3,849)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,047,759<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,650,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,615<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,613<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock warrants issued in connection with the 2009, 2010 and 2011 offerings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(12,709)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(12,709)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodSharesCashBonus', window );">Issuance of stock in lieu of cash bonus, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">147,040<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueCashBonus', window );">Issuance of stock in lieu of cash bonus</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">171<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">171<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">220,729<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">256<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">256<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodSharesServices', window );">Issuance of common stock for services, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">53,558<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueServices', window );">Issuance of common stock for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrant, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants', window );">Issuance of common stock in cashless exchange of outstanding warrants, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,151,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants', window );">Issuance of common stock in cashless exchange of outstanding warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,120<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,120<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock related to acquisition of Apthera Inc., shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,974,090<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock related to acquisition of Apthera Inc.</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,366<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements', window );">Issuance of common stock subject to employee termination agreements, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">398,453<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements', window );">Issuance of common stock subject to employee termination agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">350<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">350<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock subject to Employee Stock Purchase Plan, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,824<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock subject to Employee Stock Purchase Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition', window );">Stock based compensation expense for directors and employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,774<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,774<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(123)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(123)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices', window );">Value of common stock warrants issued (expense) in exchange for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">108<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">108<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(11,485)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(11,485)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(11,485)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2011</a></td>
        <td class="nump">$ 10,112<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,112<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 81,184<span></span></td>
        <td class="num">$ (67,228)<span></span></td>
        <td class="num">$ (3,849)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47,811,453<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustments to additional paid in capital shares to be redeemed for exercise of warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_AdjustmentsToAdditionalPaidInCapitalSharesToBeRedeemedForExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustments to additional paid in capital warrant expense in exchange for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_AdjustmentsToAdditionalPaidInCapitalWarrantExpenseInExchangeForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NetTransactionsWithParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net transactions with Parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NetTransactionsWithParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period for reimbursement of expenses shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodForReimbursementOfExpensesShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodSharesCashBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares cash bonus</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodSharesCashBonus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares employee termination agreements</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodSharesEmployeeTerminationAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares for additional intellectual properties</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodSharesForAdditionalIntellectualProperties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares in exchange of warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodSharesInExchangeOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodSharesServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares services</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodSharesServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares stock commitment fee under standby equity distribution agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodSharesStockCommitmentFeeUnderStandbyEquityDistributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodSharesToDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares to directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodSharesToDirectors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodSharesWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares warrants exercised</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodSharesWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueCashBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value cash bonus</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueCashBonus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value employee termination agreements</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueEmployeeTerminationAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value for additional intellectual properties</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueForAdditionalIntellectualProperties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value for reimbursement of expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueForReimbursementOfExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value in exchange of warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueInExchangeOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value services</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value stock commitment fee under standby equity distribution agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueStockCommitmentFeeUnderStandbyEquityDistributionAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueToDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value to directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueToDirectors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_StockIssuedDuringPeriodValueWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value warrants exercised</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_StockIssuedDuringPeriodValueWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to nonvested shares during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonvestedSharesRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 4110<br><br> -Paragraph 1, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Warrant<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6923874&amp;loc=d3e4724-112606<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 14<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 53<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValueAcquiredCostMethod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>2.&#160;&#160;&#160;&#160;Basis of Presentation and Summary of Significant Accounting Policies </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Uses of estimates in preparation of financial statements </i>&#8212; The preparation of financial statements in
   accordance with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
   liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Principles of Consolidation </i>&#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned
   subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Cash and Cash Equivalents </i>&#8212;
   The Company considers all highly-liquid debt instruments with an original maturity of 90&#160;days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Restricted Cash </i>&#8212; Restricted cash consists of certificates of deposit on hand with the Company&#8217;s financial institutions
   as collateral for its corporate credit cards. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Fair Value of Financial Instruments </i>&#8212; The carrying amounts reported
   in the balance sheet for cash equivalents, accounts payable, convertible notes payable and capital leases approximate their fair values due to their short-term nature and market rates of interest. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Equipment and Furnishings</i> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based
   on the estimated useful lives (generally three to five years for equipment and furniture) of the related assets. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Goodwill
   and Intangible Assets </i>&#8212; Goodwill has an indefinite useful life and is not amortized but is evaluated for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The In-Process Research&#160;&#038; Development (&#8220;IPR&#038;D&#8221;) asset is considered an indefinite-lived intangible asset and is not
   subject to amortization. IPR&#038;D must be tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment test consists of a comparison of the fair value of the
   IPR&#038;D with its carrying amount. If the carrying amount of the IPR&#038;D exceeds its fair value, an impairment loss must be recognized in an amount equal to that excess. After an impairment loss is recognized, the adjusted carrying amount of the
   IPR&#038;D will be its new accounting basis. Subsequent reversal of a previously recognized impairment loss is prohibited. The initial determination and subsequent evaluation for impairment, of the IPR&#038;D asset requires management to make
   significant judgments and estimates. The Company believes no impairment of its IPR&#038;D exists as of December 31, 2011. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The
   Company records intangible assets at historical cost or fair value, if acquired through an acquisition. Intangible assets consist primarily of acquired in process research and development and clinical data that has been generated thereof. Goodwill
   is tested for impairment annually utilizing the &#8220;fair value&#8221; methodology. The annual measurement date is December&#160;31. Factors the Company considers important that could trigger an interim review for impairment include, but are not
   limited to, the following: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="1%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">significant changes in the manner of its use of acquired assets or the strategy for its overall business; </font></p>
   </td>
   </tr>
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="1%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">significant negative industry or economic trends; </font></p>
   </td>
   </tr>
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="1%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">significant decline in stock price for a sustained period; and </font></p>
   </td>
   </tr>
   </table>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%"><font size="1">&#160;</font></td>
   <td width="1%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">significant decline in market capitalization relative to net book value. </font></p>
   </td>
   </tr>
   </table>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Goodwill is
   evaluated for impairment using a two-step process. The first step is to compare the fair value to the carrying amount (the &#8220;First Step&#8221;). If the carrying amount exceeds the fair value, a second step must be followed to calculate potential
   impairment (the &#8220;Second Step&#8221;). Otherwise, if the fair value exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill, the Company determines
   fair value using the Income Approach, or more specifically the Discounted Cash Flow Method. This valuation method requires management to project revenues, operating expenses, working capital investment, capital spending and cash flows for the
   reporting unit over a multi-year period, as well as determine the weighted average cost of capital to be used as a discount rate. The 2011 analysis confirmed that fair values exceeded carrying values and, therefore, no impairment existed.</font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Contingent Consideration </i>&#8212; Contingent consideration is recorded at the estimated fair value as of the acquisition date. The
   fair value of the contingent consideration is remeasured at each reporting period with any adjustments in fair value included in our consolidated statement of expenses. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   <i>Patents and Patent Application Costs </i>&#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the
   patents is uncertain. Patent costs are, therefore, expensed as incurred. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Share-based Compensation </i>&#8212; The Company
   follows the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, &#8220;<i>Compensation&#160;&#8212; Stock Compensation&#8221; </i>(&#8220;ASC 718&#8221;), which requires
   the measurement and recognition of compensation expense for all stock based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value
   estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">For
   stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220; <i>Equity Based Payments to Non-
   Employees</i> .&#8221; Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of
   these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the
   fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company recognized ($70,000) and $743,000 of stock based compensation expense related to non-employee stock options for the years
   ended December&#160;31, 2011 and 2010, respectively. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Derivative Financial Instruments </i>&#8212; During the normal course
   of business, from time to time, the Company issues warrants and options to vendors as consideration to perform services. It may also issue warrants as part of a debt or equity financing. The Company does not enter into any derivative contracts for
   speculative purposes. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company recognizes all derivatives as assets or liabilities measured at fair value with changes in
   fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with FASB ASC Topic 815-40, &#8220;<i>Derivatives and Hedging&#160;&#8212; Contracts
   in Entity&#8217;s Own Stock,&#8221; </i>the value of these warrants is required to be recorded as a liability, as the holders have an option to put the warrants back to the Company upon the occurrence of certain events set forth in the warrant
   agreement. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Obligations to Repurchase Shares of the Company&#8217;s Equity Securities </i>&#8212; In accordance with FASB ASC
   Topic 480-10, <i>&#8220;Distinguishing Liabilities from Equity,&#8221;</i> the Company recognizes all obligations to repurchase shares of its equity securities that require or may require the Company to settle the obligation by transferring assets, as
   liabilities or assets in some circumstances measured at fair value with changes in fair value reflected as current period income or loss and are accounted for as such. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Research and
   Development Expenses </i>&#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, clinical trial related expenses, facilities, supplies, external
   services and overhead directly related to the Company&#8217;s research and development departments as well as costs to acquire technology licenses. We recognize expenses for these costs based on a variety of factors, including estimates provided by
   third parties or the Company&#8217;s employees, measuring changes in activities and reviewing various milestones that may have been achieved. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   <i>Income Taxes </i>&#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts
   in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;<i>Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</i> These temporary differences will result in taxable or deductible amounts in future years when the reported
   amounts of the assets or liabilities are recovered or settled. <i>ASC 740-10</i> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be
   realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other
   positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#8217;s income tax
   provision or benefit. The recognition and measurement of benefits related to the Company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by
   taxing authorities. Differences between actual results and the Company&#8217;s assumptions or changes in the Company&#8217;s assumptions in future periods are recorded in the period they become known </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Concentrations of Credit Risk </i>&#8212; Financial instruments that potentially subject the Company to significant concentrations of
   credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of December&#160;31, 2011, the Company&#8217;s cash
   equivalents were invested in money market mutual funds. The Company&#8217;s investment policy disallows investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The Company has not experienced any
   losses on its deposits of cash and cash equivalents. All of the non-interest bearing cash balances were fully insured at December&#160;31, 2011 due to temporary federal program in effect from December&#160;31, 2010 through December&#160;31, 2012.
   Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning in 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and the non-interest bearing cash balances may again
   exceed federally insured limits. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Comprehensive Loss </i>&#8212; The Company&#8217;s comprehensive loss is equal to its net
   loss for all periods presented. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Parent Company&#8217;s Net Deficit </i>&#8212; The Parent Company&#8217;s Net Deficit of the
   Predecessor consists of CytRx&#8217;s initial investment in RXi and subsequent changes in RXi&#8217;s net investment resulting from RXi being an integrated part of CytRx. All disbursements for the Predecessor were made by CytRx. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation, or accounting, and significant accounting policies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>89</ContextCount>
  <ElementCount>184</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>7</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0110 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0111 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0120 - Statement - Consolidated Statements of Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Expenses</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0130 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StatementsOfStockholderEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0140 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0141 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0201 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0203 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0204 - Disclosure - Apthera Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/SubsidiaryAcquisition</Role>
      <ShortName>Apthera Acquisition</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0205 - Disclosure - RXi Spin-Out</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/SpinOut</Role>
      <ShortName>RXi Spin-Out</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0206 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0207 - Disclosure - Capital Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/CapitalLeaseObligations</Role>
      <ShortName>Capital Lease Obligations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0208 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0209 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0210 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0211 - Disclosure - Development Stage Supplemental Equity Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/DevelopmentStageSupplementalEquityDisclosure</Role>
      <ShortName>Development Stage Supplemental Equity Disclosure</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0212 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0213 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0214 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0215 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0216 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0217 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0218 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0110 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 0111 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0120 - Statement - Consolidated Statements of Expenses</Log>
    <Log type="Info">Process Flow-Through: 0131 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0140 - Statement - Consolidated Statements of Cash Flows</Log>
    <Log type="Info">Process Flow-Through: 0141 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</Log>
  </Logs>
  <InputFiles>
    <File>rxii-20111231.xml</File>
    <File>rxii-20111231.xsd</File>
    <File>rxii-20111231_cal.xml</File>
    <File>rxii-20111231_def.xml</File>
    <File>rxii-20111231_lab.xml</File>
    <File>rxii-20111231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Based Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 12 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-->
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>12.&#160;&#160;&#160;&#160;Stock Based Compensation </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Options to Purchase Shares of Common Stock </i>&#8212; The Company follows the provisions ASC&#160;718 which requires
   the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value
   estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">For
   stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50, Non-employee option grants that do not vest immediately upon grant
   are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, is being
   re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the
   future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   The Company is currently using the Black-Scholes option-pricing model to determine the fair value of all its option grants. For options grants issued for the year ended December&#160;31, 2011 and 2010,
   the following assumptions were used: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="58%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2010</b></font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average risk free interest rate</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">0.92%&#160;-&#160;3.16%</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">1.88%&#160;-&#160;3.28%</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average volatility</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">98.61%&#160;-&#160;113.87%</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">118.3%&#160;-&#160;133.62%</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected lives (years)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">4.71 - 9.25</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">6 - 10</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected dividend yield</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">0%</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">0%</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The weighted average fair value of options granted during the years ended December&#160;31, 2011 and 2010
   was $0.89 and $4.31 per share, respectively. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company&#8217;s expected common stock price volatility assumption is based
   upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the Company&#8217;s options of
   ten years with the average vesting term of four years for an average of six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that
   Galena has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an
   annualized forfeiture rate of 15% for options granted to its employees, 8% for options granted to senior management and no forfeiture rate for the directors. The Company will record additional expense if the actual forfeitures are lower than
   estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company
   recorded approximately $3,001,000 and $4,368,000 of stock-based compensation for the years ended December&#160;31, 2011 and 2010, respectively. As of December&#160;31, 2011, there was $1,012,000 of unrecognized compensation cost related to
   outstanding options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted average period of 3.3 years. </font></p>
   <p style="font-size:1px;margin-top:6px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On November&#160;4,
   2009, as part of a plan succession in leadership, Tod Woolf,&#160;Ph.D., resigned as our President, Chief Executive Officer and a member of our Board of Directors. According to the Separation Agreement between Dr.&#160;Woolf and the Company,
   Dr.&#160;Woolf received in one lump sum payment his full severance equivalent to a six (6)&#160;month salary ($187,500), six (6)&#160;months acceleration of vesting of all of his outstanding unvested Stock Options as of November&#160;4, 2009, and an
   offer to join the Company&#8217;s Scientific Advisory Board (SAB) for 3&#160;years (the &#8220;New Position&#8221;). In addition, and as part of the Separation Agreement, the Company agreed to extend the exercise period for all of Dr.&#160;Woolf&#8217;s
   vested Stock Options as of November&#160;4, 2009, to the later of: (i)&#160;a period of two (2)&#160;years from his resignation (until November&#160;4, 2011), or (ii)&#160;ninety (90)&#160;days following the end of the term of the SAB&#160;Agreement
   (February&#160;4, 2013)&#160;or such earlier date as the SAB&#160;Agreement may be terminated pursuant to the terms of the SAB&#160;Agreement provided Dr.&#160;Woolf has not violated the non-competition provisions of the SAB&#160;Agreement prior to
   the date of exercise (whether or not the SAB&#160;Agreement is still in effect at that time). Notwithstanding any provision of the Company&#8217;s 2007 Incentive Plan, the Company also agreed that Dr.&#160;Woolf&#8217;s previously awarded Stock
   Options shall continue to vest during his continuing role in the Company in the New Position. The total expense for 2011 and 2010 was $65,000 and $193,000, respectively. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   During the fiscal year ended December&#160;31, 2011, we granted to our President and Chief Executive Officer 300,000 stock options subject to performance-based vesting. The aggregate fair market value of
   the stock option grant was valued using the lattice model and is being amortized to compensation expense over the vesting period. Compensation expense recognized related to this grant was approximately $23,000 for the year ended December&#160;31,
   2011. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of December&#160;31, 2011, an aggregate of 8,750,000&#160;shares of common stock were reserved for issuance under the
   Company&#8217;s 2007 Incentive Plan, including 6,163,137&#160;shares subject to outstanding common stock options granted under this plan and 1,299,717&#160;shares available for future grants. The administrator of the plan determines the times when an
   option may become exercisable. Vesting periods of options granted to date include vesting upon grant to vesting at the end of a four year period. The options will expire, unless previously exercised, no later than ten years from the grant date. The
   Company is using unissued shares for all shares issued for options, restricted share awards and ESPP issuances. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following
   table summarizes the options&#8217; activity of the Company&#8217;s stock option plan: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="73%">&#160;</td>
   <td valign="bottom" width="7%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Stock<br />Options</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Exercise&#160;Price</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding&#160;&#8212; January&#160;1, 2010</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,582,339</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.16</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">926,768</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.81</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercised</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(53,500</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.75</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(122,471</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.85</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding&#160;&#8212; December&#160;31, 2010</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,333,136</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.10</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,322,500</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.21</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercised</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeited</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1,492,499</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4.99</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding&#160;&#8212; December&#160;31, 2011</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,163,137</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3.03</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable&#160;&#8212; December&#160;31, 2010</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,155,900</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.22</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable&#160;&#8212; December&#160;31, 2011</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,673,768</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3.40</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The weighted average remaining contractual life of options outstanding and exercisable at
   December&#160;31, 2011 was 7.87 years and 7.56 years, respectively. The weighted average remaining contractual life of options outstanding and exercisable at December&#160;31, 2010 was 7.35 years and 7.09 years, respectively. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The aggregate intrinsic value of outstanding options as of December&#160;31, 2011 and 2010 is $0 and $137,000, respectively. The aggregate
   intrinsic value of exercisable options as of December&#160;31, 2011 and 2010 is $0 and $34,000, respectively. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price
   of the underlying options. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The aggregate intrinsic value of options exercised during 2010 was approximately $164,000. There
   were no options exercised during 2011. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Employee Stock Purchase Plan</i> &#8212;&#160;The Company also has an employee stock
   purchase plan (&#8220;ESPP&#8221;) which allows employees to contribute up to 15% of their cash earnings, subject to certain maximums, to be used to purchase shares of our common stock on each semi-annual purchase date. The purchase price is equal to
   85% of the market value per share on either the first or last day of the semi-annual period, whichever is lower. Our ESPP is non-compensatory pursuant to the provisions of generally accepted accounting principles for share-based compensation
   expense. The ESPP contains an &#8220;evergreen provision&#8221; with annual increases in the number of shares available for issuance on the first day of each year through January&#160;1, 2015 equal to the lesser of: (a)&#160;250,000 shares increased
   on each anniversary of the adoption of the Plan by one percent (1%)&#160;of the total shares of stock then outstanding and (b)&#160;1,000,000 shares.&#160;As of December&#160;31, 2011, an aggregate of 231,176 shares of common stock were authorized
   and available for issuance under the ESPP. Under the evergreen provision, on January&#160;1, 2012, an additional 250,000 shares were authorized under our ESPP. The Company has issued 18,824 shares under the ESPP through December&#160;31, 2011.
   </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Restricted Stock Units </i>&#8212; In addition to options to purchase shares of common stock, the Company may grant
   restricted stock units (&#8220;RSU&#8221;) as part of its compensation package. Each RSU is granted at the fair market value based on the date of grant. Vesting is determined on a grant by grant basis. </font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In 2011 and 2010, the Company granted a total of 220,728 and 43,541 RSUs, respectively. The RSUs granted in 2011 and 2010 had an aggregate
   intrinsic value of $256,000 and $112,000. As of December&#160;31, 2011 and 2010, all of the RSUs had vested in full. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
